FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Salinas, H
Dursun, A
Konstantinidis, I
Nguyen, D
Shellito, P
Hodin, R
Bordeianou, L
AF Salinas, Harry
Dursun, Abdulmentin
Konstantinidis, Ioannis
Nguyen, Deanna
Shellito, Paul
Hodin, Richard
Bordeianou, Liliana
TI Does preoperative total parenteral nutrition in patients with ulcerative
colitis produce better outcomes?
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Article
DE Inflammatory bowel disease; Ulcerative colitis; Colorectal surgery;
Nutrition
ID SURGERY
AB Malnutrition is a frequent problem in patients with ulcerative colitis (UC) leading to increased postoperative complication rates. Preoperative total parenteral nutrition (TPN) has been shown to reduce complications in some subgroups of patients, but has not been studied in UC. We investigated the impact of preoperative TPN on postoperative complication rates in patients undergoing surgery for UC.
This paper is a review of 235 patients who underwent surgery for UC; 56 received preoperative TPN and 179 did not. Postoperative complication rates were compared.
Both had similar rates of anastomotic leak (5.4 vs. 2.8 %, p = 0.356), infection (12.5 vs. 20.1 %, p = 0.199), ileus/bowel obstruction (21.4 vs. 15.6 %, p = 0.315), cardiac complications (3.6 vs. 0 %, p = 0.056), wound dehiscence (3.6 vs. 1.7 %, p = 0.595), reoperation (10.7 vs. 3.9 %, p = 0.086), and death (1.8 vs. 0 %, p = 0.238). The TPN group was more malnourished (albumin 2.49 vs. 3.45, p < 0.001), more often on steroids (83.9 vs. 57.5 %, p < 0.001), had more emergent surgery (10.7 vs. 3.4 %, p = 0.029), more severe colitis (89.3 vs. 65.9 %, p = 0.001), and lower Surgical Apgar Score (6.15 vs. 6.57, p = 0.033). After controlling for these with logistic regression, the TPN group still had higher complication rates (OR 2.32, p = 0.04). When line infections were excluded, TPN did not significantly affect outcomes (OR 1.5, p = 0.311)
There were no differences in postoperative complications when line infections were excluded. Our data does not support routine preoperative TPN in patients with UC. However, it may lead to equal surgical outcomes in the sickest and most malnourished patients at the cost of line-related morbidity.
C1 [Nguyen, Deanna] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Dept Gastroenterol, Boston, MA 02114 USA.
[Shellito, Paul; Hodin, Richard; Bordeianou, Liliana] Massachusetts Gen Hosp, Crohns & Colitis Ctr, Dept Surg, Boston, MA 02114 USA.
RP Bordeianou, L (reprint author), Massachusetts Gen Hosp, Crohns & Colitis Ctr, Dept Surg, 15 Parkman St,ACC 460, Boston, MA 02114 USA.
EM lbordeianou@partners.org
NR 8
TC 4
Z9 4
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0179-1958
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD NOV
PY 2012
VL 27
IS 11
BP 1479
EP 1483
DI 10.1007/s00384-012-1535-2
PG 5
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 024DK
UT WOS:000310088000011
PM 23011545
ER
PT J
AU Chan, HN
Rush, AJ
Nierenberg, AA
Trivedi, M
Wisniewski, SR
Balasubramani, GK
Friedman, ES
Gaynes, BN
Davis, L
Morris, D
Fava, M
AF Chan, Herng Nieng
Rush, A. John
Nierenberg, Andrew A.
Trivedi, Madhukar
Wisniewski, Stephen R.
Balasubramani, G. K.
Friedman, Edward S.
Gaynes, Bradley N.
Davis, Lori
Morris, David
Fava, Maurizio
TI Correlates and outcomes of depressed out-patients with greater and fewer
anxious symptoms: a CO-MED report
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE Anxiety; depression; outcomes; treatment prediction
ID STAR-ASTERISK-D; MEASUREMENT-BASED CARE; DIAGNOSTIC SCREENING
QUESTIONNAIRE; NONANXIOUS DEPRESSION; MAJOR DEPRESSION;
CLINICAL-PRACTICE; QUICK INVENTORY; RATING-SCALE; OUTPATIENTS; DISORDER
AB The objective of this paper was to determine whether the presence of more vs. fewer anxious symptom features, at baseline, are associated with other clinical features and treatment outcomes in out-patients with major depressive disorder (MDD). This single-blind, randomized trial enrolled 665 MDD outpatients to compare the efficacy of two antidepressant medication combinations against escitalopram after 12-wk acute treatment and follow-up (total 28 wk). The sample was divided into those with greater (vs. fewer) anxiety features using the anxiety/somatization subscale of the baseline 17-item Hamilton Rating Scale for Depression. Baseline sociodemographic and clinical features, treatment features and outcomes compared these two groups. Overall, 74.7% of participants met the threshold for 'anxious features'. They were more likely to be female, have other concurrent anxiety disorders, more severe depression, more lethargic and melancholic features and poorer cognitive and physical functioning, quality of life and work and social adjustment. In acute treatment, participants with anxious features received comparatively higher doses of mirtazapine and venlafaxine and reported more side-effects. The groups with and without anxious features did not differ in treatment outcomes and side-effect burden. Despite being associated with a distinct clinical profile, baseline anxious features were not clinically useful in predicting acute treatment outcomes or differential treatment response.
C1 [Trivedi, Madhukar; Morris, David] Univ Texas SW Med Ctr Dallas, Dept Psychiat, Dallas, TX 75390 USA.
[Chan, Herng Nieng] Singapore Gen Hosp, Dept Psychiat, Singapore 0316, Singapore.
[Rush, A. John] Natl Univ Singapore, Duke NUS Grad Med Sch, Singapore 117548, Singapore.
[Nierenberg, Andrew A.; Fava, Maurizio] Massachusetts Gen Hosp, Depress Clin & Res Program, Boston, MA 02114 USA.
[Wisniewski, Stephen R.; Balasubramani, G. K.] Univ Pittsburgh, Grad Sch Publ Hlth, Epidemiol Data Ctr, Pittsburgh, PA USA.
[Friedman, Edward S.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Gaynes, Bradley N.] Univ N Carolina, Sch Med, Dept Psychiat, Chapel Hill, NC USA.
[Davis, Lori] VA Med Ctr, Res & Dev Serv, Tuscaloosa, AL USA.
[Davis, Lori] Univ Alabama Birmingham, Sch Med, Dept Psychiat, Birmingham, AL USA.
[Morris, David] Columbia Univ, New York State Psychiat Inst, Coll Phys & Surg, New York, NY USA.
[Morris, David] Columbia Univ, Dept Psychiat, Coll Phys & Surg, New York, NY USA.
RP Trivedi, M (reprint author), Univ Texas SW Med Ctr Dallas, Dept Psychiat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM madhukar.trivedi@utsouthwestern.edu
RI Trivedi, Madhukar/A-9029-2013;
OI Wisniewski, Stephen/0000-0002-3877-9860; Gaynes,
Bradley/0000-0002-8283-5030; Rush, Augustus/0000-0003-2004-2382;
Goundappa K, Balasubramani/0000-0001-7221-1825
FU Abbott Laboratories, Inc.; AstraZeneca; Bristol-Myers Squibb Company
(BMS); Eisai Pharmaceuticals; Janssen; VA, NIMH, Shire; Southwestern
Oncology Group, Department of Defense (DoD); Abbott Laboratories;
Alkermes; Aspect Medical Systems; Astra-Zeneca; Bristol-Myers Squibb
Company; Cephalon; Forest Pharmaceuticals Inc.; GlaxoSmithKline; J & J
Pharmaceuticals; Lichtwer Pharma GmbH; Eli Lilly Company; Lorex
Pharmaceuticals; Novartis; Organon Inc.; PamLab, LLC; Pfizer Inc.;
Pharmavite; Roche; Sanofi/Synthelabo; Solvay Pharmaceuticals, Inc.;
Wyeth-Ayerst Laboratories; Indevus; Pfizer; Sanofi-Aventis;
Wyeth-Ayerst; Cyberonics; NorthStar/St. Jude Medical; Medtronics;
Repligen; National Institute of Mental Health; Agency for Healthcare
Research and Quality; M-3 Information; MGH from NIMH; Pam labs; Pfizer
Pharmaceuticals and Shire; Astra Zeneca; Eli Lilly; Janssen
Pharmaceuticals; Bristol-Myers Squibb; University of Michigan, Brain
Resource; Otsuka Pharmaceuticals; royalties from Guilford Publications;
University of Texas Southwestern Medical Center; Cephalon, Inc.; Corcept
Therapeutics, Inc.; Cyberonics, Inc.; Forest Pharmaceuticals; Janssen
Pharmaceutica; Merck; National Alliance for Research in Schizophrenia
and Depression; Pharmacia Upjohn; Predix Pharmaceuticals
FX Dr Davis has received research support (no personal income) from Abbott
Laboratories, Inc.; AstraZeneca; Bristol-Myers Squibb Company (BMS);
Eisai Pharmaceuticals; Janssen; VA, NIMH, Shire; AstraZeneca;
Southwestern Oncology Group, Department of Defense (DoD). She has done
advising/consulting for Cyberonics; Abbott; Shire; Constella; Eli Lilly,
has done speaking engagements for Abbott Laboratories; Cyberonics;
Sanofi-Aventis; and AstraZeneca and has equity holdings in Pfizer (until
2009). Dr Fava has received research support from Abbott Laboratories;
Alkermes; Aspect Medical Systems; Astra-Zeneca; Bristol-Myers Squibb
Company; Cephalon; Forest Pharmaceuticals Inc.; GlaxoSmithKline; J & J
Pharmaceuticals; Lichtwer Pharma GmbH; Eli Lilly & Company; Lorex
Pharmaceuticals; Novartis; Organon Inc.; PamLab, LLC; Pfizer Inc.;
Pharmavite; Roche; Sanofi/Synthelabo; Solvay Pharmaceuticals, Inc.;
Wyeth-Ayerst Laboratories. He has provided advisory/consulting services
to Aspect Medical Systems; Astra-Zeneca; Bayer AG; Biovail
Pharmaceuticals, Inc.; BrainCells, Inc.; Bristol-Myers Squibb Company;
Cephalon; Compellis; Cypress Pharmaceuticals; Dov Pharmaceuticals; EPIX
Pharmaceuticals; Fabre-Kramer Pharmaceuticals, Inc.; Forest
Pharmaceuticals Inc.; GlaxoSmithKline; Grunenthal GmBH; J & J
Pharmaceuticals; Janssen Pharmaceutica; Jazz Pharmaceuticals; Knoll
Pharmaceutical Company; Eli Lilly & Company; Lundbeck; MedAvante, Inc.;
Novartis; Nutrition 21; Organon Inc.; PamLab, LLC; Pfizer Inc.;
PharmaStar; Pharmavite; Roche; Sanofi/Synthelabo; Sepracor; Solvay
Pharmaceuticals, Inc.; Somerset Pharmaceuticals; Wyeth-Ayerst
Laboratories. He has been on speaking bureaus for AstraZeneca;
Bristol-Myers Squibb Company; Cephalon; Forest Pharmaceuticals Inc.;
GlaxoSmithKline; Eli Lilly & Company; Novartis; Organon Inc.; Pfizer
Inc.; PharmaStar; Wyeth-Ayerst Laboratories. Dr Fava has equity holdings
(excluding mutual funds/blinded trusts) with Compellis and MedAvante. Dr
Friedman has received grant/research support: Aspect Medical Systems;
Indevus; AstraZeneca; Bristol-Myers Squibb; Pfizer; Sanofi-Aventis;
Wyeth-Ayerst; Cyberonics; Novartis; NorthStar/St. Jude Medical;
Medtronics; Repligen. He has been on speaker bureaus or advisory boards
for AstraZeneca; GlaxoSmithKline; Pfizer; Wyeth-Ayerst. Dr Gaynes has
received grant/research from the National Institute of Mental Health;
Agency for Healthcare Research and Quality; and M-3 Information. Dr
Nierenberg is a full time employee of the Massachusetts General Hospital
(MGH). He has served as a consultant to the American Psychiatric
Association (only travel expenses paid) and Appliance Computing Inc.
(Mindsite), Brandeis University. Through the MGH Clinical Trials Network
and Institute, he has consulted for Brain Cells, Inc Dianippon
Sumitomo/Sepracor Novartis, PGx Health, Shire, Schering-Plough,
Targacept and Takeda/lundbeck Pharmaceuticals. He received
grant/research support through MGH from NIMH, Pam labs, Pfizer
Pharmaceuticals and Shire. He received honoraria from Belvior
Publishing, University of Texas Southwestern Dallas, Hillside Hospital,
American Drug Utilization Review, American Society for Clinical
Psychopharmacology, Baystate Medical Center, Columbia University,
IMEDEX, MJ Consulting, New York State, MBl Publishing, Physicians
Postgraduate Press, SUNY Buffalo, University of Wisconsin and the
University of Pisa. Dr Nierenberg is a presenter for the Massachusetts
General Hospital Psychiatry Academy (MGHPA).; The education programs
conducted by the MGHPA were supported through Independent Medical
Education (IME) grants from the following pharmaceutical companies in
2008: Astra Zeneca, Eli Lilly and Janssen Pharmaceuticals; in 2009 Astra
Zeneca, Eli Lilly and Bristol-Myers Squibb. No speaker bureaus or boards
since 2003. He is on the advisory boards of Appliance Computing, Inc.,
Brain Cells, Inc., Eli Lilly and Company and Takeda/lundbeck and
Targacept. Dr Nierenberg owns stock options in Appliance Computing, Inc.
and Brain Cells, Inc. Through MGH, he is named for copyrights to the
Clinical Positive Affect Scale and the MGH Structured Clinical Interview
for the Montgomery Asberg Depression Scale exclusively licensed to the
MGH Clinical Trials Network and Institute (CTNI). Also, through MGH, Dr
Nierenberg has a patent extension application for the combination of
buspirone, bupropion and melatonin for the treatment of depression. Dr
Rush has received consultant fees from University of Michigan, Brain
Resource; speaking fees from Otsuka Pharmaceuticals; research support
from National Institute of Mental Health and royalties from Guilford
Publications and the University of Texas Southwestern Medical Center. Dr
Trivedi has been a consultant for Abbott Laboratories, Inc.; Akzo
(Organon Pharmaceuticals Inc.); AstraZeneca; Bayer; Bristol-Myers Squibb
Company; Cephalon, Inc.; Cyberonics, Inc.; Eli Lilly & Company;
Fabre-Kramer Pharmaceuticals, Inc. Forest Pharmaceuticals;
GlaxoSmithKline; Janssen Pharmaceutica Products, LP; Johnson & Johnson
PRD; Eli Lilly & Company; Meade Johnson; Neuronetics; Parke-Davis
Pharmaceuticals, Inc.; Pfizer, Inc.; Pharmacia & Upjohn; Sepracor;
Solvay Pharmaceuticals, Inc.; VantagePoint; and Wyeth-Ayerst
Laboratories. He has served on speakers bureaus for Abdi Brahim; Akzo
(Organon Pharmaceuticals Inc.); Bristol-Myers Squibb Company; Cephalon,
Inc.; Cyberonics, Inc.; Forest Pharmaceuticals; GlaxoSmithKline; Janssen
Pharmaceutica Products, LP; Eli Lilly & Company; Pharmacia & Upjohn;
Solvay Pharmaceuticals, Inc.; and Wyeth-Ayerst Laboratories. He has also
received grant support from Bristol-Myers Squibb Company; Cephalon,
Inc.; Corcept Therapeutics, Inc.; Cyberonics, Inc.; Eli Lilly & Company;
Forest Pharmaceuticals; GlaxoSmithKline; Janssen Pharmaceutica; Merck;
National Institute of Mental Health; National Alliance for Research in
Schizophrenia and Depression; Novartis; Pfizer Inc.; Pharmacia & Upjohn;
Predix Pharmaceuticals; Solvay Pharmaceuticals, Inc.; and Wyeth-Ayerst
Laboratories. Dr Wisniewski has been a consultant for: Cyberonic Inc.
(2005-2009), ImaRx Therapeutics, Inc. (2006), Bristol-Myers Squibb
Company (2007-08), Organon (2007), Case-Western University (2007),
Singapore Clinical Research Institute (2009), Dey Pharmaceuticals
(2010), Venebio (2010), Dey (2010).
NR 47
TC 11
Z9 12
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD NOV
PY 2012
VL 15
IS 10
BP 1387
EP 1399
DI 10.1017/S1461145711001660
PG 13
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 019LD
UT WOS:000309740200003
PM 22129562
ER
PT J
AU Galimberti, F
Busch, AM
Chinyengetere, F
Ma, T
Sekula, D
Memoli, VA
Dragnev, KH
Liu, F
Johnson, KC
Guo, YL
Freemantle, SJ
Andrew, AS
Greninger, P
Robbins, DJ
Settleman, J
Benes, C
Dmitrovsky, E
AF Galimberti, Fabrizio
Busch, Alexander M.
Chinyengetere, Fadzai
Ma, Tian
Sekula, David
Memoli, Vincent A.
Dragnev, Konstantin H.
Liu, Fang
Johnson, Kevin C.
Guo, Yongli
Freemantle, Sarah J.
Andrew, Angeline S.
Greninger, Patricia
Robbins, David J.
Settleman, Jeff
Benes, Cyril
Dmitrovsky, Ethan
TI Response to inhibition of smoothened in diverse epithelial cancer cells
that lack smoothened or patched 1 mutations
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE hedgehog; smoothened; patched; lung cancer
ID GENOTYPE-CORRELATED SENSITIVITY; HEDGEHOG PATHWAY INHIBITOR;
LUNG-CANCER; CYCLIN-E; KINASE INHIBITORS; SIGNALING PATHWAY; KRAS
MUTATIONS; SONIC-HEDGEHOG; RESISTANCE; GROWTH
AB Hedgehog (HH) pathway Smoothened (Smo) inhibitors are active against Gorlin syndrome-associated basal cell carcinoma (BCC) and medulloblastoma where Patched (Ptch) mutations occur. We interrogated 705 epithelial cancer cell lines for growth response to the Smo inhibitor cyclopamine and for expressed HH pathway-regulated species in a linked genetic database. Ptch and Smo mutations that respectively conferred Smo inhibitor response or resistance were undetected. Previous studies revealed HH pathway activation in lung cancers. Therefore, findings were validated using lung cancer cell lines, transgenic and transplantable murine lung cancer models, and human normal-malignant lung tissue arrays in addition to testing other Smo inhibitors. Cyclopamine sensitivity most significantly correlated with high cyclin E (P=0.000009) and low insulin-like growth factor binding protein 6 (IGFBP6) (P=0.000004) levels. Gli family members were associated with response. Cyclopamine resistance occurred with high GILZ (P=0.002) expression. Newer Smo inhibitors exhibited a pattern of sensitivity similar to cyclopamine. Gain of cyclin E or loss of IGFBP6 in lung cancer cells significantly increased Smo inhibitor response. Cyclin E-driven transgenic lung cancers expressed a gene profile implicating HH pathway activation. Cyclopamine treatment significantly reduced proliferation of murine and human lung cancers. Smo inhibition reduced lung cancer formation in a syngeneic mouse model. In human normal-malignant lung tissue arrays cyclin E, IGFBP6, Glil and GILZ were each differentially expressed. Together, these findings indicate that Smo inhibitors should be considered in cancers beyond those with activating HH pathway mutations. This includes tumors that express genes indicating basal HH pathway activation.
C1 [Galimberti, Fabrizio; Busch, Alexander M.; Chinyengetere, Fadzai; Ma, Tian; Sekula, David; Liu, Fang; Johnson, Kevin C.; Guo, Yongli; Freemantle, Sarah J.; Robbins, David J.; Dmitrovsky, Ethan] Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.
[Memoli, Vincent A.] Geisel Sch Med Dartmouth, Dept Pathol, Hanover, NH 03755 USA.
[Andrew, Angeline S.] Geisel Sch Med Dartmouth, Dept Community & Family Med, Hanover, NH 03755 USA.
[Dragnev, Konstantin H.; Dmitrovsky, Ethan] Geisel Sch Med Dartmouth, Dept Med, Hanover, NH 03755 USA.
[Memoli, Vincent A.; Dragnev, Konstantin H.; Andrew, Angeline S.; Robbins, David J.; Dmitrovsky, Ethan] Geisel Sch Med Dartmouth, Norris Cotton Canc Ctr, Hanover, NH 03755 USA.
Dartmouth Hitchcock Med Ctr, Lebanon, NH 03756 USA.
[Greninger, Patricia; Settleman, Jeff; Benes, Cyril] Massachusetts Gen Hosp, Ctr Canc, Ctr Mol Therapeut, Charlestown, MA 02129 USA.
RP Dmitrovsky, E (reprint author), Geisel Sch Med Dartmouth, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.
EM ethan.dmitrovsky@dartmouth.edu
FU National Institutes of Health (NIH); National Cancer Institute (NCI)
[R01-CA087546, R01-CA111422, R03-CA132166]; Samuel Waxman Cancer
Research Foundation; Merck; American Cancer Society; FM Kirby
Foundation; NIH National Research Service [T32-CA009658]
FX This study was supported by National Institutes of Health (NIH) and
National Cancer Institute (NCI) grants R01-CA087546 (E.D.), R01-CA111422
(E.D.), R03-CA132166 (E.D.), a Samuel Waxman Cancer Research Foundation
award (E.D.), a research grant from Merck (E.D.) and an American Cancer
Society Clinical Research Professorship (E.D.) supported by a gift from
the FM Kirby Foundation. A.M.B. was supported by an NIH National
Research Service Award (T32-CA009658). We thank Dr Jason Sparkowski
(Merck) for providing MK-4101.
NR 38
TC 6
Z9 7
U1 0
U2 3
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2012
VL 41
IS 5
BP 1751
EP 1761
DI 10.3892/ijo.2012.1599
PG 11
WC Oncology
SC Oncology
GA 024MU
UT WOS:000310114100025
PM 22923130
ER
PT J
AU Subramanian, RR
Yamakawa, A
AF Subramanian, Romesh R.
Yamakawa, Akio
TI Combination therapy targeting Raf-1 and MEK causes apoptosis of HCT116
colon cancer cells
SO INTERNATIONAL JOURNAL OF ONCOLOGY
LA English
DT Article
DE Raf; MEK; apoptosis; cancer; RNA interference
ID NF-KAPPA-B; KINASE-ACTIVITY; NEOPLASTIC PHENOTYPE; SIGNALING PATHWAYS;
TUMOR-CELLS; RAS GENES; PHOSPHORYLATION; ACTIVATION; MUTATIONS;
INDUCTION
AB Members of the Ras protooncogene family are mutated in approximately 75% of colon cancers. The Raf kinases (Raf-1, b-Raf and a-Raf) directly interact with Ras and serve as mediators of mitogenic signals. Expression of the constitutively active alleles of Raf or Ras gene families results in oncogenesis in a number of model systems. Previous studies emphasized the importance of Raf-1 and b-Raf in preventing apoptosis in addition to their roles in cell growth. In the present study, we examined whether inhibition of the Raf-1 or b-Raf kinase decreases cell growth and increases apoptosis in colon cancer cells. c-Raf and b-Raf were depleted in colon cancer cell lines, such as HCT116, HT29 and Colo205, containing Ras or b-Raf mutations by RNA interference (RNAi). The results showed that colon cancer cells with activating Ras mutations undergo apoptosis following Raf-1 inhibition, as determined by cell cycle analysis and the release of cytochrome c. Moreover, in b-Raf mutant colon cancers, the inhibition of b-Raf as compared to Raf-1 is crucial for cancer cell death. There is increasing evidence for both MEK-independent Raf signaling and Raf-independent MEK signaling. Thus, we investigated whether targeting multiple points of the mitogen-activated protein kinase (MAPK) pathway with a MEK inhibitor and Raf RNAi increases cancer cell death. The results showed that combination therapy, inhibiting Raf and MEK kinases simultaneously, increased apoptosis in colon cancer cells. Taken together, our data demonstrate that combination therapy targeting the MAPK pathway at two distinct points, Raf kinase and MEK, has greater efficacy in increasing cancer cell death and is likely to improve therapeutic outcomes for patients.
C1 [Subramanian, Romesh R.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Subramanian, Romesh R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Subramanian, RR (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, 44 Binney St, Boston, MA 02115 USA.
EM romesh.r.subramanian@gmail.com
NR 38
TC 6
Z9 6
U1 0
U2 2
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1019-6439
J9 INT J ONCOL
JI Int. J. Oncol.
PD NOV
PY 2012
VL 41
IS 5
BP 1855
EP 1862
DI 10.3892/ijo.2012.1602
PG 8
WC Oncology
SC Oncology
GA 024MU
UT WOS:000310114100036
PM 22922669
ER
PT J
AU Maserejian, NN
Hauser, R
Tavares, M
Trachtenberg, FL
Shrader, P
McKinlay, S
AF Maserejian, N. N.
Hauser, R.
Tavares, M.
Trachtenberg, F. L.
Shrader, P.
McKinlay, S.
TI Dental Composites and Amalgam and Physical Development in Children
SO JOURNAL OF DENTAL RESEARCH
LA English
DT Article
DE composite resins; bisphenol A-glycidyl methacrylate; dental amalgam;
body mass index; menarche; child
ID BISPHENOL-A EXPOSURE; BIS-GMA; BEVERAGE CONSUMPTION; TRIAL; FERTILITY;
BEHAVIOR; RELEASE; MERCURY; RESIN; MICE
AB Resin-based composite dental restoration materials may release bisphenol-A, an endocrine-disrupting chemical. Using secondary analysis of a randomized clinical safety trial of amalgam vs. composites, we tested the hypothesis that dental restoration materials affect children's growth. Children (N = 218 boys, N = 256 girls) aged 6 to 10 yrs at baseline with >= 2 decayed posterior teeth were randomized to amalgam or composites (bisphenol-A-diglycidyl-dimethacrylate composite for permanent teeth, urethane-dimethacrylate compomer for primary teeth) for treatment of posterior caries throughout follow-up. Primary outcomes for this analysis were 5-year changes in BMI-for-age z-scores, body fat percentage (BF%), and height velocity; exploratory analyses (n = 113) examined age at menarche. Results showed no significant differences between treatment assignment and changes in physical development in boys [(composites vs. amalgam) BF%, 4.9 vs. 5.7, p = 0.49; (BMI-z-score) 0.13 vs. 0.25, p = 0.36] or girls (8.8 vs. 7.7, p = 0.95; 0.36 vs. 0.21, p = 0.49). Children with more treatment on primary teeth had greater increases in BF% regardless of material type. Girls assigned to composites had lower risk of menarche during follow-up (hazard ratio = 0.57, 95% CI 0.35-0.95). Overall, there were no significant differences in physical development over 5 years in children treated with composites or amalgam. Additional studies examining these restoration materials in relation to age at menarche are warranted (clinicaltrials.gov number NCT00065988).
C1 [Maserejian, N. N.; Trachtenberg, F. L.; Shrader, P.; McKinlay, S.] New England Res Inst, Watertown, MA 02472 USA.
[Hauser, R.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Hauser, R.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Hauser, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hauser, R.] Harvard Univ, Sch Med, Boston, MA USA.
[Tavares, M.] Forsyth Inst, Cambridge, MA USA.
RP Maserejian, NN (reprint author), New England Res Inst, 9 Galen St, Watertown, MA 02472 USA.
EM nmaserejian@neriscience.com
FU National Institute of Environmental Health Sciences (NIEHS)
[R01ES019155]
FX The analyses presented in this paper were funded by Award Number
R01ES019155 from the National Institute of Environmental Health Sciences
(NIEHS). The NIEHS had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; or
preparation, review, or approval of the manuscript. The data collection
was supported by a cooperative agreement (U01 DE11886) between the New
England Research Institutes and the National Institute of Dental and
Craniofacial Research (NIDCR), both of which participated in the design
and conduct of the New England Children's Amalgam Trial, including
collection and management of data. The NIDCR had no role in the analyses
or interpretation of data for this manuscript, or in the preparation,
review, or approval of the manuscript. The content of this work is
solely the responsibility of the authors and does not necessarily
represent the official views of the National Institute of Environmental
Health Sciences, the National Institute of Dental and Craniofacial
Research, or the National Institutes of Health. The authors declare no
potential conflicts of interest with respect to the authorship and/or
publication of this article.
NR 34
TC 11
Z9 11
U1 1
U2 16
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0022-0345
J9 J DENT RES
JI J. Dent. Res.
PD NOV
PY 2012
VL 91
IS 11
BP 1019
EP 1025
DI 10.1177/0022034512458691
PG 7
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA 022CG
UT WOS:000309932100004
PM 22972857
ER
PT J
AU Ahluwalia, SC
Gordon, HS
AF Ahluwalia, Sangeeta C.
Gordon, Howard S.
TI Advance Care Planning Safeguards
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Letter
C1 [Ahluwalia, Sangeeta C.] Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Los Angeles, CA 90073 USA.
[Gordon, Howard S.] Univ Illinois, Jesse Brown Vet Affairs Med Ctr, Chicago, IL USA.
RP Ahluwalia, SC (reprint author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, 11301 Wilshire Blvd,111-G, Los Angeles, CA 90073 USA.
EM sangeeta.ahluwalia@va.gov
RI Gordon, Howard/E-4420-2010
OI Gordon, Howard/0000-0002-6712-5954
NR 3
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2012
VL 27
IS 11
BP 1404
EP 1404
DI 10.1007/s11606-012-2190-6
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 025CJ
UT WOS:000310161500005
PM 22878859
ER
PT J
AU Billings, JA
AF Billings, J. Andrew
TI Advance Care Planning Safeguards
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Letter
C1 [Billings, J. Andrew] Massachusetts Gen Hosp, Cambridge Hlth Alliance, Cambridge, MA 02138 USA.
[Billings, J. Andrew] Harvard Univ, Sch Med, Ctr Palliat Care, Cambridge, MA 02138 USA.
RP Billings, JA (reprint author), Massachusetts Gen Hosp, Cambridge Hlth Alliance, 11 1-2 Hilliard St, Cambridge, MA 02138 USA.
EM jbillings@partners.org
NR 5
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2012
VL 27
IS 11
BP 1405
EP 1405
DI 10.1007/s11606-012-2191-5
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 025CJ
UT WOS:000310161500006
ER
PT J
AU Morris, DA
Johnson, KS
Ammarell, N
Arnold, RM
Tulsky, JA
Steinhauser, KE
AF Morris, Deborah A.
Johnson, Kimberly S.
Ammarell, Natalie
Arnold, Robert M.
Tulsky, James A.
Steinhauser, Karen E.
TI What is Your Understanding of Your Illness? A Communication Tool to
Explore Patients' Perspectives of Living with Advanced Illness
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE communication; qualitative research; advanced illness; patient-centered
care; palliative care
ID OBSTRUCTIVE PULMONARY-DISEASE; OF-LIFE CARE; BREAKING BAD-NEWS; ADVANCED
CANCER; HEART-FAILURE; PALLIATIVE-CARE; PROGNOSIS; AWARENESS;
PREFERENCES; INFORMATION
AB Provider communication courses and guidelines stress the use of open-ended questions, such as "what is your understanding of your illness?," to explore patients' perceptions of their illness severity, yet descriptions of patients' responses are largely absent from the current literature. These questions are most often used by clinicians as they deliver bad news to cancer patients or address code status at the end of life, but have not been well studied in other diseases or earlier in the disease course.
To explore the responses of patients living with serious illness to the question "what is your understanding of your illness?" and to identify similarities and differences in themes and language used by cancer and non-cancer patients to discuss their illness.
We conducted a qualitative analysis of patients' responses to "what is your understanding of your illness?"
Two hundred nine subjects, 69 with cancer, 70 CHF, and 70 COPD, who had an estimated 50 % 2-year survival. Mean age was 66 years.
Responses were recorded at the baseline interview of a larger, longitudinal study of patients with advanced life-limiting illness (cancer, CHF, or COPD). After thematic content analysis using open coding, investigators conducted pattern analysis to examine variation associated with diagnosis.
We identified five major themes: naming the diagnosis or describing the pathophysiology, illness history, prognosis, symptoms, and causality. Responses varied by diagnosis. Cancer patients' responses more often included specific diagnostic details and prognosis, while non-cancer patients referenced symptoms and causality.
Patients' responses to the open-ended question "what is your understanding of your illness?" can provide the clinician with important information and insight on how they view their illness in a non-acute setting. The identified themes can serve as a foundation for patient-centered communication strategies as we strive to build a mutual understanding of illness with patients.
C1 [Morris, Deborah A.] VA Med Ctr, Durham, NC 27701 USA.
[Morris, Deborah A.] Duke Med Ctr, Durham, NC 27701 USA.
[Morris, Deborah A.; Johnson, Kimberly S.; Ammarell, Natalie; Tulsky, James A.; Steinhauser, Karen E.] Durham Vet Affairs Med Ctr, Ctr Hlth Serv Res Primary Care, Durham, NC USA.
[Johnson, Kimberly S.] Durham Vet Affairs Med Ctr, Geriatr Res & Clin Ctr, Durham, NC USA.
[Tulsky, James A.; Steinhauser, Karen E.] Duke Univ, Ctr Palliat Care, Durham, NC USA.
[Morris, Deborah A.; Johnson, Kimberly S.; Tulsky, James A.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
[Johnson, Kimberly S.] Duke Univ, Sch Med, Div Geriatr, Durham, NC USA.
[Ammarell, Natalie; Tulsky, James A.] Duke Univ, Sch Nursing, Durham, NC USA.
[Arnold, Robert M.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA.
[Arnold, Robert M.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Morris, DA (reprint author), VA Med Ctr, 411 W Chapel Hill St,Suite 500, Durham, NC 27701 USA.
EM damorri1@gmail.com
FU Durham NC VA Medical Center; NIH/NINR RFP [PA-00-127]; Beeson Career
Development Award in Aging Research [5K08AG028975]
FX This material is the result of work supported with resources and the use
of facilities at the Durham NC VA Medical Center. The views expressed in
this article are those of the authors and do not necessarily represent
the views of the Department of Veterans Affairs.; This research was
supported by a grant from the NIH/NINR RFP PA-00-127 "Trajectories of
Serious Illness Patients and Caregivers" and the 5K08AG028975 Beeson
Career Development Award in Aging Research (KSJ).
NR 37
TC 6
Z9 7
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2012
VL 27
IS 11
BP 1460
EP 1466
DI 10.1007/s11606-012-2109-2
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 025CJ
UT WOS:000310161500014
PM 22638605
ER
PT J
AU Roy, B
Castiglioni, A
Kraemer, RR
Salanitro, AH
Willett, LL
Shewchuk, RM
Qu, HY
Heudebert, G
Centor, RM
AF Roy, Brita
Castiglioni, Analia
Kraemer, Ryan R.
Salanitro, Amanda H.
Willett, Lisa L.
Shewchuk, Richard M.
Qu, Haiyan
Heudebert, Gustavo
Centor, Robert M.
TI Using Cognitive Mapping to Define Key Domains for Successful Attending
Rounds
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE medical education; clinical teaching; ward rounds
ID NOMINAL GROUP TECHNIQUE; WARD ROUNDS; MEDICINE; PHYSICIAN; RESIDENTS;
ATTITUDES; TEACHER
AB Ward attending rounds are an integral part of internal medicine education. Being a good teacher is necessary, but not sufficient for successful rounds. Understanding perceptions of successful attending rounds (AR) may help define key areas of focus for enhancing learning, teaching and patient care.
We sought to expand the conceptual framework of 30 previously identified attributes contributing to successful AR by: 1) identifying the most important attributes, 2) grouping similar attributes, and 3) creating a cognitive map to define dimensions and domains contributing to successful rounds.
Multi-institutional, cross-sectional study design.
We recruited residents and medical students from a university-based internal medicine residency program and a community-based family medicine residency program. Faculty attending a regional general medicine conference, affiliated with multiple institutions, also participated.
Participants performed an unforced card-sorting exercise, grouping attributes based on perceived similarity, then rated the importance of attributes on a 5-point Likert scale. We translated our data into a cognitive map through multi-dimensional scaling and hierarchical cluster analysis.
Thirty-six faculty, 49 residents and 40 students participated. The highest rated attributes (mean rating) were "Teach by example (bedside manner)" (4.50), "Sharing of attending's thought processes" (4.46), "Be approachable-not intimidating" (4.45), "Insist on respect for all team members" (4.43), "Conduct rounds in an organized, efficient & timely fashion" (4.39), and "State expectations for residents/students" (4.37). Attributes were plotted on a two-dimensional cognitive map, and adequate convergence was achieved. We identified five distinct domains of related attributes: 1) Learning Atmosphere, 2) Clinical Teaching, 3) Teaching Style, 4) Communicating Expectations, and 5) Team Management.
We identified five domains of related attributes essential to the success of ward attending rounds.
C1 [Roy, Brita] Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA.
[Castiglioni, Analia; Heudebert, Gustavo; Centor, Robert M.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Salanitro, Amanda H.] Tennessee Valley Healthcare Syst Geriatr Res Educ, Dept Vet Affairs, Nashville, TN USA.
[Salanitro, Amanda H.] Vanderbilt Univ, Sect Hosp Med, Nashville, TN USA.
[Willett, Lisa L.] Univ Alabama Birmingham, Dept Med, Div Gen Internal Med, Birmingham, AL 35294 USA.
[Shewchuk, Richard M.; Qu, Haiyan] Univ Alabama Birmingham, Sch Hlth Profess, Dept Hlth Serv Adm, Birmingham, AL USA.
[Heudebert, Gustavo] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA.
RP Roy, B (reprint author), Univ Alabama Birmingham, Dept Internal Med, Birmingham, AL 35294 USA.
EM britaroy@uab.edu
NR 21
TC 10
Z9 10
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2012
VL 27
IS 11
BP 1492
EP 1498
DI 10.1007/s11606-012-2121-6
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 025CJ
UT WOS:000310161500018
PM 22722975
ER
PT J
AU Huetsch, JC
Uman, JE
Udris, EM
Au, DH
AF Huetsch, John C.
Uman, Jane E.
Udris, Edmunds M.
Au, David H.
TI Predictors of Adherence to Inhaled Medications Among Veterans with COPD
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE medication adherence; pulmonary diseases; health behavior; veterans
ID OBSTRUCTIVE PULMONARY-DISEASE; REFILL ADHERENCE; NONADHERENCE;
SALMETEROL; THERAPY; FLUTICASONE; PERSISTENCE; TRIAL; DRUGS
AB Factors contributing to medication nonadherence among patients with chronic obstructive pulmonary disease (COPD) are poorly understood.
To identify patient characteristics that are predictive of adherence to inhaled medications for COPD and, for patients on multiple inhalers, to assess whether adherence to one medication class was associated with adherence to other medication classes.
Cohort study using data from Veteran Affairs (VA) electronic databases.
This study included 2,730 patients who underwent pulmonary function testing between 2003 and 2007 at VA facilities in the Northwestern United States, and who met criteria for COPD.
We used pharmacy records to estimate adherence to inhaled corticosteroids (ICS), ipratropium bromide (IP), and long-acting beta-agonists (LABA) over two consecutive six month periods. We defined patients as adherent if they had refilled medications to have 80 % of drug available over the time period. We also collected information on their demographics, behavioral habits, COPD severity, and comorbidities.
Adherence to medications was poor, with 19.8 % adherent to ICS, 30.6 % adherent to LABA, and 25.6 % adherent to IP. Predictors of adherence to inhaled therapies were highly variable and dependent on the medication being examined. In adjusted analysis, being adherent to a medication at baseline was the strongest predictor of future adherence to that same medication [(Odds ratio, 95 % confidence interval) ICS: 4.79 (3.22-7.12); LABA: 6.60 (3.92-11.11); IP: 14.13 (10.00-19.97)], but did not reliably predict adherence to other classes of medication.
Among patients with COPD, past adherence to one class of inhaled medication strongly predicted future adherence to the same class of medication, but only weakly predicted adherence to other classes of medication.
C1 [Huetsch, John C.; Uman, Jane E.; Udris, Edmunds M.; Au, David H.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.
[Huetsch, John C.] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
[Au, David H.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA.
RP Au, DH (reprint author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, 1100 Olive Way,Suite 1400, Seattle, WA 98101 USA.
EM dau@uw.edu
FU American Lung Association [CI-51755N]; HSR&D, VA Puget Sound Health Care
System; NHLBI; AHRQ; Department of Veterans Affairs; Gilead Sciences
FX This project was funded by the American Lung Association, grant #
CI-51755N. Dr. Au was funded by HSR&D, VA Puget Sound Health Care
System. The views expressed in this manuscript are those of the authors
and do not necessarily represent the opinions of the Department of
Veterans Affairs.; Dr. Huetsch, Mr. Udris, and Ms. Uman report no
conflicts of interest. Dr. Au is a research advisor for Bosch. He also
receives grants from NHLBI, AHRQ, the Department of Veterans Affairs,
and Gilead Sciences.
NR 29
TC 14
Z9 14
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2012
VL 27
IS 11
BP 1506
EP 1512
DI 10.1007/s11606-012-2130-5
PG 7
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 025CJ
UT WOS:000310161500020
PM 22782274
ER
PT J
AU Patel, MS
Volpp, KG
AF Patel, Mitesh S.
Volpp, Kevin G.
TI Leveraging Insights from Behavioral Economics to Increase the Value of
Health-Care Service Provision
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE health-care costs; health-care value; restaurant food labeling;
asymmetric paternalism; nudges
ID RESTAURANTS; CHARGES; CHOICES
AB United States health expenditures continue to escalate at unsustainable rates. A recent movement around increasing price transparency has been suggested as a way of reducing the rate of increase in expenditures, with legislative efforts taking place at both the state and federal level. While this seems on the surface like a good idea, simply providing information on prices to physicians, particularly trainees, may not achieve the type of large changes in practice patterns that proponents expect. The manner in which price transparency is implemented will likely play a significant role in its effectiveness as an intervention. In this article, the authors review efforts of transparency and default options from other contexts and leverage insights from behavioral economics to provide recommendations for increasing the likelihood that price transparency will lead to physicians weighing the relative value of interventions.
C1 [Patel, Mitesh S.; Volpp, Kevin G.] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
[Volpp, Kevin G.] Univ Penn, Leonard Davis Inst Hlth Econ, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Penn CMU Roybal P30 Ctr Behav Econ & Hlth, Philadelphia, PA USA.
[Volpp, Kevin G.] Univ Penn, Wharton Sch, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Patel, MS (reprint author), Hosp Univ Penn, Dept Med, 3400 Spruce St,100 Centrex, Philadelphia, PA 19104 USA.
EM Mitesh.Patel@uphs.upenn.edu
NR 24
TC 9
Z9 9
U1 4
U2 20
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD NOV
PY 2012
VL 27
IS 11
BP 1544
EP 1547
DI 10.1007/s11606-012-2050-4
PG 4
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA 025CJ
UT WOS:000310161500024
PM 22549296
ER
PT J
AU Abuabara, K
Freeman, EE
Dellavalle, R
AF Abuabara, Katrina
Freeman, Esther E.
Dellavalle, Robert
TI The Role of Systematic Reviews and Meta-analysis in Dermatology
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY
LA English
DT Review
ID RANDOMIZED CONTROLLED-TRIALS; RESEARCH QUESTION; CLINICAL-TRIALS;
PATIENT-CARE; QUALITY
C1 [Abuabara, Katrina] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.
[Freeman, Esther E.] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Dellavalle, Robert] Denver VA Med Ctr, Dermatol Serv, Denver, CO USA.
RP Abuabara, K (reprint author), Univ Penn, Dept Dermatol, 3400 Spruce St,2 Maloney, Philadelphia, PA 19104 USA.
EM Katrina_abuabara@uphs.upenn.edu
RI Dellavalle, Robert/L-2020-2013
OI Dellavalle, Robert/0000-0001-8132-088X
NR 14
TC 7
Z9 7
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0022-202X
J9 J INVEST DERMATOL
JI J. Invest. Dermatol.
PD NOV
PY 2012
VL 132
IS 11
BP 1
EP 5
DI 10.1038/jid.2012.392
PG 5
WC Dermatology
SC Dermatology
GA 022XJ
UT WOS:000309997200001
PM 23069910
ER
PT J
AU Guo, SZ
Som, AT
Waeber, C
Lo, EH
AF Guo, Shuzhen
Som, Angel T.
Waeber, Christian
Lo, Eng H.
TI Vascular neuroprotection via TrkB- and Akt-dependent cell survival
signaling
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE human cerebral endothelial cells; neural cell death; neurovascular unit;
trophic coupling
ID BLOOD-BRAIN-BARRIER; NEUROTROPHIC FACTOR; ENDOTHELIAL-CELLS; TROPHIC
SUPPORT; IN-VITRO; DEATH; ISCHEMIA; AUTOPHAGY; NEURONS; STROKE
AB The cerebral endothelium can be a vital source of signaling factors such as brain-derived neurotrophic factor that defends the neuronal parenchyma against stress and injury. But the underlying mechanisms remain to be fully defined. Here, we use cell models to ask how vascular neuroprotection is sustained. Human brain endothelial cells were grown in culture, and conditioned media were transferred to primary rat cortical neurons. Brain endothelial cell-conditioned media activated neuronal Akt signaling and protected neurons against hypoxia and oxygen-glucose deprivation. Blockade of Akt phosphorylation with the PI3-kinase inhibitor LY294002 negated this vascular neuroprotective effect. Upstream of Akt signaling, the brain-derived neurotrophic factor receptor TrkB (neurotrophic tyrosine kinase receptor, type 2) was involved because depletion with TrkB/Fc eliminated the ability of endothelial-conditioned media to protect neurons against hypoxia. Downstream of Akt signaling, activation of GSK-3 beta (glycogen synthase kinase 3 beta), caspase 9, caspase 3 and Bad pathways were detected. Taken together, these findings suggest that the molecular basis for vascular neuroprotection involves TrkB-Akt signaling that ameliorates neuronal apoptosis. Further investigation of these mechanisms may reveal new approaches for augmenting endogenous vascular neuroprotection in stroke, brain injury, and neurodegeneration.
C1 [Guo, Shuzhen; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neuroprotect Res Lab, Charlestown, MA 02129 USA.
[Guo, Shuzhen; Lo, Eng H.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Charlestown, MA 02129 USA.
RP Guo, SZ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neuroprotect Res Lab, Charlestown, MA 02129 USA.
EM Sguo@partners.org; Lo@helix.mgh.harvard.edu
RI Waeber, Christian/A-8333-2009
OI Waeber, Christian/0000-0001-6078-0027
FU National Institutes of Health [P01-NS55104]; Massachusetts General
Hospital
FX This study is supported in part by National Institutes of Health Grant
P01-NS55104, and a Claflin award from Massachusetts General Hospital to
S.G.
NR 35
TC 9
Z9 11
U1 2
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD NOV
PY 2012
VL 123
SU 2
SI SI
BP 58
EP 64
DI 10.1111/j.1471-4159.2012.07944.x
PG 7
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 019LK
UT WOS:000309740900007
PM 23050643
ER
PT J
AU Khan, M
Dhammu, TS
Sakakima, H
Shunmugavel, A
Gilg, AG
Singh, AK
Singh, I
AF Khan, Mushfiquddin
Dhammu, Tajinder S.
Sakakima, Harutoshi
Shunmugavel, Anadakumar
Gilg, Anne G.
Singh, Avtar K.
Singh, Inderjit
TI The inhibitory effect of S-nitrosoglutathione on blood-brain barrier
disruption and peroxynitrite formation in a rat model of experimental
stroke
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE BBB; endothelial dysfunction; GSNO; ischemia reperfusion; peroxynitrite;
S-nitrosylation
ID FOCAL CEREBRAL-ISCHEMIA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; ACID
PHENETHYL ESTER; NEUROPROTECTIVE EFFICACY; PLATELET ACTIVATION;
NITROSO-GLUTATHIONE; NEUROVASCULAR UNIT; ENDOTHELIAL-CELLS; DOPAMINE
NEURONS
AB The hallmark of stroke injury is endothelial dysfunction leading to bloodbrain barrier (BBB) leakage and edema. Among the causative factors of BBB disruption are accelerating peroxynitrite formation and the resultant decreased bioavailability of nitric oxide (NO). S-nitrosoglutathione (GSNO), an S-nitrosylating agent, was found not only to reduce the levels of peroxynitrite but also to protect the integrity of BBB in a rat model of cerebral ischemia and reperfusion (IR). A treatment with GSNO (3 mu mol/kg) after IR reduced 3-nitrotyrosine levels in and around vessels and maintained NO levels in brain. This mechanism protected endothelial function by reducing BBB leakage, increasing the expression of Zonula occludens-1 (ZO-1), decreasing edema, and reducing the expression of matrix metalloproteinase-9 and E-selectin in the neurovascular unit. An administration of the peroxynitrite-forming agent 3-morpholino sydnonimine (3 mu mol/kg) at reperfusion increased BBB leakage and decreased the expression of ZO-1, supporting the involvement of peroxynitrite in BBB disruption and edema. Mechanistically, the endothelium-protecting action of GSNO was invoked by reducing the activity of nuclear factor kappa B and increasing the expression of S-nitrosylated proteins. Taken together, the results support the ability of GSNO to improve endothelial function by reducing nitroxidative stress in stroke.
C1 [Khan, Mushfiquddin; Dhammu, Tajinder S.; Sakakima, Harutoshi; Shunmugavel, Anadakumar; Gilg, Anne G.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Singh, Avtar K.] Med Univ S Carolina, Dept Pathol & Lab Med, Charleston, SC 29425 USA.
[Singh, Avtar K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Singh, I (reprint author), Med Univ S Carolina, Dept Pediat, 171 Ashley Ave, Charleston, SC 29425 USA.
EM khanm@musc.edu
FU NIH [NS-72511, NS-22576, NS-37766]; Veteran Administration; NIH from the
Extramural Research Facilities Program of the National Center for
Research Resources [C06 RR018823, C06 RR015455]
FX These studies were supported by grants from NIH (NS-72511, NS-22576 and
NS-37766) and Veteran Administration merit awards. This work was also
supported by the NIH, Grants C06 RR018823 and No C06 RR015455 from the
Extramural Research Facilities Program of the National Center for
Research Resources. We are grateful to Dr. Tom Smith from the MUSC
Writing Center for his valuable editing and correction of the
manuscript. The authors have no conflict of interest and have not
received grants etc. from any commercial body.
NR 61
TC 19
Z9 19
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD NOV
PY 2012
VL 123
SU 2
SI SI
BP 86
EP 97
DI 10.1111/j.1471-4159.2012.07947.x
PG 12
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 019LK
UT WOS:000309740900010
PM 23050646
ER
PT J
AU Stetler, RA
Leak, RK
Yin, W
Zhang, LL
Wang, SP
Gao, YQ
Chen, J
AF Stetler, R. Anne
Leak, Rehana K.
Yin, Wei
Zhang, Lili
Wang, Suping
Gao, Yanqin
Chen, Jun
TI Mitochondrial biogenesis contributes to ischemic neuroprotection
afforded by LPS pre-conditioning
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article
DE ischemia; ischemic tolerance; mitochondrial biogenesis; neurons;
pre-conditioning
ID RESPIRATORY FACTOR-I; TOLL-LIKE RECEPTORS; BRAIN-INJURY; NEONATAL-RAT;
NEURONS; LIPOPOLYSACCHARIDE; ACTIVATION; GROWTH; DYSFUNCTION; RESISTANCE
AB Although alterations in mitochondrial dynamics are associated with cellular responses to injury, the functional role of these dynamic changes in ischemic neurons is underexplored. One of these dynamic responses to injury includes mitochondrial biogenesis. Various sublethal pre-conditioning stimuli that induce an ischemic-tolerant state [e.g., lipopolysaccharide (LPS)] may also induce mitochondrial biogenesis. Using neuron-enriched cultures, we found that sublethal LPS pre-conditioning induced both ischemic tolerance and markers of mitochondrial biogenesis with overlapping doseresponse temporal kinetics. Sublethal LPS transiently increased the expression of critical components of the mitochondrial transcriptional machinery, including nuclear respiratory factor 1 (NRF1) and mitochondrial transcription factor A (TFAM), as well as mtDNA copy number, mitochondrial protein levels, and markers of functional mitochondria, such as increased cellular ATP content, citrate synthase activity, and maximal respiration capacity. Importantly, knockdown of TFAM abrogated both the induction of mitochondrial biogenesis and the neuroprotective pre-conditioning effects of LPS. Several signaling pathways coordinated these events. AMPK inhibition suppressed NRF1 and TFAM expression by LPS, whereas PI3K/Akt signaling was necessary for the nuclear translocation of NRF1 and subsequent induction of TFAM. This is the first demonstration that LPS pre-conditioning initiates multiple signaling pathways leading to mitochondrial biogenesis in neurons and that these dynamic changes contribute to ischemic tolerance.
C1 [Stetler, R. Anne; Yin, Wei; Zhang, Lili; Wang, Suping; Chen, Jun] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
[Stetler, R. Anne; Zhang, Lili; Gao, Yanqin; Chen, Jun] State Key Lab Med Neurobiol, Shanghai, Peoples R China.
[Stetler, R. Anne; Zhang, Lili; Gao, Yanqin; Chen, Jun] Inst Brain Sci, Shanghai, Peoples R China.
[Stetler, R. Anne; Wang, Suping; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Leak, Rehana K.] Duquesne Univ, Mylan Sch Pharm, Div Pharmaceut Sci, Pittsburgh, PA 15219 USA.
[Stetler, R. Anne; Yin, Wei; Zhang, Lili; Wang, Suping; Chen, Jun] Univ Pittsburgh, Sch Med, Ctr Cerebrovasc Dis Res, Pittsburgh, PA 15261 USA.
RP Chen, J (reprint author), Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA.
EM stetlerra@upmc.edu; chenj2@upmc.edu
RI Gao, Yanqin/I-6790-2016;
OI Gao, Yanqin/0000-0002-4915-9819; Leak, Rehana/0000-0003-2817-7417
FU NIH/NINDS [NS43802, NS45048, NS36736, NS56118]; Chinese Natural Science
Foundation [30670642, 30870794, 81020108021]; VA Career Scientist Award
FX This project was supported by NIH/NINDS grants NS43802, NS45048,
NS36736, and NS56118 (to J.C.); and Chinese Natural Science Foundation
grants 30670642, 30870794, and 81020108021 (to Y.G.). J.C. is the RK
Mellon Endowed Chair of UPMC and a recipient of the VA Career Scientist
Award. We thank Pat Strickler for excellent secretarial support.
NR 43
TC 14
Z9 16
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
J9 J NEUROCHEM
JI J. Neurochem.
PD NOV
PY 2012
VL 123
SU 2
SI SI
BP 125
EP 137
DI 10.1111/j.1471-4159.2012.07951.x
PG 13
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 019LK
UT WOS:000309740900014
PM 23050650
ER
PT J
AU Chen, SZ
Charness, ME
AF Chen, Suzhen
Charness, Michael E.
TI Ethanol disrupts axon outgrowth stimulated by netrin-1, GDNF, and L1 by
blocking their convergent activation of Src family kinase signaling
(Retracted article. See vol. 132, pg. 756, 2015)
SO JOURNAL OF NEUROCHEMISTRY
LA English
DT Article; Retracted Publication
DE alcohol; axon outgrowth; CGN; GDNF; netrin-1; Src family kinase
ID CEREBELLAR GRANULE CELLS; DEPENDENT NEUROPROTECTIVE PROTEIN; NEURITE
OUTGROWTH; TYROSINE PHOSPHORYLATION; ADHESION MOLECULE; NERVOUS-SYSTEM;
LIPID RAFTS; C-RET; NEURONS; GUIDANCE
AB Pre-natal alcohol exposure causes fetal alcohol spectrum disorders (FASD), the most common, preventable cause of developmental disability. The developing cerebellum is particularly vulnerable to the effects of ethanol. We reported that ethanol inhibits the stimulation of axon outgrowth in cerebellar granule neurons (CGN) by NAP, an active motif of activity-dependent neuroprotective protein (ADNP), by blocking NAP activation of Fyn kinase and its downstream signaling molecule, the scaffolding protein Cas. Here, we asked whether ethanol inhibits the stimulation of axon outgrowth by diverse axon guidance molecules through a common action on the Src family kinases (SFK). We first demonstrated that netrin-1, glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule L1 stimulate axon outgrowth in CGNs by activating SFK, Cas, and extracellular signal-regulated kinase 1 and 2 (ERK1/2). The specific SFK inhibitor, PP2, blocked the stimulation of axon outgrowth and the activation of the SFK-Cas-ERK1/2 signaling pathway by each of these axon-guidance molecules. In contrast, brain-derived neurotrophic factor (BDNF) stimulated axon outgrowth and activated ERK1/2 without first activating SFK or Cas. Clinically relevant concentrations of ethanol inhibited axon outgrowth and the activation of the SFK-Cas-ERK1/2 pathway by netrin-1, GDNF, and L1, but did not disrupt BDNF-induced axon outgrowth or ERK1/2 activation. These results indicate that SFK, but not ERK1/2, is a primary target for ethanol inhibition of axon outgrowth. The ability of ethanol to block the convergent activation of the SFK-Cas-ERK1/2 pathway by netrin-1, GDNF, L1, and ADNP could contribute significantly to the pathogenesis of FASD.
C1 [Chen, Suzhen] VA Boston Healthcare Syst, W Roxbury, MA 02132 USA.
Harvard Univ, Dept Neurol, Sch Med, W Roxbury, MA USA.
RP Chen, SZ (reprint author), VA Boston Healthcare Syst, 1400 VFW Pkwy, W Roxbury, MA 02132 USA.
EM suzhen_chen@hms.harvard.edu
FU ABMRF; National Institute on Alcohol Abuse and Alcoholism
[2R01AA012974]; NIAAA, as a component of the Collaborative Initiative on
Fetal Alcohol Spectrum Disorders [U24-AA014811]; Medical Research
Service, Department of Veterans Affairs
FX We thank Carrie Menkari, Devon M. Fitzgerald, and Lazaros Yiannos for
their excellent technical assistance. This study was supported in part
by the ABMRF Award (S. C.), the National Institute on Alcohol Abuse and
Alcoholism Grant 2R01AA012974 (M. E. C.), NIAAA U24-AA014811, as a
component of the Collaborative Initiative on Fetal Alcohol Spectrum
Disorders (M. E. C) and the Medical Research Service, Department of
Veterans Affairs (M. E. C). Dr. Charness is a member of the scientific
advisory board for Allon Therapeutics, which is developing clinical
applications for NAPVSIPQ (NAP). Dr. Charness holds stock options in
Allon Therapeutics, and has two patents related to the study to declare.
This does not alter the authors' adherence to all the Journal of
Neurochemistry policies on sharing data and materials. Conceived and
designed the experiments: SC, MC; Performed the experiments: SC;
Analyzed the data: SC, MC; Wrote the paper: SC, MC.
NR 52
TC 9
Z9 11
U1 1
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3042
EI 1471-4159
J9 J NEUROCHEM
JI J. Neurochem.
PD NOV
PY 2012
VL 123
IS 4
BP 602
EP 612
DI 10.1111/j.1471-4159.2012.07954.x
PG 11
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 021WU
UT WOS:000309916900014
PM 22924694
ER
PT J
AU Zanetta, VC
Rosman, BM
Bromley, B
Shipp, TD
Chow, JS
Campbell, JB
Herndon, CDA
Passerotti, CC
Cendron, M
Retik, AB
Nguyen, HT
AF Zanetta, Vitor C.
Rosman, Brian M.
Bromley, Bryan
Shipp, Thomas D.
Chow, Jeanne S.
Campbell, Jeffrey B.
Herndon, C. D. Anthony
Passerotti, Carlo C.
Cendron, Marc
Retik, Alan B.
Nguyen, Hiep T.
TI Variations in Management of Mild Prenatal Hydronephrosis Among
Maternal-Fetal Medicine Obstetricians, and Pediatric Urologists and
Radiologists
SO JOURNAL OF UROLOGY
LA English
DT Article
DE data collection; hydronephrosis; pediatrics; prenatal diagnosis;
pyelectasis
ID RENAL PELVIS DILATION; ANTENATAL HYDRONEPHROSIS; DETECTED
HYDRONEPHROSIS; CYSTOURETHROGRAPHY; INFANTS
AB Purpose: There are no current guidelines for diagnosing and managing mild prenatal hydronephrosis. Variations in physician approach make it difficult to analyze outcomes and establish optimal management. We determined the variability of diagnostic approach and management regarding prenatal hydronephrosis among maternal-fetal medicine obstetricians, pediatric urologists and pediatric radiologists.
Materials and Methods: Online surveys were sent to mailing lists for national societies for each specialty. Participants were surveyed regarding criteria for diagnosing mild prenatal hydronephrosis and recommendations for postnatal management, including use of antibiotic prophylaxis, followup scheduling and type of followup imaging.
Results: A total of 308 maternal-fetal medicine obstetricians, 126 pediatric urologists and 112 pediatric radiologists responded. Pediatric urologists and radiologists were divided between Society for Fetal Urology criteria and use of anteroposterior pelvic diameter for diagnosis, while maternal-fetal medicine obstetricians preferred using the latter. For postnatal evaluation radiologists preferred using personal criteria, while urologists preferred using anteroposterior pelvic diameter or Society for Fetal Urology grading system. There was wide variation in the use of antibiotic prophylaxis among pediatric urologists. Regarding the use of voiding cystourethrography/radionuclide cystography in patients with prenatal hydronephrosis, neither urologists nor radiologists were consistent in their recommendations. Finally, there was no agreement on length of followup for mild prenatal hydronephrosis.
Conclusions: We observed a lack of uniformity regarding grading criteria in diagnosing hydronephrosis prenatally and postnatally among maternal-fetal medicine obstetricians, pediatric urologists and pediatric radiologists. There was also a lack of agreement on the management of mild intermittent prenatal hydronephrosis, resulting in these cases being managed inconsistently. A unified set of guidelines for diagnosis, evaluation and management of mild intermittent prenatal hydronephrosis would allow more effective evaluation of outcomes.
C1 [Zanetta, Vitor C.; Rosman, Brian M.; Cendron, Marc; Retik, Alan B.; Nguyen, Hiep T.] Childrens Hosp, Dept Urol, Boston, MA 02115 USA.
[Chow, Jeanne S.] Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
[Bromley, Bryan; Shipp, Thomas D.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Campbell, Jeffrey B.] Childrens Hosp, Dept Pediat Urol, Aurora, CO USA.
[Herndon, C. D. Anthony] Univ Virginia, Dept Urol, Charlottesville, VA USA.
[Passerotti, Carlo C.] Univ Sao Paulo, Dept Urol, Sao Paulo, Brazil.
RP Nguyen, HT (reprint author), Childrens Hosp, Dept Urol, Hunnewell 353,300 Longwood Ave, Boston, MA 02115 USA.
EM Hiep.Nguyen@childrens.harvard.edu
NR 23
TC 15
Z9 17
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-5347
J9 J UROLOGY
JI J. Urol.
PD NOV
PY 2012
VL 188
IS 5
BP 1935
EP 1939
DI 10.1016/j.juro.2012.07.011
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 028QY
UT WOS:000310438600091
PM 22999539
ER
PT J
AU Kumar, V
Gu, YH
Basu, S
Berglund, A
Eschrich, SA
Schabath, MB
Forster, K
Aerts, HJWL
Dekker, A
Fenstermacher, D
Goldgof, DB
Hall, LO
Lambin, P
Balagurunathan, Y
Gatenby, RA
Gillies, RJ
AF Kumar, Virendra
Gu, Yuhua
Basu, Satrajit
Berglund, Anders
Eschrich, Steven A.
Schabath, Matthew B.
Forster, Kenneth
Aerts, Hugo J. W. L.
Dekker, Andre
Fenstermacher, David
Goldgof, Dmitry B.
Hall, Lawrence O.
Lambin, Philippe
Balagurunathan, Yoganand
Gatenby, Robert A.
Gillies, Robert J.
TI Radiomics: the process and the challenges
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE Radiomics; Imaging; Image features; Tumor; Segmentation
ID CONTRAST-ENHANCED MRI; FALSE DISCOVERY RATE; IMAGE SEGMENTATION;
GRAPH-CUTS; SPATIAL HETEROGENEITY; SURVIVAL PREDICTION;
FEATURE-SELECTION; CROSS-VALIDATION; TEXTURE ANALYSIS; MEDICAL IMAGES
AB "Radiomics" refers to the extraction and analysis of large amounts of advanced quantitative imaging features with high throughput from medical images obtained with computed tomography, positron emission tomography or magnetic resonance imaging. Importantly, these data are designed to be extracted from standard-of-care images, leading to a very large potential subject pool. Radiomics data are in a mineable form that can be used to build descriptive and predictive models relating image features to phenotypes or gene protein signatures. The core hypothesis of radiomics is that these models, which can include biological or medical data, can provide valuable diagnostic, prognostic or predictive information. The radiomics enterprise can be divided into distinct processes, each with its own challenges that need to be overcome: (a) image acquisition and reconstruction, (b) image segmentation and rendering, (c) feature extraction and feature qualification and (d) databases and data sharing for eventual (e) ad hoc informatics analyses. Each of these individual processes poses unique challenges. For example, optimum protocols for image acquisition and reconstruction have to be identified and harmonized. Also, segmentations have to be robust and involve minimal operator input. Features have to be generated that robustly reflect the complexity of the individual volumes, but cannot be overly complex or redundant. Furthermore, informatics databases that allow incorporation of image features and image annotations, along with medical and genetic data, have to be generated. Finally, the statistical approaches to analyze these data have to be optimized, as radiomics is not a mature field of study. Each of these processes will be discussed in turn, as well as some of their unique challenges and proposed approaches to solve them. The focus of this article will be on images of non-small-cell lung cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kumar, Virendra; Gu, Yuhua; Balagurunathan, Yoganand; Gillies, Robert J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA.
[Basu, Satrajit; Goldgof, Dmitry B.; Hall, Lawrence O.] Univ S Florida, Dept Comp Sci & Engn, Tampa, FL 33620 USA.
[Berglund, Anders; Eschrich, Steven A.; Fenstermacher, David] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Bioinformat, Tampa, FL 33612 USA.
[Schabath, Matthew B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA.
[Forster, Kenneth] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiat Oncol, Tampa, FL 33612 USA.
[Aerts, Hugo J. W. L.; Dekker, Andre; Lambin, Philippe] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Dept Radiat Oncol MAASTRO, Maastricht, Netherlands.
[Gatenby, Robert A.; Gillies, Robert J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, Tampa, FL 33612 USA.
[Aerts, Hugo J. W. L.] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol,Computat Biol & Func, Boston, MA 02115 USA.
RP Gillies, RJ (reprint author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA.
EM robert.gillies@moffitt.org
RI Eschrich, Steven/K-6848-2013; Aerts, Hugo/P-6350-2015; Kumar,
Virendra/H-4874-2016; Schabath, Matthew/J-3763-2016;
OI Gillies, Robert/0000-0002-8888-7747; Aerts, Hugo/0000-0002-2122-2003;
Kumar, Virendra/0000-0002-1569-1989; Schabath,
Matthew/0000-0003-3241-3216; Dekker, Andre/0000-0002-0422-7996
FU NCI NIH HHS [P30 CA076292, U01 CA143062]
NR 97
TC 116
Z9 120
U1 33
U2 83
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0730-725X
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD NOV
PY 2012
VL 30
IS 9
SI SI
BP 1234
EP 1248
DI 10.1016/j.mri.2012.06.010
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 022GO
UT WOS:000309946000005
PM 22898692
ER
PT J
AU Kapur, T
Egger, J
Damato, A
Schmidt, EJ
Viswanathan, AN
AF Kapur, Tina
Egger, Jan
Damato, Antonio
Schmidt, Ehud J.
Viswanathan, Akila N.
TI 3-T MR-guided brachytherapy for gynecologic malignancies
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE Brachytherapy; Segmentation; Bias correction; MR susceptibility
artifact; Visualization; Registration
ID SOCIETY CONSENSUS GUIDELINES; LOCALLY ADVANCED-CARCINOMA;
CERVICAL-CANCER BRACHYTHERAPY; DOSE-RATE BRACHYTHERAPY; AMERICAN
BRACHYTHERAPY; VOLUME PARAMETERS; SEGMENTATION; RECOMMENDATIONS;
RECONSTRUCTION; REGISTRATION
AB Gynecologic malignancies are a leading cause of death in women worldwide. Standard treatment for many primary and recurrent gynecologic cancer cases includes external-beam radiation followed by brachytherapy. Magnetic resonance (MR) imaging is beneficial in diagnostic evaluation, in mapping the tumor location to tailor radiation dose and in monitoring the tumor response to treatment. Initial studies of MR guidance in gynecologic brachytherapy demonstrate the ability to optimize tumor coverage and reduce radiation dose to normal tissues, resulting in improved outcomes for patients.
In this article, we describe a methodology to aid applicator placement and treatment planning for 3 Tesla (3-1) MR-guided brachytherapy that was developed specifically for gynecologic cancers. This methodology has been used in 18 cases from September 2011 to May 2012 in the Advanced Multimodality Image Guided Operating (AMIGO) suite at Brigham and Women's Hospital. AMIGO comprises state-of-the-art tools for MR imaging, image analysis and treatment planning. An MR sequence using three-dimensional (3D)-balanced steady-state free precession in a 3-T MR scanner was identified as the best sequence for catheter identification with ballooning artifact at the tip. 3D treatment planning was performed using MR images. Items in development include software designed to support virtual needle trajectory planning that uses probabilistic bias correction, graph-based segmentation and image registration algorithms. The results demonstrate that 3-T MR image guidance has a role in gynecologic brachytherapy. These novel developments have the potential to improve targeted treatment to the tumor while sparing the normal tissues. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Damato, Antonio; Viswanathan, Akila N.] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
[Damato, Antonio; Viswanathan, Akila N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kapur, Tina; Egger, Jan; Schmidt, Ehud J.] Harvard Univ, Brigham & Womens Hosp, Dept Radiol, Sch Med, Boston, MA 02115 USA.
RP Viswanathan, AN (reprint author), Brigham & Womens Hosp, Dept Radiat Oncol, 75 Francis St, Boston, MA 02115 USA.
EM aviswanathan@lroc.harvand.edu
FU NIH [P41EB015898, P41RR019703, R03EB013792, U54EB005149, K07CA117979]
FX The authors would like to acknowledge the support of the AMIGO clinical
staff in enabling this clinical study; Brendan Whalen and Dan Kacher for
providing AMIGO architectural plans; Sam Song, PhD, for generating the
CAD models of gynecologic devices; Jorgen Hansen for providing photos of
the applicators; and Junichi Tokuda, PhD, for the AMIGO photo. We thank
Prof. Dr. Horst K. Hahn and Fraunhofer MeVis in Bremen, Germany, for
their support by providing an academic license for MeVisLab software. We
thank Barbara Silver for proofreading the manuscript. The work was
supported by NIH grants P41EB015898, P41RR019703, R03EB013792 and
U54EB005149. Dr. Viswanathan has received support from NIH grant
K07CA117979.
NR 40
TC 36
Z9 36
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0730-725X
EI 1873-5894
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD NOV
PY 2012
VL 30
IS 9
SI SI
BP 1279
EP 1290
DI 10.1016/j.mri.2012.06.003
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 022GO
UT WOS:000309946000009
PM 22898699
ER
PT J
AU Kurland, BF
Gerstner, ER
Mountz, JM
Schwartz, LH
Ryan, CW
Graham, MM
Buatti, JM
Fennessy, FM
Eikman, EA
Kumar, V
Forster, KM
Wahl, RL
Lieberman, FS
AF Kurland, Brenda F.
Gerstner, Elizabeth R.
Mountz, James M.
Schwartz, Lawrence H.
Ryan, Christopher W.
Graham, Michael M.
Buatti, John M.
Fennessy, Fiona M.
Eikman, Edward A.
Kumar, Virendra
Forster, Kenneth M.
Wahl, Richard L.
Lieberman, Frank S.
TI Promise and pitfalls of quantitative imaging in oncology clinical trials
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE MRI; CT; PET; Quantitative imaging; Clinical trials; Cancer
ID POSITRON-EMISSION-TOMOGRAPHY; ADVANCED BREAST-CANCER; GASTROINTESTINAL
STROMAL TUMORS; CELL LUNG-CANCER; APPARENT DIFFUSION-COEFFICIENT;
STANDARDIZED UPTAKE VALUES; LOCALIZED PROSTATE-CANCER; SOFT-TISSUE
SARCOMAS; NEOADJUVANT CHEMOTHERAPY; RESPONSE CRITERIA
AB Quantitative imaging using computed tomography, magnetic resonance imaging and positron emission tomography modalities will play an increasingly important role in the design of oncology trials addressing molecularly targeted, personalized therapies. The advent of molecularly targeted therapies, exemplified by antiangiogenic drugs, creates new complexities in the assessment of response. The Quantitative Imaging Network addresses the need for imaging modalities which can accurately and reproducibly measure not just change in tumor size but changes in relevant metabolic parameters, modulation of relevant signaling pathways, drug delivery to tumor and differentiation of apoptotic cell death from other changes in tumor volume. This article provides an overview of the applications of quantitative imaging to phase 0 through phase 3 oncology trials. We describe the use of a range of quantitative imaging modalities in specific tumor types including malignant gliomas, lung cancer, head and neck cancer, lymphoma, breast cancer, prostate cancer and sarcoma. In the concluding section, we discuss potential constraints on clinical trials using quantitative imaging, including complexity of trial conduct, impact on subject recruitment, incremental costs and institutional barriers. Strategies for overcoming these constraints are presented. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kurland, Brenda F.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98019 USA.
[Gerstner, Elizabeth R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Mountz, James M.; Lieberman, Frank S.] Univ Pittsburgh, Pittsburgh, PA USA.
[Schwartz, Lawrence H.] Columbia Univ, New York, NY USA.
[Ryan, Christopher W.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Graham, Michael M.; Buatti, John M.] Univ Iowa, Iowa City, IA USA.
[Fennessy, Fiona M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Eikman, Edward A.; Kumar, Virendra; Forster, Kenneth M.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Wahl, Richard L.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
RP Kurland, BF (reprint author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98019 USA.
EM bkurland@fhcrc.org
RI Kumar, Virendra/H-4874-2016;
OI Kumar, Virendra/0000-0002-1569-1989; Kurland, Brenda/0000-0002-5669-0595
FU National Institutes of Health, Quantitative Imaging Network
[U01-CA148131]
FX This work is supported by the National Institutes of Health,
Quantitative Imaging Network (U01-CA148131). The authors are grateful to
Robert Nordstrom, Larry Clarke, Hannah Linden, David Mankoff, Mark Muzi,
Savannah Partridge, Mia Levy and Daniel Rubin for helpful discussions
and to Alicia DePastino for administrative support.
NR 103
TC 27
Z9 27
U1 0
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0730-725X
EI 1873-5894
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD NOV
PY 2012
VL 30
IS 9
SI SI
BP 1301
EP 1312
DI 10.1016/j.mri.2012.06.009
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 022GO
UT WOS:000309946000011
PM 22898682
ER
PT J
AU Fedorov, A
Beichel, R
Kalpathy-Cramer, J
Finet, J
Fillion-Robin, JC
Pujol, S
Bauer, C
Jennings, D
Fennessy, F
Sonka, M
Buatti, J
Aylward, S
Miller, JV
Pieper, S
Kikinis, R
AF Fedorov, Andriy
Beichel, Reinhard
Kalpathy-Cramer, Jayashree
Finet, Julien
Fillion-Robin, Jean-Christophe
Pujol, Sonia
Bauer, Christian
Jennings, Dominique
Fennessy, Fiona
Sonka, Milan
Buatti, John
Aylward, Stephen
Miller, James V.
Pieper, Steve
Kikinis, Ron
TI 3D Slicer as an image computing platform for the Quantitative Imaging
Network
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE Cancer imaging; Quantitative imaging; Software tools; Medical imaging;
Imaging biomarkers; Image analysis; MRI; PET; CT; Brain; Head and neck;
Prostate; Glioblastima; Cancer treatment response
ID RESPONSE CRITERIA; SOLID TUMORS; MRI DATA; VISUALIZATION; DIFFUSION;
SEGMENTATION; TRACTOGRAPHY; SYSTEM; DICOM; THERAPY
AB Quantitative analysis has tremendous but mostly unrealized potential in healthcare to support objective and accurate interpretation of the clinical imaging. In 2008, the National Cancer Institute began building the Quantitative Imaging Network (QIN) initiative with the goal of advancing quantitative imaging in the context of personalized therapy and evaluation of treatment response. Computerized analysis is an important component contributing to reproducibility and efficiency of the quantitative imaging techniques. The success of quantitative imaging is contingent on robust analysis methods and software tools to bring these methods from bench to bedside.
3D Slicer is a free open-source software application for medical image computing. As a clinical research tool, 3D Slicer is similar to a radiology workstation that supports versatile visualizations but also provides advanced functionality such as automated segmentation and registration for a variety of application domains. Unlike a typical radiology workstation, 3D Slicer is free and is not tied to specific hardware. As a programming platform, 3D Slicer facilitates translation and evaluation of the new quantitative methods by allowing the biomedical researcher to focus on the implementation of the algorithm and providing abstractions for the common tasks of data communication, visualization and user interface development. Compared to other tools that provide aspects of this functionality, 3D Slicer is fully open source and can be readily extended and redistributed. In addition, 3D Slicer is designed to facilitate the development of new functionality in the form of 3D Slicer extensions.
In this paper, we present an overview of 3D Slicer as a platform for prototyping, development and evaluation of image analysis tools for clinical research applications. To illustrate the utility of the platform in the scope of QIN, we discuss several use cases of 3D Slicer by the existing QIN teams, and we elaborate on the future directions that can further facilitate development and validation of imaging biomarkers using 3D Slicer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Fedorov, Andriy; Pujol, Sonia; Fennessy, Fiona; Kikinis, Ron] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Beichel, Reinhard; Bauer, Christian; Sonka, Milan; Buatti, John] Univ Iowa, Iowa City, IA 52242 USA.
[Kalpathy-Cramer, Jayashree; Jennings, Dominique] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Charlestown, MA 02129 USA.
[Finet, Julien; Fillion-Robin, Jean-Christophe; Aylward, Stephen] Kitware Inc, Clifton Pk, NY 12065 USA.
[Miller, James V.] GE Res, Niskayuna, NY 12309 USA.
[Pieper, Steve] Isomics Inc, Cambridge, MA 02138 USA.
RP Fedorov, A (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
EM fedorov@bwh.harvard.edu
OI Kalpathy-Cramer, Jayashree/0000-0001-8906-9618; Fedorov,
Andrey/0000-0003-4806-9413
FU NIH [U01CA151261, P41EB015898, P41RR13218, U54EB005149, 1R01CA111288,
U01-CA140206, 1U01CA154601-01, 4R00LM009889-03]
FX We would like to thank all current and past users and developers of 3D
Slicer for their contribution to this software. The authors have been
supported in part by the following NIH grants. BWH: U01CA151261,
P41EB015898, P41RR13218, U54EB005149 and 1R01CA111288; University of
Iowa: U01-CA140206; GE: P41RR13218 and U54EB005149; MGH: 1U01CA154601-01
and 4R00LM009889-03. We are grateful to the various agencies and
programs that funded support and development of 3D Slicer over the
years.
NR 69
TC 411
Z9 422
U1 11
U2 76
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0730-725X
EI 1873-5894
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD NOV
PY 2012
VL 30
IS 9
SI SI
BP 1323
EP 1341
DI 10.1016/j.mri.2012.05.001
PG 19
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 022GO
UT WOS:000309946000013
PM 22770690
ER
PT J
AU Yankeelov, TE
Peterson, TE
Abramson, RG
Garcia-Izquierdo, D
Arlinghaus, LR
Li, X
Atuegwu, NC
Catana, C
Manning, HC
Fayad, ZA
Gore, JC
AF Yankeelov, Thomas E.
Peterson, Todd E.
Abramson, Richard G.
Garcia-Izquierdo, David
Arlinghaus, Lori R.
Li, Xia
Atuegwu, Nkiruka C.
Catana, Ciprian
Manning, H. Charles
Fayad, Zahi A.
Gore, John C.
TI Simultaneous PET-MRI m oncology: a solution looking for a problem?
SO MAGNETIC RESONANCE IMAGING
LA English
DT Article
DE PET; MRI; Attenuation; Motion; Reconstruction; AIF; Multimodality
ID POSITRON-EMISSION-TOMOGRAPHY; PARTIAL-VOLUME CORRECTION; IRON-OXIDE
NANOPARTICLES; IN-VIVO EVALUATION; WHOLE-BODY MRI; MAGNETIC-RESONANCE;
ATTENUATION-CORRECTION; COMPUTED-TOMOGRAPHY; RESPIRATORY MOTION;
SIMULTANEOUS PET/MRI
AB With the recent development of integrated positron emission tomography magnetic resonance imaging (PET-MRI) scanners, new possibilities for quantitative molecular imaging of cancer are realized. However, the practical advantages and potential clinical benefits of the ability to record PET and MRI data simultaneously must be balanced against the substantial costs and other requirements of such devices. In this review, we highlight several of the key areas where integrated PET MRI measurements, obtained simultaneously, are anticipated to have a significant impact on clinical and/or research studies. These areas include the use of MR-based motion corrections and/or a priori anatomical information for improved reconstruction of PET data, improved arterial input function characterization for PET kinetic modeling, the use of dual-modality contrast agents, and patient comfort and practical convenience. For widespread acceptance, a compelling case could be made if the combination of quantitative MRI and specific PET biomarkers significantly improves our ability to assess tumor status and response to therapy, and some likely candidates are now emerging. We consider the relative advantages and disadvantages afforded by PET MRI and summarize current opinions and evidence as to the likely value of PET MRI in the management of cancer. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Yankeelov, Thomas E.] Vanderbilt Univ, Inst Imaging Sci, Med Ctr, Med Ctr N AA 1105, Nashville, TN 37232 USA.
[Yankeelov, Thomas E.; Peterson, Todd E.; Abramson, Richard G.; Arlinghaus, Lori R.; Li, Xia; Atuegwu, Nkiruka C.; Manning, H. Charles; Gore, John C.] Vanderbilt Univ, Dept Radiol & Radiol Sci, Nashville, TN 37232 USA.
[Yankeelov, Thomas E.; Peterson, Todd E.; Gore, John C.] Vanderbilt Univ, Dept Phys & Astron, Nashville, IN 37232 USA.
[Yankeelov, Thomas E.; Manning, H. Charles; Gore, John C.] Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37232 USA.
[Yankeelov, Thomas E.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA.
[Garcia-Izquierdo, David; Fayad, Zahi A.] Mt Sinai Med Ctr, Translat & Mol Imaging Inst, New York, NY 10029 USA.
[Garcia-Izquierdo, David; Fayad, Zahi A.] Mt Sinai Med Ctr, Dept Radiol, New York, NY 10029 USA.
[Catana, Ciprian] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Catana, Ciprian] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Manning, H. Charles] Vanderbilt Univ, Dept Neurosurg, Nashville, TN 37232 USA.
[Fayad, Zahi A.] Mt Sinai Med Ctr, Dept Cardiol, New York, NY 10029 USA.
[Gore, John C.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA.
RP Yankeelov, TE (reprint author), Vanderbilt Univ, Inst Imaging Sci, Med Ctr, Med Ctr N AA 1105, Nashville, TN 37232 USA.
EM thomas.yankeelov@vanderbilt.edu
FU National Institutes of Health [NCI U01 CA142565, NCI R01CA138599, NCI
1P50 CA098131, NCI P30 CA68485, NCI 1R01 CA140628, NCI K25 CA127349, NCI
1RC1 CA145138, NHLBI R01 HL071021, R01 HL078667, NCI 1 R01
CA137254-01A1, NCI U01CA154601-01]
FX T.E.Y., T.E.P, H.C.M., L.R.A., X.L., N.C.A. and J.C.G. thank the
National Institutes of Health for support through NCI U01 CA142565, NCI
R01CA138599, NCI 1P50 CA098131, NCI P30 CA68485, NCI 1R01 CA140628, NCI
K25 CA127349 and NCI 1RC1 CA145138. Additionally, we thank the Kleberg
Foundation for generous support of the molecular imaging program at
Vanderbilt University. D.I.G. and Z.A.F. thank the NIH for support
through NHLBI R01 HL071021 and R01 HL078667. C.C. and B.R. thank the NIH
for support through NCI 1 R01 CA137254-01A1 and NCI U01CA154601-01. We
thank Dr. Bruce Rosen, M.D., Ph.D. for reviewing and editing an early
version of the manuscript.
NR 99
TC 41
Z9 42
U1 1
U2 32
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0730-725X
EI 1873-5894
J9 MAGN RESON IMAGING
JI Magn. Reson. Imaging
PD NOV
PY 2012
VL 30
IS 9
SI SI
BP 1342
EP 1356
DI 10.1016/j.mri.2012.06.001
PG 15
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 022GO
UT WOS:000309946000014
PM 22795930
ER
PT J
AU Danagoulian, GS
Qin, L
Nayak, KS
Colen, RR
Mukundan, S
Harris, MB
Jolesz, FA
Shankaranarayanan, A
Copen, WA
Schmidt, EJ
AF Danagoulian, Giovanna S.
Qin, Lei
Nayak, Krishna S.
Colen, Rivka R.
Mukundan, Srinivasan, Jr.
Harris, Mitchell B.
Jolesz, Ferenc A.
Shankaranarayanan, Ajit
Copen, William A.
Schmidt, Ehud J.
TI Comparison of wideband steady-state free precession and T2-weighted fast
spin echo in spine disorder assessment at 1.5 and 3 T
SO MAGNETIC RESONANCE IN MEDICINE
LA English
DT Article
DE MRI; Spine; Myelography; nerves
ID LOW-BACK-PAIN; MAGNETIZATION-TRANSFER; DIFFUSION; MYELOGRAPHY;
RESOLUTION; TISSUE; TESLA; SSFP; CT
AB Wideband steady-state free precession (WB-SSFP) is a modification of balanced steady-state free precession utilizing alternating repetition times to reduce susceptibility-induced balanced steady-state free precession limitations, allowing its use for high-resolution myelographic-contrast spinal imaging. Intertissue contrast and spatial resolution of complete-spine-coverage 3D WB-SSFP were compared with those of 2D T2-weighted fast spin echo, currently the standard for spine T2-imaging. Six normal subjects were imaged at 1.5 and 3 T. The signal-to-noise ratio efficiency (SNR per unit-time and unit-volume) of several tissues was measured, along with four intertissue contrast-to-noise ratios; nerve-ganglia:fat, intradural-nerves:cerebrospinal fluid, nerve-ganglia:muscle, and muscle:fat. Patients with degenerative and traumatic spine disorders were imaged at both MRI fields to demonstrate WB-SSFP clinical advantages and disadvantages. At 3 T, WB-SSFP provided spinal contrast-to-noise ratios 3.75.2 times that of fast spin echo. At 1.5 T, WB-SSFP contrast-to-noise ratio was 33.5 times that of fast spin echo, excluding a 1.7 ratio for intradural-nerves:cerebrospinal fluid. WB-SSFP signal-to-noise ratio efficiency was also higher. Three-dimensional WB-SSFP disadvantages relative to 2D fast spin echo are reduced edema hyperintensity, reduced muscle signal, and higher motion sensitivity. WB-SSFP's high resolution and contrast-to-noise ratio improved visualization of intradural nerve bundles, foraminal nerve roots, and extradural nerve bundles, improving detection of nerve compression in radiculopathy and spinal-stenosis. WB-SSFP's high resolution permitted reformatting into orthogonal planes, providing distinct advantages in gauging fine spine pathology. Magn Reson Med, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Danagoulian, Giovanna S.; Qin, Lei; Colen, Rivka R.; Mukundan, Srinivasan, Jr.; Jolesz, Ferenc A.; Schmidt, Ehud J.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Nayak, Krishna S.] Univ So Calif, Dept Elect Engn, Los Angeles, CA 90089 USA.
[Harris, Mitchell B.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Shankaranarayanan, Ajit] GE Healthcare Appl Sci Lab, Menlo Pk, CA USA.
[Copen, William A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Schmidt, EJ (reprint author), Brigham & Womens Hosp, Dept Radiol, Rm 11C,221 Longwood Ave, Boston, MA 02115 USA.
EM eschmidt3@partners.org
FU NIH [U41RR019703, R25-CA89017-06A2]
FX Grant sponsor: NIH; Grant numbers: U41RR019703 and R25-CA89017-06A2
NR 30
TC 0
Z9 1
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0740-3194
J9 MAGN RESON MED
JI Magn. Reson. Med.
PD NOV
PY 2012
VL 68
IS 5
BP 1527
EP 1535
DI 10.1002/mrm.24163
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 023UR
UT WOS:000310062300019
PM 22287191
ER
PT J
AU Korenjak, M
Anderssen, E
Ramaswamy, S
Whetstine, JR
Dyson, NJ
AF Korenjak, Michael
Anderssen, Endre
Ramaswamy, Sridhar
Whetstine, Johnathan R.
Dyson, Nicholas J.
TI RBF Binding to both Canonical E2F Targets and Noncanonical Targets
Depends on Functional dE2F/dDP Complexes
SO MOLECULAR AND CELLULAR BIOLOGY
LA English
DT Article
ID RETINOBLASTOMA TUMOR-SUPPRESSOR; CELL-CYCLE PROGRESSION; TRANSCRIPTION
FACTOR; DROSOPHILA EMBRYOGENESIS; PROLIFERATING CELLS; CDC2 PROMOTER;
PROTEIN; DIFFERENTIATION; GENE; EXPRESSION
AB The retinoblastoma (RB) family of proteins regulate transcription. These proteins lack intrinsic DNA-binding activity but are recruited to specific genomic locations through interactions with sequence-specific DNA-binding factors. The best-known target of RB protein (pRB) is the E2F transcription factor; however, many other chromatin-associated proteins have been described that may allow RB family members to act at additional sites. To gain a perspective on the scale of E2F-dependent and E2F-independent functions, we generated genome-wide binding profiles of RBF1 and dE2F proteins in Drosophila larvae. RBF1 and dE2F2 associate with a large number of binding sites at genes with diverse biological functions. In contrast, dE2F1 was detected at a smaller set of promoters, suggesting that it overrides repression by RBF1/dE2F2 at a specific subset of targets. Approximately 15% of RBF1-bound regions lacked consensus E2F-binding motifs. To test whether RBF1 action at these sites is E2F independent, we examined dDP mutant larvae that lack any functional dE2F/dDP heterodimers. As measured by chromatin immunoprecipitation-microarray analysis (ChIP-chip), ChIP-quantitative PCR (qPCR), and cell fractionation, the stable association of RBF1 with chromatin was eliminated in dDP mutants. This requirement for dDP was seen at classic E2F-regulated promoters and at promoters that lacked canonical E2F-binding sites. These results suggest that E2F/DP complexes are essential for all genomic targeting of RBF1.
C1 [Dyson, Nicholas J.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Dyson, NJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA.
EM Dyson@helix.mgh.harvard.edu
FU Tosteson Postdoctoral Fellowship Award; DFG Forschungsstipendium;
National Cancer Institute; National Institutes of Health [R01CA64402,
GM053203]; Ellison Medical Foundation [CA059267, R01GM097360]
FX M.K. was supported by a Tosteson Postdoctoral Fellowship Award and a DFG
Forschungsstipendium. Research reported in this publication was
supported by awards from the National Cancer Institute and National
Institutes of Health grants R01CA64402 and GM053203 (to N.J.D). N.J.D.
is the Saltonstall Scholar of the Massachusetts General Hospital Cancer
Center. J.R.W. is supported by the Ellison Medical Foundation, grants
CA059267 and R01GM097360.
NR 68
TC 21
Z9 22
U1 0
U2 3
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0270-7306
J9 MOL CELL BIOL
JI Mol. Cell. Biol.
PD NOV
PY 2012
VL 32
IS 21
BP 4375
EP 4387
DI 10.1128/MCB.00536-12
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 022OS
UT WOS:000309969300011
PM 22927638
ER
PT J
AU Bourdette, D
Yadav, V
AF Bourdette, Dennis
Yadav, Vijayshree
TI Treat patients with radiologically isolated syndrome when the MRI brain
scan shows dissemination in time: No
SO MULTIPLE SCLEROSIS JOURNAL
LA English
DT Editorial Material
ID UNSUSPECTED MULTIPLE-SCLEROSIS
C1 [Bourdette, Dennis; Yadav, Vijayshree] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Bourdette, Dennis; Yadav, Vijayshree] Portland VA Med Ctr, MS Ctr Excellence W, Portland, OR USA.
RP Bourdette, D (reprint author), Oregon Hlth & Sci Univ, Dept Neurol L226, Portland, OR 97239 USA.
EM bourdett@ohsu.edu
NR 10
TC 6
Z9 6
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1352-4585
J9 MULT SCLER J
JI Mult. Scler. J.
PD NOV
PY 2012
VL 18
IS 11
BP 1529
EP 1530
DI 10.1177/1352458512462075
PG 2
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 026BM
UT WOS:000310245100005
PM 23100523
ER
PT J
AU Calado, DP
Sasaki, Y
Godinho, SA
Pellerin, A
Kochert, K
Sleckman, BP
de Alboran, IM
Janz, M
Rodig, S
Rajewsky, K
AF Calado, Dinis Pedro
Sasaki, Yoshiteru
Godinho, Susana A.
Pellerin, Alex
Koechert, Karl
Sleckman, Barry P.
Moreno de Alboran, Ignacio
Janz, Martin
Rodig, Scott
Rajewsky, Klaus
TI The cell-cycle regulator c-Myc is essential for the formation and
maintenance of germinal centers
SO NATURE IMMUNOLOGY
LA English
DT Article
ID CENTER B-CELLS; TRANSCRIPTION FACTOR; KAPPA-B; PROTOONCOGENE EXPRESSION;
GENE-EXPRESSION; IN-VIVO; BCL6; RESPONSES; ORIGIN; MICE
AB Germinal centers (GCs) are sites of intense B cell proliferation and are central for T cell dependent antibody responses. However, the role of c-Myc, a key cell-cycle regulator, in this process has been questioned. Here we identified c-Myc(+) B cell subpopulations in immature and mature GCs and found, by genetic ablation of Myc, that they had indispensable roles in the formation and maintenance of GCs. The identification of these functionally critical cellular subsets has implications for human B cell lymphomagenesis, which originates mostly from GC B cells and frequently involves MYC chromosomal translocations. As these translocations are generally dependent on transcription of the recombining partner loci, the c-Myc(+) GC subpopulations may be at a particularly high risk for malignant transformation.
C1 [Calado, Dinis Pedro; Pellerin, Alex; Rajewsky, Klaus] Harvard Univ, Childrens Hosp, Program Cellular & Mol Med, Sch Med, Boston, MA 02115 USA.
[Calado, Dinis Pedro; Pellerin, Alex; Rajewsky, Klaus] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA USA.
[Calado, Dinis Pedro; Koechert, Karl; Janz, Martin; Rajewsky, Klaus] Max Delbruck Ctr Mol Med, Berlin, Germany.
[Sasaki, Yoshiteru] Kyoto Univ, Dept Mol & Cellular Physiol, Grad Sch Med, Kyoto, Japan.
[Godinho, Susana A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol,Dept Cell Biol, Boston, MA 02115 USA.
[Sleckman, Barry P.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Moreno de Alboran, Ignacio] Natl Biotechnol Ctr, Dept Immunol & Oncol, Madrid, Spain.
[Janz, Martin] Univ Med Sch, Charite, Berlin, Germany.
[Rodig, Scott] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Calado, DP (reprint author), Harvard Univ, Childrens Hosp, Program Cellular & Mol Med, Sch Med, Boston, MA 02115 USA.
EM dinis.calado@mdc-berlin.de; klaus.rajewsky@mdc-berlin.de
FU National Cancer Institute [PO1CA092625]; Leukemia and Lymphoma Society;
European Research Council
FX We thank D. Ghitza, J. Wang, J. Grundy, J. Xia, C. Grosse, B.
Wollert-Wulff and M. Bamberg for technical assistance; M. Ottaviano and
M. Bezohra for administrative assistance; the Rajewsky laboratory
members for critical comments and suggestions; and D. Dominguez-Sola and
R. Dalla-Favera for sharing unpublished results. Supported by the
National Cancer Institute (PO1CA092625 to KR.), the Leukemia and
Lymphoma Society (KR. and D.P.C.) and the European Research Council
(KR.).
NR 48
TC 77
Z9 78
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD NOV
PY 2012
VL 13
IS 11
BP 1092
EP 1100
DI 10.1038/ni.2418
PG 9
WC Immunology
SC Immunology
GA 024EO
UT WOS:000310091700012
PM 23001146
ER
PT J
AU Gautier, EL
Shay, T
Miller, J
Greter, M
Jakubzick, C
Ivanov, S
Helft, J
Chow, A
Elpek, KG
Gordonov, S
Mazloom, AR
Ma'ayan, A
Chua, WJ
Hansen, TH
Turley, SJ
Merad, M
Randolph, GJ
AF Gautier, Emmanuel L.
Shay, Tal
Miller, Jennifer
Greter, Melanie
Jakubzick, Claudia
Ivanov, Stoyan
Helft, Julie
Chow, Andrew
Elpek, Kutlu G.
Gordonov, Simon
Mazloom, Amin R.
Ma'ayan, Avi
Chua, Wei-Jen
Hansen, Ted H.
Turley, Shannon J.
Merad, Miriam
Randolph, Gwendalyn J.
CA Immunological Genome Consortium
TI Gene-expression profiles and transcriptional regulatory pathways that
underlie the identity and diversity of mouse tissue macrophages
SO NATURE IMMUNOLOGY
LA English
DT Article
ID DENDRITIC CELL; STEADY-STATE; BONE-MARROW; IN-VIVO; DIFFERENTIATION;
HETEROGENEITY; PROGENITORS; HOMEOSTASIS; ACTIVATION; REVEALS
AB We assessed gene expression in tissue macrophages from various mouse organs. The diversity in gene expression among different populations of macrophages was considerable. Only a few hundred mRNA transcripts were selectively expressed by macrophages rather than dendritic cells, and many of these were not present in all macrophages. Nonetheless, well-characterized surface markers, including MerTK and Fc gamma R1 (CD64), along with a cluster of previously unidentified transcripts, were distinctly and universally associated with mature tissue macrophages. TCEF3, C/EBP-alpha, Bach1 and CREG-1 were among the transcriptional regulators predicted to regulate these core macrophage-associated genes. The mRNA encoding other transcription factors, such as Gata6, was associated with single macrophage populations. We further identified how these transcripts and the proteins they encode facilitated distinguishing macrophages from dendritic cells.
C1 [Gautier, Emmanuel L.; Jakubzick, Claudia; Randolph, Gwendalyn J.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA.
[Gautier, Emmanuel L.; Miller, Jennifer; Greter, Melanie; Jakubzick, Claudia; Helft, Julie; Chow, Andrew; Merad, Miriam; Randolph, Gwendalyn J.] Mt Sinai Sch Med, Inst Immunol, New York, NY USA.
[Gautier, Emmanuel L.; Ivanov, Stoyan; Chua, Wei-Jen; Hansen, Ted H.; Randolph, Gwendalyn J.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA.
[Miller, Jennifer; Greter, Melanie; Helft, Julie; Chow, Andrew; Merad, Miriam] Mt Sinai Sch Med, Dept Med, New York, NY USA.
[Miller, Jennifer; Greter, Melanie; Helft, Julie; Chow, Andrew; Merad, Miriam] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY USA.
[Shay, Tal] Broad Inst, Cambridge, MA USA.
[Elpek, Kutlu G.; Turley, Shannon J.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
[Elpek, Kutlu G.; Turley, Shannon J.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Gordonov, Simon; Mazloom, Amin R.; Ma'ayan, Avi] Mt Sinai Sch Med, Dept Pharmacol, New York, NY USA.
[Gordonov, Simon; Mazloom, Amin R.; Ma'ayan, Avi] Mt Sinai Sch Med, Syst Therapeut & Syst Biol Ctr New York, New York, NY USA.
RP Randolph, GJ (reprint author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA.
EM grandolph@path.wustl.edu
RI Shay, Tal/J-4028-2016; Gautier, Emmanuel L./E-2259-2017;
OI Shay, Tal/0000-0003-0755-1350; Gautier, Emmanuel L./0000-0003-2976-7566;
Yankelevich, Wei-Jen/0000-0002-5234-7845; Malhotra,
Deepali/0000-0002-8215-7639; Ivanov, Stoyan/0000-0002-0527-2297; Gazit,
Roi/0000-0002-0548-2147; Kim, Charles/0000-0001-6474-8227
FU National Institute of Allergy and Infectious Diseases of the US National
Institutes of Health [R24 AI072073]; US National Institutes of Health
[R01AI049653, R01AI061741, P50GM071558-03, R01DK08854, 5T32DA007135-27];
American Heart Association [10POST4160140]
FX We thank our colleagues of the ImmGen Project consortium; V. Jojic, J.
Ericson, S. Davis and C. Benoist for contributions; eBioscience and
Affymetrix for material support of the ImmGen Project; and M. Colonna
(Washington University School of Medicine) for monoclonal antibodies
(including anti-Siglec-H) and other reagents. Supported by the National
Institute of Allergy and Infectious Diseases of the US National
Institutes of Health (R24 AI072073 to fund the ImmGen Project,
spearheaded by C. Benoist), the US National Institutes of Health
(R01AI049653 and R01AI061741 to G.J.R.; P50GM071558-03 and R01DK08854 to
A.M.; and5T32DA007135-27 to ARM.) and the American Heart Association
(10POST4160140 to E.L.G.).
NR 34
TC 489
Z9 494
U1 11
U2 63
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1529-2908
J9 NAT IMMUNOL
JI Nat. Immunol.
PD NOV
PY 2012
VL 13
IS 11
BP 1118
EP 1128
DI 10.1038/ni.2419
PG 11
WC Immunology
SC Immunology
GA 024EO
UT WOS:000310091700015
PM 23023392
ER
PT J
AU Stelmack, JA
Tang, XYC
Reda, DJ
Stroupe, KT
Rinne, S
Massof, RW
AF Stelmack, Joan A.
Tang, Xiaoyin C.
Reda, Domenic J.
Stroupe, Kevin T.
Rinne, Stephen
Massof, Robert W.
CA LOVIT II Study Grp
TI VA LOVIT II: a protocol to compare low vision rehabilitation and basic
low vision
SO OPHTHALMIC AND PHYSIOLOGICAL OPTICS
LA English
DT Article
DE low vision; low vision rehabilitation; reading rehabilitation; vision
rehabilitation
ID QUALITY-OF-LIFE; VISUAL FUNCTIONING QUESTIONNAIRE; INTERVENTION TRIAL
LOVIT; VETERANS-AFFAIRS; IMPAIRED VISION; MACULAR DEGENERATION;
OLDER-PEOPLE; DEPRESSION; OUTCOMES; HEALTH
AB Citation information: Stelmack JA, Tang XC, Reda DJ, Stroupe KT, Rinne S & Massof RW. VA LOVIT II: a protocol to compare low vision rehabilitation and basic low vision. Ophthalmic Physiol Opt 2012, 32, 461471. doi: 10.1111/j.1475-1313.2012.00933.x Abstract Purpose: To compare the effectiveness of low vision rehabilitation (LVR) and basic low vision (LV) in a single masked multicentre randomised controlled trial (RCT). Methods: Three hundred and thirty patients eligible for US. Veterans Affairs (VA) healthcare services with primary eye diagnosis (better-seeing eye) of macular disease and best-corrected distance visual acuity of 0.401.00 logMAR (6/15 to 6/60 or 20/50 to 20/200 Snellen) are being enrolled at seven VA facilities. All participants receive an optometric LV examination; and they are eligible to receive the same LV devices that are provided without charge. In LVR, a LV therapist dispenses devices and provides 2 or 3 (1(1/2) to 2(1/2) h) therapy sessions with assigned homework to teach effective use of remaining vision and LV devices. Contact time with the therapist depends upon the devices prescribed and the patients progress in learning the skills that are taught. In basic LV, devices are dispensed by the optometrist without LV therapy. Contact time for dispensing is one hour or less depending on LV devices prescribed. The primary outcome measure is a comparison of the changes in visual reading ability (estimated from patients difficulty ratings of reading items on the VA LV VFQ-48 questionnaire) between the treatment and control arms from pre-intervention baseline to 4 months (2 months after completion of treatment). Secondary outcome measures are changes in overall visual ability, visual ability domain scores calculated from subsets of items (mobility, visual information processing and visual motor skills), Short Form-36, and Minnesota Low Vision Reading Test scores. Cost-effectiveness analysis will be conducted using VA LV VFQ-48 scores and QALYS computed from EuroQol scores. Results: A total of 137 patients representing 41.5% of the study target of 330 patients were randomised from October 2010 to March 2012. Among those 137 patients, mean age was 80.2 (S.D. +/- 9.9) years at enrollment; 97.1% of the patients were males; 94.2% were white. Mean best corrected VA was 0.65 (S.D. +/- 0.3) logMAR (approximately Snellen 6/27 or 20/90) at baseline. Conclusions: LOVIT II is the first multicentre RCT comparing the effectiveness and cost-effectiveness of LVR and basic LV for patients with macular diseases and near normal or moderate levels of visual impairment.
C1 [Stelmack, Joan A.; Tang, Xiaoyin C.; Reda, Domenic J.; Stroupe, Kevin T.; Rinne, Stephen] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Hines, IL 60141 USA.
[Stelmack, Joan A.] Univ Illinois, Chicago Sch Med, Dept Ophthalmol & Visual Sci, Chicago, IL USA.
[Stelmack, Joan A.; Rinne, Stephen] Illinois Coll Optometry, Chicago, IL USA.
[Massof, Robert W.] Johns Hopkins Wilmer Eye Inst, Baltimore, MD USA.
RP Stelmack, JA (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
EM joan.stelmack@med.va.gov
RI Raasch, Thomas/A-3588-2013
FU Department of Veterans Affairs Rehabilitation Research and Development
Service [C958R]
FX Funding for this research was provided by the Department of Veterans
Affairs Rehabilitation Research and Development Service grant C958R.
NR 42
TC 4
Z9 4
U1 2
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0275-5408
J9 OPHTHAL PHYSL OPT
JI Ophthalmic Physiol. Opt.
PD NOV
PY 2012
VL 32
IS 6
BP 461
EP 471
DI 10.1111/j.1475-1313.2012.00933.x
PG 11
WC Ophthalmology
SC Ophthalmology
GA 019NW
UT WOS:000309747600004
PM 22958237
ER
PT J
AU Janas, MM
Wang, BB
Harris, AS
Aguiar, M
Shaffer, JM
Subrahmanyam, YVBK
Behlke, MA
Wucherpfennig, KW
Gygi, SP
Gagnon, E
Novina, CD
AF Janas, Maja M.
Wang, Bingbing
Harris, Abigail S.
Aguiar, Mike
Shaffer, Jonathan M.
Subrahmanyam, Yerramilli V. B. K.
Behlke, Mark A.
Wucherpfennig, Kai W.
Gygi, Steven P.
Gagnon, Etienne
Novina, Carl D.
TI Alternative RISC assembly: Binding and repression of microRNA-mRNA
duplexes by human Ago proteins
SO RNA-A PUBLICATION OF THE RNA SOCIETY
LA English
DT Article
DE Argonautes; fluorescence lifetime imaging microscopy (FLIM); microRNAs;
RISC loading
ID CYTOPLASMIC PROCESSING BODIES; ARGONAUTE SILENCING COMPLEX;
CRYSTAL-STRUCTURE; POSTTRANSCRIPTIONAL REGULATION; TRANSLATIONAL
REPRESSION; DEPENDENT LOCALIZATION; MAMMALIAN-CELLS; MIRNA PATHWAY;
IN-VITRO; EXPRESSION
AB MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally regulate protein output from the majority of human mRNAs. In contrast to the consensus view that all miRNAs are associated with Argonaute (Ago) proteins, we determine that miRNAs are expressed in a 13-fold excess relative to Agos in HeLa cells and that miRNAs are bound to mRNAs in a sevenfold excess relative to Agos, implying the existence of miRNA-mRNA duplexes not stoichiometrically bound by Agos. We show that all four human Agos can repress miRNA-mRNA duplexes, but only Ago2 can cleave small interfering RNA-mRNA duplexes in vitro. We visualize direct Ago binding to miRNA-mRNA duplexes in live cells using fluorescence lifetime imaging microscopy. In contrast to the consensus view that Agos bind miRNA duplexes, these data demonstrate that Agos can bind and repress miRNA-mRNA duplexes and support a model of catalytic Ago function in translational repression.
C1 [Janas, Maja M.; Wang, Bingbing; Wucherpfennig, Kai W.; Gagnon, Etienne; Novina, Carl D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Janas, Maja M.; Wang, Bingbing; Novina, Carl D.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA.
[Janas, Maja M.; Wang, Bingbing; Novina, Carl D.] Broad Inst MIT & Harvard, Cambridge, MA 02141 USA.
[Harris, Abigail S.; Shaffer, Jonathan M.; Subrahmanyam, Yerramilli V. B. K.] Qiagen Inc, Frederick, MD 21703 USA.
[Aguiar, Mike; Gygi, Steven P.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Behlke, Mark A.] Integrated DNA Technol, Coralville, IA USA.
RP Gagnon, E (reprint author), Univ Montreal, Dept Microbiol & Immunol, Inst Res Immunol & Canc, Montreal, PQ H3T 1J4, Canada.
EM etienne.gagnon@umontreal.ca; carl_novina@dfci.harvard.edu
FU Cancer Research Institute Postdoctoral Fellowship; Distinguished Young
Scholars Award from the W.M. Keck Foundation
FX We thank Dr. Lisa Cameron for help with microscopy, Dr. Ashish Lal
(National Institutes of Health) for the RL-MYC 3' UTR reporter plasmid,
and Dr. Zissimos Mourelatos (University of Pennsylvania) for anti-pan
Ago antibody. All microscopy was performed at the confocal microscopy
core at Dana-Farber Cancer Institute. This work was supported by the
Cancer Research Institute Postdoctoral Fellowship to E.G. and a
Distinguished Young Scholars Award from the W.M. Keck Foundation to
C.D.N.
NR 63
TC 36
Z9 37
U1 0
U2 15
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1355-8382
J9 RNA
JI RNA-Publ. RNA Soc.
PD NOV
PY 2012
VL 18
IS 11
BP 2041
EP 2055
DI 10.1261/rna.035675.112
PG 15
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 023TH
UT WOS:000310058000009
PM 23019594
ER
PT J
AU Paik, DY
Janzen, DM
Schafenacker, AM
Velasco, VS
Shung, MS
Cheng, DH
Huang, JT
Witte, ON
Memarzadeh, S
AF Paik, Daniel Y.
Janzen, Deanna M.
Schafenacker, Amanda M.
Velasco, Victor S.
Shung, May S.
Cheng, Donghui
Huang, Jiaoti
Witte, Owen N.
Memarzadeh, Sanaz
TI Stem-Like Epithelial Cells Are Concentrated in the Distal End of the
Fallopian Tube: A Site for Injury and Serous Cancer Initiation
SO STEM CELLS
LA English
DT Article
DE Adult stem cells; Clonal assays; Self-renewal; Tissue-specific stem
cells
ID CILIARY BEAT FREQUENCY; OVARIAN-CANCER; PROSTATE-CANCER;
MENSTRUAL-CYCLE; ELECTRON-MICROSCOPY; COLORECTAL-CANCER; ANDROGEN
RECEPTOR; MULLERIAN DUCT; ORIGIN; MOUSE
AB The reproductive role of the fallopian tube is to transport the sperm and egg. The tube is positioned to act as a bridge between the ovary where the egg is released and the uterus where implantation occurs. Throughout reproductive years, the fallopian tube epithelium undergoes repetitive damage and regeneration. Although a reservoir of adult epithelial stem cells must exist to replenish damaged cells, they remain unidentified. Here, we report isolation of a subset of basally located human fallopian tube epithelia (FTE) that lack markers of ciliated (beta-tubulin; TUBB4) or secretory (PAX8) differentiated cells. These undifferentiated cells expressed cell surface antigens: epithelial cell adhesion molecule, CD44, and integrin a 6. This FTE subpopulation was fivefold enriched for cells capable of clonal growth and self-renewal suggesting that they contain the FTE stem-like cells (FTESCs). A twofold enrichment of the FTESC was found in the distal compared to the proximal end of the tube. The distal fimbriated end of the fallopian tube is a well-characterized locus for initiation of serous carcinomas. An expansion of the cells expressing markers of FTESC was detected in tubal intraepithelial carcinomas and in fallopian tubes from patients with invasive serous cancer. These findings suggest that FTESC may play a role in the initiation of serous tumors. Characterization of these stem-like cells will provide new insight into how the FTE regenerate, respond to injury, and may initiate cancer. STEM CELLS2012;30:24872497
C1 [Witte, Owen N.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Los Angeles, CA 90095 USA.
[Paik, Daniel Y.; Janzen, Deanna M.; Schafenacker, Amanda M.; Velasco, Victor S.; Shung, May S.; Memarzadeh, Sanaz] Univ Calif Los Angeles, Dept Obstet & Gynecol, David Geffen Sch Med, Los Angeles, CA 90024 USA.
[Cheng, Donghui; Witte, Owen N.] Univ Calif Los Angeles, Howard Hughes Med Inst, Los Angeles, CA 90024 USA.
[Huang, Jiaoti] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90095 USA.
[Witte, Owen N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.
[Memarzadeh, Sanaz] VA Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
RP Memarzadeh, S (reprint author), Univ Calif Los Angeles, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, 610 Charles E Young Dr E,3017 Terasaki Life Sci B, Los Angeles, CA 90095 USA.
EM smemarzadeh@mednet.ucla.edu
FU Veteran Affairs CDA-2 Career Development Award; Mary Kay Foundation
Award; Prostate Cancer Foundation Young Investigators Award; STOP Cancer
Award; Broad Stem Cell Research Center Research Award; Liz Tilberis
Scholars Program from the Ovarian Cancer Research Fund, Inc.;
Gynecologic Cancer Foundation St. Louis Ovarian Cancer Awareness
Research Grant; Ovarian Cancer Circle
FX We thank Brooke Nakamura for technical support. We thank Drs. Andrew
Goldstein and Yang Zong for helpful conversations related to this
project. We thank the UCLA Tissue Procurement Core Laboratory for their
assistance in providing human fallopian tube specimens. S. M. is
supported by a Veteran Affairs CDA-2 Career Development Award, a gift
from the Scholars in Translational Medicine Program, Mary Kay Foundation
Award, Prostate Cancer Foundation Young Investigators Award, STOP Cancer
Award, and the Broad Stem Cell Research Center Research Award. This work
was also supported by the Liz Tilberis Scholars Program from the Ovarian
Cancer Research Fund, Inc., the Gynecologic Cancer Foundation St. Louis
Ovarian Cancer Awareness Research Grant, and the Ovarian Cancer Circle
inspired by Robin Babbini. O.N.W. is a Howard Hughes Medical Institute
investigator.
NR 52
TC 35
Z9 37
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1066-5099
J9 STEM CELLS
JI Stem Cells
PD NOV
PY 2012
VL 30
IS 11
BP 2487
EP 2497
DI 10.1002/stem.1207
PG 11
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Oncology; Cell Biology; Hematology
SC Cell Biology; Biotechnology & Applied Microbiology; Oncology; Hematology
GA 023ZP
UT WOS:000310077000013
PM 22911892
ER
PT J
AU Kilbourne, AM
Greenwald, DE
Bauer, MS
Charns, MP
Yano, EM
AF Kilbourne, Amy M.
Greenwald, Devra E.
Bauer, Mark S.
Charns, Martin P.
Yano, Elizabeth M.
TI Mental Health Provider Perspectives Regarding Integrated Medical Care
for Patients with Serious Mental Illness
SO ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES
RESEARCH
LA English
DT Article
DE Integrated care; Serious mental illness; Quality of care
ID QUALITY-OF-CARE; BIPOLAR DISORDER; VETERANS-AFFAIRS; PROGRAMS; DISEASE;
ACCESS; SATISFACTION; INCENTIVES; CONTINUITY; SERVICES
AB Integrated care for medical conditions is essential for persons with serious mental illness (SMI). This qualitative study describes mental health provider perspectives regarding barriers and facilitators of integrated care for patients with SMI. We interviewed providers from a national sample of Veterans Health Administration facilities that scored in the top or bottom percentile in medical care quality. Providers from high-performing sites reported substantial in-person contacts with general medical providers, while providers from low-performing sites reported stigma and limited communication with medical providers as major concerns. Interventions to improve mental health and medical provider communication may facilitate integrated care for persons with SMI.
C1 [Kilbourne, Amy M.] VA Ann Arbor Ctr Clin Management Res, Ann Arbor, MI 48105 USA.
[Kilbourne, Amy M.] Univ Michigan, Sch Med, Dept Psychiat, Ann Arbor, MI USA.
[Greenwald, Devra E.] VA Pittsburgh Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Bauer, Mark S.; Charns, Martin P.] VA Boston Ctr Org Management & Leadership Res COL, Boston, MA USA.
[Bauer, Mark S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Charns, Martin P.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Yano, Elizabeth M.] VA Greater Angeles Healthcare Syst, VA Greater Angeles HSR&D, Ctr Excellence Study Healthcare Provider Behav, Los Angeles, CA USA.
[Yano, Elizabeth M.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA.
RP Kilbourne, AM (reprint author), VA Ann Arbor Ctr Clin Management Res, 2215 Fuller Rd, Ann Arbor, MI 48105 USA.
EM amykilbo@umich.edu
OI Charns, Martin/0000-0002-7102-5331
NR 42
TC 9
Z9 9
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0894-587X
J9 ADM POLICY MENT HLTH
JI Adm. Policy. Ment. Health
PD NOV
PY 2012
VL 39
IS 6
BP 448
EP 457
DI 10.1007/s10488-011-0365-9
PG 10
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 021CM
UT WOS:000309862900004
PM 21735302
ER
PT J
AU Kim, K
Brown, EE
Choi, CB
Alarc, ME
Kelly, JA
Glenn, SB
Ojwang, JO
Adler, A
Lee, HS
Boackle, SA
Criswell, LA
Alarc, GS
Edberg, JC
Stevens, AM
Jacob, CO
Gilkeson, GS
Kamen, DL
Tsao, BP
Anaya, JM
Guthridge, JM
Nath, SK
Richardson, B
Sawalha, AH
Kang, YM
Shim, SC
Suh, CH
Lee, SK
Kim, CS
Merrill, JT
Petri, M
Ramsey-Goldman, R
Vil, LM
Niewold, TB
Martin, J
Pons-Estel, BA
Vyse, TJ
Freedman, BI
Moser, KL
Gaffney, PM
Williams, A
Comeau, M
Reveille, JD
James, JA
Eld, RHS
Langefeld, CD
Kaufman, KM
Harley, JB
Kang, C
Kimberly, RP
Bae, SC
AF Kim, Kwangwoo
Brown, Elizabeth E.
Choi, Chan-Bum
Alarc, Marta E.
Kelly, Jennifer A.
Glenn, Stuart B.
Ojwang, Joshua O.
Adler, Adam
Lee, Hye-Soon
Boackle, Susan A.
Criswell, Lindsey A.
Alarc, Graciela S.
Edberg, Jeffrey C.
Stevens, Anne M.
Jacob, Chaim O.
Gilkeson, Gary S.
Kamen, Diane L.
Tsao, Betty P.
Anaya, Juan-Manuel
Guthridge, Joel M.
Nath, Swapan K.
Richardson, Bruce
Sawalha, Amr H.
Kang, Young Mo
Shim, Seung Cheol
Suh, Chang-Hee
Lee, Soo-Kon
Kim, Chang-sik
Merrill, Joan T.
Petri, Michelle
Ramsey-Goldman, Rosalind
Vil, Luis M.
Niewold, Timothy B.
Martin, Javier
Pons-Estel, Bernardo A.
Vyse, Timothy J.
Freedman, Barry I.
Moser, Kathy L.
Gaffney, Patrick M.
Williams, Adrienne
Comeau, Mary
Reveille, John D.
James, Judith A.
Eld, R. Hal Sco
Langefeld, Carl D.
Kaufman, Kenneth M.
Harley, John B.
Kang, Changwon
Kimberly, Robert P.
Bae, Sang-Cheol
CA BIOLUPUS
GENLES
TI Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic
lupus erythematosus susceptibility in multiple ancestries
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Article
ID INTERCELLULAR-ADHESION MOLECULE-1; FUNCTIONAL VARIANT; DISEASE-ACTIVITY;
CELL-ADHESION; INTEGRIN; ITGAM; GENE; EXPRESSION; METAANALYSIS; SELECTIN
AB Objective Systemic lupus erythematosus (SLE; OMIM 152700) is a chronic autoimmune disease for which the aetiology includes genetic and environmental factors. ITGAM, integrin a. (complement component 3 receptor 3 subunit) encoding a ligand for intracellular adhesion molecule (ICAM) proteins, is an established SLE susceptibility locus. This study aimed to evaluate the independent and joint effects of genetic variations in the genes that encode ITGAM and ICAM.
Methods The authors examined several markers in the ICAM1-ICAM4-ICAM5 locus on chromosome 19p13 and the single ITGAM polymorphism (rs1143679) using a large-scale case-control study of 17 481 unrelated participants from four ancestry populations. The single-marker association and gene-gene interaction were analysed for each ancestry, and a meta-analysis across the four ancestries was performed.
Results The A-allele of ICAM1-ICAM4-ICAM5 rs3093030, associated with elevated plasma levels of soluble ICAM1, and the A-allele of ITGAM rs1143679 showed the strongest association with increased SLE susceptibility in each of the ancestry populations and the trans-ancestry meta-analysis (ORmeta = 1.16, 95% CI 1.11 to 1.22; p = 4.88 x 10(-10) and ORmeta = 1.67, 95% CI 1.55 to 1.79; p = 3.32 x 10(-46), respectively). The effect of the ICAM single-nucleotide polymorphisms (SNPs) was independent of the effect of the ITGAM SNP rs1143679, and carriers of both ICAM rs3093030-AA and ITGAM rs1143679-AA had an OR of 4.08 compared with those with no risk allele in either SNP (95% CI 2.09 to 7.98; p = 3.91 x 10(-5)).
Conclusion These findings are the first to suggest that an ICAM-integrin-mediated pathway contributes to susceptibility to SLE.
C1 [Kim, Kwangwoo; Kang, Changwon] Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
[Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.
[Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Med, Dept Epidemiol, Birmingham, AL 35294 USA.
[Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA.
[Brown, Elizabeth E.; Alarc, Graciela S.; Edberg, Jeffrey C.; Kimberly, Robert P.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Med, Birmingham, AL 35294 USA.
[Choi, Chan-Bum; Lee, Hye-Soon; Bae, Sang-Cheol] Hanyang Univ Hosp Rheumat Dis, Dept Rheumatol, Seoul 133792, South Korea.
[Alarc, Marta E.; Kelly, Jennifer A.; Glenn, Stuart B.; Ojwang, Joshua O.; Adler, Adam; Guthridge, Joel M.; Nath, Swapan K.; Sawalha, Amr H.; Merrill, Joan T.; Moser, Kathy L.; Gaffney, Patrick M.; Kaufman, Kenneth M.] Oklahoma Med Res Fdn, Arthrit & Clin Immunol Program, Oklahoma City, OK 73104 USA.
[Alarc, Marta E.; BIOLUPUS] Univ Granada Junta de Andaluca, Area Human DNA Variabil, Ctr Gen & Invest Oncol GENYO, Granada, Spain.
[Boackle, Susan A.] Univ Colorado, Div Rheumatol, Denver Sch Med, Aurora, CO USA.
[Criswell, Lindsey A.] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthrit, San Francisco, CA 94143 USA.
[Stevens, Anne M.] Univ Washington, Seattle Childrens Hosp, Seattle, WA 98195 USA.
[Jacob, Chaim O.] Univ So Calif, Lupus Genet Grp, Los Angeles, CA USA.
[Gilkeson, Gary S.; Kamen, Diane L.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Tsao, Betty P.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Anaya, Juan-Manuel] Univ Nacl Rosario, Ctr Autoimmune Dis Res, Bogota, Colombia.
[Richardson, Bruce] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA.
[Richardson, Bruce] US Dept Vet Affairs, Med Ctr, Ann Arbor, MI USA.
[Sawalha, Amr H.; James, Judith A.; Eld, R. Hal Sco] Univ Oklahoma, Hlth Sci Ctr, Dept Med, Oklahoma City, OK USA.
[Sawalha, Amr H.; Kaufman, Kenneth M.] US Dept Vet Affairs, Dept Med, Med Ctr, Oklahoma City, OK USA.
[Kang, Young Mo] Kyungpook Natl Univ, Dept Internal Med Rheumatol, Sch Med, Taegu, South Korea.
[Shim, Seung Cheol] Eulji Univ, Div Rheumatol, Dept Med, Eulji Medi Bio Res Inst, Taejon, South Korea.
[Suh, Chang-Hee] Ajou Univ, Dept Rheumatol, Sch Med, Suwon 441749, South Korea.
[Lee, Soo-Kon] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea.
[Kim, Chang-sik] Chungnam Natl Univ, Dept Ophthalmol, Sch Med, Taejon, South Korea.
[Petri, Michelle] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Ramsey-Goldman, Rosalind] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Vil, Luis M.] Univ Puerto Rico, Dept Med, San Juan, PR 00936 USA.
[Niewold, Timothy B.] Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA.
[Martin, Javier] CSIC, Dept Immunol, Inst Biomed Parasitologa L pez Neyra, Granada, Spain.
[Pons-Estel, Bernardo A.; GENLES] Sanatorio Parque, Dept Med, Rosario, Argentina.
[Vyse, Timothy J.] Kings Coll London, Div Genet, Guys Hosp, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Mol Med, Guys Hosp, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Immunol, Guys Hosp, London WC2R 2LS, England.
[Vyse, Timothy J.] Kings Coll London, Div Infect & Inammatory Dis, Guys Hosp, London WC2R 2LS, England.
[Freedman, Barry I.; Williams, Adrienne; Comeau, Mary; Langefeld, Carl D.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA.
[Freedman, Barry I.; Williams, Adrienne; Comeau, Mary; Langefeld, Carl D.] Wake Forest Sch Med, Dept Internal Med, Winston Salem, NC USA.
[Reveille, John D.] Univ Texas Hlth Sci Ctr Houston, Div Rheumatol, Houston, TX USA.
[Harley, John B.] Cincinnati Childrens Hosp Med Ctr, US Dept Vet Affairs, Med Ctr, Cincinnati, OH USA.
RP Kang, C (reprint author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.
EM ckang@kaist.ac.kr; Robert.Kimberly@ccc.uab.edu; scbae@hanyang.ac.kr
RI Kang, Changwon/C-1938-2011; Martin, Javier/B-8141-2008; Anaya,
Juan-Manuel/J-1960-2016;
OI Anaya, Juan-Manuel/0000-0002-6444-1249; Universidad del Rosario,
Biblioteca/0000-0003-3491-9392; Kimberly, Robert/0000-0002-5330-3086;
Suh, Chang-Hee/0000-0001-6156-393X; Alarcon Riquelme, Marta
Eugenia/0000-0002-7632-4154; Niewold, Timothy/0000-0003-3532-6660
FU US NIH [AR042460, AR043274, AR043814, AR044804, AR048940, AR052300,
AR053483, AR058554, AR060366, AR43727, AR62277, CA141700-01, GM063483,
HD07463, K08-AI083790, K24-AR002138, M01-RR00079, N01-AR-6-227,
P01-AR49084, P30-DK42086, P30-AR055385]; Lupus Foundation of America;
Alliance for Lupus Research; Kirkland Scholar Award; US Department of
Veterans Affairs; Korean Healthcare Technology Research and Development
Project [A111218-11-GM01]; Korea Research Program for New Drug Target
Discovery [20090083335]; National Research Foundation of Korea
[2010-0014162]; Lupus Research Institute Novel Research Grant; Alliance
for Lupus Research Target Identification in Lupus Grant; Arthritis
National Research Foundation Eng Tan Scholar Award; ESF in the framework
of the Research Networking Programme European Science Foundation-The
Identification of Novel Genes and Biomarkers for Systemic Lupus
Erythematosus (BIOLUPUS) [07-RNP-083]; Swedish Research Council; Swedish
Association against Rheumatism; Swedish International Development
Agency; Gustaf Vth 80th-Jubilee Foundation; Instituto de Salud Carlos
III [PS09/00129]; FEDER funds of the European Union; Consejer'a de Salud
de la Junta de Andaluc'a
FX The work was supported by grants from US NIH (AI063622, AI071651,
AI082714, AI083194, AI094377, AI24717, AR042460, AR043274, AR043814,
AR044804, AR048940, AR052300, AR053483, AR058554, AR060366, AR43727,
AR62277, CA141700-01, GM063483, HD07463, K08-AI083790, K24-AR002138,
M01-RR00079, N01-AR-6-227, P01-AR49084, P30-DK42086, P30-AR055385,
P60-AR049459 P60-AR053308, P60-2-AR30692, PO1-AR49084, PR094002,
R01-AR33062, R21-AI070304, RR015577, RR020143, UL1RR024999, UL1RR025005,
UL1RR025741, UL1RR029882 and 5UL1RR025777), the Lupus Foundation of
America, the Alliance for Lupus Research, a Kirkland Scholar Award, the
US Department of Veterans Affairs, the Korean Healthcare Technology
Research and Development Project (A111218-11-GM01), the Korea Research
Program for New Drug Target Discovery (20090083335), the National
Research Foundation of Korea (2010-0014162), the Lupus Research
Institute Novel Research Grant, the Alliance for Lupus Research Target
Identification in Lupus Grant, the Arthritis National Research
Foundation Eng Tan Scholar Award, the ESF in the framework of the
Research Networking Programme European Science Foundation-The
Identification of Novel Genes and Biomarkers for Systemic Lupus
Erythematosus (BIOLUPUS) 07-RNP-083, the Swedish Research Council, the
Swedish Association against Rheumatism, the Swedish International
Development Agency, the Gustaf Vth 80th-Jubilee Foundation, the
Instituto de Salud Carlos III (PS09/00129) partly financed by the FEDER
funds of the European Union, and a grant from the Consejer'a de Salud de
la Junta de Andaluc'a.
NR 30
TC 16
Z9 16
U1 1
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD NOV
PY 2012
VL 71
IS 11
BP 1809
EP 1814
DI 10.1136/annrheumdis-2011-201110
PG 6
WC Rheumatology
SC Rheumatology
GA 018IZ
UT WOS:000309654900009
PM 22523428
ER
PT J
AU Stein, NR
Mills, MA
Arditte, K
Mendoza, C
Borah, AM
Resick, PA
Litz, BT
AF Stein, Nathan R.
Mills, Mary Alice
Arditte, Kimberly
Mendoza, Crystal
Borah, Adam M.
Resick, Patricia A.
Litz, Brett T.
CA STRONG STAR Consortium
TI A Scheme for Categorizing Traumatic Military Events
SO BEHAVIOR MODIFICATION
LA English
DT Article
DE PTSD; trauma; OEF/OIF; classification
ID POSTTRAUMATIC-STRESS-DISORDER; VIETNAM COMBAT VETERANS; WAR ZONE
STRESSORS; PSYCHOMETRIC PROPERTIES; INVENTORY; EXPOSURE; SEVERITY;
VICTIMS; RELIABILITY; VALIDATION
AB A common assumption among clinicians and researchers is that war trauma primarily involves fear-based reactions to life-threatening situations. However, the authors believe that there are multiple types of trauma in the military context, each with unique perievent and postevent response patterns. To test this hypothesis, they reviewed structured clinical interviews of 122 active duty service members and assigned the reported index (principal, most currently distressing) events to one or more of the following categories: Life Threat to Self, Life Threat to Others, Aftermath of Violence, Traumatic Loss, Moral Injury by Self, and Moral Injury by Others. They found high interrater reliability for the coding scheme and support for the construct validity of the categorizations. In addition, they discovered that certain categories were related to psychiatric symptoms (e.g., reexperiencing of the traumatic event, guilt, anger) and negative thoughts about the world. Their study provides tentative support for use of these event categories.
C1 [Stein, Nathan R.; Mills, Mary Alice; Arditte, Kimberly; Resick, Patricia A.; Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA USA.
[Resick, Patricia A.; Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Borah, Adam M.] Carl R Darnall Army Med Ctr, Ft Hood, TX USA.
[Mendoza, Crystal] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Stein, NR (reprint author), 1 Corp Pl, Middletown, RI 02842 USA.
EM nathan.stein@va.gov
NR 38
TC 20
Z9 20
U1 3
U2 21
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-4455
J9 BEHAV MODIF
JI Behav. Modificat.
PD NOV
PY 2012
VL 36
IS 6
SI SI
BP 787
EP 807
DI 10.1177/0145445512446945
PG 21
WC Psychology, Clinical
SC Psychology
GA 022BP
UT WOS:000309930300003
PM 22679239
ER
PT J
AU Hassija, CM
Jakupcak, M
Gray, MJ
AF Hassija, Christina M.
Jakupcak, Matthew
Gray, Matt J.
TI Numbing and Dysphoria Symptoms of Posttraumatic Stress Disorder Among
Iraq and Afghanistan War Veterans: A Review of Findings and Implications
for Treatment
SO BEHAVIOR MODIFICATION
LA English
DT Article
DE PTSD; numbing; dysphoria; veterans
ID CONFIRMATORY FACTOR-ANALYSIS; BORDERLINE PERSONALITY-DISORDER;
DIALECTICAL BEHAVIOR-THERAPY; RANDOMIZED CONTROLLED-TRIAL; ADMINISTERED
PTSD SCALE; MENTAL-HEALTH PROBLEMS; WORLD-TRADE-CENTER; QUALITY-OF-LIFE;
FUNCTIONAL IMPAIRMENT; PROLONGED EXPOSURE
AB Iraq and Afghanistan war veterans experience significant rates of posttraumatic stress disorder (PTSD) and other trauma-related mental health conditions. Understanding how specific PTSD symptomatology affects physical health and psychosocial functioning may be useful in improving the conceptualization of PTSD nosology and informing treatment approaches for this population. Confirmatory factor analytic evidence supports four-factor models of PTSD symptoms that classify emotional numbing and/or dysphoria symptoms as a distinct PTSD symptom cluster, and these symptoms appear to be related to poorer psychological adjustment among returning Iraq and Afghanistan war veterans. This review briefly describes current conceptualizations of numbing/dysphoria symptoms of PTSD and summarizes research on the factor structure of PTSD symptoms. Then, the literature on the influence of numbing/dysphoria symptoms on physical and psychological health among these veterans is reviewed, and implications for treatment and directions for future research are presented.
C1 [Hassija, Christina M.] Natl Ctr PTSD VA Palo Alto Hlth Care Syst, Menlo Pk, CA USA.
[Hassija, Christina M.; Gray, Matt J.] Univ Wyoming, Laramie, WY 82071 USA.
[Jakupcak, Matthew] VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA.
[Jakupcak, Matthew] Univ Washington, Seattle, WA 98195 USA.
RP Hassija, CM (reprint author), VA Palo Alto Hlth Care Syst, Natl Ctr Posttraumat Stress Disorder, 795 Willow Rd, Menlo Pk, CA 94025 USA.
EM Christina.Hassija2@va.gov
NR 67
TC 9
Z9 9
U1 5
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-4455
J9 BEHAV MODIF
JI Behav. Modificat.
PD NOV
PY 2012
VL 36
IS 6
SI SI
BP 834
EP 856
DI 10.1177/0145445512453735
PG 23
WC Psychology, Clinical
SC Psychology
GA 022BP
UT WOS:000309930300005
PM 22977267
ER
PT J
AU Steenkamp, MM
Nickerson, A
Maguen, S
Dickstein, BD
Nash, WP
Litz, BT
AF Steenkamp, Maria M.
Nickerson, Angela
Maguen, Shira
Dickstein, Benjamin D.
Nash, William P.
Litz, Brett T.
TI Latent Classes of PTSD Symptoms in Vietnam Veterans
SO BEHAVIOR MODIFICATION
LA English
DT Article
DE PTSD; veterans; latent class; Vietnam
ID POSTTRAUMATIC-STRESS-DISORDER; PERITRAUMATIC DISSOCIATION; THEATER
VETERANS; SEXUAL ASSAULT; MENTAL-HEALTH; RISK-FACTORS; SUBTHRESHOLD;
PREVALENCE; RESILIENCE; SURVIVORS
AB The authors examined heterogeneity in posttraumatic stress disorder (PTSD) symptom presentation among veterans (n = 335) participating in the clinical interview subsample of the National Vietnam Veterans Readjustment Study. Latent class analysis was used to identify clinically homogeneous subgroups of Vietnam War combat veterans. Consistent with previous research, three classes emerged from the analysis, namely, veterans with no disturbance (61.4% of the cohort), intermediate disturbance (25.6%), and pervasive disturbance (12.5%). The authors also examined physical injury, war-zone stressor exposure, peritraumatic dissociation, and general dissociation as predictors of class membership. The findings are discussed in the context of recent conceptual frameworks that posit a range of posttraumatic outcomes and highlight the sizable segment of military veterans who suffer from intermediate (subclinical) PTSD symptoms.
C1 [Steenkamp, Maria M.; Nickerson, Angela; Dickstein, Benjamin D.; Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Nickerson, Angela] Univ New S Wales, Sch Psychol, Kensington, NSW 2033, Australia.
[Maguen, Shira] San Francisco VA Med Ctr, San Francisco, CA USA.
[Maguen, Shira] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Nash, William P.] VA San Diego Healthcare Syst, San Diego, CA USA.
[Steenkamp, Maria M.; Litz, Brett T.] Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
RP Steenkamp, MM (reprint author), VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.
EM maria.steenkamp2@va.gov
NR 42
TC 21
Z9 21
U1 3
U2 6
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0145-4455
J9 BEHAV MODIF
JI Behav. Modificat.
PD NOV
PY 2012
VL 36
IS 6
SI SI
BP 857
EP 874
DI 10.1177/0145445512450908
PG 18
WC Psychology, Clinical
SC Psychology
GA 022BP
UT WOS:000309930300006
PM 22798638
ER
PT J
AU Martin, NE
Chen, MH
Nguyen, PL
Beard, CJ
Loffredo, MJ
Kantoff, PW
D'Amico, AV
AF Martin, Neil E.
Chen, Ming-Hui
Nguyen, Paul L.
Beard, Clair J.
Loffredo, Marian J.
Kantoff, Philip W.
D'Amico, Anthony V.
TI Biopsy Gleason score and the duration of testosterone suppression among
men treated with external beam radiation and 6 months of combined
androgen blockade
SO BJU INTERNATIONAL
LA English
DT Article
DE testosterone; prostatic neoplasms; radiotherapy; androgen blockade
ID LOCALIZED PROSTATE-CANCER; RANDOMIZED CONTROLLED-TRIAL; HORMONE AGONIST
TREATMENT; SERUM TESTOSTERONE; RADICAL PROSTATECTOMY; DEPRIVATION
THERAPY; NORMALIZATION; TIME; STEROIDOGENESIS; RADIOTHERAPY
AB OBJECTIVE
To determine whether the biopsy Gleason score is associated with duration of testosterone suppression following 6 months of combined androgen blockade (CAB) and radiation therapy (RT) in men with prostate cancer (PCa).
PATIENTS AND METHODS
The study cohort consisted of 221 men with PCa treated with RT and 6 months of CAB between 1996 and 2005.
We defined the duration of testosterone suppression as the time between the last day of CAB and the date the testosterone returned to >= 252 ng/dL. We used Cox regression multivariable analysis to relate biopsy Gleason score to duration of testosterone suppression following cessation of CAB.
RESULTS
A biopsy Gleason score of 8-10 had an adjusted hazard ratio (AHR) of 1.56 (95% confidence interval [CI] 1.04, 2.34; P = 0.03) for a shorter time to testosterone normalization relative to Gleason 6. Specifically, the 51 men with biopsy Gleason score of 8-10 had a median time to testosterone normalization of 17.0 months compared with 22.1 months and 23.8 months for those with biopsy Gleason <= 6 and 7, respectively.
Increasing age was significantly associated with a longer duration of testosterone suppression (AHR of 0.95 [95% CI 0.92, 0.97; P < 0.001]) as was a higher baseline PSA (AHR 0.82 [95% CI 0.69, 0.97; P = 0.02]).
CONCLUSION
A biopsy Gleason score of 8-10 was associated with a shorter period of testosterone suppression following 6 months of CAB and RT. These data are consistent with the hypothesis that a factor released from high-grade PCa cells may impact on testosterone production.
C1 [Martin, Neil E.] Harvard Univ, Dana Farber Canc Inst, Dept Radiat Oncol, Brigham & Womens Hosp,Med Sch, Boston, MA 02115 USA.
[Chen, Ming-Hui] Univ Connecticut, Dept Stat, Storrs, CT 06269 USA.
[Kantoff, Philip W.] Harvard Univ, Dana Farber Canc Inst, Dept Med Oncol, Sch Med, Boston, MA 02115 USA.
RP Martin, NE (reprint author), Harvard Univ, Dana Farber Canc Inst, Dept Radiat Oncol, Brigham & Womens Hosp,Med Sch, 75 Francis St,ASB I L2, Boston, MA 02115 USA.
EM neil_martin@dfci.harvard.edu
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
FU Prostate Cancer Foundation
FX NEM is supported by a Young Investigator award from the Prostate Cancer
Foundation. PLN is supported by a generous gift from an anonymous donor.
NR 31
TC 2
Z9 2
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
J9 BJU INT
JI BJU Int.
PD NOV
PY 2012
VL 110
IS 9
BP 1252
EP 1256
DI 10.1111/j.1464-410X.2012.11118.x
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA 024DC
UT WOS:000310087000009
PM 22564379
ER
PT J
AU Klippel, S
Jakubikova, J
Delmore, J
Ooi, M
McMillin, D
Kastritis, E
Laubach, J
Richardson, PG
Anderson, KC
Mitsiades, CS
AF Klippel, Steffen
Jakubikova, Jana
Delmore, Jake
Ooi, Melissa
McMillin, Douglas
Kastritis, Efstathios
Laubach, Jacob
Richardson, Paul G.
Anderson, Kenneth C.
Mitsiades, Constantine S.
TI Methyljasmonate displays in vitro and in vivo activity against multiple
myeloma cells
SO BRITISH JOURNAL OF HAEMATOLOGY
LA English
DT Article
DE multiple myeloma; jasmonates; ATP depletion; metabolic activity;
aldo-keto reductases
ID METHYL JASMONATE; PROSTATE-CANCER; INDUCE APOPTOSIS; DRUG-RESISTANCE;
LUNG-CANCER; AKR1C2; OVEREXPRESSION; METABOLISM; EXPRESSION; BORTEZOMIB
AB Jasmonates, plant stress hormones, have been demonstrated to be effective in killing various types of cancer cells. We therefore tested if methyljasmonate (MJ) has activity against multiple myeloma (MM) in vitro and in vivo. MM cell lines and primary MM tumour cells responded to MJ in vitro at concentrations that did not significantly affect normal haematopoietic cells, without stroma-mediated resistance. Brief MJ exposures of MM cells caused release of Hexokinase 2 (HK2) from mitochondria, rapid ATP depletion, perturbation of major intracellular signalling pathways, and ensuing mainly apoptotic cell death. Sensitivity to MJ correlated with lower cellular glucose consumption and lactate production, as well as lower intracellular protein levels of HK2, phosphorylated Voltage-dependent anion channel 2/3 (pVDAC2/3) and Aldo-keto reductase family 1 member C1 (AKR1C1), which represent potential biomarkers of responsiveness to MJ treatment, especially as AKR1C1 transcript levels also correlate with clinical outcome in bortezomib- or dexamethasone-treated MM patients. Interestingly, MJ synergized with bortezomib in vitro and prolonged survival of immunocompromised mice harbouring diffuse lesions of MM.1S cells compared to vehicle-treated mice (P=0.0046). These studies indicate that jasmonates represent a new, promising strategy to treat MM.
C1 [Mitsiades, Constantine S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02215 USA.
RP Mitsiades, CS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM Constantine_Mitsiades@dfci.harvard.edu
FU Dana-Farber Cancer Institute; Chambers Medical Foundation; Paul
Stepanian Fund; Richard Corman Fund; National Institutes of Health
[RO1-50947]; OSI Pharmaceuticals; Amgen Pharmaceuticals; AVEO Pharma;
EMD Serono; Sunesis; Gloucester Pharmaceuticals; Genzyme; Johnson
Johnson
FX Supported by 'Dunkin Donuts Rising Stars' Program at the Dana-Farber
Cancer Institute (to C. S. M), the Chambers Medical Foundation (P. G. R
and C. S. M.), the Paul Stepanian Fund (C. S. M, P. G. R.), the Richard
Corman Fund (P. G. R., C.S.M.) and National Institutes of Health Grants
RO1-50947 ( C. S. M and K.C.A).; CSM has received in the past honoraria
from Millennium Pharmaceuticals, Novartis Pharmaceuticals, Bristol-Myers
Squibb, Merck & Co., Centrocor, Celgene, Arno Therapeutics; licensing
royalties from PharmaMar; and research funding from OSI Pharmaceuticals,
Amgen Pharmaceuticals, AVEO Pharma, EMD Serono, Sunesis, Gloucester
Pharmaceuticals, Genzyme and Johnson & Johnson. PGR is on Advisory
Boards of Millennium Pharmaceuticals, Celgene, Novartis, Bristol-Myers
Squibb and Johnson & Johnson. KCA is on Advisory Boards of Millennium
Pharmaceuticals, Celgene, Bristol Myers Squibb, Merck, and Onyx.
NR 26
TC 8
Z9 8
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1048
J9 BRIT J HAEMATOL
JI Br. J. Haematol.
PD NOV
PY 2012
VL 159
IS 3
BP 340
EP 351
DI 10.1111/j.1365-2141.2012.09253.x
PG 12
WC Hematology
SC Hematology
GA 019DO
UT WOS:000309717500010
PM 22970818
ER
PT J
AU Inglott, MA
Lerner, EA
Pilowsky, PM
Farnham, MMJ
AF Inglott, Melissa A.
Lerner, Ethan A.
Pilowsky, Paul M.
Farnham, Melissa M. J.
TI Activation of PAC1 and VPAC receptor subtypes elicits differential
physiological responses from sympathetic preganglionic neurons in the
anaesthetized rat
SO BRITISH JOURNAL OF PHARMACOLOGY
LA English
DT Article
DE PACAP; vasoactive intestinal polypeptide; maxadilan; PACAP(6-38); blood
pressure; sympathetic; adrenaline; noradrenaline; adrenal medulla
ID VASOACTIVE-INTESTINAL-PEPTIDE; BLOOD-FLOW; IN-VIVO; ARRIVE GUIDELINES;
CHROMAFFIN CELLS; NERVE ACTIVITY; SAND FLIES; POLYPEPTIDE; MAXADILAN;
INCREASES
AB BACKGROUND AND PURPOSE Pituitary adenylate cyclase-activating polypeptide (PACAP) is an excitatory neuropeptide with central and peripheral cardiovascular actions. Intrathecal PACAP increases splanchnic sympathetic nerve activity and heart rate, but not mean arterial pressure (MAP). We hypothesize that the three PACAP receptors (PAC1, VPAC1 and VPAC2) have different actions in central cardiovascular control, and that their summed effect results in the lack of MAP response observed following intrathecal PACAP injection. EXPERIMENTAL APPROACH The effects of the PACAP receptors on baseline cardiovascular parameters were investigated using selective agonists and antagonists administered into the intrathecal space of urethane-anaesthetized, vagotomized and artificially ventilated male Sprague-Dawley rats. KEY RESULTS Selective activation of the PACAP receptors had different effects on MAP. When activated by maxadilan, PAC1 receptors increased MAP. The VPAC receptors decreased MAP when both were activated with vasoactive intestinal polypeptide or when only VPAC1 receptors were activated. The PAC1 and VPAC2 receptor antagonist PACAP(638) had no cardiovascular effects, suggesting that PACAP is not tonically released. CONCLUSIONS AND IMPLICATIONS PACAP neurotransmission was not responsible for the moment-to-moment tonic regulation of central cardiovascular control mechanisms. Nevertheless, PACAP release within the spinal cord may have pleiotropic effects on sympathetic outflow depending on the postsynaptic receptor type. PAC1 and VPAC receptor subtypes produced opposing changes in blood pressure when activated by intrathecal PACAP-38 in the anaesthetized Sprague-Dawley rat, resulting in no net change in MAP.
C1 [Inglott, Melissa A.; Pilowsky, Paul M.; Farnham, Melissa M. J.] Macquarie Univ, Australian Sch Adv Med, Sydney, NSW 2109, Australia.
[Lerner, Ethan A.] Massachusetts Gen Hosp, Dept Dermatol, Cutaneous Biol Res Ctr, Charlestown, MA USA.
RP Pilowsky, PM (reprint author), Macquarie Univ, Australian Sch Adv Med, F10A, Sydney, NSW 2109, Australia.
EM paul.pilowsky@mq.edu.au
OI Farnham, Melissa/0000-0002-7612-1015; Pilowsky, Paul/0000-0003-3500-467X
FU National Health and Medical Research Council of Australia [457080,
457069, 604002, 1024489]; The Australian Research Council [DP110102110,
DE120100992]; Macquarie University [9200800903, 9200901700]; National
Heart Foundation of Australia [G11S5957]; National Institutes of Health
(USA) [1R01AR057744]; Australian Postgraduate Award
FX Work in the authors' laboratories is supported by grants from the
National Health and Medical Research Council of Australia (457080,
457069, 604002, 1024489), The Australian Research Council (DP110102110,
DE120100992), Macquarie University (9200800903, 9200901700), the
National Heart Foundation of Australia (G11S5957) and the National
Institutes of Health (USA; 1R01AR057744). M.A.I. was supported by an
Australian Postgraduate Award.
NR 34
TC 8
Z9 8
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0007-1188
J9 BRIT J PHARMACOL
JI Br. J. Pharmacol.
PD NOV
PY 2012
VL 167
IS 5
BP 1089
EP 1098
DI 10.1111/j.1476-5381.2012.02045.x
PG 10
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 017OI
UT WOS:000309599400014
PM 22612450
ER
PT J
AU Serafini, G
Pompili, M
Innamorati, M
Rihmer, Z
Sher, L
Girardi, P
AF Serafini, Gianluca
Pompili, Maurizio
Innamorati, Marco
Rihmer, Zoltan
Sher, Leo
Girardi, Paolo
TI Can Cannabis Increase the Suicide Risk in Psychosis? A Critical Review
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Cannabis use; suicidal behavior; psychosis; youths; prevention
ID DELIBERATE SELF-HARM; SUBSTANCE USE; YOUNG-PEOPLE; AFFECTIVE
TEMPERAMENTS; GENERAL-POPULATION; MENTAL-HEALTH; PSYCHIATRIC-PATIENTS;
DEPRESSIVE SYMPTOMS; HIGHER HOPELESSNESS; COMPLETED SUICIDE
AB Objectives: This paper aimed to critically review the current literature concerning the possible association between cannabis use and suicidal behavior in patients with psychosis and in non-psychotic samples.
Methods: We performed a detailed Pubmed/Medline, Scopus, PsycLit, and PsycInfo search to identify all papers and book chapters focusing on the association between cannabis use, and suicidal behavior during the period between 1980 and 2011.
Results: Most, but not all studies reported an association between suicidal behavior and cannabis use both in psychotic and non-psychotic samples. However, there were also some studies suggesting a weak (not direct) association between these two phenomena. Overall, those who attempt or complete suicide are characterized by additional risk factors such as mood disorders, stressful life events, interpersonal problems, poor social support, lonely lives, and feelings of hopelessness.
Limitations: It was not possible to perform a meta-analysis due to the high heterogeneity of individual data.
Conclusions: Cannabis use was a relevant risk factor associated with both suicidal attempts and behaviors in psychotic and non-psychotic samples. Preventive programs should be directed on reducing cannabis use, particularly in psychotic subjects. Evidence suggests that targeted suicide prevention programs can be also developed in specific at-risk subgroups such as those at genetic or clinical high risk of psychosis.
C1 [Serafini, Gianluca; Pompili, Maurizio; Girardi, Paolo] Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, I-00189 Rome, Italy.
[Pompili, Maurizio; Innamorati, Marco] Harvard Univ, Sch Med, McLean Hosp, Cambridge, MA 02138 USA.
[Rihmer, Zoltan] Semmelweis Univ, Dept Clin & Theoret Mental Hlth, Kutvolgyi Clin Ctr, H-1125 Budapest, Hungary.
[Rihmer, Zoltan] Semmelweis Univ, Dept Psychiat & Psychotherapy, H-1125 Budapest, Hungary.
[Sher, Leo] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Sher, Leo] James J Peters Vet Adm Med Ctr, Dept Psychiat, New York, NY USA.
RP Serafini, G (reprint author), Univ Roma La Sapienza, St Andrea Hosp, Dept Neurosci Mental Hlth & Sensory Organs, Suicide Prevent Ctr, 1035-1039 Via Grottarossa, I-00189 Rome, Italy.
EM gianluca.serafini@uniroma1.it
RI Innamorati, Marco/H-8877-2013;
OI Innamorati, Marco/0000-0003-1389-2290; Pompili,
Maurizio/0000-0003-1886-4977
NR 87
TC 11
Z9 11
U1 5
U2 20
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD NOV
PY 2012
VL 18
IS 32
BP 5165
EP 5187
PG 23
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 016JA
UT WOS:000309512900028
PM 22716157
ER
PT J
AU McGrath, LM
Weill, S
Robinson, EB
MacRae, R
Smoller, JW
AF McGrath, Lauren M.
Weill, Sydney
Robinson, Elise B.
MacRae, Rebecca
Smoller, Jordan W.
TI Bringing a developmental perspective to anxiety genetics
SO DEVELOPMENT AND PSYCHOPATHOLOGY
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; COMORBIDITY SURVEY REPLICATION; ENVIRONMENTAL
RISK-FACTORS; DSM-IV DISORDERS; PANIC DISORDER; BEHAVIORAL-INHIBITION;
JAPANESE POPULATION; MIDDLE CHILDHOOD; SOCIAL ANXIETY;
PRESCHOOL-CHILDREN
AB Despite substantial recent advancements in psychiatric genetic research, progress in identifying the genetic basis of anxiety disorders has been limited. We review the candidate gene and genome-wide literatures in anxiety, which have made limited progress to date. We discuss several reasons for this hindered progress, including small samples sizes, heterogeneity, complicated comorbidity profiles, and blurred lines between normative and pathological anxiety. To address many of these challenges, we suggest a developmental, multivariate framework that can inform and enhance anxiety phenotypes for genetic research. We review the psychiatric and genetic epidemiological evidence that supports such a framework, including the early onset and chronic course of anxiety disorders, shared genetic risk factors among disorders both within and across time, and developmentally dynamic genetic influences. We propose three strategies for developmentally sensitive phenotyping: examination of early temperamental risk factors, use of latent factors to model underlying anxiety liability, and use of developmental trajectories as phenotypes. Expanding the range of phenotypic approaches will be important for advancing studies of the genetic architecture of anxiety disorders.
C1 [McGrath, Lauren M.; Weill, Sydney; Robinson, Elise B.; Smoller, Jordan W.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[MacRae, Rebecca] MIT, Cambridge, MA 02139 USA.
RP McGrath, LM (reprint author), Massachusetts Gen Hosp, Simches Res Bldg,6th Floor,185 Cambridge St, Boston, MA 02114 USA.
EM mcgrath@pngu.mgh.harvard.edu
OI Robinson, Elise/0000-0003-2314-2792; McGrath, Lauren/0000-0001-6928-9656
FU NIMH NIH HHS [K24 MH094614, K24-MH094614, T32 MH016259, T32 MH017119,
T32-MH017119, T32-MH16259]
NR 147
TC 11
Z9 11
U1 4
U2 31
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 0954-5794
J9 DEV PSYCHOPATHOL
JI Dev. Psychopathol.
PD NOV
PY 2012
VL 24
IS 4
SI SI
BP 1179
EP 1193
DI 10.1017/S0954579412000636
PG 15
WC Psychology, Developmental
SC Psychology
GA 021ZX
UT WOS:000309925800003
PM 23062290
ER
PT J
AU Xavier, R
AF Xavier, Ramnik
TI GWAS, Genes and IBD Pathogenesis
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Meeting Abstract
C1 [Xavier, Ramnik] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Gastrointestinal Unit, Boston, MA 02114 USA.
[Xavier, Ramnik] Harvard Univ, Sch Med, Broad Inst Harvard & MIT, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD NOV
PY 2012
VL 57
IS 11
BP 2728
EP 2728
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 021EJ
UT WOS:000309867800005
ER
PT J
AU Akiba, Y
Kaunitz, JD
AF Akiba, Yasutada
Kaunitz, Jonathan D.
TI May the Truth Be with You: Lubiprostone as EP Receptor Agonist/ClC-2
Internalizing "Inhibitor"
SO DIGESTIVE DISEASES AND SCIENCES
LA English
DT Editorial Material
ID IRRITABLE-BOWEL-SYNDROME; TRANSMEMBRANE CONDUCTANCE REGULATOR; CHLORIDE
CHANNEL ACTIVATOR; CYSTIC-FIBROSIS; CLC-2 CHLORIDE; BICARBONATE
SECRETION; EPITHELIAL-CELLS; CLINICAL-TRIAL; CONSTIPATION; COLON
C1 [Akiba, Yasutada] W Los Angeles VA Med Ctr, Los Angeles, CA 90073 USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA.
[Akiba, Yasutada; Kaunitz, Jonathan D.] Brentwood Biomed Res Inst, Los Angeles, CA 90073 USA.
RP Akiba, Y (reprint author), W Los Angeles VA Med Ctr, 11301 Wilshire Blvd,Bldg 114,Suite 217, Los Angeles, CA 90073 USA.
EM yakiba@mednet.ucla.edu
FU NIDDK NIH HHS [R01 DK54221]
NR 32
TC 2
Z9 2
U1 1
U2 4
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0163-2116
J9 DIGEST DIS SCI
JI Dig. Dis. Sci.
PD NOV
PY 2012
VL 57
IS 11
BP 2740
EP 2742
DI 10.1007/s10620-012-2410-2
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 021EJ
UT WOS:000309867800022
PM 23001408
ER
PT J
AU Krestin, GP
Grenier, PA
Hricak, H
Jackson, VP
Khong, PL
Miller, JC
Muellner, A
Schwaiger, M
Thrall, JH
AF Krestin, G. P.
Grenier, P. A.
Hricak, H.
Jackson, V. P.
Khong, P. L.
Miller, J. C.
Muellner, A.
Schwaiger, M.
Thrall, J. H.
TI Integrated diagnostics: proceedings from the 9th biennial symposium of
the International Society for Strategic Studies in Radiology
SO EUROPEAN RADIOLOGY
LA English
DT Article
DE Radiology; Diagnostic techniques and procedures; Informatics;
Algorithms; Efficiency; Organizational
ID HEALTH-CARE QUALITY; ACUTE CHEST-PAIN; IN-VIVO; ROTTERDAM SCAN;
MEDICINE; TECHNOLOGY; TOMOGRAPHY; VALIDATION; BIOMARKERS; DISEASE
AB The International Society for Strategic Studies in Radiology held its 9th biennial meeting in August 2011. The focus of the programme was integrated diagnostics and massive computing. Participants discussed the opportunities, challenges, and consequences for the discipline of radiology that will likely arise from the integration of diagnostic technologies. Diagnostic technologies are increasing in scope, including advanced imaging techniques, new molecular imaging agents, and sophisticated point-of-use devices. Advanced information technology (IT), which is increasingly influencing the practice of medicine, will aid clinical communication and the development of "population images" that represent the phenotype of particular diseases, which will aid the development of diagnostic algorithms. Integrated diagnostics offer increased operational efficiency and benefits to patients through quicker and more accurate diagnoses. As physicians with the most expertise in IT, radiologists are well placed to take the lead in introducing IT solutions and cloud computing to promote integrated diagnostics. To achieve this, radiologists must adapt to include quantitative data on biomarkers in their reports. Radiologists must also increase their role as participating physicians, collaborating with other medical specialties, not only to avoid being sidelined by other specialties but also to better prepare as leaders in the selection and sequence of diagnostic procedures.
Key Points
aEuro cent New diagnostic technologies are yielding unprecedented amounts of diagnostic information.
aEuro cent Advanced IT/cloud computing will aid integration and analysis of diagnostic data.
aEuro cent Better diagnostic algorithms will lead to faster diagnosis and more rapid treatment.
C1 [Krestin, G. P.] Univ Med Ctr Rotterdam, Dept Radiol, Erasmus MC, Rotterdam, Netherlands.
[Grenier, P. A.] Hop La Pitie Salpetriere, Serv Radiol Polyvalente Diagnost & Intervent, Paris 13, France.
[Hricak, H.; Muellner, A.] Mem Sloane Kettering Canc Ctr, Dept Radiol, New York, NY 10065 USA.
[Jackson, V. P.] Indiana Univ Sch Med, Dept Radiol, Indianapolis, IN 46202 USA.
[Khong, P. L.] Univ Hong Kong, Dept Radiol, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
[Miller, J. C.; Thrall, J. H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02114 USA.
[Miller, J. C.; Thrall, J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Schwaiger, M.] Tech Univ Munich, Klinikum Rechts Isar, Nukl Med Klin & Poliklin, D-81675 Munich, Germany.
RP Krestin, GP (reprint author), Univ Med Ctr Rotterdam, Dept Radiol, Erasmus MC, Rotterdam, Netherlands.
EM g.p.krestin@erasmusmc.nl
OI schwaiger, markus /0000-0002-2305-7144
NR 75
TC 2
Z9 3
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0938-7994
J9 EUR RADIOL
JI Eur. Radiol.
PD NOV
PY 2012
VL 22
IS 11
BP 2283
EP 2294
DI 10.1007/s00330-012-2510-6
PG 12
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 021EZ
UT WOS:000309869400001
PM 22699871
ER
PT J
AU Haas, RLM
DeLaney, TF
O'Sullivan, B
Keus, RB
Le Pechoux, C
Olmi, P
Poulsen, JP
Seddon, B
Wang, D
AF Haas, Rick L. M.
DeLaney, Thomas F.
O'Sullivan, Brian
Keus, Ronald B.
Le Pechoux, Cecile
Olmi, Patricia
Poulsen, Jan-Peter
Seddon, Beatrice
Wang, Dian
TI Radiotherapy for Management of Extremity Soft Tissue Sarcomas: Why,
When, and Where?
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Review
DE Radiotherapy; Soft tissue sarcoma; Target volume delineation
ID MODULATED RADIATION-THERAPY; LOCAL-CONTROL; POSTOPERATIVE RADIOTHERAPY;
RANDOMIZED-TRIAL; PREOPERATIVE RADIOTHERAPY; SPARING SURGERY; PHASE-II;
COMPLICATIONS; FRACTURES; CHEMORADIATION
AB This critical review will focus on published data on the indications for radiotherapy in patients with extremity soft tissue sarcomas and its role in local control, survival, and treatment complications. The differences between pre- and postoperative radiotherapy will be discussed and consensus recommendations on target volume delineation proposed. (C) 2012 Elsevier Inc.
C1 [Haas, Rick L. M.] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands.
[DeLaney, Thomas F.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[O'Sullivan, Brian] Princess Margaret Hosp, Dept Radiat Oncol, Toronto, ON M4X 1K9, Canada.
[Keus, Ronald B.] Arnhems Radiotherapeut Inst, Dept Radiotherapy, Arnhem, Netherlands.
[Le Pechoux, Cecile] Inst Gustave Roussy, Dept Radiotherapy, F-94805 Villejuif, France.
[Olmi, Patricia] Ist Nazl Studio & Cura Tumori, Dept Radiotherapy, Milan, Italy.
[Poulsen, Jan-Peter] Oslo Univ Hosp, Norwegian Radium Hosp, Dept Radiotherapy, Oslo, Norway.
[Seddon, Beatrice] Univ Coll London Hosp, Dept Radiotherapy, London, England.
[Wang, Dian] Med Coll Wisconsin, Dept Radiat Oncol, Milwaukee, WI 53226 USA.
RP Haas, RLM (reprint author), Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Radiotherapy, Amsterdam, Netherlands.
EM r.haas@nki.nl
NR 31
TC 39
Z9 40
U1 1
U2 10
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD NOV 1
PY 2012
VL 84
IS 3
BP 572
EP 580
DI 10.1016/j.ijrobp.2012.01.062
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 017AI
UT WOS:000309560600034
PM 22520481
ER
PT J
AU Pashtan, IM
Recht, A
Ancukiewicz, M
Brachtel, E
Abi-Raad, RF
D'Alessandro, HA
Levy, A
Wo, JY
Hirsch, AE
Kachnic, LA
Goldberg, S
Specht, M
Gadd, M
Smith, BL
Powell, SN
Taghian, AG
AF Pashtan, Itai M.
Recht, Abram
Ancukiewicz, Marek
Brachtel, Elena
Abi-Raad, Rita F.
D'Alessandro, Helen A.
Levy, Antonin
Wo, Jennifer Y.
Hirsch, Ariel E.
Kachnic, Lisa A.
Goldberg, Saveli
Specht, Michelle
Gadd, Michelle
Smith, Barbara L.
Powell, Simon N.
Taghian, Alphonse G.
TI External Beam Accelerated Partial-Breast Irradiation Using 32 Gy in 8
Twice-Daily Fractions: 5-Year Results of a Prospective Study
SO INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
LA English
DT Article
ID CONFORMAL RADIATION-THERAPY; CONSERVING THERAPY; PROGESTERONE-RECEPTOR;
CONSENSUS STATEMENT; ESTROGEN-RECEPTOR; AMERICAN SOCIETY;
RANDOMIZED-TRIAL; CANCER; RISK; RADIOTHERAPY
AB Purpose: External beam accelerated partial breast irradiation (APBI) is an increasingly popular technique for treatment of patients with early stage breast cancer following breast-conserving surgery. Here we present 5-year results of a prospective trial.
Methods and Materials: From October 2003 through November 2005, 98 evaluable patients with stage I breast cancer were enrolled in the first dose step (32 Gy delivered in 8 twicedaily fractions) of a prospective, multi-institutional, dose escalation clinical trial of 3-dimensional conformal external beam APBI (3D-APBI). Median age was 61 years; median tumor size was 0.8 cm; 89% of tumors were estrogen receptor positive; 10% had a triple-negative-phenotype; and 1% had a HER-2-positive subtype. Median follow-up was 71 months (range, 2-88 months; interquartile range, 64-75 months).
Results: Five patients developed ipsilateral breast tumor recurrence (IBTR), for a 5-year actuarial IBTR rate of 5% (95% confidence interval [CI], 1%-10%). Three of these cases occurred in patients with triple-negative disease and 2 in non-triple-negative patients, for 5-year actuarial IBTR rates of 33% (95% CI, 0%-57%) and 2% (95% CI, 0%-6%; P<.0001), respectively. On multivariable analysis, triple-negative phenotype was the only predictor of IBTR, with borderline statistical significance after adjusting for tumor grade (P = . 0537).
Conclusions: Overall outcomes were excellent, particularly for patients with estrogen receptor-positive disease. Patients in this study with triple-negative breast cancer had a significantly higher IBTR rate than patients with other receptor phenotypes when treated with 3D-APBI. Larger, prospective 3D-APBI clinical trials should continue to evaluate the effect of hormone receptor phenotype on IBTR rates. (c) 2012 Elsevier Inc.
C1 [Abi-Raad, Rita F.; Levy, Antonin; Wo, Jennifer Y.; Goldberg, Saveli; Powell, Simon N.; Taghian, Alphonse G.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Pashtan, Itai M.] Harvard Radiat Oncol Program, Boston, MA USA.
[Recht, Abram] Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
[Brachtel, Elena] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[D'Alessandro, Helen A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Hirsch, Ariel E.] Boston Univ, Sch Med, Dept Radiat Oncol, Boston Med Ctr, Boston, MA 02118 USA.
[Kachnic, Lisa A.; Specht, Michelle; Gadd, Michelle; Smith, Barbara L.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Taghian, AG (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St, Boston, MA 02114 USA.
EM ataghian@partners.org
OI , Antonin/0000-0003-4798-8899
FU National Institutes of Health (NIH) National Cancer Institute (NCI)
[R01CA139118, P50CA089393]
FX This work was supported in part by National Institutes of Health (NIH)
National Cancer Institute (NCI) grants R01CA139118 and P50CA089393 (to
A.G.T.). The content is solely the responsibility of the authors and
does not necessarily represent the official views of NIH or NCI.
NR 20
TC 19
Z9 19
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0360-3016
J9 INT J RADIAT ONCOL
JI Int. J. Radiat. Oncol. Biol. Phys.
PD NOV 1
PY 2012
VL 84
IS 3
BP E271
EP E277
DI 10.1016/j.ijrobp.2012.04.019
PG 7
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 017AI
UT WOS:000309560600002
PM 22652104
ER
PT J
AU Vargas-Lowy, D
Chitnis, T
AF Vargas-Lowy, David
Chitnis, Tanuja
TI Pathogenesis of Pediatric Multiple Sclerosis
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE pathogenesis; multiple sclerosis; demyelination
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; VITAMIN-D-RECEPTOR;
EPSTEIN-BARR-VIRUS; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC
ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; B-CELL FOLLICLES; BLOOD
MONONUCLEAR-CELLS; REGULATORY T-CELLS; EARLY-ONSET MS
AB Onset of multiple sclerosis in childhood occurs in 3-5% of patients. There is limited, but growing knowledge about the underlying pathobiology of pediatric MS. It is crucial to better understand this area in order to address central questions in the field: 1) Can pediatric multiple sclerosis inform us about factors related to disease initiation and propagation? 2) What are the biomarkers of disease course in pediatric multiple sclerosis; 3) Does pediatric multiple sclerosis pathogenesis differ from adult-onset multiple sclerosis; 4) How can we optimize treatment in pediatric demyelinating diseases? 5) Can pediatric multiple sclerosis provide insights into the environmental risk factors for multiple sclerosis in general? Here we review the current knowledge of the pathogenesis of multiple sclerosis in children, and address the five questions raised above.
C1 [Vargas-Lowy, David; Chitnis, Tanuja] Brigham & Womens Hosp, Ctr Neurol Dis, Dept Neurol, Boston, MA 02115 USA.
[Chitnis, Tanuja] Massachusetts Gen Hosp, Partners Pediat MS Ctr, Boston, MA 02114 USA.
RP Chitnis, T (reprint author), Massachusetts Gen Hosp Children, Partners Pediat Multiple Sclerosis Ctr, Boston, MA 02114 USA.
EM tchitnis@partners.org
NR 169
TC 12
Z9 13
U1 2
U2 15
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
J9 J CHILD NEUROL
JI J. Child Neurol.
PD NOV
PY 2012
VL 27
IS 11
BP 1394
EP 1407
DI 10.1177/0883073812456084
PG 14
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 023IL
UT WOS:000310026000004
PM 22952316
ER
PT J
AU Lawson, EH
Gibbons, MM
Ko, CY
Shekelle, PG
AF Lawson, Elise H.
Gibbons, Melinda Maggard
Ko, Clifford Y.
Shekelle, Paul G.
TI The appropriateness method has acceptable reliability and validity for
assessing overuse and underuse of surgical procedures
SO JOURNAL OF CLINICAL EPIDEMIOLOGY
LA English
DT Review
DE Appropriateness; Surgery; Reliability; Validity; Overuse; Underuse
ID UPPER GASTROINTESTINAL ENDOSCOPY; CORONARY REVASCULARIZATION; EXPERT
PANELS; CAROTID-ENDARTERECTOMY; MYOCARDIAL-INFARCTION; EXPLICIT
CRITERIA; PHYSICIAN RATINGS; KNEE REPLACEMENT; CATARACT-SURGERY;
GUIDELINES
AB Objective: To summarize the findings of methodological studies on the RAND/University of California Los Angeles (RAND/UCLA) appropriateness method, which was developed to assess if variation in the use of surgical procedures is because of overuse and/or underuse.
Study Design and Setting: A MEDLINE literature search was performed. Studies were included if they assessed the reliability or validity of the RAND/UCLA appropriateness method for a surgical procedure or the effect of altering panelist composition or eliminating in-person discussion between rating rounds. Information was abstracted on procedure, study design, and findings.
Results: One thousand six hundred one titles were identified, and 37 met the inclusion criteria. The test-retest reliability is good to very good (kappa, 0.64-0.81) for total knee and hip joint replacement, coronary artery bypass grafting (CABG), and carotid endarterectomy (CEA). The interpanel reliability is moderate to very good (kappa, 0.52-0.83) for CABG and hysterectomy. Construct validity has been demonstrated by comparing the appropriateness method with guidelines and/or evidence-based approaches for endoscopy, colonoscopy, CABG, hysterectomy, and CEA. Predictive validity has been studied for cardiac revascularization, in which concordance with appropriateness classification is associated with better clinical outcomes.
Conclusion: Our findings support use of the appropriateness method to assess variation in the rates of the procedures studied by identifying overuse and underuse. Further methodological research should be conducted as appropriateness criteria are developed and implemented for a broader range of procedures. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lawson, Elise H.] Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Lawson, Elise H.; Ko, Clifford Y.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL 60611 USA.
[Gibbons, Melinda Maggard] Olive View UCLA Med Ctr, Dept Surg, Sylmar, CA 91342 USA.
[Ko, Clifford Y.; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA 90073 USA.
[Ko, Clifford Y.; Shekelle, Paul G.] VA Greater Los Angeles Healthcare Syst, Dept Med, Los Angeles, CA 90073 USA.
[Shekelle, Paul G.] RAND Corp, Santa Monica, CA 90401 USA.
RP Lawson, EH (reprint author), Univ Calif Los Angeles, Med Ctr, Dept Surg, David Geffen Sch Med, 10833 LeConte Ave,CHS 72-215, Los Angeles, CA 90095 USA.
EM elawson@mednet.ucla.edu
FU American College of Surgeons through RWJF CSP
FX The authors acknowledge Dr Angela Ingraham for her help with the initial
screening of articles. This study received no external funding. Dr
Lawson's time was supported by the American College of Surgeons through
RWJF CSP. The remaining three authors participated through their roles
as advisors to the RWJF CSP.
NR 59
TC 23
Z9 23
U1 0
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0895-4356
J9 J CLIN EPIDEMIOL
JI J. Clin. Epidemiol.
PD NOV
PY 2012
VL 65
IS 11
BP 1133
EP 1143
DI 10.1016/j.jclinepi.2012.07.002
PG 11
WC Health Care Sciences & Services; Public, Environmental & Occupational
Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 017DY
UT WOS:000309571500002
PM 23017632
ER
PT J
AU Hao, SC
Hunter, TD
Gunnarsson, C
March, JL
White, SA
Ladapo, JA
Reynolds, MR
AF Hao, Steven C.
Hunter, Tina D.
Gunnarsson, Candace
March, Jamie L.
White, Sarah A.
Ladapo, Joseph A.
Reynolds, Matthew R.
TI Acute safety outcomes in younger and older patients with atrial
fibrillation treated with catheter ablation
SO JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY
LA English
DT Article
DE Catheter ablation; Atrial fibrillation; Radiofrequency ablation; Stroke
ID ANTIARRHYTHMIC-DRUGS; RADIOFREQUENCY ABLATION; PREVALENCE; MANAGEMENT;
TRIAL; EFFICACY; THERAPY; HEALTH; RISK; AGE
AB Catheter ablation for atrial fibrillation (AF) has been demonstrated to be safe and effective in subsets of patients with AF, but primarily in patients age < 65. This study compared acute safety in patients age a parts per thousand yen65 vs. those < 65 who have undergone catheter ablation for AF.
A retrospective analysis of data from two Thomson Reuters MarketScanA (R) research databases was performed on 5,947 patients who underwent catheter ablation for treatment of AF. Acute safety was measured as a composite endpoint of procedure-related adverse events coded a parts per thousand currency sign7 days post-procedure. A logistic regression model was fitted to this endpoint, using age (< 65, a parts per thousand yen65) and relevant covariates. Peri-procedural mortality rates were examined among patients with inpatient ablation procedures, where death rates could be determined by discharge status.
The acute safety event rate was nearly identical between both groups. This finding persisted after adjusting for covariates in the logistic regression model (p = 0.6648). There were no peri-procedural mortalities among the 3,575 index ablation procedures performed in an inpatient setting.
Acute safety of catheter ablation for AF in patients a parts per thousand yen65 was consistent with that of younger patients. A prior history of hypertension and stroke was associated with a high risk for complications with AF ablation. These findings in a large, real world population may have implications for Medicare patients with AF.
C1 [Hunter, Tina D.; Gunnarsson, Candace] S2 Stat Solut Inc, Cincinnati, OH 45241 USA.
[Hao, Steven C.] Sutter Pacific Med Fdn, San Francisco, CA 94115 USA.
[March, Jamie L.; White, Sarah A.] Biosense Webster Inc, Global Hlth Econ Outcomes Res & Policy, Diamond Bar, CA 91765 USA.
[Ladapo, Joseph A.] New York Univ, Sch Med, Dept Med, New York, NY 10016 USA.
[Reynolds, Matthew R.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Reynolds, Matthew R.] VA Boston Healthcare Syst, Cardiol, W Roxbury, MA 02132 USA.
RP Gunnarsson, C (reprint author), S2 Stat Solut Inc, 11176 Main St, Cincinnati, OH 45241 USA.
EM candaceg@s2stats.com
OI Ladapo, Joseph/0000-0002-8518-4800
FU Biosense Webster, Inc.; Sanofi-Aventis; Biosense Webster, Inc., Diamond
Bar, CA
FX Steven Hao, MD, FACC, FHRS is a consultant for Biosense Webster, Inc.,
and Medtronic. Tina Hunter, PhD and Candace Gunnarsson, EdD are
employees of S2 Statistical Solutions, Inc., which is a paid
consultant to Biosense Webster, Inc. Jamie March, MBA, and Sarah White,
MPH were employed by Biosense Webster, Inc., when the research was
conducted. Joseph Ladapo, MD, PhD is a paid consultant for S2
Statistical Solutions, Inc. Matthew Reynolds, MD, MSc has received
research grants on behalf of Biosense Webster, Inc., and Sanofi-Aventis
and consulting/honoraria from Biosense Webster, Inc., Sanofi-Aventis,
and St. Jude Medical. This study was funded by Biosense Webster, Inc.,
Diamond Bar, CA
NR 27
TC 6
Z9 6
U1 1
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1383-875X
J9 J INTERV CARD ELECTR
JI J. Interv. Card. Electrophysiol.
PD NOV
PY 2012
VL 35
IS 2
BP 173
EP 182
DI 10.1007/s10840-012-9690-5
PG 10
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 021CF
UT WOS:000309862200007
PM 22714547
ER
PT J
AU Kloverpris, HN
Harndahl, M
Leslie, AJ
Carlson, JM
Ismail, N
van der Stok, M
Huang, KHG
Chen, FB
Riddell, L
Steyn, D
Goedhals, D
van Vuuren, C
Frater, J
Walker, BD
Carrington, M
Ndung'u, T
Buus, S
Goulder, P
AF Kloverpris, Henrik N.
Harndahl, Mikkel
Leslie, Alasdair J.
Carlson, Jonathan M.
Ismail, Nasreen
van der Stok, Mary
Huang, Kuan-Hsiang Gary
Chen, Fabian
Riddell, Lynn
Steyn, Dewald
Goedhals, Dominique
van Vuuren, Cloete
Frater, John
Walker, Bruce D.
Carrington, Mary
Ndung'u, Thumbi
Buus, Soren
Goulder, Philip
TI HIV Control through a Single Nucleotide on the HLA-B Locus
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL RESPONSES; CLASS-I ALLELES; IMMUNE
CONTROL; ANTIGEN PRESENTATION; SELECTION PRESSURE; MICROPOLYMORPHISM;
EPITOPES; AIDS; ASSOCIATIONS
AB Genetic variation within the HLA-B locus has the strongest impact on HIV disease progression of any polymorphisms within the human genome. However, identifying the exact mechanism involved is complicated by several factors. HLA-Bw4 alleles provide ligands for NK cells and for CD8 T cells, and strong linkage disequilibrium between HLA class I alleles complicates the discrimination of individual HLA allelic effects from those of other HLA and non-HLA alleles on the same haplotype. Here, we exploit an experiment of nature involving two recently diverged HLA alleles, HLA-B(star)42:01 and HLA-B(star)42:02, which differ by only a single amino acid. Crucially, they occur primarily on identical HLA class I haplotypes and, as Bw6 alleles, do not act as NK cell ligands and are therefore largely unconfounded by other genetic factors. We show that in an outbred cohort (n = 2,093) of HIV C-clade-infected individuals, a single amino acid change at position 9 of the HLA-B molecule critically affects peptide binding and significantly alters the cytotoxic T lymphocyte (CTL) epitopes targeted, measured directly ex vivo by gamma interferon (IFN-gamma) enzyme-linked immunospot (ELISPOT) assay (P = 2 x 10(-10)) and functionally through CTL escape mutation (P = 2 x 10(-8)). HLA-B(star)42:01, which presents multiple Gag epitopes, is associated with a 0.52 log(10) lower viral-load set point than HLA-B(star)42:02 (P = 0.02), which presents no p24 Gag epitopes. The magnitude of this effect from a single amino acid difference in the HLA-A(star)30:01/B(star)42/Cw(star)17:01 haplotype is equivalent to 75% of that of HLA-B(star)57:03, the most protective HLA class I allele in this population. This naturally controlled experiment represents perhaps the clearest demonstration of the direct impact of a particular HIV-specific CTL on disease control.
C1 [Kloverpris, Henrik N.; Leslie, Alasdair J.; Goulder, Philip] Univ Oxford, Dept Paediat, Oxford, England.
[Harndahl, Mikkel; Buus, Soren] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Copenhagen, Denmark.
[Ismail, Nasreen; van der Stok, Mary; Walker, Bruce D.; Ndung'u, Thumbi; Goulder, Philip] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Program, Durban, South Africa.
[Walker, Bruce D.; Carrington, Mary; Ndung'u, Thumbi; Goulder, Philip] Massachusetts Inst Technol & Harvard, Massachusetts Gen Hosp, Ragon Inst, Boston, MA USA.
[Chen, Fabian] Royal Berkshire Hosp, Dept Sexual Hlth, Reading RG1 5AN, Berks, England.
[Riddell, Lynn] Northampton Gen Hosp, Northamptonshire Healthcare Natl Hlth Serv Trust, Dept Genitourinary Med, Northampton, England.
[Huang, Kuan-Hsiang Gary; Frater, John] Univ Oxford, Nuffield Dept Clin Med, Oxford, England.
[Carlson, Jonathan M.] Microsoft Res, eSci Grp, Los Angeles, CA USA.
[Steyn, Dewald; Goedhals, Dominique; van Vuuren, Cloete] Univ Orange Free State, Bloemfontein, South Africa.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Carrington, Mary] SAIC Frederick Inc, Canc & Inflammat Program, Expt Immunol Lab, Frederick Natl Lab Canc Res, Frederick, MD USA.
RP Kloverpris, HN (reprint author), Univ Oxford, Dept Paediat, Oxford, England.
EM henrik.kloverpris@paediatrics.ox.ac.uk
RI Buus, Soren/F-5446-2010;
OI Buus, Soren/0000-0001-8363-1999; Ndung'u, Thumbi/0000-0003-2962-3992
FU Wellcome Trust; National Institutes of Health [RO1 AI46995]; Frederick
National Laboratory for Cancer Research [HHSN261200800001E]; NIH,
Frederick National Laboratory, Center for Cancer Research
FX This work was supported by the Wellcome Trust (P.G.) and National
Institutes of Health grant RO1 AI46995. This project has been funded in
whole or in part with federal funds from the Frederick National
Laboratory for Cancer Research under contract no. HHSN261200800001E.
This research was supported in part by the Intramural Research Program
of the NIH, Frederick National Laboratory, Center for Cancer Research.
NR 52
TC 20
Z9 20
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2012
VL 86
IS 21
BP 11493
EP 11500
DI 10.1128/JVI.01020-12
PG 8
WC Virology
SC Virology
GA 018JT
UT WOS:000309657100008
PM 22896606
ER
PT J
AU Vomaske, J
Denton, M
Kreklywich, C
Andoh, T
Osborn, JM
Chen, D
Messaoudi, I
Orloff, SL
Streblow, DN
AF Vomaske, Jennifer
Denton, Michael
Kreklywich, Craig
Andoh, Takeshi
Osborn, Jessica M.
Chen, Daniel
Messaoudi, Ilhem
Orloff, Susan L.
Streblow, Daniel N.
TI Cytomegalovirus CC Chemokine Promotes Immune Cell Migration
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TRANSPLANT VASCULAR SCLEROSIS; LATENT HUMAN CYTOMEGALOVIRUS; APOE
KNOCKOUT MICE; RAT SMALL-BOWEL; CHRONIC REJECTION; ALLOGRAFT-REJECTION;
CARDIAC ALLOGRAFTS; HEART-TRANSPLANTS; INFECTION; RECEPTOR
AB Cytomegaloviruses manipulate the host chemokine/receptor axis by altering cellular chemokine expression and by encoding multiple chemokines and chemokine receptors. Similar to human cytomegalovirus (HCMV), rat cytomegalovirus (RCMV) encodes multiple CC chemokine-analogous proteins, including r129 (HCMV UL128 homologue) and r131 (HCMV UL130 and MCMV m129/130 homologues). Although these proteins play a role in CMV entry, their function as chemotactic cytokines remains unknown. In the current study, we examined the role of the RCMV chemokine r129 in promoting cellular migration and in accelerating transplant vascular sclerosis (TVS) in our rat heart transplant model. We determined that r129 protein is released into culture supernatants of infected cells and is expressed with late viral gene kinetics during RCMV infection and highly expressed in heart and salivary glands during in vivo rat infections. Using the recombinant r129 protein, we demonstrated that r129 induces migration of lymphocytes isolated from rat peripheral blood, spleen, and bone marrow and from a rat macrophage cell line. Using antibody-mediated cell sorting of rat splenocytes, we demonstrated that r129 induces migration of naive/central memory CD4(+) T cells. Through ligand-binding assays, we determined that r129 binds rat CC chemokine receptors CCR3, CCR4, CCR5, and CCR7. In addition, mutational analyses identified functional domains of r129 resulting in recombinant proteins that fail to induce migration (r129-Delta NT and -C31A) or alter the chemotactic ability of the chemokine (r129-F43A). Two of the mutant proteins (r129-C31A and -Delta NT) also act as dominant negatives by inhibiting migration induced by wild-type r129. Furthermore, infection of rat heart transplant recipients with RCMV containing the r129-Delta NT mutation prevented CMV-induced acceleration of TVS. Together our findings indicate that RCMV r129 is highly chemotactic, which has important implications during RCMV infection and reactivation and acceleration of TVS.
C1 [Vomaske, Jennifer; Denton, Michael; Osborn, Jessica M.; Chen, Daniel; Messaoudi, Ilhem; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
[Kreklywich, Craig; Andoh, Takeshi; Orloff, Susan L.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
[Kreklywich, Craig; Andoh, Takeshi; Orloff, Susan L.] Portland VA Med Ctr, Portland, OR USA.
[Vomaske, Jennifer; Denton, Michael; Osborn, Jessica M.; Chen, Daniel; Messaoudi, Ilhem; Streblow, Daniel N.] Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA.
RP Streblow, DN (reprint author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
EM streblow@ohsu.edu
FU National Institutes of Health [HL 083194, HL 66238-01, HL 088603]
FX This work was supported by research grants from the National Institutes
of Health to D. N. Streblow (HL 083194), S. L. Orloff (HL 66238-01), and
J. A. Nelson (HL 088603).
NR 55
TC 13
Z9 13
U1 0
U2 5
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD NOV
PY 2012
VL 86
IS 21
BP 11833
EP 11844
DI 10.1128/JVI.00452-12
PG 12
WC Virology
SC Virology
GA 018JT
UT WOS:000309657100039
PM 22915808
ER
PT J
AU Kelly, JM
Bianchi, MT
AF Kelly, Jessica M.
Bianchi, Matt T.
TI Mammalian sleep genetics
SO NEUROGENETICS
LA English
DT Review
DE Phenotype; Architecture; Electroencephalogram; Transgenic; Circadian
ID EYE-MOVEMENT SLEEP; KNOCK-OUT MICE; TRANSGENIC MOUSE MODEL; GABA(A)
RECEPTOR SUBTYPE; PROTEIN-DEFICIENT MICE; GATED ION CHANNELS;
OREXIN-NULL MICE; PRION PROTEIN; REM-SLEEP; ALZHEIMERS-DISEASE
AB Mammalian sleep is a complex phenomenon governed by the interplay of neural circuits and signaling systems. The impact of genetic manipulations on sleep-wake dynamics provides important insights into this complex behavior. Here we review the sleep-related phenotypes of over 50 transgenic animal models spanning a variety of signaling systems. This heterogeneous literature includes outcomes spanning motor activity patterns, sleep-wake stage architecture, responses to sleep deprivation, circadian rhythmicity, and other perturbations such as food restriction, temperature challenge, and infection exposure. Insights from these animal experiments hold potential to converge with the well-known sleep-wake neurocircuitry as well as the increasingly available human genetic information, especially in patient populations exhibiting sleep-wake pathology.
C1 [Kelly, Jessica M.; Bianchi, Matt T.] Massachusetts Gen Hosp, Dept Neurol, Sleep Div, Boston, MA 02114 USA.
RP Bianchi, MT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Sleep Div, 55 Fruit St, Boston, MA 02114 USA.
EM mtbianchi@partners.org
FU Department of Neurology, Massachusetts General Hospital; Center for
Integration of Medicine and Innovative Technology; Harvard Catalyst KL2
Medical Research Investigator Fellowship
FX Dr. Bianchi receives funding from the Department of Neurology,
Massachusetts General Hospital, a Young Clinician Award from the Center
for Integration of Medicine and Innovative Technology, and a Harvard
Catalyst KL2 Medical Research Investigator Fellowship.
NR 173
TC 5
Z9 5
U1 2
U2 14
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
J9 NEUROGENETICS
JI Neurogenetics
PD NOV
PY 2012
VL 13
IS 4
BP 287
EP 326
DI 10.1007/s10048-012-0341-x
PG 40
WC Genetics & Heredity; Clinical Neurology
SC Genetics & Heredity; Neurosciences & Neurology
GA 021DV
UT WOS:000309866400001
PM 22976546
ER
PT J
AU Flaherty, KT
Infante, JR
Daud, A
Gonzalez, R
Kefford, RF
Sosman, J
Hamid, O
Schuchter, L
Cebon, J
Ibrahim, N
Kudchadkar, R
Burris, HA
Falchook, G
Algazi, A
Lewis, K
Long, GV
Puzanov, I
Lebowitz, P
Singh, A
Little, S
Sun, P
Allred, A
Ouellet, D
Kim, KB
Patel, K
Weber, J
AF Flaherty, Keith T.
Infante, Jeffery R.
Daud, Adil
Gonzalez, Rene
Kefford, Richard F.
Sosman, Jeffrey
Hamid, Omid
Schuchter, Lynn
Cebon, Jonathan
Ibrahim, Nageatte
Kudchadkar, Ragini
Burris, Howard A., III
Falchook, Gerald
Algazi, Alain
Lewis, Karl
Long, Georgina V.
Puzanov, Igor
Lebowitz, Peter
Singh, Ajay
Little, Shonda
Sun, Peng
Allred, Alicia
Ouellet, Daniele
Kim, Kevin B.
Patel, Kiran
Weber, Jeffrey
TI Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID DOSE-ESCALATION TRIAL; CELL LUNG-CANCER; RAF INHIBITORS; METASTATIC
MELANOMA; IMPROVED SURVIVAL; RESISTANCE; KINASE; EFFICACY; PATHWAY;
SAFETY
AB Background
Resistance to therapy with BRAF kinase inhibitors is associated with reactivation of the mitogen-activated protein kinase (MAPK) pathway. To address this problem, we conducted a phase 1 and 2 trial of combined treatment with dabrafenib, a selective BRAF inhibitor, and trametinib, a selective MAPK kinase (MEK) inhibitor.
Methods
In this open-label study involving 247 patients with metastatic melanoma and BRAF V600 mutations, we evaluated the pharmacokinetic activity and safety of oral dabrafenib (75 or 150 mg twice daily) and trametinib (1, 1.5, or 2 mg daily) in 85 patients and then randomly assigned 162 patients to receive combination therapy with dabrafenib (150 mg) plus trametinib (1 or 2 mg) or dabrafenib monotherapy. The primary end points were the incidence of cutaneous squamous-cell carcinoma, survival free of melanoma progression, and response. Secondary end points were overall survival and pharmacokinetic activity.
Results
Dose-limiting toxic effects were infrequently observed in patients receiving combination therapy with 150 mg of dabrafenib and 2 mg of trametinib (combination 150/2). Cutaneous squamous-cell carcinoma was seen in 7% of patients receiving combination 150/2 and in 19% receiving monotherapy (P = 0.09), whereas pyrexia was more common in the combination 150/2 group than in the monotherapy group (71% vs. 26%). Median progression-free survival in the combination 150/2 group was 9.4 months, as compared with 5.8 months in the monotherapy group (hazard ratio for progression or death, 0.39; 95% confidence interval, 0.25 to 0.62; P<0.001). The rate of complete or partial response with combination 150/2 therapy was 76%, as compared with 54% with monotherapy (P = 0.03).
Conclusions
Dabrafenib and trametinib were safely combined at full monotherapy doses. The rate of pyrexia was increased with combination therapy, whereas the rate of proliferative skin lesions was nonsignificantly reduced. Progression-free survival was significantly improved. (Funded by GlaxoSmithKline; ClinicalTrials.gov number, NCT01072175.)
C1 [Kudchadkar, Ragini; Weber, Jeffrey] Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA.
[Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Ibrahim, Nageatte] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Infante, Jeffery R.; Burris, Howard A., III] Vanderbilt Univ, Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA.
[Sosman, Jeffrey; Puzanov, Igor] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Daud, Adil; Algazi, Alain] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Gonzalez, Rene; Lewis, Karl] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Kefford, Richard F.; Long, Georgina V.] Univ Sydney, Melanoma Inst Australia, Westmead Inst Canc Res, Sydney, NSW 2006, Australia.
[Kefford, Richard F.; Long, Georgina V.] Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
[Cebon, Jonathan] Austin Hosp, Ludwig Inst Canc Res, Heidelberg, Vic 3084, Australia.
[Hamid, Omid] Angeles Clin & Res Inst, Los Angeles, CA USA.
[Schuchter, Lynn] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Falchook, Gerald] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA.
[Kim, Kevin B.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Div Canc Med, Houston, TX 77030 USA.
[Lebowitz, Peter; Singh, Ajay; Little, Shonda; Sun, Peng; Allred, Alicia; Ouellet, Daniele; Patel, Kiran] GlaxoSmithKline, Collegeville, PA USA.
RP Weber, J (reprint author), Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA.
EM jeffrey.weber@moffitt.org
RI Long, Georgina/C-1771-2013
FU GlaxoSmithKline
FX Supported by GlaxoSmithKline.
NR 27
TC 801
Z9 814
U1 5
U2 95
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 1
PY 2012
VL 367
IS 18
BP 1694
EP 1703
DI 10.1056/NEJMoa1210093
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 028RS
UT WOS:000310440800006
ER
PT J
AU Greene, MF
AF Greene, Michael F.
TI Two Hundred Years of Progress in the Practice of Midwifery
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Review
ID IN-VITRO FERTILIZATION; SICKLE-CELL-ANEMIA; MATERNAL PLASMA;
PRENATAL-DIAGNOSIS; PREGNANCY; DNA; DELIVERY; TRIAL; RATES;
ERYTHROBLASTOSIS
C1 [Greene, Michael F.] Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02114 USA.
[Greene, Michael F.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA USA.
RP Greene, MF (reprint author), Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, 55 Fruit St, Boston, MA 02114 USA.
EM mfgreene@partners.org
NR 50
TC 5
Z9 6
U1 1
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 1
PY 2012
VL 367
IS 18
BP 1732
EP 1740
DI 10.1056/NEJMra1209764
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 028RS
UT WOS:000310440800010
PM 23113484
ER
PT J
AU Rosenbaum, L
AF Rosenbaum, Lisa
TI How Much Would You Give to Save a Dying Bird? Patient Advocacy and
Biomedical Research
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID HIGH-DOSE CHEMOTHERAPY; BREAST-CANCER
C1 [Rosenbaum, Lisa] Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
[Rosenbaum, Lisa] Univ Penn, Robert Wood Johnson Fdn, Clin Scholars Program, Philadelphia, PA 19104 USA.
RP Rosenbaum, L (reprint author), Univ Penn, Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
NR 8
TC 2
Z9 2
U1 0
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD NOV 1
PY 2012
VL 367
IS 18
BP 1755
EP 1759
DI 10.1056/NEJMms1207114
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA 028RS
UT WOS:000310440800016
PM 23113489
ER
PT J
AU Eckstein, F
Mc Culloch, CE
Lynch, JA
Nevitt, M
Kwoh, CK
Maschek, S
Hudelmaier, M
Sharma, L
Wirth, W
AF Eckstein, F.
Mc Culloch, C. E.
Lynch, J. A.
Nevitt, M.
Kwoh, C. K.
Maschek, S.
Hudelmaier, M.
Sharma, L.
Wirth, W.
CA OA Initiative Investigators Grp
TI How do short-term rates of femorotibial cartilage change compare to
long-term changes? Four year follow-up data from the osteoarthritis
initiative
SO OSTEOARTHRITIS AND CARTILAGE
LA English
DT Article
DE Short term; Long term; Knee; Cartilage thickness; Magnetic resonance
imaging; Osteoarthritis
ID MULTICENTER CLINICAL-TRIAL; SYMPTOMATIC KNEE OSTEOARTHRITIS;
QUANTITATIVE MRI; 3 TESLA; PRECISION; PROGRESSION; MORPHOLOGY;
SENSITIVITY; MORPHOMETRY; DESIGN
AB Objective: To compare unbiased estimates of short- vs long-term cartilage loss in osteoarthritic knees.
Method: 441 knees [216 Kellgren Lawrence (KL) grade 2, 225 la grade 3] from participants of the Osteoarthritis Initiative were studied over a 4-year period. Femorotibial cartilage thickness was determined using 3 T double echo steady state magnetic resonance imaging, the readers being blinded to time points. Because common measurement time points bias correlations, short-term change (year-1 to year-2: Y1 -> Y2) was compared with long-term change (baseline to year-4: BL -> Y4), and initial (BL -> Y1) with subsequent (Y2 -> Y4) observation periods.
Results: The mean femorotibial cartilage thickness change (standardized response mean) was -1.2%/-0.8% (-0.42/-0.28) over 1 (BL -> Y1/Y1 -> Y2), -2.1%/-2.5% (-0.56/-0.55) over 2 (BL -> Y2/Y2 -> Y4), -3.3% (-0.63) over 3 (Y1 -> Y4), and -4.5% (-0.78) over 4 years. Spearman correlations were 0.33 for Y1 -> Y2 vs BL -> Y4, and 0.17 for BL -> Y1 vs Y2 -> Y4 change. Percent agreement between knees showing progression during Y1 -> Y2 vs BL -> Y4 was 59%, and 64% for BL -> Y1 vs Y2 -> Y4. The area under the receiver operating characteristic curve was 0.66 for using Y1 -> Y2 to predict BL -> Y4, and 0.59 for using BL -> Y1 to predict Y2 -> Y4 change.
Conclusion: Weak to moderate correlations and agreement were observed between individual short- vs long-term cartilage loss, and between initial and subsequent observation periods. Hence, longer observation periods are recommended to achieve robust results on cartilage loss in individual knees. At cohort and subcohort level (e.g., KLG3 vs KLG2 knees), the mean cartilage loss increased almost linearly with the length of the observation period and was constant throughout the study. (C) 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
C1 [Eckstein, F.; Maschek, S.; Hudelmaier, M.; Wirth, W.] Paracelsus Med Univ, Inst Anat & Musculoskeletal Res, Salzburg, Austria.
[Eckstein, F.; Maschek, S.; Hudelmaier, M.; Wirth, W.] Chondrometr GmbH, Ainring, Germany.
[Mc Culloch, C. E.; Lynch, J. A.; Nevitt, M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kwoh, C. K.] Univ Pittsburgh, Div Rheumatol & Clin Immunol, Pittsburgh, PA USA.
[Kwoh, C. K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Sharma, L.] Northwestern Univ, Feinberg Sch Med, Div Rheumatol, Evanston, IL 60208 USA.
RP Eckstein, F (reprint author), PMU, Inst Anat & Musculoskeletal Res, Strubergasse 21, A-5020 Salzburg, Austria.
EM felix.eckstein@pmu.ac.at
RI Wirth, Wolfgang/C-8724-2011
OI Wirth, Wolfgang/0000-0002-2297-8283
FU OAI [N01-AR-2-2258, N01-AR-2-2259, N01-AR-2-2260, N01-AR-2-2261,
N01-AR-2-2262]; National Institutes of Health, a branch of the
Department of Health and Human Services; Merck Research Laboratories;
Novartis Pharmaceuticals Corporation; GlaxoSmithKline; Pfizer, Inc.; OAI
coordinating center at UCSF [N01-AR-2-2258]; Division of Rheumatology,
Feinberg School of Medicine, Northwestern University [R01 AR52918];
University of Pittsburgh [HHSN2682010000 21C]
FX The study and image acquisition was funded by the OAI, a public private
partnership comprised five contracts (N01-AR-2-2258; N01-AR-2-2259;
N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262), funded by the National
Institutes of Health, a branch of the Department of Health and Human
Services, and conducted by the OAI Study Investigators. Private funding
partners include Merck Research Laboratories; Novartis Pharmaceuticals
Corporation; GlaxoSmithKline; and Pfizer, Inc. Private sector funding
for the OAI is managed by the Foundation for the National Institutes of
Health. The image analysis of this study was funded by a vendor contract
from the OAI coordinating center at UCSF (N01-AR-2-2258), an ancillary
study to the OAI held by the Division of Rheumatology, Feinberg School
of Medicine, Northwestern University (R01 AR52918), and a contract held
by the University of Pittsburgh [Pivotal OAI MRI Analyses (POMA),
NIH/NHLBI Contract No. HHSN2682010000 21C]. The sponsors were not
directly involved in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review, or approval of the manuscript. However, the manuscript has
received approval of the OAI Publications Committee based on a review of
its scientific content and data interpretation.
NR 30
TC 20
Z9 20
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1063-4584
J9 OSTEOARTHR CARTILAGE
JI Osteoarthritis Cartilage
PD NOV
PY 2012
VL 20
IS 11
BP 1250
EP 1257
DI 10.1016/j.joca.2012.06.019
PG 8
WC Orthopedics; Rheumatology
SC Orthopedics; Rheumatology
GA 020YV
UT WOS:000309853400006
PM 22800771
ER
PT J
AU Hostetler, CM
Anacker, AMJ
Loftis, JM
Ryabinin, AE
AF Hostetler, Caroline M.
Anacker, Allison M. J.
Loftis, Jennifer M.
Ryabinin, Andrey E.
TI Social housing and alcohol drinking in male-female pairs of prairie
voles (Microtus ochrogaster)
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Prairie voles; Social behavior; Alcohol self-administration; Social
influence
ID EXTENDED OLFACTORY AMYGDALA; RAT LINES; NUCLEUS-ACCUMBENS; ANXIETY
DISORDERS; ETHANOL INTAKE; VOLUNTARY ETHANOL; BEHAVIOR; AMPHETAMINE;
MODULATION; AGGRESSION
AB Social environment influences alcohol consumption in humans; however, animal models have only begun to address biological underpinnings of these effects.
We investigated whether social influences on alcohol drinking in the prairie vole are specific to the sex of the social partner.
In Experiment 1, control, sham, and gonadectomized voles were placed either in mesh-divided housing with a same-sex sibling or isolation with access to ethanol. In Experiment 2, animals were given an elevated plus maze test (EPM) and then females were paired with a castrated male followed by isolation or mesh-divided housing with access to ethanol. In Experiment 3, subjects categorized as low or high drinkers based on initial ethanol intake were placed in mesh-divided housing with an opposite-sex partner of the same or opposite drinking group and ethanol access. Subjects were then moved back to isolation for a final ethanol access period.
Same-sex pairs showed social facilitation of drinking similar to previous reports. Gonadectomy did not affect alcohol drinking. Opposite-sex paired animals in Experiment 2 did not differ in alcohol drinking based on social housing. EPM measures suggested a relationship between anxiety-like behaviors and drinking that depended on social environment. Experiment 3 identified moderate changes in alcohol preference based on social housing, but these effects were influenced by the animal's own drinking behavior and were independent of their partner's drinking.
Social influences on alcohol self-administration in prairie voles differ based on the sex of a social partner, consistent with human drinking behavior.
C1 [Hostetler, Caroline M.; Anacker, Allison M. J.; Ryabinin, Andrey E.] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
[Loftis, Jennifer M.] Portland VA Med Ctr, Res & Dev Serv, Portland, OR 97239 USA.
[Loftis, Jennifer M.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97239 USA.
RP Hostetler, CM (reprint author), Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97239 USA.
EM caroline.hostetler@gmail.com
FU NIH [5T32AA007468-24, AA016886]; Portland VA Medical Center, Portland,
Oregon
FX We gratefully acknowledge Davelle Cocking, Lindsay Swanson, and the
Veterinary Medical Unit (VMU) animal care staff from the Portland VA
Medical Center for assistance on this project. This research was funded
by NIH 5T32AA007468-24 (to CMH) and NIH AA016886 (to AER). This material
is the result of work supported with resources and the use of facilities
at the Portland VA Medical Center, Portland, Oregon.
NR 62
TC 15
Z9 15
U1 5
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD NOV
PY 2012
VL 224
IS 1
BP 121
EP 132
DI 10.1007/s00213-012-2836-4
PG 12
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 018SB
UT WOS:000309681900011
PM 22903359
ER
PT J
AU Negahdar, M
Aukrust, I
Johansson, BB
Molnes, J
Molven, A
Matschinsky, FM
Sovik, O
Kulkarni, RN
Flatmark, T
Njolstad, PR
Bjorkhaug, L
AF Negahdar, Maria
Aukrust, Ingvild
Johansson, Bente B.
Molnes, Janne
Molven, Anders
Matschinsky, Franz M.
Sovik, Oddmund
Kulkarni, Rohit N.
Flatmark, Torgeir
Njolstad, Pal Rasmus
Bjorkhaug, Lise
TI GCK-MODY diabetes associated with protein misfolding, cellular
self-association and degradation
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE GCK-MODY; Catalytic activity; Protein misfolding; Self-association;
Dimerization; Degradation
ID HUMAN PANCREATIC GLUCOKINASE; YOUNG TYPE-2 MODY-2; REGULATORY PROTEIN;
BETA-CELL; BINDING PROTEIN; WILD-TYPE; MUTATIONS; GLUCOSE; STABILITY;
HYPERGLYCEMIA
AB GCK-MODY, dominantly inherited mild fasting hyperglycemia, has been associated with >600 different mutations in the glucokinase (GK)-encoding gene (GCK). When expressed as recombinant pancreatic proteins, some mutations result in enzymes with normal/near-normal catalytic properties. The molecular mechanism(s) of GCK-MODY due to these mutations has remained elusive. Here, we aimed to explore the molecular mechanisms for two such catalytically 'normal' GCK mutations (S263P and G264S) in the F260-L270 loop of GK. When stably overexpressed in HEK293 cells and MIN6 beta-cells, the S263P- and G264S-encoded mutations generated misfolded proteins with an increased rate of degradation (S263P>G264S) by the protein quality control machinery, and a propensity to self-associate (G264S>S263P) and form dimers (SDS resistant) and aggregates (partly Triton X-100 insoluble), as determined by pulse-chase experiments and subcellular fractionation. Thus, the GCK-MODY mutations S263P and G264S lead to protein misfolding causing destabilization, cellular dimerization/aggregation and enhanced rate of degradation. In silico predicted conformational changes of the F260-L270 loop structure are considered to mediate the dimerization of both mutant proteins by a domain swapping mechanism. Thus, similar properties may represent the molecular mechanisms for additional unexplained GCK-MODY mutations, and may also contribute to the disease mechanism in other previously characterized GCK-MODY inactivating mutations. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Negahdar, Maria; Aukrust, Ingvild; Johansson, Bente B.; Molnes, Janne; Sovik, Oddmund; Njolstad, Pal Rasmus; Bjorkhaug, Lise] Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway.
[Negahdar, Maria; Aukrust, Ingvild; Johansson, Bente B.; Bjorkhaug, Lise] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.
[Negahdar, Maria; Aukrust, Ingvild; Flatmark, Torgeir] Univ Bergen, Dept Biomed, N-5020 Bergen, Norway.
[Aukrust, Ingvild; Kulkarni, Rohit N.] Harvard Univ, Sect Islet Cell Biol & Regenerat Med, Bingham & Womans Hosp, Joslin Diabet Ctr,Sch Med, Boston, MA 02215 USA.
[Johansson, Bente B.; Molnes, Janne; Njolstad, Pal Rasmus] Haukeland Hosp, Dept Pediat, N-5021 Bergen, Norway.
[Molven, Anders] Univ Bergen, Gade Inst, N-5020 Bergen, Norway.
[Molven, Anders] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
[Matschinsky, Franz M.] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA.
[Matschinsky, Franz M.] Univ Penn, Sch Med, Diabet Res Ctr, Philadelphia, PA 19104 USA.
RP Njolstad, PR (reprint author), Univ Bergen, Dept Clin Med, N-5020 Bergen, Norway.
EM pal.njolstad@uib.no
OI Johansson, Bente Berg/0000-0001-8893-1915; Gundersen, Lise
Bjorkhaug/0000-0002-9695-4559
FU Research Council of Norway, Helse Vest; Novo Nordisk Foundation; Nils
Norman Foundation; Bergen Medical Research Foundation; Meltzer
Foundation; KG Jebsen Foundation; University of Bergen; Norwegian
Research Council
FX This work was supported by funds from the Research Council of Norway,
Helse Vest, the Novo Nordisk Foundation, the Nils Norman Foundation, the
Bergen Medical Research Foundation, the Meltzer Foundation, the KG
Jebsen Foundation, and the University of Bergen. We thank Joao Leandro,
Department of Biomedicine, University of Bergen, for his supporting
information and Ali Sepulveda Munoz, Department of Biomedicine,
University of Bergen, for expert technical assistance with the French
press. The mass spectrometry analyses were conducted by the Proteomics
Unit at the University of Bergen (PROBE), supported by the National
Program for Research in Functional Genomics (FUGE) funded by the
Norwegian Research Council.
NR 65
TC 5
Z9 5
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD NOV
PY 2012
VL 1822
IS 11
BP 1705
EP 1715
DI 10.1016/j.bbadis.2012.07.005
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 017BX
UT WOS:000309566200007
PM 22820548
ER
PT J
AU Moyer, CE
Delevich, KM
Fish, KN
Asafu-Adjei, JK
Sampson, AR
Dorph-Petersen, KA
Lewis, DA
Sweet, RA
AF Moyer, Caitlin E.
Delevich, Kristen M.
Fish, Kenneth N.
Asafu-Adjei, Josephine K.
Sampson, Allan R.
Dorph-Petersen, Karl-Anton
Lewis, David A.
Sweet, Robert A.
TI Reduced Glutamate Decarboxylase 65 Protein Within Primary Auditory
Cortex Inhibitory Boutons in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE GAD65; postmortem human tissue; primary auditory cortex; quantitative
microscopy; schizophrenia; stereology
ID GAMMA OSCILLATION FREQUENCY; MISMATCH NEGATIVITY GENERATION;
DORSOLATERAL PREFRONTAL CORTEX; ACTIVITY-DEPENDENT REGULATION; DENDRITIC
SPINE DENSITY; SUPERIOR TEMPORAL GYRUS; STEADY-STATE RESPONSES;
SHORT-TERM-MEMORY; VISUAL-CORTEX; ACID DECARBOXYLASE
AB Background: Schizophrenia is associated with perceptual and physiological auditory processing impairments that may result from primary auditory cortex excitatory and inhibitory circuit pathology. High-frequency oscillations are important for auditory function and are often reported to be disrupted in schizophrenia. These oscillations may, in part, depend on upregulation of gamma-aminobutyric acid synthesis by glutamate decarboxylase 65 (GAD65) in response to high interneuron firing rates. It is not known whether levels of GAD65 protein or GAD65-expressing boutons are altered in schizophrenia.
Methods: We studied two cohorts of subjects with schizophrenia and matched control subjects, comprising 27 pairs of subjects. Relative fluorescence intensity, density, volume, and number of GAD65-immunoreactive boutons in primary auditory cortex were measured using quantitative confocal microscopy and stereologic sampling methods. Bouton fluorescence intensities were used to compare the relative expression of GAD65 protein within boutons between diagnostic groups. Additionally, we assessed the correlation between previously measured dendritic spine densities and GAD65-immunoreactive bouton fluorescence intensities.
Results: GAD65-immunoreactive bouton fluorescence intensity was reduced by 40% in subjects with schizophrenia and was correlated with previously measured reduced spine density. The reduction was greater in subjects who were not living independently at time of death. In contrast, GAD65-immunoreactive bouton density and number were not altered in deep layer 3 of primary auditory cortex of subjects with schizophrenia.
Conclusions: Decreased expression of GAD65 protein within inhibitory boutons could contribute to auditory impairments in schizophrenia. The correlated reductions in dendritic spines and GAD65 protein suggest a relationship between inhibitory and excitatory synapse pathology in primary auditory cortex.
C1 [Sweet, Robert A.] Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Pittsburgh, PA 15213 USA.
[Moyer, Caitlin E.; Fish, Kenneth N.; Lewis, David A.; Sweet, Robert A.] Univ Pittsburgh, Ctr Neurosci, Pittsburgh, PA 15213 USA.
[Asafu-Adjei, Josephine K.; Sampson, Allan R.] Univ Pittsburgh, Dept Stat, Pittsburgh, PA 15213 USA.
[Lewis, David A.] Univ Pittsburgh, Dept Neurosci, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.
[Sweet, Robert A.] Vet Affairs Pittsburgh Healthcare Syst, Vet Integrated Serv Network Mental Illness Res 4, Educ & Clin Ctr, Pittsburgh, PA USA.
[Dorph-Petersen, Karl-Anton] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark.
[Dorph-Petersen, Karl-Anton] Aarhus Univ, Ctr Stochast Geometry & Adv Bioimaging, Aarhus, Denmark.
RP Sweet, RA (reprint author), Univ Pittsburgh, Dept Psychiat, Western Psychiat Inst & Clin, Biomed Sci Tower,Room W1645,3811 OHara St, Pittsburgh, PA 15213 USA.
EM SweetRA@upmc.edu
RI Lewis, David/G-4053-2014; Dorph-Petersen, Karl-Anton/A-9039-2015;
OI Lewis, David/0000-0002-3225-6778; Dorph-Petersen,
Karl-Anton/0000-0002-6676-034X; Moyer, Caitlin/0000-0002-2571-2595;
Delevich, Kristen/0000-0001-5698-0093
FU Bristol-Myers Squibb Foundation; Bristol-Myers Squibb; Curridium Ltd;
Pfizer; [MH071533]; [MH084053]; [MH085108]
FX This work was supported by Grants MH071533 (RAS), MH084053 (DAL), and
MH085108 (KNF).; ARS is a statistical consultant to Johnson & Johnson
Pharmaceutical Research and Development. DAL currently receives
investigator-initiated research support from the Bristol-Myers Squibb
Foundation, Bristol-Myers Squibb, Curridium Ltd, and Pfizer and in 2007
to 2010 served as a consultant in the areas of target identification and
validation and new compound development to AstraZeneca, BioLine RX,
Bristol-Myers Squibb, Hoffman-Roche, Lilly, Merck, Neurogen, and SK Life
Science. CEM, KMD, KNF, JKA-A, K-AD-P, and RAS have no biomedical
financial interests or potential conflicts of interest to disclose. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institute of
Mental Health, the National Institutes of Health, the Department of
Veterans Affairs, or the United States Government.
NR 90
TC 14
Z9 14
U1 3
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD NOV 1
PY 2012
VL 72
IS 9
BP 734
EP 743
DI 10.1016/j.biopsych.2012.04.010
PG 10
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 017SF
UT WOS:000309610500005
PM 22624794
ER
PT J
AU Whitesell, L
Santagata, S
Lin, NU
AF Whitesell, L.
Santagata, S.
Lin, N. U.
TI Inhibiting HSP90 to Treat Cancer: A Strategy in Evolution
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE Cancer evolution; clinical trial; combination chemotherapy; drug
resistance
ID HEAT-SHOCK-PROTEIN; PHASE-II TRIAL; REFRACTORY ADVANCED CANCERS;
TYROSINE KINASE INHIBITORS; METASTATIC PROSTATE-CANCER; C-TERMINAL
DOMAIN; CELL LUNG-CANCER; BREAST-CANCER; DRUG-RESISTANCE; SOLID TUMORS
AB Since the identification of the first HSP90 inhibitor almost two decades ago, there has been substantial progress made in the development of potent and selective molecules that inhibit this chaperone and that have anticancer activity. In turn, these compounds have been invaluable for probing how HSP90 supports the profound changes in cellular physiology that characterize the malignant state. Unfortunately, when used as single agents HSP90 inhibitors have demonstrated disappointing activity against advanced cancers in most of the clinical trials reported to date. This problem may be due to the major pharmacological liabilities of the first-generation HSP90 inhibitors that have been most extensively studied. We suggest, however, that it may well be intrinsic to the target itself. Systemically tolerable exposure to HSP90 inhibitors may not be highly cytotoxic for the majority of common clinical cancers. Instead, HSP90 inhibitors might better be used to enhance the activity of other antineoplastic agents while simultaneously reducing the capacity of tumors to adapt and evolve drug resistance; the overall result being more durable disease control. This review will focus on these fundamental issues with the goal of suggesting ways to make the clinical development of HSP90 inhibitors become less empiric and ultimately more successful.
C1 [Whitesell, L.; Santagata, S.] Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Santagata, S.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Lin, N. U.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Whitesell, L (reprint author), Nine Cambridge Ctr, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
EM whitesell@wi.mit.edu
FU Komen Foundation; Johnson and Johnson Focused Funding Program; NIH
[K08-NS064168]; Valvano foundation; Brain Science Foundation; Berry
Junior Faculty Award
FX Our gratitude goes to Susan Lindquist and members of the Lindquist lab
for valuable conversations, advice and insights. L.W. is supported in
part by funds from the Komen Foundation and the Johnson and Johnson
Focused Funding Program. S.S. is supported by grants from the NIH
(K08-NS064168), the Valvano foundation and the Brain Science Foundation.
N.U.L. acknowledges support from a Berry Junior Faculty Award. We
apologize to many of our colleagues for being unable to cite and discuss
their important work in this rapidly advancing field due to space
limitations. Their contributions in expanding our understanding of HSP90
and improving the care of cancer patients are invaluable.
NR 153
TC 33
Z9 34
U1 3
U2 22
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PD NOV
PY 2012
VL 12
IS 9
BP 1108
EP 1124
PG 17
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 018KD
UT WOS:000309658100003
PM 22804235
ER
PT J
AU Brashear, A
Mink, JW
Hill, DF
Boggs, N
Mccall, WV
Stacy, MA
Snively, B
Light, LS
Sweadner, KJ
Ozelius, LJ
Morrison, L
AF Brashear, Allison
Mink, Jonathan W.
Hill, Deborah F.
Boggs, Niki
Mccall, W. Vaughn
Stacy, Mark A.
Snively, Beverly
Light, Laney S.
Sweadner, Kathleen J.
Ozelius, Laurie J.
Morrison, Leslie
TI ATP1A3 mutations in infants: a new rapid-onset dystonia-Parkinsonism
phenotype characterized by motor delay and ataxia
SO DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY
LA English
DT Article
ID GENE
AB We report new clinical features of delayed motor development, hypotonia, and ataxia in two young children with mutations (R756H and D923N) in the ATP1A3 gene. In adults, mutations in ATP1A3 cause rapid-onset dystoniaParkinsonism (RDP, DYT12) with abrupt onset of fixed dystonia. The parents and children were examined and videotaped, and samples were collected for mutation analysis. Case 1 presented with fluctuating spells of hypotonia, dysphagia, mutism, dystonia, and ataxia at 9 months. After three episodes of hypotonia, she developed ataxia, inability to speak or swallow, and eventual seizures. Case 2 presented with hypotonia at 14 months and pre-existing motor delay. At age 4 years, he had episodic slurred speech, followed by ataxia, drooling, and dysarthria. He remains mute. Both children had ATP1A3 gene mutations. To our knowledge, these are the earliest presentations of RDP, both with fluctuating features. Both children were initially misdiagnosed. RDP should be considered in children with discoordinated gait, and speech and swallowing difficulties.
C1 [Brashear, Allison; Hill, Deborah F.] Wake Forest Sch Med, Dept Neurol, Winston Salem, NC 27157 USA.
[Mink, Jonathan W.] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY USA.
[Boggs, Niki; Mccall, W. Vaughn] Wake Forest Sch Med, Dept Psychiat, Winston Salem, NC 27157 USA.
[Stacy, Mark A.] Duke Univ, Sch Med, Dept Neurol, Durham, NC USA.
[Snively, Beverly; Light, Laney S.] Wake Forest Sch Med, Div Publ Hlth Sci, Dept Biostat Sci, Winston Salem, NC 27157 USA.
[Sweadner, Kathleen J.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Sweadner, Kathleen J.] Harvard Univ, Sch Med, Boston, MA USA.
[Ozelius, Laurie J.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY USA.
[Ozelius, Laurie J.] Mt Sinai Sch Med, Dept Neurol, New York, NY USA.
[Morrison, Leslie] Univ New Mexico, Dept Neurol, Albuquerque, NM 87131 USA.
RP Brashear, A (reprint author), Wake Forest Sch Med, Dept Neurol, Med Ctr Blvd, Winston Salem, NC 27157 USA.
EM abrashea@wakehealth.edu
RI Brashear, Allison/G-3853-2015;
OI Morrison, Leslie/0000-0002-0092-193X
FU National Institute of Neurological Disorders and Stroke
[5R01NS058949-05]; Lung GO Sequencing Project [HL-102923]; WHI
Sequencing Project [HL-102924]; Broad GO Sequencing Project [HL-102925];
Seattle GO Sequencing Project [HL-102926]; Heart GO Sequencing Project
[HL-103010]
FX This study was supported by the National Institute of Neurological
Disorders and Stroke 5R01NS058949-05 (to AB). We thank Dr William B
Dobyns for his initial description of RDP. We also thank the National
Heart, Lung, and Blood Institute GO Exome Sequencing Project 10 and its
ongoing studies, which produced and provided exome variant calls for
comparison: the Lung GO Sequencing Project (HL-102923), the WHI
Sequencing Project (HL-102924), the Broad GO Sequencing Project
(HL-102925), the Seattle GO Sequencing Project (HL-102926), and the
Heart GO Sequencing Project (HL-103010).
NR 10
TC 41
Z9 42
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0012-1622
J9 DEV MED CHILD NEUROL
JI Dev. Med. Child Neurol.
PD NOV
PY 2012
VL 54
IS 11
BP 1065
EP 1067
DI 10.1111/j.1469-8749.2012.04421.x
PG 3
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA 017OB
UT WOS:000309598500025
PM 22924536
ER
PT J
AU Liu, CT
Ng, MCY
Rybin, D
Adeyemo, A
Bielinski, SJ
Boerwinkle, E
Borecki, I
Cade, B
Chen, YDI
Djousse, L
Fornage, M
Goodarzi, MO
Grant, SFA
Guo, X
Harris, T
Kabagambe, E
Kizer, JR
Liu, Y
Lunetta, KL
Mukamal, K
Nettleton, JA
Pankow, JS
Patel, SR
Ramos, E
Rasmussen-Torvik, L
Rich, SS
Rotimi, CN
Sarpong, D
Shriner, D
Sims, M
Zmuda, JM
Redline, S
Kao, WH
Siscovick, D
Florez, JC
Rotter, JI
Dupuis, J
Wilson, JG
Bowden, DW
Meigs, JB
AF Liu, C-T
Ng, M. C. Y.
Rybin, D.
Adeyemo, A.
Bielinski, S. J.
Boerwinkle, E.
Borecki, I.
Cade, B.
Chen, Y. D. I.
Djousse, L.
Fornage, M.
Goodarzi, M. O.
Grant, S. F. A.
Guo, X.
Harris, T.
Kabagambe, E.
Kizer, J. R.
Liu, Y.
Lunetta, K. L.
Mukamal, K.
Nettleton, J. A.
Pankow, J. S.
Patel, S. R.
Ramos, E.
Rasmussen-Torvik, L.
Rich, S. S.
Rotimi, C. N.
Sarpong, D.
Shriner, D.
Sims, M.
Zmuda, J. M.
Redline, S.
Kao, W. H.
Siscovick, D.
Florez, J. C.
Rotter, J. I.
Dupuis, J.
Wilson, J. G.
Bowden, D. W.
Meigs, J. B.
TI Transferability and fine-mapping of glucose and insulin quantitative
trait loci across populations: CARe, the Candidate Gene Association
Resource
SO DIABETOLOGIA
LA English
DT Article
DE African ancestry; Genetics; Genome-wide association; LD mapping;
Minorities; Type 2 diabetes
ID GENOME-WIDE ASSOCIATION; LARGE-SCALE ASSOCIATION; AFRICAN-AMERICANS;
FASTING GLUCOSE; SUSCEPTIBILITY LOCI; ATHEROSCLEROSIS RISK;
DIABETES-MELLITUS; TCF7L2 GENE; TYPE-2; VARIANTS
AB Hyperglycaemia disproportionately affects African-Americans (AfAs). We tested the transferability of 18 single-nucleotide polymorphisms (SNPs) associated with glycaemic traits identified in European ancestry (EuA) populations in 5,984 non-diabetic AfAs.
We meta-analysed SNP associations with fasting glucose (FG) or insulin (FI) in AfAs from five cohorts in the Candidate Gene Association Resource. We: (1) calculated allele frequency differences, variations in linkage disequilibrium (LD), fixation indices (F(st)s) and integrated haplotype scores (iHSs); (2) tested EuA SNPs in AfAs; and (3) interrogated within +/- 250 kb around each EuA SNP in AfAs.
Allele frequency differences ranged from 0.6% to 54%. F-st exceeded 0.15 at 6/16 loci, indicating modest population differentiation. All iHSs were < 2, suggesting no recent positive selection. For 18 SNPs, all directions of effect were the same and 95% CIs of association overlapped when comparing EuA with AfA. For 17 of 18 loci, at least one SNP was nominally associated with FG in AfAs. Four loci were significantly associated with FG (GCK, p = 5.8 x 10(-8); MTNR1B, p = 8.5 x 10(-9); and FADS1, p = 2.2 x 10(-4)) or FI (GCKR, p = 5.9 x 10(-4)). At GCK and MTNR1B the EuA and AfA SNPs represented the same signal, while at FADS1, and GCKR, the EuA and best AfA SNPs were weakly correlated (r (2) < 0.2), suggesting allelic heterogeneity for association with FG at these loci.
Few glycaemic SNPs showed strict evidence of transferability from EuA to AfAs. Four loci were significantly associated in both AfAs and those with EuA after accounting for varying LD across ancestral groups, with new signals emerging to aid fine-mapping.
C1 [Djousse, L.; Mukamal, K.; Florez, J. C.; Meigs, J. B.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Liu, C-T; Lunetta, K. L.; Dupuis, J.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Ng, M. C. Y.; Liu, Y.; Bowden, D. W.] Wake Forest Univ, Bowman Gray Sch Med, Ctr Diabet Res, Ctr Genom & Personalized Med Res, Winston Salem, NC USA.
[Rybin, D.] Boston Univ, Data Coordinating Ctr, Boston, MA 02215 USA.
[Adeyemo, A.; Ramos, E.; Rotimi, C. N.; Shriner, D.] NHGRI, Bethesda, MD 20892 USA.
[Bielinski, S. J.] Mayo Clin, Rochester, MN USA.
[Boerwinkle, E.; Fornage, M.; Nettleton, J. A.] Univ Texas Hlth Sci Ctr Houston, Houston, TX USA.
[Borecki, I.] Washington Univ, St Louis, MO USA.
[Cade, B.; Djousse, L.; Patel, S. R.; Redline, S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chen, Y. D. I.; Goodarzi, M. O.; Guo, X.; Rotter, J. I.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
[Djousse, L.] Boston VA Healthcare Syst, Boston, MA USA.
[Grant, S. F. A.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Harris, T.] NIA, Bethesda, MD 20892 USA.
[Kabagambe, E.] Univ Alabama Birmingham, Birmingham, AL USA.
[Kizer, J. R.] Cornell Univ, New York, NY 10021 USA.
[Liu, Y.] Wake Forest Univ, Dept Epidemiol & Prevent, Winston Salem, NC 27109 USA.
[Lunetta, K. L.; Dupuis, J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Pankow, J. S.] Univ Minnesota, Minneapolis, MN USA.
[Rasmussen-Torvik, L.] Northwestern Univ, Chicago, IL 60611 USA.
[Rich, S. S.] Univ Virginia, Charlottesville, VA USA.
[Sarpong, D.] Jackson State Univ, Jackson, MS USA.
[Zmuda, J. M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA.
[Kao, W. H.] Johns Hopkins Univ, Baltimore, MD USA.
[Siscovick, D.] Univ Washington, Seattle, WA 98195 USA.
[Florez, J. C.] Massachusetts Gen Hosp, Diabet Unit, Boston, MA 02114 USA.
[Florez, J. C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Florez, J. C.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Bowden, D. W.] Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27103 USA.
[Bowden, D. W.] Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27103 USA.
[Meigs, J. B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Sims, M.; Wilson, J. G.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA.
RP Meigs, JB (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
EM jmeigs@partners.org
RI Bielinski, Suzette/A-2238-2009; Djousse, Luc/F-5033-2017;
OI Bielinski, Suzette/0000-0002-2905-5430; Djousse,
Luc/0000-0002-9902-3047; Lunetta, Kathryn/0000-0002-9268-810X; Rybin,
Denis/0000-0002-3657-4829; Dupuis, Josee/0000-0003-2871-3603; Adeyemo,
Adebowale/0000-0002-3105-3231; Patel, Sanjay/0000-0002-9142-5172
FU NIDDK [R01 2 DK078616, K24 DK080140]; Doris Duke Charitable Foundation;
NHLBI MESA [N01HC95165-21-0-1]; NHBLI [N01-HC-55015, N01-HC-55016,
N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, N01-HC-55022];
CFS: Case Western Reserve University [NIH HL 46380, M01RR00080]; Jackson
State University [N01-HC-95170]; University of Mississippi
[N01-HC-95171]; Tougaloo College [N01-HC-95172]; University of Alabama
at Birmingham [N01-HC-48047, N01-HC-95095]; University of Minnesota
[N01-HC-48048]; Northwestern University [N01-HC-48049]; Kaiser
Foundation Research Institute [N01-HC-48050]; Tufts-New England Medical
Center [N01-HC-45204]; Wake Forest University [N01-HC-45205];
Harbor-UCLA Research and Education Institute [N01-HC-05187]; University
of California Irvine [N01-HC-45134, N01-HC-95100]; [RO1 DK066358];
[5RC1HL099911-025UC2HL103010-02]; [N01-HD-95159]; [N01-HC-95169];
[RR-024156]; [R01-HL-071205]
FX This work was supported by NIDDK R01 2 DK078616 and NIDDK K24 DK080140
to J. B. Meigs, a Doris Duke Charitable Foundation Clinical Scientist
Development Award to J. C. Florez, RO1 DK066358 to D. W. Bowden,
5RC1HL099911-025UC2HL103010-02 and the NHLBI MESA contract
N01HC95165-21-0-1 to S. S. Rich.; ARIC is carried out as a collaborative
study supported by NHBLI contracts N01-HC-55015, N01-HC-55016,
N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and
N01-HC-55022. CFS: Case Western Reserve University (NIH HL 46380,
M01RR00080).; JHS is carried out as a collaborative study supported by
Jackson State University (N01-HC-95170), University of Mississippi
(N01-HC-95171), Tougaloo College (N01-HC-95172);; MESA is conducted and
supported by the NHLBI in collaboration with MESA investigators. Support
is provided by grants and contracts N01-HD-95159 through N01-HC-95169,
RR-024156, and R01-HL-071205.; CARDIA is carried out as a collaborative
study supported by University of Alabama at Birmingham (N01-HC-48047),
University of Minnesota (N01-HC-48048), Northwestern University
(N01-HC-48049), Kaiser Foundation Research Institute (N01-HC-48050),
University of Alabama at Birmingham (N01-HC-95095), Tufts-New England
Medical Center (N01-HC-45204), Wake Forest University (N01-HC-45205),
Harbor-UCLA Research and Education Institute (N01-HC-05187), University
of California Irvine (N01-HC-45134, N01-HC-95100).
NR 57
TC 12
Z9 12
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD NOV
PY 2012
VL 55
IS 11
BP 2970
EP 2984
DI 10.1007/s00125-012-2656-4
PG 15
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 017AR
UT WOS:000309561600013
PM 22893027
ER
PT J
AU Ho, T
Gerber, L
Aronson, WJ
Terris, MK
Presti, JC
Kane, CJ
Amling, CL
Freedland, SJ
AF Ho, Tammy
Gerber, Leah
Aronson, William J.
Terris, Martha K.
Presti, Joseph C.
Kane, Christopher J.
Amling, Christopher L.
Freedland, Stephen J.
TI Obesity, Prostate-Specific Antigen Nadir, and Biochemical Recurrence
After Radical Prostatectomy: Biology or Technique? Results from the
SEARCH Database
SO EUROPEAN UROLOGY
LA English
DT Article
DE Prostate cancer; PSA nadir; Obesity; Radical prostatectomy; Biochemical
recurrence
ID BODY-MASS INDEX; NATURAL-HISTORY; CANCER; RISK; MEN; PROGRESSION;
INSULIN; DISEASE; IMPACT; LEVEL
AB Background: Obesity is associated with an increased risk of biochemical recurrence (BCR) after radical prostatectomy (RP). It is unclear whether this is due to technical challenges related to operating on obese men or other biologic factors.
Objective: To examine whether obesity predicts higher prostate-specific antigen (PSA) nadir (as a measure of residual PSA-producing tissue) after RP and if this accounts for the greater BCR risk in obese men.
Design, setting, and participants: A retrospective analysis of 1038 RP patients from 2001 to 2010 in the multicenter US Veterans Administration-based Shared Equal Access Regional Cancer Hospital database with median follow-up of 41 mo.
Intervention: All patients underwent RP.
Outcome measurements and statistical analysis: We evaluated the relationship between body mass index (BMI) and ultrasensitive PSA nadir within 6 mo after RP. Adjusted proportional hazards models were used to examine the association between BMI and BCR with and without PSA nadir.
Results and limitations: Mean BMI was 28.5 kg/m(2). Higher BMI was associated with higher PSA nadir on both univariable (p = 0.001) and multivariable analyses (p < 0.001). Increased BMI was associated with increased BCR risk (hazard ratio [HR]: 1.06; p = 0.007). Adjusting for PSA nadir slightly attenuated, but did not eliminate, this association (HR: 1.04, p = 0.043). When stratified by PSA nadir, obesity only significantly predicted BCR in men with an undetectable nadir (p = 0.006). Unfortunately, other clinically relevant end points such as metastasis or mortality were not available.
Conclusions: Obese men are more likely to have a higher PSA nadir, suggesting that either more advanced disease or technical issues confound an ideal operation. However, even after adjusting for the increased PSA nadir, obesity remained predictive of BCR, suggesting that tumors in obese men are growing faster. This provides further support for the idea that obesity is biologically associated with prostate cancer progression. Published by Elsevier B.V. on behalf of European Association of Urology.
C1 [Freedland, Stephen J.] Duke Univ, Sch Med, Div Urol, Dept Pathol, Durham, NC 27710 USA.
[Ho, Tammy; Gerber, Leah; Freedland, Stephen J.] Duke Univ, Sch Med, Duke Prostate Ctr, Div Urol Surg,Dept Surg, Durham, NC 27710 USA.
[Ho, Tammy; Gerber, Leah; Freedland, Stephen J.] Vet Affairs Med Ctr, Dept Surg, Urol Sect, Durham, NC USA.
[Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Urol Sect, Los Angeles, CA USA.
[Aronson, William J.] Univ Calif Los Angeles, Los Angeles Sch Med, Dept Urol, Los Angeles, CA USA.
[Terris, Martha K.] Vet Affairs Med Ctr, Urol Sect, Augusta, GA USA.
[Terris, Martha K.] Med Coll Georgia, Urol Sect, Augusta, GA 30912 USA.
[Presti, Joseph C.] Stanford Univ, Sch Med, Dept Urol, Palo Alto, CA 94304 USA.
[Presti, Joseph C.] Vet Affairs Med Ctr, Urol Sect, Palo Alto, CA 94304 USA.
[Kane, Christopher J.] Univ Calif San Diego, Sch Med, Div Urol, San Diego, CA 92103 USA.
[Amling, Christopher L.] Oregon Hlth & Sci Univ, Div Urol, Portland, OR 97201 USA.
RP Freedland, SJ (reprint author), Duke Univ, Sch Med, Div Urol, Dept Pathol, Box 2626 DUMC, Durham, NC 27710 USA.
EM steve.freedland@duke.edu
OI Terris, Martha/0000-0002-3843-7270
FU US Department of Veterans Affairs; US Department of Defense Prostate
Cancer Research Program; American Urological Association
Foundation/Astellas Rising Star in Urology Award; Georgia Cancer
Coalition; National Institutes of Health [P50 CA58236, R01CA100938, P50
CA92131-01A1]
FX This study was supported by the US Department of Veterans Affairs, US
Department of Defense Prostate Cancer Research Program, the American
Urological Association Foundation/Astellas Rising Star in Urology Award,
National Institutes of Health Specialized Programs of Research
Excellence Grant P50 CA58236, the Georgia Cancer Coalition, National
Institutes of Health R01CA100938, and National Institutes of Health
Specialized Programs of Research Excellence Grant P50 CA92131-01A1.
Views and opinions of, and endorsements by the author(s) do not reflect
those of the US Army or the Department of Defense.
NR 30
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PD NOV
PY 2012
VL 62
IS 5
BP 910
EP 916
DI 10.1016/j.eururo.2012.08.015
PG 7
WC Urology & Nephrology
SC Urology & Nephrology
GA 016WE
UT WOS:000309549700034
PM 22921964
ER
PT J
AU Choueiri, TK
Cheville, J
Palescandolo, E
Fay, AP
Kantoff, PW
Atkins, MB
McKenney, JK
Brown, V
Lampron, ME
Zhou, M
Hirsch, MS
Signoretti, S
AF Choueiri, Toni K.
Cheville, John
Palescandolo, Emanuele
Fay, Andre P.
Kantoff, Philip W.
Atkins, Michael B.
McKenney, Jesse K.
Brown, Victoria
Lampron, Megan E.
Zhou, Ming
Hirsch, Michelle S.
Signoretti, Sabina
TI BRAF Mutations in Metanephric Adenoma of the Kidney
SO EUROPEAN UROLOGY
LA English
DT Article
DE Small renal mass; Diagnosis; BRAF; Mutation; Metanephric adenoma
ID HUMAN CANCER; SENESCENCE; NEOPLASMS; MELANOMA; GENE; LESIONS; IMPACT;
NEVI
AB Background: Metanephric adenoma(MA) of the kidney is a rare, indolent tumor that may be difficult to differentiate from other small renal masses (SRMs). Genetic alterations associated with MA remain largely unknown.
Objective: We aimed at defining genetic events in MA of the kidney and determining their influence in the management of this disease.
Design, setting, and participants: Multiplexed mass spectrometric genotyping was performed on 29 MA cases after tumor DNA extraction. We also conducted a mutational screen in an additional 129 renal neoplasms. Immunohistochemistry was performed on the MA cases to assess molecular markers of signaling pathway activation. Patients' baseline characteristics, as well as follow-up data, were captured.
Outcome measurements and statistical analysis: We used descriptive statistics for baseline clinical characteristics and incidence of mutations. The Wilcoxon rank-sum test was used to correlate patient characteristics with mutational status.
Results and limitations: We identified the v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation in 26 of 29 MA cases. These results were validated in all cases using the commercially available BRAF Pyro Kit (QIAGEN). In contrast, BRAF mutations were rare in the other 129 non-MA renal neoplasms that were screened. We detected a BRAF mutation (V600E) in only one papillary renal cell carcinoma case. In all MA tumors, we documented expression of phosphorylated mitogen-activated protein kinase and phosphorylated extracellular signal-regulated kinase, accompanied by immunoreactivity for p16 (INK4a). All patients were treated with a partial or radical nephrectomy, and after a median follow-up of 26.5 mo, there were no local or distant recurrences. Limitations include the retrospective nature of this study.
Conclusions: BRAF V600E mutations are present in approximately 90% of all MA cases, serving as a potential valuable diagnostic tool in the differential diagnosis of SRMs undergoing a percutaneous biopsy. The presence of BRAF V600E and mitogen-activated protein kinase activation in a largely benign tumor supports the necessity for secondary events (eg, p16 loss) in BRAF-driven oncogenesis. (C) 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.
C1 [Choueiri, Toni K.; Palescandolo, Emanuele; Fay, Andre P.; Kantoff, Philip W.; Lampron, Megan E.; Signoretti, Sabina] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Choueiri, Toni K.; Kantoff, Philip W.; Brown, Victoria; Hirsch, Michelle S.; Signoretti, Sabina] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Choueiri, Toni K.; Kantoff, Philip W.; Atkins, Michael B.; Hirsch, Michelle S.; Signoretti, Sabina] Harvard Univ, Sch Med, Boston, MA USA.
[Cheville, John] Mayo Clin, Rochester, MN USA.
[Atkins, Michael B.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[McKenney, Jesse K.] Stanford Univ, Stanford, CA 94305 USA.
[Zhou, Ming] Cleveland Clin, Cleveland, OH 44106 USA.
RP Choueiri, TK (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,DANA 1230, Boston, MA 02215 USA.
EM toni_choueiri@dfci.harvard.edu; ssignoretti@partners.org
FU Dana-Farber/Harvard Cancer Center (DF/HCC) Kidney Cancer SPORE
Director's Choice Award; Trust Family Fund for Kidney Cancer Research
FX This work was supported by a Dana-Farber/Harvard Cancer Center (DF/HCC)
Kidney Cancer SPORE Director's Choice Award to Sabina Signoretti and
Toni K. Choueiri, and by the Trust Family Fund for Kidney Cancer
Research.
NR 28
TC 25
Z9 28
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0302-2838
J9 EUR UROL
JI Eur. Urol.
PD NOV
PY 2012
VL 62
IS 5
BP 917
EP 922
DI 10.1016/j.eururo.2012.05.051
PG 6
WC Urology & Nephrology
SC Urology & Nephrology
GA 016WE
UT WOS:000309549700035
PM 22727996
ER
PT J
AU Xi, MC
Fung, SJ
Zhang, JH
Sampogna, S
Chase, MH
AF Xi, Mingchu
Fung, Simon J.
Zhang, Jianhua
Sampogna, Sharon
Chase, Michael H.
TI The amygdala and the pedunculopontine tegmental nucleus: Interactions
controlling active (rapid eye movement) sleep
SO EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE REM sleep; Amygdala; PPT; Electrical stimulation; Intracellular
recording
ID ANTERODORSAL PONTINE TEGMENTUM; PARADOXICAL SLEEP; BRAIN-STEM;
REM-SLEEP; RETICULAR-FORMATION; PONTOGENICULOOCCIPITAL WAVES;
ELECTRICAL-STIMULATION; ACETYLCHOLINE-RELEASE; INDUCTION ZONE;
MEDULLA-OBLONGATA
AB There is a consensus that active sleep (AS; i.e., REM sleep) is produced by cholinergic projections from the pedunculopontine tegmental nuclei (PPT) that activate AS-on neurons in the nucleus pontis oralis (NPO) that are components of the AS-Generator. However, there is a growing body of evidence indicating that other sites, such as the amygdala, also participate in the control of AS by inducing the discharge of AS-Generator neurons. In this regard, we recently reported that there are direct, excitatory (glutamatergic) projections from the central nucleus of the amygdala (CNA) to presumptive AS-Generator neurons in the NPO. We therefore hypothesized that the CNA and the PPT act alone, as well as in concert, to promote AS. To test this hypothesis, the effects of stimulation of the CNA and the PPT on the activity of NPO neurons, recorded intracellularly, were examined in urethane-anesthetized rats. Stimulation of either the CNA or the PPT evoked short-latency excitatory postsynaptic potentials (EPSPs) in the same neurons within the NPO. The amplitude of PPT-evoked EPSPs that were recorded from NPO neurons increased by 20.1 to 58.6% when stimulation of the PPT was preceded by stimulation of the CNA at an interval of 0 to 12 ms: maximal potentiation occurred at an interval of 4 to 6 ms. Concurrent subthreshold stimulation of the CNA and the PPT resulted in the discharge of NPO neurons. NPO neurons that were activated following CNA and/or PPT stimulation were identified morphologically and found to be multipolar with diameters >20 mu m; similar neurons in the same NPO site have been previously identified as AS-Generator neurons. The present data demonstrate the presence of converging excitatory synaptic inputs from the CNA and the PPT that are capable of promoting the discharge of AS-Generator neurons in the NPO. Therefore, we suggest that the occurrence of AS depends upon interactions between cholinergic projections from the PVT and glutamatergic projections from the CNA as well as inputs from other sites that project to AS-Generator neurons. Published by Elsevier Inc.
C1 [Xi, Mingchu; Fung, Simon J.; Zhang, Jianhua; Sampogna, Sharon; Chase, Michael H.] WebSci Int, Los Angeles, CA 90024 USA.
[Xi, Mingchu; Fung, Simon J.; Zhang, Jianhua; Chase, Michael H.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Chase, Michael H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90025 USA.
RP Xi, MC (reprint author), WebSci Int, 1251 Westwood Blvd, Los Angeles, CA 90024 USA.
EM mxi@websciences.org
FU NIH [NS 60917]
FX This research was supported by NIH grant NS 60917. We are grateful to
Mr. Vincent Lim, Ms. Nichole Stevens and Mr. Daniel Bronson for their
excellent technical assistance.
NR 60
TC 7
Z9 7
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0014-4886
J9 EXP NEUROL
JI Exp. Neurol.
PD NOV
PY 2012
VL 238
IS 1
BP 44
EP 51
DI 10.1016/j.expneurol.2012.08.001
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 017XV
UT WOS:000309625400006
PM 22971360
ER
PT J
AU Yock, TI
Caruso, PA
AF Yock, Torunn I.
Caruso, Paul A.
TI RISK OF SECOND CANCERS AFTER PHOTON AND PROTON RADIOTHERAPY: A REVIEW OF
THE DATA
SO HEALTH PHYSICS
LA English
DT Article
DE National Council on Radiation Protection and Measurements; cancer;
health effects; medical radiation
ID CENTRAL-NERVOUS-SYSTEM; ATOMIC-BOMB SURVIVORS; INITIAL
CLINICAL-OUTCOMES; LONG-TERM SURVIVORS; CHILDHOOD-CANCER;
RADIATION-THERAPY; 5-YEAR SURVIVORS; ADULT SURVIVORS; BRAIN-TUMORS;
SOLID CANCER
AB Control rates for pediatric and adult malignancies are now approximately 80 and 60%, respectively, due to dramatic improvements in surgery, chemotherapy, and radiotherapy. However, radiotherapy is responsible for many of the adverse late effects of treatment, which is now well documented in the literature. The most serious and life threatening side effect of radiotherapy that affects both children and adults is radiation-induced second primary cancers. Health Phys. 103(5):577-585; 2012
C1 [Yock, Torunn I.; Caruso, Paul A.] Massachusetts Gen Hosp, Dept Radiat Oncol, COXLL, Boston, MA 02114 USA.
RP Yock, TI (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, COXLL, 100 Blossom St, Boston, MA 02114 USA.
EM tyock@partners.org
NR 71
TC 11
Z9 12
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD NOV
PY 2012
VL 103
IS 5
BP 577
EP 585
DI 10.1097/HP.0b013e3182609ba4
PG 9
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA 016MI
UT WOS:000309522300011
PM 23032887
ER
PT J
AU Paganetti, H
AF Paganetti, Harald
TI ASSESSMENT OF THE RISK FOR DEVELOPING A SECOND MALIGNANCY FROM SCATTERED
AND SECONDARY RADIATION IN RADIATION THERAPY
SO HEALTH PHYSICS
LA English
DT Article
DE National Council on Radiation Protection and Measurements; risk
estimates; medical radiation; radiation damage
ID CHILDHOOD-CANCER SURVIVOR; ATOMIC-BOMB SURVIVORS; OUT-OF-FIELD; RELATIVE
BIOLOGICAL EFFECTIVENESS; NEUTRON DOSE-EQUIVALENT; JAPANESE A-BOMB;
LONG-TERM RISK; PROTON THERAPY; SOLID CANCER; PROSTATE-CANCER
AB With the average age of radiation therapy patients decreasing and the advent of more complex treatment options comes the concern that the incidences of radiation-induced cancer might increase in the future. The carcinogenic effects of radiation are not well understood for the entire dose range experienced in radiation therapy. Longer epidemiologic studies are needed to improve current risk models and reduce uncertainties of current risk model parameters. On the other hand, risk estimations are needed today to judge the risks versus benefits of modern radiation therapy techniques. This paper describes the current state-of-the-art in risk modeling for radiation-induced malignancies in radiation therapy, distinguishing between two volumes: first, the organs within the main radiation field receiving low or intermediate doses (typically between 0.1 and 50 Gy); and second, the organs far away from the treatment volume receiving low doses mainly due to scattered and secondary radiation (typically below 0.1 Gy). The dosimetry as well as the risk model formalisms are outlined. Furthermore, example calculations and results are presented for intensity-modulated photon therapy versus proton therapy. Health Phys. 103(5):652-661; 2012
C1 Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Paganetti, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM hpaganetti@partners.org
FU NCI NIH HHS [P01 CA021239]
NR 96
TC 11
Z9 12
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD NOV
PY 2012
VL 103
IS 5
BP 652
EP 661
DI 10.1097/HP.0b013e318261113d
PG 10
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA 016MI
UT WOS:000309522300019
PM 23032895
ER
PT J
AU Held, KD
AF Held, Kathryn D.
TI SUMMARY: ACHIEVEMENTS, CRITICAL ISSUES, AND THOUGHTS ON THE FUTURE
SO HEALTH PHYSICS
LA English
DT Article
DE National Council on Radiation Protection and Measurements; cancer;
exposure, radiation; medical radiation
AB The number of individuals exposed to particle radiations in cancer treatment worldwide is increasing rapidly, and space agencies are developing plans for long duration, deep space missions in which humans could be exposed to significant levels of radiation from charged particles. Hence, the NCRP 47th Annual Meeting on "Scientific and Policy Challenges of Particle Radiations in Medical Therapy and Space Missions" was a timely opportunity to showcase the current scientific knowledge regarding charged particles, enhance cross-fertilization between the oncology and space scientific communities, and identify common needs and challenges to both communities as well as ways to address those challenges. This issue of Health Physics contains papers from talks presented at that meeting and highlights provocative questions and the ample opportunities for synergism between space and particle-therapy research to further understanding of the biological impacts of particle radiations. Health Phys. 103(5):681-684; 2012
C1 Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Held, KD (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiat Oncol, Cox 302,55 Fruit St, Boston, MA 02114 USA.
EM kheld@partners.org
FU NASA [NNX07AE40G, NNX12AB61G]; MGH Federal Share of Program Income [C06
CA059267]
FX Research in K. D. Held's laboratory is supported by NASA grants
#NNX07AE40G and NNX12AB61G and the MGH Federal Share of Program Income
under C06 CA059267.
NR 23
TC 0
Z9 0
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0017-9078
EI 1538-5159
J9 HEALTH PHYS
JI Health Phys.
PD NOV
PY 2012
VL 103
IS 5
BP 681
EP 684
DI 10.1097/HP.0b013e318264b2f5
PG 4
WC Environmental Sciences; Public, Environmental & Occupational Health;
Nuclear Science & Technology; Radiology, Nuclear Medicine & Medical
Imaging
SC Environmental Sciences & Ecology; Public, Environmental & Occupational
Health; Nuclear Science & Technology; Radiology, Nuclear Medicine &
Medical Imaging
GA 016MI
UT WOS:000309522300023
PM 23032899
ER
PT J
AU Hosseini, A
Van de Velde, S
Gill, TJ
Li, GA
AF Hosseini, Ali
Van de Velde, Samuel
Gill, Thomas J.
Li, Guoan
TI Tibiofemoral cartilage contact biomechanics in patients after
reconstruction of a ruptured anterior cruciate ligament
SO JOURNAL OF ORTHOPAEDIC RESEARCH
LA English
DT Article
DE anterior cruciate ligament (ACL); cartilage deformation; fluoroscopy;
ACL reconstruction; postoperative osteoarthritis (OA)
ID PATELLAR TENDON GRAFT; BONE-MARROW LESIONS; JOINT KINEMATICS; TIBIAL
ROTATION; KNEE OSTEOARTHRITIS; ACL RECONSTRUCTION; SINGLE-BUNDLE;
FOLLOW-UP; IN-VITRO; DEFORMATION
AB We investigated the in vivo cartilage contact biomechanics of the tibiofemoral joint in patients after reconstruction of a ruptured anterior cruciate ligament (ACL). A dual fluoroscopic and MR imaging technique was used to investigate the cartilage contact biomechanics of the tibiofemoral joint during in vivo weight-bearing flexion of the knee in eight patients 6 months following clinically successful reconstruction of an acute isolated ACL rupture. The location of tibiofemoral cartilage contact, size of the contact area, cartilage thickness at the contact area, and magnitude of the cartilage contact deformation of the ACL-reconstructed knees were compared with those previously measured in intact (contralateral) knees and ACL-deficient knees of the same subjects. Contact biomechanics of the tibiofemoral cartilage after ACL reconstruction were similar to those measured in intact knees. However, at lower flexion, the abnormal posterior and lateral shift of cartilage contact location to smaller regions of thinner tibial cartilage that has been described in ACL-deficient knees persisted in ACL-reconstructed knees, resulting in an increase of the magnitude of cartilage contact deformation at those flexion angles. Reconstruction of the ACL restored some of the in vivo cartilage contact biomechanics of the tibiofemoral joint to normal. Clinically, recovering anterior knee stability might be insufficient to prevent post-operative cartilage degeneration due to lack of restoration of in vivo cartilage contact biomechanics. (c) 2012 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 30:17811788, 2012
C1 [Hosseini, Ali; Van de Velde, Samuel; Gill, Thomas J.; Li, Guoan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Bioengn Lab, Boston, MA 02114 USA.
RP Li, GA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Bioengn Lab, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM gli1@partners.org
FU NIH [R01 AR055612, F32 AR056451]
FX The authors gratefully acknowledge the support of NIH (R01 AR055612, F32
AR056451) and thank Bijoy Thomas, Louis DeFrate, and Jeffrey Bingham for
their technical assistance.
NR 42
TC 36
Z9 38
U1 3
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0736-0266
J9 J ORTHOP RES
JI J. Orthop. Res.
PD NOV
PY 2012
VL 30
IS 11
BP 1781
EP 1788
DI 10.1002/jor.22122
PG 8
WC Orthopedics
SC Orthopedics
GA 015OL
UT WOS:000309455700013
PM 22528687
ER
PT J
AU Hazlett, EA
Collazo, T
Zelmanova, Y
Entis, JJ
Chu, KW
Goldstein, KE
Roussos, P
Haznedar, MM
Koenigsberg, HW
New, AS
Buchsbaum, MS
Hershowitz, JP
Siever, LJ
Byne, W
AF Hazlett, Erin A.
Collazo, Tyson
Zelmanova, Yuliya
Entis, Jonathan J.
Chu, King-Wai
Goldstein, Kim E.
Roussos, Panos
Haznedar, M. Mehmet
Koenigsberg, Harold W.
New, Antonia S.
Buchsbaum, Monte S.
Hershowitz, Julian P.
Siever, Larry J.
Byne, William
TI Anterior limb of the internal capsule in schizotypal personality
disorder: Fiber-tract counting, volume, and anisotropy
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizotypal personality disorder; Diffusion tensor imaging;
Tractography; Magnetic resonance imaging; Anisotropy; Internal capsule
ID THALAMIC MEDIODORSAL NUCLEUS; POOR-OUTCOME SCHIZOPHRENIA; WHITE-MATTER
ABNORMALITIES; 1ST-EPISODE SCHIZOPHRENIA; TEMPORAL LOBES; BASAL GANGLIA;
FRONTAL LOBES; DIFFUSION; MRI; BRAIN
AB Mounting evidence suggests that white matter abnormalities and altered subcortical-cortical connectivity may be central to the pathology of schizophrenia (SZ). The anterior limb of the internal capsule (ALIC) is an important thalamo-frontal white-matter tract shown to have volume reductions in SZ and to a lesser degree in schizotypal personality disorder (SPD). While fractional anisotropy (FA) and connectivity abnormalities in the ALIC have been reported in SZ, they have not been examined in SPD. In the current study, magnetic resonance (MRI) and diffusion tensor imaging (DTI) were obtained in age-and sex-matched individuals with SPD (n = 33) and healthy controls (HCs; n = 38). The ALIC was traced bilaterally on five equally spaced dorsal-to-ventral axial slices from each participant's MRI scan and co-registered to DTI for the calculation of FA. Tractography was used to examine tracts between the ALIC and two key Brodmann areas (BAs; BA10, BA45) within the dorsolateral prefrontal cortex (DLPFC). Compared with HCs, the SPD participants exhibited (a) smaller relative volume at the mid-ventral ALIC slice level but not the other levels; (b) normal FA within the ALIC; (c) fewer relative number of tracts between the most-dorsal ALIC levels and BA10 but not BA45 and (d) fewer dorsal ALIC-DLPFC tracts were associated with greater symptom severity in SPD. In contrast to prior SZ studies that report lower FA, individuals with SPD show sparing. Our findings are consistent with a pattern of milder thalamo-frontal dysconnectivity in SPD than schizophrenia. Published by Elsevier B.V.
C1 [Hazlett, Erin A.; Collazo, Tyson; Zelmanova, Yuliya; Entis, Jonathan J.; Goldstein, Kim E.; Roussos, Panos; Haznedar, M. Mehmet; Koenigsberg, Harold W.; New, Antonia S.; Hershowitz, Julian P.; Siever, Larry J.; Byne, William] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Hazlett, Erin A.; Chu, King-Wai; Roussos, Panos; New, Antonia S.; Siever, Larry J.; Byne, William] James J Peters VAMC, VISN Mental Illness Res Educ & Clin Ctr MIRECC 3, Bronx, NY 10468 USA.
[Haznedar, M. Mehmet; Koenigsberg, Harold W.; New, Antonia S.; Siever, Larry J.; Byne, William] James J Peters VAMC, Dept Psychiat, Bronx, NY 10468 USA.
[Buchsbaum, Monte S.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Buchsbaum, Monte S.] Univ Calif San Diego, Dept Radiol, San Diego, CA 92103 USA.
RP Hazlett, EA (reprint author), James J Peters VAMC, Mental Illness Res Educ & Clin Ctr MIRECC VISN 3, 130 W Kingsbridge Rd,Room 6A-45, Bronx, NY 10468 USA.
EM erin.hazlett@mssm.edu
RI Roussos, Panos/J-7090-2013
OI Roussos, Panos/0000-0002-4640-6239
FU NIMH [1R01MH073911]; Mental Illness Research Education and Clinical
Center; VISN3 Veterans Health Administration; National Center for
Research Resources, National Institutes of Health [UL1RR029887]
FX Funding for this study was provided by NIMH grant 1R01MH073911 to Dr.
Erin Hazlett. Partial support was also provided by the Mental Illness
Research Education and Clinical Center, VISN3 Veterans Health
Administration, and grant UL1RR029887 from the National Center for
Research Resources, National Institutes of Health. The funding sources
had no role in the study design, collection, analysis, interpretation of
data, writing of the manuscript, or in the decision to submit the paper
for publication.
NR 67
TC 9
Z9 9
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2012
VL 141
IS 2-3
BP 119
EP 127
DI 10.1016/j.schres.2012.08.022
PG 9
WC Psychiatry
SC Psychiatry
GA 016IN
UT WOS:000309511300002
PM 22995934
ER
PT J
AU Li, XB
Xia, SG
Bertisch, HC
Branch, CA
DeLisi, LE
AF Li, Xiaobo
Xia, Shugao
Bertisch, Hilary C.
Branch, Craig A.
DeLisi, Lynn E.
TI Unique topology of language processing brain network: A systems-level
biomarker of schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Genetic high risk; Language processing network; fMRI;
Graph theoretical techniques
ID SUPERIOR TEMPORAL GYRUS; SMALL-WORLD NETWORKS; HIGH-RISK; AUDITORY
COMPREHENSION; LOW-FREQUENCY; ACTIVATION; FMRI; INDIVIDUALS; MRI;
ABNORMALITIES
AB Objective: Schizophrenia is a severe and heritable brain disorder. Language impairment has been hypothesized to spur its onset and underlie the characteristic symptoms. In this study, we investigate whether altered topological pattern of the language processing brain network exists and could be a potential biomarker of schizophrenia. We hypothesized that both patients with schizophrenia and the genetic high risk population would show significantly weakened efficiencies of the network hubs for normal language processing, especially at left inferior frontal and bilateral temporal lobes.
Method: Language task-based fMRI data from 21 patients with schizophrenia, 22 genetic high risk subjects and 36 controls were analyzed. Graph theoretic and post hoc analyses of the fMRI data, and correlations between the functional network features and scores of language tests were carried out.
Results: Compared to controls, patients with schizophrenia and the high risk subjects showed significantly weakened network hubs in left inferior frontal and right fusiform gyri. A unique topology of super active and intercommunicating network hubs at left fusiform gyrus and right inferior/middle frontal gyri, which were associated with the behavioral language impairment was found in the patient group, compared to the high risk and control groups.
Conclusions: Aberrant systems-level topology of language processing network, especially significantly weakened network hubs in left inferior frontal and right fusiform gyri, may serve as a candidate biomarker of schizophrenia. Supported by existing findings, the hyperactive left fusiform gyrus communicating with right frontal lobe might be the key neurophysiological component causing hallucinations in schizophrenia. These findings provided a new systems-level diagnostic target for the disorder. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Li, Xiaobo] Yeshiva Univ, Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Dept Radiol, Bronx, NY 10461 USA.
[Li, Xiaobo] Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10467 USA.
[Li, Xiaobo] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA.
[Bertisch, Hilary C.] NYU, Sch Med, New York, NY 10003 USA.
[DeLisi, Lynn E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Brockton, MA 02401 USA.
RP Li, XB (reprint author), Yeshiva Univ, Albert Einstein Coll Med, Gruss Magnet Resonance Res Ctr, Dept Radiol, 1300 Morris Pk Ave,Gruss 204, Bronx, NY 10461 USA.
EM xli.nki.cabi@gmail.com
RI Xia, Shugao/F-6845-2013
OI Xia, Shugao/0000-0002-2960-3468
FU NIMH [R21 MH071720]
FX This project was partially supported by a grant from NIMH, R21 MH071720.
NR 41
TC 15
Z9 16
U1 2
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2012
VL 141
IS 2-3
BP 128
EP 136
DI 10.1016/j.schres.2012.07.026
PG 9
WC Psychiatry
SC Psychiatry
GA 016IN
UT WOS:000309511300003
PM 22917951
ER
PT J
AU Hill, M
Crumlish, N
Clarke, M
Whitty, P
Owens, E
Renwick, L
Browne, S
Macklin, EA
Kinsella, A
Larkin, C
Waddington, JL
O'Callaghan, E
AF Hill, Michele
Crumlish, Niall
Clarke, Mary
Whitty, Peter
Owens, Elizabeth
Renwick, Laoise
Browne, Stephen
Macklin, Eric A.
Kinsella, Anthony
Larkin, Conall
Waddington, John L.
O'Callaghan, Eadbhard
TI Prospective relationship of duration of untreated psychosis to
psychopathology and functional outcome over 12 years
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE First-episode; Follow-up
ID PERSISTENT NEGATIVE SYMPTOMS; 2-YEAR FOLLOW-UP; 1ST-EPISODE
SCHIZOPHRENIA; SYNDROME-SCALE; 1ST EPISODE; ILLNESS; IMPACT; PREDICTORS;
ASSOCIATION; DISORDER
AB Background: The duration of untreated psychosis is well recognised as an independent predictor of symptomatic and functional outcome in the short term and has facilitated the development of worldwide early intervention programmes. However, the extent and mechanisms by which it might influence prognosis beyond a decade remain poorly understood.
Methods: The authors examined the relationship between duration of untreated psychosis and outcome 12 years after a first episode of psychosis and assessed whether its relationship with function is affected by symptoms in a prospective, 12-year follow-up of an epidemiologically-based inception cohort.
Results: Longer duration of untreated psychosis predicted poorer remission status, more severe positive and negative symptoms, and greater impairment in general functioning, social functioning and quality of life at 12 years on standardised measures, independent of other factors at baseline. It was not associated with gainful employment, for which education was the only predictor, or independent living, for which age was the only predictor. The relationship between duration of untreated psychosis and functional outcome was mediated by concurrent psychopathology, particularly negative symptoms.
Conclusions: These results provide qualified support for the potential long-term benefit of reduction in the duration of untreated psychosis in terms of improvement in symptoms and functional outcome. Its failure to predict real-life outcomes such as independent living and gainful employment could reflect the importance of pre-existing socio-cultural factors such as individual opportunity. The relationship between duration of untreated psychosis and negative symptoms was largely responsible for its effect on function, suggesting a possible long-term protective mechanism against disability. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Hill, Michele; Macklin, Eric A.] Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA.
[Hill, Michele; Macklin, Eric A.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Hill, Michele; Crumlish, Niall; Clarke, Mary; Whitty, Peter; Owens, Elizabeth; Renwick, Laoise; Browne, Stephen; Larkin, Conall; Waddington, John L.; O'Callaghan, Eadbhard] St John God Adult Psychiat Serv, Cluain Mhuire Family Ctr, Dublin, Ireland.
[Crumlish, Niall] Trinity Coll Dublin, Dept Psychiat, Dublin, Ireland.
[Hill, Michele; Clarke, Mary; Whitty, Peter; Browne, Stephen; Larkin, Conall; O'Callaghan, Eadbhard] Univ Coll Dublin, Dept Psychiat, Dublin 2, Ireland.
[Macklin, Eric A.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Clarke, Mary; Owens, Elizabeth; Renwick, Laoise; Kinsella, Anthony; O'Callaghan, Eadbhard] DELTA DETECT Early Intervent Psychosis Serv, Dun Laoghaire, Dublin, Ireland.
[Waddington, John L.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
RP Hill, M (reprint author), Massachusetts Gen Hosp, Schizophrenia Program, Boston, MA 02114 USA.
EM michelehill1@gmail.com
RI Macklin, Eric/E-2955-2013; Renwick, Laoise/O-5128-2014
OI Macklin, Eric/0000-0003-1618-3502; Renwick, Laoise/0000-0001-7060-4537
FU Stanley Medical Research Institute, USA; Health Research Board of
Ireland; NIH [UL1 RR 025758]; Harvard University and its affiliated
academic health care centres
FX This prospective study was initiated under funding from the Stanley
Medical Research Institute, USA, with long-term follow-up funded by the
Health Research Board of Ireland.; Assistance with analysis was
supported by the Harvard Catalyst vertical bar The Harvard Clinical and
Translational Science Center (NIH Award # UL1 RR 025758 and financial
contributions from Harvard University and its affiliated academic health
care centres).
NR 39
TC 33
Z9 34
U1 2
U2 13
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2012
VL 141
IS 2-3
BP 215
EP 221
DI 10.1016/j.schres.2012.08.013
PG 7
WC Psychiatry
SC Psychiatry
GA 016IN
UT WOS:000309511300016
PM 23006501
ER
PT J
AU Horan, WP
Foti, D
Hajcak, G
Wynn, JK
Green, MF
AF Horan, William P.
Foti, Dan
Hajcak, Greg
Wynn, Jonathan K.
Green, Michael F.
TI Intact motivated attention in schizophrenia: Evidence from event-related
potentials (vol 135, pg 95, 2012)
SO SCHIZOPHRENIA RESEARCH
LA English
DT Correction
C1 [Horan, William P.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90073 USA.
[Horan, William P.; Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Foti, Dan; Hajcak, Greg] SUNY Stony Brook, Stony Brook, NY USA.
RP Horan, WP (reprint author), Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, 11301 Wilshire Blvd,Bldg 210,Mail Code 210A,Rm 11, Los Angeles, CA 90073 USA.
EM horan@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
NR 1
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD NOV
PY 2012
VL 141
IS 2-3
BP 288
EP 289
DI 10.1016/j.schres.2012.08.004
PG 2
WC Psychiatry
SC Psychiatry
GA 016IN
UT WOS:000309511300033
ER
PT J
AU Ma, BY
AF Ma, Bangyi
TI Two-Step Method in Pediatric Chemistry Tests With Insufficient Sample
Volume
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Meeting Abstract
C1 [Ma, Bangyi] Massachusetts Gen Hosp, Dept Pathol, Chem Core Lab, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD NOV 1
PY 2012
VL 138
SU 2
MA 195
BP A195
EP A195
PG 1
WC Pathology
SC Pathology
GA V45XH
UT WOS:000209848800155
ER
PT J
AU Knapp, H
Anaya, HD
AF Knapp, Herschel
Anaya, Henry D.
TI Implementation Science in the Real World: A Streamlined Model
SO JOURNAL FOR HEALTHCARE QUALITY
LA English
DT Article
DE implementation science; organizational change; performance improvement
models; process design/redesign/reengineering; quality improvement
AB The process of quality improvement may involve enhancing or revising existing practices or the introduction of a novel element. Principles of Implementation Science provide key theories to guide these processes, however, such theories tend to be highly technical in nature and do not provide pragmatic nor streamlined approaches to real-world implementation. This paper presents a concisely comprehensive six step theory-based Implementation Science model that we have successfully used to launch more than two-dozen self-sustaining implementations. In addition, we provide an abbreviated case study in which we used our streamlined theoretical model to successfully guide the development and implementation of an HIV testing/linkage to care campaign in homeless shelter settings in Los Angeles County.
C1 [Knapp, Herschel; Anaya, Henry D.] US Dept Vet Affairs, Washington, DC 20422 USA.
[Anaya, Henry D.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Knapp, H (reprint author), US Dept Vet Affairs, Washington, DC 20422 USA.
EM Herschel.Knapp@va.gov
NR 14
TC 3
Z9 3
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1062-2551
EI 1945-1474
J9 J HEALTHC QUAL
JI J. Healthc. Qual.
PD NOV-DEC
PY 2012
VL 34
IS 6
BP 27
EP 35
DI 10.1111/j.1945-1474.2012.00220.x
PG 9
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA V36OQ
UT WOS:000209221400004
PM 23163970
ER
PT J
AU Fields, BG
Kuna, ST
AF Fields, Barry G.
Kuna, Samuel T.
TI Comparing methods of respiratory event detection during the treatment of
obstructive sleep apnea
SO JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH
LA English
DT Review
DE apnea-hypopnea index; automatic event detection; obstructive sleep
apnea; polysomnogram; positive airway pressure
AB Renewed focus on comparative effectiveness research presents a unique opportunity to develop optimal clinical management pathways for patients with obstructive sleep apnea. With this momentum comes the challenge of measuring treatment effect on sleep-disordered breathing, especially in large, multisite studies. In-laboratory polysomnography, the current gold standard sleep assessment of obstructive sleep apnea severity, is costly and imposes significant participant burden. Alternatives include home unattended sleep testing and overnight pulse oximetry recording. Research studies using positive airway pressure treatment have the additional option of using the information recorded by the patient's positive airway pressure device to assess treatment effectiveness. Recent research has shown relatively good agreement between manual identification of residual respiratory events in overnight in-laboratory polysomnography and the automatic event detection utilized in positive airway pressure machines. In addition to assessing the effects of interventions on sleep disordered breathing, obstructive sleep apnea-related comparative effectiveness studies need to assess the impact of the interventions on patient burden, cost of therapy, timeliness of care, improved quality of life and other clinically relevant outcomes.
C1 [Fields, Barry G.] Univ Penn, Philadelphia, PA 19104 USA.
[Fields, Barry G.] Philadelphia Vet Affairs Med Ctr, Penn Sleep Ctr, Philadelphia, PA 19104 USA.
[Kuna, Samuel T.] Philadelphia Vet Affairs Med Ctr 111P, Vet Integrated Serv Network Reg Sleep Ctr 4, Philadelphia, PA 19104 USA.
RP Fields, BG (reprint author), Univ Penn, 3624 Market St,Suite 205, Philadelphia, PA 19104 USA.
EM barry.fields@uphs.upenn.edu
FU Philips-Respironics
FX S Kuna receives grant support from Philips-Respironics. The authors have
no other relevant affiliation or financial involvement with any
organization or entity with a financial interest in or financial
conflict with the subject matter or materials discussed in the
manuscript apart from those disclosed.
NR 39
TC 0
Z9 0
U1 1
U2 2
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 2042-6305
EI 2042-6313
J9 J COMP EFFECT RES
JI J. Comp. Eff. Res.
PD NOV
PY 2012
VL 1
IS 6
BP 489
EP 499
DI 10.2217/CER.12.58
PG 11
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA V32SL
UT WOS:000208970800012
PM 24236468
ER
PT J
AU Abbott, KV
Li, NYK
Branski, RC
Rosen, CA
Grillo, E
Steinhauer, K
Hebda, PA
AF Abbott, Katherine Verdolini
Li, Nicole Y. K.
Branski, Ryan C.
Rosen, Clark A.
Grillo, Elizabeth
Steinhauer, Kimberly
Hebda, Patricia A.
TI Vocal Exercise May Attenuate Acute Vocal Fold Inflammation
SO JOURNAL OF VOICE
LA English
DT Article
DE Vocal fold inflammation; Wound healing; Tissue mobilization; Resonant
voice
ID PHONATION THRESHOLD PRESSURE; FIBEROPTIC LARYNGEAL SURGERY; RANDOMIZED
CONTROLLED-TRIAL; CELLS IN-VITRO; MECHANICAL STRAIN; STEROID INJECTION;
RABBIT MODEL; AIR-PRESSURE; VOICE; POLYMORPHISMS
AB Objectives/Hypotheses. The objective was to assess the utility of selected "resonant voice" (RV) exercises for the reduction of acute vocal fold inflammation. The hypothesis was that relatively large-amplitude, low-impact vocal fold exercises associated with RV would reduce inflammation more than spontaneous speech (SS) and possibly more than voice rest.
Study Design. The study design was prospective, randomized, and double blind.
Methods. Nine vocally healthy adults underwent a 1-hour vocal loading procedure, followed by randomization to a SS condition, vocal rest condition, or RV exercise condition. Treatments were monitored in clinic for 4 hours and continued extraclinically until the next morning. At baseline (BL), immediately after loading, after the 4-hour in-clinic treatment, and 24 hours post-BL, secretions were suctioned from the vocal folds bilaterally and submitted to enzyme-linked immunosorbent assay to estimate concentrations of key markers of tissue injury and inflammation: interleukin (IL)-1 beta, IL-6, IL-8, tumor necrosis factor a, matrix metalloproteinase (MMP)-8, and IL-10.
Results. Complete data sets were obtained for three markers-IL-1 beta, IL-6, and MMP-8-for one subject in each treatment condition. For these markers, results were poorest at 24-hour follow-up in the SS condition, sharply improved in the voice rest condition, and was the best in the RV condition. Average results for all markers and responsive subjects with normal BL mediator concentrations revealed an almost identical pattern.
Conclusions. Some forms of tissue mobilization may be useful to attenuate acute vocal fold inflammation.
C1 [Abbott, Katherine Verdolini; Rosen, Clark A.; Hebda, Patricia A.] Univ Pittsburgh, Dept Commun Sci & Disorders, Pittsburgh, PA 15260 USA.
[Abbott, Katherine Verdolini; Rosen, Clark A.] Univ Pittsburgh, Dept Otolaryngol, Voice Ctr, Sch Med, Pittsburgh, PA 15260 USA.
[Abbott, Katherine Verdolini; Rosen, Clark A.; Hebda, Patricia A.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15260 USA.
[Li, Nicole Y. K.] Univ Wisconsin, Dept Surg, Madison, WI USA.
[Branski, Ryan C.] NYU, Sch Med, Dept Otolaryngol, New York, NY USA.
[Grillo, Elizabeth] W Chester Univ, Dept Commun Disorders, W Chester, PA 19380 USA.
[Steinhauer, Kimberly] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Hebda, Patricia A.] Univ Pittsburgh, Dept Otolaryngol, Div Pediat, Otolaryngol Wound Healing Lab,Sch Med, Pittsburgh, PA 15260 USA.
[Hebda, Patricia A.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA.
RP Abbott, KV (reprint author), Univ Pittsburgh, Dept Commun Sci & Disorders, 4033 Forbes Tower, Pittsburgh, PA 15260 USA.
OI Branski, Ryan/0000-0003-1190-9036
FU National Institute on Deafness and Other Communication Disorders [R01
DC5643]
FX The study was supported by R01 DC5643 from the National Institute on
Deafness and Other Communication Disorders. Preliminary data were
presented at the 34th Symposium: Care of the Professional Voice; June
2005; Philadelphia, PA. The authors acknowledge the substantial
contributions of Dr Priya Krishna and Maria Dietrich in data collection
and management as well as Dr Elaine Rubenstein for statistical
consulting and Mr Neil Szuminsky for the development of software for
data analysis.
NR 67
TC 4
Z9 4
U1 2
U2 7
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0892-1997
EI 1873-4588
J9 J VOICE
JI J. Voice
PD NOV
PY 2012
VL 26
IS 6
AR 814.e1
DI 10.1016/j.jvoice.2012.03.008
PG 13
WC Otorhinolaryngology
SC Otorhinolaryngology
GA 041VC
UT WOS:000311428300030
ER
PT J
AU Ettenhofer, ML
Melrose, RJ
Delawalla, Z
Castellon, SA
Okonek, A
AF Ettenhofer, Mark L.
Melrose, Rebecca J.
Delawalla, Zainab
Castellon, Steven A.
Okonek, Anna
TI Correlates of Functional Status Among OEF/OIF Veterans With a History of
Traumatic Brain Injury
SO MILITARY MEDICINE
LA English
DT Article
AB This study was conducted to identify factors related to functional status within a clinical sample of Veterans of Operation Enduring Freedom (OEF) and Operation Iraqi Freedom (OFF) with a history of traumatic brain injury (TBI). Medical chart review was conducted for a consecutive group of OEF/OIF Veterans who were referred for neuropsychological evaluation within a Veterans Affairs Medical Center Polytrauma Program related to history of TBI (n = 57). Level of involvement in occupational and academic activity, presence or absence of housing insecurity, and clinician ratings of overall functioning served as indicators of functional status. Reduced functional status was most strongly related to poorer cognitive function, particularly motor function, processing speed, and executive function. Lower levels of functioning were also related to increased severity of postconcussive symptoms, lower levels of education, and ongoing medication treatment for sleep or psychiatric symptoms. Comprehensive evaluation of cognitive, affective, and behavioral functioning among OEF/OIF Veterans with a history of TBI is likely to provide valuable information to inform rehabilitation strategies and identify potential warning signs for poor postdeployment reintegration. Increased awareness of these factors may aid clinicians in identifying patients at risk for poor outcomes and in more effectively targeting symptoms for intervention.
C1 [Ettenhofer, Mark L.] Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, Bethesda, MD 20814 USA.
[Melrose, Rebecca J.; Delawalla, Zainab; Castellon, Steven A.; Okonek, Anna] VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Melrose, Rebecca J.; Castellon, Steven A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Okonek, Anna] Univ Calif Los Angeles, Dept Psychol, Los Angeles, CA 90095 USA.
RP Ettenhofer, ML (reprint author), Uniformed Serv Univ Hlth Sci, Dept Med & Clin Psychol, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA.
FU VA Greater Los Angeles Healthcare System; Uniformed Services University
of the Health Sciences; Department of Veterans Affairs
FX Financial support was provided by VA Greater Los Angeles Healthcare
System, the Uniformed Services University of the Health Sciences, and
the Department of Veterans Affairs (Career Development Award to R.
Melrose; Office of Academic Affiliations, Special Fellowship Program in
Advanced Geriatrics).
NR 50
TC 9
Z9 9
U1 4
U2 7
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD NOV
PY 2012
VL 177
IS 11
BP 1272
EP 1278
DI 10.7205/MILMED-D-12-00095
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA V33OF
UT WOS:000209027400007
PM 23198501
ER
PT J
AU Buerhaus, PI
DesRoches, C
Applebaum, S
Hess, R
Norman, LD
Donelan, K
AF Buerhaus, Peter I.
DesRoches, Catherine
Applebaum, Sandra
Hess, Robert
Norman, Linda D.
Donelan, Karen
TI Are Nurses Ready for Health Care Reform? A Decade of Survey Research
SO NURSING ECONOMICS
LA English
DT Article
AB As health care delivery organizations react to the changes brought about by public and private sector reform initiatives, RNs can anticipate that, in addition to intended outcomes, there will be unpredictable pressures and unintended consequences arising from reform.
Biennial national surveys of RNs conducted over the past decade have explored various changes in the nursing workforce, quality of the workplace environment, staffing and payment policies, and RNs' views of health policy, including their expectations of health reform.
The latest survey results offer a picture of RNs' capacity to practice successfully in a care delivery environment that, over the current decade, is expected to emphasize teams, care coordination, and become driven increasingly by payment incentives that reward quality, safety, and efficiency.
If RNs are provided with strong clinical leadership, participate in developing an achievable vision of the future, and if supported to take risks and innovate to improve the quality and efficiency of care delivery, then the profession is likely to thrive rather than struggle during the health reform years that lie ahead.
Increasing the education and preparation of nursing leaders, and particularly unit-level managers, will be increasingly vital for nursing to prosper in the future.
C1 [Buerhaus, Peter I.] Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Ctr Interdisciplinary Hlth Workforce Studies, Nashville, TN 37235 USA.
[DesRoches, Catherine] Math Policy Res, Princeton, NJ USA.
[Applebaum, Sandra] Harris Interact, New York, NY USA.
[Hess, Robert] Gannett Healthcare Grp, Global Programming, Voorhees, NJ USA.
[Norman, Linda D.] Vanderbilt Univ, Sch Nursing, Nashville, TN 37240 USA.
[Donelan, Karen] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
RP Buerhaus, PI (reprint author), Vanderbilt Univ, Med Ctr, Inst Med & Publ Hlth, Ctr Interdisciplinary Hlth Workforce Studies, Nashville, TN 37235 USA.
NR 10
TC 3
Z9 3
U1 0
U2 4
PU JANNETTI PUBLICATIONS, INC
PI PITMAN
PA EAST HOLLY AVENUE, BOX 56, PITMAN, NJ 08071-0056 USA
SN 0746-1739
J9 NURS ECON
JI Nurs. Econ.
PD NOV-DEC
PY 2012
VL 30
IS 6
BP 318
EP 330
PG 13
WC Nursing
SC Nursing
GA V35RR
UT WOS:000209166500004
PM 23346730
ER
PT J
AU Lajonchere, C
Jones, N
Coury, DL
Perrin, JM
AF Lajonchere, Clara
Jones, Nancy
Coury, Daniel L.
Perrin, James M.
TI Leadership in Health Care, Research, and Quality Improvement for
Children and Adolescents With Autism Spectrum Disorders: Autism
Treatment Network and Autism Intervention Research Network on Physical
Health
SO PEDIATRICS
LA English
DT Article
DE autism spectrum disorder
C1 [Lajonchere, Clara; Jones, Nancy] Autism Speaks, Los Angeles, CA USA.
[Coury, Daniel L.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA.
[Coury, Daniel L.] Ohio State Univ, Sch Med, Columbus, OH 43210 USA.
[Perrin, James M.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02114 USA.
[Perrin, James M.] MassGen Hosp Children, Boston, MA USA.
RP Perrin, JM (reprint author), Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, 100 Cambridge St 1542, Boston, MA 02114 USA.
EM jperrin@partners.org
RI Coury, Daniel/E-2925-2011
NR 32
TC 12
Z9 12
U1 4
U2 8
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2012
VL 130
SU 2
BP S62
EP S68
DI 10.1542/peds.2012-0900C
PG 7
WC Pediatrics
SC Pediatrics
GA V40NO
UT WOS:000209485500003
PM 23118255
ER
PT J
AU Mahajan, R
Bernal, MP
Panzer, R
Whitaker, A
Roberts, W
Handen, B
Hardan, A
Anagnostou, E
Veenstra-VanderWeele, J
AF Mahajan, Rajneesh
Bernal, Maria Pilar
Panzer, Rebecca
Whitaker, Agnes
Roberts, Wendy
Handen, Benjamin
Hardan, Antonio
Anagnostou, Evdokia
Veenstra-VanderWeele, Jeremy
TI Clinical Practice Pathways for Evaluation and Medication Choice for
Attention-Deficit/Hyperactivity Disorder Symptoms in Autism Spectrum
Disorders
SO PEDIATRICS
LA English
DT Article
DE ADHD symptoms; autism spectrum disorders; hyperactivity; impulsivity;
inattention
AB BACKGROUND AND OBJECTIVE: Hyperactivity, impulsivity, and inattention (referred to as "ADHD [attention-deficit/hyperactivity disorder] symptoms") occur in 41% to 78% of children with autism spectrum disorders ASDs). These symptoms often affect quality of life, interfering with learning or interventions that target primary ASD symptoms. This practice pathway describes the guidelines for evaluation and treatment of children and adolescents with ASD and comorbid ADHD symptoms.
METHODS: Current research in this area is limited, and, therefore, these recommendations are based on a systematic literature review and expert consensus in the Autism Speaks Autism Treatment Network Psychopharmacology Committee.
RESULTS: The recommended practice pathway includes the Symptom Evaluation Pathway for systematic assessment of ADHD symptoms across settings; examination for comorbid sleep, medical, or psychiatric comorbidities that may contribute to symptoms; and evaluation of behavioral interventions that may ameliorate these symptoms. For children for whom medication is being considered to target the ADHD symptoms, the medication choice pathway provides guidance on the selection of the appropriate agent based on a review of available research, assessment of specific advantages and disadvantages of each agent, and dosing considerations.
CONCLUSIONS: These recommendations provide a framework for primary care providers treating children who have ASD and ADHD symptoms. Our systematic review of the current evidence indicates the need for more randomized controlled trials of the medications for ADHD symptoms in ASD. There will also be a need for studies of the effectiveness of these practice pathways in the future.
C1 [Mahajan, Rajneesh] Kennedy Krieger Inst, Dept Psychiat, Baltimore, MD 21211 USA.
[Mahajan, Rajneesh] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Bernal, Maria Pilar] Kaiser Permanente No Calif, Dept Psychiat, San Jose, CA USA.
[Panzer, Rebecca] MassGen Hosp Children, Dept Pediat, Boston, MA USA.
[Whitaker, Agnes] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY USA.
[Whitaker, Agnes] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Roberts, Wendy] Univ Toronto, Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada.
[Handen, Benjamin] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA.
[Handen, Benjamin] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Hardan, Antonio] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA.
[Anagnostou, Evdokia] Holland Bloorview Kids Rehabil Hosp, Dept Pediat, Toronto, ON, Canada.
[Anagnostou, Evdokia] Univ Toronto, Toronto, ON, Canada.
[Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Med Ctr, Dept Psychiat, Nashville, TN USA.
[Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
[Veenstra-VanderWeele, Jeremy] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
RP Mahajan, R (reprint author), Kennedy Krieger Inst, Ctr Autism & Related Disorders, 3901 Green Spring Ave, Baltimore, MD 21211 USA.
EM mahajan@kennedykrieger.org
RI Veenstra-VanderWeele, Jeremy/K-1935-2015
OI Veenstra-VanderWeele, Jeremy/0000-0002-6349-1076
NR 66
TC 25
Z9 27
U1 7
U2 9
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2012
VL 130
SU 2
BP S125
EP S138
DI 10.1542/peds.2012-0900J
PG 14
WC Pediatrics
SC Pediatrics
GA V40NO
UT WOS:000209485500010
PM 23118243
ER
PT J
AU Malow, BA
Byars, K
Johnson, K
Weiss, S
Bernal, P
Goldman, SE
Panzer, R
Coury, DL
Glaze, DG
AF Malow, Beth A.
Byars, Kelly
Johnson, Kyle
Weiss, Shelly
Bernal, Pilar
Goldman, Suzanne E.
Panzer, Rebecca
Coury, Daniel L.
Glaze, Dan G.
TI A Practice Pathway for the Identification, Evaluation, and Management of
Insomnia in Children and Adolescents With Autism Spectrum Disorders
SO PEDIATRICS
LA English
DT Article
DE actigraphy; education; sleep; sleep latency
AB OBJECTIVE: This report describes the development of a practice pathway for the identification, evaluation, and management of insomnia in children and adolescents who have autism spectrum disorders (ASDs).
METHODS: The Sleep Committee of the Autism Treatment Network (ATN) developed a practice pathway, based on expert consensus, to capture best practices for an overarching approach to insomnia by a general pediatrician, primary care provider, or autism medical specialist, including identification, evaluation, and management. A field test at 4 ATN sites was used to evaluate the pathway. In addition, a systematic literature review and grading of evidence provided data regarding treatments of insomnia in children who have neurodevelopmental disabilities.
RESULTS: The literature review revealed that current treatments for insomnia in children who have ASD show promise for behavioral/educational interventions and melatonin trials. However, there is a paucity of evidence, supporting the need for additional research. Consensus among the ATN sleep medicine committee experts included: (1) all children who have ASD should be screened for insomnia; (2) screening should be done for potential contributing factors, including other medical problems; (3) the need for therapeutic intervention should be determined; (4) therapeutic interventions should begin with parent education in the use of behavioral approaches as a first-line approach; (5) pharmacologic therapy may be indicated in certain situations; and (6) there should be follow-up after any intervention to evaluate effectiveness and tolerance of the therapy. Field testing of the practice pathway by autism medical specialists allowed for refinement of the practice pathway.
CONCLUSIONS: The insomnia practice pathway may help health care providers to identify and manage insomnia symptoms in children and adolescents who have ASD. It may also provide a framework to evaluate the impact of contributing factors on insomnia and to test the effectiveness of nonpharmacologic and pharmacologic treatment strategies for the nighttime symptoms and daytime functioning and quality of life in ASD.
C1 [Malow, Beth A.; Bernal, Pilar] Vanderbilt Univ, Med Ctr, Dept Neurol, Nashville, TN USA.
[Malow, Beth A.] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA.
[Malow, Beth A.; Bernal, Pilar] Vanderbilt Univ, Med Ctr, Kennedy Ctr, Nashville, TN USA.
[Byars, Kelly] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA.
[Johnson, Kyle] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA.
[Weiss, Shelly] Holland Bloorview Kids Rehabil Hosp, Toronto, ON, Canada.
[Goldman, Suzanne E.] Kaiser Permanente Northern, San Jose, CA USA.
[Panzer, Rebecca] MassGen Hosp Children, Boston, MA USA.
[Coury, Daniel L.] Nationwide Childrens Hosp, Dept Pediat, Columbus, OH USA.
[Glaze, Dan G.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA.
[Glaze, Dan G.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA.
RP Malow, BA (reprint author), Vanderbilt Sleep Disorders Div, 1161 21st Ave South,Room A-0116, Nashville, TN 37232 USA.
EM beth.malow@vanderbilt.edu
RI Coury, Daniel/E-2925-2011
NR 52
TC 42
Z9 44
U1 2
U2 10
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2012
VL 130
SU 2
BP S106
EP S124
DI 10.1542/peds.2012-0900I
PG 19
WC Pediatrics
SC Pediatrics
GA V40NO
UT WOS:000209485500009
PM 23118242
ER
PT J
AU Perrin, JM
Coury, DL
Hyman, SL
Cole, L
Reynolds, AM
Clemons, T
AF Perrin, James M.
Coury, Daniel L.
Hyman, Susan L.
Cole, Lynn
Reynolds, Ann M.
Clemons, Traci
TI Complementary and Alternative Medicine Use in a Large Pediatric Autism
Sample
SO PEDIATRICS
LA English
DT Article
DE autism spectrum disorders; complementary and alternative medicine
AB BACKGROUND AND OBJECTIVE: Children and adolescents with autism spectrum disorder (ASD) often use complementary and alternative medicine (CAM), usually along with other medical care. This study aimed to determine associations of ASD diagnostic category, co-existing conditions, and use of medications with use of CAM.
METHODS: We used the Autism Speaks Autism Treatment Network patient registry, which collects information on CAM use, medical conditions, and psychotropic medication at enrollment. CAM was categorized as special diets versus "other" CAM; ASD was defined as autism, pervasive developmental disorder (PDD), or Asperger's. Gastrointestinal symptoms, seizure disorders, sleep problems, and medication use were determined from parent report. Child Behavior Checklist (CBCL) scores were used to measure behavioral symptoms. Logistic regression was used to determine associations of diagnostic category, other medical conditions, and medication use with CAM treatments, controlling for demographic characteristics.
RESULTS: Of 3413 subjects in the registry as of April 2011, 3173 had complete data on CAM use: 896 (28%) reported any use; 548 (17%), special diets; and 643 (20%), other CAM. Higher rates of CAM use were associated with gastrointestinal symptoms (odds ratio [OR] = 1.88), seizures (OR = 1.58), and CBCL total score >70 (OR = 1.29). Children with PDD (OR = 0.62), Asperger's (OR = 0.66), or using medications (0.69) had lower rates.
CONCLUSIONS: Children with ASD use more CAM when they have coexisting gastrointestinal symptoms, seizure disorders, and behavior problems. This study suggests the importance of asking about CAM use in children with ASD, especially those with complex symptoms.
C1 [Perrin, James M.] Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, Boston, MA 02114 USA.
[Coury, Daniel L.] Ohio State Univ, Sch Med, Nationwide Childrens Hosp, Columbus, OH 43210 USA.
[Hyman, Susan L.; Cole, Lynn] Univ Rochester, Sch Med, Golisano Childrens Hosp, Rochester, NY USA.
[Reynolds, Ann M.] Univ Colorado, Childrens Hosp Colorado, Aurora, CO USA.
[Clemons, Traci] EMMES Corp, Rockville, MD USA.
RP Perrin, JM (reprint author), Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, 100 Cambridge St,1542, Boston, MA 02114 USA.
EM jperrin@partners.org
RI Coury, Daniel/E-2925-2011;
OI Reynolds, Ann/0000-0002-0836-746X
NR 14
TC 25
Z9 25
U1 2
U2 7
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2012
VL 130
SU 2
BP S77
EP S82
DI 10.1542/peds.2012-0900E
PG 6
WC Pediatrics
SC Pediatrics
GA V40NO
UT WOS:000209485500005
PM 23118257
ER
PT J
AU Perrin, JM
Coury, DL
Jones, N
Lajonchere, C
AF Perrin, James M.
Coury, Daniel L.
Jones, Nancy
Lajonchere, Clara
TI The Autism Treatment Network and Autism Intervention Research Network on
Physical Health: Future Directions
SO PEDIATRICS
LA English
DT Article
DE autism spectrum disorder
C1 [Perrin, James M.] Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, Boston, MA 02114 USA.
[Coury, Daniel L.] Nationwide Childrens Hosp, Columbus, OH USA.
[Coury, Daniel L.] Ohio State Univ, Sch Med, Columbus, OH 43210 USA.
[Jones, Nancy; Lajonchere, Clara] Autism Speaks, Los Angeles, CA USA.
RP Perrin, JM (reprint author), Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, 100 Cambridge St,1542, Boston, MA 02114 USA.
EM jperrin@partners.org
RI Coury, Daniel/E-2925-2011
NR 11
TC 3
Z9 3
U1 2
U2 4
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2012
VL 130
SU 2
BP S198
EP S201
DI 10.1542/peds.2012-0900S
PG 4
WC Pediatrics
SC Pediatrics
GA V40NO
UT WOS:000209485500019
PM 23118252
ER
PT J
AU Perrin, JM
Coury, DL
AF Perrin, James M.
Coury, Daniel L.
TI Untitled
SO PEDIATRICS
LA English
DT Editorial Material
C1 [Perrin, James M.] Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, Boston, MA 02114 USA.
[Coury, Daniel L.] Ohio State Univ, Sch Med, Nationwide Childrens Hosp, Dept Pediat, Columbus, OH 43210 USA.
RP Perrin, JM (reprint author), Harvard Univ, Sch Med, MassGen Hosp Children, Dept Pediat, 100 Cambridge St 1542, Boston, MA 02114 USA.
EM jperrin@partners.org
NR 0
TC 3
Z9 3
U1 1
U2 1
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD NOV
PY 2012
VL 130
SU 2
BP S57
EP S58
DI 10.1542/peds.2012-0900A
PG 2
WC Pediatrics
SC Pediatrics
GA V40NO
UT WOS:000209485500001
PM 23118253
ER
PT J
AU Kim, SS
Subramanian, SV
Sorensen, G
Perry, MJ
Christiani, DC
AF Kim, Seung-Sup
Subramanian, S. V.
Sorensen, Glorian
Perry, Melissa J.
Christiani, David C.
TI Association between change in employment status and new-onset depressive
symptoms in South Korea - a gender analysis
SO SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH
LA English
DT Article
DE depression; gender difference; mental health
AB Objectives This study aimed to investigate the association of change in employment status with new-onset depressive symptoms, particularly differences stemming from workers' gender, in South Korea.
Methods We analyzed data from the ongoing Korean Welfare Panel Study. After excluding participants who had depressive symptoms at baseline (2007), we analyzed 2891 participants who became a precarious or permanent worker or unemployed at follow-up (2008) among waged workers who were permanent or precarious workers at baseline. Workers were classified as permanent workers if they had full-time, secure jobs and were directly hired by their employers; workers not meeting all these criteria were classified as precarious workers. Depressive symptoms were assessed annually using the 11-item Center for Epidemiologic Studies Depression Scale. To reduce potential bias due to pre-existing health conditions, we also examined the association in a subpopulation excluding participants with any pre-existing chronic disease or disability.
Results Compared to those who maintained permanent employment, workers who became unemployed following precarious employment had higher odds of developing depressive symptoms [odds ratio (OR) 2.30, 95% confidence interval (95% CI) 1.01-5.25]. In gender-stratified analyses, new-onset depressive symptoms were strongly associated with the change from precarious to permanent employment (OR 2.57, 95% CI 1.20-5.52) as well as the change from permanent to precarious employment (OR 2.88, 95% CI 1.24-6.66) among females; no significant association was observed in the male subpopulation.
Conclusions This study found that changes from precarious to permanent work or from permanent to precarious work were associated with new-onset depressive symptoms among South Korean women.
C1 [Kim, Seung-Sup; Perry, Melissa J.] George Washington Univ, Dept Environm & Occupat Hlth, Sch Publ Hlth & Hlth Serv, Washington, DC 20037 USA.
[Subramanian, S. V.; Sorensen, Glorian] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Sorensen, Glorian] Dana Faber Canc Inst, Ctr Community Based Res, Boston, MA USA.
[Perry, Melissa J.; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
RP Kim, SS (reprint author), George Washington Univ, Dept Environm & Occupat Hlth, Sch Publ Hlth & Hlth Serv, 2300 I St NW, Washington, DC 20037 USA.
EM sskim@gwu.edu
NR 52
TC 19
Z9 21
U1 3
U2 8
PU SCANDINAVIAN JOURNAL WORK ENVIRONMENT & HEALTH
PI HELSINKI
PA TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND
SN 0355-3140
EI 1795-990X
J9 SCAND J WORK ENV HEA
JI Scand. J. Work Environ. Health
PD NOV
PY 2012
VL 38
IS 6
BP 537
EP 545
DI 10.5271/sjweh.3286
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA V31KY
UT WOS:000208883700006
PM 22370923
ER
PT J
AU Illangasekare, S
Tello, M
Hutton, H
Moore, R
Anderson, J
Baron, J
Chander, G
AF Illangasekare, Samantha
Tello, Monique
Hutton, Heidi
Moore, Richard
Anderson, Jean
Baron, Jillian
Chander, Geetanjali
TI Clinical and Mental Health Correlates and Risk Factors for Intimate
Partner Violence among HIV-Positive Women in an Inner-City HIV Clinic
SO WOMENS HEALTH ISSUES
LA English
DT Article
AB Background: Intimate partner violence (IPV) is a serious health concern for women in the United States, and HIV-positive women experience more frequent and severe abuse compared with HIV-negative women. The goals of this study were to determine the prevalence of IPV among HIV-infected women receiving care in an urban clinic and to determine the HIV clinical and mental health correlates of IPV among HIV-positive women.
Methods: We conducted a cross-sectional survey among 196 women visiting an inner-city HIV clinic. Women were eligible if they were 18 years of age or older, English speaking, and received both HIV primary and gynecologic care at the clinic. The survey queried demographics, drug and alcohol history, depressive symptoms, and IPV, using the Partner Violence Scale. Antiretroviral therapy (ART), CD4 cell count, HIV-1 RNA level, and appointment adherence were abstracted from clinical records.
Findings: Overall, 26.5% of women reported experiencing IPV in the past year. There were no differences in socio-demographics, substance use, ART prescription, CD4 count, or HIV-1 RNA level between women who experienced IPV and those who had not. Women with mild and severe depressive symptoms were significantly more likely to report IPV compared with those without, with adjusted odds ratios of 3.4 and 5.5, respectively. Women who missed gynecologic appointments were 1.9 times more likely to report experiencing IPV.
Conclusions: IPV is prevalent among women presenting for HIV care, and depressive symptoms or missed gynecologic appointments should prompt further screening for IPV. Copyright (C) 2012 by the Jacobs Institute of Women's Health. Published by Elsevier Inc.
C1 [Illangasekare, Samantha] Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Urban Hlth Inst, Baltimore, MD 21205 USA.
[Tello, Monique] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Hutton, Heidi] Johns Hopkins Med Inst, Dept Psychiat, Baltimore, MD 21205 USA.
[Moore, Richard; Baron, Jillian; Chander, Geetanjali] Johns Hopkins Med Inst, Div Gen Internal Med, Dept Med, Baltimore, MD 21205 USA.
[Anderson, Jean] Johns Hopkins Med Inst, Dept Gynecol & Obstet, Baltimore, MD 21205 USA.
RP Illangasekare, S (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Johns Hopkins Urban Hlth Inst, 2013 E Monument St, Baltimore, MD 21205 USA.
EM sillanga@jhsph.edu
FU NIAAA NIH HHS [K23 AA015313]; NIDA NIH HHS [K24 DA000432]; NIMH NIH HHS
[F31 MH084716]
NR 30
TC 9
Z9 9
U1 3
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1049-3867
EI 1878-4321
J9 WOMEN HEALTH ISS
JI Womens Health Iss.
PD NOV-DEC
PY 2012
VL 22
IS 6
BP E563
EP E569
DI 10.1016/j.whi.2012.07.007
PG 7
WC Public, Environmental & Occupational Health; Women's Studies
SC Public, Environmental & Occupational Health; Women's Studies
GA V33SU
UT WOS:000209039300008
PM 22939089
ER
PT J
AU Smith, RM
Dyer, GSM
Antonangeli, K
Arredondo, N
Bedlion, H
Dalal, A
Deveny, GM
Joseph, G
Lauria, D
Lockhart, SH
Lucien, S
Marsh, S
Rogers, SO
Salzarulo, H
Shah, S
Toussaint, RJ
Wagoner, J
AF Smith, R. M.
Dyer, G. S. M.
Antonangeli, K.
Arredondo, N.
Bedlion, H.
Dalal, A.
Deveny, G. M.
Joseph, G.
Lauria, D.
Lockhart, S. H.
Lucien, S.
Marsh, S.
Rogers, S. O.
Salzarulo, H.
Shah, S.
Toussaint, R. J.
Wagoner, J.
TI Disaster triage after the Haitian earthquake
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Disaster triage; Compartment syndrome; Sepsis; Haiti earthquake
ID WENCHUAN EARTHQUAKE; CRUSH INJURY; EXPERIENCE; CHINA
AB In the aftermath of the devastating Haitian earthquake, we became the primary relief service for a large group of severely injured earthquake victims. Finding ourselves virtually isolated with extremely limited facilities and a group of critically injured patients whose needs vastly outstripped the available resources we employed a disaster triage system to organize their clinical care. This report describes the specific injury profile of this group of patients, their clinical course, and the management philosophy that we employed. It provides useful lessons for similar situations in the future. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Smith, R. M.] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Dyer, G. S. M.; Bedlion, H.; Lucien, S.; Rogers, S. O.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Wagoner, J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Shah, S.] Rhode Isl Hosp, Providence, RI USA.
[Joseph, G.] Albert Einstein Hosp, Bronx, NY USA.
[Marsh, S.; Salzarulo, H.] Blue Ridge Orthoped, Seneca, SC USA.
[Marsh, S.; Salzarulo, H.] Partners Hlth, Boston, MA USA.
[Lockhart, S. H.] Sutter Hlth, Walnut Creek, CA USA.
RP Smith, RM (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, YAW3600C,55 Fruit St, Boston, MA 02114 USA.
EM rmsmith1@partners.org
NR 15
TC 3
Z9 4
U1 4
U2 12
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD NOV
PY 2012
VL 43
IS 11
BP 1811
EP 1815
DI 10.1016/j.injury.2011.07.015
PG 5
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 014VR
UT WOS:000309404300006
PM 21868011
ER
PT J
AU Helmerhorst, GTT
Lindenhovius, ALC
Vrahas, M
Ring, D
Kloen, P
AF Helmerhorst, Gijs T. T.
Lindenhovius, Anneluuk L. C.
Vrahas, Mark
Ring, David
Kloen, Peter
TI Satisfaction with pain relief after operative treatment of an ankle
fracture
SO INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED
LA English
DT Article
DE Narcotics; Opioid; Pain medication; Ankle fracture; Operative treatment
ID ADULT ATTACHMENT; DISABILITY; PREDICTORS; INTENSITY
AB Background: American patients are prescribed more opioid pain medication than Dutch patients after operative treatment of an ankle fracture, but it is possible that pain is undertreated in Dutch patients. This study tests if there is a difference in pain and satisfaction with pain relief between Dutch and American patients after operative treatment of ankle fractures.
Methods: Thirty American and 30 Dutch patients were enrolled in a prospective comparative study prior to operative treatment of ankle fractures. Patients rated pain and satisfaction with pain relief on postoperative day 1 (POD1) and at time of suture removal (SR). Pain and satisfaction scores were compared and multivariable analysis identified their predictors.
Results: At POD1, a third of Dutch patients used no opioids and a sixth took strong opioids. At SR, only 4 of 30 (13%) were taking tramadol and half were taking no medication. All of the American patients used strong opioid pain medication on POD1 and 19 of 30 (63%) were still taking strong opioids at SR. Patients that did not use opioids and Dutch patients had less pain and equivalent satisfaction with pain relief compared to patients that used opioids and American patients respectively. Nationality was the best predictor of pain intensity at POD1. Opioid medication was the best predictor of pain at SR and decreased satisfaction with pain management.
Conclusions: Pain and satisfaction with pain relief are culturally mediated. Patients that use non-opioid pain medication report less pain and greater satisfaction with pain relief than patients managed with opioid pain medication. Level of evidence: Level I, Prognostic Study with more than 80% follow-up. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Helmerhorst, Gijs T. T.; Kloen, Peter] Univ Amsterdam, Acad Med Ctr, Dept Orthopaed Surg, NL-1105 AZ Amsterdam, Netherlands.
[Vrahas, Mark] Massachusetts Gen Hosp, Orthopaed Trauma Serv, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Helmerhorst, GTT (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Orthopaed Surg, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM ghelmerhorst@gmail.com; alclindenhovius@gmail.com; mvrahas@partners.org;
dring@partners.org; p.kloen@amc.uva.nl
FU Biomet; Skeletal Dynamics; Wright Medical
FX David Ring is a Consultant for Wright Medical and Skeletal Dynamics; has
research contracts with Biomet and Skeletal Dynamics; and receives
royalties from Wright Medical.
NR 13
TC 11
Z9 11
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0020-1383
J9 INJURY
JI Injury-Int. J. Care Inj.
PD NOV
PY 2012
VL 43
IS 11
BP 1958
EP 1961
DI 10.1016/j.injury.2012.08.018
PG 4
WC Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery
SC General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery
GA 014VR
UT WOS:000309404300031
PM 22901424
ER
PT J
AU Lamus, C
Hamalainen, MS
Temereanca, S
Brown, EN
Purdon, PL
AF Lamus, Camilo
Haemaelaeinen, Matti S.
Temereanca, Simona
Brown, Emery N.
Purdon, Patrick L.
TI A spatiotemporal dynamic distributed solution to the MEG inverse problem
SO NEUROIMAGE
LA English
DT Article
DE MEG/EEG; Source localization; Inverse problem; Dynamic spatiotemporal
modeling
ID SURFACE-BASED ANALYSIS; HUMAN BRAIN; SOURCE RECONSTRUCTION;
ELECTRICAL-ACTIVITY; SOURCE LOCALIZATION; MAXIMUM-LIKELIHOOD; BAYESIAN
FRAMEWORK; EEG GENERATION; EM ALGORITHM; MCMC METHODS
AB MEG/EEG are non-invasive imaging techniques that record brain activity with high temporal resolution. However, estimation of brain source currents from surface recordings requires solving an ill-conditioned inverse problem. Converging lines of evidence in neuroscience, from neuronal network models to resting-state imaging and neurophysiology, suggest that cortical activation is a distributed spatiotemporal dynamic process, supported by both local and long-distance neuroanatomic connections. Because spatiotemporal dynamics of this kind are central to brain physiology, inverse solutions could be improved by incorporating models of these dynamics. In this article, we present a model for cortical activity based on nearest-neighbor autoregression that incorporates local spatiotemporal interactions between distributed sources in a manner consistent with neurophysiology and neuroanatomy. We develop a dynamic Maximum a Posteriori Expectation-Maximization (dMAP-EM) source localization algorithm for estimation of cortical sources and model parameters based on the Kalman Filter, the Fixed Interval Smoother, and the EM algorithms. We apply the dMAP-EM algorithm to simulated experiments as well as to human experimental data. Furthermore, we derive expressions to relate our dynamic estimation formulas to those of standard static models, and show how dynamic methods optimally assimilate past and future data. Our results establish the feasibility of spatiotemporal dynamic estimation in large-scale distributed source spaces with several thousand source locations and hundreds of sensors, with resulting inverse solutions that provide substantial performance improvements over static methods. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Lamus, Camilo; Temereanca, Simona; Brown, Emery N.; Purdon, Patrick L.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Lamus, Camilo; Brown, Emery N.; Purdon, Patrick L.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Haemaelaeinen, Matti S.; Temereanca, Simona] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Haemaelaeinen, Matti S.; Brown, Emery N.] Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
RP Lamus, C (reprint author), 77 Massachusetts Ave,Room 46-6057, Cambridge, MA 02139 USA.
EM lamus@mit.edu
RI Hamalainen, Matti/C-8507-2013
FU NIBIB NIH HHS [R01 EB006385, R01 EB006385-05]; NIH HHS [DP1 OD003646,
DP1 OD003646-05, DP2 OD006454, DP2 OD006454-01]
NR 73
TC 17
Z9 17
U1 0
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD NOV 1
PY 2012
VL 63
IS 2
BP 894
EP 909
DI 10.1016/j.neuroimage.2011.11.020
PG 16
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 013VY
UT WOS:000309335200025
PM 22155043
ER
PT J
AU Roth, MK
Bingham, B
Shah, A
Joshi, A
Frazer, A
Strong, R
Morilak, DA
AF Roth, Megan K.
Bingham, Brian
Shah, Aparna
Joshi, Ankur
Frazer, Alan
Strong, Randy
Morilak, David A.
CA STRONG STAR Consortium
TI Effects of chronic plus acute prolonged stress on measures of coping
style, anxiety, and evoked HPA-axis reactivity
SO NEUROPHARMACOLOGY
LA English
DT Article
DE PTSD; Stress; Coping style; Anxiety; HPA-axis
ID MEDIAL PREFRONTAL CORTEX; PITUITARY-ADRENOCORTICAL AXIS; NATIONAL
COMORBIDITY SURVEY; URINARY CORTISOL EXCRETION; CHRONIC MILD STRESS;
LEARNED HELPLESSNESS; BASOLATERAL AMYGDALA; EXTINGUISHED FEAR; STRIA
TERMINALIS; MENTAL-DISORDERS
AB Exposure to psychological trauma is the precipitating factor for PTSD. In addition, a history of chronic or traumatic stress exposure is a predisposing risk factor. We have developed a Chronic plus Acute Prolonged Stress (CAPS) treatment for rats that models some of the characteristics of stressful events that can lead to PTSD in humans. We have previously shown that CAPS enhances acute fear responses and impairs extinction of conditioned fear. Further, CAPS reduced the expression of glucocorticoid receptors in the medial prefrontal cortex. In this study we examined the effects of CAPS exposure on behavioral stress coping style, anxiety-like behaviors, and acute stress reactivity of the hypothalamic pituitary adrenal (HPA) axis. Male Sprague-Dawley rats were exposed to CAPS treatment, consisting of chronic intermittent cold stress (4 degrees C, 6 h/day, 14,days) followed on day 15 by a single 1-h session of sequential acute stressors (social defeat, immobilization, swim). After CAPS or control treatment, different groups were tested for shock probe defensive burying, novelty suppressed feeding, or evoked activation of adrenocorticotropic hormone (ACTH) and corticosterone release by an acute immobilization stress. CAPS resulted in a decrease in active burying behavior and an increase in immobility in the shock probe test. Further. CAPS-treated rats displayed increases in the latency to feed in the novelty suppressed feeding test, despite an increase in food intake in the home cage. CAPS treatment also reduced the HPA response to a subsequent acute immobilization stress. These results further validate CAPS treatment as a rat model of relevance to PTSD, and together with results reported previously, suggest that CAPS impairs fear extinction, shifts coping behavior from an active to a more passive strategy, increases anxiety, and alters HPA reactivity, resembling many aspects of human PTSD. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Roth, Megan K.; Bingham, Brian; Shah, Aparna; Joshi, Ankur; Frazer, Alan; Strong, Randy; Morilak, David A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA.
[Roth, Megan K.; Bingham, Brian; Shah, Aparna; Joshi, Ankur; Frazer, Alan; Strong, Randy; Morilak, David A.] Univ Texas Hlth Sci Ctr San Antonio, Ctr Biomed Neurosci, San Antonio, TX 78229 USA.
[Frazer, Alan; Strong, Randy] S Texas Vet Hlth Care Network, Audie L Murphy Div, San Antonio, TX 78229 USA.
RP Morilak, DA (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM morilak@uthscsa.edu
OI Bingham, Brian/0000-0001-8266-203X
FU NIMH [F32 MH090693, R01 MH053851]; Department of Veterans Affairs Office
of Research and Development; Department of Defense through the U.S. Army
Medical Research and Materiel Command [W81XWH-08-2-0118]
FX This work was supported by a NIMH National Research Service Award
individual postdoctoral fellowship F32 MH090693 (MKR), NIMH research
grant R01 MH053851 (DAM), Department of Veterans Affairs Office of
Research and Development (AF, RS), and by funding provided to the STRONG
STAR Multidisciplinary PTSD Research Consortium by the Department of
Defense through the U.S. Army Medical Research and Materiel Command,
Congressionally Directed Medical Research Programs, Psychological Health
and Traumatic Brain Injury Research Program award W81XWH-08-2-0118. The
views expressed in this paper are solely those of the authors and do not
reflect an endorsement by or official policy of the Department of
Defense or the U.S. Government.
NR 74
TC 23
Z9 24
U1 2
U2 35
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3908
EI 1873-7064
J9 NEUROPHARMACOLOGY
JI Neuropharmacology
PD NOV
PY 2012
VL 63
IS 6
BP 1118
EP 1126
DI 10.1016/j.neuropharm.2012.07.034
PG 9
WC Neurosciences; Pharmacology & Pharmacy
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 015IC
UT WOS:000309438600020
PM 22842072
ER
PT J
AU Granger, M
Grupp, SA
Kletzel, M
Kretschmar, C
Naranjo, A
London, WB
Diller, L
AF Granger, Meaghan
Grupp, Stephan A.
Kletzel, Morris
Kretschmar, Cynthia
Naranjo, Arlene
London, Wendy B.
Diller, Lisa
TI Feasibility of a tandem autologous peripheral blood stem cell transplant
regimen for high risk neuroblastoma in a cooperative group setting: A
Pediatric Oncology Group study: A Report from the Children's Oncology
Group
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE high risk neuroblastoma; Myeloablative therapy; peripheral blood stem
cell transplant; POG 9640; tandem transplant
ID UNTREATED DISSEMINATED NEUROBLASTOMA; BONE-MARROW-TRANSPLANTATION; II
INVESTIGATIONAL WINDOW; HIGH-DOSE THERAPY; MYELOABLATIVE THERAPY;
13-CIS-RETINOIC ACID; RANDOMIZED-TRIAL; RAPID-SEQUENCE; MEGATHERAPY;
RESCUE
AB Background The Pediatric Oncology Group performed a pilot study to assess the feasibility of tandem high dose chemotherapy (HDC) with stem cell rescue (HDC/SCR). We report here the results of this single arm trial of induction chemotherapy, local control measures (surgery and local radiation), and tandem HDC/SCR. Procedure Patients with high risk neuroblastoma (NBL) underwent five cycles of induction chemotherapy and resection of primary tumors. Peripheral blood stem cells (PBSC) were collected after Course 3 without exvivo manipulation. Myeloablative chemotherapy was performed in rapid sequence after induction chemotherapy and surgery. The ability of patients to complete both cycles of HDC/SCR was a primary endpoint. Transplant-related toxicity, progression-free survival (PFS) and overall survival (OS) were recorded. Results A total of 33 patients were enrolled. Twenty-two patients completed at least one HDC/SCR procedure and 17 patients completed both. Only one patient had insufficient stem cells collected for both transplants. There was one transplant-related death; engraftment was rapid and toxicity was as expected. The PFS of the 33 patients treated on this study is 24.2%+/- 7.5% and OS is 36.4%+/- 8.4% at 5 years. For patients who received at least one transplant PFS is 36.4%+/- 11.0% and OS is 45.5%+/- 11.2% at 5 years. Conclusions The treatment of high risk NBL with tandem HDC/SCR is feasible in terms of transplant-related mortality and the ability to collect adequate PBSC for two transplants. The outcomes from this intensified treatment have been used to design a Children's Oncology Group Phase III study testing the efficacy of tandem HDC/SCR. Pediatr Blood Cancer 2012; 59: 902907. (C) 2012 Wiley Periodicals, Inc.
C1 [Granger, Meaghan] Cook Childrens Med Ctr, Dept Hematol & Oncol, Ft Worth, TX 76104 USA.
[Grupp, Stephan A.] Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Oncol, Philadelphia, PA 19104 USA.
[Kletzel, Morris] Childrens Mem Hosp, Div Oncol, Chicago, IL 60614 USA.
[Kretschmar, Cynthia] Tufts Med Ctr, Div Pediat Oncol, Boston, MA USA.
[Naranjo, Arlene] Univ Florida, Dept Biostat, Gainesville, FL 32611 USA.
[London, Wendy B.; Diller, Lisa] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[London, Wendy B.; Diller, Lisa] Childrens Hosp, Dept Med, Boston, MA 02115 USA.
RP Granger, M (reprint author), Cook Childrens Med Ctr, Dept Hematol & Oncol, 901 7th Ave,Suite 220, Ft Worth, TX 76104 USA.
EM meaghan.grangermd@cookchildrens.org
FU Sanford Trust; WW Smith Trust; Friends-for-Life Foundation; COG NIH [U10
CA98543, U10 CA98413]; POG [U10 CA29139, U10 CA57745]
FX Grant sponsor: Sanford and WW Smith Trusts; Grant sponsor:
Friends-for-Life Foundation; Grant sponsor: COG NIH Chairman's Grants;
Grant numbers: U10 CA98543, U10 CA98413; Grant sponsor: POG Grants;
Grant numbers: U10 CA29139, U10 CA57745.
NR 17
TC 7
Z9 7
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD NOV
PY 2012
VL 59
IS 5
BP 902
EP 907
DI 10.1002/pbc.24207
PG 6
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 004BW
UT WOS:000308656100024
PM 22744917
ER
PT J
AU Merryman, R
Stevenson, KE
Gostic, WJ
Neuberg, D
O'Brien, J
Sallan, SE
Silverman, LB
AF Merryman, Reid
Stevenson, Kristen E.
Gostic, William J., II
Neuberg, Donna
O'Brien, Jane
Sallan, Stephen E.
Silverman, Lewis B.
TI Asparaginase-associated myelosuppression and effects on dosing of other
chemotherapeutic agents in childhood acute lymphoblastic leukemia
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE acute lymphoblastic leukemia (ALL); asparaginase; myelosuppression
ID ONCOLOGY-GROUP
AB Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents. Pediatr Blood Cancer 2012; 59: 925927. (C) 2012 Wiley Periodicals, Inc.
C1 [Merryman, Reid; Gostic, William J., II; Sallan, Stephen E.; Silverman, Lewis B.] Harvard Univ, Sch Med, Boston, MA USA.
[Stevenson, Kristen E.; Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[O'Brien, Jane; Sallan, Stephen E.; Silverman, Lewis B.] Childrens Hosp, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
RP Silverman, LB (reprint author), 450 Brookline Ave, Boston, MA 02215 USA.
EM Lewis_Silverman@dfci.harvard.edu
FU Enzon Inc.
FX Conflict of Interest: Dr. Sallan has received research funding from and
acted as a consultant to Enzon Inc. Dr. Silverman has received honoraria
from and acted as a consultant to EUSA Pharmaceuticals and Enzon
Pharmaceuticals.
NR 9
TC 5
Z9 8
U1 0
U2 0
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD NOV
PY 2012
VL 59
IS 5
BP 925
EP 927
DI 10.1002/pbc.24182
PG 3
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 004BW
UT WOS:000308656100029
PM 22532399
ER
PT J
AU Fligor, BJ
Krasker, JD
Villaluna, D
Krailo, M
Frazier, AL
AF Fligor, Brian J.
Krasker, Jennie D.
Villaluna, Doojduen
Krailo, Mark
Frazier, A. Lindsay
TI "Accelerated ear-age": A new measure of chemotherapy-induced ototoxicity
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE chemotherapy; ototoxicity; pediatric hematology; oncology; pediatric
oncology
ID PRACTICAL GRADING SYSTEM; HEARING-LOSS; CISPLATIN OTOTOXICITY; CHILDREN
AB Currently, there are several different scales that grade chemotherapy-induced ototoxicity. This report highlights how the implications of the conclusions drawn from each scale differ and compare these prior scales to a more functionally based scale developed at Children's Hospital Boston. Additionally, this report introduces the concept of ear-age, akin to the age at which one would expect the observed decrease in hearing as a consequence of normative aging (but documented in a child or young adult following chemotherapy). Pediatr Blood Cancer 2012; 59: 947949. (C) 2012 Wiley Periodicals, Inc.
C1 [Fligor, Brian J.] Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA 02115 USA.
[Fligor, Brian J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Krasker, Jennie D.] Wellesley Coll, Wellesley, MA 02181 USA.
[Villaluna, Doojduen; Krailo, Mark] Childrens Oncol Grp, Arcadia, CA USA.
[Frazier, A. Lindsay] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Frazier, A. Lindsay] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Fligor, BJ (reprint author), LO 367 300 Longwood Ave, Boston, MA 02115 USA.
EM brian.fligor@childrens.harvard.edu
NR 16
TC 2
Z9 2
U1 0
U2 3
PU WILEY PERIODICALS, INC
PI SAN FRANCISCO
PA ONE MONTGOMERY ST, SUITE 1200, SAN FRANCISCO, CA 94104 USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD NOV
PY 2012
VL 59
IS 5
BP 947
EP 949
DI 10.1002/pbc.24169
PG 3
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 004BW
UT WOS:000308656100036
PM 22492682
ER
PT J
AU Tsai, AC
AF Tsai, Alexander C.
TI A typology of structural approaches to HIV prevention: A commentary on
Roberts and Matthews
SO SOCIAL SCIENCE & MEDICINE
LA English
DT Article
DE AIDS/HIV; Behavioral interventions; Biomedicine; Developing countries;
International health; Social determinants
ID RESOURCE-LIMITED SETTINGS; SUB-SAHARAN AFRICA; INTIMATE-PARTNER
VIOLENCE; SOUTH-AFRICA; ANTIRETROVIRAL THERAPY; PUBLIC-HEALTH;
SOCIOECONOMIC DISPARITIES; PREEXPOSURE PROPHYLAXIS; HOSPITAL
PERFORMANCE; MORTALITY TRENDS
AB Renewed enthusiasm for biomedical HIV prevention strategies has followed the recent publication of several high-profile HIV antiretroviral therapy-based HIV prevention trials. In a recent article, Roberts and Matthews (2012) accurately note some of the shortcomings of these individually targeted approaches to HIV prevention and advocate for increased emphasis on structural interventions that have more fundamental effects on the population distribution of HIV. However, they make some implicit assumptions about the extent to which structural interventions are user-independent and more sustainable than biomedical or behavioral interventions. In this article. I elaborate a simple typology of structural interventions along these two axes and suggest that they may be neither user-independent nor sustainable and therefore subject to the same sustainability concerns, costs, and potential unintended consequences as biomedical and behavioral interventions. (C) 2012 Elsevier Ltd. All rights reserved.
C1 Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
RP Tsai, AC (reprint author), Massachusetts Gen Hosp, Ctr Global Hlth, Room 1529-E3,100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM actsai@partners.org
OI Tsai, Alexander/0000-0001-6397-7917
FU U.S. National Institute of Mental Health Mentored Patient-Oriented
Research Career Development Award [K23 MH-096620]
FX I thank David Bangsberg, MD, MPH, Ingrid Katz, MD, MHS, Mark Siedner,
MD, MPH, and especially Kristin Hung, MD for thoughtful and constructive
comments on earlier drafts of this manuscript. This acknowledgment
should not be construed as permitting inference about their endorsement
of any manuscript contents or conclusions. Salary support was provided
through U.S. National Institute of Mental Health Mentored
Patient-Oriented Research Career Development Award K23 MH-096620.
NR 96
TC 11
Z9 11
U1 2
U2 13
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0277-9536
J9 SOC SCI MED
JI Soc. Sci. Med.
PD NOV
PY 2012
VL 75
IS 9
BP 1562
EP 1567
DI 10.1016/j.socscimed.2012.06.033
PG 6
WC Public, Environmental & Occupational Health; Social Sciences, Biomedical
SC Public, Environmental & Occupational Health; Biomedical Social Sciences
GA 013IS
UT WOS:000309299700002
PM 22877933
ER
PT J
AU Vahdat, LT
Thomas, ES
Roche, HH
Hortobagyi, GN
Sparano, JA
Yelle, L
Fornier, MN
Martin, M
Bunnell, CA
Mukhopadhyay, P
Peck, RA
Perez, EA
AF Vahdat, Linda T.
Thomas, Eva S.
Roche, Henri H.
Hortobagyi, Gabriel N.
Sparano, Joseph A.
Yelle, Louise
Fornier, Monica N.
Martin, Miguel
Bunnell, Craig A.
Mukhopadhyay, Pralay
Peck, Ronald A.
Perez, Edith A.
TI Ixabepilone-associated peripheral neuropathy: data from across the phase
II and III clinical trials
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Neuropathy; Ixabepilone; Epothilone; Breast cancer; Microtubules
ID METASTATIC BREAST-CANCER; EPOTHILONE-B-ANALOG; PLUS CAPECITABINE;
ANTHRACYCLINE; BMS-247550; TAXANE; CHEMOTHERAPY; RESISTANT; PACLITAXEL;
DOCETAXEL
AB Dose-limiting neuropathy is a major adverse event associated with most of the microtubule-stabilizing agent-based chemotherapy regimens. Ixabepilone, a semisynthetic analogue of the natural epothilone B, has activity against a wide range of tumor types. Peripheral neuropathy (PN), associated with ixabepilone treatment, is usually mild to moderate, predominantly sensory and cumulative. Preclinical studies demonstrate that ixabepilone and taxanes produce a similar neurotoxicity profile.
We searched databases of phase II/III clinical trials involving patients receiving ixabepilone as a monotherapy or in combination with capecitabine for incidences of neuropathy. Potential risk factors for grade 3/4 PN were identified by a Cox regression analysis on a dataset of 1,540 patients with different tumor types across multiple studies.
Rates for incidence of ixabepilone-induced severe PN (Common Terminology Criteria for Adverse Events grade 3/4) ranged from 1% in early untreated breast cancer up to 24% in heavily pretreated metastatic breast cancer; grade 4 PN was rare (a parts per thousand currency sign1%). Common symptoms included numbness, paresthesias, and sometimes dysesthesias. Cox regression analysis identified only preexisting neuropathy as a risk factor for increased ixabepilone-associated PN. The management of PN has been primarily through dose adjustments (dose delays and/or dose reduction). Patients had resolution of their neuropathy within a median time of 5 to 6 weeks.
PN is a dose-limiting toxicity associated with ixabepilone treatment, is reversible in most patients, and can be managed with dose reduction and delays.
C1 [Vahdat, Linda T.] Weill Cornell Med Coll, Weill Cornell Breast Ctr, New York, NY USA.
[Thomas, Eva S.] Kaiser Permanente, Oakland, CA USA.
[Roche, Henri H.] Inst Claudius Regaud, Toulouse, France.
[Hortobagyi, Gabriel N.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Sparano, Joseph A.] Albert Einstein Comprehens Canc Ctr, Bronx, NY USA.
[Yelle, Louise] Hop Notre Dame de Bon Secours, Ctr Hosp Univ Montreal, Montreal, PQ H2L 4K8, Canada.
[Fornier, Monica N.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Martin, Miguel] Hosp Gen Gregorio Maranon, Med Oncol Serv, Madrid, Spain.
[Bunnell, Craig A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mukhopadhyay, Pralay; Peck, Ronald A.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Perez, Edith A.] Mayo Clin, Jacksonville, FL 32224 USA.
RP Vahdat, LT (reprint author), Weill Cornell Med Coll, Weill Cornell Breast Ctr, New York, NY USA.
EM ltv2001@med.cornell.edu
RI Roche, Henri/O-9211-2014;
OI Roche, Henri/0000-0001-7463-205X; Vahdat, Linda/0000-0002-3522-7382;
MARTIN, MIGUEL/0000-0001-9237-3231
NR 30
TC 11
Z9 11
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV
PY 2012
VL 20
IS 11
BP 2661
EP 2668
DI 10.1007/s00520-012-1384-0
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 013YS
UT WOS:000309342800003
PM 22382588
ER
PT J
AU Varadarajan, P
Toro, JJ
Lee, S
Schneider, D
Neumon, B
Frye, B
Craig, RM
Haile, DJ
Freytes, CO
AF Varadarajan, Prakash
Toro, Juan J.
Lee, Shuko
Schneider, Deanna
Neumon, Bonita
Frye, Brenda
Craig, Robert M.
Haile, David J.
Freytes, Cesar O.
TI Hematopoietic progenitor cell transplantation toxicities in multiple
myeloma patients with bisphosphonate-induced osteonecrosis of the jaw: a
longitudinal cohort study
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Autologous hematopoietic progenitor cell transplantation; Multiple
myeloma; Osteonecrosis of the jaw
ID ZOLEDRONIC ACID; CHEMOTHERAPY; TRIAL
AB There is no information regarding the toxicity associated with autologous hematopoietic progenitor cell transplantation (AHPCT) in patients with multiple myeloma (MM) who have bisphosphonate-induced osteonecrosis of the jaw (ONJ). There is also limited information regarding long-term outcome of these patients.
In this retrospective cohort study, we compared the toxicity after AHPCT in MM patients with and without ONJ. We also analyzed the response rate and overall survival of this population of patients.
During the study period, 176 patients underwent AHPCT at our institution for MM. Ten patients with ONJ prior to AHPCT were matched to 40 control patients without ONJ. The incidence and severity of transplantation-associated toxicities were similar in both groups, including mucositis, 50 % in patients with ONJ vs. 68 % in controls (p = 0.889) and febrile days, median 1 vs. 3 days, respectively (p = 0.524). Myeloid engraftment and hospital length of stay were also similar between patients with ONJ and controls. There were significantly more complete remissions in patients with ONJ than in control patients (45 % vs. 15 %, p = 0.0336), but survival between the groups was not significantly different (log-rank p = 0.0818).
We conclude that the incidence and severity of transplantation-associated toxicities are similar in MM patients with and without ONJ. Long-term survival was also similar between both groups.
C1 [Varadarajan, Prakash; Toro, Juan J.; Lee, Shuko; Schneider, Deanna; Neumon, Bonita; Frye, Brenda; Craig, Robert M.; Haile, David J.; Freytes, Cesar O.] S Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Varadarajan, Prakash; Toro, Juan J.; Haile, David J.; Freytes, Cesar O.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Varadarajan, P (reprint author), Mail Code 8221,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM varadarajan@uthscsa.edu
NR 23
TC 1
Z9 1
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD NOV
PY 2012
VL 20
IS 11
BP 2969
EP 2975
DI 10.1007/s00520-012-1429-4
PG 7
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 013YS
UT WOS:000309342800038
PM 22418599
ER
PT J
AU Cardone, A
Lopez, F
Affortunato, F
Busco, G
Hofer, AM
Mallamaci, R
Martinelli, C
Colella, M
Farinola, GM
AF Cardone, Antonio
Lopez, Francesco
Affortunato, Francesco
Busco, Giovanni
Hofer, Aldebaran M.
Mallamaci, Rosanna
Martinelli, Carmela
Colella, Matilde
Farinola, Gianluca M.
TI An aryleneethynylene fluorophore for cell membrane staining
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
LA English
DT Article
DE Aryleneethynylene; Fluorescent marker; pH-insensitive; Membranes;
Cross-coupling
ID FLUORESCENCE; POLYMERS; GLUCOSE; POLY(ARYLENEETHYNYLENE)S; SUBSTITUENTS;
ETHYNYLENE)S; SENSITIVITY; MICROSCOPY; LIPOSOMES; OLIGOMERS
AB The use of an amphiphilic aryleneethynylene fluorophore as a plasma membrane marker in fixed and living mammalian cells and liposome model systems is demonstrated. We show here that the optical properties of the novel dye are almost independent on pH, in the range 5.0-8.0. Spectroscopic characterization performed on unilamellar liposomes ascertained that the fluorescence intensity of the aryleneethynylene fluorophore greatly increases after incorporation in lipidic membranes. Experiments performed on different mammalian cells demonstrated that the novel membrane marker exhibits fast staining and a good photostability that make it a suitable tool for live cell imaging. Importantly, the aryleneethynylene fluorophore was also shown to be a fast and reliable blue membrane marker in classical multicolor immunofluorescence experiments. This study adds new important findings to the recent exploitation of the wide class of aryleneethynylene molecules as luminescent markers for biological investigations. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Farinola, Gianluca M.] Univ Bari Aldo Moro, Dipartimento Chim, I-70125 Bari, Italy.
[Cardone, Antonio; Affortunato, Francesco; Martinelli, Carmela] UOS Bari, Consiglio Nazl Ric, Ist Chim Composti OrganoMetallici, I-70125 Bari, Italy.
[Lopez, Francesco] Univ Molise, Dipartimento Agr Ambiente & Alimenti DIAAA, I-86100 Campobasso, Italy.
[Lopez, Francesco] Univ Molise, CSGI, I-86100 Campobasso, Italy.
[Busco, Giovanni; Mallamaci, Rosanna; Colella, Matilde] Univ Bari Aldo Moro, Dipartimento Biosci Biotecnol & Sci Farmacol, I-70125 Bari, Italy.
[Hofer, Aldebaran M.] VA Boston Healthcare Syst, W Roxbury, MA 02132 USA.
[Hofer, Aldebaran M.] Brigham & Womens Hosp, Dept Surg, W Roxbury, MA 02132 USA.
[Hofer, Aldebaran M.] Harvard Univ, Sch Med, W Roxbury, MA 02132 USA.
RP Farinola, GM (reprint author), Univ Bari Aldo Moro, Dipartimento Chim, Via Orabona 4, I-70125 Bari, Italy.
EM matilde.colella@uniba.it; farinola@chimica.uniba.it
RI Lopez, Francesco/F-1282-2011; Colella, Matilde/G-9246-2011;
OI Lopez, Francesco/0000-0003-4807-831X; Colella,
Matilde/0000-0002-9584-7030; Farinola, Gianluca
Maria/0000-0002-1601-2810
FU Ministero dell'Istruzione, dell'Universita e della Ricerca (MIUR); Fondo
per gli Investimenti della Ricerca di Base (FIRB ITA-USA) [RBIN04PH77]
FX This work was financially supported by the Ministero dell'Istruzione,
dell'Universita e della Ricerca (MIUR), "Progetto PRIN 2009 PRAM8L", and
by Fondo per gli Investimenti della Ricerca di Base (FIRB ITA-USA).
"grant RBIN04PH77".
NR 44
TC 13
Z9 13
U1 0
U2 25
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2736
J9 BBA-BIOMEMBRANES
JI Biochim. Biophys. Acta-Biomembr.
PD NOV
PY 2012
VL 1818
IS 11
BP 2808
EP 2817
DI 10.1016/j.bbamem.2012.06.011
PG 10
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 010GC
UT WOS:000309081700035
PM 22749749
ER
PT J
AU Guo, YQ
Xu, F
Lu, TJ
Duan, ZF
Zhang, Z
AF Guo, Yuqi
Xu, Feng
Lu, Tianjian
Duan, Zhenfeng
Zhang, Zhan
TI Interleukin-6 signaling pathway in targeted therapy for cancer
SO CANCER TREATMENT REVIEWS
LA English
DT Review
DE Interleukin-6; Stat3; Monoclonal antibodies; Targeted therapy; Cancer
ID ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY; ENDOTHELIAL GROWTH-FACTOR;
RENAL-CELL CARCINOMA; EPITHELIAL OVARIAN-CANCER; SILTUXIMAB CNTO 328;
MULTIPLE-MYELOMA; PROSTATE-CANCER; COLORECTAL-CANCER; BREAST-CANCER;
RECEPTOR ANTIBODY
AB Interleukin-6 (IL-6) is a multifunctional cytokine which plays an important role in a wide range of biologic activities in different types of cell including tumor cells. IL-6 is involved in the host immune defense mechanism as well as the modulation of growth and differentiation in various malignancies. These effects are mediated by several signaling pathways, in particular the signal transducer and transcription activator 3 (Stat3). There exists abundant evidence demonstrating that deregulated overexpression of IL-6 was associated with tumor progression through inhibition of cancer cell apoptosis, stimulation of angiogenesis, and drug resistance. Clinical studies have revealed that increased serum IL-6 concentrations in patients are associated with advanced tumor stages of various cancers (e.g., multiple myeloma, non-small cell lung carcinoma, colorectal cancer, renal cell carcinoma, prostate cancer, breast cancer and ovarian cancer) and short survival in patients. Therefore, blocking IL-6 signaling is a potential therapeutic strategy for cancer (i.e., anti-IL-6 therapy) characterized by pathological IL-6 overproduction. Preliminary clinical evidence has shown that antibody targeted IL-6 therapy was well tolerated in cancer patients. In this review, we detail the progress of the current understanding of IL-6 signaling pathway in cancer as well as an antibody targeted IL-6 therapy for human cancer. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Guo, Yuqi; Zhang, Zhan] Zhengzhou Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Zhengzhou 450052, Peoples R China.
[Guo, Yuqi; Duan, Zhenfeng; Zhang, Zhan] Massachusetts Gen Hosp, Sarcoma Biol Lab, Ctr Sarcoma & Connect Tissue Oncol, Boston, MA 02114 USA.
[Xu, Feng; Lu, Tianjian] Xi An Jiao Tong Univ, Sch Life Sci & Technol, Minist Educ, Key Lab Biomed Informat Engn, Xian 710049, Peoples R China.
[Xu, Feng; Lu, Tianjian] Xi An Jiao Tong Univ, Biomed Engn & Biomech Ctr, Xian 710049, Peoples R China.
RP Zhang, Z (reprint author), Zhengzhou Univ, Affiliated Hosp 3, Dept Obstet & Gynecol, Zhengzhou 450052, Peoples R China.
EM ttahozzu@yahoo.com
OI Duan, Zhenfeng/0000-0002-8543-083X
FU National Natural Science Foundation of China; National Cancer Institute,
NIH (Nanotechnology Platform); Ovarian Cancer Research Foundation
(OCRF); National 111 Project of China
FX Dr. Zhang is supported by the National Natural Science Foundation of
China. Dr. Duan work is supported, in part, through a Grant from The
National Cancer Institute, NIH (Nanotechnology Platform) and a Grant
from the Ovarian Cancer Research Foundation (OCRF). Dr.Xue's and Dr.Lu's
work is supported by the National Natural Science Foundation of China
and the National 111 Project of China.
NR 122
TC 192
Z9 198
U1 13
U2 89
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-7372
EI 1532-1967
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PD NOV
PY 2012
VL 38
IS 7
BP 904
EP 910
DI 10.1016/j.ctrv.2012.04.007
PG 7
WC Oncology
SC Oncology
GA 011FD
UT WOS:000309149400009
PM 22651903
ER
PT J
AU Korkmaz, O
Ay, H
Ulupinar, E
Tuncel, N
AF Korkmaz, OrhanTansel
Ay, Hakan
Ulupinar, Emel
Tuncel, Nese
TI Vasoactive Intestinal Peptide Enhances Striatal Plasticity and Prevents
Dopaminergic Cell Loss in Parkinsonian Rats
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Vasoactive intestinal peptide; Medium spiny neurons; 6-OHDA; Optical
fractionator; TH immunohistochemistry; Striatum
ID MEDIUM SPINY NEURONS; VIP-INDUCED NEUROPROTECTION; MAST-CELLS; CORTICAL
REGULATION; SUBSTANTIA-NIGRA; TOTAL NUMBER; DISEASE; BRAIN; MOUSE;
GLUTAMATE
AB Destruction of the nigrostriatal dopaminergic pathway by the administration of 6-OHDA generates an animal model of Parkinson's disease. The main characteristic of this progressive neurological disorder is the loss of the dopaminergic neurons located in the substantia nigra pars compacta (SNc). Dopaminergic inputs from the SNc innervate the medium spiny neurons of the striatum and modulate the spontaneous activity of the primary output nuclei of the basal ganglia, globus pallidus interna, and substantia nigra pars reticulata. In our previous studies, we showed that systematically administered vasoactive intestinal peptide (VIP) is effective at reversing motor deficits, decreasing neuronal cell death, and repairing the myelin sheet in parkinsonian rats. In the current study, the effects of VIP on the dendritic morphology of the striatal neurons and the number of dopaminergic neurons in the SNc were examined in 6-OHDA-lesioned rats using Golgi-Cox staining and design-based stereological methods, respectively. Adult Sprague-Dawley rats were separated into sham-operated, bilaterally 6-OHDA lesioned and lesioned + i.p. VIP-injected (25 ng/kg) groups. VIP was first injected 1 h after the intrastriatal 6-OHDA microinjection (every 2 days for 15 days). The 6-OHDA significantly decreased the total number of dopaminergic neurons, branching, and spine density of the medium spiny neurons in the striatum. VIP significantly increased the number of neurons immunostained with tyrosine hydroxylase and the density of spines without altering the branching and the total length of dendrites. In conclusion, VIP might display synaptogenetic activity by enhancing the spine density in the striatum of the parkinsonian rats.
C1 [Korkmaz, OrhanTansel; Tuncel, Nese] Eskisehir Osmangazi Univ, Dept Physiol & Neurophysiol, Fac Med, TR-26040 Eskisehir, Turkey.
[Ay, Hakan; Ulupinar, Emel] Eskisehir Osmangazi Univ, Dept Anat, Fac Med, TR-26040 Eskisehir, Turkey.
[Korkmaz, OrhanTansel] VA Boston Healthcare Syst, Dept Vet Affairs, Boston, MA 02130 USA.
[Korkmaz, OrhanTansel] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
RP Tuncel, N (reprint author), Eskisehir Osmangazi Univ, Dept Physiol & Neurophysiol, Fac Med, TR-26040 Eskisehir, Turkey.
EM ntuncel@ogu.edu.tr
NR 61
TC 4
Z9 5
U1 0
U2 6
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD NOV
PY 2012
VL 48
IS 3
BP 565
EP 573
DI 10.1007/s12031-012-9781-x
PG 9
WC Biochemistry & Molecular Biology; Neurosciences
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 008LS
UT WOS:000308959100011
PM 22544516
ER
PT J
AU Rajabi, H
Ahmad, R
Jin, CN
Joshi, MD
Guha, M
Alam, M
Kharbanda, S
Kufe, D
AF Rajabi, Hasan
Ahmad, Rehan
Jin, Caining
Joshi, Maya Datt
Guha, Minakshi
Alam, Maroof
Kharbanda, Surender
Kufe, Donald
TI MUC1-C oncoprotein confers androgen-independent growth of human prostate
cancer cells
SO PROSTATE
LA English
DT Article
DE MUC1-C; androgen receptor; prostate cancer; androgen-independent growth;
targeted therapy
ID CARCINOMA-ASSOCIATED ANTIGEN; BETA-CATENIN; MUCIN 1; MESENCHYMAL
TRANSITION; REGULATORY LOOP; SIGNALING AXIS; C-SRC; RECEPTOR;
EXPRESSION; GENE
AB BACKGROUND The mucin 1 (MUC1) heterodimeric oncoprotein is overexpressed in human prostate cancers with aggressive pathologic and clinical features. However, few insights are available regarding the functional role of MUC1 in prostate cancer. METHODS Effects of MUC1-C on androgen receptor (AR) expression were determined by RT-PCR, immunoblotting and AR promoter activation. Coimmunoprecipitations, direct binding assays, and chromatin immunoprecipitation (ChIP) studies were performed to assess the interaction between MUC1-C and AR. Cells were analyzed for invasion, growth in androgen-depleted medium, and sensitivity to MUC1-C inhibitors. RESULTS The present studies in androgen-dependent LNCaP and LAPC4 prostate cancer cells demonstrate that the oncogenic MUC1-C subunit suppresses AR expression. The results show that MUC1-C activates a posttranscriptional mechanism involving miR-135b-mediated downregulation of AR mRNA levels. The results further demonstrate that MUC1-C forms a complex with AR through a direct interaction between the MUC1-C cytoplasmic domain and the AR DNA-binding domain (DBD). In addition, MUC1-C associates with AR in a complex that occupies the PSA promoter. The interaction between MUC1-C and AR is associated with induction of the epithelial-mesenchymal transition (EMT) and increased invasion. MUC1-C also conferred growth in androgen-depleted medium and resistance to bicalutamide treatment. Moreover, expression of MUC1-C resulted in sensitivity to the MUC1-C inhibitor GO-203 with inhibition of growth in vitro. GO-203 treatment also inhibited growth of established tumor xenografts in nude mice. CONCLUSIONS These findings indicate that MUC1-C suppresses AR expression in prostate cancer cells and confers a more aggressive androgen-independent phenotype that is sensitive to MUC1-C inhibition. Prostate 72:16591668, 2012. (c) 2012 Wiley Periodicals, Inc.
C1 [Rajabi, Hasan; Ahmad, Rehan; Jin, Caining; Joshi, Maya Datt; Guha, Minakshi; Alam, Maroof; Kufe, Donald] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kharbanda, Surender] Genus Oncol, Boston, MA USA.
RP Kufe, D (reprint author), 44 Binney St,Dana 830, Boston, MA 02115 USA.
EM donald_kufe@dfci.harvard.edu
FU Department of Defense [W81XWH-08-1-0093]; National Cancer Institute
[CA97098]
FX Grant sponsor: Department of Defense Prostate Cancer Idea Award; Grant
number: W81XWH-08-1-0093; Grant sponsor: National Cancer Institute;
Grant number: CA97098.
NR 51
TC 21
Z9 23
U1 1
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-4137
J9 PROSTATE
JI Prostate
PD NOV
PY 2012
VL 72
IS 15
BP 1659
EP 1668
DI 10.1002/pros.22519
PG 10
WC Endocrinology & Metabolism; Urology & Nephrology
SC Endocrinology & Metabolism; Urology & Nephrology
GA 014WG
UT WOS:000309405800007
PM 22473899
ER
PT J
AU Schonenberger, A
Billeter, AT
Seifert, B
Neuhaus, V
Trentz, O
Turina, M
AF Schoenenberger, Amadea
Billeter, Adrian T.
Seifert, Burkhardt
Neuhaus, Valentin
Trentz, Otmar
Turina, Matthias
TI Opportunities for improved trauma care of the elderly - A single center
analysis of 2090 severely injured patients
SO ARCHIVES OF GERONTOLOGY AND GERIATRICS
LA English
DT Article
DE Trauma; Injury; Mortality; Elderly; Age; Brain
ID MULTIPLE-ORGAN FAILURE; BRAIN-INJURY; OLDER-ADULTS; AGE; OUTCOMES;
PREDICTORS; MORTALITY; SCORE
AB Purpose: Western trauma centers are increasingly confronted with elderly trauma patients in parallel to an increase of the elderly population. The purpose of this study was to identify shortcomings and opportunities for improvement in the treatment of elderly trauma patients.
Materials and methods: Retrospective analysis of a prospectively collected single-center trauma database. Patients were grouped according to age and analyzed using univariate and multivariate analysis.
Results: 158 patients (7.6%) were older than 75 years, and 604 patients (28.9%) were between 50 and 75 years. Although comparable with respect to injury severity (injury severity score (ISS) 29-33) and age-adjusted Acute Physiologic and Chronic Health Evaluation (APACHE) score, there was a significant increase in mortality beyond the age of 50 (>75 years: 63.9%), with age being an independent predictor of mortality. Despite a similar rate and severity of head injuries (affecting 71% of all patients), mortality of head injuries was highest in patients >75 years (70.2%), accounting for the increased mortality in this group. Patients >75 years old were less likely to undergo craniotomy, and withdrawal of medical support occurred five times more frequently. Surviving patients >50 years required shorter ICU care than patients below 50 years (7.8 vs. 12.4 days).
Conclusions: With increasing life expectancy and sustained independence, elderly trauma patients have become a regular occurrence in trauma services. Despite comparable injury severity and physiologic status upon admission, these patients suffer from disproportionately high mortality rates. Closed head injuries account for the majority of fatalities, regardless of the extent of therapeutic measures applied. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Turina, Matthias] Cleveland Clin, Dept Colorectal Surg, Inst Digest Dis, Cleveland, OH 44195 USA.
[Schoenenberger, Amadea; Billeter, Adrian T.; Neuhaus, Valentin; Trentz, Otmar; Turina, Matthias] Univ Zurich Hosp, Div Trauma Surg, Dept Surg, CH-8091 Zurich, Switzerland.
[Billeter, Adrian T.] Univ Louisville Hosp, Price Inst Surg Res, Louisville, KY 40201 USA.
[Seifert, Burkhardt] Univ Zurich, Inst Social & Prevent Med, Div Biostat, CH-8001 Zurich, Switzerland.
[Neuhaus, Valentin] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Turina, M (reprint author), Cleveland Clin, Dept Colorectal Surg, Inst Digest Dis, Main Campus,Mail Code A-30,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM mturina73@hotmail.com
OI Seifert, Burkhardt/0000-0002-5829-2478; Billeter,
Adrian/0000-0001-8724-4793; Neuhaus, Valentin/0000-0003-4012-5628
NR 26
TC 5
Z9 5
U1 1
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-4943
J9 ARCH GERONTOL GERIAT
JI Arch. Gerontol. Geriatr.
PD NOV-DEC
PY 2012
VL 55
IS 3
BP 660
EP 666
DI 10.1016/j.archger.2012.02.013
PG 7
WC Geriatrics & Gerontology
SC Geriatrics & Gerontology
GA 004GC
UT WOS:000308667900022
PM 22465302
ER
PT J
AU Ferguson, KK
Hauser, R
Altshul, L
Meeker, JD
AF Ferguson, Kelly K.
Hauser, Russ
Altshul, Larisa
Meeker, John D.
TI Serum concentrations of p, p '-DDE, HCB, PCBs and reproductive hormones
among men of reproductive age
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Article
DE Persistent organic pollutants (POPS); Endocrine disruption; Male
reproduction; Human; Environment; Fertility; Xenobiotics
ID RAT LEYDIG-CELLS; POLYCHLORINATED-BIPHENYLS; ADULT MALE; ENDOGENOUS
HORMONES; PLASMA-LEVELS; IN-VITRO; TESTOSTERONE; EXPOSURE; POPULATION;
P,P-DDE
AB Exposure to polychlorinated biphenyls (PCBs) has been associated with changes in reproductive hormone levels, however most groups studied have been highly exposed. We investigated the association of PCBs, hexachlorobenzene (HCB) and p, p'-DDE with serum sex hormones in 341 adult men from a US infertility clinic with exposure levels consistent with those observed in the general population. In crude regression models we observed several negative associations of PCBs and HCB with steroid hormone-binding globulin (SHBG) and total and free testosterone. After adjustment for lipids, age and BMI, nearly all significant associations were attenuated. A negative relationship remained between PCB 118 and SHBG (p < 0.01), and relationships of dioxin-like PCBs with SHBG and total testosterone, and between PCB 118 and total testosterone, were suggestive. These results suggest a minimal relationship between PCB exposures at low background levels similar to those observed in the general population of the US and circulating reproductive hormones. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Ferguson, Kelly K.; Meeker, John D.] Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA.
[Hauser, Russ; Altshul, Larisa] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Androl Lab, Boston, MA 02114 USA.
[Altshul, Larisa] Environm Hlth & Engn Inc, Needham, MA USA.
[Hauser, Russ] Massachusetts Gen Hosp, In Vitro Fertilizat Unit, Boston, MA 02114 USA.
RP Meeker, JD (reprint author), Univ Michigan, Sch Publ Hlth, Dept Environm Hlth Sci, 6635 SPH Tower,1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM meekerj@umich.edu
OI Meeker, John/0000-0001-8357-5085; Ferguson, Kelly/0000-0001-8467-3250
FU National Institute of Environmental Health Sciences (NIEHS)
[P30ES000002, R01ES009718, R01ES018872, P20ES018171, P42ES017198,
P30ES017885]; US Environmental Protection Agency (USEPA) [RD83480001]
FX This work was supported by grants P30ES000002, R01ES009718, R01ES018872,
P20ES018171, P42ES017198, and P30ES017885 from the National Institute of
Environmental Health Sciences (NIEHS), and RD83480001 from the US
Environmental Protection Agency (USEPA).
NR 44
TC 8
Z9 9
U1 1
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0890-6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD NOV
PY 2012
VL 34
IS 3
BP 429
EP 435
DI 10.1016/j.reprotox.2012.04.006
PG 7
WC Reproductive Biology; Toxicology
SC Reproductive Biology; Toxicology
GA 003NU
UT WOS:000308619400019
PM 22564984
ER
PT J
AU Rich, S
Ali, S
Calkins, GW
Michaelson, JS
AF Rich, Stephanie
Ali, Shihab
Calkins, Geoffrey W.
Michaelson, James S.
TI SURVIVAL TRENDS IN CHILDHOOD HEMATOLOGICAL MALIGNANCIES
SO INTERNATIONAL JOURNAL OF BIOMATHEMATICS
LA English
DT Article
DE Childhood; hematological malignancies; survival trends
AB Survival of patients with childhood hematological malignancies has increased markedly in the past decades. To examine the fine-scale details of how this progress has occurred, we carried out Kaplan-Meier cause-specific survival analysis using the Surveillance Epidemiology and End Results (SEER) dataset for patients with childhood hematological malignancies - Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Lymphoblastic Leukemia and Myeloid Leukemia - diagnosed in five eras: 1983-1987; 1988-1992; 1993-1997; 1998-2002 and 2003-2007. We generated Kaplan-Meier estimates of survival for each of the first 24 years after diagnosis. These figures agree with previously reported five- and ten-year values and attest to the remarkable increase in survival that has occurred over the past three decades of medical progress. The trend towards progressively increasing survival shows no sign of slowing, suggesting that we may expect further increases in survival in the years ahead. Most of the increase in survival for childhood hematological malignancies has occurred by reducing the risk of death in the first two years after diagnosis. This may be largely explained by the fact that this is the time period when patients are at highest risk of death.
C1 [Rich, Stephanie; Ali, Shihab; Calkins, Geoffrey W.; Michaelson, James S.] Massachusetts Gen Hosp, Lab Quantitat Med, Cambridge, MA 02139 USA.
[Michaelson, James S.] Massachusetts Gen Hosp, Dept Surg, Cambridge, MA 02139 USA.
[Michaelson, James S.] Massachusetts Gen Hosp, Dept Pathol, Cambridge, MA 02139 USA.
RP Rich, S (reprint author), Massachusetts Gen Hosp, Lab Quantitat Med, 65 Landsdowne St,Suite 200, Cambridge, MA 02139 USA.
EM michaelj@helix.mgh.harvard.edu
NR 2
TC 0
Z9 0
U1 0
U2 0
PU WORLD SCIENTIFIC PUBL CO PTE LTD
PI SINGAPORE
PA 5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE
SN 1793-5245
J9 INT J BIOMATH
JI Int. J. Biomath.
PD NOV
PY 2012
VL 5
IS 6
AR 1250053
DI 10.1142/S1793524512500532
PG 9
WC Mathematical & Computational Biology
SC Mathematical & Computational Biology
GA 993IG
UT WOS:000307850700006
ER
PT J
AU Haug, U
Knudsen, AB
Kuntz, KM
AF Haug, Ulrike
Knudsen, Amy B.
Kuntz, Karen M.
TI How should individuals with a false-positive fecal occult blood test for
colorectal cancer be managed? A decision analysis
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE colorectal cancer; screening; fecal occult blood
ID LOW-DOSE ASPIRIN; NEGATIVE SCREENING COLONOSCOPY; SOCIETY-TASK-FORCE;
LARGE-INTESTINE; LARGE-BOWEL; COST-EFFECTIVENESS; POLYPS; AUTOPSY;
PREVALENCE; RISK
AB Several industrialized nations recommend fecal occult blood testing (FOBT) to screen for colorectal cancer (CRC), but corresponding screening guidelines do not specify how individuals with a prior false-positive FOBT result (fpFOBT) should be managed in terms of subsequent CRC screening. Accordingly, we conducted a decision analysis to compare different strategies for managing such individuals. We used a previously developed CRC microsimulation model, SimCRC, to calculate life-years and the lifetime number of colonoscopies (as a measure of required resources) for a cohort of 50-year-olds to whom FOBT-based CRC screening is offered annually from 50 to 75 years. We compared three management strategies for individuals with a prior fpFOBT: (i) resume screening in 10 years with 10-yearly colonoscopy (SwitchCol_long); (ii) resume screening in 1 year with annual FOBT (ContinueFOBT_Short) and (iii) resume screening in 10 years (i.e., the recommended interval following a negative colonscopy) with annual FOBT (ContinueFOBT_long). We performed sensitivity analyses on various parameters and assumptions. When using different management strategies for individuals with a prior fpFOBT, the variation in the number of life-years gained relative to no screening was <2%, whereas the variation in the lifetime number of colonoscopies was 23% (percentages are calculated as the maximum difference across strategies divided by the lowest number across strategies). The ContinueFOBT_long strategy showed the lowest lifetime number of colonoscopies per life-year gained even when key assumptions were varied. In conclusion, the ContinueFOBT_long strategy was advantageous regarding both clinical benefit and required resources. Specifying an appropriate management strategy for individuals with a prior fpFOBT may substantially reduce required resources within a FOBT-based CRC screening program without limiting its effectiveness.
C1 [Haug, Ulrike] German Canc Res Ctr, Div Prevent Oncol, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany.
[Knudsen, Amy B.] Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, Boston, MA 02114 USA.
[Kuntz, Karen M.] Univ Minnesota, Sch Publ Hlth, Div Hlth Policy & Management, Minneapolis, MN USA.
RP Haug, U (reprint author), German Canc Res Ctr, Div Prevent Oncol G110, Natl Ctr Tumor Dis, Neuenheimer Feld 460, D-69120 Heidelberg, Germany.
EM u.haug@dkfz.de
OI Haug, Ulrike/0000-0002-1886-2923
FU National Cancer Institute (NCI) [U01 CA 088204, U01 CA 152959-01];
German Cancer Aid (Deutsche Krebshilfe) [109421]
FX Grant sponsor: The National Cancer Institute (NCI); Grant numbers: U01
CA 088204, U01 CA 152959-01; Grant sponsor: The German Cancer Aid
(Deutsche Krebshilfe); Grant number: 109421
NR 39
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD NOV 1
PY 2012
VL 131
IS 9
BP 2094
EP 2102
DI 10.1002/ijc.27463
PG 9
WC Oncology
SC Oncology
GA 993XP
UT WOS:000307893600016
PM 22307927
ER
PT J
AU Klein, BA
Tenorio, EL
Lazinski, DW
Camilli, A
Duncan, MJ
Hu, LDT
AF Klein, Brian A.
Tenorio, Elizabeth L.
Lazinski, David W.
Camilli, Andrew
Duncan, Margaret J.
Hu, Linden T.
TI Identification of essential genes of the periodontal pathogen
Porphyromonas gingivalis
SO BMC GENOMICS
LA English
DT Article
DE Porphyromonas gingivalis; Transposon mutagenesis; Essential genes;
Tn-seq; Periodontal disease
ID TRANSPOSON MUTANT LIBRARY; GENOME-SCALE ANALYSIS;
STREPTOCOCCUS-PNEUMONIAE; BACTEROIDES-GINGIVALIS; VIRULENCE FACTORS;
DELETION MUTANTS; COG DATABASE; STRAIN W83; MUTAGENESIS; BACTERIUM
AB Background: Porphyromonas gingivalis is a Gram-negative anaerobic bacterium associated with periodontal disease onset and progression. Genetic tools for the manipulation of bacterial genomes allow for in-depth mechanistic studies of metabolism, physiology, interspecies and host-pathogen interactions. Analysis of the essential genes, protein-coding sequences necessary for survival of P. gingivalis by transposon mutagenesis has not previously been attempted due to the limitations of available transposon systems for the organism. We adapted a Mariner transposon system for mutagenesis of P. gingivalis and created an insertion mutant library. By analyzing the location of insertions using massively-parallel sequencing technology we used this mutant library to define genes essential for P. gingivalis survival under in vitro conditions.
Results: In mutagenesis experiments we identified 463 genes in P. gingivalis strain ATCC 33277 that are putatively essential for viability in vitro. Comparing the 463 P. gingivalis essential genes with previous essential gene studies, 364 of the 463 are homologues to essential genes in other species; 339 are shared with more than one other species. Twenty-five genes are known to be essential in P. gingivalis and B. thetaiotaomicron only. Significant enrichment of essential genes within Cluster of Orthologous Groups 'D' (cell division), 'I' (lipid transport and metabolism) and 'J' (translation/ribosome) were identified. Previously, the P. gingivalis core genome was shown to encode 1,476 proteins out of a possible 1,909; 434 of 463 essential genes are contained within the core genome. Thus, for the species P. gingivalis twenty-two, seventy-seven and twenty-three percent of the genome respectively are devoted to essential, core and accessory functions.
Conclusions: A Mariner transposon system can be adapted to create mutant libraries in P. gingivalis amenable to analysis by next-generation sequencing technologies. In silico analysis of genes essential for in vitro growth demonstrates that although the majority are homologous across bacterial species as a whole, species and strain-specific subsets are apparent. Understanding the putative essential genes of P. gingivalis will provide insights into metabolic pathways and niche adaptations as well as clinical therapeutic strategies.
C1 [Klein, Brian A.; Lazinski, David W.; Camilli, Andrew; Hu, Linden T.] Tufts Univ, Dept Mol Biol & Microbiol, Sackler Sch Biomed Sci, Boston, MA 02111 USA.
[Klein, Brian A.; Tenorio, Elizabeth L.; Hu, Linden T.] Tufts Med Ctr, Div Geog Med & Infect Dis, Boston, MA 02111 USA.
[Lazinski, David W.; Camilli, Andrew] Tufts Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02111 USA.
[Lazinski, David W.; Camilli, Andrew] Tufts Univ, Sch Med, Dept Mol Biol & Microbiol, Boston, MA 02111 USA.
[Duncan, Margaret J.] Forsyth Inst, Dept Mol Genet, Cambridge, MA 02142 USA.
RP Hu, LDT (reprint author), Tufts Univ, Dept Mol Biol & Microbiol, Sackler Sch Biomed Sci, Boston, MA 02111 USA.
EM Lhu@tuftsmedicalcenter.org
RI Hu, Linden/L-6314-2016;
OI Hu, Linden/0000-0003-1659-5558; Klein, Brian/0000-0002-7233-2114
FU National Institute Of Dental & Craniofacial Research [R21 DE016859,
F31DE022491, R01 DE015931]; National Institute of Allergy and Infectious
Diseases [R01 AI055058]; Howard Hughes Medical Institute; Russo Family
Charitable Foundation; [T32 5T32GM007310]; [T32 5T32AI007389-20]
FX This project was supported by Grants from the National Institute Of
Dental & Craniofacial Research, R21 DE016859 (LTH), F31DE022491 (BAK)
and R01 DE015931 (MJD). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institute Of Dental & Craniofacial Research or the National
Institutes of Health. Support was also received from T32 5T32GM007310
(BAK), T32 5T32AI007389-20 (ELT), National Institute of Allergy and
Infectious Diseases R01 AI055058 (AC), Howard Hughes Medical Institute
(AC) and from an award from the Russo Family Charitable Foundation.
NR 73
TC 43
Z9 1998
U1 8
U2 93
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2164
J9 BMC GENOMICS
JI BMC Genomics
PD OCT 31
PY 2012
VL 13
AR 578
DI 10.1186/1471-2164-13-578
PG 17
WC Biotechnology & Applied Microbiology; Genetics & Heredity
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA 085XC
UT WOS:000314646600001
PM 23114059
ER
PT J
AU Dittrich, AS
Winkler, T
Wellman, T
de Prost, N
Musch, G
Harris, RS
Melo, MFV
AF Dittrich, A. Susanne
Winkler, Tilo
Wellman, Tyler
de Prost, Nicolas
Musch, Guido
Harris, R. Scott
Melo, Marcos F. Vidal
TI Modeling F-18-FDG Kinetics during Acute Lung Injury: Experimental Data
and Estimation Errors
SO PLOS ONE
LA English
DT Article
ID RESPIRATORY-DISTRESS-SYNDROME; POSITRON-EMISSION-TOMOGRAPHY;
METABOLIC-ACTIVITY; MECHANICAL VENTILATION; NEUTROPHIL KINETICS;
FDG-PET; INFLAMMATION; SHEEP; PERFUSION; LAVAGE
AB Background: There is increasing interest in Positron Emission Tomography (PET) of 2-deoxy-2-[18F]flouro-D-glucose (F-18-FDG) to evaluate pulmonary inflammation during acute lung injury (ALI). We assessed the effect of extra-vascular lung water on estimates of F-18-FDG-kinetics parameters in experimental and simulated data using the Patlak and Sokoloff methods, and our recently proposed four-compartment model.
Methodology/Principal Findings: Eleven sheep underwent unilateral lung lavage and 4 h mechanical ventilation. Five sheep received intravenous endotoxin (10 ng/kg/min). Dynamic F-18-FDG PET was performed at the end of the 4 h period. F-18-FDG net uptake rate (Ki), phosphorylation rate (k(3)), and volume of distribution (F-e) were estimated in three isogravitational regions for each method. Simulations of normal and ALI F-18-FDG-kinetics were conducted to study the dependence of estimated parameters on the transport rate constants to (k(5)) and from (k(6)) the extra-vascular extra-cellular compartment. The four-compartment model described 85.7% of the studied F-18-FDG-kinetics better than the Sokoloff model. Relative to the four-compartment model the Sokoloff model exhibited a consistent positive bias in Ki (3.32 [1.30-5.65] 10(-4)/min, p<0.001) and showed inaccurate estimates of the parameters composing Ki (k(3) and F-e), even when Ki was similar for those methods. In simulations, errors in estimates of Ki due to the extra-vascular extra-cellular compartment depended on both k(5) and k(5)/k(6), with errors for the Patlak and Sokoloff methods of 0.02 [-0.01-0.18] and 0.40 [0.18-0.60] 10(-3)/min for normal lungs and of -0.47 [-0.89-0.72] and 2.35 [0.85-3.68] 10(-3)/min in ALI.
Conclusions/Significance: F-18-FDG accumulation in lung extra-vascular fluid, which is commonly increased during lung injury, can result in substantial estimation errors using the traditional Patlak and Sokoloff methods. These errors depend on the extra-vascular extra-cellular compartment volume and its transport rates with other compartments. The four-compartment model provides more accurate quantification of F-18-FDG-kinetics than those methods in the presence of increased extra-vascular fluid.
C1 [Dittrich, A. Susanne; Winkler, Tilo; Wellman, Tyler; de Prost, Nicolas; Musch, Guido; Melo, Marcos F. Vidal] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Dittrich, A. Susanne; Winkler, Tilo; Wellman, Tyler; de Prost, Nicolas; Musch, Guido; Harris, R. Scott; Melo, Marcos F. Vidal] Harvard Univ, Sch Med, Boston, MA USA.
[Harris, R. Scott] Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Unit, Boston, MA 02114 USA.
[Dittrich, A. Susanne] Univ Hosp Dresden, Dept Anesthesia & Intens Care Therapy, Dresden, Germany.
RP Melo, MFV (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM VidalMelo.Marcos@mgh.harvard.edu
RI Winkler, Tilo/B-5337-2009;
OI Winkler, Tilo/0000-0002-7276-5550; de Prost, Nicolas/0000-0002-4833-4320
FU NHLBI (National Heart, Lung and Blood Institute) [5R01HL086827]; Family
Klee Foundation (Stiftung Familie Klee); German National Academic
Foundation (Studienstiftung des deutschen Volkes)
FX This work was funded by NHLBI (National Heart, Lung and Blood Institute)
grant 5R01HL086827 to MFVM. ASF was supported in part by the Family Klee
Foundation (Stiftung Familie Klee, http://www.s-fk.de/) and by the
German National Academic Foundation (Studienstiftung des deutschen
Volkes, http://www.studienstiftung.de/). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 40
TC 7
Z9 7
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 31
PY 2012
VL 7
IS 10
AR e47588
DI 10.1371/journal.pone.0047588
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 030WJ
UT WOS:000310600500025
PM 23118881
ER
PT J
AU Higgs, MH
Kuznetsova, MS
Spain, WJ
AF Higgs, Matthew H.
Kuznetsova, Marina S.
Spain, William J.
TI Adaptation of Spike Timing Precision Controls the Sensitivity to
Interaural Time Difference in the Avian Auditory Brainstem
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID COCHLEAR NUCLEUS; COINCIDENCE DETECTION; SOUND LOCALIZATION; TONAL
STIMULI; NEURONS; LAMINARIS; CHICKEN; NERVE; OWL; MAGNOCELLULARIS
AB While adaptation is widely thought to facilitate neural coding, the form of adaptation should depend on how the signals are encoded. Monaural neurons early in the interaural time difference (ITD) pathway encode the phase of sound input using spike timing rather than firing rate. Such neurons in chicken nucleus magnocellularis (NM) adapt to ongoing stimuli by increasing firing rate and decreasing spike timing precision. We measured NM neuron responses while adapting them to simulated physiological input, and used these responses to construct inputs to binaural coincidence detector neurons in nucleus laminaris (NL). Adaptation of spike timing in NM reduced ITD sensitivity in NL, demonstrating the dominant role of timing in the short-term plasticity as well as the immediate response of this sound localization circuit.
C1 [Higgs, Matthew H.; Spain, William J.] Dept Vet Affairs Med Ctr, Neurol Sect, Seattle, WA 98108 USA.
[Higgs, Matthew H.; Kuznetsova, Marina S.; Spain, William J.] Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA.
[Kuznetsova, Marina S.] Univ Washington, Interdisciplinary Grad Program Neurobiol & Behav, Seattle, WA 98195 USA.
[Spain, William J.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
RP Spain, WJ (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM spain@u.washington.edu
FU US Department of Veterans Affairs, Office of Research and Development,
Biomedical Laboratory Research Program; Veterans Affairs Merit Review;
Veterans Affairs Epilepsy Center of Excellence; NIDCD [5F31DC009176]
FX This material is based upon work supported in part by the US Department
of Veterans Affairs, Office of Research and Development, Biomedical
Laboratory Research Program. Funding was provided by a Veterans Affairs
Merit Review to W.J.S., a Veterans Affairs Epilepsy Center of
Excellence, and NIDCD Grant No. 5F31DC009176 (M. S. K.). We thank Jason
Haensly for help performing the experiments with simulated spontaneous
input to NM. We thank Sean Slee, Adrienne Fairhall, Marc Binder, David
Perkel, and Ed Rubel for helpful discussions, Fred Rieke for comments on
a previous version of the manuscript, and Sue Usher for excellent
technical assistance.
NR 36
TC 3
Z9 3
U1 0
U2 1
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 31
PY 2012
VL 32
IS 44
BP 15489
EP 15494
DI 10.1523/JNEUROSCI.1865-12.2012
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 030LY
UT WOS:000310573400025
PM 23115186
ER
PT J
AU Xiao, YH
Isaacs, SN
AF Xiao, Yuhong
Isaacs, Stuart N.
TI Enzyme-linked immunosorbent assay (ELISA) and blocking with bovine serum
albumin (BSA)-not all BSAs are alike
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Enzyme-linked immunosorbent assay/methods; False positive reactions;
Serum albumin; Bovine/immunology; Protein binding; Vaccinia virus
complement control protein
ID ANTIBODIES; COMPLEMENT; BINDING
AB The enzyme-linked immunosorbent assay (ELISA) is an extremely common and powerful laboratory technique for detecting proteins by antibodies. Researchers frequently use bovine serum albumin (BSA) as a blocking agent to prevent non-specific binding of antigens and antibodies to the microtiter well. While studying the interactions of the vaccinia virus complement control protein (VCP) with complement, we found non-specific binding of VCP to BSA and identify a BSA preparation that did not result in non-specific binding. This work draws attention to the fact that not all BSA preparations are alike. It also highlights the need to perform critical controls to ensure that ELISA reactants do not inappropriately bind to the blocking agent. Published by Elsevier B.V.
C1 [Xiao, Yuhong; Isaacs, Stuart N.] Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA.
[Isaacs, Stuart N.] Philadelphia VA Med Ctr, Philadelphia, PA 19104 USA.
RP Isaacs, SN (reprint author), Univ Penn, Perelman Sch Med, Dept Med, Div Infect Dis, 502 Johnson Pavilion, Philadelphia, PA 19104 USA.
EM isaacs@mail.med.upenn.edu
FU NIH [U01 AI077913, U01 AI066333]; Middle Atlantic Regional Center of
Excellence in Biodefense and Emerging Infectious Diseases [U54
AI057168]; Philadelphia Veterans Affairs Medical Center
FX We would like to thank John Atkinson (Washington University, St. Louis)
for the recombinant VCP. Partial funding of this work is from NIH grants
U01 AI077913 and U01 AI066333, the Middle Atlantic Regional Center of
Excellence in Biodefense and Emerging Infectious Diseases (U54
AI057168), and the Philadelphia Veterans Affairs Medical Center.
NR 12
TC 22
Z9 22
U1 0
U2 29
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD OCT 31
PY 2012
VL 384
IS 1-2
BP 148
EP 151
DI 10.1016/j.jim.2012.06.009
PG 4
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 017EG
UT WOS:000309572300018
PM 22732194
ER
PT J
AU Greenberg, CH
Frosch, MP
Goldstein, JN
Rosand, J
Greenberg, SM
AF Greenberg, Charles H.
Frosch, Matthew P.
Goldstein, Joshua N.
Rosand, Jonathan
Greenberg, Steven M.
TI Modeling Intracerebral Hemorrhage Growth and Response to Anticoagulation
SO PLOS ONE
LA English
DT Article
ID BLOOD-PRESSURE REDUCTION; FRESH-FROZEN PLASMA; CEREBRAL-HEMORRHAGE;
HEMATOMA EXPANSION; INTRACRANIAL HEMORRHAGE; WARFARIN; THERAPY;
COAGULOPATHY; MICROBLEEDS
AB The mechanism for hemorrhage enlargement in the brain, a key determinant of patient outcome following hemorrhagic stroke, is unknown. We performed computer-based stochastic simulation of one proposed mechanism, in which hemorrhages grow in "domino" fashion via secondary shearing of neighboring vessel segments. Hemorrhages were simulated by creating an initial site of primary bleeding and an associated risk of secondary rupture at adjacent sites that decayed over time. Under particular combinations of parameters for likelihood of secondary rupture and time-dependent decay, a subset of lesions expanded, creating a bimodal distribution of microbleeds and macrobleeds. Systematic variation of the model to simulate anticoagulation yielded increases in both macrobleed occurrence (26.9%, 53.2%, and 70.0% of all hemorrhagic events under conditions simulating no, low-level, and high-level anticoagulation) and final hemorrhage size (median volumes 111, 276, and 412 under the same three conditions), consistent with data from patients with anticoagulant-related brain hemorrhages. Reversal from simulated high-level anticoagulation to normal coagulation was able to reduce final hemorrhage size only if applied relatively early in the course of hemorrhage expansion. These findings suggest that a model based on a secondary shearing mechanism can account for some of the clinically observed properties of intracerebral hemorrhage, including the bimodal distribution of volumes and the enhanced hemorrhage growth seen with anticoagulation. Future iterations of this model may be useful for elucidating the effects of hemorrhage growth of factors related to secondary shearing (such as small vessel pathology) or time-dependent decay (such as hemostatic agents).
C1 [Rosand, Jonathan; Greenberg, Steven M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
[Greenberg, Charles H.] Univ Calif San Francisco, Dept Pharmaceut Chem, Dept Bioengn & Therapeut, San Francisco, CA USA.
[Greenberg, Charles H.] Univ Calif San Francisco, Calif Inst Quantitat Biosci, San Francisco, CA USA.
[Frosch, Matthew P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, CS Kubik Lab Neuropathol, Boston, MA USA.
[Goldstein, Joshua N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Greenberg, SM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA.
EM sgreenberg@partners.org
RI Goldstein, Joshua/H-8953-2016
FU National Institutes of Health [R01 AG026484]; National Science
Foundation Graduate Research Fellowship [DGE-1144247]
FX This work was supported by the National Institutes of Health (R01
AG026484), the National Science Foundation Graduate Research Fellowship
under grant DGE-1144247. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 26
TC 11
Z9 11
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2012
VL 7
IS 10
AR e48458
DI 10.1371/journal.pone.0048458
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 032HJ
UT WOS:000310705600045
PM 23119028
ER
PT J
AU Peng, Q
Yeh, HD
Wei, LL
Enjyoj, K
Machaidze, Z
Csizmad, E
Schuetz, C
Lee, KM
Deng, SP
Robson, SC
Markmann, J
Buhler, L
AF Peng, Qiang
Yeh, Heidi
Wei, Lingling
Enjyoj, Keiichi
Machaidze, Zurab
Csizmad, Eva
Schuetz, Christian
Lee, Kang Mi
Deng, Shaoping
Robson, Simon C.
Markmann, James
Buhler, Leo
TI Mechanisms of Xenogeneic Baboon Platelet Aggregation and Phagocytosis by
Porcine Liver Sinusoidal Endothelial Cells
SO PLOS ONE
LA English
DT Article
ID IN-VITRO; XENOTRANSPLANTATION; PIG; CLEARANCE; SURVIVAL; REJECTION;
RECEPTORS
AB Background: Baboons receiving xenogeneic livers from wild type and transgenic pigs survive less than 10 days. One of the major issues is the early development of profound thrombocytopenia that results in fatal hemorrhage. Histological examination of xenotransplanted livers has shown baboon platelet activation, phagocytosis and sequestration within the sinusoids. In order to study the mechanisms of platelet consumption in liver xenotransplantation, we have developed an in vitro system to examine the interaction between pig endothelial cells with baboon platelets and to thereby identify molecular mechanisms and therapies.
Methods: Fresh pig hepatocytes, liver sinusoidal and aortic endothelial cells were isolated by collagenase digestion of livers and processing of aortae from GTKO and Gal+ MGH-miniature swine. These primary cell cultures were then tested for the differential ability to induce baboon or pig platelet aggregation. Phagocytosis was evaluated by direct observation of CFSE labeled-platelets, which are incubated with endothelial cells under confocal light microscopy. Aurintricarboxylic acid (GpIb antagonist blocking interactions with von Willebrand factor/vWF), eptifibatide (Gp IIb/IIIa antagonist), and anti-Mac-1 Ab (anti-alpha(M)beta(2) integrin Ab) were tested for the ability to inhibit phagocytosis.
Results: None of the pig cells induced aggregation or phagocytosis of porcine platelets. However, pig hepatocytes, liver sinusoidal and aortic endothelial cells (GTKO and Gal+) all induced moderate aggregation of baboon platelets. Importantly, pig liver sinusoidal endothelial cells efficiently phagocytosed baboon platelets, while pig aortic endothelial cells and hepatocytes had minimal effects on platelet numbers. Anti-MAC-1 Ab, aurintricarboxylic acid or eptifibatide, significantly decreased baboon platelet phagocytosis by pig liver endothelial cells (P<0.01).
Conclusions: Although pig hepatocytes and aortic endothelial cells directly caused aggregation of baboon platelets, only pig liver endothelial cells efficiently phagocytosed baboon platelets. Blocking vWF and integrin adhesion pathways prevented both aggregation and phagocytosis.
C1 [Peng, Qiang; Yeh, Heidi; Wei, Lingling; Machaidze, Zurab; Schuetz, Christian; Lee, Kang Mi; Deng, Shaoping; Markmann, James; Buhler, Leo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA 02115 USA.
[Enjyoj, Keiichi; Csizmad, Eva; Robson, Simon C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Ctr Liver, Boston, MA 02215 USA.
[Buhler, Leo] Univ Hosp Geneva, Dept Surg, Surg Res Unit, Geneva, Switzerland.
RP Buhler, L (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Transplant Surg, Boston, MA 02115 USA.
EM Leo.Buhler@hcuge.ch
OI Schuetz, Christian/0000-0002-6828-4543
FU Department of Transplant Surgery, Massachusetts General Hospital;
Department of Gastroenterology, Liver Center, Beth Israel Deaconess
Medical Center (Harvard Medical School, Boston); foundation Insuleman
(Switzerland); foundation Louis-Jeantet (Switzerland); National
Institutes of Health [P01 AI045897-11A1 DHS/SCR]; Transplantation
Biology Research Center, Massachusetts General Hospital
FX This work was supported by the Department of Transplant Surgery,
Massachusetts General Hospital and the Department of Gastroenterology,
Liver Center, Beth Israel Deaconess Medical Center (Harvard Medical
School, Boston), by the foundations Insuleman and Louis-Jeantet
(Switzerland) and National Institutes of Health (P01 AI045897-11A1
DHS/SCR). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.; We
thank our colleagues at the Department of Transplant Surgery,
Massachusetts General Hospital and the Transplantation Biology Research
Center, Massachusetts General Hospital for their support. In particular,
we thank David K. C. Cooper for his advice and support.
NR 21
TC 10
Z9 11
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 30
PY 2012
VL 7
IS 10
AR e47273
DI 10.1371/journal.pone.0047273
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 032HJ
UT WOS:000310705600010
PM 23118867
ER
PT J
AU Grossmann, TN
Yeh, JTH
Bowman, BR
Chu, Q
Moellering, RE
Verdine, GL
AF Grossmann, Tom N.
Yeh, Johannes T. -H.
Bowman, Brian R.
Chu, Qian
Moellering, Raymond E.
Verdine, Gregory L.
TI Inhibition of oncogenic Wnt signaling through direct targeting of
beta-catenin
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE colorectal cancer; peptide engineering; targeted therapy
ID STAPLED P53 PEPTIDE; CRYSTAL-STRUCTURE; COLORECTAL-CANCER; BH3 HELIX;
IN-VIVO; COMPLEX; ACTIVATION; APOPTOSIS; TUMORIGENESIS; TRANSCRIPTION
AB Aberrant activation of signaling by the Wnt pathway is strongly implicated in the onset and progression of numerous types of cancer. Owing to the persistent dependence of these tumors on Wnt signaling for growth and survival, inhibition of this pathway is considered an attractive mechanism-based therapeutic approach. Oncogenic activation of Wnt signaling can ensue from a variety of distinct aberrations in the signaling pathway, but most share the common feature of causing increased cellular levels of beta-catenin by interfering with its constitutive degradation. beta-Catenin serves as a central hub in Wnt signaling by engaging in crucial protein-protein interactions with both negative and positive effectors of the pathway. Direct interference with these protein-protein interactions is a biologically compelling approach toward suppression of beta-catenin hyperactivity, but such interactions have proven intransigent with respect to small-molecule targeting. Hence beta-catenin remains an elusive target for translational cancer therapy. Here we report the discovery of a hydrocarbon-stapled peptide that directly targets beta-catenin and interferes with its ability to serve as a transcriptional coactivator for T-cell factor (TCF) proteins, the downstream transcriptional regulators of the Wnt pathway.
C1 [Grossmann, Tom N.; Yeh, Johannes T. -H.; Bowman, Brian R.; Chu, Qian; Moellering, Raymond E.; Verdine, Gregory L.] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Grossmann, Tom N.; Yeh, Johannes T. -H.; Bowman, Brian R.; Chu, Qian; Moellering, Raymond E.; Verdine, Gregory L.] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.
[Verdine, Gregory L.] Dana Farber Canc Inst, Program Canc Chem Biol, Boston, MA 02115 USA.
RP Verdine, GL (reprint author), Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
EM gregory_verdine@harvard.edu
RI Grossmann, Tom/A-4175-2015
OI Grossmann, Tom/0000-0003-0179-4116
FU GlaxoSmithKline; US Department of Energy, Office of Science, Office of
Basic Energy Sciences [DE-AC02-06CH11357]; Deutsche Akademie der
Naturforscher Leopoldina [LPDS 2009-2]; Susan G. Komen for the Cure
[KG091054]; American Association for Cancer Research
FX We thank M. Kolar and Y.-W. Kim for assistance with automated
solid-phase peptide synthesis; the Broad Institute Chemical Biology
Program for access to instrumentation; A. Koehler and C. Feau at the
Broad Institute for their support of the Biacore experiments; C.
Sevenich at Technical University Dortmund, Germany for performing
high-resolution mass spectroscopy experiments; W. Xu at University of
Washington, Seattle for kindly providing the beta-catenin expression
construct; and H. Clevers at Hubrecht Institute, The Netherlands for
kindly providing TOPflash reporter construct. This research was
supported by GlaxoSmithKline. Use of the Advanced Photon Source was
supported by the US Department of Energy, Office of Science, Office of
Basic Energy Sciences, under Contract DE-AC02-06CH11357. T.N.G. is the
recipient of a fellowship (LPDS 2009-2) from Deutsche Akademie der
Naturforscher Leopoldina. J.T-H.Y. was supported by a grant from Susan
G. Komen for the Cure (KG091054). R.E.M was supported by an American
Association for Cancer Research Centennial Pre-doctoral Research
Fellowship.
NR 35
TC 69
Z9 70
U1 2
U2 45
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 30
PY 2012
VL 109
IS 44
BP 17942
EP 17947
DI 10.1073/pnas.1208396109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038BJ
UT WOS:000311149900057
PM 23071338
ER
PT J
AU Bailey, ST
Shin, HJ
Westerling, T
Liu, XS
Brown, M
AF Bailey, Shannon T.
Shin, Hyunjin
Westerling, Thomas
Liu, Xiaole Shirley
Brown, Myles
TI Estrogen receptor prevents p53-dependent apoptosis in breast cancer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE cistrome; DNA damage; nuclear receptor; nutlin; doxorubicin
ID GENE-EXPRESSION; MOLECULAR SUBTYPES; CELLULAR-RESPONSE; MICROARRAY DATA;
P53 PATHWAY; DNA-DAMAGE; ER-ALPHA; PROTEIN; SURVIVAL; BTG2
AB More than two-thirds of breast cancers express the estrogen receptor (ER) and depend on estrogen for growth and survival. Therapies targeting ER function, including aromatase inhibitors that block the production of estrogens and ER antagonists that alter ER transcriptional activity, play a central role in the treatment of ER+ breast cancers of all stages. In contrast to ER- breast cancers, which frequently harbor mutations in the p53 tumor suppressor, ER+ breast cancers are predominantly wild type for p53. Despite harboring wild-type p53, ER+ breast cancer cells are resistant to chemotherapy-induced apoptosis in the presence of estrogen. Using genome-wide approaches, we have addressed the mechanism by which ER antagonizes the proapoptotic function of p53. Interestingly, both ER agonists such as estradiol and the selective ER modulator (SERM) tamoxifen promote p53 antagonism. In contrast, the full ER antagonist fulvestrant blocks the ability of ER to inhibit p53-mediated cell death. This inhibition works through a mechanism involving the modulation of a subset of p53 and ER target genes that can predict the relapse-free survival of patients with ER+ breast cancer. These findings suggest an improved strategy for the treatment of ER+ breast cancer using antagonists that completely block ER action together with drugs that activate p53-mediated cell death.
C1 [Bailey, Shannon T.; Shin, Hyunjin; Westerling, Thomas; Liu, Xiaole Shirley; Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
[Bailey, Shannon T.; Westerling, Thomas; Brown, Myles] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Bailey, Shannon T.; Westerling, Thomas; Brown, Myles] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Bailey, Shannon T.; Westerling, Thomas; Brown, Myles] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Shin, Hyunjin; Liu, Xiaole Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Shin, Hyunjin; Liu, Xiaole Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
RP Brown, M (reprint author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02215 USA.
EM myles_brown@dfci.harvard.edu
RI Bailey, Shannon/B-8045-2014;
OI Brown, Myles/0000-0002-8213-1658
FU Novartis; Pfizer; Terri Brodeur Breast Cancer Foundation; National
Institutes of Health [P01 CA080111, R01 DK074967, R01 HG004069]
FX M.B. serves as a consultant to Novartis and receives sponsored research
support from Novartis and Pfizer.; This work was supported by a Terri
Brodeur Breast Cancer Foundation fellowship (to S.T.B.) and National
Institutes of Health Grants P01 CA080111 (to M.B.), R01 DK074967 (to
M.B.), and R01 HG004069 (to X.S.L.).
NR 57
TC 43
Z9 45
U1 1
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 30
PY 2012
VL 109
IS 44
BP 18060
EP 18065
DI 10.1073/pnas.1018858109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038BJ
UT WOS:000311149900077
PM 23077249
ER
PT J
AU Hunzicker-Dunn, ME
Lopez-Biladeau, B
Law, NC
Fiedler, SE
Carr, DW
Maizels, ET
AF Hunzicker-Dunn, Mary E.
Lopez-Biladeau, Blanca
Law, Nathan C.
Fiedler, Sarah E.
Carr, Daniel W.
Maizels, Evelyn T.
TI PKA and GAB2 play central roles in the FSH signaling pathway to PI3K and
AKT in ovarian granulosa cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID FOLLICLE-STIMULATING-HORMONE; PROTEIN-KINASE-A; HISTONE H3
PHOSPHORYLATION; GROWTH-FACTOR RECEPTORS; ANCHORING PROTEINS;
PHOSPHATIDYLINOSITOL 3-KINASE; REGULATORY SUBUNIT; ADAPTER PROTEINS;
CYCLIC-AMP; ACTIVATION
AB Controlled maturation of ovarian follicles is necessary for fertility. Follicles are restrained at an immature stage until stimulated by FSH secreted by pituitary gonadotropes. FSH acts on granulosa cells within the immature follicle to inhibit apoptosis, promote proliferation, stimulate production of steroid and protein hormones, and induce ligand receptors and signaling intermediates. The phosphoinositide 3-kinase (PI3K)/AKT (protein kinase B) pathway is a pivotal signaling corridor necessary for transducing the FSH signal. We report that protein kinase A (PKA) mediates the actions of FSH by signaling through multiple targets to activate PI3K/AKT. PKA uses a route that promotes phosphorylation of insulin receptor substrate-1 (IRS-1) on Tyr(989), a canonical binding site for the 85-kDa regulatory subunit of PI3K that allosterically activates the catalytic subunit. PI3K activation leads to activation of AKT through phosphorylation of AKT on Thr(308) and Ser(473). The adaptor growth factor receptor bound protein 2-associated binding protein 2 (GAB2) is present in a preformed complex with PI3K heterodimer and IRS-1, it is an A-kinase anchoring protein that binds the type I regulatory subunit of PKA, and it is phosphorylated by PKA on Ser(159). Overexpression of GAB2 enhances FSH-stimulated AKT phosphorylation. GAB2, thus, seems to coordinate signals from the FSH-stimulated rise in cAMP that leads to activation of PI3K/AKT. The ability of PKA to commandeer IRS-1 and GAB2, adaptors that normally integrate receptor/nonreceptor tyrosine kinase signaling into PI3K/AKT, reveals a previously unrecognized route for PKA to activate a pathway that promotes proliferation, inhibits apoptosis, enhances translation, and initiates differentiation of granulosa cells.
C1 [Hunzicker-Dunn, Mary E.; Lopez-Biladeau, Blanca; Law, Nathan C.] Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.
[Fiedler, Sarah E.; Carr, Daniel W.] Oregon Hlth & Sci Univ, Portland Vet Affairs Med Ctr, Portland, OR 97239 USA.
[Maizels, Evelyn T.] Northwestern Univ, Dept Cell & Mol Biol, Feinberg Sch Med, Chicago, IL 60611 USA.
RP Hunzicker-Dunn, ME (reprint author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.
EM mehd@wsu.edu
FU National Institutes of Health [R01HD062053, R03HD068668]; Department of
Veterans Affairs
FX We thank additional members of the Hunzicker-Dunn laboratory for their
technical and intellectual contributions. We thank John Nilson for his
critical reading of the manuscript. This work was supported by National
Institutes of Health Grants R01HD062053 (to M.E.H.-D.) and R03HD068668
(to D. W. C.) and a Merit Award from the Department of Veterans Affairs
(to D.W.C.).
NR 56
TC 37
Z9 39
U1 3
U2 12
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 30
PY 2012
VL 109
IS 44
BP E2979
EP E2988
DI 10.1073/pnas.1205661109
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038BJ
UT WOS:000311149900007
PM 23045700
ER
PT J
AU Adachi, MS
Taylor, AB
Hart, PJ
Fitzpatrick, PF
AF Adachi, Mariya S.
Taylor, Alexander B.
Hart, P. John
Fitzpatrick, Paul F.
TI Mechanistic and Structural Analyses of the Roles of Active Site Residues
in Yeast Polyamine Oxidase Fms1: Characterization of the N195A and D94N
Enzymes
SO BIOCHEMISTRY
LA English
DT Article
ID AMINO-ACID OXIDASE; MONOAMINE-OXIDASE; KINETIC MECHANISM; PH-DEPENDENCE;
SUBSTRATE-SPECIFICITY; OXYGEN ACTIVATION; FLAVOPROTEIN; OXIDATION;
METABOLISM; SPERMINE
AB Flavoprotein Fms1 from Saccharomyces cerevisiae catalyzes the oxidation of spermine in the biosynthetic pathway for pantothenic acid. The same reaction is catalyzed by the mammalian polyamine and spermine oxidases. The active site of Fms1 contains three amino acid residues positioned to interact with the polyamine substrate, His67, Asn195, and Asp94. These three residues form a hydrogen bonding triad with Asn195 being the central residue. Previous studies of the effects of mutating His67 are consistent with that residue being important both for interacting with the substrate and for maintaining the hydrogen bonds in the triad [Adachi, M. S., Taylor, A. B., Hart, P. J., and Fitzpatrick, P. F. (2012) Biochemistry Si, 4888-4897]. The N195A and D94N enzymes have now been characterized to evaluate their roles in catalysis. Both mutations primarily affect the reductive half-reaction. With N-1-acetylspermine as the substrate, the rate constant for flavin reduction decreases similar to 450-fold for both mutations; the effects with spermine as the substrate are smaller, 20-40-fold. The k(cat)/K-amine- and k(cat)-pH profiles with N-1-acetylspermine are only slightly changed from the profiles for the wild-type enzyme, consistent with the pK(a) values arising from the amine substrate or product and not from active site residues. The structure of the N195A enzyme was determined at a resolution of 2.0 angstrom. The structure shows a molecule of tetraethylene glycol in the active site and establishes that the mutation has no effect on the protein structure. Overall, the results are consistent with the role of Asn195 and Asp94 being to properly position the polyamine substrate for oxidation.
C1 [Adachi, Mariya S.; Taylor, Alexander B.; Hart, P. John; Fitzpatrick, Paul F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
[Hart, P. John] S Texas Vet Hlth Care Syst, Dept Vet Affairs, Audie Murphy Div, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
RP Fitzpatrick, PF (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.
EM fitzpatrick@biochem.uthscsa.edu
FU National Institutes of Health Grant [R01 GM058698]; Welch Foundation
[AQ-1399, AQ1245]; National Center for Research Resources
[5P41RR015301-10]; National Institute of General Medical Sciences from
the National Institutes of Health [(8 P41 GM103403-10]; U.S. DOE
[DE-AC02-06CH11357]; Department of Veterans Affairs, Veterans Health
Administration, Office of Research Development, Biomedical Laboratory
Research and Development
FX This work was supported in part by National Institutes of Health Grant
R01 GM058698 (to P.F.F.) and The Welch Foundation Grants AQ-1399 (to
R.J.H.) and AQ1245 (to P.F.F.). This work is based upon research
conducted at the Advanced Photon Source on the Northeastern
Collaborative Access Team beamlines, which are supported by grants from
the National Center for Research Resources (5P41RR015301-10) and the
National Institute of General Medical Sciences (8 P41 GM103403-10) from
the National Institutes of Health. Use of the Advanced Photon Source, an
Office of Science User Facility operated for the U.S. Department of
Energy (DOE), Office of Science, by Argonne National Laboratory, was
supported by the U.S. DOE under Contract DE-AC02-06CH11357.; This
material is based upon work supported in part by the Department of
Veterans Affairs, Veterans Health Administration, Office of Research
Development, Biomedical Laboratory Research and Development. Support for
the X-ray Crystallography Core Laboratory by the University of Texas
Health Science Center at San Antonio Executive Research Committee and
the Cancer Therapy Research Center is gratefully acknowledged.
NR 35
TC 2
Z9 2
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0006-2960
J9 BIOCHEMISTRY-US
JI Biochemistry
PD OCT 30
PY 2012
VL 51
IS 43
BP 8690
EP 8697
DI 10.1021/bi3011434
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 029GX
UT WOS:000310483900020
PM 23034052
ER
PT J
AU Anderson, ML
Peterson, ED
Brennan, JM
Rao, SV
Dai, D
Anstrom, KJ
Piana, R
Popescu, A
Sedrakyan, A
Messenger, JC
Douglas, PS
AF Anderson, Monique L.
Peterson, Eric D.
Brennan, J. Matthew
Rao, Sunil V.
Dai, David
Anstrom, Kevin J.
Piana, Robert
Popescu, Andra
Sedrakyan, Art
Messenger, John C.
Douglas, Pamela S.
TI Short- and Long-Term Outcomes of Coronary Stenting in Women Versus Men
Results From the National Cardiovascular Data Registry Centers for
Medicare & Medicaid Services Cohort
SO CIRCULATION
LA English
DT Article
DE coronary disease; bare metal stents; drug-eluting stents; proportional
hazards models; sex factors
ID DRUG-ELUTING STENTS; ACUTE MYOCARDIAL-INFARCTION;
AMERICAN-HEART-ASSOCIATION; IN-HOSPITAL OUTCOMES; BARE-METAL STENTS;
GENDER-DIFFERENCES; ARTERY-DISEASE; ELDERLY-PATIENTS; INTERVENTION; SEX
AB Background-Conflicting evidence exists on sex-based outcomes after coronary stenting.
Methods and Results-Data on 426 996 patients >= 65 years old (42.3% women) from the National Cardiovascular Data Registry CathPCI Registry (2004-2008) were linked to Medicare inpatient claims to compare in-hospital outcomes by sex and long-term outcomes by sex and stent type. In-hospital complications were more frequent in women than in men: death (3869 [2.2%] versus 3737 [1.6%]; adjusted odds ratio, 1.41; 95% confidence interval [CI], 1.33-1.49), myocardial infarction (2365 [1.3%] versus 2858 [1.2%]; odds ratio, 1.19; 95% CI, 1.11-1.27), bleeding (7860 [4.4%] versus 5627 [2.3%]; odds ratio, 1.86; 95% CI, 1.79-1.93), and vascular complications (2381 [1.3%] versus 1648 [0.7%]; odds ratio, 1.85; 95% CI, 1.73-1.99). At 20.4 months, women had a lower adjusted risk of death (hazard ratio [HR], 0.92; 95% CI, 0.90-0.94) but similar rates of myocardial infarction, revascularization, and bleeding. Relative to bare metal stent use, drug-eluting stent use was associated with similar improved long-term outcomes in both sexes: death (women: adjusted HR, 0.78; 95% CI, 0.76-0.81; men: HR, 0.77; 95% CI, 0.74-0.79), myocardial infarction (women: HR, 0.79; 95% CI, 0.74-0.84; men: HR, 0.81; 95% CI, 0.77-0.85), and revascularization (women: HR, 0.93; 95% CI, 0.90-0.97; men: HR, 0.91; 95% CI, 0.88-0.94). There was no interaction between sex and stent type for long-term outcomes.
Conclusions-In contemporary coronary stenting, women have a slightly higher procedural risk than men but have better long-term survival. In both sexes, use of a drug-eluting stent is associated with lower long-term likelihood for death, myocardial infarction, and revascularization. (Circulation. 2012; 126: 2190-2199.)
C1 [Anderson, Monique L.; Peterson, Eric D.; Brennan, J. Matthew; Rao, Sunil V.; Dai, David; Anstrom, Kevin J.; Douglas, Pamela S.] Duke Univ, Duke Clin Res Inst, Med Ctr, Durham, NC USA.
[Piana, Robert] Vanderbilt Heart Inst, Nashville, TN USA.
[Popescu, Andra] Christiana Care Hlth Syst, Newark, DE USA.
[Sedrakyan, Art] Weill Cornell Med Coll, New York, NY USA.
[Messenger, John C.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Anderson, ML (reprint author), 7022 N Pavil DUMC,POB 17969, Durham, NC 27715 USA.
EM monique.anderson@duke.edu
FU Agency for Healthcare Research and Quality, US Department of Health and
Human Services, Rockville, MD, as part of the Cardiovascular Consortium
[24-EHC-1, HHSAA290-2005-0032-TO4-WA2]; Alexion; AstraZeneca; Bristol
Myers Squibb; Lilly; Innocoll Pharmaceuticals; Medtronic; Pfizer;
Proctor Gamble; Cordis
FX This project was sponsored by the Agency for Healthcare Research and
Quality, US Department of Health and Human Services, Rockville, MD, as
part of the Cardiovascular Consortium and funded under project 24-EHC-1
and work assignment number HHSAA290-2005-0032-TO4-WA2 as part of the
Developing Evidence to Inform Decisions About Effectiveness (DEcIDE)
program. The authors are responsible for its content. Statements in the
report should not be construed as endorsement by the Agency for
Healthcare Research and Quality or the US Department of Health and Human
Services. Additional support was obtained from the National
Cardiovascular Data Registry, American College of Cardiology,
Washington, DC. The funding organization had no role in the design and
conduct of the study; in the collection, analysis, and interpretation of
the data; or in the preparation, review, or approval of the manuscript.;
Dr Anstrom has received research and salary support from Alexion,
AstraZeneca, Bristol Myers Squibb, Lilly, Innocoll Pharmaceuticals,
Medtronic, Pfizer, and Proctor & Gamble; has served on data safety
monitoring boards for Pfizer and Vertex; and has provided consulting
services for Pacific Therapeutics, Bristol Myers Squibb, and
AstraZeneca. Dr Rao has received research funding from Cordis. Dr
Messenger has served as the site principal investigator for the Resolute
Study and EDUCATE study (Medtronic, Inc). The other authors report no
conflicts.
NR 44
TC 21
Z9 22
U1 3
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 30
PY 2012
VL 126
IS 18
BP 2190
EP +
DI 10.1161/CIRCULATIONAHA.112.111369
PG 19
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 028PU
UT WOS:000310435400011
PM 22988009
ER
PT J
AU Piccini, JP
Sinner, MF
Greiner, MA
Hammill, BG
Fontes, JD
Daubert, JP
Ellinor, PT
Hernandez, AF
Walkey, AJ
Heckbert, SR
Benjamin, EJ
Curtis, LH
AF Piccini, Jonathan P.
Sinner, Moritz F.
Greiner, Melissa A.
Hammill, Bradley G.
Fontes, Joao D.
Daubert, James P.
Ellinor, Patrick T.
Hernandez, Adrian F.
Walkey, Allan J.
Heckbert, Susan R.
Benjamin, Emelia J.
Curtis, Lesley H.
TI Outcomes of Medicare Beneficiaries Undergoing Catheter Ablation for
Atrial Fibrillation
SO CIRCULATION
LA English
DT Article
DE atrial fibrillation; catheter ablation; Medicare; outcome assessment
(health care)
ID CONGESTIVE-HEART-FAILURE; TERM CLINICAL-EFFICACY; UNITED-STATES;
ANTIARRHYTHMIC-DRUG; ADMINISTRATIVE DATA; LIFETIME RISK; STROKE RISK;
COMPLICATIONS; REHOSPITALIZATIONS; PREVALENCE
AB Background-Atrial fibrillation is common among older persons. Catheter ablation is increasingly used in patients for whom medical therapy has failed.
Methods and Results-We conducted a retrospective cohort study of all fee-for-service Medicare beneficiaries >= 65 years of age who underwent catheter ablation for atrial fibrillation between July 1, 2007, and December 31, 2009. The main outcome measures were major complications within 30 days and mortality, heart failure, stroke, hospitalization, and repeat ablation within 1 year. A total of 15 423 patients underwent catheter ablation for atrial fibrillation. Mean age was 72 years; 41% were women; and >95% were white. For every 1000 procedures, there were 17 cases of hemopericardium requiring intervention, 8 cases of stroke, and 8 deaths within 30 days. More than 40% of patients required hospitalization within 1 year; however, atrial fibrillation or flutter was the primary discharge diagnosis in only 38.4% of cases. Eleven percent of patients underwent repeat ablation within 1 year. Renal impairment (hazard ratio, 2.07; 95% confidence interval, 1.66-2.58), age >= 80 years (hazard ratio, 3.09; 95% confidence interval, 2.32-4.11), and heart failure (hazard ratio, 2.54; 95% confidence interval, 2.07-3.13) were major risk factors for 1-year mortality. Advanced age was a major risk factor for all adverse outcomes.
Conclusions-Major complications after catheter ablation for atrial fibrillation were associated with advanced age but were fairly infrequent. Few patients underwent repeat ablation. Randomized trials are needed to inform risk-benefit calculations for older persons with drug-refractory, symptomatic atrial fibrillation. (Circulation. 2012;126:2200-2207.)
C1 [Piccini, Jonathan P.; Greiner, Melissa A.; Hammill, Bradley G.; Daubert, James P.; Hernandez, Adrian F.; Curtis, Lesley H.] Duke Univ, Duke Clin Res Inst, Sch Med, Durham, NC 27715 USA.
[Piccini, Jonathan P.; Daubert, James P.; Hernandez, Adrian F.; Curtis, Lesley H.] Duke Univ, Dept Med, Sch Med, Durham, NC 27715 USA.
[Sinner, Moritz F.; Benjamin, Emelia J.] Framingham Heart Dis Epidemiol Study, Framingham, MA USA.
[Sinner, Moritz F.; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Sinner, Moritz F.] Univ Munich, Dept Med 1, Univ Hosp Grosshadern, Munich, Germany.
[Fontes, Joao D.; Walkey, Allan J.; Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Heckbert, Susan R.] Univ Washington, Dept Epidemiol, Sch Publ Hlth, Seattle, WA 98195 USA.
RP Curtis, LH (reprint author), Duke Univ, Duke Clin Res Inst, Sch Med, POB 17969, Durham, NC 27715 USA.
EM lesley.curtis@duke.edu
RI Hernandez, Adrian F./A-7818-2016;
OI Walkey, Allan/0000-0003-4685-6894; Hernandez, Adrian
F./0000-0003-3387-9616; Benjamin, Emelia/0000-0003-4076-2336
FU National Heart, Lung, and Blood Institute [R01HL102214, R01HL068986,
R01HL092577, R01HL104156, K24HL105780, RC1HL101056]; National Institute
on Drug Abuse [R21DA027021]; Janssen Pharmaceuticals; Biosense Webster;
Biotronik; Gilead; Medtronic; Johnson Johnson
FX This work was supported by grants R01HL102214, R01HL068986, R01HL092577,
R01HL104156, K24HL105780, and RC1HL101056 from the National Heart, Lung,
and Blood Institute and grant R21DA027021 from the National Institute on
Drug Abuse. The contents of this manuscript are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Heart, Lung, and Blood Institute; the
National Institute on Drug Abuse; or the National Institutes of Health.;
Dr Piccini reports receiving research grant funding from Janssen
Pharmaceuticals and consultant/advisory board income from Forest
Laboratories, Johnson & Johnson, Medtronic, and Titan Pharmaceuticals.
Dr Daubert reports receiving research grant funding from Biosense
Webster, Biotronik, Gilead, and Medtronic; receiving honoraria from
Biotronik, Boston Scientific, Medtronic, Sorin, and St. Jude; serving as
an expert witness for a patient with sudden cardiac death resulting from
coronary artery disease; having ownership interest in Biosense Webster
inherited by his wife/children in a generation-skipping trust for the
children; and receiving consultant/ advisory board income from Premier,
Inc. Dr Hernandez reports receiving research grant funding from Johnson
& Johnson. Dr Curtis reports receiving research grant funding from
Johnson & Johnson. Drs Piccini, Hernandez, and Curtis have made
available online detailed listings of financial disclosures
(http://www.dcri.duke.edu/about-us/conflict-of-interest/). The other
authors reported no conflicts.
NR 37
TC 37
Z9 39
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 30
PY 2012
VL 126
IS 18
BP 2200
EP +
DI 10.1161/CIRCULATIONAHA.112.109330
PG 14
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 028PU
UT WOS:000310435400012
PM 23019293
ER
PT J
AU Das, S
Aiba, T
Rosenberg, M
Hessler, K
Xiao, CY
Quintero, PA
Ottaviano, FG
Knight, AC
Graham, EL
Bostrom, P
Morissette, MR
del Monte, F
Begley, MJ
Cantley, LC
Ellinor, PT
Tomaselli, GF
Rosenzweig, A
AF Das, Saumya
Aiba, Takeshi
Rosenberg, Michael
Hessler, Katherine
Xiao, Chunyang
Quintero, Pablo A.
Ottaviano, Filomena G.
Knight, Ashley C.
Graham, Evan L.
Bostroem, Pontus
Morissette, Michael R.
del Monte, Federica
Begley, Michael J.
Cantley, Lewis C.
Ellinor, Patrick T.
Tomaselli, Gordon F.
Rosenzweig, Anthony
TI Pathological Role of Serum- and Glucocorticoid-Regulated Kinase 1 in
Adverse Ventricular Remodeling
SO CIRCULATION
LA English
DT Article
DE arrhythmia; heart failure; ion channels or ion channel; signal
transduction
ID LATE SODIUM CURRENT; CARDIAC NA+ CHANNELS; LONG-QT SYNDROME;
HEART-FAILURE; AKT ACTIVATION; IN-VIVO; PROTEIN; RANOLAZINE; MODULATION;
SGK
AB Background-Heart failure is a growing cause of morbidity and mortality. Cardiac phosphatidylinositol 3-kinase signaling promotes cardiomyocyte survival and function, but it is paradoxically activated in heart failure, suggesting that chronic activation of this pathway may become maladaptive. Here, we investigated the downstream phosphatidylinositol 3-kinase effector, serum-and glucocorticoid-regulated kinase-1 (SGK1), in heart failure and its complications. Methods and Results-We found that cardiac SGK1 is activated in human and murine heart failure. We investigated the role of SGK1 in the heart by using cardiac-specific expression of constitutively active or dominant-negative SGK1. Cardiac-specific activation of SGK1 in mice increased mortality, cardiac dysfunction, and ventricular arrhythmias. The proarrhythmic effects of SGK1 were linked to biochemical and functional changes in the cardiac sodium channel and could be reversed by treatment with ranolazine, a blocker of the late sodium current. Conversely, cardiac-specific inhibition of SGK1 protected mice after hemodynamic stress from fibrosis, heart failure, and sodium channel alterations. Conclusions-SGK1 appears both necessary and sufficient for key features of adverse ventricular remodeling and may provide a novel therapeutic target in cardiac disease. (Circulation. 2012;126:2208-2219.)
C1 [Rosenzweig, Anthony] Beth Israel Deaconess Med Ctr, Div Cardiovasc, Ctr Life Sci, Cardiovasc Inst, Boston, MA 02215 USA.
[Begley, Michael J.; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Div Signal Transduct Unit, Boston, MA 02215 USA.
[Begley, Michael J.; Cantley, Lewis C.] Beth Israel Deaconess Med Ctr, Ctr Canc, Boston, MA 02215 USA.
[Aiba, Takeshi; Tomaselli, Gordon F.] Johns Hopkins Univ, Div Cardiol, Sch Med, Baltimore, MD USA.
[Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiac Arrhythmia Serv, Boston, MA 02114 USA.
[Morissette, Michael R.] W Virginia Univ, Morgantown, WV 26506 USA.
[Bostroem, Pontus] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Bostroem, Pontus] Dana Farber Canc Inst, Boston, MA USA.
RP Rosenzweig, A (reprint author), Beth Israel Deaconess Med Ctr, Div Cardiovasc, Ctr Life Sci, Cardiovasc Inst, 3 Blackfan Cir, Boston, MA 02215 USA.
EM arosenzw@bidmc.harvard.edu
RI Cantley, Lewis/D-1800-2014
OI Cantley, Lewis/0000-0002-1298-7653
FU Leducq Foundation Network of Research Excellence; National Institutes of
Health [R01HL094677, R21HL104370, KO8HL089319, R01HL050411]
FX This research was supported by a Leducq Foundation Network of Research
Excellence (to Dr Rosenzweig) and the National Institutes of Health
(grants R01HL094677 and R21HL104370 to Dr Rosenzweig, KO8HL089319 to Dr
Das, and R01HL050411 to Dr Tomaselli). Dr Rosenzweig also gratefully
acknowledges support from Judith and David Ganz. He is a principal
faculty member of the Harvard Stem Cell Institute and an Associate
Member of the Broad Institute.
NR 43
TC 34
Z9 35
U1 0
U2 14
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 30
PY 2012
VL 126
IS 18
BP 2208
EP +
DI 10.1161/CIRCULATIONAHA.112.115592
PG 29
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 028PU
UT WOS:000310435400013
PM 23019294
ER
PT J
AU Shah, RV
Goldfine, AB
AF Shah, Ravi V.
Goldfine, Allison B.
TI Statins and Risk of New-Onset Diabetes Mellitus
SO CIRCULATION
LA English
DT Editorial Material
ID RANDOMIZED-TRIALS; ROSUVASTATIN; METAANALYSIS; CHOLESTEROL; THERAPY;
PEOPLE
C1 [Goldfine, Allison B.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
[Goldfine, Allison B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Shah, Ravi V.] Harvard Univ, Div Cardiol, Dept Med, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Goldfine, AB (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02115 USA.
EM allison.goldfine@joslin.harvard.edu
NR 7
TC 29
Z9 29
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 30
PY 2012
VL 126
IS 18
BP E282
EP E284
DI 10.1161/CIRCULATIONAHA.112.122135
PG 3
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 028PU
UT WOS:000310435400002
PM 23109518
ER
PT J
AU Ma, YB
Sun, CP
Haake, DA
Churchill, BM
Ho, CM
AF Ma, Yanbao
Sun, Chien-Pin
Haake, David A.
Churchill, Bernard M.
Ho, Chih-Ming
TI A high-order alternating direction implicit method for the unsteady
convection-dominated diffusion problem
SO INTERNATIONAL JOURNAL FOR NUMERICAL METHODS IN FLUIDS
LA English
DT Article
DE high-order method; unsteady convection-dominated diffusion equation; ADI
method; finite difference
ID FINITE-DIFFERENCE APPROXIMATIONS; ADI METHOD; COMPACT SCHEME;
NUMERICAL-SOLUTION; STABILITY ANALYSIS; EQUATION; COEFFICIENTS
AB A high-order alternating direction implicit (ADI) method for solving the unsteady convection-dominated diffusion equation is developed. The fourth-order Pade scheme is used for the discretization of the convection terms, while the second-order Pade scheme is used for the diffusion terms. The CrankNicolson scheme and ADI factorization are applied for time integration. After ADI factorization, the two-dimensional problem becomes a sequence of one-dimensional problems. The solution procedure consists of multiple use of a one-dimensional tridiagonal matrix algorithm that produces a computationally cost-effective solver. Von Neumann stability analysis is performed to show that the method is unconditionally stable. An unsteady two-dimensional problem concerning convection-dominated propagation of a Gaussian pulse is studied to test its numerical accuracy and compare it to other high-order ADI methods. The results show that the overall numerical accuracy can reach third or fourth order for the convection-dominated diffusion equation depending on the magnitude of diffusivity, while the computational cost is much lower than other high-order numerical methods. Copyright (c) 2011 John Wiley & Sons, Ltd.
C1 [Ma, Yanbao] Univ Calif Merced, Sch Engn, Merced, CA 95343 USA.
[Sun, Chien-Pin; Ho, Chih-Ming] Univ Calif Los Angeles, Dept Mech & Aerosp Engn, Los Angeles, CA 90095 USA.
[Haake, David A.; Churchill, Bernard M.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA.
[Haake, David A.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
RP Ma, YB (reprint author), Univ Calif Merced, Sch Engn, Merced, CA 95343 USA.
EM yma5@ucmerced.edu
FU National Institute of Biomedical Imaging and Bioengineering, NIH
[EB00127]; National Institute of Health [1R33DK070328]
FX The authors gratefully acknowledge the reviewers and editor for their
precious suggestions and comments. This work was supported in part by
Bioengineering Research Partnership grant EB00127 (to B. M. C.) from the
National Institute of Biomedical Imaging and Bioengineering, NIH, and in
part by grant 1R33DK070328 (to JL) from the National Institute of
Health. The authors also thank Drs Donghyun You, Samir Karaa, and Jun
Zhang for great help in implementation of boundary conditions.
NR 25
TC 5
Z9 5
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0271-2091
J9 INT J NUMER METH FL
JI Int. J. Numer. Methods Fluids
PD OCT 30
PY 2012
VL 70
IS 6
BP 703
EP 712
DI 10.1002/fld.2707
PG 10
WC Computer Science, Interdisciplinary Applications; Mathematics,
Interdisciplinary Applications; Mechanics; Physics, Fluids & Plasmas
SC Computer Science; Mathematics; Mechanics; Physics
GA 008PE
UT WOS:000308968200003
ER
PT J
AU Ames, NJ
Sulima, P
Ngo, T
Barb, J
Munson, PJ
Paster, BJ
Hart, TC
AF Ames, Nancy J.
Sulima, Pawel
Ngo, Thoi
Barb, Jennifer
Munson, Peter J.
Paster, Bruce J.
Hart, Thomas C.
TI A Characterization of the Oral Microbiome in Allogeneic Stem Cell
Transplant Patients
SO PLOS ONE
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; INTENSIVE-CARE-UNIT; DENTAL PLAQUE;
RESPIRATORY PATHOGENS; INFECTIOUS COMPLICATIONS; NOSOCOMIAL INFECTIONS;
HOST DISEASE; COLONIZATION; MICROARRAY; PNEUMONIA
AB Background: The mouth is a complex biological structure inhabited by diverse bacterial communities. The purpose of this study is to describe the effects of allogeneic stem cell transplantation on the oral microbiota and to examine differences among those patients who acquired respiratory complications after transplantation.
Methodology/Principal Findings: All patients were consented at the National Institutes of Health, Clinical Center. Bacterial DNA was analyzed from patients' oral specimens using the Human Oral Microbe Identification Microarray. The specimens were collected from four oral sites in 45 allogeneic transplantation patients. Specimens were collected at baseline prior to transplantation, after transplantation at the nadir of the neutrophil count and after myeloid engraftment. If respiratory signs and symptoms developed, additional specimens were obtained. Patients were followed for 100 days post transplantation. Eleven patients' specimens were subjected to further statistical analysis. Many common bacterial genera, such as Streptococcus, Veillonella, Gemella, Granulicatella and Camplyobacter were identified as being present before and after transplantation. Five of 11 patients developed respiratory complications following transplantation and there was preliminary evidence that the oral microbiome changed in their oral specimens. Cluster analysis and principal component analysis revealed this change in the oral microbiota.
Conclusions/Significance: After allogeneic transplantation, the oral bacterial community's response to a new immune system was not apparent and many of the most common core oral taxa remained unaffected. However, the oral microbiome was affected in patients who developed respiratory signs and symptoms after transplantation. The association related to the change in the oral microbiota and respiratory complications after transplantation will be validated by future studies using high throughput molecular methods.
C1 [Ames, Nancy J.; Ngo, Thoi] NIH, Ctr Clin, Nursing Serv, Bethesda, MD 20892 USA.
[Ames, Nancy J.; Ngo, Thoi] NIH, Ctr Clin, Patient Care Serv, Bethesda, MD 20892 USA.
[Sulima, Pawel; Hart, Thomas C.] Natl Inst Dent & Craniofacial Res, Human Craniofacial Genet Sect, Craniofacial & Skeletal Dis Branch, Bethesda, MD USA.
[Barb, Jennifer; Munson, Peter J.] NIH, Math & Stat Comp Lab, Ctr Informat Technol, Bethesda, MD 20892 USA.
[Paster, Bruce J.] Forsyth Inst, Dept Microbiol, Cambridge, MA USA.
[Paster, Bruce J.] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
RP Ames, NJ (reprint author), NIH, Ctr Clin, Nursing Serv, Bethesda, MD 20892 USA.
EM names@nih.gov
FU National Institute of Dental and Craniofacial Research of the National
Institutes of Health, Bethesda, MD; Clinical Center Nursing and Patient
Care Services of the National Institutes of Health, Bethesda, MD
FX The authors acknowledge support from the Intramural Program of the
National Institute of Dental and Craniofacial Research and the Clinical
Center Nursing and Patient Care Services of the National Institutes of
Health, Bethesda, MD.
NR 45
TC 6
Z9 6
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 29
PY 2012
VL 7
IS 10
AR e47628
DI 10.1371/journal.pone.0047628
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 032HH
UT WOS:000310705300015
PM 23144704
ER
PT J
AU Tacutu, R
Shore, DE
Budovsky, A
de Magalhaes, JP
Ruvkun, G
Fraifeld, VE
Curran, SP
AF Tacutu, Robi
Shore, David E.
Budovsky, Arie
de Magalhaes, Joao Pedro
Ruvkun, Gary
Fraifeld, Vadim E.
Curran, Sean P.
TI Prediction of C. elegans Longevity Genes by Human and Worm Longevity
Networks
SO PLOS ONE
LA English
DT Article
ID EXTENDS LIFE-SPAN; NEMATODE CAENORHABDITIS-ELEGANS; DIETARY RESTRICTION;
MESSENGER-RNA; STRESS; DISEASE; INHIBITION; SENESCENCE; RESISTANCE;
MUTATIONS
AB Intricate and interconnected pathways modulate longevity, but screens to identify the components of these pathways have not been saturating. Because biological processes are often executed by protein complexes and fine-tuned by regulatory factors, the first-order protein-protein interactors of known longevity genes are likely to participate in the regulation of longevity. Data-rich maps of protein interactions have been established for many cardinal organisms such as yeast, worms, and humans. We propose that these interaction maps could be mined for the identification of new putative regulators of longevity. For this purpose, we have constructed longevity networks in both humans and worms. We reasoned that the essential first-order interactors of known longevity-associated genes in these networks are more likely to have longevity phenotypes than randomly chosen genes. We have used C. elegans to determine whether post-developmental inactivation of these essential genes modulates lifespan. Our results suggest that the worm and human longevity networks are functionally relevant and possess a high predictive power for identifying new longevity regulators.
C1 [Tacutu, Robi; Budovsky, Arie; Fraifeld, Vadim E.] Ben Gurion Univ Negev, Shraga Segal Dept Microbiol Immunol & Genet, Ctr Multidisciplinary Res Aging, IL-84105 Beer Sheva, Israel.
[Shore, David E.; Ruvkun, Gary] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Shore, David E.; Ruvkun, Gary] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[de Magalhaes, Joao Pedro] Univ Liverpool, Inst Integrat Biol, Integrat Genom Ageing Grp, Liverpool L69 3BX, Merseyside, England.
[Curran, Sean P.] Univ So Calif, Div Biogerontol, Davis Sch Gerontol, Los Angeles, CA USA.
[Curran, Sean P.] Univ So Calif, Dept Mol & Computat Biol, Dornsife Coll Letters Arts & Sci, Los Angeles, CA USA.
[Curran, Sean P.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA.
RP Fraifeld, VE (reprint author), Ben Gurion Univ Negev, Shraga Segal Dept Microbiol Immunol & Genet, Ctr Multidisciplinary Res Aging, IL-84105 Beer Sheva, Israel.
EM vadim.fraifeld@gmail.com; spcurran@usc.edu
RI de Magalhaes, Joao Pedro/B-4741-2010
OI de Magalhaes, Joao Pedro/0000-0002-6363-2465
FU NIH [AG032308, AG16636]; Wellcome Trust [ME050495MES]; Marie Curie
International Reintegration Grant within EC-FP7; European Commission
[HEALTH-F4-2008-202047]
FX The research in this study was supported by NIH AG032308 to SPC and
AG16636 (NIA NIH HHS/United State) to GR. JPM is grateful for support
from the Wellcome Trust (ME050495MES) and from a Marie Curie
International Reintegration Grant within EC-FP7. VM was partly funded by
the European Commission FP7 Health Research Grant number
HEALTH-F4-2008-202047. No additional external funding received for this
study. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 51
TC 10
Z9 10
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 29
PY 2012
VL 7
IS 10
AR e48282
DI 10.1371/journal.pone.0048282
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 032HH
UT WOS:000310705300057
PM 23144747
ER
PT J
AU Taylor, JA
Richter, CA
Suzuki, A
Watanabe, H
Iguchi, T
Coser, KR
Shioda, T
vom Saal, FS
AF Taylor, Julia A.
Richter, Catherine A.
Suzuki, Atsuko
Watanabe, Hajime
Iguchi, Taisen
Coser, Kathryn R.
Shioda, Toshihiro
vom Saal, Frederick S.
TI Dose-Related Estrogen Effects on Gene Expression in Fetal Mouse Prostate
Mesenchymal Cells
SO PLOS ONE
LA English
DT Article
ID UROGENITAL SINUS MESENCHYME; CHAIN-REACTION ASSAYS; ANDROGEN RECEPTOR;
REPRODUCTIVE-ORGANS; SIGNALING PATHWAYS; RAT PROSTATE; CANCER CELLS;
MALE-MICE; EXPOSURE; GROWTH
AB Developmental exposure of mouse fetuses to estrogens results in dose-dependent permanent effects on prostate morphology and function. Fetal prostatic mesenchyme cells express estrogen receptor alpha (ER alpha) and androgen receptors and convert stimuli from circulating estrogens and androgens into paracrine signaling to regulate epithelial cell proliferation and differentiation. To obtain mechanistic insight into the role of different doses of estradiol (E2) in regulating mesenchymal cells, we examined E2-induced transcriptomal changes in primary cultures of fetal mouse prostate mesenchymal cells. Urogenital sinus mesenchyme cells were obtained from male mouse fetuses at gestation day 17 and exposed to 10 pM, 100 pM or 100 nM E2 in the presence of a physiological concentration of dihydrotestosterone (0.69 nM) for four days. Gene ontology studies suggested that low doses of E2 (10 pM and 100 pM) induce genes involved in morphological tissue development and sterol biosynthesis but suppress genes involved in growth factor signaling. Genes involved in cell adhesion were enriched among both up-regulated and down-regulated genes. Genes showing inverted-U-shape dose responses (enhanced by E2 at 10 pM E2 but suppressed at 100 pM) were enriched in the glycolytic pathway. At the highest dose (100 nM), E2 induced genes enriched for cell adhesion, steroid hormone signaling and metabolism, cytokines and their receptors, cell-to-cell communication, Wnt signaling, and TGF-beta signaling. These results suggest that prostate mesenchymal cells may regulate epithelial cells through direct cell contacts when estrogen level is low whereas secreted growth factors and cytokines might play significant roles when estrogen level is high.
C1 [Taylor, Julia A.; Richter, Catherine A.; vom Saal, Frederick S.] Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.
[Suzuki, Atsuko; Watanabe, Hajime; Iguchi, Taisen] Grad Univ Adv Studies SOKENDAI, Dept Basic Biol, Sokendai, Aichi, Japan.
[Suzuki, Atsuko; Watanabe, Hajime; Iguchi, Taisen] Grad Univ Adv Studies SOKENDAI, Natl Inst Nat Sci, Natl Inst Basic Biol, Okazaki Inst Integrat Biosci, Sokendai, Aichi, Japan.
[Coser, Kathryn R.; Shioda, Toshihiro] Massachusetts Gen Hosp, Ctr Canc, Mol Profiling Lab, Charlestown, MA USA.
[Coser, Kathryn R.; Shioda, Toshihiro] Harvard Univ, Sch Med, Charlestown, MA USA.
RP Taylor, JA (reprint author), Univ Missouri, Div Biol Sci, Columbia, MO 65211 USA.
EM taylorja@missouri.edu
OI Richter, Catherine/0000-0001-7322-4206
FU National Institute of Environmental Health Sciences (NIEHS) [ES11283,
ES018764, 1F32ES11549]; Ministry of Education, Culture, Sports, Science
and Technology; Ministry of Health Labor and Welfare, Japan; Susan G.
Komen for Cure [FAS0703860, KG090515]
FX This work was supported by grants from the National Institute of
Environmental Health Sciences (NIEHS) (www.niehs.nih.gov/) to FVS
(ES11283; ES018764) and to CR (1F32ES11549); a Grant-in-Aid from the
Ministry of Education, Culture, Sports, Science and Technology (B)
(http://www.mext.go.jp/english/) and a grant from the Ministry of Health
Labor and Welfare, Japan (www.mhlw.go.jp/english/) to TI, and grants
from Susan G. Komen for Cure
(http://ww5.komen.org/researchgrants/researchandgrants.html) (FAS0703860
and KG090515) to TS. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 59
TC 3
Z9 3
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 29
PY 2012
VL 7
IS 10
AR e48311
DI 10.1371/journal.pone.0048311
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 032HH
UT WOS:000310705300061
PM 23144751
ER
PT J
AU Bhatt, DL
AF Bhatt, Deepak L.
TI EXAMINATION of new drug-eluting stents-top of the class!
SO LANCET
LA English
DT Editorial Material
ID METAL CORONARY STENTS; RANDOMIZED-TRIALS; LATE THROMBOSIS; FOLLOW-UP;
RESTENOSIS; METAANALYSIS; OUTCOMES; THERAPY
C1 [Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02132 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA 02132 USA.
RP Bhatt, DL (reprint author), Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02132 USA.
EM dlbhattmd@post.harvard.edu
NR 13
TC 14
Z9 15
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 27
PY 2012
VL 380
IS 9852
BP 1453
EP 1455
DI 10.1016/S0140-6736(12)61021-6
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 026JJ
UT WOS:000310272000007
PM 22951304
ER
PT J
AU Kamran, SC
Shinagare, AB
Howard, SA
Hornick, JL
Ramaiya, NH
AF Kamran, S. C.
Shinagare, A. B.
Howard, S. A.
Hornick, J. L.
Ramaiya, N. H.
TI A-Z of malignant peripheral nerve sheath tumors
SO CANCER IMAGING
LA English
DT Review
DE Malignant peripheral nerve sheath tumor; neurofibromatosis; malignant
triton tumor; MRI; PET/CT
ID RADIOLOGIC-PATHOLOGICAL CORRELATION; TRITON TUMORS; DIFFERENTIATION;
NEUROFIBROMATOSIS; SURVIVAL; BENIGN
AB This article reviews the typical and atypical locations, imaging findings, local recurrence, and metastatic pattern of malignant peripheral nerve sheath tumors (MPNSTs). MPNSTs are rare soft tissue sarcomas, commonly occur in extremities, and are often associated with neurofibromatosis. Distinction between benign and malignant tumors can be challenging on imaging. MPNSTs have a poor prognosis; however, rhabdomyoblastic differentiation (malignant triton tumor), which has imaging features similar to MPNSTs, is associated with even more aggressive behavior.
C1 [Kamran, S. C.; Shinagare, A. B.; Howard, S. A.; Ramaiya, N. H.] Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Kamran, S. C.; Shinagare, A. B.; Howard, S. A.; Ramaiya, N. H.] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Hornick, J. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Kamran, S. C.; Shinagare, A. B.; Howard, S. A.; Hornick, J. L.; Ramaiya, N. H.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Shinagare, AB (reprint author), Dana Farber Canc Inst, Dept Imaging, 450 Brookline Ave, Boston, MA 02115 USA.
EM ashinagare@partners.org
OI Kamran, Sophia/0000-0001-9283-6515
NR 16
TC 6
Z9 7
U1 0
U2 2
PU E-MED
PI LONDON
PA PO BOX 29761, LONDON, NW3 7ZS, ENGLAND
SN 1470-7330
J9 CANCER IMAGING
JI Cancer Imaging
PD OCT 26
PY 2012
VL 12
IS 3
BP 475
EP 483
DI 10.1102/1470-7330.2012.0043
PG 9
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA 172LG
UT WOS:000321004100003
PM 23108260
ER
PT J
AU Hull, RL
Peters, MJ
Perigo, SP
Chan, CK
Wight, TN
Kinsella, MG
AF Hull, Rebecca L.
Peters, Michael J.
Perigo, Susan Potter
Chan, Christina K.
Wight, Thomas N.
Kinsella, Michael G.
TI Overall Sulfation of Heparan Sulfate from Pancreatic Islet beta-TC3
Cells Increases Maximal Fibril Formation but Does Not Determine Binding
to the Amyloidogenic Peptide Islet Amyloid Polypeptide
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; FORMATION IN-VITRO;
TRANSFORMING GROWTH-FACTOR-BETA-1; ALZHEIMERS-DISEASE;
DIABETES-MELLITUS; FORMATION RATHER; MOUSE MODEL; PROTEOGLYCAN; PROTEINS
AB Islet amyloid, a pathologic feature of type 2 diabetes, contains the islet beta-cell peptide islet amyloid polypeptide (IAPP) as its unique amyloidogenic component. Islet amyloid also contains heparan sulfate proteoglycans (HSPGs) that may contribute to amyloid formation by binding IAPP via their heparan sulfate (HS) chains. We hypothesized that beta-cells produce HS that bind IAPP via regions of highly sulfated disaccharides. Unexpectedly, HS from the beta-cell line beta-TC3 contained fewer regions of highly sulfated disaccharides compared with control normal murine mammary gland (NMuMG) cells. The proportion of HS that bound IAPP was similar in both cell lines ( 65%). The sulfation pattern of IAPP-bound versus non-bound HS from beta-TC3 cells was similar. In contrast, IAPP-bound HS from NMuMG cells contained frequent highly sulfated regions, whereas the nonbound material demonstrated fewer sulfated regions. Fibril formation from IAPP was stimulated equally by IAPP-bound beta-TC3 HS, non-bound beta-TC3 HS, and non-bound NMuMG HS but was stimulated to a greater extent by the highly sulfated IAPP-bound NMuMG HS. Desulfation of HS decreased the ability of both beta-TC3 and NMuMG HS to stimulate IAPP maximal fibril formation, but desulfated HS from both cell types still accelerated fibril formation relative to IAPP alone. In summary, neither binding to nor acceleration of fibril formation from the amyloidogenic peptide IAPP is dependent on overall sulfation in HS synthesized by beta-TC3 cells. This information will be important in determining approaches to reduce HS-IAPP interactions and ultimately prevent islet amyloid formation and its toxic effects in type 2 diabetes.
C1 [Hull, Rebecca L.; Peters, Michael J.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Hull, Rebecca L.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Wight, Thomas N.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Perigo, Susan Potter; Chan, Christina K.; Wight, Thomas N.; Kinsella, Michael G.] Benaroya Res Inst Virginia Mason, Hope Heart Matrix Biol Program, Seattle, WA 98101 USA.
RP Hull, RL (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM rhull@u.washington.edu
OI Hull, Rebecca/0000-0001-9690-4087
FU Department of Veterans Affairs, Veterans Affairs Puget Sound Health Care
System (Seattle, WA); National Institutes of Health [DK74404, HL18645,
HL92969, DK17047]
FX This work was supported by the Department of Veterans Affairs, Veterans
Affairs Puget Sound Health Care System (Seattle, WA) and National
Institutes of Health Grants DK74404 (to R. L. H.), HL18645 and HL92969
(to T. N. W.), and DK17047 (to the University of Washington Diabetes
Research Center).
NR 38
TC 3
Z9 3
U1 0
U2 7
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 26
PY 2012
VL 287
IS 44
BP 37154
EP 37164
DI 10.1074/jbc.M112.409847
PG 11
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 030RT
UT WOS:000310588500049
PM 22936797
ER
PT J
AU Massengale, M
Lu, B
Pan, JJ
Katz, JN
Solomon, DH
AF Massengale, Mei
Lu, Bing
Pan, John J.
Katz, Jeffrey N.
Solomon, Daniel H.
TI Adipokine Hormones and Hand Osteoarthritis: Radiographic Severity and
Pain
SO PLOS ONE
LA English
DT Article
ID KNEE; PROGRESSION; BIOMARKERS; OBESITY; LEPTIN; HIP
AB Introduction: Obesity's association with hand osteoarthritis cannot be fully explained by mechanical loading. We examined the relationship between adipokines and radiographic hand osteoarthritis severity and pain.
Methods: In a pilot study of 44 hand osteoarthritis patients (39 women and 5 men), serum adipokine concentrations and hand x-ray Kallman-scores were analyzed using linear regression models. Secondary analyses examined correlates of hand pain.
Results: The cohort had a mean age of 63.5 years for women and 72.6 for men; mean (standard deviation) Kallman-scores were 43.3(17.4) for women and 46.2(10.8) for men. Mean body-mass-index was 30 kg/m(2) for women and men. Mean leptin concentration was 32.2 ng/ml (women) and 18.5 ng/ml (men); mean adiponectin-total was 7.9 ng/ml (women) and 5.3 ng/ml (men); mean resistin was 7.3 ng/ml (women) and 9.4 ng/ml (men). No association was found between Kallman-scores and adipokine concentrations (R-2 = 0.00-0.04 unadjusted analysis, all p-values>0.22). Secondary analyses showed mean visual-analog-scale pain of 4.8(2.4) for women and 6.6(0.9) for men. Leptin, BMI, and history of coronary artery disease were found to be associated with visual-analog-scale scores for chronic hand pain (R-2 = 0.36 unadjusted analysis, p-values <= 0.04).
Conclusion: In this pilot study, we found that adipokine serum concentrations were not associated with hand osteoarthritis radiographic severity; the most important correlates of joint damage were age and disease duration. Leptin serum concentration, BMI, and coronary artery disease were associated with the intensity of chronic hand OA pain.
C1 [Massengale, Mei; Lu, Bing; Katz, Jeffrey N.; Solomon, Daniel H.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Solomon, Daniel H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Katz, Jeffrey N.] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Katz, Jeffrey N.] Brigham & Womens Hosp, Orthopaed & Arthrit Ctr Outcomes Res, Boston, MA 02115 USA.
[Katz, Jeffrey N.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Massengale, Mei; Lu, Bing; Katz, Jeffrey N.; Solomon, Daniel H.] Harvard Univ, Sch Med, Boston, MA USA.
[Pan, John J.] Brigham & Womens Hosp, Dept Radiol, Div Musculoskeletal Radiol, Boston, MA 02115 USA.
[Massengale, Mei] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
RP Massengale, M (reprint author), Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, 75 Francis St, Boston, MA 02115 USA.
EM hmei@partners.org
FU Harvard Catalyst; Harvard Clinical and Translational Science Center
(National Institutes of Health) [UL1 RR 025758]; Harvard University; NIH
[T32 AR 055885, K24 AR 055989, P60 AR 47782]; Harvard Catalyst
Institutional Award
FX Authors gratefully acknowledge the support from Harvard Catalyst
vertical bar The Harvard Clinical and Translational Science Center
(National Institutes of Health Award #UL1 RR 025758 and financial
contributions from Harvard University and its affiliated academic health
care centers). The content is solely the responsibility of the authors
and does not necessarily represent the official views of Harvard
Catalyst, Harvard University and its affiliated academic health care
centers, the National Center for Research Resources, or the National
Institutes of Health (NIH). MM was supported by NIH T32 AR 055885 and
Harvard Catalyst Institutional Award. DHS's effort on this project was
supported by the NIH (K24 AR 055989). DHS and NKK were supported by NIH
P60 AR 47782. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 17
TC 24
Z9 24
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 26
PY 2012
VL 7
IS 10
AR e47860
DI 10.1371/journal.pone.0047860
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026GL
UT WOS:000310262500022
PM 23110114
ER
PT J
AU Rana, S
Cerdeira, AS
Wenger, J
Salahuddin, S
Lim, KH
Ralston, SJ
Thadhani, RI
Karumanchi, SA
AF Rana, Sarosh
Cerdeira, Ana Sofia
Wenger, Julia
Salahuddin, Saira
Lim, Kee-Hak
Ralston, Steven J.
Thadhani, Ravi I.
Karumanchi, S. Ananth
TI Plasma Concentrations of Soluble Endoglin versus Standard Evaluation in
Patients with Suspected Preeclampsia
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; ANTI-ANGIOGENIC FACTORS; TYROSINE KINASE 1;
MATERNAL PLASMA; ANTIANGIOGENIC FACTORS; PREGNANCY; RISK; HYPERTENSION;
COMPLICATIONS; PROTEINURIA
AB Background: The purpose of this study was to compare plasma soluble endoglin (sEng) levels with standard clinical evaluation or plasma levels of other angiogenic proteins [soluble fms-like tyrosine kinase 1 (sFlt1) and placental growth factor (PlGF)] in predicting short-term adverse maternal and perinatal outcomes in women with suspected preeclampsia presenting prior to 34 weeks.
Methods and Findings: Data from all women presenting at <34 weeks for evaluation of preeclampsia with singleton pregnancies (July 2009-October 2010) were included in this analysis and sEng levels were measured at presentation. Data was analyzed for 170 triage encounters and presented as median {25-75th centile}. Thirty-three percent of patients (56 of 170) experienced an adverse outcome. sEng levels (ng/ml) were significantly elevated in patients who subsequently experienced adverse outcomes compared to those who did not (32.3 {18.1, 55.8} vs 4.8 {3.2, 8.6}, p<0.0001). At a 10% false positive rate, sEng had higher detection rates of adverse outcomes than the combination of highest systolic blood pressure, proteinuria and abnormal laboratory tests (80.4 {70.0, 90.8} vs 63.8 {51.4, 76.2}, respectively). Subjects in the highest quartile of sEng were more likely to deliver early compared to those in the lowest quartile (HR: 14.96 95% CI: 8.73225.62, p<0.0001). Natural log transformed sEng correlated positively with log sFlt1 levels (r = 0.87) and inversely with log PlGF levels (r = 20.79) (p<0.0001 for both). Plasma sEng had comparable area under the curve for prediction of adverse outcomes as measurement of sFlt1/PlGF ratio (0.88 {0.81, 0.95} for sEng versus 0.89 {0.83, 0.95} for sFlt1/PlGF ratio, p = 0.74).
Conclusions: In women with suspected preeclampsia presenting prior to 34 weeks of gestation, sEng performs better than standard clinical evaluation in detecting adverse maternal and fetal outcomes occurring within two weeks of presentation. Soluble endoglin was strongly correlated with sFlt1 and PlGF levels, suggesting common pathogenic pathways leading to preeclampsia.
C1 [Rana, Sarosh; Ralston, Steven J.; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Div Maternal Fetal Med, Boston, MA 02215 USA.
[Rana, Sarosh; Cerdeira, Ana Sofia; Wenger, Julia; Salahuddin, Saira; Lim, Kee-Hak; Ralston, Steven J.; Thadhani, Ravi I.; Karumanchi, S. Ananth] Harvard Univ, Sch Med, Boston, MA USA.
[Rana, Sarosh; Salahuddin, Saira; Lim, Kee-Hak; Ralston, Steven J.; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Dept Obstet & Gynecol, Boston, MA 02215 USA.
[Cerdeira, Ana Sofia; Karumanchi, S. Ananth] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Cerdeira, Ana Sofia] Gulbenkian Programme Adv Med Educ, Lisbon, Portugal.
[Wenger, Julia; Thadhani, Ravi I.] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
[Lim, Kee-Hak] Boston Maternal Fetal Med Grp, Boston, MA USA.
[Karumanchi, S. Ananth] Howard Hughes Med Inst, Chevy Chase, MD USA.
RP Rana, S (reprint author), Beth Israel Deaconess Med Ctr, Div Maternal Fetal Med, Boston, MA 02215 USA.
EM srana1@bidmc.harvard.edu
FU National Institutes of Health/National Institute of Child Health and
Human Development (NIH/NICHD); Burroughs Wellcome Fund Clinical
Scientist Award; Howard Hughes Medical Institute; Aggamin LLC
FX This work was supported by a KO8 award from National Institutes of
Health/National Institute of Child Health and Human Development
(NIH/NICHD) (to SR), a Burroughs Wellcome Fund Clinical Scientist Award
(to SAK) and the Howard Hughes Medical Institute (to SAK). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.; The authors have read the
journal's policy and have the following conflicts: Dr. Karumanchi is
co-inventor on multiple patents (USPTO #7,740,849, #7,407,658,
#7,335,362, #7,344,892) related to the use of angiogenic markers for the
diagnosis, prediction and therapy of preeclampsia). Dr. Karumanchi
reports having served as a consultant to Roche and Beckman Coulter and
has financial interest in Aggamin LLC. Dr. Thadhani is a co-inventor on
a patent (USPTO #7,344,892) related to the use of angiogenic proteins
for the prediction of preeclampsia and has financial interest in Aggamin
LLC.
NR 29
TC 20
Z9 20
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 26
PY 2012
VL 7
IS 10
AR e48259
DI 10.1371/journal.pone.0048259
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026GL
UT WOS:000310262500054
PM 23110221
ER
PT J
AU Treister, N
Duncan, C
Cutler, C
Lehmann, L
AF Treister, Nathaniel
Duncan, Christine
Cutler, Corey
Lehmann, Leslie
TI How we treat oral chronic graft-versus-host disease
SO BLOOD
LA English
DT Review
ID BONE-MARROW-TRANSPLANTATION; STEM-CELL TRANSPLANTATION; CONSENSUS
DEVELOPMENT PROJECT; WORKING GROUP-REPORT; PILOCARPINE HYDROCHLORIDE;
TOPICAL TACROLIMUS; CLINICAL-TRIALS; CHRONIC GVHD; RANDOMIZED TRIAL;
DENDRITIC CELLS
AB Chronic graft-versus-host disease (cGVHD) is a major complication of allogeneic hematopoietic cell transplantation that is associated with a diminished quality of life. The oral cavity is frequently affected, with a wide variety of signs and symptoms that can result in significant short-and long-term complications ranging from mucosal sensitivity and limited oral intake to secondary malignancy and early death. This article provides a comprehensive approach to the diagnosis and clinical management of patients with oral cGVHD, with particular attention to differential diagnosis, control of symptoms, and prevention of and screening for secondary complications. The clinical considerations and recommendations presented are intended to be practical and relevant for all clinicians involved in the care of patients with oral cGVHD, with the ultimate goal of improving care and outcomes. (Blood. 2012;120(17):3407-3418)
C1 [Treister, Nathaniel] Brigham & Womens Hosp, Div Oral Med & Dent, Boston, MA 02120 USA.
[Treister, Nathaniel] Harvard Univ, Sch Dent Med, Dept Oral Med Infect & Immun, Boston, MA 02115 USA.
[Duncan, Christine; Lehmann, Leslie] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Duncan, Christine; Cutler, Corey; Lehmann, Leslie] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Cutler, Corey] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Treister, N (reprint author), Brigham & Womens Hosp, Div Oral Med & Dent, 1620 Tremont St,3rd Fl, Boston, MA 02120 USA.
EM ntreister@partners.org
NR 76
TC 19
Z9 19
U1 0
U2 6
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 25
PY 2012
VL 120
IS 17
BP 3407
EP 3418
DI 10.1182/blood-2012-05-393389
PG 12
WC Hematology
SC Hematology
GA 044MN
UT WOS:000311623800007
PM 22898605
ER
PT J
AU Davids, MS
Deng, J
Wiestner, A
Lannutti, BJ
Wang, LL
Wu, CJ
Wilson, WH
Brown, JR
Letai, A
AF Davids, Matthew S.
Deng, Jing
Wiestner, Adrian
Lannutti, Brian J.
Wang, Lili
Wu, Catherine J.
Wilson, Wyndham H.
Brown, Jennifer R.
Letai, Anthony
TI Decreased mitochondrial apoptotic priming underlies stroma-mediated
treatment resistance in chronic lymphocytic leukemia
SO BLOOD
LA English
DT Article
ID B-CELLS; CHEMOKINE RECEPTORS; EXPRESSION; INHIBITOR; CAL-101; DISEASE;
SIGNALS; MECHANISMS; SURVIVAL; CXCR4
AB Stroma induces treatment resistance in chronic lymphocytic leukemia (CLL), possibly because of alterations in the BCL-2 family of proteins, which are key regulators of apoptosis. We previously developed BH3 profiling, a functional assay that assesses mitochondrial depolarization in response to BH3-only peptides, to measure "apoptotic priming," the proximity of a cell to the apoptotic threshold. In the present study, we use BH3 profiling to show that CLL cells from the PB are highly primed. Increased priming is associated with improved clinical response and, unexpectedly, with unmutated IGHV status. Coculturing CLL cells in vitro with stroma decreases priming. Using matched PB, BM, and lymph node compartment samples, we found in vivo that BM-derived CLL cells are the least primed. CLL cells cocultured with stroma were treated with the PI3K delta-isoform inhibitor CAL-101 (GS1101). CAL-101 caused CLL cell de-adhesion, leading to increased CLL cell priming. Stimulation of CLL cells with anti-IgM or CXCL12 caused decreased priming that could be reversed by CAL-101. Our results show that inhibition of stromal interactions leading to displacement of CLL cells into the blood by CAL-101 in vivo may increase CLL cell priming, suggesting a mechanism by which agents inducing lymphocyte redistribution might facilitate improved clinical response when used in combination with other therapies. (Blood. 2012;120(17):3501-3509)
C1 [Davids, Matthew S.; Deng, Jing; Wang, Lili; Wu, Catherine J.; Brown, Jennifer R.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Wiestner, Adrian] NHLBI, Hematol Branch, NIH, Bethesda, MD 20892 USA.
[Wilson, Wyndham H.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Lannutti, Brian J.] Gilead Sci Inc, Seattle, WA USA.
RP Letai, A (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM anthony_letai@dfci.harvard.edu
FU FLAMES Fund of the Pan-Mass Challenge; National Institutes of Health
[RO1CA129974]; Ruth L. Kirschstein National Research Service Award T32
National Cancer Institute grant; Friends of the Dana-Farber Cancer
Institute; National Institutes of Health; National Heart, Lung, and
Blood Institute; National Cancer Institute; American Association of
Cancer Research/Stand Up To Cancer Innovative Research Grant; Gilead
Sciences
FX This work was funded by the FLAMES Fund of the Pan-Mass Challenge, the
National Institutes of Health (RO1CA129974), a Ruth L. Kirschstein
National Research Service Award T32 National Cancer Institute grant, and
the Friends of the Dana-Farber Cancer Institute. M. S. D. is a Leukemia
& Lymphoma Society Special Fellow in Clinical Research and a recipient
of an National Institutes of Health Loan Repayment Program award. A. W.
and W. H. W. are supported by the Intramural Research Program of the
National Heart, Lung, and Blood Institute, the National Institutes of
Health, and the National Cancer Institute, respectively. C. J. W. is a
Damon Runyon Cancer Research Foundation Clinical Investigator and a
recipient of an American Association of Cancer Research/Stand Up To
Cancer Innovative Research Grant. J. R. B. is a Leukemia & Lymphoma
Society Scholar in Clinical Research and a Scholar of the American
Society of Hematology. A. L. is a Leukemia & Lymphoma Society Scholar
and a Scholar of the American Society of Hematology.; B.J.L. is an
employee of Gilead Sciences. J.R.B. was a paid consultant for Calistoga
Pharmaceuticals before its acquisition by Gilead Sciences. A. L. is a
cofounder of, and formerly a paid advisor to, Eutropics Pharmaceuticals,
which has purchased a license to BH3 profiling from Dana-Farber Cancer
Institute. A. L. and the Dana-Farber Cancer Institute have a patent
relating to the use of BH3 profiling in predicting chemosensitivity. The
remaining authors declare no competing financial interests.
NR 28
TC 51
Z9 51
U1 1
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 25
PY 2012
VL 120
IS 17
BP 3501
EP 3509
DI 10.1182/blood-2012-02-414060
PG 9
WC Hematology
SC Hematology
GA 044MN
UT WOS:000311623800017
PM 22955911
ER
PT J
AU Cea, M
Cagnetta, A
Fulciniti, M
Tai, YT
Hideshima, T
Chauhan, D
Roccaro, A
Sacco, A
Calimeri, T
Cottini, F
Jakubikova, J
Kong, SY
Patrone, F
Nencioni, A
Gobbi, M
Richardson, P
Munshi, N
Anderson, KC
AF Cea, Michele
Cagnetta, Antonia
Fulciniti, Mariateresa
Tai, Yu-Tzu
Hideshima, Teru
Chauhan, Dharminder
Roccaro, Aldo
Sacco, Antonio
Calimeri, Teresa
Cottini, Francesca
Jakubikova, Jana
Kong, Sun-Young
Patrone, Franco
Nencioni, Alessio
Gobbi, Marco
Richardson, Paul
Munshi, Nikhil
Anderson, Kenneth C.
TI Targeting NAD(+) salvage pathway induces autophagy in multiple myeloma
cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2)
inhibition
SO BLOOD
LA English
DT Article
ID NICOTINAMIDE ADENINE-DINUCLEOTIDE; ANTITUMOR-ACTIVITY;
MOLECULAR-MECHANISMS; MAMMALIAN TARGET; BONE-MARROW; CANCER; NAMPT;
METABOLISM; DEPLETION; RAPAMYCIN
AB Malignant cells have a higher nicotinamide adenine dinucleotide (NAD(+)) turnover rate than normal cells, making this biosynthetic pathway an attractive target for cancer treatment. Here we investigated the biologic role of a rate-limiting enzyme involved in NAD(+) synthesis, Nampt, in multiple myeloma (MM). Nampt-specific chemical inhibitor FK866 triggered cytotoxicity in MM cell lines and patient MM cells, but not normal donor as well as MM patients PBMCs. Importantly, FK866 in a dose-dependent fashion triggered cytotoxicity in MM cells resistant to conventional and novel anti-MM therapies and overcomes the protective effects of cytokines (IL-6, IGF-1) and bone marrow stromal cells. Nampt knockdown by RNAi confirmed its pivotal role in maintenance of both MM cell viability and intracellular NAD(+) stores. Interestingly, cytotoxicity of FK866 triggered autophagy, but not apoptosis. A transcriptional-dependent (TFEB) and independent (PI3K/mTORC1) activation of autophagy mediated FK866 MM cytotoxicity. Finally, FK866 demonstrated significant anti-MM activity in a xenograft-murine MM model, associated with down-regulation of ERK1/2 phosphorylation and proteolytic cleavage of LC3 in tumor cells. Our data therefore define a key role of Nampt in MM biology, providing the basis for a novel targeted therapeutic approach. (Blood. 2012;120(17):3519-3529)
C1 [Cea, Michele; Cagnetta, Antonia; Fulciniti, Mariateresa; Tai, Yu-Tzu; Hideshima, Teru; Chauhan, Dharminder; Roccaro, Aldo; Sacco, Antonio; Calimeri, Teresa; Cottini, Francesca; Jakubikova, Jana; Kong, Sun-Young; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.] Harvard Univ, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Sch Med, Boston, MA 02115 USA.
[Cea, Michele; Cagnetta, Antonia; Fulciniti, Mariateresa; Tai, Yu-Tzu; Hideshima, Teru; Chauhan, Dharminder; Roccaro, Aldo; Sacco, Antonio; Calimeri, Teresa; Cottini, Francesca; Jakubikova, Jana; Kong, Sun-Young; Richardson, Paul; Munshi, Nikhil; Anderson, Kenneth C.] Harvard Univ, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Sch Med, Boston, MA 02115 USA.
[Cea, Michele; Patrone, Franco; Nencioni, Alessio] Azienda Osped Univ San Martino IST, Ist Ricovero & Cura Carattere Sci, Dept Internal Med, Genoa, Italy.
[Cagnetta, Antonia; Gobbi, Marco] Azienda Osped Univ San Martino IST, Ist Ricovero & Cura Carattere Sci, Dept Hematol & Oncol, Genoa, Italy.
[Kong, Sun-Young] Natl Canc Ctr, Res Inst & Hosp, Goyang, South Korea.
RP Cea, M (reprint author), Harvard Univ, Dana Farber Canc Inst, LeBow Inst Myeloma Therapeut, Sch Med, M551,450 Brookline Ave, Boston, MA 02115 USA.
EM michele_cea@dfci.harvard.edu; kenneth_anderson@dfci.harvard.edu
RI Sacco, Antonio/K-4681-2016;
OI Sacco, Antonio/0000-0003-2945-9416; Roccaro, Aldo/0000-0002-1872-5128
FU National Institutes of Health [RO-1 50947, RO-1 73878]; DF/HCC SPORE in
Multiple Myeloma [P-50100707]; American Italian Cancer Foundation;
International Multiple Myeloma Foundation; Associazione Cristina Bassi;
Associazione Italiana per la Ricerca sul Cancro [START-UP P-6108]
FX This work was supported by National Institutes of Health (grants RO-1
50947, RO-1 73878), DF/HCC SPORE in Multiple Myeloma (P-50100707);
American Italian Cancer Foundation (M. C.); International Multiple
Myeloma Foundation and Associazione Cristina Bassi (A. C.); and
Associazione Italiana per la Ricerca sul Cancro (START-UP P-6108 A. N.).
K. C. A. is an American Cancer Society Clinical Research Professor.
NR 45
TC 59
Z9 62
U1 2
U2 13
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 25
PY 2012
VL 120
IS 17
BP 3519
EP 3529
DI 10.1182/blood-2012-03-416776
PG 11
WC Hematology
SC Hematology
GA 044MN
UT WOS:000311623800019
PM 22955917
ER
PT J
AU Kumar, S
Xu, JY
Perkins, C
Guo, FK
Snapper, S
Finkelman, FD
Zheng, Y
Filippi, MD
AF Kumar, Sachin
Xu, Juying
Perkins, Charles
Guo, Fukun
Snapper, Scott
Finkelman, Fred D.
Zheng, Yi
Filippi, Marie-Dominique
TI Cdc42 regulates neutrophil migration via crosstalk between WASp, CD11b,
and microtubules
SO BLOOD
LA English
DT Article
ID SRC FAMILY KINASES; SIGNAL-TRANSDUCTION; CELL-MIGRATION; LEADING-EDGE;
POLARITY; ACTIVATION; CHEMOTAXIS; POLARIZATION; ADHESION; DEFICIENCY
AB Chemotaxis promotes neutrophil participation in cellular defense by enabling neutrophil migration to infected tissue and is controlled by persistent cell polarization. One long-standing question of neutrophil polarity has been how the pseudopod and the uropod are coordinated. In our previous report, we suggested that Rho GTPase Cdc42 controls neutrophil polarity through CD11b signaling at the uropod, albeit through an unknown mechanism. Here, we show that Cdc42 controls polarity, unexpectedly, via its effector WASp. Cdc42 controls WASp activation and its distant localization to the uropod. At the uropod, WASp regulates the reorganization of CD11b integrin into detergent resistant membrane domains; in turn, CD11b recruits the microtubule end binding protein EB1 to capture and stabilize microtubules at the uropod. This organization is necessary to maintain neutrophil polarity during migration and is critical for neutrophil emigration into inflamed lungs. These results suggest unrecognized mechanism of neutrophil polarity in which WASp mediates long-distance control of the uropod by Cdc42 to maintain a proper balance between the pseudopod and the uropod. Our study reveals a new function for WASp in the control of neutrophil polarity via crosstalk between CD11b and microtubules. (Blood. 2012;120(17):3563-3574)
C1 [Kumar, Sachin; Xu, Juying; Guo, Fukun; Zheng, Yi; Filippi, Marie-Dominique] Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA.
[Perkins, Charles; Finkelman, Fred D.] Univ Cincinnati, Coll Med, Dept Internal Med, Cincinnati, OH USA.
[Perkins, Charles; Finkelman, Fred D.] Cincinnati Childrens Res Fdn, Div Immunobiol, Cincinnati, OH 45229 USA.
[Perkins, Charles; Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH USA.
[Snapper, Scott] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA.
[Snapper, Scott] Harvard Univ, Sch Med, Boston, MA USA.
RP Filippi, MD (reprint author), Cincinnati Childrens Res Fdn, Div Expt Hematol & Canc Biol, S7-605,3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM marie-dominique.filippi@cchmc.org
RI Zheng, Yi/J-7235-2015
OI Zheng, Yi/0000-0001-7089-6074
FU NIH [HL090676-MDF, 5P01 HL059561-11-SS]
FX The work was supported by NIH (HL090676-MDF; 5P01 HL059561-11-SS).
NR 50
TC 25
Z9 26
U1 6
U2 12
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 25
PY 2012
VL 120
IS 17
BP 3563
EP 3574
DI 10.1182/blood-2012-04-426981
PG 12
WC Hematology
SC Hematology
GA 044MN
UT WOS:000311623800023
PM 22932798
ER
PT J
AU Halloran, J
Hussong, SA
Burbank, R
Podlutskaya, N
Fischer, KE
Sloane, LB
Austad, SN
Strong, R
Richardson, A
Hart, MJ
Galvan, V
AF Halloran, J.
Hussong, S. A.
Burbank, R.
Podlutskaya, N.
Fischer, K. E.
Sloane, L. B.
Austad, S. N.
Strong, R.
Richardson, A.
Hart, M. J.
Galvan, V.
TI CHRONIC INHIBITION OF MAMMALIAN TARGET OF RAPAMYCIN BY RAPAMYCIN
MODULATES COGNITIVE AND NON-COGNITIVE COMPONENTS OF BEHAVIOR THROUGHOUT
LIFESPAN IN MICE
SO NEUROSCIENCE
LA English
DT Article
DE mammalian target of rapamycin; memory; depression; anxiety; brain aging;
monoamines
ID CALORIC RESTRICTION; ALZHEIMERS-DISEASE; AMYLOID-BETA; MOUSE MODEL;
MTOR; ANXIETY; MEMORY; SEROTONIN; MIDBRAIN; DEFICITS
AB Aging is, by far, the greatest risk factor for most neurodegenerative diseases. In non-diseased conditions, normal aging can also be associated with declines in cognitive function that significantly affect quality of life in the elderly. It was recently shown that inhibition of Mammalian TOR (mTOR) activity in mice by chronic rapamycin treatment extends lifespan, possibly by delaying aging {Harrison, 2009 #4}{Miller, 2011 #168}. To explore the effect of chronic rapamycin treatment on normal brain aging we determined cognitive and non-cognitive components of behavior throughout lifespan in male and female C57BL/6 mice that were fed control- or rapamycin-supplemented chow. Our studies show that rapamycin enhances cognitive function in young adult mice and blocks age-associated cognitive decline in older animals. In addition, mice fed with rapamycin-supplemented chow showed decreased anxiety and depressive-like behavior at all ages tested. Levels of three major monoamines (norepinephrine, dopamine and 5-hydroxytryptamine) and their metabolites (3,4-dihydroxyphenylacetic acid, homovanillic acid, and 5-hydroxyindolacetic acid) were significantly augmented in midbrain of rapamycin-treated mice compared to controls. Our results suggest that chronic, partial inhibition of mTOR by oral rapamycin enhances learning and memory in young adults, maintains memory in old C57BL/6J mice, and has concomitant anxiolytic and antidepressant-like effects, possibly by stimulating major monoamine pathways in brain. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Halloran, J.; Hussong, S. A.; Burbank, R.; Podlutskaya, N.; Fischer, K. E.; Sloane, L. B.; Austad, S. N.; Strong, R.; Richardson, A.; Hart, M. J.; Galvan, V.] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst, San Antonio, TX 78245 USA.
[Halloran, J.; Hussong, S. A.; Burbank, R.; Fischer, K. E.; Galvan, V.] Dept Physiol, San Antonio, TX 78229 USA.
[Hussong, S. A.; Podlutskaya, N.; Austad, S. N.; Richardson, A.] Dept Cell & Struct Biol, San Antonio, TX 78229 USA.
[Strong, R.] Dept Pharmacol, San Antonio, TX 78229 USA.
[Hart, M. J.] Dept Mol Med, San Antonio, TX 78245 USA.
[Strong, R.; Richardson, A.] Ctr Geriatr Res Educ & Clin, San Antonio, TX 78229 USA.
[Strong, R.; Richardson, A.] Audie L Murphy Div, S Texas Vet Hlth Care Network, Res Serv, San Antonio, TX 78229 USA.
RP Galvan, V (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, MSC 7755,15355 Lambda Dr, San Antonio, TX 78245 USA.
EM galvanv@uthscsa.edu
FU Alzheimer's Association [NIRG 04-1054]; New Scholar Award in Aging from
the Ellison Medical Foundation [AG-NS-0726-10]; University Research
Council Award from UTHSCSA; San Antonio Nathan Shock Center of
Excellence in the Basic Biology of Aging; NIH Recovery Act Grand
Opportunities "GO" Grant [RC2AG036613]; [T32AG21890]
FX This work was supported by NIRG 04-1054 from the Alzheimer's
Association, AG-NS-0726-10 New Scholar Award in Aging from the Ellison
Medical Foundation, and a University Research Council Award from UTHSCSA
to VG, the San Antonio Nathan Shock Center of Excellence in the Basic
Biology of Aging to AR and RS, the RC2AG036613 NIH Recovery Act Grand
Opportunities "GO" Grant to AR, and T32AG21890 to SAH.; The authors
thank Ms. Katrine Krueger for excellent administrative assistance. We
are also grateful to Dr. Elisabeth Fernandez and to Ms. Xiang Bai for
their help with monoamine measurements, and to Ms. Vanessa Soto and Mr.
John Ramos and to the South Texas Center for Biology in Medicine Animal
Facility staff for excellent animal care. This work was supported in
part by the San Antonio Nathan Shock Center of Excellence in the Basic
Biology of Aging (AR and RS), RC2AG036613 NIH Recovery Act Grand
Opportunities "GO" Grant to AR, and by NIRG 04-1054 from the Alzheimer's
Association, AG-NS-0726-10 New Scholar Award in Aging from the Ellison
Medical Foundation, and a University Research Council Award from UTHSCSA
to VG.
NR 55
TC 80
Z9 84
U1 2
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 25
PY 2012
VL 223
BP 102
EP 113
DI 10.1016/j.neuroscience.2012.06.054
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 018VM
UT WOS:000309694700011
PM 22750207
ER
PT J
AU Bonab, AA
Fricchione, JG
Gorantla, S
Vitalo, AG
Auster, ME
Levine, SJ
Scichilone, JM
Hegde, M
Foote, W
Fricchione, GL
Denninger, JW
Yarmush, DM
Fischman, AJ
Yarmush, ML
Levine, JB
AF Bonab, A. A.
Fricchione, J. G.
Gorantla, S.
Vitalo, A. G.
Auster, M. E.
Levine, S. J.
Scichilone, J. M.
Hegde, M.
Foote, W.
Fricchione, G. L.
Denninger, J. W.
Yarmush, D. M.
Fischman, A. J.
Yarmush, M. L.
Levine, J. B.
TI ISOLATION REARING SIGNIFICANTLY PERTURBS BRAIN METABOLISM IN THE
THALAMUS AND HIPPOCAMPUS
SO NEUROSCIENCE
LA English
DT Article
DE PET; FDG; IEG; brain; isolation rearing; childhood adversity; biomarker;
stress
ID MEDIAL PREFRONTAL CORTEX; ISOLATION-REARED RATS; POSTWEANING
SOCIAL-ISOLATION; EARLY GENE-EXPRESSION; SIZED SPINY NEURONS; PREPULSE
INHIBITION; ENVIRONMENTAL ENRICHMENT; ACOUSTIC STARTLE; DEFICITS;
EXTINCTION
AB Psychosocial neglect during childhood severely impairs both behavioral and physical health. The isolation rearing model in rodents has been employed by our group and others to study this clinical problem at a basic level. We previously showed that immediate early gene (IEG) expression in the hippocampus and medial prefrontal cortex (mPFC) is decreased in isolation-reared (IR) compared to group-reared (OR) rats. In the current study, we sought to evaluate: (1) whether these changes in IEG expression would be detected by the measurement of brain glucose metabolism using positron emission tomography (PET) with fluorodeoxyglucose (FDG) and (2) whether PET FDG could illuminate other brain regions with different glucose metabolism in IR compared to GR rats. We found that there were significant differences in FDG uptake in the hippocampus that were consistent with our findings for IEG expression (decreased mean FDG uptake in IR rats). In contrast, in the mPFC, the FDG uptake between IR and OR rats did not differ. Finally, we found decreased mean FDG uptake in the thalamus of the IR rats, a region we had not previously examined. The results suggest that PET FOG has the potential to be utilized as a biomarker of molecular changes in the hippocampus. Further, the differences found in thalamic brain FDG uptake suggest that further investigation of this region at the molecular and cellular levels may provide an important insight into the neurobiological basis of the adverse clinical outcomes found in children exposed to psychosocial deprivation. (c) 2012 IBRO. Published by Elsevier Ltd. All rights reserved.
C1 [Levine, J. B.] Shriners Hosp Children, Ctr Engn & Med, Boston, MA 02114 USA.
[Fricchione, J. G.; Gorantla, S.; Vitalo, A. G.; Auster, M. E.; Levine, S. J.; Scichilone, J. M.; Foote, W.; Fricchione, G. L.; Denninger, J. W.; Levine, J. B.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Hegde, M.; Yarmush, D. M.; Yarmush, M. L.; Levine, J. B.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Bonab, A. A.] Massachusetts Gen Hosp, Dept Nucl Med, Boston, MA 02114 USA.
[Fricchione, J. G.; Gorantla, S.; Vitalo, A. G.; Auster, M. E.; Levine, S. J.; Scichilone, J. M.; Foote, W.; Fricchione, G. L.; Denninger, J. W.; Levine, J. B.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.
[Fricchione, J. G.; Gorantla, S.; Vitalo, A. G.; Auster, M. E.; Levine, S. J.; Scichilone, J. M.; Hegde, M.; Yarmush, D. M.; Yarmush, M. L.; Levine, J. B.] Massachusetts Gen Hosp, Ctr Engn & Med, Boston, MA 02114 USA.
[Bonab, A. A.; Hegde, M.; Foote, W.; Fricchione, G. L.; Denninger, J. W.; Yarmush, D. M.; Fischman, A. J.; Yarmush, M. L.; Levine, J. B.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Yarmush, M. L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08855 USA.
RP Yarmush, ML (reprint author), Shriners Hosp Children, Ctr Engn & Med, 51 Blossom St, Boston, MA 02114 USA.
EM ireis@sbi.org; jblevine@partners.org
RI Hegde, Manjunath/M-3038-2014
OI Hegde, Manjunath/0000-0002-5396-2241
FU John Henry Foundation; Benson-Henry Institute (BHI) for Mind Body
Medicine at Massachusetts General Hospital; Medical Research Programs of
Shriners Burns Hospital for Children (Boston)
FX The John Henry Foundation and The Benson-Henry Institute (BHI) for Mind
Body Medicine at Massachusetts General Hospital; The Medical Research
Programs of Shriners Burns Hospital for Children (Boston). The John
Henry Foundation provides research funding to the BHI. The John Henry
Foundation itself had no role in study design, data collection,
analysis, or decision to publish, or in the preparation of the
manuscript.
NR 57
TC 2
Z9 2
U1 2
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4522
J9 NEUROSCIENCE
JI Neuroscience
PD OCT 25
PY 2012
VL 223
BP 457
EP 464
DI 10.1016/j.neuroscience.2012.07.032
PG 8
WC Neurosciences
SC Neurosciences & Neurology
GA 018VM
UT WOS:000309694700044
PM 22835621
ER
PT J
AU Liao, XY
Lochhead, P
Nishihara, R
Morikawa, T
Kuchiba, A
Yamauchi, M
Imamura, Y
Qian, ZR
Baba, Y
Shima, K
Sun, RF
Nosho, K
Meyerhardt, JA
Giovannucci, E
Fuchs, CS
Chan, AT
Ogino, S
AF Liao, Xiaoyun
Lochhead, Paul
Nishihara, Reiko
Morikawa, Teppei
Kuchiba, Aya
Yamauchi, Mai
Imamura, Yu
Qian, Zhi Rong
Baba, Yoshifumi
Shima, Kaori
Sun, Ruifang
Nosho, Katsuhiko
Meyerhardt, Jeffrey A.
Giovannucci, Edward
Fuchs, Charles S.
Chan, Andrew T.
Ogino, Shuji
TI Aspirin Use, Tumor PIK3CA Mutation, and Colorectal-Cancer Survival
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ISLAND METHYLATOR PHENOTYPE; MOLECULAR PATHOLOGICAL EPIDEMIOLOGY;
MICROSATELLITE INSTABILITY; COLON-CANCER; PERSONALIZED MEDICINE;
RANDOMIZED-TRIALS; BRAF MUTATION; RISK; METASTASIS; INHIBITION
AB BACKGROUND
Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers.
METHODS
We obtained data on 964 patients with rectal or colon cancer from the Nurses' Health Study and the Health Professionals Follow-up Study, including data on aspirin use after diagnosis and the presence or absence of PIK3CA mutation. We used a Cox proportional-hazards model to compute the multivariate hazard ratio for death. We examined tumor markers, including PTGS2, phosphorylated AKT, KRAS, BRAF, microsatellite instability, CpG island methylator phenotype, and methylation of long interspersed nucleotide element 1.
RESULTS
Among patients with mutated-PIK3CA colorectal cancers, regular use of aspirin after diagnosis was associated with superior colorectal cancer-specific survival (multivariate hazard ratio for cancer-related death, 0.18; 95% confidence interval [CI], 0.06 to 0.61; P<0.001 by the log-rank test) and overall survival (multivariate hazard ratio for death from any cause, 0.54; 95% CI, 0.31 to 0.94; P = 0.01 by the log-rank test). In contrast, among patients with wild-type PIK3CA, regular use of aspirin after diagnosis was not associated with colorectal cancer-specific survival (multivariate hazard ratio, 0.96; 95% CI, 0.69 to 1.32; P = 0.76 by the log-rank test; P = 0.009 for interaction between aspirin and PIK3CA variables) or overall survival (multivariate hazard ratio, 0.94; 95% CI, 0.75 to 1.17; P = 0.96 by the log-rank test; P = 0.07 for interaction).
CONCLUSIONS
Regular use of aspirin after diagnosis was associated with longer survival among patients with mutated-PIK3CA colorectal cancer, but not among patients with wild-type PIK3CA cancer. The findings from this molecular pathological epidemiology study suggest that the PIK3CA mutation in colorectal cancer may serve as a predictive molecular biomarker for adjuvant aspirin therapy. (Funded by The National Institutes of Health and others.)
C1 [Chan, Andrew T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02115 USA.
[Liao, Xiaoyun; Lochhead, Paul; Nishihara, Reiko; Kuchiba, Aya; Yamauchi, Mai; Imamura, Yu; Qian, Zhi Rong; Sun, Ruifang; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Liao, Xiaoyun; Lochhead, Paul; Nishihara, Reiko; Kuchiba, Aya; Yamauchi, Mai; Imamura, Yu; Qian, Zhi Rong; Sun, Ruifang; Meyerhardt, Jeffrey A.; Fuchs, Charles S.; Chan, Andrew T.; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA USA.
[Giovannucci, Edward; Ogino, Shuji] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward; Fuchs, Charles S.; Chan, Andrew T.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Morikawa, Teppei] Tokyo Univ Hosp, Dept Pathol, Tokyo 113, Japan.
[Baba, Yoshifumi] Kumamoto Univ, Dept Surg Gastroenterol, Kumamoto, Japan.
[Shima, Kaori] Kagoshima Univ, Dept Oral Pathol, Kagoshima 890, Japan.
[Nosho, Katsuhiko] Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido, Japan.
RP Chan, AT (reprint author), Massachusetts Gen Hosp, Div Gastroenterol, 55 Fruit St, Boston, MA 02115 USA.
EM achan@partners.org; shuji_ogino@dfci.harvard.edu
OI Qian, Zhi rong/0000-0003-1633-4120
FU National Institutes of Health [P01 CA87969, P01 CA55075, P50 CA127003,
R01 CA149222, R01 CA137178, R01 CA151993]; Bennett Family Fund;
Entertainment Industry Foundation through the National Colorectal Cancer
Research Alliance; Frank Knox Memorial Fellowship at Harvard University;
Chief Scientist Office, Scotland; Damon Runyon Clinical Investigator
Award
FX Supported by grants from the National Institutes of Health (P01 CA87969
and P01 CA55075; P50 CA127003, to Dr. Fuchs; R01 CA149222, to Dr.
Meyerhardt; R01 CA137178, to Dr. Chan; and R01 CA151993, to Dr. Ogino),
the Bennett Family Fund for Targeted Therapies Research, and the
Entertainment Industry Foundation through the National Colorectal Cancer
Research Alliance; by the Frank Knox Memorial Fellowship at Harvard
University and a fellowship from the Chief Scientist Office, Scotland
(to Dr. Lochhead); and by a Damon Runyon Clinical Investigator Award (to
Dr. Chan).
NR 40
TC 320
Z9 333
U1 5
U2 41
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 25
PY 2012
VL 367
IS 17
BP 1596
EP 1606
DI 10.1056/NEJMoa1207756
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024TO
UT WOS:000310131700006
PM 23094721
ER
PT J
AU Weeks, JC
Catalano, PJ
Cronin, A
Finkelman, MD
Mack, JW
Keating, NL
Schrag, D
AF Weeks, Jane C.
Catalano, Paul J.
Cronin, Angel
Finkelman, Matthew D.
Mack, Jennifer W.
Keating, Nancy L.
Schrag, Deborah
TI Patients' Expectations about Effects of Chemotherapy for Advanced Cancer
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CELL LUNG-CANCER; ADVANCED COLORECTAL-CANCER; CARE OUTCOMES RESEARCH;
QUALITY-OF-LIFE; SURVEILLANCE CONSORTIUM; MULTIPLE IMPUTATION;
RANDOMIZED-TRIAL; PALLIATIVE CARE; SUPPORTIVE CARE; TREATMENT GOALS
AB Background
Chemotherapy for metastatic lung or colorectal cancer can prolong life by weeks or months and may provide palliation, but it is not curative.
Methods
We studied 1193 patients participating in the Cancer Care Outcomes Research and Surveillance (CanCORS) study (a national, prospective, observational cohort study) who were alive 4 months after diagnosis and received chemotherapy for newly diagnosed metastatic (stage IV) lung or colorectal cancer. We sought to characterize the prevalence of the expectation that chemotherapy might be curative and to identify the clinical, sociodemographic, and health-system factors associated with this expectation. Data were obtained from a patient survey by professional interviewers in addition to a comprehensive review of medical records.
Results
Overall, 69% of patients with lung cancer and 81% of those with colorectal cancer did not report understanding that chemotherapy was not at all likely to cure their cancer. In multivariable logistic regression, the risk of reporting inaccurate beliefs about chemotherapy was higher among patients with colorectal cancer, as compared with those with lung cancer (odds ratio, 1.75; 95% confidence interval [CI], 1.29 to 2.37); among nonwhite and Hispanic patients, as compared with non-Hispanic white patients (odds ratio for Hispanic patients, 2.82; 95% CI, 1.51 to 5.27; odds ratio for black patients, 2.93; 95% CI, 1.80 to 4.78); and among patients who rated their communication with their physician very favorably, as compared with less favorably (odds ratio for highest third vs. lowest third, 1.90; 95% CI, 1.33 to 2.72). Educational level, functional status, and the patient's role in decision making were not associated with such inaccurate beliefs about chemotherapy.
Conclusions
Many patients receiving chemotherapy for incurable cancers may not understand that chemotherapy is unlikely to be curative, which could compromise their ability to make informed treatment decisions that are consonant with their preferences. Physicians may be able to improve patients' understanding, but this may come at the cost of patients' satisfaction with them. (Funded by the National Cancer Institute and others.)
C1 [Weeks, Jane C.; Cronin, Angel; Schrag, Deborah] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Catalano, Paul J.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Mack, Jennifer W.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Finkelman, Matthew D.] Tufts Univ, Sch Dent Med, Dept Publ Hlth & Community Serv, Boston, MA 02111 USA.
[Keating, Nancy L.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Keating, Nancy L.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Weeks, JC (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM jane_weeks@dfci.harvard.edu
FU National Cancer Institute (NCI) [U01 CA093344]; NCI; Dana-Farber Cancer
Institute/Cancer Research Network [U01 CA093332]; Harvard Medical
School/Northern California Cancer Center [U01 CA093324, RAND/UCLA U01
CA093348]; University of Alabama at Birmingham [U01 CA093329];
University of Iowa [U01 CA093339]; University of North Carolina [U01
CA093326]; Department of Veterans Affairs [CRS 02-164]
FX Supported by grants from the National Cancer Institute (NCI) to the
Statistical Coordinating Center (U01 CA093344) and the NCI-supported
Primary Data Collection and Research Centers, Dana-Farber Cancer
Institute/Cancer Research Network (U01 CA093332), Harvard Medical
School/Northern California Cancer Center (U01 CA093324, RAND/UCLA U01
CA093348), University of Alabama at Birmingham (U01 CA093329),
University of Iowa (U01 CA093339), and University of North Carolina (U01
CA093326); and by a Department of Veterans Affairs grant to the Durham
Veterans Affairs Medical Center (CRS 02-164).
NR 39
TC 295
Z9 297
U1 9
U2 54
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 25
PY 2012
VL 367
IS 17
BP 1616
EP 1625
DI 10.1056/NEJMoa1204410
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024TO
UT WOS:000310131700008
PM 23094723
ER
PT J
AU Pallais, JC
Blake, MA
Deshpande, V
AF Pallais, J. Carl
Blake, Michael A.
Deshpande, Vikram
TI Case 33-2012: A 34-Year-Old Woman with Episodic Paresthesias and Altered
Mental Status after Childbirth Pancreatic neuroendocrine neoplasm, grade
1 (insulinoma)
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID PERIPHERAL GLUCOSE-UPTAKE; HYPOGLYCEMIC DISORDERS; MANAGEMENT;
DIAGNOSIS; TUMORS; UNAWARENESS; MECHANISMS; PHYSIOLOGY; PREGNANCY; WOMEN
C1 [Pallais, J. Carl] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Blake, Michael A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Pallais, J. Carl] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Blake, Michael A.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Deshpande, Vikram] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Pallais, JC (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 35
TC 1
Z9 1
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 25
PY 2012
VL 367
IS 17
BP 1637
EP 1646
DI 10.1056/NEJMcpc1114037
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024TO
UT WOS:000310131700012
PM 23094726
ER
PT J
AU Hoffmann, U
Peacock, WF
Udelson, JE
AF Hoffmann, Udo
Peacock, W. Frank
Udelson, James E.
TI Coronary CT Angiography for Acute Chest Pain REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Hoffmann, Udo] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Peacock, W. Frank] Baylor Coll Med, Houston, TX 77030 USA.
[Udelson, James E.] Tufts Med Ctr, Boston, MA USA.
RP Hoffmann, U (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM uhoffmann@partners.org
NR 3
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 25
PY 2012
VL 367
IS 17
BP 1666
EP 1666
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024TO
UT WOS:000310131700025
ER
PT J
AU Gala, MK
AF Gala, Manish K.
TI Case 23-2012: A Man with Abdominal Pain and Weight Loss Reply
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Gala, MK (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 25
PY 2012
VL 367
IS 17
BP 1671
EP 1672
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024TO
UT WOS:000310131700035
ER
PT J
AU Ugai, H
Dobbins, GC
Wang, MH
Le, LP
Matthews, DA
Curiel, DT
AF Ugai, Hideyo
Dobbins, George C.
Wang, Minghui
Le, Long P.
Matthews, David A.
Curiel, David T.
TI Adenoviral protein V promotes a process of viral assembly through
nucleophosmin 1
SO VIROLOGY
LA English
DT Article
DE Adenovirus; Adenoviral assembly; Cancer gene therapy; Nucleophosmin 1;
Protein V
ID NUCLEOLAR PROTEIN; NUCLEAR-MATRIX; DNA-REPLICATION; GENE-EXPRESSION;
NUCLEOPROTEIN CORES; ATM ACTIVATION; INFECTED-CELLS; RIBOSOMAL-RNA;
MINUTE VIRUS; IN-VIVO
AB Adenoviral infection induces nucleoplasmic redistribution of a nucleolar nucleophosmin 1/NPM1/B23.1. NPM1 is preferentially localized in the nucleoli of normal cells, whereas it is also present at the nuclear matrix in cancer cells. However, the biological roles of NPM1 during infection are unknown. Here, by analyzing a pV-deletion mutant, Ad5-dV/TSB, we demonstrate that pV promotes the NPM1 translocation from the nucleoli to the nucleoplasm in normal cells, and the NPM1 translocation is correlated with adenoviral replication. Lack of pV causes a dramatic reduction of adenoviral replication in normal cells, but not cancer cells, and Ad5-dV/TSB was defective in viral assembly in normal cells. NPM1 knockdown inhibits adenoviral replication, suggesting an involvement of NPM1 in adenoviral biology. Further, we show that NPM1 interacts with empty adenovirus particles which are an intermediate during virion maturation by immunoelectron microscopy. Collectively, these data implicate that pV participates in a process of viral assembly through NPM1. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Ugai, Hideyo; Dobbins, George C.; Wang, Minghui; Curiel, David T.] Univ Alabama Birmingham, Dept Med, Div Human Gene Therapy, Birmingham, AL 35294 USA.
[Ugai, Hideyo; Dobbins, George C.; Wang, Minghui; Curiel, David T.] Univ Alabama Birmingham, Dept Obstet & Gynecol, Div Human Gene Therapy, Birmingham, AL 35294 USA.
[Ugai, Hideyo; Dobbins, George C.; Wang, Minghui; Curiel, David T.] Univ Alabama Birmingham, Dept Pathol, Div Human Gene Therapy, Birmingham, AL 35294 USA.
[Ugai, Hideyo; Dobbins, George C.; Wang, Minghui; Curiel, David T.] Univ Alabama Birmingham, Dept Surg, Div Human Gene Therapy, Birmingham, AL 35294 USA.
[Curiel, David T.] Univ Alabama Birmingham, Gene Therapy Ctr, Birmingham, AL 35294 USA.
[Le, Long P.] Massachusetts Gen Hosp, Pathol Serv, Boston, MA 02114 USA.
[Matthews, David A.] Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England.
RP Curiel, DT (reprint author), Washington Univ, Sch Med, Dept Radiat Oncol, Div Canc Biol, St Louis, MO 63108 USA.
EM dcuriel@radonc.wustl.edu
OI Matthews, David/0000-0003-4611-8795
FU Susan G. Komen for the Cure [PDF0707736, KG100194]; Wellcome Trust
[083604]; National Institutes of Health [T32-NS048039, R01CA121187]
FX We thank Dr. Roger Y. Tsien (University of California at San Diego) for
providing the mRFP1 construct, and Drs A. J. Levine (The Cancer
Institute of New Jersey), W. S. M. Wold (St. Louis University), T. Shenk
(Princeton University) for providing antibodies against adenoviral
proteins. We are also grateful to Drs. Melissa F. Chimento and Olga
Borkhsenious for technical support with transmission electron microscopy
at the High Resolution Imaging Facility in University of Alabama at
Birmingham and School of Veterinary Medicine Microscopy Center in
Louisiana State University, respectively. This work was supported by
grants from Susan G. Komen for the Cure PDF0707736 (Dr. Hideyo Ugai),
Susan G. Komen for the Cure KG100194 (Drs. David T. Curiel and Hideyo
Ugai), Grant number 083604 from the Wellcome Trust (Dr. David A
Matthews), grant T32-NS048039 from the National Institutes of Health
(Dr. George C Dobbins), and grant R01CA121187 from the National
Institutes of Health (Dr. David T. Curiel).
NR 77
TC 10
Z9 11
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD OCT 25
PY 2012
VL 432
IS 2
BP 283
EP 295
DI 10.1016/j.virol.2012.05.028
PG 13
WC Virology
SC Virology
GA 996UZ
UT WOS:000308121600006
PM 22717133
ER
PT J
AU Gebregziabher, M
Egede, L
Gilbert, GE
Hunt, K
Nietert, PJ
Mauldin, P
AF Gebregziabher, Mulugeta
Egede, Leonard
Gilbert, Gregory E.
Hunt, Kelly
Nietert, Paul J.
Mauldin, Patrick
TI Fitting parametric random effects models in very large data sets with
application to VHA national data
SO BMC MEDICAL RESEARCH METHODOLOGY
LA English
DT Article
DE Generalized linear mixed model; Homogeneity; Random effect meta
regression; Longitudinal data; Very large dataset
ID LINEAR MIXED MODELS; METAANALYSIS; REGRESSION; INFERENCE; TRIALS
AB Background: With the current focus on personalized medicine, patient/subject level inference is often of key interest in translational research. As a result, random effects models (REM) are becoming popular for patient level inference. However, for very large data sets that are characterized by large sample size, it can be difficult to fit REM using commonly available statistical software such as SAS since they require inordinate amounts of computer time and memory allocations beyond what are available preventing model convergence. For example, in a retrospective cohort study of over 800,000 Veterans with type 2 diabetes with longitudinal data over 5 years, fitting REM via generalized linear mixed modeling using currently available standard procedures in SAS (e. g. PROC GLIMMIX) was very difficult and same problems exist in Stata's gllamm or R's lme packages. Thus, this study proposes and assesses the performance of a meta regression approach and makes comparison with methods based on sampling of the full data.
Data: We use both simulated and real data from a national cohort of Veterans with type 2 diabetes (n=890,394) which was created by linking multiple patient and administrative files resulting in a cohort with longitudinal data collected over 5 years.
Methods and results: The outcome of interest was mean annual HbA1c measured over a 5 years period. Using this outcome, we compared parameter estimates from the proposed random effects meta regression (REMR) with estimates based on simple random sampling and VISN (Veterans Integrated Service Networks) based stratified sampling of the full data. Our results indicate that REMR provides parameter estimates that are less likely to be biased with tighter confidence intervals when the VISN level estimates are homogenous.
Conclusion: When the interest is to fit REM in repeated measures data with very large sample size, REMR can be used as a good alternative. It leads to reasonable inference for both Gaussian and non-Gaussian responses if parameter estimates are homogeneous across VISNs.
C1 [Gebregziabher, Mulugeta; Egede, Leonard; Gilbert, Gregory E.; Hunt, Kelly; Mauldin, Patrick] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
[Gebregziabher, Mulugeta; Hunt, Kelly; Nietert, Paul J.] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Egede, Leonard] Med Univ S Carolina, Ctr Hlth Dispar Res, Div Gen Internal Med, Charleston, SC 29425 USA.
[Mauldin, Patrick] Med Univ S Carolina, Dept Clin Pharm & Outcome Sci, Charleston, SC 29425 USA.
RP Gebregziabher, M (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Diverse Populat, Charleston, SC USA.
EM gebregz@musc.edu
RI Gilbert, Gregory/C-7735-2016;
OI Gilbert, Gregory/0000-0003-0879-5496; Nietert, Paul/0000-0002-3933-4986;
Gebregziabher, Mulugeta/0000-0002-4826-481X
FU Veterans Health Administration Health Services Research and Development
(HSRD) program [REA 08-261]
FX This work was supported, by the Veterans Health Administration Health
Services Research and Development (HSR&D) program [grant #REA 08-261,
Center for Disease Prevention and Health Interventions for Diverse
Populations]. The funding agency did not participate in the design and
conduct of the study; collection, management, analysis, and
interpretation of the data; or preparation, review, and approval of the
manuscript.
NR 51
TC 2
Z9 2
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2288
J9 BMC MED RES METHODOL
JI BMC Med. Res. Methodol.
PD OCT 24
PY 2012
VL 12
AR 163
DI 10.1186/1471-2288-12-163
PG 14
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA 071GG
UT WOS:000313577700001
PM 23095325
ER
PT J
AU Nasr, S
Tootell, RBH
AF Nasr, Shahin
Tootell, Roger B. H.
TI A Cardinal Orientation Bias in Scene-Selective Visual Cortex
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID PERCEPTION; PARAHIPPOCAMPAL; DISCRIMINATION; ROLES
AB It has long been known that human vision is more sensitive to contours at cardinal (horizontal and vertical) orientations, compared with oblique orientations; this is the "oblique effect." However, the real-world relevance of the oblique effect is not well understood. Experiments here suggest that this effect is linked to scene perception, via a common bias in the image statistics of scenes. This statistical bias for cardinal orientations is found in many "carpentered environments" such as buildings and indoor scenes, and some natural scenes. In Experiment 1, we confirmed the presence of a perceptual oblique effect in a specific set of scene stimuli. Using those scenes, we found that a well known "scene-selective" visual cortical area (the parahippocampal place area; PPA) showed distinctively higher functional magnetic resonance imaging (fMRI) activity to cardinal versus oblique orientations. This fMRI-based oblique effect was not observed in other cortical areas (including scene-selective areas transverse occipital sulcus and retrosplenial cortex), although all three scene-selective areas showed the expected inversion effect to scenes. Experiments 2 and 3 tested for an analogous selectivity for cardinal orientations using computer-generated arrays of simple squares and line segments, respectively. The results confirmed the preference for cardinal orientations in PPA, thus demonstrating that the oblique effect can also be produced in PPA by simple geometrical images, with statistics similar to those in scenes. Thus, PPA shows distinctive fMRI selectivity for cardinal orientations across a broad range of stimuli, which may reflect a perceptual oblique effect.
C1 [Nasr, Shahin; Tootell, Roger B. H.] Massachusetts Gen Hosp, Athinioula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Tootell, Roger B. H.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Tootell, Roger B. H.] NIMH, Lab Brain & Cognit, Bethesda, MD 20892 USA.
RP Nasr, S (reprint author), Massachusetts Gen Hosp, Athinioula A Martinos Ctr Biomed Imaging, 149 13th St, Charlestown, MA 02129 USA.
EM shahin@nmr.mgh.harvard.edu
FU NIH [R01 MH67529, R01 EY017081]; Martinos Center for Biomedical Imaging;
National Center for Research Resources; MIND Institute; NIMH Intramural
Research Program
FX This study was supported by NIH Grants R01 MH67529 and R01 EY017081 to
R. B. H. T., the Martinos Center for Biomedical Imaging, the National
Center for Research Resources, the MIND Institute, and the NIMH
Intramural Research Program. We thank Ali Amin-Mansour for help with
data collection, and Dr. Dara Manoach for support measuring eye
movements.
NR 25
TC 27
Z9 27
U1 4
U2 17
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 24
PY 2012
VL 32
IS 43
BP 14921
EP 14926
DI 10.1523/JNEUROSCI.2036-12.2012
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 029VD
UT WOS:000310523900009
PM 23100415
ER
PT J
AU Hashimoto, T
Serrano-Pozo, A
Hori, Y
Adams, KW
Takeda, S
Banerji, AO
Mitani, A
Joyner, D
Thyssen, DH
Bacskai, BJ
Frosch, MP
Spires-Jones, TL
Finn, MB
Holtzman, DM
Hyman, BT
AF Hashimoto, Tadafumi
Serrano-Pozo, Alberto
Hori, Yukiko
Adams, Kenneth W.
Takeda, Shuko
Banerji, Adrian Olaf
Mitani, Akinori
Joyner, Daniel
Thyssen, Diana H.
Bacskai, Brian J.
Frosch, Matthew P.
Spires-Jones, Tara L.
Finn, Mary Beth
Holtzman, David M.
Hyman, Bradley T.
TI Apolipoprotein E, Especially Apolipoprotein E4, Increases the
Oligomerization of Amyloid beta Peptide
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID FAMILIAL ALZHEIMER-DISEASE; GENOME-WIDE ASSOCIATION; A-BETA; MOUSE
MODEL; SYNAPTIC PLASTICITY; IDENTIFIES VARIANTS; FIBRIL FORMATION;
PLAQUE-FORMATION; TYPE-4 ALLELE; APOE
AB Alzheimer's disease (AD) is the most common progressive neurodegenerative disorder causing dementia. Massive deposition of amyloid beta peptide (A beta) as senile plaques in the brain is the pathological hallmark of AD, but oligomeric, soluble forms of A beta have been implicated as the synaptotoxic component. The apolipoprotein E epsilon 4 (apoE epsilon 4) allele is known to be a genetic risk factor for developing AD. However, it is still unknown how apoE impacts the process of A beta oligomerization. Here, we found that the level of A beta oligomers in APOE epsilon 4/epsilon 4AD patient brains is 2.7 times higher than those in APOE epsilon 3/epsilon 3 AD patient brains, matched for total plaque burden, suggesting that apoE4 impacts the metabolism of A beta oligomers. To test this hypothesis, we examined the effect of apoE on A beta oligomer formation. Using both synthetic A beta and a split-luciferase method for monitoring A beta oligomers, we observed that apoE increased the level of A beta oligomers in an isoform-dependent manner (E2 < E3 < E4). This effect appears to be dependent on the ApoE C-terminal domain. Moreover, these results were confirmed using endogenous apoE isolated from the TBS-soluble fraction of human brain, which increased the formation of A beta oligomers. Together, these data show that lipidated apoE, especially apoE4, increases A beta oligomers in the brain. Higher levels of A beta oligomers in the brains of APOE epsilon 4/epsilon 4 carriers compared with APOE epsilon 3/epsilon 3 carriers may increase the loss of dendritic spines and accelerate memory impairments, leading to earlier cognitive decline in AD.
C1 [Hashimoto, Tadafumi; Serrano-Pozo, Alberto; Hori, Yukiko; Adams, Kenneth W.; Takeda, Shuko; Banerji, Adrian Olaf; Mitani, Akinori; Joyner, Daniel; Thyssen, Diana H.; Bacskai, Brian J.; Frosch, Matthew P.; Spires-Jones, Tara L.; Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Unit, Charlestown, MA 02129 USA.
[Finn, Mary Beth; Holtzman, David M.] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, Hope Ctr Neurol Disorders,Dept Neurol, St Louis, MO 63110 USA.
RP Hyman, BT (reprint author), Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Unit, Bldg 114,16th St, Charlestown, MA 02129 USA.
EM bhyman@partners.org
RI Hashimoto, Tadafumi/A-7723-2013; SERRANO-POZO, ALBERTO/F-5119-2013
FU NIH [AG12406, AG13956, AG033670]; Ellison Medical Foundation/AFAR
[2009A059868]; Fundacion Alfonso Martin Escudero; Massachusetts
Alzheimer's Disease Research Center [P50 AG005134]
FX This work was supported by NIH Grants AG12406 (B. T. H.), AG13956 (D. M.
H.), and AG033670 (T.L.S.-J.), Ellison Medical Foundation/AFAR Grant
2009A059868 (T. H.), Fundacion Alfonso Martin Escudero (A. S.-P.), and
P50 AG005134 (Massachusetts Alzheimer's Disease Research Center). We
thank Drs. Zhanyun Fan and Pamela J. McLean for the construction of
split-luciferase-tagged A beta cDNA plasmids. We also thank Dr. Eloise
Hudry and Dr. Robert M. Koffie for valuable discussion.
NR 43
TC 63
Z9 65
U1 0
U2 35
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 24
PY 2012
VL 32
IS 43
BP 15181
EP 15192
DI 10.1523/JNEUROSCI.1542-12.2012
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 029VD
UT WOS:000310523900033
PM 23100439
ER
PT J
AU Lee, E
Hooker, JM
Ritter, T
AF Lee, Eunsung
Hooker, Jacob M.
Ritter, Tobias
TI Nickel-Mediated Oxidative Fluorination for PET with Aqueous [F-18]
Fluoride
SO JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY
AB A one-step oxidative fluorination for carbon-fluorine bond formation from well-defined nickel complexes with oxidant and aqueous fluoride is presented, which enables a straightforward and practical F-18 late-stage fluorination of complex small molecules with potential for PET imaging.
C1 [Lee, Eunsung; Ritter, Tobias] Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA.
[Hooker, Jacob M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Hooker, Jacob M.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Hooker, Jacob M.; Ritter, Tobias] Massachusetts Gen Hosp, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
RP Ritter, T (reprint author), Harvard Univ, Dept Chem & Chem Biol, 12 Oxford St, Cambridge, MA 02138 USA.
EM ritter@chemistry.harvard.edu
RI Lee, Eunsung/F-5308-2013;
OI Hooker, Jacob/0000-0002-9394-7708
FU NIH-NIGMS [GM088237]; NIH-NIBIB [EB013042]; [S10RR017208]
FX Funding was provided by NIH-NIGMS (GM088237) and NIH-NIBIB (EB013042),
as well as for a shared instrument grant (S10RR017208). We thank Dr. A.
Kamlet for the synthesis of material used to prepare [18F]2h.
We thank S.-L. Zheng (Harvard) for X-ray crystallographic analysis. We
thank S. Carlin (Massachusetts General Hospital) for technical
assistance with [18F]fluoride. TR is a Sloan fellow, a Lilly
Grantee, an Amgen Young Investigator, a Camille Dreyfus Teacher-Scholar,
and an AstraZeneca Awardee.
NR 23
TC 125
Z9 125
U1 6
U2 118
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0002-7863
J9 J AM CHEM SOC
JI J. Am. Chem. Soc.
PD OCT 24
PY 2012
VL 134
IS 42
BP 17456
EP 17458
DI 10.1021/ja3084797
PG 3
WC Chemistry, Multidisciplinary
SC Chemistry
GA 024IV
UT WOS:000310103800032
PM 23061667
ER
PT J
AU He, CW
Qu, XY
Wan, JB
Rong, R
Huang, LL
Cai, C
Zhou, KY
Gu, Y
Qian, SY
Kang, JX
AF He, Chengwei
Qu, Xiying
Wan, Jianbo
Rong, Rong
Huang, Lili
Cai, Chun
Zhou, Keyuan
Gu, Yan
Qian, Steven Y.
Kang, Jing X.
TI Inhibiting Delta-6 Desaturase Activity Suppresses Tumor Growth in Mice
SO PLOS ONE
LA English
DT Article
ID POLYUNSATURATED FATTY-ACIDS; PROSTATE-CANCER; TRANSGENIC MICE; CHRONIC
DISEASES; LIPID MEDIATORS; GENE-EXPRESSION; FAT-1 MICE; IN-VIVO;
ANGIOGENESIS; ACTIVATION
AB Recent studies have shown that a tumor-supportive microenvironment is characterized by high levels of pro-inflammatory and pro-angiogenic eicosanoids derived from omega-6 (n-6) arachidonic acid (AA). Although the metabolic pathways (COX, LOX, and P450) that generate these n-6 AA eicosanoids have been targeted, the role of endogenous AA production in tumorigenesis remains unexplored. Delta-6 desaturase (D6D) is the rate-limiting enzyme responsible for the synthesis of n-6 AA and increased D6D activity can lead to enhanced n-6 AA production. Here, we show that D6D activity is upregulated during melanoma and lung tumor growth and that suppressing D6D activity, either by RNAi knockdown or a specific D6D inhibitor, dramatically reduces tumor growth. Accordingly, the content of AA and AA-derived tumor-promoting metabolites is significantly decreased. Angiogenesis and inflammatory status are also reduced. These results identify D6D as a key factor for tumor growth and as a potential target for cancer therapy and prevention.
C1 [He, Chengwei; Qu, Xiying; Wan, Jianbo; Rong, Rong; Huang, Lili; Kang, Jing X.] Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA.
[He, Chengwei; Qu, Xiying; Wan, Jianbo; Rong, Rong; Huang, Lili; Kang, Jing X.] Harvard Univ, Sch Med, Boston, MA USA.
[Cai, Chun; Zhou, Keyuan; Kang, Jing X.] Guangdong Med Coll, Lab Genet Nutr & Hlth, Zhanjiang, Guangdong, Peoples R China.
[Gu, Yan; Qian, Steven Y.] N Dakota State Univ, Dept Pharmaceut Sci, Fargo, ND 58105 USA.
[He, Chengwei] Univ Macau, Inst Chinese Med Sci, State Key Lab Qual Res Chinese Med UM, Taipa, Macao Sar, Peoples R China.
RP Kang, JX (reprint author), Massachusetts Gen Hosp, Dept Med, Lab Lipid Med & Technol, Boston, MA 02114 USA.
EM jxkang@partners.org
RI Wan, Jian-Bo/D-8368-2014
OI Wan, Jian-Bo/0000-0002-6750-2617
FU National Institutes of Health [CA113605]
FX This work was supported by National Institutes of Health grant CA113605
to JXK. No additional external funding was received for this study. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 48
TC 14
Z9 15
U1 2
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2012
VL 7
IS 10
AR e47567
DI 10.1371/journal.pone.0047567
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026VC
UT WOS:000310310200052
PM 23112819
ER
PT J
AU Shah, SJ
Krumholz, HM
Reid, KJ
Rathore, SS
Mandawat, A
Spertus, JA
Ross, JS
AF Shah, Sachin J.
Krumholz, Harlan M.
Reid, Kimberly J.
Rathore, Saif S.
Mandawat, Aditya
Spertus, John A.
Ross, Joseph S.
TI Financial Stress and Outcomes after Acute Myocardial Infarction
SO PLOS ONE
LA English
DT Article
ID STABLE CORONARY-DISEASE; ARTERY-DISEASE; HEALTH-CARE; EVENTS; ANGINA;
WOMEN; HEART; PCI
AB Background: Little is known about the association between financial stress and health care outcomes. Our objective was to examine the association between self-reported financial stress during initial hospitalization and long-term outcomes after acute myocardial infarction (AMI).
Materials and Methods: We used Prospective Registry Evaluating Myocardial Infarction: Event and Recovery (PREMIER) data, an observational, multicenter US study of AMI patients discharged between January 2003 and June 2004. Primary outcomes were disease-specific and generic health status outcomes at 1 year (symptoms, function, and quality of life (QoL)), assessed by the Seattle Angina Questionnaire [SAQ] and Short Form [SF]-12. Secondary outcomes included 1-year rehospitalization and 4-year mortality. Hierarchical regression models accounted for patient socio-demographic, clinical, and quality of care characteristics, and access and barriers to care.
Results: Among 2344 AMI patients, 1241 (52.9%) reported no financial stress, 735 (31.4%) reported low financial stress, and 368 (15.7%) reported high financial stress. When comparing individuals reporting low financial stress to no financial stress, there were no significant differences in post-AMI outcomes. In contrast, individuals reporting high financial stress were more likely to have worse physical health (SF-12 PCS mean difference -3.24, 95% Confidence Interval [CI]: -4.82, -1.66), mental health (SF-12 MCS mean difference: -2.44, 95% CI: -3.83, -1.05), disease-specific QoL (SAQ QoL mean difference: -6.99, 95% CI: -9.59, -4.40), and be experiencing angina (SAQ Angina Relative Risk = 1.66, 95% CI: 1.19, 2.32) at 1 year post-AMI. While 1-year readmission rates were increased (Hazard Ratio = 1.50; 95% CI: 1.20, 1.86), 4-year mortality was no different.
Conclusions: High financial stress is common and an important risk factor for worse long-term outcomes post-AMI, independent of access and barriers to care.
C1 [Krumholz, Harlan M.; Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Fdn,Clin Scholars Program, New Haven, CT 06510 USA.
[Shah, Sachin J.; Rathore, Saif S.] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Sect Hlth Policy & Adm, New Haven, CT 06510 USA.
[Krumholz, Harlan M.] Yale Univ, Sch Med, Dept Med, Sect Cardiovasc Med, New Haven, CT 06510 USA.
[Reid, Kimberly J.; Spertus, John A.] St Lukes Hosp, Mid Amer Heart Inst, Dept Cardiol, Kansas City, MO 64111 USA.
[Mandawat, Aditya] Brigham & Womens Hosp, Dept Internal Med, Boston, MA 02115 USA.
[Spertus, John A.] Univ Missouri, Dept Cardiol, Kansas City, MO 64110 USA.
[Ross, Joseph S.] Yale Univ, Sch Med, Dept Med, Gen Internal Med Sect, New Haven, CT 06510 USA.
[Krumholz, Harlan M.; Ross, Joseph S.] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT 06504 USA.
RP Ross, JS (reprint author), Yale Univ, Sch Med, Dept Med, Robert Wood Johnson Fdn,Clin Scholars Program, New Haven, CT 06510 USA.
EM joseph.ross@yale.edu
FU Cardiovascular Therapeutics Inc, Palo Alto, Calif; Cardiovascular
Outcomes Inc, Kansas City; National Heart, Lung, and Blood Institute
Cardiovascular Outcomes Center Award [1U01HL105270-01]; National Center
for Research Resources [1UL1RR033179-01]; National Institute on Aging
[K08 AG032886]; American Federation for Aging Research through the Paul
B. Beeson Career Development Award Program; Medtronic, Inc.
FX This work was funded by Cardiovascular Therapeutics Inc, Palo Alto,
Calif., and Cardiovascular Outcomes Inc, Kansas City, Mo. Dr. Krumholz
is supported by a National Heart, Lung, and Blood Institute
Cardiovascular Outcomes Center Award (1U01HL105270-01). Dr. Spertus is
supported by the National Center for Research Resources
(1UL1RR033179-01). Dr. Ross is currently supported by the National
Institute on Aging (K08 AG032886) and by the American Federation for
Aging Research through the Paul B. Beeson Career Development Award
Program. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.; The
authors have read the journal's policy and have the following potential
conflicts of interest to disclose. Dr. Spertus reported that he had a
research grant from Cardiovascular Therapeutics Inc. to support PREMIER
and both Drs. Krumholz and Spertus were consultants for that company at
the time the PREMIER study was on-going. Drs. Krumholz and Ross
currently receive grant support from Medtronic, Inc. for work unrelated
to the PREMIER study. Dr. Krumholz reports that he chairs a scientific
advisory board for UnitedHealthcare. Dr. Spertus reports that he owns
the copyright to the Seattle Angina Questionnaire and is a member of a
scientific advisory board for UnitedHealthcare. Dr. Ross is a member of
a scientific advisory board for FAIR Health, Inc. This does not alter
the authors' adherence to all the PLOS ONE policies on sharing data and
materials.
NR 23
TC 8
Z9 8
U1 1
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 24
PY 2012
VL 7
IS 10
AR e47420
DI 10.1371/journal.pone.0047420
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026VC
UT WOS:000310310200038
PM 23112814
ER
PT J
AU Hansen, JE
Chan, G
Liu, YF
Hegan, DC
Dalal, S
Dray, E
Kwon, Y
Xu, YY
Xu, XH
Peterson-Roth, E
Geiger, E
Liu, YL
Gera, J
Sweasy, JB
Sung, P
Rockwell, S
Nishimura, RN
Weisbart, RH
Glazer, PM
AF Hansen, James E.
Chan, Grace
Liu, Yanfeng
Hegan, Denise C.
Dalal, Shibani
Dray, Eloise
Kwon, Youngho
Xu, Yuanyuan
Xu, Xiaohua
Peterson-Roth, Elizabeth
Geiger, Erik
Liu, Yilun
Gera, Joseph
Sweasy, Joann B.
Sung, Patrick
Rockwell, Sara
Nishimura, Robert N.
Weisbart, Richard H.
Glazer, Peter M.
TI Targeting Cancer with a Lupus Autoantibody
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID HOMOLOGY-DIRECTED REPAIR; DNA-DAMAGE; POLY(ADP-RIBOSE) POLYMERASE;
MAMMALIAN-CELLS; PROTEIN THERAPY; ERYTHEMATOSUS; RAD51; BRCA2;
INHIBITION; ANTIBODY
AB Systemic lupus erythematosus (SLE) is distinct among autoimmune diseases because of its association with circulating autoantibodies reactive against host DNA. The precise role that anti-DNA antibodies play in SLE pathophysiology remains to be elucidated, and potential applications of lupus autoantibodies in cancer therapy have not previously been explored. We report the unexpected finding that a cell-penetrating lupus autoantibody, 3E10, has potential as a targeted therapy for DNA repair-deficient malignancies. We find that 3E10 preferentially binds DNA single-strand tails, inhibits key steps in DNA single-strand and double-strand break repair, and sensitizes cultured tumor cells and human tumor xenografts to DNA-damaging therapy, including doxorubicin and radiation. Moreover, we demonstrate that 3E10 alone is synthetically lethal to BRCA2-deficient human cancer cells and selectively sensitizes such cells to low-dose doxorubicin. Our results establish an approach to cancer therapy that we expect will be particularly applicable to BRCA2-related malignancies such as breast, ovarian, and prostate cancers. In addition, our findings raise the possibility that lupus autoantibodies may be partly responsible for the intrinsic deficiencies in DNA repair and the unexpectedly low rates of breast, ovarian, and prostate cancers observed in SLE patients. In summary, this study provides the basis for the potential use of a lupus anti-DNA antibody in cancer therapy and identifies lupus autoantibodies as a potentially rich source of therapeutic agents.
C1 [Hansen, James E.; Liu, Yanfeng; Hegan, Denise C.; Dalal, Shibani; Peterson-Roth, Elizabeth; Geiger, Erik; Sweasy, Joann B.; Sung, Patrick; Rockwell, Sara; Glazer, Peter M.] Yale Univ, Sch Med, Dept Therapeut Radiol, New Haven, CT 06520 USA.
[Hansen, James E.; Sweasy, Joann B.; Sung, Patrick; Rockwell, Sara; Glazer, Peter M.] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA.
[Chan, Grace; Gera, Joseph; Nishimura, Robert N.; Weisbart, Richard H.] Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda, CA 91343 USA.
[Dray, Eloise; Kwon, Youngho; Xu, Yuanyuan; Sung, Patrick] Yale Univ, Dept Mol Biophys & Biochem, Sch Med, New Haven, CT 06520 USA.
[Xu, Xiaohua; Liu, Yilun] City Hope Natl Med Ctr, Beckman Res Inst, Div Radiat Biol, Duarte, CA 91010 USA.
[Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA.
[Sweasy, Joann B.] Univ Vermont, Dept Microbiol & Mol Genet, Burlington, VT 05405 USA.
[Sweasy, Joann B.; Glazer, Peter M.] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA.
[Rockwell, Sara] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA.
[Nishimura, Robert N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
RP Hansen, JE (reprint author), Yale Univ, Sch Med, Dept Therapeut Radiol, 333 Cedar St, New Haven, CT 06520 USA.
EM james.e.hansen@yale.edu; peter.glazer@yale.edu
RI Dray, Eloise/E-3938-2012; xu, xiaohua/D-1152-2011;
OI Dray, Eloise/0000-0001-6793-9838
FU Radiological Society of North America [RR1108]; Kalimeris Fund through
the Department of Therapeutic Radiology at Yale School of Medicine;
Women's Health Research at Yale Pilot Grant; U.S. Public Health Service
(USPHS) [1 RO1 NS066845-01, P01CA129186]; Veterans Affairs Merit Review
grant
FX This work was partially supported by Radiological Society of North
America Research Resident grant RR1108 (J.E.H.), the Kalimeris Fund
through the Department of Therapeutic Radiology at Yale School of
Medicine (J.E.H. and P.M.G.), a Women's Health Research at Yale Pilot
Grant (P.M.G.), U.S. Public Health Service (USPHS) grant 1 RO1
NS066845-01 (R.N.N.), a Veterans Affairs Merit Review grant (R.H.W.),
and USPHS grant P01CA129186 (P.M.G., J.B.S., P.S., and S.R.). Author
contributions: J.E.H. and P.M.G. conceived and designed the study,
analyzed the data, and wrote the paper. J.E.H., G.C., Yanfeng Liu,
D.C.H., S.D., E.D., Y.K., Y.X., X.X., E.P.-R., E.G., and R.H.W.
performed the experiments and analyzed the data. Yilun Liu, J.B.S., and
P.S. supervised the DNA binding and repair assays. J.G., S.R., and
R.N.N. supervised the xenograft experiments. Competing interests:
J.E.H., P.M.G., R.H. W., R.N.N., and G.C. are inventors on the patent
application PCT/US2012/031860, "Cell-Penetrating Anti-DNA Antibodies and
Uses Thereof to Inhibit DNA Repair." The other authors declare that they
have no competing financial interests. The 3E10 antibody and the 3E10
single chain Fv fragment were obtained by Yale University under a
material transfer agreement with the University of California, Los
Angeles.
NR 32
TC 16
Z9 16
U1 0
U2 12
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD OCT 24
PY 2012
VL 4
IS 157
AR 157ra142
DI 10.1126/scitranslmed.3004385
PG 8
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 028WM
UT WOS:000310455500004
PM 23100628
ER
PT J
AU Carroll, AE
Frakt, AB
AF Carroll, Aaron E.
Frakt, Austin B.
TI The Health Policy Election
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Carroll, Aaron E.] Indiana Univ Sch Med, Childrens Hlth Serv Res, Indianapolis, IN 46202 USA.
[Frakt, Austin B.] VA Boston Healthcare Syst, Dept Vet Affairs, Boston, MA USA.
[Frakt, Austin B.] Boston Univ, Boston, MA 02215 USA.
RP Carroll, AE (reprint author), Indiana Univ Sch Med, Childrens Hlth Serv Res, 410W10th St,HITS Bldg,Ste 1020, Indianapolis, IN 46202 USA.
EM aaecarro@iupui.edu
NR 6
TC 1
Z9 1
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0098-7484
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 24
PY 2012
VL 308
IS 16
BP 1633
EP 1634
DI 10.1001/jama.2012.13667
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 028PI
UT WOS:000310434100014
PM 23060272
ER
PT J
AU Volpp, KG
Loewenstein, G
Asch, DA
AF Volpp, Kevin G.
Loewenstein, George
Asch, David A.
TI Choosing Wisely Low-Value Services, Utilization, and Patient Cost
Sharing
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID INSURANCE DESIGN; COVERAGE; CARE
C1 [Volpp, Kevin G.; Asch, David A.] Univ Penn, Perelman Sch Med, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Loewenstein, George; Asch, David A.] Univ Penn, Perelman Sch Med, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, Dept Med, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Asch, David A.] Univ Penn, Dept Hlth Care Management, Wharton Sch, Philadelphia, PA 19104 USA.
[Volpp, Kevin G.; Asch, David A.] Penn Med Ctr Innovat, Philadelphia, PA USA.
[Loewenstein, George] Carnegie Mellon Univ, Pittsburgh, PA 15213 USA.
RP Volpp, KG (reprint author), Univ Penn, Perelman Sch Med, Ctr Hlth Equity Res & Promot, Philadelphia Vet Affairs Med Ctr, 1120 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.
EM volpp70@wharton.upenn.edu
OI Asch, David/0000-0002-7970-286X
FU NIA NIH HHS [P30 AG034546, RC2 AG036592, RC4 AG039114]
NR 7
TC 22
Z9 22
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 24
PY 2012
VL 308
IS 16
BP 1635
EP 1636
DI 10.1001/jama.2012.13616
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 028PI
UT WOS:000310434100015
PM 23093160
ER
PT J
AU Armstrong, E
Maddox, T
Carey, E
Grunwald, G
Shunk, K
AF Armstrong, Ehrin
Maddox, Thomas
Carey, Evan
Grunwald, Gary
Shunk, Kendrick
TI Very Late Stent Thrombosis is Associated with Lower Mortality than Early
Stent Thrombosis: A Report from the VHA CART Program
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Armstrong, Ehrin] Univ Calif Davis, Sacramento, CA USA.
[Maddox, Thomas; Carey, Evan; Grunwald, Gary] Univ Colorado, Denver, CO 80202 USA.
[Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B186
EP B186
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101429
ER
PT J
AU Elmariah, S
Inglessis, I
Rengifo, P
Margey, R
Baron, S
O'Callaghan, C
Cruz-Gonzalez, I
Demirjian, Z
Buonanno, F
Ning, MM
Silverman, S
Pomerantsev, E
Schainfeld, R
Dec, G
Palacios, I
AF Elmariah, Sammy
Inglessis, Ignacio
Rengifo, Pablo
Margey, Ronan
Baron, Suzanne
O'Callaghan, Caitlin
Cruz-Gonzalez, Ignacio
Demirjian, Zareh
Buonanno, Ferdinando
Ning, MingMing
Silverman, Scott
Pomerantsev, Eugene
Schainfeld, Robert
Dec, G.
Palacios, Igor
TI Long-term Outcomes After Transcatheter Closure of Patent Foramen Ovale
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Elmariah, Sammy; Inglessis, Ignacio; Rengifo, Pablo; Margey, Ronan; O'Callaghan, Caitlin; Demirjian, Zareh; Buonanno, Ferdinando; Ning, MingMing; Silverman, Scott; Pomerantsev, Eugene; Schainfeld, Robert; Dec, G.; Palacios, Igor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Cruz-Gonzalez, Ignacio] Hosp Univ Salamanca, Salamanca, Castilla, Spain.
[Cruz-Gonzalez, Ignacio] Hosp Univ Salamanca, Salamanca, Leon, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B226
EP B226
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101565
ER
PT J
AU Elmariah, S
Passeri, J
Hueter, I
Margey, R
Inglessis, I
Baker, J
Daher, M
Kodali, S
Mehrotra, P
Leon, M
Svensson, L
Agnihotri, A
Vlahakes, G
Pibarot, P
Douglas, P
Palacios, I
AF Elmariah, Sammy
Passeri, Jonathan
Hueter, Irene
Margey, Ronan
Inglessis, Ignacio
Baker, Joshua
Daher, Maureen
Kodali, Susheel
Mehrotra, Praveen
Leon, Martin
Svensson, Lars
Agnihotri, Arvind
Vlahakes, Gus
Pibarot, Philippe
Douglas, Pamela
Palacios, Igor
TI Relationship of Transcatheter and Surgical Aortic Valve Replacement with
Left Ventricular Function in High-Risk Patients with Aortic Stenosis
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Elmariah, Sammy; Passeri, Jonathan; Margey, Ronan; Inglessis, Ignacio; Baker, Joshua; Daher, Maureen; Agnihotri, Arvind; Vlahakes, Gus; Palacios, Igor] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Hueter, Irene; Kodali, Susheel; Leon, Martin] Columbia Univ, New York, NY USA.
[Svensson, Lars] Cleveland Clin, Cleveland, OH 44106 USA.
[Pibarot, Philippe] Univ Laval, Quebec Lung & Heart Inst, Quebec City, PQ, Canada.
[Douglas, Pamela] Duke Univ, Med Ctr, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B29
EP B29
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210100093
ER
PT J
AU Herrero-Garibi, J
Cruz-Gonzalez, I
Rengifo, P
Bounanno, F
Sanchez-Ledesma, M
Martin-Herrero, F
Palacios, I
AF Herrero-Garibi, Jesus
Cruz-Gonzalez, Ignacio
Rengifo, Pablo
Bounanno, Ferdinando
Sanchez-Ledesma, Maria
Martin-Herrero, Francisco
Palacios, Igor
TI Efficacy And Safety Of Percutaneous Patent Foramen Ovale Closure In
Patients With A Hypercoagulable Disorder
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Herrero-Garibi, Jesus] Univ Hosp Burgos, Burgos, Spain.
[Cruz-Gonzalez, Ignacio; Sanchez-Ledesma, Maria; Martin-Herrero, Francisco] Univ Hosp Salamanca, Salamanca, Spain.
[Rengifo, Pablo; Bounanno, Ferdinando] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Palacios, Igor] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B27
EP B27
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210100085
ER
PT J
AU Madder, R
Madden, S
Puri, R
Hendricks, M
Vanoosterhout, S
Sum, S
Kini, A
Sharma, S
Rizik, D
Brilakis, E
Shunk, K
Goldstein, J
Weisz, G
Virmani, R
Nicholls, S
Maehara, A
Mintz, G
Stone, G
Muller, J
AF Madder, Ryan
Madden, Sean
Puri, Rishi
Hendricks, Michael
Vanoosterhout, Stacie
Sum, Steve
Kini, Annapoorna
Sharma, Samin
Rizik, David
Brilakis, Emmanouil
Shunk, Kendrick
Goldstein, James
Weisz, Giora
Virmani, Renu
Nicholls, Stephen
Maehara, Akiko
Mintz, Gary
Stone, Gregg
Muller, James
TI Detection by Near-infrared Spectroscopy of Large Lipid Core Plaques at
Culprit Sites in Patients with Acute ST-Segment Elevation Myocardial
Infarction
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Madder, Ryan; Vanoosterhout, Stacie] Frederik Meijer Heart & Vasc Inst Spectrum Hlth, Grand Rapids, MI USA.
[Madden, Sean; Hendricks, Michael; Sum, Steve; Muller, James] Infraredx Inc, Burlington, MA USA.
[Puri, Rishi; Nicholls, Stephen] Cleveland Clin, Cleveland, OH 44106 USA.
[Kini, Annapoorna; Sharma, Samin] Mt Sinai Sch Med, New York, NY USA.
[Rizik, David] Scottsdale Healthcare Hosp, Scottsdale, AZ USA.
[Brilakis, Emmanouil] VA N Texas Healthcare Syst, Dallas, TX USA.
[Brilakis, Emmanouil] UT SW Med Ctr, Dallas, TX USA.
[Shunk, Kendrick] San Francisco VA Med Ctr, San Francisco, CA USA.
[Goldstein, James] Beaumont Hosp, Royal Oak, MI USA.
[Stone, Gregg] Columbia Univ, Med Ctr, New York, NY USA.
[Virmani, Renu] CVPath Inc, Gaithersburg, MD USA.
[Maehara, Akiko; Stone, Gregg] Cardiovasc Res Fdn, New York, NY USA.
[Mintz, Gary] CRF, Washington, DC USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B7
EP B7
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210100023
ER
PT J
AU Margey, R
Margey, R
Elmariah, S
Hynes, B
Renfigo-Moreno, P
Jaff, M
Schainfeld, R
Inglessis, I
Palacios, I
AF Margey, Ronan
Margey, Ronan
Elmariah, Sammy
Hynes, Brian
Renfigo-Moreno, Pablo
Jaff, Michael
Schainfeld, Robert
Inglessis, Ignacio
Palacios, Igor
TI Non-Cerebrovascular Systemic Arterial Embolic Events from Paradoxical
Embolization via Patent Foramen Ovale (PFO)
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Margey, Ronan; Margey, Ronan; Elmariah, Sammy; Hynes, Brian; Renfigo-Moreno, Pablo; Inglessis, Ignacio] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jaff, Michael; Palacios, Igor] Harvard Univ, Sch Med, Boston, MA USA.
[Schainfeld, Robert] Harvard Univ, Sch Med, Newton, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B226
EP B226
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101564
ER
PT J
AU Margey, R
Ridgway, H
Rullman, R
Spencer, J
Margey, R
McNulty, I
Mangla, A
Polena, S
Soffer, D
Jang, IK
AF Margey, Ronan
Ridgway, Helen
Rullman, Richard
Spencer, Jeff
Margey, Ronan
McNulty, Iris
Mangla, Aditya
Polena, Sotir
Soffer, Daniel
Jang, Ik-Kyung
TI Ecarin Clotting Time (ECT) more accurately reflects bivalirudin
concentration than Activated Clotting Time (ACT) in patients undergoing
Percutaneous Coronary Intervention using bivalirudin anticoagulation
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Margey, Ronan; Margey, Ronan; McNulty, Iris] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ridgway, Helen; Rullman, Richard; Spencer, Jeff] Helena Labs, Beaumont, TX USA.
[Mangla, Aditya; Soffer, Daniel] Lenox Hill Hosp, New York, NY 10021 USA.
[Polena, Sotir] Huntington Hosp, New York, NY USA.
[Jang, Ik-Kyung] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B219
EP B220
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101540
ER
PT J
AU Mauri, L
Steg, G
Matteau, A
Camenzind, E
Boersma, E
Vranckx, P
Serruys, P
O'Neill, W
Yeh, R
Wijns, W
AF Mauri, Laura
Steg, Gabriel
Matteau, Alexis
Camenzind, Edoardo
Boersma, Eric
Vranckx, Pascal
Serruys, Patrick
O'Neill, William
Yeh, Robert
Wijns, William
TI Individual and Regional Variations in Dual Antiplatelet Therapy Dose and
Duration in a Large, Randomized International Trial Comparing Two
Drug-eluting Stents: Results From PROTECT
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Mauri, Laura; Matteau, Alexis] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Mauri, Laura] Harvard Univ, Sch Med, Boston, MA USA.
[Steg, Gabriel] Hop Bichat Claude Bernard, F-75877 Paris, France.
[Camenzind, Edoardo] Univ Hosp Geneva, Geneva, Switzerland.
[Boersma, Eric; Serruys, Patrick] Erasmus MC, Thoraxctr, Rotterdam, Netherlands.
[Vranckx, Pascal] Hartctr Hasselt, Hasselt, Belgium.
[O'Neill, William] Leonard M Miller Sch Med, Miami, FL USA.
[Yeh, Robert] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Wijns, William] Cardiovasc Ctr Aalst, Aalst, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B216
EP B217
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101530
ER
PT J
AU Reed, G
Hoffman, E
Kumar, A
Maree, A
McLean, D
Buros, J
Aranki, S
Shekar, P
Agnihotri, A
Williams, L
Rosenfeld, K
Cannon, C
AF Reed, Grant
Hoffman, Elaine
Kumar, Amit
Maree, Andrew
McLean, Dalton
Buros, Jacki
Aranki, Sary
Shekar, Prem
Agnihotri, Arvind
Williams, Laura
Rosenfeld, Kenneth
Cannon, Christopher
TI Platelet Function Testing Predicts Bleeding In Patients Exposed To
Clopidogrel Undergoing Coronary Artery Bypass Grafting
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Reed, Grant; Hoffman, Elaine; Buros, Jacki; Aranki, Sary; Shekar, Prem; Williams, Laura; Cannon, Christopher] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kumar, Amit; Agnihotri, Arvind; Rosenfeld, Kenneth] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Maree, Andrew] Waterford Reg Hosp, Waterford City, Ireland.
[McLean, Dalton] LeBauer Hlth Care, Greensboro, NC USA.
NR 0
TC 1
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B210
EP B211
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101510
ER
PT J
AU Schlett, C
Maurovich-Horvat, P
Bamberg, F
Warger, W
Nakano, M
Tanaka, A
Vorpahl, M
Seifarth, H
Ferencik, M
Virmani, R
Tearney, G
Hoffmann, U
AF Schlett, Christopher
Maurovich-Horvat, Pal
Bamberg, Fabian
Warger, William
Nakano, Masataka
Tanaka, Atsushi
Vorpahl, Marc
Seifarth, Harald
Ferencik, Maros
Virmani, Renu
Tearney, Guillermo
Hoffmann, Udo
TI Value of Optical Coherence Tomography beyond the Napkin-Ring Sign in CT
Angiography for Detecting Coronary Lipid-Core Plaques as Determined by
Histology: A Multimodality Imaging Study in Human Donor Hearts
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Schlett, Christopher; Maurovich-Horvat, Pal; Warger, William; Tanaka, Atsushi; Seifarth, Harald; Ferencik, Maros; Tearney, Guillermo; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Bamberg, Fabian] Univ Munich, Hosp Grosshadern, Munich, Germany.
[Nakano, Masataka; Virmani, Renu] CVPath Inc, Gaithersburg, MD USA.
[Vorpahl, Marc] Univ Witten Herdecke, Helius Clin Wuppertal, Wuppertal, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B69
EP B69
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101043
ER
PT J
AU Scirica, B
Murphy, S
Karwatowska-Prokopczuk, E
Walker, G
Belardinelli, L
Ben-Yehuda, O
Morrow, D
AF Scirica, Benjamin
Murphy, Sabina
Karwatowska-Prokopczuk, Ewa
Walker, Gennyne
Belardinelli, Luiz
Ben-Yehuda, Ori
Morrow, David
TI Effects of ranolazine in patients with acute coronary syndrome and
stable angina according to whether they undergo percutaneous coronary
intervention: Observations from the MERLIN-TIMI 36 Trial
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Scirica, Benjamin; Murphy, Sabina; Morrow, David] Brigham & Womens Hospita, Dept Med, Div Cardiovasc, TIMI Study Grp, Boston, MA USA.
[Karwatowska-Prokopczuk, Ewa; Walker, Gennyne; Belardinelli, Luiz; Ben-Yehuda, Ori] Gilead Sci Inc, Forest City, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B210
EP B210
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101507
ER
PT J
AU Zeglin-Sawczuk, M
Jang, IK
Ashikaga, T
Kato, K
Yonetsu, T
Choi, SY
Kim, SJ
Kratlian, C
Lee, H
Dauerman, H
AF Zeglin-Sawczuk, Magdalena
Jang, Ik-Kyung
Ashikaga, Taka
Kato, Koji
Yonetsu, Taishi
Choi, So-Yeon
Kim, Soo Joong
Kratlian, Christina
Lee, Hang
Dauerman, Harold
TI Incidence and Characterization of Stent Dissections in Women Versus Men:
A Report from the Massachusetts General Hospital Optical Coherence
Tomography Registry
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Meeting Abstract
CT Transcatheter Cardiovascular Therapeutics (TCT) Symposium
CY OCT 22-26, 2012
CL Miami, FL
SP ACC
C1 [Zeglin-Sawczuk, Magdalena; Ashikaga, Taka; Dauerman, Harold] Univ Vermont, Burlington, VT USA.
[Jang, Ik-Kyung] Harvard Univ, Sch Med, Boston, MA USA.
[Kato, Koji; Yonetsu, Taishi; Choi, So-Yeon; Kim, Soo Joong; Kratlian, Christina; Lee, Hang] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
SU S
BP B71
EP B71
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025RM
UT WOS:000310210101049
ER
PT J
AU El-Haibi, CP
Bell, GW
Zhang, JW
Collmann, AY
Wood, D
Scherber, CM
Csizmadia, E
Mariani, O
Zhu, CH
Campagne, A
Toner, M
Bhatia, SN
Irimia, D
Vincent-Salomon, A
Karnoub, AE
AF El-Haibi, Christelle P.
Bell, George W.
Zhang, Jiangwen
Collmann, Anthony Y.
Wood, David
Scherber, Cally M.
Csizmadia, Eva
Mariani, Odette
Zhu, Cuihua
Campagne, Antoine
Toner, Mehmet
Bhatia, Sangeeta N.
Irimia, Daniel
Vincent-Salomon, Anne
Karnoub, Antoine E.
TI Critical role for lysyl oxidase in mesenchymal stem cell-driven breast
cancer malignancy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID TRANSITION; METASTASIS; TUMORS; BONE; HYALURONAN; GENERATION; CARCINOMA;
CD44
AB Mesenchymal stem cells (MSCs) are multipotent progenitor cells with the ability to differentiate into multiple mesoderm lineages in the course of normal tissue homeostasis or during injury. We have previously shown that MSCs migrate to sites of tumorigenesis, where they become activated by cancer cells to promote metastasis. However, the molecular and phenotypic attributes of the MSC-induced metastatic state of the cancer cells remained undetermined. Here, we show that bone marrow-derived human MSCs promote de novo production of lysyl oxidase (LOX) from human breast carcinoma cells, which is sufficient to enhance the metastasis of otherwise weakly metastatic cancer cells to the lungs and bones. We also show that LOX is an essential component of the CD44-Twist signaling axis, in which extracellular hyaluronan causes nuclear translocation of CD44 in the cancer cells, thus triggering LOX transcription by associating with its promoter. Processed and enzymatically active LOX, in turn, stimulates Twist transcription, which mediates the MSC-triggered epithelial-to-mesenchymal transition (EMT) of carcinoma cells. Surprisingly, although induction of EMT in breast cancer cells has been tightly associated with the generation of cancer stem cells, we find that LOX, despite being critical for EMT, does not contribute to the ability of MSCs to promote the formation of cancer stem cells in the carcinoma cell populations. Collectively, our studies highlight a critical role for LOX in cancer metastasis and indicate that the signaling pathways controlling stroma-induced EMT are distinct from pathways regulating the development of cancer stem cells.
C1 [El-Haibi, Christelle P.; Collmann, Anthony Y.; Zhu, Cuihua; Campagne, Antoine; Karnoub, Antoine E.] Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Pathol, Sch Med, Boston, MA 02215 USA.
[Bell, George W.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Zhang, Jiangwen] Harvard Univ, Fac Arts & Sci, Ctr Syst Biol, Cambridge, MA 02138 USA.
[Wood, David; Bhatia, Sangeeta N.] Harvard Massachusetts Inst Technol, Div Hlth Sci & Technol, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Scherber, Cally M.; Toner, Mehmet; Irimia, Daniel] Harvard Univ, Massachusetts Gen Hosp, Sch Med, BioMEMS Resource Ctr,Ctr Engn Med & Surg Serv, Boston, MA 02114 USA.
[Csizmadia, Eva] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA.
[Mariani, Odette; Campagne, Antoine; Vincent-Salomon, Anne] Inst Curie, Dept Pathol, F-75248 Paris 05, France.
RP Karnoub, AE (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Dept Pathol, Sch Med, Boston, MA 02215 USA.
EM akarnoub@bidmc.harvard.edu
RI Wood, David/P-1998-2015;
OI Wood, David/0000-0001-5225-2144; Irimia, Daniel/0000-0001-7347-2082
FU Texas A&M Health Science Center through National Institutes of Health
[P40RR017447]; Packard Foundation; National Institutes of Health
[R21CA135601]; Beth Israel Deaconess Medical Center; Sidney Kimmel
Cancer Research Foundation; Prostate and Breast Cancer Program of BIDMC;
Susan G. Komen for the Cure
FX We thank T. Chavarria, F. Reinhardt, and S. Malstrom for assistance in
animal studies; D. Louvard for helpful discussions; and R. Weinberg for
critical reading of the manuscript. BM-MSCs were provided by the Texas
A&M Health Science Center through National Institutes of Health Grant
P40RR017447. This work was supported by the Packard Foundation (S.N.B.),
National Institutes of Health Grant R21CA135601 (D. I.), Beth Israel
Deaconess Medical Center (A. E. K.), and the Sidney Kimmel Cancer
Research Foundation (A. E. K.). A. E. K. is a Kimmel Scholar, a
recipient of a Career Development Award from the Prostate and Breast
Cancer Program of BIDMC, and of a Career Catalyst Research Award from
Susan G. Komen for the Cure.
NR 38
TC 70
Z9 71
U1 0
U2 24
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 23
PY 2012
VL 109
IS 43
BP 17460
EP 17465
DI 10.1073/pnas.1206653109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AO
UT WOS:000311147800036
PM 23033492
ER
PT J
AU Kleinnijenhuis, J
Quintin, J
Preijers, F
Joosten, LAB
Ifrim, DC
Saeed, S
Jacobs, C
van Loenhout, J
de Jong, D
Stunnenberg, HG
Xavier, RJ
van der Meer, JWM
van Crevel, R
Netea, MG
AF Kleinnijenhuis, Johanneke
Quintin, Jessica
Preijers, Frank
Joosten, Leo A. B.
Ifrim, Daniela C.
Saeed, Sadia
Jacobs, Cor
van Loenhout, Joke
de Jong, Dirk
Stunnenberg, Hendrik G.
Xavier, Ramnik J.
van der Meer, Jos W. M.
van Crevel, Reinout
Netea, Mihai G.
TI Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection
from reinfection via epigenetic reprogramming of monocytes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE mycobacterium tuberculosis vaccine; innate immune memory
ID NATURAL-KILLER-CELLS; BCG VACCINATION; MYCOBACTERIUM-TUBERCULOSIS;
INFLAMMATORY RESPONSE; IMMUNE-RESPONSE; CHILD SURVIVAL; WEST-AFRICA;
BOVIS BCG; MICE; MEMORY
AB Adaptive features of innate immunity, recently described as "trained immunity," have been documented in plants, invertebrate animals, and mice, but not yet in humans. Here we show that bacille Calmette-Guerin (BCG) vaccination in healthy volunteers led not only to a four-to sevenfold increase in the production of IFN-gamma, but also to a twofold enhanced release of monocyte-derived cytokines, such as TNF and IL-1 beta, in response to unrelated bacterial and fungal pathogens. The enhanced function of circulating monocytes persisted for at least 3 mo after vaccination and was accompanied by increased expression of activation markers such as CD11b and Toll-like receptor 4. These training effects were induced through the NOD2 receptor and mediated by increased histone 3 lysine 4 trimethylation. In experimental studies, BCG vaccination induced T-and B-lymphocyte-independent protection of severe combined immunodeficiency SCID mice from disseminated candidiasis (100% survival in BCG-vaccinated mice vs. 30% in control mice). In conclusion, BCG induces trained immunity and nonspecific protection from infections through epigenetic reprogramming of innate immune cells.
C1 [Kleinnijenhuis, Johanneke; Quintin, Jessica; Joosten, Leo A. B.; Ifrim, Daniela C.; Jacobs, Cor; van der Meer, Jos W. M.; van Crevel, Reinout; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Dept Med, NL-6525 GA Nijmegen, Netherlands.
[Kleinnijenhuis, Johanneke; Quintin, Jessica; Joosten, Leo A. B.; Ifrim, Daniela C.; Jacobs, Cor; van der Meer, Jos W. M.; van Crevel, Reinout; Netea, Mihai G.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Inst Infect Inflammat & Immun N4i, NL-6525 GA Nijmegen, Netherlands.
[Preijers, Frank] Radboud Univ Nijmegen, Med Ctr, Dept Lab Med, Hematol Lab, NL-6525 GA Nijmegen, Netherlands.
[Saeed, Sadia; Stunnenberg, Hendrik G.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Fac Sci, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands.
[Saeed, Sadia; Stunnenberg, Hendrik G.] Radboud Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Fac Med, Dept Mol Biol, NL-6500 HB Nijmegen, Netherlands.
[van Loenhout, Joke] Publ Hlth Off GGD, Nijmegen, Netherlands.
[de Jong, Dirk] Radboud Univ Nijmegen, Med Ctr, Dept Gastroenterol, NL-6525 GA Nijmegen, Netherlands.
[Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Xavier, Ramnik J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Xavier, Ramnik J.] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA 02142 USA.
RP Netea, MG (reprint author), Radboud Univ Nijmegen, Med Ctr, Dept Med, NL-6525 GA Nijmegen, Netherlands.
EM M.Netea@aig.umcn.nl
RI van der Meer, Jos/C-8521-2013; Rivet, Catherine/M-7978-2014;
Stunnenberg, Hendrik/D-6875-2012; van Crevel, reinout/A-6636-2010;
Joosten, Leo/H-3138-2015; Netea, Mihai/N-5155-2014; Kleinnijenhuis,
Johanneke/P-6309-2015; Preijers, F.W.M.B./L-4586-2015; kleinnijenhuis,
johanneke/G-7978-2016
OI van der Meer, Jos/0000-0001-5120-3690;
FU Vici Grant from the Netherlands Organization for Scientific Research;
Vidi Grant from the Netherlands Organization for Scientific Research;
Higher Education Commission of Pakistan; European Seventh Framework
Programme ALLFun Project; US National Institutes of Health [AI 062773,
DK 043351, DK 83756]; Helmsley Trust
FX J.Q. and M.G.N. were supported by a Vici Grant from the Netherlands
Organization for Scientific Research (to M.G.N.). R. v. C. was supported
by a Vidi Grant from the Netherlands Organization for Scientific
Research. S. S. was supported by the Higher Education Commission of
Pakistan. D. C. I. was supported by the European Seventh Framework
Programme ALLFun Project. R.J.X. was supported by US National Institutes
of Health Grants AI 062773, DK 043351, and DK 83756 and the Helmsley
Trust.
NR 35
TC 208
Z9 208
U1 5
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 23
PY 2012
VL 109
IS 43
BP 17537
EP 17542
DI 10.1073/pnas.1202870109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AO
UT WOS:000311147800049
PM 22988082
ER
PT J
AU Huang, YH
Yuan, JP
Righi, E
Kamoun, WS
Ancukiewicz, M
Nezivar, J
Santosuosso, M
Martin, JD
Martin, MR
Vianello, F
Leblanc, P
Munn, LL
Huang, P
Duda, DG
Fukumura, D
Jain, RK
Poznansky, MC
AF Huang, Yuhui
Yuan, Jianping
Righi, Elda
Kamoun, Walid S.
Ancukiewicz, Marek
Nezivar, Jean
Santosuosso, Michael
Martin, John D.
Martin, Margaret R.
Vianello, Fabrizio
Leblanc, Pierre
Munn, Lance L.
Huang, Peigen
Duda, Dan G.
Fukumura, Dai
Jain, Rakesh K.
Poznansky, Mark C.
TI Vascular normalizing doses of antiangiogenic treatment reprogram the
immunosuppressive tumor microenvironment and enhance immunotherapy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE vascular normalization; hypoxia; myeloid-derived suppressor cell; tumor
tissue vaccine
ID THERAPEUTIC CANCER VACCINES; METASTATIC BREAST-CANCER; REGULATORY
T-CELLS; BEVACIZUMAB; PROGRESSION; GROWTH; SURVIVAL; MOUSE; BLOOD;
ANGIOGENESIS
AB The recent approval of a prostate cancer vaccine has renewed hope for anticancer immunotherapies. However, the immunosuppressive tumor microenvironment may limit the effectiveness of current immunotherapies. Antiangiogenic agents have the potential to modulate the tumor microenvironment and improve immunotherapy, but they often are used at high doses in the clinic to prune tumor vessels and paradoxically may compromise various therapies. Here, we demonstrate that targeting tumor vasculature with lower vascular-normalizing doses, but not high antivascular/antiangiogenic doses, of an anti-VEGF receptor 2 (VEGFR2) antibody results in a more homogeneous distribution of functional tumor vessels. Furthermore, lower doses are superior to the high doses in polarizing tumor-associated macrophages from an immune inhibitory M2-like phenotype toward an immune stimulatoryM1-like phenotype and in facilitating CD4(+) and CD8(+) T-cell tumor infiltration. Based on this mechanism, scheduling lower-dose anti-VEGFR2 therapy with T-cell activation induced by a whole cancer cell vaccine therapy enhanced anticancer efficacy in a CD8(+) T-cell-dependent manner in both immune-tolerant and immunogenic murine breast cancer models. These findings indicate that vascular-normalizing lower doses of anti-VEGFR2 antibody can reprogram the tumor microenvironment away from immunosuppression toward potentiation of cancer vaccine therapies. Given that the combinations of high doses of bevacizumab with chemotherapy have not improved overall survival of breast cancer patients, our study suggests a strategy to use antiangiogenic agents in breast cancer more effectively with active immunotherapy and potentially other anticancer therapies.
C1 [Huang, Yuhui; Kamoun, Walid S.; Ancukiewicz, Marek; Martin, John D.; Martin, Margaret R.; Munn, Lance L.; Huang, Peigen; Duda, Dan G.; Fukumura, Dai; Jain, Rakesh K.] Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
[Yuan, Jianping; Righi, Elda; Nezivar, Jean; Santosuosso, Michael; Vianello, Fabrizio; Leblanc, Pierre; Poznansky, Mark C.] Massachusetts Gen Hosp, Vaccine & Immunotherapy Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Edwin L Steele Lab Tumor Biol, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu
RI Munn, Lance/L-3950-2016; Martin, John/L-6892-2016; Vianello,
Fabrizio/M-5211-2016;
OI Munn, Lance/0000-0003-0698-7232; Martin, John/0000-0002-9828-8203;
Vianello, Fabrizio/0000-0002-7174-4651; Huang, Yuhui/0000-0003-1985-3575
FU Dyax; MedImmune; Roche; Enlight; Noxxon; SynDevRx; National Institutes
of Health [R01-CA115767, R01-CA126642, R01-CA096915, R21-CA139168,
R01-CA159258]; National Cancer Institutes Federal Share grant;
Department of Defense (DoD) Breast Cancer Innovator Award
[W81XWH-10-1-0016]; DoD Research Fellowship [W81XWH-11-1-0619]; Marsha
Rivkin Foundation; Friends of the Vaccine and Immunotherapy Center;
Frank Lynch Jr. Cancer Research Fund
FX R.K.J. received research grants from Dyax, MedImmune, and Roche;
consultant fees from Dyax, Enlight, Noxxon, and SynDevRx; owns equity in
Enlight, SynDevRx, and XTuit; and serves on the Board of Directors of
XTuit and Boards of Trustees of H&Q Healthcare Investors and H&Q Life
Sciences Investors. M.C.P. serves as a scientific adviser to
Evaxion-Biotech and owns equity in Celtaxsys. No reagents or funding
from these companies was used in this study. Therefore, there is no
significant financial or other competing interest in the work.; We thank
ImClone/Lilly for their gift of DC101; Glenn Dranoff for advice on
cancer vaccine preparation; Sylvie Roberge, Julia Kahn, Carolyn Smith,
Ned Kirkpatrick, Ramone Williams, Madzia Kowalski, Rachel Ingraham, and
Amy Yang for technical assistance; and Shom Goel, Vikash Chauhan,
Eleanor Ager, and Sergey Kozin for their helpful scientific input. This
work was supported by National Institutes of Health Grants R01-CA115767
and R01-CA126642 (to R.K.J.), R01-CA096915 (to D.F.), and R21-CA139168
and R01-CA159258 (to D.G.D.); a National Cancer Institutes Federal Share
grant (to M.C.P. and J.Y.); Department of Defense (DoD) Breast Cancer
Innovator Award W81XWH-10-1-0016 (to R.K.J.); DoD Research Fellowship
W81XWH-11-1-0619 (to Y.H.). This work was also supported by the Marsha
Rivkin Foundation (E.R. and M.C.P.), Friends of the Vaccine and
Immunotherapy Center, and the Frank Lynch Jr. Cancer Research Fund (J.Y.
and M.C.P.).
NR 38
TC 164
Z9 168
U1 2
U2 43
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 23
PY 2012
VL 109
IS 43
BP 17561
EP 17566
DI 10.1073/pnas.1215397109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AO
UT WOS:000311147800053
PM 23045683
ER
PT J
AU MacLean, GA
Menne, TF
Guo, GJ
Sanchez, DJ
Park, IH
Daley, GQ
Orkin, SH
AF MacLean, Glenn A.
Menne, Tobias F.
Guo, Guoji
Sanchez, Danielle J.
Park, In-Hyun
Daley, George Q.
Orkin, Stuart H.
TI Altered hematopoiesis in trisomy 21 as revealed through in vitro
differentiation of isogenic human pluripotent cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID DOWN-SYNDROME; STEM-CELLS; MEGAKARYOBLASTIC LEUKEMIA; TRANSIENT
LEUKEMIA; MOUSE MODEL; HUMAN ES; GATA1; GENERATION; MUTATIONS;
LEUKEMOGENESIS
AB Trisomy 21 is associated with hematopoietic abnormalities in the fetal liver, a preleukemic condition termed transient myeloproliferative disorder, and increased incidence of acute megakaryoblastic leukemia. Human trisomy 21 pluripotent cells of various origins, human embryionic stem (hES), and induced pluripotent stem (iPS) cells, were differentiated in vitro as a model to recapitulate the effects of trisomy on hematopoiesis. To mitigate clonal variation, we isolated disomic and trisomic subclones from the same parental iPS line, thereby generating subclones isogenic except for chromosome 21. Under differentiation conditions favoring development of fetal liver-like, gamma-globin expressing, definitive hematopoiesis, we found that trisomic cells of hES, iPS, or isogenic origins exhibited a two-to fivefold increase in a population of CD43(+)(Leukosialin)/CD235(+)(Glycophorin A) hematopoietic cells, accompanied by increased multilineage colony-forming potential in colony-forming assays. These findings establish an intrinsic disturbance of multilineage myeloid hematopoiesis in trisomy 21 at the fetal liver stage.
C1 [MacLean, Glenn A.; Menne, Tobias F.; Guo, Guoji; Sanchez, Danielle J.; Daley, George Q.; Orkin, Stuart H.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[MacLean, Glenn A.; Menne, Tobias F.; Guo, Guoji; Sanchez, Danielle J.; Daley, George Q.; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Daley, George Q.; Orkin, Stuart H.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Daley, George Q.; Orkin, Stuart H.] Harvard Univ, Sch Med, Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Park, In-Hyun] Yale Univ, Sch Med, Dept Genet, Yale Stem Cell Ctr, New Haven, CT 06520 USA.
RP Orkin, SH (reprint author), Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
EM stuart_orkin@dfci.harvard.edu
FU National Institutes of Health as part of the Progenitor Cell Biology
Consortium of the National Heart, Lung and Blood Institute [U01 HL
10001]; Harvard Stem Cell Institute; Howard Hughes Medical Institute;
Lady Tata Memorial Trust fellowship; Leukemia and Lymphoma Research Fund
fellowship; Kay Kendal Leukemia Fund fellowship
FX This work was funded by National Institutes of Health Grant U01 HL 10001
as part of the Progenitor Cell Biology Consortium of the National Heart,
Lung and Blood Institute; a seed grant of the Harvard Stem Cell
Institute and the Howard Hughes Medical Institute; a Lady Tata Memorial
Trust fellowship (to G.M.); and Leukemia and Lymphoma Research and Kay
Kendal Leukemia Fund fellowships (to T.F.M.).
NR 34
TC 51
Z9 51
U1 0
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 23
PY 2012
VL 109
IS 43
BP 17567
EP 17572
DI 10.1073/pnas.1215468109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AO
UT WOS:000311147800054
PM 23045682
ER
PT J
AU McAuliffe, SM
Morgan, SL
Wyant, GA
Tran, LT
Muto, KW
Chen, YS
Chin, KT
Partridge, JC
Poole, BB
Cheng, KH
Daggett, J
Cullen, K
Kantoff, E
Hasselbatt, K
Berkowitz, J
Muto, MG
Berkowitz, RS
Aster, JC
Matulonis, UA
Dinulescu, DM
AF McAuliffe, Shannon M.
Morgan, Stefanie L.
Wyant, Gregory A.
Tran, Lieu T.
Muto, Katherine W.
Chen, Yu Sarah
Chin, Kenneth T.
Partridge, Justin C.
Poole, Barish B.
Cheng, Kuang-Hung
Daggett, John, Jr.
Cullen, Kristen
Kantoff, Emily
Hasselbatt, Kathleen
Berkowitz, Julia
Muto, Michael G.
Berkowitz, Ross S.
Aster, Jon C.
Matulonis, Ursula A.
Dinulescu, Daniela M.
TI Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes
tumors to platinum therapy
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE tumor models; Notch3 expression patterns; isobologram and combination
index analysis; platinum-induced DNA damage response; synergistic
cytotoxic effects for GSI/cisplatin combination therapy
ID MULLERIAN-INHIBITING SUBSTANCE; GYNECOLOGIC-ONCOLOGY-GROUP; SIDE
POPULATION; STAGE-III; CISPLATIN; HETEROGENEITY; CARBOPLATIN;
PACLITAXEL; PHASE; RESISTANCE
AB Chemoresistance to platinum therapy is a major obstacle that needs to be overcome in the treatment of ovarian cancer patients. The high rates and patterns of therapeutic failure seen in patients are consistent with a steady accumulation of drug-resistant cancer stem cells (CSCs). This study demonstrates that the Notch signaling pathway and Notch3 in particular are critical for the regulation of CSCs and tumor resistance to platinum. We show that Notch3 overexpression in tumor cells results in expansion of CSCs and increased platinum chemoresistance. In contrast, gamma-secretase inhibitor (GSI), a Notch pathway inhibitor, depletes CSCs and increases tumor sensitivity to platinum. Similarly, a Notch3 siRNA knockdown increases the response to platinum therapy, further demonstrating that modulation of tumor chemosensitivity by GSI is Notch specific. Most importantly, the cisplatin/GSI combination is the only treatment that effectively eliminates both CSCs and the bulk of tumor cells, indicating that a dual combination targeting both populations is needed for tumor eradication. In addition, we found that the cisplatin/GSI combination therapy has a synergistic cytotoxic effect in Notch-dependent tumor cells by enhancing the DNA-damage response, G(2)/Mcell-cycle arrest, and apoptosis. Based on these results, we conclude that targeting the Notch pathway could significantly increase tumor sensitivity to platinum therapy. Our study suggests important clinical applications for targeting Notch as part of novel treatment strategies upon diagnosis of ovarian cancer and at recurrence. Both platinum-resistant and platinum-sensitive relapses may benefit from such an approach as clinical data suggest that all relapses after platinum therapy are increasingly platinum resistant.
C1 [McAuliffe, Shannon M.; Morgan, Stefanie L.; Wyant, Gregory A.; Tran, Lieu T.; Muto, Katherine W.; Chen, Yu Sarah; Chin, Kenneth T.; Partridge, Justin C.; Poole, Barish B.; Cheng, Kuang-Hung; Daggett, John, Jr.; Berkowitz, Julia; Aster, Jon C.; Dinulescu, Daniela M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Hasselbatt, Kathleen; Muto, Michael G.; Berkowitz, Ross S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA.
[Cullen, Kristen] Cell Signaling Technol, Danvers, MA 01923 USA.
[Kantoff, Emily; Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
RP Dinulescu, DM (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
EM DDinulescu@rics.bwh.harvard.edu
FU Department of Defense Ovarian Cancer Research Program Award
[W81XWH-10-1-0263]; V Foundation Scholar Award; Ovarian Cancer Research
Fund Liz Tilberis Award; Burroughs Wellcome; Mary Kay Ash; Rivkin
Foundations
FX This work was supported by Department of Defense Ovarian Cancer Research
Program Award W81XWH-10-1-0263 (D. M. D.), a V Foundation Scholar Award
(D. M. D.), an Ovarian Cancer Research Fund Liz Tilberis Award (D. M.
D.), by Burroughs Wellcome (D. M. D.), by the Mary Kay Ash (D. M. D.)
and Rivkin Foundations (D. M. D.), and by a generous contribution from
the Mildred Moorman Ovarian Cancer Research Fund (D.M.D.).
NR 35
TC 109
Z9 113
U1 3
U2 33
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 23
PY 2012
VL 109
IS 43
BP E2939
EP E2948
DI 10.1073/pnas.1206400109
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AO
UT WOS:000311147800007
PM 23019585
ER
PT J
AU Hall, KT
Lembo, AJ
Kirsch, I
Ziogas, DC
Douaiher, J
Jensen, KB
Conboy, LA
Kelley, JM
Kokkotou, E
Kaptchuk, TJ
AF Hall, Kathryn T.
Lembo, Anthony J.
Kirsch, Irving
Ziogas, Dimitrios C.
Douaiher, Jeffrey
Jensen, Karin B.
Conboy, Lisa A.
Kelley, John M.
Kokkotou, Efi
Kaptchuk, Ted J.
TI Catechol-O-Methyltransferase val158met Polymorphism Predicts Placebo
Effect in Irritable Bowel Syndrome
SO PLOS ONE
LA English
DT Article
ID COMT VAL(158)MET POLYMORPHISM; PREFRONTAL CORTEX;
INDIVIDUAL-DIFFERENCES; CLINICAL-TRIALS; END-POINT; GENOTYPE; DOPAMINE;
METAANALYSIS; IMPROVEMENT; RESPONSES
AB Identifying patients who are potential placebo responders has major implications for clinical practice and trial design. Catechol-O-methyltransferase (COMT), an important enzyme in dopamine catabolism plays a key role in processes associated with the placebo effect such as reward, pain, memory and learning. We hypothesized that the COMT functional val158met polymorphism, was a predictor of placebo effects and tested our hypothesis in a subset of 104 patients from a previously reported randomized controlled trial in irritable bowel syndrome (IBS). The three treatment arms from this study were: no-treatment ("waitlist"), placebo treatment alone ("limited") and, placebo treatment "augmented" with a supportive patient-health care provider interaction. The primary outcome measure was change from baseline in IBS-Symptom Severity Scale (IBS-SSS) after three weeks of treatment. In a regression model, the number of methionine alleles in COMT val158met was linearly related to placebo response as measured by changes in IBS-SSS (p = .035). The strongest placebo response occurred in met/met homozygotes treated in the augmented placebo arm. A smaller met/met associated effect was observed with limited placebo treatment and there was no effect in the waitlist control. These data support our hypothesis that the COMT val158met polymorphism is a potential biomarker of placebo response.
C1 [Hall, Kathryn T.; Kaptchuk, Ted J.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Hall, Kathryn T.; Lembo, Anthony J.; Kirsch, Irving; Jensen, Karin B.; Conboy, Lisa A.; Kelley, John M.; Kokkotou, Efi; Kaptchuk, Ted J.] Beth Israel Deaconess Med Ctr, Program Placebo Studies, Boston, MA 02215 USA.
[Lembo, Anthony J.; Kokkotou, Efi] Beth Israel Deaconess Med Ctr, Dept Gastroenterol, Boston, MA 02215 USA.
[Kirsch, Irving] Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England.
[Ziogas, Dimitrios C.] Univ Athens, Dept Internal Med, Athens, Greece.
[Douaiher, Jeffrey] Dept Surg, Baltimore, MD USA.
[Jensen, Karin B.; Kelley, John M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Psychiat, Boston, MA USA.
[Kelley, John M.] Endicott Coll, Beverly, MA USA.
RP Hall, KT (reprint author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
EM kthall@bidmc.harvard.edu
OI Jensen, Karin/0000-0003-2521-3160
FU NCCAM-NIH [R01 AT004662, K24 AT004095, 3R01AT004662-02S1, T32 AT000051,
R21 AT002860]
FX The funding received for this study came from NCCAM-NIH grants # R01
AT004662, K24 AT004095, 3R01AT004662-02S1, T32 AT000051 and R21
AT002860. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 57
TC 56
Z9 57
U1 1
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 23
PY 2012
VL 7
IS 10
AR e48135
DI 10.1371/journal.pone.0048135
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 025MO
UT WOS:000310193600048
PM 23110189
ER
PT J
AU Angin, M
King, M
Altfeld, M
Walker, BD
Wucherpfennig, KW
Addo, MM
AF Angin, Mathieu
King, Melanie
Altfeld, Marcus
Walker, Bruce D.
Wucherpfennig, Kai W.
Addo, Marylyn M.
TI Identification of HIV-1-specific regulatory T-cells using HLA class II
tetramers
SO AIDS
LA English
DT Article
ID EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HIV-1 INFECTION; REPLICATION;
SUPPRESSION; ACTIVATION; EXPANSION; BLOOD
AB Regulatory T cells (Tregs) are potent immune modulators, but their precise role in HIV pathogenesis remains incompletely understood. Most studies to date have focused on frequencies or phenotypes of 'bulk' Treg populations. However, although antigen-specific Tregs have been reported in other diseases, HIV-1 epitope-specific Tregs have not been described to date. We here report the first identification of functional HIV-1-Gag-specific regulatory T cells using human leukocyte antigen class II tetramer staining in HIV-1-infected individuals.
C1 [Angin, Mathieu; King, Melanie; Altfeld, Marcus; Walker, Bruce D.; Addo, Marylyn M.] MIT & Harvard, Ragon Inst MGH, Boston, MA USA.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD USA.
[Wucherpfennig, Kai W.] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA.
[Addo, Marylyn M.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Addo, MM (reprint author), Harvard & MIT, Ragon Inst MCH, 149 13th St,6th Floor,Suite 6620, Charlestown, MA 02129 USA.
EM maddo@partners.org
OI Angin, Mathieu/0000-0002-6867-4680
FU Elisabeth Glaser Pediatric AIDS Foundation [MV-00-9-900-1429-0-00];
MGH/ECOR; NIH NIAID [KO8 AI074405, AI074405-03S1]; Bill & Melinda Gates
Foundation; Terry and Susan Ragon Foundation; Harvard University Center
for AIDS Research (CFAR), an NIH [P30 AI060354]; NIH NIAID; NIH NCI; NIH
NICHD; NIH NHLBI; NIH NIDA; NIH NCCAM; NIH FIC; NIH OAR; NIH NIMH; NIH
NIA
FX This work was supported in part by research funding from the Elisabeth
Glaser Pediatric AIDS Foundation (Pediatric HIV Vaccine Program Award
MV-00-9-900-1429-0-00 to M.M.A.), MGH/ECOR (Physician Scientist
Development Award to M.M.A.), NIH NIAID (KO8 AI074405 and AI074405-03S1
to M.M.A.). These studies were furthermore supported by the Bill &
Melinda Gates Foundation and the Terry and Susan Ragon Foundation. This
publication resulted in part from research supported by the Harvard
University Center for AIDS Research (CFAR), an NIH funded program (P30
AI060354), which is supported by the following NIH Co-Funding and
Participating Institutes and Centers: NIAID, NCI, NICHD, NHLBI, NIDA,
NIMH, NIA, NCCAM, FIC, and OAR.
NR 19
TC 17
Z9 17
U1 2
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0269-9370
J9 AIDS
JI Aids
PD OCT 23
PY 2012
VL 26
IS 16
BP 2112
EP 2115
DI 10.1097/QAD.0b013e328358cc75
PG 4
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA 021OB
UT WOS:000309894000015
PM 22874519
ER
PT J
AU Hawkins, BM
Kennedy, KF
Giri, J
Saltzman, AJ
Rosenfield, K
Drachman, DE
White, CJ
Spertus, JA
Yeh, RW
AF Hawkins, Beau M.
Kennedy, Kevin F.
Giri, Jay
Saltzman, Adam J.
Rosenfield, Kenneth
Drachman, Douglas E.
White, Christopher J.
Spertus, John A.
Yeh, Robert W.
TI Pre-procedural Risk Quantification for Carotid Stenting Using the CAS
Score A Report From the NCDR CARE Registry
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE carotid stenosis; carotid stenting; risk score
ID ARTERY STENOSIS; MEDICARE BENEFICIARIES; ENDARTERECTOMY; OUTCOMES;
RECLASSIFICATION
AB Objectives We developed and internally validated a risk score to predict in-hospital stroke or death after carotid artery stenting (CAS).
Background A tool that accurately assesses CAS risk could aid clinical decision making and improve patient selection.
Methods Patients undergoing CAS without acute evolving stroke from April 2005 through June 2011 as part of the NCDR Carotid Artery Revascularization and Endarterectomy (CARE) Registry were included. In-hospital stroke or death was modeled using logistic regression with 35 candidate variables. Internal validation was achieved with boot-strapping, and model discrimination and calibration were assessed.
Results A total of 271 (2.4%) primary endpoint events occurred during 11,122 procedures. Independent predictors of stroke or death included impending major surgery, previous stroke, age, symptomatic lesion, atrial fibrillation, and absence of previous ipsilateral carotid endarterectomy. The model was well calibrated with moderate discriminatory ability (C-statistic: 0.71) overall, and within symptomatic (C-statistic: 0.68) and asymptomatic (C-statistic: 0.72) subgroups. The inclusion of available angiographic variables did not improve model performance (C-statistic: 0.72, integrated discrimination improvement 0.001; p = 0.21). The NCDR CAS score was developed to support prospective risk quantification.
Conclusions The NCDR CAS score, comprising 6 clinical variables, predicts in-hospital S/D after CAS. This tool may be useful to assist clinicians in evaluating optimal management, share more accurate pre-procedural risks with patients, and improve patient selection for CAS. (J Am Coll Cardiol 2012;60:1617-22) (c) 2012 by the American College of Cardiology Foundation
C1 [Hawkins, Beau M.; Giri, Jay; Saltzman, Adam J.; Rosenfield, Kenneth; Drachman, Douglas E.; Yeh, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02114 USA.
[Kennedy, Kevin F.; Spertus, John A.] Univ Missouri, St Lukes Mid Amer Heart Inst, Kansas City, MO 64110 USA.
[White, Christopher J.] Ochsner Med Ctr, John Ochsner Heart & Vasc Inst, New Orleans, LA USA.
RP Yeh, RW (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, GRB 8-843,55 Fruit St, Boston, MA 02114 USA.
EM ryeh@partners.org
RI White, Christopher/J-6686-2012
OI White, Christopher/0000-0001-8618-7539
FU American College of Cardiology Foundation's National Cardiovascular Data
Registry (NCDR); Abbott Vascular; Bard Peripheral Vascular;
Medtronic/Invatec; Atrium; Boston Scientific Corp.; Complete Conference
Management; Harvard Clinical Research Institute; Contego; Micell; Becker
Ventures; iDev Technologies, Inc.; Lutonix/Bard
FX From the *Division of Cardiology, Massachusetts General Hospital,
Harvard Medical School, Boston, Massachusetts; dagger St. Luke's
Mid-America Heart Institute, University of Missouri-Kansas City, Kansas
City, Missouri; and the double dagger John Ochsner Heart and Vascular
Institute, Ochsner Medical Center, New Orleans, Louisiana. This research
was supported by the American College of Cardiology Foundation's
National Cardiovascular Data Registry (NCDR). The views expressed in
this manuscript represent those of the author(s), and do not necessarily
represent the official views of the NCDR or its associated professional
societies identified at www.ncdr.com. The CARE Registry is an initiative
of the American College of Cardiology Foundation, The Society for
Cardiovascular Angiography and Interventions, the Society of
Interventional Radiology, the American Academy of Neurology, the
American Association of Neurological Surgeons/Congress of Neurological
Surgeons, the Society for Vascular Medicine, and the Society of Vascular
and Interventional Neurology. Dr. Yeh is an investigator at the Harvard
Clinical Research Institute and has served as a consultant for the
Kaiser Permanente Division of Research. Dr. Spertus has an ACCF contract
to serve as an analytic center for the CARE registry. Dr. White is an
investigator for the CABANA trial from Boston Scientific Corp. Dr.
Rosenfield has received research grants from Abbott Vascular, Bard
Peripheral Vascular, Medtronic/Invatec, and Atrium; has received
consulting/advisory board fees from Abbott Vascular, Boston Scientific
Corp., Complete Conference Management, Harvard Clinical Research
Institute, Contego, Micell, and Becker Ventures; has equity in Lumen
Biomedical, Medical Stimulation Corp., Angioguard (Cordis), and Micell;
and has served on the board of directors for VIVA Physicians (501C3).
Dr. Drachman has received research grant support from iDev Technologies,
Inc. and Lutonix/Bard; is member of the clinical events committee of PLC
Medical Systems, Inc.; and is a member of the Data and Safety Monitoring
Board of Prarie Education & Research Cooperative. All other authors have
reported that they have no relationships relevant to the contents of
this paper to disclose.
NR 30
TC 14
Z9 15
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
BP 1617
EP 1622
DI 10.1016/j.jacc.2012.07.026
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025OH
UT WOS:000310199700005
PM 22999733
ER
PT J
AU Varenhorst, C
Alstrom, U
Scirica, BM
Hogue, CW
Asenblad, N
Storey, RF
Steg, G
Horrow, J
Mahaffey, KW
Becker, RC
James, S
Cannon, CP
Brandrup-Wognsen, G
Wallentin, L
Held, C
AF Varenhorst, Christoph
Alstrom, Ulrica
Scirica, Benjamin M.
Hogue, Charles W.
Asenblad, Nils
Storey, Robert F.
Steg, Gabriel
Horrow, Jay
Mahaffey, Kenneth W.
Becker, Richard C.
James, Stefan
Cannon, Christopher P.
Brandrup-Wognsen, Gunnar
Wallentin, Lars
Held, Claes
TI Factors Contributing to the Lower Mortality With Ticagrelor Compared
With Clopidogrel in Patients Undergoing Coronary Artery Bypass Surgery
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE bypass; clopidogrel; myocardial infarction; surgery; ticagrelor
ID PLATELET INHIBITION; PRACTICE GUIDELINES; ASPIRIN; ANTIPLATELET;
ANTAGONIST; MANAGEMENT; PRASUGREL; UPDATE; SAFETY; TRIAL
AB Objectives This study investigated the differences in specific causes of post-coronary artery bypass graft surgery (CABG) deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Background In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had significantly lower total and cardiovascular mortality.
Methods In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treatment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically identified bleeding or infection events that either caused or subsequently contributed to death.
Results Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hemorrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infection (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more common in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p < 0.05, and bleeding: 27 vs. 9, p < 0.01, for clopidogrel and ticagrelor, respectively).
Conclusions The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Outcomes [PLATO]; NCT00391872) (J Am Coll Cardiol 2012;60:1623-30) (c) 2012 by the American College of Cardiology Foundation
C1 [Varenhorst, Christoph; Asenblad, Nils; James, Stefan; Wallentin, Lars; Held, Claes] Uppsala Univ, Uppsala Clin Res Ctr, MTC, Uppsala 75237, Sweden.
[Varenhorst, Christoph; Asenblad, Nils; James, Stefan; Wallentin, Lars; Held, Claes] Uppsala Univ, Dept Med Sci, Uppsala 75237, Sweden.
[Alstrom, Ulrica] Uppsala Univ, Dept Cardiothorac Surg & Anesthesiol, Uppsala 75237, Sweden.
[Scirica, Benjamin M.; Cannon, Christopher P.] Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA.
[Hogue, Charles W.] Johns Hopkins Univ, Sch Med, Dept Anaesthesiol & Crit Care Med, Baltimore, MD USA.
[Storey, Robert F.] Univ Sheffield, Dept Cardiovasc Sci, Sheffield, S Yorkshire, England.
[Steg, Gabriel] Hop Bichat Claude Bernard, AP HP, F-75877 Paris, France.
[Steg, Gabriel] Univ Paris Diderot, U698, INSERM, Paris, France.
[Horrow, Jay] AstraZeneca LP, Wilmington, DE USA.
[Mahaffey, Kenneth W.; Becker, Richard C.] Duke Clin Res Inst, Durham, NC USA.
[Brandrup-Wognsen, Gunnar] AstraZeneca, Molndal, Sweden.
RP Varenhorst, C (reprint author), Uppsala Univ, Uppsala Clin Res Ctr, MTC, Dag Hammar Skjolds Vag,14B,1Tr,Sci Pk, Uppsala 75237, Sweden.
EM christoph.varenhorst@ucr.uu.se
OI Varenhorst, Christoph/0000-0002-8378-3869; Held,
Claes/0000-0001-9402-7404
FU AstraZeneca; Merck; Johnson Johnson; Bayer; Daiichi Sankyo;
Bristol-Myers Squibb; Gilead Sciences; Novartis; Covidien;
Boehringer-Ingelheim; Eli Lilly Company; GlaxoSmithKline; Pozen; Regado
Biotechnologies; Sanofi Aventis; Schering Plough; Medicines Company;
Regado; MSD; Accumetrics; Essentialis; Regeneron; Takeda;
Merck/Schering-Plough; Bristol-Myers Squibb/Pfizer;
Schering-Plough/Merck; Roche
FX From the *Uppsala Clinical Research Center and Department of Medical
Sciences, Cardiology, Uppsala University, Uppsala, Sweden; dagger
Department of Cardiothoracic Surgery and Anesthesiology, Uppsala
University, Uppsala, Sweden; double dagger TIMI Study Group,
Cardiovascular Division, Brigham and Women's Hospital, Boston,
Massachusetts; Department of Anesthesiology & Critical Care Medicine,
The Johns Hopkins University School of Medicine, Baltimore, Maryland;
parallel to Department of Cardiovascular Science, University of
Sheffield, Sheffield, United Kingdom; Hopital Bichat, Assistance
Publique-Hopitaux de Paris, Paris, France; #INSERM U-698, Universite
Paris-Diderot, Paris, France; **AstraZeneca LP, Wilmington, Delaware;
dagger dagger Duke Clinical Research Institute, Durham, North Carolina;
and double dagger double dagger AstraZeneca, Molndal, Sweden. This study
was supported by AstraZeneca. Dr. Varenhorst has received a research
grant from AstraZeneca to perform this research; and is a member of the
Speakers' Bureaus for AstraZeneca, Eli Lilly & Company, and The
Medicines Company. Dr. Scirica has received research grants from Merck,
AstraZeneca, Johnson & Johnson, Bayer, Daiichi Sankyo, Bristol-Myers
Squibb, Gilead Sciences, and Novartis; and is a consultant to Gilead
Sciences, Arena, and Lexicon. Dr. Hogue has received research support
from Covidien; and is a consultant to Covidien, Merck, and Ornim. Dr.
Storey is a consultant to AstraZeneca, Accumetrics, Merck, Novartis, Eli
Lilly & Company, Daiichi Sankyo, Eisai, Iroko, The Medicines Company,
Sanofi Aventis, Bristol-Myers Squibb, and Medscape. Dr. Steg is a
consultant to AstraZeneca, Amarin, Amgen, Astellas, Bayer,
Boehringer-Ingelheim, Bristol-Myers Squibb, Eli Lilly & Company, Daiichi
Sankyo, Eisai, GlaxoSmithKline, Medtronic, Merck, Novartis, Otsuka,
Pfizer, Roche, The Medicines Company, Sanofi Aventis, and Servier; is a
member of the Speakers' Bureaus for AstraZeneca, Bayer, Bristol-Myers
Squibb, Pfizer, The Medicines Company, Sanofi Aventis, and Servier; and
has received Data Safety Monitoring Board support from Ablynx. Dr.
Horrow is the executive director of AstraZeneca LP, and has equity
ownership in the company. Dr. Mahaffey has received grant support from
AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
Sankyo, Eli Lilly & Company, GlaxoSmithKline, Johnson & Johnson, Merck,
Novartis, Pozen, Regado Biotechnologies, Sanofi Aventis, Schering
Plough, and The Medicines Company; and is a consultant to AstraZeneca,
Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eli
Lilly & Company, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer,
Polymedix, and Sanofi Aventis. Dr. Becker is a consultant to and
receives support from AstraZeneca, Bayer, Bristol-Myers Squibb, Daiichi
Sankyo, Johnson & Johnson, The Medicines Company, Merck, and Regado. Dr.
James has received institutional grants from AstraZeneca, Eli Lilly &
Company, and MSD; and honoraria from AstraZeneca, Eli Lilly & Company,
MSD, Merck, and The Medicines Company. Dr. Cannon has received grant
support from Accumetrics, AstraZeneca, Essentialis, GlaxoSmithKline,
Merck, Regeneron, Sanofi Aventis, and Takeda; is a member of the
Advisory Boards for Alnylam, Bristol-Myers Squibb, and Pfizer; has
received funds from these companies, which have been donated to charity;
and is a clinical advisor to Automated Medical Systems with equity in
the company. Dr. Wallentin is a consultant to Merck/Schering Plough,
Regado Biosciences, Evolva, Portola, C.S.L.; Behring, Athera
Biotechnologies, Boehringer-Ingelheim, AstraZeneca, GlaxoSmithKline, and
Brisol-Myers Squibb/Pfizer; has received research grants from
AstraZeneca, Merck/Schering-Plough, Boehringer-Ingelheim, Bristol-Myers
Squibb/Pfizer, and GlaxoSmithKline; and lecture fees from AstraZeneca,
Boehringer-Ingelheim, Bristol-Myers Squibb/Pfizer, GlaxoSmithKline, and
Schering-Plough/Merck. Dr. Held is on the Advisory Boards for
AstraZeneca, Roche, and Pfizer; and has received institutional grants
from Schering-Plough/Merck, GlaxoSmithKline, Bristol-Myers Squibb, and
Roche. All other authors have reported that they have no relationships
relevant to the contents of this paper to disclose.
NR 23
TC 39
Z9 45
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 23
PY 2012
VL 60
IS 17
BP 1623
EP 1630
DI 10.1016/j.jacc.2012.07.021
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025OH
UT WOS:000310199700006
PM 23021325
ER
PT J
AU Kendall, EA
Zaman, RU
Naved, RT
Rahman, MW
Kadir, MA
Arman, S
Azziz-Baumgartner, E
Gurley, ES
AF Kendall, Emily A.
Zaman, Rashid Uz
Naved, Ruchira Tabassum
Rahman, Muhammad Waliur
Kadir, Mohammad Abdul
Arman, Shaila
Azziz-Baumgartner, Eduardo
Gurley, Emily S.
TI Medically unexplained illness and the diagnosis of hysterical conversion
reaction (HCR) in women's medicine wards of Bangladeshi hospitals: a
record review and qualitative study
SO BMC WOMENS HEALTH
LA English
DT Review
DE Women's health services; Mental health; Somatoform disorders; Conversion
disorder; Diagnosis; Physician's practice patterns; Health services
needs and demand; Bangladesh
ID PRIMARY-CARE; PSYCHIATRIC-DISORDERS; SOMATOFORM DISORDERS; INCOME
COUNTRIES; SPOUSAL VIOLENCE; SOMATIC SYMPTOMS; FOLLOW-UP; SOMATIZATION;
PREVALENCE; DISTRESS
AB Background: Frequent reporting of cases of hysterical conversion reaction (HCR) among hospitalized female medical patients in Bangladesh's public hospital system led us to explore the prevalence of "HCR" diagnoses within hospitals and the manner in which physicians identify, manage, and perceive patients whom they diagnose with HCR.
Methods: We reviewed admission records from women's general medicine wards in two public hospitals to determine how often and at what point during hospitalization patients received diagnoses of HCR. We also interviewed 13 physicians about their practices and perceptions related to HCR.
Results: Of 2520 women admitted to the selected wards in 2008, 6% received diagnoses of HCR. HCR patients had wide-ranging symptoms including respiratory distress, headaches, chest pain, convulsions, and abdominal complaints. Most doctors diagnosed HCR in patients who had any medically-unexplained physical symptom. According to physician reports, women admitted to medical wards for HCR received brief diagnostic evaluations and initial treatment with short-acting tranquilizers or placebo agents. Some were referred to outpatient psychiatric treatment. Physicians reported that repeated admissions for HCR were common. Physicians noted various social factors associated with HCR, and they described failures of the current system to meet psychosocial needs of HCR patients.
Conclusions: In these hospital settings, physicians assign HCR diagnoses frequently and based on vague criteria. We recommend providing education to increase general physicians' awareness, skill, and comfort level when encountering somatization and other common psychiatric issues. Given limited diagnostic capacity for all patients, we raise concern that when HCR is used as a "wastebasket" diagnosis for unexplained symptoms, patients with treatable medical conditions may go unrecognized. We also advocate introducing non-physician hospital personnel to address psychosocial needs of HCR patients, assist with triage in a system where both medical inpatient beds and psychiatric services are scarce commodities, and help ensure appropriate follow up.
C1 [Kendall, Emily A.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Zaman, Rashid Uz] Oxford Policy Management, Oxford OX1 1BN, England.
[Naved, Ruchira Tabassum] Icddr B, Ctr Equ & Hlth Syst, Dhaka 1000, Bangladesh.
[Rahman, Muhammad Waliur; Arman, Shaila; Gurley, Emily S.] Icddr B, Ctr Communicable Dis, Dhaka 1000, Bangladesh.
[Kadir, Mohammad Abdul] Univ Queensland, Hlth Communities Res Ctr, Ipswich, Qld 4305, Australia.
[Azziz-Baumgartner, Eduardo] US Ctr Dis Control & Prevent, Epidemiol & Prevent Branch, Atlanta, GA 30075 USA.
RP Kendall, EA (reprint author), Massachusetts Gen Hosp, Dept Med, Bigelow 740,55 Fruit St, Boston, MA 02114 USA.
EM ekendall1@partners.org
RI Gurley, Emily/B-7903-2010;
OI Gurley, Emily/0000-0002-8648-9403; Kendall, Emily/0000-0002-0083-422X
FU Centers for Disease Control and Prevention (CDC), United States of
America [U01/CI000298]; National Institutes of Health (NIH), Fogarty
International Center [R24 TW007988]
FX This study was funded by the Centers for Disease Control and Prevention
(CDC), United States of America, under cooperative agreement
U01/CI000298, and by the National Institutes of Health (NIH), Fogarty
International Center grant R24 TW007988. icddr,b acknowledges with
gratitude the commitment of the CDC and NIH to its research efforts.
NR 36
TC 0
Z9 0
U1 4
U2 9
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1472-6874
J9 BMC WOMENS HEALTH
JI BMC Womens Health
PD OCT 22
PY 2012
VL 12
AR 38
DI 10.1186/1472-6874-12-38
PG 10
WC Public, Environmental & Occupational Health; Obstetrics & Gynecology
SC Public, Environmental & Occupational Health; Obstetrics & Gynecology
GA 070LR
UT WOS:000313508100001
PM 23088583
ER
PT J
AU Lambert, B
Vandeputte, J
Remacle, S
Bergiers, I
Simonis, N
Twizere, JC
Vidal, M
Rezsohazy, R
AF Lambert, Barbara
Vandeputte, Julie
Remacle, Sophie
Bergiers, Isabelle
Simonis, Nicolas
Twizere, Jean-Claude
Vidal, Marc
Rezsohazy, Rene
TI Protein interactions of the transcription factor Hoxa1
SO BMC DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE Hox; Hoxa1; ORFeome; Interactome
ID RECEPTOR DOWN-REGULATION; BINDING PROTEIN; DNA-BINDING; SPROUTY
PROTEINS; AXIAL SKELETON; HOMEOBOX GENES; CELL ADHESIONS; ALIX;
ACTIVATION; HINDBRAIN
AB Background: Hox proteins are transcription factors involved in crucial processes during animal development. Their mode of action remains scantily documented. While other families of transcription factors, like Smad or Stat, are known cell signaling transducers, such a function has never been squarely addressed for Hox proteins.
Results: To investigate the mode of action of mammalian Hoxa1, we characterized its interactome by a systematic yeast two-hybrid screening against similar to 12,200 ORF-derived polypeptides. Fifty nine interactors were identified of which 45 could be confirmed by affinity co-purification in animal cell lines. Many Hoxa1 interactors are proteins involved in cell-signaling transduction, cell adhesion and vesicular trafficking. Forty-one interactions were detectable in live cells by Bimolecular Fluorescence Complementation which revealed distinctive intracellular patterns for these interactions consistent with the selective recruitment of Hoxa1 by subgroups of partner proteins at vesicular, cytoplasmic or nuclear compartments.
Conclusions: The characterization of the Hoxa1 interactome presented here suggests unexplored roles for Hox proteins in cell-to-cell communication and cell physiology.
C1 [Lambert, Barbara; Vandeputte, Julie; Remacle, Sophie; Bergiers, Isabelle; Rezsohazy, Rene] Catholic Univ Louvain, Life Sci Inst ISV, Mol & Cellular Anim Embryol Grp, B-1348 Louvain, Belgium.
[Simonis, Nicolas] Univ Libre Brussels, Brussels, Belgium.
[Twizere, Jean-Claude] Univ Liege, GIGA R & Gembloux Agro Biotech, B-4000 Liege, Belgium.
[Vidal, Marc] Dana Farber Canc Inst, CCSB, Boston, MA 02215 USA.
[Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
RP Rezsohazy, R (reprint author), Catholic Univ Louvain, Life Sci Inst ISV, Mol & Cellular Anim Embryol Grp, B-1348 Louvain, Belgium.
EM rene.rezsohazy@uclouvain.be
OI Bergiers, Isabelle/0000-0001-9622-7960
FU Belgian Fund for Scientific Research (FNRS, FRSM) [3.4.536.06F];
Direction Generale des Technologies, de la Recherche et de l'Energie" of
the Walloon Region (WALEOII) [516054]; Fonds Speciaux de Recherche (FSR)
of the Universite catholique de Louvain (UCL); US National Human Genome
Research Institute [R01-HG001715]; Belgian Fund for Scientific Research;
FSR grant from UCL; Belspo (Belgian Federal Government)
FX We are grateful to Michael Cusick and Matija Dreze for helpful comments
on the manuscript. We are also grateful to Abdelmounaim Errachid
(IMABIOL imaging platform) for technical assistance in confocal
microscopy. We thank Samir Merabet for providing us with plasmids coding
for the VENUS VN173 and VC155 moieties and for helping us in setting up
the BiFC assay. This work was supported by the Belgian Fund for
Scientific Research (FNRS, FRSM grant 3.4.536.06F), the "Direction
Generale des Technologies, de la Recherche et de l'Energie" of the
Walloon Region (WALEOII grant no516054), the Fonds Speciaux de Recherche
(FSR) of the Universite catholique de Louvain (UCL), and by US National
Human Genome Research Institute grant R01-HG001715 to MV. BL and IB held
a FRIA fellowship from the Belgian Fund for Scientific Research and a
FSR grant from UCL. NS is supported by a return grant from Belspo
(Belgian Federal Government). MV is a Chercheur Qualifie Honoraire of
the Belgian Fund for Scientific Research.
NR 61
TC 15
Z9 16
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-213X
J9 BMC DEV BIOL
JI BMC Dev. Biol.
PD OCT 22
PY 2012
VL 12
AR 29
DI 10.1186/1471-213X-12-29
PG 17
WC Developmental Biology
SC Developmental Biology
GA 051LG
UT WOS:000312127700001
PM 23088713
ER
PT J
AU Schnell, E
Bensen, AL
Washburn, EK
Westbrook, GL
AF Schnell, Eric
Bensen, AeSoon L.
Washburn, Eric K.
Westbrook, Gary L.
TI Neuroligin-1 Overexpression in Newborn Granule Cells In Vivo
SO PLOS ONE
LA English
DT Article
ID NEWLY GENERATED NEURONS; TRAUMATIC BRAIN-INJURY; INHIBITORY SYNAPSE
FORMATION; DENTATE GYRUS; PARKINSONS-DISEASE; EXCITATORY SYNAPSES; ADULT
HIPPOCAMPUS; ADHESION MOLECULE; NEUROGENESIS; PLASTICITY
AB Adult-born dentate granule cells integrate into the hippocampal network, extend neurites and form synapses in otherwise mature tissue. Excitatory and inhibitory inputs innervate these new granule cells in a stereotyped, temporally segregated manner, which presents a unique opportunity to study synapse development in the adult brain. To examine the role of neuroligins as synapse-inducing molecules in vivo, we infected dividing neural precursors in adult mice with a retroviral construct that increased neuroligin-1 levels during granule cell differentiation. By 21 days post-mitosis, exogenous neuroligin-1 was expressed at the tips of dendritic spines and increased the number of dendritic spines. Neuroligin-1-overexpressing cells showed a selective increase in functional excitatory synapses and connection multiplicity by single afferent fibers, as well as an increase in the synaptic AMPA/NMDA receptor ratio. In contrast to its synapse-inducing ability in vitro, neuroligin-1 overexpression did not induce precocious synapse formation in adult-born neurons. However, the dendrites of neuroligin-1-overexpressing cells did have more thin protrusions during an early period of dendritic outgrowth, suggesting enhanced filopodium formation or stabilization. Our results indicate that neuroligin-1 expression selectively increases the degree, but not the onset, of excitatory synapse formation in adult-born neurons.
C1 [Schnell, Eric] Portland VA Med Ctr, Portland, OR USA.
[Schnell, Eric] OHSU Dept Anesthesiol & Perioperat Med, Portland, OR USA.
[Bensen, AeSoon L.; Washburn, Eric K.; Westbrook, Gary L.] Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97201 USA.
RP Schnell, E (reprint author), Portland VA Med Ctr, Portland, OR USA.
EM schneler@ohsu.edu
OI Schnell, Eric/0000-0002-5623-5015
FU Oregon Medical Research Foundation; Department of Veteran's Affairs
Career Development Award; National Institute of Mental Health
[R01MH46613]; NIH [P30 NS06180]
FX This work was supported by the Oregon Medical Research Foundation (ES),
a Department of Veteran's Affairs Career Development Award (ES), the
National Institute of Mental Health (R01MH46613; GLW), and the Jungers
Center Light Microscopy Image Core that is supported in part by NIH P30
NS06180. The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 79
TC 9
Z9 9
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 22
PY 2012
VL 7
IS 10
AR e48045
DI 10.1371/journal.pone.0048045
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 025MM
UT WOS:000310193400031
PM 23110172
ER
PT J
AU Croci, DO
Salatino, M
Rubinstein, N
Cerliani, JP
Cavallin, LE
Leung, HJ
Ouyang, J
Ilarregui, JM
Toscano, MA
Domaica, CI
Croci, MC
Shipp, MA
Mesri, EA
Albini, A
Rabinovich, GA
AF Croci, Diego O.
Salatino, Mariana
Rubinstein, Natalia
Cerliani, Juan P.
Cavallin, Lucas E.
Leung, Howard J.
Ouyang, Jing
Ilarregui, Juan M.
Toscano, Marta A.
Domaica, Carolina I.
Croci, Maria C.
Shipp, Margaret A.
Mesri, Enrique A.
Albini, Adriana
Rabinovich, Gabriel A.
TI Disrupting galectin-1 interactions with N-glycans suppresses
hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID PROTEIN-COUPLED RECEPTOR; TUMOR-IMMUNE PRIVILEGE; T-CELL APOPTOSIS;
GENE-EXPRESSION; PARACRINE NEOPLASIA; HERPESVIRUS VGPCR;
ENDOTHELIAL-CELLS; CANCER CELLS; INDUCTION; KSHV
AB Kaposi's sarcoma (KS), a multifocal vascular neoplasm linked to human herpesvirus-8 (HHV-8/KS-associated herpesvirus [KSHV]) infection, is the most common AIDS-associated malignancy. Clinical management of KS has proven to be challenging because of its prevalence in immunosuppressed patients and its unique vascular and inflammatory nature that is sustained by viral and host-derived paracrine-acting factors primarily released under hypoxic conditions. We show that interactions between the regulatory lectin galectin-1 (Gal-1) and specific target N-glycans link tumor hypoxia to neovascularization as part of the pathogenesis of KS. Expression of Gal-1 is found to be a hallmark of human KS but not other vascular pathologies and is directly induced by both KSHV and hypoxia. Interestingly, hypoxia induced Gal-1 through mechanisms that are independent of hypoxia-inducible factor (HIF) 1. and HIF-2. but involved reactive oxygen species-dependent activation of the transcription factor nuclear factor. B. Targeted disruption of Gal-1-N-glycan interactions eliminated hypoxia-driven angiogenesis and suppressed tumorigenesis in vivo. Therapeutic administration of a Gal-1-specific neutralizing mAb attenuated abnormal angiogenesis and promoted tumor regression in mice bearing established KS tumors. Given the active search for HIF-independent mechanisms that serve to couple tumor hypoxia to pathological angiogenesis, our findings provide novel opportunities not only for treating KS patients but also for understanding and managing a variety of solid tumors.
C1 [Croci, Diego O.; Salatino, Mariana; Cerliani, Juan P.; Ilarregui, Juan M.; Toscano, Marta A.; Domaica, Carolina I.; Rabinovich, Gabriel A.] Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Inmunopatol, RA-1428 Buenos Aires, DF, Argentina.
[Croci, Diego O.; Salatino, Mariana; Rubinstein, Natalia; Ilarregui, Juan M.; Toscano, Marta A.; Domaica, Carolina I.; Rabinovich, Gabriel A.] Univ Buenos Aires, Hosp Clin Jose de San Martin, Div Inmunogenet, RA-1120 Buenos Aires, DF, Argentina.
[Cavallin, Lucas E.; Leung, Howard J.; Mesri, Enrique A.] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Viral Oncol Program,Miami Ctr AIDS Res,Dept Micro, Miami, FL 33136 USA.
[Ouyang, Jing; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Croci, Maria C.] Univ Nacl Comahue, Fac Ciencias Med, Lab Patol, RA-8324 Cipolletti, Argentina.
[Albini, Adriana] Ist Ricovero & Cura Carattere Sci MultiMed, I-20138 Milan, Italy.
[Rabinovich, Gabriel A.] Univ Buenos Aires, Fac Ciencias Exactas & Nat, Dept Quim Biol, RA-1428 Buenos Aires, DF, Argentina.
RP Rabinovich, GA (reprint author), Consejo Nacl Invest Cient & Tecn, Inst Biol & Med Expt, Lab Inmunopatol, RA-1428 Buenos Aires, DF, Argentina.
EM gabyrabi@gmail.com
OI Albini, Adriana/0000-0002-9624-5103; Ilarregui, Juan
Martin/0000-0002-6871-6764; Domaica, Carolina Ines/0000-0001-9596-4889
FU Cancer Research Institute; Mizutani Foundation for Glycoscience;
Fundacion Sales; Agencia Nacional de Promocion Cientifica y Tecnologica
[PICT 2010-870]; University of Buenos Aires; Consejo Nacional de
Investigaciones Cientificas y Tecnicas; Associazione Italiana per la
Ricerca sul Cancro; National Institutes of Health (NIH), National Cancer
Institute (NCI) [CA136387]; NCI/OHAM supplements to the Developmental
Center for AIDS Research [5P30AI073961]; Leukemia and Lymphoma Society
SCOR grant [7009-12]
FX This work was supported by grants from the Cancer Research Institute
(G.A. Rabinovich), Mizutani Foundation for Glycoscience (G.A.
Rabinovich), Fundacion Sales (G.A. Rabinovich), Agencia Nacional de
Promocion Cientifica y Tecnologica (G.A. Rabinovich; PICT 2010-870),
University of Buenos Aires (G.A. Rabinovich), Consejo Nacional de
Investigaciones Cientificas y Tecnicas (M. Salatino and G.A.
Rabinovich), the Associazione Italiana per la Ricerca sul Cancro (A.
Albini), National Institutes of Health (NIH), National Cancer Institute
(NCI; CA136387), and NCI/OHAM supplements to the Developmental Center
for AIDS Research (E.A. Mesri; 5P30AI073961), and a Leukemia and
Lymphoma Society SCOR grant (M.A. Shipp; # 7009-12). We are grateful to
Ferioli and Ostry families for generous donations.
NR 63
TC 60
Z9 60
U1 1
U2 12
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD OCT 22
PY 2012
VL 209
IS 11
BP 1985
EP 2000
DI 10.1084/jem.20111665
PG 16
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 027QT
UT WOS:000310368800007
PM 23027923
ER
PT J
AU Kaji, T
Ishige, A
Hikida, M
Taka, J
Hijikata, A
Kubo, M
Nagashima, T
Takahashi, Y
Kurosaki, T
Okada, M
Ohara, O
Rajewsky, K
Takemori, T
AF Kaji, Tomohiro
Ishige, Akiko
Hikida, Masaki
Taka, Junko
Hijikata, Atsushi
Kubo, Masato
Nagashima, Takeshi
Takahashi, Yoshimasa
Kurosaki, Tomohiro
Okada, Mariko
Ohara, Osamu
Rajewsky, Klaus
Takemori, Toshitada
TI Distinct cellular pathways select germline-encoded and somatically
mutated antibodies into immunological memory
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID GERMINAL-CENTER FORMATION; PRIMARY IMMUNE-RESPONSE; LIVED PLASMA-CELLS;
B-CELLS; AFFINITY MATURATION; CLONAL SELECTION; PRIMARY IMMUNIZATION;
GENE-EXPRESSION; MURINE MEMORY; T-CELLS
AB One component of memory in the antibody system is long-lived memory B cells selected for the expression of somatically mutated, high-affinity antibodies in the T cell-dependent germinal center (GC) reaction. A puzzling observation has been that the memory B cell compartment also contains cells expressing unmutated, low-affinity antibodies. Using conditional Bcl6 ablation, we demonstrate that these cells are generated through proliferative expansion early after immunization in a T cell-dependent but GC-independent manner. They soon become resting and long-lived and display a novel distinct gene expression signature which distinguishes memory B cells from other classes of B cells. GC-independent memory B cells are later joined by somatically mutated GC descendants at roughly equal proportions and these two types of memory cells efficiently generate adoptive secondary antibody responses. Deletion of T follicular helper (Tfh) cells significantly reduces the generation of mutated, but not unmutated, memory cells early on in the response. Thus, B cell memory is generated along two fundamentally distinct cellular differentiation pathways. One pathway is dedicated to the generation of high-affinity somatic antibody mutants, whereas the other preserves germ line antibody specificities and may prepare the organism for rapid responses to antigenic variants of the invading pathogen.
C1 [Kaji, Tomohiro; Ishige, Akiko; Taka, Junko; Takemori, Toshitada] RIKEN Res Ctr Allergy & Immunol, Lab Immunol Memory, Yokohama, Kanagawa 2300045, Japan.
[Kubo, Masato] RIKEN Res Ctr Allergy & Immunol, Signal Network, Yokohama, Kanagawa 2300045, Japan.
[Hikida, Masaki] Kyoto Univ, Grad Sch Med, Ctr Immunoregulat Technol & Therapeut, Sakyo Ku, Kyoto 6068501, Japan.
[Takahashi, Yoshimasa] Natl Inst Infect Dis, Dept Immunol, Shinjyuku Ku, Tokyo 1628640, Japan.
[Rajewsky, Klaus] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
[Rajewsky, Klaus] Harvard Univ, Program Cellular & Mol Med, Childrens Hosp, Sch Med, Boston, MA 02115 USA.
[Rajewsky, Klaus] Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany.
RP Takemori, T (reprint author), RIKEN Res Ctr Allergy & Immunol, Lab Immunol Memory, Yokohama, Kanagawa 2300045, Japan.
EM klaus.rajewsky@mdc-berlin.de; mttoshi@rcai.riken.jp
RI Takemori, Toshitada/A-5909-2016; Ohara, Osamu/G-5448-2015; Kurosaki,
Tomohiro/D-1306-2009; Okada, Mariko/N-6933-2015
OI Ohara, Osamu/0000-0002-3328-9571; Kurosaki,
Tomohiro/0000-0002-6352-304X;
FU National Institutes of Health of the USA
FX We are grateful to Atsushi Miyawaki and Asako Sakaue-Sawano for
Fucci-expressing transgenic mice, Michael Reth for mb1-cre mice, Michel
Nussenzweig for B1-8hi mice, Garnett Kelsoe for anti-CD40L
mAb, and Yuichi Aiba for discussion. K. Rajewsky is supported by the
National Institutes of Health of the USA.
NR 60
TC 75
Z9 77
U1 3
U2 16
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
J9 J EXP MED
JI J. Exp. Med.
PD OCT 22
PY 2012
VL 209
IS 11
BP 2079
EP 2097
DI 10.1084/jem.20120127
PG 19
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA 027QT
UT WOS:000310368800013
PM 23027924
ER
PT J
AU Vickers, AJ
Cronin, AM
Maschino, AC
Lewith, G
MacPherson, H
Foster, NE
Sherman, KJ
Witt, CM
Linde, K
AF Vickers, Andrew J.
Cronin, Angel M.
Maschino, Alexandra C.
Lewith, George
MacPherson, Hugh
Foster, Nadine E.
Sherman, Karen J.
Witt, Claudia M.
Linde, Klaus
CA Acupuncture Trialists'
TI Acupuncture for Chronic Pain Individual Patient Data Meta-analysis
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Review
ID LOW-BACK-PAIN; RANDOMIZED CONTROLLED-TRIAL; CHRONIC NECK PAIN;
TENSION-TYPE HEADACHE; CONTROLLED CLINICAL-TRIAL; ELECTRICAL
NERVE-STIMULATION; STUDY COMPARING ACUPUNCTURE; TRIGGER POINT
ACUPUNCTURE; ANTI-INFLAMMATORY THERAPY; ROTATOR CUFF TENDINITIS
AB Background: Although acupuncture is widely used for chronic pain, there remains considerable controversy as to its value. We aimed to determine the effect size of acupuncture for 4 chronic pain conditions: back and neck pain, osteoarthritis, chronic headache, and shoulder pain.
Methods: We conducted a systematic review to identify randomized controlled trials (RCTs) of acupuncture for chronic pain in which allocation concealment was determined unambiguously to be adequate. Individual patient data meta-analyses were conducted using data from 29 of 31 eligible RCTs, with a total of 17 922 patients analyzed.
Results: In the primary analysis, including all eligible RCTs, acupuncture was superior to both sham and no-acupuncture control for each pain condition (P<.001 for all comparisons). After exclusion of an outlying set of RCTs that strongly favored acupuncture, the effect sizes were similar across pain conditions. Patients receiving acupuncture had less pain, with scores that were 0.23 (95% CI, 0.13-0.33), 0.16 (95% CI, 0.07-0.25), and 0.15 (95% CI, 0.07-0.24) SDs lower than sham controls for back and neck pain, osteoarthritis, and chronic headache, respectively; the effect sizes in comparison to no-acupuncture controls were 0.55 (95% CI, 0.51-0.58), 0.57 (95% CI, 0.50-0.64), and 0.42 (95% CI, 0.37-0.46) SDs. These results were robust to a variety of sensitivity analyses, including those related to publication bias.
Conclusions: Acupuncture is effective for the treatment of chronic pain and is therefore a reasonable referral option. Significant differences between true and sham acupuncture indicate that acupuncture is more than a placebo. However, these differences are relatively modest, suggesting that factors in addition to the specific effects of needling are important contributors to the therapeutic effects of acupuncture.
C1 [Vickers, Andrew J.; Maschino, Alexandra C.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol, New York, NY 10065 USA.
[Vickers, Andrew J.; Maschino, Alexandra C.] Mem Sloan Kettering Canc Ctr, Dept Biostat, New York, NY 10065 USA.
[Cronin, Angel M.] Dana Farber Canc Inst, Ctr Outcomes & Policy Res, Boston, MA 02115 USA.
[Lewith, George] Univ Southampton, Complementary & Integrated Medline Res Unit, Southampton, Hants, England.
[MacPherson, Hugh] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England.
[Foster, Nadine E.] Keele Univ, Arthrit Res UK Primary Care Ctr, Newcastle Under Lyme, Staffs, England.
[Sherman, Karen J.] Grp Hlth Res Inst, Seattle, WA USA.
[Witt, Claudia M.] Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany.
[Linde, Klaus] Tech Univ Munich, Inst Gen Practice, Munich, Germany.
RP Vickers, AJ (reprint author), Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, 307 E 63rd St, New York, NY 10065 USA.
EM vickersa@mskcc.org
RI Vas, Jorge/B-1138-2012;
OI Vas, Jorge/0000-0003-1326-856X; Lewith, George/0000-0002-2364-3960;
MacPherson, Hugh/0000-0003-4255-4768; Vickers,
Andrew/0000-0003-1525-6503
FU National Center for Complementary and Alternative Medicine (NCCAM) at
the National Institutes of Health (NIH) [R21 (AT004189I)]; Samueli
Institute; UK National Institute for Health Research (NIHR)
[RP-PG-0707-10186]
FX The Acupuncture Trialists' Collaboration is funded by an R21 (AT004189I
from the National Center for Complementary and Alternative Medicine
(NCCAM) at the National Institutes of Health (NIH) to Dr Vickers) and by
a grant from the Samueli Institute. Dr MacPherson's work has been
supported in part by the UK National Institute for Health Research
(NIHR) under its Programme Grants for Applied Research scheme
(RP-PG-0707-10186). The views expressed in this publication are those of
the author(s) and not necessarily those of the NCCAM NHS, the NIHR, or
the Department of Health in England.
NR 113
TC 273
Z9 286
U1 20
U2 107
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
EI 1538-3679
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD OCT 22
PY 2012
VL 172
IS 19
BP 1444
EP 1453
DI 10.1001/archinternmed.2012.3654
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 023XG
UT WOS:000310070200003
PM 22965186
ER
PT J
AU Zhang, YT
Steinman, MA
Kaplan, CM
AF Zhang, Yuting
Steinman, Michael A.
Kaplan, Cameron M.
TI Geographic Variation in Outpatient Antibiotic Prescribing Among Older
Adults
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID RESPIRATORY-TRACT INFECTIONS; ADVERSE-REACTIONS; PRIMARY-CARE; QUALITY
AB Background: Consequences of antibiotic overuse are substantial, especially among older adults, who are more susceptible to adverse reactions. Findings about variation in antibiotic prescribing can target policy efforts to focused areas; however, little is known about these patterns among older adults.
Methods: Using Medicare Part D data from January 1, 2007, through December 31, 2009 (comprising 1.0-1.1 million patients per year), we examined geographic variation in antibiotic use among older adults in 306 Dartmouth Atlas of Health Care hospital referral regions, 50 states and the District of Columbia, and 4 national regions (South, West, Midwest, and Northeast). In addition, we examined the quarterly change in antibiotic use across the 4 regions. Differences in patient demographics, insurance status, and clinical characteristics were adjusted for across regions.
Results: Substantial geographic and quarterly variation in outpatient antibiotic prescribing existed across regions after adjusting for population characteristics. This variation could not be explained by differences in the prevalences of the underlying conditions. For example, the ratios of the 75th percentile to the 25th percentile of adjusted annual antibiotic spending were 1.31 across states and 1.32 across regions. The highest antibiotic use was in the South, where 21.4% of patients per quarter used an antibiotic, whereas the lowest antibiotic use was in the West, where 17.4% of patients per quarter used an antibiotic (P < .01). Regardless of region, the rate of antibiotic use was highest in the first quarter (20.9% in January through March) and was lowest in the third quarter (16.9% in July through September) (P < .01).
Conclusions: Areas with high rates of antibiotic use may benefit from targeted programs to reduce unnecessary prescription. Quality improvement programs can set attainable targets using the low-prescribing areas as a reference, particularly targeting older adults.
C1 [Zhang, Yuting; Kaplan, Cameron M.] Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, Pittsburgh, PA 15261 USA.
[Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA.
[Steinman, Michael A.] San Francisco VA Med Ctr, Hlth Serv Res & Dev Serv Res Enhancement Award Pr, San Francisco, CA USA.
RP Zhang, YT (reprint author), Univ Pittsburgh, Dept Hlth Policy & Management, Grad Sch Publ Hlth, 130 De Soto St,Crabtree Hall,Room A664, Pittsburgh, PA 15261 USA.
EM ytzhang@pitt.edu
OI Zhang, Yuting/0000-0002-6460-6779
FU Centers for Medicare & Medicaid Services and the Institute of Medicine
from the National Institute of Mental Health [HHSP22320042509XI, RC1
MH088510]; Agency for Healthcare Research and Quality [R01 HS018657];
National Institute on Aging [1K23-AG030999]; American Federation for
Aging Research
FX This study was supported in part by grants HHSP22320042509XI from the
Centers for Medicare & Medicaid Services and the Institute of Medicine,
RC1 MH088510 from the National Institute of Mental Health, and R01
HS018657 from the Agency for Healthcare Research and Quality (Dr Zhang)
and by grant 1K23-AG030999 from the National Institute on Aging and the
American Federation for Aging Research (Dr Steinman).
NR 19
TC 30
Z9 30
U1 0
U2 10
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD OCT 22
PY 2012
VL 172
IS 19
BP 1465
EP 1471
DI 10.1001/archinternmed.2012.3717
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 023XG
UT WOS:000310070200007
PM 23007171
ER
PT J
AU Ngwa, W
Makrigiorgos, GM
Berbeco, RI
AF Ngwa, Wilfred
Makrigiorgos, G. Mike
Berbeco, Ross I.
TI Gold nanoparticle enhancement of stereotactic radiosurgery for
neovascular age-related macular degeneration
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID X-RAY-IRRADIATION; AMD 6-MONTH SAFETY; ANTI-VEGF AGENTS; PHOTODYNAMIC
THERAPY; RANIBIZUMAB THERAPY; FUNCTIONAL OUTCOMES; RADIATION TREATMENT;
DOSE ENHANCEMENT; ENERGY; RADIOTHERAPY
AB Age-related macular degeneration (AMD) is the leading cause of blindness in developed countries for people over the age of 50. In this work, the dosimetric feasibility of using gold nanoparticles (AuNP) as radiosensitizers to enhance kilovoltage stereotactic radiosurgery for neovascular AMD is investigated. Microdosimetry calculations at the sub-cellular level were carried out to estimate the radiation dose enhancement to individual nuclei in neovascular AMD endothelial cells (nDEF) due to photon-induced photo-/Auger electrons from x-ray-irradiated AuNP. The nDEF represents the ratio of radiation doses to the endothelial cell nuclei with and without AuNP. The calculations were carried out for a range of feasible AuNP local concentrations using the clinically applicable 100 kVp x-ray beam parameters employed by a commercially available x-ray therapy system. The results revealed nDEF values of 1.30-3.26 for the investigated concentration range of 1-7 mg g(-1), respectively. In comparison, for the same concentration range, nDEF values of 1.32-3.40, 1.31-3.33, 1.29-3.19, 1.28-3.12 were calculated for 80, 90, 110 and 120 kVp x-rays, respectively. Meanwhile, calculations as a function of distance from the AuNP showed that the dose enhancement, for 100 kVp, is markedly confined to the targeted neovascular AMD endothelial cells where AuNP are localized. These findings provide impetus for considering the application of AuNP to enhance therapeutic efficacy during stereotactic radiosurgery for neovascular AMD.
C1 [Ngwa, Wilfred] Brigham & Womens Hosp, Div Med Phys & Biophys, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Ngwa, W (reprint author), Brigham & Womens Hosp, Div Med Phys & Biophys, Dept Radiat Oncol, Dana Farber Canc Inst, 75 Francis St, Boston, MA 02115 USA.
EM wngwa@lroc.harvard.edu
NR 45
TC 15
Z9 16
U1 1
U2 29
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2012
VL 57
IS 20
BP 6371
EP 6380
DI 10.1088/0031-9155/57/20/6371
PG 10
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 016WD
UT WOS:000309549600005
PM 22995994
ER
PT J
AU Titt, U
Bednarz, B
Paganetti, H
AF Titt, U.
Bednarz, B.
Paganetti, H.
TI Comparison of MCNPX and Geant4 proton energy deposition predictions for
clinical use
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID MONTE-CARLO SIMULATIONS; DOSE DISTRIBUTIONS; TREATMENT UNCERTAINTIES;
THERAPY; NOZZLE; IMPT; SENSITIVITY; TOOLKIT; BEAMS; MODEL
AB Several different Monte Carlo codes are currently being used at proton therapy centers to improve upon dose predictions over standard methods using analytical or semi-empirical dose algorithms. There is a need to better ascertain the differences between proton dose predictions from different available Monte Carlo codes. In this investigation Geant4 and MCNPX, the two most-utilized Monte Carlo codes for proton therapy applications, were used to predict energy deposition distributions in a variety of geometries, comprising simple water phantoms, water phantoms with complex inserts and in a voxelized geometry based on clinical CT data. The Gamma analysis was used to evaluate the differences of the predictions between the codes. The results show that in all the cases the agreement was better than clinical acceptance criteria.
C1 [Titt, U.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Bednarz, B.] Univ Wisconsin, Dept Med Phys, Madison, WI 53705 USA.
[Bednarz, B.; Paganetti, H.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Bednarz, B.; Paganetti, H.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Titt, U (reprint author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 94, Houston, TX 77030 USA.
EM utitt@mdanderson.org
FU National Cancer Institute [P01CA021239]
FX This project is supported by P01CA021239 from the National Cancer
Institute. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Cancer
Institute or the National Institutes of Health.
NR 26
TC 12
Z9 12
U1 0
U2 5
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2012
VL 57
IS 20
BP 6381
EP 6393
DI 10.1088/0031-9155/57/20/6381
PG 13
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 016WD
UT WOS:000309549600006
PM 22996039
ER
PT J
AU Mallas, G
Brooks, DH
Rosenthal, A
Nudelman, RN
Mauskapf, A
Jaffer, FA
Ntziachristos, V
AF Mallas, Georgios
Brooks, Dana H.
Rosenthal, Amir
Nudelman, R. Nika
Mauskapf, Adam
Jaffer, Farouc A.
Ntziachristos, Vasilis
TI Improving quantification of intravascular fluorescence imaging using
structural information
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID OPTICAL COHERENCE TOMOGRAPHY; RAY COMPUTED-TOMOGRAPHY; IN-VIVO;
CARDIOVASCULAR-DISEASE; ULTRASOUND IMAGES; CONTRAST AGENT;
ATHEROSCLEROSIS; SEGMENTATION; INFLAMMATION; SYSTEM
AB Intravascular near-infrared fluorescence (iNIRF) imaging can enable the in vivo visualization of biomarkers of vascular pathology, including high-risk plaques. The technique resolves the bio-distribution of systemically administered fluorescent probes with molecular specificity in the vessel wall. However, the geometrical variations that may occur in the distance between fibre-tip and vessel wall can lead to signal intensity variations and challenge quantification. Herein we examined whether the use of anatomical information of the cross-section vessel morphology, obtained from co-registered intravascular ultrasound (IVUS), can lead to quantification improvements when fibre-tip and vessel wall distance variations are present. The algorithm developed employs a photon propagation model derived from phantom experiments that is used to calculate the relative attenuation of fluorescence signals as they are collected over 360. along the vessel wall, and utilizes it to restore accurate fluorescence readings. The findings herein point to quantification improvements when employing hybrid iNIRF, with possible implications to the clinical detection of high-risk plaques or blood vessel theranostics.
C1 [Mallas, Georgios; Brooks, Dana H.] Northeastern Univ, Dept Elect & Comp Engn, Commun & Digital Signal Proc Res Ctr, Boston, MA 02115 USA.
[Mallas, Georgios; Rosenthal, Amir; Mauskapf, Adam; Jaffer, Farouc A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Cardiovasc Res Ctr, Boston, MA USA.
[Rosenthal, Amir; Nudelman, R. Nika; Ntziachristos, Vasilis] Tech Univ Munich, IBMI, Munich, Germany.
[Rosenthal, Amir; Nudelman, R. Nika; Ntziachristos, Vasilis] Helmholtz Zentrum Munchen, Munich, Germany.
RP Mallas, G (reprint author), Northeastern Univ, Dept Elect & Comp Engn, Commun & Digital Signal Proc Res Ctr, 409 Dana Bldg,360 Huntington Ave, Boston, MA 02115 USA.
EM mallasgeo@gmail.com
RI Rosenthal, Amir/C-8650-2014;
OI Jaffer, Farouc/0000-0001-7980-384X
FU National Institute of Health [1R01EB004382-01A2, R01 HL 108229];
European Community [235689]; Broadview Ventures
FX This work was supported by National Institute of Health grant no
1R01EB004382-01A2 (GM, DHB, VN), European Community's Seventh Framework
Programme (FP7/2007-2013 under grant agreement no 235689 (AR)), National
Institutes of Health grant no R01 HL 108229 (FAJ.), Broadview Ventures
(FAJ, VN).
NR 30
TC 4
Z9 4
U1 0
U2 10
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2012
VL 57
IS 20
BP 6395
EP 6406
DI 10.1088/0031-9155/57/20/6395
PG 12
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 016WD
UT WOS:000309549600007
PM 22996051
ER
PT J
AU Tichauer, KM
Samkoe, KS
Klubben, WS
Hasan, T
Pogue, BW
AF Tichauer, K. M.
Samkoe, K. S.
Klubben, W. S.
Hasan, T.
Pogue, B. W.
TI Advantages of a dual-tracer model over reference tissue models for
binding potential measurement in tumors
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; IN-VIVO; RECEPTOR-BINDING;
CARCINOEMBRYONIC ANTIGEN; COMPARTMENTAL MODEL; HUMAN BRAIN; EXPRESSION;
KINETICS; TIME; RADIOIMMUNODETECTION
AB The quantification of tumor molecular expression in vivo could have a significant impact for informing and monitoring emerging targeted therapies in oncology. Molecular imaging of targeted tracers can be used to quantify receptor expression in the form of a binding potential (BP) if the arterial input curve or a surrogate of it is also measured. However, the assumptions of the most common approaches (reference tissue models) may not be valid for use in tumors. In this study, the validity of reference tissue models is investigated for use in tumors experimentally and in simulations. Three different tumor lines were grown subcutaneously in athymic mice and the mice were injected with a mixture of an epidermal growth factor receptor-targeted fluorescent tracer and an untargeted fluorescent tracer. A one-compartment plasma input model demonstrated that the transport kinetics of both tracers was significantly different between tumors and all potential reference tissues, and using the reference tissue model resulted in a theoretical underestimation in BP of 50% +/- 37%. On the other hand, the targeted and untargeted tracers demonstrated similar transport kinetics, allowing a dual-tracer approach to be employed to accurately estimate BP (with a theoretical error of 0.23% +/- 9.07%). These findings highlight the potential for using a dual-tracer approach to quantify receptor expression in tumors with abnormal hemodynamics, possibly to inform the choice or progress of molecular cancer therapies.
C1 [Tichauer, K. M.; Samkoe, K. S.; Klubben, W. S.; Pogue, B. W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Samkoe, K. S.; Pogue, B. W.] Dartmouth Med Sch, Dept Surg, Hanover, NH 03755 USA.
[Pogue, B. W.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Tichauer, KM (reprint author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
EM kenneth.tichauer@dartmouth.edu; brian.w.pogue@dartmouth.edu
OI Tichauer, Kenneth/0000-0003-1667-3026
FU NIH [P01CA84201, R01CA156177, U54CA151662]; CIHR
FX This research was funded by NIH grants P01CA84201, R01CA156177 and
U54CA151662. KMT acknowledges funding from the CIHR postdoctoral
fellowship program. We would also like to thank Kristian J Sexton and
Harold H Yang for their assistance with running the animal experiments,
and Robert W Holt for his input on data presentation.
NR 37
TC 12
Z9 12
U1 1
U2 9
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2012
VL 57
IS 20
BP 6647
EP 6659
DI 10.1088/0031-9155/57/20/6647
PG 13
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 016WD
UT WOS:000309549600021
PM 23022732
ER
PT J
AU Butterworth, KT
McGarry, CK
Clasie, B
Carabe-Fernandez, A
Schuemann, J
Depauw, N
Tang, SK
McMahon, SJ
Schettino, G
O'Sullivan, JM
Lu, HM
Kooy, H
Paganetti, H
Hounsell, AR
Held, KD
Prise, KM
AF Butterworth, Karl T.
McGarry, Conor K.
Clasie, Ben
Carabe-Fernandez, Alejandro
Schuemann, Jan
Depauw, Nicolas
Tang, Shikui
McMahon, Stephen J.
Schettino, Giuseppe
O'Sullivan, Joe M.
Lu, Hsaio-Ming
Kooy, Hanne
Paganetti, Harald
Hounsell, Alan R.
Held, Kathryn D.
Prise, Kevin M.
TI Relative biological effectiveness (RBE) and out-of-field cell survival
responses to passive scattering and pencil beam scanning proton beam
deliveries
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID MODULATED RADIATION-FIELDS; THERAPY; CANCER; RADIOTHERAPY; EXPOSURE;
IMRT
AB The relative biological effectiveness (RBE) of passive scattered (PS) and pencil beam scanned (PBS) proton beam delivery techniques for uniform beam configurations was determined by clonogenic survival. The radiobiological impact of modulated beam configurations on cell survival occurring in- or out-of-field for both delivery techniques was determined with intercellular communication intact or physically inhibited. Cell survival responses were compared to those observed using a 6 MV photon beam produced with a linear accelerator. DU-145 cells showed no significant difference in survival response to proton beams delivered by PS and PBS or 6 MV photons taking into account a RBE of 1.1 for protons at the centre of the spread out Bragg peak. Significant out-of-field effects similar to those observed for 6 MV photons were observed for both PS and PBS proton deliveries with cell survival decreasing to 50-60% survival for scattered doses of 0.05 and 0.03 Gy for passive scattered and pencil beam scanned beams respectively. The observed out-of-field responses were shown to be dependent on intercellular communication between the in-and out-of-field cell populations. These data demonstrate, for the first time, a similar RBE between passive and actively scanned proton beams and confirm that out-of-field effects may be important determinants of cell survival following exposure to modulated photon and proton fields
C1 [Butterworth, Karl T.; McGarry, Conor K.; McMahon, Stephen J.; Schettino, Giuseppe; Hounsell, Alan R.; Prise, Kevin M.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
[McGarry, Conor K.; O'Sullivan, Joe M.; Hounsell, Alan R.] Belfast Hlth & Social Care Trust, No Ireland Canc Ctr, Belfast, Antrim, North Ireland.
[Clasie, Ben; Carabe-Fernandez, Alejandro; Schuemann, Jan; Depauw, Nicolas; Tang, Shikui; Lu, Hsaio-Ming; Kooy, Hanne; Paganetti, Harald; Held, Kathryn D.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Depauw, Nicolas] Univ Wollongong, Ctr Med Phys, Wollongong, NSW 2522, Australia.
RP Butterworth, KT (reprint author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast, Antrim, North Ireland.
EM k.butterworth@qub.ac.uk
RI Prise, Kevin/N-7872-2015;
OI Prise, Kevin/0000-0001-6134-7946; Schettino,
Giuseppe/0000-0003-3284-3953; McMahon, Stephen/0000-0001-5980-6728;
McGarry, Conor/0000-0001-6396-2184
FU MGH [C06 CA059267]; Cancer Research UK [C1513/A7047, C212/A11342];
Health and Social Care Research and Development Office of the Public
Health Agency
FX The authors wish to acknowledge equal contributions to this work by KTB
and CKM, who should be considered as joint first authors. This project
was funded by MGH Federal Share of Program Income under C06 CA059267 to
KDH and by Cancer Research UK (grant no. C1513/A7047 to KMP and grant
no. C212/A11342 for ARH and SJM). CKM is supported by a training
fellowship award from the Health and Social Care Research and
Development Office of the Public Health Agency.
NR 21
TC 5
Z9 5
U1 0
U2 6
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 21
PY 2012
VL 57
IS 20
BP 6671
EP 6680
DI 10.1088/0031-9155/57/20/6671
PG 10
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 016WD
UT WOS:000309549600023
PM 23022765
ER
PT J
AU Ligibel, J
AF Ligibel, Jennifer
TI Lifestyle Factors in Cancer Survivorship
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID BODY-MASS INDEX; STAGE BREAST-CANCER; III COLON-CANCER; GROWTH-FACTOR-I;
PHYSICAL-ACTIVITY; PROSTATE-CANCER; WEIGHT-GAIN; COLORECTAL-CANCER;
SURVIVAL; RISK
AB Lifestyle factors have been linked to the risk of developing many common malignancies and, increasingly, to prognosis. Observational evidence has shown a relationship between so-called energy balance factors (ie, diet, physical activity, and body weight) and risk of cancer recurrence and mortality in cancers of the breast, prostate, colon and, perhaps, other cancers. Interventional work has shown that individuals who make favorable changes in these lifestyle factors after cancer diagnosis feel better, experience less fatigue, and may possibly even decrease risk of cancer recurrence. Other lifestyle behaviors, such as smoking and alcohol consumption, have also been linked to the development of common cancers and may have important health consequences for cancer survivors. This article reviews the evidence that links lifestyle factors to cancer outcomes, provides clinical recommendations for cancer survivors, and describes future directions for lifestyle research in cancer survivors.
C1 Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Ligibel, J (reprint author), Dana Farber Canc Inst, Boston, MA 02215 USA.
EM jligibel@partners.org
NR 85
TC 48
Z9 48
U1 1
U2 29
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2012
VL 30
IS 30
BP 3697
EP 3704
DI 10.1200/JCO.2012.42.0638
PG 8
WC Oncology
SC Oncology
GA 027LI
UT WOS:000310353400006
PM 23008316
ER
PT J
AU Ruddy, KJ
Partridge, AH
AF Ruddy, Kathryn J.
Partridge, Ann H.
TI Fertility (male and female) and Menopause
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID BREAST-CANCER SURVIVORS; QUALITY-OF-LIFE; TESTICULAR SPERM EXTRACTION;
YOUNG-WOMEN; POSTMENOPAUSAL WOMEN; OVARIAN STIMULATION; VASOMOTOR
SYMPTOMS; HOT FLASHES; EMBRYO CRYOPRESERVATION; ADJUVANT TREATMENT
AB The impact of oncologic treatments on fertility and menopausal symptoms is often significant for patients with cancer. Surgery, radiation, and chemotherapy can all damage the reproductive organs or the hypothalamic pituitary axis that controls them, impairing fertility and causing hormonally mediated symptoms such as hot flashes.
Understanding these risks and strategies to mitigate them may substantially improve cancer survivorship care. For both female and male patients who desire a future biologic child, there are a variety of fertility preservation techniques that should be considered. For cancer survivors who experience menopausal symptoms, lifestyle changes may be beneficial, and hormonal and nonhormonal pharmacologic agents are well proven to reduce symptom burden.
C1 [Ruddy, Kathryn J.; Partridge, Ann H.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02215 USA.
[Ruddy, Kathryn J.; Partridge, Ann H.] Harvard Univ, Sch Med, Boston, MA USA.
RP Partridge, AH (reprint author), Brigham & Womens Hosp, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM ahpartridge@partners.org
NR 74
TC 22
Z9 22
U1 1
U2 16
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2012
VL 30
IS 30
BP 3705
EP 3711
DI 10.1200/JCO.2012.42.1966
PG 7
WC Oncology
SC Oncology
GA 027LI
UT WOS:000310353400007
PM 23008319
ER
PT J
AU Bober, SL
Varela, VS
AF Bober, Sharon L.
Varela, Veronica Sanchez
TI Sexuality in Adult Cancer Survivors: Challenges and Intervention
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID QUALITY-OF-LIFE; LOCALIZED PROSTATE-CANCER; RADICAL RETROPUBIC
PROSTATECTOMIES; ANDROGEN DEPRIVATION THERAPY;
BONE-MARROW-TRANSPLANTATION; CASE-MATCHED CONTROLS; VERSUS-HOST-DISEASE;
LONG-TERM SURVIVORS; BREAST-CANCER; ERECTILE DYSFUNCTION
AB Sexual dysfunction is one of the most common and distressing consequences of cancer treatment. Although some treatment-related sexual adverse effects are short-term, many survivors face long-term effects such as treatment-induced menopause, altered gonadal function, and significant surgical disfigurement. Profound sexual dysfunction has been shown to have a significant negative effect on quality of life. Although these problems have been well documented and there are a range of intervention strategies that can help patients cope with treatment-related sexual problems, many survivors do not feel prepared for potential sexual changes and often do not receive adequate support to manage sexual dysfunction. Numerous barriers contribute to this underprovided aspect of survivorship care, including lack of provider training and access to readily available resources. In addition, psychological, relational, and cultural factors significantly influence sexuality but are often not taken into consideration in research and clinical practice. By taking an integrative approach and providing survivors with appropriate screening, information, and support, sexual dysfunction and accompanying distress can be significantly alleviated. In this article, we aim to provide a concise review of the most common sexual problems experienced by survivors and highlight some of the most promising evidence-based practices for assessment and intervention. We also address limitations encountered in research and practice and explore future directions, including suggestions for adopting an integrative treatment model to address sexual dysfunction in a cancer survivorship treatment setting.
C1 [Bober, Sharon L.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Sexual Hlth Program, Boston, MA 02215 USA.
[Varela, Veronica Sanchez] Perini Family Survivors Ctr, Dana Farber Canc Inst, Boston, MA USA.
RP Bober, SL (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Sexual Hlth Program, 450 Brookline Ave,D321, Boston, MA 02215 USA.
EM sharon_bober@dfci.harvard.edu
NR 109
TC 60
Z9 60
U1 0
U2 24
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2012
VL 30
IS 30
BP 3712
EP 3719
DI 10.1200/JCO.2012.41.7915
PG 8
WC Oncology
SC Oncology
GA 027LI
UT WOS:000310353400008
PM 23008322
ER
PT J
AU Wood, ME
Vogel, V
Ng, A
Foxhall, L
Goodwin, P
Travis, LB
AF Wood, Marie E.
Vogel, Victor
Ng, Andrea
Foxhall, Lewis
Goodwin, Pamela
Travis, Lois B.
TI Second Malignant Neoplasms: Assessment and Strategies for Risk Reduction
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID CHILDHOOD-CANCER SURVIVOR; LONG-TERM SURVIVORS; CONTRALATERAL
BREAST-CANCER; LI-FRAUMENI-SYNDROME; THERAPY-RELATED LEUKEMIA;
SQUAMOUS-CELL CARCINOMA; ACUTE MYELOID-LEUKEMIA; RANDOMIZED
CONTROLLED-TRIAL; SURGICAL ADJUVANT BREAST; BRCA2 MUTATION CARRIERS
AB Improvements in early detection, supportive care, and treatment have resulted in an increasing number of cancer survivors, with a current 5-year relative survival rate for all cancers combined of approximately 66.1%. For some patients, these survival advances have been offset by the long-term late effects of cancer and its treatment, with second malignant neoplasms (SMNs) comprising one of the most potentially life-threatening sequelae. The number of patients with SMNs is growing, with new SMNs now representing about one in six of all cancers reported to the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) Program. SMNs reflect not only the late effects of therapy but also the influence of shared etiologic factors (in particular, tobacco and excessive alcohol intake), genetic susceptibility, environmental exposures, host effects, and combinations of factors, including gene-environment interactions. For selected SMNs, risk is also modified by age at exposure and attained age. SMNs can be categorized into three major groups according to the predominant etiologic factor(s): (1) treatment-related, (2) syndromic, and (3) those due to shared etiologic exposures, although the nonexclusivity of these groups should be underscored. Here we provide an overview of SMNs in survivors of adult-onset cancer, summarizing the current, albeit limited, clinical evidence with regard to screening and prevention, with a focus on the provision of guidance for health care providers. The growing number of patients with second (and higher-order) cancers mandates that we also further probe etiologic influences and genetic variants that heighten risk, and that we better define high-risk groups for targeted preventive and interventional clinical strategies.
C1 [Wood, Marie E.] Univ Vermont, Div Hematol Oncol, Burlington, VT 05405 USA.
Geisinger Hlth Syst, Danville, PA USA.
[Ng, Andrea] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Foxhall, Lewis] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Goodwin, Pamela] Univ Toronto, Toronto, ON, Canada.
[Travis, Lois B.] Univ Rochester, Med Ctr, Rochester, NY USA.
RP Wood, ME (reprint author), Univ Vermont, Div Hematol Oncol, 89 Beaumont Ave,Given E214, Burlington, VT 05405 USA.
EM marie.wood@uvm.edu
RI Goodwin, Pamela/K-1477-2013
NR 148
TC 55
Z9 55
U1 1
U2 13
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2012
VL 30
IS 30
BP 3734
EP 3745
DI 10.1200/JCO.2012.41.8681
PG 12
WC Oncology
SC Oncology
GA 027LI
UT WOS:000310353400011
PM 23008293
ER
PT J
AU Goldkorn, A
Vogelzang, NJ
Fink, LM
Ely, B
Quinn, DI
Tangen, CM
Tai, YC
Twardowski, P
Van Veldhuizen, PJ
Agarwal, N
Carducci, MA
Monk, JP
Garzotto, M
Mack, PC
Lara, P
Higano, CS
Hussain, M
Cote, RJ
Thompson, IM
AF Goldkorn, Amir
Vogelzang, Nicholas J.
Fink, Louis M.
Ely, Benjamin
Quinn, David I.
Tangen, Catherine M.
Tai, Yu-Chong
Twardowski, Przemyslaw
Van Veldhuizen, Peter J.
Agarwal, Neeraj
Carducci, Michael Anthony
Monk, J. P.
Garzotto, Mark
Mack, Philip C.
Lara, Primo
Higano, Celestia S.
Hussain, Maha
Cote, Richard J.
Thompson, Ian Murchie
CA Southwest Oncology Grp
TI Circulating tumor cell (CTC) counts and CTC telomerase activity (TA) as
prognotic markers of overall survival (OS) in SWOG S0421: Docetaxel with
or without atrasentan for metastatic castration-resistant prostate
cancer (mCRPC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
C1 Univ So Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA.
US Oncol Res LLC, McKesson Specialty Hlth, The Woodlands, TX USA.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Nevada Canc Inst, Las Vegas, NV USA.
SWOG Stat Ctr, Seattle, WA USA.
CALTECH, Pasadena, CA 91125 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Univ Kansas, Ctr Canc, Westwood, KS USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Ohio State Univ, Columbus, OH 43210 USA.
Portland VA Med Ctr, Portland, OR USA.
Univ Calif Davis, Sacramento, CA 95817 USA.
Univ Washington, Seattle Canc Care Alliance, Puget Sound Oncol Consortium, Seattle, WA 98195 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Univ Miami, Leonard M Miller Sch Med, Miami, FL USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 20
PY 2012
VL 30
IS 30
SU S
PG 1
WC Oncology
SC Oncology
GA V31YY
UT WOS:000208920100002
ER
PT J
AU Wedick, NM
Mantzoros, CS
Ding, EL
Brennan, AM
Rosner, B
Rimm, EB
Hu, FB
van Dam, RM
AF Wedick, Nicole M.
Mantzoros, Christos S.
Ding, Eric L.
Brennan, Aoife M.
Rosner, Bernard
Rimm, Eric B.
Hu, Frank B.
van Dam, Rob M.
TI The effects of caffeinated and decaffeinated coffee on sex
hormone-binding globulin and endogenous sex hormone levels: a randomized
controlled trial
SO NUTRITION JOURNAL
LA English
DT Article
DE Coffee; Sex hormones; Randomized trial
ID POSTMENOPAUSAL WOMEN; RISK; PREMENOPAUSAL; CONSUMPTION; ESTRADIOL;
ALCOHOL; MEN
AB Background: Findings from observational studies suggest that sex hormone-binding globulin (SHBG) and endogenous sex hormones may be mediators of the putative relation between coffee consumption and lower risk of type 2 diabetes. The objective of this study was to evaluate the effects of caffeinated and decaffeinated coffee on SHBG and sex hormone levels.
Findings: After a two-week run-in phase with caffeine abstention, we conducted an 8-week parallel-arm randomized controlled trial. Healthy adults (n = 42) were recruited from the Boston community who were regular coffee consumers, nonsmokers, and overweight. Participants were randomized to five 6-ounce cups of caffeinated or decaffeinated instant coffee or water (control group) per day consumed with each meal, mid-morning, and mid-afternoon. The main outcome measures were SHBG and sex hormones [i.e., testosterone, estradiol, dehydroepiandrosterone sulfate]. No significant differences were found between treatment groups for any of the studied outcomes at week 8. At 4 weeks, decaffeinated coffee was associated with a borderline significant increase in SHBG in women, but not in men. At week 4, we also observed several differences in hormone concentrations between the treatment groups. Among men, consumption of caffeinated coffee increased total testosterone and decreased total and free estradiol. Among women, decaffeinated coffee decreased total and free testosterone and caffeinated coffee decreased total testosterone.
Conclusions: Our data do not indicate a consistent effect of caffeinated coffee consumption on SHBG in men or women, however results should be interpreted with caution given the small sample size. This is the first randomized trial investigating the effects of caffeinated and decaffeinated coffee on SHBG and sex hormones and our findings necessitate further examination in a larger intervention trial.
C1 [Wedick, Nicole M.; Ding, Eric L.; Rimm, Eric B.; Hu, Frank B.; van Dam, Rob M.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Mantzoros, Christos S.] Harvard Univ, Sch Med, Boston VA Healthcare Syst, Endocrinol Sect, Boston, MA 02115 USA.
[Mantzoros, Christos S.; Brennan, Aoife M.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Endocrinol Diabet & Metab, Boston, MA 02115 USA.
[Ding, Eric L.; Rosner, Bernard; Rimm, Eric B.; Hu, Frank B.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA.
[Rosner, Bernard] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Rimm, Eric B.; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[van Dam, Rob M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Med, Singapore 117595, Singapore.
[van Dam, Rob M.] Natl Univ Singapore, Saw Swee Hock Sch Publ Hlth, Singapore 117548, Singapore.
RP Wedick, NM (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM nwedick@hsph.harvard.edu
RI van Dam, Rob/F-9674-2010;
OI van Dam, Rob/0000-0002-7354-8734; Ding, Eric/0000-0002-5881-8097
FU Harvard Catalyst Human Research Center Laboratory Support Award; Boston
Obesity Nutrition Research Center pilot and feasibility grant
[2005-P-000377/2]; National Institutes of Health - National Center for
Research Resources [M01-RR-01032]; National Institute of Diabetes and
Digestive and Kidney Diseases [58785, 79929, 81913, AG032030]; [UL1
RR025758]
FX We gratefully thank the participants of the Coffee Trial for their
participation. We also thank the General Clinical Research Center (GCRC)
nurses at Beth Israel Deaconess Medical Center for assistance with
collection of the samples for this research, and the GCRC nutritionists
for conducting the dietary assessments, body composition measurements,
and dispensing of treatment. We thank the Harvard Catalyst Human
Research Center Laboratory for the timely and careful measurement of the
sex hormones used for this analysis. The research for this study was
financially supported by a Harvard Catalyst Human Research Center
Laboratory Support Award, a Boston Obesity Nutrition Research Center
pilot and feasibility grant (grant#: 2005-P-000377/2), and a National
Institutes of Health - National Center for Research Resources grant
M01-RR-01032 (Harvard Clinical and Translational Science Center) and
grant number UL1 RR025758. The Mantzoros Lab is also supported by the
National Institute of Diabetes and Digestive and Kidney Diseases grants
58785, 79929 and 81913, and AG032030.
NR 13
TC 8
Z9 8
U1 1
U2 5
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1475-2891
J9 NUTR J
JI Nutr. J.
PD OCT 19
PY 2012
VL 11
AR 86
DI 10.1186/1475-2891-11-86
PG 6
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 041VF
UT WOS:000311428600001
PM 23078574
ER
PT J
AU Oyoshi, MK
He, R
Li, YT
Mondal, S
Yoon, J
Afshar, R
Chen, M
Lee, DM
Luo, HBR
Luster, AD
Cho, JS
Miller, LS
Larson, A
Murphy, GF
Geha, RS
AF Oyoshi, Michiko K.
He, Rui
Li, Yitang
Mondal, Subhanjan
Yoon, Juhan
Afshar, Roshi
Chen, Mei
Lee, David M.
Luo, Hongbo R.
Luster, Andrew D.
Cho, John S.
Miller, Lloyd S.
Larson, Allison
Murphy, George F.
Geha, Raif S.
TI Leukotriene B4-Driven Neutrophil Recruitment to the Skin Is Essential
for Allergic Skin Inflammation
SO IMMUNITY
LA English
DT Article
ID INFL AMMATORY ARTHRITIS; T-CELL RECRUITMENT; ATOPIC-DERMATITIS; AIRWAY
HYPERRESPONSIVENESS; A(4) HYDROLASE; RECEPTOR BLT1; MURINE MODEL; B-4;
MICE; 5-LIPOXYGENASE
AB Scratching triggers skin flares in atopic dermatitis. We demonstrate that scratching of human skin and tape stripping of mouse skin cause neutrophil influx. In mice, this influx was largely dependent on the generation of leukotriene B4 (LTB4) by neutrophils and their expression of the LTB4 receptor BLT1. Allergic skin inflammation in response to epicutaneous (EC) application of ovalbumin to tape-stripped skin was severely impaired in Ltb4r1(-/-) mice and required expression of BLT1 on both T cells and non-T cells. Cotransfer of wild-type (WT) neutrophils, but not neutrophils deficient in BLT1 or the LTB4-synthesizing enzyme LTA4H, restored the ability of WT CD4(+) effector T cells to transfer allergic skin inflammation to Ltb4r1(-/-) recipients. Pharmacologic blockade of LTB4 synthesis inhibited allergic skin inflammation elicited by cutaneous antigen challenge in previously EC-sensitized mice. Our results demonstrate that a neutrophil-T cell axis reliant on LTB4-BLT1 interaction is required for allergic skin inflammation.
C1 [Oyoshi, Michiko K.; He, Rui; Yoon, Juhan; Geha, Raif S.] Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.
[Li, Yitang; Mondal, Subhanjan; Luo, Hongbo R.] Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.
[Afshar, Roshi; Luster, Andrew D.] Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Chen, Mei; Lee, David M.] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA.
[Larson, Allison; Murphy, George F.] Brigham & Womens Hosp, Dermatopathol Program, Boston, MA 02115 USA.
[Cho, John S.; Miller, Lloyd S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Dermatol, Los Angeles, CA 90095 USA.
[Oyoshi, Michiko K.; He, Rui; Li, Yitang; Mondal, Subhanjan; Yoon, Juhan; Afshar, Roshi; Chen, Mei; Lee, David M.; Luo, Hongbo R.; Luster, Andrew D.; Larson, Allison; Murphy, George F.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Oyoshi, Michiko K.; He, Rui; Li, Yitang; Mondal, Subhanjan; Yoon, Juhan; Afshar, Roshi; Chen, Mei; Lee, David M.; Luo, Hongbo R.; Luster, Andrew D.; Larson, Allison; Murphy, George F.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Oyoshi, Michiko K.; He, Rui; Li, Yitang; Mondal, Subhanjan; Yoon, Juhan; Afshar, Roshi; Chen, Mei; Lee, David M.; Luo, Hongbo R.; Luster, Andrew D.; Larson, Allison; Murphy, George F.; Geha, Raif S.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Oyoshi, MK (reprint author), Boston Childrens Hosp, Div Immunol, Boston, MA 02115 USA.
EM michiko.oyoshi@childrens.harvard.edu; raif.geha@childrens.harvard.edu
RI Larson, Allison/N-4263-2015;
OI Larson, Allison/0000-0001-8534-7078; Miller, Lloyd/0000-0002-8332-2210
FU Atopic Dermatitis Research Network National Institutes of
Health/National Institute of Allergy and Infectious Diseases
[HHSN272201000020C]; U.S. Public Health Service [AR-047417, AI
065858-03, HL-085100, AI-076471, HL-092020, GM-076084]; American Cancer
Society [AI-050892, AI-040618, R01 AI078910, T32 AR058921, R24 CA92865];
Boston Children's Hospital Faculty Career Development Fellowship
FX This work was supported by the Atopic Dermatitis Research Network
National Institutes of Health/National Institute of Allergy and
Infectious Diseases contract HHSN272201000020C (R.S.G.); U.S. Public
Health Service grants AR-047417 (R.S.G.), AI 065858-03 (D.M.L.)
HL-085100, AI-076471, and HL-092020, GM-076084; a Research Scholar Grant
from the American Cancer Society (H.R.L.); and AI-050892 and AI-040618
(A.D.L.), R01 AI078910 (L.S.M.), T32 AR058921 (J.S.C.), R24 CA92865
(UCLA Small Animal Imaging Resource Program); and the Boston Children's
Hospital Faculty Career Development Fellowship (M.K.O.). D.M.L. is
currently an employee of Novartis Pharma AG and owns stock and/or
options >$10,000 and has ownership and consulting income >$10,000 from
Synovex. M.C. is currently an employee of Pfizer. We thank M.J. Massaad
and H.C. Oettgen for reading the manuscript. We also thank J. Beaupre
for her technical assistance.
NR 39
TC 44
Z9 47
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
J9 IMMUNITY
JI Immunity
PD OCT 19
PY 2012
VL 37
IS 4
BP 747
EP 758
DI 10.1016/j.immuni.2012.06.018
PG 12
WC Immunology
SC Immunology
GA 025JQ
UT WOS:000310185400018
PM 23063331
ER
PT J
AU Wang, XF
Wang, SZ
Lu, YB
Gibson, MP
Liu, Y
Yuan, BZ
Feng, JQ
Qin, CL
AF Wang, Xiaofang
Wang, Suzhen
Lu, Yongbo
Gibson, Monica P.
Liu, Ying
Yuan, Baozhi
Feng, Jian Q.
Qin, Chunlin
TI FAM20C Plays an Essential Role in the Formation of Murine Teeth
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID DENTIN MATRIX PROTEIN-1; AMELOGENESIS IMPERFECTA PHENOTYPE; TOOTH ROOT
DEVELOPMENT; MICE DISPLAY; ODONTOBLAST DIFFERENTIATION; ENAMEL DEFECTS;
SIALOPHOSPHOPROTEIN; EXPRESSION; MOUSE; LEADS
AB FAM20Cis highly expressed in bone and tooth. Previously, we showed that Fam20C conditional knock-out (KO) mice manifest hypophosphatemic rickets, which highlights the crucial roles of this molecule in promoting bone formation and mediating phosphate homeostasis. In this study, we characterized the dentin, enamel, and cementum of Sox2-Cre-mediated Fam20C KO mice. The KO mice exhibited small malformed teeth, severe enamel defects, very thin dentin, less cementum than normal, and overall hypomineralization in the dental mineralized tissues. In situ hybridization and immunohistochemistry analyses revealed remarkable down-regulation of dentin matrix protein 1 (DMP1) and dentin sialophosphoprotein in odontoblasts, along with a sharply reduced expression of ameloblastin and amelotin in ameloblasts. Collectively, these data indicate that FAM20Cis essential to the differentiation and mineralization of dental tissues through the regulation of molecules critical to the differentiation of tooth-formative cells.
C1 [Wang, Xiaofang; Wang, Suzhen; Lu, Yongbo; Gibson, Monica P.; Liu, Ying; Feng, Jian Q.; Qin, Chunlin] Texas A&M Hlth Sci Ctr Baylor Coll Dent, Dept Biomed Sci, Dallas, TX 75246 USA.
[Yuan, Baozhi] Univ Wisconsin, Dept Med, Madison, WI 53705 USA.
[Yuan, Baozhi] William S Middleton Mem Vet Adm Med Ctr, Dept Vet Affairs, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA.
RP Qin, CL (reprint author), Texas A&M Hlth Sci Ctr Baylor Coll Dent, Dept Biomed Sci, 3302 Gaston Ave, Dallas, TX 75246 USA.
EM cqin@bcd.tamhsc.edu
FU National Institutes of Health [DE005092]
FX This work was supported, in whole or in part, by National Institutes of
Health Grant DE005092 (to C. Q.).
NR 37
TC 27
Z9 27
U1 0
U2 4
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 19
PY 2012
VL 287
IS 43
BP 35934
EP 35942
DI 10.1074/jbc.M112.386862
PG 9
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 027PA
UT WOS:000310364000015
PM 22936805
ER
PT J
AU Liu, YY
Kogai, T
Schultz, JJ
Mody, K
Brent, GA
AF Liu, Yan-Yun
Kogai, Takahiko
Schultz, James J.
Mody, Kaizeen
Brent, Gregory A.
TI Thyroid Hormone Receptor Isoform-specific Modification by Small
Ubiquitin-like Modifier (SUMO) Modulates Thyroid Hormone-dependent Gene
Regulation
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRANSCRIPTIONAL ACTIVITY; BRAIN-DEVELOPMENT; RESPONSE ELEMENT; BETA;
SUMOYLATION; MICE; BINDING; REPRESSOR; PROTEIN; ALPHA
AB Thyroid hormone receptor (TR) alpha and beta mediate thyroid hormone action at target tissues. TR isoforms have specific roles in development and in adult tissues. The mechanisms underlying TR isoform-specific action, however, are not well understood. We demonstrate that posttranslational modification of TR by conjugation of smallSUMOtoTR alpha and TR beta plays an important role in triiodothyronine (T3) action and TR isoform specificity. TR alpha was sumoylated at lysines 283 and 389, and TR beta at lysines 50, 146, and 443. Sumoylation of TR beta was ligand-dependent, and sumoylation of TR alpha was ligand-independent. TR alpha-SUMO conjugation utilized the E3 ligase PIASx beta and TR beta-SUMO conjugation utilized predominantly PIAS1. SUMO1 and SUMO3 conjugation to TR was important for T3-dependent gene regulation, as demonstrated in transient transfection assay and studies of endogenous gene regulation. The functional role of SUMO1 and SUMO3 in T3 induction in transient expression assays was closely matched to the pattern of TR and cofactor recruitment to thyroid hormone response elements (TREs) as determined by ChIP assays. SUMO1 was required for the T3-induced recruitment of the co-activator CREB-binding protein (CBP) and release of nuclear receptor co-repressor (NCoR) on a TRE but had no significant effect on TR DNA binding. SUMO1 was required for T3-mediated recruitment of NCoR and release of CBP from the TSH beta-negative TRE. SUMO3 was required for T3-stimulated TR binding to the TSH beta-negative TRE and recruitment of NCoR. These findings demonstrate that conjugation of SUMO to TR has a TR-isoform preference and is important for T3-dependent gene induction and repression.
C1 [Liu, Yan-Yun] Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Dept Med, Los Angeles, CA 90073 USA.
Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Dept Physiol, Los Angeles, CA 90073 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90073 USA.
RP Liu, YY (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Mol Endocrinol Lab, Dept Med, Bldg 114,Rm 229,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM yyl@ucla.edu; gbrent@ucla.edu
FU Veterans Affairs Merit Review Funds
FX This work was supported by Veterans Affairs Merit Review Funds.
NR 35
TC 10
Z9 10
U1 2
U2 9
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 19
PY 2012
VL 287
IS 43
BP 36499
EP 36508
DI 10.1074/jbc.M112.344317
PG 10
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 027PA
UT WOS:000310364000069
PM 22930759
ER
PT J
AU Matthews, PC
Listgarten, J
Carlson, JM
Payne, R
Huang, KHG
Frater, J
Goedhals, D
Steyn, D
van Vuuren, C
Paioni, P
Jooste, P
Ogwu, A
Shapiro, R
Mncube, Z
Ndung'u, T
Walker, BD
Heckerman, D
Goulder, PJR
AF Matthews, Philippa C.
Listgarten, Jennifer
Carlson, Jonathan M.
Payne, Rebecca
Huang, Kuan-Hsiang Gary
Frater, John
Goedhals, Dominique
Steyn, Dewald
van Vuuren, Cloete
Paioni, Paolo
Jooste, Pieter
Ogwu, Anthony
Shapiro, Roger
Mncube, Zenele
Ndung'u, Thumbi
Walker, Bruce D.
Heckerman, David
Goulder, Philip J. R.
TI Co-Operative Additive Effects between HLA Alleles in Control of HIV-1
SO PLOS ONE
LA English
DT Article
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL RESPONSES; DISEASE PROGRESSION;
IMMUNE CONTROL; SELECTION PRESSURE; VIRAL LOAD; NK CELLS; INFECTION;
VIREMIA; ASSOCIATION
AB Background: HLA class I genotype is a major determinant of the outcome of HIV infection, and the impact of certain alleles on HIV disease outcome is well studied. Recent studies have demonstrated that certain HLA class I alleles that are in linkage disequilibrium, such as HLA-A*74 and HLA-B*57, appear to function co-operatively to result in greater immune control of HIV than mediated by either single allele alone. We here investigate the extent to which HLA alleles - irrespective of linkage disequilibrium - function co-operatively.
Methodology/Principal Findings: We here refined a computational approach to the analysis of >2000 subjects infected with C-clade HIV first to discern the individual effect of each allele on disease control, and second to identify pairs of alleles that mediate 'co-operative additive' effects, either to improve disease suppression or to contribute to immunological failure. We identified six pairs of HLA class I alleles that have a co-operative additive effect in mediating HIV disease control and four hazardous pairs of alleles that, occurring together, are predictive of worse disease outcomes (q<0.05 in each case). We developed a novel 'sharing score' to quantify the breadth of CD8+ T cell responses made by pairs of HLA alleles across the HIV proteome, and used this to demonstrate that successful viraemic suppression correlates with breadth of unique CD8+ T cell responses (p = 0.03).
Conclusions/Significance: These results identify co-operative effects between HLA Class I alleles in the control of HIV-1 in an extended Southern African cohort, and underline complementarity and breadth of the CD8+ T cell targeting as one potential mechanism for this effect.
C1 [Matthews, Philippa C.; Payne, Rebecca; Paioni, Paolo; Goulder, Philip J. R.] Univ Oxford, Dept Paediat, Oxford, England.
[Listgarten, Jennifer; Carlson, Jonathan M.; Heckerman, David] Microsoft Res, ESci Grp, Los Angeles, CA USA.
[Huang, Kuan-Hsiang Gary; Frater, John] Univ Oxford, Nuffield Dept Med, Oxford, England.
[Goedhals, Dominique] Univ Orange Free State, Dept Med Microbiol & Virol, Natl Hlth Lab Serv, Bloemfontein, South Africa.
[Steyn, Dewald; van Vuuren, Cloete] Univ Orange Free State, Dept Internal Med, Bloemfontein, South Africa.
[Jooste, Pieter] Univ Orange Free State, Kimberley Hosp, Dept Paediat, Kimberley, Northern Cape, South Africa.
[Ogwu, Anthony; Shapiro, Roger] Botswana Harvard AIDS Inst Partnership, Gaborone, Botswana.
[Shapiro, Roger] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Mncube, Zenele; Ndung'u, Thumbi; Walker, Bruce D.; Goulder, Philip J. R.] Univ KwaZulu Natal, Doris Duke Med Res Inst, HIV Pathogenesis Programme, Durban, South Africa.
[Ndung'u, Thumbi; Walker, Bruce D.] Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA.
RP Matthews, PC (reprint author), Univ Oxford, Dept Paediat, Oxford, England.
EM p.matthews@doctors.org.uk
OI Matthews, Philippa/0000-0002-4036-4269; Ndung'u,
Thumbi/0000-0003-2962-3992
FU UK Medical Research Council; Oxford Radcliffe Hospitals Medical Research
Fund; Wellcome Trust; National Institutes of Health; Bill and Melinda
Gates Foundation; South African AIDS Vaccine Initiative
FX PM was funded by the UK Medical Research Council and Oxford Radcliffe
Hospitals Medical Research Fund. PG was funded by Wellcome Trust and is
an Elizabeth Glaser Paediatric AIDS Foundation Scientist. TN holds the
South African Department of Science and Technology/National Research
Foundation Research Chair in Systems Biology of HIV/AIDS. The Durban
cohort was funded by grants from the Wellcome Trust, The National
Institutes of Health, The Bill and Melinda Gates Foundation and the
South African AIDS Vaccine Initiative. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 33
TC 14
Z9 14
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 19
PY 2012
VL 7
IS 10
AR e47799
DI 10.1371/journal.pone.0047799
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 023QT
UT WOS:000310050200047
PM 23094091
ER
PT J
AU Tan, KL
Scott, DW
Hong, FX
Kahl, BS
Fisher, RI
Bartlett, NL
Advani, RH
Buckstein, R
Rimsza, LM
Connors, JM
Steidl, C
Gordon, LI
Horning, SJ
Gascoyne, RD
AF Tan, King L.
Scott, David W.
Hong, Fangxin
Kahl, Brad S.
Fisher, Richard I.
Bartlett, Nancy L.
Advani, Ranjana H.
Buckstein, Rena
Rimsza, Lisa M.
Connors, Joseph M.
Steidl, Christian
Gordon, Leo I.
Horning, Sandra J.
Gascoyne, Randy D.
TI Tumor-associated macrophages predict inferior outcomes in classic
Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
SO BLOOD
LA English
DT Article
ID INTERNATIONAL PROGNOSTIC SCORE; MICROENVIRONMENT; MARKERS; SURVIVAL;
SERIES; CD163
AB Increased tumor-associated macrophages (TAMs) are reported to be associated with poor prognosis in classic Hodgkin lymphoma (CHL). We investigated the prognostic significance of TAMs in the E2496 Intergroup trial, a multicenter phase 3 randomized controlled trial comparing ABVD and Stanford V chemotherapy in locally extensive and advanced stage CHL. Tissue microarrays were constructed from formalin-fixed, paraffin-embedded tumor tissue and included 287 patients. Patients were randomly assigned into training (n = 143) and validation (n = 144) cohorts. Immunohistochemistry for CD68 and CD163, and in situ hybridization for EBV-encoded RNA were performed. CD68 and CD163 IHC were analyzed by computer image analysis; optimum thresholds for overall survival (OS) were determined in the training cohort and tested in the independent validation cohort. Increased CD68 and CD163 expression was significantly associated with inferior failure-free survival and OS in the validation cohort. Increased CD68 and CD163 expression was associated with increased age, EBV-encoded RNA positivity, and mixed cellularity subtype of CHL. Multivariate analysis in the validation cohort showed increased CD68 or CD163 expression to be significant independent predictors of inferior failure-free survival and OS. We demonstrate the prognostic significance of TAMs in locally extensive and advanced-stage CHL in a multicenter phase 3 randomized controlled clinical trial. (Blood. 2012;120(16):3280-3287)
C1 [Tan, King L.; Scott, David W.; Connors, Joseph M.; Steidl, Christian; Gascoyne, Randy D.] British Columbia Canc Agcy, Ctr Lymphoid Canc, Vancouver, BC V5Z 1L3, Canada.
[Tan, King L.; Scott, David W.; Connors, Joseph M.; Steidl, Christian; Gascoyne, Randy D.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Hong, Fangxin] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Kahl, Brad S.] Univ Wisconsin, Dept Med Hematol Oncol, Madison, WI USA.
[Fisher, Richard I.] Univ Rochester, James P Wilmot Canc Ctr, Rochester, NY USA.
[Bartlett, Nancy L.] Washington Univ, Sch Med, St Louis, MO USA.
[Advani, Ranjana H.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Buckstein, Rena] Sunnybrook Med Ctr, Odette Canc Ctr, Toronto, ON, Canada.
[Rimsza, Lisa M.] Univ Arizona, Dept Pathol, Tucson, AZ USA.
[Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Gordon, Leo I.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Chicago, IL 60611 USA.
[Horning, Sandra J.] Genentech Inc, San Francisco, CA 94080 USA.
RP Gascoyne, RD (reprint author), British Columbia Canc Agcy, Ctr Lymphoid Canc, 675 W 10th Ave,Room 5-113, Vancouver, BC V5Z 1L3, Canada.
EM rgascoyn@bccancer.bc.ca
OI Gordon, Leo/0000-0003-1666-7064
FU Public Health Service [CA21115, CA23318, CA66636, CA17145, CA11083,
CA32102, CA38926, CA77202, CA21076, CA77470]; National Cancer Institute,
National Institutes of Health; Department of Health and Human Services;
Terry Fox Foundation Strategic Health Research Training Program in
Cancer Research at Canadian Institutes of Health Research [TGT-53912];
Cancer Research Society; Michael Smith Foundation for Health Research
FX This work was coordinated by the Eastern Cooperative Oncology Group (Dr
Robert L. Comis, Chair) and supported in part by Public Health Service
(grants CA21115, CA23318, CA66636, CA17145, CA11083, CA32102, CA38926,
CA77202, CA21076, and CA77470), the National Cancer Institute, National
Institutes of Health, and the Department of Health and Human Services.
Biospecimens were provided by the ECOG Pathology Coordinating Office and
Reference Laboratory. K. L. T and D. W. S were supported by the Terry
Fox Foundation Strategic Health Research Training Program in Cancer
Research at Canadian Institutes of Health Research (postdoctoral
fellowships grant TGT-53912). C. S. was supported by postdoctoral
fellowships of the Cancer Research Society (Steven E. Drabin Fellowship)
and the Michael Smith Foundation for Health Research.
NR 36
TC 82
Z9 84
U1 0
U2 7
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD OCT 18
PY 2012
VL 120
IS 16
BP 3280
EP 3287
DI 10.1182/blood-2012-04-421057
PG 8
WC Hematology
SC Hematology
GA 044KX
UT WOS:000311619200019
PM 22948049
ER
PT J
AU Oubaha, M
Lin, MI
Margaron, Y
Filion, D
Price, EN
Zon, LI
Cote, JF
Gratton, JP
AF Oubaha, Malika
Lin, Michelle I.
Margaron, Yoran
Filion, Dominic
Price, Emily N.
Zon, Leonard I.
Cote, Jean-Francois
Gratton, Jean-Philippe
TI Formation of a PKC zeta/beta-catenin complex in endothelial cells
promotes angiopoietin-1-induced collective directional migration and
angiogenic sprouting
SO BLOOD
LA English
DT Article
ID VE-CADHERIN; IN-VIVO; TIP CELLS; POLARITY; MORPHOGENESIS; CDC42; TIE2;
PERMEABILITY; ACTIVATION; JUNCTIONS
AB Angiogenic sprouting requires that cell-cell contacts be maintained during migration of endothelial cells. Angiopoietin-1 (Ang-1) and vascular endothelial growth factor act oppositely on endothelial cell junctions. We found that Ang-1 promotes collective and directional migration and, in contrast to VEGF, induces the formation of a complex formed of atypical protein kinase C (PKC)-zeta and beta-catenin at cell-cell junctions and at the leading edge of migrating endothelial cells. This complex brings Par3, Par6, and adherens junction proteins at the front of migrating cells to locally activate Rac1 in response to Ang-1. The colocalization of PKC zeta and beta-catenin at leading edge along with PKC zeta-dependent stabilization of cell-cell contacts promotes directed and collective endothelial cell migration. Consistent with these results, down-regulation of PKC zeta in endothelial cells alters Ang-1-induced sprouting in vitro and knockdown in developing zebrafish results in intersegmental vessel defects caused by a perturbed directionality of tip cells and by loss of cell contacts between tip and stalk cells. These results reveal that PKC zeta and beta-catenin function in a complex at adherens junctions and at the leading edge of migrating endothelial cells to modulate collective and directional migration during angiogenesis. (Blood. 2012;120(16):3371-3381)
C1 [Oubaha, Malika; Filion, Dominic; Gratton, Jean-Philippe] Univ Montreal, Inst Rech Clin Montreal, Lab Endothelial Cell Biol, Montreal, PQ H2W 1R7, Canada.
[Lin, Michelle I.; Price, Emily N.; Zon, Leonard I.] Harvard Univ, Sch Med, Stem Cell Program, Div Hematol Oncol,Childrens Hosp Boston, Boston, MA USA.
[Lin, Michelle I.; Price, Emily N.; Zon, Leonard I.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Margaron, Yoran; Cote, Jean-Francois] Univ Montreal, IRCM, Lab Cytoskeletal Org & Cell Migrat, Montreal, PQ H2W 1R7, Canada.
RP Gratton, JP (reprint author), Univ Montreal, Inst Rech Clin Montreal, Lab Endothelial Cell Biol, 110 Pins Ave W, Montreal, PQ H2W 1R7, Canada.
EM jean-philippe.gratton@ircm.qc.ca
FU Canadian Institutes of Health Research [MOP-86464, MOP-111031]; Canadian
Cancer Society Research Institute [CCSRI-019104]; American Heart
Association postdoctoral fellowship; Fonds de la Recherche en Sante du
Quebec postdoctoral fellowship; National Institutes of Health
[5PO1HL32262-29, 5R01HL048801-18]; FRSQ Junior 2 career award
FX This work was supported by grants from the Canadian Institutes of Health
Research to J.-P.G. (MOP-86464 and MOP-111031); Canadian Cancer Society
Research Institute to J.-F.C. (CCSRI-019104); American Heart Association
postdoctoral fellowship to M.I.L.; Fonds de la Recherche en Sante du
Quebec postdoctoral fellowship to Y.M.; and the National Institutes of
Health to L.I.Z. (5PO1HL32262-29 and 5R01HL048801-18). J.-F.C. holds a
FRSQ Junior 2 career award. J.-P.G. holds a Tier 2 Canada Research Chair
in Endothelial Cell Signaling and Angiogenesis.
NR 50
TC 9
Z9 9
U1 1
U2 8
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 18
PY 2012
VL 120
IS 16
BP 3371
EP 3381
DI 10.1182/blood-2012-03-419721
PG 11
WC Hematology
SC Hematology
GA 044KX
UT WOS:000311619200029
PM 22936663
ER
PT J
AU Burton, DR
Ahmed, R
Barouch, DH
Butera, ST
Crotty, S
Godzik, A
Kaufmann, DE
McElrath, MJ
Nussenzweig, MC
Pulendran, B
Scanlan, CN
Schief, WR
Silvestri, G
Streeck, H
Walker, BD
Walker, LM
Ward, AB
Wilson, IA
Wyatt, R
AF Burton, Dennis R.
Ahmed, Rafi
Barouch, Dan H.
Butera, Salvatore T.
Crotty, Shane
Godzik, Adam
Kaufmann, Daniel E.
McElrath, M. Juliana
Nussenzweig, Michel C.
Pulendran, Bali
Scanlan, Chris N.
Schief, William R.
Silvestri, Guido
Streeck, Hendrik
Walker, Bruce D.
Walker, Laura M.
Ward, Andrew B.
Wilson, Ian A.
Wyatt, Richard
TI A Blueprint for HIV Vaccine Discovery
SO CELL HOST & MICROBE
LA English
DT Review
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T FOLLICULAR HELPER; AUTOLOGOUS
NEUTRALIZING ANTIBODY; RESPIRATORY SYNCYTIAL VIRUS; HUMAN
MONOCLONAL-ANTIBODIES; VESICULAR STOMATITIS-VIRUS; SITE-SPECIFIC
ANALYSIS; CD4 BINDING-SITE; ENVELOPE GLYCOPROTEINS; B-CELLS
AB Despite numerous attempts over many years to develop an HIV vaccine based on classical strategies, none has convincingly succeeded to date. A number of approaches are being pursued in the field, including building upon possible efficacy indicated by the recent RV144 clinical trial, which combined two HIV vaccines. Here, we argue for an approach based, in part, on understanding the HIV envelope spike and its interaction with broadly neutralizing antibodies (bnAbs) at the molecular level and using this understanding to design immunogens as possible vaccines. BnAbs can protect against virus challenge in animal models, and many such antibodies have been isolated recently. We further propose that studies focused on how best to provide T cell help to B cells that produce bnAbs are crucial for optimal immunization strategies. The synthesis of rational immunogen design and immunization strategies, together with iterative improvements, offers great promise for advancing toward an HIV vaccine.
C1 [Burton, Dennis R.; Butera, Salvatore T.; Schief, William R.; Walker, Laura M.; Wyatt, Richard] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Burton, Dennis R.; Schief, William R.; Wyatt, Richard] Scripps Res Inst, IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
[Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA.
[Ward, Andrew B.; Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA.
[Ahmed, Rafi; Pulendran, Bali; Silvestri, Guido] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA.
[Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Div Vaccine Res, Boston, MA 02215 USA.
[Crotty, Shane] La Jolla Inst Allergy & Immunol, Div Vaccine Discovery, La Jolla, CA 92037 USA.
[Godzik, Adam] Sanford Burnham Med Res Inst, Grad Sch Biomed Sci, La Jolla, CA 92037 USA.
[McElrath, M. Juliana] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98109 USA.
[Nussenzweig, Michel C.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA.
[Nussenzweig, Michel C.] Rockefeller Univ, Lab Mol Immunol, New York, NY 10065 USA.
[Scanlan, Chris N.] Univ Oxford, Dept Biochem, Oxford Glycobiol Inst, Oxford OX1 3QU, England.
[Burton, Dennis R.; Barouch, Dan H.; Kaufmann, Daniel E.; Streeck, Hendrik; Walker, Bruce D.] MIT, Massachusetts Gen Hosp, Ragon Inst, Boston, MA 02114 USA.
[Burton, Dennis R.; Barouch, Dan H.; Kaufmann, Daniel E.; Streeck, Hendrik; Walker, Bruce D.] Harvard Univ, Boston, MA 02114 USA.
[Silvestri, Guido] Emory Univ, Yerkes Natl Primate Res Ctr, Atlanta, GA 30329 USA.
[Burton, Dennis R.; Ahmed, Rafi; Barouch, Dan H.; Butera, Salvatore T.; Crotty, Shane; Godzik, Adam; Kaufmann, Daniel E.; McElrath, M. Juliana; Nussenzweig, Michel C.; Pulendran, Bali; Scanlan, Chris N.; Schief, William R.; Silvestri, Guido; Walker, Bruce D.; Ward, Andrew B.; Wilson, Ian A.; Wyatt, Richard] Scripps Res Inst, Scripps Ctr HIV AIDS Vaccine Immunol & Immunogen, La Jolla, CA 92037 USA.
RP Burton, DR (reprint author), Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
EM burton@scripps.edu
RI Godzik, Adam/A-7279-2009; Ward, Andrew/F-9203-2014
OI Godzik, Adam/0000-0002-2425-852X; Ward, Andrew/0000-0001-7153-3769
FU Howard Hughes Medical Institute; NIAID NIH HHS [UM1 AI100663, R01
AI084817]; NIDDK NIH HHS [R37 DK057665]
NR 148
TC 190
Z9 195
U1 6
U2 79
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1931-3128
J9 CELL HOST MICROBE
JI Cell Host Microbe
PD OCT 18
PY 2012
VL 12
IS 4
SI SI
BP 396
EP 407
DI 10.1016/j.chom.2012.09.008
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 032LI
UT WOS:000310719700004
PM 23084910
ER
PT J
AU Chakkalakal, JV
Jones, KM
Basson, MA
Brack, AS
AF Chakkalakal, Joe V.
Jones, Kieran M.
Basson, M. Albert
Brack, Andrew S.
TI The aged niche disrupts muscle stem cell quiescence
SO NATURE
LA English
DT Article
ID FIBROBLAST-GROWTH-FACTOR; SKELETAL-MUSCLE; SELF-RENEWAL; SATELLITE
CELLS; ADULT MUSCLE; PROGENITOR CELLS; IN-VIVO; REGENERATION;
MYOGENESIS; FIBERS
AB The niche is a conserved regulator of stem cell quiescence and function. During ageing, stem cell function declines. To what extent and by what means age-related changes within the niche contribute to this phenomenon are unknown. Here we demonstrate that the aged muscle stem cell niche, the muscle fibre, expresses Fgf2 under homeostatic conditions, driving a subset of satellite cells to break quiescence and lose their self-renewing capacity. We show in mice that relatively dormant aged satellite cells robustly express sprouty 1 (Spry1), an inhibitor of fibroblast growth factor (FGF) signalling. Increasing FGF signalling in aged satellite cells under homeostatic conditions by removing Spry1 results in the loss of quiescence, satellite cell depletion and diminished regenerative capacity. Conversely, reducing niche-derived FGF activity through inhibition of Fgfr1 signalling or overexpression of Spry1 in satellite cells prevents their depletion. These experiments identify an age-dependent change in the stem cell niche that directly influences stem cell quiescence and function.
C1 [Chakkalakal, Joe V.; Brack, Andrew S.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Jones, Kieran M.; Basson, M. Albert] Kings Coll London, Dept Craniofacial Dev & Stem Cell Biol, London SE1 9RT, England.
[Brack, Andrew S.] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Brack, Andrew S.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Brack, AS (reprint author), Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
EM Brack.Andrew@mgh.harvard.edu
OI Basson, M. Albert/0000-0001-9834-7528; Chakkalakal,
Joe/0000-0002-8440-7312
FU MGH; Harvard Stem Cell Institute; NIH [R01 AR060868, R01 AR061002];
Wellcome Trust [WT091475]; MGH ECOR Postdoctoral Fellow Award; BBSRC
Doctoral Training Award [BB/F017626/1]
FX We thank H. Hock, K. Hochedlinger and R. Friesel for the generous
provision of reagents, and G. Estrada for technical assistance. We are
also grateful to L. Prickett-Rice, K. Folz-Donahue and M. Weglarz for
cell sorting. This work was supported by MGH start-up funds, Harvard
Stem Cell Institute grants and NIH grants (R01 AR060868, R01 AR061002)
(A. S. B.); a Wellcome Trust grant (WT091475) (M. A. B.); and an MGH
ECOR Postdoctoral Fellow Award (J.V.C.) and a BBSRC Doctoral Training
Award (BB/F017626/1) (K.M.J.).
NR 55
TC 190
Z9 197
U1 3
U2 51
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 18
PY 2012
VL 490
IS 7420
BP 355
EP +
DI 10.1038/nature11438
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 021XI
UT WOS:000309918500036
PM 23023126
ER
PT J
AU Jensen, JK
Medina, HM
Norgaard, BL
Ovrehus, KA
Jensen, JM
Nielsen, LH
Maurovich-Horvat, P
Engel, LC
Januzzi, JL
Hoffmann, U
Truong, QA
AF Jensen, Jesper K.
Medina, Hector M.
Norgaard, Bjarne L.
Ovrehus, Kristian A.
Jensen, Jesper M.
Nielsen, Lene H.
Maurovich-Horvat, Pal
Engel, Leif-Christopher
Januzzi, James L.
Hoffmann, Udo
Truong, Quynh A.
TI Association of ischemic stroke to coronary artery disease using computed
tomography coronary angiography
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Acute ischemic stroke; Coronary atherosclerosis; Coronary CT angiography
ID HEALTH-CARE PROFESSIONALS; ATHEROSCLEROTIC PLAQUE;
CARDIOVASCULAR-DISEASE; CEREBRAL INFARCTION; GUIDELINES; CALCIFICATION;
INDIVIDUALS; PREVALENCE; STATEMENT; STENOSIS
AB Background: While patients with coronary artery disease (CAD) and cerebrovascular disease share similar risk factor profiles, data on whether IS can be considered a "CAD equivalent" are limited. We aimed to determine whether ischemic stroke is an independent predictor of CAD by using cardiac computed tomography angiography (CTA).
Methods: We analyzed the CTA in 392 patients with no history of CAD (24 patients with acute IS and 368 patients with acute chest pain). Extent of plaque burden was additionally dichotomized into 0-4 versus >4 segments.
Results: Patients with IS had a near 5-fold increase odds of having coronary artery plaque (odds ratio [OR] 4.9, P<0.01) as compared to those without IS. After adjustment for age, gender, and traditional cardiac risk factors, there remained a near 4-fold increase odds for coronary plaque (adjusted OR 3.7, P=0.04). When stratified by extent of plaque, patients with IS had over 18-fold increase odds of having >4 segments of plaque than 0-4 segments as compared to patients without stroke (OR 18.3, P<0.01), which remained significantly associated in adjusted analysis (adjusted OR 12.1, P<0.001).
Conclusion: Acute IS is independently associated with higher risk and greater extent of CAD compared to patients with acute chest pain at low-to-intermediate risk for acute coronary syndrome. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Jensen, Jesper K.; Norgaard, Bjarne L.; Ovrehus, Kristian A.; Jensen, Jesper M.; Nielsen, Lene H.] Vejle Hosp, Dept Cardiol, Vejle, Denmark.
[Medina, Hector M.; Maurovich-Horvat, Pal; Engel, Leif-Christopher; Hoffmann, Udo; Truong, Quynh A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiac MR PET CT Program,Dept Radiol, Cambridge, MA 02138 USA.
[Januzzi, James L.; Truong, Quynh A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Cardiol, Cambridge, MA 02138 USA.
RP Jensen, JK (reprint author), Odense Univ Hosp, Dept Cardiol, DK-5000 Odense C, Denmark.
EM jesperkjensen@dadlnet.dk
OI Maurovich-Horvat, Pal/0000-0003-0885-736X
FU P.A Messerschmidt Foundation, Copenhagen; Familien Hede Nielsens
Foundation, Horsens; Danish Medical Association, Copenhagen; Kirsten
Anthonius Foundation, Aarhus
FX We are greatly indebted to Jens O. Kjaersgaard for helping with the
clinical evaluation of the patients. This project was supported with
grants from P.A Messerschmidt Foundation, Copenhagen, Familien Hede
Nielsens Foundation, Horsens, The Danish Medical Association, Copenhagen
and Kirsten Anthonius Foundation, Aarhus.
NR 29
TC 6
Z9 7
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
EI 1874-1754
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 18
PY 2012
VL 160
IS 3
BP 171
EP 174
DI 10.1016/j.ijcard.2011.04.006
PG 4
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 017LZ
UT WOS:000309592700013
PM 21543126
ER
PT J
AU Pascual-Figal, DA
Bonaque, JC
Manzano-Fernandez, S
Fernandez, A
Garrido, IP
Pastor-Perez, F
Lax, A
Valdes, M
Januzzi, JL
AF Pascual-Figal, Domingo A.
Bonaque, Juan C.
Manzano-Fernandez, Sergio
Fernandez, Asuncion
Garrido, Iris P.
Pastor-Perez, Francisco
Lax, Antonio
Valdes, M.
Januzzi, James L.
TI Red blood cell distribution width predicts new-onset anemia in heart
failure patients
SO INTERNATIONAL JOURNAL OF CARDIOLOGY
LA English
DT Article
DE Red blood cell distribution width; Anemia; Heart failure; Hemoglobin
ID IRON-DEFICIENCY; PROGNOSTIC MARKER; DARBEPOETIN-ALPHA; DOUBLE-BLIND;
MORTALITY; MECHANISMS; DISEASE; COHORT; ERYTHROPOIESIS; HEMOGLOBIN
AB Background: Hematologic abnormalities such as elevated red blood cell distribution width (RDW) as well as anemia are prognostically meaningful among heart failure (HF) patients. The inter-relationship between these hematologic abnormalities in HF is unclear, however. We therefore aimed to assess whether RDW is predicting changes in hemoglobin concentrations as well as onset of anemia.
Methods: 268 consecutive non-anemic patients with acutely decompensated HF (ADHF) were enrolled at hospital discharge and RDW was measured. At 6 month follow-up, change in hemoglobin as well as new-onset anemia was studied as a function of RDW at discharge.
Results: RDW at discharge correlated negatively with hemoglobin values at 6 months (r = -0.220; p<0.001); a greater decrease in hemoglobin concentration occurred in those with higher values of RDW at discharge (p=0.004), independently of baseline hemoglobin concentration and other risk factors. At 6 months, 54 patients (20%) developed new-onset anemia. RDW values at discharge were significantly higher among patients who developed new-onset anemia (15.1 +/- 2.2 vs. 14.2 +/- 1.4, p=0.005). In integrated discrimination improvement analyses, the addition of RDW measurement improved the ability to predict new-onset anemia (IDI 0.0531, p<0.001), beyond known risk factors as hemoglobin, renal function, age, diabetes mellitus, sex and HF symptom severity. In adjusted analyses, patients with RDW>15% (derived from receiver operating characteristic analysis) had a tripling of the risk of new-onset anemia (OR=3.1, 95% CI 1.5-5.1, p=0.002).
Conclusion: Among non-anemic patients with ADHF, RDW measurement at the time of hospital discharge independently predicts lower hemoglobin concentrations and new-onset anemia over a 6-month follow up period. (C) 2011 Elsevier Ireland Ltd. All rights reserved.
C1 [Pascual-Figal, Domingo A.; Bonaque, Juan C.; Manzano-Fernandez, Sergio; Fernandez, Asuncion; Garrido, Iris P.; Pastor-Perez, Francisco; Lax, Antonio; Valdes, M.] Univ Murcia, Sch Med, Serv Cardiol, Virgen de la Arrixaca Hosp, Murcia, Spain.
[Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Pascual-Figal, DA (reprint author), Univ Hosp Virgen de la Arrixaca, Dept Cardiol, Heart Failure Unit, Ctra Madrid Cartagena S-N, Murcia 30120, Spain.
EM dapascual@servicam.com
RI Pascual Figal, Domingo /B-3794-2008
OI Pascual Figal, Domingo /0000-0002-4993-9540
FU national network of investigation on heart failure "REDINSCOR":
Instituto de Salud Carlos III, Ministry of Health, Madrid, Spain
[RD06/0003/0013]; Balson Clinical Scholar fund
FX This study was supported by the national network of investigation on
heart failure "REDINSCOR": Grant RD06/0003/0013, Instituto de Salud
Carlos III, Ministry of Health, Madrid, Spain. Dr. Januzzi is supported
in part by the Balson Clinical Scholar fund.
NR 29
TC 18
Z9 18
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-5273
J9 INT J CARDIOL
JI Int. J. Cardiol.
PD OCT 18
PY 2012
VL 160
IS 3
BP 196
EP 200
DI 10.1016/j.ijcard.2011.04.018
PG 5
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 017LZ
UT WOS:000309592700018
PM 21555160
ER
PT J
AU Dienstag, JL
Cosimi, AB
AF Dienstag, Jules L.
Cosimi, A. Benedict
TI Liver Transplantation - A Vision Realized
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Dienstag, Jules L.] Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA.
[Cosimi, A. Benedict] Massachusetts Gen Hosp, Dept Surg, Transplantat Unit, Boston, MA 02114 USA.
[Cosimi, A. Benedict] Harvard Univ, Sch Med, Boston, MA USA.
RP Dienstag, JL (reprint author), Massachusetts Gen Hosp, Dept Med, Gastrointestinal Unit, Boston, MA 02114 USA.
NR 6
TC 24
Z9 26
U1 1
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 18
PY 2012
VL 367
IS 16
BP 1483
EP 1485
DI 10.1056/NEJMp1210159
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021SA
UT WOS:000309904500005
PM 22992048
ER
PT J
AU Anasetti, C
Logan, BR
Lee, SJ
Waller, EK
Weisdorf, DJ
Wingard, JR
Cutler, CS
Westervelt, P
Woolfrey, A
Couban, S
Ehninger, G
Johnston, L
Maziarz, RT
Pulsipher, MA
Porter, DL
Mineishi, S
McCarty, JM
Khan, SP
Anderlini, P
Bensinger, WI
Leitman, SF
Rowley, SD
Bredeson, C
Carter, SL
Horowitz, MM
Confer, DL
AF Anasetti, Claudio
Logan, Brent R.
Lee, Stephanie J.
Waller, Edmund K.
Weisdorf, Daniel J.
Wingard, John R.
Cutler, Corey S.
Westervelt, Peter
Woolfrey, Ann
Couban, Stephen
Ehninger, Gerhard
Johnston, Laura
Maziarz, Richard T.
Pulsipher, Michael A.
Porter, David L.
Mineishi, Shin
McCarty, John M.
Khan, Shakila P.
Anderlini, Paolo
Bensinger, William I.
Leitman, Susan F.
Rowley, Scott D.
Bredeson, Christopher
Carter, Shelly L.
Horowitz, Mary M.
Confer, Dennis L.
CA Blood And Marrow Transplant Clinic
TI Peripheral-Blood Stem Cells versus Bone Marrow from Unrelated Donors
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID VERSUS-HOST-DISEASE; COLONY-STIMULATING FACTOR; TERM-FOLLOW-UP;
RANDOMIZED-TRIAL; CHRONIC GRAFT; PROGENITOR CELLS; ALLOGENEIC
TRANSPLANTATION; LEUKEMIA; RECIPIENTS; MALIGNANCIES
AB BACKGROUND
Randomized trials have shown that the transplantation of filgrastim-mobilized peripheral-blood stem cells from HLA-identical siblings accelerates engraftment but increases the risks of acute and chronic graft-versus-host disease (GVHD), as compared with the transplantation of bone marrow. Some studies have also shown that peripheral-blood stem cells are associated with a decreased rate of relapse and improved survival among recipients with high-risk leukemia.
METHODS
We conducted a phase 3, multicenter, randomized trial of transplantation of peripheral-blood stem cells versus bone marrow from unrelated donors to compare 2-year survival probabilities with the use of an intention-to-treat analysis. Between March 2004 and September 2009, we enrolled 551 patients at 48 centers. Patients were randomly assigned in a 1: 1 ratio to peripheral-blood stem-cell or bone marrow transplantation, stratified according to transplantation center and disease risk. The median follow-up of surviving patients was 36 months (interquartile range, 30 to 37).
RESULTS
The overall survival rate at 2 years in the peripheral-blood group was 51% (95% confidence interval [CI], 45 to 57), as compared with 46% (95% CI, 40 to 52) in the bone marrow group (P = 0.29), with an absolute difference of 5 percentage points (95% CI, -3 to 14). The overall incidence of graft failure in the peripheral-blood group was 3% (95% CI, 1 to 5), versus 9% (95% CI, 6 to 13) in the bone marrow group (P = 0.002). The incidence of chronic GVHD at 2 years in the peripheral-blood group was 53% (95% CI, 45 to 61), as compared with 41% (95% CI, 34 to 48) in the bone marrow group (P = 0.01). There were no significant between-group differences in the incidence of acute GVHD or relapse.
CONCLUSIONS
We did not detect significant survival differences between peripheral-blood stem-cell and bone marrow transplantation from unrelated donors. Exploratory analyses of secondary end points indicated that peripheral-blood stem cells may reduce the risk of graft failure, whereas bone marrow may reduce the risk of chronic GVHD. (Funded by the National Heart, Lung, and Blood Institute-National Cancer Institute and others; ClinicalTrials.gov number, NCT00075816.)
C1 [Anasetti, Claudio] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Logan, Brent R.; Horowitz, Mary M.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Lee, Stephanie J.; Woolfrey, Ann; Bensinger, William I.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Waller, Edmund K.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Weisdorf, Daniel J.] Univ Minnesota, Med Ctr, Minneapolis, MN 55455 USA.
[Khan, Shakila P.] Mayo Clin, Rochester, MN USA.
[Confer, Dennis L.] Natl Marrow Donor Program, Minneapolis, MN USA.
[Cutler, Corey S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Westervelt, Peter] Washington Univ, Siteman Canc Ctr, St Louis, MO USA.
[Couban, Stephen] Dalhousie Univ, Halifax, NS, Canada.
[Bredeson, Christopher] Ottawa Hosp, Ottawa, ON, Canada.
[Ehninger, Gerhard] Univ Hosp Dresden, Dresden, Germany.
[Johnston, Laura] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Maziarz, Richard T.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Pulsipher, Michael A.] Univ Utah, Primary Childrens Med Ctr, Salt Lake City, UT USA.
[Porter, David L.] Univ Penn, Philadelphia, PA 19104 USA.
[Mineishi, Shin] Univ Michigan, Ann Arbor, MI 48109 USA.
[McCarty, John M.] Virginia Commonwealth Univ, Massey Canc Ctr, Richmond, VA 23284 USA.
[Anderlini, Paolo] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Leitman, Susan F.] NIH, Bethesda, MD 20892 USA.
[Carter, Shelly L.] EMMES Corp, Rockville, MD USA.
[Rowley, Scott D.] Hackensack Univ, John Theurer Canc Ctr, Hackensack, NJ USA.
[Wingard, John R.] Univ Florida, Shands Canc Ctr, Gainesville, FL USA.
RP Anasetti, C (reprint author), Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
EM claudio.anasetti@moffitt.org
FU National Heart, Lung, and Blood Institute-National Cancer Institute;
National Heart, Lung, and Blood Institute; National Cancer Institute
[U10HL069294]; Office of Naval Research; National Marrow Donor Program
FX Funded by the National Heart, Lung, and Blood Institute-National Cancer
Institute and others; ClinicalTrials.gov number, NCT00075816.; Supported
by a grant from the National Heart, Lung, and Blood Institute and the
National Cancer Institute (U10HL069294), by the Office of Naval
Research, and by the National Marrow Donor Program.
NR 29
TC 212
Z9 216
U1 1
U2 13
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 18
PY 2012
VL 367
IS 16
BP 1487
EP 1496
DI 10.1056/NEJMoa1203517
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021SA
UT WOS:000309904500006
PM 23075175
ER
PT J
AU Devanand, DP
Mintzer, J
Schultz, SK
Andrews, HF
Sultzer, DL
de la Pena, D
Gupta, S
Colon, S
Schimming, C
Pelton, GH
Levin, B
AF Devanand, D. P.
Mintzer, Jacobo
Schultz, Susan K.
Andrews, Howard F.
Sultzer, David L.
de la Pena, Danilo
Gupta, Sanjay
Colon, Sylvia
Schimming, Corbett
Pelton, Gregory H.
Levin, Bruce
TI Relapse Risk after Discontinuation of Risperidone in Alzheimer's Disease
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ATYPICAL ANTIPSYCHOTIC MEDICATIONS; PLACEBO-CONTROLLED TRIALS;
NURSING-HOME RESIDENTS; DOUBLE-BLIND; CATIE-AD; NEUROPSYCHIATRIC
INVENTORY; COGNITIVE DECLINE; RANDOMIZED TRIAL; ELDERLY-PATIENTS;
DEMENTIA
AB BACKGROUND
Among patients with Alzheimer's disease who have had a response to antipsychotic medication for psychosis or agitation-aggression, the risk of a recurrence of symptoms after discontinuation of the medication has not been established.
METHODS
Patients with Alzheimer's disease and psychosis or agitation-aggression received open-label treatment with risperidone for 16 weeks. Those who had a response to risperidone therapy were then randomly assigned, in a double-blind fashion, to one of three regimens: continued risperidone therapy for 32 weeks (group 1), risperidone therapy for 16 weeks followed by placebo for 16 weeks (group 2), or placebo for 32 weeks (group 3). The primary outcome was the time to relapse of psychosis or agitation.
RESULTS
A total of 180 patients received open-label risperidone (mean dose, 0.97 mg daily). The severity of psychosis and agitation were reduced, although there was a mild increase in extrapyramidal signs; 112 patients met the criteria for response to treatment, of whom 110 underwent randomization. In the first 16 weeks after randomization, the rate of relapse was higher in the group that received placebo than in the groups that received risperidone (60% [24 of 40 patients in group 3] vs. 33% [23 of 70 in groups 1 and 2]; P = 0.004; hazard ratio with placebo, 1.94; 95% confidence interval [CI], 1.09 to 3.45; P = 0.02). During the next 16 weeks, the rate of relapse was higher in the group that was switched from risperidone to placebo than in the group that continued to receive risperidone (48% [13 of 27 patients in group 2] vs. 15% [2 of 13 in group 1]; P = 0.02; hazard ratio, 4.88; 95% CI, 1.08 to 21.98; P = 0.02). The rates of adverse events and death after randomization did not differ significantly among the groups, although comparisons were based on small numbers of patients, especially during the final 16 weeks.
CONCLUSIONS
In patients with Alzheimer's disease who had psychosis or agitation that had responded to risperidone therapy for 4 to 8 months, discontinuation of risperidone was associated with an increased risk of relapse. (Funded by the National Institutes of Health and others; ClinicalTrials.gov number, NCT00417482.)
C1 [Devanand, D. P.; Pelton, Gregory H.] Columbia Univ, New York State Psychiat Inst, Div Geriatr Psychiat, New York, NY 10032 USA.
[Devanand, D. P.; Andrews, Howard F.; Pelton, Gregory H.] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA.
[Devanand, D. P.; Andrews, Howard F.; Pelton, Gregory H.] Columbia Univ, Dept Neurol, New York, NY 10032 USA.
[Devanand, D. P.; Andrews, Howard F.; Pelton, Gregory H.] Columbia Univ, Coll Physicians & Surg, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY 10032 USA.
[Andrews, Howard F.; Levin, Bruce] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA.
[Gupta, Sanjay] Global Res & Consulting, Buffalo, NY USA.
[Schimming, Corbett] Mt Sinai Sch Med, Dept Psychiat, New York, NY USA.
[Mintzer, Jacobo] Med Univ S Carolina, Dept Neurosci, Div Translat Res, Charleston, SC USA.
[Mintzer, Jacobo] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC USA.
[Schultz, Susan K.] Univ Iowa, Carver Coll Med, Dept Psychiat, Iowa City, IA USA.
[Sultzer, David L.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Sultzer, David L.] VA Greater Angeles Hlth Syst, Los Angeles, CA USA.
[de la Pena, Danilo] Res Ctr Clin Studies, Norwalk, CT USA.
[Colon, Sylvia] VA Med Ctr, Dept Psychiat, Tuscaloosa, AL USA.
RP Devanand, DP (reprint author), Columbia Univ, New York State Psychiat Inst, Div Geriatr Psychiat, 1051 Riverside Dr,Unit 126, New York, NY 10032 USA.
EM dpd3@columbia.edu
FU National Institutes of Health [R01 AG021488, R01 AG17761]; Department of
Veterans Affairs
FX Supported by grants from the National Institutes of Health (R01 AG021488
and R01 AG17761) and the Department of Veterans Affairs.
NR 39
TC 47
Z9 49
U1 1
U2 12
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 18
PY 2012
VL 367
IS 16
BP 1497
EP 1507
DI 10.1056/NEJMoa1114058
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021SA
UT WOS:000309904500007
PM 23075176
ER
PT J
AU Glassock, RJ
Khorashadi, L
Kushner, YB
AF Glassock, Richard J.
Khorashadi, Leila
Kushner, Yael B.
TI Case 32-2012: A 35-Year-Old Man with Respiratory and Renal Failure
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; DIFFUSE ALVEOLAR HEMORRHAGE; PULMONARY
CAPILLARITIS; LUNG HEMORRHAGE; VASCULITIS; NEPHRITIS;
GLOMERULONEPHRITIS; ANTIBODIES
C1 [Glassock, Richard J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Khorashadi, Leila] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Kushner, Yael B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Khorashadi, Leila] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Kushner, Yael B.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Glassock, RJ (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
FU Harvard Medical School Department of Continuing Education; QuestCor;
BioMarin; Novartis; Eli Lilly; Bristol-Myers Squibb; Genentech; Vifor;
Genzyme-Sanofi; American Renal Associates; Renal Ventures
FX This case was presented at the Harvard Medical School postgraduate
course MGH Nephrology Update (Directors, Drs. Mario F. Rubin, Hasan
Bazari, and M. Amin Arnaout), sponsored by the Harvard Medical School
Department of Continuing Education.; Dr. Glassock reports receiving
consulting fees from QuestCor, BioMarin, Novartis, Eli Lilly,
Bristol-Myers Squibb, Genentech, Vifor, Genzyme-Sanofi, and American
Renal Associates; receiving fees for expert opinions for patients and
caregivers in legal cases involving renal disease and for expert
testimony for the defense in a lawsuit involving alleged renal injury
from volatile hydrocarbons; receiving lecture fees from Renal Ventures
and Genentech; receiving payment from Lighthouse Learning for the
development of educational presentations; receiving editorial stipends
from UpToDate; receiving royalties from Oxford Medical Publishers and
UpToDate; owning stock or stock options in Reata and La Jolla
Pharmaceuticals; and serving as an unpaid board member for LABioMed and
UKRO. No other potential conflict of interest relevant to this article
was reported.
NR 30
TC 2
Z9 2
U1 0
U2 7
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 18
PY 2012
VL 367
IS 16
BP 1540
EP 1553
DI 10.1056/NEJMcpc1201412
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021SA
UT WOS:000309904500012
PM 23075181
ER
PT J
AU Martinez, HG
Quinones, MP
Jimenez, F
Estrada, C
Clark, KM
Suzuki, K
Miura, N
Ohno, N
Ahuja, SK
Ahuja, SS
AF Martinez, Hernan G.
Quinones, Marlon P.
Jimenez, Fabio
Estrada, Carlos
Clark, Kassandra M.
Suzuki, Kazuo
Miura, Noriko
Ohno, Naohito
Ahuja, Sunil K.
Ahuja, Seema S.
TI Important role of CCR2 in a murine model of coronary vasculitis
SO BMC IMMUNOLOGY
LA English
DT Article
DE CCR2; Coronary vasculitis; Treg; Treg/Th17 imbalance
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; PERIPHERAL-BLOOD MONOCYTES; ACUTE
KAWASAKI-DISEASE; REGULATORY T-CELLS; INTRAVENOUS IMMUNOGLOBULIN;
CANDIDA-ALBICANS; KNOCKOUT MICE; PROPAGERMANIUM; RECEPTOR;
ATHEROSCLEROSIS
AB Background: Chemokines and their receptors play a role in the innate immune response as well as in the disruption of the balance between pro-inflammatory Th17 cells and regulatory T cells (Treg), underlying the pathogenesis of coronary vasculitis in Kawasaki disease (KD).
Results: Here we show that genetic inactivation of chemokine receptor (CCR)-2 is protective against the induction of aortic and coronary vasculitis following injection of Candida albicans water-soluble cell wall extracts (CAWS). Mechanistically, both T and B cells were required for the induction of vasculitis, a role that was directly modulated by CCR2. CAWS administration promoted mobilization of CCR2-dependent inflammatory monocytes (iMo) from the bone marrow (BM) to the periphery as well as production of IL-6. IL-6 was likely to contribute to the depletion of Treg and expansion of Th17 cells in CAWS-injected Ccr2(+/+) mice, processes that were ameliorated following the genetic inactivation of CCR2.
Conclusion: Collectively, our findings provide novel insights into the role of CCR2 in the pathogenesis of vasculitis as seen in KD and highlight novel therapeutic targets, specifically for individuals resistant to first-line treatments.
C1 [Martinez, Hernan G.; Jimenez, Fabio; Estrada, Carlos; Clark, Kassandra M.; Ahuja, Seema S.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7870, San Antonio, TX 78229 USA.
[Martinez, Hernan G.; Jimenez, Fabio; Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX 78229 USA.
[Quinones, Marlon P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Suzuki, Kazuo] Chiba Univ, Grad Sch Med, Dept Immunol, Inflammat Program, Chiba 2608670, Japan.
[Miura, Noriko; Ohno, Naohito] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Immunopharmacol Microbial Prod, Hachioji, Tokyo 1920392, Japan.
[Ahuja, Sunil K.] S Texas Vet Hlth Care Syst, Vet Adm Ctr Aids & HIV Infect 1, San Antonio, TX USA.
RP Ahuja, SS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med MC 7870, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM ahuja@uthscsa.edu
FU Veterans Administration [Merit Review]; National Institutes of Health
[R01 AR 052755]
FX This work was supported by the Veterans Administration [Merit Review]
and National Institutes of Health [R01 AR 052755] to S.S.A.
NR 42
TC 8
Z9 8
U1 0
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2172
J9 BMC IMMUNOL
JI BMC Immunol.
PD OCT 17
PY 2012
VL 13
AR 56
DI 10.1186/1471-2172-13-56
PG 12
WC Immunology
SC Immunology
GA 053JU
UT WOS:000312268400001
PM 23074996
ER
PT J
AU Makino, CL
Wen, XH
Olshevskaya, EV
Peshenko, IV
Savchenko, AB
Dizhoor, AM
AF Makino, Clint L.
Wen, Xiao-Hong
Olshevskaya, Elena V.
Peshenko, Igor V.
Savchenko, Andrey B.
Dizhoor, Alexander M.
TI Enzymatic Relay Mechanism Stimulates Cyclic GMP Synthesis in Rod
Photoresponse: Biochemical and Physiological Study in Guanylyl Cyclase
Activating Protein 1 Knockout Mice
SO PLOS ONE
LA English
DT Article
ID OUTER SEGMENTS; DIFFUSION-COEFFICIENT; IN-VIVO; PHOTORECEPTORS; CALCIUM;
EXPRESSION; RETGC; GCAPS; PHOTOTRANSDUCTION; CLONING
AB Regulation of cGMP synthesis by retinal membrane guanylyl cyclase isozymes (RetGC1 and RetGC2) in rod and cone photoreceptors by calcium-sensitive guanylyl cyclase activating proteins (GCAP1 and GCAP2) is one of the key molecular mechanisms affecting the response to light and is involved in congenital retinal diseases. The objective of this study was to identify the physiological sequence of events underlying RetGC activation in vivo, by studying the electrophysiological and biochemical properties of mouse rods in a new genetic model lacking GCAP1. The GCAP1(-/-) retinas expressed normal levels of RetGC isozymes and other phototransduction proteins, with the exception of GCAP2, whose expression was elevated in a compensatory fashion. RetGC activity in GCAP1(-/-) retinas became more sensitive to Ca2+ and slightly increased. The bright flash response in electroretinogram (ERG) recordings recovered quickly in GCAP1(-/-), as well as in RetGC1(-/-) GCAP1(-/-), and RetGC2(-/-) GCAP1(-/-) hybrid rods, indicating that GCAP2 activates both RetGC isozymes in vivo. Individual GCAP1(-/-) rod responses varied in size and shape, likely reflecting variable endogenous GCAP2 levels between different cells, but single-photon response (SPR) amplitude and time-to-peak were typically increased, while recovery kinetics remained faster than in wild type. Recovery from bright flashes in GCAP1(-/-) was prominently biphasic, because rare, aberrant SPRs producing the slower tail component were magnified. These data provide strong physiological evidence that rod photoresponse recovery is shaped by the sequential recruitment of RetGC isozyme activation by GCAPs according to the different GCAP sensitivities for Ca2+ and specificities toward RetGC isozymes. GCAP1 is the 'first-response' sensor protein that stimulates RetGC1 early in the response and thus limits the SPR amplitude, followed by activation of GCAP2 that adds stimulation of both RetGC1 and RetGC2 to speed-up photoreceptor recovery.
C1 [Olshevskaya, Elena V.; Peshenko, Igor V.; Savchenko, Andrey B.; Dizhoor, Alexander M.] Salus Univ, Dept Basic Sci, Elkins Pk, PA USA.
[Olshevskaya, Elena V.; Peshenko, Igor V.; Savchenko, Andrey B.; Dizhoor, Alexander M.] Salus Univ, Penn Coll Optometry, Elkins Pk, PA USA.
[Makino, Clint L.; Wen, Xiao-Hong] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Makino, Clint L.; Wen, Xiao-Hong] Harvard Univ, Sch Med, Boston, MA USA.
RP Dizhoor, AM (reprint author), Salus Univ, Dept Basic Sci, Elkins Pk, PA USA.
EM adizhoor@salus.edu
OI Makino, Clint/0000-0002-6005-9069
FU National Institutes of Health [EY11522, EY011358, EY014104]; Lion's of
Massachusetts; Pennsylvania Department of Health Formula Grant
FX This work was supported by National Institutes of Health grants EY11522
(AMD) and EY011358, EY014104 (CLM), Lion's of Massachusetts, and
Pennsylvania Department of Health Formula Grant. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 46
TC 24
Z9 24
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e47637
DI 10.1371/journal.pone.0047637
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900081
PM 23082185
ER
PT J
AU Soberman, RJ
MacKay, CR
Vaine, CA
Ryan, GB
Cerny, AM
Thompson, MR
Nikolic, B
Primo, V
Christmas, P
Sheiffele, P
Aronov, L
Knipe, DM
Kurt-Jones, EA
AF Soberman, Roy J.
MacKay, Christopher R.
Vaine, Christine A.
Ryan, Glennice Bowen
Cerny, Anna M.
Thompson, Mikayla R.
Nikolic, Boris
Primo, Valeria
Christmas, Peter
Sheiffele, Paul
Aronov, Lisa
Knipe, David M.
Kurt-Jones, Evelyn A.
TI CD200R1 Supports HSV-1 Viral Replication and Licenses Pro-Inflammatory
Signaling Functions of TLR2
SO PLOS ONE
LA English
DT Article
ID HERPES-SIMPLEX-VIRUS; CENTRAL-NERVOUS-SYSTEM; INHIBITORY LIGAND CD200;
IMMUNE-RESPONSE; TYPE-1 INFECTION; DENDRITIC CELLS; INNATE IMMUNITY;
KAPPA-B; RECEPTOR; HOST
AB The CD200R1:CD200 axis is traditionally considered to limit tissue inflammation by down-regulating pro-inflammatory signaling in myeloid cells bearing the receptor. We generated CD200R1(-/-) mice and employed them to explore both the role of CD200R1 in regulating macrophage signaling via TLR2 as well as the host response to an in vivo, TLR2-dependent model, herpes simplex virus 1 (HSV-1) infection. CD200R1(-/-) peritoneal macrophages demonstrated a 70-75% decrease in the generation of IL-6 and CCL5 (Rantes) in response to the TLR2 agonist Pam(2)CSK(4) and to HSV-1. CD200R1(-/-) macrophages could neither up-regulate the expression of TLR2, nor assemble a functional inflammasome in response to HSV-1. CD200R1(-/-) mice were protected from HSV-1 infection and exhibited dysfunctional TLR2 signaling. Finally, both CD200R1(-/-) mice and CD200R1(-/-) fibroblasts and macrophages showed a markedly reduced ability to support HSV-1 replication. In summary, our data demonstrate an unanticipated and novel requirement for CD200R1 in "licensing'' pro-inflammatory functions of TLR2 and in limiting viral replication that are supported by ex vivo and in vivo evidence.
C1 [Soberman, Roy J.; Vaine, Christine A.; Nikolic, Boris; Primo, Valeria; Christmas, Peter] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit,Dept Med, Charlestown, MA USA.
[MacKay, Christopher R.; Ryan, Glennice Bowen; Cerny, Anna M.; Thompson, Mikayla R.; Kurt-Jones, Evelyn A.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA USA.
[Sheiffele, Paul; Aronov, Lisa] InGenious Targeting Lab Inc, Stony Brook, NY USA.
[Knipe, David M.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
RP Soberman, RJ (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Renal Unit,Dept Med, Charlestown, MA USA.
EM Soberman@helix.mgh.harvard.edu; evelyn.kurt-jones@umassmed.edu
RI Mackay, Charles/A-9673-2008;
OI Mackay, Charles/0000-0002-6338-7340; Vaine,
Christine/0000-0003-2645-8223
FU National Institutes of Health [R01AI068871, R01AI068871-S4, P01
AI083215-01]; Diabetes Endocrinology Research Center [DK32520]; UMass
CFAR from the National Institutes of Health [5P30 AI-42845]
FX This work was supported by grants R01AI068871 (RJS), R01AI068871-S4 (RJS
and CV), P01 AI083215-01 (EAK-J and DMK) and UMass CFAR Grant 5P30
AI-42845 (EAK-J) from the National Institutes of Health. Core resources
supported by the Diabetes Endocrinology Research Center grant DK32520
were also used. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 52
TC 7
Z9 7
U1 1
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e47740
DI 10.1371/journal.pone.0047740
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900101
PM 23082204
ER
PT J
AU Zhao, W
Zheng, XF
Liu, YY
Yang, WL
Amirbekian, V
Diaz, LE
Huang, XD
AF Zhao, Wen
Zheng, Xiaofeng
Liu, Yuying
Yang, Wenlu
Amirbekian, Vardan
Diaz, Luis E.
Huang, Xudong
TI An MRI Study of Symptomatic Adhesive Capsulitis
SO PLOS ONE
LA English
DT Article
ID ROTATOR INTERVAL LESIONS; FROZEN SHOULDER; CORACOHUMERAL LIGAMENT;
ARTHROGRAPHY; DIAGNOSIS; ANATOMY; PATHOLOGY; RELEASE; MOTION
AB Background: Appilication of MR imaging to diagnose Adhesive Capsulitis (AC) has previously been described. However, there is insufficient information available for the MRI analysis of AC. This study is to describe and evaluate the pathomorphology of the shoulder in Asian patients with AC compared to healthy volunteers.
Methodology/Principal Findings: 60 Asian patients with clinically diagnosed AC and 60 healthy volunteers without frozen shoulder underwent MRI of the shoulder joint. All subjects who were age- and sex-matched control ones underwent routine MRI scans of the affected shoulder, including axial, oblique coronal, oblique sagittal T1WI SE and coronal oblique T2WI FSE sequences. Significant abnormal findings were observed on MRI, especially at the rotator cuff interval. The coracohumeral ligament (CHL), articular capsule thickness in the rotator cuff interval as well as the fat space under coracoid process were evaluated. MRI showed that patients with adhesive capsulitis had a significantly thickened coracohumeral ligament and articular capsule in the rotator cuff interval compared to the control subjects (4.2 vs. 2.4 mm, 7.2 vs. 4.4 mm; p<0.05). Partial or complete obliteration of the subcoracoid fat triangle was significantly more frequent in patients with adhesive capsulitis compared with control subjects (73% vs. 13%, 26% vs. 1.6%; p<0.001). Synovitis-like abnormality around the long biceps tendon was significantly more common in patients with adhesive capsulitis than in control subjects. With regards to the inter-observer variability, two MR radiologists had an excellent kappa value of 0.86.
Conclusions/Significance: MRI can be used to show characteristic findings in diagnosing AC. Thickening of the CHL and the capsule at the rotator cuff interval and complete obliteration of the fat triangle under the coracoid process have been shown to be the most characteristic MR findings seen with AC.
C1 [Huang, Xudong] Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
[Huang, Xudong] Harvard Univ, Sch Med, Charlestown, MA USA.
[Zhao, Wen] Beijing Aerosp Gen Hosp, Dept Orthoped, Beijing, Peoples R China.
[Zheng, Xiaofeng] Beijing Aerosp Gen Hosp, Dept Radiol, Beijing, Peoples R China.
[Liu, Yuying] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA.
[Yang, Wenlu] Shanghai Maritime Univ, Informat Engn Coll, Dept Elect Engn, Shanghai, Peoples R China.
[Amirbekian, Vardan] Brigham & Womens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Amirbekian, Vardan] Harvard Univ, Sch Med, Boston, MA USA.
[Diaz, Luis E.] Boston Univ, Sch Med, Dept Radiol, Boston, MA 02118 USA.
[Diaz, Luis E.] VA Boston Healthcare Syst, Boston, MA USA.
RP Huang, XD (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA 02129 USA.
EM xhuang3@partners.org
FU Beijing General Aerospace Hospital; Radiology Department of Brigham and
Women's Hospital (BWH)
FX This study was supported by research funds from the Beijing General
Aerospace Hospital. XH is partially supported by the Radiology
Department of Brigham and Women's Hospital (BWH). No additional external
funding received for this study. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 32
TC 10
Z9 10
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2012
VL 7
IS 10
AR e47277
DI 10.1371/journal.pone.0047277
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 038AF
UT WOS:000311146900048
PM 23082152
ER
PT J
AU Katz, JN
Wright, EA
Wright, J
Malchau, H
Mahomed, NN
Stedman, M
Baron, JA
Losina, E
AF Katz, Jeffrey N.
Wright, Elizabeth A.
Wright, John
Malchau, Henrik
Mahomed, Nizar N.
Stedman, Margaret
Baron, John A.
Losina, Elena
TI Twelve-Year Risk of Revision After Primary Total Hip Replacement in the
US Medicare Population
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Article
ID NORWEGIAN ARTHROPLASTY REGISTER; PRIMARY OSTEOARTHRITIS; IMPLANTS;
FAILURE; INDEX; OLDER
AB Background: There is limited population-based literature on rates and risk factors for revision following primary total hip replacement.
Methods: We performed a retrospective cohort study of Medicare beneficiaries who had elective total hip replacement for osteoarthritis between July 1, 1995, and June 30, 1996. Patients were followed with use of Medicare claims through 2008. The primary end point was revision total hip replacement as indicated by hospital discharge codes according to the International Classification of Diseases, Ninth Revision. We used the Kaplan-Meier method to plot the risks of revision and of death over a twelve-year follow-up period. We used Cox proportional hazard regression models to identify preoperative risk factors for revision of primary total hip replacement. We conducted sensitivity analyses to account for competing risks of major comorbid conditions.
Results: The risk of revision total hip replacement for patients remaining alive was approximately 2% per year for the first eighteen months and then 1% per year for the remainder of the follow-up period. The absolute risk of death over the twelve-year follow-up period exceeded the risk of revision total hip replacement by a factor of ten (59% vs. 5.7%) in patients older than seventy-five years at the time of primary total hip replacement and by a factor of three (29% vs. 9.4%) in patients sixty-five to seventy-five years old at the time of surgery. In multivariate Cox proportional hazard models, the relative risk of revision was higher in men than in women (hazard ratio [HR], 1.23; 95% confidence interval [95% CI], 1.15, 1.31) and in patients sixty-five to seventy-five years of age at the time of primary total hip replacement than in those over seventy-five years (HR, 1.47; 95% CI, 1.37, 1.58). Patients of surgeons who performed fewer than six total hip replacements annually in the Medicare population had a higher risk of revision than those whose surgeons performed more than twelve per year (HR, 1.21; 95% CI, 1.12, 1.32).
Conclusions: Efforts to reduce the number of revision hip arthroplasties should be targeted at revisions occurring in the first eighteen months following the index arthroplasty, when revision risk is higher, and at younger patients, who are more likely to survive long enough to require revision.
C1 [Katz, Jeffrey N.] Brigham & Womens Hosp, Orthoped & Arthrit Ctr Outcomes Res, Dept Orthoped Surg, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Orthoped Surg, Boston, MA 02114 USA.
Univ Toronto, Dept Orthoped Surg, Univ Hlth Network, Toronto, ON M5T 2S8, Canada.
Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
RP Katz, JN (reprint author), Brigham & Womens Hosp, Orthoped & Arthrit Ctr Outcomes Res, Dept Orthoped Surg, 75 Francis St,OBC 4-016, Boston, MA 02115 USA.
EM jnkatz@partners.org
OI Stedman, Margaret/0000-0001-9271-8332; Malchau,
Henrik/0000-0002-4291-2441
FU National Institutes of Health (NIH)
FX This study was funded by the National Institutes of Health (NIH). The
NIH played no role in our investigation beyond providing the funding.
NR 20
TC 29
Z9 30
U1 0
U2 8
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD OCT 17
PY 2012
VL 94A
IS 20
BP 1825
EP 1832
DI 10.2106/JBJS.K.00569
PG 8
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 028IT
UT WOS:000310416700001
PM 23079874
ER
PT J
AU Schwab, JH
Springfield, DS
Raskin, KA
Mankin, HJ
Hornicek, FJ
AF Schwab, Joseph H.
Springfield, Dempsey S.
Raskin, Kevin A.
Mankin, Henry J.
Hornicek, Francis J.
TI What's New in Primary Bone Tumors
SO JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME
LA English
DT Reprint
ID GIANT-CELL TUMOR; EWINGS-SARCOMA; ZOLEDRONIC ACID; OSTEOSARCOMA;
CHONDROSARCOMA; EXPRESSION; RECEPTOR; GROWTH; CHORDOMA; OUTCOMES
RP Schwab, JH (reprint author), Massachusetts Gen Hosp, Orthopaed Oncol Serv, 55 Fruit St, Boston, MA 02114 USA.
EM jhschwab@partners.org
NR 55
TC 17
Z9 18
U1 0
U2 8
PU JOURNAL BONE JOINT SURGERY INC
PI NEEDHAM
PA 20 PICKERING ST, NEEDHAM, MA 02192 USA
SN 0021-9355
J9 J BONE JOINT SURG AM
JI J. Bone Joint Surg.-Am. Vol.
PD OCT 17
PY 2012
VL 94A
IS 20
BP 1913
EP 1919
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA 028IT
UT WOS:000310416700012
PM 23079883
ER
PT J
AU Teo, AKK
Kulkarni, RN
AF Teo, Adrian Kee Keong
Kulkarni, Rohit N.
TI Setting sail for glucose homeostasis with the AKAP150-PP2B-anchor
SO EMBO JOURNAL
LA English
DT Editorial Material
ID PROTEIN-KINASE-A; INSULIN-SECRETION; PHOSPHORYLATION
AB Glucose-stimulated insulin secretion, controlled by multiple protein phosphorylation events, is critical for the regulation of glucose homeostasis. Protein kinase A (PKA) is known to play a role in beta cell physiology, but the role of its anchoring protein is not fully understood. Hinke et al (2012) illustrate the significance of A-kinase anchoring protein 150 in tethering protein phosphatase 2B to mediate nutrient-stimulated insulin secretion and thus modulate glucose homeostasis.
C1 [Kulkarni, Rohit N.] Harvard Univ, Brigham & Womens Hosp, Sect Islet Cell Biol & Regenerat Med, Joslin Diabet Ctr,Sch Med, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Kulkarni, RN (reprint author), Harvard Univ, Brigham & Womens Hosp, Sect Islet Cell Biol & Regenerat Med, Joslin Diabet Ctr,Sch Med, Boston, MA 02115 USA.
EM rohit.kulkarni@joslin.harvard.edu
RI Teo, Adrian/A-4009-2013
OI Teo, Adrian/0000-0001-5901-7075
FU NIDDK NIH HHS [R01 DK 55523, R01 DK055523, R01 DK 67536, R01 DK067536]
NR 10
TC 1
Z9 1
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0261-4189
J9 EMBO J
JI Embo J.
PD OCT 17
PY 2012
VL 31
IS 20
BP 3956
EP 3957
DI 10.1038/emboj.2012.265
PG 2
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 023SJ
UT WOS:000310055400003
PM 22983555
ER
PT J
AU Hayes, SM
Salat, DH
Verfaellie, M
AF Hayes, Scott M.
Salat, David H.
Verfaellie, Mieke
TI Default Network Connectivity in Medial Temporal Lobe Amnesia
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID FUNCTIONAL CONNECTIVITY; RESTING-STATE; HIPPOCAMPAL DAMAGE;
ALZHEIMERS-DISEASE; EPISODIC MEMORY; CORPUS-CALLOSUM; CEREBRAL-CORTEX;
WORKING-MEMORY; MODE NETWORK; HUMAN BRAIN
AB There is substantial overlap between the brain regions supporting episodic memory and the default network. However, in humans, the impact of bilateral medial temporal lobe (MTL) damage on a large-scale neural network such as the default mode network is unknown. To examine this issue, resting fMRI was performed with amnesic patients and control participants. Seed-based functional connectivity analyses revealed robust default network connectivity in amnesia in cortical default network regions such as medial prefrontal cortex, posterior medial cortex, and lateral parietal cortex, as well as evidence of connectivity to residual MTL tissue. Relative to control participants, decreased posterior cingulate cortex connectivity to MTL and increased connectivity to cortical default network regions including lateral parietal and medial prefrontal cortex were observed in amnesic patients. In contrast, somatomotor network connectivity was intact in amnesic patients, indicating that bilateral MTL lesions may selectively impact the default network. Changes in default network connectivity in amnesia were largely restricted to the MTL subsystem, providing preliminary support from MTL amnesic patients that the default network can be fractionated into functionally and structurally distinct components. To our knowledge, this is the first examination of the default network in amnesia.
C1 [Hayes, Scott M.; Verfaellie, Mieke] VA Boston Healthcare Syst, Memory Disorders Res Ctr, Boston, MA 02130 USA.
[Hayes, Scott M.; Verfaellie, Mieke] Boston Univ, Sch Med, Boston, MA 02130 USA.
[Hayes, Scott M.; Salat, David H.] VA Boston Healthcare Syst, Neuroimaging Res Vet Ctr, Boston, MA 02130 USA.
[Salat, David H.] MGH Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Hayes, SM (reprint author), VA Boston Healthcare Syst, Memory Disorders Res Ctr 151A, 150 S Huntington Ave, Boston, MA 02130 USA.
EM smhayes@bu.edu
OI Verfaellie, Mieke/0000-0001-5535-4584
FU Department of Veterans Affairs Rehabilitation Research and Development
Service [e7822w]; Clinical Science Research and Development Service;
National Institutes of Health [R01 MH093431]
FX This work was supported by the Department of Veterans Affairs
Rehabilitation Research and Development Service (Career Development
Award e7822w to S. M. H.), Clinical Science Research and Development
Service (to M. V.), and the National Institutes of Health (Grant R01
MH093431). We thank Amanda Mikedis for assistance with MRI data
collection, Dr. Ginette Lafleche for clinical neuropsychological
assessment, and Dr. Margaret Keane for helpful comments and discussion.
NR 46
TC 14
Z9 14
U1 0
U2 11
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 17
PY 2012
VL 32
IS 42
BP 14622
EP 14630
DI 10.1523/JNEUROSCI.0700-12.2012
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 023RY
UT WOS:000310054000016
PM 23077048
ER
PT J
AU Bickart, KC
Hollenbeck, MC
Barrett, LF
Dickerson, BC
AF Bickart, Kevin C.
Hollenbeck, Mark C.
Barrett, Lisa Feldman
Dickerson, Bradford C.
TI Intrinsic Amygdala-Cortical Functional Connectivity Predicts Social
Network Size in Humans
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID MEDIAL PREFRONTAL CORTEX; MACAQUE MONKEYS; RHESUS-MONKEY;
INDIVIDUAL-DIFFERENCES; NEURAL BASIS; DIFFERENTIAL CONNECTIONS;
CHARITABLE DONATION; FACIAL EXPRESSIONS; DECISION-MAKING; HUMAN BRAIN
AB Using resting-state functional magnetic resonance imaging data from two independent samples of healthy adults, we parsed the amygdala's intrinsic connectivity into three partially distinct large-scale networks that strongly resemble the known anatomical organization of amygdala connectivity in rodents and monkeys. Moreover, in a third independent sample, we discovered that people who fostered and maintained larger and more complex social networks not only had larger amygdala volumes, but also amygdalae with stronger intrinsic connectivity within two of these networks: one putatively subserving perceptual abilities and one subserving affiliative behaviors. Our findings were anatomically specific to amygdalar circuitry in that individual differences in social network size and complexity could not be explained by the strength of intrinsic connectivity between nodes within two networks that do not typically involve the amygdala(i.e., the mentalizing and mirror networks), and were behaviorally specific in that amygdala connectivity did not correlate with other self-report measures of sociality.
C1 [Bickart, Kevin C.] Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA.
[Hollenbeck, Mark C.; Barrett, Lisa Feldman; Dickerson, Bradford C.] Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Hollenbeck, Mark C.; Barrett, Lisa Feldman; Dickerson, Bradford C.] Psychiat Neuroimaging Res Program, Charlestown, MA 02129 USA.
[Barrett, Lisa Feldman] Northwestern Univ, Dept Psychol, Boston, MA 02115 USA.
[Hollenbeck, Mark C.; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Frontotemporal Disorders Unit, Charlestown, MA 02129 USA.
[Hollenbeck, Mark C.; Dickerson, Bradford C.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Dickerson, BC (reprint author), MGH Frontotemporal Disorders Unit, 149 13th St,Suite 2691, Charlestown, MA 02129 USA.
EM bradd@nmr.mgh.harvard.edu
FU U.S. National Institutes of Health [DP1OD003312]; U.S. National
Institute on Aging [R01-AG030311, R01-AG029411, P50-AG005134]
FX This study was supported by grants from the U.S. National Institutes of
Health Director's Pioneer Award (DP1OD003312) and the U.S. National
Institute on Aging (R01-AG030311, R01-AG029411 and P50-AG005134). The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health or the National Institute on Aging. We thank Randy Buckner for
providing the data used in the analysis of the discovery sample and the
tools used for fcMRI preprocessing and Rebecca Dautoff for assistance.
NR 102
TC 64
Z9 65
U1 5
U2 31
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 17
PY 2012
VL 32
IS 42
BP 14729
EP 14741
DI 10.1523/JNEUROSCI.1599-12.2012
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 023RY
UT WOS:000310054000026
PM 23077058
ER
PT J
AU Rigotti, NA
AF Rigotti, Nancy A.
TI Strategies to Help a Smoker Who Is Struggling to Quit
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID NICOTINE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIAL;
SMOKING-CESSATION PHARMACOTHERAPIES; SUSTAINED-RELEASE BUPROPION;
RECEPTOR PARTIAL AGONIST; OPEN-LABEL TRIAL; TOBACCO DEPENDENCE; CHRONIC
DISEASE; ADVERSE EVENTS; UNITED-STATES
AB Tobacco use is the leading preventable cause of death worldwide. Stopping tobacco use benefits virtually every smoker. Most of the 19% of US residents who smoke want to quit and have tried to do so. Most individual quit attempts fail, but two-thirds of smokers use no treatment when trying to quit. Treating tobacco dependence is one of the most cost-effective actions in health care. With a brief intervention, physicians can prompt smokers to attempt to quit and connect them to evidence-based treatment that includes pharmacotherapy and behavioral support (ie, counseling). Physicians can link smokers to effective counseling support offered by a free national network of telephone quit lines. Smokers who use nicotine replacement therapy (NRT), bupropion, or varenicline when trying to quit double their odds of success. The most effective way to use NRT is to combine the long-acting nicotine patch with a shorter-acting product (lozenge, gum, inhaler, or nasal spray) and extend treatment beyond 12 weeks. Observational studies have not confirmed case reports of behavior changes associated with varenicline and bupropion, and these drugs' benefits outweigh potential risks. A chronic disease management model is effective for treating tobacco dependence, which deserves as high a priority in health care systems as treating other chronic diseases like diabetes and hypertension. JAMA. 2012;308(15):1573-1580 www.jama.com
C1 [Rigotti, Nancy A.] Harvard Univ, Massachusetts Gen Hosp, Div Gen Med, Dept Med,Med Sch, Boston, MA 02114 USA.
[Rigotti, Nancy A.] Harvard Univ, Sch Med, Tobacco Res & Treatment Ctr, Boston, MA 02114 USA.
RP Rigotti, NA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Div Gen Med, Dept Med,Med Sch, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM nrigotti@partners.org
FU Nabi Biopharmaceuticals Inc; Pfizer Inc.; National Institutes of Health,
National Heart, Lung, and Blood Institute [5K24HL4440-10]
FX The author has completed and submitted the ICMJE Form for Disclosure of
Potential Conflicts of Interest and reported that she has received
royalties from UpToDate Inc and research grants to her institution from
Nabi Biopharmaceuticals Inc, and Pfizer Inc. She also reported that she
has served as an unpaid consultant for Pfizer Inc and Alere Wellbeing
Inc.; This was supported by grant 5K24HL4440-10, a Mid-Career
Investigator Award in Patient-Oriented Research from the National
Institutes of Health, National Heart, Lung, and Blood Institute.
NR 65
TC 45
Z9 45
U1 1
U2 23
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 17
PY 2012
VL 308
IS 15
BP 1573
EP 1580
DI 10.1001/jama.2012.13043
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 021AQ
UT WOS:000309858100024
PM 23073954
ER
PT J
AU Kostis, WJ
AF Kostis, William J.
TI Absolute Risk Reduction Due to Statin Use According to Sex
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Letter
C1 Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
RP Kostis, WJ (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St,GRB800, Boston, MA 02114 USA.
EM wkostis@partners.org
NR 2
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 16
PY 2012
VL 60
IS 16
BP 1580
EP 1580
DI 10.1016/j.jacc.2012.03.081
PG 1
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 025OB
UT WOS:000310198200022
PM 23058318
ER
PT J
AU Wong, EB
Omar, T
Setlhako, GJ
Osih, R
Feldman, C
Murdoch, DM
Martinson, NA
Bangsberg, DR
Venter, WDF
AF Wong, Emily B.
Omar, Tanvier
Setlhako, Gosetsemang J.
Osih, Regina
Feldman, Charles
Murdoch, David M.
Martinson, Neil A.
Bangsberg, David R.
Venter, W. D. F.
TI Causes of Death on Antiretroviral Therapy: A Post-Mortem Study from
South Africa
SO PLOS ONE
LA English
DT Article
ID RECONSTITUTION INFLAMMATORY SYNDROME; HIV-POSITIVE PATIENTS; SUB-SAHARAN
AFRICA; EARLY MORTALITY; AUTOPSY; TUBERCULOSIS; DISEASE; ADULTS;
PATHOLOGY; COHORT
AB Background: Mortality in the first months of antiretroviral therapy (ART) is a significant clinical problem in sub-Saharan Africa. To date, no post-mortem study has investigated the causes of mortality in these patients.
Methods: HIV-positive adults who died as in-patients at a Johannesburg academic hospital underwent chart-review and ultrasound-guided needle autopsy for histological and microbiological examination of lung, liver, spleen, kidney, bone marrow, lymph node, skin and cerebrospinal fluid. A clinico-pathologic committee considered all available data and adjudicated immediate and contributing causes of death.
Results: Thirty-nine adults were enrolled: 1 14 pre-ART, 15 early-ART (7-90 days), and 10 late-ART (>90 days). Needle sampling yielded adequate specimen in 100% of kidney, skin, heart and cerebrospinal fluid samples, 97% of livers and lungs, 92% of bone marrows, 87% of spleens and 68% of lymph nodes. Mycobacterial infections were implicated in 69% of deaths (26 of 27 of these due to M. tuberculosis), bacterial infections in 33%, fungal infections in 21%, neoplasm in 26%, and non-infectious organ failure in 26%. Immune reconstitution inflammatory syndrome (IRIS) was implicated in 73% of early-ART deaths. Post-mortem investigations revealed previously undiagnosed causes of death in 49% of cases. Multiple pathologies were common with 62% of subjects with mycobacterial infection also having at least one other infectious or neoplastic cause of death.
Conclusions: Needle biopsy was efficient and yielded excellent pathology. The large majority of deaths in all three groups were caused by M. tuberculosis suggesting an urgent need for improved diagnosis and expedited treatment prior to and throughout the course of antiretroviral therapy. Complex, unrecognized co-morbidities pose an additional challenge.
C1 [Wong, Emily B.; Setlhako, Gosetsemang J.; Osih, Regina; Venter, W. D. F.] Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.
[Wong, Emily B.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Wong, Emily B.] Univ KwaZulu Natal, KwaZulu Natal Res Inst TB & HIV, Durban, South Africa.
[Omar, Tanvier] Univ Witwatersrand, Fac Hlth Sci, Sch Pathol, Johannesburg, South Africa.
[Setlhako, Gosetsemang J.; Feldman, Charles] Univ Witwatersrand, Charlotte Maxeke Johannesburg Acad Hosp, Dept Internal Med, Johannesburg, South Africa.
[Murdoch, David M.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Martinson, Neil A.] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
[Martinson, Neil A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Bangsberg, David R.] Harvard Univ, Sch Med, Ragon Inst MGH MIT & Harvard, Massachusetts Gen Hosp,Ctr Global Hlth, Boston, MA 02115 USA.
RP Wong, EB (reprint author), Univ Witwatersrand, Wits Reprod Hlth & HIV Inst, Johannesburg, South Africa.
EM emily.wong@k-rith.org
FU Fogarty International Center at the National Institutes of Health
[R24TW007988, RTW007373/0, D43TW000010-21S1]; President's Emergency Plan
for AIDS Relief [674-A-00-08-00005-00]; National Research Foundation of
South Africa
FX This work was supported by the Fogarty International Center at the
National Institutes of Health (www.fic.nih.gov, R24TW007988 supported
and provided research training to E. B. W. and G.J.S.; RTW007373/0
supported N.M. and provided research training to W. D. F. V.; and
D43TW000010-21S1 provided research training to T.O.), the President's
Emergency Plan for AIDS Relief (www.pepfar.gov, 674-A-00-08-00005-00
supported R.O., G.J.S, W. D. F. V.), and the National Research
Foundation of South Africa (www.nrf.ac.za, supported C. F.). The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 42
TC 54
Z9 54
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2012
VL 7
IS 10
AR e47542
DI 10.1371/journal.pone.0047542
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 024UX
UT WOS:000310135800054
PM 23094059
ER
PT J
AU Clark, K
MacKenzie, KF
Petkevicius, K
Kristariyanto, Y
Zhang, JZ
Choi, HG
Peggie, M
Plater, L
Pedrioli, PGA
McIver, E
Gray, NS
Arthur, JSC
Cohen, P
AF Clark, Kristopher
MacKenzie, Kirsty F.
Petkevicius, Kasparas
Kristariyanto, Yosua
Zhang, Jiazhen
Choi, Hwan Geun
Peggie, Mark
Plater, Lorna
Pedrioli, Patrick G. A.
McIver, Ed
Gray, Nathanael S.
Arthur, J. Simon C.
Cohen, Philip
TI Phosphorylation of CRTC3 by the salt-inducible kinases controls the
interconversion of classically activated and regulatory macrophages
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE Toll-like receptor; AMPK-related kinases; MRT67307; MRT199665;
HG-9-91-01
ID INNATE IMMUNITY; CROSS-TALK; IN-VIVO; FAMILY; CREB; POLARIZATION;
RECEPTORS; CYTOKINE; AMPK
AB Macrophages acquire strikingly different properties that enable them to play key roles during the initiation, propagation, and resolution of inflammation. Classically activated (M1) macrophages produce proinflammatory mediators to combat invading pathogens and respond to tissue damage in the host, whereas regulatory macrophages (M2b) produce high levels of anti-inflammatory molecules, such as IL-10, and low levels of proinflammatory cytokines, like IL-12, and are important for the resolution of inflammatory responses. A central problem in this area is to understand how the formation of regulatory macrophages can be promoted at sites of inflammation to prevent and/or alleviate chronic inflammatory and autoimmune diseases. Here, we demonstrate that the salt-inducible kinases (SIKs) restrict the formation of regulatory macrophages and that their inhibition induces striking increases in many of the characteristic markers of regulatory macrophages, greatly stimulating the production of IL-10 and other anti-inflammatory molecules. We show that SIK inhibitors elevate IL-10 production by inducing the dephosphorylation of cAMP response element-binding protein (CREB)-regulated transcriptional coactivator (CRTC) 3, its dissociation from 14-3-3 proteins and its translocation to the nucleus where it enhances a gene transcription program controlled by CREB. Importantly, the effects of SIK inhibitors on IL-10 production are lost in macrophages that express a drug-resistant mutant of SIK2. These findings identify SIKs as a key molecular switch whose inhibition reprograms macrophages to an anti-inflammatory phenotype. The remarkable effects of SIK inhibitors on macrophage function suggest that drugs that target these protein kinases may have therapeutic potential for the treatment of inflammatory and autoimmune diseases.
C1 [Clark, Kristopher; MacKenzie, Kirsty F.; Petkevicius, Kasparas; Kristariyanto, Yosua; Zhang, Jiazhen; Peggie, Mark; Plater, Lorna; Arthur, J. Simon C.; Cohen, Philip] Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.
[Pedrioli, Patrick G. A.; Cohen, Philip] Univ Dundee, Scottish Inst Cell Signaling, Coll Life Sci, Sir James Black Ctr, Dundee DD1 5EH, Scotland.
[Choi, Hwan Geun; Gray, Nathanael S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[McIver, Ed] Med Res Council Technol, London NW7 1AD, England.
RP Cohen, P (reprint author), Univ Dundee, MRC, Prot Phosphorylat Unit, Dundee DD1 5EH, Scotland.
EM p.cohen@dundee.ac.uk
RI Arthur, J. Simon/B-8058-2010
OI Arthur, J. Simon/0000-0002-8135-1958
FU UK Medical Research Council; AstraZeneca; Boehringer Ingelheim;
GlaxoSmithKline; Janssen Pharmaceutica; Merck-Serono; Pfizer
FX We thank Shizuo Akira (University of Osaka) for generously providing the
TBK1/IKKe-/- MEFs; Tomi Makela (University of Helsinki) for
the LKB1-/-MEFs; Alan Ashworth (Institute of Cancer Research)
for the LKB1flox/flox mice; Denise Harding who synthesized
MRT199665 under the supervision of E.M.; George Allen and Alan Prescott
for help with light microscopy; Catherine Johnson for providing 14-3-3
reagents; Julia Carr and Gail Fraser for genotyping; the University of
Dundee Resource Centre (coordinated by Don Tennant and Lorraine Malone)
for housing the mice; the International Centre for Kinase Profiling
(www.kinase-screen.mrc.ac.uk) for establishing the potency and
selectivity of the inhibitors; and the Medical Research Council-Protein
Phosphorylation Unit's DNA Sequencing Service (coordinated by Nicholas
Helps) and the Antibody Production Team (coordinated by Hilary
McLauchlan and James Hastie) for outstanding technical support. The work
was supported by the UK Medical Research Council, AstraZeneca,
Boehringer Ingelheim, GlaxoSmithKline, Janssen Pharmaceutica,
Merck-Serono, and Pfizer.
NR 25
TC 61
Z9 63
U1 0
U2 11
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 16
PY 2012
VL 109
IS 42
BP 16986
EP 16991
DI 10.1073/pnas.1215450109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 029SK
UT WOS:000310515800052
PM 23033494
ER
PT J
AU Choi, YJ
Li, XY
Hydbring, P
Sanda, T
Stefano, J
Christie, AL
Signoretti, S
Look, AT
Kung, AL
von Boehmer, H
Sicinski, P
AF Choi, Yoon Jong
Li, Xiaoyu
Hydbring, Per
Sanda, Takaomi
Stefano, Joanna
Christie, Amanda L.
Signoretti, Sabina
Look, A. Thomas
Kung, Andrew L.
von Boehmer, Harald
Sicinski, Piotr
TI The Requirement for Cyclin D Function in Tumor Maintenance
SO CANCER CELL
LA English
DT Article
ID TRANSGENIC MICE; CELLULAR SENESCENCE; OXIDATIVE STRESS; BREAST-CANCER;
IN-VIVO; TUMORIGENESIS; CELLS; GENE; ONCOGENESIS; INHIBITION
AB D-cyclins represent components of cell cycle machinery. To test the efficacy of targeting D-cyclins in cancer treatment, we engineered mouse strains that allow acute and global ablation of individual D-cyclins in a living animal. Ubiquitous shutdown of cyclin D1 or inhibition of cyclin D-associated kinase activity in mice bearing ErbB2-driven mammary carcinomas triggered tumor cell senescence, without compromising the animals' health. Ablation of cyclin D3 in mice bearing Notch 1-driven T cell acute lymphoblastic leukemias (T-ALL) triggered tumor cell apoptosis. Such selective killing of leukemic cells can also be achieved by inhibiting cyclin D associated kinase activity in mouse and human T-ALL models. Inhibition of cyclin D-kinase activity represents a highly-selective anticancer strategy that specifically targets cancer cells without significantly affecting normal tissues.
C1 [Choi, Yoon Jong; Hydbring, Per; Stefano, Joanna; Sicinski, Piotr] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Sanda, Takaomi; Look, A. Thomas] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Li, Xiaoyu; von Boehmer, Harald] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Christie, Amanda L.; Kung, Andrew L.] Dana Farber Canc Inst, Lurie Family Imaging Ctr, Boston, MA 02215 USA.
[Signoretti, Sabina] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Signoretti, Sabina] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Sanda, Takaomi; Look, A. Thomas] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Choi, Yoon Jong; Hydbring, Per; Sicinski, Piotr] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Li, Xiaoyu; von Boehmer, Harald] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
[Sanda, Takaomi; Look, A. Thomas; Kung, Andrew L.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Sicinski, P (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
EM peter_sicinski@dfci.harvard.edu
OI Kung, Andrew/0000-0002-9091-488X
FU Swedish Foundation; Wennergren Foundation; NIH [R01 CA083688, P01
CA080111, P01 CA109901]; Claudia Adams Barr grant; Novartis; National
Cancer Institute [1K99CA157951]; William Lawrence and Blanche Hughes
Foundation; Children's Leukemia Research Association; Japan Society for
the Promotion of Science
FX We thank Drs. K. Kozar for initial help with gene-targeting constructs;
E. Sicinska, Y. Geng, L. Anders, and Q. Yu for reagents, advice, and
expertise. P.H. was partly supported by a fellowship from the Swedish
Wennergren Foundations. This work was supported by NIH Grants R01
CA083688 and P01 CA080111 to P.S., P01 CA109901 to A.T.L., H.v.B., and
P.S., and Claudia Adams Barr grant to X.L. P.S. is a consultant and a
recipient of a research grant from Novartis. T.S. is supported by grants
from the National Cancer Institute (1K99CA157951), the William Lawrence
and Blanche Hughes Foundation, the Children's Leukemia Research
Association, and the Japan Society for the Promotion of Science.
NR 51
TC 80
Z9 81
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
EI 1878-3686
J9 CANCER CELL
JI Cancer Cell
PD OCT 16
PY 2012
VL 22
IS 4
BP 438
EP 451
DI 10.1016/j.ccr.2012.09.015
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 024MS
UT WOS:000310113900006
PM 23079655
ER
PT J
AU Zhang, XW
Zhao, XH
Fiskus, W
Lin, JH
Lwin, T
Rao, R
Zhang, YZ
Chan, JC
Fu, K
Marquez, VE
Chen-Kiang, S
Moscinski, LC
Seto, E
Dalton, WS
Wright, KL
Sotomayor, E
Bhalla, K
Tao, JG
AF Zhang, Xinwei
Zhao, Xiaohong
Fiskus, Warren
Lin, Jianhong
Lwin, Tint
Rao, Rekha
Zhang, Yizhuo
Chan, John C.
Fu, Kai
Marquez, Victor E.
Chen-Kiang, Selina
Moscinski, Lynn C.
Seto, Edward
Dalton, William S.
Wright, Kenneth L.
Sotomayor, Eduardo
Bhalla, Kapil
Tao, Jianguo
TI Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a
Therapeutic Target of Histone Modification in Aggressive B-Cell
Lymphomas
SO CANCER CELL
LA English
DT Article
ID MANTLE-CELL; EXPRESSION; CANCER; DEACETYLASE; REPRESSION; TUMORIGENESIS;
RECRUITMENT; LEUKEMIA; MODEL
AB We investigated the transcriptional and epigenetic repression of miR-29 by MYC, HDAC3, and EZH2 in mantle cell lymphoma and other MYC-associated lymphomas. We demonstrate that miR-29 is repressed by MYC through a corepressor complex with HDAC3 and EZH2. MYC contributes to EZH2 upregulation via repression of the EZH2 targeting miR-26a, and EZH2 induces MYC via inhibition of the MYC targeting miR-494 to create positive feedback. Combined inhibition of HDAC3 and EZH2 cooperatively disrupted the MYC-EZH2-miR-29 axis, resulting in restoration of miR-29 expression, downregulation of miR-29-targeted genes, and lymphoma growth suppression in vitro and in vivo. These findings define a MYC-mediated miRNA repression mechanism, shed light on MYC lymphomagenesis mechanisms, and reveal promising therapeutic targets for aggressive B-cell malignancies.
C1 [Zhang, Xinwei; Zhao, Xiaohong; Lwin, Tint; Moscinski, Lynn C.; Dalton, William S.; Sotomayor, Eduardo; Tao, Jianguo] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33613 USA.
[Zhang, Xinwei; Zhao, Xiaohong; Lwin, Tint; Moscinski, Lynn C.; Dalton, William S.; Sotomayor, Eduardo; Tao, Jianguo] H Lee Moffitt Canc Ctr & Res Inst, Expt Therapeut Program, Tampa, FL 33613 USA.
[Seto, Edward] H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33613 USA.
[Wright, Kenneth L.] H Lee Moffitt Canc Ctr & Res Inst, Immunol Program, Tampa, FL 33613 USA.
[Zhang, Xinwei; Zhang, Yizhuo] Tianjin Canc Hosp, Dept Immunol & Malignant Hematol, Tianjin 300060, Peoples R China.
[Fiskus, Warren; Rao, Rekha; Bhalla, Kapil] Univ Kansas, Ctr Canc, Kansas City, KS 66160 USA.
[Lin, Jianhong] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chan, John C.; Fu, Kai] Univ Nebraska Med Ctr, Dept Pathol, Omaha, NE 68198 USA.
[Marquez, Victor E.] NCI, Chem Biol Lab, Ctr Canc Res, Frederick, MD 21702 USA.
[Chen-Kiang, Selina] Weill Cornell Med Coll, Dept Pathol, New York, NY 10065 USA.
RP Tao, JG (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33613 USA.
EM jianguo.tao@moffitt.org
FU National Cancer Institute [R01 CA137123]; Maher Fund; Susan and John
Sykes Lymphoma Research Fund; Lymphoma Research Foundation
FX We are grateful to the Tissue Procurement and Molecular Core Laboratory
at Moffitt Cancer Center for providing specimens and molecular analysis.
We thank Rasa Hamilton for editorial assistance. This work was supported
by grants from the National Cancer Institute (Grant R01 CA137123 to
J.T.), the Maher Fund (to J.T.), the Susan and John Sykes Lymphoma
Research Fund (to J.T.) and the Lymphoma Research Foundation (to J.T.).
NR 21
TC 109
Z9 114
U1 2
U2 25
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD OCT 16
PY 2012
VL 22
IS 4
BP 506
EP 523
DI 10.1016/j.ccr.2012.09.003
PG 18
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 024MS
UT WOS:000310113900011
PM 23079660
ER
PT J
AU Caro, P
Kishan, AU
Norberg, E
Stanley, IA
Chapuy, B
Ficarro, SB
Polak, K
Tondera, D
Gounarides, J
Yin, H
Zhou, F
Green, MR
Chen, LF
Monti, S
Marto, JA
Shipp, MA
Danial, NN
AF Caro, Pilar
Kishan, Amar U.
Norberg, Erik
Stanley, Illana A.
Chapuy, Bjoern
Ficarro, Scott B.
Polak, Klaudia
Tondera, Daniel
Gounarides, John
Yin, Hong
Zhou, Feng
Green, Michael R.
Chen, Linfeng
Monti, Stefano
Marto, Jarrod A.
Shipp, Margaret A.
Danial, Nika N.
TI Metabolic Signatures Uncover Distinct Targets in Molecular Subsets of
Diffuse Large B Cell Lymphoma
SO CANCER CELL
LA English
DT Article
ID FATTY-ACID OXIDATION; ACTIVATED RECEPTOR-GAMMA; GLUTAMINE-METABOLISM;
CANCER-CELLS; EXPRESSION; PATHWAYS; TUMOR; GROWTH; TISSUE; PROLIFERATION
AB Molecular signatures have identified several subsets of diffuse large B cell lymphoma (DLBCL) and rational targets within the B cell receptor (BCR) signaling axis. The OxPhos-DLBCL subset, which harbors the signature of genes involved in mitochondrial metabolism, is insensitive to inhibition of BCR survival signaling but is functionally undefined. We show that, compared with BCR-DLBCLs, OxPhos-DLBCLs display enhanced mitochondrial energy transduction, greater incorporation of nutrient-derived carbons into the tricarboxylic acid cycle, and increased glutathione levels. Moreover, perturbation of the fatty acid oxidation program and glutathione synthesis proved selectively toxic to this tumor subset. Our analysis provides evidence for distinct metabolic fingerprints and associated survival mechanisms in DLBCL and may have therapeutic implications.
C1 [Caro, Pilar; Kishan, Amar U.; Norberg, Erik; Stanley, Illana A.; Ficarro, Scott B.; Polak, Klaudia; Tondera, Daniel; Zhou, Feng; Marto, Jarrod A.; Danial, Nika N.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Chapuy, Bjoern; Green, Michael R.; Chen, Linfeng; Shipp, Margaret A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ficarro, Scott B.; Zhou, Feng; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
[Kishan, Amar U.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Norberg, Erik; Stanley, Illana A.; Danial, Nika N.] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Ficarro, Scott B.; Zhou, Feng; Marto, Jarrod A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Gounarides, John; Yin, Hong] Novartis Inst Biomed Res, Cambridge, MA 02139 USA.
[Monti, Stefano] Broad Inst, Cambridge, MA 02142 USA.
[Monti, Stefano] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02218 USA.
RP Danial, NN (reprint author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
EM nika_danial@dfci.harvard.edu
RI Green, Michael/F-3482-2013;
OI Green, Michael/0000-0001-6309-9472; Monti, Stefano/0000-0002-9376-0660
FU Alexandra Jane Miliotis Fellowship in Pediatric Oncology; Harvard-MIT
Division of Health Sciences and Technology; Howard Hughes Medical
Institute; Swedish Research Council; Novartis Institutes for Biomedical
Research; National Institutes of Health [PO1 CA092625]; German Research
Foundation DFG [Ch 735/1-1]; Burroughs Welcome Fund
FX We thank Eric Smith for manuscript preparation. We gratefully
acknowledge George Rogers, Martin Brand, David Ferrick, Min Wu, and
Orian Shirihai for advice on respirometry; Wei Jiang and Frank Cook for
assistance with LC-MS/MS and GC/MS; and Georg Lenz and Frank Stegmeier
for HBL-1 and U2932 DLBCL cell lines. A.U.K. was supported by the
Alexandra Jane Miliotis Fellowship in Pediatric Oncology, the IDEA2
Program Grant from the Harvard-MIT Division of Health Sciences and
Technology, and a Medical Student Research Training Fellowship from the
Howard Hughes Medical Institute. E.N. was supported by a postdoctoral
fellowship from the Swedish Research Council. This work was supported in
part by funding from the Novartis Institutes for Biomedical Research
(N.N.D.), National Institutes of Health Grant PO1 CA092625 (M.A.S.), and
the German Research Foundation DFG Ch 735/1-1 (B.C.). The authors
acknowledge generous support provided through the Dana-Farber Cancer
Institute Strategic Research Initiative (to JAM.). N.N.D. is a recipient
of the Burroughs Welcome Fund Career Award in Biomedical Sciences and a
consultant for the Novartis Institutes for Biomedical Research.
NR 41
TC 89
Z9 92
U1 4
U2 31
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1535-6108
J9 CANCER CELL
JI Cancer Cell
PD OCT 16
PY 2012
VL 22
IS 4
BP 547
EP 560
DI 10.1016/j.ccr.2012.08.014
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA 024MS
UT WOS:000310113900014
PM 23079663
ER
PT J
AU Shahian, DM
O'Brien, SM
Sheng, SB
DeLong, ER
Peterson, ED
Grau-Sepulveda, MV
Grover, FL
Mayer, JE
Jacobs, JP
Weiss, JM
Weintraub, WS
Klein, LW
Shaw, RE
Garratt, K
Moussa, I
Shewan, CM
Dangas, GD
Edwards, FH
AF Shahian, David M.
O'Brien, Sean M.
Sheng, Shubin
DeLong, Elizabeth R.
Peterson, Eric D.
Grau-Sepulveda, Maria V.
Grover, Frederick L.
Mayer, John E.
Jacobs, Jeffrey P.
Weiss, Jocelyn M.
Weintraub, William S.
Klein, Lloyd W.
Shaw, Richard E.
Garratt, Kirk
Moussa, Issam
Shewan, Cynthia M.
Dangas, George D.
Edwards, Fred H.
TI Response to Letter Regarding Article, "Predictors of Long-Term Survival
After Coronary Artery Bypass Grafting Surgery: Results From the Society
of Thoracic Surgeons Adult Cardiac Surgery Database (the ASCERT Study)"
SO CIRCULATION
LA English
DT Letter
C1 [Shahian, David M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[O'Brien, Sean M.; Sheng, Shubin; DeLong, Elizabeth R.; Peterson, Eric D.; Grau-Sepulveda, Maria V.] Duke Clin Res Inst, Durham, NC USA.
[Grover, Frederick L.] Univ Colorado, Sch Med, Denver, CO USA.
[Mayer, John E.] Childrens Hosp, Boston, MA 02115 USA.
[Jacobs, Jeffrey P.] Congenital Heart Inst Florida, St Petersburg, FL USA.
[Weiss, Jocelyn M.] Amer Coll Cardiol, Washington, DC USA.
[Weintraub, William S.] Christiana Care Ctr Outcomes Res, Newark, DE USA.
[Klein, Lloyd W.] Gottlieb Mem Hosp, Melrose Pk, IL USA.
[Shaw, Richard E.] Calif Pacific Med Ctr, San Francisco, CA USA.
[Garratt, Kirk] Lenox Hill Heart & Vasc Inst New York, New York, NY USA.
[Moussa, Issam] Mayo Clin, Jacksonville, FL 32224 USA.
[Shewan, Cynthia M.] Soc Thorac Surg, Chicago, IL USA.
[Dangas, George D.] Columbia Univ, Med Ctr, New York, NY USA.
[Edwards, Fred H.] Univ Florida Shands Jacksonville, Jacksonville, FL USA.
RP Shahian, DM (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI O'Brien, Sean/H-6268-2013
NR 1
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 16
PY 2012
VL 126
IS 16
BP E259
EP E259
DI 10.1161/CIRCULATIONAHA.112.130989
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 022PX
UT WOS:000309973700005
ER
PT J
AU Xu, J
Shao, Z
Glass, K
Bauer, DE
Pinello, L
Van Handel, B
Hou, S
Stamatoyannopoulos, JA
Mikkola, HKA
Yuan, GC
Orkin, SH
AF Xu, Jian
Shao, Zhen
Glass, Kimberly
Bauer, Daniel E.
Pinello, Luca
Van Handel, Ben
Hou, Serena
Stamatoyannopoulos, John A.
Mikkola, Hanna K. A.
Yuan, Guo-Cheng
Orkin, Stuart H.
TI Combinatorial Assembly of Developmental Stage-Specific Enhancers
Controls Gene Expression Programs during Human Erythropoiesis
SO DEVELOPMENTAL CELL
LA English
DT Article
ID EMBRYONIC STEM-CELLS; INTERFERON REGULATORY FACTOR-2; FETAL-HEMOGLOBIN
EXPRESSION; GENOME-WIDE ANALYSIS; ERYTHROID-CELLS; HISTONE
MODIFICATIONS; CHROMATIN OCCUPANCY; C-MYB; IDENTIFICATION;
DIFFERENTIATION
AB Gene-distal enhancers are critical for tissue-specific gene expression, but their genomic determinants within a specific lineage at different stages of development are unknown. Here we profile chromatin state maps, transcription factor occupancy, and gene expression profiles during human erythroid development at fetal and adult stages. Comparative analyses of human erythropoiesis identify developmental stage-specific enhancers as primary determinants of stage-specific gene expression programs. We find that erythroid master regulators GATA1 and TAL1 act cooperatively within active enhancers but confer little predictive value for stage specificity. Instead, a set of stage-specific coregulators collaborates with master regulators and contributes to differential gene expression. We further identify and validate IRF2, IRF6, and MYB as effectors of an adult-stage expression program. Thus, the combinatorial assembly of lineage-specific master regulators and transcriptional coregulators within developmental stage-specific enhancers determines gene expression programs and temporal regulation of transcriptional networks in a mammalian genome.
C1 [Glass, Kimberly; Pinello, Luca; Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Xu, Jian; Shao, Zhen; Bauer, Daniel E.; Hou, Serena; Orkin, Stuart H.] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Hematol Oncol, Boston, MA 02115 USA.
[Xu, Jian; Shao, Zhen; Bauer, Daniel E.; Hou, Serena; Orkin, Stuart H.] Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst,Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Van Handel, Ben; Mikkola, Hanna K. A.] Univ Calif Los Angeles, Dept Mol Cell & Dev Biol, Los Angeles, CA 90095 USA.
[Stamatoyannopoulos, John A.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA.
Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Yuan, GC (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
EM gcyuan@jimmy.harvard.edu; stuart_orkin@dfci.harvard.edu
RI cheng, yong/I-4270-2012
FU National Institutes of Health (NIH); NIH ARRA grant [RCHL101553]; NIDDK
Career Development Award [K01DK093543]
FX We thank V.G. Sankaran, D. Higgs, D.A. Williams, L.I. Zon, E.H.
Bresnick, and members of the Orkin laboratory for discussions. We thank
Z. Herbert for assistance with Helicos sequencing, F. Abderazzaq and R.
Rubio at the Center for Cancer Computational Biology sequencing facility
at Dana-Farber Cancer Institute (DFCI) for assistance with Illumina
HiSeq2000, E. Fox at Microarray Core at DFCI for microarray analyses,
and R. Tomaino and S. Gygi at the Taplin Mass Spectrometry Facility for
assistance with protein identification. This work was supported by
funding from the National Institutes of Health (NIH) (to S.H.O.,
G.-C.Y., J.A.S., and H.K.A.M.) and NIH ARRA grant RCHL101553 (to
S.H.O.). S.H.O. is an Investigator of the Howard Hughes Medical
Institute (HHMI). J.X. is an HHMI-Helen Hay Whitney Foundation fellow
and is supported by a NIDDK Career Development Award K01DK093543.
NR 54
TC 65
Z9 65
U1 0
U2 16
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1534-5807
J9 DEV CELL
JI Dev. Cell
PD OCT 16
PY 2012
VL 23
IS 4
BP 796
EP 811
DI 10.1016/j.devcel.2012.09.003
PG 16
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 023LR
UT WOS:000310036200015
PM 23041383
ER
PT J
AU Grosse-Sundrup, M
Henneman, JP
Sandberg, WS
Bateman, BT
Uribe, JV
Nguyen, NT
Ehrenfeld, JM
Martinez, EA
Kurth, T
Eikermann, M
AF Grosse-Sundrup, Martina
Henneman, Justin P.
Sandberg, Warren S.
Bateman, Brian T.
Uribe, Jose Villa
Nicole Thuy Nguyen
Ehrenfeld, Jesse M.
Martinez, Elizabeth A.
Kurth, Tobias
Eikermann, Matthias
TI Intermediate acting non-depolarizing neuromuscular blocking agents and
risk of postoperative respiratory complications: prospective propensity
score matched cohort study
SO BRITISH MEDICAL JOURNAL
LA English
DT Article
ID POSTANESTHESIA CARE-UNIT; TRACHEAL INTUBATION; PULMONARY COMPLICATIONS;
NONCARDIAC SURGERY; CONTROLLED-TRIAL; MUSCLE-ACTIVITY; BLOCKADE;
ANESTHESIA; MORBIDITY; REVERSAL
AB Objective To determine whether use of intermediate acting neuromuscular blocking agents during general anesthesia increases the incidence of postoperative respiratory complications.
Design Prospective, propensity score matched cohort study.
Setting General teaching hospital in Boston, Massachusetts, United States, 2006-10.
Participants 18 579 surgical patients who received intermediate acting neuromuscular blocking agents during surgery were matched by propensity score to 18 579 reference patients who did not receive such agents.
Main outcome measures The main outcome measures were oxygen desaturation after extubation (hemoglobin oxygen saturation <90% with a decrease in oxygen saturation after extubation of >3%) and reintubations requiring unplanned admission to an intensive care unit within seven days of surgery. We also evaluated effects on these outcome variables of qualitative monitoring of neuromuscular transmission (train-of-four ratio) and reversal of neuromuscular blockade with neostigmine to prevent residual postoperative neuromuscular blockade.
Results The use of intermediate acting neuromuscular blocking agents was associated with an increased risk of postoperative desaturation less than 90% after extubation (odds ratio 1.36, 95% confidence interval 1.23 to 1.51) and reintubation requiring unplanned admission to an intensive care unit (1.40, 1.09 to 1.80). Qualitative monitoring of neuromuscular transmission did not decrease this risk and neostigmine reversal increased the risk of postoperative desaturation less than 90% (1.32, 1.20 to 1.46) and reintubation (1.76, 1.38 to 2.26).
Conclusion The use of intermediate acting neuromuscular blocking agents during anesthesia was associated with an increased risk of clinically meaningful respiratory complications. Our data suggest that the strategies used in our trial to prevent residual postoperative neuromuscular blockade should be revisited.
C1 [Grosse-Sundrup, Martina; Henneman, Justin P.; Bateman, Brian T.; Uribe, Jose Villa; Nicole Thuy Nguyen; Martinez, Elizabeth A.; Eikermann, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Sandberg, Warren S.; Ehrenfeld, Jesse M.] Vanderbilt Univ, Sch Med, Dept Anaesthesiol, Nashville, TN 37212 USA.
[Bateman, Brian T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02114 USA.
[Kurth, Tobias] INSERM, Unit Neuroepidemio 708, Bordeaux, France.
[Kurth, Tobias] Univ Bordeaux, Bordeaux, France.
[Kurth, Tobias] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02114 USA.
[Eikermann, Matthias] Univ Klinikum Essen, Klin Anaesthesie & Intens Med, Essen, Germany.
RP Eikermann, M (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anaesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM meikermann@partners.org
OI Ehrenfeld, Jesse/0000-0003-3427-0140; Kurth, Tobias/0000-0001-7169-2620
FU Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts
General Hospital, Boston, United States; French National Research
Agency; US National Institutes of Health; Migraine Research Foundation;
Parkinson's Disease Foundation; Merck; Pfizer; ResMed Foundation;
Department of Anesthesia; Critical Care and Pain Medicine of the
Massachusetts General Hospital
FX This study was funded by the Department of Anesthesia, Critical Care and
Pain Medicine, Massachusetts General Hospital, Boston, United States.;
All authors have completed the ICMJE uniform disclosure form at
www.icmje.org/coi_disclosure.pdf (available on request from the
corresponding author) and declare: that this study has been funded only
by academic research funds; TK has received investigator initiated
research funding from the French National Research Agency, the US
National Institutes of Health, the Migraine Research Foundation, and the
Parkinson's Disease Foundation. He has received honorariums from
Allergan, the American Academy of Neurology, and Merck for educational
lectures, from the BMJ for editorial services, and from MAP
Pharmaceutical for contributing to a scientific advisory panel. ME has
received investigator initiated research funding from Merck, Pfizer, and
the ResMed Foundation, as well as the Department of Anesthesia and
Critical Care and Pain Medicine of the Massachusetts General Hospital.
He has received honorariums from Hill-Rom for giving advise, and from
the American Thoracic Society, Brown University, Michigan University,
and Vanderbilt University for educational lectures, and from the Journal
Anesthesiology for editorial services; the authors have no financial
relationships with any organisation or company that might have an
interest in the submitted work in the previous three years; and no other
relationships or activities that could appear to have influenced the
submitted work.
NR 47
TC 65
Z9 67
U1 0
U2 10
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BRIT MED J
JI Br. Med. J.
PD OCT 16
PY 2012
VL 345
AR e6329
DI 10.1136/bmj.e6329
PG 14
WC Medicine, General & Internal
SC General & Internal Medicine
GA 024WG
UT WOS:000310140600001
PM 23077290
ER
PT J
AU Buttery, SM
Kono, K
Stokasimov, E
Pellman, D
AF Buttery, Shawnna M.
Kono, Keiko
Stokasimov, Ema
Pellman, David
TI Regulation of the formin Bnr1 by septins and a MARK/Par1-family
septin-associated kinase
SO MOLECULAR BIOLOGY OF THE CELL
LA English
DT Article
ID MITOTIC SIGNALING NETWORK; SACCHAROMYCES-CEREVISIAE; BUDDING YEAST;
ACTIN NUCLEATION; CELL-CYCLE; POLARIZED GROWTH; PROTEIN-KINASE; GIN4
KINASE; CYTOSKELETON; BNI1P
AB Formin-family proteins promote the assembly of linear actin filaments and are required to generate cellular actin structures, such as actin stress fibers and the cytokinetic actomyosin contractile ring. Many formin proteins are regulated by an autoinhibition mechanism involving intramolecular binding of a Diaphanous inhibitory domain and a Diaphanous autoregulatory domain. However, the activation mechanism for these Diaphanous-related formins (DRFs) is not completely understood. Although small GTPases play an important role in relieving autoinhibition, other factors likely contribute. Here we describe a requirement for the septin Shs1 and the septin-associated kinase Gin4 for the localization and in vivo activity of the budding yeast DRF Bnr1. In budding yeast strains in which the other formin, Bni1, is conditionally inactivated, the loss of Gin4 or Shs1 results in the loss of actin cables and cell death, similar to the loss of Bnr1. The defects in these strains can be suppressed by constitutive activation of Bnr1. Gin4 is involved in both the localization and activation of Bnr1, whereas the septin Shs1 is required for Bnr1 activation but not its localization. Gin4 promotes the activity of Bnr1 independently of the Gin4 kinase activity, and Gin4 lacking its kinase domain binds to the critical localization region of Bnr1. These data reveal novel regulatory links between the actin and septin cytoskeletons.
C1 [Pellman, David] Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
Harvard Univ, Childrens Hosp, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Childrens Hosp, Sch Med, Dept Pediat Hematol Oncol, Boston, MA 02115 USA.
RP Pellman, D (reprint author), Harvard Univ, Childrens Hosp, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
EM david_pellman@dfci.harvard.edu
FU National Institutes of Health National Research Service Award [F32
GM076895]; National Institutes of Health [GM61345]
FX We thank A. Bretscher, B. Goode, J. Thorner, and M. Iwase for strains
and/or plasmids. We thank D. Kellogg for plasmids and the Gin4 antibody.
We are grateful to Chiwa Kuroda for technical support. We acknowledge
members of the Pellman lab for helpful discussions. S.M.B. was supported
by National Institutes of Health National Research Service Award F32
GM076895. D.P. was supported by National Institutes of Health Grant
GM61345.
NR 69
TC 12
Z9 12
U1 1
U2 6
PU AMER SOC CELL BIOLOGY
PI BETHESDA
PA 8120 WOODMONT AVE, STE 750, BETHESDA, MD 20814-2755 USA
SN 1059-1524
J9 MOL BIOL CELL
JI Mol. Biol. Cell
PD OCT 15
PY 2012
VL 23
IS 20
BP 4041
EP 4053
DI 10.1091/mbc.E12-05-0395
PG 13
WC Cell Biology
SC Cell Biology
GA 052UU
UT WOS:000312224800013
PM 22918953
ER
PT J
AU Cai, A
Keskin, DB
DeLuca, DS
Alonso, A
Zhang, WD
Zhang, GL
Hammond, NN
Nardi, V
Stone, RM
Neuberg, D
Sidney, J
Brusic, V
Wu, CJ
AF Cai, Ann
Keskin, Derin B.
DeLuca, David S.
Alonso, Anselmo
Zhang, Wandi
Zhang, Guang Lan
Hammond, Naa Norkor
Nardi, Valentina
Stone, Richard M.
Neuberg, Donna
Sidney, John
Brusic, Vladimir
Wu, Catherine J.
TI Mutated BCR-ABL Generates Immunogenic T-cell Epitopes in CML Patients
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA;
GRAFT-VERSUS-LEUKEMIA; MHC CLASS-I; SELECTIVE INHIBITOR;
IMATINIB-RESISTANT; ACCELERATED-PHASE; IMMUNE-RESPONSES; TYROSINE
KINASE; FOLLOW-UP
AB Purpose: Characterization of an approach to identify leukemia neoantigens arising in the context of drug resistance.
Experimental Design: We assessed whether leukemia neoantigens could be generated from drug-resistant mutations in BCR-ABL after imatinib relapse in patients with chronic myelogenous leukemia (CML).
Results: We computationally predicted that approximately 70 peptides derived from 26 BCR-ABL mutations would bind eight common alleles of MHC class I (IC50 < 1,000 nmol/L). Seven of nine imatinib-resistant CML patients were predicted to generate at least 1 peptide that binds autologous HLA alleles. We predicted and confirmed that an E255K mutation-derived peptide would bind HLA-A3 with high affinity (IC50 28 nmol/L), and showed that this peptide is endogenously processed and presented. Polyfunctional E255K-specific CD8+ T cells were detected in two imatinib-resistant HLA-A3+ CML patients concurrent with an effective anti-CML response to further therapy.
Conclusions: Our in vitro studies support the hypothesis that leukemia-driven genetic alterations are targeted by the immune system in association with a clinical response, and suggest the possibility of immunizing relapsed patients with CML against newly acquired tumor neoantigens. Clin Cancer Res; 18(20); 5761-72. (C) 2012 AACR.
C1 [Wu, Catherine J.] Massachusetts Gen Hosp, Harvard Inst Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cai, Ann] Harvard Univ, Sch Med, Harvard Mit Div Hlth Sci & Technol, Boston, MA USA.
[Zhang, Guang Lan; Stone, Richard M.; Brusic, Vladimir; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Cai, Ann; Keskin, Derin B.; DeLuca, David S.; Alonso, Anselmo; Zhang, Wandi; Zhang, Guang Lan; Hammond, Naa Norkor; Brusic, Vladimir; Wu, Catherine J.] Massachusetts Gen Hosp, Canc Vaccine Ctr, Boston, MA 02114 USA.
[Neuberg, Donna] Massachusetts Gen Hosp, Dept Biostat & Computat Biol, Boston, MA 02114 USA.
[Nardi, Valentina] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Sidney, John] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
RP Wu, CJ (reprint author), Massachusetts Gen Hosp, Harvard Inst Med, Dana Farber Canc Inst, Room 418,77 Ave Louis Pasteur, Boston, MA 02115 USA.
EM cwu@partners.org
FU Howard Hughes Medical Institute; Department of Defense
[W81XWH-07-1-0080]; Claudia Adams Barr Program Award; NCI
[5R21CA115043-2]; Damon-Runyon Cancer Research Foundation [CI-38-07]
FX A. Cai is supported by a grant from the Howard Hughes Medical Institute.
C. J. Wu is supported by a grant from the Department of Defense
(W81XWH-07-1-0080), the Claudia Adams Barr Program Award, the Miles and
Eleanor Shore Award, NCI (5R21CA115043-2), the Early Career
Physician-Scientist Award of the Howard Hughes Medical Institute, and is
a Damon-Runyon Clinical Investigator supported in part by the
Damon-Runyon Cancer Research Foundation (CI-38-07).
NR 50
TC 16
Z9 17
U1 0
U2 3
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2012
VL 18
IS 20
BP 5761
EP 5772
DI 10.1158/1078-0432.CCR-12-1182
PG 12
WC Oncology
SC Oncology
GA 048JW
UT WOS:000311908500027
PM 22912393
ER
PT J
AU Bauer, DE
Mitchell, CM
Strait, KM
Lathan, CS
Stelow, EB
Luer, SC
Muhammed, S
Evans, AG
Sholl, LM
Rosai, J
Giraldi, E
Oakley, RP
Rodriguez-Galindo, C
London, WB
Sallan, SE
Bradner, JE
French, CA
AF Bauer, Daniel E.
Mitchell, Chelsey M.
Strait, Kelly M.
Lathan, Christopher S.
Stelow, Edward B.
Lueer, Sonja C.
Muhammed, Somala
Evans, Andrew G.
Sholl, Lynette M.
Rosai, Juan
Giraldi, Eugenia
Oakley, Richard P.
Rodriguez-Galindo, Carlos
London, Wendy B.
Sallan, Stephen E.
Bradner, James E.
French, Christopher A.
TI Clinicopathologic Features and Long-term Outcomes of NUT Midline
Carcinoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID UPPER AERODIGESTIVE TRACT; BRD4-NUT FUSION ONCOGENE; AGGRESSIVE
CARCINOMA; THYMIC CARCINOMA; YOUNG-PATIENTS; TRANSLOCATION;
REARRANGEMENT; DIFFERENTIATION; T(15/19); CHILDREN
AB Purpose: NUT midline carcinoma (NMC) is a poorly differentiated squamous cancer characterized by rearrangement of the NUT gene. Research advances have provided opportunities for targeted therapy in NMC, yet the clinical features of this rare disease have not been systematically characterized. We report on a large population of such patients to identify the disease characteristics and treatments, correlate them with outcome, and to consider clinical recommendations.
Experimental Design: A clinical database was established using retrospective demographic and outcomes data available on all known cases of NMC. Questionnaires were completed by treating physicians. Pathologic, demographic, and clinical variables were assessed for 63 patients, the largest cohort of patients with NMC studied to date. Outcome data from 54 patients were available for survival analyses.
Results: The diagnosis of NMC has increased annually since 2007. Since 2009, there has been an observed increase in the age at diagnosis (P < 0.05). Geographic distribution of patients with NMC has been concentrated in the United States (n = 41, 65%). The median overall survival for patients with NMC was 6.7 months. The 2-year progression-free survival (PFS) was 9% with a 95% confidence interval (CI) of 1% to 17% [1-year PFS 15% (5-24%) and 2-year overall survival (OS) was 19% with a 95% CI of 7%-31% (1-year OS: 30% (27-34%)]. Multivariate analysis suggested that extent of surgical resection and initial radiotherapy were independent predictors of PFS and OS. Notably, no chemotherapeutic regimen was associated with improved outcome.
Conclusions: NMC portends a poor prognosis among all squamous cell neoplasms and seems to be frequently unrecognized. The finding that conventional chemotherapy has been inadequate indicates a pressing need for the development of targeted therapeutics. Intensive local therapies such as gross total resection and radiotherapy might be associated with enhanced survival. Clin Cancer Res; 18(20); 5773-9. (C) 2012 AACR.
C1 [Mitchell, Chelsey M.; Evans, Andrew G.; Sholl, Lynette M.; French, Christopher A.] Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, Boston, MA 02115 USA.
[Bauer, Daniel E.; Strait, Kelly M.; Muhammed, Somala; Rodriguez-Galindo, Carlos; London, Wendy B.; Sallan, Stephen E.] Harvard Univ, Sch Med, Dept Pediat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Bauer, Daniel E.; Strait, Kelly M.; Muhammed, Somala; Rodriguez-Galindo, Carlos; London, Wendy B.; Sallan, Stephen E.] Harvard Univ, Sch Med, Div Hematol Oncol, Childrens Hosp Boston, Boston, MA 02115 USA.
[Lathan, Christopher S.; Oakley, Richard P.; Bradner, James E.] Harvard Univ, Sch Med, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Stelow, Edward B.] Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA.
[Lueer, Sonja C.] Univ Bern, Inselspital, Univ Childrens Hosp Bern, Dept Pediat Hematol Oncol, CH-3010 Bern, Switzerland.
[Rosai, Juan] Italiano Int Ctr Oncol Pathol Consultat, Ctr Diagnost, Milan, Italy.
[Giraldi, Eugenia] Osped Riuniti Bergamo, Dept Pediat, I-24100 Bergamo, Italy.
RP French, CA (reprint author), Harvard Univ, Brigham & Womens Hosp, Dept Pathol, Sch Med, 75 Francis St, Boston, MA 02115 USA.
EM james_bradner@dfci.harvard.edu
FU Adolescent and Young Adult Gap Fund; Smith Family Foundation; NIH
[3K01CA124581-03S1, 1R01CA124633, 3R01CA124633-04S1]
FX This work was supported by the Adolescent and Young Adult Gap Fund (to
J. E. Bradner and C. A. French), the Smith Family Foundation (to J. E.
Bradner) and the NIH grants 3K01CA124581-03S1 (to C. S. Lathan),
1R01CA124633, and 3R01CA124633-04S1 (to C. A. French).
NR 25
TC 57
Z9 59
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2012
VL 18
IS 20
BP 5773
EP 5779
DI 10.1158/1078-0432.CCR-12-1153
PG 7
WC Oncology
SC Oncology
GA 048JW
UT WOS:000311908500028
PM 22896655
ER
PT J
AU Wang, ZGC
Birkbak, NJ
Culhane, AC
Drapkin, R
Fatima, A
Tian, RY
Schwede, M
Alsop, K
Daniels, KE
Piao, HY
Liu, J
Etemadmoghadam, D
Miron, A
Salvesen, HB
Mitchell, G
DeFazio, A
Quackenbush, J
Berkowitz, RS
Iglehart, JD
Bowtell, DDL
Matulonis, UA
AF Wang, Zhigang C.
Birkbak, Nicolai Juul
Culhane, Aedin C.
Drapkin, Ronny
Fatima, Aquila
Tian, Ruiyang
Schwede, Matthew
Alsop, Kathryn
Daniels, Kathryn E.
Piao, Huiying
Liu, Joyce
Etemadmoghadam, Dariush
Miron, Alexander
Salvesen, Helga B.
Mitchell, Gillian
DeFazio, Anna
Quackenbush, John
Berkowitz, Ross S.
Iglehart, J. Dirk
Bowtell, David D. L.
Matulonis, Ursula A.
CA Australian Ovarian Canc Study Grp
TI Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer
Predict Treatment Outcome
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID NEGATIVE BREAST-CANCER; LOSS-OF-HETEROZYGOSITY; POLY(ADP-RIBOSE)
POLYMERASE; HOMOLOGOUS RECOMBINATION; CISPLATIN RESISTANCE; EXPRESSION
PROFILES; BRCA1 MUTATIONS; SNP ARRAYS; CARCINOMA; TUMORS
AB Purpose: High-grade serous cancer (HGSC) is the most common cancer of the ovary and is characterized by chromosomal instability. Defects in homologous recombination repair (HRR) are associated with genomic instability in HGSC, and are exploited by therapy targeting DNA repair. Defective HRR causes uniparental deletions and loss of heterozygosity (LOH). Our purpose is to profile LOH in HGSC and correlate our findings to clinical outcome, and compare HGSC and high-grade breast cancers.
Experimental Design: We examined LOH and copy number changes using single nucleotide polymorphism array data from three HGSC cohorts and compared results to a cohort of high-grade breast cancers. The LOH profiles in HGSC were matched to chemotherapy resistance and progression-free survival (PFS).
Results: LOH-based clustering divided HGSC into two clusters. The major group displayed extensive LOH and was further divided into two subgroups. The second group contained remarkably less LOH. BRCA1 promoter methylation was associated with the major group. LOH clusters were reproducible when validated in two independent HGSC datasets. LOH burden in the major cluster of HGSC was similar to triple-negative, and distinct from other high-grade breast cancers. Our analysis revealed an LOH cluster with lower treatment resistance and a significant correlation between LOH burden and PFS.
Conclusions: Separating HGSC by LOH-based clustering produces remarkably stable subgroups in three different cohorts. Patients in the various LOH clusters differed with respect to chemotherapy resistance, and the extent of LOH correlated with PFS. LOH burden may indicate vulnerability to treatment targeting DNA repair, such as PARP1 inhibitors. Clin Cancer Res; 18(20); 5806-15. (C) 2012 AACR.
C1 [Wang, Zhigang C.; Birkbak, Nicolai Juul; Fatima, Aquila; Tian, Ruiyang; Miron, Alexander; Iglehart, J. Dirk] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Culhane, Aedin C.; Schwede, Matthew; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Drapkin, Ronny; Daniels, Kathryn E.; Piao, Huiying; Liu, Joyce; Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Drapkin, Ronny; Piao, Huiying] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Berkowitz, Ross S.] Brigham & Womens Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02115 USA.
[Birkbak, Nicolai Juul] Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Etemadmoghadam, Dariush; Bowtell, David D. L.] Peter MacCallum Canc Ctr, Canc Genom Program, Melbourne, Vic, Australia.
[Etemadmoghadam, Dariush; Bowtell, David D. L.] Peter MacCallum Canc Ctr, Dept Biochem, Melbourne, Vic, Australia.
[Etemadmoghadam, Dariush; Bowtell, David D. L.] Peter MacCallum Canc Ctr, Dept Pathol, Melbourne, Vic, Australia.
[Alsop, Kathryn; Mitchell, Gillian] Peter MacCallum Canc Ctr, Familial Canc Ctr, Melbourne, Vic, Australia.
[Alsop, Kathryn; Mitchell, Gillian] Univ Melbourne, Melbourne, Vic, Australia.
[DeFazio, Anna] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Dept Gynaecol Oncol, Westmead, NSW 2145, Australia.
[DeFazio, Anna] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia.
[Salvesen, Helga B.] Haukeland Hosp, Dept Obstet & Gynecol, Bergen, Norway.
[Salvesen, Helga B.] Univ Bergen, Dept Clin Med, Bergen, Norway.
RP Iglehart, JD (reprint author), Dana Farber Canc Inst, Dept Canc Biol, 450 Brookline Ave, Boston, MA 02215 USA.
EM jiglehart@partners.org; umatulonis@partners.org
RI deFazio, Anna/D-3939-2013; Drapkin, Ronny/E-9944-2016; Bowtell,
David/H-1007-2016; salvesen, Helga/C-1187-2017
OI deFazio, Anna/0000-0003-0057-4744; Drapkin, Ronny/0000-0002-6912-6977;
Bowtell, David/0000-0001-9089-7525; salvesen, Helga/0000-0002-4438-8831
FU Breast Cancer Research Foundation, New York, NY; Susan F. Smith Center
for Women's Cancers Program at Dana-Farber Cancer Institute; Danish
Council for Independent Research-Medical Sciences (FSS); Ovarian Cancer
SPORE [P50 CA105009]; Ovarian Cancer Research Fund; Robert and Deborah
First Fund; U.S. Army Medical Research and Materiel Command
[DAMD17-01-1-0729]; US Department of Defense [W81XWH-08-1-0684,
W81XWH-08-1-0685]; Cancer Australia; National Breast Cancer Foundation
[509303]; Peter MacCallum Cancer Centre Foundation; Cancer Council
Victoria; Queensland Cancer Fund; Cancer Council New South Wales; Cancer
Council South Australia; Cancer Foundation of Western Australia; Cancer
Council Tasmania; National Health and Medical Research Council of
Australia (NHMRC); NHMRC; The Norwegian Cancer Society; The Research
Council of Norway
FX This study was funded by the Breast Cancer Research Foundation, New
York, NY. Funds from the Susan F. Smith Center for Women's Cancers
Program at Dana-Farber Cancer Institute partially supported the genomic
studies. N. J. Birkbak was funded by the Danish Council for Independent
Research-Medical Sciences (FSS). R. Drapkin was supported by Ovarian
Cancer SPORE P50 CA105009, Ovarian Cancer Research Fund, and Robert and
Deborah First Fund. The Australian Ovarian Cancer Study was supported by
the U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729),
the US Department of Defense (W81XWH-08-1-0684 and W81XWH-08-1-0685),
Cancer Australia and National Breast Cancer Foundation (509303), the
Peter MacCallum Cancer Centre Foundation, Cancer Council Victoria,
Queensland Cancer Fund, Cancer Council New South Wales, Cancer Council
South Australia, Cancer Foundation of Western Australia, Cancer Council
Tasmania, and the National Health and Medical Research Council of
Australia (NHMRC). The Gynaecological Oncology Biobank at Westmead, a
member of the Australasian Biospecimen Network-Oncology group, is also
funded by NHMRC. H. B. Salvesen was supported by funds from The
Norwegian Cancer Society and The Research Council of Norway.
NR 48
TC 60
Z9 61
U1 1
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 15
PY 2012
VL 18
IS 20
BP 5806
EP 5815
DI 10.1158/1078-0432.CCR-12-0857
PG 10
WC Oncology
SC Oncology
GA 048JW
UT WOS:000311908500032
PM 22912389
ER
PT J
AU Tateno, M
Park, TW
Kato, TA
Umene-Nakano, W
Saito, T
AF Tateno, Masaru
Park, Tae Woo
Kato, Takahiro A.
Umene-Nakano, Wakako
Saito, Toshikazu
TI Hikikomori as a possible clinical term in psychiatry: a questionnaire
survey
SO BMC PSYCHIATRY
LA English
DT Article
DE Hikikomori; Social withdrawal; School refusal; Psychiatric diagnosis;
Developmental disorders
ID CULTURE-BOUND SYNDROME; SOCIAL WITHDRAWAL; AUTISM-SPECTRUM; COMMUNITY
POPULATION; YOUNG-PEOPLE; JAPAN; DEPRESSION; PREVALENCE; DISORDERS
AB Background: The word hikikomori, the abnormal avoidance of social contact, has become increasingly well-known. However, a definition of this phenomenon has not been discussed thoroughly. The aim of this study is to gain a better understanding of the perception of hikikomori amongst health-related students and professionals and to explore possible psychiatric conditions underlying hikikomori.
Methods: A total of 1,038 subjects were requested to complete a questionnaire regarding hikikomori phenomenon.
Results: While some differences in the perception of hikikomori do exist, all subjects tended to disagree with the statement, "hikikomori is NOT a disorder". Regarding the underlying psychiatric disorders of hikikomori, approximately 30% of psychiatrists chose schizophrenia as the most applicable ICD-10 diagnosis for hikikomori, whereas 50% of pediatricians chose neurotic or stress-related disorders.
Conclusions: An argument still exists regarding the relationship between hikikomori and psychiatric disorders. We propose that the term hikikomori could be used to describe severe social withdrawal in the setting of a number of psychiatric disorders.
C1 [Tateno, Masaru; Saito, Toshikazu] Sapporo Med Univ, Sch Med, Dept Neuropsychiat, Chuo Ku, Sapporo, Hokkaido 0608543, Japan.
[Park, Tae Woo] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02114 USA.
[Park, Tae Woo] VA Boston Healthcare Syst, Boston, MA 02114 USA.
[Kato, Takahiro A.] Kyushu Univ, Grad Sch Med Sci, Dept Neuropsychiat, Higashi Ku, Fukuoka 8128582, Japan.
[Umene-Nakano, Wakako] Univ Occupat & Environm Hlth, Sch Med, Dept Psychiat, Yahatanishi Ku, Kitakyushu, Fukuoka 8078555, Japan.
RP Tateno, M (reprint author), Sapporo Med Univ, Sch Med, Dept Neuropsychiat, Chuo Ku, South 1,West 16, Sapporo, Hokkaido 0608543, Japan.
EM tatema@sapmed.ac.jp
FU World Psychiatric Association (WPA)
FX The authors thank Yasuyo Suzuki, Kiyoji Matsuyama (Sapporo Medical
University), Takeshi Ujiie (Hokkaido Ujiie Clinic for Psychosomatic
Children) for their contributions for data collection, and Ryuji Sasaki
(Sapporo Medical University) for his technical assistance for on-line
questionnaire. This study was partially supported by the World
Psychiatric Association (WPA) Research Fund 2010 to TAK.
NR 35
TC 13
Z9 13
U1 2
U2 28
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-244X
J9 BMC PSYCHIATRY
JI BMC Psychiatry
PD OCT 15
PY 2012
VL 12
AR 169
DI 10.1186/1471-244X-12-169
PG 7
WC Psychiatry
SC Psychiatry
GA 044RJ
UT WOS:000311640400001
PM 23061675
ER
PT J
AU Strange, A
Riley, BP
Spencer, CCA
Morris, DW
Pirinen, M
O'Dushlaine, CT
Su, Z
Maher, BS
Freeman, C
Cormican, P
Bellenguez, C
Kenny, EM
Band, G
Wormley, B
Donohoe, G
Dilthey, A
Moutsianas, L
Quinn, E
Edkins, S
Judge, R
Coleman, K
Hunt, S
Tropea, D
Roche, S
Cummings, L
Kelleher, E
McKeon, P
Dinan, T
McDonald, C
Murphy, KC
O'Callaghan, E
O'Neill, FA
Waddington, JL
Walsh, D
Giannoulatou, E
Langford, C
Deloukas, P
Gray, E
Dronov, S
Potter, S
Pearson, R
Vukcevic, D
Tashakkori-Ghanbaria, A
Blackwell, JM
Bramon, E
Brown, MA
Casas, JP
Duncanson, A
Jankowski, J
Markus, HS
Mathew, CG
Palmer, CNA
Plomin, R
Rautanen, A
Sawcer, SJ
Trembath, RC
Viswanathan, AC
Wood, NW
Stone, J
Scolnick, E
Purcell, S
Sklar, P
Ripke, S
Walters, J
Owen, MJ
O'Donovan, MC
Peltonen, L
McVean, G
Kendler, KS
Gill, M
Donnelly, P
Corvin, A
AF Strange, Amy
Riley, Brien P.
Spencer, Chris C. A.
Morris, Derek W.
Pirinen, Matti
O'Dushlaine, Colm T.
Su, Zhan
Maher, Brion S.
Freeman, Colin
Cormican, Paul
Bellenguez, Celine
Kenny, Elaine M.
Band, Gavin
Wormley, Brandon
Donohoe, Gary
Dilthey, Alexander
Moutsianas, Loukas
Quinn, Emma
Edkins, Sarah
Judge, Roisin
Coleman, Kim
Hunt, Sarah
Tropea, Daniela
Roche, Siobhan
Cummings, Liz
Kelleher, Eric
McKeon, Patrick
Dinan, Ted
McDonald, Colm
Murphy, Kieran C.
O'Callaghan, Eadbhard
O'Neill, Francis A.
Waddington, John L.
Walsh, Dermot
Giannoulatou, Eleni
Langford, Cordelia
Deloukas, Panos
Gray, Emma
Dronov, Serge
Potter, Simon
Pearson, Richard
Vukcevic, Damjan
Tashakkori-Ghanbaria, Avazeh
Blackwell, Jenefer M.
Bramon, Elvira
Brown, Matthew A.
Casas, Juan P.
Duncanson, Audrey
Jankowski, Janusz
Markus, Hugh S.
Mathew, Christopher G.
Palmer, Colin N. A.
Plomin, Robert
Rautanen, Anna
Sawcer, Stephen J.
Trembath, Richard C.
Viswanathan, Ananth C.
Wood, Nicholas W.
Stone, Jennifer
Scolnick, Ed
Purcell, Shaun
Sklar, Pamela
Ripke, Stephan
Walters, James
Owen, Michael J.
O'Donovan, Michael C.
Peltonen, Leena
McVean, Gil
Kendler, Ken S.
Gill, Michael
Donnelly, Peter
Corvin, Aiden
CA Irish Schizophrenia Genomics Conso
SGENE Consortium
Schizophrenia Working Grp Psychiat
Wellcome Trust Case Control Consor
TI Genome-Wide Association Study Implicates HLA-C*01:02 as a Risk Factor at
the Major Histocompatibility Complex Locus in Schizophrenia
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE CACNA1I; genetics; genome-wide association study; HLAC; major
histocompatibility complex; polygene score; schizophrenia
ID CLASSICAL HLA ALLELES; TOURETTE-SYNDROME; DISRUPTION; BREAKPOINT;
DELETIONS; IMMP2L; GENE
AB Background: We performed a genome-wide association study (GWAS) to identify common risk variants for schizophrenia.
Methods: The discovery scan included 1606 patients and 1794 controls from Ireland, using 6,212,339 directly genotyped or imputed single nucleotide polymorphisms (SNPs). A subset of this sample (270 cases and 860 controls) was subsequently included in the Psychiatric GWAS Consortium-schizophrenia GWAS meta-analysis.
Results: One hundred eight SNPs were taken forward for replication in an independent sample of 13,195 cases and 31,021 control subjects. The most significant associations in discovery, corrected for genomic inflation, were (rs204999, p combined = 1.34 x 10(-9) and in combined samples (rs2523722 p combined = 2.88 x 10(-16)) mapped to the major histocompatibility complex (MHC) region. We imputed classical human leukocyte antigen (HLA) alleles at the locus; the most significant finding was with HLA-C*01:02. This association was distinct from the top SNP signal. The HLA alleles DRB1*03:01 and B*08:01 were protective, replicating a previous study.
Conclusions: This study provides further support for involvement of MHC class I molecules in schizophrenia. We found evidence of association with previously reported risk alleles at the TCF4, VRK2, and ZNF804A loci.
C1 [Strange, Amy; Spencer, Chris C. A.; Pirinen, Matti; Su, Zhan; Freeman, Colin; Bellenguez, Celine; Band, Gavin; Moutsianas, Loukas; Giannoulatou, Eleni; Pearson, Richard; Vukcevic, Damjan; Rautanen, Anna; Donnelly, Peter] Wellcome Trust Ctr Human Genet, Oxford, England.
[Riley, Brien P.; Maher, Brion S.; Wormley, Brandon; Kendler, Ken S.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Psychiat, Richmond, VA USA.
[Riley, Brien P.; Maher, Brion S.; Wormley, Brandon; Kendler, Ken S.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Dept Human Genet, Richmond, VA USA.
[Morris, Derek W.; O'Dushlaine, Colm T.; Cormican, Paul; Kenny, Elaine M.; Donohoe, Gary; Quinn, Emma; Judge, Roisin; Coleman, Kim; Tropea, Daniela; Cummings, Liz; Kelleher, Eric; Gill, Michael; Corvin, Aiden] Trinity Coll Dublin, Inst Mol Med, Dept Psychiat, Dublin, Ireland.
[Dilthey, Alexander; Moutsianas, Loukas; McVean, Gil] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
[Edkins, Sarah; Hunt, Sarah; Langford, Cordelia; Deloukas, Panos; Gray, Emma; Dronov, Serge; Potter, Simon; Tashakkori-Ghanbaria, Avazeh; Peltonen, Leena] Wellcome Trust Sanger Inst, Cambridge, England.
[Roche, Siobhan; McKeon, Patrick] St Patricks Univ Hosp, Dublin, Ireland.
[Dinan, Ted] Natl Univ Ireland Univ Coll Cork, Dept Psychiat, Cork, Ireland.
[McDonald, Colm] Natl Univ Ireland, Dept Psychiat, Galway, Ireland.
[Murphy, Kieran C.] Beaumont Hosp, RCSI Educ & Res Ctr, Dept Psychiat, Dublin 9, Ireland.
[O'Callaghan, Eadbhard] Dun Laoghaire Co, DETECT Early Intervent Psychosis Serv, Dublin, Ireland.
[O'Neill, Francis A.] Queens Univ Belfast, Dept Psychiat, Belfast, Antrim, North Ireland.
[O'Neill, Francis A.] Univ Oxford, Dept Stat, Oxford OX1 3TG, England.
[Waddington, John L.] Royal Coll Surgeons Ireland, Dublin 2, Ireland.
[Walsh, Dermot] Hlth Res Board, Dublin 2, Ireland.
[Blackwell, Jenefer M.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Subiaco, WA, Australia.
[Blackwell, Jenefer M.] Univ Cambridge, Cambridge Inst Med Res, Sch Clin Med, Cambridge, England.
[Bramon, Elvira] Kings Coll London, NIHR Biomed Res Ctr Mental Hlth, Inst Psychiat, Dept Psychosis Studies, London WC2R 2LS, England.
[Bramon, Elvira] S London & Maudsley NHS Fdn Trust, London, England.
[Brown, Matthew A.] Univ Queensland, Princess Alexandra Hosp, Univ Queensland Diamantina Inst, Brisbane, Qld, Australia.
[Casas, Juan P.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England.
[Casas, Juan P.] UCL, Dept Epidemiol & Publ Hlth, London, England.
[Duncanson, Audrey] Wellcome Trust Res Labs, London, England.
[Jankowski, Janusz] Queen Mary Univ London, Ctr Digest Dis, London, England.
[Jankowski, Janusz] Leicester Royal Infirm, Ctr Digest Dis, Leicester, Leics, England.
[Jankowski, Janusz] Univ Oxford, Dept Clin Pharmacol, Oxford, England.
[Markus, Hugh S.] St Georges Univ London, London, England.
[Mathew, Christopher G.; Trembath, Richard C.] Guys Hosp, Kings Coll London, Sch Med, Dept Med & Mol Genet, London SE1 9RT, England.
[Palmer, Colin N. A.] Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.
[Plomin, Robert] Kings Coll London, Social Genet & Dev Psychiat Ctr, Inst Psychiat, London, England.
[Sawcer, Stephen J.] Univ Cambridge, Addenbrookes Hosp, Dept Clin Neurosci, Cambridge CB2 2QQ, England.
[Viswanathan, Ananth C.] Moorfields Eye Hosp NHS Fdn Trust, NIHR Biomed Res Ctr Ophthalmol, London, England.
[Viswanathan, Ananth C.] UCL Inst Ophthalmol, London, England.
[Wood, Nicholas W.] Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
[Stone, Jennifer; Scolnick, Ed; Purcell, Shaun; Sklar, Pamela] Massachusetts Gen Hosp, Broad Inst, Boston, MA 02114 USA.
[Stone, Jennifer; Scolnick, Ed; Purcell, Shaun; Sklar, Pamela] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Ripke, Stephan; Walters, James; Owen, Michael J.; O'Donovan, Michael C.] Cardiff Univ, MRC Ctr Neuropsychiat Genet &Genom, Sch Med, Cardiff, S Glam, Wales.
[Morris, Derek W.; O'Dushlaine, Colm T.; Cormican, Paul; Kenny, Elaine M.; Donohoe, Gary; Quinn, Emma; Judge, Roisin; Coleman, Kim; Tropea, Daniela; Cummings, Liz; Gill, Michael; Corvin, Aiden] Trinity Coll Dublin, Inst Mol Med, Neuropsychiat Genet Grp, Dublin, Ireland.
RP Corvin, A (reprint author), St James Hosp, Trinity Ctr Hlth Sci, Dept Psychiat, Dublin 8, Ireland.
EM acorvin@tcd.ie
RI Palmer, Colin/C-7053-2008; Deloukas, Panos/B-2922-2013; Maher,
Brion/F-9185-2010; McDonald, Colm/C-1430-2009; Wood,
Nicholas/C-2505-2009; Jankowski, Janusz/H-2706-2012; Blackwell,
Jenefer/H-3015-2015;
OI Donohoe, Gary/0000-0003-3037-7426; Tropea, Daniela/0000-0001-9730-6636;
Pirinen, Matti/0000-0002-1664-1350; Palmer, Colin/0000-0002-6415-6560;
Deloukas, Panos/0000-0001-9251-070X; Wood, Nicholas/0000-0002-9500-3348;
Jankowski, Janusz/0000-0003-2130-9181; Corvin,
Aiden/0000-0001-6717-4089; Giannoulatou, Eleni/0000-0002-7084-6736;
Gillman, Matthew/0000-0002-2340-6930; Walters,
James/0000-0002-6980-4053; Plomin, Robert/0000-0002-0756-3629
FU Wellcome Trust Case Control Consortium [085475/B/08/Z, 085475/Z/08/Z];
Wellcome Trust [072894/Z/03/Z, 090532/Z/09/Z, 075491/Z/04/B,
068545/Z/02]; NIMH [MH 41953, MH083094]; Science Foundation Ireland
[08/IN.1/B1916]; Wolfson-Royal Society; Medical Research Council
[G0000934]
FX The authors sincerely thank all patients who contributed to this study
and all staff who facilitated their involvement. Funding for this study
was provided by the Wellcome Trust Case Control Consortium 2 project
(085475/B/08/Z and 085475/Z/08/Z), the Wellcome Trust (072894/Z/03/Z,
090532/Z/09/Z and 075491/Z/04/B), NIMH grants (MH 41953 and MH083094)
and Science Foundation Ireland (08/IN.1/B1916). P. Donnelly was
supported in part by a Wolfson-Royal Society Merit Award. We also thank
S. Bertrand, J. Bryant, S. L. Clark, J. S. Conquer, T. Dibling, J. C.
Eldred, S. Gamble, C. Hind, A. Wilk, C. R. Stribling and S. Taylor of
the Wellcome Trust Sanger Institute's Sample and Genotyping Facilities
for technical assistance. We thank S. Leslie for support with the HLA
imputation analysis. We acknowledge use of the Irish GeneBank sample,
the British 1958 Birth Cohort DNA collection funded by the Medical
Research Council (grant G0000934) and the Wellcome Trust (grant
068545/Z/02) and of the UK National Blood Service controls funded by the
Wellcome Trust.
NR 37
TC 44
Z9 45
U1 0
U2 24
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD OCT 15
PY 2012
VL 72
IS 8
BP 620
EP 628
DI 10.1016/j.biopsych.2012.05.035
PG 9
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 016UQ
UT WOS:000309545400003
ER
PT J
AU Han, S
Yang, BZ
Kranzler, HR
Oslin, D
Anton, R
Farrer, LA
Gelernter, J
AF Han, Shizhong
Yang, Bao-Zhu
Kranzler, Henry R.
Oslin, David
Anton, Raymond
Farrer, Lindsay A.
Gelernter, Joel
TI Linkage Analysis Followed by Association Show NRG1 Associated with
Cannabis Dependence in African Americans
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Association; candidate gene; cannabis dependence; linkage; NRG1; SNP
ID GENOME-WIDE LINKAGE; HETEROZYGOUS NEUREGULIN-1 MICE; MULTILOCUS GENOTYPE
DATA; USE DISORDERS; ALCOHOL-DEPENDENCE; SEMISTRUCTURED ASSESSMENT;
MISSING HERITABILITY; NICOTINE DEPENDENCE; COCAINE DEPENDENCE;
DRUG-DEPENDENCE
AB Background: A genetic contribution to cannabis dependence (CaD) has been established but susceptibility genes for CaD remain largely unknown.
Methods: We employed a multistage design to identify genetic variants underlying CaD. We first performed a genome-wide linkage scan for CaD in 384 African American (AA) and 354 European American families ascertained for genetic studies of cocaine and opioid dependence. We then conducted association analysis under the linkage peak, first using data from a genome-wide association study from the Study of Addiction: Genetics and Environment, followed by replication studies of prioritized single nucleotide polymorphisms (SNPs) in independent samples.
Results: We identified the strongest linkage evidence with CaD (logarithm of odds = 2.9) on chromosome 8p21.1 in AAs. In the association analysis of the Study of Addiction: Genetics and Environment sample under the linkage peak, we identified one SNP (rs17664708) associated with CaD in both AAs (odds ratio [OR] = 2.93, p = .0022) and European Americans (OR = 1.38, p = .02). This SNP, located at NRG1, a susceptibility gene for schizophrenia, was prioritized for further study. We replicated the association of rs17664708 with CaD in an independent AAs sample (OR = 2.81, p = .0068). The joint analysis of the two AA samples demonstrated highly significant association between rs17664708 and CaD with adjustment for either global (p = .00044) or local ancestry (p = .00075).
Conclusions: Our study shows that NRG1 is probably a susceptibility gene for CaD, based on convergent evidence of linkage and replicated associations in two independent AA samples.
C1 [Gelernter, Joel] Yale Univ, Vet Affairs Connecticut Healthcare Ctr, Sch Med, Dept Psychiat, West Haven, CT 06516 USA.
[Kranzler, Henry R.; Oslin, David] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA.
[Kranzler, Henry R.; Oslin, David] Philadelphia Vet Affairs Med Ctr, Vet Integrated Serv Network Mental Illness Res Ed, Philadelphia, PA USA.
[Anton, Raymond] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Med Biomed Genet, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Ophthalmol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Genet & Genom, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Biostat, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Med, Dept Epidemiol, Boston, MA 02118 USA.
[Farrer, Lindsay A.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA.
[Gelernter, Joel] Yale Univ, Sch Med, Dept Neurobiol, New Haven, CT USA.
RP Gelernter, J (reprint author), Yale Univ, Vet Affairs Connecticut Healthcare Ctr, Sch Med, Dept Psychiat, 950 Campbell Ave,116A2, West Haven, CT 06516 USA.
EM joel.gelernter@yale.edu
OI Farrer, Lindsay/0000-0001-5533-4225
FU National Institutes of Health (NIH) [R01 DA12690, R01 DA12849, RC2
DA028909, R01 DA18432, R01 AA11330, R01 AA017535, RO1 DA030976, K01
DA24758]; Veterans Affairs (VA) Connecticut Reserve Educational
Assistance Program center; VA Merit Grant; VA National Center for
Posttraumatic Stress Disorder Research; VA Connecticut and Veterans
Integrated Service Network 4 Mental Illness Research, Education and
Clinical Center Centers; Alcoholic Beverage Medical Research Foundation;
National Institutes of Health [N01-HG-65403]; NIH Genes, Environment and
Health Initiative [U01 HG004422, U01HG004438]; Gene Environment
Association Studies under the Genes, Environment and Health Initiative;
National Institute on Alcohol Abuse and Alcoholism; National Institute
on Drug Abuse; NIH [HHSN268200782096C]; Eli Lilly; Alkermes;
GlaxoSmithKline; Merck; Lundbeck; Roche; American College of
Neuropsychopharmacology Alcohol Clinical Trials Initiative; Alcohol
Clinical Trials Initiative
FX This study was supported by National Institutes of Health (NIH) Grants
R01 DA12690, R01 DA12849, RC2 DA028909, R01 DA18432, R01 AA11330, R01
AA017535, RO1 DA030976, K01 DA24758, and the Veterans Affairs (VA)
Connecticut Reserve Educational Assistance Program center, a VA Merit
Grant, VA National Center for Posttraumatic Stress Disorder Research,
and the VA Connecticut and Veterans Integrated Service Network 4 Mental
Illness Research, Education and Clinical Center Centers. It was also
partially supported by the Alcoholic Beverage Medical Research
Foundation Grant (SH).; We are grateful to the volunteer families and
individuals who participated in this research study. We gratefully
acknowledge the assistance in recruitment and assessment provided at
McLean Hospital by Roger Weiss, M. D., and at the Medical University of
South Carolina by Kathleen Brady, M. D., Ph.D. Genotyping services of
linkage analysis and our GWAS study were provided by the Center for
Inherited Disease Research and Yale University (Keck Center). The Center
for Inherited Disease Research is fully funded through a federal
contract from the National Institutes of Health to The Johns Hopkins
University (contract number N01-HG-65403). We are grateful to Ann Marie
Lacobelle, Michelle Cucinelli, Christa Robinson, and Greg Kay for their
excellent technical assistance, to the Semi-Structured Assessment for
Drug Dependence and Alcoholism interviewers who devoted substantial time
and effort to phenotype the study sample, and to John Farrell for
database management assistance.; The datasets used for the analyses
described in this manuscript were obtained from the database of
Genotypes and Phenotypes at
http://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs0
00092.v1.p1 through database of Genotypes and Phenotypes accession
number phs000092.v1.p. Funding support for the Study of Addiction:
Genetics and Environment was provided through the NIH Genes, Environment
and Health Initiative (U01 HG004422). The Study of Addiction: Genetics
and Environment is one of the genome-wide association studies funded as
part of the Gene Environment Association Studies under the Genes,
Environment and Health Initiative. Assistance with phenotype
harmonization and genotype cleaning, as well as with general study
coordination, was provided by the Gene Environment Association Studies
Coordinating Center (U01 HG004446).; Assistance with data cleaning was
provided by the National Center for Biotechnology Information. Support
for collection of datasets and samples was provided by the Collaborative
Study on the Genetics of Alcoholism (U10 AA008401), the Collaborative
Genetic Study of Nicotine Dependence (P01 CA089392), and the Family
Study of Cocaine Dependence (R01 DA013423). Funding support for
genotyping, which was performed at the Johns Hopkins University Center
for Inherited Disease Research, was provided by the NIH Genes,
Environment and Health Initiative (U01HG004438), the National Institute
on Alcohol Abuse and Alcoholism, the National Institute on Drug Abuse,
and the NIH contract "High throughput genotyping for studying the
genetic contributions to human disease" (HHSN268200782096C).; Dr.
Kranzler has been a paid consultant for Alkermes, GlaxoSmithKline,
Gilead, Eli Lilly, Lundbeck, and Roche. Dr. Anton has received honoraria
or grant support from Eli Lilly, Alkermes, GlaxoSmithKline, Merck,
Lundbeck, and Roche and is a shareholder in Alcomed. Drs. Kranzler and
Anton also report associations with Eli Lilly, Janssen, Schering Plough,
Lundbeck, Alkermes, GlaxoSmithKline, Abbott, and Johnson & Johnson, as
these companies provide support to the American College of
Neuropsychopharmacology Alcohol Clinical Trials Initiative, and both
receive support from the Alcohol Clinical Trials Initiative. The other
authors reported no biomedical financial interests or potential
conflicts of interest.
NR 66
TC 12
Z9 12
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD OCT 15
PY 2012
VL 72
IS 8
BP 637
EP 644
DI 10.1016/j.biopsych.2012.02.038
PG 8
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 016UQ
UT WOS:000309545400005
PM 22520967
ER
PT J
AU Zhang, XY
Zhang, WF
Zhou, DF
Chen, DC
Xiu, MH
Wu, HR
Haile, CN
Kosten, TA
Kosten, TR
AF Zhang, Xiang Yang
Zhang, Wu-Fang
Zhou, Dong-Feng
Chen, Da Chun
Xiu, Mei Hong
Wu, Hao-Ran
Haile, Colin N.
Kosten, Therese A.
Kosten, Thomas R.
TI Brain-Derived Neurotrophic Factor Levels and Its Val66Met Gene
Polymorphism Predict Tardive Dyskinesia Treatment Response to Ginkgo
Biloba
SO BIOLOGICAL PSYCHIATRY
LA English
DT Article
DE Brain-derived neurotrophic factor; extract of ginkgo biloba; genotype;
pharmacogenetics; schizophrenia; tardive dyskinesia
ID ACTIVITY-DEPENDENT SECRETION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND;
SCHIZOPHRENIC-PATIENTS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; EXTRACT;
NEURONS; BDNF; ASSOCIATION
AB Background: Tardive dyskinesia (TD) has no well-accepted treatments or known pathophysiology, but low brain-derived neurotrophic factor (BDNF) may play an important role in its pathophysiology. Ginkgo biloba (EGb-761) is a potent antioxidant that has neuroprotective effects mediated through enhancing BDNF levels. We hypothesized that treatment with EGb-761 would increase serum BDNF levels and reduce TD, particularly among schizophrenia patients who have the BDNF valine 66 to methionine (Val66Met) genotype (Val/Val).
Methods: Serum BDNF levels and genotyping for the BDNF gene Val66Met polymorphism were assessed in Chinese schizophrenic patients with (n = 368) and without (n = 563) TD as well as healthy control subjects (n = 546). About half of the TD patients (n = 157) then participated in a double-blind, randomized, placebo-control 12-week treatment with 240 mg per day of EGb-761. Serum BDNF levels were measured again at posttreatment. Clinical efficacy was determined using the Abnormal Involuntary Movement Scale (AIMS).
Results: TD patients had lower BDNF levels than the non-TD patients and healthy controls. EGb-761 treatment improved symptoms of TD and increased BDNF levels compared with placebo treatment. Moreover, the improvement of AIMS total score correlated with the increase in BDNF levels. Furthermore, improvement in the AIMS score was greatest in those with the Val/Val allele and lowest with the Met/Met allele.
Conclusions: The BDNF system may be implicated in the pathophysiology of TD and its improvement with antioxidant treatment. Furthermore, patients with the genetic potential for greater BDNF release (Val/Val at 66) may obtain a greater reduction in TD from EGb-761 treatment.
C1 [Zhang, Xiang Yang; Haile, Colin N.; Kosten, Therese A.; Kosten, Thomas R.] Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA.
[Zhang, Xiang Yang; Chen, Da Chun; Xiu, Mei Hong; Kosten, Thomas R.] Beijing HuiLongGuan Hosp, Psychiat Res Ctr, Beijing, Peoples R China.
[Zhang, Wu-Fang; Zhou, Dong-Feng] Peking Univ, Inst Mental Hlth, Key Lab Mental Hlth, Minist Hlth, Beijing 100871, Peoples R China.
[Wu, Hao-Ran] Hebei Prov Rong Jun Hosp, Baoding, Peoples R China.
RP Zhang, XY (reprint author), VA Med Ctr, Res Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM xyzhang@bcm.edu
OI Haile, Colin/0000-0001-8293-7291
FU Stanley Medical Research Institute [03T-459, 05T-726]; Department of
Veterans Affairs, South Central VA Health Care Network (VISN 16); Mental
Illness Research, Education and Clinical Center (MIRECC); U.S. National
Institutes of Health [P50-DA18827, U01-MH79639]
FX This study was funded by the Stanley Medical Research Institute (Grant
Nos. 03T-459 and 05T-726), the Department of Veterans Affairs, South
Central VA Health Care Network (VISN 16); Mental Illness Research,
Education and Clinical Center (MIRECC); and U.S. National Institutes of
Health Grant Nos. P50-DA18827 and U01-MH79639.
NR 43
TC 22
Z9 25
U1 1
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0006-3223
EI 1873-2402
J9 BIOL PSYCHIAT
JI Biol. Psychiatry
PD OCT 15
PY 2012
VL 72
IS 8
BP 700
EP 706
DI 10.1016/j.biopsych.2012.04.032
PG 7
WC Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA 016UQ
UT WOS:000309545400014
PM 22695185
ER
PT J
AU Peppercorn, J
Shapira, I
Deshields, T
Kroetz, D
Friedman, P
Spears, P
Collyar, DE
Shulman, LN
Dressler, L
Bertagnolli, MM
AF Peppercorn, Jeffrey
Shapira, Iuliana
Deshields, Teressa
Kroetz, Deanna
Friedman, Paula
Spears, Patricia
Collyar, Deborah E.
Shulman, Lawrence N.
Dressler, Lynn
Bertagnolli, Monica M.
TI Ethical Aspects of Participation in the Database of Genotypes and
Phenotypes of the National Center For Biotechnology Information The
Cancer and Leukemia Group B Experience
SO CANCER
LA English
DT Article
DE ethics; informed consent; genome-wide association study; Database of
Genotypes and Phenotypes of the National Center for Biotechnology
Information; future use of tissue
ID GENOME-WIDE ASSOCIATION; STORED BIOLOGICAL SAMPLES; TIME GENERAL
CONSENT; BREAST-CANCER; GENETIC RESEARCH; PROSTATE-CANCER;
SUSCEPTIBILITY LOCI; FUTURE-RESEARCH; INCIDENTAL FINDINGS; ENDOCRINE
THERAPY
AB BACKGROUND: The rapid pace of genetics research, coupled with evolving standards for informed consent, can create ethical challenges regarding future use of tissue or information from completed clinical trials. The Cancer and Leukemia Group B (CALGB) Oncology Cooperative Group was faced with an ethical dilemma regarding sharing genetic data from a completed genome-wide association study (GWAS) that was conducted as part of a large, multicenter breast cancer clinical trial with a national database: the Database of Genotypes and Phenotypes National Center for Biotechnology Information (dbGaP). METHODS: The CALGB Ethics Committee conducted a series of multidisciplinary meetings and teleconferences involving patient advocates, bioethicists, clinical researchers, and clinical oncologists to evaluate the ethical issues raised by this case and to identify lessons for improving informed consent to future genetics research in oncology trials. RESULTS: The Ethics Committee recommended that GWAS data be provided to dbGaP consistent with documented consent for future use of tissue among trial participants. Ethical issues, including adequacy of informed consent to future research, limitations of privacy in modern genetics research, the potential impact of population-based genetics research on health disparities, and recontact of research participants for clinical care or further research, were identified as major ethical considerations in this area. CONCLUSIONS: Although modern standards for informed consent should not prohibit research or sharing of data consistent with participant's intent and the public interest, there is an urgent need for national consensus on the appropriate use of archived tissue and standardized informed consent for future research among cancer clinical trial participants. Cancer 2012;118:5060-8. (C) 2012 American Cancer Society.
C1 [Peppercorn, Jeffrey] Duke Univ, Div Med Oncol, Med Ctr, Durham, NC 27710 USA.
[Shapira, Iuliana] Hofstra Univ, Dept Med, N Shore LIJ Hlth Syst, Manhasset, NY USA.
[Deshields, Teressa] Barnes Jewish Hosp, Dept Psychooncol, St Louis, MO 63110 USA.
[Kroetz, Deanna] Univ Calif San Francisco, Dept Biopharmaceut Sci & Pharmaceut Chem, San Francisco, CA 94143 USA.
[Friedman, Paula] Canc & Leukemia Grp B, Chicago, IL USA.
[Collyar, Deborah E.] Correlat Sci Operat, Canc & Leukemia Grp B, Chicago, IL USA.
[Shulman, Lawrence N.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02115 USA.
[Dressler, Lynn] Univ N Carolina, Inst Pharmacogen & Individualized Therapy, Chapel Hill, NC USA.
[Bertagnolli, Monica M.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
RP Peppercorn, J (reprint author), Duke Univ, Div Med Oncol, Med Ctr, Box 3446, Durham, NC 27710 USA.
EM jeffrey.peppercorn@duke.edu
FU Greenwall Foundation Faculty Scholars Program in Bioethics
FX Dr. Peppercorn is supported by the Greenwall Foundation Faculty Scholars
Program in Bioethics.
NR 78
TC 10
Z9 10
U1 2
U2 17
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
J9 CANCER-AM CANCER SOC
JI Cancer
PD OCT 15
PY 2012
VL 118
IS 20
BP 5060
EP 5068
DI 10.1002/cncr.27515
PG 9
WC Oncology
SC Oncology
GA 024BL
UT WOS:000310082500019
PM 22415847
ER
PT J
AU Bashir, T
Cloninger, C
Artinian, N
Anderson, L
Bernath, A
Holmes, B
Benavides-Serrato, A
Sabha, N
Nishimura, RN
Guha, A
Gera, J
AF Bashir, Tariq
Cloninger, Cheri
Artinian, Nicholas
Anderson, Lauren
Bernath, Andrew
Holmes, Brent
Benavides-Serrato, Angelica
Sabha, Nesrin
Nishimura, Robert N.
Guha, Abhijit
Gera, Joseph
TI Conditional Astroglial Rictor Overexpression Induces Malignant Glioma in
Mice
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; NEURAL STEM-CELLS; MOUSE ASTROCYTOMA MODEL;
ADULT MAMMALIAN BRAIN; SUBVENTRICULAR ZONE; MTOR COMPLEX;
GLIOBLASTOMA-MULTIFORME; CELLULAR COMPOSITION; PTEN LOSS; PATHWAY
AB Background: Hyperactivation of the mTORC2 signaling pathway has been shown to contribute to the oncogenic properties of gliomas. Moreover, overexpression of the mTORC2 regulatory subunit Rictor has been associated with increased proliferation and invasive character of these tumor cells.
Methodology/Principal Findings: To determine whether Rictor overexpression was sufficient to induce glioma formation in mice, we inserted a Cre-lox-regulated human Rictor transgene into the murine ROSA26 locus. This floxed Rictor strain was crossed with mice expressing the Cre recombinase driven from the glial fibrillary acidic protein (GFAP) promoter whose expression is limited to the glial cell compartment. Double transgenic GFAP-Cre/Rictor(loxP/loxP) mice developed multifocal infiltrating glioma containing elevated mTORC2 activity and typically involved the subventricular zone (SVZ) and lateral ventricle. Analysis of Rictor-dependent signaling in these tumors demonstrated that in addition to elevated mTORC2 activity, an mTORC2-independent marker of cortical actin network function, was also elevated. Upon histological examination of the neoplasms, many displayed oligodendroglioma-like phenotypes and expressed markers associated with oligodendroglial lineage tumors. To determine whether upstream oncogenic EGFRvIII signaling would alter tumor phenotypes observed in the GFAP-Cre/Rictor(loxP/loxP) mice, transgenic GFAP-EGFRvIII; GFAP-Cre/Rictor(loxP/loxP) mice were generated. These mice developed mixed astrocytic-oligodendroglial tumors, however glioma formation was accelerated and correlated with increased mTORC2 activity. Additionally, the subventricular zone within the GFAP-Cre/Rictor(loxP/loxP) mouse brain was markedly expanded, and a further proliferation within this compartment of the brain was observed in transgenic GFAP-EGFRvIII; GFAP-Cre/Rictor(loxP/loxP) mice.
Conclusion/Significance: These data collectively establish Rictor as a novel oncoprotein and support the role of dysregulated Rictor expression in gliomagenesis via mTOR-dependent and mTOR-independent mechanisms. Furthermore, oncogenic EGFRvIII signaling appears to potentiate the in vivo proliferative capacity of GFAP-Cre/Rictor(loxP/loxP) gliomas.
C1 [Bashir, Tariq; Cloninger, Cheri; Artinian, Nicholas; Anderson, Lauren; Bernath, Andrew; Holmes, Brent; Benavides-Serrato, Angelica; Nishimura, Robert N.; Gera, Joseph] Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA.
[Gera, Joseph] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.
[Nishimura, Robert N.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA.
[Sabha, Nesrin; Guha, Abhijit] Univ Toronto, Hosp Sick Children, Res Inst, Labatt Brain Tumor Res Ctr, Toronto, ON M5G 1X8, Canada.
[Gera, Joseph] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA.
[Gera, Joseph] Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90024 USA.
RP Gera, J (reprint author), Greater Los Angeles Vet Affairs Healthcare Syst, Dept Res & Dev, Los Angeles, CA USA.
EM jgera@mednet.ucla.edu
FU National Institutes of Health [R01CA109312]; Veterans Administration
FX This work was supported, in part, by National Institutes of Health grant
R01CA109312 and funds from the Veterans Administration. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 57
TC 17
Z9 19
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2012
VL 7
IS 10
AR e47741
DI 10.1371/journal.pone.0047741
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022WO
UT WOS:000309995100158
PM 23077666
ER
PT J
AU Schneider, JC
Trinh, NHT
Selleck, E
Fregni, F
Salles, SS
Ryan, CM
Stein, J
AF Schneider, Jeffrey C.
Trinh, Nhi-Ha T.
Selleck, Elizabeth
Fregni, Felipe
Salles, Sara S.
Ryan, Colleen M.
Stein, Joel
TI The Long-Term Impact of Physical and Emotional Trauma: The Station
Nightclub Fire
SO PLOS ONE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; BECK DEPRESSION INVENTORY; BURN INJURIES;
PSYCHOMETRIC PROPERTIES; HEALTH-STATUS; EVENT SCALE; POPULATION;
PREVALENCE; PREDICTORS; VERSION
AB Background: Survivors of physical and emotional trauma experience enduring occupational, psychological and quality of life impairments. Examining survivors from a large fire provides a unique opportunity to distinguish the impact of physical and emotional trauma on long-term outcomes. The objective is to detail the multi-dimensional long-term effects of a large fire on its survivor population and assess differences in outcomes between survivors with and without physical injury.
Methods and Findings: This is a survey-based cross-sectional study of survivors of The Station fire on February 20, 2003. The relationships between functional outcomes and physical injury were evaluated with multivariate regression models adjusted for pre-injury characteristics and post-injury outcomes. Outcome measures include quality of life (Burn Specific Health Scale-Brief), employment (time off work), post-traumatic stress symptoms (Impact of Event Scale-Revised) and depression symptoms (Beck Depression Inventory). 104 fire survivors completed the survey; 47% experienced a burn injury. There was a 42% to 72% response rate range. Although depression and quality of life were associated with burn injury in univariate analyses (p<0.05), adjusted analyses showed no significant relationship between burn injury and these outcomes (p = 0.91; p = .51). Post-traumatic stress symptoms were not associated with burn injury in the univariate (p = 0.13) or adjusted analyses (p = 0.79). Time off work was the only outcome in which physical injury remained significant in the multivariate analysis (p = 0.03).
Conclusions: Survivors of this large fire experienced significant life disruption, including occupational, psychological and quality of life sequelae. The findings suggest that quality of life, depression and post-traumatic stress outcomes are related to emotional trauma, not physical injury. However, physical injury is correlated with employment outcomes. The long-term impact of this traumatic event underscores the importance of longitudinal and mental health care for trauma survivors, with attention to those with and without physical injuries.
C1 [Schneider, Jeffrey C.; Fregni, Felipe] Harvard Univ, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Sch Med, Boston, MA 02115 USA.
[Trinh, Nhi-Ha T.] Massachusetts Gen Hosp, Dept Psychiat, Depress & Clin Res Program, Boston, MA 02114 USA.
[Fregni, Felipe] Harvard Univ, Lab Neuromodulat, Spaulding Rehabil Hosp, Sch Med, Boston, MA USA.
[Salles, Sara S.] Univ Kentucky, Dept Phys Med & Rehabil, Lexington, KY USA.
[Ryan, Colleen M.] Massachusetts Gen Hosp, Dept Surg, Sumner Redstone Burn Ctr, Boston, MA 02114 USA.
[Ryan, Colleen M.] Shriners Hosp Children Boston, Boston, MA USA.
[Stein, Joel] New York Presbyterian Hosp, New York, NY USA.
[Stein, Joel] Weill Cornell Med Coll, Div Rehabil Med, New York, NY USA.
[Stein, Joel] Columbia Univ, Dept Rehabil & Regenerat Med, Med Ctr, New York, NY USA.
RP Schneider, JC (reprint author), Harvard Univ, Dept Phys Med & Rehabil, Spaulding Rehabil Hosp, Sch Med, Boston, MA 02115 USA.
EM jcschneider@partners.org
FU International Association of Fire Fighters
FX This project was supported by a pilot grant from the International
Association of Fire Fighters. The funders had no role in the study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 41
TC 6
Z9 6
U1 3
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2012
VL 7
IS 10
AR e47339
DI 10.1371/journal.pone.0047339
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022WO
UT WOS:000309995100093
PM 23077593
ER
PT J
AU Wang, H
Yang, YP
Wang, GJ
Wang, SM
Yeap, BY
Sykes, M
Yang, YG
AF Wang, Hui
Yang, Yanping
Wang, Guanjun
Wang, Shumei
Yeap, Beow Yong
Sykes, Megan
Yang, Yong-Guang
TI Donor Bone Marrow-Derived T Cells Inhibit GVHD Induced by Donor
Lymphocyte Infusion in Established Mixed Allogeneic Hematopoietic
Chimeras
SO PLOS ONE
LA English
DT Article
ID VERSUS-HOST-DISEASE; REFRACTORY HEMATOLOGIC MALIGNANCIES;
REGULATORY-CELLS; TRANSPLANTATION; INDUCTION; THERAPY; SUPPRESSION;
ENVIRONMENT; TOLERANCE; REJECTION
AB Delayed administration of donor lymphocyte infusion (DLI) to established mixed chimeras has been shown to achieve antitumor responses without graft-vs.-host disease (GVHD). Herein we show that de novo donor BM-derived T cells that are tolerant of the recipients are important in preventing GVHD in mixed chimeras receiving delayed DLI. Mixed chimeras lacking donor BM-derived T cells developed significantly more severe GVHD than those with donor BM-derived T cells after DLI, even though both groups had comparable levels of total T cells at the time of DLI. Post-DLI depletion of donor BM-derived T cells in mixed chimeras, as late as 20 days after DLI, also provoked severe GVHD. Although both CD4 and CD8 T cells contributed to the protection, the latter were significantly more effective, suggesting that inhibition of GVHD was not mainly mediated by CD4 regulatory T cells. The lack of donor BM-derived T cells was associated with markedly increased accumulation of DLI-derived alloreactive T cells in parenchymal GVHD target tissues. Thus, donor BM-derived T cells are an important factor in determining the risk of GVHD and therefore, offer a potential therapeutic target for preventing and ameliorating GVHD in the setting of delayed DLI in established mixed chimeras.
C1 [Wang, Hui; Sykes, Megan; Yang, Yong-Guang] Columbia Univ Coll Phys & Surg, Columbia Ctr Translat Immunol, New York, NY 10032 USA.
[Wang, Hui; Yang, Yanping; Wang, Shumei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA.
[Yang, Yanping; Wang, Guanjun; Yang, Yong-Guang] Jilin Univ, Bethune Hosp 1, Changchun 130023, Jilin, Peoples R China.
[Yeap, Beow Yong] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
RP Yang, YG (reprint author), Columbia Univ Coll Phys & Surg, Columbia Ctr Translat Immunol, 630 W 168th St, New York, NY 10032 USA.
EM yy2324@columbia.edu
FU NIH [PO1 CA111519, RC1 HL100117, R01 AI064569]
FX This work was supported by grants from NIH (PO1 CA111519, RC1 HL100117
and R01 AI064569). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 29
TC 2
Z9 2
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 15
PY 2012
VL 7
IS 10
AR e47120
DI 10.1371/journal.pone.0047120
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 022WO
UT WOS:000309995100064
PM 23077554
ER
PT J
AU Rothman, RD
Baggish, AL
O'Callaghan, C
Lowry, PA
Bhatt, AB
MacRae, CA
Yannekis, G
Sanborn, DM
Mela, T
Yeh, RW
Palacios, I
Vlahakes, GJ
Fifer, MA
AF Rothman, Richard D.
Baggish, Aaron L.
O'Callaghan, Caitlin
Lowry, Patricia A.
Bhatt, Ami B.
MacRae, Calum A.
Yannekis, Gia
Sanborn, Danita M.
Mela, Theofanie
Yeh, Robert W.
Palacios, Igor
Vlahakes, Gus J.
Fifer, Michael A.
TI Management Strategy in 249 Consecutive Patients With Obstructive
Hypertrophic Cardiomyopathy Referred to a Dedicated Program
SO AMERICAN JOURNAL OF CARDIOLOGY
LA English
DT Article
ID OUTFLOW TRACT OBSTRUCTION; ALCOHOL SEPTAL ABLATION; ASSOCIATION
TASK-FORCE; LONG-TERM SURVIVAL; SYMPTOMATIC PATIENTS; PRACTICE
GUIDELINES; SUBAORTIC STENOSIS; DOUBLE-BLIND; DISOPYRAMIDE; CROSSOVER
AB The likelihood of success of conservative management of obstructive hypertrophic cardiomyopathy (HC) and the predictors of failure of conservative therapy are not known. We therefore evaluated the efficacy of an algorithm for the management of symptoms and predictors of failed conservative therapy in 249 consecutive symptomatic patients with obstructive HC referred to a dedicated HC program for management in general or for septal reduction therapy (SRT) in particular. There was considerable practice variation in the extent to which conservative therapy was optimized before referral for SRT. Over 3.7 +/- 2.9-year follow-up, symptoms resolved with addition of or increase in dosage of a beta blocker, calcium channel blocker, or disopyramide in 16%, 10%, and 10% of patients, respectively. Pacing with short atrioventricular delay controlled symptoms in 4 of 9 patients. In 63% of patients, conservative measures failed to control symptoms. Multivariate predictors of failure of conservative therapy were presence of New York Heart Association class III or IV symptoms (hazard ratio 2.0, 95% confidence interval 1.4 to 2.9, p = 0.001) and greater septal wall thickness (hazard ratio 1.06, 95% confidence interval 1.02 to 1.10, p = 0.003) at presentation. At time of presentation, 93 patients (37%) were already on optimal therapy and were referred for SRT. Of the remaining 156 patients who did not require immediate SRT, 93 (60%) were free from a recommendation for SRT at the end of the follow-up period. In conclusion, in symptomatic patients with obstructive HC, conservative therapy is successful in >1/3 of referred patients at 3.7-year follow-up, obviating SRT in these patients. Clinicians in programs offering SRT should optimize conservative therapy before recommending SRT. (C) 2012 Elsevier Inc. All rights reserved. (Am J Cardiol 2012;110:1169-1174)
C1 [Rothman, Richard D.; Baggish, Aaron L.; O'Callaghan, Caitlin; Lowry, Patricia A.; Bhatt, Ami B.; MacRae, Calum A.; Yannekis, Gia; Sanborn, Danita M.; Mela, Theofanie; Yeh, Robert W.; Palacios, Igor; Fifer, Michael A.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Vlahakes, Gus J.] Massachusetts Gen Hosp, Dept Surg, Cardiac Surg Div, Boston, MA 02114 USA.
[Vlahakes, Gus J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Rothman, RD (reprint author), Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
EM rrothman@partners.org
NR 22
TC 3
Z9 3
U1 0
U2 3
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9149
J9 AM J CARDIOL
JI Am. J. Cardiol.
PD OCT 15
PY 2012
VL 110
IS 8
BP 1169
EP 1174
DI 10.1016/j.amjcard.2012.05.056
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 026EI
UT WOS:000310256700016
PM 22766229
ER
PT J
AU Ogino, S
King, EE
Beck, AH
Sherman, ME
Milner, DA
Giovannucci, E
AF Ogino, Shuji
King, Emily E.
Beck, Andrew H.
Sherman, Mark E.
Milner, Danny A.
Giovannucci, Edward
TI Interdisciplinary Education to Integrate Pathology and Epidemiology:
Towards Molecular and Population-Level Health Science
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE education; public health professional; health care reform;
individualized medicine; interdisciplinary communication; molecular
epidemiology; pathology
ID ISLAND METHYLATOR PHENOTYPE; BODY-MASS INDEX; ONE-CARBON METABOLISM;
TUMOR MICROSATELLITE INSTABILITY; COLORECTAL-CANCER RISK; LIFE-STYLE
FACTORS; MLH1-93G-GREATER-THAN-A PROMOTER POLYMORPHISM; ACID SYNTHASE
EXPRESSION; GREATER-THAN T; COLON-CANCER
AB In recent decades, epidemiology, public health, and medical sciences have been increasingly compartmentalized into narrower disciplines. The authors recognize the value of integration of divergent scientific fields in order to create new methods, concepts, paradigms, and knowledge. Herein they describe the recent emergence of molecular pathological epidemiology (MPE), which represents an integration of population and molecular biologic science to gain insights into the etiologies, pathogenesis, evolution, and outcomes of complex multifactorial diseases. Most human diseases, including common cancers (such as breast, lung, prostate, and colorectal cancers, leukemia, and lymphoma) and other chronic diseases (such as diabetes mellitus, cardiovascular diseases, hypertension, autoimmune diseases, psychiatric diseases, and some infectious diseases), are caused by alterations in the genome, epigenome, transcriptome, proteome, metabolome, microbiome, and interactome of all of the above components. In this era of personalized medicine and personalized prevention, we need integrated science (such as MPE) which can decipher diseases at the molecular, genetic, cellular, and population levels simultaneously. The authors believe that convergence and integration of multiple disciplines should be commonplace in research and education. We need to be open-minded and flexible in designing integrated education curricula and training programs for future students, clinicians, practitioners, and investigators.
C1 [Ogino, Shuji; Beck, Andrew H.; Giovannucci, Edward] Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA 02215 USA.
[Ogino, Shuji; King, Emily E.; Milner, Danny A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji; King, Emily E.; Beck, Andrew H.; Milner, Danny A.; Giovannucci, Edward] Harvard Univ, Sch Med, Boston, MA USA.
[Ogino, Shuji; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Beck, Andrew H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Sherman, Mark E.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Milner, Danny A.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Ogino, S (reprint author), Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, 450 Brookline Ave,Room JF-215C, Boston, MA 02215 USA.
EM shuji_ogino@dfci.harvard.edu
FU National Institutes of Health [R01 CA151993, K23 AI072033, P01 CA87969,
P01 CA55075]; Intramural Research Program of the National Cancer
Institute, National Institutes of Health
FX This work was supported in part by National Institutes of Health grants
(grant R01 CA151993 to Shuji Ogino, grant K23 AI072033 to Danny A.
Milner, grant P01 CA87969 to Susan E. Hankinson, and grant P01 CA55075
to Walter C. Willett) and in part by the Intramural Research Program of
the National Cancer Institute, National Institutes of Health.
NR 86
TC 32
Z9 33
U1 0
U2 20
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD OCT 15
PY 2012
VL 176
IS 8
BP 659
EP 667
DI 10.1093/aje/kws226
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 024ZW
UT WOS:000310152800001
PM 22935517
ER
PT J
AU Ogino, S
Beck, AH
King, EE
Sherman, ME
Milner, DA
Giovannucci, E
AF Ogino, Shuji
Beck, Andrew H.
King, Emily E.
Sherman, Mark E.
Milner, Danny A.
Giovannucci, Edward
TI Ogino et al. Respond to "The 21st Century Epidemiologist"
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
ID COLORECTAL-CANCER RISK; BODY-MASS INDEX; MOLECULAR PATHOLOGICAL
EPIDEMIOLOGY; LIFE-STYLE FACTORS; MICROSATELLITE INSTABILITY;
PHYSICAL-ACTIVITY; SURVIVAL; DIAGNOSIS; THERAPY; FIELD
C1 [Ogino, Shuji; Beck, Andrew H.; Giovannucci, Edward] Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, Boston, MA 02215 USA.
[Ogino, Shuji; King, Emily E.; Milner, Danny A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji; Beck, Andrew H.; King, Emily E.; Milner, Danny A.; Giovannucci, Edward] Harvard Univ, Sch Med, Boston, MA USA.
[Ogino, Shuji; Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Beck, Andrew H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Sherman, Mark E.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA.
[Milner, Danny A.] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA.
[Giovannucci, Edward] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Giovannucci, Edward] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
RP Ogino, S (reprint author), Dana Farber Harvard Canc Ctr, Canc Epidemiol Program, 450 Brookline Ave,Room JF-215C, Boston, MA 02215 USA.
EM shuji_ogino@dfci.harvard.edu
FU Intramural NIH HHS; NCI NIH HHS [P01 CA055075, P01 CA087969, P01
CA55075, P01 CA87969, R01 CA151993]; NIAID NIH HHS [K23 AI072033]
NR 29
TC 8
Z9 8
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD OCT 15
PY 2012
VL 176
IS 8
BP 672
EP 674
DI 10.1093/aje/kws229
PG 3
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 024ZW
UT WOS:000310152800003
PM 22935516
ER
PT J
AU Gilman, SE
Loucks, EB
AF Gilman, Stephen E.
Loucks, Eric B.
TI Invited Commentary: Does the Childhood Environment Influence the
Association Between Every X and Every Y in Adulthood?
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
DE causal inference; education; health; mortality; siblings; social
epidemiology
ID PARENTAL DIFFERENTIAL TREATMENT; CORONARY-HEART-DISEASE;
SOCIOECONOMIC-STATUS; MATERNAL SMOKING; BIRTH-ORDER; LIFE-COURSE;
EDUCATIONAL-ATTAINMENT; SIBLING DIFFERENCES; EARLY ADVERSITY; HEALTH
AB The conditions under which children are raised have a long-term impact on health throughout the life course. Because childhood conditions can have such a strong influence on adult risk factors for disease, failure to account for their influences could distort observed associations between adult risk factors and subsequent health outcomes. In other words, childhood conditions could confound the association between every X and Y when X is measured in adulthood. Comparisons of health outcomes between exposed and unexposed siblings have the potential to eliminate confounding effects due to vulnerability factors shared between siblings (i.e., 50 of their genes and aspects of the childhood environment that affect siblings equally). In a large, population-based study of siblings in Denmark, Sndergaard et al. (Am J Epidemiol. 2012;176(8):675683) found that individuals with higher educational qualifications lived longer than did their siblings with lower educational qualifications. Their results provide evidence for the returns to health resulting from investment in expanded educational opportunities. However, even sibling designs are not conclusive regarding causality; they remain subject to the unmeasured confounding influences of factors that vary within families. Nonetheless, sibling-based approaches should be used more often in studies of adult risk factors to address the long-term influences of the childhood environment on health.
C1 [Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA.
[Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Gilman, Stephen E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Loucks, Eric B.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA.
RP Gilman, SE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
EM sgilman@hsph.harvard.edu
RI Gilman, Stephen/E-7632-2010; Loucks, Eric/I-1272-2014
OI Gilman, Stephen/0000-0002-8331-6419; Loucks, Eric/0000-0002-9962-0386
FU NIA NIH HHS [R01 AG023397, AG023397]; NIMH NIH HHS [MH087544, R01
MH087544]
NR 60
TC 12
Z9 12
U1 3
U2 14
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD OCT 15
PY 2012
VL 176
IS 8
BP 684
EP 688
DI 10.1093/aje/kws228
PG 5
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 024ZW
UT WOS:000310152800005
PM 23024136
ER
PT J
AU Raab, MS
Breitkreutz, I
Anderhub, S
Ronnest, MH
Leber, B
Larsen, TO
Weiz, L
Konotop, G
Hayden, PJ
Podar, K
Fruehauf, J
Nissen, F
Mier, W
Haberkorn, U
Ho, AD
Goldschmidt, H
Anderson, KC
Clausen, MH
Kramer, A
AF Raab, Marc S.
Breitkreutz, Iris
Anderhub, Simon
Ronnest, Mads H.
Leber, Blanka
Larsen, Thomas O.
Weiz, Ludmila
Konotop, Gleb
Hayden, Patrick J.
Podar, Klaus
Fruehauf, Johannes
Nissen, Felix
Mier, Walter
Haberkorn, Uwe
Ho, Anthony D.
Goldschmidt, Hartmut
Anderson, Kenneth C.
Clausen, Mads H.
Kraemer, Alwin
TI GF-15, a Novel Inhibitor of Centrosomal Clustering, Suppresses Tumor
Cell Growth In Vitro and In Vivo
SO CANCER RESEARCH
LA English
DT Article
ID CANCER-CELLS; MULTIPLE-MYELOMA; MICROTUBULE DYNAMICS; GRISEOFULVIN
ANALOGS; KINETOCHORE PAIRS; INSTABILITY; ABERRATIONS; PROGRESSION;
CENTRIOLES; STABILITY
AB In contrast to normal cells, malignant cells are frequently aneuploid and contain multiple centrosomes. To allow for bipolar mitotic division, supernumerary centrosomes are clustered into two functional spindle poles in many cancer cells. Recently, we have shown that griseofulvin forces tumor cells with supernumerary centrosomes to undergo multipolar mitoses resulting in apoptotic cell death. Here, we describe the characterization of the novel small molecule GF-15, a derivative of griseofulvin, as a potent inhibitor of centrosomal clustering in malignant cells. At concentrations where GF-15 had no significant impact on tubulin polymerization, spindle tension was markedly reduced in mitotic cells upon exposure to GF-15. Moreover, isogenic cells with conditional centrosome amplification were more sensitive to GF-15 than parental controls. In a wide array of tumor cell lines, mean inhibitory concentrations (IC50) for proliferation and survival were in the range of 1 to 5 mu mol/L and were associated with apoptotic cell death. Importantly, treatment of mouse xenograft models of human colon cancer and multiple myeloma resulted in tumor growth inhibition and significantly prolonged survival. These results show the in vitro and in vivo antitumor efficacy of a prototype small molecule inhibitor of centrosomal clustering and strongly support the further evaluation of this new class of molecules. Cancer Res; 72(20); 5374-85. (C) 2012 AACR.
C1 [Anderhub, Simon; Leber, Blanka; Weiz, Ludmila; Kraemer, Alwin] Univ Heidelberg, German Canc Res, Clin Cooperat Unit Mol Hematol Oncol, D-69120 Heidelberg, Germany.
[Raab, Marc S.; Anderhub, Simon; Leber, Blanka; Weiz, Ludmila; Ho, Anthony D.; Kraemer, Alwin] Univ Heidelberg, Dept Internal Med 5, D-69120 Heidelberg, Germany.
[Breitkreutz, Iris; Podar, Klaus; Goldschmidt, Hartmut] Univ Heidelberg, Natl Ctr Tumor Dis, D-69120 Heidelberg, Germany.
[Raab, Marc S.; Weiz, Ludmila; Konotop, Gleb] Univ Heidelberg Hosp, German Canc Res Ctr DKFZ, Max Eder Grp Expt Therapies Hematol Malignancies, Heidelberg, Germany.
[Nissen, Felix; Mier, Walter; Haberkorn, Uwe] Univ Heidelberg Hosp, Dept Nucl Med, Heidelberg, Germany.
[Raab, Marc S.; Breitkreutz, Iris; Hayden, Patrick J.; Podar, Klaus; Anderson, Kenneth C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fruehauf, Johannes] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
[Ronnest, Mads H.; Clausen, Mads H.] Tech Univ Denmark, Ctr Nanomed & Theranost, DK-2800 Lyngby, Denmark.
[Ronnest, Mads H.; Clausen, Mads H.] Tech Univ Denmark, Dept Chem, DK-2800 Lyngby, Denmark.
[Ronnest, Mads H.; Larsen, Thomas O.] Tech Univ Denmark, Dept Syst Biol, Ctr Microbial Biotechnol, DK-2800 Lyngby, Denmark.
RP Kramer, A (reprint author), Univ Heidelberg, German Canc Res, Clin Cooperat Unit Mol Hematol Oncol, Neuenheimer Feld 581, D-69120 Heidelberg, Germany.
EM a.kraemer@dkfz.de
RI Clausen, Mads/A-9656-2015
OI Clausen, Mads/0000-0001-9649-1729
FU Max-Eder-Program, Deutsche Krebshilfe; Hopp-Foundation; DFG; Deutsche
Krebshilfe; Tumorzentrum Heidelberg/Mannheim; Danish Research Council
[274-07-0561]; Danish Cancer Society; Karen Krieger Fonden; NIH [RO
CA50947, PO-1 CA78378, P50 CA100707]
FX This work was supported by a grant of the Max-Eder-Program, Deutsche
Krebshilfe (M.S. Raab); the Hopp-Foundation (H. Goldschmidt); the DFG
(A. Kramer); a Deutsche Krebshilfe grant (M. S. Raab and A. Kramer); the
Tumorzentrum Heidelberg/Mannheim (A. Kramer); the Danish Research
Council (ref. 274-07-0561; M. H. Ronnest, T.O. Larsen, and M. H.
Clausen); the Danish Cancer Society and Karen Krieger Fonden (M. H.
Clausen); the NIH grants RO CA50947, PO-1 CA78378, and P50 CA100707
(K.C. Anderson).
NR 40
TC 27
Z9 27
U1 0
U2 18
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
J9 CANCER RES
JI Cancer Res.
PD OCT 15
PY 2012
VL 72
IS 20
BP 5374
EP 5385
DI 10.1158/0008-5472.CAN-12-2026
PG 12
WC Oncology
SC Oncology
GA 022PR
UT WOS:000309972700026
PM 22942257
ER
PT J
AU Gallant-Behm, CL
Ramsey, MR
Bensard, CL
Nojek, I
Tran, J
Liu, MH
Ellisen, LW
Espinosa, JM
AF Gallant-Behm, Corrie L.
Ramsey, Matthew R.
Bensard, Claire L.
Nojek, Ignacio
Tran, Jack
Liu, Minghua
Ellisen, Leif W.
Espinosa, Joaquin M.
TI Delta Np63 alpha represses anti-proliferative genes via H2A.Z deposition
SO GENES & DEVELOPMENT
LA English
DT Article
DE transcriptional repression; squamous cell carcinoma; oncogene; SAMD9L;
SRCAP; corepressor
ID SQUAMOUS-CELL CARCINOMA; HISTONE H2A.Z; EPITHELIAL DEVELOPMENT; P53
HOMOLOG; STEM-CELLS; P63; BINDING; PROLIFERATION; TRANSCRIPTION;
MAINTENANCE
AB Delta Np63 alpha is a member of the p53 family of transcription factors that functions as an oncogene in squamous cell carcinomas (SCCs). Because Delta Np63 alpha and p53 bind virtually identical DNA sequence motifs, it has been proposed that Delta Np63 alpha functions as a dominant-negative inhibitor of p53 to promote proliferation and block apoptosis. However, most SCCs concurrently overexpress Delta Np63 alpha and inactivate p53, suggesting the autonomous action of these oncogenic events. Here we report the discovery of a novel mechanism of transcriptional repression by Delta Np63 alpha that reconciles these observations. We found that although both proteins bind the same genomic sites, they regulate largely nonoverlapping gene sets. Upon activation, p53 binds all enhancers regardless of Delta Np63 alpha status but fails to transactivate genes repressed by Delta Np63 alpha. We found that Delta Np63 alpha associates with the SRCAP chromatin regulatory complex involved in H2A/H2A.Z exchange and mediates H2A.Z deposition at its target loci. Interestingly, knockdown of SRCAP subunits or H2A.Z leads to specific induction of Delta Np63 alpha-repressed genes. We identified SAMD9L as a key anti-proliferative gene repressed by Delta Np63 alpha and H2A.Z whose depletion suffices to reverse the arrest phenotype caused by Delta Np63 alpha knockdown. Collectively, these results illuminate a molecular pathway contributing to the autonomous oncogenic effects of Delta Np63 alpha.
C1 [Gallant-Behm, Corrie L.; Bensard, Claire L.; Nojek, Ignacio; Tran, Jack; Liu, Minghua; Espinosa, Joaquin M.] Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA.
[Gallant-Behm, Corrie L.; Bensard, Claire L.; Nojek, Ignacio; Tran, Jack; Liu, Minghua; Espinosa, Joaquin M.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA.
[Ramsey, Matthew R.; Ellisen, Leif W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Espinosa, JM (reprint author), Univ Colorado, Howard Hughes Med Inst, Boulder, CO 80309 USA.
EM joaquin.espinosa@colorado.edu
FU NIH [2R01CA117907-06, R01 DE-015945, F32CA159521-01]; ACS/Mass Biotech
Council Cancer Research Challenge-AstraZeneca Pharmaceuticals LP
Fellowship [PF-09-100-01 MGO]
FX We thank the Taplin Mass Spectrometry facility (Harvard Medical School)
for performing the mass spectrometry analysis. This work was supported
by NIH grants 2R01CA117907-06 (to J.M.E.), R01 DE-015945 (to L.W.E.),
and F32CA159521-01 (to C.L.G-B.), and by the ACS/Mass Biotech Council
Cancer Research Challenge-AstraZeneca Pharmaceuticals LP Fellowship
PF-09-100-01 MGO (M.R.R.). J.M.E. is an HHMI Early Career Scientist. The
content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health or other supporting agencies.
NR 47
TC 22
Z9 22
U1 0
U2 5
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
J9 GENE DEV
JI Genes Dev.
PD OCT 15
PY 2012
VL 26
IS 20
BP 2325
EP 2336
DI 10.1101/gad.198069.112
PG 12
WC Cell Biology; Developmental Biology; Genetics & Heredity
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 022RE
UT WOS:000309978500008
PM 23019126
ER
PT J
AU Manka, JT
Vinson, PN
Gregory, KJ
Zhou, Y
Williams, R
Gogi, K
Days, E
Jadhav, S
Herman, EJ
Lavreysen, H
Mackie, C
Bartolome, JM
Macdonald, GJ
Steckler, T
Daniels, JS
Weaver, CD
Niswender, CM
Jones, CK
Conn, PJ
Lindsley, CW
Stauffer, SR
AF Manka, Jason T.
Vinson, Paige N.
Gregory, Karen J.
Zhou, Ya
Williams, Richard
Gogi, Kiran
Days, Emily
Jadhav, Satya
Herman, Elizabeth J.
Lavreysen, Hilde
Mackie, Claire
Bartolome, Jose M.
Macdonald, Gregor J.
Steckler, Thomas
Daniels, J. Scott
Weaver, C. David
Niswender, Colleen M.
Jones, Carrie K.
Conn, P. Jeffrey
Lindsley, Craig W.
Stauffer, Shaun R.
TI Optimization of an ether series of mGlu(5) positive allosteric
modulators: Molecular determinants of MPEP-site interaction crossover
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Metabotropic glutamate receptor 5; mGlu(5); Positive allosteric
modulator (PAM); Non-MPEP
ID RECEPTOR SUBTYPE 5; METABOTROPIC GLUTAMATE RECEPTORS; RAT
BEHAVIORAL-MODELS; IN-VIVO ACTIVITY; CNS DISORDERS; DISCOVERY; MGLUR5;
PHARMACOLOGY; PROGRESS; POTENT
AB We report the optimization of a series of non-MPEP site metabotropic glutamate receptor 5 (mGlu(5)) positive allosteric modulators (PAMs) based on a simple acyclic ether series. Modifications led to a gain of MPEP site interaction through incorporation of a chiral amide in conjunction with a nicotinamide core. A highly potent PAM, 8v (VU0404251), was shown to be efficacious in a rodent model of psychosis. These studies suggest that potent PAMs within topologically similar chemotypes can be developed to preferentially interact or not interact with the MPEP allosteric binding site. (c) 2012 Elsevier Ltd. All rights reserved.
C1 [Manka, Jason T.; Vinson, Paige N.; Gregory, Karen J.; Zhou, Ya; Williams, Richard; Gogi, Kiran; Days, Emily; Jadhav, Satya; Herman, Elizabeth J.; Daniels, J. Scott; Weaver, C. David; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
[Manka, Jason T.; Vinson, Paige N.; Gregory, Karen J.; Zhou, Ya; Williams, Richard; Gogi, Kiran; Jadhav, Satya; Herman, Elizabeth J.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Med Ctr, Vanderbilt Ctr Neurosci Drug Discovery, Nashville, TN 37232 USA.
[Manka, Jason T.; Zhou, Ya; Williams, Richard; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Specialized Chem Ctr Probe Dev MLPCN, Nashville, TN 37232 USA.
[Lindsley, Craig W.; Stauffer, Shaun R.] Vanderbilt Univ, Dept Chem, Nashville, TN 37232 USA.
[Days, Emily; Weaver, C. David] Vanderbilt Univ, Vanderbilt Inst Chem Biol, Nashville, TN 37232 USA.
[Lavreysen, Hilde; Macdonald, Gregor J.; Steckler, Thomas] Janssen Res & Dev, Neurosci, B-2340 Beerse, Belgium.
[Mackie, Claire] Janssen Res & Dev, CREATe ADME Tox, B-2340 Beerse, Belgium.
[Bartolome, Jose M.] Janssen Res & Dev, Neurosci Med Chem, Toledo 45007, Spain.
[Gregory, Karen J.] Monash Univ, MIPS, Parkville, Vic, Australia.
[Gregory, Karen J.] Monash Univ, Dept Pharmacol, Parkville, Vic, Australia.
[Jones, Carrie K.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN 37212 USA.
RP Stauffer, SR (reprint author), Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA.
EM shaun.stauffer@vanderbilt.edu
RI Zhou, Ya/F-1220-2013;
OI Gregory, Karen/0000-0002-3833-2137
FU NIH [NS031373-15, MH073676-04]; Johnson Johnson; NARSAD; NHMRC
FX This work was supported in part by grants from the NIH (NS031373-15,
MH073676-04) and from an industry sponsored contract from Johnson &
Johnson. K.J.G. thanks NARSAD and NHMRC for fellowship support. The
authors thank Daryl F. Venable for technical assistance with radioligand
binding assays.
NR 33
TC 11
Z9 11
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD OCT 15
PY 2012
VL 22
IS 20
BP 6481
EP 6485
DI 10.1016/j.bmcl.2012.08.043
PG 5
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 017RW
UT WOS:000309609500032
PM 22981332
ER
PT J
AU Sumpter, TL
Dangi, A
Matta, BM
Huang, C
Stolz, DB
Vodovotz, Y
Thomson, AW
Gandhi, CR
AF Sumpter, Tina L.
Dangi, Anil
Matta, Benjamin M.
Huang, Chao
Stolz, Donna B.
Vodovotz, Yoram
Thomson, Angus W.
Gandhi, Chandrashekhar R.
TI Hepatic Stellate Cells Undermine the Allostimulatory Function of Liver
Myeloid Dendritic Cells via STAT3-Dependent Induction of IDO
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID REGULATORY T-CELLS; RAT-LIVER; INDOLEAMINE 2,3-DIOXYGENASE; IN-VIVO;
ISCHEMIA/REPERFUSION INJURY; TRANSPLANT RECIPIENTS; TRYPTOPHAN
CATABOLISM; ENDOTHELIN RECEPTORS; STAT3 ACTIVATION; UP-REGULATION
AB Hepatic stellate cells (HSCs) are critical for hepatic wound repair and tissue remodeling. They also produce cytokines and chemokines that may contribute to the maintenance of hepatic immune homeostasis and the inherent tolerogenicity of the liver. The functional relationship between HSCs and the professional migratory APCs in the liver, that is, dendritic cells (DCs), has not been evaluated. In this article, we report that murine liver DCs colocalize with HSCs in vivo under normal, steady-state conditions, and cluster with HSCs in vitro. In vitro, HSCs secrete high levels of DC chemoattractants, such as M.P-1 alpha and MCP-1, as well as cytokines that modulate DC activation, including TNF-alpha, IL-6, and IL-1 beta. Culture of HSCs with conventional liver myeloid (m) DCs resulted in increased IL-6 and IL-10 secretion compared with that of either cell population alone. Coculture also resulted in enhanced expression of costimulatory (CD80, CD86) and coinhibitory (B7-H1) molecules on mDCs. HSC-induced mDC maturation required cell-cell contact and could be blocked, in part, by neutralizing MIP-1 alpha or MCP-1. HSC-induced mDC maturation was dependent on activation of STAT3 in mDCs and, in part, on HSC-secreted IL-6. Despite upregulation of costimulatory molecules, mDCs conditioned by HSCs demonstrated impaired ability to induce allogeneic T cell proliferation, which was independent of B7-H1, but dependent upon HSC-induced STAT3 activation and subsequent upregulation of IDO. In conclusion, by promoting IDO expression, HSCs may act as potent regulators of liver mDCs and function to maintain hepatic homeostasis and tolerogenicity. The Journal of Immunology, 2012, 189:3848-3858.
C1 [Sumpter, Tina L.; Dangi, Anil; Matta, Benjamin M.; Huang, Chao; Vodovotz, Yoram; Thomson, Angus W.; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg, Pittsburgh, PA 15213 USA.
[Sumpter, Tina L.] Univ Pittsburgh, Sch Med, Dept Dermatol, Pittsburgh, PA 15213 USA.
[Dangi, Anil; Huang, Chao; Gandhi, Chandrashekhar R.] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15240 USA.
[Matta, Benjamin M.; Thomson, Angus W.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA.
[Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol, Pittsburgh, PA 15213 USA.
[Gandhi, Chandrashekhar R.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA.
RP Gandhi, CR (reprint author), Univ Pittsburgh, Sch Med, Thomas E Starzl Transplantat Inst, Dept Surg, E-1540 BST,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM Gandhics@upmc.edu
FU National Institutes of Health [PO1AI81678, T32 AI74490]; Veterans
Administration Merit Review Award; American Society of Transplantation
Basic Science Fellowship; American Liver Foundation Roger Jenkins
Fellowship
FX This work was supported by National Institutes of Health Grants
PO1AI81678 (to A.W.T. and C.R.G.) and T32 AI74490 (to A.W.T.), a
Veterans Administration Merit Review Award (to C.R.G.), and an American
Society of Transplantation Basic Science Fellowship and an American
Liver Foundation Roger Jenkins Fellowship (to T.L.S.).
NR 85
TC 14
Z9 15
U1 0
U2 1
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2012
VL 189
IS 8
BP 3848
EP 3858
DI 10.4049/jimmunol.1200819
PG 11
WC Immunology
SC Immunology
GA 017LH
UT WOS:000309590900012
PM 22962681
ER
PT J
AU Chou, CK
Schietinger, A
Liggitt, HD
Tan, XX
Funk, S
Freeman, GJ
Ratliff, TL
Greenberg, NM
Greenberg, PD
AF Chou, Cassie K.
Schietinger, Andrea
Liggitt, H. Denny
Tan, Xiaoxia
Funk, Sarah
Freeman, Gordon J.
Ratliff, Timothy L.
Greenberg, Norman M.
Greenberg, Philip D.
TI Cell-Intrinsic Abrogation of TGF-beta Signaling Delays but Does Not
Prevent Dysfunction of Self/Tumor-Specific CD8 T Cells in a Murine Model
of Autochthonous Prostate Cancer
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID GROWTH-FACTOR-BETA; CHRONIC VIRAL-INFECTION; TRANSGENIC MOUSE MODEL;
ADOPTIVE IMMUNOTHERAPY; POSITIVE SELECTION; ANTITUMOR IMMUNITY; CTLA-4
BLOCKADE; SOLID TUMORS; PHASE-I; ANTIGEN
AB Adoptive T cell therapy (ACT) for the treatment of established cancers is actively being pursued in clinical trials. However, poor in vivo persistence and maintenance of antitumor activity of transferred T cells remain major problems. TGF-beta is a potent immunosuppressive cytokine that is often expressed at high levels within the tumor microenvironment, potentially limiting T cell-mediated antitumor activity. In this study, we used a model of autochthonous murine prostate cancer to evaluate the effect of cell-intrinsic abrogation of TGF-beta signaling in self/tumor-specific CD8 T cells used in ACT to target the tumor in situ. We found that persistence and antitumor activity of adoptively transferred effector T cells deficient in TGF-beta signaling were significantly improved in the cancerous prostate. However, over time, despite persistence in peripheral lymphoid organs, the numbers of transferred cells in the prostate decreased and the residual prostate-infiltrating T cells were no longer functional. These findings reveal that TGF-beta negatively regulates the accumulation and effector function of transferred self/tumor-specific CD8 T cells and highlight that, when targeting a tumor Ag that is also expressed as a self-protein, additional substantive obstacles are operative within the tumor microenvironment, potentially hampering the success of ACT for solid tumors. The Journal of Immunology, 2012, 189: 3936-3946.
C1 [Chou, Cassie K.; Schietinger, Andrea; Greenberg, Philip D.] Univ Washington, Sch Med, Dept Immunol, Seattle, WA 98105 USA.
[Liggitt, H. Denny] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98105 USA.
[Tan, Xiaoxia; Funk, Sarah; Greenberg, Philip D.] Univ Washington, Sch Med, Dept Med Oncol, Seattle, WA 98105 USA.
[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Ratliff, Timothy L.] Purdue Univ, Ctr Canc Res, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA.
[Greenberg, Norman M.; Greenberg, Philip D.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA.
RP Greenberg, PD (reprint author), Univ Washington, Dept Med, Off Hlth Sci Ctr H 461, Box 356425,1959 NE Pacific St, Seattle, WA 98195 USA.
EM pgreen@uw.edu
FU National Institutes of Health [R01 CA33084, P01 AI56299]; U.S. Army
Medical Research and Materiel Command [W81XWH-09-1-0139]
FX This work was supported by National Institutes of Health Grants R01
CA33084 (to P.D.G.) and P01 AI56299 (to G.J.F.). C.K.C. received support
as provided by the Cancer Research Institute Institutional Pre-Doctoral
Award and a Pre-Doctoral Prostate Cancer Training Award from the U.S.
Army Medical Research and Materiel Command under Grant W81XWH-09-1-0139.
NR 80
TC 11
Z9 12
U1 0
U2 7
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
J9 J IMMUNOL
JI J. Immunol.
PD OCT 15
PY 2012
VL 189
IS 8
BP 3936
EP 3946
DI 10.4049/jimmunol.1201415
PG 11
WC Immunology
SC Immunology
GA 017LH
UT WOS:000309590900020
PM 22984076
ER
PT J
AU Tanwar, PS
Kaneko-Tarui, T
Zhang, LH
Teixeira, JM
AF Tanwar, Pradeep S.
Kaneko-Tarui, Tomoko
Zhang, LiHua
Teixeira, Jose M.
TI Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli
cell polarity and spermatogenesis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PEUTZ-JEGHERS-SYNDROME; TUBEROUS SCLEROSIS COMPLEX; ACTIVATED
PROTEIN-KINASE; SEMINIFEROUS EPITHELIUM; RAT TESTIS; TESTICULAR CANCER;
TUMOR SUPPRESSION; MOUSE MODEL; IN-VIVO; LKB1
AB Male patients with PeutzJeghers syndrome (PJS) have defective spermatogenesis and are at increased risk of developing Sertoli cell tumors. Mutations in the Liver Kinase B1 (LKB1/STK11) gene are associated with the pathogenesis of PJS and have been identified in non-PJS patients with sporadic testicular cancers. The mechanisms controlled by LKB1 signaling in Sertoli cell functions and testicular biology have not been described. We have conditionally deleted the Lkb1 gene (Lkb1(cko)) in somatic testicular cells to define the molecular mechanisms involved in the development of the testicular phenotype observed in PJS patients. Focal vacuolization in some of the seminiferous tubules was observed in 4-week-old mutant testes but germ cell development appeared to be normal. However, similar to PJS patients, we observed progressive germ cell loss and Sertoli cell only tubules in Lkb1(cko) testes from mice older than 10 weeks, accompanied by defects in Sertoli cell polarity and testicular junctional complexes and decreased activation of the MAP/microtubule affinity regulating and focal adhesion kinases. Suppression of AMP kinase and activation of mammalian target of rapamycin (mTOR) signaling were also observed in Lkb1(cko) testes. Loss of Tsc1 or Tsc2 copies the progressive Lkb1(cko) phenotype, suggesting that dysregulated activation of mTOR contributes to the pathogenesis of the Lkb1(cko) testicular phenotype. Pten(cko) mice had a normal testicular phenotype, which could be explained by the comparative lack of mTOR activation detected. These studies describe the importance of LKB1 signaling in testicular biology and the possible molecular mechanisms driving the pathogenesis of the testicular defects observed in PJS patients.
C1 [Tanwar, Pradeep S.; Kaneko-Tarui, Tomoko; Zhang, LiHua; Teixeira, Jose M.] Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Vincent Ctr Reprod Biol Thier 931, Boston, MA 02114 USA.
[Tanwar, Pradeep S.; Kaneko-Tarui, Tomoko; Zhang, LiHua; Teixeira, Jose M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Tanwar, Pradeep S.] Univ Newcastle, Sch Biomed Sci & Pharm, Callaghan, NSW 2308, Australia.
RP Teixeira, JM (reprint author), Massachusetts Gen Hosp, Dept Obstet Gynecol & Reprod Biol, Vincent Ctr Reprod Biol Thier 931, 55 Fruit St, Boston, MA 02114 USA.
EM teixeira@helix.mgh.harvard.edu
OI Teixeira, Jose/0000-0002-6438-5064
FU NICHD [HD052701]; Vincent Memorial Research Funds
FX This work is supported by an NICHD grant HD052701 (to J.M.T.) and
Vincent Memorial Research Funds.
NR 73
TC 29
Z9 32
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2012
VL 21
IS 20
BP 4394
EP 4405
DI 10.1093/hmg/dds272
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 015QF
UT WOS:000309460300003
PM 22791749
ER
PT J
AU Do, R
Kathiresan, S
Abecasis, GR
AF Do, Ron
Kathiresan, Sekar
Abecasis, Goncalo R.
TI Exome sequencing and complex disease: practical aspects of rare variant
association studies
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; SINGLE-NUCLEOTIDE POLYMORPHISMS; DE-NOVO
MUTATIONS; FACTOR-H POLYMORPHISM; MACULAR DEGENERATION; SUSCEPTIBILITY
LOCI; GENETIC ASSOCIATION; FRAMESHIFT MUTATION; COMMON DISEASES;
HIGH-THROUGHPUT
AB Genetic association and linkage studies can provide insights into complex disease biology, guiding the development of new diagnostic and therapeutic strategies. Over the past decade, genetic association studies have largely focused on common, easy to measure genetic variants shared between many individuals. These common variants typically have subtle functional consequence and translating the resulting association signals into biological insights can be challenging. In the last few years, exome sequencing has emerged as a cost-effective strategy for extending these studies to include rare coding variants, which often have more marked functional consequences. Here, we provide practical guidance in the design and analysis of complex trait association studies focused on rare, coding variants.
C1 [Do, Ron; Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Do, Ron; Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Do, Ron; Kathiresan, Sekar] Harvard Univ, Sch Med, Boston, MA USA.
[Do, Ron; Kathiresan, Sekar] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Abecasis, Goncalo R.] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ann Arbor, MI 48109 USA.
RP Abecasis, GR (reprint author), M4614 SPH 1 Tower,1415 Washington Hts, Ann Arbor, MI 48109 USA.
EM goncalo@umich.edu
RI Abecasis, Goncalo/B-7840-2010;
OI Abecasis, Goncalo/0000-0003-1509-1825
FU US National Institutes of Health; CIHR; University of Michigan; National
Human Genome Research Institute
FX This work was supported in part by research grants from the US National
Institutes of Health. R. D. is funded by a CIHR Banting Fellowship.
Funding to pay the Open Access publication charges for this article was
provided by the University of Michigan and the National Human Genome
Research Institute.
NR 104
TC 66
Z9 70
U1 80
U2 108
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2012
VL 21
SI 1
BP R1
EP R9
DI 10.1093/hmg/dds387
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 015QP
UT WOS:000309461300001
PM 22983955
ER
PT J
AU Wylie, KP
Rojas, DC
Tanabe, J
Martin, LF
Tregellas, JR
AF Wylie, Korey P.
Rojas, Donald C.
Tanabe, Jody
Martin, Laura F.
Tregellas, Jason R.
TI Nicotine increases brain functional network efficiency
SO NEUROIMAGE
LA English
DT Article
DE Nicotine; Acetylcholine; Graph theory; Small-world; Network; fMRI
ID SMALL-WORLD NETWORKS; ALZHEIMERS-DISEASE; ACETYLCHOLINE-RECEPTOR;
TRANSDERMAL NICOTINE; BIPOLAR DISORDER; SCHIZOPHRENIA; CONNECTIVITY;
MATTER; ATTENTION; COGNITION
AB Despite the use of cholinergic therapies in Alzheimer's disease and the development of cholinergic strategies for schizophrenia, relatively little is known about how the system modulates the connectivity and structure of large-scale brain networks. To better understand how nicotinic cholinergic systems alter these networks, this study examined the effects of nicotine on measures of whole-brain network communication efficiency. Resting state fMRI was acquired from fifteen healthy subjects before and after the application of nicotine or placebo transdermal patches in a single blind, crossover design. Data, which were previously examined for default network activity, were analyzed with network topology techniques to measure changes in the communication efficiency of whole-brain networks. Nicotine significantly increased local efficiency, a parameter that estimates the network's tolerance to local errors in communication. Nicotine also significantly enhanced the regional efficiency of limbic and paralimbic areas of the brain, areas which are especially altered in diseases such as Alzheimer's disease and schizophrenia. These changes in network topology may be one mechanism by which cholinergic therapies improve brain function. Published by Elsevier Inc.
C1 [Wylie, Korey P.; Rojas, Donald C.; Martin, Laura F.; Tregellas, Jason R.] Univ Colorado, Dept Psychiat, Aurora, CO 80045 USA.
[Tanabe, Jody] Univ Colorado, Dept Radiol, Aurora, CO 80045 USA.
[Tregellas, Jason R.] Eastern Colorado Hlth Syst, Res Serv 151, Denver VA Med Ctr, Res Serv, Denver, CO 80220 USA.
RP Tregellas, JR (reprint author), Anschutz Med Campus Bldg 500,Mail Stop F546,13001, Aurora, CO 80045 USA.
EM Jason.Tregellas@UCDenver.edu
RI Tregellas, Jason/J-3637-2015;
OI Rojas, Don/0000-0001-6560-9616
FU VA Biomedical Laboratory and Clinical Science Research and Development
Service; National Association for Research in Schizophrenia and
Affective Disorders (NARSAD); Blowitz-Ridgeway Foundation; NIH/NIDDK
[R01 DK089095]; NIH/NIMH [P50 MH-086383]
FX The research was supported by the VA Biomedical Laboratory and Clinical
Science Research and Development Service, the National Association for
Research in Schizophrenia and Affective Disorders (NARSAD), the
Blowitz-Ridgeway Foundation, NIH/NIDDK R01 DK089095 and NIH/NIMH P50
MH-086383.
NR 53
TC 18
Z9 18
U1 1
U2 28
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD OCT 15
PY 2012
VL 63
IS 1
BP 73
EP 80
DI 10.1016/j.neuroimage.2012.06.079
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 005SN
UT WOS:000308770300008
PM 22796985
ER
PT J
AU Yang, AI
Wang, XY
Doyle, WK
Halgren, E
Carlson, C
Belcher, TL
Cash, SS
Devinsky, O
Thesen, T
AF Yang, Andrew I.
Wang, Xiuyuan
Doyle, Werner K.
Halgren, Eric
Carlson, Chad
Belcher, Thomas L.
Cash, Sydney S.
Devinsky, Orrin
Thesen, Thomas
TI Localization of dense intracranial electrode arrays using magnetic
resonance imaging
SO NEUROIMAGE
LA English
DT Article
DE Intracranial EEG; Electrocorticography; Electrode localization; Image
co-registration; Epilepsy surgery; MRI
ID HUMAN CEREBRAL-CORTEX; SUBDURAL ELECTRODES; EPILEPSY SURGERY;
PRESURGICAL EVALUATION; GEOMETRICALLY ACCURATE; IMPLANTED ELECTRODES;
DIGITAL PHOTOGRAPHY; MUTUAL INFORMATION; EEG ELECTRODES; BRAIN SHIFT
AB Intracranial electrode arrays are routinely used in the pre-surgical evaluation of patients with medically refractory epilepsy, and recordings from these electrodes have been increasingly employed in human cognitive neurophysiology due to their high spatial and temporal resolution. For both researchers and clinicians, it is critical to localize electrode positions relative to the subject-specific neuroanatomy. In many centers, a post-implantation MRI is utilized for electrode detection because of its higher sensitivity for surgical complications and the absence of radiation. However, magnetic susceptibility artifacts surrounding each electrode prohibit unambiguous detection of individual electrodes, especially those that are embedded within dense grid arrays. Here, we present an efficient method to accurately localize intracranial electrode arrays based on pre- and post-implantation MR images that incorporates array geometry and the individual's cortical surface. Electrodes are directly visualized relative to the underlying gyral anatomy of the reconstructed cortical surface of individual patients. Validation of this approach shows high spatial accuracy of the localized electrode positions (mean of 0.96 mm +/- 0.81 mm for 271 electrodes across 8 patients). Minimal user input, short processing time, and utilization of radiation-free imaging are strong incentives to incorporate quantitatively accurate localization of intracranial electrode arrays with MRI for research and clinical purposes. Co-registration to a standard brain atlas further allows inter-subject comparisons and relation of intracranial EEG findings to the larger body of neuroimaging literature. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Thesen, Thomas] NYU, Sch Med, Comprehens Epilepsy Ctr, Dept Neurol, New York, NY 10016 USA.
[Doyle, Werner K.; Devinsky, Orrin] NYU, Sch Med, Dept Neurosurg, New York, NY 10016 USA.
[Halgren, Eric; Thesen, Thomas] Univ Calif San Diego, Dept Radiol, San Diego, CA 92093 USA.
[Halgren, Eric; Thesen, Thomas] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA.
[Halgren, Eric; Thesen, Thomas] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA.
[Cash, Sydney S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol,Epilepsy Div, Boston, MA 02114 USA.
RP Thesen, T (reprint author), NYU, Sch Med, Comprehens Epilepsy Ctr, Dept Neurol, 223 E 34th St, New York, NY 10016 USA.
EM thomas.thesen@med.nyu.edu
RI Wang, Xiuyuan/A-7500-2013;
OI Wang, Xiuyuan/0000-0001-6356-3386; Devinsky, Orrin/0000-0003-0044-4632
FU FACES (Finding a Cure for Epilepsy and Seizures); National Institute of
Health [NS18741]
FX The authors thank Henry Rusinek for helpful discussions, and Uzma
Samadani, Andrew Dykstra, Mederic Descoins, Hyungwon Kim, and John Kim
for comments on drafts of the manuscript. This study was supported in
part by a grant from FACES (Finding a Cure for Epilepsy and Seizures) to
T.T. and National Institute of Health (grant number NS18741) to E.H.
NR 53
TC 15
Z9 15
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD OCT 15
PY 2012
VL 63
IS 1
BP 157
EP 165
DI 10.1016/j.neuroimage.2012.06.039
PG 9
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 005SN
UT WOS:000308770300017
PM 22759995
ER
PT J
AU Domoto-Reilly, K
Sapolsky, D
Brickhouse, M
Dickerson, BC
AF Domoto-Reilly, Kimiko
Sapolsky, Daisy
Brickhouse, Michael
Dickerson, Bradford C.
CA Alzheimer's Dis Neuroimaging Initi
TI Naming impairment in Alzheimer's disease is associated with left
anterior temporal lobe atrophy
SO NEUROIMAGE
LA English
DT Article
DE Magnetic resonance imaging; Cerebral cortex; Alzheimer's disease;
Language; Anterior temporal lobe; Semantic memory
ID PRIMARY-PROGRESSIVE-APHASIA; MILD COGNITIVE IMPAIRMENT; SEMANTIC MEMORY
IMPAIRMENT; SURFACE-BASED ANALYSIS; HUMAN CEREBRAL-CORTEX; CORTICAL
SURFACE; AD DEMENTIA; PROCESSING DEFICITS; COORDINATE SYSTEM; SYMPTOM
SEVERITY
AB There is considerable debate about the neuroanatomic localization of semantic memory, the knowledge of culturally shared elements such as objects, concepts, and people. Two recent meta-analyses of functional imaging studies (fMRI and PET) sought to identify cortical regions involved in semantic processing. Binder and colleagues (Binder et al., 2009) identified several regions of interest, widely distributed throughout the frontal, parietal, and temporal cortices. In contrast, Lambon Ralph and colleagues (2010) focused on the anterior temporal lobe, and found that when the potential for signal loss is accounted for (due, for example, to distortion artifact or field of view restriction), significant regional activation is detected. We set out to determine whether the anterior temporal lobe plays a significant role in picture naming, a task which relies on semantic memory. We examined a relatively large sample of patients with early Alzheimer's disease (N = 145), a multifocal disease process typically characterized in the early stages by problems with episodic memory and executive function. Hypothesis-driven analyses based on regions of interest derived from the meta-analyses as well as exploratory analyses across the entire cerebral cortex demonstrated a highly specific correlation between cortical thinning of the left anterior temporal lobe and impaired naming performance. These findings lend further support to theories that include a prominent role for the anterior temporal lobe in tasks that rely on semantic memory. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Domoto-Reilly, Kimiko; Sapolsky, Daisy; Brickhouse, Michael; Dickerson, Bradford C.] Harvard Univ, Sch Med, Boston, MA USA.
[Domoto-Reilly, Kimiko; Sapolsky, Daisy; Brickhouse, Michael; Dickerson, Bradford C.] Massachusetts Gen Hosp, Frontotemporal Dementia Unit, Boston, MA 02114 USA.
[Domoto-Reilly, Kimiko; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Sapolsky, Daisy; Brickhouse, Michael; Dickerson, Bradford C.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Sapolsky, Daisy] Massachusetts Gen Hosp, Dept Speech & Language Pathol, Boston, MA 02114 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Massachusetts Alzheimers Dis Res Ctr, Boston, MA 02114 USA.
[Dickerson, Bradford C.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
RP Domoto-Reilly, K (reprint author), MGH Frontotemporal Disorders Unit, 149 13th St,Suite 2691, Boston, MA 02129 USA.
EM kdomoto-reilly@partners.org
RI Kowall, Neil/G-6364-2012; Preda, Adrian /K-8889-2013; Saykin,
Andrew/A-1318-2007
OI Kowall, Neil/0000-0002-6624-0213; Preda, Adrian /0000-0003-3373-2438;
Saykin, Andrew/0000-0002-1376-8532
FU Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health) [U01 AG024904]; National Institute on Aging; National
Institute of Biomedical Imaging and Bioengineering; Canadian Institutes
of Health Research; NIH [P30 AG010129, K01 AG030514]; Dana Foundation;
Alzheimer's Association; [MA R01-AG29411]; [R21-AG29840];
[P50-AG005134]
FX Data collection and sharing for this project was funded by the
Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes
of Health Grant U01 AG024904). ADNI is funded by the National Institute
on Aging, the National Institute of Biomedical Imaging and
Bioengineering, and through generous contributions from the following:
Abbott; Alzheimer's Association; Alzheimer's Drug Discovery Foundation;
Amorfix Life Sciences Ltd.; AstraZeneca; Bayer HealthCare; Bio-Clinica,
Inc.; Biogen Idec Inc.; Bristol-Myers Squibb Company; Eisai Inc.; Elan
Pharmaceuticals Inc.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd
and its affiliated company Genentech, Inc.; GE Healthcare; Innogenetics,
N.V.; Janssen Alzheimer Immunotherapy Research & Development, LLC.;
Johnson & Johnson Pharmaceutical Research & Development LLC.; Medpace,
Inc.; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; Novartis
Pharmaceuticals Corporation; Pfizer Inc.; Servier; Synarc Inc.; and
Takeda Pharmaceutical Company. The Canadian Institutes of Health
Research is providing funds to support ADNI clinical sites in Canada.
Private sector contributions are facilitated by the Foundation for the
National Institutes of Health (www.fnih.org). The grantee organization
is the Northern California Institute for Research and Education, and the
study is coordinated by the Alzheimer's Disease Cooperative Study at the
University of California, San Diego. ADNI data are disseminated by the
Laboratory for Neuro Imaging at the University of California, Los
Angeles. This research was also supported by NIH grants P30 AG010129,
K01 AG030514, and the Dana Foundation. In addition, this work was
supported by grants from the MA R01-AG29411, R21-AG29840, P50-AG005134,
and the Alzheimer's Association. The authors express special
appreciation to Dr. Jeffrey Binder for sharing data with us.
NR 64
TC 22
Z9 23
U1 1
U2 42
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD OCT 15
PY 2012
VL 63
IS 1
BP 348
EP 355
DI 10.1016/j.neuroimage.2012.06.018
PG 8
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 005SN
UT WOS:000308770300037
PM 22728617
ER
PT J
AU Setsompop, K
Cohen-Adad, J
Gagoski, BA
Raij, T
Yendiki, A
Keil, B
Wedeen, VJ
Wald, LL
AF Setsompop, K.
Cohen-Adad, J.
Gagoski, B. A.
Raij, T.
Yendiki, A.
Keil, B.
Wedeen, V. J.
Wald, L. L.
TI Improving diffusion MRI using simultaneous multi-slice echo planar
imaging
SO NEUROIMAGE
LA English
DT Article
DE Diffusion MRI; Simultaneous multi-slice; CAIPIRINHA; Parallel imaging
ID SPIN-ECHO; SELECTIVE EXCITATION; FIBER ORIENTATION; TENSOR MRI; IMAGES;
GRADIENT; EPI; RECONSTRUCTIONS; ARRAYS; SIGNAL
AB In diffusion MRI, simultaneous multi-slice single-shot EPI acquisitions have the potential to increase the number of diffusion directions obtained per unit time, allowing more diffusion encoding in high angular resolution diffusion imaging (HARDI) acquisitions. Nonetheless, unaliasing simultaneously acquired, closely spaced slices with parallel imaging methods can be difficult, leading to high g-factor penalties (i.e., lower SNR). The CAIPIRINHA technique was developed to reduce the g-factor in simultaneous multi-slice acquisitions by introducing interslice image shifts and thus increase the distance between aliased voxels. Because the CAIPIRINHA technique achieved this by controlling the phase of the RF excitations for each line of k-space, it is not directly applicable to single-shot EPI employed in conventional diffusion imaging. We adopt a recent gradient encoding method, which we termed "blipped-CAIPI", to create the image shifts needed to apply CAIPIRINHA to EPI. Here, we use pseudo-multiple replica SNR and bootstrapping metrics to assess the performance of the blipped-CAIPI method in 3 x simultaneous multi-slice diffusion studies. Further, we introduce a novel image reconstruction method to reduce detrimental ghosting artifacts in these acquisitions. We show that data acquisition times for Q-ball and diffusion spectrum imaging (DSI) can be reduced 3-fold with a minor loss in SNR and with similar diffusion results compared to conventional acquisitions. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Setsompop, K.; Cohen-Adad, J.; Raij, T.; Yendiki, A.; Keil, B.; Wedeen, V. J.; Wald, L. L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
[Setsompop, K.; Cohen-Adad, J.; Raij, T.; Yendiki, A.; Keil, B.; Wedeen, V. J.; Wald, L. L.] Harvard Univ, Sch Med, Boston, MA USA.
[Gagoski, B. A.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
RP Setsompop, K (reprint author), Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA.
EM kawin@nmr.mgh.harvard.edu
RI Keil, Boris/P-1411-2014; Setsompop, Kawin/P-1464-2014; Wald,
Lawrence/D-4151-2009
OI Setsompop, Kawin/0000-0003-0455-7634;
FU NIH, NIBIB [K99EB012107, R01EB006847]; NIH Blueprint for Neuroscience
Research [U01MH093765]; NSF [PHY-0855161]; NIH, NIMH [R01MH652456]; NIH,
NCRR [P41RR14075]
FX Grant support: NIH: NIBIB K99EB012107, NIBIB R01EB006847, NIMH
R01MH652456, NCRR P41RR14075, and the NIH Blueprint for Neuroscience
Research U01MH093765 the Human Connectome project. NSF: PHY-0855161.
NR 43
TC 62
Z9 62
U1 5
U2 32
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1053-8119
J9 NEUROIMAGE
JI Neuroimage
PD OCT 15
PY 2012
VL 63
IS 1
BP 569
EP 580
DI 10.1016/j.neuroimage.2012.06.033
PG 12
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 005SN
UT WOS:000308770300058
PM 22732564
ER
PT J
AU Gardner, LI
Marks, G
Craw, JA
Wilson, TE
Drainoni, ML
Moore, RD
Mugavero, MJ
Rodriguez, AE
Bradley-Springer, LA
Holman, S
Keruly, JC
Sullivan, M
Skolnik, PR
Malitz, F
Metsch, LR
Raper, JL
Giordano, TP
AF Gardner, Lytt I.
Marks, Gary
Craw, Jason A.
Wilson, Tracey E.
Drainoni, Mari-Lynn
Moore, Richard D.
Mugavero, Michael J.
Rodriguez, Allan E.
Bradley-Springer, Lucy A.
Holman, Susan
Keruly, Jeanne C.
Sullivan, Meg
Skolnik, Paul R.
Malitz, Faye
Metsch, Lisa R.
Raper, James L.
Giordano, Thomas P.
CA Retention Care Study Grp
TI A Low-Effort, Clinic-Wide Intervention Improves Attendance for HIV
Primary Care
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID MEDICAL-CARE; RETENTION; ENGAGEMENT; PREVENTION; INFECTION
AB Background. Retention in care for human immunodeficiency virus (HIV)-infected patients is a National HIV/AIDS Strategy priority. We hypothesized that retention could be improved with coordinated messages to encourage patients' clinic attendance. We report here the results of the first phase of the Centers for Disease Control and Prevention/Health Resources and Services Administration Retention in Care project.
Methods. Six HIV-specialty clinics participated in a cross-sectionally sampled pretest-posttest evaluation of brochures, posters, and messages that conveyed the importance of regular clinic attendance. 10 018 patients in 20082009 (preintervention period) and 11 039 patients in 2009-2010 (intervention period) were followed up for clinic attendance. Outcome variables were the percentage of patients who kept 2 consecutive primary care visits and the mean proportion of all primary care visits kept. Stratification variables were: new, reengaging, and active patients, HIV RNA viral load, CD4 cell count, age, sex, race or ethnicity, risk group, number of scheduled visits, and clinic site. Data were analyzed by multivariable log-binomial and linear models using generalized estimation equation methods.
Results. Clinic attendance for primary care was significantly higher in the intervention versus preintervention year. Overall relative improvement was 7.0% for keeping 2 consecutive visits and 3.0% for the mean proportion of all visits kept (P < .0001). Larger relative improvement for both outcomes was observed for new or reengaging patients, young patients and patients with elevated viral loads. Improved attendance among the new or reengaging patients was consistent across the 6 clinics, and less consistent across clinics for active patients.
Conclusion. Targeted messages on staying in care, which were delivered at minimal effort and cost, improved clinic attendance, especially for new or reengaging patients, young patients, and those with elevated viral loads.
C1 [Gardner, Lytt I.; Marks, Gary; Craw, Jason A.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA.
[Craw, Jason A.] ICF Int, Atlanta, GA USA.
[Wilson, Tracey E.] Suny Downstate Med Ctr, Dept Community Hlth Sci, Brooklyn, NY 11203 USA.
[Holman, Susan] Suny Downstate Med Ctr, Coll Med, Brooklyn, NY 11203 USA.
[Holman, Susan] Suny Downstate Med Ctr, Coll Nursing, Brooklyn, NY 11203 USA.
[Drainoni, Mari-Lynn] Edith Nourse Rogers Mem VA Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA.
[Drainoni, Mari-Lynn; Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
[Moore, Richard D.; Keruly, Jeanne C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Malitz, Faye] Hlth Resources & Serv Adm, Div Sci & Policy, Rockville, MD USA.
[Moore, Richard D.; Raper, James L.] Univ Alabama Birmingham, HIV AIDS Clin 1917, Birmingham, AL USA.
[Mugavero, Michael J.; Raper, James L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL USA.
[Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA.
[Metsch, Lisa R.] Univ Miami, Dept Epidemiol & Publ Hlth, Coral Gables, FL 33124 USA.
[Bradley-Springer, Lucy A.] Univ Colorado Denver, Sch Med, Denver, CO USA.
[Skolnik, Paul R.] Univ Connecticut, Sch Med, Dept Med, Farmington, CT USA.
[Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA.
[Giordano, Thomas P.] DeBakey VA Med Ctr, Houston, TX USA.
RP Gardner, LI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Mailstop E-45, Atlanta, GA 30333 USA.
EM lig0@cdc.gov
FU CDC; HRSA (CDC) [200-2007-23685, 200-2007-23690, 200-2007-23689,
200-2007-23687]; SUNY Downstate Medical Center [200-2007-23684];
[200-2007-23692]
FX This work was supported by the CDC and the HRSA (CDC contracts
200-2007-23685 to Baylor College of Medicine, 200-2007-23690 to Boston
Medical Center, 200-2007-23689 to Johns Hopkins University School of
Medicine, 200-2007-23687 to Research Foundation of the State University
of New York, SUNY Downstate Medical Center, 200-2007-23684 to University
of Alabama at Birmingham, and 200-2007-23692 to University of Miami
Miller School of Medicine).
NR 26
TC 33
Z9 33
U1 2
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD OCT 15
PY 2012
VL 55
IS 8
BP 1124
EP 1134
DI 10.1093/cid/cis623
PG 11
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 010BX
UT WOS:000309070500020
PM 22828593
ER
PT J
AU Martins, PN
Sheiner, P
Facciuto, M
AF Martins, Paulo N.
Sheiner, Patricia
Facciuto, Marcelo
TI Xanthogranulomatous cholecystitis mimicking gallbladder cancer and
causing obstructive cholestasis
SO HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL
LA English
DT Article
DE xanthogranulomatous cholecystitis; gallbladder cancer; obstructive
cholestasis
ID SURGICAL RESECTION; CARCINOMA; JAUNDICE; LIVER
AB BACKGROUND: Xanthogranulomatous cholecystitis (XGC) is a destructive inflammatory disease of the gallbladder that can mimic gallbladder carcinoma.
METHODS: We present the case of a 35-year-old Hispanic male complaining of right upper quadrant pain and jaundice for 2 months prior to admission. He denied a history of fever, nausea/vomiting, and weight loss. The past medical history was relevant only for diabetes. He had no previous history of jaundice or previous operations.
RESULTS: CA19-9 was slightly elevated (52 U/mL). Abdominal ultrasonography showed an irregular thickening of the gallbladder wall and no gallstones were detected. CT scan also revealed an irregular thickening of the wall of the gallbladder body suggestive of malignancy. At laparotomy, the mass was adherent to the duodenum and colon, and although the frozen section biopsy was negative, the intraoperative findings were suggestive of malignancy, and the patient underwent left liver trisegmentectomy, resection of the common bile duct and Roux-en-Y hepaticojejunostomy. Pathological examination unexpectedly revealed XGC without malignancy.
CONCLUSIONS: Preoperative and intraoperative differential diagnosis of XGC from gallbladder carcinoma remains a challenge when it is associated with inflammatory involvement of surrounding tissues. Since gallbladder carcinoma and XGC may coexist, radical resection is justified when malignancy cannot be completely ruled out. (Hepatobiliary Pancreat Dis Int 2012;11:549-552)
C1 [Martins, Paulo N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Transplant Div, Boston, MA 02114 USA.
[Sheiner, Patricia] New York Med Coll, Dept Surg, Div Hepatobiliary Surg & Transplantat, New York, NY USA.
[Facciuto, Marcelo] Mt Sinai Hosp, Div Transplantat, New York, NY 10029 USA.
RP Martins, PN (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Transplant Div, 55 Fruit St, Boston, MA 02114 USA.
EM martins.paulo@mgh.harvard.edu
NR 20
TC 3
Z9 4
U1 1
U2 7
PU ZHEJIANG UNIV SCH MEDICINE
PI HANGZHOU
PA FIRST AFFILIATED HOSPITAL, 79 QINGCHUN ROAD, HANGZHOU, 310003, PEOPLES R
CHINA
SN 1499-3872
J9 HEPATOB PANCREAT DIS
JI Hepatob. Pancreatic. Dis. Int.
PD OCT 15
PY 2012
VL 11
IS 5
BP 549
EP 552
DI 10.1016/S1499-3872(12)60223-9
PG 4
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 013VH
UT WOS:000309333500015
PM 23060404
ER
PT J
AU Demetriou, SK
Ona-Vu, K
Sullivan, EM
Dong, TK
Hsu, SW
Oh, DH
AF Demetriou, Stephanie K.
Ona-Vu, Katherine
Sullivan, Erin M.
Dong, Tiffany K.
Hsu, Shu-Wei
Oh, Dennis H.
TI Defective DNA repair and cell cycle arrest in cells expressing Merkel
cell polyomavirus T antigen
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE Merkel cell carcinoma; polyomavirus; DNA repair; cell cycle; ultraviolet
radiation
ID NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; GLOBAL
GENOMIC REPAIR; HUMAN KERATINOCYTES; TUMOR-SUPPRESSOR; IN-VITRO;
CARCINOMA; P53; DEFICIENT; INFECTION
AB The pathways by which Merkel cell polyomavirus (MCV) infection contributes to the formation of Merkel cell carcinomas are important for understanding the pathogenesis of these cancers. We hypothesized that MCV T antigen suppresses normal responses to ultraviolet radiation (UVR)-induced DNA damage. An MCV-infected cell line (MKL-1) exhibited UVR hypersensitivity, impaired repair of DNA lesions and cell cycle arrest after UVR, as well as reduced levels of the DNA damage recognition protein, XPC. When ectopically expressed in uninfected UISO cells, mutant but not wild-type T antigen resulted in loss of repair of UVR-induced cyclobutane pyrimidine dimers and reductions in XPC, p53 and p21 levels, whereas both wild-type and mutant T antigen inhibited cell cycle arrest after UVR. Similarly, only mutant T antigen in normal fibroblasts inhibited DNA repair and XPC expression, while both mutant and wild-type T antigens produced cell cycle dysregulation. Wild-type T antigen expression produced large T, 57 kT and small T antigens while mutant T antigen was only detectable as a truncated large T antigen protein. Expression of wild-type large T antigen but not small T antigen inhibited the G1 checkpoint in UISO cells, but neither wild-type large T nor small T antigens affected DNA repair, suggesting that large T antigen generates cell cycle defects, and when mutated may also impair DNA repair. These results indicate that T antigen expression by MCV can inhibit key responses to UVR-induced DNA damage and suggest that progressive MCV-mediated abrogation of genomic stability may be involved in Merkel cell carcinogenesis.
C1 [Demetriou, Stephanie K.; Ona-Vu, Katherine; Sullivan, Erin M.; Dong, Tiffany K.; Hsu, Shu-Wei; Oh, Dennis H.] San Francisco VA Med Ctr, Dermatol Res Unit, San Francisco, CA USA.
[Demetriou, Stephanie K.; Ona-Vu, Katherine; Sullivan, Erin M.; Dong, Tiffany K.; Hsu, Shu-Wei; Oh, Dennis H.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA.
RP Oh, DH (reprint author), VA Med Ctr, Dermatol Res Serv 190, 4150 Clement St, San Francisco, CA 94121 USA.
EM ohd@derm.ucsf.edu
FU National Cancer Institute [P30 CA82103]; University of California Cancer
Research Coordinating Committee; Department of Veterans Affairs; Dept.
of Veterans Affairs, Office of Research and Development, Biomedical
Laboratory
FX Grant sponsor: National Cancer Institute; Grant number: P30 CA82103;
Grant sponsors: University of California Cancer Research Coordinating
Committee, Department of Veterans Affairs; The authors thank Drs. Yuan
Chang and Patrick Moore for providing MKL-1 cells, the TAg206, TAg350,
LT206 and sT vectors and the CM8E6 antibody; Dr. T. K. Das Gupta for
UISO cells; and R. Griby of the Northern California Institute for
Research and Education for assistance with flow cytometry. Work was
supported by an HIV-associated malignancies pilot project award from NCI
(P30 CA82103), a University of California Cancer Research Coordinating
Committee grant, and a Dept. of Veterans Affairs, Office of Research and
Development, Biomedical Laboratory Research and Development (Merit
Award) (all to D.H.O.).
NR 49
TC 15
Z9 15
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 15
PY 2012
VL 131
IS 8
BP 1818
EP 1827
DI 10.1002/ijc.27440
PG 10
WC Oncology
SC Oncology
GA 993XN
UT WOS:000307893400009
PM 22261839
ER
PT J
AU Scirica, BM
Bonaca, MP
Braunwald, E
De Ferrari, GM
Isaza, D
Lewis, BS
Mehrhof, F
Merlini, PA
Murphy, SA
Sabatine, MS
Tendera, M
Van de Werf, F
Wilcox, R
Morrow, DA
AF Scirica, Benjamin M.
Bonaca, Marc P.
Braunwald, Eugene
De Ferrari, Gaetano M.
Isaza, Daniel
Lewis, Basil S.
Mehrhof, Felix
Merlini, Piera A.
Murphy, Sabina A.
Sabatine, Marc S.
Tendera, Michal
Van de Werf, Frans
Wilcox, Robert
Morrow, David A.
CA Tra 2 P-Timi 50 Steering Comm Inve
TI Vorapaxar for secondary prevention of thrombotic events for patients
with previous myocardial infarction: a prespecified subgroup analysis of
the TRA 2 degrees P-TIMI 50 trial
SO LANCET
LA English
DT Article
ID ACUTE CORONARY SYNDROMES; ATHEROTHROMBOTIC EVENTS; ANTIPLATELET THERAPY;
RECEPTOR ANTAGONIST; DOUBLE-BLIND; TASK-FORCE; CLOPIDOGREL; ASPIRIN;
INTERVENTION; PRASUGREL
AB Background Vorapaxar inhibits platelet activation by antagonising thrombin-mediated activation of the protease-activated receptor 1 on human platelets. The effect of adding other antiplatelet drugs to aspirin for long-term secondary prevention of thrombotic events in stable patients with previous myocardial infarction is uncertain. We tested this effect in a subgroup of patients from the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2 degrees P)-TIMI 50 trial.
Methods In TRA 2 degrees P-TIMI 50-a randomised, placebo-controlled, parallel trial-we randomly assigned patients with a history of atherothrombosis to receive vorapaxar (2.5 mg daily) or matching placebo in a 1:1 ratio. Patients, and those giving treatment, assessing outcomes, and analysing results were masked to treatment allocation. Patients with a qualifying myocardial infarction within the previous 2 weeks to 12 months were analysed as a pre-defined subgroup. The primary efficacy endpoint was cardiovascular death, myocardial infarction, or stroke, analysed by intention to treat. We analysed events by Kaplan-Meier analysis and compared groups with a Cox proportional hazard model. TRA 2 degrees P-TIMI 50 is registered at ClinicalTrials.gov (NCT00526474).
Findings 17 779 of 26 449 patients had a qualifying myocardial infarction and were assigned treatment (8898 to vorapaxar and 8881 to placebo). Median follow-up was 2.5 years (IQR 2.0-2.9). Cardiovascular death, myocardial infarction, or stroke occurred in 610 of 8898 patients in the vorapaxar group and 750 of 8881 in the placebo group (3-year Kaplan-Meier estimates 8.1% vs 9.7%, HR 0.80, 95% CI 0.72-0.89; p<0.0001). Moderate or severe bleeding was more common in the vorapaxar group versus the placebo group (241/8880 [3.4%, 3-year Kaplan-Meier estimate] vs 151/8849 [2.1%, 3-year Kaplan-Meier estimate], HR 1.61, 95% CI 1.31-1.97; p<0.0001). Intracranial haemorrhage occurred in 43 of 8880 patients (0.6%, 3-year Kaplan-Meier estimate) with vorapaxar versus 28 of 8849 (0.4%, 3-year Kaplan-Meier estimate) with placebo (p=0.076). Other serious adverse events were equally distributed between groups.
Interpretation For patients with a history of myocardial infarction, inhibition of protease-activated receptor 1 with vorapaxar reduces the risk of cardiovascular death or ischaemic events when added to standard antiplatelet treatment, including aspirin, and increases the risk of moderate or severe bleeding.
C1 [Scirica, Benjamin M.; Bonaca, Marc P.; Braunwald, Eugene; Murphy, Sabina A.; Sabatine, Marc S.; Morrow, David A.] Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA.
[De Ferrari, Gaetano M.] Fdn IRCCS Policlin San Matteo, Dept Cardiol, Pavia, Italy.
[Isaza, Daniel] Fdn CardioInfantil, Bogota, Colombia.
[Lewis, Basil S.] Technion Israel Inst Technol, Lady Davis Carmel Med Ctr, Haifa, Israel.
[Lewis, Basil S.] Technion Israel Inst Technol, Ruth & Bruce Rappaport Sch Med, Haifa, Israel.
[Mehrhof, Felix] Charite, Dept Cardiol, D-13353 Berlin, Germany.
[Merlini, Piera A.] Azienda Osped Niguarda Ca Granda, Div 4, Milan, Italy.
[Tendera, Michal] Med Univ Silesia, Katowice, Poland.
[Van de Werf, Frans] Katholieke Univ Leuven Hosp, Dept Cardiovasc Med, Louvain, Belgium.
[Wilcox, Robert] Univ Nottingham Hosp, Queens Med Ctr, Nottingham NG7 2UH, England.
RP Scirica, BM (reprint author), Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA.
EM bscirica@partners.org
RI De Ferrari, Gaetano/K-5188-2016;
OI De Ferrari, Gaetano/0000-0003-4940-0876; Van de Werf,
Frans/0000-0001-9479-7767
FU Merck; Abbott; AstraZeneca; Amgen; Bayer Healthcare; Bristol-Myers
Squibb; Daichii Sankyo; Eli Lilly; Gilead; GlaxoSmithKline; Merck
(SPRI); Novartis; Pfizer; Roche Diagnostics; Sanofi-Aventis; Johnson
Johnson; Brigham and Women's Hospital from BRAHMS; Critical Diagnostics;
Genzyme; Nanosphere; Takeda; Merck Sharp Dohme; Boehringer Ingelheim;
Daiichi Sankyo
FX Merck.; The TIMI Study Group has received research grants from Abbott,
AstraZeneca, Amgen, Bayer Healthcare, Bristol-Myers Squibb, Daichii
Sankyo, Eli Lilly, Gilead, GlaxoSmithKline, Merck (SPRI), Novartis,
Pfizer, Roche Diagnostics, Sanofi-Aventis, and Johnson & Johnson and
grant support through Brigham and Women's Hospital from BRAHMS, Critical
Diagnostics, Genzyme, Nanosphere, Takeda. BMS has served as a consultant
for Lexicon, Arena, Gilead, and Eisai. EB has served as a consultant for
Merck (no compensation), Amorcyte, Daiichi Sankyo, Medicines Co, Ikaria,
CardioRentis, Sanofi-Aventis, and CVRx (no compensation). GMDF has
received honoraria from Merck for presentations and participation on
advisory boards. BSL has received research support and served on
advisory boards for Merck Sharp & Dohme, Bristol-Myers Squibb,
AstraZeneca, Sanofi-Aventis, and Bayer Healthcare. FM has served on a
national advisory board for vorapaxar for Merck Sharp & Dohme and has
received honoraria from Essex Pharma for oral presentations. SAM has
served as a consultant for Eli Lilly and Amarin Pharmaceuticals. MSS has
served as a consultant for Amgen, AstraZeneca, Bristol-Myers Squibb,
Sanofi-Aventis, Daiichi-Sankyo, Eli Lilly, Diasorin, GlaxoSmithKline,
Merck, Pfizer, and Sanofi-Aventis and given accredited Continuing
Medical Education talks supported by medical education companies that
received unrestricted educational grants from AstraZeneca, Boehringer
Ingelheim, Bristol-Myers Squibb, Sanofi-Aventis, Daiichi Sankyo, Eli
Lilly. FVdW has received honoraria from Merck for presentations and
participation on advisory boards. DAM has served as consultant for Merck
(SPRI), Boeringher Ingelheim, CV Therapeutics (now Gilead Sciences),
Genentech, Ikaria, Johnson & Johnson, Menarini, Novartis, Servier, and
Roche Diagnostics.
NR 21
TC 102
Z9 107
U1 0
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD OCT 13
PY 2012
VL 380
IS 9850
BP 1317
EP 1324
DI 10.1016/S0140-6736(12)61269-0
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 022BZ
UT WOS:000309931400030
PM 22932716
ER
PT J
AU Liu, S
Ren, JN
Han, G
Wang, GF
Gu, GS
Xia, QY
Li, JS
AF Liu, Song
Ren, Jianan
Han, Gang
Wang, Gefei
Gu, Guosheng
Xia, Qiuyuan
Li, Jieshou
TI Mean platelet volume: a controversial marker of disease activity in
Crohn's disease
SO EUROPEAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE Crohn's disease; Mean platelet volume; C-reactive protein; Erythrocyte
sedimentation rate; Inflammatory bowel disease
ID INFLAMMATORY-BOWEL-DISEASE; C-REACTIVE PROTEIN; ULCERATIVE-COLITIS;
THERAPEUTIC IMPLICATIONS; BLOOD-PLATELETS; PATHOGENESIS; ACTIVATION;
SIZE; THROMBOEMBOLISM; DIFFERENTIATION
AB Background: We investigated and compared the capacity of mean platelet volume (MPV) and other inflammatory markers in detecting Crohn's disease (CD) activity and differentiating CD patients from healthy controls.
Methods: MPV, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) and white blood cells were measured in 61 CD patients and 50 healthy subjects. Disease activity was assessed by the Crohn's Disease Activity Index.
Results: A significant decrease in MPV was noted in patients with CD compared with healthy controls (P <0.0001), but statistical difference was not found between active and inactive CD groups. In CD, no significant correlation was found between MPV and other inflammatory markers. The overall accuracy of MPV (cutoff: 10.35 fl), CRP (cutoff: 4.85 mg/dl) and ESR (cutoff: 8.5 mm/hour) in differentiating CD patients from healthy controls was 76.6%, 65.8% and 72.1% respectively. The overall accuracy of CRP (cutoff: 4.95 mg/dl) and ESR (cutoff: 16.5 mm/hour) in determination of active CD was 80.3% and 73.8%.
Conclusions: MPV declined in CD patients compared with healthy subjects. MPV had the best accuracy in determination of CD patients and healthy controls. MPV did not show a discriminative value in disease activity.
C1 [Liu, Song; Ren, Jianan; Wang, Gefei; Gu, Guosheng; Li, Jieshou] Nanjing Univ, Sch Med, Jinling Hosp, Dept Surg, Nanjing 210002, Peoples R China.
[Liu, Song] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Boston, MA 02114 USA.
[Liu, Song] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Han, Gang] Jilin Univ, Gen Surg Ctr, Dept Gen Surg, Affiliated Hosp 2, Changchun 130041, Peoples R China.
[Xia, Qiuyuan] Nanjing Univ, Sch Med, Jinling Hosp, Dept Pathol, Nanjing 210002, Peoples R China.
RP Ren, JN (reprint author), Nanjing Univ, Sch Med, Jinling Hosp, Dept Surg, 305 E Zhongshan Rd, Nanjing 210002, Peoples R China.
EM jiananr@gmail.com
OI LIU, SONG/0000-0002-4780-9697; Ren, Jianan/0000-0002-7978-8093
FU Climb Program in Natural Science Foundation of Jiangsu Province for
Distinguished Scholars [BK2010017]
FX This work was supported by grants from the Climb Program in Natural
Science Foundation of Jiangsu Province for Distinguished Scholars (No.
BK2010017).
NR 49
TC 15
Z9 16
U1 2
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 0949-2321
J9 EUR J MED RES
JI Eur. J. Med. Res.
PD OCT 12
PY 2012
VL 17
AR 27
DI 10.1186/2047-783X-17-27
PG 7
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 055YX
UT WOS:000312455100001
PM 23058104
ER
PT J
AU Mekkaoui, C
Huang, SN
Chen, HH
Dai, GP
Reese, TG
Kostis, WJ
Thiagalingam, A
Maurovich-Horvat, P
Ruskin, JN
Hoffmann, U
Jackowski, MP
Sosnovik, DE
AF Mekkaoui, Choukri
Huang, Shuning
Chen, Howard H.
Dai, Guangping
Reese, Timothy G.
Kostis, William J.
Thiagalingam, Aravinda
Maurovich-Horvat, Pal
Ruskin, Jeremy N.
Hoffmann, Udo
Jackowski, Marcel P.
Sosnovik, David E.
TI Fiber architecture in remodeled myocardium revealed with a quantitative
diffusion CMR tractography framework and histological validation
SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
LA English
DT Article
DE Diffusion tensor imaging; Tractography; Myocardium; Remodeling; Heart
ID OVINE LEFT-VENTRICLE; CARDIAC FIBER; TENSOR MRI; LAMINAR STRUCTURE;
INFARCTION; HEART; RECONSTRUCTION; ORIENTATION; WALL; MICROSTRUCTURE
AB Background: The study of myofiber reorganization in the remote zone after myocardial infarction has been performed in 2D. Microstructural reorganization in remodeled hearts, however, can only be fully appreciated by considering myofibers as continuous 3D entities. The aim of this study was therefore to develop a technique for quantitative 3D diffusion CMR tractography of the heart, and to apply this method to quantify fiber architecture in the remote zone of remodeled hearts.
Methods: Diffusion Tensor CMR of normal human, sheep, and rat hearts, as well as infarcted sheep hearts was performed ex vivo. Fiber tracts were generated with a fourth-order Runge-Kutta integration technique and classified statistically by the median, mean, maximum, or minimum helix angle (HA) along the tract. An index of tract coherence was derived from the relationship between these HA statistics. Histological validation was performed using phase-contrast microscopy.
Results: In normal hearts, the subendocardial and subepicardial myofibers had a positive and negative HA, respectively, forming a symmetric distribution around the midmyocardium. However, in the remote zone of the infarcted hearts, a significant positive shift in HA was observed. The ratio between negative and positive HA variance was reduced from 0.96 +/- 0.16 in normal hearts to 0.22 +/- 0.08 in the remote zone of the remodeled hearts (p<0.05). This was confirmed histologically by the reduction of HA in the subepicardium from -52.03 degrees +/- 2.94 degrees in normal hearts to -37.48 degrees +/- 4.05 degrees in the remote zone of the remodeled hearts (p < 0.05).
Conclusions: A significant reorganization of the 3D fiber continuum is observed in the remote zone of remodeled hearts. The positive (rightward) shift in HA in the remote zone is greatest in the subepicardium, but involves all layers of the myocardium. Tractography-based quantification, performed here for the first time in remodeled hearts, may provide a framework for assessing regional changes in the left ventricle following infarction.
C1 [Mekkaoui, Choukri; Huang, Shuning; Chen, Howard H.; Dai, Guangping; Reese, Timothy G.; Kostis, William J.; Sosnovik, David E.] Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Kostis, William J.; Thiagalingam, Aravinda; Ruskin, Jeremy N.; Sosnovik, David E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
[Mekkaoui, Choukri; Huang, Shuning; Chen, Howard H.; Dai, Guangping; Reese, Timothy G.; Maurovich-Horvat, Pal; Hoffmann, Udo] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Jackowski, Marcel P.] Univ Sao Paulo, Inst Math & Stat, Dept Comp Sci, Sao Paulo, Brazil.
[Sosnovik, David E.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Sosnovik, David E.] Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Sosnovik, DE (reprint author), Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
EM sosnovik@nmr.mgh.harvard.edu
RI Jackowski, Marcel/G-7602-2012;
OI Maurovich-Horvat, Pal/0000-0003-0885-736X
FU National Institutes of Health [R01 HL093038, P41RR14075]; Medical
Discovery Fund Award from the Massachusetts General Hospital
FX We thank Dr. Bruce R. Rosen for his support of this study. This research
was supported in part by the following National Institutes of Health
grants R01 HL093038 (D.E.S.), P41RR14075 (Athinoula A. Martinos Center
for Biomedical Imaging) and by a Medical Discovery Fund Award from the
Massachusetts General Hospital (C.M.).
NR 27
TC 25
Z9 29
U1 1
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1097-6647
J9 J CARDIOVASC MAGN R
JI J. Cardiov. Magn. Reson.
PD OCT 12
PY 2012
VL 14
AR 70
DI 10.1186/1532-429X-14-70
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 044NS
UT WOS:000311627500001
PM 23061749
ER
PT J
AU Lee, KY
Kahn, CR
AF Lee, Kevin Y.
Kahn, C. Ronald
TI Turning on Brown Fat and Muscle Metabolism: Hedging Your Bets
SO CELL
LA English
DT Editorial Material
ID ADIPOGENESIS; THERMOGENESIS
C1 [Lee, Kevin Y.; Kahn, C. Ronald] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Kahn, CR (reprint author), Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
EM c.ronald.kahn@joslin.harvard.edu
FU NIDDK NIH HHS [R01 DK082659, P30 DK036836, RC1 DK087317, R21 DK090762]
NR 10
TC 1
Z9 1
U1 1
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD OCT 12
PY 2012
VL 151
IS 2
BP 248
EP 250
DI 10.1016/j.cell.2012.09.025
PG 4
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 022RX
UT WOS:000309981000004
PM 23063118
ER
PT J
AU Handley, SA
Thackray, LB
Zhao, G
Presti, R
Miller, AD
Droit, L
Abbink, P
Maxfield, LF
Kambal, A
Duan, E
Stanley, K
Kramer, J
Macri, SC
Permar, SR
Schmitz, JE
Mansfield, K
Brenchley, JM
Veazey, RS
Stappenbeck, TS
Wang, D
Barouch, DH
Virgin, HW
AF Handley, Scott A.
Thackray, Larissa B.
Zhao, Guoyan
Presti, Rachel
Miller, Andrew D.
Droit, Lindsay
Abbink, Peter
Maxfield, Lori F.
Kambal, Amal
Duan, Erning
Stanley, Kelly
Kramer, Joshua
Macri, Sheila C.
Permar, Sallie R.
Schmitz, Joern E.
Mansfield, Keith
Brenchley, Jason M.
Veazey, Ronald S.
Stappenbeck, Thaddeus S.
Wang, David
Barouch, Dan H.
Virgin, Herbert W.
TI Pathogenic Simian Immunodeficiency Virus Infection Is Associated with
Expansion of the Enteric Virome
SO CELL
LA English
DT Article
ID GUT MICROBIOME; IMMUNE ACTIVATION; HIV-INFECTION; GENE ATG16L1;
METAGENOMICS; DISEASE; MOUSE; TRANSLOCATION; SEQUENCES; COLITIS
AB Pathogenic simian immunodeficiency virus (SIV) infection is associated with enteropathy, which likely contributes to AIDS progression. To identify candidate etiologies for AIDS enteropathy, we used next-generation sequencing to define the enteric virome during SIV infection in nonhuman primates. Pathogenic, but not nonpathogenic, SIV infection was associated with significant expansion of the enteric virome. We identified at least 32 previously undescribed enteric viruses during pathogenic SIV infection and confirmed their presence by using viral culture and PCR testing. We detected unsuspected mucosal adenovirus infection associated with enteritis as well as parvovirus viremia in animals with advanced AIDS, indicating the pathogenic potential of SIV-associated expansion of the enteric virome. No association between pathogenic SIV infection and the family-level taxonomy of enteric bacteria was detected. Thus, enteric viral infections may contribute to AIDS enteropathy and disease progression. These findings underline the importance of metagenomic analysis of the virome for understanding AIDS pathogenesis.
C1 [Abbink, Peter; Maxfield, Lori F.; Stanley, Kelly; Schmitz, Joern E.; Barouch, Dan H.] Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
[Handley, Scott A.; Thackray, Larissa B.; Zhao, Guoyan; Droit, Lindsay; Kambal, Amal; Duan, Erning; Stappenbeck, Thaddeus S.; Wang, David; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Zhao, Guoyan; Droit, Lindsay; Wang, David; Virgin, Herbert W.] Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.
[Presti, Rachel] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA.
[Miller, Andrew D.; Kramer, Joshua; Macri, Sheila C.; Mansfield, Keith] Harvard Univ, Sch Med, Dept Comparat Pathol, New England Primate Res Ctr, Southborough, MA 01772 USA.
[Miller, Andrew D.; Kramer, Joshua; Macri, Sheila C.; Mansfield, Keith] Harvard Univ, Sch Med, Dept Vet Resources, New England Primate Res Ctr, Southborough, MA 01772 USA.
[Permar, Sallie R.] Duke Univ, Med Ctr, Human Vaccine Inst, Durham, NC 27710 USA.
[Brenchley, Jason M.] NIAID, Program Barrier Immun, NIH, Bethesda, MD 20892 USA.
[Brenchley, Jason M.] NIAID, Repair & Immunopathogenesis Unit, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA.
[Veazey, Ronald S.] Tulane Univ, Tulane Natl Primate Res Ctr, Sch Med, Covington, LA 70433 USA.
[Barouch, Dan H.] Massachusetts Gen Hosp, Ragon Inst, MIT, Boston, MA 02114 USA.
[Barouch, Dan H.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Barouch, DH (reprint author), Beth Israel Deaconess Med Ctr, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
EM dbarouch@bidmc.harvard.edu; virgin@wustl.edu
RI zhou, zhenqing/H-4580-2014; Duan, Erning /H-4608-2014
FU Project 10 [U54 AI057160-08]; National Center for Research Resources
[1R01 RR032309]; Office of Research Infrastructure Programs
[OD11170-02]; Crohn's and Colitis Foundation [3132]; [AI066305];
[AI066924]; [AI078526]; [AI095985]; [AI65335]; [8P51OD011103-5]
FX This work was supported by Project 10 of U54 AI057160-08 to D. W. for
development of VirusHunter software, was initially funded by the
National Center for Research Resources 1R01 RR032309, and is currently
supported by the Office of Research Infrastructure Programs OD11170-02
to H. W. V. and D. H. B.; Crohn's and Colitis Foundation Grant 3132 to
H. W. V. and T. S. S.; grants AI066305, AI066924, AI078526, and AI095985
to D. H. B.; AI65335 to J.E.S.; and grant 8P51OD011103-5 to A. D. M. and
J.K. We would like to thank Angela Carville, Elizabeth Curran, and
Vanessa Hirsch for assistance with these experiments.
NR 38
TC 111
Z9 112
U1 1
U2 40
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD OCT 12
PY 2012
VL 151
IS 2
BP 253
EP 266
DI 10.1016/j.cell.2012.09.024
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 022RX
UT WOS:000309981000006
PM 23063120
ER
PT J
AU Vo, TT
Ryan, J
Carrasco, R
Neuberg, D
Rossi, DJ
Stone, RM
DeAngelo, DJ
Frattini, MG
Letai, A
AF Thanh-Trang Vo
Ryan, Jeremy
Carrasco, Ruben
Neuberg, Donna
Rossi, Derrick J.
Stone, Richard M.
DeAngelo, Daniel J.
Frattini, Mark G.
Letai, Anthony
TI Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines
Chemotherapeutic Success in AML
SO CELL
LA English
DT Article
ID ACUTE MYELOID-LEUKEMIA; BH3 MIMETIC ABT-737; BCL-2 FAMILY; BH3-ONLY
PROTEINS; CYTOCHROME-C; APOPTOSIS; DEATH; MCL-1; BAX; INHIBITOR
AB Despite decades of successful use of cytotoxic chemotherapy in acute myelogenous leukemia (AML), the biological basis for its differential success among individuals and for the existence of a therapeutic index has remained obscure. Rather than taking a genetic approach favored by many, we took a functional approach to ask how differential mitochondrial readiness for apoptosis ("priming") might explain individual variation in clinical behavior. We found that mitochondrial priming measured by BH3 profiling was a determinant of initial response to induction chemotherapy, relapse after remission, and requirement for allogeneic bone marrow transplantation. Differential priming between malignant myeloblasts and normal hematopoietic stem cells supports a mitochondrial basis to the therapeutic index for chemotherapy. BH3 profiling identified BCL-2 inhibition as a targeted strategy likely to have a useful therapeutic index. BH3 profiling refines predictive information provided by conventional biomarkers currently in use and thus may itself have utility as a clinical predictive biomarker.
C1 [Thanh-Trang Vo; Letai, Anthony] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Thanh-Trang Vo; Ryan, Jeremy; Carrasco, Ruben; Neuberg, Donna; Stone, Richard M.; DeAngelo, Daniel J.; Letai, Anthony] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Rossi, Derrick J.] Harvard Univ, Sch Med, Dept Stem Cell & Regenerat Biol, Boston, MA 02115 USA.
[Frattini, Mark G.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA.
RP Letai, A (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
EM anthony_letai@dfci.harvard.edu
FU NIH [F31 CA150562, P01 CA139980, R01CA129974]; Gabrielle's Angel
Foundation for Cancer Research
FX The authors gratefully acknowledge support from the following sources:
NIH grants F31 CA150562, P01 CA139980, and R01CA129974, Gabrielle's
Angel Foundation for Cancer Research. A. L. is a Leukemia and Lymphoma
Society Scholar. We thank Abbott Laboratories for providing ABT-737. We
thank Martha Wadleigh, MD, and Ilene Galinsky, RN, and the Pasquarello
Tissue Bank for help with clinical data and samples. A. L. was a
cofounder and formerly served on the scientific advisory board of
Eutropics Pharmaceuticals, which has a license for BH3 profiling.
NR 37
TC 101
Z9 102
U1 2
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD OCT 12
PY 2012
VL 151
IS 2
BP 344
EP 355
DI 10.1016/j.cell.2012.08.038
PG 12
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 022RX
UT WOS:000309981000013
PM 23063124
ER
PT J
AU Sikorski, TW
Joo, YJ
Ficarro, SB
Askenazi, M
Buratowski, S
Marto, JA
AF Sikorski, Timothy W.
Joo, Yoo Jin
Ficarro, Scott B.
Askenazi, Manor
Buratowski, Stephen
Marto, Jarrod A.
TI Proteomic Analysis Demonstrates Activator- and Chromatin-specific
Recruitment to Promoters
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID RNA-POLYMERASE-II; QUANTITATIVE PROTEOMICS; PREINITIATION COMPLEX;
TRANSCRIPTION REINITIATION; IN-VIVO; MEDIATOR; QUANTIFICATION;
IDENTIFICATION; MECHANISM; ENHANCER
AB In-depth characterization of RNA polymerase II preinitiation complexes remains an important and challenging goal. We used quantitative mass spectrometry to explore context-dependent Saccharomyces cerevisiae preinitiation complex formation at the HIS4 promoter reconstituted on naked and chromatinized DNA templates. The transcription activators Gal4-VP16 and Gal4-Gcn4 recruited a limited set of chromatin-related coactivator complexes, namely the chromatin remodeler Swi/Snf and histone acetyltransferases SAGA and NuA4, suggesting that transcription stimulation is mediated through these factors. Moreover, the two activators differentially recruited the coactivator complexes, consistent with specific activator-coactivator interactions. Chromatinized templates suppressed recruitment of basal transcription factors, thereby amplifying the effect of activators, compared with naked DNA templates. This system is sensitive, highly reproducible, and easily applicable to mapping the repertoire of proteins found at any promoter.
C1 [Sikorski, Timothy W.; Joo, Yoo Jin; Ficarro, Scott B.; Askenazi, Manor; Buratowski, Stephen; Marto, Jarrod A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Sikorski, Timothy W.; Ficarro, Scott B.; Askenazi, Manor; Marto, Jarrod A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Ficarro, Scott B.; Askenazi, Manor; Marto, Jarrod A.] Harvard Univ, Sch Med, Blais Prote Ctr, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Buratowski, S (reprint author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.
EM steveb@hms.harvard.edu; jarrod_marto@dfci.harvard.edu
FU National Institutes of Health [GM46498]; Dana-Farber Strategic Research
Initiative; National Defense Science and Engineering Graduate
predoctoral fellowship; National Research Foundation of Korea
FX This work was supported, in whole or in part, by National Institutes of
Health Grant GM46498 (to S. B.). This work was also supported by the
Dana-Farber Strategic Research Initiative (to J.A.M.).; Supported by a
National Defense Science and Engineering Graduate predoctoral
fellowship.; Supported by a National Research Foundation of Korea
postdoctoral fellowship.
NR 40
TC 5
Z9 5
U1 1
U2 13
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD OCT 12
PY 2012
VL 287
IS 42
BP 35397
EP 35408
DI 10.1074/jbc.M112.391581
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 022OF
UT WOS:000309968000047
PM 22902623
ER
PT J
AU Belden, S
Flaherty, KT
AF Belden, Sarah
Flaherty, Keith T.
TI MEK and RAF inhibitors for BRAF-mutated cancers
SO EXPERT REVIEWS IN MOLECULAR MEDICINE
LA English
DT Review
ID CELL LUNG-CANCER; MELANOMA-CELLS; TUMOR PROGRESSION; BRAF(V600E)
INHIBITION; METASTATIC MELANOMA; ACQUIRED-RESISTANCE;
MALIGNANT-MELANOMA; KINASE INHIBITION; B-RAF; MUTATIONS
AB The mitogen-activated protein kinase (MAPK) pathway has been implicated in the pathophysiology of many cancers. Under normal physiologic conditions, the RAS-RAF-mitogen-activated protein kinase kinase (MEK)-mitogen-activated protein kinase (ERK) signalling cascade interaction is initiated by ligation of a receptor-linked tyrosine kinase by its cognate growth factor. It has been demonstrated in many systems that aberrant autocrine or paracrine stimulation of growth factor receptors is pathogenic in large part because of MAPK activation. As one of the key downstream effector pathways of mutated RAS (KRAS, NRAS and HRAS), pharmacologic inhibition of components of the MAPK pathway has been pursued as a means to indirectly inhibit RAS, which remains a technical challenge for direct pharmacologic inhibition. RAF and MEK are the two non-membrane-bound, serine-threonine and tyrosine-threonine kinases, within the pathway that have been most extensively explored as drug targets. The discovery of activating BRAF mutations in cancer clarified which cancer types and subsets of certain cancers are most dependent on activation of the MAPK pathway for growth and survival. Now, with the successful translation of selective BRAF and MEK inhibitors into validated therapies for BRAF mutant melanoma, the field seeks to resolve the role for these agents in cancers harbouring RAS mutations or those driven by aberrant growth factor receptor activation.
C1 [Belden, Sarah; Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Belden, Sarah] Univ New England, Coll Osteopath Med, Biddeford, ME USA.
RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM kflaherty@partners.org
OI Belden, Sarah/0000-0002-7132-5318
NR 62
TC 18
Z9 18
U1 0
U2 28
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1462-3994
J9 EXPERT REV MOL MED
JI Expert Rev. Mol. Med.
PD OCT 12
PY 2012
VL 14
AR e17
DI 10.1017/erm.2012.11
PG 11
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental
SC Biochemistry & Molecular Biology; Research & Experimental Medicine
GA 021ZL
UT WOS:000309924600001
PM 23058743
ER
PT J
AU Rosen, MI
Black, AC
Arnsten, JH
Simoni, JM
Wagner, GJ
Goggin, K
Remien, RH
Golin, CE
Wang, Y
Bangsberg, D
Liu, HHH
AF Rosen, Marc I.
Black, Anne C.
Arnsten, Julia H.
Simoni, Jane M.
Wagner, Glann J.
Goggin, Kathleen
Remien, Robert H.
Golin, Carol E.
Wang, Yan
Bangsberg, David
Liu, Honghu H.
CA MACH14 Study Grp
TI ART adherence changes among patients in community substance use
treatment: a preliminary analysis from MACH14
SO AIDS RESEARCH AND THERAPY
LA English
DT Article
DE Medication adherence; AIDS; Substance abuse; Treatment
ID METHADONE-MAINTENANCE THERAPY; HIV TREATMENT OUTCOMES; INJECTION-DRUG
USERS; ANTIRETROVIRAL THERAPY; CONTROLLED-TRIAL; MEDICATION; HEALTH
AB Background: Opiate substitution treatment has been associated with better adherence to lifesaving antiretroviral medications, but the impact of other substance abuse treatment on adherence is unknown.
Findings: In this study, 215 patients who had been in adherence-focused research studies provided electronically-measured adherence data and a measure of whether the patient had recently been in substance abuse treatment. Recent engagement in substance abuse treatment was independently associated with significantly higher adherence, after covarying for recent substance use and other factors potentially affecting adherence.
Conclusions: The findings suggest that substance abuse treatment is associated with better adherence. Potential mechanisms by which substance abuse treatment improves adherence, such as more stability or more future-orientation, require further study.
C1 [Rosen, Marc I.; Black, Anne C.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA.
[Rosen, Marc I.; Black, Anne C.] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA.
[Arnsten, Julia H.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Arnsten, Julia H.] Albert Einstein Coll Med, Dept Psychiat & Behav Sci, Bronx, NY 10467 USA.
[Arnsten, Julia H.] Einstein Montefiore Ctr AIDS Res, Montefiore Med Ctr, Bronx, NY 10467 USA.
[Simoni, Jane M.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
[Wagner, Glann J.] RAND Corp, Hlth Unit, Santa Monica, CA 90407 USA.
[Goggin, Kathleen] Univ Missouri, Dept Psychol, Kansas City, MO 64110 USA.
[Remien, Robert H.] NY State Psychiat Inst, HIV Ctr Clin & Behav Studies, New York, NY 10032 USA.
[Remien, Robert H.] Columbia Univ, New York, NY 10032 USA.
[Golin, Carol E.] Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.
[Golin, Carol E.] Univ N Carolina, Dept Hlth Behav & Hlth Educ, Chapel Hill, NC 27599 USA.
[Golin, Carol E.] Univ N Carolina, Ctr AIDS Res, Cecil G Sheps Ctr Hlth Serv Res, Chapel Hill, NC 27599 USA.
[Wang, Yan] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA.
[Bangsberg, David] Mbarara Univ Sci & Technol, Boston, MA 02114 USA.
[Bangsberg, David] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Bangsberg, David] Ragon Inst MGH Harvard & MIT, Boston, MA 02114 USA.
[Bangsberg, David] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02114 USA.
[Bangsberg, David] Massachusetts Gen Hosp, Ctr Global Hlth, Boston, MA 02114 USA.
[Liu, Honghu H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA.
[Liu, Honghu H.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90095 USA.
[Liu, Honghu H.] Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90095 USA.
RP Rosen, MI (reprint author), Yale Univ, Sch Med, Dept Psychiat, New Haven, CT 06520 USA.
EM Marc.Rosen@Yale.edu
OI Simoni, Jane/0000-0002-8711-1576
FU National Institute of Mental Health (NIMH), Office on AIDS
[R01MH078773]; [R01DA11869]; [MH54907]; [R01 NR04749]; [MH68197];
[R01 DA13826]; [K23MH01862]; [MH01584]; [R01 AI41413]; [R01
MH61173]; [NIH/ NIAID AI38858]; [AI069419]; [K02 DA017277]; [R01
DA15215]; [NIMH P01 MH49548]; [MH58986]; [RO1MH61695]; [CC99-SD003];
[CC02-SD-003]; [R01 DA015679]
FX This research was supported by the multi-site adherence collaboration in
HIV (MACH14) grant R01MH078773 from the National Institute of Mental
Health (NIMH), Office on AIDS. The original grants of individual
participating studies are: R01DA11869, MH54907, R01 NR04749, R01
NR04749, MH68197, R01 DA13826, K23MH01862, MH01584, R01 AI41413, R01
MH61173, NIH/ NIAID AI38858, AI069419, K02 DA017277, R01 DA15215, NIMH
P01 MH49548, MH58986, RO1MH61695, CC99-SD003, CC02-SD-003 and R01
DA015679. We would like to thank all the patients who participated in
each of the individual studies. The content of the paper is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institutes of Health.
NR 19
TC 3
Z9 3
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-6405
J9 AIDS RES THER
JI Aids Res. Ther.
PD OCT 11
PY 2012
VL 9
AR 30
DI 10.1186/1742-6405-9-30
PG 5
WC Infectious Diseases
SC Infectious Diseases
GA 072XI
UT WOS:000313706600001
PM 23057423
ER
PT J
AU Bauer, DE
Kamran, SC
Orkin, SH
AF Bauer, Daniel E.
Kamran, Sophia C.
Orkin, Stuart H.
TI Reawakening fetal hemoglobin: prospects for new therapies for the
beta-globin disorders
SO BLOOD
LA English
DT Review
ID SICKLE-CELL-DISEASE; KRUPPEL-LIKE FACTOR; PLURIPOTENT STEM-CELLS;
GENOME-WIDE ASSOCIATION; YAC TRANSGENIC MICE; HUMAN GAMMA-GLOBIN; FACTOR
KLF1 CAUSES; RED-BLOOD-CELLS; TRANSCRIPTION FACTOR; GENE-EXPRESSION
AB The level of fetal hemoglobin (HbF) modifies the severity of the common beta-globin disorders. Knowledge of the normal mechanisms that repress HbF in the adult stage has remained limited until recently despite nearly 3 decades of molecular investigation, in part because of imperfect model systems. Recent studies have provided new insights into the developmental regulation of globin genes and identified specific transcription factors and epigenetic regulators responsible for physiologic silencing of HbF. Most prominent among these regulators is BCL11A, a transcriptional repressor that inhibits adult-stage HbF expression. KLF1 and c-Myb are additional critical HbF-regulating erythroid transcription factors more broadly involved in erythroid gene expression programs. Chromatin modifiers, including histone deacetylases and DNA methyltransferases, also play key roles in orchestrating appropriate globin gene expression. Taken together, these discoveries present novel therapeutic targets for further consideration. Although substantial hurdles remain, opportunities are now rich for the rational design of HbF inducers. (Blood. 2012; 120(15): 2945-2953)
C1 [Bauer, Daniel E.; Orkin, Stuart H.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Bauer, Daniel E.; Orkin, Stuart H.] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA USA.
[Bauer, Daniel E.; Kamran, Sophia C.; Orkin, Stuart H.] Harvard Univ, Sch Med, Boston, MA USA.
[Kamran, Sophia C.; Orkin, Stuart H.] Howard Hughes Med Inst, Boston, MA 02115 USA.
RP Orkin, SH (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.
EM orkin@bloodgroup.tch.harvard.edu
NR 119
TC 60
Z9 60
U1 1
U2 16
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 11
PY 2012
VL 120
IS 15
BP 2945
EP 2953
DI 10.1182/blood2012-06-292078
PG 9
WC Hematology
SC Hematology
GA 044KY
UT WOS:000311619300011
PM 22904296
ER
PT J
AU Landis, SC
Amara, SG
Asadullah, K
Austin, CP
Blumenstein, R
Bradley, EW
Crystal, RG
Darnell, RB
Ferrante, RJ
Fillit, H
Finkelstein, R
Fisher, M
Gendelman, HE
Golub, RM
Goudreau, JL
Gross, RA
Gubitz, AK
Hesterlee, SE
Howells, DW
Huguenard, J
Kelner, K
Koroshetz, W
Krainc, D
Lazic, SE
Levine, MS
Macleod, MR
McCall, JM
Moxley, RT
Narasimhan, K
Noble, LJ
Perrin, S
Porter, JD
Steward, O
Unger, E
Utz, U
Silberberg, SD
AF Landis, Story C.
Amara, Susan G.
Asadullah, Khusru
Austin, Chris P.
Blumenstein, Robi
Bradley, Eileen W.
Crystal, Ronald G.
Darnell, Robert B.
Ferrante, Robert J.
Fillit, Howard
Finkelstein, Robert
Fisher, Marc
Gendelman, Howard E.
Golub, Robert M.
Goudreau, John L.
Gross, Robert A.
Gubitz, Amelie K.
Hesterlee, Sharon E.
Howells, David W.
Huguenard, John
Kelner, Katrina
Koroshetz, Walter
Krainc, Dimitri
Lazic, Stanley E.
Levine, Michael S.
Macleod, Malcolm R.
McCall, John M.
Moxley, Richard T., III
Narasimhan, Kalyani
Noble, Linda J.
Perrin, Steve
Porter, John D.
Steward, Oswald
Unger, Ellis
Utz, Ursula
Silberberg, Shai D.
TI A call for transparent reporting to optimize the predictive value of
preclinical research
SO NATURE
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIALS; CONTROLLED CLINICAL-TRIALS; EXPERIMENTAL
STROKE; EMPIRICAL-EVIDENCE; STATISTICAL-ANALYSIS; CONSORT STATEMENT;
PUBLICATION BIAS; DRUG DEVELOPMENT; ANIMAL RESEARCH; CANCER-RESEARCH
AB The US National Institute of Neurological Disorders and Stroke convened major stakeholders in June 2012 to discuss how to improve the methodological reporting of animal studies in grant applications and publications. The main workshop recommendation is that at a minimum studies should report on sample-size estimation, whether and how animals were randomized, whether investigators were blind to the treatment, and the handling of data. We recognize that achieving a meaningful improvement in the quality of reporting will require a concerted effort by investigators, reviewers, funding agencies and journal editors. Requiring better reporting of animal studies will raise awareness of the importance of rigorous study design to accelerate scientific progress.
C1 [Landis, Story C.; Finkelstein, Robert; Gubitz, Amelie K.; Koroshetz, Walter; Porter, John D.; Utz, Ursula; Silberberg, Shai D.] Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.
[Amara, Susan G.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA 15213 USA.
[Asadullah, Khusru] Bayer HealthCare, D-13342 Berlin, Germany.
[Austin, Chris P.] NIH, Natl Ctr Adv Translat Sci, Rockville, MD 20854 USA.
[Blumenstein, Robi] CHDI Management CHDI Fdn, New York, NY 10001 USA.
[Bradley, Eileen W.] NIH, Ctr Review, Bethesda, MD 20892 USA.
[Crystal, Ronald G.] Weill Cornell Med Coll, Dept Genet Med, New York, NY 10021 USA.
[Darnell, Robert B.] Rockefeller Univ, Howard Hughes Med Inst, New York, NY 10065 USA.
[Ferrante, Robert J.] Univ Pittsburgh, Dept Neurol Surg, Pittsburgh, PA 15213 USA.
[Fillit, Howard] Alzheimers Drug Discovery Fdn, New York, NY 10019 USA.
[Fisher, Marc] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01545 USA.
[Gendelman, Howard E.] Univ Nebraska Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA.
[Golub, Robert M.] JAMA, Chicago, IL 60654 USA.
[Goudreau, John L.] Michigan State Univ, Dept Neurol, E Lansing, MI 48824 USA.
[Gross, Robert A.] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Hesterlee, Sharon E.] Parent Project Muscular Dystrophy, Hackensack, NJ 07601 USA.
[Howells, David W.] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Heidelberg, Vic 3081, Australia.
[Huguenard, John] Stanford Univ, Stanford, CA 94305 USA.
[Kelner, Katrina] AAAS, Washington, DC USA.
[Krainc, Dimitri] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Lazic, Stanley E.] F Hoffmann La Roche & Co Ltd, CH-4070 Basel, Switzerland.
[Levine, Michael S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Macleod, Malcolm R.] Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Edinburgh EH4 2XU, Midlothian, Scotland.
[Moxley, Richard T., III] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14642 USA.
[McCall, John M.] PharMac LLC, Boca Grande, FL 33921 USA.
[Narasimhan, Kalyani] Nat Neurosci, New York, NY 10013 USA.
[Noble, Linda J.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA.
[Perrin, Steve] ALS Therapy Dev Inst, Cambridge, MA 02139 USA.
[Steward, Oswald] Univ Calif Irvine, Reeve Irvine Res Ctr, Irvine, CA 92697 USA.
[Unger, Ellis] US FDA, Off New Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA.
RP Silberberg, SD (reprint author), Natl Inst Neurol Disorders & Stroke, NIH, Bethesda, MD 20892 USA.
EM silberbs@ninds.nih.gov
RI Lazic, Stanley/F-1160-2011; Huguenard, John/I-5016-2012; Darnell,
Robert/B-9022-2008;
OI Huguenard, John/0000-0002-6950-1191; Darnell,
Robert/0000-0002-5134-8088; Steward, Oswald/0000-0001-7069-8756;
Macleod, Malcolm Robert/0000-0001-9187-9839
FU NINDS
FX Funded by NINDS.
NR 64
TC 380
Z9 386
U1 8
U2 91
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 11
PY 2012
VL 490
IS 7419
BP 187
EP 191
DI 10.1038/nature11556
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 019IY
UT WOS:000309733300036
PM 23060188
ER
PT J
AU Yang, J
Loos, RJF
Powell, JE
Medland, SE
Speliotes, EK
Chasman, DI
Rose, LM
Thorleifsson, G
Steinthorsdottir, V
Maegi, R
Waite, L
Smith, AV
Yerges-Armstrong, LM
Monda, KL
Hadley, D
Mahajan, A
Li, G
Kapur, K
Vitart, V
Huffman, JE
Wang, SR
Palmer, C
Esko, T
Fischer, K
Zhao, JH
Demirkan, A
Isaacs, A
Feitosa, MF
Luan, J
Heard-Costa, NL
White, C
Jackson, AU
Preuss, M
Ziegler, A
Eriksson, J
Kutalik, Z
Frau, F
Nolte, IM
Van Vliet-Ostaptchouk, JV
Hottenga, JJ
Jacobs, KB
Verweij, N
Goel, A
Medina-Gomez, C
Estrada, K
Bragg-Gresham, JL
Sanna, S
Sidore, C
Tyrer, J
Teumer, A
Prokopenko, I
Mangino, M
Lindgren, CM
Assimes, TL
Shuldiner, AR
Hui, J
Beilby, JP
McArdle, WL
Hall, P
Haritunians, T
Zgaga, L
Kolcic, I
Polasek, O
Zemunik, T
Oostra, BA
Junttila, MJ
Groenberg, H
Schreiber, S
Peters, A
Hicks, AA
Stephens, J
Foad, NS
Laitinen, J
Pouta, A
Kaakinen, M
Willemsen, G
Vink, JM
Wild, SH
Navis, G
Asselbergs, FW
Homuth, G
John, U
Iribarren, C
Harris, T
Launer, L
Gudnason, V
O'Connell, JR
Boerwinkle, E
Cadby, G
Palmer, LJ
James, AL
Musk, AW
Ingelsson, E
Psaty, BM
Beckmann, JS
Waeber, G
Vollenweider, P
Hayward, C
Wright, AF
Rudan, I
Groop, LC
Metspalu, A
Khaw, KT
van Duijn, CM
Borecki, IB
Province, MA
Wareham, NJ
Tardif, JC
Huikuri, HV
Cupples, LA
Atwood, LD
Fox, CS
Boehnke, M
Collins, FS
Mohlke, KL
Erdmann, J
Schunkert, H
Hengstenberg, C
Stark, K
Lorentzon, M
Ohlsson, C
Cusi, D
Staessen, JA
Van der Klauw, MM
Pramstaller, PP
Kathiresan, S
Jolley, JD
Ripatti, S
Jarvelin, MR
de Geus, EJC
Boomsma, DI
Penninx, B
Wilson, JF
Campbell, H
Chanock, SJ
van der Harst, P
Hamsten, A
Watkins, H
Hofman, A
Witteman, JC
Zillikens, MC
Uitterlinden, AG
Rivadeneira, F
Zillikens, MC
Kiemeney, LA
Vermeulen, SH
Abecasis, GR
Schlessinger, D
Schipf, S
Stumvoll, M
Toenjes, A
Spector, TD
North, KE
Lettre, G
McCarthy, MI
Berndt, SI
Heath, AC
Madden, PAF
Nyholt, DR
Montgomery, GW
Martin, NG
McKnight, B
Strachan, DP
Hill, WG
Snieder, H
Ridker, PM
Thorsteinsdottir, U
Stefansson, K
Frayling, TM
Hirschhorn, JN
Goddard, ME
Visscher, PM
AF Yang, Jian
Loos, Ruth J. F.
Powell, Joseph E.
Medland, Sarah E.
Speliotes, Elizabeth K.
Chasman, Daniel I.
Rose, Lynda M.
Thorleifsson, Gudmar
Steinthorsdottir, Valgerdur
Maegi, Reedik
Waite, Lindsay
Smith, Albert Vernon
Yerges-Armstrong, Laura M.
Monda, Keri L.
Hadley, David
Mahajan, Anubha
Li, Guo
Kapur, Karen
Vitart, Veronique
Huffman, Jennifer E.
Wang, Sophie R.
Palmer, Cameron
Esko, Toenu
Fischer, Krista
Zhao, Jing Hua
Demirkan, Ayse
Isaacs, Aaron
Feitosa, Mary F.
Luan, Jian'an
Heard-Costa, Nancy L.
White, Charles
Jackson, Anne U.
Preuss, Michael
Ziegler, Andreas
Eriksson, Joel
Kutalik, Zoltan
Frau, Francesca
Nolte, Ilja M.
Van Vliet-Ostaptchouk, Jana V.
Hottenga, Jouke-Jan
Jacobs, Kevin B.
Verweij, Niek
Goel, Anuj
Medina-Gomez, Carolina
Estrada, Karol
Bragg-Gresham, Jennifer Lynn
Sanna, Serena
Sidore, Carlo
Tyrer, Jonathan
Teumer, Alexander
Prokopenko, Inga
Mangino, Massimo
Lindgren, Cecilia M.
Assimes, Themistocles L.
Shuldiner, Alan R.
Hui, Jennie
Beilby, John P.
McArdle, Wendy L.
Hall, Per
Haritunians, Talin
Zgaga, Lina
Kolcic, Ivana
Polasek, Ozren
Zemunik, Tatijana
Oostra, Ben A.
Junttila, M. Juhani
Groenberg, Henrik
Schreiber, Stefan
Peters, Annette
Hicks, Andrew A.
Stephens, Jonathan
Foad, Nicola S.
Laitinen, Jaana
Pouta, Anneli
Kaakinen, Marika
Willemsen, Gonneke
Vink, Jacqueline M.
Wild, Sarah H.
Navis, Gerjan
Asselbergs, Folkert W.
Homuth, Georg
John, Ulrich
Iribarren, Carlos
Harris, Tamara
Launer, Lenore
Gudnason, Vilmundur
O'Connell, Jeffrey R.
Boerwinkle, Eric
Cadby, Gemma
Palmer, Lyle J.
James, Alan L.
Musk, Arthur W.
Ingelsson, Erik
Psaty, Bruce M.
Beckmann, Jacques S.
Waeber, Gerard
Vollenweider, Peter
Hayward, Caroline
Wright, Alan F.
Rudan, Igor
Groop, Leif C.
Metspalu, Andres
Khaw, Kay Tee
van Duijn, Cornelia M.
Borecki, Ingrid B.
Province, Michael A.
Wareham, Nicholas J.
Tardif, Jean-Claude
Huikuri, Heikki V.
Cupples, L. Adrienne
Atwood, Larry D.
Fox, Caroline S.
Boehnke, Michael
Collins, Francis S.
Mohlke, Karen L.
Erdmann, Jeanette
Schunkert, Heribert
Hengstenberg, Christian
Stark, Klaus
Lorentzon, Mattias
Ohlsson, Claes
Cusi, Daniele
Staessen, Jan A.
Van der Klauw, Melanie M.
Pramstaller, Peter P.
Kathiresan, Sekar
Jolley, Jennifer D.
Ripatti, Samuli
Jarvelin, Marjo-Riitta
de Geus, Eco J. C.
Boomsma, Dorret I.
Penninx, Brenda
Wilson, James F.
Campbell, Harry
Chanock, Stephen J.
van der Harst, Pim
Hamsten, Anders
Watkins, Hugh
Hofman, Albert
Witteman, Jacqueline C.
Zillikens, M. Carola
Uitterlinden, Andre G.
Rivadeneira, Fernando
Zillikens, M. Carola
Kiemeney, Lambertus A.
Vermeulen, Sita H.
Abecasis, Goncalo R.
Schlessinger, David
Schipf, Sabine
Stumvoll, Michael
Toenjes, Anke
Spector, Tim D.
North, Kari E.
Lettre, Guillaume
McCarthy, Mark I.
Berndt, Sonja I.
Heath, Andrew C.
Madden, Pamela A. F.
Nyholt, Dale R.
Montgomery, Grant W.
Martin, Nicholas G.
McKnight, Barbara
Strachan, David P.
Hill, William G.
Snieder, Harold
Ridker, Paul M.
Thorsteinsdottir, Unnur
Stefansson, Kari
Frayling, Timothy M.
Hirschhorn, Joel N.
Goddard, Michael E.
Visscher, Peter M.
TI FTO genotype is associated with phenotypic variability of body mass
index
SO NATURE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; ENVIRONMENTAL SENSITIVITY; PHYSICAL-ACTIVITY;
GENETIC-VARIATION; ADULT OBESITY; LOCI; VARIANTS; CHILDHOOD; SELECTION;
TRAITS
AB There is evidence across several species for genetic control of phenotypic variation of complex traits(1-4), such that the variance among phenotypes is genotype dependent. Understanding genetic control of variability is important in evolutionary biology, agricultural selection programmes and human medicine, yet for complex traits, no individual genetic variants associated with variance, as opposed to the mean, have been identified. Here we perform a meta-analysis of genome-wide association studies of phenotypic variation using similar to 170,000 samples on height and body mass index (BMI) in human populations. We report evidence that the single nucleotide polymorphism (SNP) rs7202116 at the FTO gene locus, which is known to be associated with obesity (as measured by mean BMI for each rs7202116 genotype)(5-7), is also associated with phenotypic variability. We show that the results are not due to scale effects or other artefacts, and find no other experiment-wise significant evidence for effects on variability, either at loci other than FTO for BMI or at any locus for height. The difference in variance for BMI among individuals with opposite homozygous genotypes at the FTO locus is approximately 7%, corresponding to a difference of similar to 0.5 kilograms in the standard deviation of weight. Our results indicate that genetic variants can be discovered that are associated with variability, and that between-person variability in obesity can partly be explained by the genotype at the FTO locus. The results are consistent with reported FTO by environment interactions for BMI8, possibly mediated by DNA methylation(9,10). Our BMI results for other SNPs and our height results for all SNPs suggest that most genetic variants, including those that influence mean height or mean BMI, are not associated with phenotypic variance, or that their effects on variability are too small to detect even with samples sizes greater than 100,000.
C1 [Yang, Jian; Powell, Joseph E.] Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
[Yang, Jian; Powell, Joseph E.; Medland, Sarah E.; Nyholt, Dale R.; Montgomery, Grant W.; Martin, Nicholas G.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Loos, Ruth J. F.; Zhao, Jing Hua; Luan, Jian'an; Wareham, Nicholas J.] Inst Metab Sci, MRC Epidemiol Unit, Cambridge CB2 0QQ, England.
[Loos, Ruth J. F.] Mt Sinai Sch Med, New York, NY 10029 USA.
[Speliotes, Elizabeth K.] Univ Michigan, Dept Internal Med, Div Gastroenterol, Ann Arbor, MI 48109 USA.
[Speliotes, Elizabeth K.] Univ Michigan, Ctr Computat Med & Bioinformat, Ann Arbor, MI 48109 USA.
[Chasman, Daniel I.; Rose, Lynda M.; Ridker, Paul M.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02215 USA.
[Chasman, Daniel I.] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Thorleifsson, Gudmar; Steinthorsdottir, Valgerdur] deCODE Genet, IS-101 Reykjavik, Iceland.
[Maegi, Reedik; Esko, Toenu; Fischer, Krista; Metspalu, Andres] Univ Tartu, Estonian Genome Ctr, EE-50410 Tartu, Estonia.
[Maegi, Reedik; Mahajan, Anubha; Lindgren, Cecilia M.; Watkins, Hugh] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
[Waite, Lindsay; Frayling, Timothy M.] Hudson Alpha Inst Biotechnol, Huntsville, AL 35806 USA.
[Smith, Albert Vernon; Gudnason, Vilmundur] Iceland Heart Assoc, IS-201 Kopavogur, Iceland.
[Smith, Albert Vernon] Univ Iceland, IS-101 Reykjavik, Iceland.
[Yerges-Armstrong, Laura M.; O'Connell, Jeffrey R.] Univ Maryland, Dept Med, Sch Med, Baltimore, MD 21201 USA.
[Monda, Keri L.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27514 USA.
[Hadley, David; Strachan, David P.] Univ London, Div Populat Hlth Sci & Educ, London SW17 0RE, England.
[Li, Guo] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.
[Kapur, Karen; Kutalik, Zoltan; Jacobs, Kevin B.] Univ Lausanne, Dept Med Genet, CH-1005 Lausanne, Switzerland.
[Kapur, Karen; Kutalik, Zoltan; Jacobs, Kevin B.] Swiss Inst Bioinformat, CH-1005 Lausanne, Switzerland.
[Vitart, Veronique; Huffman, Jennifer E.; Hayward, Caroline; Wright, Alan F.] Univ Edinburgh, MRC HGU, MRC IGMM, Edinburgh EH8 9AG, Midlothian, Scotland.
[Wang, Sophie R.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Wang, Sophie R.; Palmer, Cameron] Childrens Hosp, Div Genet, Boston, MA 02115 USA.
[Wang, Sophie R.; Palmer, Cameron] Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Wang, Sophie R.; Palmer, Cameron] Childrens Hosp, Program Genom, Boston, MA 02115 USA.
[Wang, Sophie R.; Palmer, Cameron; Hirschhorn, Joel N.] Broad Inst, Metab Initiat, Cambridge, MA 02142 USA.
[Wang, Sophie R.; Palmer, Cameron; Hirschhorn, Joel N.] Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Demirkan, Ayse; Isaacs, Aaron; Oostra, Ben A.; van Duijn, Cornelia M.] Erasmus MC, Dept Epidemiol, Subdiv Genet Epidemiol, Rotterdam, Netherlands.
[Feitosa, Mary F.] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA.
[Jackson, Anne U.; Boehnke, Michael] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
[Preuss, Michael] Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany.
[Preuss, Michael; Ziegler, Andreas; Van Vliet-Ostaptchouk, Jana V.] Med Univ Lubeck, Inst Med Biometrie & Stat, D-23562 Lubeck, Germany.
[Eriksson, Joel; Hottenga, Jouke-Jan; Lorentzon, Mattias; Ohlsson, Claes] Univ Gothenburg, Ctr Bone & Arthrit Res, Inst Med, Sahlgrenska Acad, S-41345 Gothenburg, Sweden.
[Frau, Francesca; Verweij, Niek; Cusi, Daniele] Univ Milan, Dept Hlth Sci, I-20133 Milan, Italy.
[Nolte, Ilja M.; Goel, Anuj; Snieder, Harold] Univ Groningen, Unit Genet Epidemiol & Bioinformat, Dept Epidemiol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
[Medina-Gomez, Carolina; Van der Klauw, Melanie M.] Univ Groningen, Dept Endocrinol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
[Medina-Gomez, Carolina] Univ Groningen, LifeLines Cohort Study, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
[Estrada, Karol; Kaakinen, Marika; Willemsen, Gonneke; Vink, Jacqueline M.; de Geus, Eco J. C.; Boomsma, Dorret I.] Vrije Univ Amsterdam, Dept Biol Psychol, NL-1081 BT Amsterdam, Netherlands.
[Bragg-Gresham, Jennifer Lynn] SAIC Frederick Inc, Core Genotyping Facil, NCI Frederick, Frederick, MD 21702 USA.
[van der Harst, Pim] Univ Groningen, Dept Cardiol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
[Zillikens, M. Carola] Erasmus MC, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands.
[Hofman, Albert; Uitterlinden, Andre G.] Erasmus MC, Dept Epidemiol, NL-3015 GE Rotterdam, Netherlands.
[Witteman, Jacqueline C.; Rivadeneira, Fernando] Netherlands Consortiumfor Healthy Aging, Netherlands Genom Initiat, NL-2300 RC Leiden, Netherlands.
[Sanna, Serena; Abecasis, Goncalo R.] Univ Michigan, Biostat Ctr Stat Genet, Ann Arbor, MI 48109 USA.
[Sidore, Carlo] CNR, Ist Ric Genet & Biomed, I-09042 Monserrato, Italy.
[Sidore, Carlo] Univ Sassari, Dipartimento Sci Biomed, I-07100 Sassari, Italy.
[Tyrer, Jonathan] Univ Cambridge, Dept Oncol, Cambridge CB1 8RN, England.
[Teumer, Alexander; Homuth, Georg] Univ Med Greifswald, Interfac Inst Genet & Funct Genom, D-17487 Greifswald, Germany.
[Prokopenko, Inga] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7BN, England.
[Mangino, Massimo; Toenjes, Anke] Kings Coll London, Dept Twin Res & Genet Epidemiol, London SE1 7EH, England.
[Assimes, Themistocles L.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
[Shuldiner, Alan R.] Vet Adm Med Ctr, Geriatr Res & Educ Clin Ctr, Baltimore, MD 21201 USA.
[Hui, Jennie; Beilby, John P.] Univ Western Australia, PathWest Lab Med WA, Nedlands, WA 6009, Australia.
[Hui, Jennie] Univ Western Australia, Sch Populat Hlth, Nedlands, WA 6009, Australia.
[McArdle, Wendy L.] Univ Bristol, Sch Social & Community Med, Bristol BS8 2BN, Avon, England.
[Hall, Per; Groenberg, Henrik; Ingelsson, Erik] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden.
[Haritunians, Talin] Cedars Sinai Med Ctr, Med Genet Inst, Los Angeles, CA 90048 USA.
[Zgaga, Lina; Wild, Sarah H.; Rudan, Igor; Wilson, James F.; Campbell, Harry] Univ Edinburgh, Ctr Populat Hlth Sci, Sch Med, Edinburgh EH16 4TJ, Midlothian, Scotland.
[Zgaga, Lina] Univ Zagreb, Sch Med, Andrija Stampar Sch Publ Hlth, Zagreb 41001, Croatia.
[Kolcic, Ivana; Polasek, Ozren; Zemunik, Tatijana] Univ Split, Fac Med, Split 21000, Croatia.
[Junttila, M. Juhani; Huikuri, Heikki V.] Univ Oulu, Dept Internal Med, Inst Clin Med, Oulu 90014, Finland.
[Peters, Annette] Univ Kiel, Inst Klin Mol Biol, D-24098 Kiel, Germany.
[Peters, Annette] Munich Heart Alliance, D-80802 Munich, Germany.
[Hicks, Andrew A.] European Acad Bozen Bolzano EURAC, Ctr Biomed, I-39100 Bolzano, Italy.
[Stephens, Jonathan] Univ Cambridge, Dept Haematol, Cambridge CB2 0PT, England.
[Stephens, Jonathan; Jolley, Jennifer D.] NHS Blood & Transplant, Cambridge CB2 0PT, England.
[Foad, Nicola S.] Finnish Inst Occupat Hlth, Oulu 90220, Finland.
[Laitinen, Jaana] Natl Inst Hlth & Welf, Oulu 90101, Finland.
[Laitinen, Jaana] Univ Oulu, Dept Clin Sci Obstet & Gynecol, Oulu 90014, Finland.
[Pouta, Anneli] Univ Oulu, Inst Hlth Sci, Bioctr, Oulu 90014, Finland.
[Navis, Gerjan] Univ Groningen, Dept Internal Med, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands.
[Asselbergs, Folkert W.] Univ Med Ctr Utrecht, Dept Cardiol, Div Heart & Lungs, NL-3508 GA Utrecht, Netherlands.
[John, Ulrich] Univ Med Greifswald, Inst Epidemiol & Social Med, D-17475 Greifswald, Germany.
[Iribarren, Carlos] Kaiser Permanente No Calif, Div Res, Oakland, CA 94612 USA.
[Harris, Tamara; Launer, Lenore] NIA, NIH, Bethesda, MD 20892 USA.
[Boerwinkle, Eric] Univ Texas Houston, Hlth Sci Ctr, Houston, TX 77030 USA.
[Cadby, Gemma; Palmer, Lyle J.] Ontario Inst Canc Res, Toronto, ON M5G 1L7, Canada.
[James, Alan L.; Musk, Arthur W.] Univ Western Australia, Sir Charles Gairdner Hosp, Nedlands, WA 6009, Australia.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Beckmann, Jacques S.] CHUV Univ Hosp, Serv Med Genet, CH-1011 Lausanne, Switzerland.
[Waeber, Gerard; Vollenweider, Peter] Univ Lausanne Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland.
[Groop, Leif C.] Lund Univ, Ctr Diabet, Dept Clin Sci, S-20502 Malmo, Sweden.
[Khaw, Kay Tee] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge CB1 8RN, England.
[Borecki, Ingrid B.; Province, Michael A.] Washington Univ, Sch Med, Div Biostat, St Louis, MO 63110 USA.
[Tardif, Jean-Claude] Univ Montreal, Dept Med, Montreal, PQ H4J 1C5, Canada.
[Tardif, Jean-Claude; Lettre, Guillaume] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Fox, Caroline S.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Fox, Caroline S.] Boston Univ, Framingham, MA 01702 USA.
[Collins, Francis S.] NHGRI, NIH, Bethesda, MD 20892 USA.
[Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Erdmann, Jeanette; Schunkert, Heribert] Med Univ Lubeck, Deutsch Zentrum Herz Kreislauf Forsch DZHK, D-23562 Lubeck, Germany.
[Hengstenberg, Christian; Stark, Klaus] Klin & Poliklin Innere Med II, D-93053 Regensburg, Germany.
[Staessen, Jan A.] Katholieke Univ Leuven, Dept Cardiovasc Dis, B-3000 Louvain, Belgium.
[Cupples, L. Adrienne; Staessen, Jan A.] Maastricht Univ, Dept Epidemiol, NL-6200 MD Maastricht, Netherlands.
[Pramstaller, Peter P.] European Acad Bozen Bolzano EURAC, Ctr Biomed, I-39100 Bolzano, Italy.
[Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, I-39100 Bolzano, Italy.
[Pramstaller, Peter P.] Med Univ Lubeck, Dept Neurol, D-23562 Lubeck, Germany.
[Kathiresan, Sekar] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Kathiresan, Sekar] MIT, Cambridge, MA 02142 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Kathiresan, Sekar] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Kathiresan, Sekar] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Ripatti, Samuli] Univ Helsinki, Inst Mol Med Finland, FIMM, FIN-00014 Helsinki, Finland.
[Ripatti, Samuli] Natl Inst Hlth & Welf, Publ Hlth Genom Unit, Helsinki 00271, Finland.
[Ripatti, Samuli] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England.
[Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London W2 1PG, England.
[Penninx, Brenda] Univ Groningen, Dept Psychiat, Univ Med Ctr Groningen, NL-9713 GZ Groningen, Netherlands.
[Chanock, Stephen J.; Berndt, Sonja I.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20852 USA.
[Hamsten, Anders] Karolinska Inst, S-17177 Stockholm, Sweden.
[Hamsten, Anders] Dept Med, Atherosclerosis Res Unit, S-17176 Stockholm, Sweden.
[Kiemeney, Lambertus A.; Vermeulen, Sita H.] Radboud Univ Nijmegen, Med Ctr, NL-6500 HB Nijmegen, Netherlands.
[Schlessinger, David] NIA, NIH, Bethesda, MD 20892 USA.
[Schipf, Sabine] Univ Med Greifswald, Inst Community Med, D-17475 Greifswald, Germany.
[Stumvoll, Michael] Univ Leipzig, Dept Med, D-04103 Leipzig, Germany.
[Stumvoll, Michael] Univ Leipzig, IFB Adipos Dis, D-04103 Leipzig, Germany.
[Spector, Tim D.; North, Kari E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27514 USA.
[Spector, Tim D.; North, Kari E.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC 27514 USA.
[McCarthy, Mark I.] Churchill Hosp, Oxford Natl Inst Hlth Res, Biomed Res Ctr, Oxford OX3 7LJ, England.
[Heath, Andrew C.; Madden, Pamela A. F.] Washington Univ, Dept Psychiat, St Louis, MO 63110 USA.
[McKnight, Barbara] Washington Univ, Dept Biostat, St Louis, MO 63110 USA.
[Hill, William G.] Univ Edinburgh, Inst Evolutionary Biol, Edinburgh EH9 3JT, Midlothian, Scotland.
[Thorsteinsdottir, Unnur; Stefansson, Kari] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
[Frayling, Timothy M.] Univ Exeter, Inst Biomed & Clin Sci, Peninsula Med Sch, Exeter EX1 2LU, Devon, England.
[Goddard, Michael E.] Univ Melbourne, Dept Food & Agr Syst, Melbourne, Vic 3010, Australia.
[Goddard, Michael E.] Dept Primary Ind, Biosci Res Div, Bundoora, Vic 3083, Australia.
[Visscher, Peter M.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia.
RP Yang, J (reprint author), Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
RI Nyholt, Dale/C-8384-2013; Powell, Joseph/G-3027-2014; Pramstaller,
Peter/C-2357-2008; Beckmann, Jacques S /A-9772-2008; Palmer,
Lyle/K-3196-2014; Medland, Sarah/C-7630-2013; Gudnason,
Vilmundur/K-6885-2015; Abecasis, Goncalo/B-7840-2010; Colaus,
PsyColaus/K-6607-2013; van der Klauw, Melanie/A-2138-2014; Kiemeney,
Lambertus/D-3357-2009; Schreiber, Stefan/B-6748-2008; Staessen,
Jan/A-1065-2011; Ripatti, Samuli/H-9446-2014; Wilson, James
F/A-5704-2009; Polasek, Ozren/B-6002-2011; de Geus, Eco/M-9318-2015;
Montgomery, Grant/B-7148-2008; Prokopenko, Inga/H-3241-2014; Peters,
Annette/A-6117-2011; Vermeulen, H.H.M./L-4716-2015; Rudan,
Igor/I-1467-2012; Smith, Albert/K-5150-2015; Yang, Jian/A-5852-2010;
mangino, massimo/F-5134-2011; Hayward, Caroline/M-8818-2016; Erdmann,
Jeanette/P-7513-2014; Verweij, Niek/A-4499-2017; Kolcic,
Ivana/E-2713-2017; Feitosa, Mary/K-8044-2012; Hicks, Andrew/E-9518-2017;
OI Powell, Joseph/0000-0001-9031-6356; Beckmann, Jacques S
/0000-0002-9741-1900; Palmer, Lyle/0000-0002-1628-3055; Medland,
Sarah/0000-0003-1382-380X; Gudnason, Vilmundur/0000-0001-5696-0084; van
der Klauw, Melanie/0000-0001-7178-009X; Kiemeney,
Lambertus/0000-0002-2368-1326; Schreiber, Stefan/0000-0003-2254-7771;
Staessen, Jan/0000-0002-3026-1637; Ripatti, Samuli/0000-0002-0504-1202;
Wilson, James F/0000-0001-5751-9178; Polasek, Ozren/0000-0002-5765-1862;
de Geus, Eco/0000-0001-6022-2666; Montgomery, Grant/0000-0002-4140-8139;
Prokopenko, Inga/0000-0003-1624-7457; Rudan, Igor/0000-0001-6993-6884;
Smith, Albert/0000-0003-1942-5845; Yang, Jian/0000-0003-2001-2474;
mangino, massimo/0000-0002-2167-7470; Hayward,
Caroline/0000-0002-9405-9550; Esko, Tonu/0000-0003-1982-6569; Sidore,
Carlo/0000-0001-7504-7477; Goddard, Michael/0000-0001-9917-7946; sanna,
serena/0000-0002-3768-1749; Abecasis, Goncalo/0000-0003-1509-1825;
Erdmann, Jeanette/0000-0002-4486-6231; Kolcic,
Ivana/0000-0001-7918-6052; Feitosa, Mary/0000-0002-0933-2410; Hicks,
Andrew/0000-0001-6320-0411; Wang, Sophie Ran/0000-0002-7897-8389;
Heard-Costa, Nancy/0000-0001-9730-0306; Kaakinen,
Marika/0000-0002-9228-0462; Cupples, L. Adrienne/0000-0003-0273-7965;
Magi, Reedik/0000-0002-2964-6011; Zgaga, Lina/0000-0003-4089-9703; van
Vliet-Ostaptchouk, Jana/0000-0002-7943-3153; Ziegler,
Andreas/0000-0002-8386-5397; Rivadeneira, Fernando/0000-0001-9435-9441;
Verweij, Niek/0000-0002-4303-7685; Jarvelin,
Marjo-Riitta/0000-0002-2149-0630; John, Ulrich/0000-0003-0587-5298;
Watkins, Hugh/0000-0002-5287-9016; Medina-Gomez,
Carolina/0000-0001-7999-5538; Visscher, Peter/0000-0002-2143-8760;
Martin, Nicholas/0000-0003-4069-8020
FU Australian National Health and Medical Research Council (NHMRC) [241944,
389875, 389891, 389892, 389938, 442915, 442981, 496739, 496688, 552485,
613672, 613601, 1011506]; US National Institutes of Health [AA07535,
AA10248, AA014041, AA13320, AA13321, AA13326, DA12854, GM057091];
Australian Research Council (ARC) [DP1093502]
FX We acknowledge funding from the Australian National Health and Medical
Research Council (NHMRC grants 241944, 389875, 389891, 389892, 389938,
442915, 442981, 496739, 496688, 552485, 613672, 613601 and 1011506), the
US National Institutes of Health (grants AA07535, AA10248, AA014041,
AA13320, AA13321, AA13326, DA12854 and GM057091) and the Australian
Research Council (ARC grant DP1093502). A detailed list of
acknowledgements by study is provided in the Supplementary Information.
We apologize to authors whose work we could not cite owing to space
restrictions.
NR 36
TC 121
Z9 130
U1 6
U2 106
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 11
PY 2012
VL 490
IS 7419
BP 267
EP +
DI 10.1038/nature11401
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 019IY
UT WOS:000309733300051
PM 22982992
ER
PT J
AU Murooka, TT
Deruaz, M
Marangoni, F
Vrbanac, VD
Seung, E
von Andrian, UH
Tager, AM
Luster, AD
Mempel, TR
AF Murooka, Thomas T.
Deruaz, Maud
Marangoni, Francesco
Vrbanac, Vladimir D.
Seung, Edward
von Andrian, Ulrich H.
Tager, Andrew M.
Luster, Andrew D.
Mempel, Thorsten R.
TI HIV-infected T cells are migratory vehicles for viral dissemination
SO NATURE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; HUMANIZED BLT MICE; LYMPH-NODES;
VIROLOGICAL SYNAPSES; SEXUAL TRANSMISSION; IMMUNE-RESPONSES;
DOWN-MODULATION; ENVELOPE; NEF; RECEPTOR
AB After host entry through mucosal surfaces, human immunodeficiency virus-1 (HIV-1) disseminates to lymphoid tissues to establish a generalized infection of the immune system. The mechanisms by which this virus spreads among permissive target cells locally during the early stages of transmission and systemically during subsequent dissemination are not known(1). In vitro studies suggest that the formation of virological synapses during stable contacts between infected and uninfected T cells greatly increases the efficiency of viral transfer(2). It is unclear, however, whether T-cell contacts are sufficiently stable in vivo to allow for functional synapse formation under the conditions of perpetual cell motility in epithelial(3) and lymphoid tissues(4). Here, using multiphoton intravital microscopy, we examine the dynamic behaviour of HIV-infected T cells in the lymph nodes of humanized mice. We find that most productively infected T cells migrate robustly, resulting in their even distribution throughout the lymph node cortex. A subset of infected cells formed multinucleated syncytia through HIV envelope-dependent cell fusion. Both uncoordinated motility of syncytia and adhesion to CD4(+) lymph node cells led to the formation of long membrane tethers, increasing cell lengths to up to ten times that of migrating uninfected T cells. Blocking the egress of migratory T cells from the lymph nodes into efferent lymph vessels, and thus interrupting T-cell recirculation, limited HIV dissemination and strongly reduced plasma viraemia. Thus, we have found that HIV-infected T cells are motile, form syncytia and establish tethering interactions that may facilitate cell-to-cell transmission through virological synapses. Migration of T cells in lymph nodes therefore spreads infection locally, whereas their recirculation through tissues is important for efficient systemic viral spread, suggesting new molecular targets to antagonize HIV infection.
C1 [Murooka, Thomas T.; Deruaz, Maud; Marangoni, Francesco; Vrbanac, Vladimir D.; Seung, Edward; Tager, Andrew M.; Luster, Andrew D.; Mempel, Thorsten R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
[von Andrian, Ulrich H.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
[von Andrian, Ulrich H.] Harvard Univ, Sch Med, Dept Microbiol & Immunol, Boston, MA 02115 USA.
RP Mempel, TR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis, Boston, MA 02114 USA.
EM tmempel@mgh.harvard.edu
RI von Andrian, Ulrich/A-5775-2008; Marangoni, Francesco/I-9087-2012
OI Marangoni, Francesco/0000-0002-2490-849X
FU National Institutes of Health (NIH) [P01 AI0178897, R56 AI097052, R01
CA150975, P30 AI060354]; Ragon Institute of Massachusetts General
Hospital (MGH); Massachusetts Institute of Technology (MIT); Harvard;
MGH ECOR Tosteson Postdoctoral Fellowship Award; NIH [T32 AI007387]
FX We thank J. Sodroski for the pSVIIIexE7 plasmid and A. Brown for HIV
SF162R3; H. S. Shin, T. Tivey, K. Bankert and S. Tanno for technical
assistance with the generation of humanized mice; A. Peixoto and D.
Alvarez for management of the BL2+ multiphoton microscopy
facility; A. Brass, T. Allen and T. Dudek for assistance with
virological techniques; and N. Elpek, M. Byrne and A. Finzi for
technical assistance. Funding for this study was through National
Institutes of Health (NIH) grants P01 AI0178897, R56 AI097052, R01
CA150975 and P30 AI060354, and a Platform Award from the Ragon Institute
of Massachusetts General Hospital (MGH), Massachusetts Institute of
Technology (MIT) and Harvard. T. T. M. was supported by the MGH ECOR
Tosteson Postdoctoral Fellowship Award and NIH training grant T32
AI007387.
NR 38
TC 127
Z9 128
U1 1
U2 37
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD OCT 11
PY 2012
VL 490
IS 7419
BP 283
EP +
DI 10.1038/nature11398
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 019IY
UT WOS:000309733300054
PM 22854780
ER
PT J
AU Lapenta, OM
Fregni, F
Oberman, LM
Boggio, PS
AF Lapenta, Olivia Morgan
Fregni, Felipe
Oberman, Lindsay M.
Boggio, Paulo Sergio
TI Bilateral temporal cortex transcranial direct current stimulation
worsens male performance in a multisensory integration task
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Multisensory integration; tDCS; Superior temporal sulcus; Gender;
Extreme male brain theory
ID DC STIMULATION; BRAIN; MODULATION; AUTISM
AB Somatosensory integration is a critical cognitive function for human social interaction. Though somatosensory integration has been highly explored in cognitive studies: only a few studies have explored focal modulation of cortical excitability using a speech perception paradigm. In the current study, we aimed to investigate the effects of tDCS applied over the temporal cortex of healthy subjects during a go-no-go task in which stimuli were shapes and non-words. Twenty-eight subjects were randomized to receive cathodal, anodal or sham tDCS bilaterally over the superior temporal cortex (the reference electrode was on deltoid) in a counterbalanced order. The effects on judgment of congruency between shapes and non-words in healthy volunteers were measured by a go-no-go task. Our findings show a significant modification of performance according to the polarity of stimulation, task and subject gender. We found that men performed worse on the no-go condition for congruent stimuli during cathodal tDCS. For reaction time, on the other hand, there was a similar effect for anodal and cathodal stimulation. There were significantly faster responses on incongruent trials during both anodal and cathodal tDCS. Along with previous literature showing gender differences in tasks associated with speech perception, the findings of this study provide additional evidence suggesting that men may have a more focal and restricted neural processing in this multisensory integration task. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Lapenta, Olivia Morgan; Boggio, Paulo Sergio] Univ Prebiteriana Mackenzie, Ctr Hlth & Biol Sci, Social & Cognit Neurosci Lab, BR-01241001 Sao Paulo, Brazil.
[Lapenta, Olivia Morgan; Boggio, Paulo Sergio] Univ Prebiteriana Mackenzie, Ctr Hlth & Biol Sci, Dev Disorders Program, BR-01241001 Sao Paulo, Brazil.
[Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Fregni, Felipe] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Lab Neuromodulat, Boston, MA USA.
[Fregni, Felipe; Oberman, Lindsay M.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Berenson Allen Ctr Noninvas Brain Stimulat, Boston, MA 02215 USA.
RP Boggio, PS (reprint author), Univ Prebiteriana Mackenzie, Ctr Hlth & Biol Sci, Social & Cognit Neurosci Lab, Rua Piaui 181,10 Andar, BR-01241001 Sao Paulo, Brazil.
EM boggio@mackenzie.br
RI Boggio, Paulo/K-6272-2012
OI Boggio, Paulo/0000-0002-6109-0447
FU CNPq [305718/2009-6]; Master grant (CAPES-PROSUP-IES modality I)
FX PSB is supported by a CNPq researcher grant (305718/2009-6). OML was
supported by a Master grant (CAPES-PROSUP-IES modality I).
NR 15
TC 11
Z9 11
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD OCT 11
PY 2012
VL 527
IS 2
BP 105
EP 109
DI 10.1016/j.neulet.2012.08.076
PG 5
WC Neurosciences
SC Neurosciences & Neurology
GA 024EP
UT WOS:000310091800008
PM 22985520
ER
PT J
AU Kauramaki, J
Jaaskelainen, IP
Hanninen, JL
Auranen, T
Nummenmaa, A
Lampinen, J
Sams, M
AF Kauramaki, Jaakko
Jaaskelainen, Iiro P.
Hanninen, Jarno L.
Auranen, Toni
Nummenmaa, Aapo
Lampinen, Jouko
Sams, Mikko
TI Two-Stage Processing of Sounds Explains Behavioral Performance
Variations due to Changes in Stimulus Contrast and Selective Attention:
An MEG Study
SO PLOS ONE
LA English
DT Article
ID HUMAN AUDITORY-CORTEX; SUSTAINED MAGNETIC-FIELDS; SURFACE-BASED
ANALYSIS; SHORT-TERM PLASTICITY; HIGH-RESOLUTION FMRI; RECEPTIVE-FIELDS;
CRITICAL-BAND; HUMAN-BRAIN; NEUROMAGNETIC RESPONSES; NORMALIZATION MODEL
AB Selectively attending to task-relevant sounds whilst ignoring background noise is one of the most amazing feats performed by the human brain. Here, we studied the underlying neural mechanisms by recording magnetoencephalographic (MEG) responses of 14 healthy human subjects while they performed a near-threshold auditory discrimination task vs. a visual control task of similar difficulty. The auditory stimuli consisted of notch-filtered continuous noise masker sounds, and of 1020-Hz target tones occasionally (p = 0.1) replacing 1000-Hz standard tones of 300-ms duration that were embedded at the center of the notches, the widths of which were parametrically varied. As a control for masker effects, tone-evoked responses were additionally recorded without masker sound. Selective attention to tones significantly increased the amplitude of the onset M100 response at similar to 100 ms to the standard tones during presence of the masker sounds especially with notches narrower than the critical band. Further, attention modulated sustained response most clearly at 300-400 ms time range from sound onset, with narrower notches than in case of the M100, thus selectively reducing the masker-induced suppression of the tone-evoked response. Our results show evidence of a multiple-stage filtering mechanism of sensory input in the human auditory cortex: 1) one at early (similar to 100 ms) latencies bilaterally in posterior parts of the secondary auditory areas, and 2) adaptive filtering of attended sounds from task-irrelevant background masker at longer latency (similar to 300 ms) in more medial auditory cortical regions, predominantly in the left hemisphere, enhancing processing of near-threshold sounds.
C1 [Kauramaki, Jaakko; Jaaskelainen, Iiro P.; Hanninen, Jarno L.; Lampinen, Jouko; Sams, Mikko] Aalto Univ, Sch Sci, Brain & Mind Lab, Dept Biomed Engn & Computat Sci BECS, Espoo, Finland.
[Auranen, Toni] Aalto Univ, Sch Sci, OV Lounasmaa Lab, Adv Magnet Imaging Ctr, Espoo, Finland.
[Auranen, Toni] Aalto Univ, Sch Sci, OV Lounasmaa Lab, Brain Res Unit, Espoo, Finland.
[Nummenmaa, Aapo] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Nummenmaa, Aapo] Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA.
RP Kauramaki, J (reprint author), Aalto Univ, Sch Sci, Brain & Mind Lab, Dept Biomed Engn & Computat Sci BECS, Espoo, Finland.
EM jaakko.kauramaki@aalto.fi
RI Jaaskelainen, Iiro/C-7392-2012; Sams, Mikko/G-7060-2012; Auranen,
Toni/J-7137-2012
OI Jaaskelainen, Iiro/0000-0001-6001-6950;
FU Finnish Graduate School of Neuroscience; Emil Aaltonen Foundation; Ella
and Georg Ehrnrooth Foundation; Academy of Finland [127624, 129670,
130412]
FX This study was financially supported by the Finnish Graduate School of
Neuroscience (JK), Emil Aaltonen Foundation (JK), Ella and Georg
Ehrnrooth Foundation (JK) and by the Academy of Finland, grant nos.
127624 (AN), 129670 (IPJ and MS), 130412 (IJ). No additional external
funding received for this study. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 73
TC 6
Z9 8
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2012
VL 7
IS 10
AR e46872
DI 10.1371/journal.pone.0046872
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 020KP
UT WOS:000309807700039
PM 23071654
ER
PT J
AU Qi, L
Zhang, XD
Wu, JC
Lin, F
Wang, J
DiFiglia, M
Qin, ZH
AF Qi, Lin
Zhang, Xing-Ding
Wu, Jun-Chao
Lin, Fang
Wang, Jin
DiFiglia, Marian
Qin, Zheng-Hong
TI The Role of Chaperone-Mediated Autophagy in Huntingtin Degradation
SO PLOS ONE
LA English
DT Article
ID RAT-LIVER LYSOSOMES; MUTANT HUNTINGTIN; CYTOSOLIC PROTEINS; PEPTIDE
SEQUENCES; SELECTIVE UPTAKE; ALPHA-SYNUCLEIN; CELL; DISEASE;
NEURODEGENERATION; MACROAUTOPHAGY
AB Huntington Disease (HD) is caused by an abnormal expansion of polyQ tract in the protein named huntingtin (Htt). HD pathology is featured by accumulation and aggregation of mutant Htt in striatal and cortical neurons. Aberrant Htt degradation is implicated in HD pathogenesis. The aim of this study was to investigate the regulatory role of chaperone-mediated autophagy (CMA) components, heat shock protein cognate 70 (Hsc70) and lysosome-associated protein 2A (LAMP-2A) in degradation of Htt fragment 1-552aa (Htt-552). A cell model of HD was produced by overexpression of Htt-552 with adenovirus. The involvement of CMA components in degradation of Htt-552 was determined with over-expression or silencing of Hsc70 and LAMP-2A. The results confirmed previous reports that both macroautophagy and CMA were involved in degradation of Htt-552. Changing the levels of CMA-related proteins affected the accumulation of Htt-552. The lysosomal binding and luminal transport of Htt-552 was demonstrated by incubation of Htt-552 with isolated lysosomes. Expansion of the polyQ tract in Htt-552 impaired its uptake and degradation by lysosomes. Mutation of putative KFERQ motif in wild-type Htt-552 interfered with interactions between Htt-552 and Hsc70. Endogenous Hsc70 and LAMP-2A interacted with exogenously expressed Htt-552. Modulating the levels of CMA related proteins degraded endogenous full-length Htt. These studies suggest that Hsc70 and LAMP-2A through CMA play a role in the clearance of Htt and suggest a novel strategy to target the degradation of mutant Htt.
C1 [Qi, Lin; Zhang, Xing-Ding; Wu, Jun-Chao; Lin, Fang; Wang, Jin; Qin, Zheng-Hong] Soochow Univ, Sch Pharmaceut Sci, Dept Pharmacol, Suzhou, Peoples R China.
[Qi, Lin; Zhang, Xing-Ding; Wu, Jun-Chao; Lin, Fang; Wang, Jin; Qin, Zheng-Hong] Soochow Univ, Sch Pharmaceut Sci, Lab Aging & Nervous Dis, Suzhou, Peoples R China.
[DiFiglia, Marian] Massachusetts Gen Hosp, Lab Cellular Neurobiol, Charlestown, MA USA.
[DiFiglia, Marian] Harvard Univ, Sch Med, Charlestown, MA USA.
RP Qin, ZH (reprint author), Soochow Univ, Sch Pharmaceut Sci, Dept Pharmacol, Suzhou, Peoples R China.
EM qinzhenhong@suda.edu.cn
RI Zhang, Xingding/C-8780-2014
OI Zhang, Xingding/0000-0002-2759-5185
FU National Natural Science Foundation of China [30930035]; Priority
Academic Program Development of Jiangsu Higher Education Institutes;
Jiangsu Province's Outstanding Medical Academic Leader Program
[LJ201139]
FX This work was partially supported by the National Natural Science
Foundation of China (No 30930035), and by The Priority Academic Program
Development of Jiangsu Higher Education Institutes and by Jiangsu
Province's Outstanding Medical Academic Leader Program (LJ201139). The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 49
TC 30
Z9 31
U1 2
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 11
PY 2012
VL 7
IS 10
AR e46834
DI 10.1371/journal.pone.0046834
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 020KP
UT WOS:000309807700036
PM 23071649
ER
PT J
AU Qi, QB
Chu, AY
Kang, JH
Jensen, MK
Curhan, GC
Pasquale, LR
Ridker, PM
Hunter, DJ
Willett, WC
Rimm, EB
Chasman, DI
Hu, FB
Qi, L
AF Qi, Qibin
Chu, Audrey Y.
Kang, Jae H.
Jensen, Majken K.
Curhan, Gary C.
Pasquale, Louis R.
Ridker, Paul M.
Hunter, David J.
Willett, Walter C.
Rimm, Eric B.
Chasman, Daniel I.
Hu, Frank B.
Qi, Lu
TI Sugar-Sweetened Beverages and Genetic Risk of Obesity
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID BODY-MASS INDEX; FOOD FREQUENCY QUESTIONNAIRE; GENOME-WIDE ASSOCIATION;
MIDDLE-AGED WOMEN; PHYSICAL-ACTIVITY; WEIGHT-GAIN; DISEASE RISK; HEALTH;
REPRODUCIBILITY; VARIANTS
AB BACKGROUND
Temporal increases in the consumption of sugar-sweetened beverages have paralleled the rise in obesity prevalence, but whether the intake of such beverages interacts with the genetic predisposition to adiposity is unknown.
METHODS
We analyzed the interaction between genetic predisposition and the intake of sugar-sweetened beverages in relation to body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) and obesity risk in 6934 women from the Nurses' Health Study (NHS) and in 4423 men from the Health Professionals Follow-up Study (HPFS) and also in a replication cohort of 21,740 women from the Women's Genome Health Study (WGHS). The genetic-predisposition score was calculated on the basis of 32 BMI-associated loci. The intake of sugar-sweetened beverages was examined prospectively in relation to BMI.
RESULTS
In the NHS and HPFS cohorts, the genetic association with BMI was stronger among participants with higher intake of sugar-sweetened beverages than among those with lower intake. In the combined cohorts, the increases in BMI per increment of 10 risk alleles were 1.00 for an intake of less than one serving per month, 1.12 for one to four servings per month, 1.38 for two to six servings per week, and 1.78 for one or more servings per day (P < 0.001 for interaction). For the same categories of intake, the relative risks of incident obesity per increment of 10 risk alleles were 1.19 (95% confidence interval [CI], 0.90 to 1.59), 1.67 (95% CI, 1.28 to 2.16), 1.58 (95% CI, 1.01 to 2.47), and 5.06 (95% CI, 1.66 to 15.5) (P = 0.02 for interaction). In the WGHS cohort, the increases in BMI per increment of 10 risk alleles were 1.39, 1.64, 1.90, and 2.53 across the four categories of intake (P = 0.001 for interaction); the relative risks for incident obesity were 1.40 (95% CI, 1.19 to 1.64), 1.50 (95% CI, 1.16 to 1.93), 1.54 (95% CI, 1.21 to 1.94), and 3.16 (95% CI, 2.03 to 4.92), respectively (P = 0.007 for interaction).
CONCLUSIONS
The genetic association with adiposity appeared to be more pronounced with greater intake of sugar-sweetened beverages. (Funded by the National Institutes of Health and others.)
C1 [Qi, Qibin; Jensen, Majken K.; Hunter, David J.; Willett, Walter C.; Rimm, Eric B.; Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Curhan, Gary C.; Hunter, David J.; Willett, Walter C.; Rimm, Eric B.; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Chu, Audrey Y.; Ridker, Paul M.; Chasman, Daniel I.] Brigham & Womens Hosp, Dept Med, Div Prevent Med, Boston, MA 02115 USA.
[Ridker, Paul M.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc Dis, Boston, MA 02115 USA.
[Chasman, Daniel I.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
[Kang, Jae H.; Curhan, Gary C.; Pasquale, Louis R.; Hunter, David J.; Willett, Walter C.; Rimm, Eric B.; Hu, Frank B.; Qi, Lu] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Pasquale, Louis R.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02115 USA.
RP Qi, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM nhlqi@channing.harvard.edu
RI Qi, Qibin/H-9055-2012
FU National Institutes of Health; National Institutes of Health [DK091718,
HL071981, HL073168, CA87969, CA49449, CA055075, HL34594, HL088521,
U01HG004399, DK080140, 5P30DK46200, U54CA155626, DK58845,
U01HG004728-02, EY015473, DK70756, DK46200, HL043851, HL69757,
CA047988]; Merck Research Laboratories; American Heart Association
Scientist Development Award [0730094N]; Research to Prevent Blindness
award; Harvard Ophthalmology Scholar Award; Harvard Glaucoma Center of
Excellence; Amgen; Genzyme; Isis Pharmaceuticals; Vascular Biogenics;
Merck; Abbott; Novartis; AstraZeneca; Novo Nordisk; California Walnut
Commission; Kellogg
FX Funded by the National Institutes of Health and others.; Supported by
grants (DK091718, HL071981, HL073168, CA87969, CA49449, CA055075,
HL34594, HL088521, U01HG004399, DK080140, 5P30DK46200, U54CA155626,
DK58845, U01HG004728-02, EY015473, DK70756, and DK46200) from the
National Institutes of Health, with additional support for genotyping
from Merck Research Laboratories; an American Heart Association
Scientist Development Award (0730094N, to Dr. L. Qi); and a Research to
Prevent Blindness award and a Harvard Ophthalmology Scholar Award (both
to Dr. Pasquale) from the Harvard Glaucoma Center of Excellence. The
WGHS is supported by grants (HL043851, HL69757, and CA047988) from the
National Institutes of Health, with collaborative scientific support and
funding for genotyping provided by Amgen.; Dr. Ridker reports receiving
consulting fees from Genzyme, Isis Pharmaceuticals, Vascular Biogenics,
Merck, and Abbott and grant support to his institution from Novartis and
AstraZeneca and being listed as a co-inventor on patents held by his
institution that relate to the use of inflammatory biomarkers in
cardiovascular disease and diabetes (patent and royalty payments are
received by Brigham and Women's Hospital); Dr. Hu, receiving consulting
fees from Novo Nordisk and grant support to his institution from Merck
and the California Walnut Commission; and Dr. L. Qi, receiving lecture
fees from Kellogg. No other potential conflict of interest relevant to
this article was reported.
NR 44
TC 166
Z9 172
U1 6
U2 53
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 11
PY 2012
VL 367
IS 15
BP 1387
EP 1396
DI 10.1056/NEJMoa1203039
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 018ID
UT WOS:000309652700005
PM 22998338
ER
PT J
AU Yager, PH
Singhal, AB
Nogueira, RG
AF Yager, Phoebe H.
Singhal, Aneesh B.
Nogueira, Raul G.
TI Case 31-2012: An 18-Year-Old Man with Blurred Vision, Dysarthria, and
Ataxia
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; YOUNG-ADULTS;
RISK-FACTORS; INTRAVENOUS THROMBOLYSIS; MYCOPLASMA-PNEUMONIAE; POOLED
ANALYSIS; EXPERIENCE; CLASSIFICATION; HEMORRHAGE
C1 [Yager, Phoebe H.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Singhal, Aneesh B.; Nogueira, Raul G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Yager, Phoebe H.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Singhal, Aneesh B.; Nogueira, Raul G.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Yager, PH (reprint author), Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
FU Pfizer; Photothera; Stryker/Concentric Medical; Covidien/ev3
Neurovascular; CoAxia; Penumbra; Rapid Medical; Reverse Medical;
Neurointervention; Concentric Medical; Covidien
FX Dr. Singhal reports grant support to his institution from Pfizer and
Photothera and receiving fees for serving as an expert witness in
medicolegal cases involving stroke in young adults. Dr. Nogueira reports
receiving consulting fees from Stryker/Concentric Medical, Covidien/ev3
Neurovascular, CoAxia, Penumbra, Rapid Medical, Reverse Medical, and
Neurointervention; fees from Concentric Medical, Covidien, and Penumbra
for participation on committees for clinical trials; and fees for
serving on a data safety and monitoring board for Rapid Medical. No
other potential conflict of interest relevant to this article was
reported.
NR 46
TC 2
Z9 2
U1 1
U2 4
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 11
PY 2012
VL 367
IS 15
BP 1450
EP 1460
DI 10.1056/NEJMcpc1208150
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 018ID
UT WOS:000309652700013
PM 23050529
ER
PT J
AU Wilt, TJ
Brawer, MK
Aronson, WJ
AF Wilt, Timothy J.
Brawer, Michael K.
Aronson, William J.
TI Radical Prostatectomy versus Observation for Prostate Cancer REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Wilt, Timothy J.] Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Brawer, Michael K.] Myriad Genet, Salt Lake City, UT USA.
[Aronson, William J.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Wilt, TJ (reprint author), Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
EM tim.wilt@va.gov
NR 5
TC 0
Z9 0
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 11
PY 2012
VL 367
IS 15
BP 1468
EP 1469
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 018ID
UT WOS:000309652700022
ER
PT J
AU Larson, S
Comina, G
Gilman, RH
Tracey, BH
Bravard, M
Lopez, JW
AF Larson, Sandra
Comina, German
Gilman, Robert H.
Tracey, Brian H.
Bravard, Marjory
Lopez, Jose W.
TI Validation of an Automated Cough Detection Algorithm for Tracking
Recovery of Pulmonary Tuberculosis Patients
SO PLOS ONE
LA English
DT Article
ID FREQUENCY; MODELS
AB Background: A laboratory-free test for assessing recovery from pulmonary tuberculosis (TB) would be extremely beneficial in regions of the world where laboratory facilities are lacking. Our hypothesis is that analysis of cough sound recordings may provide such a test. In the current paper, we present validation of a cough analysis tool.
Methodology/Principal Findings: Cough data was collected from a cohort of TB patients in Lima, Peru and 25.5 hours of recordings were manually annotated by clinical staff. Analysis software was developed and validated by comparison to manual scoring. Because many patients cough in bursts, coughing was characterized in terms of cough epochs. Our software correctly detects 75.5% of cough episodes with a specificity of 99.6% (comparable to past results using the same definition) and a median false positive rate of 4 false positives/hour, due to the noisy, real-world nature of our dataset. We then manually review detected coughs to eliminate false positives, in effect using the algorithm as a pre-screening tool that reduces reviewing time to roughly 5% of the recording length. This cough analysis approach provides a foundation to support larger-scale studies of coughing rates over time for TB patients undergoing treatment.
C1 [Tracey, Brian H.] Tufts Univ, Dept Elect & Comp Engn, Medford, MA 02155 USA.
[Larson, Sandra] Michigan State Univ, Coll Osteopath Med, E Lansing, MI 48824 USA.
[Comina, German] Univ Nacl Ingn, Fac Ciencias, Lab Ingn Fis, Lima, Peru.
[Gilman, Robert H.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA.
[Bravard, Marjory] Massachusetts Gen Hosp, Dept Internal Med, Boston, MA 02114 USA.
[Lopez, Jose W.] Hosp Nacl Dos de Mayo, Unidad Epidemiol, Lima, Peru.
RP Tracey, BH (reprint author), Tufts Univ, Dept Elect & Comp Engn, Medford, MA 02155 USA.
EM btracey@eecs.tufts.edu
RI Tracey, Brian/I-2181-2013;
OI Lopez, Jose/0000-0003-0614-7284; Comina, German/0000-0003-2114-0486
FU National Institutes of Health [5D43TW006581, R21 AI094143]; NIH Fogarty
Foundation; Consejo Nacional de Ciencia, Tecnologia e Innovacion
Tecnologica of Peru (CONCYTEC)
FX This work was funded in part by National Institutes of Health through
awards 5D43TW006581 "Infectious Diseases Training Program in Peru'' and
R21 AI094143 "Cough-A Rapid Indication of Response to Therapy in
Pulmonary Tuberculosis''. JL and MB were supported by NIH Fogarty
Foundation fellowships. G. Comina wants to thank the Consejo Nacional de
Ciencia, Tecnologia e Innovacion Tecnologica of Peru (CONCYTEC) for
their support. The funders had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript.
NR 16
TC 6
Z9 6
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2012
VL 7
IS 10
AR e46229
DI 10.1371/journal.pone.0046229
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 054ZU
UT WOS:000312385200017
PM 23071550
ER
PT J
AU Wu, G
Zhu, J
He, FH
Wang, WW
Hu, SN
Yu, J
AF Wu, Gang
Zhu, Jiang
He, Fuhong
Wang, Weiwei
Hu, Songnian
Yu, Jun
TI Gene and Genome Parameters of Mammalian Liver Circadian Genes (LCGs)
SO PLOS ONE
LA English
DT Article
ID EMBRYONIC STEM-CELLS; EXPRESSION; CLOCK; MOUSE; RHYTHMS; TIME;
ORGANIZATION; DROSOPHILA; TRANSCRIPTION; ENTRAINMENT
AB The mammalian circadian system controls various physiology processes and behavior responses by regulating thousands of circadian genes with rhythmic expressions. In this study, we redefined circadian-regulated genes based on published results in the mouse liver and compared them with other gene groups defined relative to circadian regulations, especially the non-circadian-regulated genes expressed in liver at multiple molecular levels from gene position to protein expression based on integrative analyses of different datasets from the literature. Based on the intra-tissue analysis, the liver circadian genes or LCGs show unique features when compared to other gene groups. First, LCGs in general have less neighboring genes and larger in both genomic and 3' UTR lengths but shorter in CDS (coding sequence) lengths. Second, LCGs have higher mRNA and protein abundance, higher temporal expression variations, and shorter mRNA half-life. Third, more than 60% of LCGs form major co-expression clusters centered in four temporal windows: dawn, day, dusk, and night. In addition, larger and smaller LCGs are found mainly expressed in the day and night temporal windows, respectively, and we believe that LCGs are well-partitioned into the gene expression regulatory network that takes advantage of gene size, expression constraint, and chromosomal architecture. Based on inter-tissue analysis, more than half of LCGs are ubiquitously expressed in multiple tissues but only show rhythmical expression in one or limited number of tissues. LCGs show at least three-fold lower expression variations across the temporal windows than those among different tissues, and this observation suggests that temporal expression variations regulated by the circadian system is relatively subtle as compared with the tissue expression variations formed during development. Taken together, we suggest that the circadian system selects gene parameters in a cost effective way to improve tissue-specific functions by adapting temporal variations from the environment over evolutionary time scales.
C1 [Wu, Gang; Zhu, Jiang; He, Fuhong; Wang, Weiwei; Hu, Songnian; Yu, Jun] Chinese Acad Sci, Beijing Inst Genom, CAS Key Lab Genome Sci & Informat, Beijing, Peoples R China.
[Wu, Gang] Chinese Acad Sci, Grad Univ, Beijing, Peoples R China.
[Zhu, Jiang] Harvard Univ, Sch Med, Boston, MA USA.
[Zhu, Jiang] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[He, Fuhong] Chinese Acad Sci, Beijing Inst Genom, Lab Dis Genom & Individualized Med, Beijing, Peoples R China.
[Wang, Weiwei] Univ Alberta, Dept Med, Edmonton, AB, Canada.
RP Yu, J (reprint author), Chinese Acad Sci, Beijing Inst Genom, CAS Key Lab Genome Sci & Informat, Beijing, Peoples R China.
EM junyu@big.ac.cn
RI Zhu, Jiang/E-3049-2013;
OI Hu, Songnian/0000-0003-3966-3111
FU National Natural Science Foundation of China [2011CB944100,
2011CB944101, 90919024]; Ministry of Science and Technology
[2009FY120100]; Ministry of Science and Technology of the People's
Republic of China [2012AA020409]
FX This work is supported by grants from the National Basic Research
Program (973 Program; 2011CB944100 and 2011CB944101), National Natural
Science Foundation of China (90919024), from the Special Foundation Work
Program, the Ministry of Science and Technology (2009FY120100), from
National Programs for High Technology Research and Development (863
Program), the Ministry of Science and Technology of the People's
Republic of China (2012AA020409). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 66
TC 4
Z9 5
U1 1
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 10
PY 2012
VL 7
IS 10
AR e46961
DI 10.1371/journal.pone.0046961
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 054ZU
UT WOS:000312385200055
PM 23071677
ER
PT J
AU Lane, RF
St George-Hyslop, P
Hempstead, BL
Small, SA
Strittmatter, SM
Gandy, S
AF Lane, Rachel F.
St George-Hyslop, Peter
Hempstead, Barbara L.
Small, Scott A.
Strittmatter, Stephen M.
Gandy, Sam
TI Vps10 Family Proteins and the Retromer Complex in Aging-Related
Neurodegeneration and Diabetes
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID AMYLOID PRECURSOR PROTEIN; SPORADIC ALZHEIMERS-DISEASE; QUANTITATIVE
TRAIT LOCUS; GENOME-WIDE ASSOCIATION; LR11/SORLA EXPRESSION;
SUSCEPTIBILITY LOCI; NEUROTROPHIC FACTOR; PARKINSON DISEASE; BETA
PRODUCTION; DOWN-SYNDROME
AB Members of the vacuolar protein sorting 10 (Vps10) family of receptors (including sortilin, SorL1, SorCS1, SorCS2, and SorCS3) play pleiotropic functions in protein trafficking and intracellular and intercellular signaling in neuronal and non-neuronal cells. Interactions have been documented between Vps10 family members and the retromer coat complex, a key component of the intracellular trafficking apparatus that sorts cargo from the early endosome to the trans-Golgi network. In recent years, genes encoding several members of the Vps10 family of proteins, as well as components of the retromer coat complex, have been implicated as genetic risk factors for sporadic and autosomal dominant forms of neurodegenerative diseases, including Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease, with risk for type 2 diabetes mellitus and atherosclerosis. In addition to their functions in protein trafficking, the Vps10 family proteins modulate neurotrophic signaling pathways. Sortilin can impact the intracellular response to brain-derived neurotrophic factor (BDNF) by regulating anterograde trafficking of Trk receptors to the synapse and direct control of BDNF levels, while both sortilin and SorCS2 function as cell surface receptors to mediate acute responses to proneurotrophins. This mini-review and symposium will highlight the emerging data from this rapidly growing area of research implicating the Vps10 family of receptors and the retromer in physiological intracellular trafficking signaling by neurotrophins and in the pathogenesis of neurodegeneration.
C1 [Lane, Rachel F.] Alzheimers Drug Discovery Fdn, New York, NY 10019 USA.
[St George-Hyslop, Peter] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada.
[St George-Hyslop, Peter] Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 0XY, England.
[St George-Hyslop, Peter] Univ Cambridge, Dept Clin Neurosci, Cambridge CB2 0XY, England.
[Hempstead, Barbara L.] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA.
[Small, Scott A.] Columbia Univ, Sch Phys & Surg, Dept Neurol, New York, NY 10032 USA.
[Small, Scott A.] Columbia Univ, Sch Phys & Surg, Taub Inst, New York, NY 10032 USA.
[Strittmatter, Stephen M.] Yale Univ, Sch Med, Cellular Neurosci Neurodegenerat & Repair Program, Dept Neurol, New Haven, CT 06536 USA.
[Strittmatter, Stephen M.] Yale Univ, Sch Med, Cellular Neurosci Neurodegenerat & Repair Program, Dept Neurobiol, New Haven, CT 06536 USA.
[Gandy, Sam] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA.
[Gandy, Sam] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA.
[Gandy, Sam] Mt Sinai Sch Med, Alzheimers Dis Res Ctr, New York, NY 10029 USA.
[Gandy, Sam] James J Peters Vet Affairs Med Ctr, Bronx, NY 10468 USA.
RP Lane, RF (reprint author), Alzheimers Drug Discovery Fdn, 57 W 57th St,Suite 904, New York, NY 10019 USA.
EM RLane@alzdiscovery.org; samuel.gandy@mssm.edu
RI Strittmatter, Stephen/F-5739-2011
OI Strittmatter, Stephen/0000-0001-8188-3092
FU NIH [NS075685, NS030687, AG025161, NS074319, AG034924]; Wellcome Trust;
Canadian Institutes of Health Research; Alzheimer Society of Ontario;
Howard Hughes Medical Institute; Cure Alzheimer's Fund; US Department of
Veteran Affairs
FX We gratefully acknowledge the support of the NIH (NS075685 to S.G.,
NS030687 to B.L.H., AG025161 to S.A.S., NS074319 and AG034924 to
S.M.S.), the Wellcome Trust, Canadian Institutes of Health Research,
Alzheimer Society of Ontario, and Howard Hughes Medical Institute
(P.StG.-H.), the Cure Alzheimer's Fund (S.G.), and the US Department of
Veteran Affairs (S.G.). R.F.L. and S.G.thank Dr. Alan Attie for
providing advice and helpful conversations during the preparation of
this paper.
NR 60
TC 25
Z9 26
U1 0
U2 18
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD OCT 10
PY 2012
VL 32
IS 41
BP 14080
EP 14086
DI 10.1523/JNEUROSCI.3359-12.2012
PG 7
WC Neurosciences
SC Neurosciences & Neurology
GA 022MO
UT WOS:000309963700006
PM 23055476
ER
PT J
AU Inaba, H
Coustan-Smith, E
Cao, XY
Pounds, SB
Shurtleff, SA
Wang, KY
Raimondi, SC
Onciu, M
Jacobsen, J
Ribeiro, RC
Dahl, GV
Bowman, WP
Taub, JW
Degar, B
Leung, W
Downing, JR
Pui, CH
Rubnitz, JE
Campana, D
AF Inaba, Hiroto
Coustan-Smith, Elaine
Cao, Xueyuan
Pounds, Stanley B.
Shurtleff, Sheila A.
Wang, Kathleen Y.
Raimondi, Susana C.
Onciu, Mihaela
Jacobsen, Jeffrey
Ribeiro, Raul C.
Dahl, Gary V.
Bowman, W. Paul
Taub, Jeffrey W.
Degar, Barbara
Leung, Wing
Downing, James R.
Pui, Ching-Hon
Rubnitz, Jeffrey E.
Campana, Dario
TI Comparative Analysis of Different Approaches to Measure Treatment
Response in Acute Myeloid Leukemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID MINIMAL RESIDUAL DISEASE; MULTIPARAMETER FLOW-CYTOMETRY; RT-PCR;
CLINICAL-SIGNIFICANCE; PROGNOSTIC VALUE; COMPLETE REMISSION; DIRECTED
THERAPY; CHILDHOOD AML; RQ-PCR; RELAPSE
AB Purpose
In acute myeloid leukemia (AML), initial treatment response by morphologic analysis of bone marrow predicts long-term outcome. Response can now be assessed by minimal residual disease (MRD) monitoring with flow cytometry or polymerase chain reaction (PCR). We determined the relation among the results of these approaches and their prognostic value.
Patients and Methods
In the multicenter AML02 study, follow-up bone marrow samples from 203 children and adolescents with newly diagnosed AML were examined by flow cytometry (n = 1,514), morphology (n = 1,382), and PCR amplification of fusion transcripts (n = 508). Results were correlated with treatment outcome.
Results
Among 1,215 samples with less than 5% leukemic myeloblasts by morphology, 100 (8.2%) were MRD positive (>= 0.1%) by flow cytometry, whereas 96 (57.5%) of the 167 samples with >= 5% blasts were MRD negative. Virtually all (308 of 311; 99.0%) MRD-negative samples by PCR were also MRD negative by flow cytometry. However, only 19 (9.6%) of the 197 PCR-positive samples were flow cytometry positive, with analyses of AML1-ETO and CBF beta-MYH11 accounting for most discrepancies, whereas eight of 13 MLL-positive samples had detectable MRD by flow cytometry. MRD by flow cytometry after induction 1 or 2 predicted lower event-free survival and higher relapse rate (P < .001) and was an independent prognostic factor in a multivariable analysis; prediction was not improved by morphologic information or molecular findings.
Conclusion
In childhood AML, morphologic assessment of treatment response has limited value if MRD is measured by flow cytometry. MLL fusion transcripts can provide prognostic information in some patients, whereas monitoring of AML1-ETO and CBF beta-MYH11 transcripts is largely uninformative. J Clin Oncol 30:3625-3632. (C) 2012 by American Society of Clinical Oncology
C1 [Inaba, Hiroto] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Inaba, Hiroto; Cao, Xueyuan; Pounds, Stanley B.; Shurtleff, Sheila A.; Wang, Kathleen Y.; Raimondi, Susana C.; Onciu, Mihaela; Jacobsen, Jeffrey; Ribeiro, Raul C.; Leung, Wing; Downing, James R.; Pui, Ching-Hon; Rubnitz, Jeffrey E.] Univ Tennessee, Coll Med, Memphis, TN USA.
[Coustan-Smith, Elaine; Campana, Dario] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117595, Singapore.
[Dahl, Gary V.] Lucile Packard Childrens Hosp, Palo Alto, CA USA.
[Dahl, Gary V.] Stanford Canc Ctr, Palo Alto, CA USA.
[Bowman, W. Paul] Cook Childrens Med Ctr, Ft Worth, TX USA.
[Taub, Jeffrey W.] Childrens Hosp Michigan, Detroit, MI 48201 USA.
[Degar, Barbara] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Inaba, H (reprint author), St Jude Childrens Res Hosp, Dept Oncol, MS 260,262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM hiroto.inaba@stjude.org
OI Pounds, Stanley/0000-0002-9167-2114
FU National Institutes of Health [R01 CA115422, R25 CA23944, P30 CA21765];
American Lebanese Syrian Associated Charities
FX Supported by Grants No. R01 CA115422, R25 CA23944, and P30 CA21765 from
the National Institutes of Health and by the American Lebanese Syrian
Associated Charities.
NR 48
TC 59
Z9 59
U1 0
U2 10
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 10
PY 2012
VL 30
IS 29
BP 3625
EP 3632
DI 10.1200/JCO.2011.41.5323
PG 8
WC Oncology
SC Oncology
GA 018IM
UT WOS:000309653600013
PM 22965955
ER
PT J
AU Slatore, CG
Wiener, RS
Cooke, CR
AF Slatore, Christopher G.
Wiener, Renda Soylemez
Cooke, Colin R.
TI Is Intensive Care Unit Admission an Indicator of Patient-Centered Care
for Patients With Advanced Lung Cancer in SEER-Medicare? Reply
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Letter
ID CODE STATUS
C1 [Slatore, Christopher G.] Portland VA Med Ctr, Portland, OR USA.
[Slatore, Christopher G.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Affairs Hosp, Ctr Hlth Qual Outcomes & Econ Res, Bedford, MA USA.
[Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.
[Cooke, Colin R.] Univ Michigan, Ctr Healthcare Outcomes & Policy, Ann Arbor, MI 48109 USA.
[Cooke, Colin R.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
RP Slatore, CG (reprint author), Portland VA Med Ctr, Portland, OR USA.
OI Slatore, Christopher/0000-0003-0958-8122
NR 5
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD OCT 10
PY 2012
VL 30
IS 29
BP 3652
EP 3653
DI 10.1200/JCO.2012.45.0296
PG 3
WC Oncology
SC Oncology
GA 018IM
UT WOS:000309653600019
ER
PT J
AU Joynt, KE
Blumenthal, DM
Orav, EJ
Resnic, FS
Jha, AK
AF Joynt, Karen E.
Blumenthal, Daniel M.
Orav, E. John
Resnic, Frederic S.
Jha, Ashish K.
TI Association of Public Reporting for Percutaneous Coronary Intervention
With Utilization and Outcomes Among Medicare Beneficiaries With Acute
Myocardial Infarction
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID CARDIOVASCULAR DATA REGISTRY; MORTALITY RISK PREDICTION; UNINTENDED
CONSEQUENCES; HEART-ASSOCIATION; BYPASS-SURGERY; MANAGEMENT; UPDATE
AB Context Public reporting of patient outcomes is an important tool to improve quality of care, but some observers worry that such efforts will lead clinicians to avoid high-risk patients.
Objective To determine whether public reporting for percutaneous coronary intervention (PCI) is associated with lower rates of PCI for patients with acute myocardial infarction (MI) or with higher mortality rates in this population.
Design, Setting, and Patients Retrospective observational study conducted using data from fee-for-service Medicare patients (49 660 from reporting states and 48 142 from nonreporting states) admitted with acute MI to US acute care hospitals between 2002 and 2010. Logistic regression was used to compare PCI and mortality rates between reporting states (New York, Massachusetts, and Pennsylvania) and regional nonreporting states (Maine, Vermont, New Hampshire, Connecticut, Rhode Island, Maryland, and Delaware). Changes in PCI rates over time in Massachusetts compared with nonreporting states were also examined.
Main Outcome Measures Risk-adjusted PCI and mortality rates.
Results In 2010, patients with acute MI were less likely to receive PCI in public reporting states than in nonreporting states (unadjusted rates, 37.7% vs 42.7%, respectively; risk-adjusted odds ratio [OR], 0.82 [95% CI, 0.71-0.93]; P=.003). Differences were greatest among the 6708 patients with ST-segment elevation MI (61.8% vs 68.0%; OR, 0.73 [95% CI, 0.59-0.89]; P=.002) and the 2194 patients with cardiogenic shock or cardiac arrest (41.5% vs 46.7%; OR, 0.79 [95% CI, 0.64-0.98]; P=.03). There were no differences in overall mortality among patients with acute MI in reporting vs nonreporting states. In Massachusetts, odds of PCI for acute MI were comparable with odds in nonreporting states prior to public reporting (40.6% vs 41.8%; OR, 1.00 [95% CI, 0.71-1.41]). However, after implementation of public reporting, odds of undergoing PCI in Massachusetts decreased compared with nonreporting states (41.1% vs 45.6%; OR, 0.81 [95% CI, 0.47-1.38]; P=.03 for difference in differences). Differences were most pronounced for the 6081 patients with cardiogenic shock or cardiac arrest (prereporting: 44.2% vs 36.6%; OR, 1.40 [95% CI, 0.85-2.32]; postreporting: 43.9% vs 44.8%; OR, 0.92 [95% CI, 0.38-2.22]; P=.03 for difference in differences).
Conclusions Among Medicare beneficiaries with acute MI, the use of PCI was lower for patients treated in 3 states with public reporting of PCI outcomes compared with patients treated in 7 regional control states without public reporting. However, there was no difference in overall acute MI mortality between states with and without public reporting. JAMA. 2012;308(14):1460-1468 www.jama.com
C1 [Joynt, Karen E.; Jha, Ashish K.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Joynt, Karen E.; Resnic, Frederic S.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Orav, E. John; Jha, Ashish K.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA.
[Joynt, Karen E.; Jha, Ashish K.] VA Boston Healthcare Syst, Boston, MA USA.
[Blumenthal, Daniel M.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Joynt, KE (reprint author), 75 Francis St, Boston, MA 02115 USA.
EM kjoynt@partners.org
FU National Heart, Lung, and Blood Institute [1K23HL109177-01]
FX Funding for this study was provided by grant 1K23HL109177-01 from the
National Heart, Lung, and Blood Institute.
NR 16
TC 80
Z9 82
U1 3
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 10
PY 2012
VL 308
IS 14
BP 1460
EP 1468
DI 10.1001/jama.2012.12922
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 017GY
UT WOS:000309579300025
PM 23047360
ER
PT J
AU Yu, EW
Finkelstein, JS
AF Yu, Elaine W.
Finkelstein, Joel S.
TI Bone Density Testing in Older Women Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID OSTEOPOROSIS; FRACTURE
C1 [Yu, Elaine W.; Finkelstein, Joel S.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
RP Yu, EW (reprint author), Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
EM ewyu@partners.org
NR 6
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 10
PY 2012
VL 308
IS 14
BP 1429
EP 1429
DI 10.1001/jama.2012.12820
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 017GY
UT WOS:000309579300014
ER
PT J
AU Ho, JH
de Moura, MB
Lin, Y
Vincent, G
Thorne, S
Duncan, LM
Lin, HM
Kirkwood, JM
Becker, D
Van Houten, B
Moschos, SJ
AF Ho, Jonhan
de Moura, Michelle Barbi
Lin, Yan
Vincent, Garret
Thorne, Stephen
Duncan, Lyn M.
Lin Hui-Min
Kirkwood, John M.
Becker, Dorothea
Van Houten, Bennett
Moschos, Stergios J.
TI Importance of glycolysis and oxidative phosphorylation in advanced
melanoma
SO MOLECULAR CANCER
LA English
DT Article
DE Melanoma; Lactate dehydrogenase; Glycolysis; Mitochondria; Oxidative
phosphorylation; Monocarboxylate transporters
ID LACTATE-DEHYDROGENASE; METASTATIC MELANOMA; TRANSPORTER MCT4; CELLS;
EXPRESSION; HYPOXIA; CANCER; RESPIRATION; CARCINOMAS; METABOLISM
AB Serum lactate dehydrogenase (LDH) is a prognostic factor for patients with stage IV melanoma. To gain insights into the biology underlying this prognostic factor, we analyzed total serum LDH, serum LDH isoenzymes, and serum lactate in up to 49 patients with metastatic melanoma. Our data demonstrate that high serum LDH is associated with a significant increase in LDH isoenzymes 3 and 4, and a decrease in LDH isoenzymes 1 and 2. Since LDH isoenzymes play a role in both glycolysis and oxidative phosphorylation (OXPHOS), we subsequently determined using tissue microarray (TMA) analysis that the levels of proteins associated with mitochondrial function, lactate metabolism, and regulators of glycolysis were all elevated in advanced melanomas compared with nevic melanocytes. To investigate whether in advanced melanoma, the glycolysis and OXPHOS pathways might be linked, we determined expression of the monocarboxylate transporters (MCT) 1 and 4. Analysis of a nevus-to-melanoma progression TMA revealed that MCT4, and to a lesser extend MCT1, were elevated with progression to advanced melanoma. Further analysis of human melanoma specimens using the Seahorse XF24 extracellular flux analyzer indicated that metastatic melanoma tumors derived a large fraction of energy from OXPHOS. Taken together, these findings suggest that in stage IV melanomas with normal serum LDH, glycolysis and OXPHOS may provide metabolic symbiosis within the same tumor, whereas in stage IV melanomas with high serum LDH glycolysis is the principle source of energy.
C1 [Ho, Jonhan] Univ Pittsburgh, Dept Dermatol, Pittsburgh, PA 15213 USA.
[de Moura, Michelle Barbi; Van Houten, Bennett] Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15213 USA.
[de Moura, Michelle Barbi; Van Houten, Bennett] Univ Pittsburgh, Dept Biol Chem, Pittsburgh, PA 15213 USA.
[Lin, Yan; Lin Hui-Min] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15213 USA.
[Vincent, Garret; Kirkwood, John M.; Moschos, Stergios J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA.
[Thorne, Stephen] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Duncan, Lyn M.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Becker, Dorothea] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA.
RP Moschos, SJ (reprint author), Univ N Carolina, Dept Med, Phys Off Bldg,3rd Floor,Suite 3116,CB 7305,170 Ma, Chapel Hill, NC 27599 USA.
EM moschos@med.unc.edu
FU NIH [P50CA121973]; Pennsylvania Department of Health PA CURE award
FX We would like to thank D. Bachorski for collecting sera for LDH and
lactate studies, M. Acquafondata for antibody probing of the TMA. This
work was supported by a Career Development Award to S. J. M. from the
NIH P50CA121973 SPORE in Skin Cancer, and a Pennsylvania Department of
Health PA CURE award to B. V. H.
NR 41
TC 38
Z9 38
U1 0
U2 16
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD OCT 9
PY 2012
VL 11
AR 76
DI 10.1186/1476-4598-11-76
PG 13
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 068BZ
UT WOS:000313340800001
PM 23043612
ER
PT J
AU Liu, JQ
Liao, S
Diop-Frimpong, B
Chen, W
Goel, S
Naxerova, K
Ancukiewicz, M
Boucher, Y
Jain, RK
Xu, L
AF Liu, Jieqiong
Liao, Shan
Diop-Frimpong, Benjamin
Chen, Wei
Goel, Shom
Naxerova, Kamila
Ancukiewicz, Marek
Boucher, Yves
Jain, Rakesh K.
Xu, Lei
TI TGF-beta blockade improves the distribution and efficacy of therapeutics
in breast carcinoma by normalizing the tumor stroma
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE breast cancer; vessel normalization; drug delivery
ID GROWTH-FACTOR-BETA; SOLID TUMORS; CANCER-CELLS; EXTRACELLULAR TRANSPORT;
SOLUBLE BETAGLYCAN; VESSEL MATURATION; PROSTATE-CANCER; DELIVERY;
COLLAGEN; METASTASIS
AB Although the role of TGF-beta in tumor progression has been studied extensively, its impact on drug delivery in tumors remains far from understood. In this study, we examined the effect of TGF-beta blockade on the delivery and efficacy of conventional therapeutics and nanotherapeutics in orthotopic mammary carcinoma mouse models. We used both genetic (overexpression of sT beta RII, a soluble TGF-beta type II receptor) and pharmacologic (1D11, a TGF-beta neutralizing antibody) approaches to block TGF-beta signaling. In two orthotopic mammary carcinoma models (human MDA-MB-231 and murine 4T1 cell lines), TGF-beta blockade significantly decreased tumor growth and metastasis. TGF-beta blockade also increased the recruitment and incorporation of perivascular cells into tumor blood vessels and increased the fraction of perfused vessels. Moreover, TGF-beta blockade normalized the tumor interstitial matrix by decreasing collagen I content. As a result of this vessel and interstitial matrix normalization, TGF-beta blockade improved the intratumoral penetration of both a low-molecular-weight conventional chemotherapeutic drug and a nanotherapeutic agent, leading to better control of tumor growth.
C1 [Jain, Rakesh K.] Massachusetts Gen Hosp, Edwin L Steele Lab, Dept Radiat Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Jain, RK (reprint author), Massachusetts Gen Hosp, Edwin L Steele Lab, Dept Radiat Oncol, Boston, MA 02114 USA.
EM jain@steele.mgh.harvard.edu; lei@steele.mgh.harvard.edu
FU Dyax; MedImmune; Roche; Enlight; Noxxon; SynDevRx; American Cancer
Society [ACS122839-RSG-12-199-01]; National Institutes of Health
[R01-CA85140, R01-CA115767, R01-CA126642]; Department of Defense Breast
Cancer Research Innovator Award [W81XWH-10-1-0016]
FX R.K.J. received research grants from Dyax, MedImmune, and Roche;
received consultant fees from Dyax, Enlight, Noxxon, and SynDevRx; owns
equity in Enlight, SynDevRx, and XTuit; and serves on the Board of
Directors of XTuit and Board of Trustees of H&Q Healthcare Investors and
H&Q Life Sciences Investors. Y.B. received consultant fees from XTuit.
No reagents or funding from these companies were used in these studies.;
We thank Dannie Wang, Peigen Huang, and Carolyn Smith for their superb
technical support; and Dr. Delphine Lacorre for her protocol for the
doxorubicin distribution study. This work was supported in part by
American Cancer Society Grant ACS122839-RSG-12-199-01 (to L.X.);
National Institutes of Health Grants R01-CA85140 (to R.K.J.),
R01-CA115767 (to R.K.J.), and R01-CA126642 (to R.K.J.); and a Department
of Defense Breast Cancer Research Innovator Award W81XWH-10-1-0016 (to
R.K.J.).
NR 50
TC 70
Z9 70
U1 2
U2 18
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2012
VL 109
IS 41
BP 16618
EP 16623
DI 10.1073/pnas.1117610109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026LQ
UT WOS:000310280300051
PM 22996328
ER
PT J
AU Guo, SQ
Bai, HT
Megyola, CM
Halene, S
Krause, DS
Scadden, DT
Lu, J
AF Guo, Shangqin
Bai, Haitao
Megyola, Cynthia M.
Halene, Stephanie
Krause, Diane S.
Scadden, David T.
Lu, Jun
TI Complex oncogene dependence in microRNA-125a-induced myeloproliferative
neoplasms
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE oncogene addiction; PTPN18; spleen fibrosis
ID HEMATOPOIETIC STEM-CELLS; ACUTE MYELOID-LEUKEMIA; POLYCYTHEMIA-VERA;
MOTH-EATEN; P53 RESTORATION; BONE-MARROW; IN-VIVO; CANCER; MICRORNAS;
GENE
AB Deregulation of microRNA (miRNA) expression can lead to cancer initiation and progression. However, limited information exists on the function of miRNAs in cancer maintenance. We examined these issues in the case of myeloproliferative diseases and neoplasms (MPN), a collection of hematopoietic neoplasms regarded as preleukemic, thereby representing early neoplastic states. We report here that microRNA-125a (miR-125a)-induced MPN display a complex manner of oncogene dependence. Following a gain-of-function genomics screen, we overexpressed candidate miR-125a in vivo, which led to phenotypes consistent with an atypical MPN characterized by leukocytosis, monocytosis, splenomegaly, and progressive anemia. The diseased MPN state could be recapitulated in a doxycycline-inducible mouse model. Upon doxycycline withdrawal, the primary MPN phenotypes rapidly resolved after the discontinuation of miR-125a overexpression. However, reinduction of miR-125a led to complex phenotypes, with some animals rapidly developing lethal anemia with extensive damages in the spleen. Forced expression of miR-125a resulted in elevated cellular tyrosine phosphorylation and hypersensitivity toward hematopoietic cytokines. Furthermore, we demonstrate that miR-125a targets multiple protein phosphatases. Our data demonstrate that miR-125a-induced MPN is addicted to its sustained overexpression, and highlight the complex nature of oncogenic miRNA dependence in an early neoplastic state.
C1 [Guo, Shangqin; Megyola, Cynthia M.; Halene, Stephanie; Krause, Diane S.; Lu, Jun] Yale Univ, Sch Med, Yale Stem Cell Ctr, New Haven, CT 06520 USA.
[Guo, Shangqin; Bai, Haitao; Megyola, Cynthia M.; Lu, Jun] Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA.
[Halene, Stephanie] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA.
[Krause, Diane S.] Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06520 USA.
[Halene, Stephanie; Krause, Diane S.; Lu, Jun] Yale Univ, Sch Med, Yale Canc Ctr, New Haven, CT 06520 USA.
[Scadden, David T.] Harvard Univ, Ctr Regenerat Med, Massachusetts Gen Hosp,,Harvard Stem Cell Inst, Dept Stem Cell & Regenerat Biol, Boston, MA 02114 USA.
[Bai, Haitao] Shanghai First Peoples Hosp, Dept Hematol, Shanghai 200080, Peoples R China.
RP Lu, J (reprint author), Yale Univ, Sch Med, Yale Stem Cell Ctr, 333 Cedar St, New Haven, CT 06520 USA.
EM jun.lu@yale.edu
FU National Institutes of Health Grant [R01CA149109]; American Cancer
Society Institutional Research Grant [58-012-51]
FX We thank Rita Schlanger, Hao Zhang, Judy Wang, and Sharon Lin for their
technical assistance. This work was supported in part by National
Institutes of Health Grant R01CA149109 (to J.L.) and American Cancer
Society Institutional Research Grant 58-012-51 (to J.L.).
NR 45
TC 24
Z9 24
U1 0
U2 5
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2012
VL 109
IS 41
BP 16636
EP 16641
DI 10.1073/pnas.1213196109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026LQ
UT WOS:000310280300054
PM 23012470
ER
PT J
AU van de Water, JAJM
Bagci-Onder, T
Agarwal, AS
Wakimoto, H
Roovers, RC
Zhu, YN
Kasmieh, R
Bhere, D
Henegouwen, PMPVE
Shah, K
AF van de Water, Jeroen A. J. M.
Bagci-Onder, Tugba
Agarwal, Aayush S.
Wakimoto, Hiroaki
Roovers, Rob C.
Zhu, Yanni
Kasmieh, Randa
Bhere, Deepak
Henegouwen, Paul M. P. Van Bergen En
Shah, Khalid
TI Therapeutic stem cells expressing variants of EGFR-specific nanobodies
have antitumor effects
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; BLOOD-BRAIN-BARRIER; GLIOBLASTOMA-MULTIFORME;
CANCER-TREATMENT; LUNG-CANCER; IN-VIVO; ANTIBODY; BEVACIZUMAB;
PROGRESSION; IRINOTECAN
AB The deregulation of the epidermal growth factor receptor (EGFR) has a significant role in the progression of tumors. Despite the development of a number of EGFR-targeting agents that can arrest tumor growth, their success in the clinic is limited in several tumor types, particularly in the highly malignant glioblastoma multi-forme (GBM). In this study, we generated and characterized EGFR-specific nanobodies (ENb) and imageable and proapoptotic ENb immunoconjugates released from stem cells (SC) to ultimately develop a unique EGFR-targeted therapy for GBM. We show that ENbs released from SCs specifically localize to tumors, inhibit EGFR signaling resulting in reduced GBM growth and invasiveness in vitro and in vivo in both established and primary GBM cell lines. We also show that ENb primes GBM cells for proapoptotic tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis. Furthermore, SC-delivered immunoconjugates of ENb and TRAIL target a wide spectrum of GBM cell types with varying degrees of TRAIL resistance and significantly reduce GBM growth and invasion in both established and primary invasive GBM in mice. This study demonstrates the efficacy of SC-based EGFR targeted therapy in GBMs and provides a unique approach with clinical implications.
C1 [van de Water, Jeroen A. J. M.; Bagci-Onder, Tugba; Agarwal, Aayush S.; Wakimoto, Hiroaki; Zhu, Yanni; Kasmieh, Randa; Bhere, Deepak; Shah, Khalid] Harvard Univ, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02129 USA.
[van de Water, Jeroen A. J. M.; Bagci-Onder, Tugba; Agarwal, Aayush S.; Wakimoto, Hiroaki; Zhu, Yanni; Kasmieh, Randa; Bhere, Deepak; Shah, Khalid] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02129 USA.
[Shah, Khalid] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02129 USA.
[Wakimoto, Hiroaki] Harvard Univ, Sch Med, Dept Neurosurg, Massachusetts Gen Hosp, Boston, MA 02129 USA.
[van de Water, Jeroen A. J. M.; Roovers, Rob C.; Henegouwen, Paul M. P. Van Bergen En] Univ Utrecht, Dept Biol, Fac Sci, NL-3508 Utrecht, Netherlands.
[Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Shah, K (reprint author), Harvard Univ, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02129 USA.
EM kshah@mgh.harvard.edu
RI van de Water, Jeroen/F-1302-2011; van Bergen en Henegouwen,
Paul/B-8870-2011;
OI van de Water, Jeroen/0000-0001-6974-2270; van Bergen en Henegouwen,
Paul/0000-0001-6050-9042; Roovers, Rob/0000-0002-9715-2136
FU National Institutes of Health (NIH) Grant [R21 CA86355]; NIH [R01
CA138922, R01 NS071197]; American Cancer Society; Dutch Cancer Society;
James McDonald Foundation
FX We thank Dr. Cedric Berger for his help with FACS analysis. This work
was supported by National Institutes of Health (NIH) Grant R21 CA86355
(to K.S.), NIH Grants R01 CA138922 and R01 NS071197 (to K.S.), the
American Cancer Society (K.S.), the Dutch Cancer Society (J.A.J.
M.v.d.W.), and The James McDonald Foundation (K.S.).
NR 32
TC 16
Z9 16
U1 1
U2 13
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2012
VL 109
IS 41
BP 16642
EP 16647
DI 10.1073/pnas.1202832109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026LQ
UT WOS:000310280300055
PM 23012408
ER
PT J
AU Gordon, LB
Kleinman, ME
Miller, DT
Neuberg, DS
Giobbie-Hurder, A
Gerhard-Herman, M
Smoot, LB
Gordon, CM
Cleveland, R
Snyder, BD
Fligor, B
Bishop, WR
Statkevich, P
Regen, A
Sonis, A
Riley, S
Ploski, C
Correia, A
Quinn, N
Ullrich, NJ
Nazarian, A
Liang, MG
Huh, SY
Schwartzman, A
Kieran, MW
AF Gordon, Leslie B.
Kleinman, Monica E.
Miller, David T.
Neuberg, Donna S.
Giobbie-Hurder, Anita
Gerhard-Herman, Marie
Smoot, Leslie B.
Gordon, Catherine M.
Cleveland, Robert
Snyder, Brian D.
Fligor, Brian
Bishop, W. Robert
Statkevich, Paul
Regen, Amy
Sonis, Andrew
Riley, Susan
Ploski, Christine
Correia, Annette
Quinn, Nicolle
Ullrich, Nicole J.
Nazarian, Ara
Liang, Marilyn G.
Huh, Susanna Y.
Schwartzman, Armin
Kieran, Mark W.
TI Clinical trial of a farnesyltransferase inhibitor in children with
Hutchinson-Gilford progeria syndrome
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE SCH66336; laminopathy; cardiovascular disease; translational medicine
ID PULSE-WAVE VELOCITY; FARNESYL TRANSFERASE INHIBITORS; MOUSE MODEL;
HEALTHY-CHILDREN; REFERENCE VALUES; LAMIN; DISEASE; PROGRESSION;
PHENOTYPE; BONE
AB Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare, fatal, segmental premature aging syndrome caused by a mutation in LMNA that produces the farnesylated aberrant lamin A protein, progerin. This multisystem disorder causes failure to thrive and accelerated atherosclerosis leading to early death. Farnesyltransferase inhibitors have ameliorated disease phenotypes in preclinical studies. Twenty-five patients with HGPS received the farnesyltransferase inhibitor lonafarnib for a minimum of 2 y. Primary outcome success was predefined as a 50% increase over pretherapy in estimated annual rate of weight gain, or change from pretherapy weight loss to statistically significant on-study weight gain. Nine patients experienced a >= 50% increase, six experienced a >= 50% decrease, and 10 remained stable with respect to rate of weight gain. Secondary outcomes included decreases in arterial pulse wave velocity and carotid artery echodensity and increases in skeletal rigidity and sensorineural hearing within patient subgroups. All patients improved in one or more of these outcomes. Results from this clinical treatment trial for children with HGPS provide preliminary evidence that lonafarnib may improve vascular stiffness, bone structure, and audiological status.
C1 [Gordon, Leslie B.; Kleinman, Monica E.] Boston Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA.
[Miller, David T.; Liang, Marilyn G.; Huh, Susanna Y.] Boston Childrens Hosp, Dept Med, Boston, MA 02115 USA.
[Miller, David T.] Boston Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.
[Smoot, Leslie B.] Boston Childrens Hosp, Dept Cardiol, Boston, MA 02115 USA.
[Cleveland, Robert] Boston Childrens Hosp, Dept Radiol, Boston, MA 02115 USA.
[Snyder, Brian D.] Boston Childrens Hosp, Dept Orthoped, Boston, MA 02115 USA.
[Fligor, Brian] Boston Childrens Hosp, Dept Otolaryngol & Commun Enhancement, Boston, MA 02115 USA.
[Regen, Amy; Sonis, Andrew] Boston Childrens Hosp, Dept Dent, Boston, MA 02115 USA.
[Riley, Susan; Ploski, Christine; Correia, Annette] Boston Childrens Hosp, Dept Phys Therapy & Occupat Therapy Serv, Boston, MA 02115 USA.
[Ullrich, Nicole J.] Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA.
[Gordon, Leslie B.; Kleinman, Monica E.] Boston Childrens Hosp, Div Crit Care Med, Boston, MA 02115 USA.
[Miller, David T.] Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA.
[Gordon, Catherine M.] Boston Childrens Hosp, Div Adolescent Med, Boston, MA 02115 USA.
[Gordon, Catherine M.] Boston Childrens Hosp, Div Endocrinol, Boston, MA 02115 USA.
[Quinn, Nicolle; Huh, Susanna Y.] Boston Childrens Hosp, Div Gastroenterol & Nutr, Boston, MA 02115 USA.
[Liang, Marilyn G.] Boston Childrens Hosp, Div Dermatol, Boston, MA 02115 USA.
[Kieran, Mark W.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Gordon, Leslie B.; Gordon, Catherine M.] Brown Univ, Dept Pediat, Hasbro Childrens Hosp, Providence, RI 02903 USA.
[Gordon, Leslie B.; Gordon, Catherine M.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02903 USA.
[Neuberg, Donna S.; Giobbie-Hurder, Anita] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Neuberg, Donna S.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Gerhard-Herman, Marie] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Cardiovasc Div, Boston, MA 02115 USA.
[Bishop, W. Robert; Statkevich, Paul] Merck Res Labs, Kenilworth, NJ 07033 USA.
[Quinn, Nicolle] Boston Childrens Hosp, Clin Translat Study Unit, Boston, MA 02115 USA.
[Snyder, Brian D.] Beth Israel Deaconess Med Ctr, Ctr Adv Orthopaed Studies, Dept Orthopaed, Boston, MA 02115 USA.
[Kieran, Mark W.] Dana Farber Canc Inst, Div Pediat Oncol, Boston, MA 02215 USA.
RP Gordon, LB (reprint author), Boston Childrens Hosp, Dept Anesthesia, Boston, MA 02115 USA.
EM Leslie_Gordon@brown.edu; mark_kieran@dfci.harvard.edu
OI Kieran, Mark/0000-0003-2184-7692; Schwartzman, Armin/0000-0001-5335-1611
FU Progeria Research Foundation [PRFCLIN2007-01]; Dana-Farber Cancer
Institute Stop & Shop Pediatric Brain Tumor Program; C.J. Buckley Fund;
Kyle Johnson Fund; National Center for Research Resources, National
Institutes of Health [MO1-RR02172, UL1 RR025758-01]
FX Most importantly, we are grateful to the children with progeria and
their families and to the children who participated as control subjects
for participation in this study. Additional acknowledgments are included
in SI Results. This project was funded by Grant PRFCLIN2007-01 from The
Progeria Research Foundation, by the Dana-Farber Cancer Institute Stop &
Shop Pediatric Brain Tumor Program, the C.J. Buckley Fund, the Kyle
Johnson Fund, and by the National Center for Research Resources,
National Institutes of Health Grants MO1-RR02172 to the Boston
Children's Hospital General Clinical Research Center and UL1 RR025758-01
to the Harvard Catalyst Clinical and Translational Science Center.
NR 40
TC 83
Z9 91
U1 4
U2 53
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2012
VL 109
IS 41
BP 16666
EP 16671
DI 10.1073/pnas.1202529109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026LQ
UT WOS:000310280300059
PM 23012407
ER
PT J
AU Chen, NY
Sugihara, H
Sharma, J
Perea, G
Petravicz, J
Le, C
Sur, M
AF Chen, Naiyan
Sugihara, Hiroki
Sharma, Jitendra
Perea, Gertrudis
Petravicz, Jeremy
Le, Chuong
Sur, Mriganka
TI Nucleus basalis-enabled stimulus-specific plasticity in the visual
cortex is mediated by astrocytes
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE acetylcholine; response potentiation; glial calcium; basal forebrain;
astrocyte-neuron interactions
ID EXTRASYNAPTIC NMDA RECEPTORS; DEPENDENT GLUTAMATE RELEASE; LONG-TERM
POTENTIATION; CHOLINERGIC MODULATION; IN-VIVO; ORIENTATION SELECTIVITY;
HIPPOCAMPAL ASTROCYTES; CORTICAL-NEURONS; CEREBRAL-CORTEX; D-SERINE
AB Although cholinergic innervation of the cortex by the nucleus basalis (NB) is known to modulate cortical neuronal responses and instruct cortical plasticity, little is known about the underlying cellular mechanisms. Using cell-attached recordings in vivo, we demonstrate that electrical stimulation of the NB, paired with visual stimulation, can induce significant potentiation of visual responses in excitatory neurons of the primary visual cortex in mice. We further show with in vivo two-photon calcium imaging, ex vivo calcium imaging, and whole-cell recordings that this pairing-induced potentiation is mediated by direct cholinergic activation of primary visual cortex astrocytes via muscarinic AChRs. The potentiation is absent in conditional inositol 1,4,5 trisphosphate receptor type 2 KO mice, which lack astrocyte calcium activation, and is stimulus-specific, because pairing NB stimulation with a specific visual orientation reveals a highly selective potentiation of responses to the paired orientation compared with unpaired orientations. Collectively, these findings reveal a unique and surprising role for astrocytes in NB-induced stimulus-specific plasticity in the cerebral cortex.
C1 [Chen, Naiyan; Sugihara, Hiroki; Sharma, Jitendra; Perea, Gertrudis; Petravicz, Jeremy; Le, Chuong; Sur, Mriganka] MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, Cambridge, MA 02139 USA.
[Sharma, Jitendra] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Sur, M (reprint author), MIT, Dept Brain & Cognit Sci, Picower Inst Learning & Memory, E25-618, Cambridge, MA 02139 USA.
EM msur@mit.edu
FU Agency for Science, Technology and Research, Singapore (A*STAR)
Fellowship; Marie Curie Fellowship; National Institutes of Health
[R01EY007023, R01EY018648]; Simons Foundation
FX We thank K. D. McCarthy (University of North Carolina) for providing the
IP3R2 mice. We thank Michael Goard, Caroline Runyan, Travis
Emery, Jonathan Woodson, and Jorge Castro for discussions/technical
advice/assistance. This work was supported by an Agency for Science,
Technology and Research, Singapore (A*STAR) Fellowship (to N.C.), Marie
Curie Fellowship (to G.P.), National Institutes of Health Grants
R01EY007023 and R01EY018648 (to M.S.), and a grant from the Simons
Foundation (to M.S.).
NR 50
TC 55
Z9 55
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 9
PY 2012
VL 109
IS 41
BP E2832
EP E2841
DI 10.1073/pnas.1206557109
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 026LQ
UT WOS:000310280300013
PM 23012414
ER
PT J
AU Schleiermacher, G
Mosseri, V
London, WB
Maris, JM
Brodeur, GM
Attiyeh, E
Haber, M
Khan, J
Nakagawara, A
Speleman, F
Noguera, R
Tonini, GP
Fischer, M
Ambros, I
Monclair, T
Matthay, KK
Ambros, P
Cohn, SL
Pearson, ADJ
AF Schleiermacher, G.
Mosseri, V.
London, W. B.
Maris, J. M.
Brodeur, G. M.
Attiyeh, E.
Haber, M.
Khan, J.
Nakagawara, A.
Speleman, F.
Noguera, R.
Tonini, G. P.
Fischer, M.
Ambros, I.
Monclair, T.
Matthay, K. K.
Ambros, P.
Cohn, S. L.
Pearson, A. D. J.
TI Segmental chromosomal alterations have prognostic impact in
neuroblastoma: a report from the INRG project
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE neuroblastoma; genetic alterations; genomic profile; prognosis; INRG
ID CLINICAL-RELEVANCE; HIGHER RISK; GAIN; AMPLIFICATION; RELAPSE; TUMORS;
1P; HETEROZYGOSITY; ACCUMULATION; PROGRESSION
AB BACKGROUND: In the INRG dataset, the hypothesis that any segmental chromosomal alteration might be of prognostic impact in neuroblastoma without MYCN amplification (MNA) was tested.
METHODS: The presence of any segmental chromosomal alteration (chromosome 1p deletion, 11q deletion and/ or chromosome 17q gain) defined a segmental genomic profile. Only tumours with a confirmed unaltered status for all three chromosome arms were considered as having no segmental chromosomal alterations.
RESULTS: Among the 8800 patients in the INRG database, a genomic type could be attributed for 505 patients without MNA: 397 cases had a segmental genomic type, whereas 108 cases had an absence of any segmental alteration. A segmental genomic type was more frequent in patients > 18 months and in stage 4 disease (P < 0.0001). In univariate analysis, 11q deletion, 17q gain and a segmental genomic type were associated with a poorer event-free survival (EFS) (P < 0.0001, P = 0.0002 and P < 0.0001, respectively). In multivariate analysis modelling EFS, the parameters age, stage and a segmental genomic type were retained in the model, whereas the individual genetic markers were not (P < 0.0001 and RR = 2.56; P = 0.0002 and RR = 1.8; P = 0.01 and RR = 1.7, respectively).
CONCLUSION: A segmental genomic profile, rather than the single genetic markers, adds prognostic information to the clinical markers age and stage in neuroblastoma patients without MNA, underlining the importance of pangenomic studies. British Journal of Cancer (2012) 107, 1418-1422. doi:10.1038/bjc.2012.375 www.bjcancer.com Published online 13 September 2012 (c) 2012 Cancer Research UK
C1 [Schleiermacher, G.] Inst Curie, INSERM, U830, Lab Genet & Biol Canc, Paris, France.
[Schleiermacher, G.] Inst Curie, Dept Pediat Oncol, F-75248 Paris 05, France.
[Mosseri, V.] Inst Curie, Serv Biostat, Paris, France.
[London, W. B.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Childrens Hosp Boston, Boston, MA 02115 USA.
[Maris, J. M.; Brodeur, G. M.; Attiyeh, E.] Univ Penn, Ctr Childhood Canc Res, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Haber, M.] Univ New S Wales, Childrens Canc Inst Australia Med Res Lowy Canc R, Sydney, NSW, Australia.
[Khan, J.] NCI, Oncogen Sect, Pediat Oncol Branch, NIH, Gaithersburg, MD USA.
[Nakagawara, A.] Chiba Canc Ctr Res Inst, Lab Innovat Canc Therapeut, Chiba, Japan.
[Speleman, F.] Ghent Univ Hosp, Ctr Med Genet, Dept Paediat Hematol & Oncol, Ghent, Belgium.
[Tonini, G. P.] Natl Inst Canc Res, Genoa, Italy.
[Noguera, R.] Univ Valencia, Dept Pathol, Valencia, Spain.
[Fischer, M.] Univ Cologne, Childrens Hosp, Dept Pediat Oncol & Hematol, D-50931 Cologne, Germany.
[Fischer, M.] Univ Cologne, Ctr Mol Med Cologne, D-50931 Cologne, Germany.
[Ambros, I.; Ambros, P.] St Anna Kinderkrebsforsch, CCRI, Vienna, Austria.
[Monclair, T.] Aker Univ Hosp, Sect Paediat Surg, Div Surg, Rikshosp, Oslo, Norway.
[Matthay, K. K.] UCSF Sch Med, San Francisco, CA USA.
[Matthay, K. K.] Benioff Childrens Hosp, San Francisco, CA USA.
[Cohn, S. L.] Univ Chicago, Sect Pediat Hematol Oncol, Comer Childrens Hosp, Chicago, IL 60637 USA.
[Pearson, A. D. J.] Royal Marsden Hosp, Childrens Dept, Inst Canc Res, Sutton, Surrey, England.
RP Schleiermacher, G (reprint author), Inst Curie, INSERM, U830, Lab Genet & Biol Canc, Paris, France.
EM gudrun.schleiermacher@curie.net
RI Khan, Javed/P-9157-2014;
OI Khan, Javed/0000-0002-5858-0488; Ambros, Peter F./0000-0002-5507-7211;
Cohn, Susan/0000-0001-5749-7650
FU Annenberg Foundation
FX GS is supported by the Annenberg Foundation. The INRG database harbours
biology data from different national groups and laboratories responsible
for neuroblastoma genetics. For SIOPEN, the following members of the
SIOPEN Biology group contributed data: Clare Bedwell, Newcastle, UK;
Klaus Beiske, Oslo, Norway; Jean Benard, Villejuif, France; Nick Bown,
Newcastle, UK; Valerie Combaret, Lyon, France; Jerome Couturier, Paris,
France; Raffaella Defferrari, Genoa, Italy; Nicole Gross, Lausanne,
Switzerland; Marta Jeison, Petah Tikva, Israel: John Lunec, Newcastle,
UK; Tommy Martinsson, Goteborg, Sweden; Barbara Marques, Lisbon,
Portugal; Katia Mazzocco, Genoa, Italy; Rosa Noguera, Valencia, Spain;
Gianpaolo Tonini, Genoa, Italy; Deborah Tweddle, Newcastle, UK;
Alexander Valent, Villejuif, France; Nadine Van Roy, Ghent, Belgium;
Luigi Varesio, Genoa, Italy; Alex Vicha, Prague, Czech Republic; Eva
Villamon, Valencia, Spain. For GPOH, the following biology group members
contributed data: Franck Berthold, Cologne, Germany; Jessica Theissen,
Cologne, Germany; Manfred Schwab, Heidelberg, Germany; Frank Westermann,
Heidelberg, Germany; Freimut Schilling, Stuttgart, Germany; Sabine
Stegmaier, Stuttgart, Germany; Felix Niggli, Zurich, Switzerland. For
COG, the following biology group members contributed data: Michael
Hogarty, Philadelphia, USA; Rochelle Bagatell, Philadelphia, USA. For
Japan, the following biology group members contributed data: Miki Ohira,
Chiba, Japan; Yasuhiko Kaneko, Saitama, Japan; Junko Takita, Tokyo,
Japan; Hajime Ohkita, Tokyo, Japan (Ambros et al, 2009).
NR 26
TC 39
Z9 40
U1 1
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD OCT 9
PY 2012
VL 107
IS 8
BP 1418
EP 1422
DI 10.1038/bjc.2012.375
PG 5
WC Oncology
SC Oncology
GA 022MI
UT WOS:000309963100028
PM 22976801
ER
PT J
AU Qi, QB
Li, YP
Chomistek, AK
Kang, JH
Curhan, GC
Pasquale, LR
Willett, WC
Rimm, EB
Hu, FB
Qi, L
AF Qi, Qibin
Li, Yanping
Chomistek, Andrea K.
Kang, Jae H.
Curhan, Gary C.
Pasquale, Louis R.
Willett, Walter C.
Rimm, Eric B.
Hu, Frank B.
Qi, Lu
TI Television Watching, Leisure Time Physical Activity, and the Genetic
Predisposition in Relation to Body Mass Index in Women and Men
SO CIRCULATION
LA English
DT Article
DE body mass index; genetics; sedentary lifestyle; television viewing;
physical activity
ID TYPE-2 DIABETES-MELLITUS; FOOD FREQUENCY QUESTIONNAIRE; FTO RS9939609
POLYMORPHISM; MALE HEALTH-PROFESSIONALS; CARDIOVASCULAR-DISEASE; DIETARY
PATTERNS; ACTIVITY LEVEL; RISK; OBESITY; VARIANTS
AB Background-Previous studies on gene-lifestyle interaction and obesity have focused mostly on the FTO gene and physical activity, whereas little attention has been paid to sedentary behavior as indicated by television (TV) watching.
Methods and Results-We analyzed interactions between TV watching, leisure time physical activity, and genetic predisposition in relation to body mass index (BMI) in 7740 women and 4564 men from 2 prospective cohorts: The Nurses' Health Study and the Health Professionals Follow-up Study. Data on physical activity and TV watching were collected 2 years before assessment of BMI. A weighted genetic risk score was calculated on the basis of 32 established BMI-associated variants. In both women and men, the genetic associations with BMI strengthened with increased hours of TV watching. An increment of 10 points in the weighted genetic risk score was associated with 0.8 (SE, 0.4), 0.8 (SE, 0.2), 1.4 (SE, 0.2), 1.5 (SE, 0.2), and 3.4 (SE, 1.0) kg/m(2) higher BMI across the 5 categories of TV watching (0-1, 2-5, 6-20, 21-40, and >40 h/wk; P for interaction = 0.001). In contrast, the genetic association with BMI weakened with increased levels of physical activity. An increment of 10 points in the weighted genetic risk score was associated with 1.5 (SE, 0.2), 1.3 (SE, 0.2), 1.2 (SE, 0.2), 1.2 (SE, 0.2), and 0.8 (SE, 0.2) kg/m(2) higher BMI across the quintiles of physical activity. The interactions of TV watching and physical activity with genetic predisposition in relation to BMI were independent of each other.
Conclusions-A sedentary lifestyle, indicated by prolonged TV watching, may accentuate the predisposition to elevated adiposity, whereas greater leisure time physical activity may attenuate the genetic association. (Circulation. 2012;126:1821-1827.)
C1 [Qi, Qibin; Chomistek, Andrea K.; Willett, Walter C.; Rimm, Eric B.; Hu, Frank B.; Qi, Lu] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Curhan, Gary C.; Willett, Walter C.; Rimm, Eric B.; Hu, Frank B.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Li, Yanping; Kang, Jae H.; Curhan, Gary C.; Pasquale, Louis R.; Willett, Walter C.; Rimm, Eric B.; Hu, Frank B.; Qi, Lu] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA.
[Pasquale, Louis R.] Harvard Univ, Sch Med, Dept Ophthalmol, Massachusetts Eye & Ear Infirm, Boston, MA USA.
RP Qi, L (reprint author), Harvard Univ, Sch Publ Hlth, Dept Nutr, 665 Huntington Ave, Boston, MA 02115 USA.
EM nhlqi@channing.harvard.edu
RI Qi, Qibin/H-9055-2012; Chomistek, Andrea/A-2104-2017
OI Chomistek, Andrea/0000-0002-8764-1446
FU National Institutes of Health [DK091718, HL071981, HL073168, CA87969,
CA49449, CA055075, HL34594, HL088521, U01HG004399, DK080140,
5P30DK46200, U54CA155626, DK58845, U01HG004728-02, EY015473, DK70756,
DK46200]; American Heart Association [0730094N]; Research to Prevent
Blindness (NYC); Harvard Ophthalmology Scholar Award (Harvard Medical
School) from the Harvard Glaucoma Center of Excellence
FX This study was supported by grants DK091718, HL071981, HL073168,
CA87969, CA49449, CA055075, HL34594, HL088521, U01HG004399, DK080140,
5P30DK46200, U54CA155626, DK58845, U01HG004728-02, EY015473, DK70756,
and DK46200 from the National Institutes of Health, with additional
support for genotyping from Merck Research Laboratories, North Wales,
PA. Dr Lu Qi is a recipient of the American Heart Association Scientist
Development Award (0730094N). Dr Pasquale is supported by Research to
Prevent Blindness (NYC) and a Harvard Ophthalmology Scholar Award
(Harvard Medical School) from the Harvard Glaucoma Center of Excellence.
NR 40
TC 37
Z9 41
U1 0
U2 24
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 9
PY 2012
VL 126
IS 15
BP 1821
EP U70
DI 10.1161/CIRCULATIONAHA.112.098061
PG 9
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 019ZZ
UT WOS:000309779400010
PM 22949498
ER
PT J
AU Le, LP
Dias-Santagata, D
Pawlak, AC
Cosper, AK
Nguyen, AT
Selim, MA
Deng, A
Horick, NK
Iafrate, AJ
Mihm, MC
Hoang, MP
AF Le, Long P.
Dias-Santagata, Dora
Pawlak, Amanda C.
Cosper, Arjola K.
Anh Thu Nguyen
Selim, M. Angelica
Deng, April
Horick, Nora K.
Iafrate, A. John
Mihm, Martin C., Jr.
Hoang, Mai P.
TI Apocrine-Eccrine Carcinomas: Molecular and Immunohistochemical Analyses
SO PLOS ONE
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; SWEAT GLAND
CARCINOMAS; IN-SITU HYBRIDIZATION; FACTOR RECEPTOR GENE; CELL
LUNG-CANCER; BREAST-CANCER; MUTATIONAL-ANALYSIS; HIGH-FREQUENCY; ADNEXAL
CARCINOMAS
AB Apocrine-eccrine carcinomas are rare and associated with poor prognosis. Currently there is no uniform treatment guideline. Chemotherapeutic drugs that selectively target cancer-promoting pathways may complement conventional therapeutic approaches. However, studies on genetic alterations and EGFR and Her2 status of apocrine-eccrine carcinomas are few in number. In addition, hormonal studies have not been comprehensive and performed only on certain subsets of apocrine-eccrine carcinomas. To investigate whether apocrine-eccrine carcinomas express hormonal receptors or possess activation of oncogenic pathways that can be targeted by available chemotherapeutic agent we performed immunohistochemistry for AR, PR, ER, EGFR, and HER2 expression; fluorescence in situ hybridization (FISH) for EGFR and ERBB2 gene amplification; and molecular analyses for recurrent mutations in 15 cancer genes including AKT-1, EGFR, PIK3CA, and TP53 on 54 cases of apocrine-eccrine carcinomas. They include 10 apocrine carcinomas, 7 eccrine carcinomas, 9 aggressive digital papillary adenocarcinomas, 10 hidradenocarcinomas, 11 porocarcinomas, 1 adenoid cystic carcinoma, 4 malignant chondroid syringomas, 1 malignant spiradenoma, and 1 malignant cylindroma. AR, ER, PR, EGFR and HER2 expression was seen in 36% (19/53), 27% (14/51), 16% (8/51), 85% (44/52) and 12% (6/52), respectively. Polysomy or trisomy of EGFR was detected by FISH in 30% (14/46). Mutations of AKT-1, PIK3CA, and TP53 were detected in 1, 3, and 7 cases, respectively (11/47, 23%). Additional investigation regarding the potential treatment of rare cases of apocrine-eccrine carcinomas with PI3K/Akt/mTOR pathway inhibitors, currently in clinical testing, may be of clinical interest.
C1 [Le, Long P.; Dias-Santagata, Dora; Pawlak, Amanda C.; Cosper, Arjola K.; Anh Thu Nguyen; Iafrate, A. John; Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Le, Long P.; Dias-Santagata, Dora; Pawlak, Amanda C.; Cosper, Arjola K.; Anh Thu Nguyen; Iafrate, A. John; Hoang, Mai P.] Harvard Univ, Sch Med, Boston, MA USA.
[Selim, M. Angelica] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
[Deng, April] Univ Massachusetts, Med Ctr, Dept Pathol, Worcester, MA USA.
[Horick, Nora K.] Massachusetts Gen Hosp, Biostat Ctr, Boston, MA 02114 USA.
[Mihm, Martin C., Jr.] Brigham & Womens Hosp, Dept Dermatol, Boston, MA 02115 USA.
RP Hoang, MP (reprint author), Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
EM mhoang@partners.org
NR 60
TC 10
Z9 10
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2012
VL 7
IS 10
AR e47290
DI 10.1371/journal.pone.0047290
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 021MR
UT WOS:000309889400068
PM 23056620
ER
PT J
AU Sethi, G
Pathak, HB
Zhang, H
Zhou, Y
Einarson, MB
Vathipadiekal, V
Gunewardena, S
Birrer, MJ
Godwin, AK
AF Sethi, Geetika
Pathak, Harsh B.
Zhang, Hong
Zhou, Yan
Einarson, Margret B.
Vathipadiekal, Vinod
Gunewardena, Sumedha
Birrer, Michael J.
Godwin, Andrew K.
TI An RNA Interference Lethality Screen of the Human Druggable Genome to
Identify Molecular Vulnerabilities in Epithelial Ovarian Cancer
SO PLOS ONE
LA English
DT Article
ID TUMOR-CELL GROWTH; RIBOSOMAL-PROTEINS; SIGNALING PATHWAY; REGULATED
PROTEIN; CLINICAL-TRIALS; IN-VITRO; PLEIOTROPHIN; ANGIOGENESIS;
IDENTIFICATION; ACTIVATION
AB Targeted therapies have been used to combat many tumor types; however, few have effectively improved the overall survival in women with epithelial ovarian cancer, begging for a better understanding of this deadly disease and identification of essential drivers of tumorigenesis that can be targeted effectively. Therefore, we used a loss-of-function screening approach to help identify molecular vulnerabilities that may represent key points of therapeutic intervention. We employed an unbiased high-throughput lethality screen using a 24,088 siRNA library targeting over 6,000 druggable genes and studied their effects on growth and/or survival of epithelial ovarian cancer (EOC) cell lines. The top 300 "hits" affecting the viability of A1847 cells were rescreened across additional EOC cell lines and non-tumorigenic, human immortalized ovarian epithelial cell lines. Fifty-three gene candidates were found to exhibit effects in all tumorigenic cell lines tested. Extensive validation of these hits refined the list to four high quality candidates (HSPA5, NDC80, NUF2, and PTN). Mechanistic studies show that silencing of three genes leads to increased apoptosis, while HSPA5 silencing appears to alter cell growth through G1 cell cycle arrest. Furthermore, two independent gene expression studies show that NDC80, NUF2 and PTN were significantly aberrantly overexpressed in serous adenocarcinomas. Overall, our functional genomics results integrated with the genomics data provide an important unbiased avenue towards the identification of prospective therapeutic targets for drug discovery, which is an urgent and unmet clinical need for ovarian cancer.
C1 [Sethi, Geetika; Pathak, Harsh B.; Godwin, Andrew K.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66103 USA.
[Sethi, Geetika; Pathak, Harsh B.; Godwin, Andrew K.] Univ Kansas, Med Ctr, Lab Med, Kansas City, KS 66103 USA.
[Sethi, Geetika] Drexel Univ, Coll Med, Dept Biochem, Philadelphia, PA 19104 USA.
[Pathak, Harsh B.; Godwin, Andrew K.] Univ Kansas, Ctr Canc, Kansas City, KS USA.
[Zhou, Yan] Fox Chase Canc Ctr, Biostatist & Bioinformat Facil, Philadelphia, PA 19111 USA.
[Einarson, Margret B.] Fox Chase Canc Ctr, Translat Core Facil, Philadelphia, PA 19111 USA.
[Vathipadiekal, Vinod; Birrer, Michael J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Godwin, AK (reprint author), Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66103 USA.
EM agodwin@kumc.edu
OI Vathipadiekal, Vinod/0000-0002-8181-6890
FU Ovarian Cancer Research Fund; NCI [CA140323]; University of Kansas
Cancer Center; Kansas Bioscience Authority Eminent Scholar Program
FX The study was supported in part by a program project grant from Ovarian
Cancer Research Fund (http://www.ocrf.org) and a grant from the NCI
(CA140323) to AKG. The authors acknowledge support from the University
of Kansas Cancer Center and the Kansas Bioscience Authority Eminent
Scholar Program. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 68
TC 17
Z9 18
U1 3
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 9
PY 2012
VL 7
IS 10
AR e47086
DI 10.1371/journal.pone.0047086
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 021MR
UT WOS:000309889400054
PM 23056589
ER
PT J
AU Parker, ED
Margolis, KL
Trower, NK
Magid, DJ
Tavel, HM
Shetterly, SM
Ho, PM
Swain, BE
O'Connor, PJ
AF Parker, Emily D.
Margolis, Karen L.
Trower, Nicole K.
Magid, David. J.
Tavel, Heather M.
Shetterly, Susan M.
Ho, P. Michael
Swain, Bix E.
O'Connor, Patrick J.
TI Comparative Effectiveness of 2 beta-Blockers in Hypertensive Patients
SO ARCHIVES OF INTERNAL MEDICINE
LA English
DT Article
ID PROSPECTIVELY-DESIGNED OVERVIEWS; HEART-RATE-VARIABILITY;
BLOOD-PRESSURE; RANDOMIZED-TRIAL; CARDIOVASCULAR EVENTS; 1ST-LINE
THERAPY; ATENOLOL; PREVENTION; METAANALYSIS; GUIDELINES
AB Background: Randomized controlled trials have demonstrated the efficacy of selected beta-blockers for preventing cardiovascular (CV) events in patients following myocardial infarction (MI) or with heart failure (HF). However, the effectiveness of beta-blockers for preventing CV events in patients with hypertension has been questioned recently, but it is unclear whether this is a class effect.
Methods: Using electronic medical record and health plan data from the Cardiovascular Research Network Hypertension Registry, we compared incident MI, HF, and stroke in patients who were new beta-blocker users between 2000 and 2009. Patients had no history of CV disease and had not previously filled a prescription for a beta-blocker. Cox proportional hazards regression was used to examine the associations of atenolol and metoprolol tartrate with incident CV events using both standard covariate adjustment (n=120 978) and propensity score-matching methods (n=22 352).
Results: During follow-up (median, 5.2 years), there were 3517 incident MI, 3272 incident HF, and 3664 incident stroke events. Hazard ratios for MI, HF, and stroke in metoprolol tartrate users were 0.99 (95% CI, 0.97-1.02), 0.99 (95% CI, 0.96-1.01), and 0.99 (95% CI, 0.97-1.02), respectively. An alternative approach using propensity score matching yielded similar results in 11 176 new metoprolol tartrate users, who were similar to 11 176 new atenolol users with regard to demographic and clinical characteristics.
Conclusions: There were no statistically significant differences in incident CV events between atenolol and metoprolol tartrate users with hypertension. Large registries similar to the one used in this analysis may be useful for addressing comparative effectiveness questions that are unlikely to be resolved by randomized trials.
C1 [Parker, Emily D.; Margolis, Karen L.; Trower, Nicole K.; O'Connor, Patrick J.] HealthPartners Inst Educ & Res, Minneapolis, MN 55440 USA.
[Magid, David. J.; Tavel, Heather M.; Shetterly, Susan M.] Kaiser Permanente Colorado, Inst Hlth Res, Denver, CO USA.
[Ho, P. Michael] Univ Colorado, Denver VA Med Ctr, Denver, CO 80202 USA.
[Ho, P. Michael] Univ Colorado, Sch Med, Div Cardiol, Denver, CO USA.
[Swain, Bix E.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA.
RP Parker, ED (reprint author), HealthPartners Inst Educ & Res, Box 1524,Mail Stop 21111R, Minneapolis, MN 55440 USA.
EM Emily.D.Parker@Healthpartners.com
FU National Heart, Lung, and Blood Institute [NIH/NHLBI/U19 HL091179]
FX This project was funded by grant NIH/NHLBI/U19 HL091179 from the
National Heart, Lung, and Blood Institute and subcontract to
HealthPartners Institute for Education and Research.
NR 35
TC 6
Z9 6
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9926
J9 ARCH INTERN MED
JI Arch. Intern. Med.
PD OCT 8
PY 2012
VL 172
IS 18
BP 1406
EP 1412
DI 10.1001/archinternmed.2012.4276
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 016ST
UT WOS:000309540500008
PM 22928181
ER
PT J
AU Su, G
Sung, KE
Beebe, DJ
Friedl, A
AF Su, Gui
Sung, Kyung E.
Beebe, David J.
Friedl, Andreas
TI Functional Screen of Paracrine Signals in Breast Carcinoma Fibroblasts
SO PLOS ONE
LA English
DT Article
ID MATRIX-METALLOPROTEINASE INHIBITORS; MAMMARY-TUMOR GROWTH; STROMAL
FIBROBLASTS; GENE-EXPRESSION; CELL-PROLIFERATION; CANCER CELLS;
PROGRESSION; HEPARANASE; RECEPTOR; MICROENVIRONMENT
AB Stromal fibroblasts actively participate in normal mammary gland homeostasis and in breast carcinoma growth and progression by secreting paracrine factors; however, little is known about the identity of paracrine mediators in individual patients. The purpose of this study was to characterize paracrine signaling pathways between breast carcinoma cells and breast carcinoma-associated fibroblasts (CAF) or normal mammary fibroblasts (NF), respectively. CAF and NF were isolated from breast carcinoma tissue samples and adjacent normal mammary gland tissue of 28 patients. The fibroblasts were grown in 3D collagen gel co-culture with T47D human breast carcinoma cells and T47D cell growth was measured. CAF stimulated T47D cell growth to a significantly greater degree than NF. We detected a considerable inter-individual heterogeneity of paracrine interactions but identified FGF2, HB-EGF, heparanase-1 and SDF1 as factors that were consistently responsible for the activity of carcinoma-associated fibroblasts. CAF from low-grade but not high-grade carcinomas required insulin-like growth factor 1 and transforming growth factor beta 1 to stimulate carcinoma growth. Paradoxically, blocking of membrane-type 1 matrix metalloprotease stimulated T47D cell growth in co-culture with NF. The results were largely mirrored by treating the fibroblasts with siRNA oligonucleotides prior to co-culture, implicating the fibroblasts as principal production site for the secreted mediators. In summary, we identify a paracrine signaling network with inter-individual commonalities and differences. These findings have significant implications for the design of stroma-targeted therapies.
C1 [Su, Gui; Friedl, Andreas] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.
[Sung, Kyung E.; Beebe, David J.] Univ Wisconsin, Dept Biomed Engn, Madison, WI USA.
[Friedl, Andreas] William S Middleton Mem Vet Adm Med Ctr, Pathol & Lab Med Serv, Dept Vet Affairs, Med Ctr, Madison, WI 53705 USA.
RP Friedl, A (reprint author), Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53706 USA.
EM afriedl@wisc.edu
FU National Institutes of Health [RO1 CA107012]; Wisconsin Partnership
program
FX The work was supported by National Institutes of Health grant RO1
CA107012 and a grant from the Wisconsin Partnership program. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 48
TC 23
Z9 24
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 8
PY 2012
VL 7
IS 10
AR e46685
DI 10.1371/journal.pone.0046685
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 020RP
UT WOS:000309831500057
PM 23056402
ER
PT J
AU Paganetti, H
Athar, BS
Moteabbed, M
Adams, JA
Schneider, U
Yock, TI
AF Paganetti, Harald
Athar, Basit S.
Moteabbed, Maryam
Adams, Judith A.
Schneider, Uwe
Yock, Torunn I.
TI Assessment of radiation-induced second cancer risks in proton therapy
and IMRT for organs inside the primary radiation field
SO PHYSICS IN MEDICINE AND BIOLOGY
LA English
DT Article
ID DOSE-RESPONSE RELATIONSHIPS; EWING SARCOMA FAMILY; LONG-TERM SURVIVORS;
JAPANESE A-BOMB; CHILDHOOD-CANCER; THYROID-CANCER; FRACTIONATED
RADIOTHERAPY; PHOTON RADIOTHERAPY; PEDIATRIC-PATIENTS; HODGKINS-DISEASE
AB There is clinical evidence that second malignancies in radiation therapy occur mainly within the beam path, i.e. in the medium or high-dose region. The purpose of this study was to assess the risk for developing a radiationinduced tumor within the treated volume and to compare this risk for proton therapy and intensity-modulated photon therapy (IMRT). Instead of using data for specific patients we have created a representative scenario. Fully contoured age- and gender-specific whole body phantoms (4 year and 14 year old) were uploaded into a treatment planning system and tumor volumes were contoured based on patients treated for optic glioma and vertebral body Ewing's sarcoma. Treatment plans for IMRT and proton therapy treatments were generated. Lifetime attributable risks (LARs) for developing a second malignancy were calculated using a risk model considering cell kill, mutation, repopulation, as well as inhomogeneous organ doses. For standard fractionation schemes, the LAR for developing a second malignancy from radiation therapy alone was found to be up to 2.7% for a 4 year old optic glioma patient treated with IMRT considering a soft-tissue carcinoma risk model only. Sarcoma risks were found to be below 1% in all cases. For a 14 year old, risks were found to be about a factor of 2 lower. For Ewing's sarcoma cases the risks based on a sarcoma model were typically higher than the carcinoma risks, i.e. LAR up to 1.3% for soft-tissue sarcoma. In all cases, the risk from proton therapy turned out to be lower by at least a factor of 2 and up to a factor of 10. This is mainly due to lower total energy deposited in the patient when using proton beams. However, the comparison of a three-field and four-field proton plan also shows that the distribution of the dose, i.e. the particular treatment plan, plays a role. When using different fractionation schemes, the estimated risks roughly scale with the total dose difference in %. In conclusion, proton therapy can significantly reduce the risk for developing an in-field second malignancy. The risk depends on treatment planning parameters, i.e. an analysis based on our formalism could be applied within treatment planning programs to guide treatment plans for pediatric patients.
C1 [Paganetti, Harald; Athar, Basit S.; Moteabbed, Maryam; Adams, Judith A.; Yock, Torunn I.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Paganetti, Harald; Athar, Basit S.; Moteabbed, Maryam; Adams, Judith A.; Yock, Torunn I.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Schneider, Uwe] Univ Zurich, Vetsuisse Fac, CH-8057 Zurich, Switzerland.
[Schneider, Uwe] Hirslanden Med Ctr, Inst Radiotherapy, CH-5000 Aarau, Switzerland.
RP Paganetti, H (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
EM hpaganetti@partners.org
RI Schneider, Uwe/E-9594-2011
OI Schneider, Uwe/0000-0002-6403-204X
FU Ira Spiro award; Department of Radiation Oncology at Massachusetts
General Hospital (MGH)); Federal Share of program; Massachusetts General
Hospital Proton Therapy Research and Treatment Center [C06 CA059267]
FX The project was supported by the Ira Spiro award for translational
research by the Department of Radiation Oncology at Massachusetts
General Hospital (MGH)) and the Federal Share of program income earned
by Massachusetts General Hospital on C06 CA059267, Proton Therapy
Research and Treatment Center.
NR 61
TC 35
Z9 36
U1 1
U2 13
PU IOP PUBLISHING LTD
PI BRISTOL
PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND
SN 0031-9155
EI 1361-6560
J9 PHYS MED BIOL
JI Phys. Med. Biol.
PD OCT 7
PY 2012
VL 57
IS 19
BP 6047
EP 6061
DI 10.1088/0031-9155/57/19/6047
PG 15
WC Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging
SC Engineering; Radiology, Nuclear Medicine & Medical Imaging
GA 007VG
UT WOS:000308915900013
PM 22968191
ER
PT J
AU Cheng, T
Yang, C
Weber, N
Kim, HT
Kuo, AC
AF Cheng, Tiffany
Yang, Christina
Weber, Norbert
Kim, Hubert T.
Kuo, Alfred C.
TI Fibroblast growth factor 2 enhances the kinetics of mesenchymal stem
cell chondrogenesis
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mesenchymal stem cell; Chondrogenesis; Fibroblast growth factor 2
ID HYPERTROPHIC CHONDROCYTE KINETICS; BONE-MARROW; IN-VITRO;
DIFFERENTIATION; FGF-2; PROGENITORS; POTENTIALS; EXPRESSION; MATURATION;
EXPANSION
AB Treatment of mesenchymal stem cells (MSCs) with fibroblast growth factor 2 (FGF-2) during monolayer expansion leads to increased expression of cartilage-related molecules during subsequent pellet chondrogenesis. This may be due to faster differentiation and/or a durable change in phenotype. In order to evaluate changes over time, we assessed chondrogenesis of human MSCs at early and late time points during pellet culture using real-time PCR, measurement of glycosaminoglycan accumulation, and histology. Marked enhancement of chondrogenesis was seen early compared to controls. However, the differences from controls in gene expression dramatically diminished over time. Depending on conditions, increases in glycosaminoglycan accumulation were maintained. These results suggest that FGF-2 can enhance the kinetics of MSC chondrogenesis, leading to early differentiation, possibly by a priming mechanism. Published by Elsevier Inc.
C1 [Cheng, Tiffany; Yang, Christina; Kim, Hubert T.; Kuo, Alfred C.] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
[Cheng, Tiffany; Yang, Christina; Kim, Hubert T.; Kuo, Alfred C.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Weber, Norbert] Musculoskeletal Transplant Fdn, Edison, NJ 08837 USA.
RP Kuo, AC (reprint author), Univ Calif San Francisco, Dept Orthopaed Surg, 500 Parnassus Ave,MU 320W, San Francisco, CA 94143 USA.
EM kuoac@orthosurg.ucsf.edu
FU UCSF Department of Orthopaedic Surgery; UCSF Research Evaluation and
Allocation Committee; Musculoskeletal Transplant Foundation
FX We thank Eva Grotkopp for statistical assistance and Michelle Park for
assistance with immunohistochemistry. This work was supported by the
UCSF Department of Orthopaedic Surgery, by a pilot project grant from
the UCSF Research Evaluation and Allocation Committee, and by an
unrestricted research grant from the Musculoskeletal Transplant
Foundation, which was administered by the Northern California Institute
for Research and Education. The experiments were performed with the
resources of the Veterans Affairs Medical Center, San Francisco,
California.
NR 27
TC 12
Z9 15
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 5
PY 2012
VL 426
IS 4
BP 544
EP 550
DI 10.1016/j.bbrc.2012.08.124
PG 7
WC Biochemistry & Molecular Biology; Biophysics
SC Biochemistry & Molecular Biology; Biophysics
GA 024HT
UT WOS:000310101000018
PM 22982316
ER
PT J
AU Fromer, M
Moran, JL
Chambert, K
Banks, E
Bergen, SE
Ruderfer, DM
Handsaker, RE
McCarroll, SA
O'Donovan, MC
Owen, MJ
Kirov, G
Sullivan, PF
Hultman, CM
Sklar, P
Purcell, SM
AF Fromer, Menachem
Moran, Jennifer L.
Chambert, Kimberly
Banks, Eric
Bergen, Sarah E.
Ruderfer, Douglas M.
Handsaker, Robert E.
McCarroll, Steven A.
O'Donovan, Michael C.
Owen, Michael J.
Kirov, George
Sullivan, Patrick F.
Hultman, Christina M.
Sklar, Pamela
Purcell, Shaun M.
TI Discovery and Statistical Genotyping of Copy-Number Variation from
Whole-Exome Sequencing Depth
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; POPULATION-SCALE; SCHIZOPHRENIA; ACCURATE;
IDENTIFICATION; DUPLICATIONS; CNV
AB Sequencing of gene-coding regions (the exome) is increasingly used for studying human disease, for which copy-number variants (CNVs) are a critical genetic component. However, detecting copy number from exome sequencing is challenging because of the noncontiguous nature of the captured exons. This is compounded by the complex relationship between read depth and copy number; this results from biases in targeted genomic hybridization, sequence factors such as GC content, and batching of samples during collection and sequencing. We present a statistical tool (exome hidden Markov model [XHMM]) that uses principal-component analysis (PCA) to normalize exome read depth and a hidden Markov model (HMM) to discover exon-resolution CNV and genotype variation across samples. We evaluate performance on 90 schizophrenia trios and 1,017 case-control samples. X HMM detects a median of two rare (<1%) CNVs per individual (one deletion and one duplication) and has 79% sensitivity to similarly rare CNVs overlapping three or more exons discovered with microarrays. With sensitivity similar to state-of-the-art methods, XHMM achieves higher specificity by assigning quality metrics to the CNV calls to filter out bad ones, as well as to statistically genotype the discovered CNV in all individuals, yielding a trio call set with Mendelian-inheritance properties highly consistent with expectation. We also show that XHMM breakpoint quality scores enable researchers to explicitly search for novel classes of structural variation. For example, we apply XHMM to extract those CNVs that are highly likely to disrupt (delete or duplicate) only a portion of a gene.
C1 [Fromer, Menachem; Ruderfer, Douglas M.; Sklar, Pamela; Purcell, Shaun M.] Mt Sinai Sch Med, Div Psychiat Genom, New York, NY 10029 USA.
[Fromer, Menachem; Moran, Jennifer L.; Chambert, Kimberly; Bergen, Sarah E.; Ruderfer, Douglas M.; McCarroll, Steven A.; Purcell, Shaun M.] Broad Inst, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
[Fromer, Menachem; Banks, Eric; Handsaker, Robert E.; McCarroll, Steven A.; Purcell, Shaun M.] Broad Inst Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Fromer, Menachem; Banks, Eric; Handsaker, Robert E.; McCarroll, Steven A.; Purcell, Shaun M.] MIT, Cambridge, MA 02142 USA.
[Fromer, Menachem; Ruderfer, Douglas M.; Purcell, Shaun M.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Fromer, Menachem; Ruderfer, Douglas M.; Purcell, Shaun M.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Fromer, Menachem; Bergen, Sarah E.; Ruderfer, Douglas M.; Purcell, Shaun M.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Handsaker, Robert E.; McCarroll, Steven A.] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[O'Donovan, Michael C.; Owen, Michael J.; Kirov, George] Cardiff Univ, Neurosci & Mental Hlth Res Inst, Sch Med,Dept Psychol Med & Neurol, Med Res Council,Ctr Neuropsychiat Genet & Genom, Cardiff CF14 4XN, S Glam, Wales.
[Sullivan, Patrick F.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Sullivan, Patrick F.; Hultman, Christina M.] Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden.
RP Fromer, M (reprint author), Mt Sinai Sch Med, Div Psychiat Genom, New York, NY 10029 USA.
EM menachem.fromer@mssm.edu; shaun.purcell@mssm.edu
RI Ruderfer, Douglas/M-5795-2016; Fromer, Menachem/G-2116-2012
OI Ruderfer, Douglas/0000-0002-2365-386X; Bergen,
Sarah/0000-0002-5888-0034; O'Donovan, Michael/0000-0001-7073-2379;
Moran, Jennifer/0000-0002-5664-4716; Fromer,
Menachem/0000-0003-3749-4342
FU National Institute of Health [RC2MH089905, R01HG005827]; Sylvan Herman
Foundation
FX We would like to thank Mark DePristo, Joeseph Buxbaum, and Edward
Scolnick for their helpful discussions. This work was supported by
National Institute of Health grants RC2MH089905 (to principal
investigators S.M.P. and P.S.) and R01HG005827 (to S.M.P.) and by the
Sylvan Herman Foundation.
NR 34
TC 135
Z9 138
U1 2
U2 30
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 5
PY 2012
VL 91
IS 4
BP 597
EP 607
DI 10.1016/j.ajhg.2012.08.005
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA 017CU
UT WOS:000309568500002
PM 23040492
ER
PT J
AU Franceschini, N
van Rooij, FJA
Prins, BP
Feitosa, MF
Karakas, M
Eckfeldt, JH
Folsom, AR
Kopp, J
Vaez, A
Andrews, JS
Baumert, J
Boraska, V
Broer, L
Hayward, C
Ngwa, JS
Okada, Y
Polasek, O
Westra, HJ
Wang, YA
Del Greco, F
Glazer, NL
Kapur, K
Id, P
Lopez, LM
Schillert, A
Smith, AV
Winkler, CA
Zgaga, L
Bandinelli, S
Bergmann, S
Boban, M
Bochud, M
Chen, YD
Davies, G
Dehghan, A
Ding, JZ
Doering, A
Durda, JP
Ferrucci, L
Franco, OH
Franke, L
Gunjaca, G
Hofman, A
Hsu, FC
Kolcic, I
Kraja, A
Kubo, M
Lackner, KJ
Launer, L
Loehr, LR
Li, G
Meisinger, C
Nakamura, Y
Schwienbacher, C
Starr, JM
Takahashi, A
Torlak, V
Uitterlinden, AG
Vitart, V
Waldenberger, M
Wild, PS
Kirin, M
Zeller, T
Zemunik, T
Zhang, QY
Ziegler, A
Blankenberg, S
Boerwinkle, E
Borecki, IB
Campbell, H
Deary, IJ
Frayling, TM
Gieger, C
Harris, TB
Hicks, AA
Koenig, W
O'Donnell, CJ
Fox, CS
Pramstaller, PP
Psaty, BM
Reiner, AP
Rotter, JI
Rudan, I
Snieder, H
Tanaka, T
van Duijn, CM
Vollenweider, P
Waeber, G
Wilson, JF
Witteman, JCM
Wolffenbuttel, BHR
Wright, AF
Wu, QY
Liu, YM
Jenny, NS
North, KE
Felix, JF
Alizadeh, BZ
Cupples, LA
Perry, JRB
Morris, AP
AF Franceschini, Nora
van Rooij, Frank J. A.
Prins, Bram P.
Feitosa, Mary F.
Karakas, Mahir
Eckfeldt, John H.
Folsom, Aaron R.
Kopp, Jeffrey
Vaez, Ahmad
Andrews, Jeanette S.
Baumert, Jens
Boraska, Vesna
Broer, Linda
Hayward, Caroline
Ngwa, Julius S.
Okada, Yukinori
Polasek, Ozren
Westra, Harm-Jan
Wang, Ying A.
Del Greco M, Fabiola
Glazer, Nicole L.
Kapur, Karen
Kema, Id P.
Lopez, Lorna M.
Schillert, Arne
Smith, Albert V.
Winkler, Cheryl A.
Zgaga, Lina
Bandinelli, Stefania
Bergmann, Sven
Boban, Mladen
Bochud, Murielle
Chen, Y. D.
Davies, Gail
Dehghan, Abbas
Ding, Jingzhong
Doering, Angela
Durda, J. Peter
Ferrucci, Luigi
Franco, Oscar H.
Franke, Lude
Gunjaca, Grog
Hofman, Albert
Hsu, Fang-Chi
Kolcic, Ivana
Kraja, Aldi
Kubo, Michiaki
Lackner, Karl J.
Launer, Lenore
Loehr, Laura R.
Li, Guo
Meisinger, Christa
Nakamura, Yusuke
Schwienbacher, Christine
Starr, John M.
Takahashi, Atsushi
Torlak, Vesela
Uitterlinden, Andre G.
Vitart, Veronique
Waldenberger, Melanie
Wild, Philipp S.
Kirin, Mirna
Zeller, Tanja
Zemunik, Tatijana
Zhang, Qunyuan
Ziegler, Andreas
Blankenberg, Stefan
Boerwinkle, Eric
Borecki, Ingrid B.
Campbell, Harry
Deary, Ian J.
Frayling, Timothy M.
Gieger, Christian
Harris, Tamara B.
Hicks, Andrew A.
Koenig, Wolfgang
O'Donnell, Christopher J.
Fox, Caroline S.
Pramstaller, Peter P.
Psaty, Bruce M.
Reiner, Alex P.
Rotter, Jerome I.
Rudan, Igor
Snieder, Harold
Tanaka, Toshihiro
van Duijn, Cornelia M.
Vollenweider, Peter
Waeber, Gerard
Wilson, James F.
Witteman, Jacqueline C. M.
Wolffenbuttel, Bruce H. R.
Wright, Alan F.
Wu, Qingyu
Liu, Yongmei
Jenny, Nancy S.
North, Karl E.
Felix, Janine F.
Alizadeh, Behrooz Z.
Cupples, L. Adrienne
Perry, John R. B.
Morris, Andrew P.
CA LifeLines Cohort Study
TI Discovery and Fine Mapping of Serum Protein Loci through Transethnic
Meta-analysis
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; BIOCHEMICAL TRAITS; SMOKING-BEHAVIOR;
FC-RECEPTOR; ALBUMIN; DETERMINANTS; POPULATION; IDENTIFY; RISK; SNPS
AB Many disorders are associated with altered serum protein concentrations, including malnutrition, cancer, and cardiovascular, kidney, and inflammatory diseases. Although these protein concentrations are highly heritable, relatively little is known about their underlying genetic determinants. Through transethnic meta-analysis of European-ancestry and Japanese genome-wide association studies, we identified six loci at genome-wide significance (p < 5 x 10(-8)) for serum albumin (HPN-SCN1B, GCKR-FNDC4, SERPINF2-WDR81, TNFRSF11A-ZCCHC2, FRMDS-WDR76, and RPS11-FCGRT, in up to 53,190 European-ancestry and 9,380 Japanese individuals) and three loci for total protein (TNFRS13B, 6q21.3, and ELL2, in up to 25,539 European-ancestry and 10,168 Japanese individuals). We observed little evidence of heterogeneity in allelic effects at these loci between groups of European and Japanese ancestry but obtained substantial improvements in the resolution of fine mapping of potential causal variants by leveraging transethnic differences in the distribution of linkage disequilibrium. We demonstrated a functional role for the most strongly associated serum albumin locus, HPN, for which Hpn knockout mice manifest low plasma albumin concentrations. Other loci associated with serum albumin harbor genes related to ribosome function, protein translation, and proteasomal degradation, whereas those associated with serum total protein include genes related to immune function. Our results highlight the advantages of transethnic meta-analysis for the discovery and fine mapping of complex trait loci and have provided initial insights into the underlying genetic architecture of serum protein concentrations and their association with human disease.
C1 [Franceschini, Nora; Loehr, Laura R.; North, Karl E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
[van Rooij, Frank J. A.; Broer, Linda; Dehghan, Abbas; Franco, Oscar H.; Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Witteman, Jacqueline C. M.; Felix, Janine F.] Erasmus Univ, Med Ctr, ErasmusAGE, NL-3000 CA Rotterdam, Netherlands.
[van Rooij, Frank J. A.; Broer, Linda; Dehghan, Abbas; Franco, Oscar H.; Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Witteman, Jacqueline C. M.; Felix, Janine F.] Erasmus Univ, Med Ctr, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands.
[van Rooij, Frank J. A.; Broer, Linda; Dehghan, Abbas; Franco, Oscar H.; Hofman, Albert; Uitterlinden, Andre G.; van Duijn, Cornelia M.; Witteman, Jacqueline C. M.; Felix, Janine F.] Netherlands Genom Initiat, Netherlands Consortium Hlth Aging, NL-2300 RC Leiden, Netherlands.
[Prins, Bram P.; Vaez, Ahmad; Snieder, Harold; Alizadeh, Behrooz Z.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands.
[Feitosa, Mary F.; Kraja, Aldi; Zhang, Qunyuan; Borecki, Ingrid B.] Washington Univ, Sch Med, Dept Genet, Div Stat Genom, St Louis, MO 63108 USA.
[Karakas, Mahir; Koenig, Wolfgang] Univ Ulm, Med Ctr, Dept Internal Med Cardiol 2, D-89081 Ulm, Germany.
[Eckfeldt, John H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Folsom, Aaron R.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA.
[Kopp, Jeffrey] NIDDK, NIH, Bethesda, MD 20892 USA.
[Andrews, Jeanette S.; Hsu, Fang-Chi] Wake Forest Univ, Bowman Gray Sch Med, Dept Biostat Sci, Winston Salem, NC 27157 USA.
[Baumert, Jens; Doering, Angela; Meisinger, Christa; Gieger, Christian] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol 2, D-85764 Neuherberg, Germany.
[Boraska, Vesna; Zemunik, Tatijana] Univ Split, Sch Med, Dept Med Biol, Split 21000, Croatia.
[Hayward, Caroline; Vitart, Veronique; Wright, Alan F.] Univ Edinburgh, Western Gen Hosp, Inst Genet & Mol Med, MRC,Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
[Ngwa, Julius S.; Wang, Ying A.; Cupples, L. Adrienne] Harvard Univ, Sch Publ Hlth, Boston Univ, Sch Publ Hlth,Dept Biostat, Boston, MA 02115 USA.
[Okada, Yukinori; Takahashi, Atsushi] RIKEN, CGM, Lab Stat Anal, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
[Okada, Yukinori] Univ Tokyo, Grad Sch Med, Dept Allergy & Rheumatol, Bunkyo Ku, Tokyo 1130033, Japan.
[Polasek, Ozren; Kolcic, Ivana] Univ Split, Sch Med, Dept Publ Hlth, Split 21000, Croatia.
[Westra, Harm-Jan; Franke, Lude] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, NL-9713 GZ Groningen, Netherlands.
[Wang, Ying A.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA.
[Del Greco M, Fabiola; Schwienbacher, Christine; Hicks, Andrew A.; Pramstaller, Peter P.] Med Univ Lubeck, Affiliated Inst, Ctr Biomed, European Acad Bozen Bolzano EURAC, D-23562 Lubeck, Germany.
[Glazer, Nicole L.] Boston Univ, Sch Med, Prevent Med & Epidemiol Sect, Boston, MA 02118 USA.
[Kapur, Karen; Bergmann, Sven] Univ Lausanne, Univ Hosp Ctr, Dept Med Genet, CH-1005 Lausanne, Switzerland.
[Kema, Id P.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, NL-9700 RB Groningen, Netherlands.
[Lopez, Lorna M.; Starr, John M.; Deary, Ian J.] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh EH8 9JZ, Midlothian, Scotland.
[Lopez, Lorna M.; Davies, Gail; Deary, Ian J.] Univ Edinburgh, Dept Psychol, Edinburgh EH8 9AD, Midlothian, Scotland.
[Schillert, Arne; Ziegler, Andreas] Univ Hosp Schleswig Holstein, Inst Med Biometry & Stat, D-23538 Lubeck, Germany.
[Smith, Albert V.] Iceland Heart Assoc, IS-201 Kopavogur, Iceland.
[Smith, Albert V.] Univ Iceland, Fac Med, IS-101 Reykjavik, Iceland.
[Winkler, Cheryl A.] NCI, Mol Genet Epidemiol Sect, NIH, Frederick Natl Lab, Ft Detrick, MD 21702 USA.
[Zgaga, Lina; Kirin, Mirna; Campbell, Harry; Rudan, Igor; Wilson, James F.] Univ Edinburgh, Queens Med Res Inst, Coll Med & Vet Med, Ctr Populat Hlth Sci, Edinburgh EH16 4TJ, Midlothian, Scotland.
[Zgaga, Lina; Kirin, Mirna; Campbell, Harry; Rudan, Igor; Wilson, James F.] Univ Edinburgh, Queens Med Res Inst, Coll Med & Vet Med, Inst Genet & Mol Med, Edinburgh EH16 4TJ, Midlothian, Scotland.
[Zgaga, Lina] Univ Zagreb, Sch Med, Dept Med Stat Epidemiol & Med Informat, Zagreb 10000, Croatia.
[Bandinelli, Stefania; Gunjaca, Grog] Azienda Sanit Firenze, Geriatr Unit, I-50125 Florence, Italy.
[Kapur, Karen; Bergmann, Sven] Swiss Inst Bioinformat, CH-1015 Lausanne, Switzerland.
[Boban, Mladen] Univ Split, Sch Med, Dept Pharmacol, Split 21000, Croatia.
[Bochud, Murielle] Univ Inst Social & Prevent Med, Community Prevent Unit, CH-1005 Lausanne, Switzerland.
[Chen, Y. D.] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Los Angeles, CA 90048 USA.
[Chen, Y. D.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Ding, Jingzhong] Wake Forest Sch Med, Dept Internal Med, Sect Gerontol & Geriatr Med, Winston Salem, NC 27157 USA.
[Durda, J. Peter; Jenny, Nancy S.] Univ Vermont, Coll Med, Dept Pathol, Lab Clin Biochem Res, Burlington, VT 05405 USA.
[Ferrucci, Luigi] NIA, Longitudinal Studies Sect, Clin Res Branch, Baltimore, MD 21225 USA.
[Kubo, Michiaki] RIKEN, CGM, Lab Genotyping Dev, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
[Lackner, Karl J.] Univ Med Ctr Mainz, Inst Clin Chem & Lab Med, D-55131 Mainz, Germany.
[Launer, Lenore; Harris, Tamara B.] NIA, Lab Epidemiol Demog & Biometry, Bethesda, MD 20892 USA.
[Li, Guo] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.
[Nakamura, Yusuke] Univ Tokyo, Inst Med Sci, Ctr Human Genome, Lab Mol Med,Minato Ku, Tokyo 1088639, Japan.
[Schwienbacher, Christine] Univ Ferrara, Dept Expt & Diagnost Med, I-44121 Ferrara, Italy.
[Starr, John M.] Univ Edinburgh, Dept Psychol, Alzheimer Scotland Dementia Res Ctr, Edinburgh EH8 9JZ, Midlothian, Scotland.
[Torlak, Vesela] Univ Hosp Split, Split 21000, Croatia.
[Waldenberger, Melanie] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Epidemiol Res Unit, D-85764 Neuherberg, Germany.
[Wild, Philipp S.] Univ Med Ctr Mainz, Dept Med 2, D-55131 Mainz, Germany.
[Zeller, Tanja; Blankenberg, Stefan] Univ Heart Ctr Hamburg, Clin Gen & Intervent Cardiol, D-20246 Hamburg, Germany.
[Boerwinkle, Eric] Univ Houston, Sch Publ Hlth, Div Epidemiol, Houston, TX 77030 USA.
[Boerwinkle, Eric] Univ Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.
[Frayling, Timothy M.; Perry, John R. B.] Univ Exeter, Peninsula Med Sch, Exeter EX2 5DW, Devon, England.
[O'Donnell, Christopher J.; Fox, Caroline S.; Cupples, L. Adrienne] Natl Heart Lung & Blood Inst NHLBI Framingham Hea, Div Intramural Res, Framingham, MA 01702 USA.
[O'Donnell, Christopher J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Cardiol Div, Boston, MA 02114 USA.
[Fox, Caroline S.] NHLBI, Ctr Populat Studies, Framingham, MA 01702 USA.
[Pramstaller, Peter P.] Gen Cent Hosp, Dept Neurol, I-39100 Bolzano, Italy.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Med, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Epidemiol, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Dept Hlth Serv, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA 98101 USA.
[Reiner, Alex P.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Rotter, Jerome I.] Cedars Sinai Med Ctr, Inst Med Genet, Los Angeles, CA 90048 USA.
[Tanaka, Toshihiro] RIKEN, Lab Cardiovasc Dis, CGM, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
[Vollenweider, Peter; Waeber, Gerard] Univ Lausanne Hosp, Dept Internal Med, CH-1011 Lausanne, Switzerland.
[Wolffenbuttel, Bruce H. R.] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, NL-9713 GZ Groningen, Netherlands.
[Wu, Qingyu] Cleveland Clin, Mol Cardiol Nephrol & Hypertens Lerner Res Inst, Cleveland, OH 44195 USA.
[Liu, Yongmei] Wake Forest Univ, Bowman Gray Sch Med, Dept Epidemiol & Prevent Med, Winston Salem, NC 27157 USA.
[Morris, Andrew P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.
RP Franceschini, N (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA.
EM noraf@unc.edu; amorris@well.ox.ac.uk
RI Hayward, Caroline/M-8818-2016; Franke, Lude/P-7036-2016; Boraska Perica,
Vesna/D-8230-2017; Boban, Mladen/E-2777-2017; Kolcic, Ivana/E-2713-2017;
Feitosa, Mary/K-8044-2012; Hicks, Andrew/E-9518-2017; Wolffenbuttel,
Bruce/A-8419-2011; Deary, Ian/C-6297-2009; Smith, Albert/K-5150-2015;
Kubo, Michiaki/N-7947-2015; Bochud, Murielle/A-3981-2010; Colaus,
PsyColaus/K-6607-2013; Waldenberger, Melanie/B-5355-2014; Meisinger,
Christine/B-5358-2014; Pramstaller, Peter/C-2357-2008; Wilson, James
F/A-5704-2009; Polasek, Ozren/B-6002-2011; Tanaka,
Toshihiro/J-9310-2014; Rudan, Igor/I-1467-2012;
OI Hayward, Caroline/0000-0002-9405-9550; Franke, Lude/0000-0002-5159-8802;
Kolcic, Ivana/0000-0001-7918-6052; Feitosa, Mary/0000-0002-0933-2410;
Hicks, Andrew/0000-0001-6320-0411; Cupples, L.
Adrienne/0000-0003-0273-7965; Felix, Janine/0000-0002-9801-5774;
Wolffenbuttel, Bruce/0000-0001-9262-6921; Smith,
Albert/0000-0003-1942-5845; Bochud, Murielle/0000-0002-5727-0218;
Waldenberger, Melanie/0000-0003-0583-5093; Wilson, James
F/0000-0001-5751-9178; Polasek, Ozren/0000-0002-5765-1862; Tanaka,
Toshihiro/0000-0001-6201-9784; Rudan, Igor/0000-0001-6993-6884; Zgaga,
Lina/0000-0003-4089-9703; Gieger, Christian/0000-0001-6986-9554;
Ziegler, Andreas/0000-0002-8386-5397; Meisinger,
Christa/0000-0002-9026-6544; Ziad Alizadeh, Behrooz/0000-0002-1415-8007;
Kopp, Jeffrey/0000-0001-9052-186X; Bergmann, Sven/0000-0002-6785-9034;
Dehghan, Abbas/0000-0001-6403-016X
FU Wellcome Trust [WT081682, WT064890, WT098017, WT090532]; AHA [0675001N,
R01HL089651, U01HG004803]
FX A.P.M acknowledges financial support from the Wellcome Trust, grant
numbers WT081682, WT064890, WT098017, and WT090532. N.F. acknowledges
financial support from AHA 0675001N, R01HL089651, and U01HG004803.
NR 25
TC 40
Z9 40
U1 0
U2 13
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 5
PY 2012
VL 91
IS 4
BP 744
EP 753
DI 10.1016/j.ajhg.2012.08.021
PG 10
WC Genetics & Heredity
SC Genetics & Heredity
GA 017CU
UT WOS:000309568500017
PM 23022100
ER
PT J
AU Ott, CJ
Kopp, N
Bird, L
Paranal, RM
Qi, J
Bowman, T
Rodig, SJ
Kung, AL
Bradner, JE
Weinstock, DM
AF Ott, Christopher J.
Kopp, Nadja
Bird, Liat
Paranal, Ronald M.
Qi, Jun
Bowman, Teresa
Rodig, Scott J.
Kung, Andrew L.
Bradner, James E.
Weinstock, David M.
TI BET bromodomain inhibition targets both c-Myc and IL7R in high-risk
acute lymphoblastic leukemia
SO BLOOD
LA English
DT Article
ID OF-FUNCTION MUTATIONS; CELL-LINE; SELECTIVE-INHIBITION; HUMAN CANCERS;
B-PROGENITOR; EXPRESSION; CRLF2; REARRANGEMENT; PROTEIN; TRANSLOCATION
AB We investigated the therapeutic potential of JQ1, an inhibitor of the BET class of human bromodomain proteins, in B-cell acute lymphoblastic leukemia (B-ALL). We show that JQ1 potently reduces the viability of B-ALL cell lines with high-risk cytogenetics. Among the most sensitive were lines with rearrangements of CRLF2, which is overexpressed in similar to 10% of B-ALL. CRLF2 heterodimerizes with the IL7 receptor (IL7R) and signals through JAK2, JAK1, and STAT5 to drive proliferation and suppress apoptosis. As previously observed, JQ1 induced the down-regulation of MYC transcription, the loss of BRD4 at the MYC promoter, and the reduced expression of c-Myc target genes. Strikingly, JQ1 also down-regulated IL7R transcription, depleted BRD4 from the IL7R promoter, and reduced JAK2 and STAT5 phosphorylation. Genome-wide expression profiling demonstrated a restricted effect of JQ1 on transcription, with MYC and IL7R being among the most down-regulated genes. Indeed, IL7R was the only cytokine receptor in CRLF2-rearranged B-ALL cells significantly down-regulated by JQ1 treatment. In mice xenografted with primary human CRLF2-rearranged B-ALL, JQ1 suppressed c-Myc expression and STAT5 phosphorylation and significantly prolonged survival. Thus, bromodomain inhibition is a promising therapeutic strategy for B-ALL as well as other conditions dependent on IL7R signaling. (Blood. 2012; 120(14): 2843-2852)
C1 [Ott, Christopher J.; Kopp, Nadja; Bird, Liat; Paranal, Ronald M.; Qi, Jun; Bradner, James E.; Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Ott, Christopher J.; Kopp, Nadja; Bird, Liat; Paranal, Ronald M.; Qi, Jun; Bowman, Teresa; Rodig, Scott J.; Kung, Andrew L.; Bradner, James E.; Weinstock, David M.] Harvard Univ, Sch Med, Boston, MA USA.
[Bowman, Teresa; Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Kung, Andrew L.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
RP Weinstock, DM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 510B, Boston, MA 02215 USA.
EM james_bradner@dfci.harvard.edu; dweinstock@partners.org
OI Kung, Andrew/0000-0002-9091-488X
FU National Institutes of Health/National Cancer Institute [R01
CA151898-01]; Leukemia & Lymphoma Society; Damon-Runyon Cancer Research
Foundation; American Society of Hematology
FX This work was supported by the National Institutes of Health/National
Cancer Institute (R01 CA151898-01, D.M.W.), the Leukemia & Lymphoma
Society (C.J.O. and J.E.B.), a Damon-Runyon Cancer Research Foundation
Innovator Award (J.E.B.), and the American Society of Hematology (Junior
Faculty Scholar Awards, J.E.B. and D.M.W.).
NR 52
TC 145
Z9 146
U1 7
U2 22
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 4
PY 2012
VL 120
IS 14
BP 2843
EP 2852
DI 10.1182/blood-2012-02-413021
PG 10
WC Hematology
SC Hematology
GA 044KA
UT WOS:000311616900016
PM 22904298
ER
PT J
AU van Bodegom, D
Zhong, J
Kopp, N
Dutta, C
Kim, MS
Bird, L
Weigert, O
Tyner, J
Pandey, A
Yoda, A
Weinstock, DM
AF van Bodegom, Diederik
Zhong, Jun
Kopp, Nadja
Dutta, Chaitali
Kim, Min-Sik
Bird, Liat
Weigert, Oliver
Tyner, Jeffrey
Pandey, Akhilesh
Yoda, Akinori
Weinstock, David M.
TI Differences in signaling through the B-cell leukemia oncoprotein CRLF2
in response to TSLP and through mutant JAK2
SO BLOOD
LA English
DT Article
ID THYMIC STROMAL LYMPHOPOIETIN; ACUTE LYMPHOBLASTIC-LEUKEMIA; I CYTOKINE
RECEPTOR; OF-FUNCTION MUTATIONS; MOLECULAR-CLONING; INTERLEUKIN-7
RECEPTOR; ACTIVATING MUTATION; TRANSDUCTION; KINASES; STAT5
AB Approximately 10% of B-cell acute lymphoblastic leukemias (B-ALLs) overexpress the cytokine receptor subunit CRLF2, which may confer a poor prognosis. CRLF2 binds its ligand thymic stromal lymphopoietin (TSLP) as a heterodimer with IL7R. Subsets of CRLF2-overexpressing B-ALLs also have a gain-of-function CRLF2 F232C mutation or activating mutations in JAK2. Whether these mutant alleles confer differences in signaling has not been addressed. Through a domain mutation analysis, we demonstrate a distinct dependence on the CRLF2 intracellular tyrosine Y368 in signaling by CRLF2 F232C, but not signaling induced by TSLP or through CRLF2/mutant JAK2. In contrast, CRLF2 signaling in each context is strictly dependent on both the CRLF2 box1 domain and the intracellular tryptophan W286. Using a global quantitative analysis of tyrosine phosphorylation induced by TSLP, we previously identified TSLP-induced phosphorylation of multiple kinases implicated in B-cell receptor signaling, including Lyn, Btk, Hck, Syk, MAPK8, MAPK9, and MAPK10. We now demonstrate that cells dependent on CRLF2/mutant JAK2 have reduced phosphorylation at these targets, suggesting that the kinases promote TSLP-mediated proliferation but serve as negative regulators of CRLF2/mutant JAK2 signaling. Thus, targetable nodes downstream of CRLF2 differ based on the presence or absence of additional mutations in CRLF2 signaling components. (Blood. 2012; 120(14): 2853-2863)
C1 [van Bodegom, Diederik; Kopp, Nadja; Dutta, Chaitali; Bird, Liat; Weigert, Oliver; Yoda, Akinori; Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[van Bodegom, Diederik; Kopp, Nadja; Dutta, Chaitali; Bird, Liat; Weigert, Oliver; Yoda, Akinori; Weinstock, David M.] Harvard Univ, Sch Med, Boston, MA USA.
[Zhong, Jun; Kim, Min-Sik; Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Zhong, Jun; Kim, Min-Sik; Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.
[Zhong, Jun; Kim, Min-Sik; Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
[Zhong, Jun; Kim, Min-Sik; Pandey, Akhilesh] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Tyner, Jeffrey] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, Portland, OR 97201 USA.
RP Weinstock, DM (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana 510B, Boston, MA 02215 USA.
EM dweinstock@partners.org
RI Pandey, Akhilesh/B-4127-2009; Zhong, Jun/D-1662-2010; Kim,
Min-Sik/M-3488-2016;
OI Pandey, Akhilesh/0000-0001-9943-6127; Zhong, Jun/0000-0003-3148-4143;
Kim, Min-Sik/0000-0001-7317-5360; Tyner, Jeffrey/0000-0002-2133-0960
FU National Institutes of Health (NIH) [R01-CA151898-01]; NHLBI
[HHSN268201000032C]; High End Instrumentation Program of the NIH
[S10RR023025]; NIH Roadmap grant "Technology Center for Networks and
Pathways" [U54 RR 020839]
FX This work was supported by National Institutes of Health (NIH)
R01-CA151898-01 (D.M.W.), a contract HHSN268201000032C from the NHLBI
(A.P.), grant S10RR023025 from the High End Instrumentation Program of
the NIH (A.P.), and NIH Roadmap grant "Technology Center for Networks
and Pathways" U54 RR 020839 (A.P.).
NR 43
TC 11
Z9 11
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD OCT 4
PY 2012
VL 120
IS 14
BP 2853
EP 2863
DI 10.1182/blood-2012-02-413252
PG 11
WC Hematology
SC Hematology
GA 044KA
UT WOS:000311616900017
PM 22915648
ER
PT J
AU Koboldt, DC
Fulton, RS
McLellan, MD
Schmidt, H
Kalicki-Veizer, J
McMichael, JF
Fulton, LL
Dooling, DJ
Ding, L
Mardis, ER
Wilson, RK
Ally, A
Balasundaram, M
Butterfield, YSN
Carlsen, R
Carter, C
Chu, A
Chuah, E
Chun, HJE
Coope, RJN
Dhalla, N
Guin, R
Hirst, C
Hirst, M
Holt, RA
Lee, D
Li, HYI
Mayo, M
Moore, RA
Mungall, AJ
Pleasance, E
Robertson, AG
Schein, JE
Shafiei, A
Sipahimalani, P
Slobodan, JR
Stoll, D
Tam, A
Thiessen, N
Varhol, RJ
Wye, N
Zeng, T
Zhao, YJ
Birol, I
Jones, SJM
Marra, MA
Cherniack, AD
Saksena, G
Onofrio, RC
Pho, NH
Carter, SL
Schumacher, SE
Tabak, B
Hernandez, B
Gentry, J
Nguyen, H
Crenshaw, A
Ardlie, K
Beroukhim, R
Winckler, W
Getz, G
Gabriel, SB
Meyerson, M
Chin, L
Park, PJ
Kucherlapati, R
Hoadley, KA
Auman, JT
Fan, C
Turman, YJ
Shi, Y
Li, L
Topal, MD
He, XP
Chao, HH
Prat, A
Silva, GO
Iglesia, MD
Zhao, W
Usary, J
Berg, JS
Adams, M
Booker, J
Wu, JY
Gulabani, A
Bodenheimer, T
Hoyle, AP
Simons, JV
Soloway, MG
Mose, LE
Jefferys, SR
Balu, S
Parker, JS
Hayes, DN
Perou, CM
Malik, S
Mahurkar, S
Shen, H
Weisenberger, DJ
Triche, T
Lai, PH
Bootwalla, MS
Maglinte, DT
Berman, BP
Van den Berg, DJ
Baylin, SB
Laird, PW
Creighton, CJ
Donehower, LA
Getz, G
Noble, M
Voet, D
Saksena, G
Gehlenborg, N
DiCara, D
Zhang, JH
Zhang, HL
Wu, CJ
Liu, SY
Lawrence, MS
Zou, LH
Sivachenko, A
Lin, P
Stojanov, P
Jing, R
Cho, J
Sinha, R
Park, RW
Nazaire, MD
Robinson, J
Thorvaldsdottir, H
Mesirov, J
Park, PJ
Chin, L
Reynolds, S
Kreisberg, RB
Bernard, B
Bressler, R
Erkkila, T
Lin, J
Thorsson, V
Zhang, W
Shmulevich, I
Ciriello, G
Weinhold, N
Schultz, N
Gao, JJ
Cerami, E
Gross, B
Jacobsen, A
Sinha, R
Aksoy, BA
Antipin, Y
Reva, B
Shen, RL
Taylor, BS
Ladanyi, M
Sander, C
Anur, P
Spellman, PT
Lu, YL
Liu, WB
Verhaak, RRG
Mills, GB
Akbani, R
Zhang, NX
Broom, BM
Casasent, TD
Wakefield, C
Unruh, AK
Baggerly, K
Coombes, K
Weinstein, JN
Haussler, D
Benz, CC
Stuart, JM
Benz, SC
Zhu, JC
Szeto, CC
Scott, GK
Yau, C
Paul, EO
Carlin, D
Wong, C
Sokolov, A
Thusberg, J
Mooney, S
Ng, S
Goldstein, TC
Ellrott, K
Grifford, M
Wilks, C
Ma, S
Craft, B
Yan, CH
Hu, Y
Meerzaman, D
Gastier-Foster, JM
Bowen, J
Ramirez, NC
Black, AD
Pyatt, RE
White, P
Zmuda, EJ
Frick, J
Lichtenberg, T
Brookens, R
George, MM
Gerken, MA
Harper, HA
Leraas, KM
Wise, LJ
Tabler, TR
McAllister, C
Barr, T
Hart-Kothari, M
Tarvin, K
Saller, C
Sandusky, G
Mitchell, C
Iacocca, MV
Brown, J
Rabeno, B
Czerwinski, C
Petrelli, N
Dolzhansky, O
Abramov, M
Voronina, O
Potapova, O
Marks, JR
Suchorska, WM
Murawa, D
Kycler, W
Ibbs, M
Korski, K
Spychala, A
Murawa, P
Brzezinski, JJ
Perz, H
Lazniak, R
Teresiak, M
Tatka, H
Leporowska, E
Bogusz-Czerniewicz, M
Malicki, J
Mackiewicz, A
Wiznerowicz, M
Le, XV
Kohl, B
Tien, NV
Thorp, R
Bang, NV
Sussman, H
Phu, BD
Hajek, R
Hung, NP
Tran, VTP
Thang, HQ
Khan, KZ
Penny, R
Mallery, D
Curley, E
Shelton, C
Yena, P
Ingle, JN
Couch, FJ
Lingle, WL
King, TA
Gonzalez-Angulo, AM
Mills, GB
Dyer, MD
Liu, SY
Meng, XL
Patangan, M
Waldman, F
Stoppler, H
Rathmell, WK
Thorne, L
Huang, M
Boice, L
Hill, A
Morrison, C
Gaudioso, C
Bshara, W
Daily, K
Egea, SC
Pegram, MD
Gomez-Fernandez, C
Dhir, R
Bhargava, R
Brufsky, A
Shriver, CD
Hooke, JA
Campbell, JL
Mural, RJ
Hu, H
Somiari, S
Larson, C
Deyarmin, B
Kvecher, L
Kovatich, AJ
Ellis, MJ
King, TA
Hu, H
Couch, FJ
Mural, RJ
Stricker, T
White, K
Olopade, O
Ingle, JN
Luo, CQ
Chen, YQ
Marks, JR
Waldman, F
Wiznerowicz, M
Bose, R
Chang, LW
Beck, AH
Gonzalez-Angulo, AM
Pihl, T
Jensen, M
Sfeir, R
Kahn, A
Chu, A
Kothiyal, P
Wang, ZN
Snyder, E
Pontius, J
Ayala, B
Backus, M
Walton, J
Baboud, J
Berton, D
Nicholls, M
Srinivasan, D
Raman, R
Girshik, S
Kigonya, P
Alonso, S
Sanbhadti, R
Barletta, S
Pot, D
Sheth, M
Demchok, JA
Shaw, KRM
Yang, LM
Eley, G
Ferguson, ML
Tarnuzzer, RW
Zhang, JS
Dillon, LAL
Buetow, K
Fielding, P
Ozenberger, BA
Guyer, MS
Sofia, HJ
Palchik, JD
AF Koboldt, Daniel C.
Fulton, Robert S.
McLellan, Michael D.
Schmidt, Heather
Kalicki-Veizer, Joelle
McMichael, Joshua F.
Fulton, Lucinda L.
Dooling, David J.
Ding, Li
Mardis, Elaine R.
Wilson, Richard K.
Ally, Adrian
Balasundaram, Miruna
Butterfield, Yaron S. N.
Carlsen, Rebecca
Carter, Candace
Chu, Andy
Chuah, Eric
Chun, Hye-Jung E.
Coope, Robin J. N.
Dhalla, Noreen
Guin, Ranabir
Hirst, Carrie
Hirst, Martin
Holt, Robert A.
Lee, Darlene
Li, Haiyan I.
Mayo, Michael
Moore, Richard A.
Mungall, Andrew J.
Pleasance, Erin
Robertson, A. Gordon
Schein, Jacqueline E.
Shafiei, Arash
Sipahimalani, Payal
Slobodan, Jared R.
Stoll, Dominik
Tam, Angela
Thiessen, Nina
Varhol, Richard J.
Wye, Natasja
Zeng, Thomas
Zhao, Yongjun
Birol, Inanc
Jones, Steven J. M.
Marra, Marco A.
Cherniack, Andrew D.
Saksena, Gordon
Onofrio, Robert C.
Pho, Nam H.
Carter, Scott L.
Schumacher, Steven E.
Tabak, Barbara
Hernandez, Bryan
Gentry, Jeff
Huy Nguyen
Crenshaw, Andrew
Ardlie, Kristin
Beroukhim, Rameen
Winckler, Wendy
Getz, Gad
Gabriel, Stacey B.
Meyerson, Matthew
Chin, Lynda
Park, Peter J.
Kucherlapati, Raju
Hoadley, Katherine A.
Auman, J. Todd
Fan, Cheng
Turman, Yidi J.
Shi, Yan
Li, Ling
Topal, Michael D.
He, Xiaping
Chao, Hann-Hsiang
Prat, Aleix
Silva, Grace O.
Iglesia, Michael D.
Zhao, Wei
Usary, Jerry
Berg, Jonathan S.
Adams, Michael
Booker, Jessica
Wu, Junyuan
Gulabani, Anisha
Bodenheimer, Tom
Hoyle, Alan P.
Simons, Janae V.
Soloway, Matthew G.
Mose, Lisle E.
Jefferys, Stuart R.
Balu, Saianand
Parker, Joel S.
Hayes, D. Neil
Perou, Charles M.
Malik, Simeen
Mahurkar, Swapna
Shen, Hui
Weisenberger, Daniel J.
Triche, Timothy, Jr.
Lai, Phillip H.
Bootwalla, Moiz S.
Maglinte, Dennis T.
Berman, Benjamin P.
Van den Berg, David J.
Baylin, Stephen B.
Laird, Peter W.
Creighton, Chad J.
Donehower, Lawrence A.
Getz, Gad
Noble, Michael
Voet, Doug
Saksena, Gordon
Gehlenborg, Nils
DiCara, Daniel
Zhang, Juinhua
Zhang, Hailei
Wu, Chang-Jiun
Liu, Spring Yingchun
Lawrence, Michael S.
Zou, Lihua
Sivachenko, Andrey
Lin, Pei
Stojanov, Petar
Jing, Rui
Cho, Juok
Sinha, Raktim
Park, Richard W.
Nazaire, Marc-Danie
Robinson, Jim
Thorvaldsdottir, Helga
Mesirov, Jill
Park, Peter J.
Chin, Lynda
Reynolds, Sheila
Kreisberg, Richard B.
Bernard, Brady
Bressler, Ryan
Erkkila, Timo
Lin, Jake
Thorsson, Vesteinn
Zhang, Wei
Shmulevich, Ilya
Ciriello, Giovanni
Weinhold, Nils
Schultz, Nikolaus
Gao, Jianjiong
Cerami, Ethan
Gross, Benjamin
Jacobsen, Anders
Sinha, Rileen
Aksoy, B. Arman
Antipin, Yevgeniy
Reva, Boris
Shen, Ronglai
Taylor, Barry S.
Ladanyi, Marc
Sander, Chris
Anur, Pavana
Spellman, Paul T.
Lu, Yiling
Liu, Wenbin
Verhaak, Roel R. G.
Mills, Gordon B.
Akbani, Rehan
Zhang, Nianxiang
Broom, Bradley M.
Casasent, Tod D.
Wakefield, Chris
Unruh, Anna K.
Baggerly, Keith
Coombes, Kevin
Weinstein, John N.
Haussler, David
Benz, Christopher C.
Stuart, Joshua M.
Benz, Stephen C.
Zhu, Jingchun
Szeto, Christopher C.
Scott, Gary K.
Yau, Christina
Paul, Evan O.
Carlin, Daniel
Wong, Christopher
Sokolov, Artem
Thusberg, Janita
Mooney, Sean
Sam Ng
Goldstein, Theodore C.
Ellrott, Kyle
Grifford, Mia
Wilks, Christopher
Ma, Singer
Craft, Brian
Yan, Chunhua
Hu, Ying
Meerzaman, Daoud
Gastier-Foster, Julie M.
Bowen, Jay
Ramirez, Nilsa C.
Black, Aaron D.
Pyatt, Robert E.
White, Peter
Zmuda, Erik J.
Frick, Jessica
Lichtenberg, Taram.
Brookens, Robin
George, Myra M.
Gerken, Mark A.
Harper, Hollie A.
Leraas, Kristen M.
Wise, Lisa J.
Tabler, Teresa R.
McAllister, Cynthia
Barr, Thomas
Hart-Kothari, Melissa
Tarvin, Katie
Saller, Charles
Sandusky, George
Mitchell, Colleen
Iacocca, Mary V.
Brown, Jennifer
Rabeno, Brenda
Czerwinski, Christine
Petrelli, Nicholas
Dolzhansky, Oleg
Abramov, Mikhail
Voronina, Olga
Potapova, Olga
Marks, Jeffrey R.
Suchorska, Wiktoria M.
Murawa, Dawid
Kycler, Witold
Ibbs, Matthew
Korski, Konstanty
Spychala, Arkadiusz
Murawa, Pawel
Brzezinski, Jacek J.
Perz, Hanna
Lazniak, Radoslaw
Teresiak, Marek
Tatka, Honorata
Leporowska, Ewa
Bogusz-Czerniewicz, Marta
Malicki, Julian
Mackiewicz, Andrzej
Wiznerowicz, Maciej
Xuan Van Le
Kohl, Bernard
Nguyen Viet Tien
Thorp, Richard
Nguyen Van Bang
Sussman, Howard
Bui Duc Phu
Hajek, Richard
Nguyen Phi Hung
Tran Viet The Phuong
Huynh Quyet Thang
Khan, Khurram Zaki
Penny, Robert
Mallery, David
Curley, Erin
Shelton, Candace
Yena, Peggy
Ingle, James N.
Couch, Fergus J.
Lingle, Wilma L.
King, Tari A.
Gonzalez-Angulo, Ana Maria
Mills, Gordon B.
Dyer, Mary D.
Liu, Shuying
Meng, Xiaolong
Patangan, Modesto
Waldman, Frederic
Stoeppler, Hubert
Rathmell, W. Kimryn
Thorne, Leigh
Huang, Mei
Boice, Lori
Hill, Ashley
Morrison, Carl
Gaudioso, Carmelo
Bshara, Wiam
Daily, Kelly
Egea, Sophie C.
Pegram, Mark D.
Gomez-Fernandez, Carmen
Dhir, Rajiv
Bhargava, Rohit
Brufsky, Adam
Shriver, Craig D.
Hooke, Jeffrey A.
Campbell, Jamie Leigh
Mural, Richard J.
Hu, Hai
Somiari, Stella
Larson, Caroline
Deyarmin, Brenda
Kvecher, Leonid
Kovatich, Albert J.
Ellis, Matthew J.
King, Tari A.
Hu, Hai
Couch, Fergus J.
Mural, Richard J.
Stricker, Thomas
White, Kevin
Olopade, Olufunmilayo
Ingle, James N.
Luo, Chunqing
Chen, Yaqin
Marks, Jeffrey R.
Waldman, Frederic
Wiznerowicz, Maciej
Bose, Ron
Chang, Li-Wei
Beck, Andrew H.
Gonzalez-Angulo, Ana Maria
Pihl, Todd
Jensen, Mark
Sfeir, Robert
Kahn, Ari
Chu, Anna
Kothiyal, Prachi
Wang, Zhining
Snyder, Eric
Pontius, Joan
Ayala, Brenda
Backus, Mark
Walton, Jessica
Baboud, Julien
Berton, Dominique
Nicholls, Matthew
Srinivasan, Deepak
Raman, Rohini
Girshik, Stanley
Kigonya, Peter
Alonso, Shelley
Sanbhadti, Rashmi
Barletta, Sean
Pot, David
Sheth, Margi
Demchok, John A.
Shaw, Kenna R. Mills
Yang, Liming
Eley, Greg
Ferguson, Martin L.
Tarnuzzer, Roy W.
Zhang, Jiashan
Dillon, Laura A. L.
Buetow, Kenneth
Fielding, Peter
Ozenberger, Bradley A.
Guyer, Mark S.
Sofia, Heidi J.
Palchik, Jacqueline D.
CA Canc Genome Atlas Network
TI Comprehensive molecular portraits of human breast tumours
SO NATURE
LA English
DT Article
ID BASAL-LIKE; MUTATIONAL EVOLUTION; HIGH-FREQUENCY; PIK3CA GENE; P53
STATUS; LUMINAL-B; CANCER; SUBTYPES; PATHWAYS; SUPPRESSOR
AB We analysed primary breast cancers by genomic DNA copy number arrays, DNA methylation, exome sequencing, messenger RNA arrays, microRNA sequencing and reverse-phase protein arrays. Our ability to integrate information across platforms provided key insights into previously defined gene expression subtypes and demonstrated the existence of four main breast cancer classes when combining data from five platforms, each of which shows significant molecular heterogeneity. Somatic mutations in only three genes (TP53, PIK3CA and GATA3) occurred at >10% incidence across all breast cancers; however, there were numerous subtype-associated and novel gene mutations including the enrichment of specific mutations in GATA3, PIK3CA and MAP3K1 with the luminal A subtype. We identified two novel protein-expression-defined subgroups, possibly produced by stromal/microenvironmental elements, and integrated analyses identified specific signalling pathways dominant in each molecular subtype including a HER2/phosphorylated HER2/EGFR/phosphorylated EGFR signature within the HER2-enriched expression subtype. Comparison of basal-like breast tumours with high-grade serous ovarian tumours showed many molecular commonalities, indicating a related aetiology and similar therapeutic opportunities. The biological finding of the four main breast cancer subtypes caused by different subsets of genetic and epigenetic abnormalities raises the hypothesis that much of the clinically observable plasticity and heterogeneity occurs within, and not across, these major biological subtypes of breast cancer.
C1 [Hoadley, Katherine A.; He, Xiaping; Chao, Hann-Hsiang; Prat, Aleix; Silva, Grace O.; Iglesia, Michael D.; Zhao, Wei; Berg, Jonathan S.; Adams, Michael; Weisenberger, Daniel J.] Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
[Koboldt, Daniel C.; Fulton, Robert S.; McLellan, Michael D.; Schmidt, Heather; Kalicki-Veizer, Joelle; McMichael, Joshua F.; Fulton, Lucinda L.; Dooling, David J.; Ding, Li; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Genome Inst, St Louis, MO 63108 USA.
[Ding, Li; Mardis, Elaine R.; Wilson, Richard K.] Washington Univ, Dept Genet, St Louis, MO 63110 USA.
[Mardis, Elaine R.; Wilson, Richard K.; Ellis, Matthew J.; Bose, Ron] Washington Univ, Siteman Canc Ctr, St Louis, MO 63110 USA.
[Ally, Adrian; Balasundaram, Miruna; Butterfield, Yaron S. N.; Carlsen, Rebecca; Carter, Candace; Chu, Andy; Chuah, Eric; Chun, Hye-Jung E.; Coope, Robin J. N.; Dhalla, Noreen; Guin, Ranabir; Hirst, Carrie; Hirst, Martin; Holt, Robert A.; Lee, Darlene; Li, Haiyan I.; Mayo, Michael; Moore, Richard A.; Mungall, Andrew J.; Pleasance, Erin; Robertson, A. Gordon; Schein, Jacqueline E.; Shafiei, Arash; Sipahimalani, Payal; Slobodan, Jared R.; Stoll, Dominik; Tam, Angela; Thiessen, Nina; Varhol, Richard J.; Wye, Natasja; Zeng, Thomas; Zhao, Yongjun; Birol, Inanc; Jones, Steven J. M.; Marra, Marco A.] BC Canc Agcy, Canadas Michael Smith Genome Sci Ctr, Vancouver, BC V5Z, Canada.
[Cherniack, Andrew D.; Saksena, Gordon; Onofrio, Robert C.; Pho, Nam H.; Carter, Scott L.; Schumacher, Steven E.; Tabak, Barbara; Hernandez, Bryan; Gentry, Jeff; Huy Nguyen; Crenshaw, Andrew; Ardlie, Kristin; Beroukhim, Rameen; Winckler, Wendy; Getz, Gad; Gabriel, Stacey B.; Meyerson, Matthew] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Schumacher, Steven E.; Tabak, Barbara; Beroukhim, Rameen; Nguyen Phi Hung] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Beroukhim, Rameen] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Beroukhim, Rameen; Meyerson, Matthew; Chin, Lynda] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Beroukhim, Rameen; Meyerson, Matthew; Chin, Lynda] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Meyerson, Matthew; Beck, Andrew H.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Chin, Lynda] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02115 USA.
[Park, Peter J.; Gehlenborg, Nils; Park, Peter J.] Harvard Univ, Sch Med, Ctr Biomed Informat, Boston, MA 02115 USA.
[Kucherlapati, Raju] Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA.
[Kucherlapati, Raju] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Hoadley, Katherine A.; Fan, Cheng; Turman, Yidi J.; Shi, Yan; Li, Ling; Topal, Michael D.; He, Xiaping; Chao, Hann-Hsiang; Prat, Aleix; Silva, Grace O.; Iglesia, Michael D.; Zhao, Wei; Usary, Jerry; Berg, Jonathan S.; Wu, Junyuan; Gulabani, Anisha; Bodenheimer, Tom; Hoyle, Alan P.; Simons, Janae V.; Soloway, Matthew G.; Mose, Lisle E.; Jefferys, Stuart R.; Balu, Saianand; Parker, Joel S.; Hayes, D. Neil; Perou, Charles M.; Malik, Simeen; Mahurkar, Swapna; Shen, Hui; Weisenberger, Daniel J.; Rathmell, W. Kimryn; Thorne, Leigh; Huang, Mei; Boice, Lori; Hill, Ashley] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
[Auman, J. Todd] Univ N Carolina, Eshelman Sch Pharm, Chapel Hill, NC 27599 USA.
[Auman, J. Todd] Univ N Carolina, Inst Pharmacogenet & Individualized Therapy, Chapel Hill, NC 27599 USA.
[Topal, Michael D.; Booker, Jessica; Weisenberger, Daniel J.] Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA.
[Shen, Hui] Univ N Carolina, Div Med Oncol, Dept Internal Med, Chapel Hill, NC 27599 USA.
[Triche, Timothy, Jr.; Lai, Phillip H.; Bootwalla, Moiz S.; Maglinte, Dennis T.; Berman, Benjamin P.; Van den Berg, David J.; Laird, Peter W.] Univ So Calif, USC Epigenome Ctr, Los Angeles, CA 90033 USA.
[Baylin, Stephen B.] Johns Hopkins Univ, Div Canc Biol, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA.
[Creighton, Chad J.; Donehower, Lawrence A.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA.
[Creighton, Chad J.; Donehower, Lawrence A.] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Donehower, Lawrence A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.
[Donehower, Lawrence A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.
[Getz, Gad; Noble, Michael; Voet, Doug; Saksena, Gordon; Gehlenborg, Nils; DiCara, Daniel; Zhang, Hailei; Liu, Spring Yingchun; Lawrence, Michael S.; Zou, Lihua; Sivachenko, Andrey; Lin, Pei; Stojanov, Petar; Jing, Rui; Cho, Juok; Sinha, Raktim; Park, Richard W.; Nazaire, Marc-Danie; Robinson, Jim; Thorvaldsdottir, Helga; Mesirov, Jill; Chin, Lynda] Eli & Edythe L Broad Inst Massachusetts Inst Tech, Cambridge, MA 02142 USA.
[Zhang, Juinhua; Chin, Lynda] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Inst Appl Canc Sci, Houston, TX 77054 USA.
[Wu, Chang-Jiun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77054 USA.
[Park, Peter J.] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Park, Peter J.] Childrens Hosp, Informat Program, Boston, MA 02115 USA.
[Reynolds, Sheila; Kreisberg, Richard B.; Bernard, Brady; Bressler, Ryan; Lin, Jake; Thorsson, Vesteinn; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA 98109 USA.
[Erkkila, Timo] Tampere Univ Technol, FIN-33101 Tampere, Finland.
[Zhang, Wei] Univ Texas MD Anderson Canc Ctr, Canc Genom Core Lab, Houston, TX 77030 USA.
[Ciriello, Giovanni; Weinhold, Nils; Schultz, Nikolaus; Gao, Jianjiong; Cerami, Ethan; Gross, Benjamin; Jacobsen, Anders; Sinha, Rileen; Aksoy, B. Arman; Antipin, Yevgeniy; Reva, Boris; Taylor, Barry S.; Sander, Chris] Mem Sloan Kettering Canc Ctr, Computat Biol Ctr, New York, NY 10065 USA.
[Shen, Ronglai] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10065 USA.
[Ladanyi, Marc] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10065 USA.
[Anur, Pavana; Spellman, Paul T.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Lu, Yiling; Mills, Gordon B.; Gonzalez-Angulo, Ana Maria] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA.
[Lu, Yiling; Mills, Gordon B.] Univ Texas MD Anderson Canc Ctr, Kleberg Ctr Mol Markers, Houston, TX 77030 USA.
[Liu, Wenbin; Verhaak, Roel R. G.; Akbani, Rehan; Zhang, Nianxiang; Broom, Bradley M.; Casasent, Tod D.; Wakefield, Chris; Unruh, Anna K.; Baggerly, Keith; Coombes, Kevin; Weinstein, John N.] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.
[Haussler, David; Stuart, Joshua M.; Benz, Stephen C.; Zhu, Jingchun; Szeto, Christopher C.; Paul, Evan O.; Carlin, Daniel; Wong, Christopher; Sokolov, Artem; Sam Ng; Goldstein, Theodore C.; Ellrott, Kyle; Grifford, Mia; Wilks, Christopher; Ma, Singer; Craft, Brian] Univ Calif Santa Cruz, Dept Biomol Engn, Santa Cruz, CA 95064 USA.
[Haussler, David; Stuart, Joshua M.; Benz, Stephen C.; Zhu, Jingchun; Szeto, Christopher C.; Paul, Evan O.; Carlin, Daniel; Wong, Christopher; Sokolov, Artem; Sam Ng; Goldstein, Theodore C.; Ellrott, Kyle; Grifford, Mia; Wilks, Christopher; Ma, Singer; Craft, Brian] Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA.
[Haussler, David] Univ Calif Santa Cruz, Howard Hughes Med Inst, Santa Cruz, CA 95064 USA.
[Benz, Christopher C.; Scott, Gary K.; Yau, Christina; Thusberg, Janita; Mooney, Sean] Buck Inst Res Aging, Novato, CA 94945 USA.
[Yan, Chunhua; Hu, Ying; Meerzaman, Daoud; Buetow, Kenneth] NCI, Ctr Bioinformat & Informat Technol, Rockville, MD 20852 USA.
[Gastier-Foster, Julie M.; Ramirez, Nilsa C.; Pyatt, Robert E.; White, Peter] Ohio State Univ, Coll Med, Dept Pathol, Columbus, OH 43205 USA.
[Gastier-Foster, Julie M.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43205 USA.
[Gastier-Foster, Julie M.; Bowen, Jay; Ramirez, Nilsa C.; Black, Aaron D.; Pyatt, Robert E.; White, Peter; Zmuda, Erik J.; Frick, Jessica; Lichtenberg, Taram.; Brookens, Robin; George, Myra M.; Gerken, Mark A.; Harper, Hollie A.; Leraas, Kristen M.; Wise, Lisa J.; Tabler, Teresa R.; McAllister, Cynthia; Barr, Thomas; Hart-Kothari, Melissa] Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.
[Tarvin, Katie] ABS Inc, Indianapolis, IN 46204 USA.
[Saller, Charles] ABS Inc, Wilmington, DE 19801 USA.
[Sandusky, George; Mitchell, Colleen] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Iacocca, Mary V.; Brown, Jennifer; Rabeno, Brenda; Czerwinski, Christine; Petrelli, Nicholas] Christiana Care, Helen F Graham Canc Ctr, Newark, DE 19713 USA.
[Dolzhansky, Oleg] Moscow Hlth Dept, Moscow City Clin Oncol Dispensary 1, Moscow 105005, Russia.
[Dolzhansky, Oleg] Moscow Hlth Dept, Cent IHC Lab, Moscow 105005, Russia.
[Abramov, Mikhail] Russian Canc Res Ctr, Moscow 115478, Russia.
[Voronina, Olga; Potapova, Olga] Cureline Inc, San Francisco, CA 94080 USA.
[Marks, Jeffrey R.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA.
[Suchorska, Wiktoria M.; Murawa, Dawid; Kycler, Witold; Ibbs, Matthew; Korski, Konstanty; Spychala, Arkadiusz; Murawa, Pawel; Brzezinski, Jacek J.; Perz, Hanna; Lazniak, Radoslaw; Teresiak, Marek; Tatka, Honorata; Leporowska, Ewa; Bogusz-Czerniewicz, Marta; Malicki, Julian; Mackiewicz, Andrzej; Wiznerowicz, Maciej] Greater Poland Canc Ctr, PL-61866 Poznan, Poland.
[Bogusz-Czerniewicz, Marta; Malicki, Julian; Mackiewicz, Andrzej] Poznan Univ Med Sci, PL-61701 Poznan, Poland.
[Xuan Van Le; Kohl, Bernard] ILSBio LLC, Chestertown, MD 21620 USA.
[Nguyen Viet Tien] Minist Hlth, Hanoi, Vietnam.
[Thorp, Richard; Khan, Khurram Zaki] ILSBio LLC, Karachi, Pakistan.
[Nguyen Van Bang; Bui Duc Phu] Hue Cent Hosp, Hue City, Vietnam.
[Sussman, Howard] Stanford Univ, Med Ctr, Stanford, CA 94305 USA.
[Hajek, Richard] Univ Texas MD Anderson Canc Ctr, Ctr Minor Hlth Res, Houston, TX 77030 USA.
[Nguyen Phi Hung] Natl Canc Inst, Hanoi, Vietnam.
[Tran Viet The Phuong] Ho Chi Minh City Canc Ctr, Ho Chi Minh City, Vietnam.
[Huynh Quyet Thang] Can Tho Canc Ctr, Can Tho, Vietnam.
[Penny, Robert; Mallery, David; Curley, Erin; Shelton, Candace; Yena, Peggy] Int Genom Consortium, Phoenix, AZ 85004 USA.
[Ingle, James N.; Couch, Fergus J.; Lingle, Wilma L.] Mayo Clin, Rochester, MN 55905 USA.
[King, Tari A.] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10065 USA.
[Mills, Gordon B.; Dyer, Mary D.; Liu, Shuying; Meng, Xiaolong; Patangan, Modesto] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA.
[Waldman, Frederic] Univ Calif San Francisco, San Francisco, CA 94143 USA.
Canc Diagnost, San Juan Capistrano, CA 92675 USA.
Quest Diagnost, Nichols Inst, San Juan Capistrano, CA 92675 USA.
[Stoeppler, Hubert] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
[Thorne, Leigh; Huang, Mei; Boice, Lori] UNC Lineberger Canc Ctr, Dept Pathol, UNC Tissue Procurement Facil, Chapel Hill, NC 27599 USA.
[Morrison, Carl; Gaudioso, Carmelo; Bshara, Wiam] Roswell Pk Canc Inst, Dept Pathol, Buffalo, NY 14263 USA.
[Daily, Kelly; Egea, Sophie C.; Pegram, Mark D.; Gomez-Fernandez, Carmen] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Pathol, Miami, FL 33136 USA.
[Dhir, Rajiv] Univ Pittsburgh, Pittsburgh, PA 15213 USA.
[Bhargava, Rohit; Brufsky, Adam] Univ Pittsburgh Med Ctr, Magee Womens Hosp, Pittsburgh, PA 15213 USA.
[Shriver, Craig D.; Hooke, Jeffrey A.; Campbell, Jamie Leigh] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20899 USA.
[Mural, Richard J.; Hu, Hai; Somiari, Stella; Larson, Caroline; Deyarmin, Brenda; Kvecher, Leonid; Luo, Chunqing; Chen, Yaqin] Windber Res Inst, Windber, PA 15963 USA.
[Kovatich, Albert J.] MDR Global LLC, Windber, PA 15963 USA.
[Ellis, Matthew J.; Bose, Ron] Washington Univ, Breast Canc Program, St Louis, MO 63110 USA.
[Ellis, Matthew J.; Bose, Ron] Washington Univ, Dept Internal Med, Div Oncol, St Louis, MO 63110 USA.
[Stricker, Thomas; White, Kevin] Univ Chicago, Inst Genom & Syst Biol, Chicago, IL 60637 USA.
[Olopade, Olufunmilayo] Univ Chicago, Ctr Clin Canc Genet, Chicago, IL 60637 USA.
[Chang, Li-Wei] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.
[Pihl, Todd; Jensen, Mark; Sfeir, Robert; Kahn, Ari; Chu, Anna; Kothiyal, Prachi; Wang, Zhining; Snyder, Eric; Pontius, Joan; Ayala, Brenda; Backus, Mark; Walton, Jessica; Baboud, Julien; Berton, Dominique; Nicholls, Matthew; Srinivasan, Deepak; Raman, Rohini; Girshik, Stanley; Kigonya, Peter; Alonso, Shelley; Sanbhadti, Rashmi; Barletta, Sean; Pot, David] SRA Int, Fairfax, VA 22033 USA.
[Sheth, Margi; Demchok, John A.; Shaw, Kenna R. Mills; Yang, Liming; Tarnuzzer, Roy W.; Zhang, Jiashan; Dillon, Laura A. L.; Fielding, Peter] NCI, Canc Genome Atlas Program Off, Ctr Canc Genom, Bethesda, MD 20892 USA.
[Eley, Greg] Scimentis LLC, TCGA, Statham, GA 30666 USA.
[Ferguson, Martin L.] MLF Consulting, Arlington, MA 02474 USA.
[Ozenberger, Bradley A.; Guyer, Mark S.; Sofia, Heidi J.; Palchik, Jacqueline D.] NHGRI, NIH, Bethesda, MD 20892 USA.
RP Perou, CM (reprint author), Univ N Carolina, Dept Genet, Chapel Hill, NC 27599 USA.
EM cperou@med.unc.edu
RI Jones, Steven/C-3621-2009; Marra, Marco/B-5987-2008; Birol,
Inanc/G-5440-2011; Holt, Robert/C-3303-2009; Laird, Peter/G-8683-2012;
Prat, Aleix/P-8561-2014; Jacobsen, Anders/K-1081-2013; Schein,
Jacquie/G-3674-2015; White, Peter/E-4301-2011; Gastier-Foster,
Julie/E-3105-2011; Schumacher, Steven/E-9821-2013; Gao,
Jianjiong/B-5673-2016; Reva, Boris/B-6436-2014; Tang, Macy/B-9798-2014;
Berman, Benjamin/D-5942-2014; Waha, Andreas/J-2950-2014; Hirst,
Martin/B-7684-2016
OI Sinha, Rileen/0000-0001-5497-5055; Casasent, Anna/0000-0002-7857-179X;
Gehlenborg, Nils/0000-0003-0327-8297; Birol, Inanc/0000-0003-0950-7839;
Schultz, Nikolaus/0000-0002-0131-4904; Ibbs,
Matthew/0000-0003-2510-3447; Benz, Stephen/0000-0002-4067-0602; Triche,
Tim/0000-0001-5665-946X; Hayes, D. Neil/0000-0001-6203-7771; Pot,
David/0000-0002-1480-9826; Prat, Aleix/0000-0003-2377-540X; Jacobsen,
Anders/0000-0001-6847-4980; White, Peter/0000-0002-5218-5903;
Schumacher, Steven/0000-0002-6819-5647; Gao,
Jianjiong/0000-0002-5739-1781; Reva, Boris/0000-0002-8805-389X;
FU USA National Institutes of Health [U24CA143883, U24CA143858,
U24CA143840, U24CA143799, U24CA143835, U24CA143845, U24CA143882,
U24CA143867, U24CA143866, U24CA143848, U24CA144025, U54HG003079,
P50CA116201, P50CA58223]; Susan G. Komen for the Cure; US Department of
Defense through the Henry M. Jackson Foundation for the Advancement of
Military Medicine; Breast Cancer Research Foundation
FX We thank M. Sheth and S. Lucas for administrative coordination of TCGA
activities, and C. Gunter for critical reading of the manuscript. This
work was supported by the following grants from the USA National
Institutes of Health: U24CA143883, U24CA143858, U24CA143840,
U24CA143799, U24CA143835, U24CA143845, U24CA143882, U24CA143867,
U24CA143866, U24CA143848, U24CA144025, U54HG003079, P50CA116201 and
P50CA58223. Additional support was provided by the Susan G. Komen for
the Cure, the US Department of Defense through the Henry M. Jackson
Foundation for the Advancement of Military Medicine, and the Breast
Cancer Research Foundation. The views expressed in this paper are those
of the authors and do not reflect the official policy of the Department
of Defense, or US Government.
NR 56
TC 2909
Z9 2944
U1 95
U2 721
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD OCT 4
PY 2012
VL 490
IS 7418
BP 61
EP 70
DI 10.1038/nature11412
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 015LG
UT WOS:000309446800032
ER
PT J
AU Koven, S
AF Koven, Suzanne
TI Head and Shoulder
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Koven, Suzanne] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Koven, Suzanne] Harvard Univ, Sch Med, Boston, MA USA.
RP Koven, S (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 4
PY 2012
VL 367
IS 14
BP 1284
EP 1285
DI 10.1056/NEJMp1209766
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014WJ
UT WOS:000309406100004
PM 23034019
ER
PT J
AU Roe, MT
Armstrong, PW
Fox, KAA
White, HD
Prabhakaran, D
Goodman, SG
Cornel, JH
Bhatt, DL
Clemmensen, P
Martinez, F
Ardissino, D
Nicolau, JC
Boden, WE
Gurbel, PA
Ruzyllo, W
Dalby, AJ
McGuire, DK
Leiva-Pons, JL
Parkhomenko, A
Gottlieb, S
Topacio, GO
Hamm, C
Pavlides, G
Goudev, AR
Oto, A
Tseng, CD
Merkely, B
Gasparovic, V
Corbalan, R
Cinteza, M
McLendon, RC
Winters, KJ
Brown, EB
Lokhnygina, Y
Aylward, PE
Huber, K
Hochman, JS
Ohman, EM
AF Roe, Matthew T.
Armstrong, Paul W.
Fox, Keith A. A.
White, Harvey D.
Prabhakaran, Dorairaj
Goodman, Shaun G.
Cornel, Jan H.
Bhatt, Deepak L.
Clemmensen, Peter
Martinez, Felipe
Ardissino, Diego
Nicolau, Jose C.
Boden, William E.
Gurbel, Paul A.
Ruzyllo, Witold
Dalby, Anthony J.
McGuire, Darren K.
Leiva-Pons, Jose L.
Parkhomenko, Alexander
Gottlieb, Shmuel
Topacio, Gracita O.
Hamm, Christian
Pavlides, Gregory
Goudev, Assen R.
Oto, Ali
Tseng, Chuen-Den
Merkely, Bela
Gasparovic, Vladimir
Corbalan, Ramon
Cinteza, Mircea
McLendon, R. Craig
Winters, Kenneth J.
Brown, Eileen B.
Lokhnygina, Yuliya
Aylward, Philip E.
Huber, Kurt
Hochman, Judith S.
Ohman, E. Magnus
CA TRILOGY ACS Investigators
TI Prasugrel versus Clopidogrel for Acute Coronary Syndromes without
Revascularization
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID MYOCARDIAL-INFARCTION; MEDICAL-MANAGEMENT; OUTCOMES; INTERVENTION;
PREDICTORS; STRATEGY; TRIAL
AB Background
The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated.
Methods
In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel.
Results
At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P = 0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P = 0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group.
Conclusions
Among patients with unstable angina or myocardial infarction without ST- segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.)
C1 [Roe, Matthew T.; McLendon, R. Craig; Lokhnygina, Yuliya; Ohman, E. Magnus] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27705 USA.
[Roe, Matthew T.; Ohman, E. Magnus] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27705 USA.
[Armstrong, Paul W.] Univ Alberta, Div Cardiol, Edmonton, AB, Canada.
[Goodman, Shaun G.] Univ Toronto, St Michaels Hosp, Dept Med, Div Cardiol, Toronto, ON M5B 1W8, Canada.
[Fox, Keith A. A.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland.
[White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.
[Prabhakaran, Dorairaj] Ctr Chron Dis Control, New Delhi, India.
[Cornel, Jan H.] Med Ctr Alkmaar, Dept Cardiol, Alkmaar, Netherlands.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Clemmensen, Peter] Univ Copenhagen, Rigshosp, DK-2100 Copenhagen, Denmark.
[Martinez, Felipe] Natl Univ Cordoba, Dept Cardiol, Cordoba, Argentina.
[Ardissino, Diego] Azienda Osped Univ Parma, Div Cardiol, Parma, Italy.
[Nicolau, Jose C.] Univ Sao Paulo, Sch Med, Heart Inst InCor, Sao Paulo, Brazil.
[Boden, William E.] Albany Med Coll, Stratton VA Med Ctr, Dept Med, Albany, NY 12208 USA.
[Hochman, Judith S.] NYU, Sch Med, Leon H Charney Div Cardiol, Cardiovasc Clin Res Ctr, New York, NY USA.
[Hochman, Judith S.] NYU Langone Med Ctr, New York, NY USA.
[Gurbel, Paul A.] Sinai Hosp Baltimore, Sinai Ctr Thrombosis Res, Baltimore, MD USA.
[Ruzyllo, Witold] Inst Cardiol, Dept Coronary Artery Dis, Warsaw, Poland.
[Dalby, Anthony J.] Milpark Hosp, Johannesburg, South Africa.
[McGuire, Darren K.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Leiva-Pons, Jose L.] Hosp Cent Dr Morones Prieto, Dept Cardiol, San Luis Potosi, Mexico.
[Parkhomenko, Alexander] Inst Cardiol, Kiev, Ukraine.
[Gottlieb, Shmuel] Bikur Cholim Hosp, Dept Cardiol, Jerusalem, Israel.
[Topacio, Gracita O.] Med Ctr Manila, Dept Med, Manila, Philippines.
[Hamm, Christian] Kerckhoff Heart Ctr, Bad Nauheim, Germany.
[Pavlides, Gregory] Onassis Cardiac Surg Ctr, Div Cardiol, Kallithea, Greece.
[Goudev, Assen R.] Queen Giovanna Univ Hosp, Dept Cardiol, Sofia, Bulgaria.
[Oto, Ali] Hacettepe Univ, Fac Med, Dept Cardiol, TR-06100 Ankara, Turkey.
[Tseng, Chuen-Den] Natl Taiwan Univ, Coll Med, Div Cardiol, Taipei 10764, Taiwan.
[Merkely, Bela] Semmelweis Univ, Ctr Heart, H-1085 Budapest, Hungary.
[Gasparovic, Vladimir] Clin Hosp Ctr Zagreb, Dept Intens Care Med, Zagreb, Croatia.
[Corbalan, Ramon] Pontificia Univ Catolica Chile, Fac Med, Div Cardiovasc, Santiago, Chile.
[Cinteza, Mircea] Emergency Univ Hosp Bucharest, Div Cardiol, Bucharest, Romania.
[Winters, Kenneth J.; Brown, Eileen B.] Eli Lilly, Indianapolis, IN USA.
[Aylward, Philip E.] Flinders Univ S Australia, Med Ctr, S Australian Hlth & Med Res Inst, Adelaide, SA 5001, Australia.
[Huber, Kurt] Wilhelminenhospital, Dept Med Cardiol & Emergency Med 3, Vienna, Austria.
RP Roe, MT (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, 2400 Pratt St,Rm 7035, Durham, NC 27705 USA.
EM matthew.roe@duke.edu
RI Nicolau, Jose/E-1487-2012; Zateyshchikov, Dmitry/D-6575-2012; Manolis,
Antonis/F-5003-2014; Prunier, Fabrice/A-5210-2011; Henrion,
Daniel/J-8141-2015; Verheugt, F.W.A./H-8105-2014; Ponikowski,
Piotr/O-6454-2015; Gurevich, Victor/H-2935-2013; Widimsky,
Petr/P-8088-2016; Ferrari, Emile/R-2917-2016;
OI Zamoryakhin, Dmitry/0000-0001-8632-5890; Volpe,
Massimo/0000-0002-9642-8380; Hochman, Judith/0000-0002-5889-5981;
Prabhakaran, Dorairaj/0000-0002-3172-834X; Mahon,
Niall/0000-0002-2872-2297; Zateyshchikov, Dmitry/0000-0001-7065-2045;
Henrion, Daniel/0000-0003-1094-0285; Ponikowski,
Piotr/0000-0002-3391-7064; Gurevich, Victor/0000-0002-6815-444X;
Widimsky, Petr/0000-0001-5686-7752; Van de Werf,
Frans/0000-0001-9479-7767
FU Eli Lilly; Daiichi Sankyo
FX Funded by Eli Lilly and Daiichi Sankyo
NR 18
TC 306
Z9 321
U1 10
U2 78
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 4
PY 2012
VL 367
IS 14
BP 1297
EP 1309
DI 10.1056/NEJMoa1205512
PG 13
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014WJ
UT WOS:000309406100006
PM 22920930
ER
PT J
AU Ware, JH
Harrington, D
Hunter, DJ
D'Agostino, RB
AF Ware, James H.
Harrington, David
Hunter, David J.
D'Agostino, Ralph B.
TI Missing Data
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Ware, James H.] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Hunter, David J.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Harrington, David] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[D'Agostino, Ralph B.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
RP Ware, JH (reprint author), Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
NR 1
TC 41
Z9 41
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 4
PY 2012
VL 367
IS 14
BP 1353
EP 1354
DI 10.1056/NEJMsm1210043
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014WJ
UT WOS:000309406100015
ER
PT J
AU Flaherty, KT
Robert, C
Schadendorf, D
AF Flaherty, Keith T.
Robert, Caroline
Schadendorf, Dirk
CA METRIC Study Grp
TI Early Surgery for Infective Endocarditis REPLY
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Robert, Caroline] Inst Gustave Roussy, Villejuif, France.
[Schadendorf, Dirk] Univ Hosp Essen, Essen, Germany.
RP Flaherty, KT (reprint author), Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
EM kflaherty@partners.org
NR 0
TC 0
Z9 0
U1 1
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 4
PY 2012
VL 367
IS 14
BP 1365
EP 1365
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014WJ
UT WOS:000309406100021
ER
PT J
AU Brown, EN
Solt, K
AF Brown, Emery N.
Solt, Ken
TI Management of Opioid Analgesic Overdose
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Letter
C1 [Brown, Emery N.; Solt, Ken] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Brown, EN (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM enb@neurostat.mit.edu
NR 5
TC 0
Z9 0
U1 0
U2 2
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD OCT 4
PY 2012
VL 367
IS 14
BP 1370
EP 1371
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014WJ
UT WOS:000309406100031
PM 23034040
ER
PT J
AU Galon, J
Pages, F
Marincola, FM
Angell, HK
Thurin, M
Lugli, A
Zlobec, I
Berger, A
Bifulco, C
Botti, G
Tatangelo, F
Britten, CM
Kreiter, S
Chouchane, L
Delrio, P
Arndt, H
Asslaber, M
Maio, M
Masucci, GV
Mihm, M
Vidal-Vanaclocha, F
Allison, JP
Gnjatic, S
Hakansson, L
Huber, C
Singh-Jasuja, H
Ottensmeier, C
Zwierzina, H
Laghi, L
Grizzi, F
Ohashi, PS
Shaw, PA
Clarke, BA
Wouters, BG
Kawakami, Y
Hazama, S
Okuno, K
Wang, E
O'Donnell-Tormey, J
Lagorce, C
Pawelec, G
Nishimura, MI
Hawkins, R
Lapointe, R
Lundqvist, A
Khleif, SN
Ogino, S
Gibbs, P
Waring, P
Sato, N
Torigoe, T
Itoh, K
Patel, PS
Shukla, SN
Palmqvist, R
Nagtegaal, ID
Wang, YL
D'Arrigo, C
Kopetz, S
Sinicrope, FA
Trinchieri, G
Gajewski, TF
Ascierto, PA
Fox, BA
AF Galon, Jerome
Pages, Franck
Marincola, Francesco M.
Angell, Helen K.
Thurin, Magdalena
Lugli, Alessandro
Zlobec, Inti
Berger, Anne
Bifulco, Carlo
Botti, Gerardo
Tatangelo, Fabiana
Britten, Cedrik M.
Kreiter, Sebastian
Chouchane, Lotfi
Delrio, Paolo
Arndt, Hartmann
Asslaber, Martin
Maio, Michele
Masucci, Giuseppe V.
Mihm, Martin
Vidal-Vanaclocha, Fernando
Allison, James P.
Gnjatic, Sacha
Hakansson, Leif
Huber, Christoph
Singh-Jasuja, Harpreet
Ottensmeier, Christian
Zwierzina, Heinz
Laghi, Luigi
Grizzi, Fabio
Ohashi, Pamela S.
Shaw, Patricia A.
Clarke, Blaise A.
Wouters, Bradly G.
Kawakami, Yutaka
Hazama, Shoichi
Okuno, Kiyotaka
Wang, Ena
O'Donnell-Tormey, Jill
Lagorce, Christine
Pawelec, Graham
Nishimura, Michael I.
Hawkins, Robert
Lapointe, Rejean
Lundqvist, Andreas
Khleif, Samir N.
Ogino, Shuji
Gibbs, Peter
Waring, Paul
Sato, Noriyuki
Torigoe, Toshihiko
Itoh, Kyogo
Patel, Prabhu S.
Shukla, Shilin N.
Palmqvist, Richard
Nagtegaal, Iris D.
Wang, Yili
D'Arrigo, Corrado
Kopetz, Scott
Sinicrope, Frank A.
Trinchieri, Giorgio
Gajewski, Thomas F.
Ascierto, Paolo A.
Fox, Bernard A.
TI Cancer classification using the Immunoscore: a worldwide task force
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
ID MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; T-CELL SUBSETS; COLORECTAL-CANCER;
BREAST-CANCER; IMMUNE CELLS; MICROSATELLITE INSTABILITY; IMMUNOTHERAPY
BIOMARKERS; TUMOR-MARKERS; MELANOMA; CHEMOTHERAPY
AB Prediction of clinical outcome in cancer is usually achieved by histopathological evaluation of tissue samples obtained during surgical resection of the primary tumor. Traditional tumor staging (AJCC/UICC-TNM classification) summarizes data on tumor burden (T), presence of cancer cells in draining and regional lymph nodes (N) and evidence for metastases (M). However, it is now recognized that clinical outcome can significantly vary among patients within the same stage. The current classification provides limited prognostic information, and does not predict response to therapy. Recent literature has alluded to the importance of the host immune system in controlling tumor progression. Thus, evidence supports the notion to include immunological biomarkers, implemented as a tool for the prediction of prognosis and response to therapy. Accumulating data, collected from large cohorts of human cancers, has demonstrated the impact of immune-classification, which has a prognostic value that may add to the significance of the AJCC/UICC TNM-classification. It is therefore imperative to begin to incorporate the ` Immunoscore' into traditional classification, thus providing an essential prognostic and potentially predictive tool. Introduction of this parameter as a biomarker to classify cancers, as part of routine diagnostic and prognostic assessment of tumors, will facilitate clinical decision-making including rational stratification of patient treatment. Equally, the inherent complexity of quantitative immunohistochemistry, in conjunction with protocol variation across laboratories, analysis of different immune cell types, inconsistent region selection criteria, and variable ways to quantify immune infiltration, all underline the urgent requirement to reach assay harmonization. In an effort to promote the Immunoscore in routine clinical settings, an international task force was initiated. This review represents a follow-up of the announcement of this initiative, and of the J Transl Med. editorial from January 2012. Immunophenotyping of tumors may provide crucial novel prognostic information. The results of this international validation may result in the implementation of the Immunoscore as a new component for the classification of cancer, designated TNM-I (TNM-Immune).
C1 [Galon, Jerome; Pages, Franck; Angell, Helen K.] INSERM, U872, Lab Integrat Canc Immunol, F-75006 Paris, France.
[Galon, Jerome; Pages, Franck; Angell, Helen K.] Univ Paris 05, Paris, France.
[Galon, Jerome; Pages, Franck; Angell, Helen K.] Univ Paris 06, Ctr Rech Cordeliers, Paris, France.
[Galon, Jerome; Pages, Franck; Berger, Anne] HEGP, AP HP, Paris, France.
[Galon, Jerome; Marincola, Francesco M.; Gajewski, Thomas F.; Fox, Bernard A.] Soc Immunotherapy Canc, Milwaukee, WI USA.
[Marincola, Francesco M.; Wang, Ena] NIH, IDIS, Ctr Clin, Bethesda, MD 20892 USA.
[Marincola, Francesco M.; Wang, Ena; Trinchieri, Giorgio] NIH, Trans NIH Ctr Human Immunol CHI, Bethesda, MD 20892 USA.
[Thurin, Magdalena] NCI, Canc Diag Program, NIH, Rockville, MD USA.
[Lugli, Alessandro; Zlobec, Inti] Univ Bern, Inst Pathol, CH-3010 Bern, Switzerland.
[Bifulco, Carlo] Providence Portland Med Ctr, Dept Pathol, Portland, OR USA.
[Botti, Gerardo; Tatangelo, Fabiana] Ist Nazl Studio & Cura Tumori Fdn G Pascale, Dept Pathol, Naples, Italy.
[Britten, Cedrik M.; Kreiter, Sebastian; Huber, Christoph] Johannes Gutenberg Univ Mainz, TRON Translat Oncol, Univ Med Ctr, D-55122 Mainz, Germany.
[Chouchane, Lotfi] Weill Cornell Med Coll, Doha, Qatar.
[Delrio, Paolo] Ist Nazl Studio & Cura Tumori Fdn G Pascale, Colorectal Surg Dept, Naples, Italy.
[Arndt, Hartmann] Univ Erlangen Nurnberg, Dept Pathol, D-91054 Erlangen, Germany.
[Asslaber, Martin] Med Univ Graz, Inst Pathol, Graz, Austria.
[Maio, Michele] Univ Hosp Siena, Div Med Oncol & Immunotherapy, Ist Toscano Tumori, Siena, Italy.
[Masucci, Giuseppe V.] Karolinska Univ, Dept Oncol Pathol, Karolinska Inst, Stockholm, Sweden.
[Mihm, Martin; Ogino, Shuji] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Mihm, Martin] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Vidal-Vanaclocha, Fernando] CEU San Pablo Univ, Sch Med, Madrid, Spain.
[Vidal-Vanaclocha, Fernando] HM Hosp Madrid Sci Fdn, Inst Appl Mol Med, Madrid, Spain.
[Allison, James P.; Gnjatic, Sacha] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York, NY 10021 USA.
[Hakansson, Leif] Lund Univ, Lund, Sweden.
[Singh-Jasuja, Harpreet] Immat Biotechnol GmbH, Tubingen, Germany.
[Ottensmeier, Christian] Univ Southampton, Fac Med, Expt Canc Med Ctr, Southampton SO9 5NH, Hants, England.
[Zwierzina, Heinz] Med Univ Innsbruck, Dept Haematol & Oncol, A-6020 Innsbruck, Austria.
[Laghi, Luigi; Grizzi, Fabio] Humanitas Clin & Res Ctr, Milan, Italy.
[Laghi, Luigi; Grizzi, Fabio] Humanitas Clin & Res Ctr, Dept Gastroenterol, Milan, Italy.
[Ohashi, Pamela S.] Univ Hlth Network, Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON, Canada.
[Ohashi, Pamela S.] Univ Hlth Network, Princess Margaret Hosp, Campbell Family Inst Canc Res, Toronto, ON, Canada.
[Shaw, Patricia A.; Clarke, Blaise A.; Wouters, Bradly G.] Princess Margaret Canc Ctr, Ontario Canc Inst, Dept Lab Med, Toronto, ON, Canada.
[Shaw, Patricia A.; Clarke, Blaise A.; Wouters, Bradly G.] Princess Margaret Canc Ctr, Ontario Canc Inst, Dept Pathobiol, Toronto, ON, Canada.
[Shaw, Patricia A.; Clarke, Blaise A.; Wouters, Bradly G.] Princess Margaret Canc Ctr, Ontario Canc Inst, Dept Radiat Oncol, Toronto, ON, Canada.
[Kawakami, Yutaka] Keio Univ, Sch Med, Div Cellular Signaling, Inst Adv Med Res, Tokyo, Japan.
[Hazama, Shoichi] Yamaguchi Univ, Dept Digest Surg & Surg Oncol, Grad Sch Med, Yamaguchi, Japan.
[Okuno, Kiyotaka] Kinki Univ, Sch Med, Dept Surg, Osaka 589, Japan.
[O'Donnell-Tormey, Jill] Inst Canc Res, New York, NY USA.
[Lagorce, Christine] Avicenne Hosp, AP HP, Dept Pathol, Bobigny, France.
[Pawelec, Graham] Univ Tubingen, Med Res Ctr, Tubingen, Germany.
[Nishimura, Michael I.] Loyola Univ, Med Ctr, Inst Oncol, Cardinal Bernardin Canc Ctr, Maywood, IL 60153 USA.
[Hawkins, Robert] Univ Manchester, Sch Canc & Imaging Sci, Christie Hosp NHS Trust, Manchester, Lancs, England.
[Lapointe, Rejean] Univ Montreal CRCHUM, Res Ctr, Univ Hosp, Montreal, PQ, Canada.
[Lapointe, Rejean] Inst Canc Montreal, Montreal, PQ, Canada.
[Lundqvist, Andreas] Karolinska Inst, Dept Oncol Pathol, Stockholm, Sweden.
[Khleif, Samir N.] Georgia Hlth Sci Univ Canc Ctr, Augusta, GA USA.
[Ogino, Shuji] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Gibbs, Peter] Royal Melbourne Hosp, Dept Med Oncol, Melbourne, Vic, Australia.
[Waring, Paul] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia.
[Sato, Noriyuki; Torigoe, Toshihiko] Sapporo Med Univ, Dept Pathol, Sch Med, Sapporo, Hokkaido, Japan.
[Itoh, Kyogo] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan.
[Patel, Prabhu S.; Shukla, Shilin N.] Gujarat Canc Res Inst, Ahmadabad, Gujarat, India.
[Palmqvist, Richard] Umea Univ, Dept Med Biosci, Umea, Sweden.
[Nagtegaal, Iris D.] Radboud Univ Nijmegen, Dept Pathol, Med Ctr, NL-6525 ED Nijmegen, Netherlands.
[Wang, Yili] Xi An Jiao Tong Univ, Inst Canc Res, Ctr Translat Med, Xian 710049, Peoples R China.
[D'Arrigo, Corrado] NHS, Dept Histopathol, Dorset Cty Hosp, DCHFT, Dorchester, England.
[Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Sinicrope, Frank A.] Mayo Clin, Rochester, MN 55905 USA.
[Sinicrope, Frank A.] Mayo Coll Med, Rochester, MN 55905 USA.
[Trinchieri, Giorgio] NCI, Canc Inflammat Program, Ctr Canc Res, NIH, Frederick, MD 21701 USA.
[Trinchieri, Giorgio] NIH, Trans NIH Ctr Human Immunol CHI, Frederick, MD USA.
[Trinchieri, Giorgio] NCI, Canc Inflammat Program, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
[Gajewski, Thomas F.] Univ Chicago, Chicago, IL 60637 USA.
[Ascierto, Paolo A.] Ist Nazl Studio & Cura Tumori Fdn G Pascale, Med Oncol & Innovat Therapies Unit, Naples, Italy.
[Ascierto, Paolo A.] Fdn Melanoma Onlus, Naples, Italy.
[Fox, Bernard A.] Providence Portland Med Ctr, Earle A Chiles Res Inst, Robert W Franz Canc Ctr, Lab Mol & Tumor Immunol, Portland, OR USA.
[Fox, Bernard A.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.
RP Galon, J (reprint author), INSERM, U872, Lab Integrat Canc Immunol, F-75006 Paris, France.
EM jerome.galon@crc.jussieu.fr
RI Nagtegaal, Iris/A-2448-2014; Kawakami, Yutaka /E-7429-2013; Ottensmeier,
Christian/E-8131-2012;
OI Nagtegaal, Iris/0000-0003-0887-4127; Wouters,
Bradly/0000-0002-8187-592X; Gibbs, Peter/0000-0003-1423-4484; Kawakami,
Yutaka /0000-0003-4836-2855; Ottensmeier, Christian/0000-0003-3619-1657;
Masucci, Giuseppe/0000-0002-9583-2306; Kopetz,
Scott/0000-0001-9647-3416; coral, sandra/0000-0002-1308-3082; Pawelec,
Graham/0000-0002-3600-0163; Lundqvist, Andreas/0000-0002-9709-2970
FU NCI NIH HHS [K05 CA142885]
NR 39
TC 190
Z9 193
U1 13
U2 106
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD OCT 3
PY 2012
VL 10
AR 205
DI 10.1186/1479-5876-10-205
PG 9
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 092FN
UT WOS:000315104900001
PM 23034130
ER
PT J
AU Banks, WA
Niehoff, ML
Ponzio, NM
Erickson, MA
Zalcman, SS
AF Banks, William A.
Niehoff, Michael L.
Ponzio, Nicholas M.
Erickson, Michelle A.
Zalcman, Steven S.
TI Pharmacokinetics and modeling of immune cell trafficking: quantifying
differential influences of target tissues versus lymphocytes in SJL and
lipopolysaccharide-treated mice
SO JOURNAL OF NEUROINFLAMMATION
LA English
DT Article
DE Blood-brain barrier; Brain; Cellular trafficking; Encephalitis; Immune;
Lymphocytes; Multiple sclerosis; Neuroinflammation; Neuroimmune;
Pharmacokinetics
ID BLOOD-BRAIN-BARRIER; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS;
CENTRAL-NERVOUS-SYSTEM; ENCEPHALITIS; LEUKOCYTE; MIGRATION; TRANSPORT;
INVASION; MOUSE; ENTRY
AB Background: Immune cell trafficking into the CNS and other tissues plays important roles in health and disease. Rapid quantitative methods are not available that could be used to study many of the dynamic aspects of immune cell-tissue interactions.
Methods: We used pharmacokinetics and modeling to quantify and characterize the trafficking of radioactively labeled lymphocytes into brain and peripheral tissues. We used variance from two-way ANOVAs with 2 x 2 experimental designs to model the relative influences of lymphocytes and target tissues in trafficking.
Results: We found that in male CD-1 mice, about 1 in 5,000 intravenously injected lymphocytes entered each gram of brain. Uptake by brain was 2 to 3 times higher in naive SJL females, but uptake by spleen and clearance from blood was lower, demonstrating a dichotomy in immune cell distribution. Treatment of CD-1 mice with lipopolysaccharide (LPS) increased immune cell uptake into brain but decreased uptake by spleen and axillary nodes.
Conclusions: Differences in brain uptake and in uptake by spleen between SJL and CD-1 mice were primarily determined by lymphocytes, whereas differences in uptake with LPS were primarily determined by lymphocytes for the brain but by the tissues for the spleen and the axillary lymph node. These results show that immune cells normally enter the CNS and that tissues and immune cells interact in ways that can be quantified by pharmacokinetic models.
C1 [Banks, William A.; Erickson, Michelle A.] Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
[Banks, William A.; Erickson, Michelle A.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Banks, William A.] VAPSHCS, Seattle, WA 98108 USA.
[Niehoff, Michael L.] St Louis Univ, Sch Med, Div Geriatr Med, Dept Internal Med, St Louis, MO 63104 USA.
[Ponzio, Nicholas M.] Univ Med & Dent New Jersey, UMDNJ, Newark, NJ USA.
[Erickson, Michelle A.] St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.
[Zalcman, Steven S.] Univ Med & Dent New Jersey, UMDNJ, Dept Psychiat, Newark, NJ USA.
RP Banks, WA (reprint author), Vet Affairs Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
EM wabanks1@uw.edu
FU VA Merit Review [NS050547, AG029839, MH74689, MH68021]
FX Supported by VA Merit Review (WAB), NS050547 (WAB), AG029839 (WAB),
MH74689 (SSZ), and MH68021 (SSZ).
NR 30
TC 4
Z9 4
U1 0
U2 0
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1742-2094
J9 J NEUROINFLAMM
JI J. Neuroinflamm.
PD OCT 3
PY 2012
VL 9
AR 231
DI 10.1186/1742-2094-9-231
PG 14
WC Immunology; Neurosciences
SC Immunology; Neurosciences & Neurology
GA 033OB
UT WOS:000310806100001
PM 23034075
ER
PT J
AU Murdoch, DR
Slow, S
Chambers, ST
Jennings, LC
Stewart, AW
Priest, PC
Florkowski, CM
Livesey, JH
Camargo, CA
Scragg, R
AF Murdoch, David R.
Slow, Sandy
Chambers, Stephen T.
Jennings, Lance C.
Stewart, Alistair W.
Priest, Patricia C.
Florkowski, Christopher M.
Livesey, John H.
Camargo, Carlos A., Jr.
Scragg, Robert
TI Effect of Vitamin D-3 Supplementation on Upper Respiratory Tract
Infections in Healthy Adults The VIDARIS Randomized Controlled Trial
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID YOUNG FINNISH MEN; SYMPTOM SURVEY; COMMUNITY; CHOLECALCIFEROL;
TUBERCULOSIS; ASSOCIATION; PREVENTION; PNEUMONIA; FRACTURES; DISEASE
AB Context Observational studies have reported an inverse association between serum 25-hydroxyvitamin D (25-OHD) levels and incidence of upper respiratory tract infections (URTIs). However, results of clinical trials of vitamin D supplementation have been inconclusive.
Objective To determine the effect of vitamin D supplementation on incidence and severity of URTIs in healthy adults.
Design, Setting, and Participants Randomized, double-blind, placebo-controlled trial conducted among 322 healthy adults between February 2010 and November 2011 in Christchurch, New Zealand.
Intervention Participants were randomly assigned to receive an initial dose of 200 000 IU oral vitamin D-3, then 200 000 IU 1 month later, then 100 000 IU monthly (n = 161), or placebo administered in an identical dosing regimen (n = 161), for a total of 18 months.
Main Outcome Measures The primary end point was number of URTI episodes. Secondary end points were duration of URTI episodes, severity of URTI episodes, and number of days of missed work due to URTI episodes.
Results The mean baseline 25-OHD level of participants was 29 (SD, 9) ng/mL. Vitamin D supplementation resulted in an increase in serum 25-OHD levels that was maintained at greater than 48 ng/mL throughout the study. There were 593 URTI episodes in the vitamin D group and 611 in the placebo group, with no statistically significant differences in the number of URTIs per participant (mean, 3.7 per person in the vitamin D group and 3.8 per person in the placebo group; risk ratio, 0.97; 95% CI, 0.85-1.11), number of days of missed work as a result of URTIs (mean, 0.76 days in each group; risk ratio, 1.03; 95% CI, 0.81-1.30), duration of symptoms per episode (mean, 12 days in each group; risk ratio, 0.96; 95% CI, 0.73-1.25), or severity of URTI episodes. These findings remained unchanged when the analysis was repeated by season and by baseline 25-OHD levels.
Conclusion In this trial, monthly administration of 100 000 IU of vitamin D did not reduce the incidence or severity of URTIs in healthy adults.
C1 [Murdoch, David R.; Slow, Sandy; Chambers, Stephen T.; Jennings, Lance C.; Florkowski, Christopher M.] Univ Otago, Dept Pathol, Christchurch 8011, New Zealand.
[Murdoch, David R.; Jennings, Lance C.; Florkowski, Christopher M.; Livesey, John H.] Christchurch Hosp, Canterbury Hlth Labs, Christchurch, New Zealand.
[Chambers, Stephen T.] Christchurch Hosp, Dept Infect Dis, Christchurch, New Zealand.
[Stewart, Alistair W.; Scragg, Robert] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand.
[Priest, Patricia C.] Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
RP Murdoch, DR (reprint author), Univ Otago, Dept Pathol, POB 4345, Christchurch 8011, New Zealand.
EM david.murdoch@otago.ac.nz
FU Health Research Council of New Zealand
FX The study was funded by the Health Research Council of New Zealand.
NR 28
TC 89
Z9 96
U1 0
U2 14
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 3
PY 2012
VL 308
IS 13
BP 1333
EP 1339
DI 10.1001/jama.2012.12505
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014IV
UT WOS:000309369300027
PM 23032549
ER
PT J
AU Bangalore, S
Steg, PG
Deedwania, P
Crowley, K
Eagle, KA
Goto, S
Ohman, EM
Cannon, CP
Smith, SC
Zeymer, U
Hoffman, EB
Messerli, FH
Bhatt, DL
AF Bangalore, Sripal
Steg, Ph Gabriel
Deedwania, Prakash
Crowley, Kevin
Eagle, Kim A.
Goto, Shinya
Ohman, E. Magnus
Cannon, Christopher P.
Smith, Sidney C., Jr.
Zeymer, Uwe
Hoffman, Elaine B.
Messerli, Franz H.
Bhatt, Deepak L.
CA REACH Registry Investigators
TI beta-Blocker Use and Clinical Outcomes in Stable Outpatients With and
Without Coronary Artery Disease
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENT RATES;
AMERICAN-HEART-ASSOCIATION; BLOOD-PRESSURE; PROPENSITY SCORE;
HYPERTENSION; RISK; METAANALYSIS; THERAPY; ATHEROTHROMBOSIS
AB Context beta-Blockers remain the standard of care after a myocardial infarction (MI). However, the benefit of beta-blocker use in patients with coronary artery disease (CAD) but no history of MI, those with a remote history of MI, and those with only risk factors for CAD is unclear.
Objective To assess the association of beta-blocker use with cardiovascular events in stable patients with a prior history of MI, in those with CAD but no history of MI, and in those with only risk factors for CAD.
Design, Setting, and Patients Longitudinal, observational study of patients in the Reduction of Atherothrombosis for Continued Health (REACH) registry who were divided into 3 cohorts: known prior MI (n = 14 043), known CAD without MI (n = 12 012), or those with CAD risk factors only (n = 18 653). Propensity score matching was used for the primary analyses. The last follow-up data collection was April 2009.
Main Outcome Measures The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke. The secondary outcome was the primary outcome plus hospitalization for atherothrombotic events or a revascularization procedure.
Results Among the 44 708 patients, 21 860 were included in the propensity score-matched analysis. With a median follow-up of 44 months (interquartile range, 35-45 months), event rates were not significantly different in patients with beta-blocker use compared with those without beta-blocker use for any of the outcomes tested, even in the prior MI cohort (489 [16.93%] vs 532 [18.60%], respectively; hazard ratio [HR], 0.90 [95% CI, 0.79-1.03]; P = .14). In the CAD without MI cohort, the associated event rates were not significantly different in those with beta-blocker use for the primary outcome (391 [12.94%]) vs without beta-blocker use (405 [13.55%]) (HR, 0.92[95% CI, 0.79-1.08]; P = .31), with higher rates for the secondary outcome (1101 [30.59%] vs 1002 [27.84%]; odds ratio [OR], 1.14 [95% CI, 1.03-1.27]; P = .01) and for the tertiary outcome of hospitalization (870 [24.17%] vs 773 [21.48%]; OR, 1.17 [95% CI, 1.04-1.30]; P = .01). In the cohort with CAD risk factors only, the event rates were higher for the primary outcome with beta-blocker use (467 [14.22%]) vs without beta-blocker use (403 [12.11%]) (HR, 1.18 [95% CI, 1.02-1.36]; P = .02), for the secondary outcome (870 [22.01%] vs 797 [20.17%]; OR, 1.12 [95% CI, 1.00-1.24]; P = .04) but not for the tertiary outcomes of MI (89 [2.82%] vs 68 [2.00%]; HR, 1.36 [95% CI, 0.97-1.90]; P = .08) and stroke (210 [6.55%] vs 168 [5.12%]; HR, 1.22 [95% CI, 0.99-1.52]; P = .06). However, in those with recent MI (<= 1 year), beta-blocker use was associated with a lower incidence of the secondary outcome (OR, 0.77 [95% CI, 0.64-0.92]).
Conclusion In this observational study of patients with either CAD risk factors only, known prior MI, or known CAD without MI, the use of beta-blockers was not associated with a lower risk of composite cardiovascular events. JAMA. 2012;308(13):1340-1349
C1 [Bangalore, Sripal] NYU, Sch Med, Cardiovasc Clin Res Ctr, New York, NY 10016 USA.
[Steg, Ph Gabriel] Univ Paris Diderot, Hosp Bichat, AP HP, INSERM,U698, Paris, France.
[Deedwania, Prakash] Univ Calif San Francisco, Dept Internal Med Cardiol, Sch Med, Fresno, CA USA.
[Crowley, Kevin; Cannon, Christopher P.; Hoffman, Elaine B.; Bhatt, Deepak L.] TIMI Study Grp, Boston, MA USA.
[Eagle, Kim A.] Univ Michigan Hlth Syst, Cardiovasc Ctr, Ann Arbor, MI USA.
[Goto, Shinya] Tokai Univ, Sch Med, Isehara, Kanagawa 25911, Japan.
[Ohman, E. Magnus] Duke Univ, Med Ctr, Durham, NC USA.
[Cannon, Christopher P.; Bhatt, Deepak L.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Cannon, Christopher P.; Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Smith, Sidney C., Jr.] Univ N Carolina, Ctr Cardiovasc Sci & Med, Chapel Hill, NC USA.
[Zeymer, Uwe] Herzzentrum Ludwigshafen, Ludwigshafen, Germany.
[Zeymer, Uwe] Inst Herzinfarktforsch Ludwigshafen, Ludwigshafen, Germany.
[Messerli, Franz H.] St Lukes Roosevelt Hosp, New York, NY 10025 USA.
[Bhatt, Deepak L.] VA Boston Healthcare Syst, Boston, MA USA.
RP Bangalore, S (reprint author), NYU, Sch Med, Cardiovasc Clin Res Ctr, 550 1st Ave, New York, NY 10016 USA.
EM sripalbangalore@gmail.com
RI Bangalore, Sripal/B-6246-2013;
OI Bangalore, Sripal/0000-0001-9485-0652
FU sanofi-aventis; Servier [U-698]; New York University School of Medicine;
Ablynx; Amarin; Amgen; Astellas; AstraZeneca; Bayer; Boehringer
Ingelheim; Bristol-Meyers Squibb; Daiichi Sankyo; Eisai;
GlaxoSmithKline; Lilly; Medtronic; Merck Sharp Dohme; Novartis; Otsuka;
Pfizer; Roche; Medicines Company; Forest Pharmaceuticals; Daichii
Sankyo; Asteras; Medtronics Japan; Mitsubishi Tanabe; Takeda; Mochida;
Eli Lilly Company; Maquet; Accumetrics; Essentials; Merck; Regeneron;
Ethicon; Waksman Foundation (Tokyo, Japan)
FX The authors have completed and submitted the ICMJE Form for Disclosure
of Potential Conflicts of Interest. Dr Steg reported receiving a
research grant from sanofi-aventis and Servier awarded to INSERM U-698
and the New York University School of Medicine; serving as a consultant
or receiving speakers fees from Ablynx, Amarin, Amgen, Astellas,
AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Meyers Squibb, Daiichi
Sankyo, Eisai, GlaxoSmithKline, Lilly, Medtronic, Merck Sharp & Dohme,
Novartis, Otsuka, Pfizer, Roche, sanofi-aventis, Servier, the Medicines
Company; and holding stock in Aterovax. Dr Deedwania reported serving as
a consultant or receiving speakers fees from Forest Pharmaceuticals,
Novartis, Daichii Sankyo, Servier, and Pfizer. Dr Goto reported
receiving consulting fees and honoraria from Eisai, sanofi-aventis,
Otsuka, Bayer, Novartis, AstraZeneca, Asteras, Pfizer, Medtronics Japan,
Mitsubishi Tanabe, Takeda, Daiichi Sankyo, Mochida, Merck Sharp & Dohme;
and receiving research grants from sanofi-aventis, Eisai, Boehringer
Ingelheim, Otsuka, and Daiichi Sankyo. Dr Ohman reported receiving
research grants from Daiichi Sankyo, Eli Lilly & Company, Maquet;
serving as a consultant to AstraZeneca, Boehringer Ingelheim,
Bristol-Myers Squibb, Gilead Sciences, LipoScience, Merck, Pozen, Roche,
sanofi-aventis, the Medicines Company, and WebMD; and serving on the
speakers bureau for Boehringer Ingelheim, Gilead Sciences, and the
Medicines Company. Dr Cannon reported receiving research grants or
support from Accumetrics, AstraZeneca, Essentials, GlaxoSmithKline,
Merck, Regeneron, sanofi-aventis, and Takeda; serving on advisory boards
(but funds donated to charity) for Bristol-Myers Squibb, Alnylam,
Pfizer, and CSL; receiving honoraria for the development of independent
educational symposia for Pfizer and AstraZeneca; and serving as a
clinical advisor for and owning equity in Automedics Medical Systems. Dr
Bhatt reported serving on an advisory board for Medscape Cardiology;
serving on the boards of directors for Boston VA Research Institute and
the Society of Chest Pain Centers; serving as chair for the American
Heart Association Get With The Guidelines Science Subcommittee;
receiving honoraria from the American College of Cardiology for serving
as editor of Clinical Trials, Cardiosource, Duke Clinical Research
Institute for serving on clinical trial steering committees, Slack
Publications for serving as chief medical editor of Cardiology Today
Intervention, and WebMD for serving on continuing medical education
steering committees; serving as senior associate editor for the Journal
of Invasive Cardiology; receiving research grants from Amarin,
AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic,
sanofi-aventis, and the Medicines Company; and unfunded research from
FlowCo, PLx Pharma, and Takeda. Drs Bangalore, Eagle, Smith Jr, Zeymer,
Hoffman, and Messerli and Mr Crowley did not report any disclosures.;
The REACH Registry is sponsored by sanofi-aventis, Bristol-Myers Squibb,
and the Waksman Foundation (Tokyo, Japan) and is endorsed by the World
Heart Federation. Statistical analyses of the REACH database by TIMI
Study Group statisticians were funded by sanofi-aventis.
NR 47
TC 159
Z9 168
U1 5
U2 19
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 3
PY 2012
VL 308
IS 13
BP 1340
EP 1349
DI 10.1001/jama.2012.12559
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014IV
UT WOS:000309369300028
PM 23032550
ER
PT J
AU Han, J
Mody, M
Ahlfors, SP
AF Han, Jooman
Mody, Maria
Ahlfors, Seppo P.
TI Gamma phase locking modulated by phonological contrast during auditory
comprehension in reading disability
SO NEUROREPORT
LA English
DT Article
DE gamma-band oscillations; magnetoencephalography; phase-locking value;
phonological processing; sentence context; speech perception
ID DYSLEXIC-CHILDREN; DEVELOPMENTAL DYSLEXIA; CORTICAL OSCILLATIONS;
SPEECH-PERCEPTION; BRAIN; PERSISTENCE; CONTEXT; BAND
AB Children with specific reading impairment may have subtle deficits in speech perception related to difficulties in phonological processing. The aim of this study was to examine brain oscillatory activity related to phonological processing in the context of auditory sentence comprehension using magnetoencephalography to better understand these deficits. Good and poor readers, 16-18 years of age, were tested on speech perception of sentence-terminal incongruent words that were phonologically manipulated to be similar or dissimilar to corresponding congruent target words. Functional coupling between regions was measured using phase-locking values (PLVs). Gamma-band (30-45 Hz) PLV between auditory cortex and superior temporal sulcus in the right hemisphere was differentially modulated in the two groups by the degree of phonological contrast between the congruent and the incongruent target words in the latency range associated with semantic processing. Specifically, the PLV was larger in the phonologically similar than in the phonologically dissimilar condition in the good readers. This pattern was reversed in the poor readers, whose lower PLV in the phonologically similar condition may be indicative of the impaired phonological coding abilities of the group, and consequent vulnerability under perceptually demanding conditions. Overall, the results support the role of gamma oscillations in spoken language processing. NeuroReport 23:851-856 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Han, Jooman; Mody, Maria; Ahlfors, Seppo P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Mody, Maria; Ahlfors, Seppo P.] Harvard MIT Div Hlth Sci & Technol, Cambridge, MA USA.
RP Han, J (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Athinoula Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM jooman@nmr.mgh.harvard.edu
RI Ahlfors, Seppo/P-3644-2016
FU NIH [NS057500, HD046171]; National Center for Research Resources
[P41RR14075]
FX This study was supported by the NIH Grants NS057500, HD046171, and The
National Center for Research Resources (P41RR14075). The authors thank
Surina Basho and Shira Schwartz for various aspects of data collection
and analysis.
NR 25
TC 5
Z9 5
U1 2
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0959-4965
J9 NEUROREPORT
JI Neuroreport
PD OCT 3
PY 2012
VL 23
IS 14
BP 851
EP 856
DI 10.1097/WNR.0b013e32835818e1
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 001FJ
UT WOS:000308445600009
PM 22889887
ER
PT J
AU Rubenfeld, GD
Slutsky, AS
Thompson, BT
AF Rubenfeld, Gordon D.
Slutsky, Arthur S.
Thompson, B. Taylor
CA ARDS Definition Task Force
TI Definition of Acute Respiratory Distress Syndrome Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
ID ACUTE LUNG INJURY; VENTILATION
C1 [Rubenfeld, Gordon D.; Slutsky, Arthur S.] Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
[Thompson, B. Taylor] Massachusetts Gen Hosp, Pulm Crit Care Unit, Boston, MA 02114 USA.
RP Rubenfeld, GD (reprint author), Univ Toronto, Interdept Div Crit Care Med, Toronto, ON, Canada.
EM gordon.rubenfeld@sunnybrook.ca
NR 4
TC 0
Z9 0
U1 2
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD OCT 3
PY 2012
VL 308
IS 13
BP 1322
EP 1322
DI 10.1001/2012.jama.11901
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 014IV
UT WOS:000309369300018
ER
PT J
AU Asmal, M
Seaman, M
Lin, WY
Chung, RT
Letvin, NL
Geiben-Lynn, R
AF Asmal, Mohammed
Seaman, Michael
Lin, Wenyu
Chung, Raymond T.
Letvin, Norman L.
Geiben-Lynn, Ralf
TI Inhibition of HCV by the serpin antithrombin III
SO VIROLOGY JOURNAL
LA English
DT Article
DE Antithrombin III; Hepatitis C virus; OR6 replicon cells; NF kappa B; P38
MAPK; ERK1/2
ID HEPATITIS-C VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; LEUKOCYTE PROTEASE
INHIBITOR; ALPHA-2A PLUS RIBAVIRIN; HIV-INFECTED PATIENTS;
HEPATOCELLULAR-CARCINOMA; RISK-FACTORS; SIGNALING PATHWAY; LIVER
FIBROSIS; CORE PROTEIN
AB Background: Although there have been dramatic strides made recently in the treatment of chronic hepatitis C virus infection, interferon-alpha based therapy remains challenging for certain populations, including those with unfavorable IL28B genotypes, psychiatric co-morbidity, HIV co-infection, and decompensated liver disease. We have recently shown that ATIII, a serine protease inhibitor (serpin), has broad antiviral properties.
Results: We now show that ATIII is capable of inhibiting HCV in the OR6 replicon model at micromolar concentrations. At a mechanistic level using gene-expression arrays, we found that ATIII treatment down-regulated multiple host cell signal transduction factors involved in the pathogenesis of cirrhosis and hepatocellular carcinoma, including Jun, Myc and BMP2. Using a protein interactive network analysis we found that changes in gene-expression caused by ATIII were dependent on three nodes previously implicated in HCV disease progression or HCV replication: NF kappa B, P38 MAPK, and ERK1/2.
Conclusions: Our findings suggest that ATIII stimulates a novel innate antiviral host cell defense different from current treatment options.
C1 [Asmal, Mohammed; Seaman, Michael; Letvin, Norman L.; Geiben-Lynn, Ralf] Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA.
[Asmal, Mohammed; Seaman, Michael; Lin, Wenyu; Chung, Raymond T.; Letvin, Norman L.; Geiben-Lynn, Ralf] Harvard Univ, Sch Med, Boston, MA 02215 USA.
[Lin, Wenyu; Chung, Raymond T.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
RP Asmal, M (reprint author), Beth Israel Deaconess Med Ctr, Div Viral Pathogenesis, Boston, MA 02215 USA.
EM masmal@partners.org
FU NIH; Department of Defense [N01 AI30048, N01 AI30049, AI067854,
AI060354-06]
FX We thank Dr. Nobuyuki Kato (Okayama University, Japan) for his kind gift
of the OR6 replicon cell-line. We thank Christa Osuna-Gutierrez (Beth
Israel Deaconess Medical Center) for critical reading of the manuscript.
This study was funded by NIH and the Department of Defense (N01 AI30048,
N01 AI30049, AI067854 and AI060354-06). We thank Dr. Carmen Plasencia
(Acceleromics, Spain) for help with the systems biology approach.
NR 69
TC 5
Z9 6
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1743-422X
J9 VIROL J
JI Virol. J.
PD OCT 2
PY 2012
VL 9
AR 226
DI 10.1186/1743-422X-9-226
PG 10
WC Virology
SC Virology
GA 053IN
UT WOS:000312265000001
PM 23031791
ER
PT J
AU O'Neill, WW
Kleiman, NS
Moses, J
Henriques, JPS
Dixon, S
Massaro, J
Palacios, I
Maini, B
Mulukutla, S
Dzavik, V
Popma, J
Douglas, PS
Ohman, M
AF O'Neill, William W.
Kleiman, Neal S.
Moses, Jeffrey
Henriques, Jose P. S.
Dixon, Simon
Massaro, Joseph
Palacios, Igor
Maini, Brijeshwar
Mulukutla, Suresh
Dzavik, Vladimir
Popma, Jeffrey
Douglas, Pamela S.
Ohman, Magnus
TI A Prospective, Randomized Clinical Trial of Hemodynamic Support With
Impella 2.5 Versus Intra-Aortic Balloon Pump in Patients Undergoing
High-Risk Percutaneous Coronary Intervention The PROTECT II Study
SO CIRCULATION
LA English
DT Article
DE heart-assist device; hemodynamics; Impella 2.5; stents
ID ASSIST DEVICE; REGISTRY; POWER
AB Background-Although coronary artery bypass grafting is generally preferred in symptomatic patients with severe, complex multivessel, or left main disease, some patients present with clinical features that make coronary artery bypass grafting clinically unattractive. Percutaneous coronary intervention with hemodynamic support may be feasible for these patients. Currently, there is no systematic comparative evaluation of hemodynamic support devices for this indication.
Methods and Results-We randomly assigned 452 symptomatic patients with complex 3-vessel disease or unprotected left main coronary artery disease and severely depressed left ventricular function to intra-aortic balloon pump (IABP) (n=226) or Impella 2.5 (n=226) support during nonemergent high-risk percutaneous coronary intervention. The primary end point was the 30-day incidence of major adverse events. A 90-day follow-up was required, as well, by protocol. Impella 2.5 provided superior hemodynamic support in comparison with IABP, with maximal decrease in cardiac power output from baseline of -0.04 +/- 0.24 W in comparison with -0.14 +/- 0.27 W for IABP (P=0.001). The primary end point (30-day major adverse events) was not statistically different between groups: 35.1% for Impella 2.5 versus 40.1% for IABP, P=0.227 in the intent-to-treat population and 34.3% versus 42.2%, P=0.092 in the per protocol population. At 90 days, a strong trend toward decreased major adverse events was observed in Impella 2.5-supported patients in comparison with IABP: 40.6% versus 49.3%, P=0.066 in the intent-to-treat population and 40.0% versus 51.0%, P=0.023 in the per protocol population, respectively.
Conclusions-The 30-day incidence of major adverse events was not different for patients with IABP or Impella 2.5 hemodynamic support. However, trends for improved outcomes were observed for Impella 2.5-supported patients at 90 days.
C1 [O'Neill, William W.] Univ Miami, Miami, FL USA.
[Kleiman, Neal S.] Methodist DeBakey Heart & Vasc Ctr, Houston, TX USA.
Columbia Univ, Med Ctr, New York Presbyterian Hosp, New York, NY USA.
[Henriques, Jose P. S.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
[Dixon, Simon] Beaumont Hosp, Royal Oak, MI USA.
Harvard Clin Res Inst, Boston, MA USA.
[Palacios, Igor] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Maini, Brijeshwar] Pinnacle Hlth Med Ctr, Wormleysburg, PA USA.
[Mulukutla, Suresh] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Dzavik, Vladimir] Toronto Gen Hosp, Toronto, ON, Canada.
[Popma, Jeffrey] Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Douglas, Pamela S.] Duke Clin Res Inst, Durham, NC USA.
[Ohman, Magnus] Duke Univ, Med Ctr, Durham, NC USA.
RP O'Neill, WW (reprint author), Leonard M Miller Sch Med, Dept Internal Med, Div Cardiol, 1600 NW 10th Ave, Miami, FL 33156 USA.
EM WONEILL1@hfhs.org
OI Massaro, Joseph/0000-0002-2682-4812
FU Abiomed (Danvers, MA); Abiomed; Harvard Clinical Research Institute for
biostatistics, trial design, and analyses; Abbott laboratories;
InfraReDx; Medtronic; Daiichi Sankyo; Maquet; Eli Lilly
FX This study was funded by Abiomed (Danvers, MA).; Drs O'Neill and Kleiman
report no conflicts. Dr Moses reported that his institution has received
research grant from Abiomed as site principal investigator for the
Mini-AMI trial. Dr Moses received a modest payment for participation at
some Abiomed advisory board meetings. Dr Henriques reported that his
institution has received research funding from Abiomed as investigator
site for other Impella trials. Dr Henriques received modest speaker
honoraria from Abiomed. Dr Dixon has no conflict of interest to report
for this study. Dr Massaro reported that he has received funding for the
study through Harvard Clinical Research Institute for biostatistics,
trial design, and analyses. Dr Palacios reported that he has received
modest speaker honoraria from Abiomed. Dr Maini reported that he or his
institution have received research support/speaker honoraria from Abbott
laboratories, InfraReDx, Abiomed, and Medtronic. Dr Mulukutla reported
that he received modest compensation for participation in Abiomed
advisory board meetings. Dr Dzavik reported that he has received modest
speaker honoraria from Abiomed. Dr Popma reported that his institution
(angiographic core laboratory) has received a research grant from
Abiomed for the angiographic analysis of the study. He has also received
modest funding for participation in some advisory board meetings. Dr
Douglas reported that her institution (Duke University/Duke Clinical
Research Institute) has received funding from Abiomed for the
echocardiography core laboratory analysis of the study. Dr Ohman
reported that he has received grants from Daiichi Sankyo, Maquet
(formerly Datascope), and Eli Lilly.
NR 19
TC 122
Z9 129
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD OCT 2
PY 2012
VL 126
IS 14
BP 1717
EP +
DI 10.1161/CIRCULATIONAHA.112.098194
PG 21
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 016OM
UT WOS:000309528600010
PM 22935569
ER
PT J
AU Ho, JE
Liu, CY
Lyass, A
Courchesne, P
Pencina, MJ
Vasan, RS
Larson, MG
Levy, D
AF Ho, Jennifer E.
Liu, Chunyu
Lyass, Asya
Courchesne, Paul
Pencina, Michael J.
Vasan, Ramachandran S.
Larson, Martin G.
Levy, Daniel
TI Galectin-3, a Marker of Cardiac Fibrosis, Predicts Incident Heart
Failure in the Community
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE biomarker; epidemiology; heart failure; prognosis
ID LEFT-VENTRICULAR HYPERTROPHY; SYSTOLIC DYSFUNCTION; NATRIURETIC PEPTIDE;
SERUM GALECTIN-3; FRAMINGHAM; MORTALITY; SURVIVAL; MACROPHAGES;
POPULATION; EXPRESSION
AB Objectives The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker of cardiac fibrosis, with incident heart failure (HF) in the community.
Background Gal-3 is an emerging prognostic biomarker in HF, and experimental studies suggest that Gal-3 is an important mediator of cardiac fibrosis. Whether elevated Gal-3 concentrations precede the development of HF is unknown.
Methods Gal-3 concentrations were measured in 3,353 participants in the Framingham Offspring Cohort (mean age 59 years; 53% women). The relation of Gal-3 to incident HF was assessed using proportional hazards regression.
Results Gal-3 was associated with increased left ventricular mass in age-adjusted and sex-adjusted analyses (p = 0.001); this association was attenuated in multivariate analyses (p = 0.06). A total of 166 participants developed incident HF and 468 died during a mean follow-up period of 11.2 years. Gal-3 was associated with risk for incident HF (hazard ratio [HR]: 1.28 per 1 SD increase in log Gal-3; 95% confidence interval [CI]: 1.14 to 1.43; p < 0.0001) and remained significant after adjustment for clinical variables and B-type natriuretic peptide (HR: 1.23; 95% CI: 1.04 to 1.47; p = 0.02). Gal-3 was also associated with risk for all-cause mortality (multivariable-adjusted HR: 1.15; 95% CI: 1.04 to 1.28; p = 0.01). The addition of Gal-3 to clinical factors resulted in negligible changes to the C-statistic and minor improvements in net reclassification improvement.
Conclusions Higher concentration of Gal-3, a marker of cardiac fibrosis, is associated with increased risk for incident HF and mortality. Future studies evaluating the role of Gal-3 in cardiac remodeling may provide further insights into the role of Gal-3 in the pathophysiology of HF. (J Am Coll Cardiol 2012;60:1249-56) (C) 2012 by the American College of Cardiology Foundation
C1 [Ho, Jennifer E.; Liu, Chunyu; Lyass, Asya; Courchesne, Paul; Pencina, Michael J.; Vasan, Ramachandran S.; Larson, Martin G.; Levy, Daniel] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Ho, Jennifer E.; Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[Ho, Jennifer E.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Lyass, Asya; Pencina, Michael J.; Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Cardiol Sect, Boston, MA 02118 USA.
[Vasan, Ramachandran S.] Boston Univ, Sch Med, Dept Prevent Med & Epidemiol, Boston, MA 02118 USA.
RP Levy, D (reprint author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Suite 2, Framingham, MA 01702 USA.
EM levyd@nhlbi.nih.gov
OI Larson, Martin/0000-0002-9631-1254; Ho, Jennifer/0000-0002-7987-4768;
Ramachandran, Vasan/0000-0001-7357-5970
FU National Heart, Lung, and Blood Institute's Framingham Heart Study
[N01-HC-25195]; American Heart Association Clinical Research Program
award
FX This work was supported by the National Heart, Lung, and Blood
Institute's Framingham Heart Study (Drs. Ho and Levy, contract
N01-HC-25195). Dr. Ho is supported by an American Heart Association
Clinical Research Program award. Galectin-3 assays were provided by BG
Medicine (Waltham, Massachusetts). All other authors have reported that
they have no relationships relevant to the contents of this paper to
disclose.
NR 41
TC 165
Z9 172
U1 4
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 2
PY 2012
VL 60
IS 14
BP 1249
EP 1256
DI 10.1016/j.jacc.2012.04.053
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 016HM
UT WOS:000309508400007
PM 22939561
ER
PT J
AU Morrow, DA
O'Donoghue, ML
AF Morrow, David A.
O'Donoghue, Michelle L.
TI Galectin-3 in Cardiovascular Disease
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Editorial Material
DE biomarker; epidemiology; heart failure; prognosis
ID HEART-FAILURE; HF; DYSFUNCTION; FIBROSIS
C1 [Morrow, David A.; O'Donoghue, Michelle L.] Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, Boston, MA 02115 USA.
RP Morrow, DA (reprint author), Brigham & Womens Hosp, Cardiovasc Div, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.
EM dmorrow@partners.org
NR 12
TC 12
Z9 12
U1 1
U2 8
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD OCT 2
PY 2012
VL 60
IS 14
BP 1257
EP 1258
DI 10.1016/j.jacc.2012.05.032
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 016HM
UT WOS:000309508400008
PM 22939562
ER
PT J
AU Reed, M
Huang, J
Graetz, I
Brand, R
Hsu, J
Fireman, B
Jaffe, M
AF Reed, Mary
Huang, Jie
Graetz, Ilana
Brand, Richard
Hsu, John
Fireman, Bruce
Jaffe, Marc
TI Outpatient Electronic Health Records and the Clinical Care and Outcomes
of Patients With Diabetes Mellitus
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID QUALITY-OF-CARE; INFORMATION-TECHNOLOGY; AMBULATORY-CARE; IMPACT;
DISEASE
AB Background: Physicians can receive federal payments for meaningful use of complete certified electronic health records (EHRs). Evidence is limited on how EHR use affects clinical care and outcomes.
Objective: To examine the association between use of a commercially available certified EHR and clinical care processes and disease control in patients with diabetes.
Design: Quasi-experimental design with outpatient EHR implementation sequentially across 17 medical centers. Multivariate analyses adjusted for patient characteristics, medical center, time trends, and facility-level clustering.
Setting: Kaiser Permanente Northern California, an integrated delivery system.
Patients: 169 711 patients with diabetes mellitus.
Intervention: Use of a commercially available certified EHR.
Measurements: Drug treatment intensification and hemoglobin A(1c) (HbA(1c)) and low-density lipoprotein cholesterol (LDL-C) testing and values.
Results: Use of an EHR was associated with statistically significant improvements in treatment intensification after HbA(1c) values of 9% or greater (odds ratio, 1.10 [95% CI, 1.05 to 1.15]) or LDL-C values of 2.6 to 3.3 mmol/L (100 to 129 mg/dL) (odds ratio, 1.06 [CI, 1.00 to 1.12]); increases in 1-year retesting for HbA(1c) and LDL-C levels among all patients, with the most dramatic change among patients with the worst disease control (HbA(1c) levels >= 9% or LDL-C levels >= 3.4 mmol/ L [>= 130 mg/dL]); and decreased 90-day retesting among patients with HbA(1c) levels less than 7% or LDL-C levels less than 2.6 mmol/ L (<100 mg/dL). The EHR was also associated with statistically significant reductions in HbA(1c) and LDL-C levels, with the largest reductions among patients with the worst control (0.06-mmol/ L [2.19-mg/dL] reduction among patients with baseline LDL-C levels >= 3.4 mmol/ L [>= 130 mg/dL]; P < 0.001).
Limitation: The EHR was implemented in a setting with strong baseline performance on cardiovascular care quality measures.
Conclusion: Use of a commercially available certified EHR was associated with improved drug treatment intensification, monitoring, and physiologic control among patients with diabetes, with greater improvements among patients with worse control and less testing in patients already meeting guideline-recommended glycemic and lipid targets.
C1 [Reed, Mary] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Permanente Med Grp Inc, San Francisco, CA USA.
RP Reed, M (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM mary.e.reed@kp.org
RI Graetz, Ilana/N-1189-2016
OI Graetz, Ilana/0000-0003-3664-5815
FU National Institute of Diabetes and Digestive and Kidney Diseases [NIDDK
R01DK085070]
FX National Institute of Diabetes and Digestive and Kidney Diseases.; By
the National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK R01DK085070).
NR 21
TC 41
Z9 42
U1 4
U2 15
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 2
PY 2012
VL 157
IS 7
BP 482
EP U66
DI 10.7326/0003-4819-157-7-201210020-00004
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 016MQ
UT WOS:000309523200003
PM 23027319
ER
PT J
AU Goldzweig, CL
AF Goldzweig, Caroline Lubick
TI Pushing the Envelope of Electronic Patient Portals to Engage Patients in
Their Care
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Editorial Material
C1 Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med, Los Angeles, CA 90073 USA.
RP Goldzweig, CL (reprint author), Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, David Geffen Sch Med, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM Caroline.Goldzweig@va.gov
NR 7
TC 3
Z9 3
U1 1
U2 9
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 2
PY 2012
VL 157
IS 7
BP 525
EP 526
DI 10.7326/0003-4819-157-7-201210020-00013
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 016MQ
UT WOS:000309523200010
PM 23027322
ER
PT J
AU Fan, VS
Niewoehner, DE
Lew, R
AF Fan, Vincent S.
Niewoehner, Dennis E.
Lew, Robert
TI A Comprehensive Care Management Program to Prevent Chronic Obstructive
Pulmonary Disease Hospitalizations Response
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Fan, Vincent S.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Niewoehner, Dennis E.] Minneapolis Vet Affairs Healthcare Syst, Minneapolis, MN 55417 USA.
[Lew, Robert] Vet Affairs Boston Healthcare Syst, Boston, MA 02130 USA.
RP Fan, VS (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
NR 0
TC 2
Z9 2
U1 2
U2 4
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD OCT 2
PY 2012
VL 157
IS 7
BP 530
EP 531
DI 10.7326/0003-4819-157-7-201210020-00019
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 016MQ
UT WOS:000309523200014
ER
PT J
AU Benson, MJ
Aijo, T
Chang, X
Gagnon, J
Pape, UJ
Anantharaman, V
Aravind, L
Pursiheimo, JP
Oberdoerffer, S
Liu, XS
Lahesmaa, R
Lahdesmaki, H
Rao, A
AF Benson, Micah J.
Aijo, Tarmo
Chang, Xing
Gagnon, John
Pape, Utz J.
Anantharaman, Vivek
Aravind, L.
Pursiheimo, Juha-Pekka
Oberdoerffer, Shalini
Liu, X. Shirley
Lahesmaa, Riitta
Lahdesmaki, Harri
Rao, Anjana
TI Heterogeneous nuclear ribonucleoprotein L-like (hnRNPLL) and elongation
factor, RNA polymerase II, 2 (ELL2) are regulators of mRNA processing in
plasma cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE immunoglobulin; mRNA splicing; transcriptional elongation; B cell
maturation antigen
ID B-CELL; POLY(A) SITE; MU-CHAIN; 3 ENDS; IMMUNOGLOBULIN; POLYADENYLATION;
MEMBRANE; EXPRESSION; SEQUENCE; GENE
AB B cells and plasma cells possess distinct RNA processing environments that respectively promote the expression of membrane-associated Ig by B cells versus the secretion of Ig by plasma cells. Through a combination of transcriptional profiling and screening using a lentiviral short-hairpin RNA interference library, we show that both the splicing factor hnRNPLL and the transcription elongation factor ELL2 modulate the ratio of secreted versus membrane-encoding Ighg2b transcripts in MPC11 plasmacytoma cell lines. hnRNPLL and ELL2 are both highly expressed in primary plasma cells relative to B cells, but hnRNPLL binds Ighg2b mRNA transcripts and promotes an increase in levels of the membrane-encoding Ighg2b isoform at the expense of the secreted Ighg2b isoform, whereas ELL2 counteracts this effect and drives Ig secretion by increasing the frequency of the secreted Ighg2b isoform. As in T cells, hnRNPLL also alters the splicing pattern of mRNA encoding the adhesion receptor CD44, promoting exon inclusion, and decreasing the overall level of CD44 expression. Further characterization of ELL2-dependent transcription by RNA-Seq revealed that similar to 12% of transcripts expressed by plasma cells were differentially processed because of the activities of ELL2, including B-cell maturation antigen BCMA, a receptor with a defined role in plasma cell survival. Taken together, our data identify hnRNPLL and ELL2 as regulators of pre-mRNA processing in plasma cells.
C1 [Benson, Micah J.; Gagnon, John; Pape, Utz J.; Rao, Anjana] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Benson, Micah J.; Gagnon, John; Pape, Utz J.; Rao, Anjana] Childrens Hosp, Immune Dis Inst, Boston, MA 02115 USA.
[Benson, Micah J.; Gagnon, John; Pape, Utz J.; Rao, Anjana] Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Aijo, Tarmo; Lahdesmaki, Harri] Aalto Univ, Sch Sci, Dept Informat & Comp Sci, FI-00076 Aalto, Finland.
[Chang, Xing; Rao, Anjana] La Jolla Inst Allergy & Immunol, Div Signaling & Gene Express, La Jolla, CA 92037 USA.
[Pape, Utz J.; Liu, X. Shirley] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
[Pape, Utz J.; Liu, X. Shirley] Harvard Univ, Sch Publ Hlth, Boston, MA 02215 USA.
[Anantharaman, Vivek; Aravind, L.] NIH, Natl Ctr Biotechnol Informat, Natl Lib Med, Bethesda, MD 20894 USA.
[Pursiheimo, Juha-Pekka; Lahesmaa, Riitta; Lahdesmaki, Harri] Univ Turku, Turku Ctr Biotechnol, FI-20520 Turku, Finland.
[Pursiheimo, Juha-Pekka; Lahesmaa, Riitta; Lahdesmaki, Harri] Abo Akad Univ, FI-20520 Turku, Finland.
[Oberdoerffer, Shalini] NCI, Ctr Canc Res, Mouse Canc Genet Program, Frederick, MD 21702 USA.
[Rao, Anjana] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92037 USA.
[Rao, Anjana] Sanford Consortium Regenerat Med, La Jolla, CA 92037 USA.
RP Rao, A (reprint author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
EM arao@liai.org
OI Gagnon, John/0000-0001-6208-5781; Anantharaman,
Vivek/0000-0001-8395-0009; , chang xing/0000-0002-5072-9225
FU National Institutes of Health Grants [AI080875, AI40127, CA42471,
HG4069]; Academy of Finland Grant [126063]; Centre of Excellence in
Molecular Systems Immunology and Physiology Research [250114]; European
Commission Seventh Framework Grant [EC-FP7-SYBILLA-201106]; Juvenile
Diabetes Research Foundation; Sigrid Juselius Foundation; Biocenter
Finland; Cancer Research Institute and Leukemia Lymphoma Society
FX We thank the Finnish Microarray and Sequencing Center for the analysis
of the samples. This study was supported in part by National Institutes
of Health Grants AI080875, AI40127, and CA42471 (to A.R.), and HG4069
(to X.S.L); Academy of Finland Grant 126063 (to R.L.) and Centre of
Excellence in Molecular Systems Immunology and Physiology Research
2012-2017, Decision No. 250114 (to R.L. and H.L.); European Commission
Seventh Framework Grant EC-FP7-SYBILLA-201106 (to R.L., TA, and H.L.);
the Juvenile Diabetes Research Foundation (R.L.); the Sigrid Juselius
Foundation (R.L., H.L., and A.R.); Biocenter Finland (R.L.); and
postdoctoral fellowships from the Cancer Research Institute and Leukemia
Lymphoma Society (to M.J.B.).
NR 28
TC 13
Z9 13
U1 1
U2 7
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 2
PY 2012
VL 109
IS 40
BP 16252
EP 16257
DI 10.1073/pnas.1214414109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 017SN
UT WOS:000309611400063
PM 22991471
ER
PT J
AU Vaeth, M
Schliesser, U
Muller, G
Reissig, S
Satoh, K
Tuettenberg, A
Jonuleit, H
Waisman, A
Muller, MR
Serfling, E
Sawitzki, BS
Berberich-Siebelt, F
AF Vaeth, Martin
Schliesser, Ulrike
Mueller, Gerd
Reissig, Sonja
Satoh, Kazuki
Tuettenberg, Andrea
Jonuleit, Helmut
Waisman, Ari
Mueller, Martin R.
Serfling, Edgar
Sawitzki, Birgit S.
Berberich-Siebelt, Friederike
TI Dependence on nuclear factor of activated T-cells (NFAT) levels
discriminates conventional T cells from Foxp3(+) regulatory T cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE gene regulation; tolerance; autoimmunity
ID KAPPA-B ACTIVATION; FUNCTION IN-VIVO; TRANSCRIPTION FACTOR;
GENE-EXPRESSION; TREATED MICE; C-REL; DNA; TRANSPLANTATION;
INFLAMMATION; AUTOIMMUNITY
AB Several lines of evidence suggest nuclear factor of activated T-cells (NFAT) to control regulatory T cells: thymus-derived naturally occurring regulatory T cells (nTreg) depend on calcium signals, the Foxp3 gene harbors several NFAT binding sites, and the Foxp3 (Fork head box P3) protein interacts with NFAT. Therefore, we investigated the impact of NFAT on Foxp3 expression. Indeed, the generation of peripherally induced Treg (iTreg) by TGF-beta was highly dependent on NFAT expression because the ability of CD4(+) T cells to differentiate into iTreg diminished markedly with the number of NFAT family members missing. It can be concluded that the expression of Foxp3 in TGF-beta-induced iTreg depends on the threshold value of NFAT rather than on an individual member present. This is specific for iTreg development, because frequency of nTreg remained unaltered in mice lacking NFAT1, NFAT2, or NFAT4 alone or in combination. Different from expectation, however, the function of both nTreg and iTreg was independent on robust NFAT levels, reflected by less nuclear NFAT in nTreg and iTreg. Accordingly, absence of one or two NFAT members did not alter suppressor activity in vitro or during colitis and transplantation in vivo. This scenario emphasizes an inhibition of high NFAT activity as treatment for autoimmune diseases and in transplantation, selectively targeting the proinflammatory conventional T cells, while keeping Treg functional.
C1 [Vaeth, Martin; Serfling, Edgar; Berberich-Siebelt, Friederike] Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany.
[Schliesser, Ulrike; Sawitzki, Birgit S.] Humboldt Univ, Inst Med Immunol, Charite Campus Virchow Klinikum, D-13353 Berlin, Germany.
[Mueller, Gerd] Max Delbruck Ctr Mol Med, Dept Tumor Genet & Immunogenet, D-13092 Berlin, Germany.
[Reissig, Sonja; Waisman, Ari] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Inst Mol Med, D-55131 Mainz, Germany.
[Satoh, Kazuki; Tuettenberg, Andrea; Jonuleit, Helmut] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Dermatol, D-55131 Mainz, Germany.
[Mueller, Martin R.] Childrens Hosp, Immune Dis Inst, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Mueller, Martin R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Berberich-Siebelt, F (reprint author), Univ Wurzburg, Inst Pathol, Dept Mol Pathol, D-97080 Wurzburg, Germany.
EM path230@mail.uni-wuerzburg.de
RI Jonuleit, Helmut/D-8059-2011; Sawitzki, Birgit/S-2307-2016; Waisman,
Ari/C-7383-2015
OI Jonuleit, Helmut/0000-0002-5672-9365; Waisman, Ari/0000-0003-4304-8234
FU German Research Foundation (DFG), Graduate College "Immunomodulation";
German Research Foundation (DFG) [SPP1365, TRR52/A2, TRR52/A3, TRR52/C2,
TRR52/C4]; Federal Ministry for Education and Research:
interdisciplinary center of clinical research (IZKF) in Wurzburg,
Germany
FX We thank Anjana Rao for providing Nfat2 floxed mice; Laurie H. Glimcher
for Nfat1-/- and Nfat1-/- x Nfat4-/-;
Kajsa Wing and Shimon Sakaguchi for Foxp3-IRES-cre mice; Niklas
Beyersdorf for Cd90.1 mice; Friederike Frommer and Karin Elflein for
Rag1-/- mice; Andrea Dietzel for maintaining mice; Niklas
Beyersdorf and Tea Gogishvili for providing CD28SA; Christina Kober,
Melanie Schott, Ilona Pietrowski, Doris Michel, Miriam Eckstein, Anna
Unverdorben, and Ralf Kielenbeck for excellent technical support; and
Amiya Patra, Christina Kober, Tobias Bopp, Lena Dietz, Niklas
Beyersdorf, and Thomas Hunig for helpful discussions. This work was
supported by the German Research Foundation (DFG) with the following
grants: Graduate College "Immunomodulation" (M.V.); Grant SPP1365 (to
F.B.-S.); Grants TRR52/A2 (to H.J.), /A3 (to F.B.-S.), /C2 (to A. W.),
and /C4 (to B. S.); and by the Federal Ministry for Education and
Research: interdisciplinary center of clinical research (IZKF) in
Wurzburg, Germany (F.B.-S.).
NR 52
TC 48
Z9 54
U1 1
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 2
PY 2012
VL 109
IS 40
BP 16258
EP 16263
DI 10.1073/pnas.1203870109
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 017SN
UT WOS:000309611400064
PM 22991461
ER
PT J
AU Pelletier, J
Halvorsen, K
Ha, BY
Paparcone, R
Sandler, SJ
Woldringh, CL
Wong, WP
Jun, S
AF Pelletier, James
Halvorsen, Ken
Ha, Bae-Yeun
Paparcone, Raffaella
Sandler, Steven J.
Woldringh, Conrad L.
Wong, Wesley P.
Jun, Suckjoon
TI Physical manipulation of the Escherichia coli chromosome reveals its
soft nature
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE chromosome segregation; depletion forces; polymer physics; mother
machine; optical trap
ID BACTERIAL CHROMOSOME; NUCLEOID STRUCTURE; DNA; SEGREGATION; PROTEIN;
CONDENSIN; DYNAMICS; ENTROPY; FORCE; MUKB
AB Replicating bacterial chromosomes continuously demix from each other and segregate within a compact volume inside the cell called the nucleoid. Although many proteins involved in this process have been identified, the nature of the global forces that shape and segregate the chromosomes has remained unclear because of limited knowledge of the micromechanical properties of the chromosome. In this work, we demonstrate experimentally the fundamentally soft nature of the bacterial chromosome and the entropic forces that can compact it in a crowded intracellular environment. We developed a unique "micropiston" and measured the force-compression behavior of single Escherichia coli chromosomes in confinement. Our data show that forces on the order of 100 pN and free energies on the order of 10(5) k(B)T are sufficient to compress the chromosome to its in vivo size. For comparison, the pressure required to hold the chromosome at this size is a thousand-fold smaller than the surrounding turgor pressure inside the cell. Furthermore, by manipulation of molecular crowding conditions (entropic forces), we were able to observe in real time fast (approximately 10 s), abrupt, reversible, and repeatable compaction-decompaction cycles of individual chromosomes in confinement. In contrast, we observed much slower dissociation kinetics of a histone-like protein HU from the whole chromosome during its in vivo to in vitro transition. These results for the first time provide quantitative, experimental support for a physical model in which the bacterial chromosome behaves as a loaded entropic spring in vivo.
C1 [Halvorsen, Ken; Wong, Wesley P.] Harvard Univ, Boston Childrens Hosp, Immune Dis Inst, Sch Med, Cambridge, MA 02115 USA.
[Halvorsen, Ken; Wong, Wesley P.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Cambridge, MA 02138 USA.
[Pelletier, James; Paparcone, Raffaella; Jun, Suckjoon] Harvard Univ, FAS Ctr Syst Biol, Cambridge, MA 02138 USA.
[Halvorsen, Ken; Wong, Wesley P.] Harvard Univ, Rowland Inst, Cambridge, MA 02142 USA.
[Ha, Bae-Yeun] Univ Waterloo, Dept Phys & Astron, Waterloo, ON N2L 3G1, Canada.
[Sandler, Steven J.] Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA.
[Woldringh, Conrad L.] Univ Amsterdam, Fac Sci, Swammerdam Inst Life Sci, NL-1098 SM Amsterdam, Netherlands.
[Jun, Suckjoon] Univ Calif San Diego, Dept Phys, La Jolla, CA 92093 USA.
[Jun, Suckjoon] Univ Calif San Diego, Mol Biol Sect, La Jolla, CA 92093 USA.
RP Wong, WP (reprint author), Harvard Univ, Boston Childrens Hosp, Immune Dis Inst, Sch Med, 3 Blackfan Circle, Cambridge, MA 02115 USA.
EM wong@idi.harvard.edu; suckjoon.jun@gmail.com
RI Jun, Suckjoon/K-9008-2015
OI Jun, Suckjoon/0000-0002-0139-4297
FU Natural Sciences and Engineering Research Council of Canada; Immune
Disease Institute/Harvard Medical School/Boston Children's Hospital
startup funds; National Institutes of Health [P50GM068763]; University
of California San Diego startup funds; Rowland Junior Fellows program at
Harvard University; Bauer Fellows program at Harvard University
FX S.J. thanks Bela Mulder, Marileen Dogterom, and Sander Tans at
Foundation for Fundamental Research on Matter Institute for Atomic and
Molecular Physics (FOM Institute AMOLF) for their generous support in
the early stage of this work; Wei Lien Dang, Jay Fisher, Peter Galajda,
and Nancy Kleckner for helpful discussions; and Jean-Yves Bouet for help
with biochemistry and for fruitful discussions. This work was supported
by Natural Sciences and Engineering Research Council of Canada
(B.-Y.H.), the Rowland Junior Fellows program at Harvard University and
Immune Disease Institute/Harvard Medical School/Boston Children's
Hospital startup funds (W.W.), and the Bauer Fellows program at Harvard
University, the National Institutes of Health Grant P50GM068763, and
University of California San Diego startup funds (S.J.).
NR 61
TC 59
Z9 59
U1 2
U2 27
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD OCT 2
PY 2012
VL 109
IS 40
BP E2649
EP E2656
DI 10.1073/pnas.1208689109
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 017SN
UT WOS:000309611400005
PM 22984156
ER
PT J
AU Cholas, R
Hsu, HP
Spector, M
AF Cholas, Rahmatullah
Hsu, Hu-Ping
Spector, Myron
TI Collagen Scaffolds Incorporating Select Therapeutic Agents to Facilitate
a Reparative Response in a Standardized Hemiresection Defect in the Rat
Spinal Cord
SO TISSUE ENGINEERING PART A
LA English
DT Article
ID MESENCHYMAL STEM-CELLS; SOLUBLE NOGO-66 RECEPTOR; ADULT-RAT; FUNCTIONAL
RECOVERY; AXONAL REGENERATION; NEURAL STEM; NERVOUS-SYSTEM; NEURITE
EXTENSION; SCAR FORMATION; CROSS-LINKING
AB A multifaceted therapeutic approach involving biomaterial scaffolds, neurotrophic factors, exogenous cells, and antagonists to axon growth inhibitors may ultimately prove necessary for the treatment of defects resulting from spinal cord injury (SCI). The objective of this study was to begin to lay the groundwork for such strategies by implanting type I collagen scaffolds alone and incorporating individually a soluble Nogo receptor, chondroitinase ABC (ChABC), and mesenchymal stem cells (MSCs) into a standardized 3-mm-long hemiresection defect in the rat spinal cord. Statistically significant improvement in hincllimb motor function between the first and fourth weeks post-SCI was recorded for the scaffold-alone group and for the ChABC and MSC groups, but not the control group. Four weeks post-SCI, the scaffolds appeared intact with open pores, which were infiltrated with host cells. Of note is that in some cases, a few growth-associated protein 43 (GAP-43)-positive axons were seen reaching the center of the scaffold in the scaffold-alone and ChABC groups, but not in control animals. Angiogenic cells were prevalent in the scaffolds; however, the number of both macrophages and angiogenic cells in the scaffolds was significantly less than in the control lesion at 4 weeks. The results lay the foundation for future dose response studies and to further investigate a range of therapeutic agents to enhance the regenerative response in SCI.
C1 [Cholas, Rahmatullah; Hsu, Hu-Ping; Spector, Myron] VA Boston Healthcare Syst, Tissue Engn Labs, Boston, MA 02130 USA.
[Cholas, Rahmatullah] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Hsu, Hu-Ping; Spector, Myron] Harvard Univ, Sch Med, Dept Orthoped Surg, Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Spector, M (reprint author), VA Boston Healthcare Syst, Tissue Engn Labs, Mail Stop 151,Res 150 S Huntington Ave, Boston, MA 02130 USA.
EM mspector@rics.bwh.harvard.edu
FU U.S. Department of Veterans Affairs; Veterans Health Administration;
Rehabilitation Research and Development Service; Department of Defense;
VA Research Career Scientist Award; Gates Millennium Scholars Program
FX The research reported here was supported by the U.S. Department of
Veterans Affairs, Veterans Health Administration, Rehabilitation
Research and Development Service, and the Department of Defense. MS was
supported by a VA Research Career Scientist Award, and RC received a
fellowship from the Gates Millennium Scholars Program. We thank Dr.
Daniel Lee and Dr. Paul Weinreb at Biogen Idec for generously providing
the soluble Nogo receptor. The authors are grateful to Larry Benowitz,
Ph.D., for supplying the GAP-43 antibody.
NR 82
TC 13
Z9 14
U1 1
U2 12
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1937-3341
J9 TISSUE ENG PT A
JI Tissue Eng. Part A
PD OCT
PY 2012
VL 18
IS 19-20
BP 2158
EP 2172
DI 10.1089/ten.tea.2011.0577
PG 15
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell
Biology
SC Cell Biology; Biotechnology & Applied Microbiology
GA 024OM
UT WOS:000310118500022
PM 22827732
ER
PT J
AU Zollinger, TW
Saywell, RM
Robinson, JJ
Jay, SJ
Spitznagle, MH
AF Zollinger, Terrell W.
Saywell, Robert M., Jr.
Robinson, Joshua J.
Jay, Stephen J.
Spitznagle, Miranda H.
TI Effect of Personal Characteristics on Individual Support for Indoor
Smoke-Free Air Laws, Indiana, 2008
SO PREVENTING CHRONIC DISEASE
LA English
DT Article
ID PARENTAL SMOKING; POSTNATAL EXPOSURE; RESPIRATORY HEALTH; BANS;
RESTAURANTS; PREDICTORS; CHILDREN; BELIEFS; IMPACT; BARS
AB Introduction
Policy makers should understand the attitudes and beliefs of their constituents regarding smoke-free air legislation. The purpose of this study was to evaluate the effect of selected personal characteristics on attitudes and beliefs about secondhand smoke in Indiana and on support for smoke-free air laws.
Methods
Data were obtained from the 2008 Indiana Adult Tobacco Survey of 2,140 adults and included 11 sociodemographic variables. Chi-square and multiple logistic regression analyses were used to test for significant associations between sociodemographic characteristics and support for statewide or community smoke-free air legislation.
Results
Most respondents (72.3%) indicated that they supported laws making work places smoke-free. After adjusting for the effects of the other variables, 3 were found to be significant predictors of support: being a never or former smoker, being female, and being aware of the health hazards of secondhand smoke. Age, race/ethnicity, income, urban or rural county of residence, employment status, and having children in the household were not significant when adjusting for the other characteristics.
Conclusion
Most Indiana residents support smoke-free air legislation for workplaces. The support was constant among most groups across the state, suggesting policy makers would have the backing of their constituents to pass such legislation. The results of this study suggest that efforts to gain support for smoke-free air laws should focus on men, people unaware of the health hazards from secondhand smoke, and smokers and former smokers.
C1 [Zollinger, Terrell W.; Robinson, Joshua J.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Robinson, Joshua J.] US Dept Vet Affairs, Washington, DC USA.
[Spitznagle, Miranda H.] Indiana State Dept Hlth, Indianapolis, IN 46202 USA.
RP Saywell, RM (reprint author), Indiana Univ Sch Med, Bowen Res Ctr, 714 North Senate St,Ste 205, Indianapolis, IN 46202 USA.
EM rsaywell@iupui.edu
NR 34
TC 1
Z9 1
U1 0
U2 1
PU CENTERS DISEASE CONTROL
PI ATLANTA
PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA
SN 1545-1151
J9 PREV CHRONIC DIS
JI Prev. Chronic Dis.
PD OCT
PY 2012
VL 9
AR UNSP 120091
DI 10.5888/pcd9.120091
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA 173AR
UT WOS:000321050800002
ER
PT J
AU Gardet, A
Xavier, RJ
AF Gardet, Agnes
Xavier, Ramnik J.
TI Common alleles that influence autophagy and the risk for inflammatory
bowel disease
SO CURRENT OPINION IN IMMUNOLOGY
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; SYSTEMIC-LUPUS-ERYTHEMATOSUS; INTESTINAL PANETH
CELLS; CROHNS-DISEASE; SUSCEPTIBILITY LOCI; IL-1-BETA PRODUCTION;
IMPAIRED AUTOPHAGY; GENE ATG16L1; IRGM; MITOPHAGY
AB Genetic studies of inflammatory bowel disease (IBD) have identified multiple risk loci that contain genes involved in autophagy. Although autophagy was traditionally considered to be a homeostatic response to ensure the recycling of cellular materials, it has now been additionally established to have roles in immunity and inflammation. In this review, we highlight how genetics have begun to identify a broader role for autophagy as a key pathway in Crohn's disease (CD). We review recent studies that have implicated autophagy in the regulation of mucosal homeostasis, including roles in intracellular defense, vesicular trafficking, and inflammatory signaling. Finally, we discuss studies that have begun to demonstrate how CD risk polymorphisms cause defects in autophagy and promote a breakdown of intestinal homeostasis.
C1 [Gardet, Agnes; Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA.
[Gardet, Agnes; Xavier, Ramnik J.] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Boston, MA 02114 USA.
[Xavier, Ramnik J.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA.
[Xavier, Ramnik J.] MIT, Cambridge, MA 02139 USA.
RP Gardet, A (reprint author), Massachusetts Gen Hosp, Ctr Study Inflammatory Bowel Dis, Gastrointestinal Unit, Boston, MA 02114 USA.
EM agardet@partners.org; xavier@molbio.mgh.harvard.edu
FU Crohn's and Colitis Foundation of America; NIH [DK043351, DK083756,
DK086502]
FX This work was supported by funding from the Crohn's and Colitis
Foundation of America, and NIH grants DK043351, DK083756, and DK086502
to R.J.X.
NR 70
TC 14
Z9 14
U1 1
U2 13
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0952-7915
J9 CURR OPIN IMMUNOL
JI Curr. Opin. Immunol.
PD OCT
PY 2012
VL 24
IS 5
BP 522
EP 529
DI 10.1016/j.coi.2012.08.001
PG 8
WC Immunology
SC Immunology
GA 148MH
UT WOS:000319248200003
PM 23041451
ER
PT J
AU Hu, XL
Daly, M
AF Hu, Xinli
Daly, Mark
TI What have we learned from six years of GWAS in autoimmune diseases, and
what is next?
SO CURRENT OPINION IN IMMUNOLOGY
LA English
DT Review
ID GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE;
RHEUMATOID-ARTHRITIS; CELIAC-DISEASE; SUSCEPTIBILITY VARIANTS;
GENE-EXPRESSION; RARE VARIANTS; RISK; HERITABILITY; INCREASES
AB Genome-wide association studies (GWAS) have discovered hundreds of common genetic variants that predispose humans to autoimmune diseases, opening up unprecedented potential for elucidating the pathways and processes of disease. To understand the role of these variants in susceptibility, we need to derive mechanistic insight by integration of genetic results with other biological data types and also with careful functional studies. In many cases, such studies have highlighted coherent biological processes at a high level and elucidated specific mechanisms that contribute to autoimmunity and inflammation. The understanding of the genetic component of autoimmune etiology will become more complete as fine-mapping and sequencing data become readily available. A comprehensive catalog of human immune phenotypes could provide a functional basis for assessing genetic influence on immune function and variation in response to therapeutic interventions, as well as for rationally designing new targeted therapeutics.
C1 [Hu, Xinli] Harvard Univ, Sch Med, Harvard MIT Div Hlth Sci & Technol, Boston, MA USA.
[Hu, Xinli] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Rheumatol, Boston, MA 02115 USA.
[Hu, Xinli] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA.
[Hu, Xinli; Daly, Mark] Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Daly, Mark] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Daly, Mark] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Daly, M (reprint author), Broad Inst MIT & Harvard, Program Med & Populat Genet, Cambridge, MA 02142 USA.
EM mjdaly@atgu.mgh.harvard.edu
NR 44
TC 12
Z9 12
U1 0
U2 11
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0952-7915
J9 CURR OPIN IMMUNOL
JI Curr. Opin. Immunol.
PD OCT
PY 2012
VL 24
IS 5
BP 571
EP 575
DI 10.1016/j.coi.2012.09.001
PG 5
WC Immunology
SC Immunology
GA 148MH
UT WOS:000319248200010
PM 23017373
ER
PT J
AU Biederman, J
Fried, R
AF Biederman, J.
Fried, R.
TI The effects of lisdexamfetamine dimesylate on the driving performance of
young adults with ADHD
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 25th Congress of the European-College-of-Neuropsychopharmacology (ECNP)
CY OCT 13-17, 2012
CL Vienna, AUSTRIA
SP European Coll Neuropsychopharmacol (ECNP)
C1 [Biederman, J.; Fried, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 2
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD OCT
PY 2012
VL 22
SU 2
BP S436
EP S436
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 130VQ
UT WOS:000317948600575
ER
PT J
AU Biederman, J
Petty, C
Faraone, SV
AF Biederman, J.
Petty, C.
Faraone, S. V.
TI Adult outcome of attention deficit hyperactivity disorder: a controlled
16-year follow-up study
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 25th Congress of the European-College-of-Neuropsychopharmacology (ECNP)
CY OCT 13-17, 2012
CL Vienna, AUSTRIA
SP European Coll Neuropsychopharmacol (ECNP)
C1 [Biederman, J.; Petty, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Faraone, S. V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
[Faraone, S. V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
NR 2
TC 0
Z9 0
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD OCT
PY 2012
VL 22
SU 2
BP S435
EP S435
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 130VQ
UT WOS:000317948600574
ER
PT J
AU Manor, I
Ben-Hayun, R
Aharon, J
Salomy, D
Weizman, A
Danieli, Y
Megiddo, D
Newcorn, J
Biederman, J
Adler, LA
AF Manor, I.
Ben-Hayun, R.
Aharon, J.
Salomy, D.
Weizman, A.
Danieli, Y.
Megiddo, D.
Newcorn, J.
Biederman, J.
Adler, L. A.
TI Metadoxine: a novel non-stimulant extended-release drug for treating
ADHD
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 25th Congress of the European-College-of-Neuropsychopharmacology (ECNP)
CY OCT 13-17, 2012
CL Vienna, AUSTRIA
SP European Coll Neuropsychopharmacol (ECNP)
C1 [Manor, I.] Geha Mental Hlth Ctr, ADHD Unit, Petah Tiqwa, Israel.
[Ben-Hayun, R.; Aharon, J.] Rambam Hlth Ctr, Neurol Ambulatory Dept, Haifa, Israel.
[Salomy, D.] Geha Mental Hlth Ctr, ADHD Unit, Petah Tiqwa, Israel.
[Weizman, A.] Geha Mental Hlth Ctr, Res Unit, Petah Tiqwa, Israel.
[Danieli, Y.; Megiddo, D.] Alcobra Ltd, Tel Aviv, Israel.
[Newcorn, J.] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Biederman, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Adler, L. A.] NYU Med Ctr, New York, NY 10016 USA.
[Adler, L. A.] Mem Sloan Kettering Canc Ctr, Psychiat Serv, Dept Psychiat, New York, NY 10021 USA.
[Adler, L. A.] Mem Sloan Kettering Canc Ctr, Psychiat Serv, Dept Child & Adolescent Psychiat, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD OCT
PY 2012
VL 22
SU 2
BP S144
EP S144
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 130VQ
UT WOS:000317948600086
ER
PT J
AU Papakostas, G
AF Papakostas, G.
TI MDD: treatment limitations and ongoing challenges
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 25th Congress of the European-College-of-Neuropsychopharmacology (ECNP)
CY OCT 13-17, 2012
CL Vienna, AUSTRIA
SP European Coll Neuropsychopharmacol (ECNP)
C1 [Papakostas, G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Papakostas, G.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD OCT
PY 2012
VL 22
SU 2
BP S444
EP S444
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 130VQ
UT WOS:000317948600592
ER
PT J
AU Tarazi, F
Choi, YK
Adham, N
Kiss, B
Gyertyan, I
AF Tarazi, F.
Choi, Y. K.
Adham, N.
Kiss, B.
Gyertyan, I.
TI Effects of chronic exposure of cariprazine on dopamine receptor subtypes
SO EUROPEAN NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 25th Congress of the European-College-of-Neuropsychopharmacology (ECNP)
CY OCT 13-17, 2012
CL Vienna, AUSTRIA
SP European Coll Neuropsychopharmacol (ECNP)
C1 [Tarazi, F.] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA USA.
[Choi, Y. K.] Massachusetts Gen Hosp, Res Ctr, Belmont, MA USA.
[Adham, N.] Forest Res Inst, Jersey City, NJ USA.
[Kiss, B.; Gyertyan, I.] Gedeon Richter Plc, Pharmacol & Safety Res, Budapest, Hungary.
NR 1
TC 1
Z9 1
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0924-977X
J9 EUR NEUROPSYCHOPHARM
JI Eur. Neuropsychopharmacol.
PD OCT
PY 2012
VL 22
SU 2
BP S349
EP S350
PG 2
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 130VQ
UT WOS:000317948600431
ER
PT J
AU Swenson, ER
AF Swenson, Erik R.
TI Normal Exercise Capacity in Chronic Mountain Sickness How High Can the
Hematocrit Go Without Consequence?
SO CHEST
LA English
DT Editorial Material
ID HIGH-ALTITUDE; GAS-EXCHANGE; HEMODILUTION; POLYCYTHEMIA; TOLERANCE
C1 [Swenson, Erik R.] Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, Div Pulm & Crit Care Med, Seattle, WA 98108 USA.
RP Swenson, ER (reprint author), Univ Washington, Med Serv, VA Puget Sound Hlth Care Syst, S-111 PULM,1660 S Columbian Way, Seattle, WA 98108 USA.
EM eswenson@u.washington.edu
NR 12
TC 2
Z9 3
U1 2
U2 4
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD OCT
PY 2012
VL 142
IS 4
BP 823
EP 825
DI 10.1378/chest.12-0933
PG 3
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 120EI
UT WOS:000317153200005
PM 23032448
ER
PT J
AU Metersky, ML
Fine, MJ
Mortensen, EM
AF Metersky, Mark L.
Fine, Michael J.
Mortensen, Eric M.
TI The Effect of Marital Status on the Presentation and Outcomes of Elderly
Male Veterans Hospitalized for Pneumonia
SO CHEST
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; MORTALITY; EPIDEMIOLOGY; VALIDATION; CARE
AB Background: Although marital status has been shown to affect the outcomes of many conditions, there are limited data on the relationships between marital status and the presentation and outcomes of pneumonia.
Methods: We used Veterans Affairs administrative databases to identify a retrospective cohort of male veterans age >= 65 years hospitalized for pneumonia between 2002 and 2007. We assessed unadjusted and adjusted associations between marital status and mortality, hospital length of stay, and readmission to the hospital using generalized linear mixed-effect models with admitting hospital as a random effect and adjusted for baseline patient characteristics.
Results: There were 48,635 patients (26,558 married and 22,077 unmarried) in the study. Married men had a slightly higher Charlson comorbidity score (3.0 vs 2.8, P<.0001) but were less likely to require ICU admission, ventilator support, and vasopressor treatment during the first 48 h of hospitalization. Married patients had significantly lower crude and adjusted in-hospital mortality (9.4% vs 10.6%; adjusted OR, 0.87; 95% CI, 0.81-0.93) and mortality during the 90 days after hospital discharge (14.7% vs 16.0%; adjusted OR, 0.92; 95% CI, 0.88-0.98). Their adjusted incidence rate ratio length of stay was also lower (0.92; 95% CI, 0.91-0.92).
Conclusions: Unmarried elderly men admitted to the hospital with pneumonia have a higher risk of in-hospital and postdischarge mortality, despite having a lower degree of comorbidity. Although marital status may be a surrogate marker for other predictors, it is an easily identifiable one. These results should be considered by those responsible for care-transition decisions for patients hospitalized with pneumonia.
C1 [Metersky, Mark L.] Univ Connecticut, Sch Med, Div Pulm & Crit Care Med, Farmington, CT 06030 USA.
[Fine, Michael J.] VA Pittsburgh Healthcare Syst, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Fine, Michael J.] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, VA North Texas Vet Hlth Care Syst, Dallas, TX 75390 USA.
[Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA.
[Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
RP Metersky, ML (reprint author), Univ Connecticut, Ctr Hlth, Div Pulm & Crit Care Med, 263 Farmington Ave, Farmington, CT 06030 USA.
EM Metersky@nso.uchc.edu
OI Mortensen, Eric/0000-0002-3880-5563
FU National Institute of Nursing Research [R01NR010828]
FX This study was supported by the National Institute of Nursing Research
[Grant R01NR010828].
NR 25
TC 5
Z9 5
U1 0
U2 0
PU AMER COLL CHEST PHYSICIANS
PI NORTHBROOK
PA 3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA
SN 0012-3692
J9 CHEST
JI Chest
PD OCT
PY 2012
VL 142
IS 4
BP 982
EP 987
DI 10.1378/chest.11-3183
PG 6
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA 120EI
UT WOS:000317153200025
PM 22459780
ER
PT J
AU Rincon-Choles, H
Abboud, HE
Lee, S
Shade, RE
Rice, KS
Carey, KD
Comuzzie, AG
Barnes, JL
AF Rincon-Choles, Hernan
Abboud, Hanna E.
Lee, Shuko
Shade, Robert E.
Rice, Karen S.
Carey, K. Dee
Comuzzie, Anthony G.
Barnes, Jeffrey L.
TI Renal Histopathology of a Baboon Model with Type 2 Diabetes
SO TOXICOLOGIC PATHOLOGY
LA English
DT Article
DE glomerular basement membrane; mesangium; diabetic nephropathy; baboon;
renal morphology
ID NOCTURNAL BLOOD-PRESSURE; ELDERLY HYPERTENSIVE PATIENTS; PAPIO-HAMADRYAS
MODEL; HETEROGENEOUS NATURE; MICROALBUMINURIA; MESANGIOLYSIS;
PROGRESSION; LESIONS; KIDNEY; DETERMINANTS
AB Naturally occurring type 2 diabetes has been found in a colony of baboons. Ongoing characterization of the baboon colony maintained at the Southwest National Primate Research Center has revealed a significant range of glucose sensitivity with some animals clearly diabetic. Seven baboons, four with diabetes and three without diabetes, underwent histopathological investigation. Three diabetic animals were diagnosed using fasting blood glucose, hemoglobin A1C, and intravenous glucose tolerance test, and a fourth one was known to have hyperglycemia. One control baboon and three baboons with diabetes had microalbuminuria. On kidney biopsy, diabetic baboons had thickening of the glomerular basement membrane and mesangial matrix expansion compared to controls. Immunohistochemistry showed the diabetic animals had increased mesangial expression of cellular fibronectin ED-A. Two diabetic animals with microalbuminuria had evidence of mesangiolysis with the formation of an early nodule. One diabetic animal had a Kimmestiel-Wilson nodule. We conclude that the baboon represents a useful primate model of diabetes and nephropathy that resembles the nephropathy associated with type 2 diabetes in humans.
C1 [Rincon-Choles, Hernan; Abboud, Hanna E.; Lee, Shuko; Barnes, Jeffrey L.] South Texas Vet Hlth Care Syst, Audie L Murphy Div, San Antonio, TX USA.
[Rincon-Choles, Hernan; Abboud, Hanna E.; Barnes, Jeffrey L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Shade, Robert E.; Rice, Karen S.; Carey, K. Dee; Comuzzie, Anthony G.] Southwest Reg Primate Res Ctr, San Antonio, TX USA.
[Comuzzie, Anthony G.] Texas Biomed Res Inst, Dept Genet, San Antonio, TX USA.
RP Barnes, JL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, MSC 7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM barnesj@uthscsa.edu
FU Research Career Development Award, Veterans Administration; George M.
O'Brien Kidney Center, National Institutes of Health [P50-DK-061597];
NIH [4R37-DK-033665-19-23, 5U01-DK-57295-05, HL28972, U10-52636,
P51-RR1-13986]; South Texas Veterans Health Care System
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: Dr. H.
Rincon-Choles is a recipient of a Research Career Development Award from
the Veterans Administration. Other sources of support are George M.
O'Brien Kidney Center from the National Institutes of Health grant
P50-DK-061597, NIH grants 4R37-DK-033665-19-23, 5U01-DK-57295-05,
HL28972, U10-52636, and P51-RR1-13986 (to the Southwest Regional Primate
Research Center), and Research Enhancement Award Program from the South
Texas Veterans Health Care System.
NR 34
TC 2
Z9 2
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0192-6233
J9 TOXICOL PATHOL
JI Toxicol. Pathol.
PD OCT
PY 2012
VL 40
IS 7
BP 1020
EP 1030
DI 10.1177/0192623312444025
PG 11
WC Pathology; Toxicology
SC Pathology; Toxicology
GA 119DS
UT WOS:000317078200005
PM 22552392
ER
PT J
AU Vasudevan, S
AF Vasudevan, S.
TI Functional validation of microRNA-target RNA interactions
SO METHODS
LA English
DT Review
DE MicroRNA; Target; Base-pairing
ID C VIRUS-RNA; CULTURED-MAMMALIAN-CELLS; LIVER-SPECIFIC MICRORNA; SHORT
HAIRPIN RNAS; MESSENGER-RNA; BINDING PROTEIN; GENE-EXPRESSION;
CAENORHABDITIS-ELEGANS; DOWN-REGULATION; NONCODING RNAS
AB MicroRNAs are small, non-coding RNA regulators of gene expression with important outcomes in cell state, proliferation, metabolism, immunity and development; their deregulation leads to significant clinical consequences. MicroRNAs and their associated target RNAs can be identified by genetic, bioinformatic and biochemical methods. MicroRNAs can recognize target mRNAs via direct base-pairing and recruit effector complexes to modulate their gene expression in a sequence-specific manner. MicroRNA interactions with target RNAs produce their roles in gene expression. The following are some of the validation methods employed to confirm functionally relevant microRNA interactions with their target mRNAs. Each method involves interference with the microRNA or the target mRNA to disable their interaction, which should lead to loss of microRNA-mediated gene expression if the interaction is functionally consequential. Subsequent alleviation of the interference and restoration of productive base-pairing interactions between the microRNA and target should rescue microRNA-mediated gene expression and confirm the functional requirement for direct microRNA-target mRNA interaction. Characterization of functional microRNA interactions with their target mRNAs will provide significant insights into their gene expression regulatory mechanism and lead to the development of potential therapeutic approaches to manipulate these interactions and their consequent gene expression outcomes. (C) 2012 Elsevier Inc. All rights reserved.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA.
RP Vasudevan, S (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA 02114 USA.
EM vasudevan.shobha@mgh.harvard.edu
FU Leukemia and Lymphoma Society [3300-09]; Cancer Research Institute;
Smith Family Foundation
FX This work was supported by a Leukemia and Lymphoma Society Special
Fellowship 3300-09, a Cancer Research Institute Investigator, the D. and
M-E Ryder, Smith Family Foundation Awards and MGH start-up funds to SV.
I thank S. S. Truesdell and J. C. Schroeder for technical help and S.
Lee and SI. Bukhari for critical reading.
NR 75
TC 10
Z9 11
U1 3
U2 23
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
J9 METHODS
JI Methods
PD OCT
PY 2012
VL 58
IS 2
BP 126
EP 134
DI 10.1016/j.ymeth.2012.08.002
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 107QH
UT WOS:000316235300008
PM 22910526
ER
PT J
AU Brusic, A
Hainz, U
Wadleigh, M
Neuberg, D
Su, M
Canning, CM
DeAngelo, DJ
Stone, RM
Lee, JS
Mulligan, RC
Ritz, J
Dranoff, G
Sasada, T
Wu, CJ
AF Brusic, Ana
Hainz, Ursula
Wadleigh, Martha
Neuberg, Donna
Su, Mei
Canning, Christine M.
DeAngelo, Daniel J.
Stone, Richard M.
Lee, Jeng-Shin
Mulligan, Richard C.
Ritz, Jerome
Dranoff, Glenn
Sasada, Tetsuro
Wu, Catherine J.
TI Detecting T-cell reactivity to whole cell vaccines Proof of concept
analysis of T-cell response to K562 cell antigens in CML patients
SO ONCOIMMUNOLOGY
LA English
DT Article
DE chronic myeloid leukemia; cross-presentation; GM-CSF; immune monitoring;
K562; whole cell vaccine
ID CHRONIC MYELOID-LEUKEMIA; DONOR LYMPHOCYTE INFUSION; COLONY-STIMULATING
FACTOR; APOPTOTIC TUMOR-CELLS; DENDRITIC CELLS; GM-CSF;
CANCER-IMMUNOTHERAPY; MYELOGENOUS LEUKEMIA; CROSS-PRESENTATION; RESIDUAL
DISEASE
AB BCR-ABL(+) K562 cells hold clinical promise as a component of cancer vaccines, either as bystander cells genetically modified to express immunostimulatory molecules, or as a source of leukemia antigens. To develop a method for detecting T-cell reactivity against K562 cell-derived antigens in patients, we exploited the dendritic cell (DC)-mediated cross-presentation of proteins generated from apoptotic cells. We used UVB irradiation to consistently induce apoptosis of K562 cells, which were then fed to autologous DCs. These DCs were used to both stimulate and detect antigen-specific CD8(+) T-cell reactivity. As proof-of-concept, we used cross-presented apoptotic influenza matrix protein-expressing K562 cells to elicit reactivity from matrix protein-reactive T cells. Likewise, we used this assay to detect increased anti-CML antigen T-cell reactivity in CML patients that attained long-lasting clinical remissions following immunotherapy (donor lymphocyte infusion), as well as in 2 of 3 CML patients vaccinated with lethally irradiated K562 cells that were modified to secrete high levels of granulocyte macrophage colony-stimulating factor (GM-CS F). This methodology can be readily adapted to examine the effects of other whole tumor cell-based vaccines, a scenario in which the precise tumor antigens that stimulate immune responses are unknown.
C1 [Brusic, Ana; Hainz, Ursula; Wadleigh, Martha; Su, Mei; Canning, Christine M.; DeAngelo, Daniel J.; Stone, Richard M.; Ritz, Jerome; Dranoff, Glenn; Sasada, Tetsuro; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Brusic, Ana] Monash Univ, Melbourne, Vic 3004, Australia.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat, Boston, MA 02115 USA.
[Wadleigh, Martha; DeAngelo, Daniel J.; Stone, Richard M.; Ritz, Jerome; Dranoff, Glenn; Sasada, Tetsuro; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wadleigh, Martha; DeAngelo, Daniel J.; Stone, Richard M.; Ritz, Jerome; Dranoff, Glenn; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA.
[Lee, Jeng-Shin; Mulligan, Richard C.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
RP Wu, CJ (reprint author), Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
EM cwu@partners.org
OI Ritz, Jerome/0000-0001-5526-4669
FU Department of Defense [W81XWH-07-1-0080]; Miles and Eleanor Shore Award,
NCI [5R21CA115043-2]; Early Career Physician-Scientist Award of the
Howard Hughes Medical Institute
FX The authors would like to acknowledge Nathalie Blachere and Nir Hacohen
for their insightful discussions in the development of this research. We
thank Mr Quinlan L. Sievers for excellent technical assistance. We would
like to acknowledge the generous support from the Pasquarello Tissue
Bank, and from the clinical transplant teams at the DFCI, Boston. We
also acknowledge support from the Department of Defense for this
project. C.J.W. acknowledges support from the Department of Defense
(W81XWH-07-1-0080), the Miles and Eleanor Shore Award, NCI
(5R21CA115043-2), the Early Career Physician-Scientist Award of the
Howard Hughes Medical Institute, and is a Damon-Runyon Cancer Research
Foundation Clinical Investigator (CI-38-07).
NR 54
TC 5
Z9 5
U1 0
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD OCT
PY 2012
VL 1
IS 7
BP 1095
EP 1103
DI 10.4161/onci.20954
PG 9
WC Oncology; Immunology
SC Oncology; Immunology
GA 108GL
UT WOS:000316279900010
PM 23170257
ER
PT J
AU Swenson, ER
Bartsch, P
AF Swenson, Erik R.
Baertsch, Peter
TI High-Altitude Pulmonary Edema
SO COMPREHENSIVE PHYSIOLOGY
LA English
DT Article
ID ALVEOLAR EPITHELIAL-CELLS; ACUTE MOUNTAIN-SICKNESS; ENDOTHELIAL
GROWTH-FACTOR; NITRIC-OXIDE SYNTHASE; STRESS DOPPLER-ECHOCARDIOGRAPHY;
INDUCED PERMEABILITY INCREASES; CARBONIC-ANHYDRASE INHIBITION; RAPID
INTRAVENOUS-INFUSION; HYPOXIA-INDUCIBLE FACTOR; I/D GENE POLYMORPHISM
AB High-altitude pulmonary edema (HAPE), a not uncommon form of acute altitude illness, can occur within days of ascent above 2500 to 3000 m. Although life-threatening, it is avoidable by slow ascent to permit acclimatization or with drug prophylaxis. The critical pathophysiology is an excessive rise in pulmonary vascular resistance or hypoxic pulmonary vasoconstriction (HPV) leading to increased microvascular pressures. The resultant hydrostatic stress causes dynamic changes in the permeability of the alveolar capillary barrier and mechanical injurious damage leading to leakage of large proteins and erythrocytes into the alveolar space in the absence of inflammation. Bronchoalveolar lavage and hemodynamic pressure measurements in humans confirm that elevated capillary pressure induces a high-permeability noninflammatory lung edema. Reduced nitric oxide availability and increased endothelin in hypoxia are the major determinants of excessive HPV in HAPE-susceptible individuals. Other hypoxia-dependent differences in ventilatory control, sympathetic nervous system activation, endothelial function, and alveolar epithelial active fluid reabsorption likely contribute additionally to HAPE susceptibility. Recent studies strongly suggest nonuniform regional hypoxic arteriolar vasoconstriction as an explanation for how HPV occurring predominantly at the arteriolar level causes leakage. In areas of high blood flow due to lesser HPV, edema develops due to pressures that exceed the dynamic and structural capacity of the alveolar capillary barrier to maintain normal fluid balance. This article will review the pathophysiology of the vasculature, alveolar epithelium, innervation, immune response, and genetics of the lung at high altitude, as well as therapeutic and prophylactic strategies to reduce the morbidity and mortality of HAPE. Published 2012. Compr Physiol 2:2753-2773, 2012.
C1 [Swenson, Erik R.; Baertsch, Peter] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
[Swenson, Erik R.; Baertsch, Peter] Heidelberg Univ, Med Klin, Krehl Klin, Heidelberg, Germany.
RP Swenson, ER (reprint author), Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
EM eswenson@u.washington.edu
NR 233
TC 18
Z9 21
U1 1
U2 23
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2040-4603
J9 COMPR PHYSIOL
JI Compr. Physiol.
PD OCT
PY 2012
VL 2
IS 4
BP 2753
EP 2773
DI 10.1002/cphy.c100029
PG 21
WC Physiology
SC Physiology
GA 085ZN
UT WOS:000314652900015
PM 23720264
ER
PT J
AU Adams, GR
Bamman, MM
AF Adams, Gregory R.
Bamman, Marcas M.
TI Characterization and Regulation of Mechanical Loading-Induced
Compensatory Muscle Hypertrophy
SO COMPREHENSIVE PHYSIOLOGY
LA English
DT Article
ID HUMAN SKELETAL-MUSCLE; MYOSIN HEAVY-CHAIN; GROWTH-FACTOR-I; SATELLITE
CELL-PROLIFERATION; SERUM RESPONSE FACTOR; LEUKEMIA INHIBITORY FACTOR;
BLOOD-FLOW RESTRICTION; MESSENGER-RNA TRANSLATION; CROSS-SECTIONAL AREA;
MYOFIBRILLAR PROTEIN-SYNTHESIS
AB In mammalian systems, skeletal muscle exists in a dynamic state that monitors and regulates the physiological investment in muscle size to meet the current level of functional demand. This review attempts to consolidate current knowledge concerning development of the compensatory hypertrophy that occurs in response to a sustained increase in the mechanical loading of skeletal muscle. Topics covered include: defining and measuring compensatory hypertrophy, experimental models, loading stimulus parameters, acute responses to increased loading, hyperplasia, myofiber-type adaptations, the involvement of satellite cells, mRNA translational control, mechanotransduction, and endocrinology. The authors conclude with their impressions of current knowledge gaps in the field that are ripe for future study. (C) 2012 American Physiological Society. Compr Physiol 2:2829-2870, 2012.
C1 [Adams, Gregory R.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA.
[Bamman, Marcas M.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA.
[Bamman, Marcas M.] Univ Alabama Birmingham, UAB Ctr Exercise Med, Birmingham, AL USA.
[Bamman, Marcas M.] Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, Birmingham, AL USA.
RP Adams, GR (reprint author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA.
EM gradams@uci.edu
NR 524
TC 23
Z9 24
U1 0
U2 22
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2040-4603
J9 COMPR PHYSIOL
JI Compr. Physiol.
PD OCT
PY 2012
VL 2
IS 4
BP 2829
EP 2870
DI 10.1002/cphy.c110066
PG 42
WC Physiology
SC Physiology
GA 085ZN
UT WOS:000314652900018
PM 23720267
ER
PT J
AU Tobin, MJ
Laghi, F
Jubran, A
AF Tobin, Martin J.
Laghi, Franco
Jubran, Amal
TI Ventilatory Failure, Ventilator Support, and Ventilator Weaning
SO COMPREHENSIVE PHYSIOLOGY
LA English
DT Article
ID OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-DISTRESS-SYNDROME;
END-EXPIRATORY PRESSURE; CONTROLLED MECHANICAL VENTILATION; AIRWAY
OCCLUSION PRESSURE; CONGESTIVE-HEART-FAILURE; INSPIRATORY MOTOR OUTPUT;
INTENSIVE-CARE-UNIT; CENTRAL SLEEP-APNEA; PROPORTIONAL ASSIST
VENTILATION
AB The development of acute ventilatory failure represents an inability of the respiratory control system to maintain a level of respiratory motor output to cope with the metabolic demands of the body. The level of respiratory motor output is also the main determinant of the degree of respiratory distress experienced by such patients. As ventilatory failure progresses and patient distress increases, mechanical ventilation is instituted to help the respiratory muscles cope with the heightened workload. While a patient is connected to a ventilator, a physician's ability to align the rhythm of the machine with the rhythm of the patient's respiratory centers becomes the primary determinant of the level of rest accorded to the respiratory muscles. Problems of alignment are manifested as failure to trigger, double triggering, an inflationary gas-flow that fails to match inspiratory demands, and an inflation phase that persists after a patient's respiratory centers have switched to expiration. With recovery from disorders that precipitated the initial bout of acute ventilatory failure, attempts are made to discontinue the ventilator (weaning). About 20% of weaning attempts fail, ultimately, because the respiratory controller is unable to sustain ventilation and this failure is signaled by development of rapid shallow breathing. Substantial advances in the medical management of acute ventilatory failure that requires ventilator assistance are most likely to result from research yielding novel insights into the operation of the respiratory control system. (C) 2012 American Physiological Society. Compr Physiol 2:2871-2921, 2012.
C1 [Tobin, Martin J.; Laghi, Franco; Jubran, Amal] US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA.
[Tobin, Martin J.; Laghi, Franco; Jubran, Amal] Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA.
RP Tobin, MJ (reprint author), US Dept Vet Affairs, Vet Affairs Edward Hines Jr Hosp, Div Pulm & Crit Care Med, Roosevelt Rd & 5th Ave, Hines, IL 60141 USA.
EM mtobin2@lumc.edu
NR 319
TC 20
Z9 20
U1 0
U2 5
PU JOHN WILEY & SONS INC
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 2040-4603
J9 COMPR PHYSIOL
JI Compr. Physiol.
PD OCT
PY 2012
VL 2
IS 4
BP 2871
EP 2921
DI 10.1002/cphy.c110030
PG 51
WC Physiology
SC Physiology
GA 085ZN
UT WOS:000314652900019
PM 23720268
ER
PT J
AU Iovieno, N
Papakostas, GI
AF Iovieno, Nadia
Papakostas, George I.
TI Correlation Between Different Levels of Placebo Response Rate and
Clinical Trial Outcome in Major Depressive Disorder: A Meta-Analysis
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DIAGNOSTIC CRITERIA; SCALE
AB Objective: To investigate the relationship between specific levels of placebo response rates and the drug response rate and the relative risk of response to drug versus placebo in clinical trials of antidepressant monotherapy and adjunctive polypharmacy for MDD.
Data Sources: MEDLINE/PubMed databases were searched for studies published in the English language between January 1980 and March 2011 by using the search terms depression, placebo, augmentation, adjunct, adjunctive, and each of the antidepressant agents identified. The search was supplemented by manual bibliographic review and examination of relevant review articles.
Study Selection: The analysis included randomized, double-blind, placebo-controlled trials of antidepressants used as monotherapy for MDD, 4 weeks or longer, and of augmentation/combination treatments for antidepressant partial responders/nonresponders with MDD, 1 week or longer. 169 antidepressant monotherapy studies and 35 adjunctive polypharmacy studies were found eligible for inclusion in our analysis.
Data Extraction: Data extracted included number of patients enrolled, patient characteristics, drug dosages and scheme (fixed vs flexible dosing), duration of the trial, and response rates.
Results: In antidepressant monotherapy studies, a higher placebo response rate correlated with a lower risk ratio of responding to antidepressant versus placebo (P < .001) and correlated with higher antidepressant response rates (P < .001); the number needed to treat (NNT) for response was approximately 4, 6, and 9 in trials with placebo response rates < 30%, >= 30% and < 40%, and >= 40%, respectively. In adjunctive trials, a higher placebo response rate correlated with a lower risk ratio of responding to the adjunctive drug versus placebo (P < .001) and correlated with a trend toward statistical significance with higher response rates to the adjunctive drug (P = .050); the NNT was approximately 6, 7, 11, and 17 in trials with placebo response rates < 20%, >= 20% and < 30%, >= 30% and < 40%, and 40%, respectively.
Conclusions:These results suggest that the relative efficacy of the active drug compared to placebo in clinical trials for MDD is highly heterogeneous across studies with different placebo response rates, with a worse performance in showing a superiority of the drug versus placebo for studies with placebo response rates >= 30% and >= 40%, respectively, for monotherapy and adjunctive trials. It is important to maintain placebo response rates below this critical threshold, since this is one of the most challenging obstacles for new treatment development in MDD. J Clin Psychiatry 2012;73(10):1300-1306 (c) Copyright 2012 Physicians Postgraduate Press, Inc.
C1 Massachusetts Gen Hosp, Dept Psychiat, Depress Clin & Res Program, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Iovieno, N (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, 1 Bowdoin Sq, Boston, MA 02114 USA.
EM niovieno@partners.org
RI Papakostas, George/I-6905-2013
OI Papakostas, George/0000-0002-2465-5103
FU AstraZeneca; Bristol-Myers Squibb; Forest; National Institute of Mental
Health; PAMLAB; Pfizer; Ridge Diagnostics
FX Dr Papakostas has served as a consultant to Abbott AstraZeneca,
Brainsway, Bristol-Myers Squibb, Cephalon, Dey Pharma, Eli Lilly,
GlaxoSmithICline, Evotec AG, Inflabloc, Jazz, Otsuka, PAMLAB, Pfizer,
Pierre Fabre, Ridge Diagnostics (formerly known as Precision Human
Biolaboratories), Shire, Theracos, and Wyeth; has received honoraria
from Abbott, Astra Zeneca, Bristol-Myers Squibb, Brainsway, Cephalon,
Dey Pharma, Eli Lilly, Evotec AG, GlaxoSmithKline, Inflabloc, Jazz,
Lundbeck, Otsuka, PAMLAB, Pfizer, Pierre Fabre, Ridge Diagnostics,
Shire, Theracos, Titan, and Wyeth; has received research support from
AstraZeneca, Bristol-Myers Squibb, Forest, the National Institute of
Mental Health, PAMLAB, Pfizer, and Ridge Diagnostics; and has served
(not currently) on the speaker's bureau for Bristol Myers Squibb and
Pfizer. Dr Iovieno reports no competing interests.
NR 21
TC 31
Z9 31
U1 1
U2 15
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD OCT
PY 2012
VL 73
IS 10
BP 1300
EP 1306
DI 10.4088/JCP.11r07485
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 090SP
UT WOS:000315000600003
PM 23140647
ER
PT J
AU Wozniak, J
Faraone, SV
Martelon, M
McKillop, HN
Biederman, J
AF Wozniak, Janet
Faraone, Stephen V.
Martelon, MaryKate
McKillop, Hannah N.
Biederman, Joseph
TI Further Evidence for Robust Familiality of Pediatric Bipolar I Disorder:
Results From a Very Large Controlled Family Study of Pediatric Bipolar I
Disorder and a Meta-Analysis
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID DEFICIT HYPERACTIVITY DISORDER; SPECTRUM DISORDERS; ONSET MANIA;
CHILDREN; ADOLESCENTS; COMORBIDITY; RELATIVES; ADHD; PREVALENCE;
CHILDHOOD
AB Objective: To determine the risk for bipolar I disorder in first-degree relatives of children with DSM-IV bipolar I disorder via meta-analysis and expanded controlled study.
Data Sources and Extraction: For the meta-analysis, PubMed was searched for scientific articles published in the world literature in English through 2011. The keywords searched were bipolar disorder, first-degree relatives, family study, and control. All online abstracts were reviewed, and relevant full manuscripts were collected and reviewed. Citations were also examined for other potentially relevant articles. The analysis included only controlled family studies that examined rates of bipolar I disorder in all first-degree relatives (parents and siblings) of pediatric bipolar I probands and that had age- and sex-matched controls. Family history studies were excluded, as were studies that were not in English, did not report bipolar I rates for all first-degree relatives, or reported only bipolar spectrum rates. Also excluded were family studies that included only adult probands. A meta-analysis was conducted of the 5 controlled family studies of pediatric bipolar I probands that met the search criteria using the random-effects model of DerSimonian and Laird.
Method: For the family study, our previous sample of DSM-IV bipolar I probands was greatly expanded using structured diagnostic interviews, The new study included 239 children aged 6-17 years who satisfied full DSM-IV diagnostic criteria for bipolar I disorder (n = 726 first-degree relatives), 162 attention-deficit/hyperactivity disorder (ADHD) probands (without bipolar I disorder; n = 511 first-degree relatives), and 136 healthy control probands (without ADHD or bipolar I disorder; n = 411 first-degree relatives). The Kaplan-Meier cumulative failure function was used to calculate survival curves and cumulative lifetime risk in relatives. Cox proportional hazard models were used to calculate the risk of bipolar I disorder in relatives.
Results: The pooled odds ratio for bipolar I disorder in relatives was estimated to be 6.96 (95% confidence interval [CI], 4.8-10.1). First-degree relatives of bipolar I probands were also significantly more likely than first-degree relatives of both ADHD probands (hazard ratio [HR] = 3.02; 95% CI, 1.85-4.93; P < .001) and control probands (HR = 2.83; 95% CI, 1.65-4.84; P < .001) to have bipolar I disorder.
Conclusions: Our results document an increased familial risk for bipolar I disorder in relatives of pediatric probands with DSM-IV bipolar I disorder. J Clin Psychiatry 2012;73(10):1328-1334 (c) Copyright 2012 Physicians Postgraduate Press, Inc.
C1 [Wozniak, Janet; Martelon, MaryKate; McKillop, Hannah N.; Biederman, Joseph] Massachusetts Gen Hosp, Program Pediat Psychopharmacol, Boston, MA 02114 USA.
[Wozniak, Janet; Martelon, MaryKate; McKillop, Hannah N.; Biederman, Joseph] Massachusetts Gen Hosp, Program Adult ADHD, Boston, MA 02114 USA.
[Wozniak, Janet; Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Psychiat, Syracuse, NY 13210 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Dept Neurosci & Physiol, Syracuse, NY 13210 USA.
RP Wozniak, J (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 6A, Boston, MA 02114 USA.
EM jwozniak@partners.org
OI Faraone, Stephen/0000-0002-9217-3982
FU McNeil; Shire; Eli Lilly; Janssen; Johnson Johnson; Pfizer; UCB; Zeo;
Sunovion; GlaxoSmithKline; Axon; Boehringer-Ingelheim; Covance;
Cephalon; Impax; Jazz; King; Luitpold; Novartis; Neurogen; Novadel;
Sanofi-Aventis; Sepracor; Takeda; UCB (Schwarz); Wyeth; Alcobra;
National Institutes of Health; Elminda; MGH Psychiatry Academy; Abbott;
Alza; AstraZeneca; Boston University; Bristol-Myers Squibb; Celltech;
Esai; Fundacion Areces (Spain); Forest; Glaxo; Gliatech; Hastings
Center; Medice (Germany); Merck; MMC Pediatric; NARSAD; National
Institute on Drug Abuse; New River; National Institute of Child Health
and Human Development; National Institute of Mental Health; Noven;
Neurosearch; Organon; Otsuka; Pharmacia; Phase V Communications;
Physicians Academy; Prechter Foundation; Quantia Communications; Reed
Exhibitions; Spanish Child Psychiatry Association; Stanley Foundation;
Veritas; National Institutes of Health [K08MH001503, R01MH066237,
R01MH050657, R01HD036317]; Heinz C. Prechter Bipolar Research Fund; MGH
Pediatric Psychopharmacology Council; Susan G. Berk Endowed Fund for
Juvenile Bipolar Disorder
FX In 2011, Dr Wozniak received research support from McNeil and Shire.
Before 2011, she received research support, consultation fees, or
speaker's fees from Eli Lilly, Janssen, Johnson & Johnson, McNeil,
Pfizer, and Shire. She is the author of the book, Is Your Child
Bipolar?, published in May 2009 by Bantam Books. In 2011, her spouse,
John Winkelman, MD, PhD, received consultation fees from Pfizer, UCB,
Zeo, and Sunovion and research support from GlaxoSmithKline. In the
past, he has received research support, consultation fees, or speaker's
fees from Axon, Boehringer-Ingelheim, Covance, Cephalon, Eli Lilly,
GlaxoSmithKline, Impax, Jazz, King, Luitpold, Novartis, Neurogen,
Novadel, Pfizer, Sanofi-Aventis, Sepracor, Sunovion, Takeda, UCB
(Schwarz), Wyeth, and Zeo. In the past year, Dr Faraone received
consulting income and research support from Shire and Alcobra and
research support from the National Institutes of Health. In previous
years, he received consulting fees, was on advisory boards, or
participated in continuing medical education programs sponsored by
Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. He receives
royalties from books published by Guilford Press (Straight Talk About
Your Child's Mental Health) and Oxford University Press (Schizophrenia:
The Facts). Dr Biederman currently receives research support from
Elminda, Janssen, McNeil, and Shire. In 2011, he gave a single unpaid
talk for Juste Pharmaceutical Spain, received honoraria from the Dr
Manuel Camelo AC in Monterrey, Mexico; provided single consultations for
Shionogi and Cipher (the honoraria for these consultations were paid to
the Department of Psychiatry at MGH); and received honoraria from the
MGH Psychiatry Academy for a tuition-funded CME course. In previous
years, he received research support, consultation fees, or speaker's
fees from Abbott, Alza, AstraZeneca, Boston University, Bristol-Myers
Squibb, Celltech, Cephalon, Eli Lilly, Esai, Fundacion Areces (Spain),
Forest, Glaxo, Gliatech, Hastings Center, Janssen, McNeil, Medice
(Germany), Merck, MMC Pediatric, NARSAD, National Institute on Drug
Abuse, New River, National Institute of Child Health and Human
Development, National Institute of Mental Health, Novartis, Noven,
Neurosearch, Organon, Otsuka, Pfizer, Pharmacia, Phase V Communications,
Physicians Academy, Prechter Foundation, Quantia Communications, Reed
Exhibitions, Shire, Spanish Child Psychiatry Association, Stanley
Foundation, UCB, Veritas, and Wyeth. Mss Martelon and McKillop report no
conflict of interest.; This work was supported by National Institutes of
Health grants K08MH001503 and R01MH066237 to Dr Wozniak and R01MH050657
and R01HD036317 to Dr Biederman. This work was also supported by a grant
from the Heinz C. Prechter Bipolar Research Fund, the support of members
of the MGH Pediatric Psychopharmacology Council, and the Susan G. Berk
Endowed Fund for Juvenile Bipolar Disorder.
NR 39
TC 12
Z9 12
U1 1
U2 8
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD OCT
PY 2012
VL 73
IS 10
BP 1328
EP 1334
DI 10.4088/JCP.12m07770
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA 090SP
UT WOS:000315000600009
PM 23140652
ER
PT J
AU Tomasetti, C
AF Tomasetti, Cristian
TI STOCHASTIC MODELLING OF MULTIPLE RANDOM GENETIC MUTATIONS UNDER THE
CANCER STEM CELL HYPOTHESIS
SO MATHEMATICAL POPULATION STUDIES
LA English
DT Article
DE branching processes; genetic mutations; stem cells; tumor growth; tumor
heterogeneity
ID CLONAL EXPANSION; RESISTANCE; POPULATIONS; PROGRESSION; SENSITIVITY;
EVOLUTION; TUMORS
AB The probability distribution for the size of each of the various cancer cell subpopulations created by random genetic mutations is expressed in the case of non-exponential growth of cancer and in the case of a heterogeneous tumor cell population.
C1 [Tomasetti, Cristian] Harvard Univ, Dept Biostat, Boston, MA 02115 USA.
[Tomasetti, Cristian] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
RP Tomasetti, C (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02215 USA.
EM cristian@jimmy.harvard.edu
OI Tomasetti, Cristian/0000-0003-3277-4804
FU National Institute of Health [T32 CA009337]
FX The author thanks Prof. Giovanni Parmigiani for his support and
encouragement. The author's work was supported in part by the National
Institute of Health under Grant T32 CA009337.
NR 15
TC 0
Z9 0
U1 0
U2 6
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 0889-8480
J9 MATH POPUL STUD
JI Math. Popul. Stud.
PD OCT 1
PY 2012
VL 19
IS 4
BP 200
EP 213
DI 10.1080/08898480.2012.725379
PG 14
WC Demography; Mathematics, Interdisciplinary Applications; Social
Sciences, Mathematical Methods; Statistics & Probability
SC Demography; Mathematics; Mathematical Methods In Social Sciences
GA 093XB
UT WOS:000315225400004
ER
PT J
AU Zhu, J
Gaiha, GD
John, SP
Pertel, T
Chin, CR
Gao, G
Qu, HJ
Walker, BD
Elledge, SJ
Brass, AL
AF Zhu, Jian
Gaiha, Gaurav D.
John, Sinu P.
Pertel, Thomas
Chin, Christopher R.
Gao, Geng
Qu, Hongjing
Walker, Bruce D.
Elledge, Stephen J.
Brass, Abraham L.
TI Reactivation of Latent HIV-1 by Inhibition of BRD4
SO CELL REPORTS
LA English
DT Article
ID RNA-POLYMERASE-II; NF-KAPPA-B; IMMUNODEFICIENCY-VIRUS TYPE-1;
BROMODOMAIN PROTEIN BRD4; LONG TERMINAL REPEAT; P-TEFB; TRANSCRIPTIONAL
ELONGATION; POSTINTEGRATION LATENCY; INTERACTING DOMAIN; CELL-LINE
AB HIV-1 depends on many host factors for propagation. Other host factors, however, antagonize HIV-1 and may have profound effects on viral activation. Curing HIV-1 requires the reduction of latent viral reservoirs that remain in the face of antiretroviral therapy. Using orthologous genetic screens, we identified bromodomain containing 4 (BRD4) as a negative regulator of HIV-1 replication. Antagonism of BRD4, via RNA interference or with a small molecule inhibitor, JQ1, both increased proviral transcriptional elongation and alleviated HIV-1 latency in cell-line models. In multiple instances, JQ1, when used in combination with the NF-kappa B activators Prostratin or PHA, enhanced the in vitro reactivation of latent HIV-1 in primary T cells. These data are consistent with a model wherein BRD4 competes with the virus for HIV-1 dependency factors (HDFs) and suggests that combinatorial therapies that activate HDFs and antagonize HIV-1 competitive factors may be useful for curing HIV-1 infection.
C1 [Zhu, Jian; Gao, Geng; Qu, Hongjing; Elledge, Stephen J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet, Boston, MA 02127 USA.
[Gaiha, Gaurav D.; John, Sinu P.; Pertel, Thomas; Chin, Christopher R.; Walker, Bruce D.; Brass, Abraham L.] MIT, Massachusetts Gen Hosp, Ragon Inst, Charlestown, MA 02129 USA.
[Gaiha, Gaurav D.; John, Sinu P.; Pertel, Thomas; Chin, Christopher R.; Walker, Bruce D.; Brass, Abraham L.] Harvard Univ, Charlestown, MA 02129 USA.
[Walker, Bruce D.; Elledge, Stephen J.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
RP Elledge, SJ (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Genet, Boston, MA 02127 USA.
EM selledge@genetics.med.harvard.edu; abraham.brass@umassmed.edu
OI Pertel, Thomas/0000-0002-2286-6011
FU Bill and Melinda Gates Foundation; NIH [1R01AI091786]
FX We thank the ICCB-L; C. Shamu, J. Smith, S. Chang, S. Rudnicki, S.
Johnston, K. Rudnicki, and D. Wrobel of Ragon Institute (RI); M.
Boyarina, K. Donnelly, and P. Richtmeyer of Brigham and Women's
Hospital; and M. Hinely. We thank X. Yu (RI) and M. Lichterfeld (MGH)
for helpful discussions, and we thank J. Rohrbach and D. Kavanagh (RI)
for help with primary T cell experiments. This research was funded by a
generous donation from the Bill and Melinda Gates Foundation. A.L.B. is
grateful to the Charles H. Hood Foundation, the Phillip T. and Susan M.
Ragon Foundation, the Harvard and UMass CFARs, and the NIH
(1R01AI091786) for their generous support; B.D.W. and S.J.E. are
Investigators with the Howard Hughes Medical Institute.
NR 39
TC 82
Z9 82
U1 1
U2 22
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD OCT
PY 2012
VL 2
IS 4
BP 807
EP 816
DI 10.1016/j.celrep.2012.09.008
PG 10
WC Cell Biology
SC Cell Biology
GA 083IA
UT WOS:000314455600013
PM 23041316
ER
PT J
AU Mak, AB
Nixon, AML
Kittanakom, S
Stewart, JM
Chen, GI
Curak, J
Gingras, AC
Mazitschek, R
Neel, BG
Stagljar, I
Moffat, J
AF Mak, Anthony B.
Nixon, Allison M. L.
Kittanakom, Saranya
Stewart, Jocelyn M.
Chen, Ginny I.
Curak, Jasna
Gingras, Anne-Claude
Mazitschek, Ralph
Neel, Benjamin G.
Stagljar, Igor
Moffat, Jason
TI Regulation of CD133 by HDAC6 Promotes beta-Catenin Signaling to Suppress
Cancer Cell Differentiation
SO CELL REPORTS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; HUMAN HEMATOPOIETIC STEM; DEACETYLASE
HDAC6; PROGENITOR CELLS; PLASMA-MEMBRANE; COLON-CANCER; PROTEIN;
ANTIGEN; PROMININ; TUBULIN
AB The pentaspan membrane glycoprotein CD133 marks lineage-specific cancer progenitor cells and is associated with poor prognosis in a number of tumor types. Despite its utility as a cancer progenitor cell marker, CD133 protein regulation and molecular function remain poorly understood. We find that the deacetylase HDAC6 physically associates with CD133 to negatively regulate CD133 trafficking down the endosomal-lysosomal pathway for degradation. We further demonstrate that CD133, HDAC6, and the central molecule of the canonical Wnt signaling pathway, beta-catenin, can physically associate as a ternary complex. This association stabilizes beta-catenin via HDAC6 deacetylase activity, which leads to activation of beta-catenin signaling targets. Downregulation of either CD133 or HDAC6 results in increased beta-catenin acetylation and degradation, which correlates with decreased proliferation in vitro and tumor xenograft growth in vivo. Given that CD133 marks progenitor cells in a wide range of cancers, targeting CD133 may be a means to treat multiple cancer types.
C1 [Mak, Anthony B.; Nixon, Allison M. L.; Kittanakom, Saranya; Curak, Jasna; Stagljar, Igor; Moffat, Jason] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada.
[Mak, Anthony B.; Nixon, Allison M. L.; Kittanakom, Saranya; Curak, Jasna; Stagljar, Igor; Moffat, Jason] Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5S 3E1, Canada.
[Mak, Anthony B.; Nixon, Allison M. L.; Chen, Ginny I.; Curak, Jasna; Gingras, Anne-Claude; Stagljar, Igor; Moffat, Jason] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada.
[Stagljar, Igor] Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada.
[Stewart, Jocelyn M.; Neel, Benjamin G.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.
[Chen, Ginny I.; Gingras, Anne-Claude] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Mazitschek, Ralph] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02142 USA.
[Stewart, Jocelyn M.; Neel, Benjamin G.] Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.
RP Moffat, J (reprint author), Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada.
EM j.moffat@utoronto.ca
RI Mazitschek, Ralph/E-3741-2013; Gingras, Anne-Claude/E-9982-2010
OI Mazitschek, Ralph/0000-0002-1105-689X; Gingras,
Anne-Claude/0000-0002-6090-4437
FU doctoral Canada Graduate Scholarship from the Natural Sciences and
Engineering Research Council; Stem Cell Network; Canadian Cancer
Research Society; Canadian Institutes of Health Research; Ontario
Institute for Cancer Research; Canadian Foundation for Innovation;
Ontario Ministry of Research and Innovation
FX We thank P. Mero, Y. Fedyshyn, B. Fedyshyn, J. Snider, P-A. Penttila,
and V. Wong for technical assistance and S-P. Ip for assistance with
Figure 7. We thank Drs. B. Gallie and R. Rottapel for providing reagents
and J. Woodgett for comments on the manuscript. A.B.M. was supported by
a doctoral Canada Graduate Scholarship from the Natural Sciences and
Engineering Research Council. This work was supported by funds from the
Stem Cell Network to J.M., Canadian Cancer Research Society to I.S.,
Canadian Institutes of Health Research to I.S. and J.M., Ontario
Institute for Cancer Research to J.M., the Canadian Foundation for
Innovation to J.M., and the Ontario Ministry of Research and Innovation
to J.M. J.M. is a Tier II Canada Research Chair in Functional Genomics
of Cancer and is a Research Fellow in the Canadian Institute for
Advanced Research.
NR 39
TC 54
Z9 54
U1 0
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD OCT
PY 2012
VL 2
IS 4
BP 951
EP 963
DI 10.1016/j.celrep.2012.09.016
PG 13
WC Cell Biology
SC Cell Biology
GA 083IA
UT WOS:000314455600025
PM 23084749
ER
PT J
AU Li, HH
Li, Q
Liu, PY
Liu, YL
Li, J
Wasserloos, K
Chao, W
You, M
Oury, TD
Chhinder, S
Hackam, DJ
Billiar, TR
Leikauf, GD
Pitt, BR
Zhang, LM
AF Li, Hui-Hua
Li, Quan
Liu, Pengyuan
Liu, Yulin
Li, Jin
Wasserloos, Karla
Chao, Wei
You, Ming
Oury, Tim D.
Chhinder, Sodhi
Hackam, David J.
Billiar, Timothy R.
Leikauf, George D.
Pitt, Bruce R.
Zhang, Li-Ming
TI WNT1-Inducible Signaling Pathway Protein 1 Contributes to
Ventilator-Induced Lung Injury
SO AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY
LA English
DT Article
DE genome-wide association study; acute lung injury; acute respiratory
distress syndrome
ID RESPIRATORY-DISTRESS-SYNDROME; NITRIC-OXIDE SYNTHASE; TOLL-LIKE; FACTOR
LSF; RECEPTOR; MICE; ACTIVATION; MOUSE; IDENTIFICATION; INFLAMMATION
AB Although strides have been made to reduce ventilator-induced lung injury (VILI), critically ill patients can vary in sensitivity to VILI, suggesting gene-environment interactions could contribute to individual susceptibility. This study sought to uncover candidate genes associated with VILI using a genome-wide approach followed by functional analysis of the leading candidate in mice. Alveolar-capillary permeability after high tidal volume (HTV) ventilation was measured in 23 mouse strains, and haplotype association mapping was performed. A locus was identified on chromosome 15 that contained ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (Asap1), adenylate cyclase 8 (Adcy8), WNT1-inducible signaling pathway protein 1 (Wisp1), and N-myc downstream regulated 1 (Ndrg1). Information from published studies guided initial assessment to Wisp1. After HTV, lung WISP1 protein increased in sensitive A/J mice, but was unchanged in resistant CBA/J mice. Anti-WISP1 antibody decreased HTV-induced alveolar-capillary permeability in sensitive A/Jmice, and recombinant WISP1 protein increased HTV-induced alveolar-capillary permeability in resistant CBA/J mice. HTV-induced WISP1 coimmunoprecipitated with glycosylated Toll-like receptor (TLR) 4 in A/J lung homogenates. After HTV, WISP1 increased in strain-matched control lungs, but was unchanged in TLR4 gene-targeted lungs. In peritoneal macrophages from strain-matched mice, WISP1 augmented LPS-induced TNF release that was inhibited in macrophages from TLR4 or CD14 antigen gene-targeted mice, and was attenuated in macrophages from myeloid differentiation primary response gene 88 gene-targeted or TLR adaptor molecule 1 mutant mice. These findings support a role for WISP1 as an endogenous signal that acts through TLR4 signaling to increase alveolar-capillary permeability in VILI.
C1 [Li, Hui-Hua; Li, Quan; Zhang, Li-Ming] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15213 USA.
[Li, Quan; Chhinder, Sodhi; Hackam, David J.; Billiar, Timothy R.] Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA.
[Li, Jin; Wasserloos, Karla; Leikauf, George D.; Pitt, Bruce R.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15213 USA.
[Oury, Tim D.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Pathol, Pittsburgh, PA 15213 USA.
[Liu, Yulin] Drexel Univ, Coll Med, Allegheny Gen Hosp, Dept Pathol & Lab Med, Pittsburgh, PA USA.
[Liu, Pengyuan; You, Ming] Med Coll Wisconsin, Wisconsin Canc Ctr, Milwaukee, WI 53226 USA.
[Chao, Wei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA.
[Li, Quan] Tongji Univ, Sch Med, Dept Anesthesiol, Shanghai Peoples Hosp 10, Shanghai 200092, Peoples R China.
RP Zhang, LM (reprint author), Univ Pittsburgh, Sch Med, Dept Anesthesiol, 200 Lothrop St,MUH N467, Pittsburgh, PA 15213 USA.
EM zhangl1@anes.upmc.edu
RI Li, Huihua/B-8795-2012;
OI Leikauf, George/0000-0002-4514-7060
FU Anesthesia Seed Grant; National Institutes of Health [HL79456, HL65697,
ES015675, HL077763, HL085655, GM50441, GM080906]
FX This work was supported by Anesthesia Seed Grant and National Institutes
of Health grants HL79456 (L.M.Z.), HL65697 (B. R. P.), ES015675,
HL077763, HL085655 (G. D. L.), GM50441 (T. R. B.), and GM080906 (W. C.).
NR 50
TC 14
Z9 14
U1 0
U2 2
PU AMER THORACIC SOC
PI NEW YORK
PA 61 BROADWAY, FL 4, NEW YORK, NY 10006 USA
SN 1044-1549
J9 AM J RESP CELL MOL
JI Am. J. Respir. Cell Mol. Biol.
PD OCT
PY 2012
VL 47
IS 4
BP 528
EP 535
DI 10.1165/rcmb.2012-0127OC
PG 8
WC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
SC Biochemistry & Molecular Biology; Cell Biology; Respiratory System
GA 082QA
UT WOS:000314405800015
PM 22700866
ER
PT J
AU Khalili, JS
Liu, SJ
Rodriguez-Cruz, TG
Whittington, M
Wardell, S
Liu, CW
Zhang, MY
Cooper, ZA
Frederick, DT
Li, YF
Zhang, M
Joseph, RW
Bernatchez, C
Ekmekcioglu, S
Grimm, E
Radvanyi, LG
Davis, RE
Davies, MA
Wargo, JA
Hwu, P
Lizee, G
AF Khalili, Jahan S.
Liu, Shujuan
Rodriguez-Cruz, Tania G.
Whittington, Mayra
Wardell, Seth
Liu, Chengwen
Zhang, Minying
Cooper, Zachary A.
Frederick, Dennie T.
Li, Yufeng
Zhang, Min
Joseph, Richard W.
Bernatchez, Chantale
Ekmekcioglu, Suhendan
Grimm, Elizabeth
Radvanyi, Laszlo G.
Davis, Richard E.
Davies, Michael A.
Wargo, Jennifer A.
Hwu, Patrick
Lizee, Gregory
TI Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression
Via Induction of Interleukin-1 in Melanoma
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID METASTATIC MELANOMA; TUMOR PROGRESSION; SUPPRESSOR-CELLS;
IMMUNE-RESPONSE; BREAST-CANCER; FIBROBLASTS; IMMUNOTHERAPY;
INFLAMMATION; DEATH; MICROENVIRONMENT
AB Purpose: In this study, we assessed the specific role of BRAF(V600E) signaling in modulating the expression of immune regulatory genes in melanoma, in addition to analyzing downstream induction of immune suppression by primary human melanoma tumor-associated fibroblasts (TAF).
Experimental Design: Primary human melanocytes and melanoma cell lines were transduced to express WT or V600E forms of BRAF, followed by gene expression analysis. The BRAF(V600E) inhibitor vemurafenib was used to confirm targets in BRAF(V600E)-positive melanoma cell lines and in tumors from melanoma patients undergoing inhibitor treatment. TAF lines generated from melanoma patient biopsies were tested for their ability to inhibit the function of tumor antigen-specific T cells, before and following treatment with BRAF(V600E)-upregulated immune modulators. Transcriptional analysis of treated TAFs was conducted to identify potential mediators of T-cell suppression.
Results: Expression of BRAF(V600E) induced transcription of interleukin 1 alpha (IL-1 alpha) and IL-1 beta in melanocytes and melanoma cell lines. Further, vemurafenib reduced the expression of IL-1 protein in melanoma cell lines and most notably in human tumor biopsies from 11 of 12 melanoma patients undergoing inhibitor treatment. Treatment of melanoma-patient-derived TAFs with IL-1 alpha/beta significantly enhanced their ability to suppress the proliferation and function of melanoma-specific cytotoxic T cells, and this inhibition was partially attributable to upregulation by IL-1 of COX-2 and the PD-1 ligands PD-L1 and PD-L2 in TAFs.
Conclusions: This study reveals a novel mechanism of immune suppression sensitive to BRAF(V600E) inhibition, and indicates that clinical blockade of IL-1 may benefit patients with BRAF wild-type tumors and potentially synergize with immunotherapeutic interventions. Clin Cancer Res; 18(19); 5329-40. (C)2012 AACR.
C1 [Khalili, Jahan S.; Liu, Shujuan; Rodriguez-Cruz, Tania G.; Whittington, Mayra; Wardell, Seth; Liu, Chengwen; Zhang, Minying; Li, Yufeng; Joseph, Richard W.; Bernatchez, Chantale; Ekmekcioglu, Suhendan; Grimm, Elizabeth; Radvanyi, Laszlo G.; Davies, Michael A.; Hwu, Patrick; Lizee, Gregory] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Ctr Canc Immunol Res, Houston, TX 77054 USA.
[Zhang, Min; Davis, Richard E.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77054 USA.
[Davies, Michael A.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Div Canc Med, Houston, TX 77054 USA.
[Cooper, Zachary A.; Frederick, Dennie T.; Wargo, Jennifer A.] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
RP Lizee, G (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Ctr Canc Immunol Res, 7455 Fannin,1SCR2-3030, Houston, TX 77054 USA.
EM glizee@mdanderson.org
OI Cooper, Zachary/0000-0003-1059-0940
FU Roche-Genentech; GlaxoSmithKline; CPRIT [RP110248]; SPORE [CA093459];
CCSG [P30CA16672]; Transocean
FX Michael A. Davies has served on advisory boards and received research
funding from Roche-Genentech and GlaxoSmithKline. No potential conflicts
of interest were declared by the other authors.; Financial support for
this work was provided in part from the CPRIT grant RP110248, SPORE
grant CA093459, CCSG grant NCI#P30CA16672, and a charitable grant from
Transocean.
NR 50
TC 94
Z9 96
U1 0
U2 15
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 1
PY 2012
VL 18
IS 19
BP 5329
EP 5340
DI 10.1158/1078-0432.CCR-12-1632
PG 12
WC Oncology
SC Oncology
GA 048JF
UT WOS:000311906600019
PM 22850568
ER
PT J
AU Hu, LM
Wu, C
Zhao, XY
Heist, R
Su, L
Zhao, Y
Han, BH
Cao, SY
Chu, MJ
Dai, JC
Dong, J
Shu, YQ
Xu, L
Chen, YJ
Wang, Y
Lu, F
Jiang, Y
Yu, DK
Chen, HY
Tan, W
Ma, HX
Chen, JP
Jin, GF
Wu, TC
Lu, DR
Christiani, DC
Lin, DX
Hu, ZB
Shen, HB
AF Hu, Lingmin
Wu, Chen
Zhao, Xueying
Heist, Rebecca
Su, Li
Zhao, Yang
Han, Baohui
Cao, Songyu
Chu, Minjie
Dai, Juncheng
Dong, Jing
Shu, Yongqian
Xu, Lin
Chen, Yijiang
Wang, Yi
Lu, Feng
Jiang, Yue
Yu, Dianke
Chen, Hongyan
Tan, Wen
Ma, Hongxia
Chen, Jiaping
Jin, Guangfu
Wu, Tangchun
Lu, Daru
Christiani, David C.
Lin, Dongxin
Hu, Zhibin
Shen, Hongbing
TI Genome-Wide Association Study of Prognosis in Advanced Non-Small Cell
Lung Cancer Patients Receiving Platinum-Based Chemotherapy
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID PRIMARY BREAST-CANCER; GENE-EXPRESSION; ADJUVANT CHEMOTHERAPY; SURVIVAL;
POLYMORPHISMS; ADENOCARCINOMA; METHYLATION; POPULATION; VARIANTS;
FEATURES
AB Purpose: Genetic variation may influence chemotherapy response and overall survival in cancer patients.
Experimental design: We conducted a genome-wide scan in 535 advanced-stage non-small cell lung cancer (NSCLC) patients from two independent cohorts (307 from Nanjing and 228 from Beijing). A replication was carried out on an independent cohort of 340 patients from Southeastern China followed by a second validation on 409 patients from the Massachusetts General Hospital (Boston, MA).
Results: Consistent associations with NSCLC survival were identified for five single-nucleotide polymorphisms (SNP) in Chinese populations with P values ranging from 3.63 x 10(-5) to 4.19 x 10(-7) in the additive genetic model. The minor allele of three SNPs (rs7629386 at 3p22.1, rs969088 at 5p14.1, and rs3850370 at 14q24.3) were associated with worse NSCLC survival while 2 (rs41997 at 7q31.31 and rs12000445 at 9p21.3) were associated with better NSCLC survival. In addition, rs7629386 at 3p22.1 (CTNNB1) and rs3850370 at 14q24.3 (SNW1-ALKBH1-NRXN3) were further replicated in the Caucasian population.
Conclusion: In this three-stage genome-wide association studies, we identified five SNPs as markers for survival of advanced-stage NSCLC patients treated with first-line platinum-based chemotherapy in Chinese Han populations. Two of these SNPs, rs7629386 and rs3850370, could also be markers for survival among Caucasian patients. Clin Cancer Res; 18(19); 5507-14. (C) 2012 AACR.
C1 [Hu, Lingmin; Cao, Songyu; Chu, Minjie; Dai, Juncheng; Dong, Jing; Lu, Feng; Jiang, Yue; Ma, Hongxia; Chen, Jiaping; Jin, Guangfu; Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Nanjing 210029, Jiangsu, Peoples R China.
[Hu, Lingmin; Cao, Songyu; Chu, Minjie; Dai, Juncheng; Dong, Jing; Lu, Feng; Jiang, Yue; Ma, Hongxia; Chen, Jiaping; Jin, Guangfu; Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Sch Publ Hlth, Key Lab Modern Toxicol, Minist Educ, Nanjing 210029, Jiangsu, Peoples R China.
[Hu, Lingmin; Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, State Key Lab Reprod Med, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China.
[Hu, Lingmin; Hu, Zhibin; Shen, Hongbing] Nanjing Med Univ, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Ctr Canc, Nanjing 210029, Jiangsu, Peoples R China.
[Shu, Yongqian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China.
[Chen, Yijiang] Nanjing Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Nanjing 210029, Jiangsu, Peoples R China.
[Xu, Lin] Nanjing Med Univ, Affiliated Canc Hosp, Dept Thorac Surg, Jiangsu Canc Hosp, Nanjing 210029, Jiangsu, Peoples R China.
[Wang, Yi] Nanjing Thorac Hosp, Dept Resp Dis, Nanjing, Jiangsu, Peoples R China.
[Wu, Chen; Yu, Dianke; Tan, Wen; Lin, Dongxin] Chinese Acad Med Sci, Canc Inst & Hosp, State Key Lab Mol Oncol, Beijing 100730, Peoples R China.
[Wu, Chen; Yu, Dianke; Tan, Wen; Lin, Dongxin] Chinese Acad Med Sci, Canc Inst & Hosp, Dept Etiol & Carcinogenesis, Beijing 100730, Peoples R China.
[Wu, Chen; Yu, Dianke; Tan, Wen; Lin, Dongxin] Peking Union Med Coll, Beijing 100021, Peoples R China.
[Zhao, Xueying; Chen, Hongyan; Lu, Daru] Fudan Univ, State Key Lab Genet Engn, Ctr Fudan VARI Genet Epidemiol, Shanghai 200433, Peoples R China.
[Zhao, Xueying; Chen, Hongyan; Lu, Daru] Fudan Univ, MOE Key Lab Contemporary Anthropol, Sch Life Sci, Shanghai 200433, Peoples R China.
[Han, Baohui] Shanghai Jiao Tong Univ, Dept Resp Dis, Shanghai Chest Hosp, Shanghai 200030, Peoples R China.
[Wu, Tangchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan 430074, Peoples R China.
[Wu, Tangchun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan 430074, Peoples R China.
[Heist, Rebecca; Su, Li; Zhao, Yang; Christiani, David C.] Harvard Univ, Sch Publ Hlth, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Shen, HB (reprint author), Nanjing Med Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM zhibin_hu@njmu.edu.cn; hbshen@njmu.edu.cn
FU National Natural Science Foundation of China [81270044, 30972541,
30901233, 30730080, 30425001]; China National High-Tech Research and
Development Program Grant [2009AA022705]; National Key Basic Research
Program Grant [2011CB503805]; NIH [CA092824-07, U19-CA148127-01];
Jiangsu Key Discipline of Medicine [XK200718]; Priority Academic Program
Development of Jiangsu Higher Education Institutions (Public Health and
Preventive Medicine)
FX This work is funded by the National Natural Science Foundation of China
(81270044, 30972541, 30901233, 30730080, and 30425001), the China
National High-Tech Research and Development Program Grant
(2009AA022705), the National Key Basic Research Program Grant
(2011CB503805), NIH (CA092824-07, U19-CA148127-01), Jiangsu Key
Discipline of Medicine (XK200718), and Priority Academic Program
Development of Jiangsu Higher Education Institutions (Public Health and
Preventive Medicine).
NR 43
TC 29
Z9 29
U1 2
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD OCT 1
PY 2012
VL 18
IS 19
BP 5507
EP 5514
DI 10.1158/1078-0432.CCR-12-1202
PG 8
WC Oncology
SC Oncology
GA 048JF
UT WOS:000311906600035
PM 22872573
ER
PT J
AU Tanzi, RE
AF Tanzi, Rudolph E.
TI The Genetics of Alzheimer Disease
SO COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LA English
DT Article
ID AMYLOID BETA-PROTEIN; GENOME-WIDE ASSOCIATION; PRECURSOR PROTEIN;
A-BETA; SYSTEMATIC METAANALYSES; IDENTIFIES VARIANTS; MISSENSE
MUTATIONS; APOLIPOPROTEIN-E; COMMON VARIANTS; IN-VIVO
AB Family history is the second strongest risk factor for Alzheimer disease (AD) following advanced age. Twin and family studies indicate that genetic factors are estimated to play a role in at least 80% of AD cases. The inheritance of AD exhibits a dichotomous pattern. On one hand, rare mutations in APP, PSEN1, and PSEN2 virtually guarantee early-onset (<60 years) familial AD, which represents similar to 5% of AD. On the other hand, common gene polymorphisms, such as the 14 and 12 variants of the APOE gene, can influence susceptibility for similar to 50% of the common late-onset AD. These four genes account for 30%-50% of the inheritability of AD. Genome-wide association studies have recently led to the identification of 11 additional AD candidate genes. This paper reviews the past, present, and future attempts to elucidate the complex and heterogeneous genetic underpinnings of AD.
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med,Genet & Aging Res Unit, MassGen Inst Neurodegenerat Dis,Dept Neurol, Boston, MA 02129 USA.
RP Tanzi, RE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Genet & Aging Res Unit, MassGen Inst Neurodegenerat Dis,Dept Neurol, Boston, MA 02129 USA.
EM tanzi@helix.mgh.harvard.edu
NR 60
TC 49
Z9 50
U1 0
U2 19
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 2157-1422
J9 CSH PERSPECT MED
JI Cold Spring Harb. Perspect. Med.
PD OCT
PY 2012
VL 2
IS 10
AR a006296
DI 10.1101/cshperspect.a006296
PG 10
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA 080YW
UT WOS:000314281700001
ER
PT J
AU Phelan, E
Potenza, A
Slough, C
Zurakowski, D
Kamani, D
Randolph, G
AF Phelan, Eimear
Potenza, Andre
Slough, Cristian
Zurakowski, David
Kamani, Dipti
Randolph, Gregory
TI Recurrent Laryngeal Nerve Monitoring during Thyroid Surgery: Normative
Vagal and Recurrent Laryngeal Nerve Electrophysiological Data
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE intraoperative nerve monitoring; vagal nerve; recurrent laryngeal nerve;
electromyography
ID THYROARYTENOID MUSCLES; CANINE MODEL; ELECTROMYOGRAPHY; DIAGNOSIS;
PARALYSIS; PATTERNS; ERRORS; AUDIT
AB Objective. Injury to the recurrent laryngeal nerve (RLN) remains a significant cause of morbidity during thyroid surgery. Intraoperative nerve monitoring (IONM) is being applied in many centers to facilitate nerve identification. The aim of this study was to elucidate normative human vagal and recurrent laryngeal nerve electromyograhic (EMG) parameters during standard IONM application.
Study Design. A prospective IONM study conducted over an 8-month period. Internal review board (IRB) approval was obtained.
Settings. Department of Otolaryngology, Division of Thyroid and Parathyroid Surgery, Massachusetts Eye and Ear Infirmary, Boston.
Subjects and Methods. All patients who were scheduled for routine thyroid, parathyroid, or neck exploration surgery were invited to participate. All patients had a preoperative and postoperative laryngeal examination to assess vocal cord function. Any patient with an abnormal preoperative laryngeal examination was excluded.
Results. Fifty-eight patients participated in this study. The right and left RLN latencies were similar. The left vagus latency was greater than the right vagus but was not significant. The RLN latency was significantly less than the vagus nerve. The right vagus nerve amplitude was significantly greater than the left. There was no difference between male and female amplitudes for either the RLN or vagus nerve.
Conclusion. This study highlights the electrophysiological/EMG differences and similarities between the RLN and vagus nerve. Normative amplitude measurements for bilateral RLN and vagus nerve stimulation are presented. There are limited data available in the literature on normal RLN and vagal EMG signals generated during thyroid surgery.
C1 [Phelan, Eimear; Potenza, Andre; Slough, Cristian; Kamani, Dipti; Randolph, Gregory] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Otolaryngol,Div Thyroid & Parathyroid Surg, Boston, MA 02114 USA.
[Zurakowski, David] Harvard Univ, Sch Med, Dept Anesthesia, Childrens Hosp Boston, Boston, MA 02115 USA.
[Zurakowski, David] Harvard Univ, Sch Med, Dept Surg, Childrens Hosp Boston, Boston, MA 02115 USA.
RP Phelan, E (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Thyroid Parathyroid Head & Neck Surg, Boston, MA 02114 USA.
EM eimearphelan@hotmail.com
NR 24
TC 13
Z9 14
U1 1
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD OCT
PY 2012
VL 147
IS 4
BP 640
EP 646
DI 10.1177/0194599812447915
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 080ZL
UT WOS:000314283700008
PM 22581635
ER
PT J
AU Dennis, M
Wang, GY
Luo, J
Lin, Y
Dohadwala, M
Abemayor, E
Elashoff, DA
Sharma, S
Dubinett, SM
St John, MA
AF Dennis, Miranda
Wang, Guanyu
Luo, Jie
Lin, Yuan
Dohadwala, Mariam
Abemayor, Elliot
Elashoff, David A.
Sharma, Sherven
Dubinett, Steven M.
St John, Maie A.
TI Snail Controls the Mesenchymal Phenotype and Drives Erlotinib Resistance
in Oral Epithelial and Head and Neck Squamous Cell Carcinoma Cells
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE Snail; E-cadherin; epithelial-mesenchymal transition (EMT); erlotinib
ID E-CADHERIN; EXPRESSION; TRANSITIONS; CANCER
AB Objective. The presence of regional metastases in patients with head and neck squamous cell carcinoma (HNSCC) is a common and adverse event associated with poor prognosis. The authors' recent work on human HNSCC tissues underlies Snail's role as a molecular prognostic marker for HNSCC. Snail positivity is significantly predictive of poorly differentiated, lymphovascular invasive, and regionally metastatic tumors. Here, the authors investigate the capacity of Snail to drive epithelial-mesenchymal transition (EMT) in human oral epithelial cell lines and its ability to confer drug resistance.
Study Design. Snail was overexpressed in HNSCC and oral epithelial cell lines. Anchorage independent growth assays, wound healing assays, invasion and migration assays, spheroid modeling, and cell survival assays were performed.
Setting. Academic tertiary medical center.
Subjects and Methods. Snail overexpressing HNSCC (OSC, Tu212, Tu686) and oral epithelial cell lines (HOK 16-B, OKF-6) were evaluated using assays for wound healing, invasion and migration, 3-dimensional growth, Western blot, and immunofluorescence.
Results. The overexpression of Snail in human HNSCC and oral epithelial cell lines drives EMT. The transfection of Snail confers the expression of a mesenchymal molecular signature, including downregulation of the epithelial adherens, such as E-cadherin and beta-catenin, and induction of mesenchymal markers. Snail-overexpressing cell lines demonstrate rapid growth in Anchorage-independent growth assays, a decreased capacity to form tight spheroids, an increased resistance to erlotinib, and an increased capacity for invasion.
Conclusion. Snail controls the mesenchymal phenotype and drives erlotinib resistance in HNSCC cells. Snail may prove to be a useful marker in predicting epidermal growth factor receptor inhibitor responsiveness.
C1 [Dennis, Miranda; Abemayor, Elliot; St John, Maie A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, Los Angeles, CA 90095 USA.
[Wang, Guanyu; Luo, Jie; Lin, Yuan; Dohadwala, Mariam; Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90095 USA.
[Wang, Guanyu; Luo, Jie; Lin, Yuan; Dohadwala, Mariam; Sharma, Sherven; Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Dept Med, Los Angeles, CA 90095 USA.
[Abemayor, Elliot; Elashoff, David A.; Dubinett, Steven M.; St John, Maie A.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
[Elashoff, David A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Biostat, Los Angeles, CA 90095 USA.
[Sharma, Sherven; Dubinett, Steven M.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP St John, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Div Head & Neck Surg, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.
EM mstjohn@mednet.ucla.edu
RI lin, yuan/E-6062-2011
FU American Academy of Otolaryngology-American Head & Neck Society Surgeon
Scientist Career Development Award; Tobacco-Related Disease Research
Program of the University of California; STOP Cancer Foundation; Jonsson
Cancer Center; NIDCR [K23]
FX This study was supported by the American Academy of
Otolaryngology-American Head & Neck Society Surgeon Scientist Career
Development Award (MSJ), the Tobacco-Related Disease Research Program of
the University of California (MSJ), the STOP Cancer Foundation (MSJ),
The Jonsson Cancer Center, and NIDCR K23 (MSJ).
NR 13
TC 7
Z9 7
U1 0
U2 6
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD OCT
PY 2012
VL 147
IS 4
BP 726
EP 732
DI 10.1177/0194599812446407
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 080ZL
UT WOS:000314283700021
PM 22568942
ER
PT J
AU Friedmann, DR
Eubig, J
Winata, LS
Pramanik, BK
Merchant, SN
Lalwani, AK
AF Friedmann, David R.
Eubig, Jan
Winata, Leon S.
Pramanik, Bidyut K.
Merchant, Saumil N.
Lalwani, Anil K.
TI Prevalence of Jugular Bulb Abnormalities and Resultant Inner Ear
Dehiscence: A Histopathologic and Radiologic Study
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE jugular bulb; high-riding jugular bulb; jugular bulb diverticulum; inner
ear dehiscence
AB Objective. Jugular bulb abnormalities (JBA), including high-riding jugular bulb (HRJB) and jugular bulb diverticulum (JBD), can erode into the inner ear. In this study, the authors investigate the prevalence and consequences of JBA and their erosion into inner ear structures using temporal bone histopathology and computed tomography (CT).
Study Design. Cross-sectional study of temporal bone histopathology and radiology.
Setting. Academic medical center.
Subjects and Methods. In total, 1579 temporal bone specimens and 100 CT of the temporal bones (200 ears) were examined for JBA and any associated dehiscence of inner ear structures. Temporal bone specimens were examined for histological consequences of inner ear erosion. Jugular bulb dimensions were measured on axial CT scans and compared across groups. Accompanying demographic and clinical information were reviewed.
Results. High jugular bulbs were noted in 8.2% (130/1579) of temporal bone specimens and in 8.5% (17/200) of temporal bone CT. The prevalence of JBA increases during the first 4 decades of life and stabilizes thereafter. High-riding jugular bulbs eroded inner ear structures such as the vestibular aqueduct, vertical facial nerve, or posterior semicircular canal in 2.8% (44/1579) of cases histologically and 1.5% (3/200) radiologically. In most, jugular bulb-mediated inner ear dehiscence was clinically and radiologically silent.
Conclusion. Jugular bulb abnormalities are common. They are present in 10% to 15% individuals and are primarily acquired by the fourth decade of life. In 1% to 3% of cases, the HRJB erodes into the inner ear and most frequently involves the vestibular aqueduct.
C1 [Friedmann, David R.] NYU, Dept Otolaryngol, Sch Med, New York, NY 10016 USA.
[Eubig, Jan; Pramanik, Bidyut K.] NYU, Dept Radiol, Sch Med, New York, NY 10016 USA.
[Winata, Leon S.; Merchant, Saumil N.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
[Lalwani, Anil K.] Columbia Univ Coll Phys & Surg, Dept Otolaryngol, Div Otol & Neurotol, New York, NY 10032 USA.
RP Lalwani, AK (reprint author), Columbia Univ Coll Phys & Surg, Dept Otolaryngol, Div Otol & Neurotol, 180 Ft Washington Ave,8th Floor, New York, NY 10032 USA.
EM akl2144@columbia.edu
FU National Institutes of Health [U24DC011943]
FX National Institutes of Health grant U24DC011943 to Saumil N. Merchant,
funding for maintenance of Massachusetts Eye and Ear Infirmary
Laboratory of Otopathology.
NR 6
TC 18
Z9 18
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD OCT
PY 2012
VL 147
IS 4
BP 750
EP 756
DI 10.1177/0194599812448615
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 080ZL
UT WOS:000314283700025
PM 22619257
ER
PT J
AU Mulligan, JK
White, DR
Wang, EW
Sansoni, SR
Moses, H
Yawn, RJ
Wagner, C
Casey, SE
Mulligan, RM
Schlosser, RJ
AF Mulligan, Jennifer K.
White, David R.
Wang, Eric W.
Sansoni, S. Ritter
Moses, Helen
Yawn, Robert J.
Wagner, Carol
Casey, Sarah E.
Mulligan, Ryan M.
Schlosser, Rodney J.
TI Vitamin D-3 Deficiency Increases Sinus Mucosa Dendritic Cells in
Pediatric Chronic Rhinosinusitis with Nasal Polyps
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE vitamin D; allergic fungal rhinosinusitis; dendritic cell; pediatric
chronic rhinosinusitis
ID ALLERGIC FUNGAL RHINOSINUSITIS; REGULATORY T-CELLS; CHILDHOOD ASTHMA;
MOUSE MODEL; IN-VIVO; DISEASE; HEALTH; PERSPECTIVES; INFLAMMATION;
TRAFFICKING
AB Objective. Dendritic cells are professional antigen presenting cells, capable of initiating Th1 or Th2 responses, and have been implicated in the pathogenesis of a number of diseases, including sinusitis. Vitamin D-3 is a steroid hormone that acts on dendritic cells in a manner similar to corticosteroids. Investigators examined whether children with allergic fungal rhinosinusitis (AFRS) or chronic rhinosinusitis with nasal polyposis (CRSwNP) were vitamin D-3 deficient and the relationship of vitamin D-3 deficiency to dendritic cell infiltrate in the sinus mucosa.
Setting. Tertiary care university hospital. Study Design. Retrospective, controlled study using samples collected from pediatric patients seen from August 2009 to July 2011.
Subjects and Methods. Plasma levels of 25-hydroxy vitamin D-3 were measured by enzyme-linked immunosorbent assay in children (<= 18 years old) with AFRS, CRSwNP, or CRS without nasal polyposis (CRSsNP) and in controls undergoing surgery for adenotonsillar hypertrophy. Vitamin D-3 levels were confirmed using clinical diagnostic methods for those with CRSwNP or AFRS. Tissue samples were immunohistochemically stained for the dendritic cell marker CD209 and the costimulatory molecules CD80 and CD86.
Results. There was no difference in mean vitamin D-3 levels between control and CRSsNP, whereas mean CRSwNP and AFRS levels were both well below the minimum recommended level of 30 ng/mL and significantly lower than control and CRSsNP levels. CD209(+) dendritic cells inversely correlated with vitamin D-3 but not costimulatory molecule expression.
Conclusions. These studies identify that children with CRSwNP or AFRS are vitamin D-3 deficient, which may be linked to increased dendritic cell infiltrate. These results suggest a role for vitamin D-3 as a key player in the immunopathology of pediatric CRSwNP.
C1 [Mulligan, Jennifer K.; Mulligan, Ryan M.; Schlosser, Rodney J.] Ralph H Johnson VA Med Ctr, Med Univ S Carolina, Charleston, SC 29425 USA.
[Mulligan, Jennifer K.; White, David R.; Wang, Eric W.; Sansoni, S. Ritter; Moses, Helen; Yawn, Robert J.; Mulligan, Ryan M.; Schlosser, Rodney J.] Med Univ S Carolina, Div Rhinol & Sinus Surg, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA.
[Wagner, Carol] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Casey, Sarah E.] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA.
RP Mulligan, JK (reprint author), Med Univ S Carolina, Res Serv, Ralph H Johnson VA Med Ctr, MSC 550,135 Rutledge Ave, Charleston, SC 29425 USA.
EM konopa@musc.edu
OI Wang, Eric/0000-0002-1180-5854
FU American Society of Pediatric Otolaryngology/Centralized Otolaryngology
Research Efforts; Flight Attendant Medical Research Institute (FAMRI);
Medtronic; Arthocare; NeilMed
FX David R. White, Medtronic, Inc, ad hoc consultant (tonsil product, no
relationship to this manuscript); Rodney J. Schlosser, BrainLAB,
Olympus, Sunovian, NeilMed, consultant/advisory board; Medtronic,
Arthocare, NeilMed, grant support. (These disclosures are not related to
this manuscript.).; These studies were funded by grants to JKM from the
American Society of Pediatric Otolaryngology/Centralized Otolaryngology
Research Efforts and grants to JKM and RJS from the Flight Attendant
Medical Research Institute (FAMRI).
NR 45
TC 24
Z9 24
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD OCT
PY 2012
VL 147
IS 4
BP 773
EP 781
DI 10.1177/0194599812448852
PG 9
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA 080ZL
UT WOS:000314283700028
PM 22627120
ER
PT J
AU Garrison, MW
Kawamura, NM
Wen, MM
AF Garrison, Mark W.
Kawamura, Nathan M.
Wen, Mary M.
TI Ceftaroline fosamil: a new cephalosporin active against resistant
Gram-positive organisms including MRSA
SO EXPERT REVIEW OF ANTI-INFECTIVE THERAPY
LA English
DT Article
DE ceftaroline; Gram-positive resistance; methicillin-resistant
Staphylococcus aureus; review; vancomycin-intermediate S. aureus;
vancomycin-resistant S. aureus
ID IN-VITRO ACTIVITY; COMMUNITY-ACQUIRED PNEUMONIA; INTERMEDIATE
STAPHYLOCOCCUS-AUREUS; BROAD-SPECTRUM CEPHALOSPORIN; PENICILLIN-BINDING
PROTEINS; RABBIT ENDOCARDITIS MODEL; METHICILLIN-RESISTANT;
UNITED-STATES; STREPTOCOCCUS-PNEUMONIAE; VIVO EFFICACY
AB Expert Rev. Anti Infect. Ther. 10(10), 1087-1103 (2012) The growing prevalence of resistant Gram-positive pathogens such as methicillin-resistant Staphylococcus aureus continues to pose a dilemma to clinicians. With strains developing reduced susceptibility to vancomycin, effective and well-tolerated antibiotics to combat these resistant pathogens are needed. Ceftaroline is a new parenteral cephalosporin that has been available in the USA for almost 2 years. Similar to other cephalosporins, it is well tolerated with mostly mild adverse events; however, compared with existing parenteral cephalosporins, ceftaroline has the unique attribute of being bactericidal against resistant Gram-positive aerobes including both hospital- and community-acquired methicillin-resistant S. aureus, S. aureus strains with reduced susceptibility or complete resistance to vancomycin, and resistant Streptococcus pneumoniae including multidrug-resistant strains. Current indications in the USA and Europe include treatment of adults with complicated skin, skin-structure infections and community-acquired pneumonia. This paper will review the properties of ceftaroline, its spectrum of activity, clinical use, safety profile and future role.
C1 [Garrison, Mark W.; Kawamura, Nathan M.; Wen, Mary M.] Washington State Univ, Coll Pharm, Spokane, WA 99210 USA.
[Garrison, Mark W.] Deaconess Med Ctr, Spokane, WA 99204 USA.
RP Garrison, MW (reprint author), Washington State Univ, Coll Pharm, Spokane, WA 99210 USA.
EM garrism@wsu.edu
FU R.W Johnson Pharmaceutical Research Institute; Pfizer Inc.; Glaxo
SmithKline; Bayer Corporation
FX MW Garrison has participated as a speaker fir Forest Pharmaceuticals
Inc., Pfizer Inc. (formerly Wyeth Pharmaceuticals) and
Ortho-McNeil-Janssen Pharmaceuticals, Inc. He has also received research
grants from the R.W Johnson Pharmaceutical Research Institute, Pfizer
Inc., Glaxo SmithKline and Bayer Corporation. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those
disclosed above.
NR 68
TC 10
Z9 11
U1 1
U2 10
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1478-7210
J9 EXPERT REV ANTI-INFE
JI Expert Rev. Anti-Infect. Ther.
PD OCT
PY 2012
VL 10
IS 10
BP 1087
EP 1103
DI 10.1586/ERI.12.112
PG 17
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 066LR
UT WOS:000313222800009
PM 23167512
ER
PT J
AU Siddiq, DM
Darouiche, RO
AF Siddiq, Danish M.
Darouiche, Rabih O.
TI Infectious complications associated with percutaneous nephrostomy
catheters: Do we know enough?
SO INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS
LA English
DT Review
DE Percutaneous nephrostomy catheter; Infectious complications;
Pyonephrosis; pathogenesis; Diagnosis and treatment
ID URINARY-TRACT-INFECTIONS; ANTIBIOTIC-PROPHYLAXIS; BACTERIAL BIOFILM;
DISEASES-SOCIETY; TUBE PLACEMENT; NEPHROLITHOTOMY; EXPERIENCE;
UROSEPSIS; DRAINAGE; BLADDER
AB The percutaneous nephrostomy catheter (PCNC) has evolved since its inception. Over more than half a century, it has gone from a temporary maneuver to a permanent fixture in a large proportion of patients who have incurable illnesses with obstructed renal drainage systems. Unfortunately, the research looking specifically at infectious complications associated with PCNCs suffers from oversimplification as studies predominantly assess sepsis alone. There are no standardized definitions or criteria to define the various infectious complications described in this paper. Although the PCNC has a relative paucity of infectious complications, which represents an excellent marker for patient care, the low rate of infection dictates a large sample size for sufficiently-powered research studies to be able to find a significant impact of interventional measures. In this review article, we discuss various aspects of pathogenesis and treatment of the different subtypes of PCNC-associated infections.
C1 [Siddiq, Danish M.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
[Darouiche, Rabih O.] Spinal Cord Injury & Med Serv, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA.
RP Siddiq, DM (reprint author), Baylor Coll Med, Dept Med, Infect Dis Sect, BCM 286,Room N-1319,1 Baylor Plaza, Houston, TX 77030 USA.
EM siddiq@bcm.edu
NR 55
TC 0
Z9 0
U1 0
U2 6
PU WICHTIG EDITORE
PI MILAN
PA 72/74 VIA FRIULI, 20135 MILAN, ITALY
SN 0391-3988
J9 INT J ARTIF ORGANS
JI Int. J. Artif. Organs
PD OCT
PY 2012
VL 35
IS 10
BP 898
EP 907
DI 10.5301/ijao.5000146
PG 10
WC Engineering, Biomedical; Transplantation
SC Engineering; Transplantation
GA 066LX
UT WOS:000313223400023
PM 23065896
ER
PT J
AU Samedy, K
Griffin, MTQ
Capitulo, KL
Fitzpatrick, JJ
AF Samedy, Ketly
Griffin, Mary T. Quinn
Capitulo, Kathleen Leask
Fitzpatrick, Joyce J.
TI Perceptions of Structural Empowerment: Differences Between Nationally
Certified Perinatal Nurses and Perinatal Nurses Who Are Not Nationally
Certified
SO JOURNAL OF CONTINUING EDUCATION IN NURSING
LA English
DT Article
ID PSYCHOLOGICAL EMPOWERMENT; MODEL
AB Background: Although there has been previous research linking perceptions of empowerment to specialty certification among critical care nurses, no research in this area has been conducted among nationally certified perinatal nurses.
Methods: A comparative quantitative survey design was used. Participants included 80 perinatal registered nurses from one community hospital in New York.
Results: Registered nurses who were nationally certified in a perinatal specialty had higher total empowerment scores and higher scores on five of the six subscales.
Conclusion: This study supports the results of previous studies focused on differences in empowerment among nationally certified nurses and nurses without national certification. Because much of the preparation for certification is done within continuing education, nurse leaders must be cognizant of the value of certification and must develop and implement programs to support certification in the workplace. J Contin Educ Nurs 2012;43(10):463-466.
C1 [Griffin, Mary T. Quinn; Fitzpatrick, Joyce J.] Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, Cleveland, OH 44106 USA.
[Samedy, Ketly] N Shore Long Isl Jewish Hlth Syst, Patient Care Serv Ambulatory OB GYN MFM, Manhasset, NY USA.
[Capitulo, Kathleen Leask] James J Peters VA Med Ctr, Bronx, NY USA.
RP Fitzpatrick, JJ (reprint author), Case Western Reserve Univ, Frances Payne Bolton Sch Nursing, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM joyce.fitzpatrick@case.edu
NR 12
TC 5
Z9 5
U1 3
U2 8
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0022-0124
J9 J CONTIN EDUC NURS
JI J. Contin. Educ. Nursing
PD OCT
PY 2012
VL 43
IS 10
BP 463
EP 466
DI 10.3928/00220124-20120301-74
PG 4
WC Nursing
SC Nursing
GA 064TD
UT WOS:000313097400010
PM 22390162
ER
PT J
AU Pastor, WA
Huang, Y
Henderson, HR
Agarwal, S
Rao, A
AF Pastor, William A.
Huang, Yun
Henderson, Hope R.
Agarwal, Suneet
Rao, Anjana
TI The GLIB technique for genome-wide mapping of 5-hydroxymethylcytosine
SO NATURE PROTOCOLS
LA English
DT Article
ID 5-FORMYLCYTOSINE; DNA
AB 5-Hydroxymethylcytosine (5hmC) is a newly discovered DNA base present at detectable levels in most mammalian cell types and tissues. It is generated by Tet-enzyme-mediated oxidation of 5-methylcytosine (5mC). 5hmC is important both because of its potential role in regulating gene expression and because it may be an intermediate in DNA demethylation. Here we describe a technique termed GLIB (glucosylation, periodate oxidation and biotinylation), which combines several enzymatic and chemical modification steps to attach biotin to 5hmC. Biotin-containing genomic DNA fragments are then enriched using streptavidin beads, eluted and sequenced. GLIB is capable of quantitatively tagging and precipitating fragments containing a single 5hmC molecule. Sample preparation and GLIB can be conducted in 2-3 d.
C1 [Pastor, William A.; Huang, Yun; Henderson, Hope R.; Rao, Anjana] La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
[Agarwal, Suneet] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Agarwal, Suneet] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Agarwal, Suneet] Harvard Stem Cell Inst, Boston, MA USA.
RP Rao, A (reprint author), La Jolla Inst Allergy & Immunol, La Jolla, CA USA.
EM arao@liai.org
OI Huang, Yun/0000-0001-5950-9168
FU National Science Foundation; US National Institutes of Health (NIH)
[AI44432, HD065812]; California Institute for Regenerative Medicine
[RM1-01729]; Leukemia and Lymphoma Society [6187-12]; NIH [HL089150];
Harvard Clinical and Translational Science Center (NIH) [1 UL1 RR
025758-02]
FX W.A.P. was supported by a predoctoral graduate research fellowship from
the National Science Foundation. Y.H. is supported by a postdoctoral
fellowship from the Leukemia and Lymphoma Society. This study was
supported by US National Institutes of Health (NIH) grants AI44432 and
HD065812, grant RM1-01729 from the California Institute for Regenerative
Medicine and Translational Research grant 6187-12 from the Leukemia and
Lymphoma Society (to A. R.) as well as NIH grant HL089150 and a pilot
grant from the Harvard Clinical and Translational Science Center (NIH
grant 1 UL1 RR 025758-02) (to S.A.).
NR 11
TC 29
Z9 31
U1 1
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1754-2189
J9 NAT PROTOC
JI Nat. Protoc.
PD OCT
PY 2012
VL 7
IS 10
BP 1909
EP 1917
DI 10.1038/nprot.2012.104
PG 9
WC Biochemical Research Methods
SC Biochemistry & Molecular Biology
GA 016HK
UT WOS:000309508200013
PM 23018194
ER
PT J
AU Iverson, KM
Follette, VM
Pistorello, J
Fruzzetti, AE
AF Iverson, Katherine M.
Follette, Victoria M.
Pistorello, Jacqueline
Fruzzetti, Alan E.
TI An Investigation of Experiential Avoidance, Emotion Dysregulation, and
Distress Tolerance in Young Adult Outpatients With Borderline
Personality Disorder Symptoms
SO PERSONALITY DISORDERS-THEORY RESEARCH AND TREATMENT
LA English
DT Article
DE borderline personality disorder; experiential avoidance; emotion
dysregulation; distress tolerance
ID DELIBERATE SELF-HARM; SCALE; VALIDATION; VALIDITY; ANXIETY
AB In this study we investigated 3 domains of emotional functioning-emotion dysregulation, distress tolerance, and experiential avoidance-in young adult outpatients with borderline personality disorder (BPD) symptoms. Participants were 40 young adult outpatients at a university counseling center who reported current suicidal ideation and met diagnostic criteria for BPD or experienced subthreshold BPD symptoms (i.e., met diagnostic criteria for 3 or 4 symptoms). Participants completed 3 self-report measures of emotional functioning-experiential avoidance (Acceptance and Action Questionnaire-2; Bond et al., 2011; Hayes et al., 2004), emotion dysregulation (Difficulties in Emotion Regulation Scale; Gratz & Roemer, 2004), and distress tolerance (Distress Tolerance Scale; Simons & Gaher, 2005)-and a behavioral measure of distress tolerance (Paced Auditory Serial Addition Task-Computerized; Lejuez, Kehler, & Brown, 2003), in addition to self-report measures of depression and BPD symptom severity. Partial correlations demonstrated that both emotion dysregulation and experiential avoidance were significantly associated with BPD symptom severity after accounting for depression. However, neither the self-report nor behavioral measure of distress tolerance were related to BPD symptom severity. A regression analysis with emotion dysregulation and experiential avoidance as independent variables revealed that only experiential avoidance was significantly associated with BPD symptom severity after controlling for depression symptoms. The current findings suggest that experiential avoidance may be a central process in BPD symptom severity. Future research directions are discussed.
C1 [Iverson, Katherine M.] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA.
[Iverson, Katherine M.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
[Follette, Victoria M.; Pistorello, Jacqueline; Fruzzetti, Alan E.] Univ Nevada, Dept Psychol, Reno, NV 89557 USA.
RP Iverson, KM (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, 150 S Huntington Ave,116B-3, Boston, MA 02130 USA.
EM katherine.iverson@va.gov
FU NIMH NIH HHS [T32 MH019836, T32 MH019836-03, R34 MH071904, R34
MH071904-01A1, T32MH019836, R34MH071904]
NR 34
TC 22
Z9 22
U1 1
U2 29
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1949-2715
J9 PERSONAL DISORD
JI Personal. Disord.
PD OCT
PY 2012
VL 3
IS 4
BP 415
EP 422
DI 10.1037/a0023703
PG 8
WC Psychology, Clinical
SC Psychology
GA 057MT
UT WOS:000312568400006
PM 22452755
ER
PT J
AU Flemming, JA
Vagefi, PA
Freise, C
Yao, FY
Terrault, N
AF Flemming, Jennifer A.
Vagefi, Parsia A.
Freise, Chris
Yao, Francis Y.
Terrault, Norah
TI Limiting Donors to Those of Younger Age in Hepatitis C infected Liver
Transplant Recipients Does Not Increase Wait-list Time, Drop-out or
Death
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Flemming, Jennifer A.; Freise, Chris; Yao, Francis Y.; Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Vagefi, Parsia A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 8
BP 194A
EP 194A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601008
ER
PT J
AU Schaefer, EA
Motola, D
Lin, C
Meixiong, J
Jilg, N
Brisac, C
Fusco, DN
Cheng, D
Chusri, P
Lin, WY
Musunuru, K
Cowan, CA
Chung, RT
Peng, LF
AF Schaefer, Esperance A.
Motola, Daniel
Lin, Carol
Meixiong, James
Jilg, Nikolaus
Brisac, Cynthia
Fusco, Dahlene N.
Cheng, Du
Chusri, Pattranuch
Lin, Wenyu
Musunuru, Kiran
Cowan, Chad A.
Chung, Raymond T.
Peng, Lee F.
TI Apolipoprotein B 100 is critical for HCV infection and for the pro-viral
effects of microRNA-122 in vitro
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Schaefer, Esperance A.; Motola, Daniel; Lin, Carol; Meixiong, James; Jilg, Nikolaus; Brisac, Cynthia; Fusco, Dahlene N.; Cheng, Du; Chusri, Pattranuch; Lin, Wenyu; Chung, Raymond T.; Peng, Lee F.] Massachusetts Gen Hosp, Med GI Unit, Boston, MA 02114 USA.
[Motola, Daniel; Musunuru, Kiran; Cowan, Chad A.] Harvard Univ, Stem Cell Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 59
BP 221A
EP 221A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601059
ER
PT J
AU Ioannou, G
Berry, K
AF Ioannou, George
Berry, Kristin
TI Serum alpha-fetoprotein level can improve eligibility criteria for liver
transplantation in patients with hepatocellular carcinoma
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Ioannou, George] Univ Washington, Seattle, WA 98195 USA.
[Ioannou, George; Berry, Kristin] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 96
BP 240A
EP 241A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601096
ER
PT J
AU Fuchs, BC
Wang, HF
Yang, Y
Polasek, M
Wei, L
Lauwers, GY
Tanabe, KK
Caravan, P
AF Fuchs, Bryan C.
Wang, Huifang
Yang, Yan
Polasek, Miloslav
Wei, Lan
Lauwers, Gregory Y.
Tanabe, Kenneth K.
Caravan, Peter
TI Molecular MR Imaging of Collagen to Diagnose and Stage Liver Fibrosis
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Fuchs, Bryan C.; Wang, Huifang; Yang, Yan; Polasek, Miloslav; Wei, Lan; Lauwers, Gregory Y.; Tanabe, Kenneth K.; Caravan, Peter] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Polasek, Miloslav/G-5949-2014
NR 0
TC 1
Z9 1
U1 0
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 142
BP 263A
EP 264A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601142
ER
PT J
AU Stewart, RK
Huang, C
Murase, N
Kimura, S
Gandhi, CR
AF Stewart, Rachel K.
Huang, Chao
Murase, Noriko
Kimura, Shoko
Gandhi, Chandrashekhar R.
TI Development of a stellate cell-depleted mouse model to investigate their
role in liver pathophysiology
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Huang, Chao; Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA USA.
[Stewart, Rachel K.; Huang, Chao; Murase, Noriko; Kimura, Shoko; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 242
BP 314A
EP 314A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601242
ER
PT J
AU Berendsen, TA
Bruinsma, BG
Saeidi, N
Izamis, ML
Usta, OB
Puts, CF
Uygun, K
Toner, M
Yarmush, ML
AF Berendsen, Tim A.
Bruinsma, Bote G.
Saeidi, Nima
Izamis, Maria-Louisa
Usta, O. Berk
Puts, Catheleyne F.
Uygun, Korkut
Toner, Mehmet
Yarmush, Martin L.
TI Supercooling: a novel technique for 96-hour preservation and successful
transplantation of rat livers
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Berendsen, Tim A.; Bruinsma, Bote G.; Saeidi, Nima; Izamis, Maria-Louisa; Usta, O. Berk; Puts, Catheleyne F.; Uygun, Korkut; Yarmush, Martin L.] Mass Gen Hosp, Boston, MA USA.
[Berendsen, Tim A.; Bruinsma, Bote G.; Saeidi, Nima; Izamis, Maria-Louisa; Usta, O. Berk; Puts, Catheleyne F.; Uygun, Korkut; Yarmush, Martin L.] Harvard Univ, Sch Med, Boston, MA USA.
[Berendsen, Tim A.; Bruinsma, Bote G.; Saeidi, Nima; Izamis, Maria-Louisa; Usta, O. Berk; Puts, Catheleyne F.; Uygun, Korkut; Toner, Mehmet; Yarmush, Martin L.] Ctr Engn Med, Liver Grp, Boston, MA USA.
RI USTA, O. Berk/A-5818-2008
OI USTA, O. Berk/0000-0001-9328-568X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 258
BP 321A
EP 321A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601258
ER
PT J
AU Bruinsma, BG
Berendsen, TA
Izamis, ML
Yarmush, ML
Uygun, K
AF Bruinsma, Bote G.
Berendsen, Tim A.
Izamis, Maria-Louisa
Yarmush, Martin L.
Uygun, Korkut
TI Improving extended cold storage of the liver for transplantation using
subnormothermic machine perfusion
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Bruinsma, Bote G.; Berendsen, Tim A.; Izamis, Maria-Louisa; Yarmush, Martin L.; Uygun, Korkut] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Bruinsma, Bote G.; Berendsen, Tim A.; Izamis, Maria-Louisa; Yarmush, Martin L.; Uygun, Korkut] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 268
BP 325A
EP 325A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601267
ER
PT J
AU Izamis, ML
Berendsen, TA
Perk, S
Uygun, K
Yarmush, ML
AF Izamis, Maria-Louisa
Berendsen, Tim A.
Perk, Sinem
Uygun, Korkut
Yarmush, Martin L.
TI Machine Perfusion Diagnoses, Prognoses and Optimizes Donor Organs in
Perfusion
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Izamis, Maria-Louisa; Berendsen, Tim A.; Perk, Sinem; Uygun, Korkut; Yarmush, Martin L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 275
BP 328A
EP 328A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955601274
ER
PT J
AU Hezode, C
Hirschfield, GM
Ghesquiere, W
Sievert, W
Rodriguez-Torres, M
Shafran, SD
Thuluvath, PJ
Tatum, HA
Waked, I
Esmat, GE
Lawitz, E
Rustgi, VK
Pol, S
Weis, N
Pockros, P
Bourliere, M
Serfaty, L
Vierling, JM
Fried, MW
Weiland, O
Brunetto, MR
Everson, GT
Zeuzem, S
Kwo, PY
Sulkowski, MS
Brau, N
Wind-Rotolo, M
Liu, ZH
Hughes, EA
Schnittman, SM
Yin, PD
AF Hezode, Christophe
Hirschfield, Gideon M.
Ghesquiere, Wayne
Sievert, William
Rodriguez-Torres, Maribel
Shafran, Stephen D.
Thuluvath, Paul J.
Tatum, Harvey A.
Waked, Imam
Esmat, Gamal E.
Lawitz, Eric
Rustgi, Vinod K.
Pol, Stanislas
Weis, Nina
Pockros, Paul
Bourliere, Marc
Serfaty, Lawrence
Vierling, John M.
Fried, Michael W.
Weiland, Ola
Brunetto, Maurizia R.
Everson, Gregory T.
Zeuzem, Stefan
Kwo, Paul Y.
Sulkowski, Mark S.
Brau, Norbert
Wind-Rotolo, Megan
Liu, Zhaohui
Hughes, Eric A.
Schnittman, Steven M.
Yin, Philip D.
TI Daclatasvir, an NS5A Replication Complex Inhibitor, Combined With
Peginterferon Alfa-2a and Ribavirin in Treatment-Naive HCV-Genotype 1 or
4 Subjects: Phase 2b COMMAND-1 SVR12 Results
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Hezode, Christophe] Univ Paris Est, Hop Henri Mondor, Creteil, France.
[Hirschfield, Gideon M.] Toronto Western Hosp, Toronto, ON M5T 2S8, Canada.
[Ghesquiere, Wayne] Vancouver Isl Hlth Author, Victoria, BC, Canada.
[Sievert, William] Monash Med Ctr, Melbourne, Vic, Australia.
[Rodriguez-Torres, Maribel] Fdn Invest, San Juan, PR USA.
[Shafran, Stephen D.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada.
[Thuluvath, Paul J.] St Johns Mercy Med Ctr, Baltimore, MD USA.
[Tatum, Harvey A.] Opt Hlth Res LLC, Tulsa, OK USA.
[Waked, Imam] Natl Liver Inst, Shibin Al Kawm, Egypt.
[Esmat, Gamal E.] Fac Med Hepatol & Trop Med, Cairo, Egypt.
[Lawitz, Eric] Alamo Med Res, San Antonio, TX USA.
[Rustgi, Vinod K.] Metropolitan Res, Fairfax, VA USA.
[Pol, Stanislas] Univ Paris 05, INSERM, Hop Cochin, U1610, Paris, France.
[Pol, Stanislas] Univ Paris 05, Liver Unit, Hop Cochin, Paris, France.
[Weis, Nina] Copenhagen Univ Hosp, Hvidovre, Denmark.
[Pockros, Paul] Scripps Clin, La Jolla, CA USA.
[Bourliere, Marc] St Joseph Hosp, Marseille, France.
[Serfaty, Lawrence] Hop St Antoine, F-75571 Paris, France.
[Vierling, John M.] Baylor Coll Med, Houston, TX 77030 USA.
[Fried, Michael W.] Univ N Carolina, Chapel Hill, NC USA.
[Weiland, Ola] Karolinska Univ Hosp, Stockholm, Sweden.
[Brunetto, Maurizia R.] Azienda Osped Univ Pisana, Pisa, Italy.
[Everson, Gregory T.] Univ Colorado, Denver, CO 80202 USA.
[Zeuzem, Stefan] Goethe Univ Frankfurt, Frankfurt, Germany.
[Kwo, Paul Y.] Indiana Univ, Indianapolis, IN 46204 USA.
[Sulkowski, Mark S.] Johns Hopkins Univ, Baltimore, MD USA.
[Brau, Norbert] James J Peters VAMC, New York, NY USA.
[Wind-Rotolo, Megan; Liu, Zhaohui] Bristol Myers Squibb Res & Dev, Hopewell, NJ USA.
[Hughes, Eric A.] Bristol Myers Squibb Res & Dev, Princeton, NJ USA.
[Schnittman, Steven M.; Yin, Philip D.] Bristol Myers Squibb Clin Res & Dev, Wallingford, CT USA.
NR 0
TC 30
Z9 30
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 755
BP 553A
EP 554A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602134
ER
PT J
AU Yu, L
Morishima, C
Ioannou, G
AF Yu, Lei
Morishima, Chihiro
Ioannou, George
TI Dietary Cholesterol Intake is Associated with Liver Disease Progression
in Hepatitis C Infection: Analysis of the HALT-C trial
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Yu, Lei; Morishima, Chihiro; Ioannou, George] Univ Washington, Seattle, WA 98195 USA.
[Ioannou, George] Vet Affairs Puget Sound Healthcare Syst, Med, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 940
BP 647A
EP 648A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602319
ER
PT J
AU Lin, WY
Zhao, L
Cheng, D
Chusri, P
Zhao, H
Jilg, N
Fusco, DN
Schaefer, EA
Brisac, C
Peng, LF
Chung, RT
AF Lin, Wenyu
Zhao, Lei
Cheng, Du
Chusri, Pattranuch
Zhao, Hong
Jilg, Nikolaus
Fusco, Dahlene N.
Schaefer, Esperance A.
Brisac, Cynthia
Peng, Lee F.
Chung, Raymond T.
TI The anti-HCV effector genes SART1 and EFTUD2 regulate IFN stimulated
genes through a nonclassical mechanism
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Lin, Wenyu; Zhao, Lei; Cheng, Du; Chusri, Pattranuch; Zhao, Hong; Jilg, Nikolaus; Fusco, Dahlene N.; Schaefer, Esperance A.; Brisac, Cynthia; Peng, Lee F.; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Gastrointestinal Unit,Dept Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1023
BP 686A
EP 686A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602400
ER
PT J
AU Fusco, DN
Brisac, C
Huang, YW
Xie, T
Zhao, H
Schaefer, EA
Chusri, P
Jilg, N
Cheng, D
Zhao, L
Zhang, LL
Peng, LF
Lin, WY
Brass, A
Chung, RT
AF Fusco, Dahlene N.
Brisac, Cynthia
Huang, Yi-Wen
Xie, Tiao
Zhao, Hong
Schaefer, Esperance A.
Chusri, Pattranuch
Jilg, Nikolaus
Cheng, Du
Zhao, Lei
Zhang, Leiliang
Peng, Lee F.
Lin, Wenyu
Brass, Abraham
Chung, Raymond T.
TI Identification of Interferon Effector Genes as New Targets for HCV
Antiviral Development
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Fusco, Dahlene N.; Brisac, Cynthia; Schaefer, Esperance A.; Chusri, Pattranuch; Jilg, Nikolaus; Cheng, Du; Zhao, Lei; Peng, Lee F.; Lin, Wenyu; Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Brass, Abraham] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Huang, Yi-Wen] Cathay Gen Hosp, Taipei, Taiwan.
[Huang, Yi-Wen] Taipei Med Univ, Taipei, Taiwan.
[Xie, Tiao] Harvard Univ, Sch Med, Boston, MA USA.
[Zhao, Hong] Peking Univ, Hosp 1, Beijing 100871, Peoples R China.
[Zhang, Leiliang] Chinese Acad Med Sci, Inst Pathogen Biol, Beijing 100730, Peoples R China.
[Zhang, Leiliang] Peking Union Med Coll, Beijing 100021, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1031
BP 690A
EP 690A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602408
ER
PT J
AU Cheng, D
Lin, WY
Schaefer, EA
Jilg, N
Fusco, DN
Chusri, P
Zhao, L
Brisac, C
Peng, LF
Gong, GZ
Mizoguchi, E
Chung, RT
AF Cheng, Du
Lin, Wenyu
Schaefer, Esperance A.
Jilg, Nikolaus
Fusco, Dahlene N.
Chusri, Pattranuch
Zhao, Lei
Brisac, Cynthia
Peng, Lee F.
Gong, Guozhong
Mizoguchi, Emiko
Chung, Raymond T.
TI CHI3L1 reciprocally promotes HCV replication and stimulates hepatocyte
profibrogenic cytokine release
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Cheng, Du; Lin, Wenyu; Schaefer, Esperance A.; Jilg, Nikolaus; Fusco, Dahlene N.; Chusri, Pattranuch; Zhao, Lei; Brisac, Cynthia; Peng, Lee F.; Mizoguchi, Emiko; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA.
[Cheng, Du; Gong, Guozhong] Second Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1047
BP 697A
EP 697A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602424
ER
PT J
AU Jilg, N
Kroy, DC
Lauer, GM
Chung, RT
AF Jilg, Nikolaus
Kroy, Daniela C.
Lauer, Georg M.
Chung, Raymond T.
TI HCV does not induce PD-L1 expression on hepatocytes: implications for T
cell exhaustion
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Jilg, Nikolaus; Kroy, Daniela C.; Lauer, Georg M.; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1051
BP 699A
EP 699A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602428
ER
PT J
AU Ehedego, H
Boekschoten, MV
Muller, M
Sicinski, P
Gassler, N
Liedtke, C
Trautwein, C
AF Ehedego, Haksier
Boekschoten, Mark V.
Muller, Michael
Sicinski, Peter
Gassler, Nikolaus
Liedtke, Christian
Trautwein, Christian
TI Loss of Cyclin E1 attenuates hepatitis and hepatocarcinogenesis in
Nemo(Delta hepa) mice
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Ehedego, Haksier; Liedtke, Christian; Trautwein, Christian] Univ Hosp Aachen, Dept Med 3, Aachen, Germany.
[Gassler, Nikolaus] Univ Hosp Aachen, Dept Pathol, Aachen, Germany.
[Boekschoten, Mark V.; Muller, Michael] Wageningen Univ, Dept Nutr Metab & Genom, Wageningen, Netherlands.
[Sicinski, Peter] DFCI, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1253
BP 787A
EP 788A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602628
ER
PT J
AU Chusri, P
Cheng, D
Jilg, N
Fusco, DN
Schaefer, EA
Peng, LF
Chung, RT
Lin, WY
Brisac, C
Maneekarn, N
O'Brien, A
Kumthip, K
Zhao, L
AF Chusri, Pattranuch
Cheng, Du
Jilg, Nikolaus
Fusco, Dahlene N.
Schaefer, Esperance A.
Peng, Lee F.
Chung, Raymond T.
Lin, Wenyu
Brisac, Cynthia
Maneekarn, Niwat
O'Brien, Amornrat
Kumthip, Kattareeya
Zhao, Lei
TI HCV induces hepatocyte TGF-beta 1 release through activation of ER
Stress and the unfolded protein response
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Chusri, Pattranuch; Cheng, Du; Jilg, Nikolaus; Fusco, Dahlene N.; Schaefer, Esperance A.; Peng, Lee F.; Chung, Raymond T.; Lin, Wenyu; Brisac, Cynthia; Zhao, Lei] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Maneekarn, Niwat; O'Brien, Amornrat; Kumthip, Kattareeya] Chiang Mai Univ, Chiang Mai 50000, Thailand.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1260
BP 790A
EP 791A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955602635
ER
PT J
AU Mueller, JL
Corey, KE
Chung, RT
Misdraji, J
Gelrud, LG
AF Mueller, Jessica L.
Corey, Kathleen E.
Chung, Raymond T.
Misdraji, Joseph
Gelrud, Louis G.
TI Non-alcoholic steatohepatitis is frequent in young patients with
diabetes
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Mueller, Jessica L.; Corey, Kathleen E.; Chung, Raymond T.; Misdraji, Joseph] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gelrud, Louis G.] St Marys Hosp, Richmond, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1522
BP 906A
EP 906A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603120
ER
PT J
AU Ho, SB
Groessl, EJ
Brau, N
Cheung, R
Weingart, KR
Ward, M
Sklar, M
Phelps, TE
Marcus, S
Wasil, MM
Tisi, AS
Huynh, LK
Robinson, S
AF Ho, Samuel B.
Groessl, Erik J.
Brau, Norbert
Cheung, Ramsey
Weingart, Kimberly R.
Ward, Megan
Sklar, Marisa
Phelps, Tyler E.
Marcus, Sonja
Wasil, Michelene M.
Tisi, Amelia S.
Huynh, Lia K.
Robinson, Shannon
TI Multisite randomized trial of an Integrated Care (IC) model for HCV
patients with psychiatric and substance use co-morbidities: final
results of impact on treatment initiation
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Ho, Samuel B.; Groessl, Erik J.; Weingart, Kimberly R.; Ward, Megan; Sklar, Marisa; Wasil, Michelene M.; Robinson, Shannon] VA San Diego Healthcare Syst, San Diego, CA USA.
[Ho, Samuel B.; Groessl, Erik J.; Robinson, Shannon] Univ Calif San Diego, San Diego, CA 92103 USA.
[Brau, Norbert; Marcus, Sonja; Tisi, Amelia S.] James J Peters VA Med Ctr, Bronx, NY USA.
[Cheung, Ramsey; Phelps, Tyler E.; Huynh, Lia K.] VA Palo Alto Healthcare Syst, Palo Alto, CA USA.
[Brau, Norbert] Mt Sinai Sch Med, New York, NY USA.
[Cheung, Ramsey] Stanford Univ, Palo Alto, CA 94304 USA.
NR 0
TC 3
Z9 3
U1 2
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1736
BP 1000A
EP 1001A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603332
ER
PT J
AU Hasham, A
Zhang, WJ
Lotay, V
Dieterich, DT
Tomer, Y
AF Hasham, Alia
Zhang, Weijia
Lotay, Vaneet
Dieterich, Douglas T.
Tomer, Yaron
TI Chronic Hepatitis C virus (HCV) and interferon-induced thyroiditis
(IIT): Mapping susceptibility genes with potential to identify high-risk
groups
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Hasham, Alia; Tomer, Yaron] Mt Sinai Med Ctr, Dept Med, Div Endocrinol, New York, NY 10029 USA.
[Lotay, Vaneet] Mt Sinai Med Ctr, Inst Personalized Med, New York, NY 10029 USA.
[Dieterich, Douglas T.] Mt Sinai Med Ctr, Dept Med, Div Liver Dis, New York, NY 10029 USA.
[Hasham, Alia; Tomer, Yaron] James J Peters VA Med Ctr, Bronx, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1783
BP 1024A
EP 1024A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603379
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Mittimani, K
Siriki, R
Rahman, MA
Ang, LP
Win, S
Brown, RS
AF Basu, Patrick
Shah, Niraj J.
Farhat, Sakina
Mittimani, Kavya
Siriki, Ravi
Rahman, Md A.
Ang, Lynn P.
Win, S.
Brown, Robert S.
TI Pegylated Interferon Alfa, Nitazoxanide, Telapravir and Ribavirin in
prior experienced chronic hepatitis C Genotype 1 patients - A randomized
Placebo control clinical Pilot Trial (INTRIGUE-C)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Basu, Patrick; Brown, Robert S.] Columbia Univ, Sch Phys & Surg, New York, NY USA.
[Basu, Patrick; Farhat, Sakina; Mittimani, Kavya; Siriki, Ravi; Rahman, Md A.; Ang, Lynn P.; Win, S.] N Shore Forest Hills Hosp, Hofstra Med Sch NY, New York, NY USA.
[Shah, Niraj J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1806
BP 1035A
EP 1035A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603402
ER
PT J
AU Safaie, P
Dharel, N
Jacobs, WC
Chen, J
Nasser, I
Lau, D
AF Safaie, Parham
Dharel, Narayan
Jacobs, W. Carl
Chen, Jie
Nasser, Imad
Lau, Daryl
TI Patterns of intrahepatic expression of HBV surface and core antigens in
chronic hepatitis B patients with and without hepatocellular carcinoma
(HCC)
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Safaie, Parham; Dharel, Narayan; Jacobs, W. Carl; Chen, Jie; Nasser, Imad; Lau, Daryl] Harvard Univ, Sch Med, BIDMC, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1860
BP 1059A
EP 1060A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603455
ER
PT J
AU McGhan, AA
Kaplan, DE
AF McGhan, Alyson A.
Kaplan, David E.
TI Cirrhosis diagnosis rates, liver transplantation rates, and
Child-Turcotte-Pugh stage critically impact the efficacy of
hepatocellular carcinoma surveillance to improve HCC-related survival in
a US Veteran population
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[McGhan, Alyson A.; Kaplan, David E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1935
BP 1092A
EP 1093A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603528
ER
PT J
AU McGhan, AA
Kaplan, DE
AF McGhan, Alyson A.
Kaplan, David E.
TI Costs of palliative treatments of intermediate and advanced stage
hepatocellular carcinoma may exceed usually accepted limits of cost
effectiveness
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Kaplan, David E.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[McGhan, Alyson A.; Kaplan, David E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1944
BP 1097A
EP 1097A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603537
ER
PT J
AU Brewer, JE
Gerry, AB
Bennett, AD
Pumphrey, NJ
Kaplan, DE
Jakobsen, BK
AF Brewer, Joanna E.
Gerry, Andrew B.
Bennett, Alan D.
Pumphrey, Nick J.
Kaplan, David E.
Jakobsen, Bent K.
TI T-cells from cirrhotic patients transduced with optimized T-cell
receptor have potent effector functions against hepatocellular
carcinoma-associated antigens in vitro
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Brewer, Joanna E.; Gerry, Andrew B.; Bennett, Alan D.; Pumphrey, Nick J.; Jakobsen, Bent K.] Adaptimmune Ltd, Abingdon, Oxon, England.
[Kaplan, David E.] Philadelphia VA Med Ctr, Res Sect, Philadelphia, PA USA.
[Kaplan, David E.] Univ Penn, Dept Med, Div Gastroenterol, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 1983
BP 1114A
EP 1114A
PG 1
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603576
ER
PT J
AU Vodovotz, Y
Prelich, JG
Zamora, R
Murase, N
Gandhi, CR
AF Vodovotz, Yoram
Prelich, John G.
Zamora, Ruben
Murase, Noriko
Gandhi, Chandrashekhar R.
TI Augmenter of Liver Regeneration (ALR) is a Novel Damage-Associated
Molecular Pattern Molecule That Predicts Liver Damage: In Vitro, In
Vivo, and In Silico Studies
SO HEPATOLOGY
LA English
DT Meeting Abstract
CT 63rd Annual Meeting of the
American-Association-for-the-Study-of-Liver-Diseases (AASLD)
CY NOV 09-13, 2012
CL Boston, MA
SP Amer Assoc Study Liver Dis
C1 [Vodovotz, Yoram; Zamora, Ruben; Murase, Noriko; Gandhi, Chandrashekhar R.] Univ Pittsburgh, Pittsburgh, PA USA.
[Prelich, John G.; Gandhi, Chandrashekhar R.] VA Pittsburgh Healthcare Syst, Res & Dev, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0270-9139
J9 HEPATOLOGY
JI Hepatology
PD OCT
PY 2012
VL 56
SU 1
MA 2005
BP 1122A
EP 1123A
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA 035OD
UT WOS:000310955603598
ER
PT J
AU Margey, R
Elmariah, S
Hynes, BG
Renfigo-Moreno, P
Schainfeld, R
Jaff, MR
Inglessis, I
Palacios, IF
AF Margey, R.
Elmariah, S.
Hynes, B. G.
Renfigo-Moreno, P.
Schainfeld, R.
Jaff, M. R.
Inglessis, I.
Palacios, I. F.
TI Non-Cerebrovascular Systemic Arterial Embolic Events Due to Paradoxical
Embolization Via Patent Foramen Ovale (PFO)
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Meeting Abstract
C1 [Margey, R.; Schainfeld, R.; Jaff, M. R.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Margey, R.; Schainfeld, R.; Jaff, M. R.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD OCT
PY 2012
VL 181
SU 8
MA 32
BP S320
EP S321
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 053GV
UT WOS:000312260300033
ER
PT J
AU Margey, R
Elmariah, S
Renfigo-Moreno, P
Inglessis, I
Palacios, IF
AF Margey, R.
Elmariah, S.
Renfigo-Moreno, P.
Inglessis, I.
Palacios, I. F.
TI Long Term Prevention of Recurrent Cerebrovascular Events with
Transcatheter Patent Foramen Ovale Closure-Findings in Contrast to the
Closure I Trial
SO IRISH JOURNAL OF MEDICAL SCIENCE
LA English
DT Meeting Abstract
C1 [Margey, R.; Elmariah, S.; Renfigo-Moreno, P.; Inglessis, I.; Palacios, I. F.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER LONDON LTD
PI LONDON
PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND
SN 0021-1265
J9 IRISH J MED SCI
JI Irish J. Med. Sci.
PD OCT
PY 2012
VL 181
SU 8
MA 24
BP S318
EP S318
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 053GV
UT WOS:000312260300025
ER
PT J
AU Peterson, A
Mattek, N
Clemons, A
Bowman, GL
Buracchio, T
Kaye, J
Quinn, J
AF Peterson, A.
Mattek, N.
Clemons, A.
Bowman, G. L.
Buracchio, T.
Kaye, J.
Quinn, J.
TI Serum vitamin d concentrations are associated with falling and cognitive
function in older adults
SO JOURNAL OF NUTRITION HEALTH & AGING
LA English
DT Article
DE Accidental falls; cognitive function; vitamin D
ID ALZHEIMERS-DISEASE; MUSCLE FUNCTION; GAIT; RISK
AB To elucidate the mechanism through which vitamin D is associated with decreased falls.
This was a convenience sample from a larger observational study examining correlations between vitamin D and 1) falls, 2) motor function, and 3) cognition (n=159).
Falls data were collected via weekly on-line surveys completed in the participants' homes. Yearly evaluations of motor and cognitive function were conducted in an out-patient setting of a large tertiary medical center.
Participants from the Intelligent Systems for Assessment of Aging Changes Study (ISAAC), a community-based cohort study of independently living older adults over age 70, who had vitamin D concentration within 6 months of clinical evaluations were included in the analysis.
Participants mean age was 85 years and 74% were women. Fallers (n=37) had significantly lower vitamin D concentration (32.9ng/ml) compared to non-fallers (39.2ng/ml) (p < 0.01). The relationship between vitamin D and falls remained significant after adjusting for age, health status (via CIRS), and supplement use (p=0.004). Vitamin D concentration were significantly associated with cognitive impairment (Clinical Dementia Rating = 0.5) (p=0.02) and MMSE (p < 0.01) after adjusting for age, gender, and education. Vitamin D concentrations did not correlate with any motor measures.
Vitamin D concentrations correlated with cognition and falls, but not with motor measures. Further research is needed to demonstrate a causal relationship between vitamin D and cognitive function and determine if cognition plays a role in falls reduction.
C1 [Peterson, A.; Buracchio, T.; Kaye, J.; Quinn, J.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA.
[Buracchio, T.; Kaye, J.] Oregon Hlth & Sci Univ, Oregon Ctr Aging & Technol, Portland, OR 97239 USA.
[Peterson, A.; Buracchio, T.; Kaye, J.; Quinn, J.] Portland VA Med Ctr, Portland, OR USA.
RP Peterson, A (reprint author), Oregon Hlth & Sci Univ, Dept Neurol, 3181 SW Samuel Jackson Pk Rd,Mail Code OP32, Portland, OR 97239 USA.
EM peterami@ohsu.edu
OI Kaye, Jeffrey/0000-0002-9971-3478
FU National Institute of Health [P30-AG008017, P30-AG024978, R01-AG024059,
K01-AG23014, K23- AT004777]; Department of Veterans Affairs
[P30-AG008017, M01-RR000334]; Intel Corporation
FX Supported by National Institute of Health grants P30-AG008017,
P30-AG024978, R01-AG024059, K01-AG23014, K23- AT004777, the Department
of Veterans Affairs P30-AG008017 and M01-RR000334, and Intel
Corporation.
NR 26
TC 20
Z9 21
U1 0
U2 21
PU SPRINGER FRANCE
PI PARIS
PA 22 RUE DE PALESTRO, PARIS, 75002, FRANCE
SN 1279-7707
J9 J NUTR HEALTH AGING
JI J. Nutr. Health Aging
PD OCT
PY 2012
VL 16
IS 10
BP 898
EP 901
DI 10.1007/s12603-012-0378-4
PG 4
WC Geriatrics & Gerontology; Nutrition & Dietetics
SC Geriatrics & Gerontology; Nutrition & Dietetics
GA 052NY
UT WOS:000312206100005
PM 23208029
ER
PT J
AU Kessler, ER
Bowles, DW
Flaig, TW
Lam, ET
Jimeno, A
AF Kessler, E. R.
Bowles, D. W.
Flaig, T. W.
Lam, E. T.
Jimeno, A.
TI AXITINIB, A NEW THERAPEUTIC OPTION IN RENAL CELL CARCINOMA
SO DRUGS OF TODAY
LA English
DT Article
DE Axitinib; Renal cell carcinoma; Platelet-derived growth factor receptor;
Proto-oncogene c-Kit; VHL gene
ID ENDOTHELIAL GROWTH-FACTOR; QUALITY-OF-LIFE; TYROSINE KINASE INHIBITOR;
ADVANCED SOLID TUMORS; INTERFERON-ALPHA; PHASE-II; JAPANESE PATIENTS;
ANGIOGENESIS INHIBITOR; ANTITUMOR-ACTIVITY; CANCER
AB Axitinib is a small-molecule protein-tyrosine kinase receptor inhibitor specifically targeting this family of receptors, in addition to platelet-derived growth factor receptor and proto-onco gene c-Kit. Improved knowledge of kidney cancer development, and specifically mutations in the VHL gene, has supported the targeting of angiogenesis pathways. Axitinib is the most recently approved agent for use in metastatic renal cell carcinoma. This review will focus on the preclinical pharmacology, pharmacokinetics and clinical activity of this agent, and describe its place in the current treatment of renal cell carcinoma.
C1 [Kessler, E. R.; Bowles, D. W.; Flaig, T. W.; Lam, E. T.; Jimeno, A.] Univ Colorado, Sch Med, Div Med Oncol, Denver, CO USA.
[Bowles, D. W.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Jimeno, A (reprint author), Univ Colorado Denver, Div Med Oncol, 12801 E 17th Ave,MS 8117, Aurora, CO 80045 USA.
EM antonio.jimeno@ucdenver.edu
NR 63
TC 5
Z9 6
U1 0
U2 7
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 1699-3993
J9 DRUG TODAY
JI Drugs Today
PD OCT
PY 2012
VL 48
IS 10
BP 633
EP 644
DI 10.1358/dot.2012.48.10.1860768
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 047RX
UT WOS:000311860200001
PM 23110259
ER
PT J
AU Ravicz, ME
Rosowski, JJ
AF Ravicz, Michael E.
Rosowski, John J.
TI Chinchilla middle-ear admittance and sound power: High-frequency
estimates and effects of inner-ear modifications
SO JOURNAL OF THE ACOUSTICAL SOCIETY OF AMERICA
LA English
DT Article
ID IN-SITU CALIBRATION; INPUT IMPEDANCE; REFLECTION COEFFICIENT; TYMPANIC
MEMBRANE; EXTERNAL-EAR; HEARING-LOSS; PRESSURE; TRANSMISSION; EARDRUM;
MECHANICS
AB The middle-ear input admittance relates sound power into the middle ear (ME) and sound pressure at the tympanic membrane (TM). ME input admittance was measured in the chinchilla ear canal as part of a larger study of sound power transmission through the ME into the inner ear. The middle ear was open, and the inner ear was intact or modified with small sensors inserted into the vestibule near the cochlear base. A simple model of the chinchilla ear canal, based on ear canal sound pressure measurements at two points along the canal and an assumption of plane-wave propagation, enables reliable estimates of Y-TM, the ME input admittance at the TM, from the admittance measured relatively far from the TM. Y-TM appears valid at frequencies as high as 17 kHz, a much higher frequency than previously reported. The real part of Y-TM decreases with frequency above 2 kHz. Effects of the inner-ear sensors (necessary for inner ear power computation) were small and generally limited to frequencies below 3 kHz. Computed power reflectance was similar to 0.1 below 3.5 kHz, lower than with an intact ME below 2.5 kHz, and nearly 1 above 16 kHz. (C) 2012 Acoustical Society of America. [http://dx.doi.org/10.1121/1.4750487]
C1 [Ravicz, Michael E.; Rosowski, John J.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Rosowski, John J.] MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Rosowski, John J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Ravicz, ME (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM mike_ravicz@meei.harvard.edu
FU NIDCD
FX We thank Melissa McKinnon for animal surgery and assistance with
experiments, and the staff of the Eaton-Peabody Laboratory for technical
support. Douglas Keefe and an anonymous reviewer gave helpful comments.
Supported by NIDCD.
NR 49
TC 5
Z9 5
U1 0
U2 2
PU ACOUSTICAL SOC AMER AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0001-4966
J9 J ACOUST SOC AM
JI J. Acoust. Soc. Am.
PD OCT
PY 2012
VL 132
IS 4
BP 2437
EP 2454
DI 10.1121/1.4750487
PN 1
PG 18
WC Acoustics; Audiology & Speech-Language Pathology
SC Acoustics; Audiology & Speech-Language Pathology
GA 018HJ
UT WOS:000309650600048
PM 23039439
ER
PT J
AU Smith, RN
Malik, F
Goes, N
Farris, AB
Zorn, E
Saidman, S
Tolkoff-Rubin, N
Puri, S
Wong, WC
AF Smith, R. Neal
Malik, Fahim
Goes, Nelson
Farris, Alton B.
Zorn, Emmanuel
Saidman, Susan
Tolkoff-Rubin, Nina
Puri, Sonika
Wong, Waichi
TI Partial therapeutic response to Rituximab for the treatment of chronic
alloantibody mediated rejection of kidney allografts
SO TRANSPLANT IMMUNOLOGY
LA English
DT Article
DE Chronic humoral rejection; Donor specific antibodies; Rituximab; Renal
allograft survival
ID ANTI-CD20 MONOCLONAL-ANTIBODY; ANTIGEN-PRESENTING CELLS;
RENAL-ALLOGRAFTS; PERITUBULAR CAPILLARIES; TRANSPLANT GLOMERULOPATHY;
C4D DEPOSITS; MEMBRANOUS GLOMERULONEPHRITIS; HUMORAL REJECTION; HLA
ANTIBODIES; IN-VIVO
AB Background and Objectives: Chronic rejection leads to kidney allograft failure and develops in many kidney transplant recipients. One cause of chronic rejection, chronic antibody mediated rejection (CAMR), is attributed to alloantibodies. Maintenance immunosuppression including prednisone, mycophenolate mofetil (MMF) and calcineurin inhibitors may limit alloantibody production in some patients, but many maintain or develop alloantibody production, leading to CAMR. Therefore, no efficacious therapy to treat CAMR is presently available to prevent the progression of CAMR to kidney allograft failure.
Design, Setting, Participants, and Measurements: We performed a retrospective review of 31 subjects with CAMR, of which 14 received Rituximab and 17 subjects did not. Response to Rituximab was defined as decline or stabilization of serum creatinine for at least one year. Data reviewed included demographic, clinical, allograft, post-transplant, and pathological variables. Pathological variables in the diagnostic allograft biopsy were scored according to Banff criteria.
Results: The median survival time (MST) for allografts in the control group was 439 days, and for the Rituximab treated group was 685 days. The Rituximab group was dichotomous with 8 subjects showing a medial survival time of 1180 days, and 6 subjects having a median survival time of 431 days. The MST for the responders was statistically significant from the non-responders and controls. No pathological parameter distinguished any subset of subjects.
Conclusions: These data show that Rituximab followed by standard maintenance immunosuppression shows a therapeutic effect in the treatment of CAMR, which is confined to a subset of treated subjects, not identifiable a priori. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Smith, R. Neal; Saidman, Susan] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Malik, Fahim; Tolkoff-Rubin, Nina; Puri, Sonika; Wong, Waichi] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp,Renal Unit, Boston, MA 02114 USA.
[Goes, Nelson] Swedish Med Ctr, Seattle, WA USA.
[Farris, Alton B.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
[Zorn, Emmanuel] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Smith, RN (reprint author), Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM rnsmith@partners.org
FU NIAID NIH HHS [U19 AI102405]; NIDDK NIH HHS [R01 DK083352]
NR 41
TC 14
Z9 16
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0966-3274
J9 TRANSPL IMMUNOL
JI Transpl. Immunol.
PD OCT
PY 2012
VL 27
IS 2-3
BP 107
EP 113
DI 10.1016/j.trim.2012.08.005
PG 7
WC Immunology; Transplantation
SC Immunology; Transplantation
GA 052BZ
UT WOS:000312174000008
PM 22960786
ER
PT J
AU Neuhaus, V
King, JD
Jupiter, JB
AF Neuhaus, V
King, J. D.
Jupiter, J. B.
TI Fixation of Osteoporotic Fractures in the Upper Limb with a Locking
Compression Plate
SO ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA
LA English
DT Review
DE concepts; current; fractures; Locking Compression Plate; osteoporotic;
review
ID PROXIMAL HUMERAL FRACTURES; DISTAL RADIAL FRACTURES; PROSPECTIVE CASE
SERIES; NONOPERATIVE TREATMENT; OPERATIVE MANAGEMENT; ELDERLY-PATIENTS;
BONE; CLASSIFICATION; OSTEOSYNTHESIS; COMPLICATIONS
AB Locking Compression Plate (LCP) has the advantageous feature that screws can be locked in the plate leaving an angular stable construct. There is no need to have contact between the plate and the bone to achieve stability resulting from friction of the plate-bone-construct. Therefore the plate does not need to be contoured exactly to the bone and the healing bone's periosteal blood supply is not affected. The LCP is used as a bridging plate to gain relative stability in multi-fragmentary, diaphyseal or metaphyseal fractures. Depending on the fracture, the combination hole can also allow the LCP to achieve absolute stability similar to conventional fixation techniques.
Osteoporotic fractures have significant impact on morbidity and mortality. Proximal humeral and distal radius fractures are typical examples. These osteoporotic and often comminuted fractures are ideal settings/indications for LCP utilization in the upper extremity. However, the data quality is due to mostly small study populations not so powerful. Unquestionably there has been a clear and fashionable trend to choose operative treatment for these fractures, because the angular stability allows stable fixation and early functional mobilization.
C1 [Jupiter, J. B.] Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Yawkey Ctr, Boston, MA 02114 USA.
RP Jupiter, JB (reprint author), Massachusetts Gen Hosp, Hand & Upper Extrem Serv, Yawkey Ctr, Suite 2100,55 Fruit St, Boston, MA 02114 USA.
EM jjupiter1@partners.org
NR 45
TC 2
Z9 2
U1 2
U2 5
PU GALEN SRO
PI PRAGUE 5
PA NA BELIDLE 34, PRAGUE 5, 150 00, CZECH REPUBLIC
SN 0001-5415
J9 ACTA CHIR ORTHOP TR
JI Acta Chir. Orthop. Traumatol. Cechoslov.
PD OCT
PY 2012
VL 79
IS 5
BP 404
EP 410
PG 7
WC Orthopedics
SC Orthopedics
GA 040MU
UT WOS:000311327800002
PM 23140595
ER
PT J
AU Yamamoto, N
Schuler, M
O'Byrne, K
Hirsh, V
Mok, T
Kato, T
Yoshioka, H
Okamoto, I
Yokoyama, A
Massey, D
Jones, H
Zazulina, V
Shahidi, M
Sequist, L
Yang, JCH
AF Yamamoto, N.
Schuler, M.
O'Byrne, K.
Hirsh, V.
Mok, T.
Kato, T.
Yoshioka, H.
Okamoto, I.
Yokoyama, A.
Massey, D.
Jones, H.
Zazulina, V.
Shahidi, M.
Sequist, L.
Yang, J. C. -H.
TI LUX-LUNG 3: AFATINIB VERSUS CISPLATIN AND PEMETREXED IN JAPANESE
PATIENTS WITH ADENOCARCINOMA OF THE LUNG HARBORING AN EGFR MUTATION
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Yamamoto, N.] Shizuoka Canc Ctr, Shizuoka, Japan.
[Schuler, M.] Univ Duisburg Essen, W German Canc Ctr, Essen, Germany.
[O'Byrne, K.] St James Hosp, Dublin 8, Ireland.
[Hirsh, V.] McGill Univ, Montreal, PQ, Canada.
[Mok, T.] Prince Wales Hosp, Shatin, Hong Kong, Peoples R China.
[Kato, T.] Kanagawa Cardiovasc & Resp Ctr, Yokohama, Kanagawa, Japan.
[Yoshioka, H.] Japan Kurashiki Cent Hosp, Kurashiki, Okayama, Japan.
[Okamoto, I.] Kinki Univ, Osaka, Japan.
[Yokoyama, A.] Niigata Canc Ctr Hosp, Niigata, Japan.
[Massey, D.; Jones, H.; Zazulina, V.; Shahidi, M.] Boehringer Ingelheim Ltd, Bracknell, Berks, England.
[Sequist, L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Yang, J. C. -H.] Natl Taiwan Univ Hosp, Taipei, Taiwan.
NR 0
TC 1
Z9 1
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 8
EP 8
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300008
ER
PT J
AU Johnson, BE
AF Johnson, B. E.
TI CANCER RESEARCH AND CLINICAL ONCOLOGY FOR THE NEXT DECADE
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Johnson, B. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Cambridge, MA 02138 USA.
[Johnson, B. E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cambridge, MA 02138 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 9
EP 9
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300011
ER
PT J
AU Janne, PA
AF Jaenne, P. A.
TI BIOMARKER-BASED DRUG DEVELOPMENT IN NSCLC
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 11
EP 11
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300016
ER
PT J
AU Fuchs, C
Ikeda, M
Okusaka, T
Ohkawa, S
Mizuno, N
Haddad, V
McGreivy, J
Chang, D
AF Fuchs, C.
Ikeda, M.
Okusaka, T.
Ohkawa, S.
Mizuno, N.
Haddad, V.
McGreivy, J.
Chang, D.
TI A PHASE 3 TRIAL OF GANITUMAB WITH GEMCITABINE AS FIRST-LINE TREATMENT OF
METASTATIC PANCREATIC CANCER: A SAFETY UPDATE FROM THE GAMMA TRIAL
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Fuchs, C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ikeda, M.] Natl Canc Ctr Hosp E, Kashiwa, Chiba, Japan.
[Okusaka, T.] Natl Canc Ctr, Tokyo, Japan.
[Ohkawa, S.] Kanagawa Canc Ctr, Yokohama, Kanagawa 2410815, Japan.
[Mizuno, N.] Aichi Canc Ctr Hosp, Nagoya, Aichi 464, Japan.
[Haddad, V.] Amgen Ltd, Cambridge, England.
[McGreivy, J.] Amgen Inc, San Francisco, CA USA.
[Chang, D.] Amgen Inc, Thousand Oaks, CA 91320 USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 15
EP 15
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300029
ER
PT J
AU Nishida, T
Casali, PG
Reichardt, P
Kang, YK
Blay, JY
Joensuu, H
Maki, RG
Rutkowski, P
Hohenberger, P
Gelderblom, H
Leahy, MG
von Mehren, M
Schoffski, P
Blackstein, ME
Cesne, AL
Badalamenti, G
Xu, JM
Laurent, D
Kuss, I
Demetri, GD
AF Nishida, T.
Casali, P. G.
Reichardt, P.
Kang, Y. -K.
Blay, J. -Y.
Joensuu, H.
Maki, R. G.
Rutkowski, P.
Hohenberger, P.
Gelderblom, H.
Leahy, M. G.
von Mehren, M.
Schoffski, P.
Blackstein, M. E.
Cesne, A. L.
Badalamenti, G.
Xu, J. -M.
Laurent, D.
Kuss, I.
Demetri, G. D.
CA GRID Investigators
TI RANDOMIZED PHASE 3 TRIAL OF REGORAFENIB IN PATIENTS (PATIENTS) WITH
METASTATIC AND/OR UNRESECTABLE GASTROINTESTINAL STROMAL TUMOR (GIST)
PROGRESSING DESPITE PRIOR TREATMENT WITH AT LEAST IMATINIB (IM) AND
SUNITINIB (SU) : GRID TRIAL.
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Nishida, T.] Osaka Police Hosp, Dept Surg, Osaka, Japan.
[Casali, P. G.] Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
[Reichardt, P.] HELIOS Klinikum Bad Saarow, Bad Saarow Pieskow, Germany.
[Kang, Y. -K.] Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea.
[Blay, J. -Y.] Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France.
[Joensuu, H.] Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland.
[Maki, R. G.] Mt Sinai Sch Med, New York, NY USA.
[Rutkowski, P.] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland.
[Hohenberger, P.] Univ Mannheim, Med Ctr, Dept Surg, Mannheim, Germany.
[Gelderblom, H.] Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
[Leahy, M. G.] Christie NHS Fdn Trust, Manchester, Lancs, England.
[von Mehren, M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Schoffski, P.] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium.
[Blackstein, M. E.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Cesne, A. L.] Inst Gustave Roussy, Villejuif, France.
[Badalamenti, G.] Univ Palermo, Dept Oncol, Div Med Oncol, Palermo, Italy.
[Xu, J. -M.] Acad Mil Med Sci, Affiliated Hosp, Beijing, Peoples R China.
[Laurent, D.; Kuss, I.] Bayer HealthCare Pharmaceut, Berlin, Germany.
[Demetri, G. D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 20
EP 20
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300046
ER
PT J
AU Boyer, M
Janne, PA
Mok, T
O'Byrne, K
Paz-Ares, L
Ramalingam, SS
Liang, J
Taylor, I
Campbell, A
O'Connell, J
Letrent, S
Lee, SY
Antic, V
AF Boyer, M.
Jaenne, P. A.
Mok, T.
O'Byrne, K.
Paz-Ares, L.
Ramalingam, S. S.
Liang, J.
Taylor, I.
Campbell, A.
O'Connell, J.
Letrent, S.
Lee, S. -Y.
Antic, V.
TI ARCHER: DACOMITINIB (D; PF-00299804) VERSUS ERLOTINIB (E) FOR ADVANCED
(ADV) NSCLC; A RANDOMIZED DOUBLE-BLIND PHASE III STUDY
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Boyer, M.] Sydney Canc Ctr, Camperdown, NSW, Australia.
[Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA USA.
[Mok, T.] Chinese Univ Hong Kong, Dept Clin Oncol, State Key Lab So China, Hong Kong, Hong Kong, Peoples R China.
[O'Byrne, K.] St James Hosp, Dublin 8, Ireland.
[Paz-Ares, L.] Hosp Univ Virgen del Rocio, Seville, Spain.
[Ramalingam, S. S.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Liang, J.; Taylor, I.; Campbell, A.; O'Connell, J.] Pfizer Oncol, Groton, CT USA.
[Letrent, S.] Pfizer Oncol, La Jolla, CA USA.
[Lee, S. -Y.] Pfizer Korea, Seoul, South Korea.
[Antic, V.] Pfizer AG, Zurich, Switzerland.
RI IBIS, NUEVAS TERAPIA/P-3415-2015
NR 0
TC 0
Z9 0
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 22
EP 23
PG 2
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300053
ER
PT J
AU Bang, YJ
Ou, S
Camidge, DR
Clark, JW
Wilner, K
Tye, L
Stephenson, P
Varella-Garcia, M
Iafrate, AJ
Shaw, AT
AF Bang, Y. -J.
Ou, S.
Camidge, D. R.
Clark, J. W.
Wilner, K.
Tye, L.
Stephenson, P.
Varella-Garcia, M.
Iafrate, A. J.
Shaw, A. T.
TI CLINICAL ACTIVITY OF CRIZOTINIB IN ADVANCED NON-SMALL-CELL LUNG CANCER
(NSCLC) HARBORING ROS1 GENE REARRANGEMENT
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Bang, Y. -J.] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
[Ou, S.] Univ Calif Irvine, Irvine, CA USA.
[Camidge, D. R.; Varella-Garcia, M.] Univ Colorado, Ctr Canc, Aurora, CO USA.
[Clark, J. W.; Iafrate, A. J.; Shaw, A. T.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Wilner, K.; Tye, L.] Pfizer Oncol, La Jolla, CA USA.
[Stephenson, P.] Rho Inc, Chapel Hill, NC USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 33
EP 33
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300084
ER
PT J
AU Kris, MG
Mok, T
Ou, SHI
Martins, RG
Kim, DW
Goldberg, Z
Zhang, H
Taylor, I
Letrent, SP
Janne, PA
AF Kris, M. G.
Mok, T.
Ou, S. -H. I.
Martins, R. G.
Kim, D. -W.
Goldberg, Z.
Zhang, H.
Taylor, I.
Letrent, S. P.
Jaenne, P. A.
TI FIRST-LINE DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE
KINASE INHIBITOR, FOR PATIENTS WITH EGFR-MUTANT LUNG CANCERS
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Kris, M. G.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Mok, T.] Chinese Univ Hong Kong, Shatin, Hong Kong, Peoples R China.
[Ou, S. -H. I.] Univ Calif Irvine, Sch Med, Irvine, CA 92717 USA.
[Martins, R. G.] Univ Washington, Seattle, WA 98195 USA.
[Kim, D. -W.] Seoul Natl Univ Hosp, Seoul 110744, South Korea.
[Goldberg, Z.; Letrent, S. P.] Pfizer Oncol, La Jolla, CA USA.
[Zhang, H.] Pfizer China Res & Dev Co Ltd, Shanghai, Peoples R China.
[Taylor, I.] Pfizer Oncol, Groton, CT USA.
[Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 34
EP 34
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300086
ER
PT J
AU Ebi, H
AF Ebi, H.
TI EGFR-MEDIATED RE-ACTIVATION OF MAPK SIGNALING CONTRIBUTES TO
INSENSITIVITY OF BRAF MUTANT COLORECTAL CANCERS TO RAF INHIBITION
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Ebi, H.] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 41
EP 41
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300109
ER
PT J
AU Janne, PA
AF Jaenne, P. A.
TI TREATMENT OF EML4-ALK REARRANGED NSCLC
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Jaenne, P. A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 79
EP 79
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300253
ER
PT J
AU Sasaki, T
Ohsaki, Y
Pasi, J
AF Sasaki, T.
Ohsaki, Y.
Pasi, J.
TI ACQUIRED RESISTANCE TO ALK TYROSINE KINASE INHIBITORS
SO ANNALS OF ONCOLOGY
LA English
DT Meeting Abstract
CT 10th Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO)
CY JUL 26-28, 2012
CL Osaka, JAPAN
SP Japanese Soc Med Oncol (JSMO)
C1 [Sasaki, T.; Ohsaki, Y.] Asahikawa Med Univ Hosp, Resp Ctr, Asahikawa, Hokkaido, Japan.
[Pasi, J.] Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
J9 ANN ONCOL
JI Ann. Oncol.
PD OCT
PY 2012
VL 23
SU 11
BP 80
EP 80
PG 1
WC Oncology
SC Oncology
GA 031JC
UT WOS:000310634300254
ER
PT J
AU Goel, HL
Chang, C
Pursell, B
Leav, I
Lyle, S
Xi, HS
Hsieh, CC
Adisetiyo, H
Roy-Burman, P
Coleman, IM
Nelson, PS
Vessella, RL
Davis, RJ
Plymate, SR
Mercurio, AM
AF Goel, Hira Lal
Chang, Cheng
Pursell, Bryan
Leav, Irwin
Lyle, Stephen
Xi, Hualin Simon
Hsieh, Chung-Cheng
Adisetiyo, Helty
Roy-Burman, Pradip
Coleman, Ilsa M.
Nelson, Peter S.
Vessella, Robert L.
Davis, Roger J.
Plymate, Stephen R.
Mercurio, Arthur M.
TI VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of
IGF-IR Defi ne a Novel Mechanism of Aggressive Prostate Cancer
SO CANCER DISCOVERY
LA English
DT Article
ID ENDOTHELIAL GROWTH-FACTOR; FACTOR RECEPTOR; PTEN EXPRESSION; CARCINOMA
CELLS; TUMOR BIOLOGY; MAMMARY-GLAND; NEUROPILIN-2; VEGF; PROGRESSION;
TARGET
AB We show that the VEGF receptor neuropilin-2 (NRP2) is associated with high-grade, PTEN-null prostate cancer and that its expression in tumor cells is induced by PTEN loss as a consequence of c-Jun activation. VEGF/NRP2 signaling represses insulin-like growth factor-1 receptor (IGF-IR) expression and signaling, and the mechanism involves Bmi-1-mediated transcriptional repression of the IGF-IR. This mechanism has significant functional and therapeutic implications that were evaluated. IGF-IR expression positively correlates with PTEN and inversely correlates with NRP2 in prostate tumors. NRP2 is a robust biomarker for predicting response to IGF-IR therapy because prostate carcinomas that express NRP2 exhibit low levels of IGF-IR. Conversely, targeting NRP2 is only modestly effective because NRP2 inhibition induces compensatory IGF-IR signaling. Inhibition of both NRP2 and IGF-IR, however, completely blocks tumor growth in vivo.
C1 [Goel, Hira Lal; Chang, Cheng; Pursell, Bryan; Leav, Irwin; Lyle, Stephen; Hsieh, Chung-Cheng; Mercurio, Arthur M.] Univ Massachusetts, Sch Med, Dept Canc Biol, Worcester, MA 01605 USA.
[Xi, Hualin Simon] Univ Massachusetts, Sch Med, Bioinformat Core, Worcester, MA 01605 USA.
[Davis, Roger J.] Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA.
[Davis, Roger J.] Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.
[Adisetiyo, Helty; Roy-Burman, Pradip] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA.
[Coleman, Ilsa M.; Nelson, Peter S.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98104 USA.
[Nelson, Peter S.; Vessella, Robert L.; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Urol, Seattle, WA 98195 USA.
[Nelson, Peter S.; Vessella, Robert L.; Plymate, Stephen R.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Plymate, Stephen R.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
RP Goel, HL (reprint author), Univ Massachusetts, Sch Med, Dept Canc Biol, LRB 470,364 Plantat St, Worcester, MA 01605 USA.
EM hira.goel@umassmed.edu
OI /0000-0003-1726-3037
FU DOD Prostate Cancer grant [PC111410]; NIH [R01CA80789, CA89209,
R01CA59705, PO1 CA85859]; Pacific Northwest Prostate Cancer SPORE [P50
CA097186]; Veterans Affairs Research Program; Prostate Cancer Foundation
FX This work was supported by DOD Prostate Cancer grant PC111410 (A. M.
Mercurio); NIH grants R01CA80789 and CA89209 (A. M. Mercurio),
R01CA59705 (P. Roy-Burman), PO1 CA85859 and the Pacific Northwest
Prostate Cancer SPORE P50 CA097186 (S. R. Plymate, R. L. Vessella, and
P. S. Nelson); the Veterans Affairs Research Program (S. R. Plymate);
and an award from the Prostate Cancer Foundation (P. S. Nelson).
NR 50
TC 31
Z9 34
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD OCT
PY 2012
VL 2
IS 10
BP 906
EP 921
DI 10.1158/2159-8290.CD-12-0085
PG 16
WC Oncology
SC Oncology
GA 048IG
UT WOS:000311904000023
PM 22777769
ER
PT J
AU Ercan, D
Xu, CX
Yanagita, M
Monast, CS
Pratilas, CA
Montero, J
Butaney, M
Shimamura, T
Sholl, L
Ivanova, EV
Tadi, M
Rogers, A
Repellin, C
Capelletti, M
Maertens, O
Goetz, EM
Letai, A
Garraway, LA
Lazzara, MJ
Rosen, N
Gray, NS
Wong, KK
Janne, PA
AF Ercan, Dalia
Xu, Chunxiao
Yanagita, Masahiko
Monast, Calixte S.
Pratilas, Christine A.
Montero, Joan
Butaney, Mohit
Shimamura, Takeshi
Sholl, Lynette
Ivanova, Elena V.
Tadi, Madhavi
Rogers, Andrew
Repellin, Claire
Capelletti, Marzia
Maertens, Ophelia
Goetz, Eva M.
Letai, Anthony
Garraway, Levi A.
Lazzara, Matthew J.
Rosen, Neal
Gray, Nathanael S.
Wong, Kwok-Kin
Jaenne, Pasi A.
TI Reactivation of ERK Signaling Causes Resistance to EGFR Kinase
Inhibitors
SO CANCER DISCOVERY
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; CELL LUNG-CANCER; MAP KINASE; 1ST-LINE
TREATMENT; MET AMPLIFICATION; T790M MUTATION; OPEN-LABEL; GEFITINIB;
SENSITIVITY; PATHWAY
AB The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here, we show, in multiple complementary models, that resistance to WZ4002 develops through aberrant activation of extracellular signal-regulated kinase (ERK) signaling caused by either an amplification of mitogen-activated protein kinase 1 (MAPK1) or by downregulation of negative regulators of ERK signaling. Inhibition of MAP-ERK kinase (MEK) or ERK restores sensitivity to WZ4002 and prevents the emergence of drug resistance. We further identify MAPK1 amplification in an erlotinib-resistant EGFR-mutant non-small cell lung carcinoma patient. In addition, the WZ4002-resistant MAPK1-amplified cells also show an increase both in EGFR internalization and a decrease in sensitivity to cytotoxic chemotherapy. Our findings provide insights into mechanisms of drug resistance to EGFR kinase inhibitors and highlight rational combination therapies that should be evaluated in clinical trials.
C1 [Ercan, Dalia; Xu, Chunxiao; Yanagita, Masahiko; Butaney, Mohit; Shimamura, Takeshi; Rogers, Andrew; Repellin, Claire; Capelletti, Marzia; Wong, Kwok-Kin; Jaenne, Pasi A.] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA 02215 USA.
[Ercan, Dalia; Goetz, Eva M.; Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02215 USA.
[Xu, Chunxiao; Yanagita, Masahiko; Montero, Joan; Butaney, Mohit; Shimamura, Takeshi; Rogers, Andrew; Repellin, Claire; Capelletti, Marzia; Goetz, Eva M.; Letai, Anthony; Garraway, Levi A.; Wong, Kwok-Kin; Jaenne, Pasi A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Gray, Nathanael S.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Ivanova, Elena V.; Wong, Kwok-Kin; Jaenne, Pasi A.] Dana Farber Canc Inst, Belfer Inst Appl Canc Sci, Boston, MA 02215 USA.
[Gray, Nathanael S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Maertens, Ophelia; Garraway, Levi A.; Wong, Kwok-Kin; Jaenne, Pasi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Sholl, Lynette] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Maertens, Ophelia] Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
[Garraway, Levi A.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Monast, Calixte S.; Lazzara, Matthew J.] Univ Penn, Dept Chem & Biomol Engn, Philadelphia, PA 19104 USA.
[Pratilas, Christine A.; Tadi, Madhavi] Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA.
[Rosen, Neal] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Pratilas, Christine A.; Tadi, Madhavi; Rosen, Neal] Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA.
[Shimamura, Takeshi] Loyola Univ Chicago, Dept Mol Pharmacol & Therapeut, Inst Oncol, Stritch Sch Med, Maywood, IL USA.
RP Janne, PA (reprint author), Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, 450 Brookline Ave,HIM 223, Boston, MA 02215 USA.
EM pjanne@partners.org
OI wong, kwok kin/0000-0001-6323-235X
FU Dana-Farber Cancer Institute; Novartis Pharmaceuticals; AstraZeneca;
Merck; Chugai; NIH [R01CA114465, R01CA135257, P01CA154303, K08CA127350];
National Cancer Institute Lung SPORE [P50CA090578]; Cammarata Family
Foundation; Nirenberg Fellowship at Dana-Farber Cancer Institute;
American Cancer Society [IRG-78-002-30]
FX P. A. Janne is a consultant/advisory board member of AstraZeneca,
Boehringer Ingelheim, Pfizer, Roche, Genentech, and Sanofi, has
post-marketing royalties from Dana-Farber Cancer Institute-owned
intellectual property on EGFR mutations licensed to Lab Corp, and is an
inventor on a Dana-Farber Cancer Institute-owned patent on WZ4002.; L.
Garraway is a consultant/advisory board member and has a commercial
research grant from Novartis Pharmaceuticals. L. Garraway also has
ownership interest in Foundation Medicine.; Neal Rosen has commercial
research grants from AstraZeneca, Merck, and Chugai and is a
consultant/advisory board member of Chugai, Astra-Zeneca, GSK, Novartis,
and Millenium.; This study is supported by grants from NIH R01CA114465
(P. A. Janne), R01CA135257 (P. A. Janne), P01CA154303 (P. A. Janne,
K.-K. Wong, and N. S. Gray), K08CA127350 (C. A. Pratilas), National
Cancer Institute Lung SPORE P50CA090578 (P. A. Janne and K.-K. Wong),
the Cammarata Family Foundation Research Fund (M. Capelletti and P. A.
Janne), the Nirenberg Fellowship at Dana-Farber Cancer Institute (M.
Capelletti and P. A. Janne), and the American Cancer Society
IRG-78-002-30 (M. J. Lazzara and C. S. Monast).
NR 49
TC 105
Z9 107
U1 2
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
J9 CANCER DISCOV
JI Cancer Discov.
PD OCT
PY 2012
VL 2
IS 10
BP 934
EP 947
DI 10.1158/2159-8290.CD-12-0103
PG 14
WC Oncology
SC Oncology
GA 048IG
UT WOS:000311904000025
PM 22961667
ER
PT J
AU Bateman, BT
Hernandez-Diaz, S
Huybrechts, KF
Palmsten, K
Mogun, H
Ecker, JL
Fischer, MA
AF Bateman, Brian T.
Hernandez-Diaz, Sonia
Huybrechts, Krista F.
Palmsten, Kristin
Mogun, Helen
Ecker, Jeffrey L.
Fischer, Michael A.
TI Patterns of Outpatient Antihypertensive Medication Use During Pregnancy
in a Medicaid Population
SO HYPERTENSION
LA English
DT Article
DE hypertension; pregnancy; epidemiology; antihypertensives
ID MAJOR CONGENITAL-MALFORMATIONS; HIGH BLOOD-PRESSURE; HYPERTENSIVE
DISORDERS; RISK; PREVENTION; MANAGEMENT; INHIBITORS; STATEMENT;
DIAGNOSIS; EXPOSURE
AB Hypertensive disorders occur in approximately 6% to 8% of all pregnancies and are a significant source of maternal and fetal morbidity. Little is known about the range of agents routinely used in practice. We used Medicaid claims from 2000 to 2007 to identify completed pregnancies. We included women who were Medicaid beneficiaries from at least 3 months prior to last menstrual period to 1 month postdelivery, and were successfully linked to infant records. Maternal exposure to antihypertensive medications was derived from Medicaid pharmacy claim files, and duration of exposure was assigned based on the days' supply dispensed. We identified 1 106 757 Medicaid patients in our cohort, of whom 48 453 (4.4%) were exposed to antihypertensive medications during pregnancy. The prevalence of antihypertensive use increased from 3.5% to 4.9% during the study period. Antihypertensive medication users were older than nonusers, more likely to be white or black, and more likely to have comorbid diabetes mellitus and renal disease. Overall, 1.9% of pregnant women were exposed during the first trimester, 1.7% during the second trimester, and 3.2% during the third trimester. The range of antihypertensive medications to which patients were exposed was highly heterogeneous and frequently included agents other than methyldopa or labetalol. Angiotensin-converting enzyme inhibitor exposure, which is contraindicated in late pregnancy, occurred in 928 (4.9%) antihypertensive medication users in the second trimester and 383 (1.1%) in the third trimester. Antihypertensive use during pregnancy is relatively common and increasing. The wide range of agents used during pregnancy includes medications considered contraindicated during pregnancy. (Hypertension. 2012; 60: 913-920.) center dot Online Data Supplement
C1 [Bateman, Brian T.; Huybrechts, Krista F.; Mogun, Helen; Fischer, Michael A.] Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
[Bateman, Brian T.; Huybrechts, Krista F.; Mogun, Helen; Fischer, Michael A.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hernandez-Diaz, Sonia; Palmsten, Kristin] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Hernandez-Diaz, Sonia; Palmsten, Kristin] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Ecker, Jeffrey L.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Obstet & Gynecol, Boston, MA 02115 USA.
RP Bateman, BT (reprint author), Brigham & Womens Hosp, Dept Med, Div Pharmacoepidemiol & Pharmacoecon, 75 Francis St, Boston, MA 02115 USA.
EM BBateman@partners.org
FU National Institutes of Health [GM007592]; Agency for Healthcare Research
and Quality (AHRQ) [R01HS018533]; National Institute of Child Health and
Human Development (NICHD), National Institutes of Health [T32HD060454]
FX Supported by the National Institutes of Health (Grant GM007592 to B. T.
B.) and by the Agency for Healthcare Research and Quality (AHRQ) (Grant
R01HS018533 to S. H. D.). K. P. is supported by Training Grant
T32HD060454 in Reproductive, Perinatal, and Pediatric Epidemiology from
the National Institute of Child Health and Human Development (NICHD),
National Institutes of Health.
NR 33
TC 21
Z9 21
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0194-911X
J9 HYPERTENSION
JI Hypertension
PD OCT
PY 2012
VL 60
IS 4
BP 913
EP +
DI 10.1161/HYPERTENSIONAHA.112.197095
PG 21
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 006IF
UT WOS:000308812000013
PM 22966012
ER
PT J
AU Li, M
Mukasa, A
Inda, MD
Zhang, JH
Chin, L
Cavenee, W
Furnari, F
AF Li, Ming
Mukasa, Akitake
Inda, Maria del-Mar
Zhang, Jianhua
Chin, Lynda
Cavenee, Webster
Furnari, Frank
TI GUANYLATE-BINDING PROTEIN-1 AS A NOVEL EFFECTOR OF EPIDERMAL GROWTH
FACTOR RECEPTOR-DRIVEN INVASION IN GLIOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Li, Ming; Mukasa, Akitake; Inda, Maria del-Mar; Cavenee, Webster; Furnari, Frank] Univ Calif San Diego, Ludwig Inst, La Jolla, CA 92093 USA.
[Zhang, Jianhua; Chin, Lynda] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Zhang, Jianhua; Chin, Lynda] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 1
EP 1
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300005
ER
PT J
AU Zhu, W
Wang, QW
Clark, PA
Yang, SS
Lin, SH
Kahle, KT
Kuo, JS
Sun, DD
AF Zhu, Wen
Wang, Qiwei
Clark, Paul A.
Yang, Sung-Sen
Lin, Shih-Hua
Kahle, Kristopher T.
Kuo, John S.
Sun, Dandan
TI TEMOZOLOMIDE ACTIVATES UPSTREAM REGULATORY KINASES OF
NA+-K+-2CL-COTRANSPORTER ISOFORM 1 IN GLIOBLASTOMA CANCER CELLS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Zhu, Wen; Sun, Dandan] Univ Pittsburgh, Pittsburgh, PA USA.
[Wang, Qiwei; Clark, Paul A.; Kuo, John S.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA.
[Yang, Sung-Sen; Lin, Shih-Hua] Triserv Gen Hosp, Natl Def Med Ctr, Taipei, Taiwan.
[Kahle, Kristopher T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kahle, Kristopher T.] Harvard Univ, Sch Med, Boston, MA USA.
RI Kuo, John/D-3561-2013
OI Kuo, John/0000-0001-6809-4806
NR 0
TC 1
Z9 1
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 14
EP 15
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300062
ER
PT J
AU Taylor, TE
Wykosky, J
Schinzel, AC
Hahn, WC
Cavenee, WK
Furnari, FB
AF Taylor, Tiffany E.
Wykosky, Jill
Schinzel, Anna C.
Hahn, William C.
Cavenee, Webster K.
Furnari, Frank B.
TI AN IN VIVO LOSS OF FUNCTION SCREEN FOR GENES INVOLVED IN EPIDERMAL
GROWTH FACTOR RECEPTOR VIII-INDEPENDENT GLIOMA GROWTH
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Taylor, Tiffany E.; Wykosky, Jill; Cavenee, Webster K.; Furnari, Frank B.] Ludwig Inst Canc Res, La Jolla, CA USA.
[Schinzel, Anna C.; Hahn, William C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 18
EP 18
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300078
ER
PT J
AU Merker, VL
Slattery, WH
Muzikansky, A
Barker, FG
Plotkin, SR
AF Merker, Vanessa L.
Slattery, William H.
Muzikansky, Alona
Barker, Fred G., II
Plotkin, Scott R.
TI NATURAL HISTORY OF VESTIBULAR SCHWANNOMA IN NF2 PATIENTS: ANALYSIS USING
PROPOSED REINS CRITERIA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Merker, Vanessa L.; Muzikansky, Alona; Barker, Fred G., II; Plotkin, Scott R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Slattery, William H.] House Ear Res Inst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 23
EP 23
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300098
ER
PT J
AU Mrugala, MM
Wen, PY
Rogers, LR
AF Mrugala, Maciej M.
Wen, Patrick Y.
Rogers, Lisa R.
TI NEUROLOGICALLY-TRAINED NEURO-ONCOLOGISTS-WHERE ARE THEY FROM? A GLOBAL
ASSESSMENT USING AMERICAN ACADEMY OF NEUROLOGY NEURO-ONCOLOGY SECTION
MEMBERSHIP DATA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Mrugala, Maciej M.] Univ Washington, Seattle, WA 98195 USA.
[Mrugala, Maciej M.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Wen, Patrick Y.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wen, Patrick Y.] Harvard Univ, Sch Med, Boston, MA USA.
[Rogers, Lisa R.] Univ Hosp Case Med Ctr, Cleveland, OH USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 23
EP 24
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300100
ER
PT J
AU Tanaka, S
Klofas, LK
Wakimoto, H
Borger, DR
Iafrate, AJ
Batchelor, TT
Chi, AS
AF Tanaka, Shota
Klofas, Lindsay K.
Wakimoto, Hiroaki
Borger, Darrell R.
Iafrate, A. J.
Batchelor, Tracy T.
Chi, Andrew S.
TI ANTI-TUMOR ACTIVITY OF DUAL PI3K/MTOR INHIBITORS PF-04691502 AND
PF-05212384 IN GLIOBLASTOMA STEM-LIKE CELLS WITH DIFFERENTIAL PI3K
PATHWAY ACTIVATION
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Tanaka, Shota; Klofas, Lindsay K.; Wakimoto, Hiroaki; Borger, Darrell R.; Iafrate, A. J.; Batchelor, Tracy T.; Chi, Andrew S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 26
EP 26
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300107
ER
PT J
AU Fotovati, A
Hu, KJ
Wakimoto, H
Triscott, J
Bacha, J
Brown, DM
Dunn, SE
AF Fotovati, Abbas
Hu, Kaiji
Wakimoto, Hiro
Triscott, Joanna
Bacha, Jeffrey
Brown, Dennis M.
Dunn, Sandra E.
TI VAL-083, A NOVEL N7 ALKYLATING AGENT, SURPASSES TEMOZOLOMIDE ACTIVITY
AND INHIBITS CANCER STEM CELLS, PROVIDING A NEW POTENTIAL TREATMENT
OPTION FOR GLIOBLASTOMA MULTIFORME
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Fotovati, Abbas; Hu, Kaiji; Triscott, Joanna; Dunn, Sandra E.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Wakimoto, Hiro] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Bacha, Jeffrey; Brown, Dennis M.] Del Mar Pharmaceut BC Ltd, Vancouver, BC, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 32
EP 32
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300136
ER
PT J
AU Sperduto, PW
Shanley, R
Luo, XH
Kased, N
Sneed, PK
Roberge, D
Chao, S
Weil, R
Suh, J
Bhatt, A
Jensen, A
Brown, PD
Shih, H
Kirkpatrick, J
Gaspar, LE
Fiveash, J
Chiang, V
Knisely, J
Sperduto, CM
Lin, N
Mehta, MP
AF Sperduto, Paul W.
Shanley, Ryan
Luo, Xianghua
Kased, Norbert
Sneed, Penny K.
Roberge, David
Chao, Samuel
Weil, Robert
Suh, John
Bhatt, Amit
Jensen, Ashley
Brown, Paul D.
Shih, Helen
Kirkpatrick, John
Gaspar, Laurie E.
Fiveash, John
Chiang, Veronica
Knisely, Jonathan
Sperduto, Christina Maria
Lin, Nancy
Mehta, Minesh P.
TI EVIDENCE OF INTERACTION BETWEEN HER2 AND ESTROGEN/PROGESTERONE (ER/PR)
RECEPTOR STATUS IN PATIENTS WITH BREAST CANCER AND BRAIN METASTASES
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Shanley, Ryan; Luo, Xianghua] Univ Minnesota, Div Biostat, Minneapolis, MN USA.
[Kased, Norbert; Sneed, Penny K.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Roberge, David] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Weil, Robert] Cleveland Clin, Dept Neurosurg, Cleveland, OH 44106 USA.
[Suh, John] Cleveland Clin, Dept Radiat Oncol, Cleveland, OH 44106 USA.
[Bhatt, Amit] Univ Wisconsin, Madison, WI USA.
[Jensen, Ashley] Mayo Clin, Rochester, MN USA.
[Brown, Paul D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Shih, Helen] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Kirkpatrick, John] Duke Univ, Med Ctr, Durham, NC USA.
[Gaspar, Laurie E.] Univ Colorado, Sch Med, Aurora, CO USA.
[Fiveash, John] Univ Alabama Birmingham, Birmingham, AL USA.
[Chiang, Veronica] Yale Univ, Sch Med, New Haven, CT USA.
[Chiang, Veronica] Yale Univ, Ctr Canc, New Haven, CT USA.
[Knisely, Jonathan] Hofstra Univ, Long Isl City, NY USA.
[Sperduto, Christina Maria] Dartmouth Coll, Hanover, NH 03755 USA.
[Lin, Nancy] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mehta, Minesh P.] Northwestern Univ, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 66
EP 67
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300265
ER
PT J
AU Yin, C
Iwamoto, FM
Fraum, TJ
Nayak, L
AF Yin, Chao
Iwamoto, Fabio M.
Fraum, Tyler J.
Nayak, Lakshmi
TI PATTERNS OF TREATMENT AND SURVIVAL OF GBM PATIENTS WITH DIABETES
MELLITUS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Yin, Chao; Fraum, Tyler J.] NIH, Bethesda, MD 20892 USA.
[Iwamoto, Fabio M.] Columbia Univ, New York, NY USA.
[Nayak, Lakshmi] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 77
EP 77
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300309
ER
PT J
AU Taylor, JW
Flanagan, E
O'Neill, B
Seigal, T
Omuro, A
DeAngelis, L
Baerhing, J
Hoang-Xuan, K
Chamberlain, M
Batchelor, T
Nishikawa, R
Pinto, F
Blay, JY
Korfel, A
Schiff, D
AF Taylor, Jennie W.
Flanagan, Eoin
O'Neill, Brian
Seigal, Tali
Omuro, Antonio
DeAngelis, Lisa
Baerhing, Joachim
Hoang-Xuan, Khe
Chamberlain, Marc
Batchelor, Tracy
Nishikawa, Ryo
Pinto, Fernando
Blay, Jean-Yves
Korfel, Agnieszka
Schiff, David
TI PRESENTATION, DIAGNOSTICS AND TREATMENT OF PRIMARY LEPTOMENINGEAL
LYMPHOMA: AN INTERNATIONAL PRIMARY CNS LYMPHOMA COLLABORATIVE GROUP
SERIES
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Taylor, Jennie W.; Batchelor, Tracy] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Flanagan, Eoin; O'Neill, Brian] Mayo Clin, Rochester, MN USA.
[Seigal, Tali] Haddasah Hebrew Univ Med Ctr, Jerusalem, Israel.
[Omuro, Antonio; DeAngelis, Lisa] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Baerhing, Joachim] Yale Univ, New Haven, CT USA.
[Hoang-Xuan, Khe] La Pitie Salpetriere, Paris, France.
[Chamberlain, Marc] Univ Washington, Seattle, WA 98195 USA.
[Nishikawa, Ryo] Saitama Med Univ, Saitama, Japan.
[Pinto, Fernando] Kings Coll Hosp, London, England.
[Blay, Jean-Yves] Ctr Leon Berard, F-69373 Lyon, France.
[Korfel, Agnieszka] Charite, D-13353 Berlin, Germany.
[Schiff, David] Univ Virginia, Charlottesville, VA USA.
RI Blay, Jean-Yves/N-3966-2016;
OI Blay, Jean-Yves/0000-0001-7190-120X; Omuro, Antonio/0000-0003-4299-3664
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 79
EP 79
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300319
ER
PT J
AU Brastianos, P
Horowitz, P
Santagata, S
Jones, RT
McKenna, A
Getz, G
Ligon, K
Palescandolo, E
Van Hummelen, P
Stemmer-Rachamimov, A
Louis, D
Hahn, WC
Dunn, I
Beroukhim, R
AF Brastianos, Priscilla
Horowitz, Peleg
Santagata, Sandro
Jones, Robert T.
McKenna, Aaron
Getz, Gad
Ligon, Keith
Palescandolo, Emanuele
Van Hummelen, Paul
Stemmer-Rachamimov, Anat
Louis, David
Hahn, William C.
Dunn, Ian
Beroukhim, Rameen
TI GENOMIC CHARACTERIZATION OF MENINGIOMAS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Brastianos, Priscilla; Jones, Robert T.; Palescandolo, Emanuele; Van Hummelen, Paul; Hahn, William C.; Beroukhim, Rameen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Horowitz, Peleg; Santagata, Sandro; Ligon, Keith; Dunn, Ian] Brigham & Womens Hosp, Boston, MA 02115 USA.
[McKenna, Aaron; Getz, Gad] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Stemmer-Rachamimov, Anat; Louis, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 92
EP 92
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300367
ER
PT J
AU Narayanan, R
Ho, QH
Levin, BS
Maeder, ML
Joung, JK
Nutt, CL
Louis, DN
AF Narayanan, Radhakrishnan
Ho, Quan H.
Levin, Benjamin S.
Maeder, Morgan L.
Joung, J. K.
Nutt, Catherine L.
Louis, David N.
TI PATHWAY DISCOVERY IN GLIOBLASTOMA THERAPEUTIC RESISTANCE INDUCED BY
COMBINATORIAL TRANSCRIPTION FACTORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Narayanan, Radhakrishnan; Ho, Quan H.; Levin, Benjamin S.; Maeder, Morgan L.; Joung, J. K.; Nutt, Catherine L.; Louis, David N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Nutt, Catherine/K-8794-2012
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 94
EP 94
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300377
ER
PT J
AU Cahill, DP
Beiko, J
Suki, D
Prabhu, S
Weinberg, J
Lang, F
Sawaya, R
Rao, G
McCutcheon, I
Barker, FG
Aldape, KD
AF Cahill, Daniel P.
Beiko, Jason
Suki, Dima
Prabhu, Sujit
Weinberg, Jeff
Lang, Frederick
Sawaya, Ray
Rao, Ganesh
McCutcheon, Ian
Barker, Fred G.
Aldape, Kenneth D.
TI MULTIVARIATE PREDICTION OF IDH1 MUTATION STATUS IN MALIGNANT
ASTROCYTOMAS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Cahill, Daniel P.; Barker, Fred G.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Beiko, Jason] Univ Manitoba, Winnipeg, MB, Canada.
[Suki, Dima; Prabhu, Sujit; Weinberg, Jeff; Lang, Frederick; Sawaya, Ray; Rao, Ganesh; McCutcheon, Ian; Aldape, Kenneth D.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 99
EP 99
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300396
ER
PT J
AU Mainwaring, L
Horowitz, P
Craig, J
Garcia, D
Bergthold, G
Burns, M
Rich, B
Ramkissoon, S
Santagata, S
Eberhart, C
Ligon, A
Goumnerova, L
Stiles, C
Kieran, M
Hahn, W
Beroukhim, R
Ligon, K
AF Mainwaring, Lori
Horowitz, Peleg
Craig, Justin
Garcia, Denise
Bergthold, Guillaume
Burns, Margot
Rich, Benjamin
Ramkissoon, Shakti
Santagata, Sandro
Eberhart, Charles
Ligon, Azra
Goumnerova, Liliana
Stiles, Charles
Kieran, Mark
Hahn, William
Beroukhim, Rameen
Ligon, Keith
TI GENOMIC ANALYSIS OF PEDIATRIC LOW GRADE GLIOMAS IDENTIFIES MYB FAMILY
TRANSCRIPTION FACTORS AS CANDIDATE GLIOMA ONCOGENES
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Ligon, Keith] Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Eberhart, Charles] Johns Hopkins Univ Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 100
EP 100
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300400
ER
PT J
AU Ramkissoon, S
Olausson, KH
Correia, J
Gafni, E
Liu, HY
Theisen, M
Craig, J
Hayashi, M
Haidar, S
Maire, C
Mainwaring, LA
Burns, M
Norden, A
Wen, P
Stiles, C
Ligon, A
Kung, A
Alexander, B
Tonellato, P
Ligon, KL
AF Ramkissoon, Shakti
Olausson, Karl H.
Correia, Jessica
Gafni, Erik
Liu, Hongye
Theisen, Matthew
Craig, Justin
Hayashi, Marika
Haidar, Sam
Maire, Cecile
Mainwaring, Lori A.
Burns, Margot
Norden, Andrew
Wen, Patrick
Stiles, Charles
Ligon, Azra
Kung, Andrew
Alexander, Brian
Tonellato, Peter
Ligon, Keith L.
TI TRANSCRIPTIONAL SUBCLASSES FROM PRIMARY HUMAN GLIOBLASTOMA MULTIFORME
CELL LINES DEMONSTRATE PROGNOSTIC VALUE
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Ramkissoon, Shakti; Ligon, Keith L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Correia, Jessica; Gafni, Erik; Tonellato, Peter] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 100
EP 100
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300401
ER
PT J
AU Sloan, AE
Nock, CJ
Kerstetter, A
Supko, J
Ye, XB
Barnholtz-Sloan, JS
Miller, R
Rich, J
Takebe, N
Prados, M
Grossman, S
AF Sloan, Andrew E.
Nock, Charles J.
Kerstetter, Amber
Supko, Jeff
Ye, Xiaobu
Barnholtz-Sloan, Jill S.
Miller, Robert
Rich, Jeremy
Takebe, Naoko
Prados, Michael
Grossman, Stuart
TI TARGETING GLIOMA STEM CELLS (GSC): A BIOMARKER AND PHASE II STUDY OF
GDC-0449 IN PATIENTS WITH RECURRENT GLIOBLASTOMA MULTIFORME (GBM)
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Sloan, Andrew E.; Nock, Charles J.; Kerstetter, Amber; Barnholtz-Sloan, Jill S.; Miller, Robert] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Sloan, Andrew E.; Nock, Charles J.; Barnholtz-Sloan, Jill S.; Rich, Jeremy] Case Comprehens Canc Ctr, Cleveland, OH USA.
[Supko, Jeff] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ye, Xiaobu; Grossman, Stuart] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Rich, Jeremy] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
[Takebe, Naoko] NCI, Canc Therapy Evaluat Program, Rockville, MD USA.
[Prados, Michael] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 105
EP 105
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300418
ER
PT J
AU Lu-Emerson, C
Snuderl, M
Davidson, C
Kirkpatrick, ND
Huang, YH
Duda, DG
Ancukiewicz, M
Stemmer-Rachamimov, A
Batchelor, TT
Jain, RK
AF Lu-Emerson, Christine
Snuderl, Matija
Davidson, Christian
Kirkpatrick, Nathaniel D.
Huang, Yuhui
Duda, Dan G.
Ancukiewicz, Marek
Stemmer-Rachamimov, Anat
Batchelor, Tracy T.
Jain, Rakesh K.
TI ANTI-ANGIOGENIC THERAPY INCREASES TUMOR ASSOCIATED MACROPHAGES (TAMS) IN
RECURRENT GLIOBLASTOMA (GBM) PATIENTS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Lu-Emerson, Christine; Snuderl, Matija; Davidson, Christian; Kirkpatrick, Nathaniel D.; Huang, Yuhui; Duda, Dan G.; Ancukiewicz, Marek; Stemmer-Rachamimov, Anat; Batchelor, Tracy T.; Jain, Rakesh K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 110
EP 110
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300439
ER
PT J
AU Slavc, I
Peyrl, A
Chocholous, M
Kieran, M
Azizi, A
Czech, T
Dieckmann, K
Haberler, C
AF Slavc, Irene
Peyrl, Andreas
Chocholous, Monika
Kieran, Mark
Azizi, Amedeo
Czech, Thomas
Dieckmann, Karin
Haberler, Christine
TI METRONOMIC AND TARGETED ANTI-ANGIOGENESIS THERAPY FOR CHILDREN WITH
RECURRENT MEDULLOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Slavc, Irene; Peyrl, Andreas; Chocholous, Monika; Azizi, Amedeo; Czech, Thomas; Dieckmann, Karin; Haberler, Christine] Med Univ Vienna, Vienna, Austria.
[Kieran, Mark] Dana Faber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 114
EP 114
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300449
ER
PT J
AU Huang, R
Chen, C
Mukundan, S
Wen, P
Norden, A
AF Huang, Raymond
Chen, Christina
Mukundan, Srinivasan
Wen, Patrick
Norden, Andrew
TI RECURRENT HIGH-GRADE GLIOMA TREATED WITH BEVACIZUMAB: PREDICTIVE VALUE
OF PRETREATMENT MINIMUM APPARENT DIFFUSION COEFFICIENT IN DETERMINING
RESPONSE
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Huang, Raymond; Mukundan, Srinivasan] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chen, Christina] Harvard Univ, Sch Med, Boston, MA USA.
[Wen, Patrick; Norden, Andrew] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 127
EP 127
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300502
ER
PT J
AU Floyd, SR
Pacold, ME
Clarke, SM
Blake, E
Fydrych, A
Ho, R
Lee, MJ
Root, DE
Carpenter, AE
Sabatini, DM
French, CA
Bradner, JE
Chen, CC
Yaffe, MB
AF Floyd, Scott R.
Pacold, Michael E.
Clarke, Scott M.
Blake, Emily
Fydrych, Anna
Ho, Richard
Lee, Michael J.
Root, David E.
Carpenter, Anne E.
Sabatini, David M.
French, Christopher A.
Bradner, James E.
Chen, Clark C.
Yaffe, Michael B.
TI BROMODOMAIN PROTEIN BRD4 INSULATES CHROMATIN FROM DNA DAMAGE SIGNALING
AND IS ASSOCIATED WITH GLIOBLASTOMA RESISTANCE TO IRRADIATION
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Floyd, Scott R.; Clarke, Scott M.; Blake, Emily; Fydrych, Anna; Ho, Richard; Lee, Michael J.; Yaffe, Michael B.] Koch Inst Integrat Canc Res, Boston, MA USA.
[Pacold, Michael E.] Broad Inst Harvard & MIT, Boston, MA USA.
[Root, David E.; Carpenter, Anne E.; Sabatini, David M.] MIT, Boston, MA USA.
[French, Christopher A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Chen, Clark C.] Univ Calif San Diego, La Jolla, CA 92093 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 129
EP 129
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300509
ER
PT J
AU Kozono, D
Nitta, M
Sampetrean, O
Kimberly, N
Kushwaha, D
Merzon, D
Ligon, K
Zhu, S
Zhu, KY
Kim, TH
Kwon, CH
Becher, O
Saya, H
Chen, CC
AF Kozono, David
Nitta, Masayuki
Sampetrean, Oltea
Kimberly, Ng
Kushwaha, Deepa
Merzon, Dmitry
Ligon, Keith
Zhu, Shan
Zhu, Kaya
Kim, Tae Hyong
Kwon, Chang-Hyuk
Becher, Oren
Saya, Hideyuki
Chen, Clark C.
TI SC-47. MRI TRACKING OF FERUMOXYTOL-LABELED HUMAN STEM CELLS IN VIVO:
STUDIES LEADING TO CLINICAL USE
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Kozono, David; Nitta, Masayuki; Kimberly, Ng; Kushwaha, Deepa; Merzon, Dmitry; Ligon, Keith; Zhu, Shan; Zhu, Kaya] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sampetrean, Oltea; Saya, Hideyuki] Keio Univ, Tokyo, Japan.
[Kim, Tae Hyong; Kwon, Chang-Hyuk] Ohio State Univ, Columbus, OH 43210 USA.
[Becher, Oren] Duke Univ, Durham, NC USA.
[Chen, Clark C.] Univ Calif San Diego, San Diego, CA 92103 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 142
EP 142
DI 10.1093/neuonc/nos239
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300559
ER
PT J
AU Moon, E
Kanai, R
Yip, S
Kimura, A
Tanaka, S
Rheinbay, E
Cahill, D
Curry, W
Mohapatra, G
Iafrate, J
Chi, A
Martuza, R
Rabkin, S
Wakimoto, H
AF Moon, Esther
Kanai, Ryuichi
Yip, Stephen
Kimura, Anya
Tanaka, Shota
Rheinbay, Esther
Cahill, Daniel
Curry, William, Jr.
Mohapatra, Gayatry
Iafrate, John
Chi, Andrew
Martuza, Robert
Rabkin, Samuel
Wakimoto, Hiroaki
TI COMPARATIVE CHARACTERIZATION OF BRAIN TUMOR STEM CELLS ISOLATED FROM
NEWLY DIAGNOSED AND RECURRENT GLIOBLASTOMA
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Moon, Esther; Kanai, Ryuichi; Kimura, Anya; Tanaka, Shota; Rheinbay, Esther; Cahill, Daniel; Curry, William, Jr.; Mohapatra, Gayatry; Iafrate, John; Chi, Andrew; Martuza, Robert; Rabkin, Samuel; Wakimoto, Hiroaki] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Yip, Stephen] BC Canc Agcy, Vancouver, BC, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 151
EP 151
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300602
ER
PT J
AU Hingtgen, S
Figueiredo, JL
Farrar, C
Farrar, C
Deubgen, M
Martinez-Quintanilla, J
Bhere, D
Shah, K
AF Hingtgen, Shawn
Figueiredo, Jose-Luis
Farrar, Christian
Farrar, Christian
Deubgen, Matthias
Martinez-Quintanilla, Jordi
Bhere, Deepak
Shah, Khalid
TI REAL-TIME ASSESSMENT OF GLIOBLASTOMA SURGICAL RESECTION AND RECURRENCE
USING MULTIMODALITY IMAGING
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 17th Annual Scientific Meeting and Education Day of the
Society-for-Neuro-Oncology (SNO)
CY NOV 15-18, 2012
CL Washington, DC
SP Soc Neuro Oncol (SNO)
C1 [Hingtgen, Shawn; Figueiredo, Jose-Luis; Farrar, Christian; Farrar, Christian; Deubgen, Matthias; Martinez-Quintanilla, Jordi; Bhere, Deepak; Shah, Khalid] Harvard Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD OCT
PY 2012
VL 14
SU 6
BP 160
EP 160
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA 035TH
UT WOS:000310971300633
ER
PT J
AU Lin, HZ
Zhou, XH
Li, G
AF Lin, Huazhen
Zhou, Xiao-Hua
Li, Gang
TI A DIRECT SEMIPARAMETRIC RECEIVER OPERATING CHARACTERISTIC CURVE
REGRESSION WITH UNKNOWN LINK AND BASELINE FUNCTIONS
SO STATISTICA SINICA
LA English
DT Article
DE Diagnostic tests; kernel smoothing; nonparametric; ROC regression;
transformation models
ID OPTIMUM KERNEL ESTIMATORS; ROC CURVES; TRANSFORMATION MODELS;
LIKELIHOOD-ESTIMATION; PLACEMENT VALUES
AB In this article, we study a direct receiver operating characteristic (ROC) curve regression model with completely unknown link and baseline functions. A semiparametric procedure is proposed to estimate both the parametric and nonparametric components of the model. The resulting parameter estimates and ROC curve estimates are shown to be consistent, and asymptotically normal with a n(-1/2) convergence rate. With arbitrary link and baseline functions, our model is more robust than existing direct ROC regression models that require either complete or partially complete specification of the link and baseline functions. Moreover, the robustness of our new method is gained at little cost to efficiency, as evidenced by the parametric convergence rate of our estimators and by the simulation study. An illustrative example is given using a hearing test data set.
C1 [Lin, Huazhen] SW Univ Finance & Econ, Sch Stat, Chengdu 611130, Peoples R China.
[Zhou, Xiao-Hua] VA Puget Sound Hlth Care Syst, HSR&D Ctr Excellence, Seattle, WA 98108 USA.
[Zhou, Xiao-Hua] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[Zhou, Xiao-Hua] Peking Univ, Beijing Int Ctr Math Res, Beijing 100871, Peoples R China.
[Li, Gang] Univ Calif Los Angeles, Dept Biostat, Los Angeles, CA 90095 USA.
RP Lin, HZ (reprint author), SW Univ Finance & Econ, Sch Stat, Chengdu 611130, Peoples R China.
EM huazhenlin@hotmail.com; azhou@u.washington.edu; vli@ucla.edu
FU National Natural Science Funds for Distinguished Young Scholar
[11125104]; National Natural Science Foundation of China [11071197];
Program for New Century Excellent Talents in University
FX Lin's research was supported by the National Natural Science Funds for
Distinguished Young Scholar (No. 11125104), the National Natural Science
Foundation of China (No. 11071197) and Program for New Century Excellent
Talents in University.
NR 24
TC 1
Z9 1
U1 2
U2 5
PU STATISTICA SINICA
PI TAIPEI
PA C/O DR H C HO, INST STATISTICAL SCIENCE, ACADEMIA SINICA, TAIPEI 115,
TAIWAN
SN 1017-0405
EI 1996-8507
J9 STAT SINICA
JI Stat. Sin.
PD OCT
PY 2012
VL 22
IS 4
BP 1427
EP 1456
DI 10.5705/ss.2010.167
PG 30
WC Statistics & Probability
SC Mathematics
GA 047BN
UT WOS:000311812800011
ER
PT J
AU Braxton, CC
AF Braxton, Carla C.
TI Defining, Measuring, and Improving Surgical Quality: Beyond Teamwork and
Checklists to Systems Redesign and Transformation
SO SURGICAL INFECTIONS
LA English
DT Article
ID HEALTH-CARE; POSTOPERATIVE COMPLICATIONS; PROGRAM; HOSPITALS; SURGEONS;
NSQIP
AB Background: Surgical complications are multifactorial but often are attributable to deficiencies in the quality of care. This review examines how quality is defined in surgery, the modalities employed to measure quality, and the approaches to improving the quality of surgical care. Beyond developing a hospital environment supportive of organizational learning, the next generation of surgical performance improvement will include broader, more innovative approaches. These ideas will create partnerships among patients, clinicians, industry, the arts, hospital leaders, and other sectors to look for ways to reinvent the system rather than simply to make a better hospital.
Methods: Review of pertinent English-language literature on surgical quality, definitions of quality, quality measures, performance improvement, and organizational learning in health care.
Results: Medical care should be safe, effective, patient-centered, timely, efficient, and equitable, as defined by the Institute of Medicine core values for health care quality. There is substantive lack of agreement as to how to measure the quality of care. Although the goal of each measurement system is to give patients the ability to compare hospitals nationally, most of the methodologies measure widely different aspects of hospital care, resulting in conflicting illustrations of institutional performance and confounded decision making for patients and for purchasers of healthcare services and insurance.
Conclusions: The best pathway for surgical quality and performance improvement includes the application of systems engineering and innovation to determine ways to do better what we do currently, and to improve the present system while developing ideas for better delivery of high-quality care in the future.
C1 Baylor Coll Med, Dept Surg, DeBakey VA Med Ctr, Houston, TX 77030 USA.
RP Braxton, CC (reprint author), Baylor Coll Med, Dept Surg, DeBakey VA Med Ctr, 2002 Holcombe OCL 112, Houston, TX 77030 USA.
EM carla.braxton@bcm.edu
NR 22
TC 0
Z9 0
U1 1
U2 12
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-2964
J9 SURG INFECT
JI Surg. Infect.
PD OCT
PY 2012
VL 13
IS 5
BP 312
EP 316
DI 10.1089/sur.2012.182
PG 5
WC Infectious Diseases; Surgery
SC Infectious Diseases; Surgery
GA 047HR
UT WOS:000311830700006
PM 23116188
ER
PT J
AU Faber, M
Vanneste, S
Fregni, F
De Ridder, D
AF Faber, Margriet
Vanneste, Sven
Fregni, Felipe
De Ridder, Dirk
TI Top down prefrontal affective modulation of tinnitus with multiple
sessions of tDCS of dorsolateral prefrontal cortex
SO BRAIN STIMULATION
LA English
DT Article
DE tDCS; depression; anxiety; tinnitus; lateralization; frontal
ID DIRECT-CURRENT STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION;
PSYCHOLOGICAL DISTRESS; MOTOR CORTEX; MAJOR DEPRESSION; HOSPITAL
ANXIETY; HUMANS; BRAIN; PAIN; PERCEPTION
AB Most forms of tinnitus are attributable to reorganization and hyperactivity in the auditory central nervous system with coactivation of nonauditory brain structures. One such nonauditory brain area is the dorsolateral prefrontal cortex (DLPFC), which is important for the integration of sensory and emotional aspects of tinnitus. Based on extensive evidence that transcranial direct current stimulation can induce significant effects on DLPFC-related cognitive function, we aimed to investigate whether left or right anodal DLFPC tDCS is associated with modulation of tinnitus. We conducted a double-blind, placebo-controlled cross-over study in which 15 subjects with tinnitus were randomly assigned to receive active and sham anodal tDCS over left (n = 8) or right DLPFC (n = 7) for six sessions in a counterbalanced order; the cathode electrode was placed in the contralateral DLPFC. The results demonstrate that both active conditions-irrespective of the anodal position-can decrease tinnitus annoyance but it is not associated with improvements in tinnitus intensity when comparing pre-tDCS versus post-tDCS as well as comparing sham-tDCS versus real tDCS. Also, we show that the anode electrode placed over the left DLPFC modulates depression when comparing pre-tDCS versus post-tDCS as well as comparing sham-tDCS versus real tDCS. In addition, we also show that the anode electrode placed over the right DLPFC modulates anxiety when comparing pre-tDCS versus post-tDCS. This latter effect does not remain when we compare sham-tDCS versus real tDCS. This study further supports the involvement of the prefrontal cortex in the neural network associated with tinnitus, and also provides initial evidence for a potential brain stimulation site for tinnitus treatment in association with other treatments that can reduce tinnitus intensity. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Faber, Margriet; Vanneste, Sven; De Ridder, Dirk] Univ Antwerp Hosp, Dept Neurosurg, Antwerp, Belgium.
[Faber, Margriet; Vanneste, Sven; De Ridder, Dirk] Univ Antwerp Hosp, Tinnitus Res Initiat Clin Antwerp, Antwerp, Belgium.
[Fregni, Felipe] Spaulding Rehabil Hosp, Lab Neuromodulat, Boston, MA USA.
[Fregni, Felipe] Spaulding Rehabil Hosp, Ctr Clin Res Learning, Dept Phys Med & Rehabil, Boston, MA USA.
[Fregni, Felipe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Vanneste, S (reprint author), Univ Antwerp Hosp, BRAI2N, TRI Tinnitus Clin, Wilrijkstr 10, B-2650 Edegem, Belgium.
EM sven.vanneste@ua.ac.be
NR 54
TC 25
Z9 25
U1 1
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1935-861X
J9 BRAIN STIMUL
JI Brain Stimul.
PD OCT
PY 2012
VL 5
IS 4
BP 492
EP 498
DI 10.1016/j.brs.2011.09.003
PG 7
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 043GZ
UT WOS:000311532200007
PM 22019079
ER
PT J
AU Sinner, MF
Greiner, MA
Mi, X
Hernandez, AF
Jensen, PN
Piccini, JP
Setoguchi, S
Walkey, AJ
Heckbert, SR
Benjamin, EJ
Curtis, LH
AF Sinner, Moritz F.
Greiner, Melissa A.
Mi, Xiaojuan
Hernandez, Adrian F.
Jensen, Paul N.
Piccini, Jonathan P.
Setoguchi, Soko
Walkey, Allan J.
Heckbert, Susan R.
Benjamin, Emelia J.
Curtis, Lesley H.
TI Completion of Guideline-Recommended Initial Evaluation of Atrial
Fibrillation
SO CLINICAL CARDIOLOGY
LA English
DT Article
ID CLINICAL-PRACTICE GUIDELINES; QUALITY-OF-CARE; RISK-FACTORS; RACIAL
VARIATION; THYROID-FUNCTION; PROSTATE-CANCER; POPULATION; MEDICARE;
ICD-9-CM; FAILURE
AB Background: Guidelines recommend evaluation of cardiac function, valvular and ischemic heart disease, and thyroid, kidney, and liver function on initial diagnosis of atrial fibrillation (AF). Hypothesis: We hypothesized that initial workup of patients with newly identified AF would vary by age, sex, and burden of comorbid illness. Methods: In a retrospective analysis of a large sample of commercially insured patients 18 to 64 years old (n = 40 245) and a nationally representative 5% cohort of Medicare beneficiaries 65 years or older (n = 204 676), we measured claims for guideline-recommended services for initial evaluation of AF among patients with a new diagnosis between 2000 and 2008. Results: From 30 days before through 90 days after AF diagnosis, basic evaluation, including physician visit, electrocardiogram, and echocardiography, was completed in up to 66.6% of patients. Completion rates for all guideline-recommended evaluations were 17.4% in the commercially insured sample and 18.5% in the Medicare cohort in 2007. Evaluation rates increased over time. Blood tests assessing thyroid function were documented for approximately one-third of patients in each cohort. Increasing the observation period to 1 year before through 3 months after the AF diagnosis markedly increased completion rates, but rates of thyroid function testing remained low (50%60%). There were minor differences in evaluation completeness by sex, race, and geographic region. Conclusions: Differences in guideline-recommended evaluation rates by demographic characteristics after a new diagnosis of AF were of minor clinical importance. Basic evaluation had satisfactory completion rates; however, rates of laboratory testing were low. The contents of the manuscript are solely the responsibility of the authors and do not necessarily reflect the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health. Damon M. Seils, MA, Duke University, provided editorial assistance and prepared the manuscript. Mr. Seils did not receive compensation for his assistance apart from his employment at the institution where the study was conducted. This work was supported by grants R01HL102214, RC1HL101056, R01HL068986, R01HL092577, and T32HL007- 902 from the National Heart, Lung, and Blood Institute. Dr. Sinner was supported by the German Heart Foundation. The authors have no other funding, financial relationships, or conflicts of interest to disclose. Supporting Information may be found in the online version of this article.
C1 [Greiner, Melissa A.; Mi, Xiaojuan; Hernandez, Adrian F.; Piccini, Jonathan P.; Setoguchi, Soko; Curtis, Lesley H.] Duke Univ, Sch Med, Duke Clin Res Inst, Durham, NC 27706 USA.
[Sinner, Moritz F.] Univ Munich, Univ Hosp Grosshadern, Dept Med, Munich, Germany.
[Hernandez, Adrian F.; Piccini, Jonathan P.; Setoguchi, Soko; Curtis, Lesley H.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA.
[Jensen, Paul N.; Heckbert, Susan R.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA.
[Jensen, Paul N.; Heckbert, Susan R.] Univ Washington, Sch Med, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Walkey, Allan J.] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Dept Med, Cardiol & Prevent Med Sect, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Sinner, Moritz F.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
RP Curtis, LH (reprint author), Duke Univ, Sch Med, Duke Clin Res Inst, POB 17969, Durham, NC 27706 USA.
EM lesley.curtis@duke.edu
RI Hernandez, Adrian F./A-7818-2016;
OI Hernandez, Adrian F./0000-0003-3387-9616; Walkey,
Allan/0000-0003-4685-6894; Benjamin, Emelia/0000-0003-4076-2336
FU National Heart, Lung, and Blood Institute [R01HL102214, RC1HL101056,
R01HL068986, R01HL092577, T32HL007-902]; German Heart Foundation
FX This work was supported by grants R01HL102214, RC1HL101056, R01HL068986,
R01HL092577, and T32HL007-902 from the National Heart, Lung, and Blood
Institute. Dr. Sinner was supported by the German Heart Foundation.
NR 39
TC 2
Z9 2
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD OCT
PY 2012
VL 35
IS 10
BP 585
EP 593
DI 10.1002/clc.22055
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 015ML
UT WOS:000309450200001
PM 22976579
ER
PT J
AU Medina, HM
Cannon, CP
Fonarow, GC
Grau-Sepulveda, MV
Hernandez, AF
Peacock, WF
Laskey, W
Peterson, ED
Schwamm, L
Bhatt, DL
AF Medina, Hector M.
Cannon, Christopher P.
Fonarow, Gregg C.
Grau-Sepulveda, Maria V.
Hernandez, Adrian F.
Peacock, W. Frank
Laskey, Warren
Peterson, Eric D.
Schwamm, Lee
Bhatt, Deepak L.
CA GWTG Steering Comm Investigators
TI Reperfusion Strategies and Quality of Care in 5339 Patients Age 80 Years
or Older Presenting With ST-Elevation Myocardial Infarction: Analysis
from Get With The Guidelines-Coronary Artery Disease
SO CLINICAL CARDIOLOGY
LA English
DT Article
ID THROMBOLYTIC THERAPY; ELDERLY-PATIENTS; PRIMARY ANGIOPLASTY;
RANDOMIZED-TRIALS; POOLED ANALYSIS; INTERVENTION; MANAGEMENT;
FIBRINOLYSIS; CARDIOLOGY; OUTCOMES
AB Background: Data regarding reperfusion strategies, adherence to national guidelines, and in-hospital mortality in ST-elevation myocardial infarction (STEMI) patients age =80 years are limited. The aim of this study was to determine current reperfusion trends, medical treatment, and in-hospital mortality during STEMI in older adults. Hypothesis: Among patients aged 80 or above presenting with STEMI, adherence to guidelines, length of stay, and in-hospital mortality would be better in those receiving reperfusion versus those who did not. Methods: Using the Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) database, we examined care and in-hospital outcomes of STEMI patients =80 years old. Use of evidence-based therapies and quality measures were analyzed by reperfusion strategies. Results: A total of 5339 patients age =80 years hospitalized with STEMI were included. Of these, 42.8% (n = 2285) underwent primary percutaneous coronary intervention (PPCI), 4.8% (n = 255) underwent thrombolysis (TL), and 52.4% (n = 2799) received no reperfusion (NR). Patients with NR were more likely to be older, female, have lower body mass index, and higher prevalence of renal insufficiency and heart failure compared with PPCI or TL patients. During the last decade, there was a significant increase in the use of PPCI compared with TL as the main reperfusion strategy in this population. Adjusted in-hospital mortality in PPCI patients was lower compared with NR patients (odds ratio [OR]: 0.41, 95% confidence interval [CI]: 0.35-0.49); also, patients undergoing PPCI or TL had lower mortality compared with NR patients (OR: 0.47, 95% CI: 0.40-0.55). Conclusions: Among patients =80 years old admitted with STEMI to GWTG-CAD hospitals, less than half undergo mechanical or pharmacological reperfusion. However, the proportion of patients undergoing PPCI has increased substantially over the 8-year study period. Patients undergoing PPCI or TL had lower in-hospital mortality compared with the NR strategy. Clin. Cardiol. 2012 doi: 10.1002/clc.22036 Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) is a program of the American Heart Association and is supported in part by an unrestricted educational grant from Merck/Schering-Plough Pharmaceutical and Pfizer. The analysis of registry data was performed at Duke Clinical Research Institute (Durham, NC), which receives funding from the American Heart Association. The sponsors were not involved in the design, analysis, preparation, review, or approval of this manuscript. C.P.C.: research grants, Accumetrics, AstraZeneca, GlaxoSmithKline, Merck, Takeda; advisory board, Intekrin Therapeutics; honoraria, Bristol-Myers Squibb/Sanofi, Novartis, Alnylam; clinical advisor, Pfizer and AstraZeneca; equity, Automedics Medical Systems. A.F.H.: research grants, Johnson & Johnson/Scios, GSK, Medtronic, Novartis; honoraria, Medtronic, Novartis, AstraZeneca. G.C.F.: research grant, NIH; consultant, Novartis. F.P.: research grants, Abbott, Alere, BAS, Brahms, EKR, Nanosphere, The Medicine's Company; consultant, Abbott, Alere, Beckman Coulter, Electrocore, The Medicine's Company; speaker's bureau, Abbott, Alere; ownership interest, Comprehensive Research Associates LLC, Vital Sensors, Emergencies in Medicine LLC. L.S.: chairman, Get With The Guidelines Steering Committee. E.D.P.: research grants, BMS/Sanofi Research, Eli Lilly Research, Merck Research, Johnson & Johnson. D.L.B.
: advisory board, Medscape Cardiology; board of directors, Boston VA Research Institute, Society of Chest Pain Centers; chair, American Heart Association Get With The Guidelines Science Subcommittee; honoraria, American College of Cardiology (Editor, Clinical Trials, Cardiosource), Duke Clinical Research Institute (clinical trial steering committees), Slack Publications (Chief Medical Editor, Cardiology Today Intervention), WebMD (CME steering committees); research grants, Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; unfunded research, FlowCo, PLx Pharma, Takeda. The authors have no other funding, financial relationships, or conflicts of interest to disclose.
C1 [Medina, Hector M.] Albert Einstein Coll Med, Dept Med, Montefiore Med Ctr, Div Cardiol, Bronx, NY 10467 USA.
[Cannon, Christopher P.] TIMI Study Grp, Boston, MA USA.
[Cannon, Christopher P.; Bhatt, Deepak L.] Harvard Univ, Sch Med, Boston, MA USA.
[Grau-Sepulveda, Maria V.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Clin Res Inst, Durham, NC USA.
[Grau-Sepulveda, Maria V.; Hernandez, Adrian F.; Peterson, Eric D.] Duke Univ, Med Ctr, Durham, NC USA.
[Fonarow, Gregg C.] Ronald Reagan Univ Calif Los Angeles, Med Ctr, Los Angeles, CA USA.
[Peacock, W. Frank] Baylor Coll Med, Houston, TX 77030 USA.
[Laskey, Warren] Univ New Mexico, Albuquerque, NM 87131 USA.
[Schwamm, Lee] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Bhatt, Deepak L.] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RP Bhatt, DL (reprint author), 1400 VFW Pkwy, Boston, MA 02132 USA.
EM dlbhattmd@post.harvard.edu
RI Hernandez, Adrian F./A-7818-2016
OI Schwamm, Lee/0000-0003-0592-9145; Hernandez, Adrian
F./0000-0003-3387-9616
FU Merck/Schering-Plough Pharmaceutical; Pfizer; American Heart
Association; Accumetrics; AstraZeneca; GlaxoSmithKline; Merck; Takeda;
Johnson Johnson/Scios; GSK; Medtronic; Novartis; NIH; Abbott; Alere;
BAS; Brahms; EKR; Nanosphere; Medicine's Company; BMS/Sanofi Research;
Eli Lilly Research; Merck Research; Johnson Johnson; Amarin;
Bristol-Myers Squibb; Eisai; Ethicon; Sanofi Aventis; Medicines Company;
Guidelines-Coronary Artery Disease (GWTG-CAD)
FX Get With The Guidelines-Coronary Artery Disease (GWTG-CAD) is a program
of the American Heart Association and is supported in part by an
unrestricted educational grant from Merck/Schering-Plough Pharmaceutical
and Pfizer. The analysis of registry data was performed at Duke Clinical
Research Institute (Durham, NC), which receives funding from the
American Heart Association. The sponsors were not involved in the
design, analysis, preparation, review, or approval of this manuscript.;
C.P.C.: research grants, Accumetrics, AstraZeneca, GlaxoSmithKline,
Merck, Takeda; advisory board, Intekrin Therapeutics; honoraria,
Bristol-Myers Squibb/Sanofi, Novartis, Alnylam; clinical advisor, Pfizer
and AstraZeneca; equity, Automedics Medical Systems. A. F. H.: research
grants, Johnson & Johnson/Scios, GSK, Medtronic, Novartis; honoraria,
Medtronic, Novartis, AstraZeneca. G. C. F.: research grant, NIH;
consultant, Novartis. F. P.: research grants, Abbott, Alere, BAS,
Brahms, EKR, Nanosphere, The Medicine's Company; consultant, Abbott,
Alere, Beckman Coulter, Electrocore, The Medicine's Company; speaker's
bureau, Abbott, Alere; ownership interest, Comprehensive Research
Associates LLC, Vital Sensors, Emergencies in Medicine LLC. L. S.:
chairman, Get With The Guidelines Steering Committee. E. D. P.: research
grants, BMS/Sanofi Research, Eli Lilly Research, Merck Research, Johnson
& Johnson. D. L. B.: advisory board, Medscape Cardiology; board of
directors, Boston VA Research Institute, Society of Chest Pain Centers;
chair, American Heart Association Get With The Guidelines Science
Subcommittee; honoraria, American College of Cardiology (Editor,
Clinical Trials, Cardiosource), Duke Clinical Research Institute
(clinical trial steering committees), Slack Publications (Chief Medical
Editor, Cardiology Today Intervention), WebMD (CME steering committees);
research grants, Amarin, AstraZeneca, Bristol-Myers Squibb, Eisai,
Ethicon, Medtronic, Sanofi Aventis, The Medicines Company; unfunded
research, FlowCo, PLx Pharma, Takeda. The authors have no other funding,
financial relationships, or conflicts of interest to disclose.
NR 29
TC 14
Z9 14
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD OCT
PY 2012
VL 35
IS 10
BP 632
EP 640
DI 10.1002/clc.22036
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 015ML
UT WOS:000309450200007
PM 22744844
ER
PT J
AU Onder, TT
Daley, GQ
AF Onder, Tamer T.
Daley, George Q.
TI New lessons learned from disease modeling with induced pluripotent stem
cells
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Article
ID ZINC-FINGER NUCLEASES; HUMAN IPS CELLS; FAMILIAL ALZHEIMERS-DISEASE;
HUMAN SOMATIC-CELLS; DYSKERATOSIS-CONGENITA; GENETIC CORRECTION; DEFINED
FACTORS; MOTOR-NEURONS; REGENERATIVE MEDICINE; PATIENT
AB Cellular reprogramming and generation of induced pluripotent stem cells (iPSCs) from adult cell types have enabled the creation of patient-specific stem cells for use in disease modeling. To date, many iPSC lines have been generated from a variety of disorders, which have then been differentiated into disease-relevant cell types. When a disease-specific phenotype is detectable in such differentiated cells, the reprogramming technology provides a new opportunity to identify aberrant disease-associated pathways and drugs that can block them. Here, we highlight recent progress as well as limitations in the use of iPSCs to recapitulate disease phenotypes and to screen for therapeutics in vitro.
C1 [Onder, Tamer T.; Daley, George Q.] Childrens Hosp, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA 02115 USA.
[Onder, Tamer T.; Daley, George Q.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Onder, Tamer T.; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA.
[Onder, Tamer T.; Daley, George Q.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Onder, Tamer T.; Daley, George Q.] Harvard Stem Cell Inst, Cambridge, MA USA.
RP Daley, GQ (reprint author), Childrens Hosp, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA 02115 USA.
EM George.daley@childrens.harvard.edu
RI Onder, Tamer /H-3330-2013
OI Onder, Tamer /0000-0002-2372-9158
FU US National Institutes of Health (NIH); CHB Stem Cell Program
FX We thank Tugba Bagci-Onder for critical reading of the manuscript and
graphical design. Research was funded by grants from the US National
Institutes of Health (NIH) to G.Q.D., and the CHB Stem Cell Program.
NR 83
TC 36
Z9 38
U1 0
U2 28
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD OCT
PY 2012
VL 22
IS 5
BP 500
EP 508
DI 10.1016/j.gde.2012.05.005
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA 042KU
UT WOS:000311470900015
PM 22749051
ER
PT J
AU Piris, A
Lobo, AC
Duncan, LM
AF Piris, Adriano
Lobo, Alice Coelho
Duncan, Lyn M.
TI Melanoma Staging Where Are We Now?
SO DERMATOLOGIC CLINICS
LA English
DT Article
DE American Joint Committee on Cancer; Melanoma staging; Melanoma
classification
ID SENTINEL-LYMPH-NODE; PRIMARY CUTANEOUS MELANOMA; AMERICAN JOINT
COMMITTEE; EXTRAVASCULAR MIGRATORY METASTASIS; TUMOR-INFILTRATING
LYMPHOCYTES; MALIGNANT-MELANOMA; PROGNOSTIC-SIGNIFICANCE; MITOTIC RATE;
MICROSCOPIC SATELLITES; THIN MELANOMAS
AB The seventh version of the American Joint Committee on Cancer (AJCC) Melanoma Staging guidelines, published in 2009, has significant revisions compared with the previous version. The current schema was based on the largest melanoma patient cohort analyzed to date and is the result of a multivariate analysis of 30,946 patients with stages I, II, and III melanoma and 7972 patients with stage IV melanoma. This article summarizes the findings and the new definitions included in the 2009 AJCC Melanoma Staging and Classification. The TNM categories and the stage groupings are defined. Changes in the melanoma staging system are summarized.
C1 [Piris, Adriano; Duncan, Lyn M.] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Pathol Serv, Dermatopathol Unit, Boston, MA 02114 USA.
[Lobo, Alice Coelho] Univ Sao Paulo, Hosp Clin, Dept Dermatol, BR-05403900 Sao Paulo, Brazil.
RP Duncan, LM (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp,Pathol Serv, Dermatopathol Unit, 55 Fruit St,WRN 827, Boston, MA 02114 USA.
EM duncan@helix.mgh.harvard.edu
NR 54
TC 7
Z9 7
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0733-8635
J9 DERMATOL CLIN
JI Dermatol. Clin.
PD OCT
PY 2012
VL 30
IS 4
BP 581
EP +
DI 10.1016/j.det.2012.06.001
PG 13
WC Dermatology
SC Dermatology
GA 038RG
UT WOS:000311191200004
PM 23021047
ER
PT J
AU Azijli, K
Yuvaraj, S
Peppelenbosch, MP
Wurdinger, T
Dekker, H
Joore, J
van Dijk, E
Quax, WJ
Peters, GJ
de Jong, S
Kruyt, FAE
AF Azijli, Kaamar
Yuvaraj, Saravanan
Peppelenbosch, Maikel P.
Wurdinger, Thomas
Dekker, Henk
Joore, Jos
van Dijk, Evert
Quax, Wim J.
Peters, Godefridus J.
de Jong, Steven
Kruyt, Frank A. E.
TI Kinome profiling of non-canonical TRAIL signaling reveals
RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung
cancer cells
SO JOURNAL OF CELL SCIENCE
LA English
DT Article
DE TRAIL; Migration; NSCLC; RIP1; Kinome profiling; Src inhibitors
ID APOPTOSIS-INDUCING LIGAND; CARCINOMA-CELLS; KINASE PATHWAY; RIP KINASES;
MIGRATION; DEATH; SRC; RECEPTOR; EXPRESSION; SUPPRESSION
AB Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) triggers apoptosis selectively in tumor cells through interaction with TRAIL-R1/DR4 or TRAIL-R2/DR5 and this process is considered a promising avenue for cancer treatment. TRAIL resistance, however, is frequently encountered and hampers anti-cancer activity. Here we show that whereas H460 non-small cell lung cancer (NSCLC) cells display canonical TRAIL-dependent apoptosis, A549 and SW1573 NSCLC cells are TRAIL resistant and display pro-tumorigenic activity, in particular invasion, following TRAIL treatment. We exploit this situation to contrast TRAIL effects on the kinome of apoptosis-sensitive cells to that of NSCLC cells in which non-canonical effects predominate, employing peptide arrays displaying 1024 different kinase pseudosubstrates more or less comprehensively covering the human kinome. We observed that failure of a therapeutic response to TRAIL coincides with the activation of a non-canonical TRAIL-induced signaling pathway involving, amongst others, Src, STAT3, FAK, ERK and Akt. The use of selective TRAIL variants against TRAIL-R1 or TRAIL-R2 subsequently showed that this non-canonical migration and invasion is mediated through TRAIL-R2. Short-hairpin-mediated silencing of RIP1 kinase prevented TRAIL-induced Src and STAT3 phosphorylation and reduced TRAIL-induced migration and invasion of A549 cells. Inhibition of Src or STAT3 by shRNA or chemical inhibitors including dasatinib and 5,15-diphenylporphyrin blocked TRAIL-induced invasion. FAK, AKT and ERK were activated in a RIP1-independent way and inhibition of AKT sensitized A549 cells to TRAIL-induced apoptosis. We thus identified RIP1-dependent and -independent non-canonical TRAIL kinase cascades in which Src and AKT are instrumental and could be exploited as co-targets in TRAIL therapy for NSCLC.
C1 [Azijli, Kaamar; Yuvaraj, Saravanan; de Jong, Steven; Kruyt, Frank A. E.] Univ Groningen, Dept Med Oncol, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Azijli, Kaamar; Dekker, Henk; Peters, Godefridus J.] Vrije Univ Amsterdam Med Ctr, Dept Med Oncol, Amsterdam, Netherlands.
[Peppelenbosch, Maikel P.; Joore, Jos] Erasmus MC, Dept Gastroenterol & Hepatol, Rotterdam, Netherlands.
[Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Neurooncol Res Grp, Dept Neurosurg, Amsterdam, Netherlands.
[Wurdinger, Thomas] Vrije Univ Amsterdam Med Ctr, Dept Pediat Oncol Hematol, Amsterdam, Netherlands.
[Wurdinger, Thomas] Massachusetts Gen Hosp, Mol Neurogenet Unit, Dept Neurol, Charlestown, MA 02113 USA.
[Wurdinger, Thomas] Harvard Univ, Sch Med, Charlestown, MA 02113 USA.
[van Dijk, Evert] Pepscan Presto BV, Lelystad, Netherlands.
[Quax, Wim J.] Univ Groningen, Dept Pharmaceut Biol, NL-9700 AB Groningen, Netherlands.
RP Kruyt, FAE (reprint author), Univ Groningen, Dept Med Oncol, Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
EM a.e.kruyt@umcg.nl
RI Quax, Wim/K-2802-2012;
OI Joore, Jos/0000-0002-2744-4862
FU Dutch Top Institute Pharma [T3-112, T3-103]
FX This work was supported by the Dutch Top Institute Pharma, within the
framework of project T3-112 to F.K., S. dJ., J.J., E. vD.; and T3-103 to
M.P.
NR 43
TC 26
Z9 28
U1 2
U2 10
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 0021-9533
J9 J CELL SCI
JI J. Cell Sci.
PD OCT 1
PY 2012
VL 125
IS 19
BP 4651
EP 4661
DI 10.1242/jcs.109587
PG 11
WC Cell Biology
SC Cell Biology
GA 040CB
UT WOS:000311295900023
PM 22797920
ER
PT J
AU Yoon, JH
Di Vito, L
Jang, IK
AF Yoon, Joo Heung
Di Vito, Luca
Jang, Ik-Kyung
TI Feasibility of Frequency-Domain Optical Coherence Tomography for
Coronary Stent Imaging: A Matter of Definitions Reply
SO JOURNAL OF INVASIVE CARDIOLOGY
LA English
DT Letter
C1 [Yoon, Joo Heung] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiol, Sch Med, Boston, MA 02215 USA.
[Di Vito, Luca] San Giovanni Hosp, Rome, Italy.
[Jang, Ik-Kyung] Harvard Univ, Sch Med, Dept Med, Massachusetts Gen Hosp, Boston, MA USA.
RP Yoon, JH (reprint author), Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiol, Sch Med, Boston, MA 02215 USA.
NR 6
TC 0
Z9 0
U1 0
U2 0
PU H M P COMMUNICATIONS
PI MALVERN
PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA
SN 1042-3931
J9 J INVASIVE CARDIOL
JI J. Invasive Cardiol.
PD OCT
PY 2012
VL 24
IS 10
BP A46
EP A47
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 036LV
UT WOS:000311028600003
ER
PT J
AU Wan, ZM
Wang, SB
Kozanek, M
Passias, PG
Mansfield, FL
Wood, KB
Li, GA
AF Wan, Zongmiao
Wang, Shaobai
Kozanek, Michal
Passias, Peter G.
Mansfield, Frederick L.
Wood, Kirkham B.
Li, Guoan
TI Biomechanical Evaluation of the X-Stop Device for Surgical Treatment of
Lumbar Spinal Stenosis
SO JOURNAL OF SPINAL DISORDERS & TECHNIQUES
LA English
DT Article
DE in vivo; spinous process; kinematics; X-Stop; lumbar spine stenosis
ID NEUROGENIC INTERMITTENT CLAUDICATION; INTERSPINAL PROCESS DECOMPRESSION;
PROCESS IMPLANT; KINEMATICS; SPONDYLOLISTHESIS; MULTICENTER; EXTENSION;
INSERTION
AB Study Design: Controlled experimental study.
Objective: To evaluate the kinematical effects of X-Stop device on the spinal process at the operated and the adjacent segments before and after X-Stop surgeries during various weight-bearing postures in elderly patients with lumbar spine stenosis.
Summary of Background Data: The mechanism of interspinous process (ISP) devices is to directly distract the ISP of the implanted level to indirectly decompress the intervertebra foramen and spinal canal. Few studies have investigated the changes of ISP gap caused by X-Stop implantation using magnetic resonance imaging or radiography, but the effect of X-Stop surgery on the kinematics of spinous processes during functional activities is still unclear.
Methods: Eight patients were tested before and, on average, 7 months after surgical implantation of the X-Stop devices using a combined computed tomography/magnetic resonance imaging and dual fluoroscopic imaging system during weight-bearing standing, flexion-extension, left-right bending, and left-right twisting positions of the torso. The shortest distances of the ISPs at the operated and the adjacent levels were measured using iterative closest point method and was dissected into vertical (gap) and horizontal (lateral translation) components.
Results: At the operated levels, the shortest vertical ISP distances (gap) significantly (P < 0.05) increased by 1.5 mm during standing, 1.2 mm during left twist, 1.3 mm during extension, and 1.1 mm during flexion, whereas they also increased yet not significantly (P > 0.05) in right twist, left bend, and right bend after the X-Stop implantation. The lateral translations were not significantly affected. At both cephalad and caudad adjacent levels, the ISP distances (vertical and horizontal) were not significantly affected during all postures after X-Stop implantation.
Conclusion: The findings of this study indicate that implantation of the X-Stop devices can effectively distract the ISP space at the diseased level without causing apparent kinematic changes at the adjacent segments during the studied postures.
C1 [Li, Guoan] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed, Boston, MA 02114 USA.
[Wan, Zongmiao; Wang, Shaobai; Kozanek, Michal; Passias, Peter G.; Mansfield, Frederick L.; Wood, Kirkham B.; Li, Guoan] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Wan, Zongmiao] Cent S Univ, Xiangya Hosp 2, Changsha, Hunan, Peoples R China.
[Wang, Shaobai] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Kozanek, Michal] Comenius Univ, Fac Med, Fac Hosp Ruzinov, Dept Orthopaed & Traumatol 1, Bratislava, Slovakia.
RP Li, GA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Bioengn Lab,Dept Orthopaed, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM gli1@partners.org
FU Medtronic Inc; NIH [R21AR057989]; China Scholarship Council [2009637094]
FX Supported by a research grant of Medtronic Inc and partially supported
by NIH (R21AR057989) and China Scholarship Council (2009637094).
NR 23
TC 5
Z9 6
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1536-0652
J9 J SPINAL DISORD TECH
JI J. Spinal Disord. Tech.
PD OCT
PY 2012
VL 25
IS 7
BP 374
EP 378
DI 10.1097/BSD.0b013e318227eb84
PG 5
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 041KZ
UT WOS:000311402000010
PM 22015626
ER
PT J
AU Carchman, EH
Peitzman, AB
Simmons, RL
Zuckerbraun, BS
AF Carchman, Evie H.
Peitzman, Andrew B.
Simmons, Richard L.
Zuckerbraun, Brian S.
TI The role of acute care surgery in the treatment of severe, complicated
Clostridium difficile-associated disease
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
ID FULMINANT PSEUDOMEMBRANOUS COLITIS; HUMAN-ANTIBODY RESPONSE;
SACCHAROMYCES-BOULARDII; HOSPITALIZED-PATIENTS; HYPERVIRULENT STRAIN;
EMERGENCY COLECTOMY; ACID SUPPRESSION; UNITED-STATES; RISK-FACTORS;
TOXIN-A
AB Clostridium difficile associated disease (CDAD) is the result of colonic bacterial overgrowth with this gram positive anaerobic organism and the production of toxins that typically induce diarrhea. Most patients with CDAD respond to treatment with oral metronidazole or vancomycin, but a subset of patients will develop a severe systemic illness, multiple organ failure, and death. There are no reliable combinations of clinical or laboratory findings that will distinguish patients who will respond to medical therapy and those who will progress to a more complicated state. Early surgical consultation should be considered in patients with ileus, severe abdominal pain, significant tenderness, immunosuppression, advanced age, high white blood cell or band counts, acute renal failure, mental status changes, or cardiopulmonary compromise. The standard operation for fulminant colitis is subtotal colectomy but the high mortality of the operation, and the long-term morbidity even in survivors combine to act as deterrents to early surgical consultation and operation. Novel operative approaches that preserve the colon and minimize operative morbidity may prove to remove the barriers to earlier surgical treatment for fulminant CDAD and improve outcomes.
C1 [Zuckerbraun, Brian S.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Zuckerbraun, BS (reprint author), F1271 PUH,200 Lothrop St, Pittsburgh, PA 15213 USA.
EM zuckerbraunbs@upmc.edu
NR 79
TC 11
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD OCT
PY 2012
VL 73
IS 4
BP 789
EP 800
DI 10.1097/TA.0b013e318265d19f
PG 12
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 029OL
UT WOS:000310505100001
PM 23026914
ER
PT J
AU Alam, HB
Pusateri, AE
Kindzelski, A
Egan, D
Hoots, K
Andrews, MT
Rhee, P
Tisherman, S
Mann, K
Vostal, J
Kochanek, PM
Scalea, T
Deal, V
Sheppard, F
Sopko, G
AF Alam, Hasan B.
Pusateri, Anthony E.
Kindzelski, Andrei
Egan, Debra
Hoots, Keith
Andrews, Matthew T.
Rhee, Peter
Tisherman, Samuel
Mann, Kenneth
Vostal, Jaroslav
Kochanek, Patrick M.
Scalea, Thomas
Deal, Virgil
Sheppard, Forest
Sopko, George
CA HYPOSTAT Workshop Participants
TI Hypothermia and hemostasis in severe trauma: A new crossroads workshop
report
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Article
DE Hypothermia; trauma; coagulopathy; injury; protection
ID ISCHEMIA-REPERFUSION INJURY; PROFOUND HYPOTHERMIA; SWINE MODEL;
HEMORRHAGIC-SHOCK; LETHAL HEMORRHAGE; CARDIAC-ARREST; CIRCULATORY
ARREST; BRAIN-INJURY; EMERGENCY PRESERVATION; CARDIOPULMONARY BYPASS
AB OBJECTIVE: The hypothermia and hemostasis in severe trauma (HYPOSTAT): a new crossroads workshop was convened to evaluate the interplay among hypothermia, hemostasis, and severe trauma/hemorrhage. Trauma is the major cause of death in young individuals in the United States, with uncontrolled hemorrhage representing the major cause of preventable deaths.
DATA SOURCES: This workshop organized by the National Heart, Lung, and Blood Institute and the US Army Medical Research and Material Command as a forum for exchange of ideas among experts from diverse fields. The specific workshop goals were to (1) identify state-of-the-art and needs in knowledge of biology of hypothermia and hemostasis in the setting of significant traumatic injury; (2) provide an interdisciplinary forum to enhance knowledge regarding early detection of traumatic shock and monitoring of the level and effect of controlled hypothermia in severe trauma settings; and (3) identify future research directions of the role of therapeutic-oriented hypothermia and hemostasis in trauma with severe blood loss.
STUDY SELECTION: Not applicable.
DATA EXTRACTION: Expert opinion and literature review.
CONCLUSION: This document provides a summary of the expert opinion and highlights the recommendations that came out of the discussions at this workshop to guide scientific efforts in basic, translational, and clinical research in this area. (J Trauma Acute Care Surg. 2012;73:809-817. Copyright (C) 2012 by Lippincott Williams & Wilkins)
C1 [Alam, Hasan B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
[Alam, Hasan B.] Harvard Univ, Sch Med, Boston, MA USA.
[Pusateri, Anthony E.; Deal, Virgil; Sheppard, Forest] US Dept Def, Washington, DC 20305 USA.
[Kindzelski, Andrei; Egan, Debra; Hoots, Keith; Sopko, George] NIH, Bethesda, MD 20892 USA.
[Vostal, Jaroslav] US FDA, Silver Spring, MD USA.
[Scalea, Thomas] Univ Maryland, College Pk, MD 20742 USA.
[Andrews, Matthew T.] Univ Minnesota, Duluth, MN 55812 USA.
[Rhee, Peter] Univ Arizona, Tucson, AZ USA.
[Tisherman, Samuel; Kochanek, Patrick M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Mann, Kenneth] Univ Vermont, Burlington, VT USA.
RP Alam, HB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM hbalam@partners.org
RI Kochanek, Patrick/D-2371-2015
OI Kochanek, Patrick/0000-0002-2627-913X
NR 87
TC 7
Z9 8
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD OCT
PY 2012
VL 73
IS 4
BP 809
EP 817
DI 10.1097/TA.0b013e318265d1b8
PG 9
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 029OL
UT WOS:000310505100003
PM 23026915
ER
PT J
AU King, DR
AF King, David R.
TI Re: Is bougie-aided cricothyrotomy really "extremely fast and safe" in
the morbidly obese patient?
SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY
LA English
DT Letter
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02115 USA.
RP King, DR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02115 USA.
OI King, David/0000-0003-1028-1478
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 2163-0755
J9 J TRAUMA ACUTE CARE
JI J. Trauma Acute Care Surg.
PD OCT
PY 2012
VL 73
IS 4
BP 1032
EP 1032
DI 10.1097/TA.0b013e31826a40e0
PG 1
WC Critical Care Medicine; Surgery
SC General & Internal Medicine; Surgery
GA 029OL
UT WOS:000310505100041
PM 23026919
ER
PT J
AU Shafi, MM
Westover, MB
Cole, AJ
Kilbride, RD
Hoch, DB
Cash, SS
AF Shafi, Mouhsin M.
Westover, M. Brandon
Cole, Andrew J.
Kilbride, Ronan D.
Hoch, Daniel B.
Cash, Sydney S.
TI Absence of early epileptiform abnormalities predicts lack of seizures on
continuous EEG
SO NEUROLOGY
LA English
DT Article
ID NONCONVULSIVE STATUS EPILEPTICUS; INTENSIVE-CARE-UNIT; CRITICALLY-ILL
PATIENTS; INTRACEREBRAL HEMORRHAGE; ELECTROGRAPHIC SEIZURES;
BRAIN-INJURY; MORTALITY
AB Objective: To determine whether the absence of early epileptiform abnormalities predicts absence of later seizures on continuous EEG monitoring of hospitalized patients.
Methods: We retrospectively reviewed 242 consecutive patients without a prior generalized convulsive seizure or active epilepsy who underwent continuous EEG monitoring lasting at least 18 hours for detection of nonconvulsive seizures or evaluation of unexplained altered mental status. The findings on the initial 30-minute screening EEG, subsequent continuous EEG recordings, and baseline clinical data were analyzed. We identified early EEG findings associated with absence of seizures on subsequent continuous EEG.
Results: Seizures were detected in 70 (29%) patients. A total of 52 patients had their first seizure in the initial 30 minutes of continuous EEG monitoring. Of the remaining 190 patients, 63 had epileptiform discharges on their initial EEG, 24 had triphasic waves, while 103 had no epileptiform abnormalities. Seizures were later detected in 22% (n = 14) of studies with epileptiform discharges on their initial EEG, vs 3% (n = 3) of the studies without epileptiform abnormalities on initial EEG (p < 0.001). In the 3 patients without epileptiform abnormalities on initial EEG but with subsequent seizures, the first epileptiform discharge or electrographic seizure occurred within the first 4 hours of recording.
Conclusions: In patients without epileptiform abnormalities during the first 4 hours of recording, no seizures were subsequently detected. Therefore, EEG features early in the recording may indicate a low risk for seizures, and help determine whether extended monitoring is necessary. Neurology (R) 2012;79:1796-1801
C1 [Shafi, Mouhsin M.; Westover, M. Brandon; Cole, Andrew J.; Kilbride, Ronan D.; Hoch, Daniel B.; Cash, Sydney S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Shafi, MM (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
EM mouhsin.shafi@gmail.com
OI Hoch, Daniel/0000-0002-4294-024X
FU National Center for Research Resources: Harvard Clinical and
Translational Science Center; Center for Integration of Medicine and
Innovative Technology (CIMIT); NIH/NINDS [NS062092]
FX M. Shafi receives research support from the National Center for Research
Resources: Harvard Clinical and Translational Science Center and the
Center for Integration of Medicine and Innovative Technology (CIMIT). M.
B. Westover receives research support from the NIH/NINDS (NS062092).
A.J. Cole receives research support from the NIH/NINDS (NS062092). R.
Kilbride reports no disclosures. D. Hoch receives research support from
the NIH/NINDS (NS062092). S. Cash receives research support from the
NIH/NINDS (NS062092). Go to Neurology.org for full disclosures.
NR 23
TC 18
Z9 18
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD OCT
PY 2012
VL 79
IS 17
BP 1796
EP 1801
DI 10.1212/WNL.0b013e3182703fbc
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA 028OC
UT WOS:000310430700014
PM 23054233
ER
PT J
AU Quintiliani, LM
Bishop, HL
Greaney, ML
Whiteley, JA
AF Quintiliani, Lisa M.
Bishop, Hillary L.
Greaney, Mary L.
Whiteley, Jessica A.
TI Factors across home, work, and school domains influence nutrition and
physical activity behaviors of nontraditional college students
SO NUTRITION RESEARCH
LA English
DT Article
DE Qualitative research; Health promotion; Diet; Exercise; Humans
ID QUALITATIVE-ANALYSIS; VENDING MACHINES; DETERMINANTS
AB Nontraditional college students (older, part-time, and/or working) have less healthful nutrition and physical activity behaviors compared to traditional students, yet few health promotion efforts focus on nontraditional students. The purpose of this study was to use qualitative methods to explore factors affecting nutrition and physical activity behaviors of nontraditional students. Fourteen semi-structured individual interviews were conducted with nontraditional undergraduate students attending a large university. The sample had a median age of 25 (range, 21-64), 57% were men, 43% were racial/ethnic minorities, and 57% were employed (mean 22 hours/week). Data were coded using a systematic team-based approach. Consistent themes (mentioned by 4+ students) were identified and categorized into three domains: home, work, and school. Home (themes: neighborhood characteristics, family, partners), work (theme: work environment), and school (themes: cafeteria, vending machines) factors consistently influenced positive nutrition behaviors. Similarly, home (themes: neighborhood including safety, friends from home, partner,), work (theme: work environment), and school (themes: not having a car, campus structure, campus gym, friends at school) factors consistently influenced positive physical activity. Financial resources and perceptions of autonomy had influence across domains. Results indicate consistent influences on nutrition and physical activity behaviors across home, work, and school domains for nontraditional college students. Study findings suggest possible, and sometimes unconventional, intervention strategies to promote healthful eating and physical activity. For example, when cafeteria meal plans are not offered and financial constraints limit eating at the cafeteria, encouraging healthful choices from vending machines could be preferable to not eating at all. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Quintiliani, Lisa M.] Boston Univ, Dept Med, Boston, MA 02118 USA.
[Quintiliani, Lisa M.; Bishop, Hillary L.] Boston Med Ctr, Boston, MA 02118 USA.
[Greaney, Mary L.] Dana Farber Canc Inst, Ctr Community Based Res, Boston, MA 02115 USA.
[Whiteley, Jessica A.] Univ Massachusetts Boston, Dept Exercise & Hlth Sci, Boston, MA 02125 USA.
RP Quintiliani, LM (reprint author), MISU, Crosstown Ctr, Boston, MA 02118 USA.
EM lmquinti@bu.edu
OI Quintiliani, Lisa/0000-0002-3328-6768
FU National Cancer Institute [5R03CA139943]; National Library of Medicine
[T15LM007092]
FX Funding for this study was provided by the National Cancer Institute
(5R03CA139943; Principal Investigator Lisa Quintiliani). Additional
support was provided by Award Number T15LM007092 from the National
Library of Medicine. The authors would like to thank all of the students
who participated in this study.
NR 20
TC 4
Z9 4
U1 4
U2 42
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD OCT
PY 2012
VL 32
IS 10
BP 757
EP 763
DI 10.1016/j.nutres.2012.09.008
PG 7
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA 044VX
UT WOS:000311654400004
PM 23146772
ER
PT J
AU Nogova, L
Gardizi, M
Bos, MCA
Bitter, E
Schildhaus, HU
Heukamp, LC
Topelt, K
Zander, T
Scheffler, M
Mattonet, C
Gokkurt, E
Risse, F
Schuler, M
Sequist, L
Tian, GG
Ringeisen, F
Thomas, R
Buttner, R
Wolf, J
AF Nogova, L.
Gardizi, M.
Bos, M. C. A.
Bitter, E.
Schildhaus, H. -U
Heukamp, L. C.
Toepelt, K.
Zander, T.
Scheffler, M.
Mattonet, C.
Goekkurt, E.
Risse, F.
Schuler, M.
Sequist, L.
Tian, G. G.
Ringeisen, F.
Thomas, R.
Buettner, R.
Wolf, J.
TI Early clinical evaluation of FGFR1 inhibition in lung cancer:
Preliminary results of a phase I study in FGFR1 amplified lung cancer
patients treated with BGJ398, a pan FGFR inhibitor
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Nogova, L.; Gardizi, M.; Bos, M. C. A.; Bitter, E.; Toepelt, K.; Zander, T.; Scheffler, M.; Mattonet, C.; Wolf, J.] Univ Hosp, Dept Internal Med 1, Cologne, Germany.
[Nogova, L.; Gardizi, M.; Bos, M. C. A.; Bitter, E.; Schildhaus, H. -U; Heukamp, L. C.; Toepelt, K.; Zander, T.; Scheffler, M.; Mattonet, C.; Buettner, R.; Wolf, J.] Univ Hosp, Ctr Integrated Oncol Koln Bonn, Cologne, Germany.
[Nogova, L.; Gardizi, M.; Bos, M. C. A.; Bitter, E.; Schildhaus, H. -U; Heukamp, L. C.; Toepelt, K.; Zander, T.; Scheffler, M.; Mattonet, C.; Thomas, R.; Buettner, R.; Wolf, J.] LCGC, Cologne, Germany.
[Schildhaus, H. -U; Heukamp, L. C.; Buettner, R.] Univ Hosp Cologne, Inst Pathol, Cologne, Germany.
[Goekkurt, E.] Univ Hosp Aachen, Aachen, Germany.
[Schuler, M.] Univ Hosp Essen, W German Canc Ctr, Dept Med Oncol, Essen, Germany.
[Sequist, L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med, Boston, MA USA.
[Tian, G. G.] West Clin, Memphis, TN USA.
[Ringeisen, F.] Novartis Pharma AG, Oncol Translat Med, Basel, Switzerland.
[Thomas, R.] Univ Cologne, Dept Translat Genom, D-50931 Cologne, Germany.
RI Heukamp, Lukas/A-8338-2013
NR 0
TC 0
Z9 0
U1 0
U2 2
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2012
VL 35
SU 6
BP 137
EP 137
PG 1
GA 033BE
UT WOS:000310766700354
ER
PT J
AU Reichardt, P
Demetri, G
Kang, YK
Blay, JY
Joensuu, H
Maki, R
Rutkowski, P
Hohenberger, P
Gelderblom, H
Leahy, M
von Mehren, M
Schoffski, P
Blackstein, M
Le Cesne, A
Badalamenti, G
Xu, J
Nishida, T
Laurent, D
Kuss, I
Casali, P
AF Reichardt, P.
Demetri, G.
Kang, Y-K
Blay, J-Y
Joensuu, H.
Maki, R.
Rutkowski, P.
Hohenberger, P.
Gelderblom, H.
Leahy, M.
von Mehren, M.
Schoffski, P.
Blackstein, M.
Le Cesne, A.
Badalamenti, G.
Xu, J.
Nishida, T.
Laurent, D.
Kuss, I
Casali, P.
TI Randomized phase 3 trial of regorafenib in patients (pts) with
metastatic and/or unresectable gastrointestinal stromal tumor (GIST)
progressing despite prior treatment with at least imatinib (IM) and
sunitinib (SU) - GRID trial
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Reichardt, P.] Helios Klinikum Bad Saarow, Innere Med Klin 3, Bad Saarow Pieskow, Germany.
[Demetri, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kang, Y-K] Asan Med Ctr, Seoul, South Korea.
[Blay, J-Y] Ctr Leon Berard, F-69373 Lyon, France.
[Joensuu, H.] Univ Helsinki, Cent Hosp, Helsinki, Finland.
[Maki, R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Rutkowski, P.] Ctr Onkol, Warsaw, Poland.
[Hohenberger, P.] Univ Med, Mannheim, Germany.
[Gelderblom, H.] Leiden Univ, Med Ctr, Leiden, Netherlands.
[Leahy, M.] Christie Hosp, Manchester, Lancs, England.
[von Mehren, M.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Schoffski, P.] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium.
[Blackstein, M.] Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
[Le Cesne, A.] Inst Gustave Roussy, Villejuif, France.
[Badalamenti, G.] IntegrataOsped Univ, Policlin Paolo Giaccone, Azienda Osped Univ, Palermo, Italy.
[Xu, J.] Hosp PLA, Beijing, Peoples R China.
[Nishida, T.] Osaka Police Hosp, Osaka, Japan.
[Laurent, D.; Kuss, I] Bayer HealthCare, Berlin, Germany.
[Casali, P.] Ist Nazl Tumori, I-20133 Milan, Italy.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 5
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2012
VL 35
SU 6
BP 168
EP 168
PG 1
GA 033BE
UT WOS:000310766700436
ER
PT J
AU Hupfeld, T
Chapuy, B
Schrader, V
Trumper, L
Wulf, GG
AF Hupfeld, T.
Chapuy, B.
Schrader, V
Truemper, L.
Wulf, G. G.
TI BCR-ABL dependent activation of SALL4/ABCA3-TKI detoxification in
leukemic cells
SO ONKOLOGIE
LA English
DT Meeting Abstract
C1 [Hupfeld, T.; Schrader, V; Truemper, L.; Wulf, G. G.] UMG Gottingen, Hamatol & Onkol, Gottingen, Germany.
[Chapuy, B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0378-584X
J9 ONKOLOGIE
JI Onkologie
PD OCT
PY 2012
VL 35
SU 6
BP 188
EP 188
PG 1
GA 033BE
UT WOS:000310766700491
ER
PT J
AU Neuhaus, V
Christoforou, D
Cheriyan, T
Mudgal, CS
AF Neuhaus, Valentin
Christoforou, Dimitrios
Cheriyan, Thomas
Mudgal, Chaitanya S.
TI Evaluation and Treatment of Failed Carpal Tunnel Release
SO ORTHOPEDIC CLINICS OF NORTH AMERICA
LA English
DT Article
DE Carpal tunnel release; Evaluation; Failed; Treatment
ID SCARRED MEDIAN NERVE; MINIMI MUSCLE FLAP; FAT PAD FLAP; FLEXOR
RETINACULUM; REVISION SURGERY; RECURRENT; COMPLICATIONS; MANAGEMENT;
WRIST; REOPERATION
AB Treatment failure and complications are encountered in 1% to 25% of all carpal tunnel releases. Besides hematoma, infection, skin necrosis, and intraoperative iatrogenic injuries, persistence and recurrence should be included in this discussion. Persistence is often related to incomplete release. Similar symptoms recurring after a symptom-free interval of 6 months are considered recurrent and may be caused by intraneural or perineural scarring. Adequate diagnosis and treatment of these failures can be challenging. Operative release is the main treatment consisting of complete decompression of the median nerve. In some circumstances, coverage of the median nerve may be necessary.
C1 [Mudgal, Chaitanya S.] Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, Boston, MA 02114 USA.
RP Mudgal, CS (reprint author), Massachusetts Gen Hosp, Yawkey Ctr, Orthopaed Hand Serv, 55 Fruit St,Suite 2100, Boston, MA 02114 USA.
EM cmudgal@partners.org
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 58
TC 9
Z9 9
U1 0
U2 4
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0030-5898
J9 ORTHOP CLIN N AM
JI Orthop. Clin. North Am.
PD OCT
PY 2012
VL 43
IS 4
BP 439
EP +
DI 10.1016/j.ocl.2012.07.013
PG 10
WC Orthopedics
SC Orthopedics
GA 039PG
UT WOS:000311258400005
PM 23026459
ER
PT J
AU Dhakal, BP
Murphy, RM
Lewis, GD
AF Dhakal, Bishnu P.
Murphy, Ryan M.
Lewis, Gregory D.
TI Exercise Oscillatory Ventilation in Heart Failure
SO TRENDS IN CARDIOVASCULAR MEDICINE
LA English
DT Review
ID CHEYNE-STOKES RESPIRATION; IDIOPATHIC DILATED CARDIOMYOPATHY; PRESERVED
EJECTION FRACTION; OBSTRUCTIVE SLEEP-APNEA; CARDIAC TRANSPLANTATION;
WEDGE PRESSURE; SECONDARY; LUNG; HYPERVENTILATION; PATHOGENESIS
AB Irregular breathing characterized by cyclic variation of ventilation with a period of approximately 1 min has been recognized in patients with heart failure for almost two centuries. Periodic breathing during exercise is a noninvasive parameter that is easily recognizable during submaximal cardiopulmonary exercise testing. Recent studies have established that periodic breathing during exercise not only signals significant impairment in resting and exercise hemodynamic parameters but also potently predicts adverse events in heart failure patients. This article reviews the mechanistic basis of periodic breathing and the clinical utility of discerning patterns of irregular breathing in patients with heart failure. (Trends Cardiovasc Med 2012;22:185-191) (C) 2012 Elsevier Inc. All rights reserved.
C1 [Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Cardiol Div,Dept Med, Heart Failure & Cardiac Transplantat Unit, Boston, MA 02114 USA.
[Lewis, Gregory D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Pulm & Crit Care Unit,Dept Med, Boston, MA 02114 USA.
RP Lewis, GD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med,Cardiol Div,Dept Med, Heart Failure & Cardiac Transplantat Unit, Bigelow 800,Fruit St, Boston, MA 02114 USA.
EM glewis@partners.org
NR 48
TC 13
Z9 13
U1 0
U2 3
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 1050-1738
J9 TRENDS CARDIOVAS MED
JI Trends Cardiovasc. Med.
PD OCT
PY 2012
VL 22
IS 7
BP 185
EP 191
AR PII S1050-1738(12)00267-8
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 043GK
UT WOS:000311530700004
PM 23062973
ER
PT J
AU Hoang, MP
Kroshinsky, D
AF Hoang, Mai P.
Kroshinsky, Daniela
TI Cutaneous Reactions to Novel Therapeutics
SO AMERICAN JOURNAL OF DERMATOPATHOLOGY
LA English
DT Article
DE epidermal growth factor receptor inhibitor; Cetuximab; granulocyte
macrophage-colony-stimulating factor; interferon; kinase inhibitors;
Sorafenib; PLX4032; Vemurafenib; tumor necrosis factor alpha inhibitors;
Infliximab; Etanercept; Adalimumab
ID COLONY-STIMULATING FACTOR; CHRONIC HEPATITIS-C; NECROSIS-FACTOR-ALPHA;
OF-THE-LITERATURE; RIBAVIRIN COMBINATION THERAPY; SQUAMOUS-CELL
CARCINOMAS; REVERSIBLE ALOPECIA UNIVERSALIS;
SYSTEMIC-LUPUS-ERYTHEMATOSUS; KINASE INHIBITOR SUNITINIB; NUMMULAR
ECZEMA SECONDARY
AB In the last 2 decades the introduction new biologic agents such as tumor necrosis factor alpha inhibitors has resulted in potent disease modifying effects in a variety of immune-mediated diseases. In addition, there were major advancements in cancer treatment due to chemotherapeutic agents including granulocyte macrophage-colony-stimulating factor, interferon, epidermal growth factor receptor inhibitors, and kinase inhibitors for the treatment of hematologic malignancies as well as solid tumors. However, a variety of toxicities including cutaneous reactions is seen in association with these agents. Awareness of commonly associated skin toxicities and recognition of corresponding histologic features is of importance.
C1 [Hoang, Mai P.] Massachusetts Gen Hosp, Dermatopathol Unit, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Hoang, MP (reprint author), Massachusetts Gen Hosp, Dermatopathol Unit, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
EM mhoang@partners.org
NR 120
TC 1
Z9 2
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0193-1091
J9 AM J DERMATOPATH
JI Am. J. Dermatopathol.
PD OCT
PY 2012
VL 34
IS 7
BP 679
EP 690
DI 10.1097/DAD.0b013e31822e67eb
PG 12
WC Dermatology
SC Dermatology
GA 016VJ
UT WOS:000309547500005
PM 23000876
ER
PT J
AU Delaney, RA
Lin, A
Warner, JJP
AF Delaney, Ruth A.
Lin, Albert
Warner, Jon J. P.
TI Nonarthroplasty Options for the Management of Massive and Irreparable
Rotator Cuff Tears
SO CLINICS IN SPORTS MEDICINE
LA English
DT Article
DE Massive rotator cuff tears; Subacromial decompression; Margin
convergence; Suprascapular nerve; Tendon transfers
ID LATISSIMUS-DORSI TRANSFER; TENDON TRANSFER; ARTHROSCOPIC TREATMENT;
SUPRASCAPULAR NERVE; PECTORALIS MAJOR; FOLLOW-UP; SUBACROMIAL
DECOMPRESSION; LONG-TERM; REPAIR; SUBSCAPULARIS
AB Massive, irreparable rotator cuff tears remain a clinical challenge. In low-demand patients, debridement of the tear may relieve pain. Partial repair using the technique of margin convergence decreases the size of the tear gap and reduces strain. Biceps tenotomy or tenodesis has a role in providing pain relief in massive rotator cuff tears. Tendon transfers offer good results in patients with massive, irreparable rotator cuff tears. The treatment modality specifically chosen for the massive, irreparable rotator cuff tear must be tailored to the individual patient, their needs and expectations, and their ability to comply with intensive rehabilitation.
C1 [Lin, Albert; Warner, Jon J. P.] Massachusetts Gen Hosp, Harvard Shoulder Serv, Boston, MA 02114 USA.
[Warner, Jon J. P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Delaney, Ruth A.] Massachusetts Gen Hosp, Harvard Combined Orthopaed Residency Program, WHT 535, Boston, MA 02114 USA.
RP Warner, JJP (reprint author), Massachusetts Gen Hosp, Harvard Shoulder Serv, Yawkey Suite 3G, Boston, MA 02114 USA.
EM jwarner@partners.org
NR 60
TC 2
Z9 2
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0278-5919
J9 CLIN SPORT MED
JI Clin. Sports Med.
PD OCT
PY 2012
VL 31
IS 4
BP 727
EP +
DI 10.1016/j.csm.2012.07.008
PG 23
WC Sport Sciences
SC Sport Sciences
GA 038RZ
UT WOS:000311193100011
PM 23040556
ER
PT J
AU McClatchey, AI
Yap, AS
AF McClatchey, Andrea I.
Yap, Alpha S.
TI Contact inhibition (of proliferation) redux
SO CURRENT OPINION IN CELL BIOLOGY
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; CELL-CELL-ADHESION; VASCULAR ENDOTHELIAL
CADHERIN; HIPPO SIGNALING-PATHWAY; DENSITY-DEPENDENT INHIBITION; FACTOR
RECEPTOR; EGF RECEPTOR; NEGATIVE COOPERATIVITY; ALLOSTERIC REGULATION;
EPITHELIAL GROWTH
AB It has long been appreciated that proliferation of many cells is inhibited by density, a phenomenon that is often attributed to cell-cell contact. The basic properties of this phenomenon were established in the 1960s, along with the observation that such density-dependence was also lost in transformed cells. The mechanistic basis of contact inhibition of proliferation (CIP) has been slower to reveal itself. Here we discuss recent progress in elucidating the roles that cell-cell adhesion molecules play as receptors for CIP and in characterising the intracellular signaling pathways that mediate adhesion-dependent proliferative inhibition.
C1 [McClatchey, Andrea I.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
[McClatchey, Andrea I.] Harvard Univ, Sch Med, Dept Pathol, Charlestown, MA USA.
[Yap, Alpha S.] Univ Queensland, Mol Cell Biol Div, Inst Mol Biosci, St Lucia, Qld 4072, Australia.
RP McClatchey, AI (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
EM mcclatch@helix.mgh.harvard.edu; a.yap@uq.edu.au
RI Yap, Alpha/J-1554-2014
OI Yap, Alpha/0000-0002-1038-8956
FU National Institutes of Health [R01GM087558, R01CA113733]; MGH Research
Scholars Award; National Health and Medical Research Council of
Australia
FX We would like to thank members of the Yap and McClatchey labs for
fruitful discussions. A.I.M. is supported by National Institutes of
Health Grants (R01GM087558, R01CA113733) and an MGH Research Scholars
Award. A.S.Y. is supported by project grants and a Research Fellowship
from the National Health and Medical Research Council of Australia.
NR 75
TC 45
Z9 46
U1 0
U2 20
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0955-0674
J9 CURR OPIN CELL BIOL
JI Curr. Opin. Cell Biol.
PD OCT
PY 2012
VL 24
IS 5
BP 685
EP 694
DI 10.1016/j.ceb.2012.06.009
PG 10
WC Cell Biology
SC Cell Biology
GA 035JS
UT WOS:000310943300017
PM 22835462
ER
PT J
AU del Blanco, A
Torrente, J
Marchiori, EJ
Martinez-Ortiz, I
Moreno-Ger, P
Fernandez-Manjon, B
AF del Blanco, Angel
Torrente, Javier
Marchiori, Eugenio J.
Martinez-Ortiz, Ivan
Moreno-Ger, Pablo
Fernandez-Manjon, Baltasar
TI A Framework for Simplifying Educator Tasks Related to the Integration of
Games in the Learning Flow
SO EDUCATIONAL TECHNOLOGY & SOCIETY
LA English
DT Article
DE Game-based learning; game-authoring tool; educational sequences; general
games' integration framework
ID DESIGN; SIMULATIONS
AB The integration of educational video games in educational settings in general, and e-learning systems in particular, can be challenging for educators. We propose a framework that aims to facilitate educators' participation in the creation and modification of courses that use educational games. Our approach addresses problems identified by previous experiences with games in educational settings, including assessment of learning outcomes and student tracking. Our framework has been implemented following an application model that takes advantage of pre-existing systems: the < e-Adventure > educational video game framework and the Learning Activity Management System (LAMS). This approach has been put into practice in a case study carried out in a primary school, covering from the design of the learning experience to the development of the educational games and the deployment and evaluation with students, involving the educators actively and gathering their perceptions. The first impressions expressed by the educators support the potential of the framework in terms of the students' assessment and the personalization of the lesson. Although educators pointed out the difficulty of creating games from scratch, they appreciated the easiness of introducing existing games in their courses and adapting them to their specific educational settings.
C1 [del Blanco, Angel; Torrente, Javier; Marchiori, Eugenio J.; Martinez-Ortiz, Ivan; Moreno-Ger, Pablo; Fernandez-Manjon, Baltasar] Univ Complutense Madrid, Dept Software Engn & Artificial Intelligence, E UCM Res Grp, E-28040 Madrid, Spain.
[Fernandez-Manjon, Baltasar] Harvard Univ, Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA.
RP del Blanco, A (reprint author), Univ Complutense Madrid, Dept Software Engn & Artificial Intelligence, E UCM Res Grp, C Profesor Jose Garcia Santesmases S-N, E-28040 Madrid, Spain.
EM angel.dba@fdi.ucm.es; jtorrente@fdi.ucm.es; emarchiori@fdi.ucm.es;
imartinez@fdi.ucm.es; pablom@fdi.ucm.es; balta@fdi.ucm.es
RI Fernandez-Manjon, Baltasar/A-5281-2011; Moreno-Ger, Pablo/B-5419-2009
OI Fernandez-Manjon, Baltasar/0000-0002-8200-6216; Moreno-Ger,
Pablo/0000-0003-4817-8150
NR 40
TC 6
Z9 7
U1 2
U2 16
PU IEEE COMPUTER SOC, LEARNING TECHNOLOGY TASK FORCE
PI PALMERSTON NORTH
PA BAG 11-222, MASSEY UNIVERSITY, PALMERSTON NORTH, NEW ZEALAND
SN 1436-4522
J9 EDUC TECHNOL SOC
JI Educ. Technol. Soc.
PD OCT
PY 2012
VL 15
IS 4
BP 305
EP 318
PG 14
WC Education & Educational Research
SC Education & Educational Research
GA 032FJ
UT WOS:000310697900026
ER
PT J
AU Chan, JA
Ryan, DP
Zhu, AX
Abrams, TA
Wolpin, BM
Malinowski, P
Regan, EM
Fuchs, CS
Kulke, MH
AF Chan, Jennifer A.
Ryan, David P.
Zhu, Andrew X.
Abrams, Thomas A.
Wolpin, Brian M.
Malinowski, Paige
Regan, Eileen M.
Fuchs, Charles S.
Kulke, Matthew H.
TI Phase I study of pasireotide (SOM 230) and everolimus (RAD001) in
advanced neuroendocrine tumors
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
ID SOMATOSTATIN ANALOGS; PITUITARY-ADENOMAS; CELL-PROLIFERATION;
GLUCAGON-SECRETION; CARCINOID-SYNDROME; OCTREOTIDE; MANAGEMENT;
EFFICACY; THERAPY; GROWTH
AB Octreotide and everolimus have demonstrated efficacy in neuroendocrine tumors. Pasireotide is a somatostatin analog with binding affinity to a broader range of somatostatin receptor subtypes than octreotide. We performed a phase I study to evaluate the safety and feasibility of combining pasireotide with everolimus in patients with advanced neuroendocrine tumors. Cohorts of patients with advanced neuroendocrine tumors were treated with escalating doses of pasireotide (600-1200 mu g s.c. b.i.d., followed by pasireotide LAR 40-60 mg i.m. monthly) and everolimus (5-10 mg daily). Twenty-one patients were treated. Dose-limiting toxicities consisting of grade 3 rash and grade 3 diarrhea were observed. Twelve patients were safely treated at the maximum protocol-defined dose level of pasireotide LAR 60 mg i.m. monthly and everolimus 10 mg daily. Hyperglycemia was common; other observed toxicities were consistent with the known toxicities of either agent alone. Partial tumor response was observed in one patient; 17 (81%) patients experienced at least some tumor regression as their best response to therapy. In conclusion, pasireotide LAR 60 mg i.m. monthly in combination with everolimus 10 mg daily is feasible and associated with preliminary evidence of antitumor activity in patients with advanced neuroendocrine tumors. Further studies evaluating this combination are warranted. Endocrine-Related Cancer (2012) 19 615-623
C1 [Chan, Jennifer A.; Abrams, Thomas A.; Wolpin, Brian M.; Malinowski, Paige; Regan, Eileen M.; Fuchs, Charles S.; Kulke, Matthew H.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Ryan, David P.; Zhu, Andrew X.] Massachusetts Gen Hosp, Dept Hematol Oncol, Boston, MA 02114 USA.
RP Chan, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM jennifer_chan@dfci.harvard.edu
FU Novartis; Bayer-Onyx; Merck; Imclone-Lilly
FX J A Chan has received research funding from Novartis, Bayer-Onyx, and
Merck. A X Zhu has served as a consultant for Sanofi-aventis and
Bristol-Myers Squibb and has received research funding from Bayer-Onyx,
Imclone-Lilly. C S Fuchs has served as a consultant for Genentech,
Roche, Sanofi-aventis, Pfizer, and Infinity Pharmaceuticals. MH Kulke
has served as a consultant for Novartis. This work was supported by
Novartis.
NR 29
TC 9
Z9 9
U1 0
U2 2
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
EI 1479-6821
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD OCT
PY 2012
VL 19
IS 5
BP 615
EP 623
DI 10.1530/ERC-11-0382
PG 9
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 035AH
UT WOS:000310913500009
PM 22736724
ER
PT J
AU Bellelli, R
Castellone, MD
Garcia-Rostan, G
Ugolini, C
Nucera, C
Sadow, PM
Nappi, TC
Salerno, P
Cantisani, MC
Basolo, F
Gago, TA
Salvatore, G
Santoro, M
AF Bellelli, Roberto
Castellone, Maria Domenica
Garcia-Rostan, Ginesa
Ugolini, Clara
Nucera, Carmelo
Sadow, Peter M.
Nappi, Tito Claudio
Salerno, Paolo
Cantisani, Maria Carmela
Basolo, Fulvio
Alvarez Gago, Tomas
Salvatore, Giuliana
Santoro, Massimo
TI FOXM1 is a molecular determinant of the mitogenic and invasive phenotype
of anaplastic thyroid carcinoma
SO ENDOCRINE-RELATED CANCER
LA English
DT Article
ID FORKHEAD BOX M1; TRANSCRIPTION FACTOR FOXM1; CANCER-CELLS;
TUMOR-SUPPRESSOR; BREAST-CANCER; PIK3CA GENE; EXPRESSION; PROGRESSION;
TARGET; PROLIFERATION
AB Anaplastic thyroid carcinoma (ATC) is a very aggressive thyroid cancer. forkhead box protein M1 (FOXM1) is a member of the forkhead box family of transcription factors involved in control of cell proliferation, chromosomal stability, angiogenesis, and invasion. Here, we show that FOXM1 is significantly increased in ATCs compared with normal thyroid, well-differentiated thyroid carcinomas (papillary and/or follicular), and poorly differentiated thyroid carcinomas (P=0.000002). Upregulation of FOXM1 levels in ATC cells was mechanistically linked to lossof- function of p53 and to the hyperactivation of the phosphatidylinositol-3-kinase/AKT/FOXO3a pathway. Knockdown of FOXM1 by RNA interference inhibited cell proliferation by arresting cells in G2/M and reduced cell invasion and motility. This phenotype was associated with decreased expression of FOXM1 target genes, like cyclin B1 (CCNB1), polo-like kinase 1 (PLK1), Aurora B (AURKB), S-phase kinase-associated protein 2 (SKP2), and plasminogen activator, urokinase: uPA (PLAU). Pharmacological inhibition of FOXM1 in an orthotopic mouse model of ATC reduced tumor burden and metastasization. All together, these findings suggest that FOXM1 represents an important player in thyroid cancer progression to the anaplastic phenotype and a potential therapeutic target for this fatal cancer. Endocrine-Related Cancer (2012) 19 695-710
C1 [Bellelli, Roberto; Castellone, Maria Domenica; Nappi, Tito Claudio; Salerno, Paolo; Cantisani, Maria Carmela; Santoro, Massimo] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy.
[Bellelli, Roberto; Castellone, Maria Domenica; Nappi, Tito Claudio; Salerno, Paolo; Cantisani, Maria Carmela; Santoro, Massimo] CNR, Ist Endocrinol & Oncol Sperimentale G Salvatore, I-80125 Naples, Italy.
[Garcia-Rostan, Ginesa; Alvarez Gago, Tomas] Univ Valladolid, Spanish Res Council, Inst Biol & Mol Genet, Valladolid, Spain.
[Ugolini, Clara; Basolo, Fulvio] Univ Pisa, Dept Surg, Pisa, Italy.
[Nucera, Carmelo] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med,Ctr Vasc Biol Res,Div Canc Biol & Angioge, Human Thyroid Cancers Preclin & Translat Res Prog, Boston, MA 02215 USA.
[Sadow, Peter M.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Salvatore, Giuliana] Univ Parthenope, Dipartimento Studi Ist & Sistemi Terr, Naples, Italy.
RP Santoro, M (reprint author), Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Via Pansini 5, I-80131 Naples, Italy.
EM masantor@unina.it
OI CASTELLONE, MARIADOMENICA/0000-0003-0507-8037; BASOLO,
FULVIO/0000-0003-1657-5020
FU Associazione Italiana per la Ricerca sul Cancro (AIRC); Ministero
dell'Universita e della Ricerca (MiUR); MERIT of MIUR; Programa Ramon y
Cajal, Ministerio de Ciencia e Innovacion, Social EU Funds, Universidad
de Valladolid, Spain; American Thyroid Association for Thyroid Cancer
Research; [NIHR21CA165039-01A1]
FX This study was supported by the Associazione Italiana per la Ricerca sul
Cancro (AIRC), the Ministero dell'Universita e della Ricerca (MiUR), and
by the grant MERIT of MIUR. G Garcia-Rostan is supported by Programa
Ramon y Cajal, Ministerio de Ciencia e Innovacion, Social EU Funds,
Universidad de Valladolid, Spain. C Nucera (Principal Investigator,
Program: Human Thyroid Cancers Preclinical and Translational Research)
was funded by the NIHR21CA165039-01A1 and the American Thyroid
Association for Thyroid Cancer Research.
NR 55
TC 15
Z9 17
U1 0
U2 5
PU BIOSCIENTIFICA LTD
PI BRISTOL
PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT,
ENGLAND
SN 1351-0088
J9 ENDOCR-RELAT CANCER
JI Endocr.-Relat. Cancer
PD OCT
PY 2012
VL 19
IS 5
BP 695
EP 710
DI 10.1530/ERC-12-0031
PG 16
WC Oncology; Endocrinology & Metabolism
SC Oncology; Endocrinology & Metabolism
GA 035AH
UT WOS:000310913500015
PM 22919068
ER
PT J
AU Mathis, KI
Wynn, JK
Jahshan, C
Hellemann, G
Darque, A
Green, MF
AF Mathis, Kristopher I.
Wynn, Jonathan K.
Jahshan, Carol
Hellemann, Gerhard
Darque, Alexandra
Green, Michael F.
TI An electrophysiological investigation of attentional blink in
schizophrenia: Separating perceptual and attentional processes
SO INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY
LA English
DT Article
DE P300; ssVEP; Attentional blink; Schizophrenia
ID SERIAL VISUAL PRESENTATION; P300; METAANALYSIS; PARADIGM; ERP
AB When two visual targets are presented in a rapid serial visual presentation (RSVP) paradigm, the ability to identify the second target is reduced when it is presented 200-500 ms after the initial target. This phenomenon is referred to as the "attentional blink (AB)." Previous behavioral studies have reported aberrant AB in schizophrenia. The underlying cause, however, of the AB deficit in schizophrenia remains ambiguous. Individuals with schizophrenia consistently demonstrate impairments in early visual processing stages and later attentionally-mediated stages, yet the stage of processing that is contributing to patient-control differences on AB is unknown. The current study attempted to resolve this ambiguity by applying electrophysiological methodology to an RSVP paradigm with 70 clinically stable outpatients with schizophrenia and 63 healthy controls. The task was simplified to reduce task demands, and a suppression ratio was employed to control for possible differences between groups in the ability to identify a single stimulus within a visual stream. Early perceptual processing was assessed using the steady-state visual evoked potential (ssVEP), and attentional processing was assessed using the P300 event-related potential. Relative to the healthy controls, patients showed the expected behavioral AB deficits. These deficits coincided with reduced P300 amplitude: both performance and P300 reductions extended beyond the traditional AB window. Mean ssVEP amplitude did not differ between the groups, and the differences in P300 remained after controlling for ssVEP. These results suggest that the observed AB deficits were due to attentional, not perceptual, processing deficits. Published by Elsevier B.V.
C1 [Mathis, Kristopher I.; Wynn, Jonathan K.; Jahshan, Carol; Green, Michael F.] W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, VA Desert Pacific Mental Illness Res Educ & Clin, Los Angeles, CA 90073 USA.
[Wynn, Jonathan K.; Hellemann, Gerhard; Green, Michael F.] Univ Calif Los Angeles, Jane & Terry Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA.
[Darque, Alexandra] Univ Hosp Geneva, Lab Expt Neuropsychol, Geneva, Switzerland.
RP Mathis, KI (reprint author), W Los Angeles VA Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, VA Desert Pacific Mental Illness Res Educ & Clin, 11301 Wilshire Blvd,Bldg 210,Room 117, Los Angeles, CA 90073 USA.
EM mathis@ucla.edu
RI Wynn, Jonathan/H-3749-2014
OI Wynn, Jonathan/0000-0002-1763-8540
NR 26
TC 5
Z9 6
U1 1
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0167-8760
J9 INT J PSYCHOPHYSIOL
JI Int. J. Psychophysiol.
PD OCT
PY 2012
VL 86
IS 1
BP 108
EP 113
DI 10.1016/j.ijpsycho.2012.06.052
PG 6
WC Psychology, Biological; Neurosciences; Physiology; Psychology;
Psychology, Experimental
SC Psychology; Neurosciences & Neurology; Physiology
GA 035GB
UT WOS:000310930300011
PM 22771850
ER
PT J
AU Simon, MV
Chiappa, KH
Kilbride, RD
Rordorf, GA
Cambria, RP
Ogilvy, CS
Kwolek, CJ
LaMuraglia, GM
Conrad, MF
Furie, KL
AF Simon, Mirela V.
Chiappa, Keith H.
Kilbride, Ronan D.
Rordorf, Guy A.
Cambria, Richard P.
Ogilvy, Christopher S.
Kwolek, Christopher J.
LaMuraglia, Glenn M.
Conrad, Mark F.
Furie, Karen L.
TI Predictors of Clamp-Induced Electroencephalographic Changes During
Carotid Endarterectomies
SO JOURNAL OF CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE EEG; CEA; Cerebral ischemia; Carotid stenosis
ID CEREBRAL-BLOOD-FLOW; DUPLEX CRITERIA; ARTERY STENOSIS; HIGH-RISK; EEG;
ISCHEMIA; STROKE
AB Objective: Electroencephalograms (EEGs) detect clamp-induced cerebral ischemia during carotid endarterectomy (CEA) and thus impact management and minimize the risk of perioperative stroke. We hypothesized that age, preoperative neurologic symptoms, >= 70% contralateral carotid and bilateral vertebral stenosis increase the probability of clamp-induced EEG changes, whereas >= 70% unilateral carotid stenosis does not.
Methods: This is an observational cohort study of 299 patients who underwent CEA with EEG monitoring at a single large urban academic medical center in 2009. Univariate and multivariate logistic regression were used.
Results: Seventy percent or greater ipsilateral carotid stenosis decreases the odds of clamp-induced neurophysiologic dysfunction (odds ratio [OR] = 0.43, 95% confidence interval [CI] [0.18, 0.99], P = 0.04) after adjustment for symptomatic status, degree contralateral carotid or vertebral stenosis, and age. Preoperative neurologic symptoms, >= 70% contralateral carotid stenosis, and bilateral extracranial vertebral stenosis independently increase these odds (OR 2.62, 95% CI [1.32, 5.18], P = 0.005; OR 2.84, 95% CI [1.27, 6.34], P = 0.01; and OR 3.58, 95% CI [1.02, 12.53], P = 0.04, respectively), after adjustment for the other factors. Age >= 70 years has no significant impact.
Conclusions: Preoperative neurologic symptoms, >= 70% contralateral carotid, and bilateral vertebral stenosis increase the probability of clamp-induced ischemia as detected by intraoperative EEG, while >= 70% ipsilateral carotid stenosis decreases it.
C1 [Simon, Mirela V.; Chiappa, Keith H.; Kilbride, Ronan D.; Rordorf, Guy A.; Furie, Karen L.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Cambria, Richard P.; Kwolek, Christopher J.; LaMuraglia, Glenn M.; Conrad, Mark F.] Massachusetts Gen Hosp, Dept Vasc Surg, Boston, MA 02114 USA.
[Ogilvy, Christopher S.] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
RP Simon, MV (reprint author), Massachusetts Gen Hosp, Dept Neurol, WACC 739-G,55 Fruit St, Boston, MA 02114 USA.
EM mvsimon@partners.org
NR 31
TC 5
Z9 5
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0736-0258
J9 J CLIN NEUROPHYSIOL
JI J. Clin. Neurophysiol.
PD OCT
PY 2012
VL 29
IS 5
BP 462
EP 467
DI 10.1097/WNP.0b013e31826bde88
PG 6
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 016VK
UT WOS:000309547600015
PM 23027104
ER
PT J
AU Henrich, TJ
Sciaranghella, G
Li, JZ
Gallien, S
Ho, V
Lacasce, AS
Kuritzkes, DR
AF Henrich, T. J.
Sciaranghella, G.
Li, J. Z.
Gallien, S.
Ho, V.
Lacasce, A. S.
Kuritzkes, D. R.
TI Long-term reduction in peripheral blood HIV-1 reservoirs following
reduced-intensity conditioning allogeneic stem cell transplantation in
two HIV-positive individuals
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Henrich, T. J.; Li, J. Z.; Kuritzkes, D. R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Henrich, T. J.; Li, J. Z.; Ho, V.; Lacasce, A. S.; Kuritzkes, D. R.] Harvard Univ, Sch Med, Boston, MA USA.
[Ho, V.; Lacasce, A. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sciaranghella, G.] Ragon Inst MGH MIT & Harvard, Boston, MA USA.
[Gallien, S.] Hop St Louis, Paris, France.
EM thenrich@partners.org
RI Gallien, Sebastien/F-9930-2015
OI Gallien, Sebastien/0000-0002-8033-0936
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 16
EP 17
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200038
ER
PT J
AU Amorosa, V
Umbleja, T
Johnson, V
Kang, M
Luetkemeyer, A
Bardin, M
Haas, D
Chung, R
Yesmin, S
Coughlin, K
Martinez, A
Adams, MB
Alston-Smith, B
Tebas, P
Peters, M
AF Amorosa, V.
Umbleja, T.
Johnson, V.
Kang, M.
Luetkemeyer, A.
Bardin, M.
Haas, D.
Chung, R.
Yesmin, S.
Coughlin, K.
Martinez, A.
Adams, M. B.
Alston-Smith, B.
Tebas, P.
Peters, M.
TI The addition of nitazoxanide to peginterferon alfa-2a and ribavirin does
not significantly improve sustained virologic response in HCV
treatment-naive genotype 1 HIV-1/HCV co-infected subjects: results of
ACTG 5269
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Amorosa, V.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Amorosa, V.; Tebas, P.] Univ Penn, Philadelphia, PA 19104 USA.
[Umbleja, T.; Kang, M.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Johnson, V.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Johnson, V.] Univ Alabama Birmingham, Birmingham, AL USA.
[Luetkemeyer, A.; Peters, M.] Univ San Francisco, San Francisco, CA 94117 USA.
[Bardin, M.] Romark, Tampa, FL USA.
[Haas, D.] Vanderbilt Univ, Nashville, TN USA.
[Chung, R.] Harvard Univ, Sch Med, Boston, MA USA.
[Yesmin, S.] ACTG Operat Ctr, Bethesda, MD USA.
[Coughlin, K.] Frontiers Sci & Technol Res Fdn, Amherst, NY USA.
[Martinez, A.; Alston-Smith, B.] NIAID, DAIDS, NIH, Bethesda, MD 20892 USA.
[Adams, M. B.] Univ Rochester, Rochester, NY 14627 USA.
EM marion.peters@ucsf.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 47
EP 48
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200105
ER
PT J
AU Lo Re, V
Tate, J
Kallan, M
Lim, J
Goetz, M
Klein, M
Rimland, D
Rodriguez-Barradas, M
Butt, A
Gibert, C
Brown, S
Kostman, J
Strom, B
Reddy, R
Justice, A
Localio, R
AF Lo Re, V.
Tate, J.
Kallan, M.
Lim, J.
Goetz, M.
Klein, M.
Rimland, D.
Rodriguez-Barradas, M.
Butt, A.
Gibert, C.
Brown, S.
Kostman, J.
Strom, B.
Reddy, R.
Justice, A.
Localio, R.
TI Increased risk of hepatic decompensation and hepatocellular carcinoma in
HIV/HCV-co-infected patients compared to HCV-mono-infected patients
despite combination antiretroviral therapy
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Lo Re, V.; Kallan, M.; Kostman, J.; Strom, B.; Reddy, R.; Localio, R.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Lo Re, V.] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Tate, J.; Lim, J.; Justice, A.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Tate, J.; Lim, J.; Justice, A.] Yale Univ, Sch Med, New Haven, CT USA.
[Goetz, M.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Klein, M.] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
[Rimland, D.] Atlanta VA Med Ctr, Atlanta, GA USA.
[Rodriguez-Barradas, M.] Michael E DeBakey VA Med Ctr, Houston, TX USA.
[Butt, A.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gibert, C.] Washington DC VA Med Ctr, Washington, DC USA.
[Brown, S.] James J Peters VA Med Ctr, New York, NY USA.
EM vincentl@mail.med.upenn.edu
RI Lo Re, Vincent/N-7817-2015
NR 0
TC 0
Z9 0
U1 0
U2 3
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 47
EP 47
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200104
ER
PT J
AU Sax, P
Sypek, A
Morris, B
Losina, E
Paltiel, AD
Seage, G
Walensky, R
Weinstein, M
Eron, J
Freedberg, K
AF Sax, P.
Sypek, A.
Morris, B.
Losina, E.
Paltiel, A. D.
Seage, G.
Walensky, R.
Weinstein, M.
Eron, J.
Freedberg, K.
TI HIV cure strategies: how good must they be to improve on current
antiretroviral therapy?
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Sax, P.; Losina, E.; Walensky, R.; Freedberg, K.] Harvard Univ, Sch Med, Boston, MA USA.
[Sax, P.; Losina, E.; Walensky, R.] Brigham & Womens Hopsital, Boston, MA USA.
[Sypek, A.; Morris, B.; Walensky, R.; Freedberg, K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Losina, E.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Paltiel, A. D.] Yale Univ, Sch Med, New Haven, CT USA.
[Seage, G.; Weinstein, M.; Freedberg, K.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Eron, J.] Univ N Carolina, Gillings Sch Global Publ Hlth, Chapel Hill, NC USA.
[Eron, J.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
EM psax@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 5
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 74
EP 75
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200146
ER
PT J
AU Walensky, RP
Ross, EL
Kumarasamy, N
Wood, R
Noubary, F
Paltiel, AD
Nakamura, YM
Godbole, S
Hosseinipour, M
Hakim, JG
Kumwenda, J
Makhema, J
Akelo, V
Panchia, R
Sanne, I
Weinstein, MC
Losina, E
Mayer, KH
Grinsztejn, B
Pilotto, J
Chariyalertsak, S
Santos, B
Chen, YQ
Wang, L
Li, X
McCauley, M
Gamble, T
Piwowar-Manning, E
Cottle, L
Hoffman, I
Eron, J
Gallant, J
Swindells, S
Taha, T
Nielsen-Saines, K
Celentano, D
Essex, M
Elharrar, V
Burns, D
Seage, GR
Cohen, MS
Freedberg, KA
AF Walensky, R. P.
Ross, E. L.
Kumarasamy, N.
Wood, R.
Noubary, F.
Paltiel, A. D.
Nakamura, Y. M.
Godbole, S.
Hosseinipour, M.
Hakim, J. G.
Kumwenda, J.
Makhema, J.
Akelo, V.
Panchia, R.
Sanne, I.
Weinstein, M. C.
Losina, E.
Mayer, K. H.
Grinsztejn, B.
Pilotto, J.
Chariyalertsak, S.
Santos, B.
Chen, Y. Q.
Wang, L.
Li, X.
McCauley, M.
Gamble, T.
Piwowar-Manning, E.
Cottle, L.
Hoffman, I.
Eron, J.
Gallant, J.
Swindells, S.
Taha, T.
Nielsen-Saines, K.
Celentano, D.
Essex, M.
Elharrar, V.
Burns, D.
Seage, G. R.
Cohen, M. S.
Freedberg, K. A.
TI The cost-effectiveness of treatment as prevention: analysis of the HPTN
052 trial
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Walensky, R. P.; Ross, E. L.; Noubary, F.; Nakamura, Y. M.; Freedberg, K. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Walensky, R. P.; Freedberg, K. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Losina, E.] Harvard Ctr AIDS Res, Boston, MA USA.
[Weinstein, M. C.; Essex, M.; Seage, G. R.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Makhema, J.] Botswana Harvard AIDS Inst, Gaborone, Botswana.
[Walensky, R. P.; Losina, E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Kumarasamy, N.] YR Gaitonade Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
[Wood, R.] Univ Cape Town, ZA-7925 Cape Town, South Africa.
[Wood, R.] Desmond Tutu HIV Ctr, Cape Town, South Africa.
[Paltiel, A. D.] Yale Univ, Sch Med, New Haven, CT USA.
[Godbole, S.] NARI, Pune, Maharashtra, India.
[Hosseinipour, M.] Univ N Carolina Chapel Hill, Lilongwe, Malawi.
[Hosseinipour, M.] UNC Project Malawi, Lilongwe, Malawi.
[Hakim, J. G.] Univ Zimbabwe, Dept Med, Harare, Zimbabwe.
[Kumwenda, J.] Coll Med Johns Hopkins Project, Blantyre, Malawi.
[Akelo, V.] KEMRI CDC Res & Publ Hlth Collaborat, Kisumu, Kenya.
[Panchia, R.] Univ Witwatersrand, PHRU, Johannesburg, South Africa.
[Sanne, I.] Univ Witwatersrand, Dept Med, Johannesburg, South Africa.
[Losina, E.; Freedberg, K. A.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Mayer, K. H.] Fenway Inst, Boston, MA USA.
[Grinsztejn, B.] Fiocruz MS, Inst Pesquisa Clin Evandro Chagas, BR-21045900 Rio De Janeiro, Brazil.
[Pilotto, J.] Fiocruz MS, Hosp Geral Nova Iguacu, BR-21045900 Rio De Janeiro, Brazil.
[Pilotto, J.] Fiocruz MS, Lab AIDS & Imunol Mol IOC, BR-21045900 Rio De Janeiro, Brazil.
[Chariyalertsak, S.] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand.
[Santos, B.] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil.
[Chen, Y. Q.; Wang, L.; Li, X.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
[McCauley, M.] FHI 360, Washington, DC USA.
[Gamble, T.] FHI 360, Durham, NC USA.
[Piwowar-Manning, E.; Gallant, J.] Johns Hopkins Sch Med, Baltimore, MD USA.
[Cottle, L.] SCHARP, Seattle, WA USA.
[Hoffman, I.; Eron, J.; Cohen, M. S.] Univ N Carolina, Sch Med, Chapel Hill, NC USA.
[Swindells, S.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Taha, T.; Celentano, D.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Nielsen-Saines, K.] Univ Calif Los Angeles, David Geffen Sch Med, Div Infect Dis, Los Angeles, CA 90095 USA.
[Elharrar, V.; Burns, D.] NIAID, NIH, Bethesda, MD 20892 USA.
EM kfreedberg@partners.org
NR 0
TC 0
Z9 0
U1 1
U2 12
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 116
EP 117
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200220
ER
PT J
AU Mayer, K
Wang, L
Hoffman, I
McCauley, M
Li, X
Safren, S
Gamble, T
Talley, J
Cottle, L
Piwowar-Manning, E
Akelo, V
Badal-Faesen, S
Chotirosniramit, N
Fernandes, NM
Kumarasamy, N
Sahay, S
Makhema, J
Panchia, B
Pilotto, JHD
Santos, BR
Cohen, MS
AF Mayer, K.
Wang, L.
Hoffman, I.
McCauley, M.
Li, X.
Safren, S.
Gamble, T.
Talley, J.
Cottle, L.
Piwowar-Manning, E.
Akelo, V.
Badal-Faesen, S.
Chotirosniramit, N.
Fernandes, N. M.
Kumarasamy, N.
Sahay, S.
Makhema, J.
Panchia, B.
Pilotto, J. H. d. S.
Santos, B. R.
Cohen, M. S.
TI Sustained treatment as prevention: continued decreases in unprotected
sex and increases in virological suppression after HAART initiation
among participants in HPTN 052
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Mayer, K.] Fenway Community Hlth, Boston, MA USA.
[Wang, L.; Li, X.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Seattle, WA 98104 USA.
[Cohen, M. S.] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA.
[McCauley, M.; Gamble, T.; Talley, J.] FHI 360, Washington, DC USA.
[Safren, S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Safren, S.] Fenway Hlth, Boston, MA USA.
[Cottle, L.] SCHARP, Seattle, WA USA.
[Piwowar-Manning, E.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
[Akelo, V.] Ctr Global Hlth Res, Kenya Med Res Inst, Kisumu, Kenya.
[Badal-Faesen, S.] Univ WitwatersrandClin HIV Res Unit, Johannesburg, South Africa.
[Chotirosniramit, N.] Chiang Mai UniversityRes Inst Hlth Sci, Chiang Mai, Thailand.
[Fernandes, N. M.] Inst Pesquisa Clin Evandro Chagas, Rio De Janeiro, Brazil.
[Kumarasamy, N.] VHS, YRG CARE Med Ctr, Madras, Tamil Nadu, India.
[Sahay, S.] Natl AIDS Res Inst ICMR, Pune, Maharashtra, India.
[Makhema, J.] Botswana Harvard AIDS Inst, Gaborone, Botswana.
[Panchia, B.] Univ Witwatersrand, Perinatal HIV Res Unit, Johannesburg, South Africa.
[Pilotto, J. H. d. S.] Hosp Geral Nova Iguacu, Rio De Janeiro, Brazil.
[Pilotto, J. H. d. S.] Lab AIDS & Imunol Mol IOC, Rio De Janeiro, Brazil.
[Santos, B. R.] Hosp Nossa Senhora da Conceicao, Porto Alegre, RS, Brazil.
EM kmayer@fenwayhealth.org
NR 0
TC 0
Z9 0
U1 0
U2 13
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 118
EP 119
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200223
ER
PT J
AU Koole, O
Tsui, S
Wabwire-Mangen, F
Kwesigabo, G
Menten, J
Mulenga, M
Auld, A
Agolory, S
Mukadi, YD
Colebunders, R
Bangsberg, DR
Van Praag, E
Torpey, K
Williams, S
Kaplan, J
Zee, A
Denison, J
AF Koole, O.
Tsui, S.
Wabwire-Mangen, F.
Kwesigabo, G.
Menten, J.
Mulenga, M.
Auld, A.
Agolory, S.
Mukadi, Y. D.
Colebunders, R.
Bangsberg, D. R.
Van Praag, E.
Torpey, K.
Williams, S.
Kaplan, J.
Zee, A.
Denison, J.
TI Retention and risk factors for attrition among adults in antiretroviral
treatment (ART) programs in Tanzania, Uganda and Zambia
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Koole, O.; Menten, J.; Colebunders, R.] Inst Trop Med, B-2000 Antwerp, Belgium.
[Tsui, S.] FHI 360, Durham, NC USA.
[Wabwire-Mangen, F.] Makerere Univ, Coll Hlth Sci, Infect Dis Inst, Kampala, Uganda.
[Kwesigabo, G.] Muhimbili Univ Hlth & Allied Sci, Dar Es Salaam, Tanzania.
[Mulenga, M.] Trop Dis Res Ctr, Ndola, Zambia.
[Auld, A.; Agolory, S.; Williams, S.; Kaplan, J.; Zee, A.] Ctr Dis Control & Prevent, Div Global AIDS, Atlanta, GA USA.
[Mukadi, Y. D.; Denison, J.] FHI 360, Washington, DC USA.
[Bangsberg, D. R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Torpey, K.] FHI 360, Lagos, Nigeria.
EM okoole@itg.be
NR 0
TC 0
Z9 0
U1 0
U2 0
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 123
EP 124
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200228
ER
PT J
AU O'Laughlin, KN
Faustin, ZM
Rouhani, SA
Ware, NC
AF O'Laughlin, K. N.
Faustin, Z. M.
Rouhani, S. A.
Ware, N. C.
TI Increasing HIV testing among African refugees in Africa: intervening in
the daily survival cycle to encourage priority shifting
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [O'Laughlin, K. N.; Rouhani, S. A.; Ware, N. C.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[O'Laughlin, K. N.; Rouhani, S. A.; Ware, N. C.] Harvard Univ, Sch Med, Boston, MA USA.
[Faustin, Z. M.] Bugema Univ, Kampala, Uganda.
[Rouhani, S. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM kolaughlin@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 176
EP 177
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200332
ER
PT J
AU Drain, P
Losina, E
Chetty, S
Giddy, J
Ross, D
Katz, J
Coleman, S
Bogart, L
Freedberg, K
Walensky, R
Ingrid, B
AF Drain, P.
Losina, E.
Chetty, S.
Giddy, J.
Ross, D.
Katz, J.
Coleman, S.
Bogart, L.
Freedberg, K.
Walensky, R.
Ingrid, B.
TI Risk factors for late-stage HIV disease presentation at initial HIV
diagnosis in Durban, South Africa
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Drain, P.; Ingrid, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Losina, E.; Freedberg, K.; Walensky, R.] Harvard Ctr AIDS Res, Boston, MA USA.
[Chetty, S.; Giddy, J.] McCord Hosp, Durban, South Africa.
[Ross, D.] St Marys Hosp, Durban, South Africa.
[Katz, J.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Coleman, S.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Bogart, L.] Childrens Hosp, Boston, MA 02115 USA.
EM pkdrain@gmail.com
NR 0
TC 0
Z9 0
U1 0
U2 2
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 247
EP 247
PG 1
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200484
ER
PT J
AU Yazdanpanah, Y
Perelman, J
Alves, J
Mansinho, K
Dilorenzo, MA
Park, JE
Losina, E
Walensky, RP
Noubary, F
Barros, H
Freedberg, KA
Paltiel, AD
AF Yazdanpanah, Y.
Perelman, J.
Alves, J.
Mansinho, K.
Dilorenzo, M. A.
Park, J. -E.
Losina, E.
Walensky, R. P.
Noubary, F.
Barros, H.
Freedberg, K. A.
Paltiel, A. D.
TI Routine HIV screening in Portugal: clinical impact and
cost-effectiveness
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Yazdanpanah, Y.] Hosp Bichat Claude Bernard, Paris, France.
[Perelman, J.; Alves, J.] Univ Nova Lisboa, Natl Sch Publ Hlth, P-1200 Lisbon, Portugal.
[Mansinho, K.] Hosp Ctr Lisboa Ocidental, Lisbon, Portugal.
[Dilorenzo, M. A.; Park, J. -E.; Walensky, R. P.; Noubary, F.; Freedberg, K. A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Walensky, R. P.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Losina, E.; Freedberg, K. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Losina, E.; Freedberg, K. A.] Boston Univ, Sch Publ Hlth, Boston, MA USA.
[Barros, H.] Univ Porto, Inst Publ Hlth, P-4100 Oporto, Portugal.
[Paltiel, A. D.] Yale Univ, New Haven, CT USA.
EM yazdan.yazdanpanah@bch.aphp.fr
RI Perelman, Julian/B-4350-2013
OI Perelman, Julian/0000-0001-6634-9000
NR 0
TC 0
Z9 0
U1 0
U2 7
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 254
EP 255
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200496
ER
PT J
AU Walensky, RP
Sax, PE
Nakamura, YM
Weinstein, MC
Pei, PP
Freedberg, KA
Paltiel, AD
Schackman, BR
AF Walensky, R. P.
Sax, P. E.
Nakamura, Y. M.
Weinstein, M. C.
Pei, P. P.
Freedberg, K. A.
Paltiel, A. D.
Schackman, B. R.
TI The clinical and economic impact of a generic first-line antiretroviral
regimen in the US
SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY
LA English
DT Meeting Abstract
C1 [Walensky, R. P.; Freedberg, K. A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Sax, P. E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Weinstein, M. C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Paltiel, A. D.] Yale Univ, Sch Med, New Haven, CT USA.
[Schackman, B. R.] Weill Cornell Med Coll, New York, NY USA.
EM rwalensky@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 1
PU INT AIDS SOCIETY
PI GENEVA
PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND
SN 1758-2652
J9 J INT AIDS SOC
JI J. Int. AIDS Soc.
PD OCT
PY 2012
VL 15
SU 3
BP 258
EP 259
PG 2
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA 030RQ
UT WOS:000310588200503
ER
PT J
AU Amariglio, RE
Becker, JA
Carmasin, J
Wadsworth, LP
Lorius, N
Sullivan, C
Maye, JE
Gidicsin, C
Pepin, LC
Sperling, RA
Johnson, KA
Rentz, DM
AF Amariglio, Rebecca E.
Becker, J. Alex
Carmasin, Jeremy
Wadsworth, Lauren P.
Lorius, Natacha
Sullivan, Caroline
Maye, Jacqueline E.
Gidicsin, Christopher
Pepin, Lesley C.
Sperling, Reisa A.
Johnson, Keith A.
Rentz, Dorene M.
TI Subjective cognitive complaints and amyloid burden in cognitively normal
older individuals
SO NEUROPSYCHOLOGIA
LA English
DT Article
DE Preclinical Alzheimer's disease; Early detection; Amyloid imaging;
Subjective cognitive complaints
ID PITTSBURGH-COMPOUND-B; PRECLINICAL ALZHEIMERS-DISEASE;
POSITRON-EMISSION-TOMOGRAPHY; MEMORY COMPLAINTS; IMPAIRMENT; DEPOSITION;
DEMENTIA; PERFORMANCE; BRAIN; DECLINE
AB Accumulating evidence suggests that subjective cognitive complaints (SCC) may indicate subtle cognitive decline characteristic of individuals with preclinical Alzheimer's disease (AD). In this study, we sought to build upon previous studies by associating SCC and amyloid-beta deposition using positron emission tomography with Pittsburgh Compound B (PiB-PET) in cognitively normal older individuals. One-hundred thirty one subjects (mean age 73.5 +/- 6) were administered three subjective cognitive questionnaires and a brief neuropsychological battery. A relationship between a subjective memory complaints composite score and cortical PiB binding was found to be significant, even after controlling for depressive symptoms. By contrast, there were no significant relationships between objective cognitive measures of memory and executive functions and cortical PiB binding. Our study suggests that SCC may be an early indicator of AD pathology detectable prior to significant objective impairment. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Amariglio, Rebecca E.; Lorius, Natacha; Sperling, Reisa A.; Johnson, Keith A.; Rentz, Dorene M.] Brigham & Womens Hosp, Div Cognit & Behav Neurol, Dept Neurol, Boston, MA 02115 USA.
[Amariglio, Rebecca E.; Wadsworth, Lauren P.; Lorius, Natacha; Sullivan, Caroline; Sperling, Reisa A.; Johnson, Keith A.; Rentz, Dorene M.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Becker, J. Alex; Carmasin, Jeremy; Maye, Jacqueline E.; Gidicsin, Christopher; Pepin, Lesley C.; Johnson, Keith A.] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
RP Amariglio, RE (reprint author), Brigham & Womens Hosp, Div Cognit & Behav Neurol, Dept Neurol, 221 Longwood Ave, Boston, MA 02115 USA.
EM ramariglio@partners.org
FU Alzheimer's Association [IIRG-08-90934]; National Institute on Aging
[P01-AG036694-01, P50-AG00513428]
FX This work was supported by an Alzheimer's Association grant
IIRG-08-90934 (D.R.) and by National Institute on Aging grants
P01-AG036694-01 (R.S.); P50-AG00513428 (R.S.).
NR 68
TC 93
Z9 96
U1 3
U2 25
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0028-3932
EI 1873-3514
J9 NEUROPSYCHOLOGIA
JI Neuropsychologia
PD OCT
PY 2012
VL 50
IS 12
BP 2880
EP 2886
DI 10.1016/j.neuropsychologia.2012.08.011
PG 7
WC Behavioral Sciences; Neurosciences; Psychology, Experimental
SC Behavioral Sciences; Neurosciences & Neurology; Psychology
GA 035KQ
UT WOS:000310945900019
PM 22940426
ER
PT J
AU Sheth, SA
Bourne, SK
Tritos, NA
Swearingen, B
AF Sheth, Sameer A.
Bourne, Sarah K.
Tritos, Nicholas A.
Swearingen, Brooke
TI Neurosurgical Treatment of Cushing Disease
SO NEUROSURGERY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Cushing syndrome; Cushing disease; Transsphenoidal surgery;
Adrenocorticotropin; Hypercortisolism
ID TRANSSPHENOIDAL PITUITARY SURGERY; CORTICOTROPIN-RELEASING HORMONE;
LONG-TERM REMISSION; DEXAMETHASONE-SUPPRESSION TEST; SINGLE-CENTER
EXPERIENCE; DIFFERENTIAL-DIAGNOSIS; ENDOSCOPIC TECHNIQUE; CONSECUTIVE
PATIENTS; SURGICAL-MANAGEMENT; CONSENSUS STATEMENT
AB Cushing disease (CD) is caused by overproduction of adrenocorticotropin by a pituitary adenoma (or, rarely, carcinoma). The diagnosis of CD requires distinguishing it from other hypercortisolemic states with a thorough endocrine workup. CD remains a primarily surgical disease, with remission rates of 70% to 95% following microscopic or endoscopic transsphenoidal surgery.
C1 [Sheth, Sameer A.; Bourne, Sarah K.; Swearingen, Brooke] Massachusetts Gen Hosp, Dept Neurosurg, Boston, MA 02114 USA.
[Tritos, Nicholas A.] Massachusetts Gen Hosp, Dept Med, Neuroendocrine Clin Ctr, Boston, MA 02114 USA.
RP Swearingen, B (reprint author), Massachusetts Gen Hosp, Dept Neurosurg, 15 Parkman St,WACC 331, Boston, MA 02114 USA.
EM bswearingen@partners.org
NR 108
TC 5
Z9 5
U1 0
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1042-3680
J9 NEUROSURG CLIN N AM
JI Neurosurg. Clin. N. Am.
PD OCT
PY 2012
VL 23
IS 4
BP 639
EP +
DI 10.1016/j.nec.2012.06.006
PG 15
WC Clinical Neurology; Surgery
SC Neurosciences & Neurology; Surgery
GA 038PR
UT WOS:000311187100010
PM 23040749
ER
PT J
AU Fine, DA
Rozenblatt-Rosen, O
Padi, M
Korkhin, A
James, RL
Adelmant, G
Yoon, R
Guo, LX
Berrios, C
Zhang, Y
Calderwood, MA
Velmurgan, S
Cheng, JW
Marto, JA
Hill, DE
Cusick, ME
Vidal, M
Florens, L
Washburn, MP
Litovchick, L
DeCaprio, JA
AF Fine, Debrah A.
Rozenblatt-Rosen, Orit
Padi, Megha
Korkhin, Anna
James, Robert L.
Adelmant, Guillaume
Yoon, Rosa
Guo, Luxuan
Berrios, Christian
Zhang, Ying
Calderwood, Michael A.
Velmurgan, Soundarapandian
Cheng, Jingwei
Marto, Jarrod A.
Hill, David E.
Cusick, Michael E.
Vidal, Marc
Florens, Laurence
Washburn, Michael P.
Litovchick, Larisa
DeCaprio, James A.
TI Identification of FAM111A as an SV40 Host Range Restriction and
Adenovirus Helper Factor
SO PLOS PATHOGENS
LA English
DT Article
ID LARGE T-ANTIGEN; LARGE TUMOR-ANTIGEN; SIMIAN VIRUS-40; INTERACTOME
NETWORK; GENE-EXPRESSION; CELL-LINE; VIRAL-DNA; PROTEIN;
SIMIAN-VIRUS-40; SUPPRESSOR
AB The small genome of polyomaviruses encodes a limited number of proteins that are highly dependent on interactions with host cell proteins for efficient viral replication. The SV40 large T antigen (LT) contains several discrete functional domains including the LXCXE or RB-binding motif, the DNA binding and helicase domains that contribute to the viral life cycle. In addition, the LT C-terminal region contains the host range and adenovirus helper functions required for lytic infection in certain restrictive cell types. To understand how LT affects the host cell to facilitate viral replication, we expressed full-length or functional domains of LT in cells, identified interacting host proteins and carried out expression profiling. LT perturbed the expression of p53 target genes and subsets of cell-cycle dependent genes regulated by the DREAM and the B-Myb-MuvB complexes. Affinity purification of LT followed by mass spectrometry revealed a specific interaction between the LT C-terminal region and FAM111A, a previously uncharacterized protein. Depletion of FAM111A recapitulated the effects of heterologous expression of the LT C-terminal region, including increased viral gene expression and lytic infection of SV40 host range mutants and adenovirus replication in restrictive cells. FAM111A functions as a host range restriction factor that is specifically targeted by SV40 LT.
C1 [Fine, Debrah A.; Rozenblatt-Rosen, Orit; Korkhin, Anna; Yoon, Rosa; Guo, Luxuan; Berrios, Christian; Cheng, Jingwei; Litovchick, Larisa; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Fine, Debrah A.; Yoon, Rosa; Berrios, Christian; DeCaprio, James A.] Harvard Univ, Div Med Sci, Grad Sch Arts & Sci, Program Virol, Boston, MA 02115 USA.
[Fine, Debrah A.; Rozenblatt-Rosen, Orit; Padi, Megha; Korkhin, Anna; James, Robert L.; Adelmant, Guillaume; Calderwood, Michael A.; Marto, Jarrod A.; Hill, David E.; Cusick, Michael E.; Vidal, Marc; Litovchick, Larisa; DeCaprio, James A.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Genom Anal Network Perturbat Ctr Excellence Genom, Boston, MA 02115 USA.
[Padi, Megha; James, Robert L.; Adelmant, Guillaume; Calderwood, Michael A.; Velmurgan, Soundarapandian; Marto, Jarrod A.; Hill, David E.; Cusick, Michael E.; Vidal, Marc] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Padi, Megha] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Ctr Canc Computat Biol, Boston, MA 02115 USA.
[Padi, Megha] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Adelmant, Guillaume; Marto, Jarrod A.] Dana Farber Canc Inst, Blais Prote Ctr, Boston, MA 02115 USA.
[Adelmant, Guillaume; Marto, Jarrod A.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Guo, Luxuan; Cheng, Jingwei; Litovchick, Larisa; DeCaprio, James A.] Harvard Univ, Brigham & Womens Hosp, Dept Med, Sch Med, Boston, MA 02115 USA.
[Zhang, Ying; Florens, Laurence; Washburn, Michael P.] Stowers Inst Med Res, Kansas City, MO USA.
[Calderwood, Michael A.; Hill, David E.; Cusick, Michael E.; Vidal, Marc] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA.
[Washburn, Michael P.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA.
RP Fine, DA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM james_decaprio@dfci.harvard.edu
RI Hill, David/B-6617-2011; Calderwood, Mike/B-2475-2014
OI Florens, Laurence/0000-0002-9310-6650; Washburn,
Michael/0000-0001-7568-2585; Calderwood, Mike/0000-0001-6475-1418
FU Public Health Service [T32CA009361, P50HG004233, P01CA050661,
RO1CA93804, R01CA63113]
FX This work was supported in part by Public Health Service grants
T32CA009361 (DAF), P50HG004233 (JAM, DEH, MV and JAD), P01CA050661
(JAD), RO1CA93804 (JAD), and R01CA63113 (JAD). The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 44
TC 13
Z9 16
U1 0
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7374
J9 PLOS PATHOG
JI PLoS Pathog.
PD OCT
PY 2012
VL 8
IS 10
AR e1002949
DI 10.1371/journal.ppat.1002949
PG 12
WC Microbiology; Parasitology; Virology
SC Microbiology; Parasitology; Virology
GA 029XH
UT WOS:000310530300015
PM 23093934
ER
PT J
AU Noseworthy, PA
Peloso, GM
Hwang, SJ
Larson, MG
Levy, D
O'Donnell, CJ
Newton-Cheh, C
AF Noseworthy, Peter A.
Peloso, Gina M.
Hwang, Shih-Jen
Larson, Martin G.
Levy, Daniel
O'Donnell, Christopher J.
Newton-Cheh, Christopher
TI QT Interval and Long-Term Mortality Risk in the Framingham Heart Study
SO ANNALS OF NONINVASIVE ELECTROCARDIOLOGY
LA English
DT Article
DE heart rate; mortality; QT interval; sudden cardiac death
ID SUDDEN CARDIAC DEATH; MIDDLE-AGED MEN; CARDIOVASCULAR MORTALITY;
GENERAL-POPULATION; COMMON VARIANTS; CORRECTED QT; ALL-CAUSE; DISEASE;
DURATION; ASSOCIATION
AB Background: The association between QT interval and mortality has been demonstrated in large, prospective population-based studies, but the strength of the association varies considerably based on the method of heart rate correction. We examined the QT-mortality relationship in the Framingham Heart Study (FHS). Methods: Participants in the first (original cohort, n = 2,365) and second generation (offspring cohort, n = 4,530) cohorts were included in this study with a mean follow up of 27.5 years. QT interval measurements were obtained manually using a reproducible digital caliper technique. Results: Using Cox proportional hazards regression adjusting for age and sex, a 20 millisecond increase in QTc (using Bazett's correction; QT/RR1/2 interval) was associated with a modest increase in risk of all-cause mortality (HR 1.14, 95% CI 1.101.18, P < 0.0001), coronary heart disease (CHD) mortality (HR 1.15, 95% CI 1.051.26, P = 0.003), and sudden cardiac death (SCD, HR 1.19, 95% CI 1.031.37, P = 0.02). However, adjustment for heart rate using RR interval in linear regression attenuated this association. The association of QT interval with all-cause mortality persisted after adjustment for cardiovascular risk factors, but associations with CHD mortality and SCD were no longer significant. Conclusion: In FHS, there is evidence of a graded relation between QTc and all-cause mortality, CHD death, and SCD; however, this association is attenuated by adjustment for RR interval. These data confirm that using Bazett's heart rate correction, QTc, overestimates the association with mortality. An association with all-cause mortality persists despite a more complete adjustment for heart rate and known cardiovascular risk factors.
C1 [Noseworthy, Peter A.; Peloso, Gina M.; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02114 USA.
[Noseworthy, Peter A.; Peloso, Gina M.; Newton-Cheh, Christopher] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Noseworthy, Peter A.; Newton-Cheh, Christopher] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Peloso, Gina M.; Hwang, Shih-Jen; Larson, Martin G.; Levy, Daniel; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[Larson, Martin G.] Boston Univ, Dept Math & Stat, Boston, MA 02215 USA.
[Larson, Martin G.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
[Levy, Daniel] NHLBI, Ctr Populat Studies, Bethesda, MD 20892 USA.
[Levy, Daniel] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
RP Newton-Cheh, C (reprint author), Massachusetts Gen Hosp, Cardiovasc Res Ctr, 185 Cambridge St,CPZN 5-242, Boston, MA 02114 USA.
EM cnewtoncheh@chgr.mgh.harvard.edu
OI Larson, Martin/0000-0002-9631-1254
FU Max Schaldach Fellowship in Cardiac Pacing and Electrophysiology;
NIH/NHLBI [HL080025, HL098283]; Doris Duke Charitable Foundation;
Burroughs Wellcome Fund; National Heart Lung and Blood Institute of the
National Institutes of Health; Boston University School of Medicine
[N01-HC-25195]
FX This work was supported by the Max Schaldach Fellowship in Cardiac
Pacing and Electrophysiology (P.A.N.), the NIH/NHLBI (HL080025, HL098283
C. N.-C.), the Doris Duke Charitable Foundation (C. N.-C.), and the
Burroughs Wellcome Fund (C. N.-C.). The FHS was supported by the
National Heart Lung and Blood Institute of the National Institutes of
Health and Boston University School of Medicine (Contract No.
N01-HC-25195).
NR 35
TC 17
Z9 17
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1082-720X
J9 ANN NONINVAS ELECTRO
JI Ann. Noninvasive Electrocardiol.
PD OCT
PY 2012
VL 17
IS 4
BP 340
EP 348
DI 10.1111/j.1542-474X.2012.00535.x
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 026CD
UT WOS:000310248100006
PM 23094880
ER
PT J
AU DeAngelo, DJ
AF DeAngelo, D. J.
TI Managing chronic myeloid leukemia patients intolerant to tyrosine kinase
inhibitor therapy
SO BLOOD CANCER JOURNAL
LA English
DT Review
DE chronic myeloid leukemia; dasatinib; imatinib; intolerance; nilotinib;
tyrosine kinase inhibitors
ID PULMONARY ARTERIAL-HYPERTENSION; CHRONIC MYELOGENOUS LEUKEMIA; DIAGNOSED
CHRONIC-PHASE; NILOTINIB FORMERLY AMN107; CYTOGENETIC RESPONSES;
IMATINIB-RESISTANT; ACCELERATED-PHASE; FOLLOW-UP; DASATINIB TREATMENT;
FAILURE
AB The outcomes for patients with chronic myeloid leukemia have improved dramatically with the development and availability of BCR-ABL1 tyrosine kinase inhibitors (TKIs) over the past decade. TKI therapy has a superior safety profile compared with the previous standard of care, interferon-alpha, and most adverse events (AEs) observed with front-line and second-line TKI treatment are managed with supportive care. However, some patients are intolerant to TKI therapy and experience AEs that cannot be managed through dose reduction or symptomatic treatment. Careful management of AEs helps patients to remain adherent with treatment and increases their chances for successful outcomes. Proactive vigilance for potential AEs and treatment strategies that reduce symptom burden will help to minimize patient intolerance. This review discusses the most common AEs associated with intolerance to TKI therapy and treatment strategies to help manage patients at risk for or experiencing these events.
C1 Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
RP DeAngelo, DJ (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Dana D1B30, Boston, MA 02215 USA.
EM Daniel_Deangelo@dfci.harvard.edu
FU Novartis Pharmaceuticals
FX Financial support for medical editorial assistance was provided by
Novartis Pharmaceuticals. I thank Mariana Ovnic and Anna Lau of
Percolation Communications LLC for their medical editorial assistance.
NR 74
TC 6
Z9 7
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD OCT
PY 2012
VL 2
AR e95
DI 10.1038/bcj.2012.30
PG 9
WC Oncology
SC Oncology
GA 030QR
UT WOS:000310585700004
PM 23085780
ER
PT J
AU Biederman, J
Fried, R
Petty, C
Mahoney, L
Faraone, SV
AF Biederman, Joseph
Fried, Ronna
Petty, Carter
Mahoney, Laura
Faraone, Stephen V.
TI An Examination of the Impact of Attention-Deficit Hyperactivity Disorder
on IQ: A Large Controlled Family-Based Analysis
SO CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE
LA English
DT Article
DE attention-deficit hyperactivity disorder; children; intelligence
quotient; deficits
ID DEFICIT/HYPERACTIVITY DISORDER; LEARNING-DISABILITIES; FOLLOW-UP;
PERFORMANCE; CHILDREN; ADHD; ADOLESCENTS; GIRLS; HERITABILITY; OUTCOMES
AB Objective: Although children with attention-deficit hyperactivity disorder (ADHD) have, on average, lower intelligence quotient (IQ) scores than control subjects, the reasons for these deficits remain unknown. Because IQ is highly familial, we investigated whether children with ADHD have a decrement in IQ from expectations based on parental IQ.
Method: Subjects were 276 children with ADHD and 239 control subjects of similar age and sex. Expected IQ was calculated based on biological parents' estimated IQ. A significant discrepancy between observed and expected estimated IQ was defined by a child scoring 15 IQ points or more lower than expected, based on parental IQ.
Results: Compared with control subjects, children with ADHD were significantly more likely to have lower than expected estimated IQ scores based on parental IQ, though this finding was accounted for by a small subgroup of children with ADHD who had an IQ 15 points or more lower than expected, based on parental IQ. These children were more likely to be female, have higher psychopathological, neuropsychological, educational, and interpersonal deficits, as well as higher rates of perinatal complications.
Conclusions: Group differences in IQ scores between children with and without ADHD reported in the literature may be accounted for by a subgroup of children with ADHD who have a large decrement in IQ from expectations based on parental IQ. Although perinatal complications may explain these findings, more work is needed to better understand the etiology of these IQ deficits.
C1 [Biederman, Joseph; Fried, Ronna; Petty, Carter; Mahoney, Laura] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA.
[Fried, Ronna] Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY USA.
[Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Adult ADHD, Boston, MA 02114 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol, Boston, MA 02114 USA.
EM jbiederman@partners.org
OI Faraone, Stephen/0000-0002-9217-3982
FU Neal-Kimmerly Massachusetts General Hospital (MGH) Fund; MGH Pediatric
Psychopharmacology Council Fund; Elminda; Janssen; McNeil; Shire; Eli
Lilly; AstraZeneca; Abbott; Alza; Boston University; Bristol Myers
Squibb; Celltech; Cephalon; Eli Lilly and Co; Esai; Fundacion Areces
(Spain); Forest; Glaxo; Gliatech; Hastings Center; Medice
Pharmaceuticals (Germany); Merck; Matrix Medical Communications
Pediatric; National Alliance for Research in Schizophrenia and Affective
Disorders; National Institute on Drug Abuse; New River; National
Institute of Child Health and Human Development; National Institute of
Mental Health; Novartis; Noven; Neurosearch; Organon; Otsuka; Pharmacia;
Phase V Communications; Physicians Academy; The Prechter Foundation;
Quantia Communications; Reed Exhibitions; Spanish Child Psychiatry
Association; The Stanley Foundation; UCB Pharma Inc.; Veritas; Wyeth;
National institutes of Health (NIH)
FX Our study was supported in part by the Neal-Kimmerly Massachusetts
General Hospital (MGH) Fund for the Study of Cognition and the MGH
Pediatric Psychopharmacology Council Fund.; Dr Biederman is currently
receiving research support from the following sources: Elminda, Janssen,
McNeil, and Shire. In 2011, Dr Biederman gave a single unpaid talk for
Juste Pharmaceutical Spain, received honoraria from the MGH Psychiatry
Academy for a tuition-funded continuing medical education (CME) course,
and received an honorarium for presenting at an international scientific
conference on ADHD. He also received an honorarium from Cambridge
University Press for a chapter publication. Dr Biederman received
departmental royalties from a copyrighted rating scale used for ADHD
diagnoses, paid by Eli Lilly, Shire, and AstraZeneca; these royalties
are paid to the Department of Psychiatry at MGH. In 2010, Dr Biederman
received a speaker's fee from a single talk given at Fundacion Dr Manuel
Camelo AC in Monterrey, Mexico. Dr Biederman provided single
consultations for Shionogi Pharma Inc and Cipher Pharmaceuticals Inc;
the honoraria for these consultations were paid to the Department of
Psychiatry at the MGH. Dr Biederman received honoraria from the MGH
Psychiatry Academy for a tuition-funded CME course. In previous years,
Dr Biederman received research support, consultation fees, or speaker's
fees for and from the following additional sources: Abbott, Alza,
AstraZeneca, Boston University, Bristol Myers Squibb, Celltech,
Cephalon, Eli Lilly and Co, Esai, Fundacion Areces (Spain), Forest,
Glaxo, Gliatech, Hastings Center, Janssen, McNeil, Medice
Pharmaceuticals (Germany), Merck, Matrix Medical Communications
Pediatric, National Alliance for Research in Schizophrenia and Affective
Disorders, National Institute on Drug Abuse, New River, National
Institute of Child Health and Human Development, National Institute of
Mental Health, Novartis, Noven, Neurosearch, Organon, Otsuka, Pfizer,
Pharmacia, Phase V Communications, Physicians Academy, The Prechter
Foundation, Quantia Communications, Reed Exhibitions, Shire, the Spanish
Child Psychiatry Association, The Stanley Foundation, UCB Pharma Inc.,
Veritas, and Wyeth.; In the past year, Dr Faraone received consulting
fees and was on advisory boards for Shire Development and received
research support from Shire and the National institutes of Health (NIH).
In previous years, he received consulting fees or was on advisory boards
or participated in continuing medical education programs sponsored by:
Shire, McNeil, Janssen, Novartis, Pfizer, and Eli Lilly. In previous
years he received research support from Eli Lilly, Shire, Pfizer, and
the NIH. Dr Faraone receives royalties from a book published by Guilford
Press: Straight Talk about Your Child's Mental Health.
NR 24
TC 7
Z9 7
U1 2
U2 25
PU CANADIAN PSYCHIATRIC ASSOC
PI OTTAWA
PA 141 LAURIER AVENUE WEST, STE 701, OTTAWA, ONTARIO K1P 5J3, CANADA
SN 0706-7437
J9 CAN J PSYCHIAT
JI Can. J. Psychiat.-Rev. Can. Psychiat.
PD OCT
PY 2012
VL 57
IS 10
BP 608
EP 616
PG 9
WC Psychiatry
SC Psychiatry
GA 033TP
UT WOS:000310824300005
PM 23072952
ER
PT J
AU Mai, PL
Malkin, D
Garber, JE
Schiffman, JD
Weitzel, JN
Strong, LC
Wyss, O
Locke, L
Means, V
Achatz, MI
Hainaut, P
Frebourg, T
Evans, DG
Bleiker, E
Patenaude, A
Schneider, K
Wilfond, B
Peters, JA
Hwang, PM
Ford, J
Tabori, U
Ognjanovic, S
Dennis, PA
Wentzensen, IM
Greene, MH
Fraumeni, JF
Savage, SA
AF Mai, Phuong L.
Malkin, David
Garber, Judy E.
Schiffman, Joshua D.
Weitzel, Jeffrey N.
Strong, Louise C.
Wyss, Oliver
Locke, Luana
Means, Von
Achatz, Maria Isabel
Hainaut, Pierre
Frebourg, Thierry
Evans, D. Gareth
Bleiker, Eveline
Patenaude, Andrea
Schneider, Katherine
Wilfond, Benjamin
Peters, June A.
Hwang, Paul M.
Ford, James
Tabori, Uri
Ognjanovic, Simona
Dennis, Phillip A.
Wentzensen, Ingrid M.
Greene, Mark H.
Fraumeni, Joseph F., Jr.
Savage, Sharon A.
TI Li-Fraumeni syndrome: report of a clinical research workshop and
creation of a research consortium
SO CANCER GENETICS
LA English
DT Article
DE Li-Fraumeni syndrome; hereditary cancer predisposition syndrome; TP53
mutations
ID TP53 MUTATION CARRIERS; BREAST-CANCER; MITOCHONDRIAL RESPIRATION;
GERMLINE MUTATIONS; FAMILIAL SYNDROME; TELOMERE LENGTH; P53 MUTATIONS;
GENE; SURVEILLANCE; NEOPLASMS
AB Li-Fraumeni syndrome (LFS) is a rare dominantly inherited cancer predisposition syndrome that was first described in 1969. In most families, it is caused by germline mutations in the TP53 gene and is characterized by early onset of multiple specific cancers and very high lifetime cumulative cancer risk. Despite significant progress in understanding the molecular biology of TP53, the optimal clinical management of this syndrome is poorly defined. We convened a workshop on November 2, 2010, at the National Institutes of Health in Bethesda, Maryland, bringing together clinicians and scientists, as well as individuals from families with LFS, to review the state of the science, address clinical management issues, stimulate collaborative research, and engage the LFS family community. This workshop also led to the creation of the Li-Fraumeni Exploration (LiFE) Research Consortium.
C1 [Mai, Phuong L.; Peters, June A.; Wentzensen, Ingrid M.; Greene, Mark H.; Fraumeni, Joseph F., Jr.; Savage, Sharon A.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Malkin, David; Tabori, Uri] Univ Toronto, Hosp Sick Children, Dept Pediat, Div Hematol Oncol & Genet, Toronto, ON M5G 1X8, Canada.
[Malkin, David; Tabori, Uri] Univ Toronto, Hosp Sick Children, Dept Pediat, Genome Biol Program, Toronto, ON M5G 1X8, Canada.
[Garber, Judy E.; Schneider, Katherine] Dana Farber Canc Inst, Dept Med, Boston, MA 02115 USA.
[Schiffman, Joshua D.] Univ Utah, Dept Pediat, Huntsman Canc Inst, Ctr Childrens Canc Res, Salt Lake City, UT USA.
[Weitzel, Jeffrey N.] City Hope Natl Med Ctr, Dept Populat Sci, Div Clin Canc Genet, Duarte, CA 91010 USA.
[Strong, Louise C.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA.
[Achatz, Maria Isabel] Hosp AC Camargo Fund Antonio Prudente, Dept Oncogenet, Sao Paulo, Brazil.
[Achatz, Maria Isabel] Natl Inst Sci & Technol Oncogen INCITO, Sao Paulo, Brazil.
[Hainaut, Pierre] Int Prevent Res Inst, Lyon, France.
[Frebourg, Thierry] Univ Hosp, Dept Genet, INSERM, Inst Biomed Res & Innovat,U614, Rouen, Normandy, France.
[Evans, D. Gareth] Univ Manchester, St Marys Hosp, MAHSC, Manchester M13 0JH, Lancs, England.
[Bleiker, Eveline] Netherlands Canc Inst, Div Psychosocial Res & Epidemiol, Amsterdam, Netherlands.
[Patenaude, Andrea] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wilfond, Benjamin] Univ Washington, Sch Med, Dept Pediat, Div Bioeth, Seattle, WA 98195 USA.
[Hwang, Paul M.] NHLBI, Ctr Mol Med, NIH, Bethesda, MD 20892 USA.
[Ford, James] Stanford Univ, Dept Med, Sch Med, Div Oncol, Stanford, CA 94305 USA.
[Ford, James] Stanford Univ, Dept Med, Sch Med, Div Med Genet, Stanford, CA 94305 USA.
[Ognjanovic, Simona] Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA.
[Ognjanovic, Simona] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN 55455 USA.
[Dennis, Phillip A.] NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA.
RP Mai, PL (reprint author), NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
EM maip@mail.nih.gov
RI Achatz, Maria Isabel /C-5751-2013; Oncogenomica, Inct/H-9999-2013;
Hainaut, Pierre /B-6018-2012; Savage, Sharon/B-9747-2015;
OI Achatz, Maria Isabel /0000-0001-6894-1219; Hainaut, Pierre
/0000-0002-1303-1610; Savage, Sharon/0000-0001-6006-0740; Tabori,
Uri/0000-0002-5019-2683; Evans, Gareth/0000-0002-8482-5784
FU NIH Office of Rare Diseases Research; Division of Cancer Control and
Population Sciences of the NCI; intramural research program of the
Division of Cancer Epidemiology and Genetics, NCI, NIH
FX The workshop was supported by the NIH Office of Rare Diseases Research,
the Division of Cancer Control and Population Sciences of the NCI, and
the intramural research program of the Division of Cancer Epidemiology
and Genetics, NCI, NIH.
NR 40
TC 20
Z9 20
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 2210-7762
J9 CANCER GENET-NY
JI Cancer Genet.
PD OCT
PY 2012
VL 205
IS 10
BP 479
EP 487
DI 10.1016/j.cancergen.2012.06.008
PG 9
WC Oncology; Genetics & Heredity
SC Oncology; Genetics & Heredity
GA 031TQ
UT WOS:000310665600001
PM 22939227
ER
PT J
AU Zhang, X
Bedigian, AV
Wang, WC
Eggert, US
AF Zhang, Xin
Bedigian, Anne V.
Wang, Wenchao
Eggert, Ulrike S.
TI G protein-coupled receptors participate in cytokinesis
SO CYTOSKELETON
LA English
DT Article
DE cytokinesis; GPCRs
ID DROSOPHILA NERVOUS-SYSTEM; HETEROTRIMERIC G-PROTEINS; BETA-ARRESTINS;
CELL-DIVISION; TASTE RECEPTORS; ESCRT MACHINERY; DRUG TARGETS; MIDBODY;
GIPC; RHO
AB Cytokinesis, the last step during cell division, is a highly coordinated process that involves the relay of signals from both the outside and inside of the cell. We have a basic understanding of how cells regulate internal events, but how cells respond to extracellular cues is less explored. In a systematic RNAi screen of G protein-coupled receptors (GPCRs) and their effectors, we found that some GPCRs are involved in cytokinesis. RNAi knockdown of these GPCRs caused increased binucleated cell formation, and live cell imaging showed that most formed midbodies but failed at the abscission stage. OR2A4 (olfactory receptor, family 2, subfamily A, member 4) localized to cytokinetic structures in cells and its knockdown caused cytokinesis failure at an earlier stage, likely due to effects on the actin cytoskeleton. Identifying the downstream components that transmit GPCR signals during cytokinesis will be the next step and we show that GIPC1 (GIPC PDZ domain containing family, member 1), an adaptor protein for GPCRs, may play a part. RNAi knockdown of GIPC1 significantly increased binucleated cell formation. Understanding the molecular details of GPCRs and their interaction proteins in cytokinesis regulation will give us important clues about GPCRs signaling as well as how cells communicate with their environment during division. (c) 2012 Wiley Periodicals, Inc
C1 [Eggert, Ulrike S.] Kings Coll London, Dept Chem, London SE1 1UL, England.
[Eggert, Ulrike S.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England.
[Zhang, Xin; Wang, Wenchao] Chinese Acad Sci, High Magnet Field Lab, Hefei, Peoples R China.
[Zhang, Xin; Bedigian, Anne V.; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.
[Zhang, Xin; Bedigian, Anne V.; Wang, Wenchao; Eggert, Ulrike S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Eggert, US (reprint author), Kings Coll London, Dept Chem, London SE1 1UL, England.
EM ulrike.eggert@kcl.ac.uk
FU NIH [R01 GM082834]; Dana-Farber Cancer Institute
FX We thank the Nikon Imaging Center at Harvard Medical School for
assistance with microscopy and the Flow Cytometry facility at
Dana-Farber Cancer Institute for assistance with flow cytometry. We also
thank ICCB-Longwood, the screening center at Harvard Medical School for
the RNAi screen and the Drosophila RNAi Screening Center at Harvard
Medical School for the use of the OPERA microscope. This project was
funded by NIH grant R01 GM082834 (to UE) and the Dana-Farber Cancer
Institute.
NR 55
TC 27
Z9 28
U1 1
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1949-3584
J9 CYTOSKELETON
JI Cytoskeleton
PD OCT
PY 2012
VL 69
IS 10
SI SI
BP 810
EP 818
DI 10.1002/cm.21055
PG 9
WC Cell Biology
SC Cell Biology
GA 023XR
UT WOS:000310071500012
PM 22888021
ER
PT J
AU Breakeifeld, X
Prabhakar, S
Sena-Esteves, M
Saydam, O
Brenner, G
AF Breakeifeld, Xandra
Prabhakar, Shilpa
Sena-Esteves, Miguel
Saydam, Okay
Brenner, Gary
TI Therapy for schwannomas using AAV-P0-caspase and exosome-mediated
delivery of therapeutic RNA/protein
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Collaborative Congress of the
European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gen
e-Therapy
CY OCT 25-29, 2012
CL Versailles, FRANCE
SP European Soc Gene & Cell Therapy, French Soc Cell & Gene Therapy
C1 [Breakeifeld, Xandra; Prabhakar, Shilpa; Brenner, Gary] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Saydam, Okay] Med Univ Vienna, Vienna, Austria.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD OCT
PY 2012
VL 23
IS 10
BP A18
EP A18
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 027PE
UT WOS:000310364400053
ER
PT J
AU Hudry, E
Dashkoff, J
Lee, A
Koffie, RM
Hashimoto, T
Scheel, M
Spires-Jones, T
Bacskai, BJ
Davidson, B
Hyman, BT
AF Hudry, Eloise
Dashkoff, Jonathan
Lee, Allyson
Koffie, Robert M.
Hashimoto, Tadafumi
Scheel, Maria
Spires-Jones, Tara
Bacskai, Brian J.
Davidson, Beverly
Hyman, Bradley T.
TI Changes in the progression of amyloid deposition in APP/PS mice after
overexpression of different apoe isoforms through intraventricular
injection of an adeno-associated virus serotype 4
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Collaborative Congress of the
European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gen
e-Therapy
CY OCT 25-29, 2012
CL Versailles, FRANCE
SP European Soc Gene & Cell Therapy, French Soc Cell & Gene Therapy
C1 [Hudry, Eloise; Dashkoff, Jonathan; Lee, Allyson; Koffie, Robert M.; Hashimoto, Tadafumi; Spires-Jones, Tara; Bacskai, Brian J.; Hyman, Bradley T.] Massachusetts Gen Hosp, MassGeneral Inst Neurodegenerat Dis, Charlestown, MA USA.
[Scheel, Maria; Davidson, Beverly] Univ Iowa, Iowa City, IA 52242 USA.
RI Hashimoto, Tadafumi/A-7723-2013
NR 0
TC 0
Z9 0
U1 1
U2 3
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD OCT
PY 2012
VL 23
IS 10
BP A59
EP A59
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 027PE
UT WOS:000310364400178
ER
PT J
AU Kahraman, S
Aydin, C
Elpek, GO
Dirice, E
Sanlioglu, AD
AF Kahraman, Sevim
Aydin, Cigdem
Elpek, Gulsum Ozlem
Dirice, Ercument
Sanlioglu, Ahter Dilsad
TI Diabetogenic response to streptozotocin varies among NOD and NOR mice
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Collaborative Congress of the
European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gen
e-Therapy
CY OCT 25-29, 2012
CL Versailles, FRANCE
SP European Soc Gene & Cell Therapy, French Soc Cell & Gene Therapy
C1 [Kahraman, Sevim; Aydin, Cigdem; Dirice, Ercument; Sanlioglu, Ahter Dilsad] Akdeniz Univ, Hosp & Clin, Human Gene & Cell Therapy Ctr, TR-07058 Antalya, Turkey.
[Kahraman, Sevim; Aydin, Cigdem; Sanlioglu, Ahter Dilsad] Akdeniz Univ, Dept Med Biol, Fac Med, TR-07058 Antalya, Turkey.
[Elpek, Gulsum Ozlem] Akdeniz Univ, Fac Med, Dept Pathol, TR-07058 Antalya, Turkey.
[Dirice, Ercument] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD OCT
PY 2012
VL 23
IS 10
BP A77
EP A77
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 027PE
UT WOS:000310364400230
ER
PT J
AU Kahraman, S
Dirice, E
Elpek, GO
Aydin, C
Balci, MK
Omer, A
Sanlioglu, S
Sanlioglu, AD
AF Kahraman, Sevim
Dirice, Ercument
Elpek, Gulsum Ozlem
Aydin, Cigdem
Balci, Mustafa Kemal
Omer, Abdulkadir
Sanlioglu, Salih
Sanlioglu, Ahter Dilsad
TI Pancreatic acinar cells respond differentially to diabetic agents
Streptozotocin and Cyclophosphamide
SO HUMAN GENE THERAPY
LA English
DT Meeting Abstract
CT Collaborative Congress of the
European-Society-of-Gene-and-Cell-Therapy/French-Society-of-Cell-and-Gen
e-Therapy
CY OCT 25-29, 2012
CL Versailles, FRANCE
SP European Soc Gene & Cell Therapy, French Soc Cell & Gene Therapy
C1 [Kahraman, Sevim; Aydin, Cigdem; Sanlioglu, Salih; Sanlioglu, Ahter Dilsad] Akdeniz Univ, Human Gene & Cell Therapy Ctr, TR-07058 Antalya, Turkey.
[Kahraman, Sevim; Aydin, Cigdem; Sanlioglu, Salih; Sanlioglu, Ahter Dilsad] Akdeniz Univ, Dept Med Biol & Genet, TR-07058 Antalya, Turkey.
[Dirice, Ercument] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Islet Cell & Regenerat Med, Boston, MA 02115 USA.
[Elpek, Gulsum Ozlem] Akdeniz Univ, Dept Pathol, TR-07058 Antalya, Turkey.
[Balci, Mustafa Kemal] Akdeniz Univ, Div Endocrinol & Metab Dis, TR-07058 Antalya, Turkey.
[Omer, Abdulkadir] Univ Massachusets, Dept Med, Dept Endocrinol & Diabet, Worcester, MA USA.
RI BALCI, Mustafa Kemal/C-2979-2016; Sanlioglu, Salih/F-9305-2016
OI BALCI, Mustafa Kemal/0000-0002-6494-3249;
NR 0
TC 0
Z9 0
U1 0
U2 2
PU MARY ANN LIEBERT INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
J9 HUM GENE THER
JI Hum. Gene Ther.
PD OCT
PY 2012
VL 23
IS 10
BP A79
EP A79
PG 1
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA 027PE
UT WOS:000310364400236
ER
PT J
AU Chen, XY
Wu, MX
AF Chen, Xinyuan
Wu, Mei X.
TI How effective could laser-based approaches be in assisting dendritic
cell immunotherapy?
SO IMMUNOTHERAPY
LA English
DT Editorial Material
DE adjuvant; cancer vaccine; dendritic cell; immunotherapy; intradermal
injection; laser; local environment; maturation; migration;
preconditioning
ID METASTATIC MELANOMA; T-CELLS; CANCER; IMMUNIZATION; VACCINATION;
MIGRATION; VACCINES; IMMUNITY; GENERATION; MECHANISM
C1 [Chen, Xinyuan; Wu, Mei X.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA.
[Wu, Mei X.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02115 USA.
RP Wu, MX (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, 50 Blossom St,Edwards 222, Boston, MA 02114 USA.
EM mwu2@partners.org
FU NIDA NIH HHS [RC1 DA028378]
NR 20
TC 1
Z9 1
U1 0
U2 4
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1750-743X
J9 IMMUNOTHERAPY-UK
JI Immunotherapy
PD OCT
PY 2012
VL 4
IS 10
BP 983
EP 985
DI 10.2217/IMT.12.101
PG 3
WC Immunology
SC Immunology
GA 031QF
UT WOS:000310656300004
PM 23148749
ER
PT J
AU Daniels, AB
Lee, JE
MacConaill, LE
Palescandolo, E
Van Hummelen, P
Adams, SM
DeAngelis, MM
Hahn, WC
Gragoudas, ES
Harbour, JW
Garraway, LA
Kim, IK
AF Daniels, Anthony B.
Lee, Joo-Eun
MacConaill, Laura E.
Palescandolo, Emanuele
Van Hummelen, Paul
Adams, Scott M.
DeAngelis, Margaret M.
Hahn, William C.
Gragoudas, Evangelos S.
Harbour, J. William
Garraway, Levi A.
Kim, Ivana K.
TI High Throughput Mass Spectrometry-Based Mutation Profiling of Primary
Uveal Melanoma
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID COLLABORATIVE OCULAR MELANOMA; COMS RANDOMIZED-TRIAL; CHOROIDAL
MELANOMA; LUNG ADENOCARCINOMA; ONCOGENIC MUTATIONS; BAP1; SURVIVAL;
GNAQ; PREDISPOSE; METASTASES
AB PURPOSE. We assessed for mutations in a large number of oncogenes and tumor suppressor genes in primary uveal melanomas using a high-throughput profiling system.
METHODS. DNA was extracted and purified from 134 tissue samples from fresh-frozen tissues (n = 87) or formalin-fixed, paraffin-embedded tissues (n = 47) from 124 large uveal melanomas that underwent primary treatment by enucleation. DNA was subjected to whole genome amplification and MALDI-TOF mass spectrometry-based mutation profiling (> 1000 mutations tested across 120 oncogenes and tumor suppressor genes) using the OncoMap3 platform. All candidate mutations, as well as commonly occurring mutations in GNAQ and GNA11, were validated using homogeneous mass extension (hME) technology.
RESULTS. Of 123 samples, 97 (79%, representing 89 unique tumors) were amplified successfully, passed all quality control steps, and were assayed with the OncoMap platform. A total of 58 mutation calls was made for 49 different mutations across 26 different genes in 34/98 (35%) samples. Of 91 tumors that underwent hME validation, 83 (91%) harbored mutations in the GNAQ (47%) or GNA11 (44%) genes, while hME validation revealed two tumors with mutations in EGFR. These additional mutations occurred in tumors that also had mutations in GNAQ or GNA11.
CONCLUSIONS. The vast majority of primary large uveal melanomas harbor mutually-exclusive mutations in GNAQ or GNA11, but very rarely have the oncogenic mutations that are reported commonly in other cancers. When present, these other mutations were found in conjunction with GNAQ/GNA11 mutations, suggesting that these other mutations likely are not the primary drivers of oncogenesis in uveal melanoma. ( Invest Ophthalmol Vis Sci. 2012;53:6991-6996) DOI: 10.1167/iovs.12-10427
C1 [Kim, Ivana K.] Harvard Univ, Retina Serv, Massachusetts Eye & Ear Infirm, Sch Med,Dept Ophthalmol, Boston, MA 02114 USA.
[Lee, Joo-Eun; Adams, Scott M.; DeAngelis, Margaret M.] Harvard Univ, Ocular Mol Genet Inst, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
[MacConaill, Laura E.; Palescandolo, Emanuele; Van Hummelen, Paul; Hahn, William C.; Garraway, Levi A.] Dana Farber Canc Inst, Ctr Canc Genome Discovery, Dept Med Oncol, Boston, MA 02115 USA.
[MacConaill, Laura E.; Palescandolo, Emanuele; Van Hummelen, Paul; Hahn, William C.; Garraway, Levi A.] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Hahn, William C.; Garraway, Levi A.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Harbour, J. William] Washington Univ, Sch Med, Dept Ophthalmol & Visual Sci, St Louis, MO 63110 USA.
RP Kim, IK (reprint author), Harvard Univ, Retina Serv, Massachusetts Eye & Ear Infirm, Sch Med,Dept Ophthalmol, 243 Charles St, Boston, MA 02114 USA.
EM ivana_kim@meei.harvard.edu
RI DeAngelis, e/J-7863-2015
FU National Cancer Institute [R21CA139300]; Research to Prevent Blindness
PhysicianScientist Award; MEEI Bacardi Cancer Research Fund; MEEI
Melanoma Research Fund
FX Supported by Award Number R21CA139300 from the National Cancer Institute
(IKK), Research to Prevent Blindness PhysicianScientist Award (IKK),
MEEI Bacardi Cancer Research Fund, and MEEI Melanoma Research Fund.
NR 36
TC 18
Z9 18
U1 0
U2 3
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2012
VL 53
IS 11
BP 6991
EP 6996
DI 10.1167/iovs.12-10427
PG 6
WC Ophthalmology
SC Ophthalmology
GA 030SH
UT WOS:000310589900034
PM 22977135
ER
PT J
AU Stevenson, W
Cheng, SF
Emami-Naeini, P
Hua, J
Paschalis, EI
Dana, R
Saban, DR
AF Stevenson, William
Cheng, Sheng-Fu
Emami-Naeini, Parisa
Hua, Jing
Paschalis, Eleftherios I.
Dana, Reza
Saban, Daniel R.
TI Gamma-Irradiation Reduces the Allogenicity of Donor Corneas
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
ID ANTI-CD4 MONOCLONAL-ANTIBODY; CANINE TRACHEAL ALLOGRAFTS; TRANSPLANT
SURVIVAL; REJECTION; RISK; KERATOPLASTY; GRAFTS; CRYOPRESERVATION;
IMMUNOGENICITY; MECHANISMS
AB PURPOSE. To evaluate the utility and allogenicity of gamma-irradiated corneal allografts.
METHODS. Corneal buttons were harvested from C57BL/6 mice and decellularized with gamma irradiation. Cell viability was assessed using TUNEL and viability/cytotoxicity assays. Orthotopic penetrating keratoplasty was performed using irradiated or nonirradiated (freshly excised) C57BL/6 donor grafts and BALB/c or C57BL/6 recipients. Graft opacity was assessed over an 8-week period and graft survival was evaluated using Kaplan-Meier survival curves. Mixed-lymphocyte reactions and delayed-type hypersensitivity assays were performed to evaluate T-cell alloreactivity. Real-time PCR was used to investigate the corneal expression of potentially pathogenic T-helper 1, 2, and 17 cell-associated cytokines.
RESULTS. Corneal cells were devitalized by gamma irradiation as evidenced by widespread cellular apoptosis and plasma membrane disruption. Nonirradiated allograft and isograft rates of survival were superior to irradiated allograft and isograft rates of survival (P < 0.001). Mixed lymphocyte reactions demonstrated that T-cells from irradiated allograft recipients did not exhibit a secondary alloimmune response (P < 0.001). Delayed-type hypersensitivity assays demonstrated that irradiated allografts did not elicit an alloreactive delayed-type hypersensitivity response in graft recipients (P <= 0.01). The corneal expression of T-helper 1, 2, and 17 cell-associated cytokines was significantly lower in failed irradiated allografts than rejected nonirradiated allografts (P <= 0.001).
CONCLUSIONS. Gamma-irradiated corneas failed to remain optically clear following murine penetrating keratoplasty; however, gamma irradiation reduced the allogenicity of these corneas, potentially supporting their use in procedures such as anterior lamellar keratoplasty or keratoprosthesis implantation. (Invest Ophthalmol Vis Sci. 2012; 53: 7151-7158) DOI: 10.1167/iovs.12-9609
C1 [Stevenson, William; Cheng, Sheng-Fu; Emami-Naeini, Parisa; Hua, Jing; Paschalis, Eleftherios I.; Dana, Reza; Saban, Daniel R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
RP Saban, DR (reprint author), Duke Univ, Sch Med, 2351 Erwin Rd, Durham, NC 27705 USA.
EM daniel.saban@duke.edu
OI Paschalis, Eleftherios/0000-0002-4544-4452
FU Frederick N. Griffith Foundation; NIH [EY-12963]
FX Supported by the Frederick N. Griffith Foundation and NIH Grant
EY-12963.
NR 46
TC 8
Z9 8
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD OCT
PY 2012
VL 53
IS 11
BP 7151
EP 7158
DI 10.1167/iovs.12-9609
PG 8
WC Ophthalmology
SC Ophthalmology
GA 030SH
UT WOS:000310589900057
PM 22991417
ER
PT J
AU Chitsaz, S
Azadani, AN
Matthews, PB
Chuter, TA
Tseng, EE
Ge, L
AF Chitsaz, S.
Azadani, A. N.
Matthews, P. B.
Chuter, T. A.
Tseng, E. E.
Ge, L.
TI Hemodynamic determinants of aortic dissection propagation by 2D
computational modeling: implications for endovascular stent-grafting
SO JOURNAL OF CARDIOVASCULAR SURGERY
LA English
DT Article
DE Aortic diseases; Molecular dynamics simulation; Aneurysm
ID DESCENDING THORACIC AORTA; B DISSECTION; INTERNATIONAL REGISTRY;
FLUID-DYNAMICS; PLACEMENT; REPAIR; COMPLICATIONS; ANEURYSMS; DISEASE;
EXPERIENCE
AB Aim. Aortic dissection is a life-threatening aortic catastrophe where layers of the aortic wall are separated allowing blood flow within the layers. Propagation of aortic dissection is strongly linked to the rate of rise of pressure (dp/dt) experienced by the aortic wall but the hemodynamics is poorly understood. The purpose of this study was to perform computational fluid dynamics (CFD) simulations to determine the relationship between dissection propagation in the distal longitudinal direction (the tearing force) and dp/dt.
Methods. Five computational models of aortic dissection in a 2D pipe were constructed. Initiation of dissection and propagation were represented in 4 single entry tear models, 3 of which investigated the role of length of dissection and antegrade propagation, 1 of which investigated retrograde propagation. The 5th model included a distal re-entry tear. Impact of pressure field distribution on tearing force was determined.
Results. Tearing force in the longitudinal direction for dissections with a single entry tear was approximately proportional to dp/dt and L-2 where L is the length of dissection. Tearing force was much lower under steady flow than pulsatile flow conditions. Introduction of a second tear distally along the dissection away from the primary entry tear significantly reduced tearing force.
Conclusion. The hemodynamic mechanism for dissection propagation demonstrated in these models support the use of beta-blockers in medical management. Endovascular stent-graft treatment of dissection should ideally cover both entry and re-entry tears to reduce risk of retrograde propagation of aortic dissection.
C1 [Chitsaz, S.; Azadani, A. N.; Matthews, P. B.; Tseng, E. E.; Ge, L.] Univ Calif San Francisco, Med Ctr, Dept Surg, Div Cardiothorac Surg, San Francisco, CA 94143 USA.
[Chitsaz, S.; Azadani, A. N.; Matthews, P. B.; Chuter, T. A.; Tseng, E. E.; Ge, L.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Chuter, T. A.] Univ Calif San Francisco, Med Ctr, Dept Surg, Div Vasc Surg, San Francisco, CA 94143 USA.
RP Tseng, EE (reprint author), Univ Calif San Francisco, Med Ctr, Dept Surg, Div Cardiothorac Surg, 500 Parnassus Ave Suite 405W Box 0118, San Francisco, CA 94143 USA.
EM elaine.tseng@ucsfmedctr.org
RI Chitsaz, Sam/C-4586-2008
FU American Heart Association; Northern California Institute for Research
and Education
FX This work was supported by American Heart Association and Northern
California Institute for Research and Education.
NR 43
TC 3
Z9 3
U1 1
U2 8
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0021-9509
J9 J CARDIOVASC SURG
JI J. Cardiovasc. Surg.
PD OCT
PY 2012
VL 53
IS 5
BP 631
EP 640
PG 10
WC Cardiac & Cardiovascular Systems; Surgery; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology; Surgery
GA 033RR
UT WOS:000310819000008
PM 22820737
ER
PT J
AU Yoo, AJ
Hu, RL
Hakimelahi, R
Lev, MH
Nogueira, RG
Hirsch, JA
Gonzalez, RG
Schaefer, PW
AF Yoo, Albert J.
Hu, Ranliang
Hakimelahi, Reza
Lev, Michael H.
Nogueira, Raul G.
Hirsch, Joshua A.
Gonzalez, R. Gilberto
Schaefer, Pamela W.
TI CT Angiography Source Images Acquired with a Fast-Acquisition Protocol
Overestimate Infarct Core on Diffusion Weighted Images in Acute Ischemic
Stroke
SO JOURNAL OF NEUROIMAGING
LA English
DT Article
DE Acute ischemic stroke; infarct core; diffusion magnetic resonance
imaging; CT angiography source images
ID BLUNT CEREBROVASCULAR INJURIES; CEREBRAL BLOOD-VOLUME;
COMPUTED-TOMOGRAPHY; PERFUSION; THROMBOLYSIS; OCCLUSION; BENEFIT; FLOW
AB BACKGROUND AND PURPOSE
Studies have demonstrated that computed tomography (CT) angiography source images (CTA-SI) acquired under near-steady-state contrast concentration provide infarct core estimates equivalent to diffusion-weighted images (DWI). We sought to test this relationship using our current CTA protocol optimized for faster scan acquisition.
METHODS
Forty-eight consecutive acute ischemic stroke patients met the following criteria: fast-acquisition CTA and magnetic resonance imaging (MRI) within 9 hours of symptom onset, CTA-to-MRI interval under 2 hours, and anterior circulation vessel occlusion. Collaterals were graded on CTA, and lesion volumes were calculated on CTA-SI, DWI, and MR mean transit time (MTT) maps.
RESULTS The mean CTA-to-MRI interval was 36 minutes (+/- 18 minutes). In paired analysis, lesion volumes on CTA-SI were significantly larger than on DWI (45.6 cm(3) vs 29.9 cm(3); P < .0001). In 14 (29.2%) cases, there was major CTA-SI overestimation (>25 cm(3) difference) of the DWI lesion. Lower collateral score (P= .001), higher National Institutes of Health Stroke Scale (NIHSS) score (P= .01), older age (P= .01), and proximal occlusion (P < .05) were univariate predictors of major overestimation, with collateral score being the only independent predictor. The interobserver agreement was worse for CTA-SI than for DWI (P < .001 for limits of agreement).
CONCLUSIONS CTA-SI performed using a fast-acquisition protocol overestimates the infarct core on DWI. Substantial differences are observed in over 25% of cases, and are associated with reduced collateralization.
C1 [Yoo, Albert J.; Hu, Ranliang; Hakimelahi, Reza; Lev, Michael H.; Nogueira, Raul G.; Schaefer, Pamela W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Neuroradiol, Boston, MA USA.
[Yoo, Albert J.; Nogueira, Raul G.; Hirsch, Joshua A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Intervent Neuroradiol, Boston, MA USA.
RP Yoo, AJ (reprint author), Massachusetts Gen Hosp, Div Diagnost & Intervent Neuroradiol, 55 Fruit St,Gray 241, Boston, MA 02114 USA.
EM ajyoo@partners.org
FU Neuroradiology Education and Research Foundation/Boston Scientific
Fellowship in Cerebrovascular Disease Research; National Institutes of
Health through National Institute of Neurological Disorders and Stroke
[NS050041]
FX The following sources of funding were utilized, in part, for the
preparation of this manuscript: Neuroradiology Education and Research
Foundation/Boston Scientific Fellowship in Cerebrovascular Disease
Research (AJY), National Institutes of Health through a grant from the
National Institute of Neurological Disorders and Stroke NS050041 (RGG).
NR 27
TC 10
Z9 11
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1051-2284
J9 J NEUROIMAGING
JI J. Neuroimaging
PD OCT
PY 2012
VL 22
IS 4
BP 329
EP 335
DI 10.1111/j.1552-6569.2011.00627.x
PG 7
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 030IA
UT WOS:000310563200004
PM 21848682
ER
PT J
AU Singh, JA
Sperling, JW
Schleck, C
Harmsen, W
Cofield, RH
AF Singh, Jasvinder A.
Sperling, John W.
Schleck, Cathy
Harmsen, William
Cofield, Robert H.
TI Periprosthetic infections after shoulder hemiarthroplasty
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Shoulder hemiarthroplasty; humeral head replacement; infection; age
ID HUMERAL HEAD REPLACEMENT; ARTHROPLASTY; REIMPLANTATION; OBESE
AB Background: To examine the rates and predictors of deep periprosthetic infections after shoulder hemiarthroplasty.
Methods: We used prospectively collected institutional registry data on all primary shoulder hemiarthroplasty patients from 1976-2008. We estimated survival free of deep periprosthetic infections using Kaplan-Meier survival curves. Using univariate Cox regression analyses, we examined the association of patient-related factors (age, sex, body mass index), comorbidity (Deyo-Charlson index), American Society of Anesthesiologists grade, underlying diagnosis, and implant fixation with the risk of infection.
Results: A total of 1,349 patients, with a mean age of 63 years (SD, 16 years), 63% of whom were women, underwent 1,431 primary shoulder hemiarthroplasties. Mean follow-up was 8 years (SD, 7 years). Fourteen deep periprosthetic infections occurred during the follow-up, confirmed by medical record review. The most common organisms were Staphylococcus aureus, coagulase-negative Staphylococcus, and Propionibacterium acnes, each accounting for 3 cases (21% each). The 5-, 10-, and 20-year prosthetic infectionefree rates were 98.9% (95% confidence interval [CI], 98.3%-99.5%), 98.7% (95% CI, 98.1%-99.4%), and 98.7% (95% CI, 98.1%-99.4%), respectively. None of the factors evaluated were significantly associated with risk of prosthetic infection after primary shoulder hemiarthroplasty, except that an underlying diagnosis of trauma was associated with a significantly higher hazard ratio of 3.18 (95% CI, 1.06-9.56) for infection compared with all other diagnoses (P = .04). A higher body mass index showed a nonestatistically significant trend toward an association with higher hazard (P = .13).
Conclusion: The periprosthetic infection rate after shoulder hemiarthroplasty was low, estimated at 1.3% at 20-year follow-up. An underlying diagnosis of trauma was associated with a higher risk of periprosthetic infection. These patients should be observed closely for development of infection.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Sperling, John W.; Cofield, Robert H.] Mayo Clin, Dept Orthoped Surg, Sch Med, Rochester, MN USA.
[Schleck, Cathy; Harmsen, William] Mayo Clin, Dept Hlth Sci Res, Sch Med, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Dept Med, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM Jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU National Institutes of Health Clinical Translational Science Award [1
KL2 RR024151-01]; Allergan; Takeda; Savient; Wyeth; Amgen; URL
Pharmaceuticals; Novartis; Tornier and owns stock in Tornier
FX This material is the result of work supported by National Institutes of
Health Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo
Clinic Center for Clinical and Translational Research) and the resources
and use of facilities at the Birmingham VA Medical Center. The study
sponsors had no role in the study design; in the collection, analysis,
and interpretation of data; in the writing of the manuscript; and in the
decision to submit the manuscript for publication.; Jasvinder A. Singh
has received speaker honoraria from Abbott; research and travel grants
from Allergan, Takeda, Savient, Wyeth, and Amgen; and consultant fees
from Savient, URL Pharmaceuticals, and Novartis.; John W. Sperling has
received royalties from Aircast and Biomet and consultant fees from
Tornier and owns stock in Tornier.
NR 15
TC 24
Z9 25
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD OCT
PY 2012
VL 21
IS 10
BP 1304
EP 1309
DI 10.1016/j.jse.2011.08.067
PG 6
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 033EJ
UT WOS:000310776700009
PM 22154310
ER
PT J
AU Kloen, P
Helfet, DL
Lorich, DG
Paul, O
Brouwer, KM
Ring, D
AF Kloen, Peter
Helfet, David L.
Lorich, Dean G.
Paul, Omesh
Brouwer, Kim M.
Ring, David
TI Temporary joint-spanning external fixation before internal fixation of
open intra-articular distal humeral fractures: a staged protocol
SO JOURNAL OF SHOULDER AND ELBOW SURGERY
LA English
DT Article
DE Distal humerus; fracture; external fixation; spanning; Gustilo; damage
control
ID INTERCONDYLAR FRACTURES; DAMAGE CONTROL; MANAGEMENT; TRAUMA; CONVERSION;
EXTREMITY; INJURIES
AB Introduction: This study determined outcomes after temporary joint-spanning external fixation before internal fixation of open intra-articular distal humeral fractures.
Materials and methods: A retrospective case analysis was done of all patients who were treated between 2000 and 2008 in 3 level I trauma centers with temporary joint-spanning external fixation before internal fixation of an open intra-articular distal humeral fracture. Healing rates, complications, Disabilities of Arm, Shoulder and Hand ( DASH), and Smith and Cooney outcome scores were documented.
Results: The study included 16 patients. Mean follow-up was 35.2 months. Fractures united after an average of 5.2 months. No complications specifically related to the external fixation occurred. The DASH outcome score averaged 15.1. Although complications occurred in 12 patients ( 9 patients requiring surgery), 10 of 16 had an excellent/good outcome score.
Conclusions: Temporary joint-spanning external fixation before internal fixation of open intra-articular distal humeral fractures is a safe adjunct.
C1 [Kloen, Peter] Acad Med Ctr, Dept Orthopaed Surg, NL-1100 DD Amsterdam, Netherlands.
[Kloen, Peter; Helfet, David L.; Lorich, Dean G.; Paul, Omesh] Hosp Special Surg, New York, NY 10021 USA.
[Helfet, David L.; Lorich, Dean G.; Paul, Omesh] New York Presbyterian Hosp, Dept Orthopaed Surg, New York, NY USA.
[Brouwer, Kim M.; Ring, David] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Kloen, P (reprint author), Acad Med Ctr, Dept Orthopaed Surg, G4-N,Meibergdreef 9, NL-1100 DD Amsterdam, Netherlands.
EM p.kloen@amc.uva.nl
NR 25
TC 1
Z9 1
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1058-2746
J9 J SHOULDER ELB SURG
JI J. Shoulder Elbow Surg.
PD OCT
PY 2012
VL 21
IS 10
BP 1348
EP 1356
DI 10.1016/j.jse.2012.01.015
PG 9
WC Orthopedics; Sport Sciences; Surgery
SC Orthopedics; Sport Sciences; Surgery
GA 033EJ
UT WOS:000310776700016
PM 22541911
ER
PT J
AU Weisbart, RH
Gera, JF
Chan, G
Hansen, JE
Li, E
Cloninger, C
Levine, AJ
Nishimura, RN
AF Weisbart, Richard H.
Gera, Joseph F.
Chan, Grace
Hansen, James E.
Li, Erica
Cloninger, Cheri
Levine, Arnold J.
Nishimura, Robert N.
TI A Cell-Penetrating Bispecific Antibody for Therapeutic Regulation of
Intracellular Targets
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID METASTASIS IN-VIVO; CANCER-CELLS; P53; AUTOANTIBODY; INHIBITORS;
EXPRESSION; MDM2
AB The therapeutic use of antibodies is restricted by the limited access of antibodies to intracellular compartments. To overcome this limitation, we developed a cell-penetrating monoclonal antibody, mAb 3E10, as an intracellular delivery vehicle for the intracellular and intranuclear delivery of antibodies constructed as bispecific single-chain Fv fragments. Because MDM2 is an important target in cancer therapy, we selected monoclonal antibody (mAb) 3G5 for intracellular transport. mAb 3G5 binds MDM2 and blocks binding of MDM2 to p53. Here, we show that the resulting 3E10-3G5 bispecific antibody retains cell-penetrating and MDM2-binding activity, increases tumor p53 levels, and inhibits growth of MDM2-addicted tumors. The use of cell-penetrating bispecific antibodies in targeted molecular therapy will significantly broaden the spectrum of accessible intracellular targets and may have a profound impact in cancer therapy. Mol Cancer Ther; 11(10); 2169-73. (C) 2012 AACR.
C1 [Weisbart, Richard H.; Gera, Joseph F.; Chan, Grace; Hansen, James E.; Li, Erica; Cloninger, Cheri] Vet Affairs Greater Los Angeles Hlth Care Syst, Sepulveda, CA 91343 USA.
[Levine, Arnold J.] Princeton Univ, Inst Adv Study, Princeton, NJ 08544 USA.
[Nishimura, Robert N.] Univ Calif Los Angeles, Dept Neurol, Los Angeles, CA 90024 USA.
RP Weisbart, RH (reprint author), Vet Affairs Greater Los Angeles Hlth Care Syst, 161111 Plummer St, Sepulveda, CA 91343 USA.
EM rweisbar@ucla.edu
FU Merit Review Grant from the Veterans Affairs
FX This work was supported by a Merit Review Grant from the Veterans
Affairs awarded to R. H. Weisbart.
NR 15
TC 15
Z9 15
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2012
VL 11
IS 10
BP 2169
EP 2173
DI 10.1158/1535-7163.MCT-12-0476-T
PG 5
WC Oncology
SC Oncology
GA 031KP
UT WOS:000310638600010
PM 22863609
ER
PT J
AU Balko, JM
Mayer, IA
Sanders, ME
Miller, TW
Kuba, MG
Meszoely, IM
Wagle, N
Garraway, LA
Arteaga, CL
AF Balko, Justin M.
Mayer, Ingrid A.
Sanders, Melinda E.
Miller, Todd W.
Kuba, Maria G.
Meszoely, Ingrid M.
Wagle, Nikhil
Garraway, Levi A.
Arteaga, Carlos L.
TI Discordant Cellular Response to Presurgical Letrozole in Bilateral
Synchronous ER plus Breast Cancers with a KRAS Mutation or FGFR1 Gene
Amplification
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Article
ID ESTROGEN-RECEPTOR; NEOADJUVANT TREATMENT; ENDOCRINE THERAPY; TAMOXIFEN;
PHOSPHORYLATION; ANASTROZOLE; RECURRENCE; ACTIVATION; RESISTANCE; ALPHA
AB We describe herein a patient presenting with bilateral estrogen-receptor-positive (ER+) breast tumors who was enrolled in a clinical trial exploring molecular aberrations associated with hormone-refractory tumor cell proliferation. Short-term (two week) hormonal therapy with the aromatase inhibitor letrozole substantially reduced proliferation as measured by Ki67 immunohistochemistry in one tumor, whereas the second was essentially unchanged. Extensive molecular and genetic work-up of the two tumors yielded divergent lesions in the two tumors: an activating KRAS mutation in the responsive tumor and an amplification of the fibroblast growth factor receptor-1 (FGFR1) locus in the treatment-refractory tumor. These findings provide an insight to possible mechanisms of resistance to antiestrogen therapy in ER+ breast cancers. First, they illustrate the necessity of clinically approved assays to identify FGFR1 gene amplification, which occur in approximately 5% of breast tumors and have been linked to antiestrogen resistance. It is quite possible that the addition of FGFR inhibitors to ER-targeted therapy will yield a superior antitumor effect and improved patient outcome. Second, they suggest that the role of activating mutations in RAS, although rare in breast cancer, may need to be explored in the context of ER+ breast tumors. Mol Cancer Ther; 11(10); 2301-5. (C) 2012 AACR.
C1 [Balko, Justin M.; Mayer, Ingrid A.; Arteaga, Carlos L.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, Nashville, TN 37232 USA.
[Miller, Todd W.; Arteaga, Carlos L.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Canc Biol, Nashville, TN 37232 USA.
[Meszoely, Ingrid M.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Surg, Nashville, TN 37232 USA.
[Sanders, Melinda E.; Kuba, Maria G.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Pathol, Nashville, TN 37232 USA.
[Mayer, Ingrid A.; Sanders, Melinda E.; Miller, Todd W.; Meszoely, Ingrid M.; Arteaga, Carlos L.] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Breast Canc Res Program, Nashville, TN 37232 USA.
[Wagle, Nikhil] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Wagle, Nikhil; Garraway, Levi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Wagle, Nikhil; Garraway, Levi A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
[Wagle, Nikhil; Garraway, Levi A.] Broad Inst Harvard, Cambridge, MA USA.
[Wagle, Nikhil; Garraway, Levi A.] MIT, Cambridge, MA 02139 USA.
RP Arteaga, CL (reprint author), Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Dept Med, 2200 Pierce Ave,777 PRB, Nashville, TN 37232 USA.
EM carlos.arteaga@vanderbilt.edu
FU Novartis; Starr Cancer Consortium; Breast Cancer Specialized Program of
Research Excellence (SPORE) grant [P50CA98131]; ACS [CRP-07-234]; Lee
Jeans Translational Breast Cancer Research Program; Susan G. Komen for
the Cure [SAC100013]; Vanderbilt-Ingram Cancer Center [P30 CA68485];
Stand Up to Cancer Dream Team Translational Cancer Research Grant, a
Program of the Entertainment Industry Foundation [SU2C-AACR-DT0209];
[R33CA126674]
FX N. Wagle has ownership interest (including patents) in Foundation
Medicine and is a consultant/advisory board member of Foundation
Medicine. L. A. Garraway has a commercial research grant from Novartis
and has ownership interest (including patents) in Foundation Medicine.
No potential conflicts of interest were disclosed by the other authors.;
This work was supported by R33CA126674, the Starr Cancer Consortium (L.
A. Garraway and N. Wagle) and Breast Cancer Specialized Program of
Research Excellence (SPORE) grant P50CA98131 (C. L. Arteaga and J.M.
Balko). ACS Clinical Research Professorship Grant CRP-07-234 (C. L.
Arteaga), The Lee Jeans Translational Breast Cancer Research Program (C.
L. Arteaga), Susan G. Komen for the Cure grant SAC100013 (C. L.
Arteaga), and Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485.
C. L. Arteaga is supported by a Stand Up to Cancer Dream Team
Translational Cancer Research Grant, a Program of the Entertainment
Industry Foundation (SU2C-AACR-DT0209).
NR 19
TC 6
Z9 6
U1 0
U2 4
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD OCT
PY 2012
VL 11
IS 10
BP 2301
EP 2305
DI 10.1158/1535-7163.MCT-12-0511
PG 5
WC Oncology
SC Oncology
GA 031KP
UT WOS:000310638600024
PM 22879364
ER
PT J
AU Meng, R
Asmaro, K
Meng, L
Liu, Y
Ma, C
Xi, CJ
Li, GQ
Ren, CH
Luo, YM
Ling, F
Jia, JP
Hua, Y
Wang, XY
Ding, YC
Lo, EH
Ji, XM
AF Meng, Ran
Asmaro, Karam
Meng, Lu
Liu, Yu
Ma, Chun
Xi, Chunjiang
Li, Guoqing
Ren, Canghong
Luo, Yumin
Ling, Feng
Jia, Jianping
Hua, Yang
Wang, Xiaoying
Ding, Yuchuan
Lo, Eng H.
Ji, Xunming
TI Upper limb ischemic preconditioning prevents recurrent stroke in
intracranial arterial stenosis
SO NEUROLOGY
LA English
DT Article
ID CAROTID REVASCULARIZATION ENDARTERECTOMY; ACUTE MYOCARDIAL-INFARCTION;
RANDOMIZED CONTROLLED-TRIAL; TRANSCRANIAL DOPPLER; CEREBRAL-ISCHEMIA;
PROTECTS; INJURY; ATTACK; SPECT; ATHEROSCLEROSIS
AB Objective: This study aims to evaluate protective effects of brief repetitive bilateral arm ischemic preconditioning (BAIPC) on stroke recurrence in patients with symptomatic atherosclerotic intracranial arterial stenosis (IAS).
Methods: A total of 68 consecutive cases with symptomatic IAS, diagnosed by imaging, were enrolled in this prospective and randomized study. All patients received standard medical management. Patients in the BAIPC group (n = 38) underwent 5 brief cycles consisting of bilateral upper limb ischemia followed by reperfusion. The BAIPC procedure was performed twice daily over 300 consecutive days. Incidence of recurrent stroke and cerebral perfusion status in BAIPC-treated patients were compared with the untreated control group (n = 30).
Results: In the control group, incidence of recurrent stroke at 90 and 300 days were 23.3% and 26.7%, respectively. In the BAIPC group, incidence of recurrent stroke was reduced to 5% and 7.9% at 90 and 300 days (p < 0.01), respectively. The average time to recovery (modified Rankin Scale score 0-1) was also shortened by BAIPC. Cerebral perfusion status, measured by SPECT and transcranial Doppler sonography, improved remarkably in BAIPC-treated brain than in control (p < 0.01).
Conclusion: This study provides a proof-of-concept that BAIPC may be an effective way to improve cerebral perfusion and reduce recurrent strokes in patients with IAS. Further investigation of this therapeutic approach is warranted as some patients were excluded after randomization. Neurology (R) 2012; 79: 1853-1861
C1 [Meng, Ran; Liu, Yu; Ma, Chun; Xi, Chunjiang; Li, Guoqing; Ren, Canghong; Luo, Yumin; Ling, Feng; Jia, Jianping; Hua, Yang; Ji, Xunming] Capital Med Univ, Cerebral Vasc Dis Res Inst, China Amer Inst Neurosci, Xuanwu Hosp, Beijing, Peoples R China.
Capital Med Univ, Dept Neurol, Beijing Shijitan Hosp, Beijing, Peoples R China.
[Meng, Ran; Wang, Xiaoying; Lo, Eng H.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Asmaro, Karam; Ding, Yuchuan] Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI USA.
[Meng, Lu] Univ Georgia, Dept Biochem & Mol Biol, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA.
RP Ji, XM (reprint author), Capital Med Univ, Cerebral Vasc Dis Res Inst, China Amer Inst Neurosci, Xuanwu Hosp, Beijing, Peoples R China.
EM jixm70@ccmu.edu.cn
OI Jia, Jianping/0000-0003-4624-0336
FU National Natural Science Foundation, China [30870854, 30770741];
Foundation of the Beijing High Level Health Systems Talented Technical
Personnel Program, China [2009-03-02]
FX Study funding: This study was sponsored by the National Natural Science
Foundation (30870854 and 30770741, China) and the Foundation of the
Beijing High Level Health Systems Talented Technical Personnel Program
(2009-03-02, China).
NR 38
TC 68
Z9 77
U1 1
U2 28
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD OCT
PY 2012
VL 79
IS 18
BP 1853
EP 1861
DI 10.1212/WNL.0b013e318271f76a
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA 030OL
UT WOS:000310579900010
PM 23035060
ER
PT J
AU Merker, VL
Esparza, S
Smith, MJ
Stemmer-Rachamimov, A
Plotkin, SR
AF Merker, Vanessa L.
Esparza, Sonia
Smith, Miriam J.
Stemmer-Rachamimov, Anat
Plotkin, Scott R.
TI Clinical Features of Schwannomatosis: A Retrospective Analysis of 87
Patients
SO ONCOLOGIST
LA English
DT Article
DE Schwannomatosis; Schwannoma; Nerve sheath neoplasm; Malignant peripheral
nerve sheath tumor; Intractable pain
ID SPORADIC SCHWANNOMATOSIS; FAMILIAL SCHWANNOMATOSIS; TYPE-2
NEUROFIBROMATOSIS; MULTIPLE MENINGIOMAS; DIAGNOSTIC-CRITERIA; SMARCB1
MUTATION; FOLLOW-UP; NF2
AB Background. Schwannomatosis is a recently recognized form of neurofibromatosis characterized by multiple non-cutaneous schwannomas, a histologically benign nerve sheath tumor. As more cases are identified, the reported phenotype continues to expand and evolve. We describe the spectrum of clinical findings in a cohort of patients meeting established criteria for schwannomatosis.
Methods. We retrospectively reviewed the clinical records of patients seen at our institution from 1995-2011 who fulfilled either research or clinical criteria for schwannomatosis. Clinical, radiographic, and pathologic data were extracted with attention to age at onset, location of tumors, ophthalmologic evaluation, family history, and other stigmata of neurofibromatosis 1 (NF1) or NF2.
Results. Eighty-seven patients met the criteria for the study. The most common presentation was pain unassociated with a mass (46%). Seventy-seven of 87 (89%) patients had peripheral schwannomas, 49 of 66 (74%) had spinal schwannomas, seven of 77 (9%) had nonvestibular intracranial schwannomas, and four of 77 (5%) had intracranial meningiomas. Three patients were initially diagnosed with a malignant peripheral nerve sheath tumor; however, following pathologic review, the diagnoses were revised in all three cases. Chronic pain was the most common symptom (68%) and usually persisted despite aggressive surgical and medical management. Other common diagnoses included headaches, depression, and anxiety.
Conclusions. Peripheral and spinal schwannomas are common in schwannomatosis patients. Severe pain is difficult to treat in these patients and often associated with anxiety and depression. These findings support a proactive surveillance plan to identify tumors by magnetic resonance imaging scan in order to optimize surgical treatment and to treat associated pain, anxiety, and depression. The Oncologist 2012; 17: 1317-1322
C1 [Plotkin, Scott R.] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Dept Neurol, Boston, MA 02114 USA.
[Merker, Vanessa L.; Esparza, Sonia; Plotkin, Scott R.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Stemmer-Rachamimov, Anat] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Plotkin, SR (reprint author), Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Dept Neurol, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM splotkin@partners.org
RI Smith, Miriam/J-4001-2015;
OI Smith, Miriam/0000-0002-3184-0817; Merker, Vanessa/0000-0002-4542-5227
FU Harvard Medical School Center for Neurofibromatosis and Allied Disorders
FX Supported by the Harvard Medical School Center for Neurofibromatosis and
Allied Disorders.
NR 17
TC 34
Z9 37
U1 0
U2 5
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD OCT
PY 2012
VL 17
IS 10
BP 1317
EP 1322
DI 10.1634/theoncologist.2012-0162
PG 6
WC Oncology
SC Oncology
GA 029MT
UT WOS:000310500600014
PM 22927469
ER
PT J
AU Greer, JA
Traeger, L
Bemis, H
Solis, J
Hendriksen, ES
Park, ER
Pirl, WF
Temel, JS
Prigerson, HG
Safren, SA
AF Greer, Joseph A.
Traeger, Lara
Bemis, Heather
Solis, Jessica
Hendriksen, Ellen S.
Park, Elyse R.
Pirl, William F.
Temel, Jennifer S.
Prigerson, Holly G.
Safren, Steven A.
TI A Pilot Randomized Controlled Trial of Brief Cognitive-Behavioral
Therapy for Anxiety in Patients with Terminal Cancer
SO ONCOLOGIST
LA English
DT Article
DE Cancer; Anxiety; Cognitive behavior therapy; Quality of life
ID LUNG-CANCER; PSYCHOSOCIAL INTERVENTIONS; DEPRESSION SCALE; LIFE; CARE;
DISORDERS; DISTRESS; VALIDATION; PREDICTORS; SYMPTOMS
AB Introduction. Patients with terminal cancer often experience marked anxiety that is associated with poor quality of life. Although cognitive-behavioral therapy (CBT) is an evidence-based treatment for anxiety disorders, the approach needs to be adapted to address realistic concerns related to having cancer, such as worries about disease progression, disability, and death. In this pilot randomized controlled trial (clinicaltrials. gov identifier NCT00706290), we examined the feasibility and potential efficacy of brief CBT to reduce anxiety in patients with terminal cancer.
Methods. We adapted CBT by developing treatment modules targeting skills for relaxation, coping with cancer worries, and activity pacing. Adults with incurable malignancies and elevated anxiety based on the Hamilton Anxiety Rating Scale (HAM-A) were randomly assigned to individual CBT or a waitlist control group. Primary outcomes included the number of completed CBT visits and the change in HAM-A scores from baseline to 8-week follow-up per a treatment-blind evaluator. The feasibility criterion was 75% adherence to the intervention.
Results. We randomized 40 patients with terminal cancers to CBT (n = 20) or waitlist control (n = 20) groups; 70% completed posttreatment assessments. Most patients who received CBT (80%) participated in at least five of the required six therapy sessions. Analysis of covariance models, adjusted for baseline scores, showed that those assigned to CBT had greater improvements in HAM-A scores compared to the control group, with an adjusted mean difference of -5.41 (95% confidence interval: -10.78 to -0.04) and a large effect size for the intervention (Cohen's d = 0.80).
Conclusion. Providing brief CBT tailored to the concerns of patients with terminal cancer was not only feasible but also led to significant improvements in anxiety. The Oncologist 2012; 17: 1337-1345
C1 [Greer, Joseph A.] Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, Dept Psychiat, Boston, MA 02114 USA.
[Greer, Joseph A.; Traeger, Lara; Hendriksen, Ellen S.; Park, Elyse R.; Pirl, William F.; Temel, Jennifer S.; Prigerson, Holly G.; Safren, Steven A.] Harvard Univ, Sch Med, Boston, MA USA.
[Temel, Jennifer S.] Massachusetts Gen Hosp, Ctr Canc, Dept Med, Div Hematol & Oncol, Boston, MA 02114 USA.
[Prigerson, Holly G.] Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
RP Greer, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Psychiat Oncol & Behav Sci, Dept Psychiat, Yawkey Bldg,Suite 10B,55 Fruit St, Boston, MA 02114 USA.
EM jgreer2@partners.org
FU Forrest Pharmaceuticals; Allergan; Ameritox; Boston Scientific; Covidien
Mallinckrodt Inc.; Endo Pharmaceuticals; Forest Labs; K-Pax
Pharmaceuticals; Medtronics; Otsuka Pharma; ProStrakan; Purdue Pharma;
Salix; St. Jude Medical; National Cancer Institute [R03CA128478]
FX William F. Pirl: Forrest Pharmaceuticals (RF). The other authors
indicated no financial relationships.; Eduardo Bruera: None; Russell K.
Portenoy: Arsenal Medical Inc., Pfizer, Grupo Ferrer, Transcript Pharma,
Xenon (C/A); Allergan, Ameritox, Boston Scientific, Covidien
Mallinckrodt Inc., Endo Pharmaceuticals, Forest Labs, K-Pax
Pharmaceuticals, Medtronics, Otsuka Pharma, ProStrakan, Purdue Pharma,
Salix, St. Jude Medical (RF); This research was supported by a grant
from the National Cancer Institute (R03CA128478).
NR 37
TC 5
Z9 8
U1 3
U2 21
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD OCT
PY 2012
VL 17
IS 10
BP 1337
EP 1345
DI 10.1634/theoncologist.2012-0041
PG 9
WC Oncology
SC Oncology
GA 029MT
UT WOS:000310500600017
PM 22688670
ER
PT J
AU Connolly, RM
Bardia, A
AF Connolly, Roisin M.
Bardia, Aditya
TI Trastuzumab and Chemotherapy May Be Appropriate for Small,
Node-Negative, HER2-Positive Breast Cancer In Reply
SO ONCOLOGIST
LA English
DT Letter
C1 [Connolly, Roisin M.] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21287 USA.
[Bardia, Aditya] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc,Dept Med, Boston, MA USA.
RP Connolly, RM (reprint author), Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Breast Canc Program, Baltimore, MD 21287 USA.
EM rconnol2@jhmi.edu
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ALPHAMED PRESS
PI DURHAM
PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA
SN 1083-7159
J9 ONCOLOGIST
JI Oncologist
PD OCT
PY 2012
VL 17
IS 10
BP E34
EP E34
DI 10.1634/theoncologist.2012-0345
PG 1
WC Oncology
SC Oncology
GA 029MT
UT WOS:000310500600003
ER
PT J
AU Lee, AG
Oetting, TA
Blomquist, PH
Bradford, G
Culican, SM
Kloek, C
Krishnan, C
Lauer, AK
Levi, L
Naseri, A
Rubin, SE
Scott, IU
Tao, J
Tuli, S
Wright, MM
WuDunn, D
Zimmerman, MB
AF Lee, Andrew G.
Oetting, Thomas A.
Blomquist, Preston H.
Bradford, Geoffrey
Culican, Susan M.
Kloek, Carolyn
Krishnan, Chandrasekharan
Lauer, Andreas K.
Levi, Leah
Naseri, Ayman
Rubin, Steven E.
Scott, Ingrid U.
Tao, Jeremiah
Tuli, Sonal
Wright, Martha M.
WuDunn, Darrell
Zimmerman, M. Bridget
TI A Multicenter Analysis of the Ophthalmic Knowledge Assessment Program
and American Board of Ophthalmology Written Qualifying Examination
Performance
SO OPHTHALMOLOGY
LA English
DT Article
ID OKAP
AB Objective: To compare the performance on the American Board of Ophthalmology Written Qualifying Examination (WQE) with the performance on step 1 of the United States Medical Licensing Examination (USMLE) and the Ophthalmic Knowledge Assessment Program (OKAP) examination for residents in multiple residency programs.
Design: Comparative case series.
Participants: Fifteen residency programs with 339 total residents participated in this study. The data were extracted from the 5-year American Board of Ophthalmology report to each participating program in 2009 and included residency graduating classes from 2003 through 2007. Residents were included if data were available for the USMLE, OKAP examination in ophthalmology years 1 through 3, and the WQE score. Residents were excluded if one or more of the test scores were not available.
Methods: Two-sample t tests, logistic regression analysis, and receiver operating characteristic (ROC) curves were used to examine the association of the various tests (USMLE, OKAP examination year 1, OKAP examination year 2, OKAP examination year 3, and maximum OKAP examination score) as a predictor for a passing or failing grade on the WQE.
Main Outcome Measures: The primary outcome measure of this study was first time pass rate for the WQE.
Results: Using ROC analysis, the OKAP examination taken at the third year of ophthalmology residency best predicted performance on the WQE. For the OKAP examination taken during the third year of residency, the probability of passing the WQE was at least 80% for a score of 35 or higher and at least 95% for a score of 72 or higher.
Conclusions: The OKAP examination, especially in the third year of residency, can be useful to residents to predict the likelihood of success on the high-stakes WQE examination.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article. Ophthalmology 2012;119:1949-1953 (C) 2012 by the American Academy of Ophthalmology.
C1 [Lee, Andrew G.] Methodist Hosp, Dept Ophthalmol, Houston, TX 77030 USA.
[Lee, Andrew G.] Weill Cornell Med Coll, Dept Ophthalmol Neurol & Neurosurg, New York, NY USA.
[Lee, Andrew G.] Baylor Coll Med, Dept Ophthalmol, Houston, TX 77030 USA.
[Lee, Andrew G.; Oetting, Thomas A.; Zimmerman, M. Bridget] Univ Iowa Hosp & Clin, Dept Ophthalmol, Iowa City, IA 52242 USA.
[Lee, Andrew G.] Univ Texas Med Branch, Dept Ophthalmol, Galveston, TX USA.
[Blomquist, Preston H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Bradford, Geoffrey] W Virginia Univ, Morgantown, WV 26506 USA.
[Culican, Susan M.] Washington Univ, Sch Med, St Louis, MO USA.
[Kloek, Carolyn] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Krishnan, Chandrasekharan] Tufts Univ, Boston, MA 02111 USA.
[Lauer, Andreas K.] Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97201 USA.
[Levi, Leah] Univ Calif San Diego, San Diego, CA 92103 USA.
[Naseri, Ayman] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Rubin, Steven E.] N Shore Long Isl Jewish Hlth Syst, Great Neck, NY USA.
[Scott, Ingrid U.] Penn State Coll Med, Hershey, PA USA.
[Tao, Jeremiah] Univ Calif Irvine, Irvine, CA USA.
[Tuli, Sonal] Univ Florida, Gainesville, FL USA.
[Wright, Martha M.] Univ Minnesota, Minneapolis, MN USA.
[WuDunn, Darrell] Indiana Univ, Indianapolis, IN 46204 USA.
RP Lee, AG (reprint author), Methodist Hosp, Dept Ophthalmol, 6560 Fannin St,Scurlock 450, Houston, TX 77030 USA.
EM AGLee@tmhs.org
FU Research to Prevent Blindness, Inc, New York, New York
FX Supported in part by an unrestricted grant from Research to Prevent
Blindness, Inc, New York, New York.
NR 10
TC 3
Z9 3
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 1949
EP 1953
DI 10.1016/j.ophtha.2012.06.010
PG 5
WC Ophthalmology
SC Ophthalmology
GA 030PF
UT WOS:000310581900002
PM 22841987
ER
PT J
AU Liu, SH
Pavan-Langston, D
Colby, KA
AF Liu, Shaohui
Pavan-Langston, Deborah
Colby, Kathryn A.
TI Pediatric Herpes Simplex of the Anterior Segment Characteristics,
Treatment, and Outcomes
SO OPHTHALMOLOGY
LA English
DT Article
ID VIRUS KERATITIS; ORAL ACYCLOVIR; EYE DISEASE; INFECTIONS; CHILDREN;
MANAGEMENT; THERAPY; TYPE-1
AB Purpose: To describe the clinical characteristics, treatment, and outcomes of herpes simplex virus (HSV) infections of the cornea and adnexae to raise awareness and to improve management of this important eye disease in children.
Design: Retrospective case series.
Participants: Fifty-three patients (57 eyes) 16 years of age or younger with HSV keratitis (HSK), HSV blepharoconjunctivitis (HBC), or both in an academic cornea practice.
Methods: The following data were collected: age at disease onset, putative trigger factors, coexisting systemic diseases, duration of symptoms and diagnoses given before presentation, visual acuity, slit-lamp examination findings, corneal sensation, dose and duration of medications used, drug side effects, and disease recurrence.
Main Outcome Measures: Presence of residual corneal scarring, visual acuity at the last visit, changes in corneal sensation, recurrence rate, and manifestations of HSK were assessed in patients receiving long-term prophylactic systemic acyclovir.
Results: The median age at onset was 5 years. Mean follow-up was 3.6 years. Eighteen eyes had HBC only; 4 patients in this group had bilateral disease. Of 39 eyes with keratitis, 74% had stromal disease. Thirty percent of HSK cases were misdiagnosed before presentation. Seventy-nine percent of patients with keratitis had corneal scarring and 26% had vision of 20/40 or worse at the last visit. Eighty percent of patients had recurrent disease. Six of 16 patients (37%) receiving long-term oral acyclovir had recurrent HSV, at least one case of which followed a growth spurt that caused the baseline dosage of acyclovir to become subtherapeutic.
Conclusions: In a large series, pediatric HSK had a high rate of misdiagnosis, stromal involvement, recurrence, and vision loss. Oral acyclovir is effective, but the dosage must be adjusted as the child grows.
C1 [Liu, Shaohui; Pavan-Langston, Deborah; Colby, Kathryn A.] Massachusetts Eye & Ear Infirm, Cornea Serv, Boston, MA 02114 USA.
[Liu, Shaohui; Pavan-Langston, Deborah; Colby, Kathryn A.] Schepens Eye Res Inst, Boston, MA USA.
[Liu, Shaohui; Pavan-Langston, Deborah; Colby, Kathryn A.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
[Colby, Kathryn A.] Childrens Hosp, Boston, MA 02115 USA.
RP Colby, KA (reprint author), Massachusetts Eye & Ear Infirm, Cornea Serv, 243 Charles St,Suite 727, Boston, MA 02114 USA.
EM kacolby@meei.harvard.edu
FU Johnstone Fund; Stevens Fund; Foundation of the Massachusetts Eye and
Ear Infirmary, Boston, Massachussetts
FX Supported in part by the Johnstone Fund and the Stevens Fund (DP-L),
Foundation of the Massachusetts Eye and Ear Infirmary, Boston,
Massachussetts.
NR 26
TC 13
Z9 14
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2003
EP 2008
DI 10.1016/j.ophtha.2012.05.008
PG 6
WC Ophthalmology
SC Ophthalmology
GA 030PF
UT WOS:000310581900010
PM 22796308
ER
PT J
AU Schein, OD
Banta, JT
Chen, TC
Pritzker, S
Schachat, AP
AF Schein, Oliver D.
Banta, James T.
Chen, Teresa C.
Pritzker, Scott
Schachat, Andrew P.
TI Lessons Learned: Wrong Intraocular Lens
SO OPHTHALMOLOGY
LA English
DT Article
ID INCORRECT SURGICAL-PROCEDURES; OPERATING-ROOM
AB Objective: To report cases involving the placement of the wrong intraocular lens (IOL) at the time of cataract surgery where human error occurred.
Design: Retrospective small case series, convenience sample.
Participants: Seven surgical cases.
Methods: Institutional review of errors committed and subsequent improvements to clinical protocols.
Main Outcome Measures: Lessons learned and changes in procedures adapted.
Results: The pathways to a wrong IOL are many but largely reflect some combination of poor surgical team communication, transcription error, lack of preoperative clarity in surgical planning or failure to match the patient, and IOL calculation sheet with 2 unique identifiers.
Conclusions: Safety in surgery involving IOLs is enhanced both by strict procedures, such as an IOL-specific "time-out," and the fostering of a surgical team culture in which all members are encouraged to voice questions and concerns.
C1 [Schachat, Andrew P.] Cleveland Clin, Cole Eye Inst, Cleveland, OH 44106 USA.
[Schein, Oliver D.; Pritzker, Scott] Johns Hopkins Univ, Sch Med, Wilmer Eye Inst, Baltimore, MD 21205 USA.
[Banta, James T.] Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL USA.
[Chen, Teresa C.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
RP Schein, OD (reprint author), 600 N Wolfe St,Wilmer 116, Baltimore, MD 21287 USA.
EM oschein@jhmi.edu
NR 10
TC 6
Z9 6
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2059
EP 2064
DI 10.1016/j.ophtha.2012.04.011
PG 6
WC Ophthalmology
SC Ophthalmology
GA 030PF
UT WOS:000310581900019
PM 22704833
ER
PT J
AU Henderson, BA
Oetting, TA
Yang, EB
Rankin, JK
Aaron, MM
Yang, ZJ
Broocker, G
Blomquist, PH
AF Henderson, Bonnie An
Oetting, Thomas A.
Yang, Erynn Bo
Rankin, Jessica K.
Aaron, Maria M.
Yang, Zijin
Broocker, Geoffrey
Blomquist, Preston H.
TI Teaching Manual Cataract Extraction
SO OPHTHALMOLOGY
LA English
DT Letter
ID PHACOEMULSIFICATION; SURGERY
C1 [Henderson, Bonnie An] Harvard Univ, Sch Med, Ophthalm Consultants Boston, Boston, MA 02114 USA.
[Oetting, Thomas A.] Univ Iowa, Iowa City, IA USA.
[Yang, Erynn Bo] Harvard Vanguard Med Associates, Boston, MA USA.
[Aaron, Maria M.; Broocker, Geoffrey] Emory Univ, Sch Med, Atlanta, GA USA.
[Yang, Zijin] Res & Evaluat, Honolulu, HI USA.
[Blomquist, Preston H.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Rankin, Jessica K.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA 02114 USA.
RP Henderson, BA (reprint author), Harvard Univ, Sch Med, Ophthalm Consultants Boston, Boston, MA 02114 USA.
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2191
EP 2191
PG 1
WC Ophthalmology
SC Ophthalmology
GA 030PF
UT WOS:000310581900038
PM 23034293
ER
PT J
AU Kim, DY
Delori, F
Mukai, S
AF Kim, David Y.
Delori, Francois
Mukai, Shizuo
TI Smartphone Photography Safety
SO OPHTHALMOLOGY
LA English
DT Letter
ID EXPOSURE
C1 [Kim, David Y.; Mukai, Shizuo] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
[Kim, David Y.; Delori, Francois; Mukai, Shizuo] Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Delori, Francois] Schepens Eye Res Inst, Boston, MA USA.
RP Kim, DY (reprint author), Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
NR 6
TC 11
Z9 12
U1 1
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0161-6420
J9 OPHTHALMOLOGY
JI Ophthalmology
PD OCT
PY 2012
VL 119
IS 10
BP 2200
EP 2201
PG 3
WC Ophthalmology
SC Ophthalmology
GA 030PF
UT WOS:000310581900051
PM 23034305
ER
PT J
AU Watson, AJ
Singh, K
Myint-U, K
Grant, RW
Jethwani, K
Murachver, E
Harris, K
Lee, TH
Kvedar, JC
AF Watson, Alice J.
Singh, Kanwaljit
Myint-U, Khinlei
Grant, Richard W.
Jethwani, Kamal
Murachver, Ellen
Harris, Kimberly
Lee, Thomas H.
Kvedar, Joseph C.
TI Evaluating a web-based self-management program for employees with
hypertension and prehypertension: A randomized clinical trial
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID DIABETES-MELLITUS; PRESSURE CONTROL; INTERVENTIONS; EDUCATION; DESIGN
AB Background Web-based self-management programs offer a novel approach for self-insured employers seeking to improve and maintain employee health.
Methods We conducted a 6-month prospective, cluster-randomized controlled trial designed to evaluate whether worksite access to an automated, web-based, self-management program resulted in better blood pressure control. The trial was conducted at 6 EMC Corporation worksites in Massachusetts, each of which had at least 600 employees; 404 EMC employees with pre-hypertension or hypertension participated. Participants at 3 worksites received a home blood pressure cuff that uploaded readings to a Web site where they could view trends and read automated rules-based messages. Participants at 3 worksites received access to an onsite blood pressure cuff. Primary outcome measure was change in systolic blood pressure. Secondary outcome measures were change in diastolic blood pressure, proportion of participants achieving significant changes in systolic and diastolic blood pressure, and subject satisfaction.
Results Although the mean change in systolic blood pressure was not significantly different between intervention and control groups (-1.69 vs. -0.86 mm HG, respectively, P = .49) the change in diastolic blood pressure between groups was significant. (-1.08 vs. = 1.47 mm HG, respectively, P < .001). Significantly more intervention participants experienced a >10-mm Hg decrease in systolic blood pressure or >5-mm Hg decrease in diastolic blood pressure compared to controls (22% vs 17%, P = .02 and 29% vs 16%, P = .03, respectively). Intervention participants were twice as likely to report starting a new medication (P = .02) and more likely to report improved communication with their doctor (P = .02).
Conclusions Participation in an automated online self-management program resulted in improved blood pressure among employees with prehypertension or hypertension. (Am Heart J 2012;164:625-31.)
C1 [Watson, Alice J.; Singh, Kanwaljit; Myint-U, Khinlei; Jethwani, Kamal; Murachver, Ellen; Harris, Kimberly; Kvedar, Joseph C.] Partners HealthCare Ctr Connected Hlth, Boston, MA USA.
[Watson, Alice J.; Jethwani, Kamal; Kvedar, Joseph C.] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Watson, Alice J.; Singh, Kanwaljit; Grant, Richard W.; Jethwani, Kamal; Lee, Thomas H.; Kvedar, Joseph C.] Harvard Univ, Sch Med, Boston, MA USA.
[Grant, Richard W.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Lee, Thomas H.] Partners Community Healthcare Inc, Boston, MA USA.
RP Kvedar, JC (reprint author), Ctr Connected Hlth, 25 New Chardon St,Suite 400D, Boston, MA 02114 USA.
EM jkvedar@partners.org
OI Grant, Richard/0000-0002-6164-8025
NR 19
TC 18
Z9 18
U1 1
U2 14
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
J9 AM HEART J
JI Am. Heart J.
PD OCT
PY 2012
VL 164
IS 4
BP 625
EP 631
DI 10.1016/j.ahj.2012.06.013
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 029OU
UT WOS:000310506000028
PM 23067923
ER
PT J
AU Irwin, DJ
White, MT
Toledo, JB
Xie, SX
Robinson, JL
Van Deerlin, V
Lee, VMY
Leverenz, JB
Montine, TJ
Duda, JE
Hurtig, HI
Trojanowski, JQ
AF Irwin, David J.
White, Matthew T.
Toledo, Jon B.
Xie, Sharon X.
Robinson, John L.
Van Deerlin, Vivianna
Lee, Virginia M-Y
Leverenz, James B.
Montine, Thomas J.
Duda, John E.
Hurtig, Howard I.
Trojanowski, John Q.
TI Neuropathologic substrates of Parkinson disease dementia
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID LEWY BODY DISEASES; PREDICTS COGNITIVE DECLINE; ARGYROPHILIC GRAIN
DISEASE; APOLIPOPROTEIN-E GENOTYPE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE;
A-BETA; CLINICOPATHOLOGICAL CORRELATIONS; STRIATAL PATHOLOGY; BRAIN
PATHOLOGY
AB Objective: A study was undertaken to examine the neuropathological substrates of cognitive dysfunction and dementia in Parkinson disease (PD).
Methods: One hundred forty patients with a clinical diagnosis of PD and either normal cognition or onset of dementia 2 or more years after motor symptoms (PDD) were studied. Patients with a clinical diagnosis of dementia with Lewy bodies were excluded. Autopsy records of genetic data and semiquantitative scores for the burden of neurofibrillary tangles, senile plaques, Lewy bodies (LBs), and Lewy neurites (LNs) and other pathologies were used to develop a multivariate logistic regression model to determine the independent association of these variables with dementia. Correlates of comorbid Alzheimer disease (AD) were also examined.
Results: Niney-two PD patients developed dementia, and 48 remained cognitively normal. Severity of cortical LB (CLB)/LN pathology was positively associated with dementia (p < 0.001), with an odds ratio (OR) of 4.06 (95% confidence interval [CI], 1.878.81), as was apolipoprotein E4 (APOE4) genotype (p = 0.018; OR, 4.19; 95% CI, 1.2813.75). A total of 28.6% of all PD cases had sufficient pathology for comorbid AD, of whom 89.5% were demented. The neuropathological diagnosis of PDD+AD correlated with an older age of PD onset (p = 0.001; OR, 1.12; 95% CI, 1.041.21), higher CLB/LN burden (p = 0.037; OR, 2.48; 95% CI, 1.065.82), and cerebral amyloid angiopathy severity (p = 0.032; OR, 4.16; 95% CI, 1.1315.30).
Interpretation: CLB/LN pathology is the most significant correlate of dementia in PD. Additionally, APOE4 genotype may independently influence the risk of dementia in PD. AD pathology was abundant in a subset of patients, and may modify the clinical phenotype. Thus, therapies that target a-synuclein, tau, or amyloid beta could potentially improve cognitive performance in PD. ANN NEUROL 2012;72:587598
C1 [Trojanowski, John Q.] Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, HUP,Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Irwin, David J.; Duda, John E.; Hurtig, Howard I.] Parkinsons Dis & Movement Disorders Clin, Dept Neurol, Philadelphia, PA USA.
[White, Matthew T.; Xie, Sharon X.] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA.
[Leverenz, James B.] Univ Washington, Parkinsons Dis Res Educ & Clin Ctr, VA Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA 98195 USA.
[Montine, Thomas J.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA.
[Leverenz, James B.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA.
[Leverenz, James B.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Duda, John E.] Philadelphia VA Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA 19104 USA.
RP Trojanowski, JQ (reprint author), Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, HUP,Dept Pathol & Lab Med, Maloney 3rd Floor,36th & Spruce St, Philadelphia, PA 19104 USA.
EM trojanow@mail.med.upenn.edu
OI White, Matthew/0000-0002-7655-8145; Toledo, Jon/0000-0003-4366-9268
FU NIH [AG05136, T32-AG000255]; Morris K. Udall Center for Parkinson's
Disease Research [P50 NS053488, NS062684]; Alfonso Martin Escudero
Foundation
FX This study was supported by NIH grants AG05136, and Morris K. Udall
Center for Parkinson's Disease Research core grants P50 NS053488 and
NS062684. D.J.I. is supported by NIH grant T32-AG000255, Training in
Age-Related Neurodegenerative Diseases. J.B.T. is supported by a grant
of the Alfonso Martin Escudero Foundation.
NR 65
TC 120
Z9 122
U1 1
U2 15
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD OCT
PY 2012
VL 72
IS 4
BP 587
EP 598
DI 10.1002/ana.23659
PG 12
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 030CG
UT WOS:000310544900017
PM 23037886
ER
PT J
AU Zhang, YY
Xie, ZC
AF Zhang, Yiying
Xie, Zhongcong
TI Anesthetics Isoflurane and Desflurane Differently Affect Mitochondrial
Function, Learning, and Memory
SO ANNALS OF NEUROLOGY
LA English
DT Letter
ID BETA-PROTEIN-LEVELS; APOPTOSIS
C1 [Zhang, Yiying] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA.
Harvard Univ, Sch Med, Charlestown, MA USA.
RP Zhang, YY (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Charlestown, MA 02129 USA.
FU NIA NIH HHS [R01 AG041274, R21 AG038994]; NIGMS NIH HHS [R01 GM088801]
NR 5
TC 4
Z9 5
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
J9 ANN NEUROL
JI Ann. Neurol.
PD OCT
PY 2012
VL 72
IS 4
BP 630
EP 630
DI 10.1002/ana.23683
PG 1
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 030CG
UT WOS:000310544900028
PM 23109162
ER
PT J
AU Siple, JF
Morey, JM
Gutman, TE
Weinberg, KL
Collins, PD
AF Siple, Jolene F.
Morey, Jessica M.
Gutman, Tracy E.
Weinberg, Kathy L.
Collins, Peggie D.
TI Proton Pump Inhibitor Use and Association with Spontaneous Bacterial
Peritonitis in Patients with Cirrhosis and Ascites
SO ANNALS OF PHARMACOTHERAPY
LA English
DT Article
DE ascites; cirrhosis; Clostridium difficile; proton pump inhibitor;
spontaneous bacterial peritonitis
ID CLOSTRIDIUM-DIFFICILE; MANAGEMENT; DISEASE; VARICES; RISKS
AB OBJECTIVE: To evaluate the literature regarding the efficacy and safety of proton pump inhibitors (PP Is) when they are used in patients with cirrhosis and ascites.
DATA SOURCES: A literature search was conducted using MEDLINE (1966-May 2012) and Web of Science (1990-May 2012) with the terms proton pump inhibitor, antisecretory therapy, cirrhosis, ascites, spontaneous bacterial peritonitis, and Clostridium difficile. The search was restricted to articles published in English on the use of PPIs in humans. Reference citations from identified published articles were reviewed for relevant information.
STUDY SELECTION AND DATA EXTRACTION: All articles in English identified from the data sources were evaluated for inclusion. One case series, 8 retrospective case-control trials, and 1 meta-analysis were identified.
DATA SYNTHESIS: Cirrhosis may cause complications such as portal hypertension, esophageal varices, and ascites. Patients may be prescribed PPIs without clear indications or because of their propensity to develop upper gastrointestinal symptoms and bleeding. However, gastric acidity is a major nonspecific defense mechanism and there is insufficient evidence on the need for chronic acid suppression in patients with cirrhosis. It is postulated that the portal hypertensive environment in cirrhosis and the acid suppression from PPIs can increase the risk of spontaneous bacterial peritonitis and C. difficile infection in patients with cirrhosis with ascites. Several retrospective studies and 1 meta-analysis have confirmed this association.
CONCLUSIONS: Patients with cirrhosis and ascites should be monitored carefully while on PPIs for a possible increased risk of infection from spontaneous bacterial peritonitis and C. difficile. Prospective randomized trials are needed to confirm this association. Clinicians should be aware of this lesser known adverse effect of PPIs.
C1 [Siple, Jolene F.; Morey, Jessica M.; Gutman, Tracy E.; Weinberg, Kathy L.; Collins, Peggie D.] Portland VA Med Ctr, Vancouver Primary Care, Vancouver, WA USA.
RP Siple, JF (reprint author), Portland VA Med Ctr, Vancouver Primary Care, Vancouver, WA USA.
EM jolene.siple@va.gov
NR 29
TC 7
Z9 7
U1 0
U2 7
PU HARVEY WHITNEY BOOKS CO
PI CINCINNATI
PA PO BOX 42696, CINCINNATI, OH 45242 USA
SN 1060-0280
J9 ANN PHARMACOTHER
JI Ann. Pharmacother.
PD OCT
PY 2012
VL 46
IS 10
BP 1413
EP 1418
DI 10.1345/aph.1R174
PG 6
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 022HE
UT WOS:000309947700015
PM 23032651
ER
PT J
AU Czerniecki, JM
Turner, AP
Williams, RM
Hakimi, KN
Norvell, DC
AF Czerniecki, Joseph M.
Turner, Aaron P.
Williams, Rhonda M.
Hakimi, Kevin N.
Norvell, Daniel C.
TI Mobility Changes in Individuals With Dysvascular Amputation From the
Presurgical Period to 12 Months Postamputation
SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
LA English
DT Article
DE Amputation; Outcome assessment (Health Care); Rehabilitation; Walking
ID LOWER-LIMB AMPUTATION; LOCOMOTOR CAPABILITIES INDEX; RESPONSE SHIFT;
AUDIT-C; RELIABILITY; POPULATION; VALIDATION; VALIDITY; AMPUTEES; PEOPLE
AB Czerniecki JM, Turner AP, Williams RM, Hakimi KN, Norvell DC. Mobility changes in individuals with dysvascular amputation from the presurgical period to 12 months postamputation. Arch Phys Med Rehabil 2012;93:1766-73. Objectives: To describe changes in ambulation among individuals with lower-extremity amputation secondary to peripheral artery disease and/or diabetes prior to surgery through 12 months after surgery. To compare differences in ambulation by amputation level and to examine risk factors for change in ambulation over time.
Design: Prospective cohort study.
Setting: Two Veterans Affairs medical centers, 1 university hospital, and a level 1 trauma center.
Participants: Patients with peripheral artery disease or diabetes (N = 239) undergoing a first unilateral major amputation were screened for participation between September 2005 and December 2008. Among these, 57% (n = 136) met study criteria, and of these, 64% (n = 87) participated.
Interventions: Standard of care at each facility.
Main Outcome Measures: Ambulatory function measured using the Locomotor Capability Index-5.
Results: Seventy-five of the 87 (86%) subjects enrolled finished their 12-month follow-up interview. Ambulatory mobility declined during the period immediately prior to surgery (premorbid) and remained low at 6 weeks postsurgery. On average, ambulation improved after surgery but did not return to premorbid levels. In the final multivariate model, age and history of lower-extremity arterial reconstruction were significantly associated with a poorer ambulatory trajectory over time, while other factors, such as amputation level, prior alcohol use, and length of disability prior to amputation, were not.
Conclusions: The findings highlight the importance of considering premorbid ambulatory function. Informing providers and patients about the trajectory and time course of changes in ambulation can enhance patient education, patient expectations, and treatment planning.
C1 [Norvell, Daniel C.] Spectrum Res Inc, Tacoma, WA 98405 USA.
[Czerniecki, Joseph M.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Czerniecki, Joseph M.; Turner, Aaron P.; Williams, Rhonda M.; Hakimi, Kevin N.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Norvell, DC (reprint author), Spectrum Res Inc, 705 S 9th St,Suite 203, Tacoma, WA 98405 USA.
EM dan@specri.com
OI Turner, Aaron/0000-0001-6897-8003
FU US Department of Veterans Affairs, Office of Research and Development,
Rehabilitation Research and Development [A41241, B4927W]
FX Supported by the US Department of Veterans Affairs, Office of Research
and Development, Rehabilitation Research and Development (Merit Review
A41241 and Career Development Award B34927W).
NR 23
TC 9
Z9 9
U1 2
U2 11
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0003-9993
J9 ARCH PHYS MED REHAB
JI Arch. Phys. Med. Rehabil.
PD OCT
PY 2012
VL 93
IS 10
BP 1766
EP 1773
DI 10.1016/j.apmr.2012.04.011
PG 8
WC Rehabilitation; Sport Sciences
SC Rehabilitation; Sport Sciences
GA 018FP
UT WOS:000309645800011
PM 22543258
ER
PT J
AU Arvikar, SL
Strle, K
Collier, DS
Fisher, MC
McHugh, G
Kawai, T
Kantarci, A
Steere, AC
AF Arvikar, Sheila L.
Strle, Klemen
Collier, Deborah S.
Fisher, Mark C.
McHugh, Gail
Kawai, Toshihisa
Kantarci, Alpdogan
Steere, Allen C.
TI Porphyromonas Gingivalis Antibody Responses and Clinical Associations in
Patients with Early Rheumatoid Arthritis.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Arvikar, Sheila L.; Strle, Klemen; Collier, Deborah S.; Fisher, Mark C.; McHugh, Gail; Steere, Allen C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kawai, Toshihisa; Kantarci, Alpdogan] Forsyth Inst, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 1204
BP S515
EP S515
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748302279
ER
PT J
AU Belsom, R
Jain, A
Curtis, J
Yang, S
Mikuls, TR
Chen, L
Gaffo, AL
AF Belsom, Rebecca
Jain, Archana
Curtis, Jeffrey
Yang, Shuo
Mikuls, Ted R.
Chen, Lang
Gaffo, Angelo L.
TI Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis:
Baseline Characteristics and Relationship with Disease Activity
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Belsom, Rebecca; Jain, Archana; Curtis, Jeffrey; Yang, Shuo; Chen, Lang; Gaffo, Angelo L.] Univ Alabama Birmingham, Birmingham, AL USA.
[Mikuls, Ted R.] Omaha VA, Omaha, NE USA.
[Mikuls, Ted R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Gaffo, Angelo L.] Birmingham VA Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 402
BP S176
EP S176
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748300403
ER
PT J
AU Bhangle, S
Lo Re, V
Pang, WG
Chang, KM
Amorosa, V
Kostman, J
Schumacher, HR
Ogdie, A
AF Bhangle, Samir
Lo Re, Vincent
Pang, W. Gina
Chang, Kyong-Mi
Amorosa, Valerianna
Kostman, Jay
Schumacher, H. Ralph
Ogdie, Alexis
TI Prevalence, Risk Factors, and Functional Impact of Arthralgias Among
Patients with Chronic Hepatitis C Virus Infection.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Bhangle, Samir; Lo Re, Vincent; Pang, W. Gina; Kostman, Jay; Schumacher, H. Ralph; Ogdie, Alexis] Univ Penn, Philadelphia, PA 19104 USA.
[Chang, Kyong-Mi; Amorosa, Valerianna] Philadelphia VA Med Ctr, Philadelphia, PA USA.
[Schumacher, H. Ralph] VA Med Ctr, Philadelphia, PA USA.
RI Lo Re, Vincent/N-7817-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 174
BP S75
EP S76
PG 2
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748300175
ER
PT J
AU Bunni, M
Amani, Z
Mather, A
Schepp, JB
Siskind, L
Nowling, TK
AF Bunni, Marlene
Amani, Zainab
Mather, Andrew
Schepp, Jennifer Berglind
Siskind, Leah
Nowling, Tamara K.
TI Lowering Fli1 Levels Decreases the Levels of Lipid Mediators in the
Kidneys and T Cells of MRL/Lpr Lupus Prone Mice.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Bunni, Marlene; Amani, Zainab; Mather, Andrew; Schepp, Jennifer Berglind; Siskind, Leah; Nowling, Tamara K.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Nowling, Tamara K.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 2339
BP S987
EP S987
PG 1
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748305259
ER
PT J
AU Carruthers, M
Augustin, T
Stone, JH
Khosroshahi, A
AF Carruthers, Mollie
Augustin, Tamara
Stone, John H.
Khosroshahi, Arezou
TI Diagnostic Utility of Serum IgG4 in IgG4-Related Disease.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Carruthers, Mollie; Stone, John H.; Khosroshahi, Arezou] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Augustin, Tamara] N Shore Med Ctr, Salem, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 1921
BP S815
EP S816
PG 2
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748304198
ER
PT J
AU Carruthers, M
Shinagare, S
Khosroshahi, A
Deshpande, V
Stone, JH
AF Carruthers, Mollie
Shinagare, Shweta
Khosroshahi, Arezou
Deshpande, Vikram
Stone, John H.
TI IgG4 Plasma Cell Infiltration in Granulomatosis with Polyangiitis
(formerly Wegener's) Lung Biopsies.
SO ARTHRITIS AND RHEUMATISM
LA English
DT Meeting Abstract
CT Annual Scientific Meeting of the American-College-of-Rheumatology (ACR)
and Association-of-Rheumatology-Health-Professionals (ARHP)
CY NOV 09-14, 2012
CL Washington, DC
SP Amer Coll Rheumatol (ACR), Assoc Rheumatol Hlth Profess (ARHP)
C1 [Carruthers, Mollie; Shinagare, Shweta; Khosroshahi, Arezou; Deshpande, Vikram; Stone, John H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0004-3591
J9 ARTHRITIS RHEUM-US
JI Arthritis Rheum.
PD OCT
PY 2012
VL 64
IS 10
SU S
MA 1534
BP S656
EP S657
PG 2
WC Rheumatology
SC Rheumatology
GA 019OD
UT WOS:000309748303255
ER
EF